There XXX O
was XXX O
no XXX O
correlation XXX O
between XXX O
serum XXX B-GENE
LH XXX I-GENE
and XXX O
chronological XXX O
or XXX O
bone XXX O
age XXX O
in XXX O
this XXX O
age XXX O
group XXX O
, XXX O
which XXX O
suggests XXX O
that XXX O
the XXX O
correlation XXX O
found XXX O
is XXX O
not XXX O
due XXX O
to XXX O
age-related XXX O
parallel XXX O
phenomena XXX O
. XXX O

In XXX O
reviewing XXX O
a XXX O
number XXX O
of XXX O
the XXX O
most XXX O
intensely XXX O
studied XXX O
environmentally XXX O
inducible XXX O
promoters XXX O
it XXX O
becomes XXX O
clear XXX O
that XXX O
the XXX O
presence XXX O
of XXX O
two XXX O
cis-acting XXX O
elements XXX O
are XXX O
critical XXX O
for XXX O
promoter XXX O
activity XXX O
, XXX O
one XXX O
of XXX O
which XXX O
is XXX O
the XXX O
G-box XXX O
( XXX O
CCACGTGG XXX B-GENE
) XXX O
. XXX O

Nodular XXX O
involvement XXX O
of XXX O
the XXX O
left XXX O
lung XXX O
and XXX O
infiltration XXX O
of XXX O
the XXX O
mucosa XXX O
of XXX O
the XXX O
left XXX O
lower XXX O
lobe XXX O
bronchus XXX O
followed XXX O
very XXX O
gradually XXX O
and XXX O
a XXX O
monoclonal XXX O
gammopathy XXX O
( XXX O
IgA--Type XXX B-GENE
Kappa XXX I-GENE
) XXX O
was XXX O
demonstrated XXX O
. XXX O

Beta-endorphin XXX B-GENE
, XXX O
ACTH XXX B-GENE
and XXX O
cortisol XXX O
secretion XXX O
were XXX O
measured XXX O
in XXX O
twelve XXX O
healthy XXX O
adult XXX O
males XXX O
after XXX O
nasal XXX O
spray XXX O
administration XXX O
200 XXX O
IU XXX O
salmon XXX B-GENE
calcitonin XXX I-GENE
. XXX O

Transcription XXX O
from XXX O
the XXX O
promoter XXX O
containing XXX O
the XXX O
mutated XXX O
direct XXX O
repeats XXX O
was XXX O
increased XXX O
greatly XXX O
, XXX O
consistent XXX O
with XXX O
the XXX O
conclusion XXX O
that XXX O
these XXX O
motifs XXX O
functions XXX O
in XXX O
vivo XXX O
to XXX O
repress XXX O
GPT XXX B-GENE
gene XXX I-GENE
expression XXX O
. XXX O

Fifty XXX O
min XXX O
after XXX O
release XXX O
from XXX O
stress XXX O
, XXX O
increases XXX O
in XXX O
plasma XXX O
corticosterone XXX O
levels XXX O
induced XXX O
by XXX O
stress XXX O
recovered XXX O
in XXX O
the XXX O
biting XXX O
group XXX O
but XXX O
remained XXX O
high XXX O
in XXX O
the XXX O
non-biting XXX O
group XXX O
. XXX O

Analysis XXX O
of XXX O
1 XXX O
Mb XXX O
of XXX O
published XXX O
sequence XXX O
from XXX O
the XXX O
region XXX O
of XXX O
conserved XXX O
synteny XXX O
on XXX O
human XXX O
chromosome XXX O
5q31-q33 XXX O
identified XXX O
45 XXX O
gene XXX O
candidates XXX O
, XXX O
including XXX O
35 XXX O
expressed XXX O
genes XXX O
in XXX O
the XXX O
human XXX B-GENE
IL-4 XXX I-GENE
cytokine XXX I-GENE
gene XXX I-GENE
cluster XXX I-GENE
. XXX O

If XXX O
this XXX O
is XXX O
present XXX O
, XXX O
such XXX O
patients XXX O
should XXX O
be XXX O
closely XXX O
monitored XXX O
, XXX O
and XXX O
any XXX O
atypical XXX O
lesions XXX O
biopsied XXX O
. XXX O

Analysis XXX O
of XXX O
the XXX O
sequence XXX O
identified XXX O
four XXX O
open XXX O
reading XXX O
frames XXX O
( XXX O
ORFs XXX O
) XXX O
which XXX O
are XXX O
designated XXX O
UL1 XXX B-GENE
, XXX O
UL2 XXX B-GENE
, XXX O
UL3 XXX B-GENE
, XXX O
and XXX O
UL3 XXX B-GENE
. XXX I-GENE
5 XXX I-GENE
based XXX O
on XXX O
their XXX O
homology XXX O
with XXX O
proteins XXX O
of XXX O
herpes XXX O
simplex XXX O
virus-1 XXX O
( XXX O
HSV-1 XXX O
) XXX O
, XXX O
pseudorabies XXX O
virus XXX O
( XXX O
PRV XXX O
) XXX O
, XXX O
equine XXX O
herpesvirus-1 XXX O
, XXX O
and XXX O
varicella-zoster XXX O
virus XXX O
. XXX O

Diary XXX O
. XXX O

Protease XXX B-GENE
activities XXX O
in XXX O
cultures XXX O
of XXX O
the XXX O
streptococcal XXX O
strains XXX O
were XXX O
associated XXX O
with XXX O
species XXX O
of XXX O
different XXX O
molecular XXX O
masses XXX O
ranging XXX O
from XXX O
130 XXX O
to XXX O
200 XXX O
kDa XXX O
, XXX O
suggesting XXX O
posttranslational XXX O
processing XXX O
possibly XXX O
as XXX O
a XXX O
result XXX O
of XXX O
autoproteolysis XXX O
at XXX O
post-proline XXX O
peptide XXX O
bonds XXX O
in XXX O
the XXX O
N-terminal XXX O
parts XXX O
of XXX O
the XXX O
molecules XXX O
. XXX O

Cell XXX O
lines XXX O
are XXX O
checked XXX O
to XXX O
find XXX O
out XXX O
whether XXX O
they XXX O
develop XXX O
tumors XXX O
in XXX O
nude XXX O
mice XXX O
followed XXX O
by XXX O
an XXX O
analysis XXX O
of XXX O
the XXX O
karyotype XXX O
. XXX O

PATIENTS XXX O
AND XXX O
METHODS XXX O
: XXX O
Between XXX O
June XXX O
1991 XXX O
and XXX O
December XXX O
1996 XXX O
, XXX O
we XXX O
administered XXX O
the XXX O
nucleoside XXX O
analog XXX O
2-chlorodeoxyadenosine XXX O
( XXX O
2-CDA XXX O
) XXX O
to XXX O
73 XXX O
children XXX O
with XXX O
primary XXX O
AML XXX O
and XXX O
20 XXX O
children XXX O
with XXX O
secondary XXX O
AML XXX O
or XXX O
myelodysplastic XXX O
syndrome XXX O
( XXX O
MDS XXX O
) XXX O
. XXX O

First XXX O
, XXX O
the XXX O
finding XXX O
of XXX O
a XXX O
monomeric XXX B-GENE
Alu XXX I-GENE
family XXX I-GENE
repeat XXX I-GENE
at XXX O
the XXX O
junction XXX O
between XXX O
nonhomology XXX O
block XXX O
I XXX O
and XXX O
homology XXX O
block XXX O
Y XXX O
of XXX O
the XXX O
alpha XXX B-GENE
2 XXX I-GENE
gene-containing XXX I-GENE
unit XXX I-GENE
in XXX I-GENE
rhesus XXX I-GENE
macaque XXX I-GENE
suggests XXX O
that XXX O
the XXX O
dimeric XXX B-GENE
Alu XXX I-GENE
family XXX I-GENE
repeat XXX I-GENE
, XXX O
Alu XXX B-GENE
3 XXX I-GENE
, XXX O
at XXX O
the XXX O
orthologous XXX O
position XXX O
in XXX O
human XXX O
was XXX O
generated XXX O
by XXX O
insertion XXX O
of XXX O
a XXX O
monomeric XXX B-GENE
Alu XXX I-GENE
family XXX I-GENE
repeat XXX I-GENE
into XXX O
the XXX O
3' XXX O
end XXX O
of XXX O
another XXX O
preexisting XXX O
Alu XXX B-GENE
family XXX I-GENE
repeat XXX I-GENE
. XXX O

Vertebrate XXX B-GENE
synapsins XXX I-GENE
constitute XXX O
a XXX O
family XXX O
of XXX O
synaptic XXX O
proteins XXX O
that XXX O
participate XXX O
in XXX O
the XXX O
regulation XXX O
of XXX O
neurotransmitter XXX O
release XXX O
. XXX O

The XXX O
results XXX O
indicate XXX O
that XXX O
DNA XXX O
methylation XXX O
, XXX O
chromatin XXX O
structure XXX O
, XXX O
and XXX O
transactivation XXX O
at XXX O
an XXX O
Sp1 XXX B-GENE
site XXX I-GENE
contribute XXX O
to XXX O
the XXX O
highly XXX O
restricted XXX O
expression XXX O
of XXX O
this XXX O
myelomonocytic XXX O
lineage XXX O
specific XXX O
gene XXX O
. XXX O

Within-subject XXX O
BP XXX O
differences XXX O
between XXX O
fish XXX O
oil XXX O
and XXX O
corn XXX O
oil XXX O
treatment XXX O
were XXX O
similar XXX O
for XXX O
Dinamap XXX O
( XXX O
3 XXX O
. XXX O
2 XXX O
+ XXX O
/ XXX O
- XXX O
1 XXX O
. XXX O
8 XXX O
/ XXX O
2 XXX O
. XXX O
5 XXX O
+ XXX O
/ XXX O
- XXX O
1 XXX O
. XXX O
0 XXX O
mm XXX O
Hg XXX O
) XXX O
and XXX O
for XXX O
24-h XXX O
ABP XXX O
( XXX O
2 XXX O
. XXX O
5 XXX O
+ XXX O
/ XXX O
- XXX O
1 XXX O
. XXX O
0 XXX O
/ XXX O
2 XXX O
. XXX O
3 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
8 XXX O
mm XXX O
Hg XXX O
) XXX O
, XXX O
but XXX O
were XXX O
more XXX O
significant XXX O
with XXX O
the XXX O
latter XXX O
. XXX O

Steroid XXX O
glucuronides XXX O
in XXX O
amniotic XXX O
fluid XXX O
at XXX O
term XXX O
. XXX O

Phd XXX B-GENE
antibody-immunoreactive XXX O
peptides XXX O
are XXX O
seen XXX O
in XXX O
light-adapted XXX O
mouse XXX O
retinal XXX O
cytosolic XXX O
and XXX O
nuclear XXX O
extracts XXX O
. XXX O

Serotonin XXX B-GENE
5-HT2 XXX I-GENE
receptor XXX I-GENE
binding XXX O
on XXX O
blood XXX O
platelets XXX O
as XXX O
a XXX O
state XXX O
dependent XXX O
marker XXX O
in XXX O
major XXX O
affective XXX O
disorder XXX O
. XXX O

By XXX O
contrast XXX O
, XXX O
d XXX O
( XXX O
T2AG3T XXX O
) XXX O
and XXX O
d XXX O
( XXX O
T2G4T XXX O
) XXX O
form XXX O
only XXX O
the XXX O
G-quadruplex XXX O
monomer XXX O
structures XXX O
independent XXX O
of XXX O
K XXX O
cation XXX O
concentration XXX O
as XXX O
reported XXX O
previously XXX O
[ XXX O
Sen XXX O
, XXX O
D XXX O
. XXX O
, XXX O
& XXX O
Gilbert XXX O
, XXX O
W XXX O
. XXX O

Hematocrit XXX O
and XXX O
PaO2 XXX O
did XXX O
not XXX O
change XXX O
. XXX O

Fibrin XXX B-GENE
gels XXX O
and XXX O
their XXX O
possible XXX O
implication XXX O
for XXX O
surface XXX O
hemorheology XXX O
in XXX O
health XXX O
and XXX O
disease XXX O
. XXX O

Standard XXX O
reference XXX O
sources XXX O
indicate XXX O
that XXX O
an XXX O
able-bodied XXX O
11-year-old XXX O
child XXX O
of XXX O
comparable XXX O
height XXX O
requires XXX O
1 XXX O
, XXX O
493 XXX O
kcal XXX O
/ XXX O
d XXX O
for XXX O
support XXX O
of XXX O
basal XXX O
metabolic XXX O
functions XXX O
. XXX O

The XXX O
intron XXX O
RNA XXX O
consists XXX O
of XXX O
2492 XXX O
nucleotides XXX O
which XXX O
can XXX O
be XXX O
folded XXX O
into XXX O
a XXX O
secondary XXX O
structure XXX O
with XXX O
all XXX O
the XXX O
expected XXX O
sequence XXX O
motifs XXX O
of XXX O
subgroup-IIA1 XXX O
introns XXX O
( XXX O
Michel XXX O
et XXX O
al XXX O
. XXX O

In XXX O
the XXX O
control XXX O
group XXX O
, XXX O
platelet XXX O
markers XXX O
increased XXX O
1 XXX O
h XXX O
after XXX O
surgery XXX O
. XXX O

It XXX O
was XXX O
also XXX O
suggested XXX O
that XXX O
the XXX O
biological XXX O
activities XXX O
of XXX O
5-FU XXX O
, XXX O
ADM XXX O
and XXX O
MMC XXX O
in XXX O
FAMLIP XXX O
were XXX O
stable XXX O
in XXX O
FULIP XXX O
, XXX O
ADRLIP XXX O
and XXX O
MMCLIP XXX O
. XXX O

The XXX O
neural XXX O
mechanism XXX O
of XXX O
parkinsonian XXX O
motor XXX O
symptoms XXX O
, XXX O
i XXX O
. XXX O
e XXX O
. XXX O
, XXX O
rigidity XXX O
, XXX O
tremor XXX O
and XXX O
akinesia XXX O
, XXX O
which XXX O
are XXX O
the XXX O
result XXX O
of XXX O
nigrostriatal XXX O
dopamine XXX O
deficiency XXX O
, XXX O
is XXX O
interpreted XXX O
from XXX O
long-term XXX O
observations XXX O
on XXX O
the XXX O
effect XXX O
of XXX O
surgical XXX O
and XXX O
pharmacological XXX O
treatment XXX O
of XXX O
the XXX O
disease XXX O
in XXX O
relation XXX O
to XXX O
the XXX O
neuropathological XXX O
findings XXX O
within XXX O
the XXX O
substantia XXX O
nigra XXX O
zona XXX O
compacta XXX O
( XXX O
SNc XXX O
) XXX O
. XXX O

We XXX O
have XXX O
designated XXX O
the XXX O
protein XXX O
"cellular XXX B-GENE
NBP" XXX I-GENE
( XXX O
CNBP XXX B-GENE
) XXX O
. XXX O

After XXX O
description XXX O
of XXX O
his XXX O
short XXX O
life XXX O
and XXX O
an XXX O
explanation XXX O
of XXX O
the XXX O
light XXX O
conductor XXX O
Bozzini's XXX O
merit XXX O
is XXX O
emphasized XXX O
, XXX O
by XXX O
his XXX O
invention XXX O
as XXX O
first XXX O
physician XXX O
to XXX O
have XXX O
made XXX O
accessible XXX O
to XXX O
medicine XXX O
endoscopic XXX O
diagnostic XXX O
possibilities XXX O
. XXX O

Paroxysmal XXX O
fluctuations XXX O
in XXX O
observed XXX O
parasitemia XXX O
in XXX O
Plasmodium XXX O
falciparum XXX O
malaria XXX O
. XXX O

We XXX O
have XXX O
earlier XXX O
evolved XXX O
an XXX O
experimental XXX O
model XXX O
by XXX O
means XXX O
of XXX O
which XXX O
changes XXX O
identical XXX O
to XXX O
the XXX O
microembolism XXX O
syndrome XXX O
can XXX O
be XXX O
induced XXX O
from XXX O
a XXX O
reproducible XXX O
musculo-skeletal XXX O
trauma XXX O
in XXX O
pigs XXX O
observed XXX O
under XXX O
long-term XXX O
anesthesia XXX O
under XXX O
standardized XXX O
conditions XXX O
. XXX O

The XXX O
results XXX O
suggest XXX O
followings--1 XXX O
) XXX O
both XXX O
eosinophils XXX O
and XXX O
neutrophils XXX O
participate XXX O
in XXX O
hypersecretion XXX O
of XXX O
type XXX O
Ib XXX O
in XXX O
atopic XXX O
cases XXX O
, XXX O
and XXX O
only XXX O
eosinophils XXX O
in XXX O
non-atopic XXX O
cases XXX O
. XXX O

In XXX O
budding XXX O
yeast XXX O
, XXX O
this XXX O
latter XXX O
checkpoint XXX O
response XXX O
involves XXX O
the XXX O
proteins XXX O
Mad1 XXX B-GENE
, XXX I-GENE
2 XXX I-GENE
, XXX I-GENE
3 XXX I-GENE
, XXX O
Bub1 XXX B-GENE
and XXX O
Bub3 XXX B-GENE
, XXX O
whose XXX O
vertebrate XXX O
counterparts XXX O
localize XXX O
to XXX O
unattached XXX O
kinetochores XXX O
. XXX O

A XXX O
transcript XXX O
of XXX O
about XXX O
2 XXX O
kb XXX O
is XXX O
expected XXX O
for XXX O
each XXX O
PPO XXX B-GENE
. XXX O

Plane XXX O
wave XXX O
geometry XXX O
is XXX O
impractical XXX O
for XXX O
clinical XXX O
use XXX O
but XXX O
the XXX O
results XXX O
of XXX O
this XXX O
work XXX O
encouraged XXX O
us XXX O
to XXX O
further XXX O
develop XXX O
the XXX O
P3 XXX O
approximation XXX O
for XXX O
a XXX O
spherical XXX O
geometry XXX O
, XXX O
described XXX O
in XXX O
this XXX O
paper XXX O
. XXX O

In XXX O
Wnt XXX B-GENE
signaling XXX O
, XXX O
beta-catenin XXX B-GENE
and XXX O
plakoglobin XXX B-GENE
transduce XXX O
signals XXX O
to XXX O
the XXX O
nucleus XXX O
through XXX O
interactions XXX O
with XXX O
TCF-type XXX B-GENE
transcription XXX I-GENE
factors XXX I-GENE
. XXX O

Microstructure XXX O
and XXX O
conductivity XXX O
of XXX O
hierarchical XXX O
laminate XXX O
composites XXX O
. XXX O

There XXX O
is XXX O
no XXX O
TATA XXX O
box XXX O
around XXX O
the XXX O
transcriptional XXX O
start XXX O
points XXX O
( XXX O
tsp XXX O
) XXX O
, XXX O
as XXX O
determined XXX O
by XXX O
primer XXX O
extension XXX O
analysis XXX O
. XXX O

VE-DEF XXX O
animals XXX O
had XXX O
significantly XXX O
higher XXX O
( XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
levels XXX O
of XXX O
myocardial XXX O
lipid XXX O
peroxidation XXX O
and XXX O
lower XXX O
( XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
protein XXX O
thiols XXX O
following XXX O
I-R XXX O
compared XXX O
to XXX O
the XXX O
CON XXX O
animals XXX O
. XXX O

Five XXX O
different XXX O
subtypes XXX O
of XXX O
spondyloarthropathy XXX O
( XXX O
SpA XXX O
) XXX O
are XXX O
now XXX O
recognized XXX O
. XXX O

Changes XXX O
in XXX O
ionic XXX O
content XXX O
of XXX O
the XXX O
mucous XXX O
suggest XXX O
that XXX O
cholinergic XXX O
mechanisms XXX O
affect XXX O
pressure XXX O
in XXX O
the XXX O
excretory XXX O
duct XXX O
of XXX O
the XXX O
gland XXX O
. XXX O

Application XXX O
of XXX O
the XXX O
method XXX O
to XXX O
a XXX O
representative XXX O
set XXX O
of XXX O
50 XXX O
known XXX O
genes XXX O
from XXX O
Arabidopsis XXX O
thaliana XXX O
showed XXX O
significant XXX O
improvement XXX O
in XXX O
prediction XXX O
accuracy XXX O
compared XXX O
to XXX O
previous XXX O
spliced XXX O
alignment XXX O
methods XXX O
. XXX O

All XXX O
adults XXX O
attending XXX O
the XXX O
outpatient XXX O
clinics XXX O
of XXX O
a XXX O
dermatological XXX O
hospital XXX O
on XXX O
predetermined XXX O
days XXX O
were XXX O
given XXX O
the XXX O
12-item XXX O
General XXX O
Health XXX O
Questionnaire XXX O
. XXX O

The XXX O
BAL-to-plasma XXX O
specific XXX O
activity XXX O
of XXX O
urea XXX O
was XXX O
about XXX O
twice XXX O
that XXX O
of XXX O
Na+ XXX O
, XXX O
indicating XXX O
that XXX O
urea XXX O
diffused XXX O
into XXX O
the XXX O
ELF XXX O
more XXX O
rapidly XXX O
than XXX O
Na+ XXX O
during XXX O
the XXX O
70 XXX O
s XXX O
that XXX O
elapsed XXX O
between XXX O
the XXX O
time XXX O
the XXX O
radioactive XXX O
urea XXX O
and XXX O
Na+ XXX O
were XXX O
injected XXX O
into XXX O
the XXX O
circulation XXX O
and XXX O
the XXX O
time XXX O
when XXX O
lavage XXX O
was XXX O
complete XXX O
. XXX O

This XXX O
intracellular XXX O
signaling XXX O
, XXX O
known XXX O
as XXX O
the XXX O
unfolded XXX O
protein XXX O
response XXX O
( XXX O
UPR XXX O
) XXX O
, XXX O
is XXX O
mediated XXX O
by XXX O
the XXX O
cis-acting XXX O
ER XXX B-GENE
stress XXX I-GENE
response XXX I-GENE
element XXX I-GENE
( XXX O
ERSE XXX B-GENE
) XXX O
in XXX O
mammals XXX O
. XXX O

Multiple XXX O
dosing XXX O
four XXX O
times XXX O
daily XXX O
for XXX O
7 XXX O
days XXX O
of XXX O
indoprofen XXX O
200 XXX O
mg XXX O
, XXX O
a XXX O
non-steroidal XXX O
anti-inflammatory XXX O
drug XXX O
with XXX O
a XXX O
short XXX O
half-life XXX O
( XXX O
t1 XXX O
/ XXX O
2 XXX O
) XXX O
, XXX O
revealed XXX O
drug XXX O
accumulation XXX O
in XXX O
eight XXX O
elderly XXX O
subjects XXX O
. XXX O

The XXX O
standard XXX O
method XXX O
for XXX O
calculating XXX O
the XXX O
composite XXX O
score XXX O
on XXX O
the XXX O
S-B XXX O
IV XXX O
excludes XXX O
subtests XXX O
with XXX O
a XXX O
raw XXX O
score XXX O
of XXX O
0 XXX O
, XXX O
which XXX O
overestimates XXX O
cognitive XXX O
functioning XXX O
in XXX O
young XXX O
biologically XXX O
high XXX O
risk XXX O
children XXX O
. XXX O

A XXX O
multicentre XXX O
study XXX O
involving XXX O
9 XXX O
Italian XXX O
institutions XXX O
was XXX O
carried XXX O
out XXX O
to XXX O
compare XXX O
the XXX O
efficacy XXX O
and XXX O
safety XXX O
of XXX O
ranitidine XXX O
150 XXX O
mg XXX O
b XXX O
. XXX O
i XXX O
. XXX O
d XXX O
. XXX O
and XXX O
ranitidine XXX O
300 XXX O
mg XXX O
nocte XXX O
in XXX O
the XXX O
treatment XXX O
of XXX O
reflux XXX O
oesophagitis XXX O
. XXX O

The XXX O
astronaut XXX O
crew XXX O
operates XXX O
the XXX O
payload XXX O
and XXX O
documents XXX O
its XXX O
operation XXX O
. XXX O

Stems XXX O
contain XXX O
distinctly XXX O
less XXX O
P XXX B-GENE
protein XXX I-GENE
mRNA XXX I-GENE
and XXX O
the XXX O
relative XXX O
level XXX O
in XXX O
roots XXX O
is XXX O
very XXX O
low XXX O
but XXX O
still XXX O
clearly XXX O
detectable XXX O
. XXX O

The XXX O
activity XXX O
of XXX O
the XXX O
transcription XXX B-GENE
factor XXX I-GENE
CREB XXX I-GENE
is XXX O
regulated XXX O
by XXX O
extracellular XXX O
stimuli XXX O
that XXX O
result XXX O
in XXX O
its XXX O
phosphorylation XXX O
at XXX O
a XXX O
critical XXX O
serine XXX O
residue XXX O
, XXX O
Ser133 XXX O
. XXX O

A XXX O
randomized XXX O
, XXX O
multicenter XXX O
study XXX O
comparing XXX O
the XXX O
efficacy XXX O
and XXX O
tolerability XXX O
of XXX O
tropisetron XXX O
, XXX O
a XXX O
new XXX O
5-HT3 XXX B-GENE
receptor XXX I-GENE
antagonist XXX O
, XXX O
with XXX O
a XXX O
metoclopramide-containing XXX O
antiemetic XXX O
cocktail XXX O
in XXX O
the XXX O
prevention XXX O
of XXX O
cisplatin-induced XXX O
emesis XXX O
. XXX O

In XXX O
studies XXX O
of XXX O
many XXX O
different XXX O
phenotypically XXX O
distinct XXX O
cells XXX O
, XXX O
the XXX O
CRE XXX B-GENE
of XXX O
the XXX O
somatostatin XXX B-GENE
gene XXX I-GENE
promoter XXX I-GENE
is XXX O
a XXX O
prototype XXX O
of XXX O
a XXX O
highly XXX O
cAMP-responsive XXX B-GENE
element XXX I-GENE
regulated XXX O
by XXX O
CREB XXX B-GENE
. XXX O

Capsular XXX O
antigens XXX O
of XXX O
Staphylococcus XXX O
aureus XXX O
. XXX O

Copyright XXX O
2001 XXX O
Academic XXX O
Press XXX O
. XXX O

Althoug XXX O
RBF XXX O
tended XXX O
to XXX O
increase XXX O
after XXX O
the XXX O
therapy XXX O
, XXX O
there XXX O
was XXX O
no XXX O
statistically XXX O
significant XXX O
change XXX O
in XXX O
RBF XXX O
, XXX O
GFR XXX O
and XXX O
cardiac XXX O
output XXX O
. XXX O

We XXX O
suggest XXX O
that XXX O
apart XXX O
from XXX O
the XXX O
World XXX O
Summit XXX O
for XXX O
Children's XXX O
under-five XXX O
mortality XXX O
target XXX O
for XXX O
the XXX O
year XXX O
2000 XXX O
, XXX O
intraregional XXX O
targets XXX O
to XXX O
reduce XXX O
geographical XXX O
inequalities XXX O
in XXX O
under-five XXX O
mortality XXX O
should XXX O
be XXX O
specified XXX O
. XXX O

A XXX O
114-base XXX O
pair XXX O
sequence XXX O
of XXX O
predominantly XXX O
repeating XXX O
purine-pyrimidine XXX O
nucleotides XXX O
separates XXX O
these XXX O
two XXX O
d XXX O
( XXX O
AC XXX O
) XXX O
repeats XXX O
. XXX O

The XXX O
ERH XXX B-GENE
expression XXX O
profile XXX O
is XXX O
similar XXX O
, XXX O
to XXX O
that XXX O
of XXX O
An3 XXX B-GENE
, XXX O
which XXX O
localizes XXX O
to XXX O
the XXX O
animal XXX O
hemisphere XXX O
of XXX O
oocytes XXX O
and XXX O
is XXX O
abundantly XXX O
expressed XXX O
in XXX O
the XXX O
embryo XXX O
. XXX O

It XXX O
was XXX O
found XXX O
that XXX O
the XXX O
ROSP XXX O
undergoes XXX O
a XXX O
number XXX O
of XXX O
fluctuations XXX O
in XXX O
the XXX O
negative XXX O
and XXX O
positive XXX O
directions XXX O
with XXX O
a XXX O
gradually XXX O
decreasing XXX O
amplitude XXX O
in XXX O
the XXX O
course XXX O
of XXX O
5-25 XXX O
days XXX O
following XXX O
the XXX O
operation XXX O
, XXX O
after XXX O
which XXX O
relatively XXX O
stable XXX O
negative XXX O
values XXX O
of XXX O
the XXX O
ROSP XXX O
are XXX O
established XXX O
on XXX O
the XXX O
average XXX O
in XXX O
electrodes XXX O
implanted XXX O
to XXX O
the XXX O
level XXX O
of XXX O
the XXX O
dura XXX O
mater XXX O
, XXX O
and XXX O
positive XXX O
values XXX O
in XXX O
electrodes XXX O
implanted XXX O
to XXX O
the XXX O
level XXX O
of XXX O
the XXX O
pia XXX O
mater XXX O
. XXX O

By XXX O
comparison XXX O
, XXX O
in XXX O
nontumorigenic XXX O
Ad5 XXX O
cells XXX O
, XXX O
class XXX B-GENE
I XXX I-GENE
expression XXX O
is XXX O
high XXX O
due XXX O
to XXX O
negligible XXX O
binding XXX O
of XXX O
COUP-TF XXX B-GENE
and XXX O
strong XXX O
binding XXX O
of XXX O
NF-kappaB XXX B-GENE
. XXX O

After XXX O
surgery XXX O
, XXX O
patients XXX O
self XXX O
administered XXX O
one XXX O
of XXX O
three XXX O
possible XXX O
postsurgical XXX O
medications XXX O
, XXX O
which XXX O
included XXX O
placebo XXX O
, XXX O
codeine XXX O
60 XXX O
mg XXX O
, XXX O
and XXX O
ibuprofen XXX O
400 XXX O
mg XXX O
, XXX O
when XXX O
their XXX O
pain XXX O
reached XXX O
a XXX O
moderate XXX O
or XXX O
severe XXX O
intensity XXX O
. XXX O

A XXX O
short XXX O
open XXX O
reading XXX O
frame XXX O
( XXX O
ORF2 XXX O
) XXX O
, XXX O
of XXX O
unknown XXX O
function XXX O
, XXX O
is XXX O
present XXX O
in XXX O
all XXX O
FIV XXX O
isolates XXX O
. XXX O

Probable XXX O
progressive XXX O
multifocal XXX O
leukoencephalopathy XXX O
( XXX O
PML XXX O
) XXX O
was XXX O
diagnosed XXX O
on XXX O
the XXX O
basis XXX O
of XXX O
clinical XXX O
picture XXX O
and XXX O
magnetic XXX O
resonance XXX O
imaging XXX O
in XXX O
a XXX O
63-year-old XXX O
man XXX O
with XXX O
a XXX O
complete XXX O
remission XXX O
of XXX O
a XXX O
non-Hodgkin's XXX O
lymphoma XXX O
. XXX O

Perhaps XXX O
in XXX O
addition XXX O
to XXX O
, XXX O
or XXX O
as XXX O
part XXX O
of XXX O
, XXX O
its XXX O
essential XXX O
function XXX O
in XXX O
late XXX O
mitosis XXX O
, XXX O
MOB1 XXX B-GENE
is XXX O
required XXX O
for XXX O
a XXX O
cell XXX O
cycle XXX O
reset XXX O
function XXX O
necessary XXX O
for XXX O
the XXX O
initiation XXX O
of XXX O
the XXX O
spindle XXX O
pole XXX O
body XXX O
duplication XXX O
. XXX O

High XXX O
radial XXX O
r XXX O
values XXX O
with XXX O
small XXX O
standard XXX O
deviations XXX O
were XXX O
observed XXX O
in XXX O
normal XXX O
LV XXX O
( XXX O
0 XXX O
. XXX O
972 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
016 XXX O
) XXX O
and XXX O
in XXX O
non-MI XXX O
regions XXX O
( XXX O
0 XXX O
. XXX O
964 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
018 XXX O
) XXX O
, XXX O
indicating XXX O
temporally XXX O
homogeneous XXX O
radial XXX O
shortening XXX O
. XXX O

Foreigners XXX O
return XXX O
. XXX O

Catha XXX O
edulis XXX O
, XXX O
a XXX O
plant XXX O
that XXX O
has XXX O
amphetamine XXX O
effects XXX O
. XXX O

Observation XXX O
of XXX O
dipolar XXX O
interactions XXX O
between XXX O
Pb0 XXX O
defects XXX O
at XXX O
the XXX O
( XXX O
111 XXX O
) XXX O
Si XXX O
/ XXX O
SiO2 XXX O
interface XXX O
. XXX O

Peripheral XXX O
metabolism XXX O
of XXX O
androgens XXX O
takes XXX O
place XXX O
in XXX O
various XXX O
areas XXX O
within XXX O
the XXX O
pilosebaceous XXX O
unit XXX O
, XXX O
as XXX O
indicated XXX O
by XXX O
local XXX O
differences XXX O
in XXX O
the XXX O
activities XXX O
of XXX O
aromatase XXX B-GENE
, XXX O
5alpha-reductase XXX B-GENE
as XXX O
well XXX O
as XXX O
of XXX O
the XXX O
presence XXX O
of XXX O
the XXX O
androgen XXX B-GENE
receptors XXX I-GENE
. XXX O

Consequently XXX O
, XXX O
significant XXX O
differences XXX O
between XXX O
the XXX O
measured XXX O
and XXX O
calculated XXX O
methods XXX O
were XXX O
noted XXX O
in XXX O
oxygen XXX O
uptake XXX O
( XXX O
213 XXX O
+ XXX O
/ XXX O
- XXX O
41 XXX O
ml XXX O
/ XXX O
min XXX O
vs XXX O
193 XXX O
+ XXX O
/ XXX O
- XXX O
25 XXX O
ml XXX O
/ XXX O
min XXX O
, XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
001 XXX O
) XXX O
, XXX O
oxygen XXX O
delivery XXX O
( XXX O
780 XXX O
+ XXX O
/ XXX O
- XXX O
297 XXX O
ml XXX O
/ XXX O
min XXX O
vs XXX O
716 XXX O
+ XXX O
/ XXX O
- XXX O
296 XXX O
ml XXX O
/ XXX O
min XXX O
, XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
001 XXX O
) XXX O
, XXX O
and XXX O
cardiac XXX O
output XXX O
( XXX O
5 XXX O
. XXX O
8 XXX O
+ XXX O
/ XXX O
- XXX O
2 XXX O
. XXX O
2 XXX O
L XXX O
/ XXX O
min XXX O
vs XXX O
5 XXX O
. XXX O
3 XXX O
+ XXX O
/ XXX O
- XXX O
1 XXX O
. XXX O
8 XXX O
L XXX O
/ XXX O
min XXX O
, XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
001 XXX O
) XXX O
. XXX O

Transcription XXX O
readthrough XXX O
into XXX O
the XXX O
inverted XXX O
repeats XXX O
has XXX O
little XXX O
effect XXX O
on XXX O
this XXX O
event XXX O
. XXX O

PATIENTS XXX O
and XXX O
METHODS XXX O
: XXX O
Thallium-201 XXX O
myocardial XXX O
scintigraphy XXX O
was XXX O
performed XXX O
at XXX O
rest XXX O
and XXX O
after XXX O
0 XXX O
. XXX O
56 XXX O
mg XXX O
/ XXX O
kg XXX O
intravenous XXX O
dipyridamole XXX O
during XXX O
four XXX O
minutes XXX O
in XXX O
16 XXX O
patients XXX O
with XXX O
sarcoidosis XXX O
. XXX O

Previously XXX O
, XXX O
we XXX O
identified XXX O
a XXX O
51-bp XXX O
promoter XXX O
fragment XXX O
, XXX O
oligo31 XXX B-GENE
/ XXX I-GENE
32 XXX I-GENE
, XXX O
which XXX O
conferred XXX O
heat XXX O
shock XXX O
inducibility XXX O
on XXX O
the XXX O
heterologous XXX O
CYC1-lacZ XXX B-GENE
reporter XXX I-GENE
gene XXX I-GENE
in XXX O
S XXX O
. XXX O
cerevisiae XXX O
( XXX O
N XXX O
. XXX O

Among XXX O
the XXX O
transcription XXX O
factors XXX O
known XXX O
to XXX O
interact XXX O
with XXX O
Groucho-related XXX B-GENE
protein XXX I-GENE
, XXX O
only XXX O
RUNX1 XXX B-GENE
was XXX O
appreciably XXX O
downregulated XXX O
by XXX O
E2A-HLF XXX B-GENE
. XXX O

Northern XXX O
analysis XXX O
revealed XXX O
no XXX O
detectable XXX O
expression XXX O
of XXX O
the XXX O
transcript XXX O
in XXX O
diapause- XXX O
or XXX O
nondiapause-programmed XXX O
wandering XXX O
larvae XXX O
, XXX O
and XXX O
only XXX O
trace XXX O
expression XXX O
in XXX O
nondiapausing XXX O
pupae XXX O
. XXX O

Such XXX O
an XXX O
intervention XXX O
may XXX O
be XXX O
of XXX O
considerable XXX O
use XXX O
for XXX O
the XXX O
treatment XXX O
of XXX O
angiogenesis-dependent XXX O
diseases XXX O
involving XXX O
FGF-2 XXX B-GENE
. XXX O

Differential XXX O
expression XXX O
of XXX O
AP-2alpha XXX B-GENE
and XXX O
AP-2beta XXX B-GENE
in XXX O
the XXX O
developing XXX O
chick XXX O
retina XXX O
: XXX O
repression XXX O
of XXX O
R-FABP XXX B-GENE
promoter XXX I-GENE
activity XXX O
by XXX O
AP-2 XXX B-GENE
. XXX O

A XXX O
specific XXX O
distal XXX O
promoter XXX O
controls XXX O
gamma-glutamyl XXX B-GENE
transpeptidase XXX I-GENE
gene XXX I-GENE
expression XXX O
in XXX O
undifferentiated XXX O
rat XXX O
transformed XXX O
liver XXX O
cells XXX O
. XXX O

INTERVENTIONS--Patients XXX O
allocated XXX O
to XXX O
treatment XXX O
with XXX O
levodopa XXX B-GENE
/ XXX I-GENE
dopa XXX I-GENE
decarboxylase XXX I-GENE
inhibitor XXX O
alone XXX O
( XXX O
arm XXX O
1 XXX O
) XXX O
, XXX O
levodopa XXX B-GENE
/ XXX I-GENE
decarboxylase XXX I-GENE
inhibitor XXX O
/ XXX O
selegiline XXX O
in XXX O
combination XXX O
( XXX O
arm XXX O
2 XXX O
) XXX O
, XXX O
or XXX O
bromocriptine XXX O
( XXX O
arm XXX O
3 XXX O
) XXX O
. XXX O

We XXX O
analyzed XXX O
an XXX O
EBV XXX O
B-cell XXX O
clone XXX O
, XXX O
E29 XXX O
. XXX O
1 XXX O
, XXX O
derived XXX O
from XXX O
an XXX O
11 XXX O
week-old XXX O
embryo XXX O
, XXX O
and XXX O
secreting XXX O
both XXX O
IgM XXX B-GENE
kappa XXX I-GENE
and XXX O
IgM XXX B-GENE
lambda XXX I-GENE
. XXX O

The XXX O
maximum XXX O
deflections XXX O
of XXX O
phase XXX O
IV XXX O
for XXX O
Ar XXX O
and XXX O
N2 XXX O
from XXX O
extrapolated XXX O
phase XXX O
III XXX O
slopes XXX O
were XXX O
smaller XXX O
in XXX O
the XXX O
prone XXX O
position XXX O
, XXX O
suggesting XXX O
more XXX O
uniform XXX O
tracer XXX O
gas XXX O
concentrations XXX O
across XXX O
the XXX O
lungs XXX O
. XXX O

The XXX O
present XXX O
paper XXX O
elucidates XXX O
the XXX O
existing XXX O
discrepancies XXX O
, XXX O
and XXX O
offers XXX O
a XXX O
consistent XXX O
terminology XXX O
incorporating XXX O
also XXX O
such XXX O
terms XXX O
as XXX O
"additivity" XXX O
, XXX O
"potentiation" XXX O
, XXX O
and XXX O
"simple XXX O
similarity" XXX O
. XXX O

Human XXX B-GENE
ESP1 XXX I-GENE
/ XXX I-GENE
CRP2 XXX I-GENE
protein XXX I-GENE
has XXX O
two XXX O
LIM XXX B-GENE
domains XXX I-GENE
, XXX O
and XXX O
each XXX O
shares XXX O
35 XXX O
. XXX O
1% XXX O
and XXX O
77 XXX O
or XXX O
79% XXX O
identical XXX O
residues XXX O
with XXX O
human XXX B-GENE
cysteine-rich XXX I-GENE
protein XXX I-GENE
( XXX O
CRP XXX B-GENE
) XXX O
and XXX O
rat XXX B-GENE
CRIP XXX I-GENE
, XXX O
respectively XXX O
. XXX O

Human XXX O
recombinant XXX O
DNA-derived XXX O
antihemophilic XXX B-GENE
factor XXX I-GENE
( XXX O
factor XXX B-GENE
VIII XXX I-GENE
) XXX O
in XXX O
the XXX O
treatment XXX O
of XXX O
hemophilia XXX O
A XXX O
. XXX O
recombinant XXX O
Factor XXX B-GENE
VIII XXX I-GENE
Study XXX O
Group XXX O
. XXX O

However XXX O
, XXX O
patients XXX O
with XXX O
isolated XXX O
office XXX O
hypertension XXX O
had XXX O
fewer XXX O
previous XXX O
cardiovascular XXX O
complications XXX O
. XXX O

Sequence XXX O
analysis XXX O
indicates XXX O
that XXX O
in XXX O
addition XXX O
to XXX O
an XXX O
ATA XXX O
and XXX O
GC XXX O
box XXX O
, XXX O
this XXX O
region XXX O
contains XXX O
domains XXX O
that XXX O
have XXX O
been XXX O
implicated XXX O
in XXX O
the XXX O
regulation XXX O
of XXX O
other XXX O
muscle-specific XXX O
genes XXX O
: XXX O
a XXX O
CArG XXX O
box XXX O
at XXX O
-91 XXX O
bp XXX O
; XXX O
myocyte-specific XXX B-GENE
enhancer-binding XXX I-GENE
nuclear XXX I-GENE
factor XXX I-GENE
1 XXX I-GENE
binding XXX I-GENE
site XXX I-GENE
homologies XXX O
at XXX O
-58 XXX O
, XXX O
-535 XXX O
, XXX O
and XXX O
-583 XXX O
bp XXX O
; XXX O
and XXX O
a XXX O
muscle-CAAT XXX O
consensus XXX O
sequence XXX O
at XXX O
-394 XXX O
bp XXX O
relative XXX O
to XXX O
the XXX O
cap XXX O
site XXX O
. XXX O

Feed XXX O
intake XXX O
and XXX O
BW XXX O
gains XXX O
were XXX O
decreased XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
by XXX O
dietary XXX O
treatments XXX O
containing XXX O
M XXX O
. XXX O

In XXX O
nondiabetics XXX O
the XXX O
response XXX O
of XXX O
tcPO2 XXX O
but XXX O
not XXX O
of XXX O
LDF XXX O
was XXX O
influenced XXX O
by XXX O
the XXX O
values XXX O
at XXX O
rest XXX O
. XXX O

The XXX O
expression XXX O
of XXX O
ERV3 XXX B-GENE
env XXX I-GENE
mRNA XXX I-GENE
was XXX O
found XXX O
to XXX O
be XXX O
differentiation-associated XXX O
, XXX O
with XXX O
high XXX O
expression XXX O
detected XXX O
in XXX O
the XXX O
late XXX O
stages XXX O
of XXX O
monocytic XXX O
development XXX O
. XXX O

Phenylephrine XXX O
is XXX O
a XXX O
pure XXX O
alpha-1 XXX B-GENE
adrenoreceptor XXX I-GENE
agonist XXX O
known XXX O
to XXX O
produce XXX O
marked XXX O
systemic XXX O
vasoconstriction XXX O
and XXX O
associated XXX O
hypertension XXX O
with XXX O
occasional XXX O
profound XXX O
reflex XXX O
bradycardia XXX O
. XXX O

Before XXX O
turnout XXX O
, XXX O
a XXX O
morantel XXX O
sustained XXX O
release XXX O
bolus XXX O
( XXX O
MSRB XXX O
) XXX O
was XXX O
administered XXX O
to XXX O
each XXX O
animal XXX O
in XXX O
the XXX O
"treated" XXX O
category XXX O
. XXX O

Similar XXX O
waves XXX O
were XXX O
seen XXX O
on XXX O
cross-correlating XXX O
a XXX O
motor XXX O
unit XXX O
with XXX O
an XXX O
electronic XXX O
oscillator XXX O
, XXX O
confirming XXX O
that XXX O
their XXX O
occurrence XXX O
does XXX O
not XXX O
necessarily XXX O
demonstrate XXX O
the XXX O
existence XXX O
of XXX O
active XXX O
neural XXX O
interactions XXX O
. XXX O

Another XXX O
sequence XXX O
, XXX O
GGGXGGAG XXX B-GENE
, XXX O
which XXX O
is XXX O
repeated XXX O
several XXX O
times XXX O
in XXX O
many XXX O
polyomaviruses XXX O
and XXX O
adenoviruses XXX O
, XXX O
and XXX O
which XXX O
is XXX O
thought XXX O
to XXX O
play XXX O
a XXX O
role XXX O
in XXX O
DNA XXX O
replication XXX O
and XXX O
/ XXX O
or XXX O
transcription XXX O
, XXX O
is XXX O
not XXX O
found XXX O
in XXX O
the XXX O
JCV XXX B-GENE
sequence XXX I-GENE
presented XXX O
. XXX O

Five XXX O
patients XXX O
developed XXX O
metastatic XXX O
spread XXX O
, XXX O
and XXX O
all XXX O
of XXX O
them XXX O
died XXX O
of XXX O
tumor XXX O
. XXX O

A XXX O
study XXX O
of XXX O
human XXX O
genes XXX O
coding XXX O
for XXX O
U4 XXX B-GENE
small XXX I-GENE
nuclear XXX I-GENE
RNA XXX I-GENE
is XXX O
presented XXX O
. XXX O

A XXX O
cAMP XXX B-GENE
response XXX I-GENE
element XXX I-GENE
( XXX O
CRE XXX B-GENE
) XXX O
consensus XXX O
signal XXX O
was XXX O
identified XXX O
in XXX O
the XXX O
5'-noncoding XXX O
region XXX O
. XXX O
cAMP XXX O
regulates XXX O
the XXX O
expression XXX O
of XXX O
Kv1 XXX B-GENE
. XXX I-GENE
5 XXX I-GENE
gene XXX I-GENE
in XXX O
a XXX O
cell-specific XXX O
manner XXX O
. XXX O

A XXX O
hypothesis XXX O
. XXX O

Acute XXX O
decrease XXX O
in XXX O
body XXX O
temperature XXX O
( XXX O
TB XXX O
) XXX O
lowered XXX O
PaCO2 XXX O
( XXX O
32 XXX O
. XXX O
5 XXX O
to XXX O
14 XXX O
. XXX O
5 XXX O
mmHg XXX O
) XXX O
and XXX O
[ XXX O
HCO3- XXX O
] XXX O
a XXX O
( XXX O
24 XXX O
. XXX O
20 XXX O
mEq XXX O
/ XXX O
L XXX O
to XXX O
17 XXX O
. XXX O
56 XXX O
mEq XXX O
/ XXX O
L XXX O
) XXX O
, XXX O
increased XXX O
pHa XXX O
( XXX O
7 XXX O
. XXX O
481 XXX O
to XXX O
7 XXX O
. XXX O
608 XXX O
) XXX O
and XXX O
diminished XXX O
the XXX O
[ XXX O
OH- XXX O
] XXX O
/ XXX O
[ XXX O
H+ XXX O
] XXX O
ratio XXX O
, XXX O
but XXX O
had XXX O
no XXX O
significant XXX O
effect XXX O
on XXX O
[ XXX O
SID XXX O
] XXX O
or XXX O
[ XXX O
Atot XXX O
] XXX O
, XXX O
although XXX O
both XXX O
total XXX O
phosphorus XXX O
[ XXX O
PT XXX O
] XXX O
and XXX O
inorganic XXX O
phosphate XXX O
[ XXX O
Pi XXX O
] XXX O
increased XXX O
. XXX O

However XXX O
, XXX O
the XXX O
truncated XXX O
deer XXX B-GENE
receptor XXX I-GENE
lacks XXX O
the XXX O
most XXX O
C-terminal XXX O
tyrosine XXX O
residue XXX O
in XXX O
the XXX O
intracellular XXX O
domain XXX O
which XXX O
is XXX O
believed XXX O
to XXX O
be XXX O
essential XXX O
for XXX O
activation XXX O
of XXX O
the XXX O
beta-casein XXX B-GENE
promoter XXX I-GENE
. XXX O

As XXX O
a XXX O
complement XXX O
to XXX O
genome-wide XXX O
mapping XXX O
and XXX O
sequencing XXX O
efforts XXX O
, XXX O
it XXX O
is XXX O
often XXX O
important XXX O
to XXX O
generate XXX O
detailed XXX O
maps XXX O
and XXX O
sequence XXX O
data XXX O
for XXX O
specific XXX O
regions XXX O
of XXX O
interest XXX O
. XXX O

Rats XXX O
underwent XXX O
either XXX O
a XXX O
90-95% XXX O
JIB XXX O
or XXX O
a XXX O
sham XXX O
operation XXX O
. XXX O

Ig XXX B-GENE
D-JH XXX I-GENE
recombinations XXX O
may XXX O
precede XXX O
TcR XXX B-GENE
gene XXX I-GENE
recombination XXX O
in XXX O
these XXX O
early XXX O
T XXX O
cell XXX O
lines XXX O
, XXX O
and XXX O
some XXX O
but XXX O
not XXX O
all XXX O
express XXX O
sterile XXX O
Cmu XXX B-GENE
transcripts XXX I-GENE
. XXX O

We XXX O
have XXX O
previously XXX O
shown XXX O
that XXX O
ARNO XXX B-GENE
localizes XXX O
to XXX O
the XXX O
plasma XXX O
membrane XXX O
in XXX O
vivo XXX O
and XXX O
efficiently XXX O
catalyzes XXX O
ARF6 XXX B-GENE
nucleotide XXX O
exchange XXX O
in XXX O
vitro XXX O
. XXX O

In XXX O
contrast XXX O
, XXX O
the XXX O
contractile XXX O
action XXX O
of XXX O
arachidonic XXX O
acid XXX O
, XXX O
via XXX O
a XXX O
presumed XXX O
cyclooxygenase XXX B-GENE
product XXX O
that XXX O
mediated XXX O
the XXX O
contractions XXX O
caused XXX O
by XXX O
both XXX O
TF XXX B-GENE
and XXX O
EGF XXX B-GENE
, XXX O
was XXX O
not XXX O
blocked XXX O
by XXX O
any XXX O
of XXX O
the XXX O
signal XXX O
pathway XXX O
probe XXX O
inhibitors XXX O
. XXX O

Among XXX O
these XXX O
, XXX O
ACT1 XXX B-GENE
was XXX O
isolated XXX O
four XXX O
times XXX O
, XXX O
and XXX O
NSR1 XXX B-GENE
three XXX O
times XXX O
. XXX O

An XXX O
unusual XXX O
feature XXX O
of XXX O
these XXX O
replicative XXX O
genes XXX O
is XXX O
that XXX O
the XXX O
smaller XXX O
mRNA XXX O
begins XXX O
within XXX O
a XXX O
long XXX O
open XXX O
reading XXX O
frame XXX O
of XXX O
the XXX O
larger XXX O
mRNA XXX O
. XXX O

LDL XXX O
cholesterol XXX O
decreased XXX O
from XXX O
4 XXX O
. XXX O
74 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
87 XXX O
to XXX O
3 XXX O
. XXX O
78 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
78 XXX O
mmol XXX O
/ XXX O
l XXX O
after XXX O
8 XXX O
weeks XXX O
on XXX O
simvastatin XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
001 XXX O
) XXX O
, XXX O
and XXX O
apo XXX B-GENE
B XXX I-GENE
fell XXX O
from XXX O
142 XXX O
+ XXX O
/ XXX O
- XXX O
31 XXX O
to XXX O
112 XXX O
+ XXX O
/ XXX O
- XXX O
22 XXX O
mg XXX O
/ XXX O
dl XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
001 XXX O
) XXX O
. XXX O

Defective XXX O
provirus XXX O
genomes XXX O
of XXX O
human XXX O
T-cell XXX O
leukemia XXX O
virus XXX O
type XXX O
I XXX O
are XXX O
frequently XXX O
detected XXX O
in XXX O
lymphocytes XXX O
from XXX O
infected XXX O
individuals XXX O
and XXX O
in XXX O
infected XXX O
cell XXX O
lines XXX O
. XXX O

Further XXX O
, XXX O
we XXX O
show XXX O
that XXX O
this XXX O
EIA-inducible XXX B-GENE
CBF XXX I-GENE
/ XXX I-GENE
cdc2 XXX I-GENE
is XXX O
related XXX O
to XXX O
the XXX O
CBF XXX B-GENE
which XXX O
was XXX O
shown XXX O
to XXX O
activate XXX O
the XXX O
heat XXX B-GENE
shock XXX I-GENE
protein XXX I-GENE
70 XXX I-GENE
promoter XXX I-GENE
. XXX O

This XXX O
result XXX O
suggested XXX O
that XXX O
mutant XXX B-GENE
I299 XXX I-GENE
has XXX O
diminished XXX O
cap-binding XXX O
activity XXX O
. XXX O

The XXX O
volume XXX O
of XXX O
blood XXX O
to XXX O
the XXX O
flap XXX O
ranges XXX O
from XXX O
1 XXX O
to XXX O
2 XXX O
ml XXX O
/ XXX O
min XXX O
, XXX O
collateral XXX O
circulation XXX O
to XXX O
the XXX O
flap XXX O
exists XXX O
, XXX O
but XXX O
is XXX O
negligible XXX O
, XXX O
and XXX O
there XXX O
is XXX O
little XXX O
change XXX O
in XXX O
the XXX O
capillary XXX O
blood XXX O
flow XXX O
as XXX O
the XXX O
flap XXX O
ages XXX O
. XXX O

Serum XXX O
induction XXX O
of XXX O
a XXX O
MEF2 XXX B-GENE
reporter XXX I-GENE
gene XXX I-GENE
was XXX O
not XXX O
observed XXX O
in XXX O
a XXX O
line XXX O
of XXX O
NIH XXX O
3T3 XXX O
cells XXX O
which XXX O
contain XXX O
low XXX O
MEF2 XXX B-GENE
site XXX I-GENE
binding XXX O
activity XXX O
. XXX O

The XXX O
rate XXX O
of XXX O
resectability XXX O
is XXX O
low XXX O
and XXX O
5-year XXX O
survival XXX O
is XXX O
very XXX O
poor XXX O
. XXX O

A XXX O
simple XXX O
registration XXX O
as XXX O
an XXX O
incentive XXX O
for XXX O
improvement XXX O
. XXX O

Effects XXX O
of XXX O
a XXX O
selective XXX O
monoamine XXX B-GENE
oxidase XXX I-GENE
( XXX I-GENE
MAO XXX I-GENE
) XXX I-GENE
--A XXX I-GENE
inhibitor XXX O
, XXX O
clorgyline XXX O
, XXX O
a XXX O
selective XXX O
MAO-B XXX B-GENE
inhibitor XXX O
, XXX O
deprenyl XXX O
, XXX O
and XXX O
a XXX O
non-selective XXX O
MAO XXX B-GENE
inhibitor XXX O
, XXX O
nialamide XXX O
, XXX O
were XXX O
investigated XXX O
on XXX O
footshock-induced XXX O
aggression XXX O
( XXX O
FIA XXX O
) XXX O
in XXX O
paired XXX O
rats XXX O
. XXX O

IFI XXX B-GENE
16 XXX I-GENE
mRNA XXX I-GENE
was XXX O
found XXX O
to XXX O
be XXX O
constitutively XXX O
expressed XXX O
in XXX O
lymphoid XXX O
cells XXX O
and XXX O
in XXX O
cell XXX O
lines XXX O
of XXX O
both XXX O
the XXX O
T XXX O
and XXX O
B XXX O
lineages XXX O
. XXX O

1- XXX O
( XXX O
1-Naphthyl XXX O
) XXX O
piperazine XXX O
( XXX O
1-NP XXX O
) XXX O
has XXX O
been XXX O
reported XXX O
to XXX O
have XXX O
serotonin XXX O
antagonist XXX O
properties XXX O
at XXX O
the XXX O
5-HT2 XXX B-GENE
subtype XXX I-GENE
of XXX O
receptor XXX O
, XXX O
and XXX O
it XXX O
has XXX O
been XXX O
suggested XXX O
that XXX O
it XXX O
may XXX O
have XXX O
agonist XXX O
actions XXX O
at XXX O
the XXX O
5-HT1 XXX B-GENE
site XXX I-GENE
. XXX O

"In XXX O
vitro" XXX O
study XXX O
of XXX O
dentin XXX B-GENE
adhesion XXX O
to XXX O
adhesives XXX O
made XXX O
from XXX O
urethane XXX O
molecules XXX O
with XXX O
free XXX O
groups XXX O
of XXX O
isocyanate XXX O
. XXX O

RESULTS XXX O
: XXX O
The XXX O
LV XXX O
maximum XXX O
brightness XXX O
and XXX O
area XXX O
under XXX O
the XXX O
curve XXX O
showed XXX O
significant XXX O
negative XXX O
correlations XXX O
( XXX O
p XXX O
= XXX O
< XXX O
0 XXX O
. XXX O
004 XXX O
) XXX O
with XXX O
the XXX O
FIO2 XXX O
, XXX O
while XXX O
the XXX O
minimum XXX O
brightness XXX O
showed XXX O
a XXX O
significant XXX O
positive XXX O
correlation XXX O
( XXX O
p XXX O
= XXX O
< XXX O
0 XXX O
. XXX O
002 XXX O
) XXX O
. XXX O

Both XXX O
HEF1 XXX B-GENE
and XXX O
Cas XXX B-GENE
were XXX O
found XXX O
to XXX O
complex XXX O
with XXX O
the XXX O
related XXX B-GENE
adhesion XXX I-GENE
focal XXX I-GENE
tyrosine XXX I-GENE
kinase XXX I-GENE
( XXX O
RAFTK XXX B-GENE
) XXX O
, XXX O
and XXX O
when XXX O
tyrosine XXX O
phosphorylated XXX O
, XXX O
with XXX O
the XXX O
adapter XXX O
molecule XXX O
CrkL XXX B-GENE
. XXX O

Statistical XXX O
analysis XXX O
of XXX O
the XXX O
degrees XXX O
of XXX O
secondary XXX O
spinal XXX O
cord XXX O
compression XXX O
was XXX O
performed XXX O
in XXX O
group-1 XXX O
dogs XXX O
by XXX O
measuring XXX O
and XXX O
comparing XXX O
ratios XXX O
of XXX O
the XXX O
vertical XXX O
to XXX O
the XXX O
horizontal XXX O
diameters XXX O
of XXX O
the XXX O
transverse XXX O
spinal XXX O
cord XXX O
sections XXX O
from XXX O
locations XXX O
within XXX O
( XXX O
T12 XXX O
to XXX O
L1 XXX O
) XXX O
and XXX O
out XXX O
of XXX O
( XXX O
T11 XXX O
, XXX O
T11-12 XXX O
, XXX O
L1-2 XXX O
, XXX O
and XXX O
L2 XXX O
) XXX O
the XXX O
region XXX O
of XXX O
surgical XXX O
intervention XXX O
. XXX O

The XXX O
nucleotide XXX O
sequences XXX O
of XXX O
the XXX O
human XXX B-GENE
and XXX I-GENE
murine XXX I-GENE
ornithine XXX I-GENE
decarboxylase XXX I-GENE
mRNAs XXX I-GENE
share XXX O
an XXX O
85% XXX O
homology XXX O
, XXX O
even XXX O
in XXX O
their XXX O
3'-noncoding XXX O
regions XXX O
. XXX O

These XXX O
studies XXX O
show XXX O
that XXX O
UCRBP XXX B-GENE
binds XXX O
to XXX O
various XXX O
target XXX O
motifs XXX O
that XXX O
are XXX O
distinct XXX O
from XXX O
the XXX O
UCR XXX B-GENE
motif XXX I-GENE
: XXX O
the XXX O
adeno-associated XXX B-GENE
virus XXX I-GENE
P5 XXX I-GENE
promoter XXX I-GENE
and XXX O
elements XXX O
in XXX O
the XXX O
immunoglobulin XXX B-GENE
light- XXX I-GENE
and XXX I-GENE
heavy-chain XXX I-GENE
genes XXX I-GENE
, XXX O
as XXX O
well XXX O
as XXX O
elements XXX O
in XXX O
ribosomal XXX B-GENE
protein XXX I-GENE
genes XXX I-GENE
. XXX O

Using XXX O
5'RACE XXX O
and XXX O
reverse XXX O
transcription-PCR XXX O
( XXX O
RT-PCR XXX O
) XXX O
methodologies XXX O
, XXX O
we XXX O
cloned XXX O
these XXX O
sequences XXX O
from XXX O
brain XXX O
and XXX O
placenta XXX O
and XXX O
found XXX O
this XXX O
material XXX O
to XXX O
be XXX O
composed XXX O
of XXX O
alternatively XXX O
spliced XXX O
exons XXX O
using XXX O
a XXX O
previously XXX O
reported XXX O
noncoding XXX B-GENE
exon XXX I-GENE
( XXX I-GENE
1A XXX I-GENE
) XXX I-GENE
and XXX O
a XXX O
novel XXX O
97-bp XXX B-GENE
noncoding XXX I-GENE
exon XXX I-GENE
( XXX I-GENE
1B XXX I-GENE
) XXX I-GENE
. XXX O

PACAP XXX B-GENE
mRNA XXX I-GENE
was XXX O
widely XXX O
expressed XXX O
in XXX O
most XXX O
human XXX O
tissues XXX O
; XXX O
in XXX O
transfected XXX O
cells XXX O
, XXX O
PACAP XXX B-GENE
was XXX O
diffusely XXX O
expressed XXX O
in XXX O
the XXX O
cytoplasm XXX O
. XXX O

Malignant XXX O
lymphoma XXX O
is XXX O
very XXX O
heterogeneous XXX O
in XXX O
terms XXX O
of XXX O
its XXX O
biological XXX O
behavior XXX O
. XXX O

Number XXX O
and XXX O
size XXX O
of XXX O
silver-stained XXX O
nucleoli XXX O
( XXX O
Ag-NOR XXX O
clusters XXX O
) XXX O
in XXX O
canine XXX O
seminomas XXX O
: XXX O
correlation XXX O
with XXX O
histological XXX O
features XXX O
and XXX O
tumour XXX O
behaviour XXX O
. XXX O

These XXX O
data XXX O
further XXX O
define XXX O
a XXX O
role XXX O
for XXX O
TRADD XXX B-GENE
and XXX O
TRAF2 XXX B-GENE
in XXX O
JNK XXX B-GENE
activation XXX O
and XXX O
confirm XXX O
that XXX O
LMP1 XXX B-GENE
utilizes XXX O
signalling XXX O
mechanisms XXX O
used XXX O
by XXX O
the XXX O
TNF XXX B-GENE
receptor XXX I-GENE
/ XXX I-GENE
CD40 XXX I-GENE
family XXX I-GENE
to XXX O
elicit XXX O
its XXX O
pleiotropic XXX O
activities XXX O
. XXX O

Biologically XXX O
significant XXX O
amounts XXX O
of XXX O
platelet XXX B-GENE
activating XXX I-GENE
factor XXX I-GENE
were XXX O
eluted XXX O
from XXX O
the XXX O
sorbent XXX O
during XXX O
the XXX O
entire XXX O
treatment XXX O
time XXX O
. XXX O

H19 XXX B-GENE
and XXX O
Igf2 XXX B-GENE
monoallelic XXX O
expression XXX O
is XXX O
regulated XXX O
in XXX O
two XXX O
distinct XXX O
ways XXX O
by XXX O
a XXX O
shared XXX O
cis XXX O
acting XXX O
regulatory XXX O
region XXX O
upstream XXX O
of XXX O
H19 XXX B-GENE
. XXX O

Recombination XXX O
, XXX O
replication XXX O
, XXX O
repair XXX O
: XXX O
from XXX O
complexity XXX O
to XXX O
harmony XXX O
. XXX O

Elevated XXX O
expression XXX O
of XXX O
full-length XXX B-GENE
UhpB XXX I-GENE
or XXX O
of XXX O
a XXX O
soluble XXX O
hybrid XXX O
protein XXX O
, XXX O
GST-Bc XXX B-GENE
, XXX O
which XXX O
is XXX O
glutathione XXX B-GENE
S-transferase XXX I-GENE
( XXX O
GST XXX B-GENE
) XXX O
fused XXX O
to XXX O
the XXX O
cytoplasmic XXX O
C-terminal XXX O
portion XXX O
of XXX O
UhpB XXX B-GENE
, XXX O
results XXX O
in XXX O
complete XXX O
blockage XXX O
of XXX O
uhpT XXX B-GENE
expression XXX O
in XXX O
a XXX O
uhp XXX B-GENE
( XXX I-GENE
+ XXX I-GENE
) XXX I-GENE
strain XXX O
. XXX O

Apoptosis XXX O
of XXX O
small XXX O
cells XXX O
is XXX O
still XXX O
observed XXX O
after XXX O
co-transfection XXX O
of XXX O
JBD XXX B-GENE
and XXX O
LMP1 XXX B-GENE
but XXX O
in XXX O
addition XXX O
a XXX O
few XXX O
apoptotic XXX O
HD-MyZ XXX O
cells XXX O
with XXX O
large XXX O
fused XXX O
nuclear XXX O
masses XXX O
are XXX O
identified XXX O
suggesting XXX O
that XXX O
specific XXX O
inhibition XXX O
of XXX O
JNK XXX B-GENE
leads XXX O
also XXX O
to XXX O
apoptosis XXX O
of XXX O
LMP1 XXX B-GENE
induced XXX O
RS XXX O
cells XXX O
. XXX O

Recombination XXX O
between XXX O
feline XXX O
leukemia XXX O
virus XXX O
subgroup XXX O
B XXX O
or XXX O
C XXX O
and XXX O
endogenous XXX O
env XXX B-GENE
elements XXX O
alters XXX O
the XXX O
in XXX O
vitro XXX O
biological XXX O
activities XXX O
of XXX O
the XXX O
viruses XXX O
. XXX O

Propranolol XXX O
( XXX O
Inderal XXX O
) XXX O
administered XXX O
in XXX O
a XXX O
dose XXX O
which XXX O
blocks XXX O
the XXX O
beta-adrenergic XXX O
apparatus XXX O
of XXX O
the XXX O
heart XXX O
prevents XXX O
the XXX O
development XXX O
of XXX O
the XXX O
positive XXX O
inotropic XXX O
effect XXX O
of XXX O
therapeutic XXX O
doses XXX O
of XXX O
strophanthin XXX O
K XXX O
on XXX O
a XXX O
hypodynamic XXX O
left XXX O
ventricular XXX O
myocardium XXX O
. XXX O

Multivariate XXX O
logistic XXX O
regression XXX O
analysis XXX O
indicated XXX O
that XXX O
seropositivity XXX O
was XXX O
strongly XXX O
associated XXX O
with XXX O
the XXX O
prevalence XXX O
of XXX O
hepatitis XXX O
B XXX O
in XXX O
an XXX O
employee's XXX O
country XXX O
of XXX O
birth XXX O
and XXX O
with XXX O
age XXX O
. XXX O

In XXX O
the XXX O
rat XXX B-GENE
rnu XXX I-GENE
allele XXX I-GENE
described XXX O
here XXX O
, XXX O
a XXX O
nonsense XXX O
mutation XXX O
in XXX O
exon XXX O
8 XXX O
of XXX O
the XXX O
whn XXX B-GENE
gene XXX I-GENE
was XXX O
identified XXX O
. XXX O

The XXX O
present XXX O
study XXX O
investigated XXX O
dose XXX O
dependence XXX O
and XXX O
time XXX O
course XXX O
effects XXX O
of XXX O
the XXX O
benzodiazepine XXX O
( XXX O
BDZ XXX O
) XXX O
partial XXX O
inverse XXX O
agonist XXX O
, XXX O
RO19-4603 XXX O
( XXX O
0 XXX O
. XXX O
005-0 XXX O
. XXX O
30 XXX O
mg XXX O
/ XXX O
kg XXX O
) XXX O
alone XXX O
, XXX O
and XXX O
in XXX O
combination XXX O
with XXX O
the XXX O
BDZ XXX B-GENE
receptor XXX I-GENE
antagonists XXX O
flumazenil XXX O
, XXX O
ZK XXX O
93426 XXX O
, XXX O
and XXX O
CGS XXX O
8216 XXX O
( XXX O
20 XXX O
mg XXX O
/ XXX O
kg XXX O
) XXX O
in XXX O
selectively XXX O
bred XXX O
alcohol-preferring XXX O
( XXX O
P XXX O
) XXX O
rats XXX O
provided XXX O
a XXX O
two-bottle XXX O
choice XXX O
test XXX O
between XXX O
ethanol XXX O
( XXX O
EtOH XXX O
) XXX O
( XXX O
10% XXX O
v XXX O
/ XXX O
v XXX O
) XXX O
, XXX O
and XXX O
a XXX O
palatable XXX O
saccharin XXX O
( XXX O
0 XXX O
. XXX O
0125% XXX O
g XXX O
/ XXX O
v XXX O
) XXX O
solution XXX O
. XXX O

Similar XXX O
memory XXX O
impairments XXX O
found XXX O
in XXX O
medial XXX O
septal-vertical XXX O
diagonal XXX O
band XXX O
of XXX O
Broca XXX O
and XXX O
nucleus XXX O
basalis XXX O
lesioned XXX O
rats XXX O
: XXX O
are XXX O
memory XXX O
defects XXX O
induced XXX O
by XXX O
nucleus XXX O
basalis XXX O
lesions XXX O
related XXX O
to XXX O
the XXX O
degree XXX O
of XXX O
non-specific XXX O
subcortical XXX O
cell XXX O
loss XXX O
? XXX O
The XXX O
function XXX O
of XXX O
nucleus XXX O
basalis XXX O
( XXX O
NB XXX O
) XXX O
and XXX O
medial XXX O
septal-vertical XXX O
diagonal XXX O
band XXX O
of XXX O
Broca XXX O
( XXX O
MS-VDBB XXX O
) XXX O
in XXX O
a XXX O
place XXX O
navigation XXX O
task XXX O
requiring XXX O
reference XXX O
memory XXX O
was XXX O
investigated XXX O
. XXX O

The XXX O
carcinogen XXX O
bioassay XXX O
therefore XXX O
is XXX O
a XXX O
very XXX O
important XXX O
component XXX O
of XXX O
the XXX O
battery XXX O
of XXX O
toxicological XXX O
tests XXX O
used XXX O
in XXX O
hazard XXX O
evaluation XXX O
. XXX O

Four XXX O
p53 XXX B-GENE
DNA-binding XXX I-GENE
domain XXX I-GENE
peptides XXX I-GENE
bind XXX O
natural XXX O
p53-response XXX B-GENE
elements XXX I-GENE
and XXX O
bend XXX O
the XXX O
DNA XXX O
. XXX O

Bitter XXX O
cassava XXX O
contains XXX O
cyanogenic XXX O
glycosides XXX O
; XXX O
processing XXX O
breaks XXX O
them XXX O
down XXX O
to XXX O
acetone XXX O
cyanohydrin XXX O
and XXX O
hydrogen XXX O
cyanide XXX O
. XXX O

RESULTS XXX O
: XXX O
Average XXX O
age XXX O
at XXX O
symptom XXX O
onset XXX O
was XXX O
41 XXX O
. XXX O
2 XXX O
years XXX O
. XXX O

The XXX O
fragments XXX O
of XXX O
each XXX O
region XXX O
were XXX O
amplified XXX O
by XXX O
polymerase XXX B-GENE
chain XXX O
reaction XXX O
and XXX O
analyzed XXX O
by XXX O
gel XXX O
electrophoresis XXX O
to XXX O
detect XXX O
single-strand XXX O
conformation XXX O
polymorphism XXX O
. XXX O

Two XXX O
out XXX O
of XXX O
five XXX O
patients XXX O
undergoing XXX O
selective XXX O
spinal XXX O
arteriography XXX O
developed XXX O
transient XXX O
neurological XXX O
complications XXX O
during XXX O
the XXX O
injection XXX O
of XXX O
Urografin XXX O
310 XXX O
M XXX O
. XXX O

To XXX O
investigate XXX O
the XXX O
molecular XXX O
mechanisms XXX O
of XXX O
this XXX O
Tax-mediated XXX O
inhibition XXX O
, XXX O
we XXX O
analyzed XXX O
its XXX O
effect XXX O
on XXX O
the XXX O
transcriptional XXX O
activity XXX O
of XXX O
the XXX O
myogenic XXX O
MyoD XXX B-GENE
protein XXX I-GENE
, XXX O
which XXX O
was XXX O
used XXX O
as XXX O
a XXX O
paradigm XXX O
of XXX O
bHLH XXX B-GENE
factors XXX I-GENE
. XXX O

When XXX O
the XXX O
73-bp XXX O
fragment XXX O
was XXX O
fused XXX O
to XXX O
an XXX O
alpha1-globin XXX B-GENE
promoter-CAT XXX I-GENE
construct XXX I-GENE
and XXX O
cotransfected XXX O
with XXX O
CCAAT XXX B-GENE
transcription XXX I-GENE
factor XXX I-GENE
1 XXX I-GENE
( XXX O
CTF1 XXX B-GENE
) XXX O
/ XXX B-GENE
NF1 XXX I-GENE
into XXX O
Drosophila XXX O
Schneider XXX O
SL2 XXX O
insect XXX O
cells XXX O
( XXX O
which XXX O
lack XXX O
NF1-like XXX B-GENE
proteins XXX I-GENE
) XXX O
trans-activation XXX O
of XXX O
CAT XXX B-GENE
activity XXX O
was XXX O
observed XXX O
. XXX O

The XXX O
deubiquitinating XXX O
enzyme XXX O
DUB-2 XXX B-GENE
is XXX O
induced XXX O
in XXX O
response XXX O
to XXX O
IL-2 XXX B-GENE
but XXX O
as XXX O
yet XXX O
its XXX O
function XXX O
has XXX O
not XXX O
been XXX O
determined XXX O
. XXX O

Occupational XXX O
asthma XXX O
and XXX O
rhinoconjunctivitis XXX O
from XXX O
inhalation XXX O
of XXX O
crystalline XXX O
bovine XXX B-GENE
serum XXX I-GENE
albumin XXX I-GENE
powder XXX O
. XXX O

The XXX O
relative XXX O
abundance XXX O
of XXX O
each XXX O
alternatively XXX O
spliced XXX O
mRNA XXX O
was XXX O
determined XXX O
by XXX O
reverse XXX O
transcription-polymerase XXX O
chain XXX O
reaction XXX O
in XXX O
various XXX O
human XXX O
tissues XXX O
and XXX O
cell XXX O
lines XXX O
. XXX O

Expression XXX O
of XXX O
this XXX O
cDNA XXX O
in XXX O
vitro XXX O
yields XXX O
a XXX O
peptide XXX O
which XXX O
comigrates XXX O
with XXX O
natural XXX B-GENE
eIF-2B XXX I-GENE
alpha XXX I-GENE
in XXX O
SDS XXX O
/ XXX O
polyacrylamide XXX O
gels XXX O
. XXX O

Drosophila XXX B-GENE
Menin1 XXX I-GENE
gene XXX I-GENE
transcripts XXX I-GENE
use XXX O
alternative XXX O
polyadenylation XXX O
sites XXX O
resulting XXX O
in XXX O
4 XXX O
. XXX O
3 XXX O
and XXX O
5-kb XXX O
messages XXX O
. XXX O

Dopamine XXX O
SERS XXX O
spectra XXX O
from XXX O
these XXX O
electrodes XXX O
are XXX O
similar XXX O
to XXX O
those XXX O
obtained XXX O
at XXX O
uncoated XXX O
electrodes XXX O
. XXX O

Lead XXX O
fixation XXX O
in XXX O
dogs XXX O
achieved XXX O
with XXX O
RF XXX O
energy XXX O
. XXX O

The XXX O
importance XXX O
of XXX O
posttranslational XXX O
regulation XXX O
of XXX O
p15INK4B XXX B-GENE
by XXX O
TGF-beta XXX B-GENE
is XXX O
underlined XXX O
by XXX O
the XXX O
observation XXX O
that XXX O
in XXX O
TGF-beta-resistant XXX O
184A1L5R XXX O
, XXX O
although XXX O
the XXX O
p15 XXX B-GENE
transcript XXX I-GENE
increased XXX O
, XXX O
p15INK4B XXX B-GENE
protein XXX I-GENE
was XXX O
not XXX O
stabilized XXX O
and XXX O
did XXX O
not XXX O
accumulate XXX O
, XXX O
and XXX O
cyclin XXX B-GENE
D1-cdk XXX I-GENE
association XXX O
and XXX O
kinase XXX B-GENE
activation XXX O
were XXX O
not XXX O
inhibited XXX O
. XXX O

Further XXX O
, XXX O
the XXX O
osteo-retentive XXX O
ability XXX O
of XXX O
the XXX O
hydroxyapatite XXX O
in XXX O
the XXX O
sockets XXX O
was XXX O
seen XXX O
to XXX O
be XXX O
close XXX O
to XXX O
significance XXX O
( XXX O
after XXX O
six XXX O
months XXX O
width XXX O
differences XXX O
, XXX O
in XXX O
the XXX O
canine XXX O
region XXX O
: XXX O
P XXX O
= XXX O
0 XXX O
. XXX O
059 XXX O
, XXX O
LHS XXX O
, XXX O
and XXX O
P XXX O
= XXX O
0 XXX O
. XXX O
065 XXX O
, XXX O
RHS XXX O
) XXX O
. XXX O

After XXX O
7 XXX O
days XXX O
, XXX O
a XXX O
spontaneous XXX O
regression XXX O
of XXX O
the XXX O
morphologic XXX O
alterations XXX O
caused XXX O
by XXX O
caerulein-induced XXX O
acute XXX O
pancreatitis XXX O
occurs XXX O
; XXX O
however XXX O
, XXX O
recovery XXX O
of XXX O
the XXX O
secretory XXX O
function XXX O
of XXX O
the XXX O
pancreas XXX O
was XXX O
only XXX O
reached XXX O
after XXX O
this XXX O
period XXX O
of XXX O
time XXX O
when XXX O
L-364 XXX O
, XXX O
718 XXX O
was XXX O
administered XXX O
therapeutically XXX O
( XXX O
0 XXX O
. XXX O
1 XXX O
mg XXX O
/ XXX O
kg XXX O
/ XXX O
day XXX O
) XXX O
. XXX O

CONCLUSION XXX O
: XXX O
The XXX O
probability XXX O
of XXX O
cardiopulmonary XXX O
complications XXX O
increases XXX O
significantly XXX O
when XXX O
patients XXX O
develop XXX O
class XXX O
1 XXX O
HELLP XXX O
syndrome XXX O
. XXX O

Laboratory XXX O
studies XXX O
showed XXX O
that XXX O
the XXX O
direct XXX O
fluorescent-antibody XXX O
kits XXX O
were XXX O
the XXX O
least XXX O
sensitive XXX O
in XXX O
this XXX O
case XXX O
and XXX O
did XXX O
not XXX O
detect XXX O
fewer XXX O
than XXX O
10 XXX O
( XXX O
4 XXX O
) XXX O
elementary XXX O
bodies XXX O
per XXX O
ml XXX O
, XXX O
while XXX O
most XXX O
ELISA XXX O
kits XXX O
detected XXX O
between XXX O
130 XXX O
and XXX O
600 XXX O
elementary XXX O
bodies XXX O
per XXX O
ml XXX O
. XXX O

Sustained XXX O
activation XXX O
of XXX O
p21 XXX B-GENE
expression XXX O
is XXX O
proposed XXX O
to XXX O
be XXX O
a XXX O
distinguishing XXX O
feature XXX O
of XXX O
the XXX O
activity XXX O
of XXX O
NGF XXX B-GENE
that XXX O
contributes XXX O
to XXX O
PC12 XXX O
growth XXX O
arrest XXX O
during XXX O
differentiation XXX O

The XXX O
tryptase XXX B-GENE
locus XXX I-GENE
also XXX O
contains XXX O
at XXX O
least XXX O
four XXX O
tryptase-like XXX B-GENE
pseudogenes XXX I-GENE
, XXX O
including XXX O
mastin XXX B-GENE
, XXX O
a XXX O
gene XXX O
expressed XXX O
in XXX O
dogs XXX O
but XXX O
not XXX O
in XXX O
humans XXX O
. XXX O

Osteocalcin XXX B-GENE
( XXX O
and XXX O
urinary XXX O
hydroxyproline XXX O
) XXX O
were XXX O
not XXX O
elevated XXX O
in XXX O
isolated XXX O
hyperphosphatasaemia XXX O
, XXX O
indicating XXX O
that XXX O
mechanisms XXX O
other XXX O
than XXX O
increased XXX O
bone XXX O
turnover XXX O
may XXX O
account XXX O
for XXX O
the XXX O
markedly XXX O
elevated XXX O
serum XXX B-GENE
alkaline XXX I-GENE
phosphatase XXX I-GENE
activity XXX O
in XXX O
these XXX O
subjects XXX O
. XXX O

Possibilities XXX O
and XXX O
outlook XXX O
for XXX O
wrist XXX O
joint XXX O
endoprosthesis XXX O
. XXX O

Aberrant XXX O
protein XXX O
phosphorylation XXX O
at XXX O
tyrosine XXX O
is XXX O
responsible XXX O
for XXX O
the XXX O
growth-inhibitory XXX O
action XXX O
of XXX O
pp60v-src XXX B-GENE
expressed XXX O
in XXX O
the XXX O
yeast XXX O
Saccharomyces XXX O
cerevisiae XXX O
. XXX O

Acute XXX O
idiopathic XXX O
thrombocytopenic XXX O
purpura XXX O
presenting XXX O
a XXX O
high XXX O
serum XXX O
level XXX O
of XXX O
immunoglobulin XXX B-GENE
E XXX I-GENE
and XXX O
eosinophilia XXX O
in XXX O
an XXX O
elderly XXX O
patient XXX O
. XXX O

PrpB XXX B-GENE
showed XXX O
homology XXX O
to XXX O
carboxyphosphonoenolpyruvate XXX B-GENE
phosphonomutase XXX I-GENE
of XXX I-GENE
Streptomyces XXX I-GENE
hygroscopicus XXX I-GENE
and XXX O
to XXX O
its XXX O
homolog XXX O
in XXX O
the XXX O
carnation XXX O
Dianthus XXX O
caryophyllus XXX O
; XXX O
PrpC XXX B-GENE
was XXX O
homologous XXX O
to XXX O
both XXX O
archaeal XXX B-GENE
and XXX I-GENE
bacterial XXX I-GENE
citrate XXX I-GENE
synthases XXX I-GENE
; XXX O
PrpD XXX B-GENE
showed XXX O
homology XXX O
to XXX O
yeast XXX O
and XXX O
Bacillus XXX O
subtilis XXX O
proteins XXX O
of XXX O
unknown XXX O
function XXX O
; XXX O
PrpE XXX B-GENE
showed XXX O
homology XXX O
to XXX O
acetyl XXX B-GENE
coenzyme XXX I-GENE
A XXX I-GENE
synthetases XXX I-GENE
. XXX O

The XXX O
introduction XXX O
of XXX O
hARF4 XXX B-GENE
to XXX O
the XXX O
cells XXX O
maintained XXX O
the XXX O
balance XXX O
between XXX O
cytosolic XXX O
and XXX O
membrane-associated XXX O
Sec7p XXX B-GENE
pools XXX O
. XXX O

The XXX O
final XXX O
screening XXX O
yielded XXX O
a XXX O
clone XXX O
containing XXX O
a XXX O
2 XXX O
kilobase XXX O
( XXX O
kb XXX O
) XXX O
insert XXX O
. XXX O

METHODS XXX O
: XXX O
Twenty-two XXX O
patients XXX O
were XXX O
grouped XXX O
according XXX O
to XXX O
their XXX O
etiology XXX O
based XXX O
on XXX O
the XXX O
study XXX O
of XXX O
antiadrenal XXX O
antibodies XXX O
at XXX O
diagnosis XXX O
of XXX O
the XXX O
disease XXX O
: XXX O
7 XXX O
were XXX O
positive XXX O
( XXX O
autoimmune XXX O
etiology XXX O
or XXX O
EAA XXX O
) XXX O
, XXX O
11 XXX O
were XXX O
negative XXX O
( XXX O
tuberculous XXX O
etiology XXX O
or XXX O
EAT XXX O
) XXX O
and XXX O
in XXX O
four XXX O
serologic XXX O
study XXX O
was XXX O
not XXX O
available XXX O
( XXX O
undetermined XXX O
etiology XXX O
or XXX O
EAI XXX O
) XXX O
. XXX O

Antidromic XXX O
invasion XXX O
of XXX O
impulses XXX O
and XXX O
recurrent XXX O
collateral XXX O
inhibition XXX O
in XXX O
pyramidal XXX O
tract XXX O
neurones XXX O
. XXX O

Another XXX O
element XXX O
necessary XXX O
for XXX O
augmenting XXX O
the XXX O
amplitude XXX O
of XXX O
the XXX O
oscillation XXX O
lies XXX O
between XXX O
-178 XXX O
and XXX O
-264 XXX O
. XXX O

In XXX O
addition XXX O
to XXX O
restoring XXX O
checkpoint XXX O
control XXX O
, XXX O
overexpression XXX O
of XXX O
sum1+ XXX B-GENE
inhibits XXX O
the XXX O
normal XXX O
cell XXX O
cycle XXX O
response XXX O
to XXX O
osmotic XXX O
stress XXX O
. XXX O

For XXX O
higher XXX O
expression XXX O
of XXX O
lipA XXX B-GENE
in XXX O
S XXX O
. XXX O
lividans XXX O
, XXX O
the XXX O
gene XXX O
was XXX O
cloned XXX O
next XXX O
to XXX O
the XXX O
strong XXX O
aphII XXX B-GENE
promoter XXX I-GENE
. XXX O

Six XXX O
of XXX O
the XXX O
gstC' XXX B-GENE
mutants XXX I-GENE
, XXX O
primarily XXX O
in XXX O
the XXX O
C-terminal XXX O
half XXX O
of XXX O
C' XXX B-GENE
, XXX O
exhibited XXX O
a XXX O
defect XXX O
in XXX O
the XXX O
ability XXX O
to XXX O
bind XXX O
L XXX B-GENE
protein XXX I-GENE
. XXX O

LMP-1 XXX B-GENE
is XXX O
targeted XXX O
to XXX O
the XXX O
plasma XXX O
membrane XXX O
, XXX O
where XXX O
it XXX O
binds XXX O
TRAF XXX B-GENE
, XXX O
TRADD XXX B-GENE
, XXX O
and XXX O
JAK XXX B-GENE
molecules XXX I-GENE
to XXX O
activate XXX O
NF-kappaB- XXX O
, XXX O
AP-1- XXX O
, XXX O
and XXX O
STAT-dependent XXX O
pathways XXX O
as XXX O
does XXX O
CD40 XXX B-GENE
. XXX O

2 XXX O
. XXX O

Disruption XXX O
of XXX O
the XXX O
IRA2 XXX B-GENE
gene XXX I-GENE
resulted XXX O
in XXX O
( XXX O
i XXX O
) XXX O
increased XXX O
sensitivity XXX O
to XXX O
heat XXX O
shock XXX O
and XXX O
nitrogen XXX O
starvation XXX O
, XXX O
( XXX O
ii XXX O
) XXX O
sporulation XXX O
defects XXX O
, XXX O
and XXX O
( XXX O
iii XXX O
) XXX O
suppression XXX O
of XXX O
the XXX O
lethality XXX O
of XXX O
the XXX O
cdc25 XXX B-GENE
mutant XXX I-GENE
. XXX O

A XXX O
careful XXX O
, XXX O
radiolabelled XXX O
tissue-distribution XXX O
study XXX O
is XXX O
warranted XXX O
to XXX O
elucidate XXX O
the XXX O
complicated XXX O
metabolic XXX O
fate XXX O
of XXX O
perhexiline XXX O
. XXX O

CIITA XXX B-GENE
mRNA XXX I-GENE
is XXX O
normally XXX O
inducible XXX O
by XXX O
IFN-gamma XXX B-GENE
in XXX O
class XXX O
II XXX O
non-inducible XXX O
, XXX O
RB-defective XXX O
lines XXX O
, XXX O
and XXX O
in XXX O
one XXX O
line XXX O
, XXX O
re-expression XXX O
of XXX O
RB XXX B-GENE
has XXX O
no XXX O
effect XXX O
on XXX O
CIITA XXX B-GENE
mRNA XXX I-GENE
induction XXX O
levels XXX O
. XXX O

MutY XXX B-GENE
is XXX O
an XXX O
adenine-DNA XXX B-GENE
glycosylase XXX I-GENE
with XXX O
specificity XXX O
for XXX O
mismatches XXX O
involving XXX O
8-oxoguanine XXX O
( XXX O
oG XXX O
. XXX O
A XXX O
) XXX O
or XXX O
guanine XXX O
( XXX O
G XXX O
. XXX O
A XXX O
) XXX O
. XXX O

Susceptibilities XXX O
of XXX O
540 XXX O
anaerobic XXX O
gram-negative XXX O
bacilli XXX O
to XXX O
amoxicillin XXX O
, XXX O
amoxicillin-BRL XXX O
42715 XXX O
, XXX O
amoxicillin-clavulanate XXX O
, XXX O
temafloxacin XXX O
, XXX O
and XXX O
clindamycin XXX O
. XXX O

This XXX O
effect XXX O
was XXX O
observed XXX O
in XXX O
the XXX O
absence XXX O
of XXX O
de XXX O
novo XXX O
protein XXX O
synthesis XXX O
and XXX O
was XXX O
independent XXX O
of XXX O
histone XXX B-GENE
deacetylase XXX I-GENE
activity XXX O
. XXX O

NF-kappaB XXX B-GENE
plays XXX O
a XXX O
critical XXX O
role XXX O
in XXX O
activation XXX O
of XXX O
HIV-1 XXX O
gene XXX O
expression XXX O
by XXX O
cytokines XXX O
and XXX O
other XXX O
stimuli XXX O
, XXX O
but XXX O
the XXX O
signal XXX O
transduction XXX O
pathways XXX O
that XXX O
regulate XXX O
the XXX O
switch XXX O
from XXX O
latent XXX O
to XXX O
productive XXX O
infection XXX O
have XXX O
not XXX O
been XXX O
defined XXX O
. XXX O

PCR-derived XXX O
fragments XXX O
were XXX O
used XXX O
as XXX O
probes XXX O
for XXX O
the XXX O
isolation XXX O
of XXX O
the XXX O
U3 XXX B-GENE
snRNA XXX I-GENE
genes XXX I-GENE
from XXX O
a XXX O
genomic XXX O
library XXX O
of XXX O
Arabidopsis XXX O
. XXX O

Thus XXX O
, XXX O
in XXX O
T47D XXX O
breast XXX O
carcinoma XXX O
cells XXX O
, XXX O
IL-6 XXX B-GENE
acts XXX O
in XXX O
synergy XXX O
with XXX O
EGF XXX B-GENE
receptor XXX I-GENE
autocrine XXX O
activity XXX O
to XXX O
signal XXX O
through XXX O
the XXX O
MAPK XXX B-GENE
/ XXX I-GENE
PI3K XXX I-GENE
pathways XXX O
. XXX O

CONCLUSION XXX O
: XXX O
This XXX O
study XXX O
documents XXX O
that XXX O
regression XXX O
of XXX O
choroidal XXX O
neovascularization XXX O
that XXX O
occurred XXX O
with XXX O
alpha XXX B-GENE
interferon XXX I-GENE
treatment XXX O
was XXX O
minimal XXX O
. XXX O

The XXX O
Authors XXX O
have XXX O
proposed XXX O
to XXX O
develop XXX O
this XXX O
research XXX O
employing XXX O
a XXX O
preparation XXX O
containing XXX O
exclusively XXX O
a XXX O
cortisonic XXX O
, XXX O
the XXX O
desametazone XXX O
, XXX O
in XXX O
order XXX O
to XXX O
evaluate XXX O
the XXX O
alterations XXX O
of XXX O
the XXX O
dentinogenesis XXX O
to XXX O
be XXX O
attributed XXX O
to XXX O
such XXX O
component XXX O
. XXX O

A XXX O
5 XXX O
. XXX O
3-kb XXX O
DNA XXX O
fragment XXX O
, XXX O
which XXX O
included XXX O
the XXX O
entire XXX O
structural XXX O
porin XXX B-GENE
gene XXX I-GENE
( XXX O
named XXX O
porCa XXX B-GENE
) XXX O
and XXX O
its XXX O
flanking XXX O
regions XXX O
, XXX O
was XXX O
identified XXX O
. XXX O

The XXX O
procedure XXX O
has XXX O
been XXX O
applied XXX O
to XXX O
three XXX O
materials XXX O
: XXX O
particle XXX O
board XXX O
with XXX O
carpet XXX O
; XXX O
gypsum XXX O
board XXX O
with XXX O
wallpaper XXX O
; XXX O
and XXX O
plywood XXX O
with XXX O
polyurethane XXX O
lacquer XXX O
, XXX O
for XXX O
which XXX O
the XXX O
steady-state XXX O
emission XXX O
factors XXX O
( XXX O
mg XXX O
m-2 XXX O
h-1 XXX O
) XXX O
of XXX O
several XXX O
compounds XXX O
are XXX O
given XXX O
. XXX O

The XXX O
transactivation XXX O
function XXX O
of XXX O
EBNA2 XXX B-GENE
was XXX O
also XXX O
observed XXX O
in XXX O
the XXX O
HeLa XXX O
epithelial XXX O
cell XXX O
line XXX O
, XXX O
which XXX O
suggests XXX O
that XXX O
EBV XXX O
and XXX O
HIV-1 XXX O
infection XXX O
of XXX O
non-B XXX O
cells XXX O
may XXX O
result XXX O
in XXX O
HIV-1 XXX O
promoter XXX O
activation XXX O
. XXX O

Immunofluorescence XXX O
microscopy XXX O
revealed XXX O
extensive XXX O
deposition XXX O
of XXX O
such XXX O
extracellular XXX O
matrices XXX O
as XXX O
type XXX B-GENE
IV XXX I-GENE
collagen XXX I-GENE
and XXX O
laminin XXX B-GENE
in XXX O
the XXX O
vascular XXX O
wall XXX O
. XXX O

Members XXX O
of XXX O
the XXX O
C XXX B-GENE
/ XXX I-GENE
EBP XXX I-GENE
family XXX I-GENE
of XXX O
basic-leucine XXX B-GENE
zipper XXX I-GENE
( XXX O
bZip XXX B-GENE
) XXX O
transcription XXX O
factors XXX O
form XXX O
heterodimers XXX O
and XXX O
bind XXX O
to XXX O
the XXX O
CAAT XXX O
box XXX O
and XXX O
other XXX O
sequence-related XXX O
enhancer XXX O
motifs XXX O
. XXX O

Vitrectomy XXX O
and XXX O
removal XXX O
of XXX O
retained XXX O
lens XXX O
fragments XXX O
restores XXX O
good XXX O
visual XXX O
acuity XXX O
and XXX O
reduces XXX O
secondary XXX O
glaucoma XXX O
in XXX O
the XXX O
majority XXX O
of XXX O
patients XXX O
. XXX O

Comparison XXX O
of XXX O
the XXX O
amino XXX O
acid XXX O
sequence XXX O
of XXX O
the XXX O
M XXX B-GENE
RNA XXX I-GENE
product XXX I-GENE
of XXX I-GENE
Uukuniemi XXX I-GENE
virus XXX I-GENE
with XXX O
that XXX O
of XXX O
Punta XXX O
Toro XXX O
and XXX O
Rift XXX O
Valley XXX O
fever XXX O
viruses XXX O
showed XXX O
in XXX O
both XXX O
cases XXX O
a XXX O
weak XXX O
homology XXX O
that XXX O
was XXX O
more XXX O
pronounced XXX O
for XXX O
the XXX O
proteins XXX O
located XXX O
at XXX O
the XXX O
COOH-terminal XXX O
end XXX O
of XXX O
the XXX O
precursor XXX O
. XXX O

Adverse XXX O
reaction XXX O
of XXX O
the XXX O
apparently XXX O
healthy XXX O
partner XXX O
in XXX O
response XXX O
to XXX O
improvement XXX O
in XXX O
the XXX O
overtly XXX O
dysfunctional XXX O
partner XXX O
. XXX O

Our XXX O
study XXX O
was XXX O
addressed XXX O
to XXX O
the XXX O
synthesis XXX O
of XXX O
some XXX O
derivatives XXX O
of XXX O
this XXX O
sequence XXX O
in XXX O
order XXX O
to XXX O
obtain XXX O
both XXX O
peptide XXX O
substrates XXX O
suitable XXX O
for XXX O
the XXX O
detection XXX O
of XXX O
the XXX O
Src-like XXX B-GENE
tyrosine XXX I-GENE
kinase XXX I-GENE
activity XXX O
and XXX O
active XXX O
site-directed XXX O
inhibitors XXX O
specific XXX O
for XXX O
this XXX O
class XXX O
of XXX O
enzymes XXX O
. XXX O

The XXX O
defect XXX O
in XXX O
these XXX O
proteins XXX O
was XXX O
also XXX O
uniformly XXX O
suppressed XXX O
by XXX O
either XXX O
Mn2+ XXX O
, XXX O
or XXX O
the XXX O
Mu XXX B-GENE
B XXX I-GENE
protein XXX I-GENE
in XXX O
the XXX O
presence XXX O
of XXX O
ATP XXX O
and XXX O
target XXX O
DNA XXX O
. XXX O

As XXX O
such XXX O
the XXX O
findings XXX O
support XXX O
existing XXX O
studies XXX O
that XXX O
have XXX O
identified XXX O
given XXX O
social XXX O
characteristics XXX O
of XXX O
drink XXX O
drivers XXX O
. XXX O

We XXX O
have XXX O
measured XXX O
the XXX O
release XXX O
of XXX O
interleukin-1 XXX B-GENE
beta XXX I-GENE
( XXX O
IL-1 XXX B-GENE
) XXX O
and XXX O
tumour XXX B-GENE
necrosis XXX I-GENE
factor-alpha XXX I-GENE
( XXX O
TNF XXX B-GENE
) XXX O
by XXX O
unstimulated XXX O
monocytes XXX O
and XXX O
monocytes XXX O
stimulated XXX O
with XXX O
lipopolysaccharide XXX O
( XXX O
LPS XXX O
) XXX O
isolated XXX O
from XXX O
the XXX O
peripheral XXX O
blood XXX O
of XXX O
two XXX O
patients XXX O
with XXX O
acute XXX O
poststreptococcal XXX O
glomerulonephritis XXX O
( XXX O
AGN XXX O
) XXX O
and XXX O
16 XXX O
healthy XXX O
controls XXX O
. XXX O

SM XXX B-GENE
is XXX O
also XXX O
shown XXX O
to XXX O
be XXX O
associated XXX O
in XXX O
vivo XXX O
with XXX O
other XXX O
components XXX O
of XXX O
the XXX O
CRM XXX B-GENE
1 XXX I-GENE
export XXX O
pathway XXX O
, XXX O
including XXX O
the XXX O
small XXX B-GENE
GTPase XXX I-GENE
Ran XXX I-GENE
and XXX O
the XXX O
nucleoporin XXX B-GENE
CAN XXX I-GENE
/ XXX I-GENE
Nup214 XXX I-GENE
. XXX O

As XXX O
a XXX O
result XXX O
, XXX O
we XXX O
have XXX O
defined XXX O
two XXX O
arginine-rich XXX O
motifs XXX O
( XXX O
ARM1 XXX O
and XXX O
ARM2 XXX O
) XXX O
that XXX O
mediate XXX O
the XXX O
RNA XXX O
binding XXX O
activity XXX O
of XXX O
SU XXX B-GENE
( XXX I-GENE
S XXX I-GENE
) XXX I-GENE
. XXX O

Study XXX O
on XXX O
micromelias XXX O
in XXX O
the XXX O
mouse XXX O
fetus XXX O
caused XXX O
by XXX O
x-radiation XXX O
, XXX O
hypoxia XXX O
, XXX O
trypan XXX O
blue XXX O
injection XXX O
of XXX O
hypervitaminosis-A XXX O
upon XXX O
mother XXX O
animals XXX O
during XXX O
pregnancy XXX O
. XXX O

Raman XXX O
investigation XXX O
of XXX O
YBa2-xLaxCu3O7 XXX O
ceramics XXX O
. XXX O

Therefore XXX O
, XXX O
the XXX O
amino-terminal XXX O
sequence XXX O
of XXX O
the XXX O
purified XXX O
carA XXX B-GENE
product XXX I-GENE
is XXX O
identical XXX O
to XXX O
that XXX O
derived XXX O
from XXX O
the XXX O
nucleotide XXX O
sequence XXX O
in XXX O
both XXX O
organisms XXX O
, XXX O
P XXX O
. XXX O
stutzeri XXX O
having XXX O
four XXX O
additional XXX O
amino XXX O
acids XXX O
. XXX O

San XXX O
Martin's XXX O
psychological XXX O
traits XXX O
coupled XXX O
to XXX O
his XXX O
work XXX O
with XXX O
masonic XXX O
lodges XXX O
that XXX O
allowed XXX O
him XXX O
to XXX O
display XXX O
his XXX O
abilities XXX O
as XXX O
strategist XXX O
and XXX O
political XXX O
ruler XXX O
. XXX O

A XXX O
novel XXX O
Drosophila XXX B-GENE
A XXX I-GENE
kinase XXX I-GENE
anchor XXX I-GENE
protein XXX I-GENE
, XXX O
Drosophila XXX B-GENE
A XXX I-GENE
kinase XXX I-GENE
anchor XXX I-GENE
protein XXX I-GENE
200 XXX I-GENE
( XXX O
DAKAP200 XXX B-GENE
) XXX O
, XXX O
is XXX O
predicted XXX O
to XXX O
be XXX O
involved XXX O
in XXX O
routing XXX O
, XXX O
mediating XXX O
, XXX O
and XXX O
integrating XXX O
signals XXX O
carried XXX O
by XXX O
cAMP XXX O
, XXX O
Ca XXX O
( XXX O
2+ XXX O
) XXX O
, XXX O
and XXX O
diacylglycerol XXX O
( XXX O
Li XXX O
, XXX O
Z XXX O
. XXX O
, XXX O
Rossi XXX O
, XXX O
E XXX O
. XXX O

These XXX O
risk XXX O
factors XXX O
can XXX O
be XXX O
divided XXX O
into XXX O
2 XXX O
groups XXX O
: XXX O
local XXX O
vessel XXX O
wall-related XXX O
factors XXX O
, XXX O
and XXX O
local XXX O
( XXX O
focal XXX O
action XXX O
) XXX O
systemic XXX O
factors XXX O
. XXX O

Hand-held XXX O
, XXX O
continuous-wave XXX O
Doppler XXX O
probes XXX O
, XXX O
coupled XXX O
with XXX O
sound XXX O
spectral XXX O
analysis XXX O
, XXX O
can XXX O
successfully XXX O
predict XXX O
carotid XXX O
artery XXX O
stenosis XXX O
. XXX O

Expression XXX O
of XXX O
human XXX B-GENE
RACK1 XXX I-GENE
efficiently XXX O
relieves XXX O
E1A-mediated XXX O
growth XXX O
inhibition XXX O
in XXX O
HF7c XXX O
and XXX O
protects XXX O
human XXX O
tumor XXX O
cells XXX O
from XXX O
E1A-induced XXX O
apoptosis XXX O
. XXX O

D-cyclin-cdk XXX B-GENE
activity XXX O
is XXX O
required XXX O
for XXX O
Rb XXX B-GENE
phosphorylation XXX O
in XXX O
v-Jun-transformed XXX O
cells XXX O
, XXX O
since XXX O
ectopic XXX O
expression XXX O
of XXX O
the XXX O
cdk4- XXX O
and XXX O
cdk6-specific XXX B-GENE
inhibitor XXX I-GENE
p16 XXX B-GENE
( XXX I-GENE
INK4A XXX I-GENE
) XXX I-GENE
inhibits XXX O
both XXX O
DNA XXX O
synthesis XXX O
and XXX O
cell XXX O
proliferation XXX O
. XXX O

The XXX O
yeast XXX B-GENE
SSS1 XXX I-GENE
gene XXX I-GENE
is XXX O
essential XXX O
for XXX O
secretory XXX O
protein XXX O
translocation XXX O
and XXX O
encodes XXX O
a XXX O
conserved XXX O
protein XXX O
of XXX O
the XXX O
endoplasmic XXX O
reticulum XXX O
. XXX O

Intraoperatively XXX O
the XXX O
complement XXX B-GENE
factor XXX I-GENE
C3c XXX I-GENE
decreased XXX O
by XXX O
20% XXX O
, XXX O
while XXX O
alpha XXX B-GENE
1-antitrypsin XXX I-GENE
showed XXX O
postoperatively XXX O
an XXX O
increase XXX O
by XXX O
30% XXX O
. XXX O

Overexpression XXX O
of XXX O
CDP XXX B-GENE
/ XXX I-GENE
cut XXX I-GENE
in XXX O
ROS XXX O
17 XXX O
/ XXX O
2 XXX O
. XXX O
8 XXX O
osteosarcoma XXX O
cells XXX O
results XXX O
in XXX O
repression XXX O
of XXX O
OC XXX B-GENE
promoter XXX I-GENE
activity XXX O
; XXX O
this XXX O
repression XXX O
is XXX O
abrogated XXX O
by XXX O
mutating XXX O
OC XXX B-GENE
box XXX I-GENE
I XXX I-GENE
. XXX O

In XXX O
this XXX O
study XXX O
, XXX O
the XXX O
general XXX O
clinical XXX O
criteria XXX O
for XXX O
inhalation XXX O
injury--presence XXX O
of XXX O
facial XXX O
or XXX O
oropharyngeal XXX O
burns XXX O
, XXX O
carboxyhemoglobin XXX O
levels XXX O
, XXX O
carbonaceous XXX O
sputum XXX O
, XXX O
or XXX O
closed XXX O
space XXX O
injury--did XXX O
not XXX O
differentiate XXX O
patients XXX O
with XXX O
airway XXX O
injury XXX O
only XXX O
from XXX O
those XXX O
with XXX O
parenchymal XXX O
injury XXX O
. XXX O

Co-existence XXX O
of XXX O
these XXX O
regulatory XXX O
elements XXX O
with XXX O
other XXX O
elements XXX O
, XXX O
such XXX O
as XXX O
the XXX O
AP-2 XXX B-GENE
element XXX I-GENE
or XXX O
CCAAT XXX O
box XXX O
, XXX O
was XXX O
also XXX O
found XXX O
. XXX O

Update XXX O
on XXX O
maternal-fetal XXX O
infections XXX O
by XXX O
hepatitis XXX O
C XXX O
, XXX O
HIV XXX O
and XXX O
cytomegalovirus XXX O
. XXX O

Many XXX O
children XXX O
with XXX O
BGC XXX O
are XXX O
delayed XXX O
in XXX O
their XXX O
development XXX O
, XXX O
but XXX O
calcifications XXX O
are XXX O
not XXX O
directly XXX O
related XXX O
to XXX O
specific XXX O
forms XXX O
of XXX O
neurologic XXX O
dysfunction XXX O
. XXX O

The XXX O
presence XXX O
of XXX O
cutaneous XXX O
xanthomas XXX O
with XXX O
normal XXX O
serum XXX O
lipid XXX O
levels XXX O
is XXX O
due XXX O
to XXX O
the XXX O
antibetalipoproteic XXX O
activity XXX O
of XXX O
the XXX O
monoclonal XXX B-GENE
immunoglobulin XXX I-GENE
. XXX O

In XXX O
addition XXX O
, XXX O
these XXX O
cells XXX O
contained XXX O
one XXX O
, XXX O
two XXX O
, XXX O
or XXX O
multiple XXX O
nuclei XXX O
indicative XXX O
of XXX O
a XXX O
G2 XXX O
/ XXX O
M XXX O
delay XXX O
in XXX O
nuclear XXX O
division XXX O
and XXX O
also XXX O
a XXX O
defect XXX O
in XXX O
cytokinesis XXX O
and XXX O
/ XXX O
or XXX O
cell XXX O
separation XXX O
. XXX O

CONCLUSIONS XXX O
: XXX O
There XXX O
is XXX O
a XXX O
relation XXX O
in XXX O
the XXX O
topography XXX O
of XXX O
some XXX O
visual XXX O
field XXX O
areas XXX O
assessed XXX O
by XXX O
SWAP XXX O
and XXX O
the XXX O
inferotemporal XXX O
neuroretinal XXX O
rim XXX O
area XXX O
, XXX O
which XXX O
may XXX O
play XXX O
a XXX O
role XXX O
in XXX O
the XXX O
diagnosis XXX O
and XXX O
follow-up XXX O
of XXX O
suspected XXX O
glaucoma XXX O
. XXX O

Mutational XXX O
analysis XXX O
shows XXX O
that XXX O
both XXX O
an XXX O
AP-1 XXX B-GENE
like XXX I-GENE
sequence XXX I-GENE
( XXX O
-294 XXX B-GENE
/ XXX I-GENE
-285 XXX I-GENE
, XXX I-GENE
TGAATCATCA XXX I-GENE
) XXX O
and XXX O
an XXX O
A XXX O
/ XXX O
T-rich XXX O
myocyte XXX B-GENE
enhancer XXX I-GENE
factor XXX I-GENE
( XXX I-GENE
MEF XXX I-GENE
) XXX I-GENE
-2 XXX I-GENE
like XXX I-GENE
sequence XXX I-GENE
( XXX O
-310 XXX B-GENE
/ XXX I-GENE
-298 XXX I-GENE
, XXX I-GENE
TTAAAAATAAAAA XXX I-GENE
) XXX O
in XXX O
the XXX O
33-bp XXX O
region XXX O
are XXX O
necessary XXX O
for XXX O
the XXX O
OP-1 XXX B-GENE
effect XXX O
. XXX O

Sources XXX O
of XXX O
noise XXX O
in XXX O
these XXX O
signals XXX O
were XXX O
evaluated XXX O
in XXX O
preparations XXX O
stained XXX O
with XXX O
the XXX O
potentiometric XXX O
probe XXX O
RH-414 XXX O
. XXX O

The XXX O
effects XXX O
of XXX O
several XXX O
opioid XXX O
agonists XXX O
and XXX O
the XXX O
opioid XXX O
antagonist XXX O
naloxone XXX O
were XXX O
examined XXX O
in XXX O
rats XXX O
responding XXX O
under XXX O
a XXX O
fixed-consecutive-number XXX O
( XXX O
FCN XXX O
) XXX O
schedule XXX O
. XXX O

In XXX O
one XXX O
mechanism XXX O
, XXX O
a XXX O
specialized XXX O
ubiquitin-dependent XXX O
proteolytic XXX O
system XXX O
( XXX O
called XXX O
the XXX O
APC-dependent XXX O
proteolysis XXX O
machinery XXX O
) XXX O
degrades XXX O
the XXX O
mitotic XXX O
( XXX O
Clb XXX B-GENE
) XXX O
cyclin XXX B-GENE
subunit XXX I-GENE
. XXX O

An XXX O
essential XXX O
role XXX O
of XXX O
c-Jun XXX B-GENE
and XXX O
c-Fos XXX B-GENE
in XXX O
basal XXX O
and XXX O
PMA-stimulated XXX O
transcription XXX O
of XXX O
the XXX O
PAI-1 XXX B-GENE
gene XXX I-GENE
is XXX O
demonstrated XXX O
by XXX O
our XXX O
finding XXX O
that XXX O
antisense XXX O
c-jun XXX B-GENE
and XXX O
c-fos XXX B-GENE
oligodeoxynucleotides XXX O
both XXX O
strongly XXX O
reduced XXX O
basal XXX O
and XXX O
PMA-stimulated XXX O
PAI-1 XXX B-GENE
synthesis XXX O
. XXX O

The XXX O
responses XXX O
of XXX O
the XXX O
"stress XXX O
hormones" XXX O
cortisol XXX O
, XXX O
11-deoxycortisol XXX O
, XXX O
ACTH XXX B-GENE
, XXX O
vasopressin XXX B-GENE
( XXX O
AVP XXX B-GENE
) XXX O
, XXX O
and XXX O
corticotropin XXX B-GENE
releasing XXX I-GENE
factor XXX I-GENE
( XXX O
CRF XXX B-GENE
) XXX O
were XXX O
studied XXX O
in XXX O
6 XXX O
normal XXX O
males XXX O
in XXX O
response XXX O
to XXX O
acute XXX O
cortisol XXX O
deficiency XXX O
induced XXX O
by XXX O
the XXX O
11-beta-hydroxylase XXX B-GENE
inhibitor XXX O
, XXX O
metyrapone XXX O
. XXX O

Cestode XXX O
invasion XXX O
in XXX O
irradiated XXX O
host XXX O
organism XXX O
increases XXX O
the XXX O
negative XXX O
effect XXX O
of XXX O
ionizing XXX O
radiation XXX O
on XXX O
the XXX O
hamster XXX O
immune XXX O
system XXX O
. XXX O

Hoeben XXX O
, XXX O
F XXX O
. XXX O
J XXX O
. XXX O

These XXX O
animals XXX O
were XXX O
viable XXX O
and XXX O
fertile XXX O
. XXX O

CONCLUSION XXX O
: XXX O
MMF XXX O
( XXX O
2-3 XXX O
g XXX O
/ XXX O
day XXX O
) XXX O
is XXX O
unable XXX O
to XXX O
control XXX O
the XXX O
signs XXX O
of XXX O
mucocutaneous XXX O
Adamantiades-Behcet's XXX O
disease XXX O
. XXX O

Five XXX O
experiments XXX O
examined XXX O
the XXX O
influence XXX O
of XXX O
opiate XXX O
antagonists XXX O
on XXX O
both XXX O
the XXX O
short-term XXX O
analgesic XXX O
reaction XXX O
resulting XXX O
30 XXX O
min XXX O
after XXX O
exposure XXX O
to XXX O
inescapable XXX O
shock XXX O
and XXX O
the XXX O
long-term XXX O
analgesic XXX O
reaction XXX O
resulting XXX O
after XXX O
reexposure XXX O
to XXX O
shock XXX O
24 XXX O
hr XXX O
after XXX O
inescapable XXX O
shock XXX O
exposure XXX O
. XXX O

It XXX O
is XXX O
concluded XXX O
that XXX O
fludarabine XXX O
is XXX O
a XXX O
highly XXX O
useful XXX O
agent XXX O
in XXX O
CLL XXX O
. XXX O

These XXX O
HPV16 XXX O
E6 XXX B-GENE
/ XXX I-GENE
E7 XXX I-GENE
cDNAs XXX O
were XXX O
cloned XXX O
under XXX O
the XXX O
SV40 XXX B-GENE
enhancer XXX I-GENE
/ XXX I-GENE
promoter XXX I-GENE
and XXX O
the XXX O
MMTV XXX O
LTR XXX B-GENE
to XXX O
examine XXX O
the XXX O
activities XXX O
of XXX O
ras-collaborative XXX O
transformation XXX O
and XXX O
induction XXX O
of XXX O
cellular XXX O
DNA XXX O
synthesis XXX O
, XXX O
both XXX O
of XXX O
which XXX O
depend XXX O
on XXX O
the XXX O
E7 XXX B-GENE
gene XXX I-GENE
product XXX O
. XXX O

However XXX O
, XXX O
by XXX O
immobilized XXX O
metal XXX O
affinity XXX O
chromatography XXX O
assay XXX O
, XXX O
self-association XXX O
of XXX O
PR-A XXX B-GENE
was XXX O
3 XXX O
. XXX O
5-fold XXX O
more XXX O
efficient XXX O
than XXX O
that XXX O
of XXX O
either XXX O
the XXX O
DhLBD XXX O
or XXX O
hLBD XXX O
constructs XXX O
. XXX O

The XXX O
GafChromic XXX O
method XXX O
has XXX O
proven XXX O
to XXX O
be XXX O
an XXX O
accurate XXX O
and XXX O
rapid XXX O
method XXX O
of XXX O
analysis XXX O
and XXX O
could XXX O
be XXX O
easily XXX O
incorporated XXX O
into XXX O
a XXX O
quality XXX O
assurance XXX O
program XXX O
. XXX O

High-level XXX O
gains XXX O
( XXX O
HLGs XXX O
) XXX O
indicative XXX O
of XXX O
gene XXX O
amplifications XXX O
were XXX O
identified XXX O
at XXX O
11q13 XXX O
in XXX O
two XXX O
cases XXX O
, XXX O
and XXX O
in XXX O
one XXX O
case XXX O
each XXX O
at XXX O
2q33-34 XXX O
, XXX O
3q25-29 XXX O
, XXX O
5p15 XXX O
. XXX O
1-15 XXX O
. XXX O
2 XXX O
, XXX O
7q21-22 XXX O
, XXX O
11p11 XXX O
. XXX O
2 XXX O
, XXX O
12p11 XXX O
. XXX O
2-12 XXX O
, XXX O
and XXX O
13q34 XXX O
. XXX O

Sensitive XXX O
fluorometric XXX O
method XXX O
of XXX O
determining XXX O
SH- XXX O
and XXX O
S-S-groups XXX O
when XXX O
jointly XXX O
present XXX O
. XXX O

The XXX O
DNase XXX B-GENE
I XXX I-GENE
footprint XXX O
extended XXX O
5' XXX O
in XXX O
the XXX O
silencer XXX O
region XXX O
to XXX O
include XXX O
an XXX O
inverted XXX O
repeat XXX O
of XXX O
a XXX O
six-nucleotide XXX O
motif XXX O
( XXX O
epsilon XXX O
-267 XXX O
to XXX O
-278 XXX O
bp XXX O
) XXX O
which XXX O
shares XXX O
5 XXX O
of XXX O
6 XXX O
bases XXX O
with XXX O
the XXX O
GATA-1 XXX B-GENE
consensus XXX I-GENE
sequence XXX I-GENE
. XXX O

The XXX O
effect XXX O
of XXX O
the XXX O
opiate XXX O
antagonist XXX O
naloxone XXX O
was XXX O
evaluated XXX O
in XXX O
11 XXX O
unselected XXX O
patients XXX O
with XXX O
cerebral XXX O
ischemia XXX O
. XXX O

Thus XXX O
, XXX O
in XXX O
stress-induced XXX O
arrhythmic XXX O
disease XXX O
as XXX O
well XXX O
as XXX O
in XXX O
ischemic XXX O
heart XXX O
disease XXX O
, XXX O
the XXX O
main XXX O
pathogenetic XXX O
links XXX O
are XXX O
outside XXX O
the XXX O
heart XXX O
, XXX O
but XXX O
they XXX O
differ XXX O
from XXX O
those XXX O
observed XXX O
in XXX O
ischemia XXX O
. XXX O

Extracellular-regulated XXX B-GENE
kinase XXX I-GENE
( XXX O
ERK XXX B-GENE
) XXX O
activation XXX O
and XXX O
molecular XXX O
coupling XXX O
of XXX O
the XXX O
adaptor XXX O
proteins XXX O
p130 XXX B-GENE
Crk-associated XXX I-GENE
substrate XXX I-GENE
( XXX O
CAS XXX B-GENE
) XXX O
and XXX O
c-CrkII XXX B-GENE
( XXX O
Crk XXX B-GENE
) XXX O
represent XXX O
two XXX O
distinct XXX O
pathways XXX O
that XXX O
induce XXX O
cell XXX O
invasion XXX O
and XXX O
protect XXX O
cells XXX O
from XXX O
apoptosis XXX O
in XXX O
a XXX O
three-dimensional XXX O
collagen XXX B-GENE
matrix XXX O
. XXX O

We XXX O
demonstrate XXX O
that XXX O
both XXX O
R XXX O
and XXX O
Z XXX O
activate XXX O
the XXX O
cellular XXX O
stress XXX O
mitogen-activated XXX B-GENE
protein XXX I-GENE
( XXX I-GENE
MAP XXX I-GENE
) XXX I-GENE
kinases XXX I-GENE
, XXX O
p38 XXX B-GENE
and XXX O
JNK XXX B-GENE
, XXX O
resulting XXX O
in XXX O
phosphorylation XXX O
( XXX O
and XXX O
activation XXX O
) XXX O
of XXX O
the XXX O
cellular XXX B-GENE
transcription XXX I-GENE
factor XXX I-GENE
ATF2 XXX I-GENE
. XXX O

Hepatitis XXX O
C XXX O
virus XXX O
infection XXX O
and XXX O
lymphoproliferative XXX O
diseases XXX O
in XXX O
France XXX O
: XXX O
a XXX O
national XXX O
study XXX O
. XXX O

In XXX O
this XXX O
study XXX O
, XXX O
rabbits XXX O
were XXX O
used XXX O
to XXX O
evaluate XXX O
the XXX O
sutured XXX O
wound XXX O
reaction XXX O
with XXX O
Dexon XXX O
or XXX O
nylon XXX O
in XXX O
the XXX O
conjunctival XXX O
flap XXX O
1 XXX O
, XXX O
4 XXX O
, XXX O
7 XXX O
, XXX O
14 XXX O
and XXX O
28 XXX O
days XXX O
after XXX O
trabeculectomy XXX O
surgery XXX O
with XXX O
or XXX O
without XXX O
the XXX O
use XXX O
of XXX O
mitomycin-C XXX O
. XXX O

Mutant XXX O
enzyme XXX O
forms XXX O
were XXX O
prepared XXX O
to XXX O
eliminate XXX O
the XXX O
initial XXX O
autoprocessing XXX O
site XXX O
and XXX O
thus XXX O
form XXX O
an XXX O
active XXX O
single-chain XXX O
protein XXX O
for XXX O
structure-function XXX O
studies XXX O
. XXX O

A XXX O
new XXX O
echocardiographic XXX O
technique XXX O
is XXX O
described XXX O
with XXX O
a XXX O
conventional XXX O
M XXX O
mode XXX O
, XXX O
digitalised XXX O
2D XXX O
and XXX O
tissular XXX O
Doppler XXX O
which XXX O
has XXX O
a XXX O
comparable XXX O
ability XXX O
to XXX O
identify XXX O
the XXX O
anomalous XXX O
pathways XXX O
of XXX O
electric XXX O
conduction XXX O
using XXX O
a XXX O
non-invasive XXX O
method XXX O
. XXX O

Hepatitis XXX O
C XXX O
virus XXX O
infection XXX O
is XXX O
a XXX O
risk XXX O
factor XXX O
for XXX O
liver XXX O
failure XXX O
from XXX O
veno-occlusive XXX O
disease XXX O
after XXX O
bone XXX O
marrow XXX O
transplantation XXX O
. XXX O

NB-506 XXX O
completely XXX O
inhibits XXX O
the XXX O
capacity XXX O
of XXX O
topoisomerase XXX B-GENE
I XXX I-GENE
to XXX O
phosphorylate XXX O
, XXX O
in XXX O
vitro XXX O
, XXX O
the XXX O
human XXX B-GENE
splicing XXX I-GENE
factor XXX I-GENE
2 XXX I-GENE
/ XXX I-GENE
alternative XXX I-GENE
splicing XXX I-GENE
factor XXX I-GENE
( XXX O
SF2 XXX B-GENE
/ XXX I-GENE
ASF XXX I-GENE
) XXX O
. XXX O

An XXX O
analysis XXX O
of XXX O
synthetic XXX O
peptides XXX O
revealed XXX O
a XXX O
minimal XXX O
CTD XXX O
sequence XXX O
that XXX O
is XXX O
sufficient XXX O
to XXX O
bind XXX O
to XXX O
the XXX O
second XXX O
Rsp5 XXX B-GENE
WW XXX I-GENE
domain XXX I-GENE
( XXX O
Rsp5 XXX B-GENE
WW2 XXX I-GENE
) XXX O
in XXX O
vitro XXX O
and XXX O
in XXX O
yeast XXX O
two-hybrid XXX O
assays XXX O
. XXX O

Clinical XXX O
and XXX O
biological XXX O
correlates XXX O
of XXX O
panic XXX O
states XXX O
. XXX O

Comments XXX O
are XXX O
given XXX O
on XXX O
the XXX O
present XXX O
status XXX O
of XXX O
regulations XXX O
concerning XXX O
water XXX O
in XXX O
swimming XXX O
pools XXX O
and XXX O
baths--1991-- XXX O
( XXX O
in XXX O
connection XXX O
with XXX O
the XXX O
KOK XXX O
regulations--1972--and XXX O
the XXX O
Federal XXX O
German XXX O
standard XXX O
[ XXX O
DIN XXX O
] XXX O
No XXX O
. XXX O

The XXX O
high XXX O
degree XXX O
of XXX O
conservation XXX O
between XXX O
NQO2 XXX B-GENE
and XXX O
NQO1 XXX B-GENE
gene XXX I-GENE
organization XXX O
and XXX O
sequence XXX O
confirmed XXX O
that XXX O
NQO2 XXX B-GENE
gene XXX I-GENE
encodes XXX O
for XXX O
a XXX O
second XXX O
member XXX O
of XXX O
the XXX O
NQO XXX B-GENE
gene XXX I-GENE
family XXX I-GENE
in XXX O
human XXX O
. XXX O

The XXX O
concentration XXX O
of XXX O
mite XXX O
allergen XXX O
was XXX O
very XXX O
low XXX O
( XXX O
mean XXX O
0 XXX O
. XXX O
18 XXX O
micrograms XXX O
Der XXX O
p XXX O
milligrams XXX O
sieved XXX O
house XXX O
dust XXX O
) XXX O
, XXX O
whereas XXX O
that XXX O
of XXX O
cat XXX O
allergen XXX O
was XXX O
high XXX O
in XXX O
homes XXX O
with XXX O
a XXX O
cat XXX O
( XXX O
80 XXX O
. XXX O
8 XXX O
micrograms XXX O
Fel XXX O
d XXX O
milligrams XXX O
) XXX O
but XXX O
also XXX O
in XXX O
homes XXX O
with XXX O
no XXX O
cat XXX O
( XXX O
3 XXX O
. XXX O
2 XXX O
micrograms XXX O
Fel XXX O
d XXX O
milligrams XXX O
) XXX O
. XXX O

Joys XXX O
and XXX O
F XXX O
. XXX O

These XXX O
results XXX O
suggest XXX O
an XXX O
increased XXX O
risk XXX O
of XXX O
developing XXX O
cancer XXX O
among XXX O
polyp XXX O
patients XXX O
and XXX O
the XXX O
possibility XXX O
of XXX O
prophylactic XXX O
effect XXX O
of XXX O
polypectomy XXX O
against XXX O
subsequent XXX O
cancer XXX O
. XXX O

Such XXX O
knowledge XXX O
could XXX O
advance XXX O
diagnosis XXX O
and XXX O
treatment XXX O
of XXX O
the XXX O
patient XXX O
and XXX O
counseling XXX O
of XXX O
the XXX O
affected XXX O
family XXX O
. XXX O

Our XXX O
results XXX O
are XXX O
reassuring XXX O
and XXX O
we XXX O
therefore XXX O
advise XXX O
that XXX O
in XXX O
patients XXX O
undergoing XXX O
free XXX O
jejunum XXX O
flap XXX O
reconstruction XXX O
of XXX O
the XXX O
hypopharyngo-esophageal XXX O
tract XXX O
voice XXX O
restoration XXX O
should XXX O
be XXX O
attempted XXX O
by XXX O
placing XXX O
a XXX O
voice XXX O
prosthesis XXX O
through XXX O
a XXX O
secondary XXX O
tracheo-esophageal XXX O
puncture XXX O
and XXX O
providing XXX O
intensive XXX O
speech XXX O
training XXX O
. XXX O

The XXX O
results XXX O
indicate XXX O
that XXX O
folate XXX O
compounds XXX O
decrease XXX O
formate XXX O
accumulation XXX O
after XXX O
methanol XXX O
by XXX O
stimulating XXX O
formate XXX O
oxidation XXX O
or XXX O
utilization XXX O
and XXX O
suggest XXX O
a XXX O
possible XXX O
use XXX O
for XXX O
folates XXX O
in XXX O
the XXX O
treatment XXX O
of XXX O
certain XXX O
cases XXX O
of XXX O
human XXX O
methanol XXX O
poisoning XXX O
. XXX O

Platelet XXX O
aggregation XXX O
and XXX O
metabolic XXX O
control XXX O
are XXX O
not XXX O
affected XXX O
by XXX O
calcium XXX O
antagonist XXX O
treatment XXX O
in XXX O
type XXX O
II XXX O
diabetes XXX O
mellitus XXX O
. XXX O

Gene XXX O
expression XXX O
occurs XXX O
in XXX O
a XXX O
circadian XXX O
rhythm XXX O
and XXX O
induced XXX O
by XXX O
light XXX O
in XXX O
leaves XXX O
of XXX O
dark-adapted XXX O
plants XXX O
. XXX O

In XXX O
this XXX O
study XXX O
, XXX O
the XXX O
abilities XXX O
of XXX O
constitutive XXX O
and XXX O
conditional XXX O
forms XXX O
of XXX O
the XXX O
three XXX O
Raf XXX B-GENE
kinases XXX I-GENE
to XXX O
abrogate XXX O
the XXX O
cytokine XXX O
dependency XXX O
of XXX O
FDC-P1 XXX O
cells XXX O
were XXX O
examined XXX O
. XXX O

There XXX O
was XXX O
a XXX O
statistically XXX O
significant XXX O
correlation XXX O
between XXX O
simultaneous XXX O
weekly XXX O
average XXX O
pollen XXX O
levels XXX O
in XXX O
Philadelphia XXX O
and XXX O
in XXX O
Cherry XXX O
Hill XXX O
( XXX O
Acer XXX O
, XXX O
r XXX O
( XXX O
p XXX O
) XXX O
= XXX O
0 XXX O
. XXX O
987 XXX O
, XXX O
Quercus XXX O
, XXX O
r XXX O
( XXX O
p XXX O
) XXX O
= XXX O
0 XXX O
. XXX O
645 XXX O
, XXX O
Betula XXX O
, XXX O
r XXX O
( XXX O
p XXX O
) XXX O
= XXX O
0 XXX O
. XXX O
896 XXX O
, XXX O
Pinus XXX O
, XXX O
r XXX O
( XXX O
p XXX O
) XXX O
= XXX O
0 XXX O
. XXX O
732 XXX O
, XXX O
Cupressaceae XXX O
, XXX O
r XXX O
( XXX O
p XXX O
) XXX O
= XXX O
0 XXX O
. XXX O
695 XXX O
, XXX O
Poaceae XXX O
, XXX O
r XXX O
( XXX O
p XXX O
) XXX O
= XXX O
0 XXX O
. XXX O
950 XXX O
, XXX O
Ambrosia XXX O
, XXX O
r XXX O
( XXX O
p XXX O
) XXX O
= XXX O
0 XXX O
. XXX O
903 XXX O
, XXX O
and XXX O
Rumex XXX O
, XXX O
r XXX O
( XXX O
p XXX O
) XXX O
= XXX O
0 XXX O
. XXX O
572 XXX O
, XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
001 XXX O
) XXX O
. XXX O

Despite XXX O
an XXX O
overall XXX O
survival XXX O
rate XXX O
of XXX O
43% XXX O
, XXX O
survival XXX O
to XXX O
discharge XXX O
varied XXX O
greatly XXX O
( XXX O
0 XXX O
to XXX O
100% XXX O
) XXX O
among XXX O
the XXX O
24 XXX O
diagnostic XXX O
groups XXX O
: XXX O
tumor XXX O
lysis XXX O
syndrome XXX O
and XXX O
systemic XXX O
lupus XXX O
erythematosus XXX O
( XXX O
3 XXX O
/ XXX O
3 XXX O
patients XXX O
each XXX O
, XXX O
100% XXX O
) XXX O
, XXX O
hemolytic XXX O
uremic XXX O
syndrome XXX O
( XXX O
8 XXX O
/ XXX O
9 XXX O
patients XXX O
, XXX O
89% XXX O
) XXX O
. XXX O

Natural XXX O
FL XXX B-GENE
protein XXX I-GENE
has XXX O
been XXX O
purified XXX O
from XXX O
a XXX O
stromal XXX O
cell XXX O
line XXX O
and XXX O
shown XXX O
to XXX O
be XXX O
a XXX O
65 XXX O
kD XXX O
nondisulfide-linked XXX O
homodimeric XXX O
glycoprotein XXX O
comprised XXX O
of XXX O
30 XXX O
kD XXX O
subunits XXX O
, XXX O
each XXX O
containing XXX O
12 XXX O
kD XXX O
of XXX O
N- XXX O
and XXX O
O-linked XXX O
sugars XXX O
. XXX O

Scientific XXX O
cooperation XXX O
of XXX O
CMEA XXX O
member XXX O
countries XXX O
has XXX O
been XXX O
carried XXX O
out XXX O
since XXX O
1974 XXX O
under XXX O
the XXX O
sponsorship XXX O
of XXX O
the XXX O
Cancer XXX O
Research XXX O
Institute XXX O
, XXX O
Slovak XXX O
Academy XXX O
of XXX O
Sciences XXX O
( XXX O
Czechoslovakia XXX O
) XXX O
within XXX O
the XXX O
framework XXX O
of XXX O
CMEA XXX O
. XXX O

These XXX O
observations XXX O
provide XXX O
strong XXX O
support XXX O
for XXX O
the XXX O
idea XXX O
that XXX O
expression XXX O
of XXX O
mutant XXX O
tRNA XXX O
can XXX O
confer XXX O
a XXX O
mutator XXX O
phenotype XXX O
, XXX O
including XXX O
the XXX O
UVM-constitutive XXX O
phenotype XXX O
observed XXX O
in XXX O
mutA XXX B-GENE
and XXX O
mutC XXX B-GENE
cells XXX O
. XXX O

Prior XXX O
to XXX O
meals XXX O
2 XXX O
to XXX O
3 XXX O
times XXX O
daily XXX O
, XXX O
1-2 XXX O
tablespoons XXX O
of XXX O
Alzoon XXX O
are XXX O
recommended XXX O
. XXX O

Molecular XXX O
cloning XXX O
of XXX O
a XXX O
cysteine XXX B-GENE
synthase XXX I-GENE
cDNA XXX I-GENE
from XXX O
Citrullus XXX O
vulgaris XXX O
( XXX O
watermelon XXX O
) XXX O
by XXX O
genetic XXX O
complementation XXX O
in XXX O
an XXX O
Escherichia XXX O
coli XXX O
Cys- XXX O
auxotroph XXX O
. XXX O

Gel XXX O
filtration XXX O
and XXX O
co-immunoprecipitation XXX O
analyses XXX O
reveal XXX O
that XXX O
Mad2p XXX B-GENE
tightly XXX O
associates XXX O
with XXX O
another XXX O
spindle XXX O
checkpoint XXX O
component XXX O
, XXX O
Mad1p XXX B-GENE
. XXX O

The XXX O
absorbable XXX O
perisplenic XXX O
mesh XXX O
is XXX O
an XXX O
important XXX O
improvement XXX O
, XXX O
and XXX O
in XXX O
some XXX O
cases XXX O
it XXX O
may XXX O
replace XXX O
other XXX O
techniques XXX O
for XXX O
arresting XXX O
splenic XXX O
bleeding XXX O
. XXX O

Administration XXX O
of XXX O
adrenaline XXX O
resulted XXX O
in XXX O
a XXX O
large XXX O
overestimation XXX O
of XXX O
the XXX O
SaO2 XXX O
in XXX O
6 XXX O
of XXX O
the XXX O
7 XXX O
measurements XXX O
. XXX O

This XXX O
finding XXX O
represents XXX O
both XXX O
a XXX O
potentially XXX O
important XXX O
mechanism XXX O
by XXX O
which XXX O
HPV XXX O
gene XXX O
expression XXX O
can XXX O
be XXX O
regulated XXX O
and XXX O
an XXX O
interesting XXX O
model XXX O
for XXX O
the XXX O
study XXX O
of XXX O
transcriptional XXX O
cooperativity XXX O
. XXX O

Expression XXX O
of XXX O
h6 XXX O
. XXX O
1 XXX O
in XXX O
COS-1 XXX O
cells XXX O
led XXX O
to XXX O
the XXX O
production XXX O
of XXX O
a XXX O
typical XXX O
type XXX B-GENE
IV XXX I-GENE
PDE XXX I-GENE
activity XXX O
in XXX O
that XXX O
cAMP XXX O
, XXX O
but XXX O
not XXX O
cGMP XXX O
, XXX O
served XXX O
as XXX O
substrate XXX O
and XXX O
its XXX O
activity XXX O
was XXX O
insensitive XXX O
to XXX O
either XXX O
Ca2+ XXX O
/ XXX O
CaM XXX O
or XXX O
cGMP XXX O
but XXX O
was XXX O
inhibited XXX O
by XXX O
low XXX O
concentrations XXX O
of XXX O
rolipram XXX O
. XXX O
( XXX O
ABSTRACT XXX O
TRUNCATED XXX O
AT XXX O
400 XXX O
WORDS XXX O
) XXX O

In XXX O
conclusion XXX O
, XXX O
to XXX O
study XXX O
and XXX O
overcome XXX O
TI XXX O
region-based XXX O
expression XXX O
problems XXX O
it XXX O
is XXX O
worthwhile XXX O
to XXX O
start XXX O
out XXX O
with XXX O
a XXX O
versatile XXX O
vector XXX O
containing XXX O
exhaustive XXX O
mutations XXX O
in XXX O
the XXX O
periShine-Dalgarno XXX O
sequences XXX O
; XXX O
as XXX O
a XXX O
rule XXX O
the XXX O
coding XXX O
MTI XXX O
subregion XXX O
can XXX O
be XXX O
kept XXX O
unchanged XXX O
. XXX O

In XXX O
the XXX O
group XXX O
of XXX O
asthmatics XXX O
statistically XXX O
significant XXX O
correlation XXX O
was XXX O
found XXX O
between XXX O
PC20 XXX O
PGF2 XXX O
alpha XXX O
and XXX O
histamine XXX O
values XXX O
( XXX O
r XXX O
= XXX O
0 XXX O
. XXX O
538 XXX O
, XXX O
p XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
. XXX O

PURPOSE XXX O
: XXX O
The XXX O
objective XXX O
of XXX O
this XXX O
study XXX O
was XXX O
to XXX O
assess XXX O
first XXX O
embryo XXX O
cleavage XXX O
( XXX O
FEC XXX O
) XXX O
25-27 XXX O
h XXX O
after XXX O
intracytoplasmic XXX O
sperm XXX O
injection XXX O
( XXX O
ICSI XXX O
) XXX O
as XXX O
a XXX O
parameter XXX O
for XXX O
the XXX O
embryo XXX O
selection XXX O
process XXX O
. XXX O

The XXX O
recommendation XXX O
is XXX O
made XXX O
that XXX O
specific XXX O
sub-groups XXX O
of XXX O
attempters XXX O
need XXX O
to XXX O
be XXX O
identified XXX O
and XXX O
may XXX O
warrant XXX O
specialized XXX O
intervention XXX O
strategies XXX O
. XXX O

The XXX O
deduced XXX O
bovine XXX O
EFIA#1 XXX B-GENE
amino XXX O
acid XXX O
( XXX O
aa XXX O
) XXX O
sequence XXX O
is XXX O
98% XXX O
identical XXX O
to XXX O
rat XXX O
EFIA XXX B-GENE
and XXX O
100% XXX O
identical XXX O
to XXX O
human XXX B-GENE
EFIA XXX I-GENE
/ XXX I-GENE
DbpB XXX I-GENE
/ XXX I-GENE
YB-1 XXX I-GENE
family XXX I-GENE
member XXX O
DNA-binding XXX B-GENE
protein XXX I-GENE
B XXX I-GENE
( XXX O
DbpB XXX B-GENE
) XXX O
. XXX O

The XXX O
STE20 XXX B-GENE
gene XXX I-GENE
, XXX O
encoding XXX O
a XXX O
protein XXX B-GENE
kinase XXX I-GENE
required XXX O
for XXX O
pheromone XXX O
signal XXX O
transduction XXX O
, XXX O
has XXX O
recently XXX O
been XXX O
identified XXX O
in XXX O
a XXX O
genetic XXX O
screen XXX O
for XXX O
high-gene-dosage XXX O
suppressors XXX O
of XXX O
a XXX O
partly XXX O
defective XXX O
G XXX B-GENE
beta XXX I-GENE
mutation XXX O
. XXX O

The XXX O
author XXX O
gives XXX O
an XXX O
account XXX O
of XXX O
antipsychotic XXX O
, XXX O
analgetic XXX O
, XXX O
myorelaxing XXX O
and XXX O
vasodilatating XXX O
effects XXX O
of XXX O
some XXX O
calcium XXX O
antagonists XXX O
, XXX O
and XXX O
their XXX O
clinical XXX O
application XXX O
is XXX O
discussed XXX O
. XXX O

Quantitative XXX O
computed XXX O
tomography XXX O
for XXX O
measuring XXX O
vertebral XXX O
bone XXX O
mineral XXX O
content XXX O
offers XXX O
high XXX O
sensitivity XXX O
and XXX O
reproducibility XXX O
. XXX O

Autoregulation XXX O
enables XXX O
different XXX O
pathways XXX O
to XXX O
control XXX O
CCAAT XXX B-GENE
/ XXX I-GENE
enhancer XXX I-GENE
binding XXX I-GENE
protein XXX I-GENE
beta XXX I-GENE
( XXX O
C XXX B-GENE
/ XXX I-GENE
EBP XXX I-GENE
beta XXX I-GENE
) XXX O
transcription XXX O
. XXX O

Little XXX O
or XXX O
no XXX O
protection XXX O
was XXX O
detected XXX O
using XXX O
adrenal XXX O
cortex XXX O
, XXX O
adrenal XXX O
medulla XXX O
, XXX O
liver XXX O
, XXX O
kidney XXX O
cortex XXX O
, XXX O
spleen XXX O
, XXX O
or XXX O
T-lymphocyte XXX O
total XXX O
RNA XXX O
. XXX O

Furthermore XXX O
, XXX O
a XXX O
pTyr317 XXX B-GENE
Shc XXX I-GENE
phosphopeptide XXX I-GENE
selectively XXX O
recognized XXX O
Grb2 XXX B-GENE
, XXX O
Sos1 XXX B-GENE
, XXX O
SHIP XXX B-GENE
, XXX O
and XXX O
the XXX O
p85 XXX B-GENE
subunit XXX I-GENE
of XXX O
phosphatidylinositol XXX B-GENE
3' XXX I-GENE
kinase XXX I-GENE
from XXX O
mast XXX O
cells XXX O
, XXX O
as XXX O
characterized XXX O
by XXX O
mass XXX O
spectrometry XXX O
. XXX O

A XXX O
5' XXX O
RNA XXX O
stem-loop XXX O
participates XXX O
in XXX O
the XXX O
transcription XXX O
attenuation XXX O
mechanism XXX O
that XXX O
controls XXX O
expression XXX O
of XXX O
the XXX O
Bacillus XXX B-GENE
subtilis XXX I-GENE
trpEDCFBA XXX I-GENE
operon XXX I-GENE
. XXX O

A XXX O
second XXX O
even XXX O
more XXX O
significant XXX O
match XXX O
to XXX O
this XXX O
E XXX O
. XXX O
coli XXX O
region XXX O
was XXX O
found XXX O
in XXX O
the XXX O
retroviral XXX B-GENE
ribonuclease XXX I-GENE
H XXX I-GENE
( XXX O
RNase XXX B-GENE
H XXX I-GENE
) XXX O
domain XXX O
, XXX O
and XXX O
corresponds XXX O
precisely XXX O
to XXX O
a XXX O
region XXX O
that XXX O
has XXX O
been XXX O
aligned XXX O
by XXX O
previous XXX O
investigators XXX O
with XXX O
the XXX O
E XXX B-GENE
. XXX I-GENE
coli XXX I-GENE
RNase XXX I-GENE
H XXX I-GENE
, XXX O
suggesting XXX O
that XXX O
Pol XXX B-GENE
I XXX I-GENE
helices XXX O
O XXX O
and XXX O
P XXX O
are XXX O
homologous XXX O
to XXX O
helices XXX O
A XXX O
and XXX O
D XXX O
of XXX O
the XXX O
RNase XXX B-GENE
H XXX I-GENE
crystal XXX O
structure XXX O
, XXX O
respectively XXX O
. XXX O

Relationship XXX O
of XXX O
CDK-activating XXX B-GENE
kinase XXX I-GENE
and XXX O
RNA XXX B-GENE
polymerase XXX I-GENE
II XXX I-GENE
CTD XXX B-GENE
kinase XXX I-GENE
TFIIH XXX B-GENE
/ XXX I-GENE
TFIIK XXX I-GENE
. XXX O

In XXX O
conclusion XXX O
: XXX O
( XXX O
i XXX O
) XXX O
TECRA XXX O
kit XXX O
is XXX O
suggested XXX O
to XXX O
be XXX O
used XXX O
for XXX O
screening XXX O
SE XXX O
producing XXX O
strains XXX O
; XXX O
( XXX O
ii XXX O
) XXX O
SET-RPLA XXX O
and XXX O
RIDASCREEN XXX O
kits XXX O
are XXX O
suitable XXX O
for XXX O
epidemiological XXX O
investigation XXX O
of XXX O
SE XXX O
types XXX O
, XXX O
but XXX O
the XXX O
lack XXX O
of XXX O
ability XXX O
for XXX O
detecting XXX O
SEE XXX O
, XXX O
long XXX O
time XXX O
required XXX O
for XXX O
testing XXX O
with XXX O
SET-RPLA XXX O
kit XXX O
and XXX O
high XXX O
background XXX O
when XXX O
using XXX O
RIDASCREEN XXX O
kit XXX O
must XXX O
be XXX O
overcome XXX O
; XXX O
and XXX O
( XXX O
iii XXX O
) XXX O
because XXX O
of XXX O
the XXX O
complicated XXX O
test XXX O
procedures XXX O
and XXX O
the XXX O
lack XXX O
of XXX O
ability XXX O
for XXX O
detecting XXX O
SEE XXX O
, XXX O
the XXX O
practicality XXX O
of XXX O
SET-EIA XXX O
kit XXX O
in XXX O
screening XXX O
and XXX O
epidemiological XXX O
research XXX O
purposes XXX O
is XXX O
low XXX O
. XXX O

Significantly XXX O
greater XXX O
improvement XXX O
( XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
in XXX O
the XXX O
sertraline XXX O
group XXX O
first XXX O
became XXX O
apparent XXX O
by XXX O
the XXX O
end XXX O
of XXX O
week XXX O
3 XXX O
on XXX O
the XXX O
Y-BOCS XXX O
and XXX O
the XXX O
CGI XXX O
Improvement XXX O
scale XXX O
, XXX O
and XXX O
by XXX O
the XXX O
end XXX O
of XXX O
weeks XXX O
6 XXX O
and XXX O
8 XXX O
, XXX O
respectively XXX O
, XXX O
on XXX O
the XXX O
NIMH XXX O
and XXX O
CGI XXX O
Severity XXX O
scale XXX O
. XXX O

Young XXX O
fish XXX O
( XXX O
Oreochromis XXX O
mossambicus XXX O
) XXX O
were XXX O
exposed XXX O
to XXX O
microgravity XXX O
( XXX O
mug XXX O
) XXX O
for XXX O
9 XXX O
to XXX O
10 XXX O
days XXX O
during XXX O
space XXX O
missions XXX O
STS-55 XXX O
and XXX O
STS-84 XXX O
, XXX O
or XXX O
to XXX O
hypergravity XXX O
( XXX O
hg XXX O
) XXX O
for XXX O
9 XXX O
days XXX O
. XXX O

Both XXX O
the XXX O
MVBF XXX O
and XXX O
the XXX O
maximum XXX O
EMG XXX O
activity XXX O
in XXX O
the XXX O
right XXX O
masseter XXX O
and XXX O
the XXX O
left XXX O
anterior XXX O
temporalis XXX O
muscles XXX O
were XXX O
significantly XXX O
decreased XXX O
during XXX O
muscle XXX O
pain XXX O
when XXX O
the XXX O
subjects XXX O
bit XXX O
on XXX O
the XXX O
painful XXX O
side XXX O
. XXX O

Molecular XXX O
cloning XXX O
of XXX O
rat XXX B-GENE
SH2-containing XXX I-GENE
inositol XXX I-GENE
phosphatase XXX I-GENE
2 XXX I-GENE
( XXX O
SHIP2 XXX B-GENE
) XXX O
and XXX O
its XXX O
role XXX O
in XXX O
the XXX O
regulation XXX O
of XXX O
insulin XXX B-GENE
signaling XXX O
. XXX O

The XXX O
C-terminal XXX O
region XXX O
contains XXX O
the XXX O
PTP-like XXX B-GENE
domain XXX I-GENE
, XXX O
whereas XXX O
the XXX O
N-terminal XXX O
region XXX O
shows XXX O
no XXX O
homology XXX O
to XXX O
any XXX O
known XXX O
mammalian XXX O
protein XXX O
. XXX O

It XXX O
may XXX O
be XXX O
dependent XXX O
on XXX O
location XXX O
of XXX O
a XXX O
focus XXX O
( XXX O
according XXX O
to XXX O
EEG XXX O
) XXX O
as XXX O
well XXX O
as XXX O
on XXX O
the XXX O
character XXX O
and XXX O
manifestation XXX O
of XXX O
the XXX O
accompanying XXX O
neuropsychologic XXX O
symptomatology XXX O
. XXX O

Selective XXX O
activation XXX O
of XXX O
adrenaline XXX O
secretion XXX O
by XXX O
the XXX O
rat XXX O
adrenal XXX O
in XXX O
neuroglycopenia XXX O
detected XXX O
via XXX O
microdialysis XXX O
. XXX O

A XXX O
limited XXX O
sampling XXX O
strategy XXX O
was XXX O
used XXX O
based XXX O
on XXX O
a XXX O
bayesian XXX O
parameter XXX O
estimation XXX O
algorithm XXX O
that XXX O
is XXX O
part XXX O
of XXX O
the XXX O
ADAPT XXX O
II XXX O
software XXX O
package XXX O
. XXX O

A XXX O
single XXX O
base XXX O
change XXX O
( XXX O
A8G XXX O
) XXX O
in XXX O
either XXX O
sequence XXX O
reduces XXX O
hnRNP XXX B-GENE
A2 XXX I-GENE
binding XXX O
and XXX O
, XXX O
in XXX O
the XXX O
case XXX O
of XXX O
A2RE-2 XXX B-GENE
, XXX O
inhibits XXX O
RNA XXX O
transport XXX O
. XXX O

Halothane XXX O
is XXX O
metabolized XXX O
by XXX O
an XXX O
oxidative XXX O
pathway XXX O
to XXX O
stable XXX O
, XXX O
nonvolatile XXX O
end XXX O
products XXX O
, XXX O
trifluoroacetic XXX O
acid XXX O
( XXX O
TFAA XXX O
) XXX O
and XXX O
bromide XXX O
( XXX O
Br- XXX O
) XXX O
, XXX O
and XXX O
by XXX O
reductive XXX O
pathways XXX O
to XXX O
Br-and XXX O
inorganic XXX O
fluoride XXX O
( XXX O
F- XXX O
) XXX O
. XXX O

Hepatitis XXX O
B XXX O
vaccine XXX O
: XXX O
still XXX O
has XXX O
its XXX O
problems XXX O
. XXX O

We XXX O
have XXX O
cloned XXX O
a XXX O
kinase XXX O
, XXX O
Nlk XXX B-GENE
, XXX O
that XXX O
is XXX O
a XXX O
murine XXX B-GENE
homolog XXX I-GENE
of XXX I-GENE
the XXX I-GENE
Drosophila XXX I-GENE
nemo XXX I-GENE
( XXX O
nmo XXX B-GENE
) XXX O
gene XXX O
. XXX O

The XXX O
UV XXX O
induction XXX O
of XXX O
c-jun XXX B-GENE
is XXX O
mediated XXX O
by XXX O
two XXX O
UV XXX B-GENE
response XXX I-GENE
elements XXX I-GENE
consisting XXX O
of XXX O
AP-1-like XXX B-GENE
sequences XXX I-GENE
within XXX O
its XXX O
5' XXX O
control XXX O
region XXX O
. XXX O

We XXX O
found XXX O
that XXX O
TCR XXX B-GENE
signaling XXX O
induces XXX O
AP-1 XXX B-GENE
binding XXX O
to XXX O
this XXX O
site XXX O
and XXX O
regulates XXX O
the XXX O
fasl XXX B-GENE
promoter XXX I-GENE
function XXX O
in XXX O
a XXX O
fashion XXX O
dependent XXX O
on XXX O
NF-kappaB XXX B-GENE
binding XXX O
. XXX O

Specifically XXX O
, XXX O
I XXX O
use XXX O
molecular XXX O
markers XXX O
that XXX O
identify XXX O
particular XXX O
neuroectodermal XXX O
domains XXX O
, XXX O
all XXX O
neuroblasts XXX O
or XXX O
individual XXX O
neuroblasts XXX O
, XXX O
to XXX O
show XXX O
that XXX O
in XXX O
DER XXX B-GENE
mutant XXX I-GENE
embryos XXX O
( XXX O
1 XXX O
) XXX O
intermediate XXX O
column XXX O
neuroblasts XXX O
do XXX O
not XXX O
form XXX O
, XXX O
( XXX O
2 XXX O
) XXX O
medial XXX O
column XXX O
neuroblasts XXX O
often XXX O
acquire XXX O
identities XXX O
inappropriate XXX O
for XXX O
their XXX O
position XXX O
, XXX O
while XXX O
( XXX O
3 XXX O
) XXX O
lateral XXX O
neuroblasts XXX O
develop XXX O
normally XXX O
. XXX O

The XXX O
acfD XXX B-GENE
gene XXX I-GENE
encompasses XXX O
254 XXX O
nt XXX O
that XXX O
are XXX O
predicted XXX O
to XXX O
encode XXX O
an XXX O
88-amino-acid XXX O
( XXX O
aa XXX O
) XXX O
protein XXX O
. XXX O

The XXX O
primary XXX O
structure XXX O
of XXX O
the XXX O
GAL7 XXX B-GENE
5' XXX I-GENE
flanking XXX I-GENE
region XXX I-GENE
has XXX O
many XXX O
features XXX O
common XXX O
to XXX O
those XXX O
of XXX O
multicellular XXX O
eukaryotic XXX O
genes XXX O
. XXX O

Hisako XXX O
Minowa XXX O
who XXX O
has XXX O
worked XXX O
as XXX O
a XXX O
psychiatric XXX O
counsellor XXX O
in XXX O
industry XXX O
for XXX O
the XXX O
past XXX O
20 XXX O
years XXX O
. XXX O

Finally XXX O
, XXX O
nonphotosynthetic XXX O
mutants XXX O
, XXX O
including XXX O
the XXX O
tscA-lacking XXX B-GENE
photosystem XXX I-GENE
I XXX I-GENE
mutant XXX I-GENE
, XXX O
H13 XXX O
, XXX O
did XXX O
not XXX O
show XXX O
evidence XXX O
of XXX O
light-stimulated XXX O
RNA XXX O
processing XXX O
. XXX O

Under XXX O
the XXX O
same XXX O
hematocrit XXX O
and XXX O
flow XXX O
conditions XXX O
, XXX O
the XXX O
rate XXX O
of XXX O
oxygen XXX O
saturation XXX O
decrease XXX O
was XXX O
significantly XXX O
higher XXX O
for XXX O
the XXX O
sickle XXX O
cells XXX O
than XXX O
for XXX O
normal XXX O
cells XXX O
. XXX O

The XXX O
genomic XXX O
structure XXX O
of XXX O
brk XXX B-GENE
consists XXX O
of XXX O
8 XXX O
exons XXX O
, XXX O
whose XXX O
boundaries XXX O
are XXX O
distinct XXX O
from XXX O
other XXX O
non-receptor XXX O
PTK XXX B-GENE
family XXX I-GENE
members XXX O
, XXX O
again XXX O
indicating XXX O
a XXX O
structural XXX O
and XXX O
functional XXX O
divergence XXX O
. XXX O

The XXX O
syncytial XXX O
microvillous XXX O
projections XXX O
seemed XXX O
to XXX O
be XXX O
more XXX O
numerous XXX O
and XXX O
longer XXX O
in XXX O
CNF XXX O
, XXX O
otherwise XXX O
the XXX O
structure XXX O
of XXX O
the XXX O
trophoblastic XXX O
layer XXX O
of XXX O
the XXX O
villi XXX O
and XXX O
the XXX O
lining XXX O
of XXX O
the XXX O
subtrophoblastic XXX O
vessels XXX O
were XXX O
identical XXX O
in XXX O
CNF XXX O
and XXX O
controls XXX O
. XXX O

This XXX O
study XXX O
was XXX O
undertaken XXX O
to XXX O
define XXX O
the XXX O
mechanism XXX O
for XXX O
the XXX O
respiratory XXX O
inhibition XXX O
observed XXX O
during XXX O
high-frequency XXX O
oscillatory XXX O
ventilation XXX O
( XXX O
HFOV XXX O
) XXX O
. XXX O

These XXX O
cells XXX O
averaged XXX O
17 XXX O
microns XXX O
in XXX O
diameter XXX O
and XXX O
reproduced XXX O
by XXX O
fission XXX O
, XXX O
forming XXX O
clusters XXX O
of XXX O
two XXX O
or XXX O
four XXX O
daughter XXX O
cells XXX O
. XXX O

Then XXX O
we XXX O
correlated XXX O
HRCT XXX O
findings XXX O
with XXX O
the XXX O
clinical XXX O
features XXX O
, XXX O
pulmonary XXX O
functions XXX O
and XXX O
methacholine XXX O
PC20 XXX O
( XXX O
PC20M XXX O
) XXX O
and XXX O
studied XXX O
their XXX O
clinical XXX O
significance XXX O
. XXX O

From XXX O
the XXX O
above XXX O
results XXX O
, XXX O
we XXX O
might XXX O
infer XXX O
that XXX O
the XXX O
seizure XXX O
type XXX O
of XXX O
TLE XXX O
and XXX O
a XXX O
high XXX O
frequency XXX O
of XXX O
seizure XXX O
are XXX O
two XXX O
major XXX O
independent XXX O
precipitate XXX O
factors XXX O
for XXX O
abnormal XXX O
latencies XXX O
of XXX O
P300 XXX O
in XXX O
the XXX O
epileptic XXX O
patients XXX O
. XXX O

The XXX O
regulatory XXX O
region XXX O
also XXX O
has XXX O
a XXX O
sequence XXX O
similar XXX O
to XXX O
the XXX O
binding XXX O
site XXX O
for XXX O
a XXX O
liver-specific XXX O
transcription XXX O
factor XXX O
, XXX O
hepatocyte XXX B-GENE
nuclear XXX I-GENE
factor XXX I-GENE
1 XXX I-GENE
( XXX O
HNF-1 XXX B-GENE
) XXX O
, XXX O
at XXX O
positions XXX O
-120 XXX O
to XXX O
-132 XXX O
. XXX O

Deletion XXX O
mutagenesis XXX O
demonstrated XXX O
that XXX O
these XXX O
two XXX O
elements XXX O
are XXX O
involved XXX O
in XXX O
the XXX O
positive XXX O
regulation XXX O
of XXX O
MLC-2 XXX B-GENE
gene XXX I-GENE
transcription XXX O
. XXX O

Horseradish XXX B-GENE
peroxidase XXX I-GENE
as XXX O
a XXX O
permeability XXX O
marker XXX O
in XXX O
injured XXX O
rat XXX O
caudal XXX O
and XXX O
iliac XXX O
arteries XXX O
. XXX O

Recent XXX O
investigations XXX O
have XXX O
detailed XXX O
a XXX O
selective XXX O
dye XXX O
release XXX O
technique XXX O
in XXX O
which XXX O
a XXX O
pulse XXX O
of XXX O
laser XXX O
light XXX O
induces XXX O
the XXX O
release XXX O
of XXX O
a XXX O
fluorescent XXX O
dye XXX O
from XXX O
temperature-sensitive XXX O
liposomes XXX O
circulating XXX O
in XXX O
the XXX O
retinal XXX O
vasculature XXX O
. XXX O

Using XXX O
the XXX O
sequence XXX O
data XXX O
obtained XXX O
from XXX O
the XXX O
human XXX B-GENE
TCRAC XXX I-GENE
/ XXX I-GENE
TCRDC XXX I-GENE
region XXX I-GENE
, XXX O
we XXX O
have XXX O
extended XXX O
a XXX O
polymerase XXX B-GENE
chain XXX O
reaction-based XXX O
assay XXX O
to XXX O
test XXX O
for XXX O
the XXX O
expression XXX O
of XXX O
the XXX O
individual XXX O
TCRAJ XXX B-GENE
gene XXX I-GENE
segments XXX I-GENE
. XXX O

No XXX O
therapy XXX O
exists XXX O
for XXX O
halting XXX O
the XXX O
progression XXX O
of XXX O
the XXX O
disease XXX O
with XXX O
the XXX O
possible XXX O
exception XXX O
of XXX O
laser XXX O
photocoagulation XXX O
treatment XXX O
used XXX O
to XXX O
ablate XXX O
subretinal XXX O
neovascular XXX O
membranes XXX O
in XXX O
an XXX O
attempt XXX O
to XXX O
avoid XXX O
complications XXX O
of XXX O
subretinal XXX O
hemorrhages XXX O
. XXX O

Association XXX O
of XXX O
stress XXX O
during XXX O
delivery XXX O
with XXX O
increased XXX O
numbers XXX O
of XXX O
nucleated XXX O
cells XXX O
and XXX O
hematopoietic XXX O
progenitor XXX O
cells XXX O
in XXX O
umbilical XXX O
cord XXX O
blood XXX O
. XXX O

The XXX O
pharmacokinetic XXX O
parameters XXX O
which XXX O
helped XXX O
predict XXX O
these XXX O
toxicities XXX O
included XXX O
area XXX O
under XXX O
the XXX O
curve XXX O
and XXX O
peak XXX O
plasma XXX O
level XXX O
. XXX O

In XXX O
contrast XXX O
, XXX O
capsid XXX O
proteins XXX O
derived XXX O
from XXX O
the XXX O
P1 XXX B-GENE
precursor XXX I-GENE
with XXX O
a XXX O
valine XXX O
substitution XXX O
at XXX O
the XXX O
amino XXX O
terminus XXX O
of XXX O
VP1 XXX B-GENE
( XXX O
VP1-G001V XXX B-GENE
) XXX O
assembled XXX O
empty XXX O
capsid XXX O
particles XXX O
but XXX O
were XXX O
deficient XXX O
in XXX O
assembling XXX O
RNA-containing XXX O
virions XXX O
. XXX O

OBJECTIVE XXX O
: XXX O
This XXX O
study XXX O
was XXX O
conducted XXX O
to XXX O
assess XXX O
the XXX O
relative XXX O
roles XXX O
of XXX O
99mTc-sestamibi XXX O
scintimammography XXX O
and XXX O
sonography XXX O
in XXX O
the XXX O
evaluation XXX O
of XXX O
breast XXX O
lesions XXX O
that XXX O
are XXX O
indeterminate XXX O
or XXX O
suspicious XXX O
on XXX O
mammography XXX O
or XXX O
clinical XXX O
examination XXX O
. XXX O

The XXX O
glial XXX O
cyst XXX O
wall XXX O
was XXX O
lined XXX O
in XXX O
part XXX O
by XXX O
flattened XXX O
or XXX O
cuboidal XXX O
epithelium XXX O
. XXX O

Analysis XXX O
of XXX O
the XXX O
5' XXX O
flanking XXX O
region XXX O
of XXX O
the XXX O
gene XXX O
also XXX O
revealed XXX O
the XXX O
presence XXX O
of XXX O
multiple XXX O
TATA XXX O
and XXX O
CAAT XXX O
sequences XXX O
. XXX O

In XXX O
the XXX O
infected XXX O
neonates XXX O
serum XXX O
alpha-amylase XXX B-GENE
value XXX O
, XXX O
as XXX O
determined XXX O
by XXX O
the XXX O
blue XXX O
starch XXX O
method XXX O
, XXX O
was XXX O
only XXX O
40% XXX O
that XXX O
of XXX O
healthy XXX O
controls XXX O
; XXX O
the XXX O
mean XXX O
value XXX O
of XXX O
175 XXX O
. XXX O
1 XXX O
+ XXX O
/ XXX O
- XXX O
64 XXX O
. XXX O
9 XXX O
IU XXX O
/ XXX O
l XXX O
for XXX O
healthy XXX O
neonates XXX O
was XXX O
significantly XXX O
higher XXX O
( XXX O
p XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
0010 XXX O
) XXX O
than XXX O
the XXX O
value XXX O
of XXX O
82 XXX O
. XXX O
8 XXX O
+ XXX O
/ XXX O
- XXX O
44 XXX O
. XXX O
4 XXX O
IU XXX O
/ XXX O
l XXX O
for XXX O
the XXX O
infected XXX O
neonates XXX O
. XXX O

Motivational XXX O
factors XXX O
focusing XXX O
on XXX O
attitudes XXX O
, XXX O
perceived XXX O
susceptibility XXX O
to XXX O
pregnancy XXX O
, XXX O
and XXX O
normative XXX O
factors XXX O
were XXX O
also XXX O
relevant XXX O
. XXX O

Evaluation XXX O
of XXX O
the XXX O
Du XXX O
Pont XXX O
aca XXX O
ammonia XXX O
procedure XXX O
. XXX O

The XXX O
abscess XXX O
was XXX O
debrided XXX O
and XXX O
the XXX O
septum XXX O
was XXX O
patched XXX O
with XXX O
a XXX O
single XXX O
layer XXX O
of XXX O
autologous XXX O
pericardium XXX O
. XXX O

In XXX O
wild-type XXX O
cells XXX O
, XXX O
SSM1b XXX B-GENE
transcripts XXX I-GENE
accumulate XXX O
to XXX O
twice XXX O
the XXX O
level XXX O
of XXX O
SSM1a XXX B-GENE
transcripts XXX I-GENE
, XXX O
suggesting XXX O
that XXX O
SSM1b XXX B-GENE
is XXX O
responsible XXX O
for XXX O
the XXX O
majority XXX O
of XXX O
the XXX O
Ssm1p XXX B-GENE
pool XXX O
. XXX O

There XXX O
was XXX O
either XXX O
no XXX O
change XXX O
or XXX O
an XXX O
improvement XXX O
in XXX O
renographic XXX O
findings XXX O
( XXX O
t1 XXX O
/ XXX O
2 XXX O
time XXX O
and XXX O
/ XXX O
or XXX O
split XXX O
function XXX O
) XXX O
in XXX O
40 XXX O
patients XXX O
( XXX O
93% XXX O
) XXX O
. XXX O

Biochemical XXX O
analysis XXX O
reveals XXX O
that XXX O
KS1 XXX B-GENE
is XXX O
a XXX O
nuclear XXX O
protein XXX O
containing XXX O
two XXX O
transcriptional XXX O
repressor XXX O
domains XXX O
, XXX O
R1 XXX B-GENE
and XXX O
R2 XXX B-GENE
. XXX O

Is XXX O
criticism XXX O
of XXX O
patient XXX O
care XXX O
justified XXX O
and XXX O
does XXX O
it XXX O
have XXX O
educational XXX O
value XXX O
? XXX O
Patients' XXX O
criticism XXX O
contributes XXX O
to XXX O
improved XXX O
patient XXX O
care XXX O
. XXX O

To XXX O
gain XXX O
insight XXX O
into XXX O
the XXX O
expression XXX O
of XXX O
the XXX O
AtCP1 XXX B-GENE
gene XXX I-GENE
, XXX O
northern XXX O
blot XXX O
analysis XXX O
was XXX O
carried XXX O
out XXX O
. XXX O

These XXX O
TxRE XXX B-GENE
contain XXX O
cyclic XXX B-GENE
AMP-responsive XXX I-GENE
elements XXX I-GENE
( XXX O
CRE XXX B-GENE
) XXX O
, XXX O
but XXX O
, XXX O
remarkably XXX O
, XXX O
the XXX O
"TGACGTCA" XXX B-GENE
consensus XXX I-GENE
is XXX O
never XXX O
strictly XXX O
conserved XXX O
in XXX O
any XXX O
viral XXX O
strain XXX O
( XXX O
e XXX O
. XXX O
g XXX O
. XXX O
, XXX O
AGACGTCA XXX O
, XXX O
TGACGGCA XXX B-GENE
, XXX O
TGACCTCA XXX B-GENE
) XXX O
. XXX O

Three XXX O
large XXX O
field XXX O
placement XXX O
errors XXX O
( XXX O
two XXX O
patients XXX O
with XXX O
11 XXX O
. XXX O
5 XXX O
and XXX O
16 XXX O
. XXX O
0 XXX O
mm XXX O
distances XXX O
of XXX O
the XXX O
planned XXX O
versus XXX O
simulated XXX O
isocenter XXX O
, XXX O
respectively XXX O
and XXX O
one XXX O
patient XXX O
with XXX O
a XXX O
7 XXX O
degree XXX O
rotational XXX O
error XXX O
) XXX O
were XXX O
detected XXX O
and XXX O
, XXX O
as XXX O
with XXX O
the XXX O
smaller XXX O
errors XXX O
, XXX O
were XXX O
immediately XXX O
corrected XXX O
. XXX O

Natl XXX O
. XXX O

Variables XXX O
evaluated XXX O
were XXX O
number XXX O
of XXX O
weekly XXX O
anginal XXX O
events XXX O
, XXX O
data XXX O
from XXX O
ergometric XXX O
exercise XXX O
testing XXX O
with XXX O
simultaneous XXX O
electrocardiographic XXX O
registration XXX O
, XXX O
semiquantitative XXX O
evaluation XXX O
of XXX O
Tc-99m XXX O
2-methoxy XXX O
isobutyl XXX O
isonitrile XXX O
( XXX O
MIBI XXX O
) XXX O
scans XXX O
and XXX O
rheologic XXX O
variables XXX O
. XXX O

The XXX O
sequencing XXX O
of XXX O
the XXX O
conditional XXX O
lethal XXX O
mutation XXX O
ts-A13 XXX O
, XXX O
localized XXX O
in XXX O
the XXX O
nrdE XXX B-GENE
cistron XXX I-GENE
, XXX O
and XXX O
the XXX O
lethality XXX O
of XXX O
insertional XXX O
mutations XXX O
targeted XXX O
in XXX O
the XXX O
internal XXX O
region XXX O
of XXX O
nrdE XXX B-GENE
and XXX O
nrdF XXX B-GENE
, XXX O
demonstrated XXX O
the XXX O
essential XXX O
role XXX O
of XXX O
this XXX O
locus XXX O
. XXX O

RESULTS XXX O
: XXX O
We XXX O
identified XXX O
a XXX O
full-length XXX O
cDNA XXX O
with XXX O
an XXX O
open XXX O
reading XXX O
frame XXX O
of XXX O
2883 XXX O
bp XXX O
corresponding XXX O
to XXX O
a XXX O
predicted XXX O
protein XXX O
of XXX O
961 XXX O
amino XXX O
acids XXX O
that XXX O
shares XXX O
greater XXX O
than XXX O
95% XXX O
homology XXX O
with XXX O
the XXX O
rat XXX B-GENE
gamma-aminobutyric XXX I-GENE
acid XXX I-GENE
B XXX I-GENE
( XXX I-GENE
GABAB XXX I-GENE
) XXX I-GENE
receptor XXX I-GENE
. XXX O

The XXX O
FinO XXX B-GENE
protein XXX I-GENE
of XXX O
IncF XXX O
plasmids XXX O
binds XXX O
FinP XXX B-GENE
antisense XXX I-GENE
RNA XXX I-GENE
and XXX O
its XXX O
target XXX O
, XXX O
traJ XXX B-GENE
mRNA XXX I-GENE
, XXX O
and XXX O
promotes XXX O
duplex XXX O
formation XXX O
. XXX O

Because XXX O
of XXX O
the XXX O
operon XXX O
structure XXX O
of XXX O
this XXX O
organism XXX O
, XXX O
traditional XXX O
methods XXX O
such XXX O
as XXX O
insertional XXX O
mutagenesis XXX O
run XXX O
the XXX O
risk XXX O
of XXX O
introducing XXX O
polar XXX O
effects XXX O
on XXX O
downstream XXX O
genes XXX O
or XXX O
creating XXX O
secondary XXX O
mutations XXX O
elsewhere XXX O
in XXX O
the XXX O
genome XXX O
. XXX O

However XXX O
, XXX O
mechanisms XXX O
underlying XXX O
HIV-1 XXX O
gene XXX O
expression XXX O
in XXX O
the XXX O
CNS XXX O
are XXX O
poorly XXX O
understood XXX O
. XXX O

The XXX O
analysis XXX O
of XXX O
the XXX O
prevalence XXX O
values XXX O
shows XXX O
clearly XXX O
that XXX O
the XXX O
global XXX O
MS-frequency XXX O
is XXX O
closer XXX O
related XXX O
to XXX O
the XXX O
geomagnetic XXX O
than XXX O
to XXX O
the XXX O
geographic XXX O
latitude XXX O
. XXX O

A XXX O
single XXX O
rectal XXX O
dose XXX O
of XXX O
25 XXX O
mg XXX O
/ XXX O
kg XXX O
will XXX O
obtain XXX O
this XXX O
lower XXX O
concentration XXX O
within XXX O
1 XXX O
h XXX O
of XXX O
administration XXX O
and XXX O
maintain XXX O
it XXX O
for XXX O
up XXX O
to XXX O
6 XXX O
h XXX O
. XXX O

During XXX O
a XXX O
single XXX O
LAD XXX O
occlusion XXX O
lasting XXX O
35 XXX O
minutes XXX O
( XXX O
series XXX O
I XXX O
, XXX O
n XXX O
= XXX O
10 XXX O
) XXX O
9 XXX O
microns XXX O
TMs XXX O
were XXX O
infused XXX O
immediately XXX O
and XXX O
30 XXX O
minutes XXX O
after XXX O
ligation XXX O
, XXX O
15 XXX O
microns XXX O
TMs XXX O
being XXX O
infused XXX O
after XXX O
15-20 XXX O
minutes XXX O
. XXX O

Selective XXX O
translation XXX O
initiation XXX O
by XXX O
ribosome XXX O
jumping XXX O
in XXX O
adenovirus-infected XXX O
and XXX O
heat-shocked XXX O
cells XXX O
. XXX O

The XXX O
number XXX O
of XXX O
elements XXX O
and XXX O
their XXX O
sizes XXX O
relative XXX O
to XXX O
the XXX O
configuration XXX O
were XXX O
varied XXX O
in XXX O
a XXX O
series XXX O
of XXX O
five XXX O
experiments XXX O
. XXX O

The XXX O
median XXX O
durations XXX O
for XXX O
response XXX O
and XXX O
survival XXX O
time XXX O
in XXX O
the XXX O
late XXX O
phase XXX O
II XXX O
trial XXX O
were XXX O
2 XXX O
. XXX O
3 XXX O
months XXX O
and XXX O
5 XXX O
. XXX O
8 XXX O
months XXX O
, XXX O
respectively XXX O
. XXX O

None XXX O
of XXX O
the XXX O
five XXX O
proprotein XXX O
processing XXX O
proteases XXX B-GENE
tested XXX O
were XXX O
capable XXX O
of XXX O
cleaving XXX O
human XXX B-GENE
pro-LPH XXX I-GENE
, XXX O
strongly XXX O
suggesting XXX O
that XXX O
they XXX O
are XXX O
not XXX O
involved XXX O
in XXX O
the XXX O
maturation XXX O
of XXX O
this XXX O
enzyme XXX O
. XXX O

Single-alanine-substitution XXX O
mutations XXX O
had XXX O
minimal XXX O
, XXX O
if XXX O
any XXX O
, XXX O
effects XXX O
on XXX O
S-induced XXX O
cell-to-cell XXX O
fusion XXX O
. XXX O

Examination XXX O
of XXX O
the XXX O
immediate XXX O
sequence XXX O
5' XXX O
to XXX O
the XXX O
mRNA XXX O
start XXX O
site XXX O
reveals XXX O
no XXX O
TATA XXX O
box XXX O
and XXX O
multiple XXX O
known XXX O
enhancer XXX O
sequences XXX O
. XXX O

The XXX O
Klebsiella XXX B-GENE
aerogenes XXX I-GENE
gene XXX I-GENE
maoA XXX I-GENE
, XXX O
which XXX O
is XXX O
involved XXX O
in XXX O
the XXX O
synthesis XXX O
of XXX O
monoamine XXX B-GENE
oxidase XXX I-GENE
, XXX O
was XXX O
induced XXX O
by XXX O
tyramine XXX O
and XXX O
the XXX O
related XXX O
compounds XXX O
, XXX O
subjected XXX O
to XXX O
catabolite XXX O
and XXX O
ammonium XXX O
ion XXX O
repression XXX O
, XXX O
and XXX O
cloned XXX O
. XXX O

We XXX O
show XXX O
that XXX O
LexA-GAL4 XXX B-GENE
and XXX O
LexA-Bicoid XXX B-GENE
fusion XXX I-GENE
proteins XXX I-GENE
are XXX O
both XXX O
dependent XXX O
on XXX O
SNF2 XXX B-GENE
, XXX O
SNF5 XXX B-GENE
, XXX O
and XXX O
SNF6 XXX B-GENE
for XXX O
activation XXX O
of XXX O
target XXX O
genes XXX O
containing XXX O
one XXX O
or XXX O
multiple XXX O
lexA XXX B-GENE
operators XXX I-GENE
. XXX O

Alternative XXX O
transcript XXX O
of XXX O
the XXX O
nonselective-type XXX O
endothelin XXX B-GENE
receptor XXX I-GENE
from XXX O
rat XXX O
brain XXX O
. XXX O

The XXX O
incidence XXX O
of XXX O
cryptosporidiosis XXX O
in XXX O
young XXX O
children XXX O
was XXX O
determined XXX O
by XXX O
staining XXX O
of XXX O
faecal XXX O
specimens XXX O
with XXX O
a XXX O
modified XXX O
Kinyoun XXX O
stain XXX O
. XXX O

To XXX O
begin XXX O
to XXX O
characterize XXX O
the XXX O
role XXX O
of XXX O
the XXX O
RNA XXX B-GENE
subunits XXX I-GENE
in XXX O
enzyme XXX O
function XXX O
and XXX O
substrate XXX O
specificity XXX O
, XXX O
we XXX O
swapped XXX O
two XXX O
hairpin XXX O
structures XXX O
( XXX O
MRP3 XXX B-GENE
and XXX O
P3 XXX B-GENE
) XXX O
between XXX O
RNase XXX B-GENE
MRP XXX I-GENE
RNA XXX I-GENE
and XXX O
RNase XXX B-GENE
P XXX I-GENE
RNA XXX I-GENE
of XXX I-GENE
S XXX I-GENE
. XXX I-GENE
cerevisiae XXX I-GENE
. XXX O

The XXX O
electrodes XXX O
themselves XXX O
do XXX O
not XXX O
need XXX O
to XXX O
be XXX O
polished XXX O
prior XXX O
to XXX O
their XXX O
use XXX O
but XXX O
are XXX O
observed XXX O
to XXX O
be XXX O
slightly XXX O
recessed XXX O
from XXX O
the XXX O
surrounding XXX O
insulating XXX O
surface XXX O
. XXX O

The XXX O
central XXX O
visual XXX O
fields XXX O
of XXX O
2165 XXX O
normal XXX O
and XXX O
106 XXX O
glaucoma XXX O
eyes XXX O
were XXX O
measured XXX O
using XXX O
a XXX O
threshold XXX O
related XXX O
suprathreshold XXX O
strategy XXX O
. XXX O

Thus XXX O
, XXX O
we XXX O
have XXX O
identified XXX O
an XXX O
activation XXX O
target XXX O
of XXX O
a XXX O
human XXX O
activator XXX O
, XXX O
Oct-1 XXX B-GENE
, XXX O
within XXX O
its XXX O
cognate XXX O
basal XXX O
transcription XXX O
complex XXX O
. XXX O

Comparisons XXX O
with XXX O
other XXX O
known XXX O
germins XXX B-GENE
and XXX O
germin-like XXX B-GENE
proteins XXX I-GENE
indicate XXX O
that XXX O
these XXX O
Arabidopsis XXX O
GLP XXX B-GENE
subfamilies XXX O
are XXX O
unique XXX O
from XXX O
wheat XXX O
germin XXX B-GENE
. XXX O

Bone XXX O
marrow XXX O
abnormalities XXX O
in XXX O
Hodgkin's XXX O
disease XXX O
are XXX O
reviewed XXX O
and XXX O
the XXX O
current XXX O
understanding XXX O
of XXX O
the XXX O
pathological XXX O
mechanisms XXX O
leading XXX O
to XXX O
aplastic XXX O
anemia XXX O
is XXX O
discussed XXX O
. XXX O

That XXX O
of XXX O
the XXX O
T2 XXX B-GENE
gene XXX I-GENE
contains XXX O
numerous XXX O
potential XXX O
sites XXX O
for XXX O
binding XXX O
the XXX O
mammalian XXX B-GENE
transcription XXX I-GENE
factor XXX I-GENE
SP1 XXX I-GENE
, XXX O
but XXX O
no XXX O
TATA XXX O
or XXX O
CCAAT XXX O
sequences XXX O
are XXX O
evident XXX O
near XXX O
to XXX O
its XXX O
5' XXX O
end XXX O
, XXX O
although XXX O
these XXX O
latter XXX O
features XXX O
are XXX O
associated XXX O
with XXX O
the XXX O
human XXX B-GENE
T1 XXX I-GENE
gene XXX I-GENE
. XXX O

For XXX O
this XXX O
purpose XXX O
, XXX O
the XXX O
immediate XXX O
and XXX O
the XXX O
final XXX O
( XXX O
after XXX O
swelling XXX O
) XXX O
fixation XXX O
strengths XXX O
of XXX O
two XXX O
variations XXX O
of XXX O
the XXX O
swellable XXX O
bone XXX O
anchor XXX O
designs XXX O
( XXX O
a XXX O
smooth XXX O
anchor XXX O
and XXX O
a XXX O
screw XXX O
anchor XXX O
) XXX O
were XXX O
measured XXX O
in XXX O
two XXX O
different XXX O
foams XXX O
( XXX O
used XXX O
to XXX O
simulate XXX O
bone XXX O
) XXX O
with XXX O
different XXX O
densities XXX O
. XXX O

Similar XXX O
observations XXX O
were XXX O
made XXX O
with XXX O
unilateral XXX O
pneumothorax XXX O
of XXX O
15 XXX O
cmH2O XXX O
for XXX O
30 XXX O
min XXX O
. XXX O

The XXX O
unphosphorylated XXX O
form XXX O
of XXX O
RNA XXX B-GENE
polymerase XXX I-GENE
II XXX I-GENE
is XXX O
designated XXX O
IIA XXX B-GENE
, XXX O
whereas XXX O
the XXX O
phosphorylated XXX O
form XXX O
is XXX O
designated XXX O
IIO XXX B-GENE
. XXX O

When XXX O
desipramine XXX O
was XXX O
injected XXX O
16 XXX O
hrs XXX O
after XXX O
fluoxetine XXX O
injection XXX O
, XXX O
brain XXX O
levels XXX O
of XXX O
desipramine XXX O
were XXX O
no XXX O
longer XXX O
elevated XXX O
. XXX O

When XXX O
comparing XXX O
the XXX O
barley XXX B-GENE
PSI-K XXX I-GENE
and XXX O
PSI-G XXX B-GENE
with XXX O
the XXX O
reported XXX O
PSI-K XXX B-GENE
sequence XXX I-GENE
from XXX I-GENE
Synechococcus XXX I-GENE
vulcanus XXX I-GENE
, XXX O
the XXX O
degree XXX O
of XXX O
similarity XXX O
is XXX O
equal XXX O
, XXX O
suggesting XXX O
that XXX O
an XXX O
ancestral XXX O
gene XXX O
has XXX O
been XXX O
duplicated XXX O
in XXX O
a XXX O
chloroplast XXX O
progenitor XXX O
but XXX O
not XXX O
in XXX O
a XXX O
cyanobacterial XXX O
. XXX O

These XXX O
discoloration's XXX O
can XXX O
be XXX O
treated XXX O
in XXX O
several XXX O
ways XXX O
but XXX O
up XXX O
to XXX O
lately XXX O
tooth XXX O
structure XXX O
had XXX O
to XXX O
be XXX O
removed XXX O
in XXX O
an XXX O
irreversible XXX O
manner XXX O
in XXX O
order XXX O
to XXX O
provide XXX O
sufficient XXX O
bulk XXX O
for XXX O
the XXX O
new XXX O
restorative XXX O
material XXX O
. XXX O

Outcome XXX O
of XXX O
severe XXX O
congenital XXX O
hypothyroidism XXX O
. XXX O

The XXX O
effect XXX O
of XXX O
L-methionine XXX O
supplementation XXX O
on XXX O
the XXX O
utilization XXX O
of XXX O
a XXX O
soy XXX O
protein XXX O
isolate XXX O
( XXX O
SPI XXX O
) XXX O
was XXX O
evaluated XXX O
by XXX O
short-term XXX O
nitrogen XXX O
balance XXX O
studies XXX O
in XXX O
young XXX O
women XXX O
. XXX O

It XXX O
was XXX O
demonstrated XXX O
that XXX O
the XXX O
processing XXX O
signals XXX O
in XXX O
the XXX O
transcript XXX O
, XXX O
i XXX O
. XXX O
e XXX O
. XXX O
both XXX O
donor XXX O
splice XXX O
sites XXX O
and XXX O
the XXX O
polyadenylation XXX O
site XXX O
located XXX O
in XXX O
the XXX O
muscle-specific XXX O
intron XXX O
, XXX O
have XXX O
to XXX O
be XXX O
weak XXX O
. XXX O

A XXX O
prerequisite XXX O
for XXX O
the XXX O
synthesis XXX O
of XXX O
sialylated XXX O
glycoconjugates XXX O
is XXX O
the XXX O
activated XXX O
sugar-nucleotide XXX O
cytidine XXX O
5'-monophosphate XXX O
N-acetylneuraminic XXX O
acid XXX O
( XXX O
CMP-Neu5Ac XXX O
) XXX O
, XXX O
which XXX O
provides XXX O
a XXX O
substrate XXX O
for XXX O
Golgi XXX B-GENE
sialyltransferases XXX I-GENE
. XXX O

We XXX O
conclude XXX O
that XXX O
at XXX O
these XXX O
low XXX O
levels XXX O
studied XXX O
, XXX O
aluminum XXX O
accumulates XXX O
in XXX O
intestinal XXX O
tissue XXX O
, XXX O
and XXX O
that XXX O
this XXX O
accumulation XXX O
is XXX O
enhanced XXX O
by XXX O
citrate XXX O
ligand XXX O
. XXX O

The XXX O
Rlm1 XXX B-GENE
protein XXX I-GENE
, XXX O
a XXX O
member XXX O
of XXX O
the XXX O
MADS XXX B-GENE
box XXX I-GENE
family XXX I-GENE
of XXX O
transcription XXX O
factors XXX O
, XXX O
functions XXX O
downstream XXX O
of XXX O
Mpk1 XXX B-GENE
in XXX O
the XXX O
pathway XXX O
. XXX O

Incorporation XXX O
of XXX O
the XXX O
polyene XXX O
antibiotic XXX O
amphotericin XXX O
B XXX O
( XXX O
AMB XXX O
) XXX O
in XXX O
liposomes XXX O
results XXX O
in XXX O
a XXX O
marked XXX O
reduction XXX O
in XXX O
drug XXX O
toxicity XXX O
with XXX O
no XXX O
loss XXX O
of XXX O
antifungal XXX O
potency XXX O
. XXX O

Expression XXX O
of XXX O
constitutively XXX O
active XXX O
MEK1 XXX B-GENE
, XXX O
the XXX O
kinase XXX O
that XXX O
activates XXX O
ERKs XXX B-GENE
, XXX O
or XXX O
overexpression XXX O
of XXX O
ERK2 XXX B-GENE
, XXX O
but XXX O
not XXX O
JNK1 XXX B-GENE
, XXX O
inhibited XXX O
Stat3 XXX B-GENE
activation XXX O
. XXX O

Pretreatment XXX O
of XXX O
cells XXX O
or XXX O
mouse XXX O
skin XXX O
with XXX O
antisense XXX O
oligonucleotides XXX O
of XXX O
PKCzeta XXX B-GENE
impaired XXX O
UV-induced XXX O
activation XXX O
of XXX O
AP-1 XXX B-GENE
in XXX O
JB6 XXX O
cells XXX O
as XXX O
well XXX O
as XXX O
in XXX O
AP-1-luciferase XXX B-GENE
transgenic XXX O
mice XXX O
. XXX O

Serum XXX B-GENE
amylase XXX I-GENE
became XXX O
markedly XXX O
elevated XXX O
( XXX O
2 XXX O
, XXX O
624 XXX O
CU XXX O
/ XXX O
100 XXX O
ml XXX O
) XXX O
, XXX O
as XXX O
did XXX O
the XXX O
serum XXX O
FFA XXX O
( XXX O
29 XXX O
. XXX O
19 XXX O
mEq XXX O
/ XXX O
liter XXX O
) XXX O
. XXX O

Multivariate XXX O
predictors XXX O
were XXX O
concentric XXX O
remodeling XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
0001 XXX O
; XXX O
odds XXX O
ratio XXX O
, XXX O
13 XXX O
. XXX O
5 XXX O
) XXX O
, XXX O
left XXX O
ventricular XXX O
ejection XXX O
fraction XXX O
> XXX O
2 XXX O
SD XXX O
above XXX O
normal XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
0001 XXX O
) XXX O
, XXX O
and XXX O
single-vessel XXX O
left XXX O
circumflex XXX O
disease XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
0007 XXX O
; XXX O
odds XXX O
ratio XXX O
, XXX O
7 XXX O
. XXX O
6 XXX O
) XXX O
. XXX O

Restriction XXX B-GENE
enzyme XXX I-GENE
and XXX O
heteroduplex XXX O
analyses XXX O
confirmed XXX O
that XXX O
sequences XXX O
unique XXX O
to XXX O
FeSV XXX O
( XXX O
src XXX B-GENE
sequences XXX I-GENE
) XXX O
are XXX O
located XXX O
at XXX O
the XXX O
center XXX O
of XXX O
the XXX O
FeSV XXX O
genome XXX O
and XXX O
are XXX O
approximately XXX O
1 XXX O
. XXX O
5 XXX O
kilobase XXX O
pairs XXX O
in XXX O
length XXX O
. XXX O

Similar XXX O
results XXX O
were XXX O
also XXX O
obtained XXX O
with XXX O
a XXX O
HepG2 XXX O
hepatoblastoma XXX O
cell XXX O
line XXX O
carrying XXX O
wt XXX B-GENE
p53 XXX I-GENE
. XXX O

Bronchial XXX O
mucosa XXX O
tattooing XXX O
in XXX O
persons XXX O
exposed XXX O
to XXX O
different XXX O
industrial XXX O
aerosols XXX O
did XXX O
not XXX O
depend XXX O
on XXX O
the XXX O
forms XXX O
of XXX O
PC XXX O
, XXX O
DB XXX O
and XXX O
the XXX O
diseases' XXX O
stages XXX O
. XXX O

Allagille's XXX O
syndrome XXX O
associated XXX O
with XXX O
antenatal XXX O
ascites XXX O
. XXX O

Studies XXX O
on XXX O
the XXX O
hereditary XXX O
nature XXX O
of XXX O
sole XXX O
prints--with XXX O
special XXX O
reference XXX O
to XXX O
interdigital XXX O
and XXX O
triradii XXX O
. XXX O

We XXX O
infer XXX O
that XXX O
the XXX O
dominant XXX O
negative XXX O
inhibition XXX O
results XXX O
from XXX O
both XXX O
direct XXX O
proteolysis XXX O
of XXX O
the XXX O
beta-galactosidase XXX B-GENE
tetramer XXX I-GENE
by XXX O
the XXX O
fusion XXX O
subunit XXX O
and XXX O
detour XXX O
of XXX O
the XXX O
tetramer XXX O
to XXX O
the XXX O
lysosome XXX O
. XXX O

Exposure XXX O
to XXX O
hepatitis XXX O
B XXX O
virus XXX O
in XXX O
the XXX O
general XXX O
population XXX O
of XXX O
Hisayama XXX O
, XXX O
Japan XXX O
: XXX O
significance XXX O
of XXX O
isolated XXX O
antibody XXX O
to XXX O
hepatitis XXX B-GENE
B XXX I-GENE
surface XXX I-GENE
antigen XXX I-GENE
in XXX O
general XXX O
population XXX O
. XXX O

Hops XXX O
, XXX O
and XXX O
L XXX O
. XXX O

The XXX O
correcting XXX O
action XXX O
of XXX O
tropatepine XXX O
hydrochloride XXX O
upon XXX O
the XXX O
extrapyramidal XXX O
effects XXX O
induced XXX O
by XXX O
neuroleptics XXX O
has XXX O
been XXX O
studied XXX O
in XXX O
32 XXX O
acute XXX O
psychotic XXX O
states XXX O
. XXX O

From XXX O
August XXX O
1989 XXX O
to XXX O
October XXX O
1990 XXX O
, XXX O
83 XXX O
pregnant XXX O
Chinese XXX O
women XXX O
were XXX O
the XXX O
subjects XXX O
for XXX O
measuring XXX O
the XXX O
levels XXX O
of XXX O
plasma XXX O
functional XXX O
antithrombin XXX B-GENE
III XXX I-GENE
( XXX O
AT XXX B-GENE
III XXX I-GENE
) XXX O
activity XXX O
. XXX O

Histochemistry XXX O
and XXX O
electron XXX O
microscopy XXX O
of XXX O
acute XXX O
liver XXX O
lesions XXX O
induced XXX O
by XXX O
Aflatoxin XXX B-GENE
B1 XXX I-GENE
in XXX O
ducklings XXX O
. XXX O

Schedule XXX O
2 XXX O
, XXX O
in XXX O
which XXX O
2 XXX O
. XXX O
4 XXX O
mg XXX O
/ XXX O
kg XXX O
c-DDP XXX O
was XXX O
administered XXX O
immediately XXX O
before XXX O
X-ray XXX O
on XXX O
5 XXX O
consecutive XXX O
days XXX O
produced XXX O
the XXX O
highest XXX O
degree XXX O
of XXX O
enhancement XXX O
of XXX O
radiation XXX O
effect XXX O
( XXX O
expressed XXX O
as XXX O
dose-effect XXX O
factor XXX O
) XXX O
; XXX O
and XXX O
the XXX O
next XXX O
greatest XXX O
enhancement XXX O
was XXX O
produced XXX O
by XXX O
12 XXX O
mg XXX O
/ XXX O
kg XXX O
c-DDP XXX O
administered XXX O
24 XXX O
h XXX O
before XXX O
the XXX O
start XXX O
of XXX O
fractionated XXX O
daily XXX O
radiotherapy XXX O
. XXX O

The XXX O
relation XXX O
between XXX O
myocardial XXX B-GENE
beta-adrenergic XXX I-GENE
receptor XXX I-GENE
and XXX O
left XXX O
ventricular XXX O
( XXX O
LV XXX O
) XXX O
function XXX O
was XXX O
studied XXX O
in XXX O
10 XXX O
patients XXX O
, XXX O
aged XXX O
41 XXX O
to XXX O
61 XXX O
years XXX O
( XXX O
average XXX O
51 XXX O
) XXX O
, XXX O
with XXX O
LV XXX O
volume XXX O
overload XXX O
mainly XXX O
due XXX O
to XXX O
chronic XXX O
mitral XXX O
regurgitation XXX O
. XXX O

ArgR XXX B-GENE
was XXX O
shown XXX O
to XXX O
be XXX O
a XXX O
dimer XXX O
of XXX O
two XXX O
equal XXX O
subunits XXX O
, XXX O
each XXX O
with XXX O
a XXX O
molecular XXX O
mass XXX O
of XXX O
37 XXX O
, XXX O
000 XXX O
Da XXX O
. XXX O

The XXX O
transcription XXX B-GENE
factor XXX I-GENE
CHOP XXX I-GENE
/ XXX I-GENE
GADD153 XXX I-GENE
gene XXX I-GENE
is XXX O
induced XXX O
by XXX O
cellular XXX O
stress XXX O
and XXX O
is XXX O
involved XXX O
in XXX O
mediating XXX O
apoptosis XXX O
. XXX O

Ha-RasV12 XXX B-GENE
and XXX O
activated XXX O
proteins XXX O
in XXX O
both XXX O
the XXX O
extra-cellular XXX B-GENE
regulated XXX I-GENE
kinase XXX I-GENE
( XXX O
ERK XXX B-GENE
) XXX O
and XXX O
the XXX O
stress-activated XXX B-GENE
protein XXX I-GENE
kinase XXX I-GENE
( XXX O
SAPK XXX B-GENE
) XXX O
or XXX O
Jun XXX B-GENE
N-terminal XXX I-GENE
kinase XXX I-GENE
( XXX O
JNK XXX B-GENE
) XXX O
cascades XXX O
independently XXX O
stimulated XXX O
PEA3-mediated XXX O
gene XXX O
expression XXX O
. XXX O

Salivary XXX O
sodium XXX O
, XXX O
calcium XXX O
, XXX O
and XXX O
magnesium XXX O
concentrations XXX O
were XXX O
significantly XXX O
higher XXX O
in XXX O
the XXX O
SLE XXX O
patients XXX O
with XXX O
systemic XXX O
lupus XXX O
erythematosus XXX O
, XXX O
whereas XXX O
potassium XXX O
and XXX O
total XXX O
protein XXX O
concentrations XXX O
and XXX O
amylase XXX B-GENE
activity XXX O
did XXX O
not XXX O
differ XXX O
significantly XXX O
from XXX O
the XXX O
controls XXX O
. XXX O

These XXX O
results XXX O
indicate XXX O
that XXX O
the XXX O
PCNA XXX B-GENE
gene XXX I-GENE
is XXX O
a XXX O
likely XXX O
target XXX O
gene XXX O
of XXX O
E2F XXX B-GENE
. XXX O

The XXX O
influenza XXX O
virus XXX O
NS1 XXX B-GENE
protein XXX O
is XXX O
a XXX O
unique XXX O
posttranscriptional XXX O
regulator XXX O
that XXX O
has XXX O
two XXX O
activities XXX O
: XXX O
inhibition XXX O
of XXX O
the XXX O
nuclear XXX O
export XXX O
of XXX O
poly XXX O
A-containing XXX O
mRNAs XXX O
and XXX O
inhibition XXX O
of XXX O
pre-mRNA XXX O
splicing XXX O
. XXX O

Homology XXX O
was XXX O
also XXX O
detected XXX O
between XXX O
the XXX O
putative XXX O
transit XXX O
peptide XXX O
sequence XXX O
of XXX O
cysteine XXX B-GENE
synthase XXX I-GENE
C XXX I-GENE
and XXX O
other XXX O
mitochondrion-targeting XXX O
leader XXX O
sequences XXX O
. XXX O

Of XXX O
its XXX O
gene XXX O
products XXX O
, XXX O
E6 XXX B-GENE
binds XXX O
to XXX O
and XXX O
inactivates XXX O
p53 XXX B-GENE
tumor XXX I-GENE
suppressor XXX I-GENE
protein XXX I-GENE
by XXX O
ubiquitin XXX O
/ XXX O
proteasome-dependent XXX O
degradation XXX O
. XXX O

As XXX O
normal XXX O
B XXX O
cells XXX O
also XXX O
present XXX O
this XXX O
variant XXX O
, XXX O
the XXX O
mechanism XXX O
of XXX O
CD79b XXX B-GENE
posttranscriptional XXX O
regulation XXX O
might XXX O
reflect XXX O
the XXX O
activation XXX O
stage XXX O
of XXX O
the XXX O
normal XXX O
B XXX O
cell XXX O
from XXX O
which XXX O
B-CLL XXX O
derives XXX O
. XXX O

In XXX O
contrast XXX O
, XXX O
both XXX O
C-Lys XXX O
and XXX O
C-Thr XXX O
retained XXX O
high XXX O
levels XXX O
of XXX O
kinase XXX O
activity XXX O
and XXX O
were XXX O
capable XXX O
of XXX O
responding XXX O
to XXX O
stimulation XXX O
. XXX O

On XXX O
the XXX O
other XXX O
hand XXX O
, XXX O
hepatic XXX O
arterial XXX O
infusion XXX O
therapy XXX O
prolongs XXX O
the XXX O
survival XXX O
of XXX O
H3 XXX O
patients XXX O
only XXX O
. XXX O

C XXX O
. XXX O
, XXX O
Sun XXX O
, XXX O
J XXX O
. XXX O
, XXX O
Hsu XXX O
, XXX O
M XXX O
. XXX O
-Y XXX O
. XXX O
, XXX O
Vallejo-Ramirez XXX O
, XXX O
J XXX O
. XXX O
, XXX O
Inouye XXX O
, XXX O
S XXX O
. XXX O
, XXX O
and XXX O
Inouye XXX O
, XXX O
M XXX O
. XXX O

Upstream XXX O
from XXX O
the XXX O
transcription XXX O
start XXX O
point XXX O
( XXX O
tsp XXX O
) XXX O
, XXX O
a XXX O
nucleotide XXX O
sequence XXX O
highly XXX O
homologous XXX O
to XXX O
the XXX O
consensus XXX O
sequence XXX O
motif XXX O
for XXX O
the XXX O
sigma XXX O
35-recognized XXX O
promoters XXX O
was XXX O
found XXX O
. XXX O

The XXX O
possible XXX O
origin XXX O
and XXX O
role XXX O
of XXX O
CSF XXX B-GENE
prolactin XXX I-GENE
are XXX O
discussed XXX O
. XXX O

Pressure XXX O
ulcers XXX O
. XXX O

We XXX O
also XXX O
found XXX O
an XXX O
eIF-4A XXX B-GENE
intronless XXX O
retroposon XXX O
which XXX O
, XXX O
when XXX O
compared XXX O
to XXX O
the XXX O
cDNA XXX O
, XXX O
contains XXX O
a XXX O
single XXX O
nucleotide XXX O
difference XXX O
. XXX O

High XXX O
levels XXX O
of XXX O
C XXX O
subunits XXX O
are XXX O
observed XXX O
in XXX O
several XXX O
subsequent XXX O
larval XXX O
and XXX O
adult XXX O
stages XXX O
of XXX O
development XXX O
. XXX O

These XXX O
alternative XXX O
splice XXX O
variants XXX O
were XXX O
detected XXX O
in XXX O
RNA XXX O
isolated XXX O
from XXX O
several XXX O
sources XXX O
, XXX O
including XXX O
primary XXX O
leptomeningeal XXX O
tissue XXX O
and XXX O
an XXX O
established XXX O
line XXX O
of XXX O
leptomeningeal XXX O
cells XXX O
( XXX O
LMC XXX O
) XXX O
. XXX O

On XXX O
the XXX O
basis XXX O
of XXX O
S1 XXX B-GENE
nuclease XXX I-GENE
protection XXX O
analysis XXX O
of XXX O
RNA XXX O
preparations XXX O
from XXX O
several XXX O
mouse XXX O
tissues XXX O
, XXX O
both XXX O
dhfr XXX B-GENE
and XXX O
divergent XXX O
genes XXX O
showed XXX O
similar XXX O
levels XXX O
of XXX O
expression XXX O
but XXX O
did XXX O
show XXX O
some XXX O
specificity XXX O
in XXX O
start XXX O
site XXX O
utilization XXX O
. XXX O

Effect XXX O
of XXX O
time XXX O
and XXX O
dose XXX O
on XXX O
alterations XXX O
following XXX O
inhalation XXX O
of XXX O
plutonium-239 XXX O
dioxide XXX O
aerosol XXX O
in XXX O
rat XXX O
. XXX O

Forty-eight XXX O
10-12-week-old XXX O
male XXX O
Sprague-Dawley XXX O
rats XXX O
were XXX O
randomized XXX O
to XXX O
receive XXX O
, XXX O
daily XXX O
for XXX O
28 XXX O
days XXX O
: XXX O
( XXX O
1 XXX O
) XXX O
CsA XXX O
vehicle XXX O
p XXX O
. XXX O
o XXX O
. XXX O
plus XXX O
FB XXX O
vehicle XXX O
sc XXX O
; XXX O
( XXX O
2 XXX O
) XXX O
CsA XXX O
( XXX O
15 XXX O
mg XXX O
/ XXX O
kg XXX O
) XXX O
p XXX O
. XXX O
o XXX O
. XXX O
plus XXX O
FB XXX O
vehicle XXX O
sc XXX O
, XXX O
( XXX O
3 XXX O
) XXX O
CsA XXX O
vehicle XXX O
p XXX O
. XXX O
o XXX O
. XXX O
plus XXX O
FB XXX O
( XXX O
1 XXX O
. XXX O
5 XXX O
mg XXX O
/ XXX O
kg XXX O
) XXX O
sc XXX O
; XXX O
and XXX O
( XXX O
4 XXX O
) XXX O
CsA XXX O
( XXX O
15 XXX O
mg XXX O
/ XXX O
kg XXX O
) XXX O
p XXX O
. XXX O
o XXX O
. XXX O
plus XXX O
FB XXX O
( XXX O
1 XXX O
. XXX O
5 XXX O
mg XXX O
/ XXX O
kg XXX O
) XXX O
sc XXX O
. XXX O

Immunofluorescence XXX O
microscopy XXX O
and XXX O
cell XXX O
fractionation XXX O
analyses XXX O
showed XXX O
that XXX O
the XXX O
110-kDa XXX O
protein XXX O
was XXX O
exclusively XXX O
nuclear XXX O
, XXX O
whereas XXX O
the XXX O
150-kDa XXX O
protein XXX O
was XXX O
present XXX O
in XXX O
both XXX O
the XXX O
cytoplasm XXX O
and XXX O
nucleus XXX O
of XXX O
human XXX O
cells XXX O
. XXX O

The XXX O
properties XXX O
of XXX O
the XXX O
phi XXX B-GENE
29 XXX I-GENE
SSB-ssDNA XXX B-GENE
complex XXX O
are XXX O
described XXX O
. XXX O

Thus XXX O
, XXX O
although XXX O
multiple XXX O
senescence XXX O
pathways XXX O
are XXX O
activated XXX O
in XXX O
response XXX O
to XXX O
a XXX O
ras XXX B-GENE
oncogene XXX I-GENE
, XXX O
inactivation XXX O
of XXX O
TGFbeta1 XXX B-GENE
secretion XXX O
or XXX O
response XXX O
is XXX O
sufficient XXX O
to XXX O
block XXX O
the XXX O
senescence XXX O
program XXX O
. XXX O

An XXX O
end XXX O
to XXX O
the XXX O
lottery XXX O
. XXX O

Possible XXX O
factors XXX O
for XXX O
the XXX O
development XXX O
of XXX O
psychotic XXX O
symptomatology XXX O
during XXX O
group XXX O
activities XXX O
and XXX O
the XXX O
role XXX O
of XXX O
group XXX O
dynamics XXX O
acting XXX O
as XXX O
stress XXX O
factors XXX O
precipitating XXX O
functional XXX O
psychoses XXX O
, XXX O
especially XXX O
bipolar XXX O
manifestations XXX O
, XXX O
are XXX O
discussed XXX O
. XXX O

Upon XXX O
differentiation XXX O
with XXX O
retinoic XXX O
acid XXX O
( XXX O
RA XXX O
) XXX O
, XXX O
transcription XXX O
of XXX O
the XXX O
Rex-1 XXX B-GENE
gene XXX I-GENE
decreases XXX O
rapidly XXX O
. XXX O

They XXX O
were XXX O
found XXX O
to XXX O
stimulate XXX O
at XXX O
nanomolar XXX O
concentrations XXX O
the XXX O
turnover XXX O
of XXX O
biosynthetically XXX O
labeled XXX O
ceramide XXX O
, XXX O
glucosylceramide XXX O
, XXX O
and XXX O
lactosylceramide XXX O
. XXX O

The XXX O
low XXX O
molecular XXX O
mass XXX O
polypeptide XXX O
complex XXX O
is XXX O
assumed XXX O
to XXX O
be XXX O
involved XXX O
in XXX O
antigen XXX O
presentation XXX O
, XXX O
generating XXX O
peptides XXX O
from XXX O
cytosolic XXX O
protein XXX O
antigens XXX O
, XXX O
which XXX O
are XXX O
subsequently XXX O
presented XXX O
to XXX O
cytotoxic XXX O
T-lymphocytes XXX O
on XXX O
the XXX O
cell XXX O
surface XXX O
. XXX O

We XXX O
found XXX O
that XXX O
multiple XXX O
tumor XXX O
suppressor XXX O
genes XXX O
( XXX O
e XXX O
. XXX O
g XXX O
. XXX O
, XXX O
p53 XXX B-GENE
, XXX O
DCC XXX B-GENE
, XXX O
APC XXX B-GENE
, XXX O
MCC XXX B-GENE
, XXX O
BRCA1 XXX B-GENE
, XXX O
and XXX O
WAF1 XXX B-GENE
/ XXX I-GENE
CIP1 XXX I-GENE
) XXX O
were XXX O
inactivated XXX O
at XXX O
different XXX O
frequencies XXX O
via XXX O
various XXX O
mechanisms XXX O
[ XXX O
e XXX O
. XXX O
g XXX O
. XXX O
, XXX O
loss XXX O
of XXX O
heterozygosity XXX O
( XXX O
LOH XXX O
) XXX O
, XXX O
loss XXX O
of XXX O
expression XXX O
( XXX O
LOE XXX O
) XXX O
, XXX O
mutation XXX O
, XXX O
and XXX O
inactivation XXX O
by XXX O
cellular XXX O
binding XXX O
protein XXX O
] XXX O
. XXX O

The XXX O
expression XXX O
of XXX O
this XXX O
clone XXX O
in XXX O
a XXX O
wee1 XXX B-GENE
/ XXX I-GENE
mik1-deficient XXX I-GENE
mutant XXX I-GENE
causes XXX O
an XXX O
elongated XXX O
cell XXX O
phenotype XXX O
under XXX O
non-permissive XXX O
growth XXX O
conditions XXX O
. XXX O

This XXX O
suggests XXX O
that XXX O
mechanisms XXX O
other XXX O
than XXX O
an XXX O
excessive XXX O
increase XXX O
in XXX O
myocardial XXX O
oxygen XXX O
demand XXX O
may XXX O
be XXX O
responsible XXX O
for XXX O
the XXX O
many XXX O
episodes XXX O
occurring XXX O
outside XXX O
the XXX O
hospital XXX O
. XXX O

These XXX O
results XXX O
provide XXX O
evidence XXX O
of XXX O
a XXX O
bypass XXX O
of XXX O
p53-induced XXX O
Waf1 XXX O
/ XXX O
Cip1-mediated XXX O
cell XXX O
cycle XXX O
regulatory XXX O
pathways XXX O
by XXX O
a XXX O
member XXX O
of XXX O
the XXX O
myb XXX B-GENE
oncogene XXX I-GENE
family XXX I-GENE
. XXX O

The XXX O
4-AP XXX O
( XXX O
4-20 XXX O
mM XXX O
) XXX O
effect XXX O
resulted XXX O
in XXX O
a XXX O
decrease XXX O
of XXX O
the XXX O
sensory XXX O
activity XXX O
, XXX O
which XXX O
was XXX O
fully XXX O
restored XXX O
by XXX O
TEA XXX O
or XXX O
Ba2+ XXX O
. XXX O

The XXX O
transcription XXX B-GENE
factor XXX I-GENE
AP-2 XXX I-GENE
is XXX O
encoded XXX O
by XXX O
a XXX O
gene XXX O
located XXX O
on XXX O
chromosome XXX O
6 XXX O
near XXX O
the XXX O
HLA XXX B-GENE
locus XXX I-GENE
. XXX O

Cerebral XXX O
vasculitis XXX O
secondary XXX O
to XXX O
Crohn's XXX O
disease XXX O
seems XXX O
to XXX O
be XXX O
a XXX O
very XXX O
rare XXX O
phenomenon XXX O
. XXX O

The XXX O
overall XXX O
prevalence XXX O
of XXX O
HBV XXX O
markers XXX O
was XXX O
higher XXX O
among XXX O
staff XXX O
members XXX O
than XXX O
in XXX O
the XXX O
blood XXX O
donors XXX O
of XXX O
our XXX O
area XXX O
. XXX O

The XXX O
routine XXX O
administration XXX O
of XXX O
fat-soluble XXX O
vitamins XXX O
appears XXX O
unnecessary XXX O
but XXX O
it XXX O
is XXX O
prudent XXX O
to XXX O
measure XXX O
prothrombin XXX B-GENE
time XXX O
and XXX O
serum XXX O
vitamins XXX O
A XXX O
and XXX O
E XXX O
at XXX O
intervals XXX O
. XXX O

Many XXX O
cytokine XXX B-GENE
receptors XXX I-GENE
employ XXX O
Janus XXX B-GENE
protein XXX I-GENE
tyrosine XXX I-GENE
kinases XXX I-GENE
( XXX O
Jaks XXX B-GENE
) XXX O
and XXX O
signal XXX B-GENE
transducers XXX I-GENE
and XXX I-GENE
activators XXX I-GENE
of XXX I-GENE
transcription XXX I-GENE
( XXX O
Stats XXX B-GENE
) XXX O
for XXX O
nuclear XXX O
signaling XXX O
. XXX O

In XXX O
contrast XXX O
to XXX O
this XXX O
mRNA XXX O
, XXX O
90% XXX O
of XXX O
alpha XXX B-GENE
and XXX I-GENE
beta XXX I-GENE
actin XXX I-GENE
mRNAs XXX I-GENE
were XXX O
translated XXX O
in XXX O
both XXX O
myoblasts XXX O
and XXX O
myotubes XXX O
. XXX O

The XXX O
term XXX O
osteomesopycnosis XXX O
is XXX O
proposed XXX O
for XXX O
a XXX O
sclerosing XXX O
bone XXX O
disease XXX O
with XXX O
dominant XXX O
inheritance XXX O
that XXX O
has XXX O
been XXX O
discovered XXX O
in XXX O
five XXX O
members XXX O
of XXX O
four XXX O
different XXX O
families XXX O
. XXX O

Kss1 XXX B-GENE
binds XXX O
specifically XXX O
to XXX O
a XXX O
GST-Dig1 XXX B-GENE
fusion XXX O
in XXX O
the XXX O
absence XXX O
of XXX O
any XXX O
other XXX O
yeast XXX O
protein XXX O
. XXX O

Men XXX O
were XXX O
more XXX O
positive XXX O
about XXX O
their XXX O
physical XXX O
fitness XXX O
than XXX O
women XXX O
. XXX O

In XXX O
early XXX O
Xenopus XXX O
embryos XXX O
, XXX O
the XXX O
transforming XXX B-GENE
growth XXX I-GENE
factor-beta XXX I-GENE
member XXX O
activin XXX B-GENE
induces XXX O
the XXX O
gene XXX B-GENE
Mix XXX I-GENE
. XXX I-GENE
2 XXX I-GENE
by XXX O
stimulating XXX O
the XXX O
formation XXX O
of XXX O
a XXX O
multiprotein XXX O
complex XXX O
, XXX O
activin-responsive XXX B-GENE
factor XXX I-GENE
( XXX O
ARF XXX B-GENE
) XXX O
. XXX O

This XXX O
mutation XXX O
also XXX O
results XXX O
in XXX O
markedly XXX O
decreased XXX O
levels XXX O
of XXX O
CAD XXX B-GENE
mRNA XXX I-GENE
and XXX O
protein XXX O
in XXX O
the XXX O
mutant XXX O
. XXX O

W XXX O
. XXX O

Described XXX O
X-ray XXX O
projection XXX O
were XXX O
performed XXX O
in XXX O
70 XXX O
patients XXX O
. XXX O

The XXX O
C XXX O
/ XXX O
D XXX O
ratio XXX O
was XXX O
equal XXX O
to XXX O
or XXX O
over XXX O
0 XXX O
. XXX O
6 XXX O
in XXX O
9 XXX O
cases XXX O
( XXX O
16 XXX O
eyes XXX O
) XXX O
, XXX O
and XXX O
the XXX O
values XXX O
were XXX O
inconsistent XXX O
between XXX O
both XXX O
eyes XXX O
in XXX O
55% XXX O
of XXX O
the XXX O
patients XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
the XXX O
time XXX O
to XXX O
engraftment XXX O
was XXX O
significantly XXX O
shorter XXX O
in XXX O
the XXX O
amifostine XXX O
arm XXX O
in XXX O
both XXX O
cohorts XXX O
. XXX O

Disability XXX O
insurance XXX O
under XXX O
social XXX O
security XXX O
. XXX O

In XXX O
nucleus XXX O
ventralis XXX O
anterior XXX O
thalami-nucleus XXX O
ventralis XXX O
lateralis XXX O
thalami XXX O
neurons XXX O
with XXX O
an XXX O
inhibitory XXX O
input XXX O
from XXX O
nucleus XXX O
entopeduncularis XXX O
, XXX O
a XXX O
shortening XXX O
of XXX O
inhibition XXX O
from XXX O
17 XXX O
. XXX O
5 XXX O
+ XXX O
/ XXX O
- XXX O
3 XXX O
. XXX O
6 XXX O
to XXX O
9 XXX O
. XXX O
1 XXX O
+ XXX O
/ XXX O
- XXX O
1 XXX O
. XXX O
8 XXX O
ms XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
under XXX O
the XXX O
haloperidol XXX O
influence XXX O
was XXX O
evident XXX O
. XXX O

The XXX O
expression XXX O
of XXX O
the XXX O
yam8 XXX B-GENE
( XXX I-GENE
+ XXX I-GENE
) XXX I-GENE
cDNA XXX I-GENE
in XXX O
the XXX O
mid1 XXX B-GENE
mutant XXX I-GENE
cells XXX O
partially XXX O
remediated XXX O
the XXX O
mid XXX O
phenotype XXX O
and XXX O
resulted XXX O
in XXX O
a XXX O
slight XXX O
increase XXX O
in XXX O
Ca XXX O
( XXX O
2+ XXX O
) XXX O
uptake XXX O
activity XXX O
. XXX O

OBJECTIVE XXX O
: XXX O
To XXX O
evaluate XXX O
the XXX O
overall XXX O
performance XXX O
of XXX O
a XXX O
new XXX O
oscillometric XXX O
wrist XXX O
blood XXX O
pressure XXX O
monitor XXX O
( XXX O
Braun XXX O
PrecisionSensor XXX O
, XXX O
Braun XXX O
GmbH XXX O
, XXX O
Kronberg XXX O
, XXX O
Germany XXX O
) XXX O
as XXX O
defined XXX O
by XXX O
the XXX O
ANSI XXX O
/ XXX O
AAMI XXX O
SP10-1992 XXX O
guidelines XXX O
, XXX O
and XXX O
to XXX O
analyze XXX O
the XXX O
data XXX O
for XXX O
the XXX O
optimized XXX O
selection XXX O
of XXX O
the XXX O
algorithm XXX O
that XXX O
derives XXX O
the XXX O
blood XXX O
pressure XXX O
values XXX O
from XXX O
the XXX O
oscillometric XXX O
blood XXX O
pressure XXX O
curves XXX O
. XXX O

Plasma XXX O
vitamin XXX O
E XXX O
, XXX O
total XXX O
lipids XXX O
and XXX O
myeloperoxidase XXX B-GENE
levels XXX O
during XXX O
spinal XXX O
surgery XXX O
. XXX O

The XXX O
marker XXX O
orders XXX O
from XXX O
the XXX O
genetic XXX O
and XXX O
RH XXX O
maps XXX O
were XXX O
consistent XXX O
. XXX O

Is XXX O
radical XXX O
trachelectomy XXX O
a XXX O
safe XXX O
alternative XXX O
to XXX O
radical XXX O
hysterectomy XXX O
for XXX O
patients XXX O
with XXX O
stage XXX O
IA-B XXX O
carcinoma XXX O
of XXX O
the XXX O
cervix XXX O
? XXX O
BACKGROUND XXX O
: XXX O
The XXX O
prognosis XXX O
associated XXX O
with XXX O
lymph XXX O
node XXX O
negative XXX O
, XXX O
early XXX O
stage XXX O
carcinoma XXX O
of XXX O
the XXX O
cervix XXX O
is XXX O
excellent XXX O
, XXX O
with XXX O
5-year XXX O
survival XXX O
rates XXX O
greater XXX O
than XXX O
90% XXX O
. XXX O

Cosmid XXX O
clones XXX O
containing XXX O
both XXX O
VNTR XXX B-GENE
sequences XXX I-GENE
were XXX O
identified XXX O
, XXX O
and XXX O
restriction XXX O
mapping XXX O
showed XXX O
them XXX O
to XXX O
be XXX O
less XXX O
than XXX O
15 XXX O
kb XXX O
apart XXX O
. XXX O

Sip1 XXX B-GENE
was XXX O
initially XXX O
identified XXX O
by XXX O
virtue XXX O
of XXX O
its XXX O
interaction XXX O
with XXX O
SC35 XXX B-GENE
, XXX O
a XXX O
splicing XXX O
factor XXX O
of XXX O
the XXX O
SR XXX B-GENE
family XXX I-GENE
. XXX O

The XXX O
administration XXX O
of XXX O
the XXX O
GnRH XXX B-GENE
agonist XXX O
reduced XXX O
the XXX O
bone XXX O
mineral XXX O
density XXX O
in XXX O
the XXX O
whole XXX O
femur XXX O
to XXX O
91 XXX O
. XXX O
0% XXX O
of XXX O
that XXX O
in XXX O
the XXX O
control XXX O
group XXX O
. XXX O

This XXX O
association XXX O
appears XXX O
to XXX O
be XXX O
mediated XXX O
by XXX O
Src-SH2 XXX B-GENE
domain XXX I-GENE
, XXX O
because XXX O
PECAM-1 XXX B-GENE
can XXX O
be XXX O
precipitated XXX O
by XXX O
a XXX O
GST-Src-SH2 XXX B-GENE
affinity XXX O
matrix XXX O
. XXX O

The XXX O
gene XXX O
for XXX O
the XXX O
RNA-dependent XXX B-GENE
eIF-2 XXX I-GENE
alpha XXX I-GENE
protein XXX I-GENE
kinase XXX I-GENE
( XXX O
PKR XXX B-GENE
) XXX O
was XXX O
isolated XXX O
from XXX O
mouse XXX O
genomic XXX O
DNA XXX O
and XXX O
characterized XXX O
. XXX O

Basic XXX B-GENE
fibroblast XXX I-GENE
growth XXX I-GENE
factor XXX I-GENE
( XXX O
bFGF XXX B-GENE
) XXX O
has XXX O
been XXX O
shown XXX O
to XXX O
induce XXX O
angiogenesis XXX O
in XXX O
various XXX O
animal XXX O
models XXX O
, XXX O
but XXX O
the XXX O
methods XXX O
of XXX O
administration XXX O
used XXX O
experimentally XXX O
are XXX O
not XXX O
clinically XXX O
feasible XXX O
. XXX O

1993 XXX O
. XXX O

The XXX O
immunosuppressant XXX O
FK506 XXX O
inhibits XXX O
amino XXX O
acid XXX O
import XXX O
in XXX O
Saccharomyces XXX O
cerevisiae XXX O
. XXX O

The XXX O
cDNA XXX O
was XXX O
expressed XXX O
in XXX O
Saccharomyces XXX O
cerevisiae XXX O
under XXX O
the XXX O
control XXX O
of XXX O
the XXX O
yeast XXX B-GENE
triose XXX I-GENE
phosphate XXX I-GENE
isomerase XXX I-GENE
promoter XXX I-GENE
. XXX O

LDL XXX B-GENE
cholesterol XXX O
decreased XXX O
from XXX O
4 XXX O
. XXX O
74 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
87 XXX O
to XXX O
3 XXX O
. XXX O
78 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
78 XXX O
mmol XXX O
/ XXX O
l XXX O
after XXX O
8 XXX O
weeks XXX O
on XXX O
simvastatin XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
001 XXX O
) XXX O
, XXX O
and XXX O
apo XXX B-GENE
B XXX I-GENE
fell XXX O
from XXX O
142 XXX O
+ XXX O
/ XXX O
- XXX O
31 XXX O
to XXX O
112 XXX O
+ XXX O
/ XXX O
- XXX O
22 XXX O
mg XXX O
/ XXX O
dl XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
001 XXX O
) XXX O
. XXX O

It XXX O
is XXX O
largely XXX O
predicted XXX O
by XXX O
lupus XXX O
anticoagulant XXX O
( XXX O
estimated XXX O
by XXX O
activated XXX O
partial XXX O
thromboplastin XXX B-GENE
time XXX O
) XXX O
and XXX O
/ XXX O
or XXX O
antibody XXX O
to XXX O
cardiolipin XXX O
. XXX O

The XXX O
effect XXX O
of XXX O
Vpu XXX B-GENE
on XXX O
class XXX O
I XXX O
biogenesis XXX O
was XXX O
analyzed XXX O
in XXX O
more XXX O
detail XXX O
using XXX O
a XXX O
Vpu-expressing XXX O
recombinant XXX O
vaccinia XXX O
virus XXX O
( XXX O
VV XXX O
) XXX O
. XXX O

Following XXX O
the XXX O
observation XXX O
that XXX O
non-organ-specific XXX O
antibodies XXX O
are XXX O
related XXX O
with XXX O
pregnancy XXX O
loss XXX O
and XXX O
preeclampsia XXX O
, XXX O
the XXX O
role XXX O
of XXX O
organ-specific XXX O
antibodies XXX O
is XXX O
currently XXX O
being XXX O
extensively XXX O
investigated XXX O
. XXX O

Keratoconjunctivitis XXX O
sicca XXX O
appears XXX O
to XXX O
be XXX O
a XXX O
common XXX O
ocular XXX O
complication XXX O
and XXX O
all XXX O
children XXX O
with XXX O
JRA XXX O
should XXX O
be XXX O
screened XXX O
for XXX O
it XXX O
with XXX O
a XXX O
comprehensive XXX O
battery XXX O
of XXX O
tests XXX O
. XXX O

Both XXX O
quantitative XXX O
and XXX O
qualitative XXX O
analysis XXX O
of XXX O
individual XXX O
cytoarchitectonic XXX O
peculiarities XXX O
of XXX O
Meynart's XXX O
nucleus XXX O
as XXX O
well XXX O
as XXX O
of XXX O
external XXX O
part XXX O
of XXX O
dorsomedial XXX O
nucleus XXX O
of XXX O
thalamus XXX O
was XXX O
performed XXX O
in XXX O
mentally XXX O
normal XXX O
individuals XXX O
. XXX O

The XXX O
increased XXX O
clearance XXX O
observed XXX O
in XXX O
young XXX O
infants XXX O
is XXX O
in XXX O
contrast XXX O
to XXX O
other XXX O
opioids XXX O
. XXX O

We XXX O
also XXX O
observed XXX O
that XXX O
the XXX O
predictive XXX O
ability XXX O
of XXX O
the XXX O
selected XXX O
attitudes XXX O
and XXX O
orientations XXX O
increased XXX O
considerably XXX O
from XXX O
1975 XXX O
to XXX O
1982 XXX O
. XXX O

An XXX O
open-label XXX O
, XXX O
placebo-controlled XXX O
, XXX O
randomized XXX O
, XXX O
two-way XXX O
crossover XXX O
study XXX O
was XXX O
performed XXX O
in XXX O
12 XXX O
healthy XXX O
volunteers XXX O
( XXX O
between XXX O
20 XXX O
and XXX O
44 XXX O
years XXX O
of XXX O
age XXX O
) XXX O
to XXX O
assess XXX O
the XXX O
effect XXX O
of XXX O
orlistat XXX O
, XXX O
a XXX O
gastrointestinal XXX B-GENE
lipase XXX I-GENE
inhibitor XXX O
that XXX O
reduces XXX O
dietary XXX O
fat XXX O
absorption XXX O
and XXX O
is XXX O
being XXX O
developed XXX O
for XXX O
weight XXX O
control XXX O
in XXX O
obesity XXX O
, XXX O
on XXX O
the XXX O
absorption XXX O
of XXX O
vitamins XXX O
A XXX O
and XXX O
E XXX O
. XXX O

Here XXX O
we XXX O
demonstrate XXX O
genetically XXX O
that XXX O
plus-strand XXX O
DNA XXX O
synthesis XXX O
of XXX O
the XXX O
yeast XXX B-GENE
Ty1 XXX I-GENE
element XXX I-GENE
is XXX O
initiated XXX O
at XXX O
two XXX O
sites XXX O
located XXX O
at XXX O
the XXX O
5' XXX O
boundary XXX O
of XXX O
the XXX O
3' XXX O
long XXX O
terminal XXX O
repeat XXX O
( XXX O
PPT1 XXX B-GENE
) XXX O
and XXX O
near XXX O
the XXX O
middle XXX O
of XXX O
the XXX O
pol XXX B-GENE
gene XXX I-GENE
in XXX O
the XXX O
integrase XXX B-GENE
coding XXX I-GENE
sequence XXX I-GENE
( XXX O
PPT2 XXX B-GENE
) XXX O
. XXX O

LA-3848-MS XXX O
. XXX O

Renal XXX O
response XXX O
to XXX O
captopril XXX O
in XXX O
severe XXX O
heart XXX O
failure XXX O
: XXX O
role XXX O
of XXX O
furosemide XXX O
in XXX O
natriuresis XXX O
and XXX O
reversal XXX O
of XXX O
hyponatremia XXX O
. XXX O

Protein XXX O
splicing XXX O
: XXX O
evidence XXX O
for XXX O
an XXX O
N-O XXX O
acyl XXX O
rearrangement XXX O
as XXX O
the XXX O
initial XXX O
step XXX O
in XXX O
the XXX O
splicing XXX O
process XXX O
. XXX O

Because XXX O
the XXX O
deletion XXX O
included XXX O
the XXX O
TK XXX B-GENE
gene XXX I-GENE
, XXX O
selection XXX O
with XXX O
gancyclovir XXX O
against XXX O
cells XXX O
not XXX O
having XXX O
undergone XXX O
recombination XXX O
was XXX O
possible XXX O
. XXX O

Concerted XXX O
action XXX O
of XXX O
three XXX O
distinct XXX O
domains XXX O
in XXX O
the XXX O
DNA XXX O
cleaving-joining XXX O
reaction XXX O
catalyzed XXX O
by XXX O
relaxase XXX B-GENE
( XXX O
TraI XXX B-GENE
) XXX O
of XXX O
conjugative XXX O
plasmid XXX O
RP4 XXX O
. XXX O

We XXX O
conclude XXX O
that XXX O
class XXX O
I XXX O
cytologic XXX O
smears XXX O
with XXX O
moderate XXX O
to XXX O
severe XXX O
inflammation XXX O
may XXX O
be XXX O
associated XXX O
with XXX O
findings XXX O
of XXX O
condylomata XXX O
and XXX O
cervical XXX O
dysplasia XXX O
. XXX O

Epigenetic XXX O
switching XXX O
of XXX O
transcriptional XXX O
states XXX O
: XXX O
cis- XXX O
and XXX O
trans-acting XXX O
factors XXX O
affecting XXX O
establishment XXX O
of XXX O
silencing XXX O
at XXX O
the XXX O
HMR XXX B-GENE
locus XXX I-GENE
in XXX O
Saccharomyces XXX O
cerevisiae XXX O
. XXX O

Flurazepam XXX O
thus XXX O
appears XXX O
to XXX O
be XXX O
an XXX O
effective XXX O
hypnotic XXX O
drug XXX O
with XXX O
the XXX O
optimum XXX O
dose XXX O
for XXX O
use XXX O
in XXX O
general XXX O
practice XXX O
being XXX O
15 XXX O
mg XXX O
at XXX O
night XXX O
. XXX O

The XXX O
( XXX O
two-motif XXX O
) XXX O
domain XXX O
fold XXX O
contains XXX O
a XXX O
pair XXX O
of XXX O
calcium XXX O
binding XXX O
sites XXX O
very XXX O
similar XXX O
to XXX O
those XXX O
found XXX O
in XXX O
a XXX O
two-domain XXX B-GENE
prokaryotic XXX I-GENE
betagamma-crystallin XXX I-GENE
fold XXX I-GENE
family XXX I-GENE
member XXX I-GENE
, XXX O
Protein XXX B-GENE
S XXX O
. XXX O

The XXX O
hTERT XXX B-GENE
gene XXX I-GENE
encompasses XXX O
more XXX O
than XXX O
37kb XXX O
and XXX O
consists XXX O
of XXX O
16 XXX O
exons XXX O
. XXX O

Surprisingly XXX O
, XXX O
the XXX O
results XXX O
of XXX O
several XXX O
experiments XXX O
suggest XXX O
that XXX O
the XXX O
TSF XXX B-GENE
genes XXX I-GENE
encode XXX O
global XXX O
regulatory XXX O
factors XXX O
. XXX O
tsf1 XXX B-GENE
to XXX O
tsf6 XXX B-GENE
mutations XXX O
derepressed XXX O
expression XXX O
from XXX O
yeast XXX B-GENE
CYC-GAL XXX I-GENE
hybrid XXX I-GENE
promoters XXX I-GENE
( XXX O
fused XXX O
to XXX O
lacZ XXX B-GENE
) XXX O
that XXX O
harbor XXX O
a XXX O
variety XXX O
of XXX O
operator XXX O
sequences XXX O
, XXX O
and XXX O
caused XXX O
pleiotropic XXX O
defects XXX O
in XXX O
cell XXX O
growth XXX O
, XXX O
mating XXX O
, XXX O
and XXX O
sporulation XXX O
. XXX O

Characterization XXX O
of XXX O
these XXX O
R XXX O
subunits XXX O
by XXX O
their XXX O
8-azido-cAMP XXX O
photoaffinity XXX O
labeling XXX O
and XXX O
immunoreactivity XXX O
, XXX O
as XXX O
well XXX O
as XXX O
by XXX O
a XXX O
phosphorylation-dependent XXX O
mobility XXX O
shift XXX O
on XXX O
sodium XXX O
dodecyl XXX O
sulfate-polyacrylamide XXX O
gel XXX O
electrophoresis XXX O
( XXX O
SDS-PAGE XXX O
) XXX O
, XXX O
indicated XXX O
subunit XXX O
sizes XXX O
of XXX O
RII XXX B-GENE
beta XXX I-GENE
( XXX O
53 XXX O
kDa XXX O
) XXX O
greater XXX O
than XXX O
RII XXX B-GENE
alpha XXX I-GENE
dephosphoform XXX O
( XXX O
51 XXX O
kDa XXX O
) XXX O
greater XXX O
than XXX O
RI XXX B-GENE
alpha XXX I-GENE
( XXX O
49 XXX O
kDa XXX O
) XXX O
. XXX O

In XXX O
general XXX O
lookback XXX O
, XXX O
all XXX O
patients XXX O
who XXX O
received XXX O
blood XXX O
before XXX O
being XXX O
tested XXX O
for XXX O
hepatitis XXX O
C XXX O
are XXX O
advised XXX O
to XXX O
undergo XXX O
testing XXX O
. XXX O

Closure XXX O
of XXX O
the XXX O
patent XXX O
ductus XXX O
arteriosus XXX O
with XXX O
a XXX O
Ligaclip XXX O
through XXX O
a XXX O
minithoracotomy XXX O
. XXX O

Improvement XXX O
of XXX O
nursing XXX O
instruction XXX O
to XXX O
be XXX O
given XXX O
at XXX O
the XXX O
time XXX O
of XXX O
discharge XXX O
from XXX O
the XXX O
ward XXX O
for XXX O
premature XXX O
infants XXX O
] XXX O
. XXX O

Taken XXX O
together XXX O
, XXX O
these XXX O
results XXX O
demonstrate XXX O
that XXX O
the XXX O
RP XXX B-GENE
, XXX O
like XXX O
the XXX O
20S XXX B-GENE
proteasome XXX I-GENE
, XXX O
is XXX O
functionally XXX O
and XXX O
structurally XXX O
conserved XXX O
among XXX O
eukaryotes XXX O
and XXX O
indicate XXX O
that XXX O
the XXX O
plant XXX B-GENE
RPT XXX I-GENE
subunits XXX I-GENE
, XXX O
like XXX O
their XXX O
yeast XXX O
counterparts XXX O
, XXX O
have XXX O
non-redundant XXX O
functions XXX O
. XXX O

Sequence XXX O
analysis XXX O
of XXX O
the XXX O
5'-flanking XXX O
region XXX O
of XXX O
the XXX O
CD69 XXX B-GENE
gene XXX I-GENE
revealed XXX O
the XXX O
presence XXX O
of XXX O
a XXX O
potential XXX O
TATA XXX O
element XXX O
30 XXX O
base XXX O
pairs XXX O
upstream XXX O
of XXX O
the XXX O
major XXX O
transcription XXX O
initiation XXX O
site XXX O
and XXX O
several XXX O
putative XXX O
binding XXX O
sequences XXX O
for XXX O
inducible XXX O
transcription XXX O
factors XXX O
( XXX O
NF-kappa XXX B-GENE
B XXX I-GENE
, XXX O
Egr-1 XXX B-GENE
, XXX O
AP-1 XXX B-GENE
) XXX O
, XXX O
which XXX O
might XXX O
mediate XXX O
the XXX O
inducible XXX O
expression XXX O
of XXX O
this XXX O
gene XXX O
. XXX O

Histogenetic XXX O
aspects XXX O
of XXX O
mesoblastic XXX O
nephroma XXX O
. XXX O

The XXX O
C-terminal XXX O
end XXX O
of XXX O
this XXX O
polypeptide XXX O
harbors XXX O
three XXX O
types XXX O
of XXX O
repeated XXX O
sequences XXX O
. XXX O

Similarly XXX O
, XXX O
PCDFs XXX O
/ XXX O
PCDDs XXX O
ratio XXX O
in XXX O
ESP XXX O
ash XXX O
was XXX O
lower XXX O
than XXX O
that XXX O
in XXX O
boiler XXX O
ash XXX O
. XXX O

All XXX O
patients XXX O
had XXX O
abnormal XXX O
von XXX B-GENE
Willebrand XXX I-GENE
factor XXX I-GENE
( XXX O
vWF XXX B-GENE
) XXX O
fragmentation XXX O
as XXX O
reflected XXX O
by XXX O
decreased XXX O
high XXX O
molecular XXX O
weight XXX O
and XXX O
increased XXX O
low XXX O
molecular XXX O
weight XXX O
vWF XXX B-GENE
multimers XXX I-GENE
in XXX O
the XXX O
circulation XXX O
. XXX O

Seventy-five XXX O
percent XXX O
of XXX O
children XXX O
who XXX O
received XXX O
a XXX O
second XXX O
transplant XXX O
for XXX O
HCV XXX O
hepatitis XXX O
had XXX O
early XXX O
histologic XXX O
recurrence XXX O
that XXX O
led XXX O
to XXX O
liver XXX O
failure XXX O
and XXX O
death XXX O
. XXX O

In XXX O
addition XXX O
to XXX O
the XXX O
bZIP XXX B-GENE
protein XXX I-GENE
Opaque2 XXX I-GENE
( XXX O
O2 XXX B-GENE
) XXX O
, XXX O
there XXX O
are XXX O
other XXX O
maize XXX O
endosperm XXX O
nuclear XXX O
proteins XXX O
that XXX O
recognize XXX O
the XXX O
O2 XXX B-GENE
box XXX I-GENE
in XXX O
22 XXX O
kDa XXX O
zein XXX B-GENE
gene XXX O
promoters XXX O
. XXX O

Year XXX O
one XXX O
of XXX O
the XXX O
first XXX O
general XXX O
practitioner XXX O
medical XXX O
unit XXX O
in XXX O
the XXX O
greater XXX O
Glasgow XXX O
area XXX O
. XXX O

Variations XXX O
in XXX O
the XXX O
5' XXX O
half XXX O
of XXX O
U3 XXX B-GENE
were XXX O
primarily XXX O
due XXX O
to XXX O
insertions XXX O
and XXX O
deletions XXX O
. XXX O

Serum XXX B-GENE
ACTH XXX I-GENE
did XXX O
not XXX O
respond XXX O
to XXX O
insulin XXX B-GENE
and XXX O
metyrapone XXX O
. XXX O

Interestingly XXX O
, XXX O
an XXX O
antibody XXX O
against XXX O
N-SMase XXX B-GENE
can XXX O
abrogate XXX O
Ox-LDL- XXX O
and XXX O
TNF-alpha-induced XXX O
apoptosis XXX O
and XXX O
therefore XXX O
may XXX O
be XXX O
useful XXX O
for XXX O
in XXX O
vivo XXX O
studies XXX O
of XXX O
apoptosis XXX O
in XXX O
experimental XXX O
animals XXX O
. XXX O

During XXX O
exercise XXX O
, XXX O
the XXX O
Pes-Ves XXX O
relation XXX O
was XXX O
shifted XXX O
toward XXX O
the XXX O
left XXX O
and XXX O
the XXX O
slope XXX O
[ XXX O
end-systolic XXX O
elastance XXX O
( XXX O
Ees XXX O
) XXX O
] XXX O
increased XXX O
from XXX O
7 XXX O
. XXX O
7 XXX O
+ XXX O
/ XXX O
- XXX O
2 XXX O
. XXX O
8 XXX O
to XXX O
12 XXX O
. XXX O
7 XXX O
+ XXX O
/ XXX O
- XXX O
4 XXX O
. XXX O
2 XXX O
( XXX O
SD XXX O
) XXX O
mmHg XXX O
/ XXX O
ml XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
. XXX O

In XXX O
addition XXX O
to XXX O
protein XXX O
binding XXX O
at XXX O
sequences XXX O
known XXX O
to XXX O
be XXX O
involved XXX O
in XXX O
the XXX O
regulation XXX O
of XXX O
transcription XXX O
, XXX O
genomic XXX O
footprinting XXX O
of XXX O
the XXX O
entire XXX O
promoter XXX O
region XXX O
also XXX O
showed XXX O
that XXX O
a XXX O
protein XXX O
factor XXX O
is XXX O
constitutively XXX O
bound XXX O
to XXX O
the XXX O
first XXX O
intron XXX O
of XXX O
the XXX O
rep3 XXX B-GENE
gene XXX I-GENE
. XXX O

The XXX O
BFA XXX O
System XXX O
reads XXX O
a XXX O
text XXX O
file XXX O
with XXX O
flows XXX O
, XXX O
measured XXX O
with XXX O
fluorescent XXX O
microsphere XXX O
technique XXX O
, XXX O
and XXX O
constructs XXX O
the XXX O
lung XXX O
anatomy XXX O
with XXX O
volumetric XXX O
pixels XXX O
showing XXX O
the XXX O
flows XXX O
with XXX O
a XXX O
color XXX O
schema XXX O
. XXX O

The XXX O
parameters XXX O
of XXX O
nonspecific XXX O
humoral XXX O
immunity--serum XXX O
immunoglobulins XXX O
and XXX O
immune XXX O
complexes--were XXX O
evaluated XXX O
in XXX O
irradiated XXX O
group XXX O
of XXX O
patients XXX O
with XXX O
uterine XXX O
cervix XXX O
carcinoma XXX O
( XXX O
Stages XXX O
IIB XXX O
and XXX O
IIIB XXX O
) XXX O
, XXX O
during XXX O
one XXX O
year XXX O
follow XXX O
up XXX O
. XXX O

Preliminary XXX O
use XXX O
of XXX O
the XXX O
Nottingham XXX O
Eczema XXX O
Severity XXX O
Score XXX O
would XXX O
support XXX O
further XXX O
development XXX O
as XXX O
a XXX O
research XXX O
tool XXX O
for XXX O
a XXX O
simple XXX O
assessment XXX O
of XXX O
disease XXX O
severity XXX O
that XXX O
could XXX O
be XXX O
used XXX O
in XXX O
epidemiological XXX O
studies XXX O
. XXX O

The XXX O
order XXX O
of XXX O
the XXX O
helicase XXX B-GENE
motif XXX I-GENE
and XXX O
the XXX O
nsP3 XXX B-GENE
homology XXX I-GENE
region XXX I-GENE
in XXX O
the XXX O
RUB XXX O
genome XXX O
is XXX O
reversed XXX O
with XXX O
respect XXX O
to XXX O
the XXX O
alphavirus XXX O
genome XXX O
indicating XXX O
that XXX O
a XXX O
genetic XXX O
rearrangement XXX O
has XXX O
occurred XXX O
during XXX O
the XXX O
evolution XXX O
of XXX O
these XXX O
viruses XXX O
. XXX O

The XXX O
ORF1 XXX O
protein XXX O
was XXX O
found XXX O
to XXX O
be XXX O
highly XXX O
homologous XXX O
to XXX O
the XXX O
putative XXX O
potexvirus XXX B-GENE
RNA XXX I-GENE
replicases XXX I-GENE
; XXX O
ORF2 XXX O
, XXX O
-3 XXX O
, XXX O
-5 XXX O
and XXX O
-6 XXX O
proteins XXX O
also XXX O
have XXX O
analogues XXX O
among XXX O
the XXX O
potex- XXX O
and XXX O
/ XXX O
or XXX O
carlavirus-encoded XXX O
proteins XXX O
. XXX O

Hybridization XXX O
signals XXX O
were XXX O
also XXX O
detected XXX O
with XXX O
total XXX O
DNAs XXX O
of XXX O
Rhizobium XXX O
leguminosarum XXX O
bv XXX O
. XXX O
phaseoli XXX O
, XXX O
Rhodobacter XXX O
capsulatus XXX O
and XXX O
Escherichia XXX O
coli XXX O
, XXX O
but XXX O
not XXX O
those XXX O
of XXX O
Xanthomonas XXX O
campestris XXX O
pv XXX O
. XXX O
campestris XXX O
and XXX O
Pseudomonas XXX O
putida XXX O
. XXX O

The XXX O
regulation XXX O
of XXX O
Myf-5 XXX B-GENE
and XXX O
MyoD XXX B-GENE
function XXX O
by XXX O
a XXX O
cAMP-dependent XXX O
pathway XXX O
may XXX O
partly XXX O
explain XXX O
how XXX O
external XXX O
signals XXX O
generated XXX O
by XXX O
serum XXX O
and XXX O
certain XXX O
peptide XXX B-GENE
growth XXX I-GENE
factors XXX I-GENE
can XXX O
be XXX O
transduced XXX O
to XXX O
the XXX O
nucleus XXX O
and XXX O
inhibit XXX O
dominant-acting XXX O
factors XXX O
that XXX O
are XXX O
responsible XXX O
for XXX O
myoblast XXX O
differentiation XXX O
. XXX O

Together XXX O
, XXX O
our XXX O
data XXX O
suggest XXX O
that XXX O
the XXX O
TR2 XXX B-GENE
orphan XXX I-GENE
receptor XXX I-GENE
may XXX O
be XXX O
a XXX O
master XXX O
regulator XXX O
in XXX O
modulating XXX O
the XXX O
activation XXX O
of XXX O
two XXX O
key XXX O
HREs XXX O
, XXX O
RARE XXX B-GENE
beta XXX I-GENE
and XXX O
CRBPIIp XXX B-GENE
, XXX O
involved XXX O
in XXX O
the XXX O
retinoic XXX O
acid XXX O
signal XXX O
transduction XXX O
pathway XXX O
. XXX O

CONCLUSIONS XXX O
: XXX O
These XXX O
routinely XXX O
collected XXX O
data XXX O
provided XXX O
quantitative XXX O
estimates XXX O
of XXX O
changes XXX O
in XXX O
CBZ XXX O
Cl XXX O
/ XXX O
F XXX O
due XXX O
to XXX O
comedication XXX O
and XXX O
an XXX O
age-related XXX O
decrease XXX O
in XXX O
Cl XXX O
/ XXX O
F XXX O
The XXX O
derived XXX O
regression XXX O
equations XXX O
reasonably XXX O
predicted XXX O
concentrations XXX O
in XXX O
a XXX O
separate XXX O
validation XXX O
set XXX O
. XXX O

We XXX O
show XXX O
here XXX O
that XXX O
the XXX O
binding XXX O
of XXX O
C1F XXX B-GENE
in XXX O
vitro XXX O
is XXX O
sensitive XXX O
to XXX O
the XXX O
concentration XXX O
of XXX O
calcium XXX O
ions XXX O
. XXX O

Bisoprolol XXX O
was XXX O
found XXX O
to XXX O
be XXX O
an XXX O
effective XXX O
beta-adrenoceptor XXX B-GENE
antagonist XXX O
, XXX O
the XXX O
pA2 XXX O
values XXX O
determined XXX O
against XXX O
isoprenaline XXX O
in XXX O
guinea XXX O
pig XXX O
atria XXX O
and XXX O
tracheal XXX O
muscle XXX O
being XXX O
7 XXX O
. XXX O
45 XXX O
and XXX O
6 XXX O
. XXX O
41 XXX O
, XXX O
respectively XXX O
. XXX O

Interestingly XXX O
, XXX O
following XXX O
induction XXX O
of XXX O
stress XXX O
by XXX O
heat XXX O
shock XXX O
, XXX O
high XXX O
salt XXX O
, XXX O
or XXX O
ethanol XXX O
, XXX O
conditions XXX O
under XXX O
which XXX O
most XXX O
mRNA XXX O
export XXX O
is XXX O
blocked XXX O
, XXX O
Npl3p XXX B-GENE
is XXX O
still XXX O
exported XXX O
from XXX O
the XXX O
nucleus XXX O
. XXX O

After XXX O
a XXX O
baseline XXX O
study XXX O
, XXX O
WPW XXX O
syndrome XXX O
was XXX O
simulated XXX O
by XXX O
stimulation XXX O
at XXX O
seven XXX O
different XXX O
sites XXX O
around XXX O
the XXX O
base XXX O
of XXX O
the XXX O
ventricles XXX O
, XXX O
and XXX O
RNV's XXX O
were XXX O
obtained XXX O
. XXX O

There XXX O
was XXX O
a XXX O
2 XXX O
. XXX O
4-fold XXX O
difference XXX O
in XXX O
CAT XXX B-GENE
produced XXX O
from XXX O
these XXX O
transcripts XXX O
in XXX O
HeLa XXX O
cells XXX O
, XXX O
which XXX O
contain XXX O
a XXX O
greater XXX O
natural XXX O
abundance XXX O
of XXX O
PTB XXX B-GENE
. XXX O

We XXX O
speculate XXX O
that XXX O
these XXX O
tumors XXX O
may XXX O
represent XXX O
congenital XXX O
hamartomatous XXX O
growths XXX O
. XXX O

We XXX O
have XXX O
isolated XXX O
cDNAs XXX O
for XXX O
a XXX O
gene XXX O
coding XXX O
for XXX O
a XXX O
G XXX B-GENE
protein XXX I-GENE
alpha XXX I-GENE
subunit XXX I-GENE
from XXX I-GENE
tomato XXX I-GENE
( XXX O
Lycopersicon XXX O
esculentum XXX O
, XXX O
cv XXX O
. XXX O

The XXX O
12 XXX B-GENE
, XXX I-GENE
000 XXX I-GENE
MW XXX I-GENE
( XXX I-GENE
12K XXX I-GENE
) XXX I-GENE
IE XXX I-GENE
polypeptide XXX I-GENE
encoded XXX O
by XXX O
IEmRNA-5 XXX B-GENE
is XXX O
translated XXX O
from XXX O
an XXX O
88 XXX O
codon XXX O
open XXX O
reading XXX O
frame XXX O
, XXX O
leaving XXX O
a XXX O
1200 XXX O
base XXX O
3' XXX O
non-translated XXX O
region XXX O
. XXX O

Evolutionary XXX O
relationships XXX O
among XXX O
putative XXX O
RNA-dependent XXX B-GENE
RNA XXX I-GENE
polymerases XXX I-GENE
encoded XXX O
by XXX O
a XXX O
mitochondrial XXX O
virus-like XXX O
RNA XXX O
in XXX O
the XXX O
Dutch XXX O
elm XXX O
disease XXX O
fungus XXX O
, XXX O
Ophiostoma XXX O
novo-ulmi XXX O
, XXX O
by XXX O
other XXX O
viruses XXX O
and XXX O
virus-like XXX O
RNAs XXX O
and XXX O
by XXX O
the XXX O
Arabidopsis XXX O
mitochondrial XXX O
genome XXX O
. XXX O

Two XXX O
independent XXX O
promoters XXX O
as XXX O
well XXX O
as XXX O
5' XXX O
untranslated XXX O
regions XXX O
regulate XXX O
Dd XXX B-GENE
ras XXX I-GENE
expression XXX O
in XXX O
Dictyostelium XXX O
. XXX O

Ischemia-induced XXX O
biphasic XXX O
arrhythmias XXX O
were XXX O
suppressed XXX O
in XXX O
both XXX O
zatebradine XXX O
and XXX O
propranolol XXX O
groups XXX O
. XXX O

All XXX O
members XXX O
are XXX O
also XXX O
capable XXX O
of XXX O
activating XXX O
in XXX O
vivo XXX O
transcription XXX O
from XXX O
promoters XXX O
that XXX O
contain XXX O
a XXX O
C XXX B-GENE
/ XXX I-GENE
EBP-binding XXX I-GENE
site XXX I-GENE
. XXX O

Also XXX O
, XXX O
except XXX O
in XXX O
one XXX O
patient XXX O
who XXX O
developed XXX O
gallstones XXX O
following XXX O
institution XXX O
of XXX O
colestipol XXX O
, XXX O
saturation XXX O
of XXX O
gallbladder XXX O
bile XXX O
with XXX O
cholesterol XXX O
was XXX O
not XXX O
markedly XXX O
increased XXX O
by XXX O
this XXX O
drug XXX O
alone XXX O
. XXX O

Amino XXX O
acid XXX O
residues XXX O
147-167 XXX O
of XXX O
the XXX O
previously XXX O
reported XXX O
sequence XXX O
are XXX O
replaced XXX O
by XXX O
new XXX O
residues XXX O
147 XXX O
to XXX O
150 XXX O
. XXX O

Morphofunctional XXX O
status XXX O
of XXX O
the XXX O
formed XXX O
elements XXX O
of XXX O
the XXX O
blood XXX O
in XXX O
rats XXX O
subjected XXX O
to XXX O
different XXX O
variants XXX O
of XXX O
combined XXX O
and XXX O
isolated XXX O
exposure XXX O
to XXX O
BR-1 XXX O
benzene XXX O
. XXX O

Thus XXX O
in XXX O
this XXX O
region XXX O
of XXX O
the XXX O
vessel XXX O
pyridinoline XXX O
represents XXX O
the XXX O
major XXX O
stabilising XXX O
crosslink XXX O
of XXX O
collagen XXX B-GENE
. XXX O

No XXX O
significant XXX O
differences XXX O
were XXX O
identified XXX O
between XXX O
groups XXX O
for XXX O
pH XXX O
, XXX O
PaCO2 XXX O
, XXX O
intracranial XXX O
pressure XXX O
, XXX O
heart XXX O
rate XXX O
, XXX O
brain XXX O
temperature XXX O
, XXX O
or XXX O
glucose XXX O
levels XXX O
. XXX O

PhoP-PhoQ XXX B-GENE
homologues XXX I-GENE
in XXX I-GENE
Pseudomonas XXX I-GENE
aeruginosa XXX I-GENE
regulate XXX O
expression XXX O
of XXX O
the XXX O
outer-membrane XXX B-GENE
protein XXX I-GENE
OprH XXX I-GENE
and XXX O
polymyxin XXX O
B XXX O
resistance XXX O
. XXX O

Thus XXX O
, XXX O
both XXX O
YY1 XXX B-GENE
and XXX O
CDP XXX B-GENE
appear XXX O
to XXX O
be XXX O
negative XXX O
regulators XXX O
of XXX O
the XXX O
differentiation-induced XXX O
HPV-6 XXX B-GENE
E1 XXX I-GENE
promoter XXX I-GENE
and XXX O
thereby XXX O
the XXX O
HPV XXX O
life XXX O
cycle XXX O
. XXX O

DNA XXX O
strand XXX O
exchange XXX O
catalyzed XXX O
by XXX O
Rad51 XXX B-GENE
protein XXX I-GENE
is XXX O
also XXX O
greatly XXX O
stimulated XXX O
by XXX O
RPA XXX B-GENE
. XXX O

Htra2-beta3 XXX B-GENE
is XXX O
developmentally XXX O
regulated XXX O
and XXX O
expressed XXX O
predominantly XXX O
in XXX O
brain XXX O
, XXX O
liver XXX O
testis XXX O
, XXX O
and XXX O
weakly XXX O
in XXX O
kidney XXX O
. XXX O

It XXX O
has XXX O
been XXX O
established XXX O
that XXX O
preoperative XXX O
irradiation XXX O
in XXX O
the XXX O
form XXX O
of XXX O
the XXX O
fractionation XXX O
of XXX O
a XXX O
single XXX O
focal XXX O
dose XXX O
of XXX O
6 XXX O
Gy XXX O
every XXX O
other XXX O
day XXX O
, XXX O
the XXX O
summary XXX O
dose XXX O
of XXX O
24 XXX O
Gy XXX O
within XXX O
8-10 XXX O
days XXX O
followed XXX O
by XXX O
surgery XXX O
1-3 XXX O
days XXX O
after XXX O
irradiation XXX O
does XXX O
not XXX O
either XXX O
complicate XXX O
its XXX O
performance XXX O
or XXX O
the XXX O
course XXX O
of XXX O
the XXX O
postoperative XXX O
period XXX O
, XXX O
and XXX O
by XXX O
the XXX O
short- XXX O
and XXX O
long-term XXX O
results XXX O
it XXX O
is XXX O
no XXX O
worse XXX O
than XXX O
the XXX O
routine XXX O
dose XXX O
fractionation XXX O
. XXX O

Effects XXX O
of XXX O
nitrogen XXX O
( XXX O
PN2 XXX O
: XXX O
5 XXX O
and XXX O
14 XXX O
MPa XXX O
) XXX O
and XXX O
helium XXX O
( XXX O
PHe XXX O
: XXX O
13 XXX O
and XXX O
14 XXX O
MPa XXX O
) XXX O
were XXX O
also XXX O
tested XXX O
. XXX O

Epidemiological XXX O
data XXX O
are XXX O
quite XXX O
controversial XXX O
but XXX O
sudden XXX O
death XXX O
occurring XXX O
during XXX O
sporting XXX O
activity XXX O
is XXX O
probably XXX O
not XXX O
a XXX O
rare XXX O
occurrence XXX O
. XXX O

A XXX O
similar XXX O
phenomenon XXX O
has XXX O
been XXX O
reported XXX O
in XXX O
a XXX O
few XXX O
humans XXX O
. XXX O

If XXX O
the XXX O
haemoglobin XXX B-GENE
concentration XXX O
( XXX O
Hb XXX B-GENE
) XXX O
was XXX O
less XXX O
than XXX O
12 XXX O
g XXX O
dL-1 XXX O
they XXX O
were XXX O
given XXX O
a XXX O
four XXX O
week XXX O
course XXX O
of XXX O
ferrous XXX O
sulphate XXX O
. XXX O

We XXX O
have XXX O
isolated XXX O
three XXX O
mutant XXX O
alleles XXX O
of XXX O
CDC4 XXX B-GENE
( XXX O
cdc4-10 XXX B-GENE
, XXX O
cdc4-11 XXX B-GENE
, XXX O
and XXX O
cdc4-16 XXX B-GENE
) XXX O
which XXX O
suppress XXX O
the XXX O
nuclear XXX O
division XXX O
defect XXX O
of XXX O
cdc20-1 XXX B-GENE
cells XXX O
. XXX O

Therefore XXX O
, XXX O
we XXX O
have XXX O
identified XXX O
a XXX O
cis-acting XXX O
element XXX O
, XXX O
the XXX O
E1 XXX B-GENE
E-box XXX I-GENE
, XXX O
located XXX O
in XXX O
the XXX O
GAP-43 XXX B-GENE
promoter XXX O
region XXX O
that XXX O
modulates XXX O
either XXX O
positively XXX O
or XXX O
negatively XXX O
the XXX O
expression XXX O
of XXX O
the XXX O
GAP-43 XXX B-GENE
gene XXX I-GENE
depending XXX O
on XXX O
which XXX O
E-box-binding XXX B-GENE
proteins XXX I-GENE
occupy XXX O
this XXX O
site XXX O
. XXX O

Scanning XXX O
mutations XXX O
throughout XXX O
the XXX O
AC XXX B-GENE
element XXX I-GENE
interfered XXX O
with XXX O
induction XXX O
but XXX O
allowed XXX O
us XXX O
to XXX O
define XXX O
five XXX O
overlapping XXX O
sites XXX O
for XXX O
regulatory XXX O
factors XXX O
in XXX O
AC XXX B-GENE
and XXX O
to XXX O
design XXX O
probes XXX O
binding XXX O
just XXX O
one XXX O
or XXX O
two XXX O
factors XXX O
. XXX O

Forty-five XXX O
patients XXX O
with XXX O
pleural XXX O
lesions XXX O
identified XXX O
on XXX O
CT XXX O
scans XXX O
were XXX O
subsequently XXX O
examined XXX O
by XXX O
MR XXX O
imaging XXX O
at XXX O
0 XXX O
. XXX O
5 XXX O
T XXX O
. XXX O

The XXX O
monoclonal XXX O
immunoglobulin XXX B-GENE
products XXX O
of XXX O
plasma XXX O
cell XXX O
neoplasm XXX O
can XXX O
give XXX O
rise XXX O
to XXX O
a XXX O
variety XXX O
of XXX O
manifestations XXX O
including XXX O
hyperviscosity XXX O
, XXX O
amyloidosis XXX O
, XXX O
cryoglobulinemia XXX O
, XXX O
neuropathy XXX O
, XXX O
and XXX O
renal XXX O
failure XXX O
. XXX O

ISS XXX O
and XXX O
the XXX O
acute XXX O
physiology XXX O
and XXX O
chronic XXX O
health XXX O
evaluation XXX O
( XXX O
APACHE XXX O
II XXX O
) XXX O
calculated XXX O
on XXX O
admission XXX O
. XXX O

When XXX O
the XXX O
coding XXX O
segments XXX O
, XXX O
including XXX O
both XXX O
framework XXX O
and XXX O
complementarity-determining XXX O
regions XXX O
, XXX O
of XXX O
these XXX O
genes XXX O
and XXX O
the XXX O
murine XXX O
probe XXX O
sequences XXX O
are XXX O
compared XXX O
by XXX O
metric XXX O
analysis XXX O
, XXX O
it XXX O
is XXX O
apparent XXX O
that XXX O
the XXX O
caiman XXX B-GENE
genes XXX I-GENE
are XXX O
only XXX O
slightly XXX O
more XXX O
related XXX O
to XXX O
each XXX O
other XXX O
than XXX O
to XXX O
the XXX O
mammalian XXX O
sequence XXX O
, XXX O
consistent XXX O
with XXX O
significant XXX O
preservation XXX O
of XXX O
nucleotide XXX O
sequence XXX O
over XXX O
an XXX O
extended XXX O
period XXX O
of XXX O
phylogenetic XXX O
time XXX O
. XXX O

Behavioral XXX O
and XXX O
electrographic XXX O
expression XXX O
of XXX O
natural XXX O
sleep XXX O
and XXX O
wakefulness XXX O
in XXX O
reptiles XXX O
. XXX O

In XXX O
summary XXX O
, XXX O
p56 XXX B-GENE
( XXX I-GENE
lck XXX I-GENE
) XXX I-GENE
activity XXX O
stimulates XXX O
G1 XXX O
/ XXX O
S XXX O
transition XXX O
in XXX O
immature XXX O
thymoblasts XXX O
and XXX O
maintains XXX O
cell XXX O
viability XXX O
via XXX O
transduction XXX O
of XXX O
constitutive XXX O
activation XXX O
signals XXX O
downstream XXX O
to XXX O
components XXX O
of XXX O
the XXX O
Ras XXX B-GENE
/ XXX I-GENE
Raf XXX I-GENE
/ XXX I-GENE
MAPK XXX I-GENE
pathway XXX I-GENE
. XXX O

A XXX O
prostaglandin XXX O
analogue XXX O
given XXX O
in XXX O
early XXX O
pregnancy XXX O
and XXX O
human XXX B-GENE
chorionic XXX I-GENE
gonadotropin XXX I-GENE
given XXX O
near XXX O
the XXX O
end XXX O
of XXX O
the XXX O
ensuing XXX O
follicular XXX O
phase XXX O
were XXX O
used XXX O
for XXX O
controlling XXX O
the XXX O
reproductive XXX O
cycle XXX O
, XXX O
timing XXX O
oocyte XXX O
collection XXX O
, XXX O
and XXX O
synchronizing XXX O
the XXX O
cycles XXX O
of XXX O
oocyte XXX O
donors XXX O
and XXX O
embryo XXX O
recipients XXX O
. XXX O

( XXX O
1992 XXX O
) XXX O
Biochemistry XXX O
31 XXX O
, XXX O
3351-3358 XXX O
] XXX O
. XXX O

However XXX O
, XXX O
an XXX O
intrinsic XXX O
DNA-binding XXX O
subunit XXX O
for XXX O
HiNF-D XXX B-GENE
was XXX O
not XXX O
identified XXX O
. XXX O

Laboratory XXX O
exam XXX O
: XXX O
IDR XXX O
of XXX O
the XXX O
tuberculin XXX O
was XXX O
high XXX O
positive XXX O
, XXX O
chest XXX O
radiography XXX O
shows XXX O
hilar XXX O
bilateral XXX O
calcifications XXX O
, XXX O
ORL XXX O
exam XXX O
shows XXX O
a XXX O
tumor XXX O
at XXX O
the XXX O
foot XXX O
of XXX O
the XXX O
epiglottis XXX O
and XXX O
anatomopathological XXX O
exam XXX O
shows XXX O
low XXX O
differentiated XXX O
epidermoid XXX O
carcinoma XXX O
. XXX O

The XXX O
ORF XXX B-GENE
4 XXX I-GENE
gene XXX I-GENE
was XXX O
minimally XXX O
active XXX O
, XXX O
whereas XXX O
the XXX O
ORF XXX B-GENE
62 XXX I-GENE
gene XXX I-GENE
gave XXX O
twofold XXX O
induction XXX O
; XXX O
both XXX O
genes XXX O
, XXX O
acting XXX O
together XXX O
, XXX O
gave XXX O
fivefold XXX O
induction XXX O
. XXX O

We XXX O
have XXX O
separated XXX O
a XXX O
dermatan XXX O
sulfate XXX O
proteoglycan XXX O
, XXX O
epiphycan XXX O
, XXX O
from XXX O
decorin XXX O
and XXX O
biglycan XXX O
by XXX O
using XXX O
dissociative XXX O
extraction XXX O
of XXX O
bovine XXX O
fetal XXX O
epiphyseal XXX O
cartilage XXX O
, XXX O
followed XXX O
by XXX O
sequential XXX O
ion-exchange XXX O
, XXX O
gel XXX O
permeation XXX O
, XXX O
hydrophobic XXX O
, XXX O
and XXX O
Zn2+ XXX O
chelate XXX O
chromatographic XXX O
steps XXX O
. XXX O

We XXX O
suggest XXX O
that XXX O
such XXX O
occlusions XXX O
occurred XXX O
at XXX O
the XXX O
time XXX O
of XXX O
the XXX O
infarction XXX O
. XXX O

In XXX O
vitro XXX O
transcription XXX O
assays XXX O
demonstrate XXX O
that XXX O
the XXX O
TCA-cycle XXX O
intermediate XXX O
, XXX O
fumarate XXX O
, XXX O
directly XXX O
and XXX O
specifically XXX O
inhibits XXX O
the XXX O
formation XXX O
of XXX O
the XXX O
clcA XXX B-GENE
transcript XXX I-GENE
. XXX O

Green XXX O
fluorescent XXX O
protein-tagged XXX O
UNC-49B XXX B-GENE
and XXX O
UNC-49C XXX B-GENE
subunits XXX I-GENE
are XXX O
coexpressed XXX O
in XXX O
muscle XXX O
cells XXX O
and XXX O
are XXX O
colocalized XXX O
to XXX O
synaptic XXX O
regions XXX O
. XXX O

Effect XXX O
of XXX O
thrombotic XXX O
and XXX O
antithrombotic XXX O
drugs XXX O
on XXX O
the XXX O
surface XXX O
charge XXX O
characteristics XXX O
of XXX O
canine XXX O
blood XXX O
vessels XXX O
: XXX O
in XXX O
vivo XXX O
and XXX O
in XXX O
vitro XXX O
studies XXX O
. XXX O

It XXX O
has XXX O
also XXX O
been XXX O
shown XXX O
that XXX O
a XXX O
variety XXX O
of XXX O
extracellular XXX O
factors XXX O
stimulate XXX O
a XXX O
pair XXX O
of XXX O
MAPK XXX B-GENE
p44 XXX B-GENE
and XXX O
MAPK XXX B-GENE
p42 XXX B-GENE
of XXX O
MAPK XXX B-GENE
family XXX I-GENE
members XXX I-GENE
. XXX O

Sp1 XXX B-GENE
binds XXX O
two XXX O
sites XXX O
in XXX O
the XXX O
CD11c XXX B-GENE
promoter XXX I-GENE
in XXX O
vivo XXX O
specifically XXX O
in XXX O
myeloid XXX O
cells XXX O
and XXX O
cooperates XXX O
with XXX O
AP1 XXX B-GENE
to XXX O
activate XXX O
transcription XXX O
. XXX O

Constitutive XXX O
protection XXX O
of XXX O
E2F XXX B-GENE
recognition XXX I-GENE
sequences XXX I-GENE
in XXX O
the XXX O
human XXX B-GENE
thymidine XXX I-GENE
kinase XXX I-GENE
promoter XXX I-GENE
during XXX O
cell XXX O
cycle XXX O
progression XXX O
. XXX O

These XXX O
contain XXX O
a XXX O
single XXX O
1977-bp XXX O
exon XXX O
that XXX O
encodes XXX O
900 XXX O
bp XXX O
of XXX O
the XXX O
5' XXX O
and XXX O
3' XXX O
untranslated XXX O
sequences XXX O
in XXX O
addition XXX O
to XXX O
a XXX O
1077-bp XXX O
open XXX O
reading XXX O
frame XXX O
identical XXX O
to XXX O
that XXX O
found XXX O
in XXX O
vascular XXX B-GENE
smooth XXX I-GENE
muscle XXX I-GENE
cell XXX I-GENE
AT1a XXX I-GENE
receptor XXX I-GENE
cDNAs XXX I-GENE
. XXX O

These XXX O
factors XXX O
belong XXX O
to XXX O
a XXX O
set XXX O
of XXX O
genetically XXX O
distinct XXX O
molecules XXX O
, XXX O
including XXX O
AP-4 XXX B-GENE
and XXX O
MLTF XXX B-GENE
, XXX O
that XXX O
bind XXX O
to XXX O
the XXX O
CACCTGTC XXX B-GENE
motif XXX I-GENE
or XXX O
related XXX O
sequences XXX O
. XXX O

Both XXX O
mutations XXX O
completely XXX O
abolished XXX O
binding XXX O
of XXX O
the XXX O
Abl XXX B-GENE
SH3 XXX I-GENE
domain XXX I-GENE
to XXX O
proline-rich XXX O
target XXX O
proteins XXX O
in XXX O
a XXX O
filter-binding XXX O
assay XXX O
. XXX O

We XXX O
conclude XXX O
that XXX O
, XXX O
in XXX O
AIDS XXX O
patients XXX O
with XXX O
cryptococcosis XXX O
, XXX O
tolerance XXX O
to XXX O
ILd-AmB XXX O
was XXX O
acceptable XXX O
when XXX O
the XXX O
daily XXX O
dosage XXX O
did XXX O
not XXX O
exceed XXX O
1 XXX O
mg XXX O
/ XXX O
kg XXX O
, XXX O
but XXX O
the XXX O
higher XXX O
1 XXX O
. XXX O
5 XXX O
mg XXX O
/ XXX O
kg XXX O
daily XXX O
dosage XXX O
was XXX O
associated XXX O
with XXX O
an XXX O
unacceptable XXX O
rate XXX O
of XXX O
nephrotoxicity XXX O
. XXX O

These XXX O
patients XXX O
appear XXX O
to XXX O
have XXX O
slightly XXX O
better XXX O
pulmonary XXX O
function XXX O
and XXX O
nutritional XXX O
status XXX O
; XXX O
yet XXX O
, XXX O
they XXX O
seem XXX O
to XXX O
have XXX O
a XXX O
higher XXX O
degree XXX O
of XXX O
health XXX O
care XXX O
utilization XXX O
. XXX O

The XXX O
p53 XXX B-GENE
tumor XXX I-GENE
suppressor XXX I-GENE
gene XXX I-GENE
product XXX I-GENE
, XXX O
a XXX O
sequence-specific XXX O
DNA-binding XXX O
protein XXX O
, XXX O
has XXX O
been XXX O
shown XXX O
to XXX O
act XXX O
as XXX O
a XXX O
transcriptional XXX O
activator XXX O
and XXX O
repressor XXX O
both XXX O
in XXX O
vitro XXX O
and XXX O
in XXX O
vivo XXX O
. XXX O

The XXX O
PCr XXX O
resynthesis XXX O
rate XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
and XXX O
the XXX O
effective XXX O
maximal XXX O
rate XXX O
of XXX O
mitochondrial XXX O
ATP XXX O
synthesis XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
also XXX O
improved XXX O
. XXX O

Semidominant XXX O
mutations XXX O
in XXX O
the XXX O
yeast XXX B-GENE
Rad51 XXX I-GENE
protein XXX I-GENE
and XXX O
their XXX O
relationships XXX O
with XXX O
the XXX O
Srs2 XXX B-GENE
helicase XXX I-GENE
. XXX O

The XXX O
smallest XXX O
of XXX O
the XXX O
mini-Mu XXX B-GENE
elements XXX I-GENE
is XXX O
only XXX O
7 XXX O
. XXX O
9 XXX O
kilobase XXX O
pairs XXX O
long XXX O
, XXX O
allowing XXX O
the XXX O
cloning XXX O
of XXX O
DNA XXX O
fragments XXX O
of XXX O
up XXX O
to XXX O
31 XXX O
. XXX O
1 XXX O
kilobase XXX O
pairs XXX O
, XXX O
and XXX O
the XXX O
largest XXX O
of XXX O
them XXX O
is XXX O
21 XXX O
. XXX O
7 XXX O
kilobase XXX O
pairs XXX O
, XXX O
requiring XXX O
that XXX O
clones XXX O
carry XXX O
insertions XXX O
of XXX O
less XXX O
than XXX O
17 XXX O
. XXX O
3 XXX O
kilobase XXX O
pairs XXX O
. XXX O

The XXX O
cis-acting XXX O
elements XXX O
that XXX O
control XXX O
promoter XXX O
activity XXX O
include XXX O
binding XXX O
sites XXX O
for XXX O
transcription XXX O
factors XXX O
Sp1 XXX B-GENE
and XXX O
alphaCbf XXX B-GENE
, XXX O
a XXX O
60-kDa XXX B-GENE
CCAAT XXX I-GENE
box-binding XXX I-GENE
protein XXX I-GENE
. XXX O

A XXX O
single-case XXX O
experimental XXX O
ABAB XXX O
multiple XXX O
baseline XXX O
design XXX O
was XXX O
employed XXX O
to XXX O
test XXX O
for XXX O
treatment XXX O
effectiveness XXX O
. XXX O

Histological XXX O
examination XXX O
showed XXX O
lichenoid XXX O
changes XXX O
, XXX O
acantholytic XXX O
blister XXX O
formation XXX O
and XXX O
apoptotic XXX O
keratinocytes XXX O
. XXX O

Patients XXX O
with XXX O
type XXX O
III XXX O
SOD XXX O
may XXX O
have XXX O
visceral XXX O
hyperalgesia XXX O
; XXX O
a XXX O
trial XXX O
of XXX O
antidepressants XXX O
or XXX O
a XXX O
therapeutic XXX O
trial XXX O
with XXX O
botulinum XXX B-GENE
toxin XXX I-GENE
injection XXX O
into XXX O
the XXX O
ampulla XXX O
should XXX O
be XXX O
considered XXX O
prior XXX O
to XXX O
more XXX O
invasive XXX O
endoscopic XXX O
therapy XXX O
. XXX O

The XXX O
sequence XXX O
of XXX O
the XXX O
pMxL1 XXX O
plasmid XXX O
containing XXX O
the XXX O
invertible XXX O
region XXX O
contains XXX O
a XXX O
perfect XXX O
tandem XXX O
repeat XXX O
of XXX O
19 XXX O
bp XXX O
in XXX O
the XXX O
orientation XXX O
1 XXX O
nonexpressed XXX O
pilin XXX B-GENE
gene XXX I-GENE
at XXX O
the XXX O
middle XXX O
of XXX O
the XXX O
recombination XXX O
junction XXX O
site XXX O
. XXX O

Considering XXX O
that XXX O
the XXX O
reactor XXX O
is XXX O
thoroughly XXX O
mixed XXX O
during XXX O
each XXX O
discharge XXX O
and XXX O
that XXX O
LD50 XXX O
= XXX O
0 XXX O
. XXX O
9 XXX O
values XXX O
are XXX O
nearly XXX O
independent XXX O
of XXX O
E XXX O
. XXX O
coli XXX O
concentrations XXX O
in XXX O
the XXX O
range XXX O
of XXX O
2 XXX O
x XXX O
10 XXX O
( XXX O
3 XXX O
) XXX O
< XXX O
or XXX O
= XXX O
E XXX O
coli XXX O
/ XXX O
cfu XXX O
mL XXX O
( XXX O
-1 XXX O
) XXX O
< XXX O
or XXX O
= XXX O
3 XXX O
x XXX O
10 XXX O
( XXX O
6 XXX O
) XXX O
, XXX O
we XXX O
ascribe XXX O
the XXX O
nonexponential XXX O
Pn XXX O
decay XXX O
of XXX O
single-strain XXX O
E XXX O
. XXX O
coli XXX O
colonies XXX O
to XXX O
a XXX O
shielding XXX O
phenomenon XXX O
where XXX O
inactive XXX O
cells XXX O
protect XXX O
the XXX O
successively XXX O
smaller XXX O
numbers XXX O
of XXX O
viable XXX O
cells XXX O
in XXX O
the XXX O
EHD XXX O
. XXX O

Perturbation XXX O
of XXX O
dNTP XXX O
pools XXX O
also XXX O
affected XXX O
the XXX O
frameshift XXX O
fidelity XXX O
of XXX O
the XXX O
replicative XXX O
yeast XXX B-GENE
DNA XXX I-GENE
polymerase XXX I-GENE
alpha XXX I-GENE
. XXX O

Although XXX O
%BF XXX O
was XXX O
correlated XXX O
with XXX O
all XXX O
the XXX O
BMIs XXX O
( XXX O
r XXX O
= XXX O
0 XXX O
. XXX O
60-0 XXX O
. XXX O
82 XXX O
) XXX O
, XXX O
applying XXX O
objective XXX O
definitions XXX O
of XXX O
obesity XXX O
based XXX O
on XXX O
BMIs XXX O
or XXX O
%BF XXX O
by XXX O
densitometry XXX O
often XXX O
produced XXX O
conflicting XXX O
results XXX O
. XXX O

The XXX O
IPL1 XXX B-GENE
gene XXX I-GENE
is XXX O
required XXX O
for XXX O
high-fidelity XXX O
chromosome XXX O
segregation XXX O
in XXX O
the XXX O
budding XXX O
yeast XXX O
Saccharomyces XXX O
cerevisiae XXX O
. XXX O

Cardiovascular XXX O
risk XXX O
factors XXX O
and XXX O
antihypertensive XXX O
treatment XXX O
. XXX O

The XXX O
system XXX O
, XXX O
designed XXX O
to XXX O
exploit XXX O
the XXX O
relatively XXX O
constant XXX O
small XXX O
intestine XXX O
transit XXX O
time XXX O
, XXX O
consists XXX O
of XXX O
a XXX O
drug-containing XXX O
core XXX O
coated XXX O
with XXX O
a XXX O
polymeric XXX O
matrix XXX O
formed XXX O
by XXX O
a XXX O
channeling XXX O
agent XXX O
( XXX O
NaCl XXX O
, XXX O
mannitol XXX O
, XXX O
and XXX O
Emdex XXX O
) XXX O
and XXX O
an XXX O
inert XXX O
polymer XXX O
( XXX O
Eudragit XXX O
RS100 XXX O
) XXX O
. XXX O

Strengthening XXX O
the XXX O
biological XXX O
weapons XXX O
convention XXX O
and XXX O
implications XXX O
on XXX O
the XXX O
pharmaceutical XXX O
and XXX O
biotechnology XXX O
industry XXX O
. XXX O

Drag XXX O
reduction XXX O
in XXX O
turbulent XXX O
flows XXX O
by XXX O
polymers XXX O
. XXX O

Neuron-specific XXX B-GENE
Bcl-2 XXX I-GENE
homology XXX I-GENE
3 XXX I-GENE
domain-only XXX I-GENE
splice XXX I-GENE
variant XXX I-GENE
of XXX O
Bak XXX B-GENE
is XXX O
anti-apoptotic XXX O
in XXX O
neurons XXX O
, XXX O
but XXX O
pro-apoptotic XXX O
in XXX O
non-neuronal XXX O
cells XXX O
. XXX O

Caries XXX O
and XXX O
parodontitis XXX O
have XXX O
been XXX O
one XXX O
of XXX O
the XXX O
most XXX O
spread XXX O
diseases XXX O
of XXX O
mankind XXX O
. XXX O

Expression XXX O
of XXX O
lacZ XXX B-GENE
from XXX O
the XXX O
promoter XXX O
of XXX O
the XXX O
Escherichia XXX B-GENE
coli XXX I-GENE
spc XXX I-GENE
operon XXX I-GENE
cloned XXX O
into XXX O
vectors XXX O
carrying XXX O
the XXX O
W205 XXX B-GENE
trp-lac XXX I-GENE
fusion XXX I-GENE
. XXX O

( XXX O
LH XXX B-GENE
P XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
, XXX O
LH XXX B-GENE
/ XXX I-GENE
FSH XXX I-GENE
P XXX O
< XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
mapping XXX O
of XXX O
the XXX O
promoter XXX O
region XXX O
and XXX O
the XXX O
identification XXX O
of XXX O
putative XXX O
promoter XXX O
regulatory XXX O
sequences XXX O
should XXX O
give XXX O
insight XXX O
into XXX O
the XXX O
transcriptional XXX O
regulation XXX O
of XXX O
UCP2 XXX B-GENE
expression--in XXX O
particular XXX O
by XXX O
anyone XXX O
of XXX O
the XXX O
above XXX O
mentioned XXX O
factors--in XXX O
vitro XXX O
and XXX O
in XXX O
vivo XXX O
. XXX O

Here XXX O
we XXX O
show XXX O
that XXX O
epidermal XXX B-GENE
growth XXX I-GENE
factor XXX I-GENE
or XXX O
platelet-derived XXX B-GENE
growth XXX I-GENE
factor XXX I-GENE
stimulation XXX O
of XXX O
intact XXX O
human XXX O
or XXX O
murine XXX O
cells XXX O
leads XXX O
to XXX O
phosphorylation XXX O
of XXX O
Nck XXX B-GENE
protein XXX I-GENE
on XXX O
tyrosine XXX O
, XXX O
serine XXX O
, XXX O
and XXX O
threonine XXX O
residues XXX O
. XXX O

Similar XXX O
to XXX O
the XXX O
mouse XXX O
gene XXX O
, XXX O
the XXX O
5' XXX O
flanking XXX O
region XXX O
of XXX O
human XXX B-GENE
CD79 XXX I-GENE
alpha XXX I-GENE
lacks XXX O
a XXX O
TATA XXX O
box XXX O
; XXX O
however XXX O
, XXX O
unlike XXX O
mouse XXX B-GENE
CD79 XXX I-GENE
alpha XXX I-GENE
, XXX O
a XXX O
classical XXX O
octamer XXX O
motif XXX O
could XXX O
not XXX O
be XXX O
identified XXX O
in XXX O
the XXX O
human XXX O
gene XXX O
. XXX O

Here XXX O
we XXX O
report XXX O
the XXX O
full-length XXX O
coding XXX O
cDNA XXX O
sequence XXX O
of XXX O
the XXX O
mouse XXX B-GENE
homologue XXX I-GENE
of XXX I-GENE
MPP3 XXX I-GENE
. XXX O

Bone XXX O
marrow XXX O
transplantation-1979 XXX O
. XXX O

Expression XXX O
of XXX O
a XXX O
dominant-negative XXX O
mutant XXX O
of XXX O
JNK1 XXX B-GENE
also XXX O
suppressed XXX O
glucose XXX O
deprivation-induced XXX O
JNK1 XXX B-GENE
activation XXX O
as XXX O
well XXX O
as XXX O
HSP70 XXX B-GENE
gene XXX I-GENE
expression XXX O
. XXX O

In XXX O
contrast XXX O
, XXX O
receptor XXX O
/ XXX O
G XXX O
protein XXX O
coupling XXX O
appeared XXX O
unaffected XXX O
by XXX O
expression XXX O
of XXX O
loop XXX O
3i XXX O
domains XXX O
derived XXX O
from XXX O
two XXX O
receptors XXX O
coupled XXX O
to XXX O
G XXX B-GENE
( XXX I-GENE
i XXX I-GENE
/ XXX I-GENE
o XXX I-GENE
) XXX I-GENE
proteins XXX I-GENE
( XXX O
M2Ach-muscarinic XXX B-GENE
and XXX I-GENE
alpha2A-adrenergic XXX I-GENE
receptors XXX I-GENE
) XXX O
. XXX O

The XXX O
first XXX O
exon XXX O
( XXX O
exon XXX O
1A XXX O
) XXX O
that XXX O
corresponded XXX O
to XXX O
the XXX O
5'-untranslated XXX O
region XXX O
of XXX O
the XXX O
GHR XXX B-GENE
1A XXX I-GENE
mRNA XXX I-GENE
was XXX O
15 XXX O
, XXX O
250 XXX O
bp XXX O
upstream XXX O
from XXX O
exon XXX O
2 XXX O
in XXX O
the XXX O
GHR XXX B-GENE
gene XXX I-GENE
. XXX O

Cardiac XXX B-GENE
myosin-binding XXX I-GENE
protein XXX I-GENE
C XXX I-GENE
( XXX O
MyBP-C XXX B-GENE
) XXX O
: XXX O
identification XXX O
of XXX O
protein XXX B-GENE
kinase XXX I-GENE
A XXX I-GENE
and XXX O
protein XXX B-GENE
kinase XXX I-GENE
C XXX I-GENE
phosphorylation XXX O
sites XXX O
. XXX O

The XXX O
limits XXX O
of XXX O
agreement XXX O
between XXX O
DBS XXX O
and XXX O
TOF XXX O
responses XXX O
were XXX O
so XXX O
wide XXX O
that XXX O
they XXX O
cannot XXX O
be XXX O
used XXX O
interchangeably XXX O
. XXX O

The XXX O
analysis XXX O
of XXX O
the XXX O
structure XXX O
of XXX O
the XXX O
sleep XXX O
period XXX O
as XXX O
a XXX O
whole XXX O
reveals XXX O
that XXX O
with XXX O
increasing XXX O
of XXX O
the XXX O
age XXX O
the XXX O
delta-wave XXX O
stage XXX O
( XXX O
DS XXX O
) XXX O
of XXX O
the XXX O
QS XXX O
( XXX O
determined XXX O
by XXX O
defined XXX O
polygraphic XXX O
parameters XXX O
) XXX O
increases XXX O
, XXX O
while XXX O
the XXX O
paradoxical XXX O
phase XXX O
of XXX O
sleep XXX O
( XXX O
PS XXX O
) XXX O
decreases XXX O
, XXX O
this XXX O
change XXX O
being XXX O
more XXX O
pronounced XXX O
during XXX O
the XXX O
first XXX O
six XXX O
months XXX O
than XXX O
during XXX O
the XXX O
second XXX O
ones XXX O
of XXX O
the XXX O
first XXX O
year XXX O
of XXX O
the XXX O
life XXX O
. XXX O

We XXX O
previously XXX O
showed XXX O
that XXX O
the XXX O
N-terminal XXX O
portion XXX O
common XXX O
to XXX O
various XXX O
chimeric XXX B-GENE
MLL XXX I-GENE
products XXX I-GENE
, XXX O
as XXX O
well XXX O
as XXX O
to XXX O
MLL-LTG9 XXX B-GENE
and XXX O
MLL-LTG19 XXX B-GENE
, XXX O
localizes XXX O
in XXX O
the XXX O
nuclei XXX O
, XXX O
and XXX O
therefore XXX O
suggested XXX O
that XXX O
it XXX O
might XXX O
play XXX O
an XXX O
important XXX O
role XXX O
in XXX O
leukemogenesis XXX O
. XXX O

Isolated XXX O
calcaneal XXX O
tuberculous XXX O
osteomyelitis XXX O
. XXX O

We XXX O
propose XXX O
that XXX O
CTS1 XXX B-GENE
and XXX I-GENE
CTS2 XXX I-GENE
of XXX I-GENE
Ci XXX I-GENE
are XXX O
members XXX O
of XXX O
two XXX O
distinct XXX O
classes XXX O
of XXX O
fungal XXX B-GENE
chitinases XXX I-GENE
, XXX O
an XXX O
observation XXX O
not XXX O
previously XXX O
reported XXX O
for XXX O
a XXX O
single XXX O
fungus XXX O
. XXX O

We XXX O
recently XXX O
characterized XXX O
a XXX O
single XXX O
yeast XXX B-GENE
hnRNP XXX I-GENE
methyltransferase XXX I-GENE
( XXX O
HMT1 XXX B-GENE
) XXX O
. XXX O

Electronic XXX O
structure XXX O
of XXX O
delta XXX O
-plutonium XXX O
and XXX O
of XXX O
single XXX O
Al XXX O
, XXX O
Ga XXX O
, XXX O
and XXX O
Sc XXX O
impurities XXX O
in XXX O
delta XXX O
-plutonium XXX O
. XXX O

Investigation XXX O
on XXX O
the XXX O
exchange XXX O
of XXX O
Ca45 XXX O
in XXX O
intact XXX O
and XXX O
burned XXX O
rats XXX O
by XXX O
the XXX O
kinetic XXX O
analysis XXX O
method XXX O
. XXX O

Telomerase XXX B-GENE
is XXX O
a XXX O
ribonucleoprotein XXX O
complex XXX O
that XXX O
synthesizes XXX O
telomeric XXX O
DNA XXX O
onto XXX O
chromosomes XXX O
using XXX O
its XXX O
RNA XXX O
component XXX O
as XXX O
template XXX O
. XXX O

OBJECTIVE XXX O
: XXX O
To XXX O
determine XXX O
whether XXX O
administration XXX O
of XXX O
misoprostol XXX O
prevents XXX O
gastric XXX O
hemorrhage XXX O
in XXX O
healthy XXX O
dogs XXX O
treated XXX O
with XXX O
high XXX O
doses XXX O
of XXX O
methylprednisolone XXX O
sodium XXX O
succinate XXX O
( XXX O
MPSS XXX O
) XXX O
. XXX O

The XXX O
gp330 XXX B-GENE
/ XXX I-GENE
Megalin XXX I-GENE
/ XXX I-GENE
LRP-2 XXX I-GENE
protein XXX I-GENE
belongs XXX O
to XXX O
the XXX O
low-density XXX B-GENE
lipoprotein XXX I-GENE
receptor XXX I-GENE
gene XXX I-GENE
family XXX I-GENE
and XXX O
is XXX O
believed XXX O
to XXX O
function XXX O
as XXX O
an XXX O
endocytic XXX O
receptor XXX O
for XXX O
the XXX O
uptake XXX O
of XXX O
lipoproteins XXX O
and XXX O
many XXX O
other XXX O
ligands XXX O
. XXX O

Moreover XXX O
, XXX O
expression XXX O
of XXX O
antisense XXX B-GENE
Ha-Ras XXX I-GENE
or XXX O
dominant XXX B-GENE
negative XXX I-GENE
Raf-1 XXX I-GENE
abrogated XXX O
the XXX O
mitogenic XXX O
effect XXX O
of XXX O
TGF-beta1 XXX B-GENE
in XXX O
TSU-Pr1 XXX O
, XXX O
and XXX O
the XXX O
TGF-beta1 XXX B-GENE
inhibition XXX O
of XXX O
DU145 XXX O
was XXX O
switched XXX O
to XXX O
stimulation XXX O
by XXX O
V12Ha-Ras XXX B-GENE
transfection XXX O
. XXX O

We XXX O
conclude XXX O
that XXX O
RPMS XXX B-GENE
acts XXX O
as XXX O
a XXX O
negative XXX O
regulator XXX O
of XXX O
EBNA2 XXX B-GENE
and XXX O
Notch XXX B-GENE
activity XXX O
through XXX O
its XXX O
interactions XXX O
with XXX O
the XXX O
CBF1-associated XXX B-GENE
corepressor XXX I-GENE
complex XXX I-GENE
. XXX O

To XXX O
study XXX O
the XXX O
structure-function XXX O
of XXX O
the XXX O
gene XXX B-GENE
5 XXX I-GENE
product XXX I-GENE
, XXX O
wild-type XXX O
and XXX O
mutant XXX O
forms XXX O
of XXX O
NS53 XXX B-GENE
were XXX O
produced XXX O
by XXX O
using XXX O
a XXX O
recombinant XXX O
baculovirus XXX O
expression XXX O
system XXX O
and XXX O
a XXX O
recombinant XXX O
vaccinia XXX O
virus XXX O
/ XXX O
T7 XXX O
( XXX O
vTF7-3 XXX O
) XXX O
expression XXX O
system XXX O
. XXX O

Effect XXX O
of XXX O
a XXX O
high-intensity XXX O
SHF XXX O
field XXX O
on XXX O
the XXX O
blood XXX O
coagulation XXX O
system XXX O
. XXX O

Functional XXX O
analysis XXX O
of XXX O
various XXX O
PTP-deficient XXX O
DT40 XXX O
B XXX O
cell XXX O
lines XXX O
stably XXX O
expressing XXX O
wild-type XXX B-GENE
chimeric XXX I-GENE
Fc XXX I-GENE
gamma XXX I-GENE
RIIB1-PECAM-1 XXX I-GENE
receptor XXX I-GENE
indicated XXX O
that XXX O
cytoplasmic XXX B-GENE
Src XXX I-GENE
homology XXX I-GENE
2-domain-containing XXX I-GENE
phosphatases XXX I-GENE
, XXX O
SHP-1 XXX B-GENE
and XXX O
SHP-2 XXX B-GENE
, XXX O
were XXX O
both XXX O
necessary XXX O
and XXX O
sufficient XXX O
to XXX O
deliver XXX O
inhibitory XXX O
negative XXX O
regulation XXX O
upon XXX O
coligation XXX O
of XXX O
BCR XXX B-GENE
complex XXX I-GENE
with XXX O
inhibitory XXX O
receptor XXX O
. XXX O

Epidemiology XXX O
and XXX O
prevention XXX O
of XXX O
hospital XXX O
infections XXX O
in XXX O
the XXX O
Local XXX O
Health XXX O
Unit XXX O
of XXX O
Sassari XXX O
: XXX O
profile XXX O
of XXX O
bacterial XXX O
resistance XXX O
and XXX O
antimicrobial XXX O
agents XXX O
of XXX O
large XXX O
usage XXX O
. XXX O

The XXX O
results XXX O
confirm XXX O
that XXX O
a XXX O
single XXX O
base XXX O
change XXX O
in XXX O
the XXX O
branchpoint XXX O
consensus XXX O
sequence XXX O
of XXX O
an XXX O
intron XXX O
can XXX O
cause XXX O
human XXX O
disease XXX O
although XXX O
this XXX O
sequence XXX O
is XXX O
poorly XXX O
conserved XXX O
in XXX O
mammals XXX O
. XXX O

Responsibility XXX O
matters--this XXX O
is XXX O
a XXX O
scientific XXX O
council XXX O
. XXX O

Prognosis XXX O
of XXX O
asymptomatic XXX O
multiple XXX O
myeloma XXX O
. XXX O

Among XXX O
38 XXX O
patients XXX O
with XXX O
inducible XXX O
reentrant XXX O
VTs XXX O
who XXX O
underwent XXX O
electrophysiologic XXX O
study XXX O
( XXX O
EPS XXX O
) XXX O
, XXX O
10 XXX O
VTs XXX O
of XXX O
six XXX O
patients XXX O
were XXX O
selected XXX O
. XXX O

The XXX O
hormonal XXX O
response XXX O
to XXX O
a XXX O
standardized XXX O
bicycle XXX O
exercise XXX O
test XXX O
was XXX O
studied XXX O
in XXX O
11 XXX O
male XXX O
cadets XXX O
exposed XXX O
to XXX O
a XXX O
course XXX O
of XXX O
107 XXX O
h XXX O
of XXX O
continuous XXX O
activity XXX O
with XXX O
less XXX O
than XXX O
2 XXX O
h XXX O
sleep XXX O
. XXX O

Only XXX O
one XXX O
DC XXX O
cardioversion XXX O
was XXX O
required XXX O
in XXX O
the XXX O
HBS XXX O
group XXX O
, XXX O
whereas XXX O
2 XXX O
DC XXX O
in XXX O
the XXX O
CBC XXX O
group XXX O
and XXX O
total XXX O
7 XXX O
DC XXX O
in XXX O
the XXX O
GIK XXX O
group XXX O
. XXX O

Inhibition XXX O
of XXX O
phosphatidylinositol-3 XXX B-GENE
kinase XXX I-GENE
did XXX O
not XXX O
have XXX O
a XXX O
significant XXX O
effect XXX O
on XXX O
p53 XXX B-GENE
conformation XXX O
but XXX O
did XXX O
have XXX O
a XXX O
weak XXX O
but XXX O
significant XXX O
effect XXX O
on XXX O
Tpo-enhanced XXX O
viability XXX O
. XXX O

This XXX O
suggests XXX O
that XXX O
alaproclate XXX O
acutely XXX O
increases XXX O
the XXX O
responsiveness XXX O
of XXX O
postsynaptic XXX O
muscarinic XXX B-GENE
and XXX I-GENE
alpha XXX I-GENE
1 XXX I-GENE
adrenoceptors XXX I-GENE
. XXX O

In XXX O
summary XXX O
, XXX O
we XXX O
conclude XXX O
that XXX O
the XXX O
adenoviral XXX O
oncoprotein XXX O
E1A XXX B-GENE
activates XXX O
transcription XXX O
from XXX O
the XXX O
endogenous XXX O
AP-2alpha XXX B-GENE
gene XXX I-GENE
, XXX O
an XXX O
effect XXX O
that XXX O
involves XXX O
transcriptional XXX O
derepression XXX O
of XXX O
the XXX O
AP-2alpha XXX B-GENE
promoter XXX I-GENE
by XXX O
interaction XXX O
of XXX O
E1A XXX B-GENE
with XXX O
the XXX O
AP-2rep XXX B-GENE
corepressor XXX O
CtBP1 XXX B-GENE
. XXX O

The XXX O
subjects XXX O
of XXX O
the XXX O
study XXX O
were XXX O
10 XXX O
normal XXX O
subjects XXX O
and XXX O
64 XXX O
patients XXX O
with XXX O
gastroduodenal XXX O
disease XXX O
. XXX O

Analysis XXX O
of XXX O
the XXX O
sequence XXX O
upstream XXX O
of XXX O
this XXX O
initiation XXX O
codon XXX O
reveals XXX O
the XXX O
presence XXX O
of XXX O
a XXX O
promotor XXX O
sequence XXX O
. XXX O

A XXX O
putative XXX O
inhibitor XXX O
( XXX O
s XXX O
) XXX O
appears XXX O
to XXX O
co-elute XXX O
in XXX O
the XXX O
inactive XXX O
fraction XXX O
that XXX O
blocked XXX O
the XXX O
L XXX B-GENE
( XXX I-GENE
alpha XXX I-GENE
) XXX I-GENE
activity XXX O
. XXX O

PROCEDURE XXX O
: XXX O
Cannulas XXX O
were XXX O
surgically XXX O
positioned XXX O
in XXX O
the XXX O
abomasal XXX O
body XXX O
and XXX O
pyloric XXX O
antrum XXX O
of XXX O
each XXX O
calf XXX O
. XXX O

Generally XXX O
ILC XXX O
and XXX O
ILVF XXX O
values XXX O
decreased XXX O
with XXX O
increasing XXX O
exposure XXX O
time XXX O
with XXX O
rate XXX O
constants XXX O
ranging XXX O
from XXX O
0 XXX O
. XXX O
03 XXX O
to XXX O
0 XXX O
. XXX O
33 XXX O
day-1 XXX O
( XXX O
wet XXX O
and XXX O
lipid XXX O
weight XXX O
) XXX O
for XXX O
ILC XXX O
and XXX O
0 XXX O
. XXX O
03 XXX O
to XXX O
0 XXX O
. XXX O
31 XXX O
day-1 XXX O
for XXX O
ILVF XXX O
. XXX O

RESULTS XXX O
: XXX O
Coronary XXX O
mortality XXX O
during XXX O
the XXX O
median XXX O
follow-up XXX O
time XXX O
of XXX O
17 XXX O
months XXX O
was XXX O
6-fold XXX O
higher XXX O
in XXX O
the XXX O
highest XXX O
tertile XXX O
for XXX O
CRP XXX B-GENE
and XXX O
IL-6 XXX B-GENE
and XXX O
3 XXX O
. XXX O
5-fold XXX O
higher XXX O
in XXX O
the XXX O
highest XXX O
tertile XXX O
for XXX O
fibrinogen XXX B-GENE
and XXX O
TNF-alpha XXX B-GENE
than XXX O
in XXX O
the XXX O
respective XXX O
combined XXX O
lower XXX O
tertiles XXX O
. XXX O

Protein XXX O
phosphorylation XXX O
appears XXX O
to XXX O
play XXX O
a XXX O
critical XXX O
role XXX O
in XXX O
uPA XXX B-GENE
gene XXX I-GENE
expression XXX O
in XXX O
these XXX O
cells XXX O
; XXX O
protein XXX O
kinase XXX O
C-activating XXX O
phorbol XXX O
esters XXX O
cooperate XXX O
with XXX O
pp60v-src XXX B-GENE
to XXX O
synergistically XXX O
increase XXX O
uPA XXX B-GENE
mRNA XXX I-GENE
, XXX O
whereas XXX O
cyclic XXX O
AMP XXX O
( XXX O
cAMP XXX O
) XXX O
-dependent XXX O
protein XXX O
kinase-activating XXX O
agents XXX O
( XXX O
e XXX O
. XXX O
g XXX O
. XXX O
, XXX O
8-bromo XXX O
cAMP XXX O
) XXX O
repress XXX O
uPA XXX B-GENE
mRNA XXX I-GENE
levels XXX O
. XXX O

Cis-regulation XXX O
downstream XXX O
of XXX O
cell XXX O
type XXX O
specification XXX O
: XXX O
a XXX O
single XXX O
compact XXX O
element XXX O
controls XXX O
the XXX O
complex XXX O
expression XXX O
of XXX O
the XXX O
CyIIa XXX B-GENE
gene XXX I-GENE
in XXX O
sea XXX O
urchin XXX O
embryos XXX O
. XXX O

One XXX O
of XXX O
these XXX O
, XXX O
an XXX O
AACA XXX O
motif XXX O
, XXX O
has XXX O
been XXX O
shown XXX O
to XXX O
be XXX O
a XXX O
negative XXX O
regulator XXX O
in XXX O
non-seed XXX O
tissues XXX O
and XXX O
has XXX O
a XXX O
similarity XXX O
to XXX O
the XXX O
barley XXX B-GENE
gibberellin XXX I-GENE
responsive XXX I-GENE
element XXX I-GENE
recognized XXX O
by XXX O
MYB-like XXX B-GENE
DNA XXX I-GENE
binding XXX I-GENE
proteins XXX I-GENE
. XXX O

Tissue XXX B-GENE
plasminogen XXX I-GENE
activator XXX I-GENE
, XXX O
its XXX O
inhibitor XXX O
and XXX O
other XXX O
parameters XXX O
of XXX O
fibrinolysis XXX O
in XXX O
blood XXX O
of XXX O
patients XXX O
operated XXX O
for XXX O
mild XXX O
hypertrophy XXX O
of XXX O
the XXX O
prostate XXX O
. XXX O

In XXX O
a XXX O
screen XXX O
for XXX O
genes XXX O
with XXX O
oncogenic XXX O
potential XXX O
expressed XXX O
by XXX O
the XXX O
murine XXX O
B6SUtA1 XXX O
myeloid XXX O
progenitor XXX O
cell XXX O
line XXX O
, XXX O
we XXX O
isolated XXX O
a XXX O
2 XXX O
. XXX O

When XXX O
given XXX O
the XXX O
choice XXX O
between XXX O
an XXX O
estrous XXX O
female XXX O
and XXX O
a XXX O
sexually XXX O
active XXX O
male XXX O
in XXX O
the XXX O
AOF XXX O
, XXX O
flutamide XXX O
females XXX O
, XXX O
as XXX O
well XXX O
as XXX O
controls XXX O
, XXX O
preferred XXX O
the XXX O
male XXX O
partner XXX O
. XXX O

Since XXX O
one XXX O
group XXX O
of XXX O
adolescents XXX O
more XXX O
difficult XXX O
to XXX O
influence XXX O
are XXX O
those XXX O
whose XXX O
parents XXX O
smoke XXX O
, XXX O
parental XXX O
involvement XXX O
in XXX O
smoking XXX O
prevention XXX O
may XXX O
be XXX O
a XXX O
powerful XXX O
enhancer XXX O
. XXX O

The XXX O
pulmonary XXX O
toxic XXX O
events XXX O
induced XXX O
by XXX O
acute XXX O
nitrogen XXX O
dioxide XXX O
( XXX O
NO XXX O
) XXX O
2 XXX O
exposure XXX O
were XXX O
studied XXX O
in XXX O
the XXX O
rat XXX O
to XXX O
develop XXX O
an XXX O
inhalation XXX O
model XXX O
to XXX O
investigate XXX O
therapeutic XXX O
measures XXX O
. XXX O

The XXX O
cryptococcal XXX B-GENE
antigen XXX I-GENE
test XXX O
was XXX O
positive XXX O
at XXX O
1 XXX O
: XXX O
125 XXX O
by XXX O
latex XXX O
agglutination XXX O
. XXX O

Overexpression XXX O
of XXX O
POG1 XXX B-GENE
inhibits XXX O
alpha-factor-induced XXX O
G1 XXX O
arrest XXX O
and XXX O
transcriptional XXX O
repression XXX O
of XXX O
the XXX O
CLN1 XXX B-GENE
and XXX O
CLN2 XXX B-GENE
genes XXX I-GENE
. XXX O

The XXX O
levels XXX O
of XXX O
NSE XXX B-GENE
and XXX O
MBP XXX B-GENE
in XXX O
the XXX O
IJVB XXX O
were XXX O
compared XXX O
to XXX O
those XXX O
in XXX O
the XXX O
PVB XXX O
. XXX O

The XXX O
method XXX O
has XXX O
been XXX O
satisfactorily XXX O
applied XXX O
to XXX O
the XXX O
determination XXX O
of XXX O
paracetamol XXX O
in XXX O
pharmaceutical XXX O
formulations XXX O
and XXX O
biological XXX O
fluids XXX O
. XXX O

When XXX O
considered XXX O
with XXX O
the XXX O
known XXX O
neurotoxic XXX O
effects XXX O
on XXX O
children XXX O
of XXX O
"low XXX O
levels" XXX O
of XXX O
exposure XXX O
to XXX O
lead XXX O
, XXX O
these XXX O
results XXX O
also XXX O
suggest XXX O
that XXX O
either XXX O
an XXX O
excessively XXX O
narrow XXX O
margin XXX O
of XXX O
safety XXX O
or XXX O
insufficient XXX O
safety XXX O
is XXX O
provided XXX O
by XXX O
present XXX O
U XXX O
. XXX O
S XXX O
. XXX O
guidelines XXX O
, XXX O
which XXX O
classify XXX O
an XXX O
elevated XXX O
blood XXX O
lead XXX O
concentration XXX O
as XXX O
25 XXX O
micrograms XXX O
/ XXX O
dl XXX O
or XXX O
greater XXX O
. XXX O

The XXX O
GT-foreign-pictures XXX O
showed XXX O
that XXX O
the XXX O
judgment XXX O
of XXX O
other XXX O
subjects XXX O
changed XXX O
toward XXX O
hedonic XXX O
and XXX O
permeability XXX O
directions XXX O
. XXX O

Quantitative XXX O
analysis XXX O
of XXX O
DNA XXX O
using XXX O
flow XXX O
cytometry XXX O
and XXX O
immunocytochemical XXX O
findings XXX O
in XXX O
16 XXX O
cases XXX O
of XXX O
cardiac XXX O
myxomas XXX O
. XXX O

The XXX O
lacS XXX B-GENE
gene XXX I-GENE
was XXX O
cloned XXX O
in XXX O
an XXX O
E XXX O
. XXX O
coli-Streptococcus XXX O
shuttle XXX O
vector XXX O
and XXX O
was XXX O
expressed XXX O
both XXX O
in XXX O
a XXX O
lacS XXX B-GENE
deletion XXX O
derivative XXX O
of XXX O
S XXX O
. XXX O
thermophilus XXX O
and XXX O
in XXX O
a XXX O
pNZ63-cured XXX O
strain XXX O
, XXX O
L XXX O
. XXX O
lactis XXX O
NZ6091 XXX O
. XXX O

The XXX O
concentrations XXX O
of XXX O
vitamin XXX O
A XXX O
precursors XXX O
and XXX O
vitamin XXX O
E XXX O
in XXX O
the XXX O
hay XXX O
were XXX O
below XXX O
currently XXX O
recommended XXX O
dietary XXX O
levels XXX O
for XXX O
llamas XXX O
, XXX O
and XXX O
alfalfa XXX O
hay XXX O
appears XXX O
to XXX O
provide XXX O
an XXX O
unreliable XXX O
source XXX O
of XXX O
vitamins XXX O
A XXX O
and XXX O
E XXX O
in XXX O
this XXX O
species XXX O
. XXX O

ATP XXX O
by XXX O
itself XXX O
also XXX O
reduced XXX O
polypeptide XXX O
binding XXX O
to XXX O
Ssb1 XXX B-GENE
/ XXX I-GENE
2p XXX I-GENE
to XXX O
a XXX O
level XXX O
that XXX O
was XXX O
intermediate XXX O
between XXX O
that XXX O
observed XXX O
for XXX O
the XXX O
Ssa XXX B-GENE
Hsp70 XXX B-GENE
proteins XXX I-GENE
tested XXX O
and XXX O
BiP XXX B-GENE
and XXX O
DnaK XXX B-GENE
. XXX O

We XXX O
compared XXX O
the XXX O
volume XXX O
of XXX O
the XXX O
pulmonary XXX O
extravascular XXX O
, XXX O
extracellular XXX O
water XXX O
space XXX O
using XXX O
sodium XXX O
and XXX O
sucrose XXX O
indicators XXX O
in XXX O
8 XXX O
normal XXX O
and XXX O
11 XXX O
edematous XXX O
rabbit XXX O
lungs XXX O
by XXX O
steady-state XXX O
techniques XXX O
. XXX O

Analysis XXX O
of XXX O
the XXX O
deduced XXX O
amino XXX O
acid XXX O
sequence XXX O
suggests XXX O
that XXX O
CHIP28 XXX B-GENE
protein XXX I-GENE
contains XXX O
six XXX O
bilayer-spanning XXX O
domains XXX O
, XXX O
two XXX O
exofacial XXX O
potential XXX O
N-glycosylation XXX O
sites XXX O
, XXX O
and XXX O
intracellular XXX O
N XXX O
and XXX O
C XXX O
termini XXX O
. XXX O

Recombinant XXX B-GENE
soluble XXX I-GENE
pMCP XXX I-GENE
that XXX O
lacked XXX O
transmembrane XXX O
and XXX O
cytoplasmic XXX O
domains XXX O
had XXX O
factor XXX B-GENE
I XXX I-GENE
cofactor XXX I-GENE
activity XXX O
in XXX O
C3b XXX B-GENE
cleavage XXX O
, XXX O
indicating XXX O
that XXX O
it XXX O
is XXX O
functionally XXX O
, XXX O
as XXX O
well XXX O
as XXX O
structurally XXX O
homologous XXX O
to XXX O
MCP XXX B-GENE
. XXX O

However XXX O
, XXX O
division XXX O
of XXX O
the XXX O
chest XXX O
wall XXX O
muscles XXX O
, XXX O
usually XXX O
with XXX O
diathermy XXX O
, XXX O
contributes XXX O
to XXX O
prolonged XXX O
pain XXX O
and XXX O
morbidity XXX O
. XXX O

Histamine XXX O
metabolism XXX O
in XXX O
hemorrhagic-hypotensive XXX O
shock XXX O
. XXX O

A XXX O
method XXX O
for XXX O
establishing XXX O
stimulus XXX O
control XXX O
of XXX O
ethanol XXX O
responding XXX O
was XXX O
developed XXX O
. XXX O

In XXX O
PAV-3 XXX O
, XXX O
the XXX O
E1A XXX B-GENE
region XXX I-GENE
is XXX O
located XXX O
between XXX O
1 XXX O
. XXX O
5 XXX O
and XXX O
3 XXX O
. XXX O
8 XXX O
map XXX O
units XXX O
. XXX O

The XXX O
article XXX O
deals XXX O
with XXX O
the XXX O
diagnosing XXX O
and XXX O
correction XXX O
of XXX O
reversible XXX O
ischemia XXX O
of XXX O
the XXX O
intestine XXX O
. XXX O

Increased XXX O
levels XXX O
of XXX O
anticardiolipin XXX B-GENE
immunoglobulin XXX I-GENE
G XXX I-GENE
may XXX O
also XXX O
cause XXX O
bleeding XXX O
. XXX O

This XXX O
region XXX O
contains XXX O
a XXX O
motif XXX O
with XXX O
partial XXX O
identity XXX O
with XXX O
the XXX O
binding XXX O
site XXX O
for XXX O
the XXX O
ubiquitous XXX O
transcription XXX O
factor XXX O
upstream XXX B-GENE
stimulatory XXX I-GENE
factor XXX I-GENE
( XXX O
USF XXX B-GENE
) XXX O
, XXX O
which XXX O
binds XXX O
to XXX O
the XXX O
human XXX B-GENE
insulin XXX I-GENE
promoter XXX I-GENE
. XXX O

The XXX O
cis-acting XXX O
element XXX O
mediating XXX O
glucocorticoid XXX O
inducibility XXX O
of XXX O
the XXX O
chicken XXX B-GENE
glutamine XXX I-GENE
synthetase XXX I-GENE
gene XXX I-GENE
has XXX O
been XXX O
identified XXX O
. XXX O

Some XXX O
of XXX O
the XXX O
PCR XXX O
products XXX O
contained XXX O
mutations XXX O
in XXX O
ATG1 XXX B-GENE
and XXX O
/ XXX O
or XXX O
ATG2 XXX B-GENE
. XXX O

The XXX O
dominant XXX O
negative XXX O
mutant XXX O
of XXX O
SHP-2 XXX B-GENE
was XXX O
found XXX O
to XXX O
inhibit XXX O
the XXX O
induction XXX O
of XXX O
tyrosine XXX O
phosphorylation XXX O
and XXX O
DNA-binding XXX O
activity XXX O
of XXX O
m-Stat5a XXX B-GENE
, XXX O
m-Stat5b XXX B-GENE
, XXX O
and XXX O
the XXX O
carboxyl-terminal XXX O
deletion XXX O
variant XXX O
m-Stat5adelta749 XXX B-GENE
, XXX O
as XXX O
well XXX O
as XXX O
the XXX O
transactivation XXX O
potential XXX O
of XXX O
m-Stat5a XXX B-GENE
and XXX O
m-Stat5b XXX B-GENE
. XXX O

Male XXX O
Japanese XXX O
quail XXX O
were XXX O
chronically XXX O
exposed XXX O
to XXX O
5000 XXX O
ppm XXX O
manganese XXX O
( XXX O
Mn XXX O
) XXX O
as XXX O
particulate XXX O
manganese XXX O
oxide XXX O
( XXX O
Mn3O4 XXX O
) XXX O
in XXX O
their XXX O
diet XXX O
from XXX O
hatching XXX O
to XXX O
75 XXX O
days XXX O
of XXX O
age XXX O
. XXX O

Routine XXX O
isotope XXX O
cystography XXX O
using XXX O
99M XXX O
Tc XXX O
sulfur XXX O
colloid XXX O
for XXX O
detection XXX O
and XXX O
follow-up XXX O
of XXX O
vesico-ureteral XXX O
reflux XXX O
. XXX O

The XXX O
detector XXX O
has XXX O
the XXX O
advantage XXX O
of XXX O
finding XXX O
both XXX O
ST XXX O
segment XXX O
deviations XXX O
and XXX O
entire XXX O
ST-T XXX O
complex XXX O
changes XXX O
thereby XXX O
providing XXX O
a XXX O
wider XXX O
characterization XXX O
of XXX O
the XXX O
potential XXX O
ischemic XXX O
events XXX O
. XXX O

We XXX O
have XXX O
overexpressed XXX O
, XXX O
purified XXX O
, XXX O
characterized XXX O
, XXX O
and XXX O
crystallized XXX O
the XXX O
BTB XXX B-GENE
/ XXX I-GENE
POZ XXX I-GENE
domain XXX I-GENE
from XXX O
PLZF XXX B-GENE
( XXX O
PLZF-BTB XXX B-GENE
/ XXX I-GENE
POZ XXX I-GENE
) XXX O
. XXX O

An XXX O
interaction XXX O
screen XXX O
with XXX O
the XXX O
repression XXX O
domain XXX O
of XXX O
the XXX O
orphan XXX B-GENE
receptor XXX I-GENE
RevErb XXX I-GENE
identified XXX O
N-CoR XXX B-GENE
, XXX O
the XXX O
corepressor XXX O
for XXX O
thyroid XXX B-GENE
hormone XXX I-GENE
receptor XXX I-GENE
( XXX O
TR XXX B-GENE
) XXX O
and XXX O
retinoic XXX B-GENE
acid XXX I-GENE
receptor XXX I-GENE
( XXX O
RAR XXX B-GENE
) XXX O
. XXX O

However XXX O
, XXX O
inclusion XXX O
of XXX O
the XXX O
neighboring XXX O
CGGAAR XXX B-GENE
motifs XXX I-GENE
from XXX O
the XXX O
ICP4 XXX B-GENE
promoter XXX I-GENE
, XXX O
which XXX O
bind XXX O
factors XXX O
GABP XXX B-GENE
alpha XXX I-GENE
and XXX I-GENE
beta XXX I-GENE
, XXX O
results XXX O
in XXX O
a XXX O
strong XXX O
synergistic XXX O
activation XXX O
. XXX O

Furthermore XXX O
, XXX O
rhoA-mediated XXX O
SRE XXX B-GENE
activation XXX O
was XXX O
blocked XXX O
by XXX O
dominant XXX O
negative XXX O
mutants XXX O
of XXX O
PKC-alpha XXX B-GENE
or XXX O
PKC-epsilon XXX B-GENE
. XXX O

The XXX O
5' XXX O
flanking XXX O
region XXX O
of XXX O
the XXX O
mouse XXX B-GENE
Met-ase-1 XXX I-GENE
gene XXX I-GENE
also XXX O
shares XXX O
considerable XXX O
regions XXX O
of XXX O
identity XXX O
with XXX O
the XXX O
5' XXX O
flanking XXX O
region XXX O
of XXX O
the XXX O
rat XXX B-GENE
Met-ase-1 XXX I-GENE
gene XXX I-GENE
. XXX O

Pol32Delta XXX B-GENE
strains XXX O
are XXX O
weak XXX O
antimutators XXX O
and XXX O
are XXX O
defective XXX O
for XXX O
damage-induced XXX O
mutagenesis XXX O
. XXX O

Although XXX O
we XXX O
predicted XXX O
that XXX O
overexpression XXX O
of XXX O
the XXX O
COOH-terminal XXX O
domains XXX O
, XXX O
which XXX O
were XXX O
thought XXX O
to XXX O
be XXX O
involved XXX O
in XXX O
the XXX O
regulation XXX O
of XXX O
SREBP XXX B-GENE
processing XXX O
, XXX O
would XXX O
result XXX O
in XXX O
disruption XXX O
of XXX O
the XXX O
SREBP-dependent XXX O
transcriptional XXX O
regulation XXX O
of XXX O
several XXX O
genes XXX O
, XXX O
the XXX O
mRNA XXX O
levels XXX O
for XXX O
3-hydroxy-3-methylglutaryl XXX B-GENE
coenzyme XXX I-GENE
A XXX I-GENE
( XXX I-GENE
HMG XXX I-GENE
CoA XXX I-GENE
) XXX I-GENE
synthase XXX I-GENE
in XXX O
these XXX O
two XXX O
cell XXX O
lines XXX O
were XXX O
regulated XXX O
in XXX O
a XXX O
sterol-dependent XXX O
manner XXX O
. XXX O

Mammalian XXX B-GENE
M-Ras XXX I-GENE
and XXX O
a XXX O
Caenorhabditis XXX O
elegans XXX O
orthologue XXX O
exhibit XXX O
conserved XXX O
structural XXX O
features XXX O
, XXX O
and XXX O
these XXX O
are XXX O
likely XXX O
to XXX O
mediate XXX O
activation XXX O
of XXX O
distinctive XXX O
signaling XXX O
paths XXX O
that XXX O
function XXX O
in XXX O
parallel XXX O
to XXX O
those XXX O
downstream XXX O
of XXX O
p21 XXX B-GENE
Ras XXX B-GENE
. XXX O

Both XXX O
increasing XXX O
basal XXX O
FSH XXX B-GENE
and XXX O
age XXX O
were XXX O
associated XXX O
significantly XXX O
with XXX O
increased XXX O
total XXX O
gonadotrophin XXX B-GENE
dose XXX O
, XXX O
and XXX O
reduced XXX O
number XXX O
of XXX O
oocytes XXX O
collected XXX O
and XXX O
pregnancy XXX O
rate XXX O
. XXX O

We XXX O
have XXX O
inactivated XXX O
Krox-20 XXX B-GENE
by XXX O
homologous XXX O
recombination XXX O
in XXX O
ES XXX O
cells XXX O
and XXX O
demonstrated XXX O
that XXX O
the XXX O
mutation XXX O
leads XXX O
to XXX O
the XXX O
deletion XXX O
of XXX O
r3 XXX B-GENE
and XXX O
r5 XXX B-GENE
. XXX O

Kinase-deficient XXX O
erbB XXX B-GENE
proteins XXX I-GENE
reduced XXX O
epidermal XXX B-GENE
growth XXX I-GENE
factor XXX I-GENE
( XXX O
EGF XXX B-GENE
) XXX O
-induced XXX O
tyrosine XXX O
phosphorylation XXX O
of XXX O
endogenous XXX O
Shc XXX B-GENE
proteins XXX I-GENE
and XXX O
also XXX O
reduced XXX O
immediate XXX O
and XXX O
sustained XXX O
EGF-induced XXX O
ERK XXX B-GENE
MAPK XXX I-GENE
activities XXX O
in XXX O
human XXX O
glioblastoma XXX O
cells XXX O
, XXX O
although XXX O
basal XXX O
ERK XXX B-GENE
MAPK XXX I-GENE
activities XXX O
were XXX O
unaffected XXX O
. XXX O

L XXX O
. XXX O
, XXX O
Greer XXX O
, XXX O
J XXX O
. XXX O
& XXX O
Carter XXX O
, XXX O
G XXX O
. XXX O

Protein XXX B-GENE
tyrosine XXX I-GENE
phosphatases XXX I-GENE
( XXX O
PTPs XXX B-GENE
) XXX O
, XXX O
together XXX O
with XXX O
protein XXX B-GENE
tyrosine XXX I-GENE
kinases XXX I-GENE
( XXX O
PTKs XXX B-GENE
) XXX O
, XXX O
are XXX O
involved XXX O
in XXX O
the XXX O
regulation XXX O
of XXX O
cell XXX O
activation XXX O
, XXX O
growth XXX O
, XXX O
and XXX O
differentiation XXX O
. XXX O

The XXX O
dichloromethane XXX O
is XXX O
removed XXX O
, XXX O
mobile XXX O
phase XXX O
solvent XXX O
is XXX O
added XXX O
, XXX O
and XXX O
aliquots XXX O
are XXX O
injected XXX O
onto XXX O
a XXX O
PRP-1 XXX O
liquid XXX O
chromatographic XXX O
column XXX O
; XXX O
fluazifop XXX O
acid XXX O
is XXX O
separated XXX O
from XXX O
coextracted XXX O
compounds XXX O
and XXX O
detected XXX O
at XXX O
an XXX O
applied XXX O
potential XXX O
of XXX O
+ XXX O
1 XXX O
. XXX O
25 XXX O
V XXX O
, XXX O
using XXX O
an XXX O
amperometric XXX O
electrochemical XXX O
detector XXX O
in XXX O
the XXX O
oxidation XXX O
mode XXX O
. XXX O

OBJECTIVES XXX O
: XXX O
The XXX O
aim XXX O
of XXX O
the XXX O
study XXX O
was XXX O
to XXX O
analyze XXX O
the XXX O
clinical XXX O
characteristics XXX O
, XXX O
treatment XXX O
and XXX O
outcome XXX O
of XXX O
310 XXX O
patients XXX O
with XXX O
hydatidiform XXX O
mole XXX O
. XXX O

The XXX O
results XXX O
from XXX O
the XXX O
first XXX O
five XXX O
years XXX O
of XXX O
follow XXX O
up XXX O
in XXX O
1972 XXX O
showed XXX O
a XXX O
4 XXX O
. XXX O
7-fold XXX O
excess XXX O
mortality XXX O
for XXX O
ischaemic XXX O
and XXX O
other XXX O
heart XXX O
diseases XXX O
( XXX O
ICD XXX O
A83-A84 XXX O
) XXX O
compared XXX O
with XXX O
a XXX O
comparable XXX O
reference XXX O
cohort XXX O
of XXX O
paper XXX O
mill XXX O
workers XXX O
. XXX O

Based XXX O
on XXX O
the XXX O
estimated XXX O
values XXX O
of XXX O
divergence XXX O
of XXX O
apobec1 XXX B-GENE
sequences XXX I-GENE
in XXX O
terms XXX O
of XXX O
the XXX O
numbers XXX O
of XXX O
synonymous XXX O
and XXX O
non-synonymous XXX O
suhstitutions XXX O
per XXX O
site XXX O
, XXX O
we XXX O
found XXX O
that XXX O
apobec1 XXX B-GENE
is XXX O
a XXX O
fairly XXX O
rapidly XXX O
evolving XXX O
protein XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
the XXX O
mouse XXX O
ortholog XXX O
( XXX O
Mharp XXX B-GENE
/ XXX I-GENE
Smarcal1 XXX I-GENE
) XXX O
was XXX O
cloned XXX O
, XXX O
and XXX O
the XXX O
Caenorhabditis XXX O
elegans XXX O
ortholog XXX O
( XXX O
CEHARP XXX B-GENE
) XXX O
was XXX O
identified XXX O
in XXX O
the XXX O
GenBank XXX O
database XXX O
. XXX O

PNRC XXX B-GENE
: XXX O
a XXX O
proline-rich XXX O
nuclear XXX O
receptor XXX O
coregulatory XXX O
protein XXX O
that XXX O
modulates XXX O
transcriptional XXX O
activation XXX O
of XXX O
multiple XXX O
nuclear XXX O
receptors XXX O
including XXX O
orphan XXX B-GENE
receptors XXX I-GENE
SF1 XXX B-GENE
( XXX O
steroidogenic XXX B-GENE
factor XXX I-GENE
1 XXX I-GENE
) XXX O
and XXX O
ERRalpha1 XXX B-GENE
( XXX O
estrogen XXX B-GENE
related XXX I-GENE
receptor XXX I-GENE
alpha-1 XXX I-GENE
) XXX O
. XXX O

A XXX O
direct XXX O
role XXX O
for XXX O
sterol XXX B-GENE
regulatory XXX I-GENE
element XXX I-GENE
binding XXX I-GENE
protein XXX I-GENE
in XXX O
activation XXX O
of XXX O
3-hydroxy-3-methylglutaryl XXX B-GENE
coenzyme XXX I-GENE
A XXX I-GENE
reductase XXX I-GENE
gene XXX I-GENE
. XXX O

We XXX O
show XXX O
that XXX O
c-Fos XXX B-GENE
( XXX O
the XXX O
c-fos XXX B-GENE
protooncogene XXX I-GENE
product XXX I-GENE
) XXX O
, XXX O
which XXX O
is XXX O
an XXX O
intrinsically XXX O
unstable XXX O
nuclear XXX O
protein XXX O
, XXX O
is XXX O
metabolically XXX O
highly XXX O
stabilized XXX O
, XXX O
and XXX O
greatly XXX O
enhances XXX O
the XXX O
transforming XXX O
efficiency XXX O
of XXX O
NIH XXX O
3T3 XXX O
cells XXX O
, XXX O
by XXX O
Mos XXX B-GENE
. XXX O

METHODS--16 XXX O
volunteered XXX O
for XXX O
spirometry XXX O
with XXX O
methacholine XXX O
provocation XXX O
test XXX O
including XXX O
a XXX O
test XXX O
for XXX O
small XXX O
airways XXX O
function XXX O
by XXX O
volume XXX O
of XXX O
trapped XXX O
gas XXX O
( XXX O
VTG XXX O
) XXX O
. XXX O

These XXX O
findings XXX O
demonstrate XXX O
that XXX O
haemodialysis XXX O
patients XXX O
with XXX O
chronic XXX O
hepatitis XXX O
C XXX O
respond XXX O
well XXX O
to XXX O
interferon XXX B-GENE
treatment XXX O
and XXX O
that XXX O
a XXX O
long-term XXX O
response XXX O
is XXX O
achieved XXX O
in XXX O
a XXX O
high XXX O
proportion XXX O
of XXX O
patients XXX O
. XXX O

MEKs XXX B-GENE
and XXX O
ERKs XXX B-GENE
inhibited XXX O
IL-6 XXX B-GENE
activation XXX O
of XXX O
Stat3 XXX B-GENE
harboring XXX O
a XXX O
mutation XXX O
at XXX O
serine-727 XXX O
, XXX O
the XXX O
major XXX O
site XXX O
for XXX O
serine XXX O
phosphorylation XXX O
, XXX O
similar XXX O
to XXX O
inhibition XXX O
of XXX O
wild-type XXX B-GENE
Stat3 XXX I-GENE
, XXX O
and XXX O
inhibited XXX O
Janus XXX B-GENE
kinases XXX I-GENE
Jak1 XXX B-GENE
and XXX O
Jak2 XXX B-GENE
upstream XXX O
of XXX O
Stat3 XXX B-GENE
in XXX O
the XXX O
Jak-STAT-signaling XXX O
pathway XXX O
. XXX O

A XXX O
reciprocal XXX O
binding XXX O
assay XXX O
using XXX O
IM-9 XXX O
cells XXX O
as XXX O
a XXX O
source XXX O
of XXX O
SHP-1 XXX B-GENE
and XXX O
SHP-2 XXX B-GENE
revealed XXX O
specific XXX O
association XXX O
of XXX O
SHP-2 XXX B-GENE
( XXX O
but XXX O
not XXX O
SHP-1 XXX B-GENE
) XXX O
with XXX O
a XXX O
glutathione XXX B-GENE
S-transferase XXX I-GENE
fusion XXX I-GENE
incorporating XXX O
GHR XXX B-GENE
cytoplasmic XXX I-GENE
domain XXX I-GENE
residues XXX I-GENE
485-620 XXX I-GENE
, XXX O
but XXX O
only XXX O
if XXX O
the XXX O
fusion XXX O
was XXX O
first XXX O
rendered XXX O
tyrosine-phosphorylated XXX O
. XXX O

The XXX O
mean XXX O
values XXX O
of XXX O
protease XXX B-GENE
activity XXX O
were XXX O
significantly XXX O
higher XXX O
in XXX O
the XXX O
test XXX O
groups XXX O
than XXX O
in XXX O
the XXX O
control XXX O
group XXX O
at XXX O
baseline XXX O
. XXX O

Although XXX O
IL-2 XXX B-GENE
and XXX O
IFN-alpha XXX B-GENE
activated XXX O
STAT1 XXX B-GENE
alpha XXX I-GENE
and XXX O
STAT5 XXX B-GENE
, XXX O
IL-2 XXX B-GENE
predominantly XXX O
activated XXX O
STAT5 XXX B-GENE
, XXX O
while XXX O
IFN-alpha XXX B-GENE
predominantly XXX O
activated XXX O
STAT1 XXX B-GENE
alpha XXX I-GENE
. XXX O

The XXX O
swa2-1 XXX B-GENE
allele XXX I-GENE
recovered XXX O
from XXX O
the XXX O
original XXX O
screen XXX O
carries XXX O
a XXX O
point XXX O
mutation XXX O
in XXX O
its XXX O
tetratricopeptide XXX O
repeat XXX O
( XXX O
TPR XXX O
) XXX O
domain XXX O
, XXX O
a XXX O
motif XXX O
not XXX O
found XXX O
in XXX O
auxilin XXX B-GENE
but XXX O
known XXX O
in XXX O
other XXX O
proteins XXX O
to XXX O
mediate XXX O
interaction XXX O
with XXX O
heat-shock XXX B-GENE
proteins XXX I-GENE
. XXX O

The XXX O
CDC7 XXX B-GENE
gene XXX I-GENE
has XXX O
two XXX O
in-frame XXX O
AUG XXX O
codons XXX O
as XXX O
possible XXX O
translation XXX O
start XXX O
sites XXX O
, XXX O
which XXX O
would XXX O
produce XXX O
58- XXX O
and XXX O
56-kDa XXX O
proteins XXX O
, XXX O
respectively XXX O
. XXX O

Natural XXX O
Haemophilus XXX O
influenzae XXX O
type XXX O
b XXX O
capsular XXX O
polysaccharide XXX O
antibodies XXX O
in XXX O
412 XXX O
infants XXX O
and XXX O
children XXX O
from XXX O
West XXX O
Africa XXX O
( XXX O
Burkina-Faso XXX O
) XXX O
and XXX O
France XXX O
: XXX O
a XXX O
cross-sectional XXX O
serosurvey XXX O
. XXX O

Intermediate XXX O
levels XXX O
of XXX O
gene XXX O
activity XXX O
were XXX O
observed XXX O
for XXX O
TnI XXX B-GENE
enhancers XXX I-GENE
containing XXX O
E-boxes XXX O
derived XXX O
from XXX O
the XXX O
MCK XXX B-GENE
left XXX I-GENE
E-box XXX I-GENE
site XXX I-GENE
or XXX O
from XXX O
the XXX O
Ig XXX B-GENE
kappa XXX I-GENE
E2 XXX I-GENE
E-box XXX I-GENE
. XXX O

A XXX O
comparison XXX O
of XXX O
the XXX O
predicted XXX O
polypeptide XXX O
sequence XXX O
of XXX O
the XXX O
Drosophila XXX O
protein XXX O
with XXX O
the XXX O
equivalent XXX O
subunits XXX O
from XXX O
mouse XXX O
and XXX O
yeast XXX O
suggests XXX O
that XXX O
they XXX O
are XXX O
closely XXX O
related XXX O
and XXX O
defines XXX O
three XXX O
conserved XXX O
regions XXX O
which XXX O
are XXX O
likely XXX O
to XXX O
be XXX O
important XXX O
for XXX O
enzyme XXX O
activity XXX O
. XXX O

Hemolytic XXX O
disease XXX O
of XXX O
African XXX O
newborn XXX O
. XXX O

Oligonucleotide XXX O
probes XXX O
corresponding XXX O
to XXX O
wild-type XXX B-GENE
and XXX I-GENE
mutant XXX I-GENE
EpRE XXX I-GENE
sequences XXX I-GENE
were XXX O
used XXX O
in XXX O
gel-shift XXX O
and XXX O
super-shift XXX O
analyses XXX O
to XXX O
identify XXX O
proteins XXX O
binding XXX O
. XXX O

CONCLUSIONS XXX O
: XXX O
Ketamine-induced XXX O
dissociative XXX O
anesthesia XXX O
produces XXX O
persistently XXX O
elevated XXX O
BIS XXX O
index XXX O
which XXX O
is XXX O
different XXX O
from XXX O
thiamylal XXX O
and XXX O
those XXX O
reported XXX O
with XXX O
other XXX O
conventional XXX O
anesthetic XXX O
agents XXX O
. XXX O

Osmotic XXX O
shock XXX O
stimulates XXX O
GLUT4 XXX B-GENE
translocation XXX O
in XXX O
3T3L1 XXX O
adipocytes XXX O
by XXX O
a XXX O
novel XXX O
tyrosine XXX B-GENE
kinase XXX I-GENE
pathway XXX O
. XXX O

They XXX O
were XXX O
called XXX O
PACE4 XXX B-GENE
and XXX O
PC4 XXX B-GENE
. XXX O

Two XXX O
Lab XXX O
8 XXX O
computer XXX O
programmes XXX O
for XXX O
use XXX O
in XXX O
the XXX O
study XXX O
of XXX O
the XXX O
isometric XXX O
and XXX O
isotonic XXX O
contractile XXX O
characteristics XXX O
of XXX O
skeletal XXX O
muscle XXX O
. XXX O

The XXX O
difficulties XXX O
to XXX O
analyse XXX O
prostaglandins XXX O
( XXX O
PG XXX O
) XXX O
by XXX O
gas-liquid XXX O
chromatography XXX O
are XXX O
mainly XXX O
due XXX O
to XXX O
the XXX O
lack XXX O
of XXX O
sensitivity XXX O
of XXX O
the XXX O
gas-chromatograph XXX O
itself XXX O
( XXX O
higher XXX O
than XXX O
200 XXX O
ng XXX O
) XXX O
and XXX O
to XXX O
the XXX O
poor XXX O
resolution XXX O
of XXX O
the XXX O
packed XXX O
columns XXX O
. XXX O

Sequences XXX O
needed XXX O
for XXX O
iron-regulated XXX O
expression XXX O
of XXX O
sid1 XXX B-GENE
were XXX O
localized XXX O
to XXX O
a XXX O
306 XXX O
bp XXX O
region XXX O
mapping XXX O
2 XXX O
. XXX O
3 XXX O
and XXX O
2 XXX O
. XXX O
6 XXX O
kb XXX O
upstream XXX O
of XXX O
the XXX O
ATG XXX O
. XXX O

cDNA XXX O
clones XXX O
encoding XXX O
Arabidopsis XXX O
thaliana XXX O
and XXX O
Zea XXX B-GENE
mays XXX I-GENE
mitochondrial XXX I-GENE
chaperonin XXX I-GENE
HSP60 XXX B-GENE
and XXX O
gene XXX O
expression XXX O
during XXX O
seed XXX O
germination XXX O
and XXX O
heat XXX O
shock XXX O
. XXX O

Therefore XXX O
, XXX O
a XXX O
prospective XXX O
Phase XXX O
II XXX O
trial XXX O
was XXX O
conducted XXX O
to XXX O
determine XXX O
the XXX O
safety XXX O
and XXX O
efficacy XXX O
of XXX O
cryosurgery XXX O
following XXX O
radiation XXX O
therapy XXX O
in XXX O
men XXX O
with XXX O
local XXX O
recurrence XXX O
. XXX O

In XXX O
turn XXX O
, XXX O
assembly XXX O
of XXX O
this XXX O
complex XXX O
mediates XXX O
the XXX O
enzymatic XXX O
activation XXX O
of XXX O
the XXX O
p21-activated XXX B-GENE
protein XXX I-GENE
kinase XXX I-GENE
1 XXX I-GENE
and XXX O
facilitates XXX O
actin XXX B-GENE
polymerization XXX O
. XXX O

Expression XXX O
and XXX O
characterization XXX O
of XXX O
recombinant XXX B-GENE
single-chain XXX I-GENE
Fv XXX I-GENE
and XXX O
Fv XXX B-GENE
fragments XXX I-GENE
derived XXX O
from XXX O
a XXX O
set XXX O
of XXX O
catalytic XXX O
antibodies XXX O
. XXX O

Although XXX O
ANP XXX B-GENE
induced XXX O
systemic XXX O
capillary XXX O
filtration XXX O
, XXX O
in XXX O
the XXX O
calf XXX O
, XXX O
filtration XXX O
was XXX O
reduced XXX O
with XXX O
ANP XXX B-GENE
. XXX O

Factors XXX O
influencing XXX O
in XXX O
vitro XXX O
skin XXX O
permeability XXX O
factor XXX O
production XXX O
by XXX O
Vibrio XXX O
cholerae XXX O
. XXX O

The XXX O
decrease XXX O
in XXX O
HDL-cholesterol XXX O
with XXX O
increasing XXX O
VLDL-triglycerides XXX O
was XXX O
relatively XXX O
much XXX O
larger XXX O
than XXX O
the XXX O
concomitant XXX O
decrease XXX O
in XXX O
apo XXX B-GENE
A-I XXX I-GENE
. XXX O

Hepatitis XXX O
B XXX O
and XXX O
liver XXX O
transplantation XXX O
. XXX O

The XXX O
clinical XXX O
and XXX O
laboratory XXX O
features XXX O
of XXX O
72 XXX O
children XXX O
with XXX O
Henoch-Schonlein XXX O
purpura XXX O
( XXX O
HSP XXX O
) XXX O
were XXX O
examined XXX O
to XXX O
determine XXX O
if XXX O
there XXX O
were XXX O
associations XXX O
between XXX O
the XXX O
laboratory XXX O
indices--including XXX O
white XXX O
blood XXX O
cell XXX O
( XXX O
WBC XXX O
) XXX O
counts XXX O
, XXX O
serum XXX B-GENE
C-reactive XXX I-GENE
protein XXX I-GENE
( XXX O
CRP XXX B-GENE
) XXX O
levels XXX O
, XXX O
platelet XXX O
( XXX O
PLT XXX O
) XXX O
counts--and XXX O
the XXX O
clinical XXX O
manifestations XXX O
of XXX O
acute XXX O
HSP XXX O
. XXX O

The XXX O
vigilance XXX O
task XXX O
and XXX O
the XXX O
measurement XXX O
of XXX O
attentional XXX O
deficits XXX O
. XXX O
pp XXX O
. XXX O

CONCLUSIONS XXX O
: XXX O
LSCC XXX O
malformation XXX O
, XXX O
like XXX O
other XXX O
inner XXX O
ear XXX O
malformations XXX O
such XXX O
as XXX O
large XXX O
vestibular XXX O
aqueduct XXX O
and XXX O
X-linked XXX O
mixed XXX O
deafness XXX O
with XXX O
perilymph XXX O
gusher XXX O
, XXX O
can XXX O
be XXX O
associated XXX O
with XXX O
CHL XXX O
, XXX O
SNHL XXX O
, XXX O
or XXX O
normal XXX O
hearing XXX O
. XXX O

Nucleotide XXX O
sequence XXX O
of XXX O
DNA XXX O
controlling XXX O
expression XXX O
of XXX O
genes XXX O
for XXX O
maltosaccharide XXX O
utilization XXX O
in XXX O
Streptococcus XXX O
pneumoniae XXX O
. XXX O

Five XXX O
of XXX O
10 XXX O
scars XXX O
studied XXX O
decreased XXX O
at XXX O
least XXX O
50% XXX O
in XXX O
linear XXX O
dimensions XXX O
. XXX O

Previously XXX O
, XXX O
we XXX O
reported XXX O
the XXX O
sequence XXX O
of XXX O
the XXX O
gene XXX B-GENE
encoding XXX I-GENE
human XXX I-GENE
K14 XXX I-GENE
( XXX O
D XXX O
. XXX O

Basal XXX O
plasma XXX O
renin XXX B-GENE
activity XXX O
( XXX O
PRA XXX O
) XXX O
was XXX O
slightly XXX O
raised XXX O
prior XXX O
to XXX O
training XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
07 XXX O
) XXX O
compared XXX O
to XXX O
the XXX O
controls XXX O
and XXX O
post-training XXX O
. XXX O

Applications XXX O
of XXX O
three-dimensional XXX O
analysis XXX O
to XXX O
the XXX O
auditory XXX O
P300 XXX O
. XXX O

Linear XXX O
eight- XXX B-GENE
or XXX I-GENE
nine-residue XXX I-GENE
D-peptides XXX I-GENE
derived XXX O
from XXX O
the XXX O
pocket-binding XXX O
domain XXX O
of XXX O
the XXX O
cyclic XXX O
molecules XXX O
also XXX O
bind XXX O
specifically XXX O
. XXX O

Another XXX O
tentative XXX O
hotspot XXX O
mutation XXX O
in XXX O
the XXX O
third XXX O
patient XXX O
, XXX O
a XXX O
frame XXX O
shift XXX O
caused XXX O
by XXX O
a XXX O
G XXX O
nucleotide XXX O
insertion XXX O
in XXX O
a XXX O
monotonous XXX O
repeat XXX O
of XXX O
six XXX O
Gs XXX O
in XXX O
HPRT XXX B-GENE
exon XXX I-GENE
3 XXX I-GENE
, XXX O
has XXX O
been XXX O
reported XXX O
previously XXX O
in XXX O
three XXX O
other XXX O
LN XXX O
patients XXX O
. XXX O

Effect XXX O
of XXX O
single XXX O
base XXX O
substitutions XXX O
at XXX O
glycine-870 XXX O
codon XXX O
of XXX O
gramicidin XXX B-GENE
S XXX I-GENE
synthetase XXX I-GENE
2 XXX I-GENE
gene XXX I-GENE
on XXX O
proline XXX O
activation XXX O
. XXX O

Inactivation XXX O
of XXX O
MAP XXX B-GENE
kinases XXX I-GENE
occurs XXX O
via XXX O
a XXX O
specific XXX O
phosphatase XXX B-GENE
, XXX O
MKP-1 XXX B-GENE
. XXX O

These XXX O
lesions XXX O
may XXX O
be XXX O
treated XXX O
by XXX O
propranolol XXX O
or XXX O
phentolamine XXX O
. XXX O

Susceptibility XXX O
to XXX O
ischemia-induced XXX O
arrhythmias XXX O
was XXX O
lower XXX O
in XXX O
1-week XXX O
diabetics XXX O
: XXX O
only XXX O
42 XXX O
% XXX O
of XXX O
diabetic XXX O
hearts XXX O
exhibited XXX O
ventricular XXX O
tachycardia XXX O
( XXX O
VT XXX O
) XXX O
and XXX O
16 XXX O
% XXX O
had XXX O
short XXX O
episodes XXX O
of XXX O
ventricular XXX O
fibrillation XXX O
( XXX O
VF XXX O
) XXX O
as XXX O
compared XXX O
to XXX O
VT XXX O
100 XXX O
% XXX O
and XXX O
VF XXX O
70 XXX O
% XXX O
( XXX O
including XXX O
sustained XXX O
VF XXX O
36 XXX O
% XXX O
) XXX O
in XXX O
the XXX O
non-diabetics XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
. XXX O

Can XXX O
thyroglobulin XXX B-GENE
assay XXX O
really XXX O
supplant XXX O
radioiodine XXX O
scans XXX O
in XXX O
patients XXX O
with XXX O
differentiated XXX O
thyroid XXX O
cancer XXX O
? XXX O

The XXX O
bactericidal XXX O
activity XXX O
of XXX O
six XXX O
new XXX O
rifamycin XXX O
derivatives--rifabutin XXX O
( XXX O
RBU XXX O
) XXX O
, XXX O
FCE XXX O
22250 XXX O
( XXX O
F22 XXX O
) XXX O
, XXX O
rifapentine XXX O
( XXX O
RPE XXX O
) XXX O
, XXX O
CGP XXX O
29861 XXX O
( XXX O
C29 XXX O
) XXX O
, XXX O
CGP XXX O
7040 XXX O
( XXX O
C70 XXX O
) XXX O
and XXX O
CGP XXX O
27557 XXX O
( XXX O
C27 XXX O
) XXX O
and XXX O
rifampicin XXX O
( XXX O
RMP XXX O
) XXX O
--have XXX O
been XXX O
measured XXX O
against XXX O
log XXX O
phase XXX O
and XXX O
, XXX O
as XXX O
a XXX O
better XXX O
test XXX O
of XXX O
sterilising XXX O
activity XXX O
, XXX O
against XXX O
stationary XXX O
phase XXX O
cultures XXX O
of XXX O
Mycobacterium XXX O
tuberculosis XXX O
, XXX O
H37Rv XXX O
. XXX O

The XXX O
intron XXX O
8 XXX O
enhancer XXX O
region XXX O
was XXX O
not XXX O
activated XXX O
by XXX O
GATA-1 XXX B-GENE
together XXX O
with XXX O
Sp1 XXX B-GENE
in XXX O
transactivation XXX O
experiments XXX O
in XXX O
COS-1 XXX O
cells XXX O
indicating XXX O
the XXX O
involvement XXX O
of XXX O
a XXX O
related XXX O
Sp1 XXX B-GENE
protein XXX I-GENE
or XXX O
of XXX O
another XXX O
unidentified XXX O
erythroid XXX O
factor XXX O
. XXX O

Estrogen XXX B-GENE
receptor-related XXX I-GENE
receptor XXX I-GENE
alpha XXX I-GENE
1 XXX I-GENE
interacts XXX O
with XXX O
coactivator XXX O
and XXX O
constitutively XXX O
activates XXX O
the XXX O
estrogen XXX B-GENE
response XXX I-GENE
elements XXX I-GENE
of XXX O
the XXX O
human XXX B-GENE
lactoferrin XXX I-GENE
gene XXX I-GENE
. XXX O

However XXX O
, XXX O
changing XXX O
the XXX O
half-site XXX O
to XXX O
the XXX O
consensus XXX B-GENE
sequence XXX I-GENE
AGGTCA XXX I-GENE
( XXX O
IRper-1 XXX B-GENE
) XXX O
increased XXX O
binding XXX O
of XXX O
AaEcR XXX B-GENE
. XXX I-GENE
AaUSP XXX I-GENE
10-fold XXX O
over XXX O
IRhsp-1 XXX B-GENE
and XXX O
, XXX O
at XXX O
the XXX O
same XXX O
time XXX O
, XXX O
reduced XXX O
the XXX O
stringency XXX O
of XXX O
the XXX O
spacer XXX O
length XXX O
requirement XXX O
, XXX O
with XXX O
IRper-0 XXX B-GENE
to XXX O
IRper-5 XXX B-GENE
showing XXX O
detectable XXX O
binding XXX O
. XXX O

Pyrrolidine XXX O
dithiocarbamate XXX O
, XXX O
a XXX O
potent XXX O
transcriptional XXX O
inhibitor XXX O
of XXX O
the XXX O
viral XXX O
LTR XXX O
, XXX O
abrogated XXX O
the XXX O
cytokine XXX O
responses XXX O
in XXX O
both XXX O
U1 XXX O
and XXX O
ACH-2 XXX O
cells XXX O
, XXX O
suggesting XXX O
a XXX O
common XXX O
TNF-alpha-mediated XXX O
transcriptional XXX O
mechanism XXX O
in XXX O
these XXX O
cell XXX O
types XXX O
despite XXX O
their XXX O
different XXX O
modes XXX O
of XXX O
provirus XXX O
latency XXX O
. XXX O

The XXX O
glucose XXX O
/ XXX O
insulin XXX O
stimulation XXX O
was XXX O
inhibited XXX O
by XXX O
the XXX O
addition XXX O
of XXX O
polyunsaturated XXX O
fatty XXX O
acids XXX O
. XXX O

MSSP-1 XXX B-GENE
produced XXX O
in XXX O
E XXX O
. XXX O
coli XXX O
as XXX O
a XXX O
fusion XXX O
protein XXX O
with XXX O
GST XXX B-GENE
specifically XXX O
interacted XXX O
with XXX O
single-stranded XXX O
TCTTAT XXX B-GENE
( XXX I-GENE
plus XXX I-GENE
myc XXX I-GENE
( XXX I-GENE
H-P XXX I-GENE
) XXX I-GENE
21 XXX I-GENE
) XXX I-GENE
and XXX O
ACT-ATT XXX B-GENE
( XXX O
in XXX O
minus XXX B-GENE
myc XXX I-GENE
( XXX I-GENE
H-P XXX I-GENE
) XXX I-GENE
21 XXX I-GENE
) XXX O
, XXX O
the XXX O
consensus XXX O
of XXX O
which XXX O
can XXX O
be XXX O
referred XXX O
to XXX O
as XXX O
A XXX B-GENE
/ XXX I-GENE
TCTA XXX I-GENE
/ XXX I-GENE
TA XXX I-GENE
/ XXX I-GENE
TT XXX I-GENE
. XXX O

Although XXX O
both XXX O
transcripts XXX O
share XXX O
the XXX O
first XXX O
nine XXX O
exons XXX O
, XXX O
exon XXX O
10 XXX O
of XXX O
ZIS-2 XXX B-GENE
is XXX O
lacking XXX O
in XXX O
ZIS-1 XXX B-GENE
, XXX O
and XXX O
instead XXX O
, XXX O
exon XXX O
11 XXX O
( XXX O
10th XXX O
exon XXX O
) XXX O
of XXX O
ZIS-1 XXX B-GENE
is XXX O
larger XXX O
in XXX O
size XXX O
, XXX O
leading XXX O
to XXX O
the XXX O
longer XXX O
3'-UTR XXX O
. XXX O

Urological XXX O
complications XXX O
are XXX O
frequent XXX O
during XXX O
and XXX O
after XXX O
the XXX O
treatment XXX O
of XXX O
gynecological XXX O
malignancy XXX O
. XXX O

Since XXX O
each XXX O
transcript XXX O
appears XXX O
to XXX O
encode XXX O
the XXX O
same XXX O
protein XXX O
, XXX O
this XXX O
complexity XXX O
may XXX O
reflect XXX O
the XXX O
need XXX O
for XXX O
lineage-specific XXX O
or XXX O
differentiation-dependent XXX O
control XXX O
of XXX O
expression XXX O
. XXX O

The XXX O
final XXX O
sigma54-dependent XXX B-GENE
DmpR XXX I-GENE
activator XXX I-GENE
regulates XXX O
transcription XXX O
of XXX O
the XXX O
dmp XXX B-GENE
operon XXX I-GENE
that XXX O
encodes XXX O
the XXX O
enzymes XXX O
for XXX O
catabolism XXX O
of XXX O
( XXX O
methyl XXX O
) XXX O
phenols XXX O
. XXX O

Electromobility XXX O
shift XXX O
and XXX O
cotransfection XXX O
assays XXX O
demonstrated XXX O
that XXX O
HNF1alpha XXX B-GENE
, XXX O
but XXX O
not XXX O
HNF4 XXX B-GENE
, XXX O
bound XXX O
to XXX O
its XXX O
cognate XXX O
site XXX O
and XXX O
transactivated XXX O
G6Pase XXX B-GENE
gene XXX I-GENE
expression XXX O
. XXX O

Although XXX O
the XXX O
N13-N20 XXX O
interpeak XXX O
interval XXX O
remained XXX O
stable XXX O
because XXX O
of XXX O
the XXX O
parallel XXX O
shift XXX O
of XXX O
the XXX O
2 XXX O
peaks XXX O
, XXX O
the XXX O
central XXX O
conduction XXX O
time XXX O
measured XXX O
from XXX O
onset XXX O
latencies XXX O
of XXX O
N11 XXX O
and XXX O
N20 XXX O
significantly XXX O
increased XXX O
. XXX O

In XXX O
nine XXX O
patients XXX O
with XXX O
renal XXX O
failure XXX O
routine XXX O
haemodialysis XXX O
was XXX O
accompanied XXX O
by XXX O
a XXX O
30 XXX O
per XXX O
cent XXX O
reduction XXX O
in XXX O
plasma XXX O
ANP XXX B-GENE
concentration XXX O
. XXX O

Striking XXX O
sequence XXX O
similarities XXX O
( XXX O
57 XXX O
and XXX O
53% XXX O
) XXX O
were XXX O
observed XXX O
with XXX O
yeast XXX O
mitochondrial XXX O
proteins XXX O
, XXX O
SMF1 XXX B-GENE
and XXX O
SMF2 XXX B-GENE
, XXX O
especially XXX O
within XXX O
putative XXX O
functional XXX O
domains XXX O
: XXX O
exon XXX O
6 XXX O
encoding XXX O
the XXX O
second XXX O
transmembrane XXX O
spanning XXX O
domain XXX O
, XXX O
site XXX O
of XXX O
the XXX O
murine XXX O
susceptibility XXX O
mutation XXX O
; XXX O
and XXX O
exon XXX O
11 XXX O
encoding XXX O
a XXX O
conserved XXX O
transport XXX O
motif XXX O
. XXX O

The XXX O
U17 XXX B-GENE
/ XXX I-GENE
U16 XXX I-GENE
and XXX O
the XXX O
U16+ XXX B-GENE
gene XXX I-GENE
products XXX I-GENE
transactivated XXX O
the XXX O
HIV XXX B-GENE
LTR XXX I-GENE
. XXX O

BACKGROUND XXX O
: XXX O
The XXX O
aim XXX O
of XXX O
this XXX O
study XXX O
was XXX O
to XXX O
determine XXX O
and XXX O
compare XXX O
interleukin-6 XXX B-GENE
( XXX O
IL-6 XXX B-GENE
) XXX O
levels XXX O
in XXX O
gingival XXX O
crevicular XXX O
fluid XXX O
( XXX O
GCF XXX O
) XXX O
and XXX O
clinical XXX O
periodontal XXX O
findings XXX O
in XXX O
patients XXX O
with XXX O
rheumatoid XXX O
arthritis XXX O
( XXX O
RA XXX O
) XXX O
and XXX O
adult XXX O
periodontitis XXX O
( XXX O
AP XXX O
) XXX O
. XXX O

NKX2 XXX B-GENE
. XXX I-GENE
1 XXX I-GENE
is XXX O
a XXX O
member XXX O
of XXX O
the XXX O
NK2 XXX B-GENE
family XXX I-GENE
of XXX O
homeodomain-containing XXX O
transcription XXX O
factors XXX O
whose XXX O
targeted XXX O
disruption XXX O
in XXX O
mouse XXX O
results XXX O
in XXX O
the XXX O
absence XXX O
of XXX O
thyroid XXX O
tissue XXX O
and XXX O
a XXX O
severely XXX O
abnormal XXX O
lung XXX O
phenotype XXX O
. XXX O

Investigated XXX O
the XXX O
reliability XXX O
, XXX O
validity XXX O
and XXX O
dimensionality XXX O
of XXX O
scores XXX O
obtained XXX O
by XXX O
acute XXX O
psychiatric XXX O
inpatients XXX O
( XXX O
N XXX O
= XXX O
120 XXX O
) XXX O
on XXX O
the XXX O
Michigan XXX O
Alcoholism XXX O
Screening XXX O
Test XXX O
adapted XXX O
to XXX O
assess XXX O
lifetime XXX O
and XXX O
current XXX O
symptomatology XXX O
. XXX O

To XXX O
minimize XXX O
reflux XXX O
into XXX O
the XXX O
blind XXX O
loop XXX O
, XXX O
a XXX O
number XXX O
of XXX O
technical XXX O
steps XXX O
are XXX O
considered XXX O
indispensable XXX O
: XXX O
1 XXX O
) XXX O
fluted XXX O
section XXX O
of XXX O
the XXX O
jejunal XXX O
stump XXX O
; XXX O
2 XXX O
) XXX O
isoperistaltic XXX O
construction XXX O
of XXX O
the XXX O
anastomosis XXX O
and XXX O
, XXX O
particularly XXX O
, XXX O
3 XXX O
) XXX O
the XXX O
creation XXX O
of XXX O
a XXX O
single XXX O
or XXX O
double XXX O
valve XXX O
system XXX O
upstream XXX O
from XXX O
the XXX O
anastomosis XXX O
by XXX O
spiral XXX O
introflexion XXX O
of XXX O
the XXX O
mucosa XXX O
using XXX O
seroserous XXX O
stitches XXX O
parallel XXX O
and XXX O
perpendicular XXX O
to XXX O
the XXX O
ileal XXX O
lumen XXX O
. XXX O

The XXX O
C-terminal XXX O
mature XXX O
region XXX O
is XXX O
highly XXX O
conserved XXX O
in XXX O
other XXX O
serine XXX B-GENE
carboxypeptidases XXX I-GENE
. XXX O

The XXX O
induction XXX O
by XXX O
pseudorabies XXX O
virus XXX O
of XXX O
an XXX O
IL-6 XXX B-GENE
construct XXX I-GENE
containing XXX O
the XXX O
IL-6 XXX B-GENE
TATA XXX I-GENE
box XXX I-GENE
and XXX O
the XXX O
RNA XXX O
start XXX O
site XXX O
( XXX O
"initiator" XXX O
or XXX O
Inr XXX B-GENE
element XXX I-GENE
) XXX O
but XXX O
not XXX O
the XXX O
MRE XXX B-GENE
region XXX I-GENE
was XXX O
also XXX O
repressed XXX O
by XXX O
Dex XXX O
in XXX O
the XXX O
presence XXX O
of XXX O
wild-type XXX B-GENE
GR XXX I-GENE
. XXX O

The XXX O
mRNA XXX O
was XXX O
converted XXX O
to XXX O
cDNA XXX O
and XXX O
amplified XXX O
by XXX O
the XXX O
polymerase XXX B-GENE
chain XXX O
reaction XXX O
technique XXX O
. XXX O

The XXX O
requirement XXX O
of XXX O
PilE XXX B-GENE
in XXX O
pilus XXX O
biogenesis XXX O
was XXX O
confirmed XXX O
by XXX O
demonstrating XXX O
that XXX O
chromosomal XXX B-GENE
pilE XXX I-GENE
insertion XXX I-GENE
mutants XXX I-GENE
were XXX O
pilus- XXX O
and XXX O
twitching-motility XXX O
deficient XXX O
. XXX O

The XXX O
continuing XXX O
development XXX O
of XXX O
ligands XXX O
that XXX O
function XXX O
as XXX O
selective XXX O
estrogens XXX O
or XXX O
antiestrogens XXX O
for XXX O
ERalpha XXX B-GENE
or XXX O
ERbeta XXX B-GENE
should XXX O
allow XXX O
optimized XXX O
tissue XXX O
selectivity XXX O
of XXX O
these XXX O
agents XXX O
for XXX O
menopausal XXX O
hormone XXX O
replacement XXX O
therapy XXX O
and XXX O
the XXX O
treatment XXX O
and XXX O
prevention XXX O
of XXX O
breast XXX O
cancer XXX O
. XXX O

Three XXX O
of XXX O
the XXX O
proteins XXX O
involved XXX O
in XXX O
checkpoint XXX O
signaling XXX O
, XXX O
Rad1 XXX B-GENE
, XXX O
Hus1 XXX B-GENE
, XXX O
and XXX O
Rad9 XXX B-GENE
, XXX O
have XXX O
been XXX O
shown XXX O
to XXX O
interact XXX O
by XXX O
immunoprecipitation XXX O
and XXX O
yeast XXX O
two-hybrid XXX O
studies XXX O
. XXX O

This XXX O
distribution XXX O
implies XXX O
that XXX O
the XXX O
polycistronic XXX O
precursor XXX O
is XXX O
imported XXX O
into XXX O
the XXX O
nucleolus XXX O
for XXX O
processing XXX O
to XXX O
the XXX O
mature XXX O
snoRNAs XXX O
, XXX O
and XXX O
that XXX O
the XXX O
import XXX O
or XXX O
processing XXX O
pathway XXX O
involves XXX O
coiled XXX O
bodies XXX O
. XXX O

There XXX O
was XXX O
also XXX O
a XXX O
highly XXX O
significant XXX O
correlation XXX O
between XXX O
total XXX O
selenium XXX O
intake XXX O
and XXX O
liver XXX O
selenium XXX O
concentration XXX O
( XXX O
r XXX O
= XXX O
0 XXX O
. XXX O
99 XXX O
, XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
after XXX O
1 XXX O
mo XXX O
of XXX O
treatment XXX O
, XXX O
but XXX O
this XXX O
time XXX O
liver XXX O
selenium XXX O
did XXX O
not XXX O
change XXX O
with XXX O
time XXX O
, XXX O
and XXX O
the XXX O
correlation XXX O
remained XXX O
highly XXX O
significant XXX O
throughout XXX O
the XXX O
investigation XXX O
. XXX O

Instead XXX O
, XXX O
affective XXX O
flattening XXX O
was XXX O
associated XXX O
with XXX O
both XXX O
dopamine XXX B-GENE
receptor XXX I-GENE
sensitivity XXX O
and XXX O
psychomotor XXX O
slowing XXX O
. XXX O

These XXX O
results XXX O
show XXX O
that XXX O
the XXX O
neonate XXX O
differs XXX O
from XXX O
the XXX O
adult XXX O
in XXX O
respect XXX O
of XXX O
both XXX O
the XXX O
nature XXX O
of XXX O
effects XXX O
of XXX O
the XXX O
drug XXX O
and XXX O
sensitivity XXX O
to XXX O
it XXX O
. XXX O

Whereas XXX O
cDNA XXX O
hybridization XXX O
to XXX O
genomic XXX O
DNA XXX O
blots XXX O
indicated XXX O
a XXX O
small XXX O
subfamily XXX O
of XXX O
G0S19 XXX B-GENE
genes XXX I-GENE
, XXX O
simple XXX O
patterns XXX O
of XXX O
bands XXX O
indicated XXX O
that XXX O
most XXX O
cDNAs XXX O
, XXX O
including XXX O
G0S30 XXX B-GENE
cDNA XXX I-GENE
, XXX O
corresponded XXX O
to XXX O
single-copy XXX O
genes XXX O
. XXX O

Substitutions XXX O
introduced XXX O
at XXX O
bases XXX O
surrounding XXX O
the XXX O
ICR2 XXX B-GENE
motif XXX I-GENE
yielded XXX O
levels XXX O
of XXX O
pRNA XXX O
replication XXX O
that XXX O
differed XXX O
, XXX O
depending XXX O
on XXX O
the XXX O
maintenance XXX O
of XXX O
a XXX O
putative XXX O
5' XXX O
stem-loop XXX O
structure XXX O
in XXX O
the XXX O
positive XXX O
strand XXX O
of XXX O
the XXX O
viral XXX O
genome XXX O
. XXX O

Pneumoscrotum XXX O
is XXX O
a XXX O
rare XXX O
condition XXX O
that XXX O
receives XXX O
little XXX O
discussion XXX O
in XXX O
standard XXX O
texts XXX O
of XXX O
urology XXX O
. XXX O

The XXX O
subunit XXX O
protein XXX O
of XXX O
curli XXX B-GENE
was XXX O
highly XXX O
homologous XXX O
at XXX O
its XXX O
amino XXX O
terminus XXX O
to XXX O
SEF-17 XXX B-GENE
, XXX O
the XXX O
subunit XXX O
protein XXX O
of XXX O
thin XXX B-GENE
, XXX O
aggregative XXX O
fimbriae XXX O
of XXX O
Salmonella XXX O
enteritidis XXX O
27655 XXX O
strain XXX O
3b XXX O
, XXX O
suggesting XXX O
that XXX O
these XXX O
fibres XXX O
form XXX O
a XXX O
novel XXX O
class XXX O
of XXX O
surface XXX O
organelles XXX O
on XXX O
enterobacteria XXX O
. XXX O

To XXX O
examine XXX O
the XXX O
possibility XXX O
that XXX O
LNNB XXX O
performance XXX O
of XXX O
the XXX O
schizophrenic XXX O
groups XXX O
may XXX O
have XXX O
been XXX O
related XXX O
to XXX O
neuroleptic XXX O
medication XXX O
, XXX O
analyses XXX O
were XXX O
completed XXX O
on XXX O
the XXX O
relationship XXX O
between XXX O
medication XXX O
levels XXX O
and XXX O
LNNB XXX O
scores XXX O
. XXX O

To XXX O
facilitate XXX O
manipulation XXX O
of XXX O
large XXX O
genomic XXX O
sequences XXX O
, XXX O
we XXX O
developed XXX O
a XXX O
method XXX O
of XXX O
converting XXX O
Escherichia XXX O
coli XXX O
P1 XXX O
artificial XXX O
chromosomes XXX O
( XXX O
PACs XXX O
) XXX O
into XXX O
yeast XXX O
artificial XXX O
chromosomes XXX O
( XXX O
YACs XXX O
) XXX O
. XXX O

The XXX O
effect XXX O
of XXX O
anticonvulsants XXX O
on XXX O
sodium-potassium-activated XXX B-GENE
ATPase XXX I-GENE
, XXX O
sodium XXX O
, XXX O
and XXX O
potassim XXX O
in XXX O
cortex XXX O
. XXX O

We XXX O
have XXX O
previously XXX O
identified XXX O
, XXX O
by XXX O
screening XXX O
a XXX O
lambda XXX O
gt11 XXX O
expression XXX O
library XXX O
, XXX O
murine XXX B-GENE
protein XXX I-GENE
mXBP XXX I-GENE
, XXX O
which XXX O
binds XXX O
to XXX O
a XXX O
sequence XXX O
which XXX O
overlaps XXX O
the XXX O
3' XXX O
end XXX O
of XXX O
the XXX O
murine XXX B-GENE
class XXX I-GENE
II XXX I-GENE
major XXX I-GENE
histocompatibility XXX I-GENE
complex XXX I-GENE
A XXX I-GENE
alpha XXX I-GENE
gene XXX I-GENE
X XXX I-GENE
box XXX I-GENE
, XXX O
a XXX O
conserved XXX O
transcription XXX O
element XXX O
found XXX O
upstream XXX O
of XXX O
all XXX O
class XXX B-GENE
II XXX I-GENE
genes XXX I-GENE
. XXX O

Purification XXX O
and XXX O
cloning XXX O
of XXX O
a XXX O
novel XXX O
serine XXX B-GENE
protease XXX I-GENE
, XXX O
RNK-Met-1 XXX B-GENE
, XXX O
from XXX O
the XXX O
granules XXX O
of XXX O
a XXX O
rat XXX O
natural XXX O
killer XXX O
cell XXX O
leukemia XXX O
. XXX O

The XXX O
fibrinogen XXX B-GENE
, XXX O
serum XXX O
proteins XXX O
, XXX O
sodium XXX O
heparin XXX O
and XXX O
membrane XXX O
contributed XXX O
to XXX O
Cm XXX O
by XXX O
20% XXX O
, XXX O
14% XXX O
, XXX O
2% XXX O
and XXX O
64% XXX O
, XXX O
respectively XXX O
. XXX O

Positive XXX O
and XXX O
significant XXX O
correlations XXX O
were XXX O
found XXX O
between XXX O
the XXX O
weeks XXX O
of XXX O
pregnancy XXX O
and XXX O
Se XXX O
levels XXX O
in XXX O
kidney XXX O
( XXX O
r XXX O
= XXX O
0 XXX O
. XXX O
433 XXX O
, XXX O
P XXX O
= XXX O
0 XXX O
. XXX O
023 XXX O
) XXX O
and XXX O
heart XXX O
( XXX O
r XXX O
= XXX O
0 XXX O
. XXX O
313 XXX O
, XXX O
P XXX O
= XXX O
0 XXX O
. XXX O
030 XXX O
) XXX O
. XXX O

The XXX O
measurement XXX O
of XXX O
NO XXX O
in XXX O
biological XXX O
systems XXX O
using XXX O
chemiluminescence XXX O
. XXX O

In XXX O
female XXX O
Sl XXX B-GENE
( XXX I-GENE
pan XXX I-GENE
) XXX I-GENE
/ XXX I-GENE
Sl XXX I-GENE
( XXX I-GENE
pan XXX I-GENE
) XXX I-GENE
mice XXX O
, XXX O
ovarian XXX O
follicle XXX O
development XXX O
is XXX O
arrested XXX O
at XXX O
the XXX O
one XXX O
layered XXX O
cuboidal XXX O
stage XXX O
as XXX O
a XXX O
result XXX O
of XXX O
reduced XXX O
KL XXX B-GENE
expression XXX O
in XXX O
follicle XXX O
cells XXX O
, XXX O
indicating XXX O
a XXX O
role XXX O
for XXX O
c-kit XXX B-GENE
in XXX O
oocyte XXX O
growth XXX O
. XXX O

The XXX O
protooncogene XXX O
c-myb XXX B-GENE
encodes XXX O
a XXX O
nuclear XXX O
transcription XXX O
factor XXX O
that XXX O
binds XXX O
to XXX O
DNA XXX O
in XXX O
a XXX O
sequence-specific XXX O
manner XXX O
and XXX O
transactivates XXX O
transcription XXX O
of XXX O
several XXX O
viral XXX O
and XXX O
cellular XXX O
genes XXX O
. XXX O

Basal XXX O
plasma XXX O
AVP XXX B-GENE
levels XXX O
and XXX O
AVP XXX B-GENE
release XXX O
after XXX O
postural XXX O
change XXX O
were XXX O
assessed XXX O
, XXX O
and XXX O
plasma XXX O
NPY XXX B-GENE
levels XXX O
were XXX O
measured XXX O
in XXX O
the XXX O
same XXX O
samples XXX O
. XXX O

The XXX O
present XXX O
study XXX O
was XXX O
initiated XXX O
to XXX O
explore XXX O
the XXX O
potential XXX O
of XXX O
a XXX O
hybrid XXX O
biological XXX O
reactor XXX O
, XXX O
combining XXX O
trickling XXX O
filter XXX O
( XXX O
TF XXX O
) XXX O
and XXX O
activated XXX O
sludge XXX O
process XXX O
( XXX O
ASP XXX O
) XXX O
, XXX O
to XXX O
treat XXX O
wastewater XXX O
containing XXX O
trichloroethylene XXX O
( XXX O
TCE XXX O
) XXX O
at XXX O
ambient XXX O
temperature XXX O
at XXX O
different XXX O
hydraulic XXX O
retention XXX O
time XXX O
( XXX O
HRT XXX O
) XXX O
. XXX O

In XXX O
the XXX O
absence XXX O
of XXX O
E1A243 XXX B-GENE
, XXX O
YY1 XXX B-GENE
represses XXX O
CRE-dependent XXX O
transcription XXX O
of XXX O
c-fos XXX B-GENE
by XXX O
physically XXX O
interacting XXX O
with XXX O
ATF XXX B-GENE
/ XXX I-GENE
CREB XXX I-GENE
proteins XXX I-GENE
bound XXX O
to XXX O
the XXX O
-67 XXX B-GENE
CRE XXX I-GENE
. XXX O

Biochemical XXX O
analysis XXX O
shows XXX O
that XXX O
Ssm1p XXX B-GENE
is XXX O
a XXX O
structural XXX O
protein XXX O
that XXX O
forms XXX O
part XXX O
of XXX O
the XXX O
largest XXX O
60S XXX B-GENE
ribosomal XXX I-GENE
subunit XXX I-GENE
, XXX O
which XXX O
does XXX O
not XXX O
exist XXX O
in XXX O
a XXX O
pool XXX O
of XXX O
free XXX O
proteins XXX O
. XXX O

To XXX O
evaluate XXX O
the XXX O
effect XXX O
of XXX O
altitude XXX O
on XXX O
adolescent XXX O
growth XXX O
and XXX O
development XXX O
, XXX O
three XXX O
groups XXX O
of XXX O
healthy XXX O
, XXX O
well-nourished XXX O
youth XXX O
of XXX O
similar XXX O
socioeconomic XXX O
status XXX O
and XXX O
ethnic XXX O
grouping XXX O
who XXX O
resided XXX O
at XXX O
sea XXX O
level XXX O
( XXX O
n XXX O
= XXX O
1262 XXX O
subjects XXX O
) XXX O
, XXX O
mid-altitude XXX O
( XXX O
n XXX O
= XXX O
1743 XXX O
subjects XXX O
) XXX O
, XXX O
and XXX O
high XXX O
altitude XXX O
( XXX O
n XXX O
= XXX O
1137 XXX O
subjects XXX O
) XXX O
were XXX O
studied XXX O
. XXX O

It XXX O
was XXX O
suggested XXX O
that XXX O
the XXX O
absence XXX O
of XXX O
pronounced XXX O
differences XXX O
between XXX O
conditions XXX O
may XXX O
have XXX O
been XXX O
due XXX O
to XXX O
the XXX O
complexity XXX O
of XXX O
the XXX O
task XXX O
or XXX O
the XXX O
type XXX O
of XXX O
prompts XXX O
employed XXX O
. XXX O

A XXX O
third XXX O
ORF XXX O
, XXX O
ORF5 XXX O
, XXX O
shows XXX O
homology XXX O
with XXX O
gene XXX B-GENE
agrB XXX I-GENE
from XXX O
Staphylococcus XXX O
aureus XXX O
, XXX O
which XXX O
is XXX O
involved XXX O
in XXX O
the XXX O
mechanism XXX O
of XXX O
regulation XXX O
of XXX O
the XXX O
virulence XXX O
phenotype XXX O
in XXX O
this XXX O
species XXX O
. XXX O

Calcifications XXX O
in XXX O
the XXX O
thoracic XXX O
aorta XXX O
at XXX O
the XXX O
level XXX O
of XXX O
the XXX O
11th XXX O
and XXX O
the XXX O
12th XXX O
thoracic XXX O
vertebrae XXX O
in XXX O
592 XXX O
men XXX O
and XXX O
333 XXX O
women XXX O
were XXX O
studied XXX O
using XXX O
computed XXX O
tomography XXX O
. XXX O

Most XXX O
patients XXX O
harboring XXX O
metronidazole- XXX O
and XXX O
clarithromycin-resistant XXX O
strains XXX O
were XXX O
eradicated XXX O
at XXX O
an XXX O
equal XXX O
rate XXX O
by XXX O
each XXX O
of XXX O
the XXX O
three XXX O
regimens XXX O
. XXX O

Here XXX O
we XXX O
show XXX O
that XXX O
the XXX O
type XXX O
of XXX O
tyrosine XXX B-GENE
kinase XXX I-GENE
receptor XXX I-GENE
stimulated XXX O
also XXX O
participates XXX O
in XXX O
the XXX O
nature XXX O
of XXX O
the XXX O
cAMP XXX O
effect XXX O
. XXX O

To XXX O
begin XXX O
to XXX O
examine XXX O
the XXX O
mechanism XXX O
controlling XXX O
expression XXX O
of XXX O
this XXX O
gene XXX O
during XXX O
the XXX O
cell-cycle XXX O
, XXX O
a XXX O
mouse XXX B-GENE
B-myb XXX I-GENE
5' XXX I-GENE
flanking XXX I-GENE
sequence XXX I-GENE
was XXX O
isolated XXX O
from XXX O
a XXX O
cosmid XXX O
library XXX O
and XXX O
shown XXX O
to XXX O
promote XXX O
efficiently XXX O
the XXX O
transcription XXX O
of XXX O
a XXX O
luciferase XXX B-GENE
reporter XXX I-GENE
gene XXX I-GENE
when XXX O
transfected XXX O
into XXX O
NIH3T3 XXX O
fibroblasts XXX O
. XXX O

The XXX O
structure XXX O
of XXX O
the XXX O
enhancer XXX O
was XXX O
also XXX O
probed XXX O
by XXX O
inserting XXX O
a XXX O
pair XXX O
of XXX O
complementary XXX O
synthetic XXX O
oligodeoxynucleotides XXX O
which XXX O
represented XXX O
the XXX O
region XXX O
between XXX O
nt XXX O
positions XXX O
-235 XXX O
and XXX O
-215 XXX O
into XXX O
a XXX O
truncated XXX O
template XXX O
which XXX O
lacked XXX O
the XXX O
enhancer XXX O
. XXX O

We XXX O
investigated XXX O
the XXX O
production XXX O
of XXX O
hyaluronan XXX O
( XXX O
HA XXX O
) XXX O
and XXX O
its XXX O
effect XXX O
on XXX O
cell XXX O
motility XXX O
in XXX O
cells XXX O
expressing XXX O
the XXX O
v-src XXX B-GENE
mutants XXX I-GENE
. XXX O

For XXX O
85Sr XXX O
, XXX O
larger-than-expected XXX O
distribution XXX O
coefficients XXX O
were XXX O
obtained XXX O
in XXX O
the XXX O
desorption XXX O
experiments XXX O
, XXX O
an XXX O
indication XXX O
of XXX O
the XXX O
irreversible XXX O
formation XXX O
of XXX O
metal-oxyhydroxides XXX O
during XXX O
a XXX O
slow XXX O
reaction XXX O
. XXX O

The XXX O
role XXX O
of XXX O
HIV XXX B-GENE
tat XXX I-GENE
, XXX O
which XXX O
is XXX O
the XXX O
main XXX O
enhancing XXX O
factor XXX O
for XXX O
viral XXX O
LTR XXX O
, XXX O
in XXX O
the XXX O
regulation XXX O
of XXX O
IL-2 XXX B-GENE
gene XXX I-GENE
transcription XXX O
has XXX O
been XXX O
studied XXX O
following XXX O
transient XXX O
expression XXX O
of XXX O
the XXX O
tat XXX B-GENE
gene XXX I-GENE
in XXX O
phorbol XXX O
ester XXX O
and XXX O
calcium XXX O
ionophore-activated XXX O
Jurkat XXX O
cells XXX O
transfected XXX O
with XXX O
IL-2 XXX B-GENE
promoter-chloramphenicol XXX I-GENE
acetyltransferase XXX I-GENE
reporter XXX I-GENE
constructs XXX I-GENE
. XXX O

In XXX O
the XXX O
study XXX O
on XXX O
PCI XXX B-GENE
mRNA XXX I-GENE
expression XXX O
in XXX O
the XXX O
reproductive XXX O
organs XXX O
, XXX O
we XXX O
first XXX O
cloned XXX O
rat XXX B-GENE
PCI XXX I-GENE
cDNA XXX I-GENE
and XXX O
then XXX O
evaluated XXX O
the XXX O
effect XXX O
of XXX O
androgen XXX O
on XXX O
the XXX O
PCI XXX B-GENE
mRNA XXX I-GENE
expression XXX O
. XXX O

Activation XXX O
of XXX O
ERK1 XXX B-GENE
/ XXX I-GENE
2 XXX I-GENE
is XXX O
correlated XXX O
with XXX O
induction XXX O
of XXX O
the XXX O
immediate-early XXX O
response XXX O
genes XXX O
. XXX O

We XXX O
argue XXX O
that XXX O
the XXX O
primary XXX O
role XXX O
of XXX O
hh XXX B-GENE
in XXX O
controlling XXX O
polarity XXX O
is XXX O
to XXX O
cause XXX O
anterior XXX O
compartment XXX O
cells XXX O
to XXX O
reverse XXX O
their XXX O
interpretation XXX O
of XXX O
an XXX O
underlying XXX O
symmetric XXX O
polarization XXX O
. XXX O

Four XXX O
ruminally XXX O
and XXX O
duodenally XXX O
cannulated XXX O
Hampshire XXX O
wethers XXX O
were XXX O
used XXX O
in XXX O
a XXX O
4 XXX O
x XXX O
4 XXX O
Latin XXX O
square XXX O
experiment XXX O
to XXX O
determine XXX O
whether XXX O
linoleoyl XXX O
methionine XXX O
and XXX O
calcium XXX O
linoleate XXX O
would XXX O
increase XXX O
duodenal XXX O
flow XXX O
of XXX O
unsaturated XXX O
fatty XXX O
acids XXX O
( XXX O
C18 XXX O
: XXX O
2 XXX O
+ XXX O
cis XXX O
C18 XXX O
: XXX O
1 XXX O
) XXX O
. XXX O

Polypeptides XXX O
of XXX O
the XXX O
same XXX O
apparent XXX O
sizes XXX O
are XXX O
detected XXX O
in XXX O
spores XXX O
of XXX O
a XXX O
cotE XXX B-GENE
null XXX O
mutant XXX O
, XXX O
on XXX O
which XXX O
basis XXX O
we XXX O
infer XXX O
that XXX O
the XXX O
products XXX O
of XXX O
the XXX O
cotJ XXX B-GENE
operon XXX I-GENE
are XXX O
required XXX O
for XXX O
the XXX O
normal XXX O
formation XXX O
of XXX O
the XXX O
inner XXX O
layers XXX O
of XXX O
the XXX O
coat XXX O
or XXX O
are XXX O
themselves XXX O
structural XXX O
components XXX O
of XXX O
the XXX O
coat XXX O
. XXX O
( XXX O
ABSTRACT XXX O
TRUNCATED XXX O
AT XXX O
400 XXX O
WORDS XXX O
) XXX O

This XXX O
domain XXX O
, XXX O
although XXX O
adjacent XXX O
to XXX O
the XXX O
5' XXX O
edge XXX O
of XXX O
the XXX O
SD XXX O
sequence XXX O
, XXX O
does XXX O
not XXX O
inhibit XXX O
ribosome XXX O
binding XXX O
as XXX O
long XXX O
as XXX O
the XXX O
single-stranded XXX O
region XXX O
of XXX O
domain XXX O
3 XXX O
is XXX O
present XXX O
. XXX O

Studies XXX O
on XXX O
the XXX O
intracutaneous XXX O
infection XXX O
of XXX O
rabbits XXX O
by XXX O
Staphylococcus XXX O
aureus XXX O
. XXX O

Differential XXX O
regulation XXX O
of XXX O
the XXX O
alpha XXX O
/ XXX O
beta XXX O
interferon-stimulated XXX O
Jak XXX B-GENE
/ XXX I-GENE
Stat XXX I-GENE
pathway XXX I-GENE
by XXX O
the XXX O
SH2 XXX B-GENE
domain-containing XXX O
tyrosine XXX B-GENE
phosphatase XXX I-GENE
SHPTP1 XXX I-GENE
. XXX O

The XXX O
retrovesical XXX O
hydatid XXX O
cyst XXX O
is XXX O
a XXX O
very XXX O
rare XXX O
site XXX O
. XXX O

Thus XXX O
, XXX O
hypoxia-inducible XXX O
nuclear XXX O
import XXX O
and XXX O
transactivation XXX O
by XXX O
recruitment XXX O
of XXX O
CBP XXX B-GENE
can XXX O
be XXX O
functionally XXX O
separated XXX O
from XXX O
one XXX O
another XXX O
and XXX O
play XXX O
critical XXX O
roles XXX O
in XXX O
signal XXX O
transduction XXX O
by XXX O
HIF-1alpha XXX B-GENE
. XXX O

Western XXX O
blot XXX O
analyses XXX O
detect XXX O
anti-E-specific XXX O
immunoreactivity XXX O
in XXX O
affinity-purified XXX O
extracts XXX O
derived XXX O
from XXX O
the XXX O
bacterial XXX O
expression XXX O
of XXX O
a XXX O
truncated XXX B-GENE
AMPD3 XXX I-GENE
cDNA XXX I-GENE
. XXX O

The XXX O
recovery XXX O
index XXX O
( XXX O
T25-T75 XXX O
) XXX O
after XXX O
the XXX O
infusion XXX O
stopped XXX O
was XXX O
similar XXX O
in XXX O
patients XXX O
who XXX O
received XXX O
mivacurium XXX O
and XXX O
those XXX O
who XXX O
received XXX O
suxamethonium XXX O
. XXX O

During XXX O
conventional XXX O
hemofiltration XXX O
using XXX O
substitution XXX O
fluid XXX O
with XXX O
a XXX O
Na+ XXX O
concentration XXX O
of XXX O
140 XXX O
mEq XXX O
/ XXX O
L XXX O
, XXX O
a XXX O
decrease XXX O
in XXX O
extracellular XXX O
fluid XXX O
volume XXX O
was XXX O
noted XXX O
whereas XXX O
the XXX O
intracellular XXX O
fluid XXX O
volume XXX O
was XXX O
unaltered XXX O
. XXX O

Cells XXX O
respond XXX O
to XXX O
the XXX O
accumulation XXX O
of XXX O
unfolded XXX O
proteins XXX O
in XXX O
the XXX O
endoplasmic XXX O
reticulum XXX O
( XXX O
ER XXX O
) XXX O
by XXX O
increasing XXX O
the XXX O
transcription XXX O
of XXX O
the XXX O
genes XXX O
encoding XXX O
ER-resident XXX O
chaperone XXX B-GENE
proteins XXX I-GENE
. XXX O

The XXX O
intracoronary XXX O
administration XXX O
of XXX O
both XXX O
drugs XXX O
markedly XXX O
reduced XXX O
the XXX O
incidence XXX O
of XXX O
VF XXX O
induced XXX O
by XXX O
the XXX O
release XXX O
of XXX O
a XXX O
40-min XXX O
coronary XXX O
artery XXX O
occlusion XXX O
. XXX O

FN-stimulated XXX O
c-Src XXX B-GENE
PTK XXX B-GENE
activity XXX O
was XXX O
enhanced XXX O
by XXX O
wild XXX O
type XXX O
FAK XXX B-GENE
expression XXX O
, XXX O
whereas XXX O
FN-stimulated XXX O
activation XXX O
of XXX O
ERK2 XXX B-GENE
was XXX O
blocked XXX O
by XXX O
expression XXX O
of XXX O
the XXX O
c-Src XXX B-GENE
binding XXX I-GENE
site XXX I-GENE
Phe-397 XXX I-GENE
mutant XXX I-GENE
of XXX O
FAK XXX B-GENE
. XXX O

In XXX O
comparison XXX O
with XXX O
normal XXX O
pregnant XXX O
women XXX O
and XXX O
normal XXX O
non-pregnant XXX O
women XXX O
, XXX O
women XXX O
with XXX O
PIH XXX O
showed XXX O
an XXX O
increase XXX O
in XXX O
heart XXX O
rate XXX O
, XXX O
suggesting XXX O
an XXX O
increased XXX O
peripheral XXX O
sympathetic XXX O
tone XXX O
, XXX O
and XXX O
an XXX O
initial XXX O
derangement XXX O
in XXX O
renal XXX O
function XXX O
as XXX O
shown XXX O
by XXX O
the XXX O
increase XXX O
in XXX O
serum XXX O
uric XXX O
acid XXX O
and XXX O
reduction XXX O
in XXX O
sodium XXX O
excretion XXX O
and XXX O
total XXX O
and XXX O
fractional XXX O
calcium XXX O
excretion XXX O
at XXX O
any XXX O
given XXX O
level XXX O
of XXX O
sodium XXX O
excretion XXX O
. XXX O

However XXX O
, XXX O
it XXX O
was XXX O
synthesized XXX O
at XXX O
both XXX O
temperatures XXX O
after XXX O
addition XXX O
of XXX O
A23187 XXX O
. XXX O

The XXX O
YccA XXX B-GENE
protein XXX I-GENE
was XXX O
found XXX O
to XXX O
be XXX O
degraded XXX O
in XXX O
an XXX O
FtsH-dependent XXX O
manner XXX O
in XXX O
vivo XXX O
and XXX O
in XXX O
vitro XXX O
, XXX O
whereas XXX O
the XXX O
YccA11 XXX B-GENE
mutant XXX I-GENE
protein XXX I-GENE
, XXX O
lacking XXX O
eight XXX O
amino XXX O
acid XXX O
residues XXX O
within XXX O
the XXX O
amino-terminal XXX O
cytoplasmic XXX O
domain XXX O
, XXX O
was XXX O
refractory XXX O
to XXX O
the XXX O
degradation XXX O
. XXX O

Interestingly XXX O
, XXX O
the XXX O
CYP71D20-encoded XXX B-GENE
enzyme XXX I-GENE
activity XXX O
was XXX O
capable XXX O
of XXX O
converting XXX O
both XXX O
5-epi-aristolochene XXX O
and XXX O
1-deoxycapsidiol XXX O
to XXX O
capsidiol XXX O
in XXX O
vitro XXX O
, XXX O
consistent XXX O
with XXX O
the XXX O
notion XXX O
that XXX O
this XXX O
P450 XXX B-GENE
enzyme XXX I-GENE
catalyzes XXX O
both XXX O
hydroxylations XXX O
of XXX O
its XXX O
hydrocarbon XXX O
substrate XXX O
. XXX O

Copyright XXX O
2000 XXX O
Academic XXX O
Press XXX O
. XXX O

Parathyroid XXX B-GENE
hormone XXX I-GENE
regulation XXX O
of XXX O
bone XXX B-GENE
sialoprotein XXX I-GENE
( XXX O
BSP XXX B-GENE
) XXX O
gene XXX O
transcription XXX O
is XXX O
mediated XXX O
through XXX O
a XXX O
pituitary-specific XXX B-GENE
transcription XXX I-GENE
factor-1 XXX I-GENE
( XXX O
Pit-1 XXX B-GENE
) XXX O
motif XXX O
in XXX O
the XXX O
rat XXX B-GENE
BSP XXX I-GENE
gene XXX I-GENE
promoter XXX I-GENE
. XXX O

Hypoglycemic XXX O
action XXX O
of XXX O
"he XXX O
xiang XXX O
zhuang XXX O
qi XXX O
gong" XXX O
and XXX O
its XXX O
mechanism XXX O
on XXX O
diabetes XXX O
mellitus XXX O
. XXX O

While XXX O
all XXX O
deletions XXX O
within XXX O
the XXX O
sequence XXX O
coding XXX O
for XXX O
the XXX O
mature XXX O
tRNA XXX O
led XXX O
to XXX O
inactivity XXX O
of XXX O
the XXX O
mutated XXX O
genes XXX O
, XXX O
substitution XXX O
of XXX O
the XXX O
central XXX O
portion XXX O
by XXX O
concatenated XXX B-GENE
Hind XXX I-GENE
III XXX I-GENE
linkers XXX I-GENE
produced XXX O
gene XXX O
units XXX O
active XXX O
in XXX O
transcription XXX O
. XXX O

Similarly XXX O
, XXX O
a XXX O
human XXX O
but XXX O
not XXX O
a XXX O
bovine XXX B-GENE
alpha XXX I-GENE
transgene XXX I-GENE
was XXX O
expressed XXX O
in XXX O
placenta XXX O
in XXX O
transgenic XXX O
mice XXX O
. XXX O

The XXX O
method XXX O
has XXX O
been XXX O
routinely XXX O
used XXX O
in XXX O
our XXX O
laboratory XXX O
for XXX O
1 XXX O
year XXX O
and XXX O
has XXX O
proven XXX O
to XXX O
be XXX O
a XXX O
reliable XXX O
procedure XXX O
for XXX O
the XXX O
biological XXX O
control XXX O
of XXX O
occupational XXX O
exposure XXX O
to XXX O
toluene XXX O
and XXX O
/ XXX O
or XXX O
xylene XXX O
. XXX O

However XXX O
, XXX O
Southern XXX O
blot XXX O
and XXX O
karyotype XXX O
analyses XXX O
did XXX O
not XXX O
reveal XXX O
any XXX O
significant XXX O
changes XXX O
in XXX O
copy XXX O
number XXX O
or XXX O
gross XXX O
rearrangements XXX O
of XXX O
the XXX O
p53 XXX B-GENE
gene XXX I-GENE
in XXX O
any XXX O
of XXX O
the XXX O
p53- XXX B-GENE
cell XXX O
lines XXX O
. XXX O

Recognition XXX O
mechanisms XXX O
of XXX O
the XXX O
minus-strand XXX O
origin XXX O
of XXX O
phage XXX O
f1 XXX O
by XXX O
Escherichia XXX B-GENE
coli XXX I-GENE
RNA XXX I-GENE
polymerase XXX I-GENE
. XXX O

Phosphorylation XXX O
and XXX O
spindle XXX O
pole XXX O
body XXX O
localization XXX O
of XXX O
the XXX O
Cdc15p XXX B-GENE
mitotic XXX I-GENE
regulatory XXX I-GENE
protein XXX I-GENE
kinase XXX I-GENE
in XXX I-GENE
budding XXX I-GENE
yeast XXX I-GENE
. XXX O

Three XXX O
pyridoxine XXX O
derivatives XXX O
have XXX O
been XXX O
isolated XXX O
from XXX O
the XXX O
fresh XXX O
stem XXX O
bark XXX O
of XXX O
Albizzia XXX O
julibrissin XXX O
DURAZZ XXX O
. XXX O
. XXX O

In XXX O
Experiment XXX O
II XXX O
, XXX O
as XXX O
performing XXX O
moderate XXX O
supine XXX O
cycling XXX O
( XXX O
55% XXX O
VO2 XXX O
max XXX O
) XXX O
for XXX O
50 XXX O
minutes XXX O
under XXX O
several XXX O
LBNP XXX O
conditions XXX O
in XXX O
5 XXX O
sedentary XXX O
women XXX O
, XXX O
there XXX O
were XXX O
correspondingly XXX O
similar XXX O
changing XXX O
manners XXX O
of XXX O
the XXX O
cardiovascular XXX O
adjustments XXX O
to XXX O
each XXX O
of XXX O
the XXX O
phases XXX O
given XXX O
in XXX O
Experiment XXX O
I XXX O
. XXX O

The XXX O
active XXX O
state XXX O
is XXX O
terminated XXX O
by XXX O
hydrolysis XXX O
of XXX O
bound XXX O
GTP XXX O
, XXX O
producing XXX O
inactive XXX O
ARF-GDP XXX B-GENE
. XXX O

All XXX O
patients XXX O
in XXX O
the XXX O
control XXX O
group XXX O
showed XXX O
a XXX O
significant XXX O
improvement XXX O
in XXX O
their XXX O
PEFR XXX O
while XXX O
only XXX O
3 XXX O
patients XXX O
in XXX O
the XXX O
treated XXX O
group XXX O
showed XXX O
an XXX O
improvement XXX O
. XXX O

A XXX O
Golgi XXX O
study XXX O
of XXX O
the XXX O
sixth XXX O
layer XXX O
of XXX O
the XXX O
cerebral XXX O
cortex XXX O
. XXX O

The XXX O
availability XXX O
of XXX O
sequence XXX O
from XXX O
multiple XXX O
species XXX O
has XXX O
permitted XXX O
us XXX O
to XXX O
determine XXX O
that XXX O
the XXX O
UBE XXX O
site XXX O
has XXX O
close XXX O
similarity XXX O
to XXX O
motifs XXX O
that XXX O
bind XXX O
members XXX O
of XXX O
the XXX O
NF-1 XXX B-GENE
family XXX I-GENE
of XXX I-GENE
transcription XXX I-GENE
factors XXX O
. XXX O

Finally XXX O
, XXX O
the XXX O
pathophysiological XXX O
aspects XXX O
of XXX O
urinary XXX O
acidification XXX O
are XXX O
discussed XXX O
, XXX O
focusing XXX O
on XXX O
renal XXX O
tubular XXX O
acidosis XXX O
models XXX O
( XXX O
induced XXX O
by XXX O
maleate XXX O
and XXX O
amphotericin XXX O
B XXX O
treatment XXX O
) XXX O
and XXX O
their XXX O
cellular XXX O
mechanisms XXX O
, XXX O
as XXX O
well XXX O
as XXX O
the XXX O
role XXX O
of XXX O
adrenal XXX O
steroids XXX O
in XXX O
urinary XXX O
acidification XXX O
. XXX O

To XXX O
address XXX O
this XXX O
issue XXX O
, XXX O
the XXX O
gene XXX O
for XXX O
factor XXX B-GENE
Y XXX I-GENE
has XXX O
been XXX O
cloned XXX O
molecularly XXX O
and XXX O
its XXX O
DNA XXX O
sequence XXX O
has XXX O
been XXX O
determined XXX O
. XXX O

Retention XXX O
behavior XXX O
of XXX O
steroids XXX O
in XXX O
gas XXX O
chromatography XXX O
with XXX O
a XXX O
series XXX O
of XXX O
combination XXX O
columns XXX O
. XXX O

We XXX O
found XXX O
that XXX O
the XXX O
relative XXX O
strengths XXX O
of XXX O
the XXX O
promoters XXX O
were XXX O
similar XXX O
in XXX O
different XXX O
contexts XXX O
. XXX O

In XXX O
MCCP XXX O
functions XXX O
of XXX O
the XXX O
source XXX O
emission XXX O
, XXX O
surface XXX O
reflection XXX O
, XXX O
photoacceptor XXX O
sensitivity XXX O
are XXX O
approximated XXX O
by XXX O
the XXX O
normal XXX O
distribution XXX O
curves XXX O
. XXX O

Regulation XXX O
at XXX O
37 XXX O
degrees XXX O
C XXX O
, XXX O
therefore XXX O
, XXX O
involves XXX O
the XXX O
action XXX O
of XXX O
three XXX O
protein XXX B-GENE
kinase XXX I-GENE
cascades XXX O
that XXX O
repress XXX O
HSF1 XXX B-GENE
through XXX O
phosphorylation XXX O
of XXX O
serine XXX O
residues XXX O
303 XXX O
, XXX O
307 XXX O
, XXX O
and XXX O
363 XXX O
and XXX O
may XXX O
promote XXX O
growth XXX O
by XXX O
suppressing XXX O
the XXX O
heat XXX O
shock XXX O
response XXX O
. XXX O

A XXX O
comparative XXX O
study XXX O
of XXX O
the XXX O
total XXX O
protein XXX O
profiles XXX O
of XXX O
wild-type XXX O
S XXX O
. XXX O
entomophila XXX O
UC9 XXX O
and XXX O
mutant XXX O
UC21 XXX O
revealed XXX O
that XXX O
the XXX O
mutant XXX O
lacked XXX O
an XXX O
approximately XXX O
44-kDa XXX O
protein XXX O
and XXX O
overexpressed XXX O
an XXX O
approximately XXX O
20-kDa XXX O
protein XXX O
. XXX O

The XXX O
images XXX O
showed XXX O
rapid XXX O
, XXX O
predominantly XXX O
urinary XXX O
excretion XXX O
of XXX O
99mTc XXX O
ciprofloxacin XXX O
, XXX O
with XXX O
low XXX O
to XXX O
absent XXX O
brain XXX O
, XXX O
lung XXX O
and XXX O
bone XXX O
marrow XXX O
uptake XXX O
and XXX O
low XXX O
liver XXX O
uptake XXX O
and XXX O
excretion XXX O
. XXX O

To XXX O
measure XXX O
the XXX O
enhancer XXX O
activity XXX O
of XXX O
DR60 XXX B-GENE
, XXX O
a XXX O
reporter XXX O
plasmid XXX O
was XXX O
constructed XXX O
that XXX O
contained XXX O
DR60 XXX B-GENE
cloned XXX O
upstream XXX O
of XXX O
the XXX O
reporter XXX O
chloramphenicol XXX B-GENE
acetyltransferase XXX I-GENE
gene XXX I-GENE
under XXX O
the XXX O
control XXX O
of XXX O
the XXX O
delayed-early XXX B-GENE
39K XXX I-GENE
promoter XXX I-GENE
. XXX O

Identification XXX O
of XXX O
an XXX O
immediate-early XXX B-GENE
gene XXX I-GENE
in XXX O
the XXX O
Marek's XXX O
disease XXX O
virus XXX O
long XXX O
internal XXX O
repeat XXX O
region XXX O
which XXX O
encodes XXX O
a XXX O
unique XXX O
14-kilodalton XXX O
polypeptide XXX O
. XXX O

Only XXX O
fully XXX O
processed XXX O
Pra XXX O
( XXX O
N0 XXX O
and XXX O
Nb XXX O
) XXX O
and XXX O
ICP35 XXX O
( XXX O
ICP35 XXX O
e XXX O
, XXX O
f XXX O
) XXX O
are XXX O
present XXX O
in XXX O
B XXX O
capsids XXX O
, XXX O
which XXX O
are XXX O
believed XXX O
to XXX O
be XXX O
precursors XXX O
of XXX O
mature XXX O
virions XXX O
. XXX O

An XXX O
alternative XXX O
method XXX O
of XXX O
UKM XXX O
is XXX O
proposed XXX O
based XXX O
on XXX O
collecting XXX O
a XXX O
small XXX O
fraction XXX O
of XXX O
spent XXX O
dialysate XXX O
flow XXX O
for XXX O
3 XXX O
consecutive XXX O
dialyses XXX O
. XXX O

The XXX O
decline XXX O
in XXX O
the XXX O
activity XXX O
of XXX O
cytochrome XXX B-GENE
oxidase XXX I-GENE
, XXX O
peroxidase XXX B-GENE
and XXX O
in XXX O
the XXX O
lipid XXX O
content XXX O
of XXX O
peripheral XXX O
neutrophils XXX O
was XXX O
followed XXX O
by XXX O
a XXX O
decrease XXX O
in XXX O
the XXX O
phagocytic XXX O
activity XXX O
. XXX O

MS XXX O
characteristics XXX O
of XXX O
coumarins XXX O
, XXX O
psoralens XXX O
and XXX O
polymethoxylated XXX O
flavones XXX O
with XXX O
different XXX O
substitution XXX O
patterns XXX O
were XXX O
determined XXX O
on XXX O
the XXX O
basis XXX O
of XXX O
the XXX O
response XXX O
obtained XXX O
with XXX O
the XXX O
APcI XXX O
interface XXX O
. XXX O

We XXX O
have XXX O
used XXX O
mutation-directed XXX O
chemical XXX O
cross-linking XXX O
with XXX O
bis XXX O
( XXX O
sulfosuccinimidyl XXX O
) XXX O
suberate XXX O
( XXX O
BS3 XXX O
) XXX O
to XXX O
investigate XXX O
the XXX O
architecture XXX O
of XXX O
the XXX O
gp41 XXX B-GENE
oligomer XXX I-GENE
. XXX O

Bacteriologic XXX O
culture XXX O
of XXX O
pancreatic XXX O
tissue XXX O
was XXX O
positive XXX O
in XXX O
6 XXX O
/ XXX O
8 XXX O
IB XXX O
and XXX O
3 XXX O
/ XXX O
17 XXX O
NIB XXX O
rats XXX O
( XXX O
p XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
. XXX O

The XXX O
clinico-pathological XXX O
data XXX O
from XXX O
a XXX O
patient XXX O
with XXX O
irreversible XXX O
post-partum XXX O
renal XXX O
failure XXX O
( XXX O
IPRF XXX O
) XXX O
are XXX O
presented XXX O
. XXX O

Study XXX O
of XXX O
the XXX O
energy XXX O
metabolism XXX O
of XXX O
the XXX O
sensomotor XXX O
cortex XXX O
and XXX O
hippocampus XXX O
by XXX O
the XXX O
( XXX O
14C XXX O
) XXX O
2-deoxyglucose XXX O
method XXX O
during XXX O
the XXX O
development XXX O
of XXX O
dissociated XXX O
states XXX O
. XXX O

In XXX O
76% XXX O
of XXX O
59 XXX O
lead-toxic XXX O
children XXX O
, XXX O
bone XXX O
lead XXX O
values XXX O
measured XXX O
by XXX O
LXRF XXX O
were XXX O
equal XXX O
to XXX O
or XXX O
greater XXX O
than XXX O
those XXX O
measured XXX O
in XXX O
normal XXX O
and XXX O
industrially XXX O
exposed XXX O
adults XXX O
. XXX O

Only XXX O
seven XXX O
patients XXX O
, XXX O
five XXX O
of XXX O
whom XXX O
have XXX O
metastatic XXX O
disease XXX O
, XXX O
survive XXX O
more XXX O
than XXX O
10 XXX O
years XXX O
after XXX O
first XXX O
presentation XXX O
; XXX O
nine XXX O
patients XXX O
, XXX O
one XXX O
of XXX O
whom XXX O
has XXX O
secondaries XXX O
, XXX O
survive XXX O
for XXX O
5 XXX O
years XXX O
or XXX O
less XXX O
. XXX O

Copyright XXX O
2001 XXX O
Academic XXX O
Press XXX O
. XXX O

The XXX O
1 XXX O
. XXX O
9-kb XXX O
C XXX B-GENE
mu XXX I-GENE
RNA XXX O
contains XXX O
the XXX O
3' XXX O
sequence XXX O
characteristic XXX O
of XXX O
secreted XXX O
mu XXX B-GENE
chain XXX I-GENE
, XXX O
whereas XXX O
the XXX O
longer XXX O
species XXX O
bear XXX O
that XXX O
of XXX O
membrane-bound XXX O
mu XXX B-GENE
chin XXX O
. XXX O

From XXX O
May XXX O
1985 XXX O
to XXX O
May XXX O
1989 XXX O
, XXX O
126 XXX O
necropsies XXX O
were XXX O
performed XXX O
at XXX O
the XXX O
Sao XXX O
Paulo XXX O
City XXX O
Morgue XXX O
on XXX O
cadavers XXX O
of XXX O
individuals XXX O
AIDS XXX O
victims XXX O
whose XXX O
unnatural XXX O
deaths XXX O
had XXX O
prompted XXX O
police XXX O
investigations XXX O
. XXX O

Rad6 XXX B-GENE
mutants XXX I-GENE
display XXX O
a XXX O
remarkably XXX O
pleiotropic XXX O
phenotype XXX O
, XXX O
implicating XXX O
the XXX O
protein XXX O
in XXX O
DNA XXX O
damage-induced XXX O
mutagenesis XXX O
, XXX O
postreplication XXX O
repair XXX O
, XXX O
repression XXX O
of XXX O
retrotransposition XXX O
, XXX O
and XXX O
sporulation XXX O
. XXX O

The XXX O
mammalian XXX B-GENE
homeodomain XXX I-GENE
proteins XXX I-GENE
encoded XXX O
by XXX O
Hox XXX B-GENE
genes XXX I-GENE
play XXX O
an XXX O
important XXX O
role XXX O
in XXX O
embryonic XXX O
development XXX O
by XXX O
providing XXX O
positional XXX O
queues XXX O
which XXX O
define XXX O
developmental XXX O
identities XXX O
along XXX O
the XXX O
anteroposterior XXX O
axis XXX O
of XXX O
developing XXX O
organisms XXX O
. XXX O

The XXX O
titer XXX O
of XXX O
anti XXX B-GENE
HSV XXX I-GENE
type XXX I-GENE
1 XXX I-GENE
and XXX O
anti XXX B-GENE
HSV XXX I-GENE
type XXX I-GENE
2 XXX I-GENE
antibodies XXX I-GENE
in XXX O
the XXX O
mothers' XXX O
and XXX O
cord XXX O
blood XXX O
was XXX O
determined XXX O
and XXX O
compared XXX O
. XXX O

Negative-staining XXX O
, XXX O
refractile XXX O
mycobacteria XXX O
in XXX O
Romanowsky-stained XXX O
smears XXX O
. XXX O

The XXX O
effective XXX O
and XXX O
low XXX O
toxic XXX O
dose XXX O
schedules XXX O
of XXX O
KW-2083 XXX O
should XXX O
be XXX O
investigated XXX O
further XXX O
. XXX O

We XXX O
have XXX O
isolated XXX O
a XXX O
new XXX O
human XXX B-GENE
RING-finger XXX I-GENE
gene XXX I-GENE
( XXX O
RNF4 XXX B-GENE
) XXX O
that XXX O
encodes XXX O
a XXX O
190-amino-acid XXX O
protein XXX O
. XXX O

The XXX O
PSS XXX B-GENE
gene XXX I-GENE
was XXX O
subcloned XXX O
into XXX O
a XXX O
1 XXX O
. XXX O
1-kb XXX O
fragment XXX O
of XXX O
the XXX O
yeast XXX O
DNA XXX O
on XXX O
the XXX O
YEp13 XXX O
vector XXX O
. XXX O

The XXX O
products XXX O
of XXX O
genes XXX O
ura10 XXX B-GENE
and XXX O
ura3 XXX B-GENE
are XXX O
proposed XXX O
to XXX O
participate XXX O
in XXX O
the XXX O
channeling XXX O
of XXX O
orotidine XXX O
monophosphate XXX O
. XXX O

Interestingly XXX O
, XXX O
an XXX O
increase XXX O
of XXX O
distance XXX O
per XXX O
se XXX O
did XXX O
not XXX O
have XXX O
a XXX O
deleterious XXX O
effect XXX O
on XXX O
translation XXX O
efficiency XXX O
. XXX O

Per XXX O
kg XXX O
FFM XXX O
SMR XXX O
was XXX O
almost XXX O
restored XXX O
to XXX O
baseline XXX O
values XXX O
for XXX O
the XXX O
EX XXX O
group XXX O
, XXX O
whereas XXX O
the XXX O
non-exercising XXX O
subjects XXX O
still XXX O
showed XXX O
depressed XXX O
values XXX O
( XXX O
EX XXX O
3 XXX O
. XXX O
7 XXX O
per XXX O
cent XXX O
and XXX O
D XXX O
+ XXX O
DE XXX O
15 XXX O
. XXX O
8 XXX O
per XXX O
cent XXX O
lower XXX O
than XXX O
before XXX O
treatment XXX O
; XXX O
P XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
. XXX O

GLUT5 XXX B-GENE
mRNA XXX I-GENE
is XXX O
expressed XXX O
at XXX O
highest XXX O
levels XXX O
in XXX O
small XXX O
intestine XXX O
and XXX O
at XXX O
much XXX O
lower XXX O
levels XXX O
in XXX O
kidney XXX O
, XXX O
skeletal XXX O
muscle XXX O
, XXX O
and XXX O
adipose XXX O
tissue XXX O
. XXX O

Characterization XXX O
of XXX O
CR1 XXX B-GENE
repeat XXX I-GENE
random XXX O
PCR XXX O
markers XXX O
for XXX O
mapping XXX O
the XXX O
chicken XXX O
genome XXX O
. XXX O

Time-activity XXX O
curves XXX O
from XXX O
the XXX O
gastric XXX O
region XXX O
of XXX O
interest XXX O
were XXX O
used XXX O
, XXX O
after XXX O
subjection XXX O
to XXX O
appropriate XXX O
corrective XXX O
procedures XXX O
, XXX O
to XXX O
calculate XXX O
the XXX O
mean XXX O
gastric XXX O
transit XXX O
time XXX O
( XXX O
MTT XXX O
90 XXX O
) XXX O
and XXX O
the XXX O
fraction XXX O
of XXX O
the XXX O
test XXX O
meal XXX O
retained XXX O
in XXX O
the XXX O
stomach XXX O
after XXX O
90 XXX O
min XXX O
( XXX O
F90 XXX O
) XXX O
. XXX O

Comparative XXX O
analysis XXX O
with XXX O
an XXX O
antiandrogen XXX O
niftolid XXX O
and XXX O
synthetic XXX B-GENE
GnRH XXX I-GENE
was XXX O
carried XXX O
out XXX O
in XXX O
22 XXX O
normal XXX O
subjects XXX O
, XXX O
14 XXX O
patients XXX O
with XXX O
primary XXX O
and XXX O
20 XXX O
ones XXX O
with XXX O
secondary XXX O
hypogonadism XXX O
, XXX O
and XXX O
in XXX O
5 XXX O
patients XXX O
with XXX O
clinical XXX O
signs XXX O
of XXX O
gonadal XXX O
insufficiency XXX O
and XXX O
obscure XXX O
diagnosis XXX O
in XXX O
order XXX O
to XXX O
elucidate XXX O
the XXX O
pituitary XXX B-GENE
gonadotropin XXX I-GENE
reserves XXX O
. XXX O

We XXX O
have XXX O
isolated XXX O
a XXX O
novel XXX O
protein XXX O
from XXX O
Drosophila XXX O
nuclear XXX O
extracts XXX O
which XXX O
binds XXX O
specifically XXX O
to XXX O
a XXX O
site XXX O
in XXX O
this XXX O
second XXX O
region XXX O
. XXX O

These XXX O
data XXX O
suggest XXX O
that XXX O
ADAM-TS12 XXX B-GENE
may XXX O
play XXX O
roles XXX O
in XXX O
pulmonary XXX O
cells XXX O
during XXX O
fetal XXX O
development XXX O
or XXX O
in XXX O
tumor XXX O
processes XXX O
through XXX O
its XXX O
proteolytic XXX O
activity XXX O
or XXX O
as XXX O
a XXX O
molecule XXX O
potentially XXX O
involved XXX O
in XXX O
regulation XXX O
of XXX O
cell XXX O
adhesion XXX O
. XXX O

Furthermore XXX O
, XXX O
overexpression XXX O
of XXX O
AML3 XXX B-GENE
/ XXX I-GENE
CBFalpha1 XXX I-GENE
could XXX O
rescue XXX O
the XXX O
AML1-ETO XXX B-GENE
repression XXX O
. XXX O

Analysis XXX O
of XXX O
Bcl-2 XXX B-GENE
/ XXX I-GENE
Bcl-2 XXX I-GENE
homodimerization XXX O
using XXX O
both XXX O
in XXX O
vitro XXX O
binding XXX O
assays XXX O
as XXX O
well XXX O
as XXX O
a XXX O
yeast XXX O
two-hybrid XXX O
method XXX O
provided XXX O
evidence XXX O
in XXX O
support XXX O
of XXX O
a XXX O
head-to-tail XXX O
model XXX O
for XXX O
Bcl-2 XXX B-GENE
/ XXX I-GENE
Bcl-2 XXX I-GENE
homodimerization XXX O
and XXX O
revealed XXX O
that XXX O
sequences XXX O
within XXX O
the XXX O
NH2-terminal XXX O
A XXX O
domain XXX O
interact XXX O
with XXX O
a XXX O
structure XXX O
that XXX O
requires XXX O
the XXX O
presence XXX O
of XXX O
both XXX O
the XXX O
carboxyl XXX O
B XXX O
and XXX O
C XXX O
domains XXX O
in XXX O
combination XXX O
. XXX O

The XXX O
5' XXX O
ends XXX O
of XXX O
F3R XXX B-GENE
late XXX O
transcripts XXX O
were XXX O
located XXX O
to XXX O
an XXX O
A XXX O
within XXX O
the XXX O
sequence XXX B-GENE
5'-TAAAG XXX I-GENE
, XXX O
41 XXX O
nt XXX O
downstream XXX O
from XXX O
the XXX O
early XXX O
promoter XXX O
and XXX O
17 XXX O
nt XXX O
upstream XXX O
from XXX O
the XXX O
initiation XXX O
codon XXX O
. XXX O

These XXX O
results XXX O
were XXX O
robust XXX O
to XXX O
changes XXX O
in XXX O
the XXX O
baseline XXX O
assumptions XXX O
of XXX O
the XXX O
model XXX O
. XXX O

Lack XXX O
of XXX O
association XXX O
between XXX O
Kawasaki XXX O
syndrome XXX O
and XXX O
infection XXX O
with XXX O
Rickettsia XXX O
conorii XXX O
, XXX O
Rickettsia XXX O
typhi XXX O
, XXX O
Coxiella XXX O
burnetii XXX O
or XXX O
Ehrlichia XXX O
phagocytophila XXX O
group XXX O
. XXX O

Determination XXX O
of XXX O
aortic XXX O
distensibility XXX O
and XXX O
its XXX O
variations XXX O
in XXX O
arterial XXX O
hypertension XXX O
. XXX O

To XXX O
elucidate XXX O
the XXX O
regulatory XXX O
mechanism XXX O
of XXX O
human XXX B-GENE
AM XXX I-GENE
gene XXX I-GENE
expression XXX O
, XXX O
functional XXX O
elements XXX O
of XXX O
5'-flanking XXX O
region XXX O
of XXX O
AM XXX B-GENE
gene XXX I-GENE
were XXX O
studied XXX O
in XXX O
human XXX O
aortic XXX O
endothelial XXX O
cells XXX O
( XXX O
HAEC XXX O
) XXX O
. XXX O

Members XXX O
of XXX O
the XXX O
AP-1 XXX B-GENE
superfamily XXX I-GENE
of XXX I-GENE
basic-leucine XXX I-GENE
zipper XXX I-GENE
factors XXX I-GENE
bind XXX O
to XXX O
the XXX O
StRE XXX B-GENE
. XXX O

Finally XXX O
, XXX O
a XXX O
complementary XXX O
footprinting XXX O
analysis XXX O
of XXX O
the XXX O
upstream XXX O
region XXX O
of XXX O
the XXX O
constitutively XXX O
expressed XXX O
HSC82 XXX B-GENE
gene XXX I-GENE
reveals XXX O
the XXX O
presence XXX O
of XXX O
three XXX O
discrete XXX O
protein XXX O
complexes XXX O
. XXX O

The XXX O
somatoform XXX O
conundrum XXX O
: XXX O
a XXX O
question XXX O
of XXX O
nosological XXX O
valves XXX O
. XXX O

Gonadotropin XXX B-GENE
levels XXX O
in XXX O
mothers XXX O
who XXX O
have XXX O
had XXX O
two XXX O
sets XXX O
of XXX O
DZ XXX O
twins XXX O
. XXX O

Human XXX B-GENE
granulocyte-macrophage XXX I-GENE
colony-stimulating XXX I-GENE
factor XXX I-GENE
( XXX O
hGM-CSF XXX B-GENE
) XXX O
activates XXX O
a XXX O
set XXX O
of XXX O
genes XXX O
such XXX O
as XXX O
c-fos XXX B-GENE
, XXX O
jun XXX B-GENE
, XXX O
myc XXX B-GENE
, XXX O
and XXX O
early XXX B-GENE
growth XXX I-GENE
response XXX I-GENE
gene XXX I-GENE
1 XXX I-GENE
( XXX O
egr-1 XXX B-GENE
) XXX O
. XXX O

When XXX O
the XXX O
LCx XXX O
was XXX O
partially XXX O
occluded XXX O
, XXX O
mild XXX O
PM-induced XXX O
tachycardia XXX O
resulted XXX O
in XXX O
decreased XXX O
AoP XXX O
( XXX O
P XXX O
= XXX O
0 XXX O
. XXX O
045 XXX O
) XXX O
as XXX O
well XXX O
as XXX O
in XXX O
decreased XXX O
SV XXX O
( XXX O
P XXX O
= XXX O
0 XXX O
. XXX O
048 XXX O
) XXX O
; XXX O
the XXX O
LVEDP XXX O
remained XXX O
high XXX O
( XXX O
P XXX O
= XXX O
0 XXX O
. XXX O
002 XXX O
) XXX O
. XXX O

Two XXX O
cases XXX O
with XXX O
marked XXX O
chronic XXX O
arm XXX O
lymphoedema XXX O
reported XXX O
major XXX O
and XXX O
persistent XXX O
improvements XXX O
in XXX O
arm XXX O
volume XXX O
for XXX O
at XXX O
least XXX O
12 XXX O
months XXX O
after XXX O
treatment XXX O
with XXX O
HBO2 XXX O
. XXX O

The XXX O
M-3 XXX O
subtype XXX O
was XXX O
an XXX O
adverse XXX O
prognostic XXX O
factor XXX O
. XXX O

Histopathology XXX O
and XXX O
pathogenesis XXX O
of XXX O
exanthematous XXX O
viroses XXX O
. XXX O

The XXX O
human XXX O
coreceptor XXX O
was XXX O
as XXX O
active XXX O
as XXX O
the XXX O
simian XXX O
for XXX O
SIV XXX O
entry XXX O
. XXX O

Quantitative XXX O
assays XXX O
in XXX O
which XXX O
the XXX O
activity XXX O
of XXX O
the XXX O
synthetic XXX B-GENE
alpha XXX I-GENE
s-1 XXX I-GENE
was XXX O
compared XXX O
to XXX O
that XXX O
of XXX O
native XXX O
purified XXX O
human XXX B-GENE
erythrocyte XXX I-GENE
type-1 XXX I-GENE
Gs XXX I-GENE
, XXX O
indicated XXX O
that XXX O
the XXX O
two XXX O
products XXX O
are XXX O
equipotent XXX O
within XXX O
a XXX O
2-fold XXX O
margin XXX O
of XXX O
error XXX O
. XXX O

The XXX O
effect XXX O
of XXX O
the XXX O
Ca XXX O
entry XXX O
blocker XXX O
nitrendipine XXX O
, XXX O
the XXX O
antioxidant XXX O
superoxide XXX B-GENE
dismutase XXX I-GENE
( XXX O
SOD XXX B-GENE
) XXX O
, XXX O
and XXX O
a XXX O
combination XXX O
of XXX O
nitrendipine XXX O
and XXX O
superoxide XXX B-GENE
dismutase XXX I-GENE
on XXX O
postischemic XXX O
renal XXX O
function XXX O
was XXX O
studied XXX O
in XXX O
four XXX O
groups XXX O
( XXX O
n XXX O
= XXX O
24 XXX O
) XXX O
of XXX O
rats XXX O
. XXX O

European XXX O
Community XXX O
Huntington's XXX O
Disease XXX O
Collaborative XXX O
Study XXX O
Group XXX O
. XXX O

Interestingly XXX O
, XXX O
a XXX O
portion XXX O
of XXX O
the XXX O
tail XXX O
domain XXX O
( XXX O
aa XXX O
, XXX O
1 XXX O
, XXX O
094-1 XXX O
, XXX O
830 XXX O
) XXX O
shares XXX O
58% XXX O
amino XXX O
acid XXX O
sequence XXX O
identity XXX O
with XXX O
a XXX O
723-aa XXX O
protein XXX O
from XXX O
mouse XXX O
brain XXX O
reported XXX O
to XXX O
be XXX O
a XXX O
glutamic XXX B-GENE
acid XXX I-GENE
decarboxylase XXX I-GENE
. XXX O

This XXX O
accurate XXX O
and XXX O
rapid XXX O
method XXX O
makes XXX O
the XXX O
MLPA XXX O
test XXX O
logistically XXX O
feasible XXX O
for XXX O
large-scale XXX O
screening XXX O
. XXX O

A XXX O
multivariate XXX O
analysis XXX O
of XXX O
risk XXX O
factors XXX O
for XXX O
relapse XXX O
examined XXX O
age XXX O
, XXX O
WBC XXX O
at XXX O
diagnosis XXX O
, XXX O
blast XXX O
count XXX O
at XXX O
diagnosis XXX O
, XXX O
percentage XXX O
of XXX O
marrow XXX O
blasts XXX O
, XXX O
FAB XXX B-GENE
subtype XXX O
, XXX O
the XXX O
number XXX O
of XXX O
remission XXX O
induction XXX O
courses XXX O
to XXX O
achieve XXX O
a XXX O
remission XXX O
, XXX O
maintenance XXX O
therapy XXX O
, XXX O
consolidation XXX O
therapy XXX O
, XXX O
marrow XXX O
cell XXX O
dose XXX O
, XXX O
donor-recipient XXX O
sex XXX O
, XXX O
GVHD XXX O
prophylaxis XXX O
regimen XXX O
and XXX O
isolation XXX O
and XXX O
decontamination XXX O
in XXX O
laminar XXX O
airflow XXX O
rooms XXX O
. XXX O

We XXX O
have XXX O
explored XXX O
the XXX O
mechanism XXX O
of XXX O
action XXX O
of XXX O
the XXX O
fibronectin XXX B-GENE
splicing XXX I-GENE
enhancer XXX I-GENE
and XXX O
found XXX O
that XXX O
the XXX O
SE XXX B-GENE
element XXX I-GENE
is XXX O
required XXX O
for XXX O
efficient XXX O
assembly XXX O
of XXX O
early XXX O
splicing XXX O
complexes XXX O
, XXX O
allowing XXX O
a XXX O
more XXX O
efficient XXX O
interaction XXX O
of XXX O
the XXX O
U2 XXX B-GENE
snRNP XXX I-GENE
with XXX O
branch XXX O
site XXX O
sequences XXX O
. XXX O

Unexpectedly XXX O
, XXX O
all XXX O
ENK-specific XXX O
motifs XXX O
formed XXX O
specific XXX O
and XXX O
highly XXX O
abundant XXX O
protein-DNA XXX O
complexes XXX O
when XXX O
nuclear XXX O
extracts XXX O
from XXX O
the XXX O
human XXX O
tumor XXX O
cell XXX O
line XXX O
( XXX O
HeLa XXX O
) XXX O
, XXX O
which XXX O
does XXX O
not XXX O
express XXX O
ENK XXX B-GENE
, XXX O
were XXX O
used XXX O
. XXX O

Subsequently XXX O
, XXX O
HD XXX O
inhibited XXX O
healing XXX O
because XXX O
it XXX O
significantly XXX O
delayed XXX O
epithelialization XXX O
and XXX O
caused XXX O
protracted XXX O
inflammation XXX O
. XXX O

The XXX O
bovine XXX B-GENE
papillomavirus XXX I-GENE
E2 XXX I-GENE
protein XXX I-GENE
can XXX O
inhibit XXX O
the XXX O
proliferation XXX O
of XXX O
HT-3 XXX O
cells XXX O
, XXX O
a XXX O
p53-negative XXX O
cervical XXX O
carcinoma XXX O
cell XXX O
line XXX O
containing XXX O
integrated XXX O
human XXX O
papillomavirus XXX O
type XXX O
30 XXX O
DNA XXX O
. XXX O

Vascular XXX O
responses XXX O
to XXX O
reactive XXX O
hyperemia XXX O
( XXX O
with XXX O
flow XXX O
increase XXX O
leading XXX O
to XXX O
endothelium-dependent XXX O
dilation XXX O
) XXX O
and XXX O
to XXX O
sublingual XXX O
glyceryl XXX O
trinitrate XXX O
( XXX O
GTN XXX O
; XXX O
endothelium-independent XXX O
dilation XXX O
) XXX O
were XXX O
recorded XXX O
. XXX O

We XXX O
compared XXX O
the XXX O
inhibitory XXX O
effect XXX O
of XXX O
naturally XXX O
occurring XXX O
mutant XXX B-GENE
hTR XXX I-GENE
beta XXX I-GENE
1 XXX I-GENE
, XXX O
artificially XXX O
created XXX O
hTR XXX B-GENE
alpha XXX I-GENE
1 XXX I-GENE
mutants XXX I-GENE
, XXX O
c-erbA XXX B-GENE
alpha XXX I-GENE
2 XXX I-GENE
and XXX O
the XXX O
human XXX B-GENE
peroxisome XXX I-GENE
proliferator-activated XXX I-GENE
receptor XXX I-GENE
( XXX O
hPPAR XXX B-GENE
) XXX O
on XXX O
three XXX O
prototypic XXX O
T3-response XXX B-GENE
elements XXX I-GENE
( XXX O
TREs XXX B-GENE
) XXX O
, XXX O
TRE-PAL XXX B-GENE
, XXX O
DR XXX B-GENE
+ XXX I-GENE
4 XXX I-GENE
and XXX O
TRE-LAP XXX B-GENE
. XXX O

The XXX O
mean XXX O
change XXX O
in XXX O
HbA1 XXX B-GENE
, XXX O
adjusted XXX O
for XXX O
the XXX O
initial XXX O
value XXX O
, XXX O
was XXX O
-0 XXX O
. XXX O
4% XXX O
in XXX O
the XXX O
experimental XXX O
and XXX O
+0 XXX O
. XXX O
5% XXX O
in XXX O
the XXX O
control XXX O
group XXX O
( XXX O
p XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
. XXX O

Regions XXX O
of XXX O
the XXX O
translated XXX O
open XXX O
reading XXX O
frames XXX O
of XXX O
cobA XXX B-GENE
and XXX O
the XXX O
third XXX O
intron XXX O
of XXX O
the XXX O
cob XXX B-GENE
gene XXX I-GENE
in XXX I-GENE
yeast XXX I-GENE
show XXX O
high XXX O
amino XXX O
acid XXX O
homology XXX O
. XXX O

Tumor-like XXX O
accumulation XXX O
on XXX O
Tl-201 XXX O
SPECT XXX O
in XXX O
subacute XXX O
hemorrhagic XXX O
cerebral XXX O
infarction XXX O
. XXX O

RNA XXX B-GENE
polymerase XXX I-GENE
IIA XXX I-GENE
was XXX O
recovered XXX O
in XXX O
transcriptionally XXX O
active XXX O
complexes XXX O
in XXX O
reactions XXX O
in XXX O
which XXX O
the XXX O
input XXX O
enzyme XXX O
was XXX O
RNA XXX B-GENE
polymerase XXX I-GENE
IIA XXX I-GENE
. XXX O

Isolation XXX O
and XXX O
genomic XXX O
structure XXX O
of XXX O
a XXX O
human XXX O
homolog XXX O
of XXX O
the XXX O
yeast XXX B-GENE
periodic XXX I-GENE
tryptophan XXX I-GENE
protein XXX I-GENE
2 XXX I-GENE
( XXX O
PWP2 XXX B-GENE
) XXX O
gene XXX O
mapping XXX O
to XXX O
21q22 XXX O
. XXX O
3 XXX O
. XXX O

In XXX O
14 XXX O
of XXX O
21 XXX O
infant XXX O
hearts XXX O
( XXX O
66% XXX O
) XXX O
with XXX O
aortic XXX O
arch XXX O
interruption XXX O
between XXX O
the XXX O
left XXX O
common XXX O
carotid XXX O
and XXX O
left XXX O
subclavian XXX O
arteries XXX O
( XXX O
type XXX O
B XXX O
of XXX O
Celoria XXX O
and XXX O
Patton XXX O
) XXX O
, XXX O
the XXX O
right XXX O
subclavian XXX O
artery XXX O
( XXX O
SA XXX O
) XXX O
arose XXX O
anomalously XXX O
. XXX O

They XXX O
also XXX O
reported XXX O
that XXX O
E XXX B-GENE
mu XXX I-GENE
pim-1 XXX I-GENE
transgenic XXX O
mice XXX O
show XXX O
greatly XXX O
accelerated XXX O
lymphoma XXX O
development XXX O
when XXX O
infected XXX O
with XXX O
wild-type XXX O
M-MuLV XXX O
at XXX O
birth XXX O
. XXX O

Among XXX O
953 XXX O
infants XXX O
in XXX O
22 XXX O
neonatal XXX O
care XXX O
units XXX O
studied XXX O
, XXX O
23% XXX O
( XXX O
median XXX O
value XXX O
, XXX O
range XXX O
0-78 XXX O
) XXX O
were XXX O
found XXX O
to XXX O
be XXX O
faecally XXX O
colonized XXX O
with XXX O
one XXX O
of XXX O
21 XXX O
distinct XXX O
nosocomial XXX O
strains XXX O
of XXX O
Escherichia XXX O
coli XXX O
, XXX O
Klebsiella XXX O
or XXX O
Enterobacter XXX O
spp XXX O
. XXX O

This XXX O
slope XXX O
was XXX O
further XXX O
significantly XXX O
decreased XXX O
at XXX O
5 XXX O
min XXX O
ischemia XXX O
( XXX O
-26 XXX O
. XXX O
5 XXX O
+ XXX O
/ XXX O
- XXX O
8 XXX O
. XXX O
8 XXX O
&mgr XXX O
; XXX O
m XXX O
/ XXX O
mmHg XXX O
) XXX O
but XXX O
returned XXX O
toward XXX O
control XXX O
values XXX O
in XXX O
short-term XXX O
hibernating XXX O
myocardium XXX O
at XXX O
90 XXX O
min XXX O
ischemia XXX O
( XXX O
-17 XXX O
. XXX O
2 XXX O
+ XXX O
/ XXX O
- XXX O
6 XXX O
. XXX O
6 XXX O
&mgr XXX O
; XXX O
m XXX O
/ XXX O
mmHg XXX O
) XXX O
. XXX O

Lipid XXX O
concentration XXX O
and XXX O
lipase XXX B-GENE
activity XXX O
in XXX O
the XXX O
epiphysis XXX O
of XXX O
adrenalectomized XXX O
rats XXX O
consuming XXX O
food XXX O
with XXX O
different XXX O
sodium XXX O
content XXX O
. XXX O

Results XXX O
showed XXX O
that XXX O
the XXX O
mean XXX O
bond XXX O
strength XXX O
of XXX O
H XXX O
. XXX O
T XXX O
. XXX O
V XXX O
. XXX O
specimens XXX O
ranged XXX O
from XXX O
9 XXX O
. XXX O
6 XXX O
to XXX O
13 XXX O
. XXX O
12 XXX O
kg XXX O
/ XXX O
cm2 XXX O
, XXX O
while XXX O
the XXX O
mean XXX O
bond XXX O
strength XXX O
of XXX O
R XXX O
. XXX O
T XXX O
. XXX O
V XXX O
. XXX O
specimens XXX O
ranged XXX O
from XXX O
0 XXX O
. XXX O
36 XXX O
to XXX O
1 XXX O
. XXX O
75 XXX O
kg XXX O
/ XXX O
cm2 XXX O
. XXX O

Nickel XXX O
is XXX O
the XXX O
most XXX O
common XXX O
cause XXX O
of XXX O
allergic XXX O
contact XXX O
dermatitis XXX O
in XXX O
Singapore XXX O
, XXX O
resulting XXX O
in XXX O
positive XXX O
reactions XXX O
in XXX O
patch XXX O
tests XXX O
between XXX O
7 XXX O
and XXX O
14% XXX O
. XXX O

One XXX O
hundred XXX O
replicate XXX O
data XXX O
sets XXX O
of XXX O
100 XXX O
subjects XXX O
each XXX O
were XXX O
simulated XXX O
for XXX O
each XXX O
missing XXX O
data XXX O
scenario XXX O
. XXX O

J XXX O
. XXX O

The XXX O
CT XXX O
characteristics XXX O
are XXX O
discussed XXX O
and XXX O
the XXX O
recent XXX O
literature XXX O
is XXX O
reviewed XXX O
. XXX O

The XXX O
rationale XXX O
for XXX O
continuous XXX O
dopaminergic XXX O
stimulation XXX O
in XXX O
patients XXX O
with XXX O
Parkinson's XXX O
disease XXX O
. XXX O

Idiopathic XXX O
bilateral XXX O
recurrent XXX O
branch XXX O
retinal XXX O
arterial XXX O
occlusion XXX O
( XXX O
IBRBRAO XXX O
) XXX O
is XXX O
a XXX O
rare XXX O
syndrome XXX O
characterized XXX O
by XXX O
migraine XXX O
headaches XXX O
, XXX O
tinnitus XXX O
, XXX O
vertigo XXX O
, XXX O
hearing XXX O
loss XXX O
, XXX O
and XXX O
recurrent XXX O
branch XXX O
retinal XXX O
artery XXX O
occlusion XXX O
of XXX O
unknown XXX O
etiology XXX O
. XXX O

The XXX O
extraordinary XXX O
stability XXX O
of XXX O
peptide--gp96 XXX B-GENE
complexes XXX I-GENE
and XXX O
the XXX O
plasticity XXX O
of XXX O
the XXX O
peptide-binding XXX O
pocket XXX O
support XXX O
the XXX O
proposed XXX O
relay XXX O
of XXX O
diverse XXX O
peptides XXX O
to XXX O
MHC XXX B-GENE
and XXX O
/ XXX O
or XXX O
other XXX O
molecules XXX O
via XXX O
molecular XXX O
recognition XXX O
. XXX O

Male-enhanced XXX B-GENE
antigen XXX I-GENE
gene XXX I-GENE
is XXX O
phylogenetically XXX O
conserved XXX O
and XXX O
expressed XXX O
at XXX O
late XXX O
stages XXX O
of XXX O
spermatogenesis XXX O
. XXX O

In XXX O
this XXX O
report XXX O
we XXX O
describe XXX O
the XXX O
isolation XXX O
of XXX O
a XXX O
Fab XXX B-GENE
fragment XXX I-GENE
( XXX O
Fab XXX B-GENE
A8 XXX I-GENE
) XXX O
showing XXX O
a XXX O
high XXX O
relative XXX O
affinity XXX O
for XXX O
the XXX O
receptor XXX O
( XXX O
0 XXX O
. XXX O
5 XXX O
nM XXX O
) XXX O
. XXX O

In XXX O
the XXX O
Center XXX O
for XXX O
Human XXX O
Genetics XXX O
in XXX O
Leuven XXX O
, XXX O
predictive XXX O
DNA-testing XXX O
for XXX O
Huntington's XXX O
disease XXX O
is XXX O
available XXX O
as XXX O
a XXX O
clinical XXX O
service XXX O
since XXX O
November XXX O
1987 XXX O
, XXX O
initially XXX O
by XXX O
DNA-linkage XXX O
and XXX O
since XXX O
mid XXX O
1993 XXX O
by XXX O
direct XXX O
mutation XXX O
analysis XXX O
. XXX O

Electrophoretic XXX O
mobility-shift XXX O
assays XXX O
performed XXX O
with XXX O
the XXX O
HNF-3 XXX B-GENE
X XXX I-GENE
and XXX I-GENE
Y XXX I-GENE
sites XXX I-GENE
demonstrated XXX O
that XXX O
both XXX O
sites XXX O
are XXX O
capable XXX O
of XXX O
binding XXX O
HNF-3alpha XXX B-GENE
and XXX O
HNF-3beta XXX B-GENE
. XXX O

In XXX O
a XXX O
Hoosier XXX O
Oncology XXX O
Group XXX O
randomized XXX O
study XXX O
involving XXX O
extensive-disease XXX O
SCLC XXX O
patients XXX O
, XXX O
VIP XXX O
was XXX O
superior XXX O
to XXX O
etoposide XXX O
/ XXX O
cisplatin XXX O
with XXX O
regard XXX O
to XXX O
median XXX O
time XXX O
to XXX O
progression XXX O
( XXX O
6 XXX O
. XXX O
6 XXX O
v XXX O
5 XXX O
. XXX O
8 XXX O
months XXX O
) XXX O
, XXX O
median XXX O
survival XXX O
times XXX O
( XXX O
9 XXX O
. XXX O
1 XXX O
v XXX O
7 XXX O
. XXX O
3 XXX O
months XXX O
) XXX O
, XXX O
and XXX O
2- XXX O
and XXX O
3-year XXX O
survival XXX O
rates XXX O
( XXX O
13% XXX O
v XXX O
5% XXX O
and XXX O
5% XXX O
v XXX O
0% XXX O
, XXX O
respectively XXX O
) XXX O
. XXX O

The XXX O
v-ets XXX B-GENE
oncogene XXX I-GENE
of XXX O
the XXX O
avian XXX O
retrovirus XXX O
E26 XXX O
differs XXX O
from XXX O
its XXX O
cellular XXX O
progenitor XXX O
p68c-ets-1 XXX B-GENE
by XXX O
two XXX O
amino XXX O
acid XXX O
substitutions XXX O
( XXX O
alanine XXX O
285 XXX O
and XXX O
isoleucine XXX O
445 XXX O
in XXX O
c-ets-1 XXX B-GENE
both XXX O
substituted XXX O
by XXX O
valine XXX O
in XXX O
v-ets XXX B-GENE
, XXX O
mutations XXX O
A XXX O
and XXX O
B XXX O
respectively XXX O
) XXX O
and XXX O
its XXX O
carboxy-terminal XXX O
end XXX O
( XXX O
mutation XXX O
C XXX O
) XXX O
. XXX O

Since XXX O
the XXX O
morphology XXX O
of XXX O
the XXX O
lesions XXX O
can XXX O
mimic XXX O
that XXX O
of XXX O
other XXX O
cutaneous XXX O
disorders XXX O
, XXX O
Bowen's XXX O
disease XXX O
is XXX O
often XXX O
not XXX O
recognized XXX O
initially XXX O
. XXX O

This XXX O
promoter XXX O
could XXX O
direct XXX O
the XXX O
constitutive XXX O
expression XXX O
of XXX O
the XXX O
reporter XXX O
beta-galactosidase XXX O
at XXX O
high XXX O
frequency XXX O
in XXX O
transfected XXX O
colonies XXX O
of XXX O
transformed XXX O
cells XXX O
that XXX O
express XXX O
L-plastin XXX B-GENE
constitutively XXX O
; XXX O
by XXX O
contrast XXX O
, XXX O
this XXX O
promoter XXX O
was XXX O
virtually XXX O
inactive XXX O
in XXX O
transfected XXX O
colonies XXX O
of XXX O
normal XXX O
fibroblasts XXX O
and XXX O
it XXX O
exhibited XXX O
a XXX O
low XXX O
frequency XXX O
of XXX O
constitutive XXX O
activation XXX O
in XXX O
transfected XXX O
colonies XXX O
of XXX O
in XXX O
vitro XXX O
SV40-transformed XXX O
fibroblasts XXX O
which XXX O
did XXX O
not XXX O
exhibit XXX O
L-plastin XXX B-GENE
expression XXX O
. XXX O

This XXX O
study XXX O
examines XXX O
the XXX O
effects XXX O
of XXX O
hypovolemia XXX O
on XXX O
the XXX O
extracellular XXX O
ptO2 XXX O
and XXX O
ptH XXX O
distributions XXX O
at XXX O
multiple XXX O
tissue XXX O
sites XXX O
using XXX O
a XXX O
recently XXX O
developed XXX O
multipoint XXX O
microelectrode XXX O
, XXX O
that XXX O
provides XXX O
simultaneous XXX O
measurements XXX O
of XXX O
ptO2 XXX O
and XXX O
ptH XXX O
. XXX O

Construction XXX O
of XXX O
a XXX O
RIP1 XXX B-GENE
deletion XXX O
strain XXX O
and XXX O
isolation XXX O
of XXX O
temperature-sensitive XXX O
mutants XXX O
. XXX O

This XXX O
regulation XXX O
could XXX O
not XXX O
be XXX O
appreciably XXX O
modified XXX O
by XXX O
enhanced XXX O
expression XXX O
of XXX O
STAT XXX B-GENE
proteins XXX I-GENE
. XXX O

These XXX O
data XXX O
showed XXX O
: XXX O
that XXX O
progesterone XXX O
secretion XXX O
is XXX O
pulsatile XXX O
throughout XXX O
the XXX O
human XXX O
luteal XXX O
phase XXX O
, XXX O
with XXX O
maximum XXX O
frequency XXX O
in XXX O
the XXX O
mid-luteal XXX O
phase XXX O
; XXX O
that XXX O
during XXX O
the XXX O
mid-luteal XXX O
phase XXX O
most XXX O
subjects XXX O
had XXX O
progesterone XXX O
levels XXX O
both XXX O
above XXX O
and XXX O
below XXX O
currently XXX O
accepted XXX O
ovulatory XXX O
thresholds XXX O
; XXX O
the XXX O
use XXX O
of XXX O
a XXX O
single XXX O
measurement XXX O
of XXX O
progesterone XXX O
in XXX O
the XXX O
mid-luteal XXX O
phase XXX O
is XXX O
not XXX O
always XXX O
a XXX O
reliable XXX O
indicator XXX O
of XXX O
ovulation XXX O
; XXX O
a XXX O
threshold XXX O
greater XXX O
than XXX O
20 XXX O
nmol XXX O
/ XXX O
l XXX O
may XXX O
yield XXX O
an XXX O
unacceptable XXX O
number XXX O
of XXX O
false XXX O
negative XXX O
results XXX O
. XXX O

The XXX O
selenium XXX O
level XXX O
and XXX O
glutathione XXX B-GENE
peroxidase XXX I-GENE
activity XXX O
in XXX O
the XXX O
blood XXX O
, XXX O
liver XXX O
, XXX O
and XXX O
stomach XXX O
mucosa XXX O
were XXX O
significantly XXX O
higher XXX O
in XXX O
the XXX O
high-selenium XXX O
diet XXX O
group XXX O
than XXX O
in XXX O
the XXX O
low-selenium XXX O
diet XXX O
group XXX O
. XXX O

Oestrogen XXX O
implant XXX O
overdose XXX O
. XXX O

Identification XXX O
and XXX O
characterization XXX O
of XXX O
specific XXX O
DNA-binding XXX O
complexes XXX O
containing XXX O
members XXX O
of XXX O
the XXX O
Myc XXX B-GENE
/ XXX I-GENE
Max XXX I-GENE
/ XXX I-GENE
Mad XXX I-GENE
network XXX I-GENE
of XXX O
transcriptional XXX O
regulators XXX O
. XXX O

Electrocardiographic XXX O
QRS XXX O
complexes XXX O
and XXX O
vectorcardiographic XXX O
QRS XXX O
loop XXX O
. XXX O

Mucoepidermoid XXX O
and XXX O
acinous XXX O
cell XXX O
carcinomas XXX O
of XXX O
salivary XXX O
tissues XXX O
. XXX O

Fifty-six XXX O
semen XXX O
samples XXX O
were XXX O
included XXX O
in XXX O
this XXX O
study XXX O
; XXX O
18 XXX O
were XXX O
subnormal XXX O
( XXX O
G1 XXX O
) XXX O
and XXX O
38 XXX O
were XXX O
normal XXX O
( XXX O
G2 XXX O
) XXX O
based XXX O
on XXX O
World XXX O
Health XXX O
Organization XXX O
criteria XXX O
, XXX O
except XXX O
for XXX O
morphology XXX O
, XXX O
which XXX O
was XXX O
evaluated XXX O
according XXX O
to XXX O
strict XXX O
criteria XXX O
. XXX O

Both XXX O
groups XXX O
then XXX O
underwent XXX O
hypnotic XXX O
induction XXX O
, XXX O
and XXX O
completed XXX O
the XXX O
test XXX O
again XXX O
( XXX O
R2 XXX O
) XXX O
. XXX O

327 XXX O
and XXX O
736 XXX O
protocols XXX O
of XXX O
postmortem XXX O
examinations XXX O
from XXX O
Moscow XXX O
hospitals XXX O
N XXX O
31 XXX O
and XXX O
57 XXX O
, XXX O
respectively XXX O
, XXX O
were XXX O
evaluated XXX O
statistically XXX O
. XXX O

We XXX O
examine XXX O
current XXX O
models XXX O
of XXX O
the XXX O
effects XXX O
of XXX O
aging XXX O
on XXX O
mean XXX O
response XXX O
time XXX O
and XXX O
show XXX O
how XXX O
they XXX O
might XXX O
be XXX O
reinterpreted XXX O
. XXX O

The XXX O
full-length XXX O
N XXX B-GENE
gene XXX I-GENE
, XXX O
encoded XXX O
by XXX O
open XXX O
reading XXX O
frame XXX O
7 XXX O
, XXX O
was XXX O
cloned XXX O
from XXX O
the XXX O
Canadian XXX O
PRRS XXX O
virus XXX O
, XXX O
PA-8 XXX O
. XXX O

All XXX O
lambs XXX O
with XXX O
B XXX O
breeding XXX O
had XXX O
significantly XXX O
higher XXX O
Hb XXX B-GENE
levels XXX O
at XXX O
the XXX O
end XXX O
of XXX O
the XXX O
experiment XXX O
than XXX O
did XXX O
NB XXX O
lambs XXX O
. XXX O
b XXX O
and XXX O
S XXX O
x XXX O
B XXX O
lambs XXX O
had XXX O
higher XXX O
( XXX O
P XXX O
< XXX O
. XXX O
05 XXX O
) XXX O
Hb XXX B-GENE
levels XXX O
than XXX O
the XXX O
D XXX O
x XXX O
B XXX O
lambs XXX O
, XXX O
and XXX O
B XXX O
lambs XXX O
had XXX O
the XXX O
highest XXX O
( XXX O
P XXX O
< XXX O
. XXX O
05 XXX O
) XXX O
mean XXX O
corpuscular XXX O
hemoglobin XXX B-GENE
concentrations XXX O
. XXX O

In XXX O
the XXX O
stable XXX O
transfectants XXX O
( XXX O
BM3 XXX O
cells XXX O
) XXX O
expressing XXX O
a XXX O
mutant XXX B-GENE
bacterial XXX I-GENE
P450 XXX I-GENE
AA XXX I-GENE
epoxygenase XXX I-GENE
, XXX O
F87V XXX O
BM3 XXX O
, XXX O
which XXX O
was XXX O
genetically XXX O
engineered XXX O
to XXX O
metabolize XXX O
arachidonic XXX O
acid XXX O
only XXX O
to XXX O
14 XXX O
, XXX O
15-EET XXX O
, XXX O
AA XXX O
did XXX O
not XXX O
induce XXX O
apoptosis XXX O
and XXX O
protected XXX O
against XXX O
agonist-induced XXX O
apoptosis XXX O
. XXX O

Pathol XXX O
. XXX O

In XXX O
sorted XXX O
bone XXX O
marrow XXX O
cells XXX O
expression XXX O
of XXX O
both XXX O
VpreB XXX B-GENE
genes XXX I-GENE
was XXX O
detected XXX O
in XXX O
pro-B XXX O
/ XXX O
pre-BI XXX O
and XXX O
large XXX O
pre-BII XXX O
cells XXX O
, XXX O
while XXX O
the XXX O
RNA XXX O
steady XXX O
state XXX O
levels XXX O
were XXX O
at XXX O
least XXX O
100-fold XXX O
lower XXX O
in XXX O
small XXX O
pre-BII XXX O
and XXX O
immature XXX O
/ XXX O
mature XXX O
B XXX O
cells XXX O
. XXX O

Clinical XXX O
evaluation XXX O
of XXX O
the XXX O
Allergan XXX O
Humphrey XXX O
500 XXX O
autorefractor XXX O
and XXX O
the XXX O
Nidek XXX O
AR-1000 XXX O
autorefractor XXX O
. XXX O

Fourteen XXX O
different XXX O
species XXX O
( XXX O
eight XXX O
Platyhelmintha XXX O
, XXX O
one XXX O
Nematoda XXX O
and XXX O
five XXX O
Crustacea XXX O
) XXX O
have XXX O
been XXX O
inventorized XXX O
. XXX O

In XXX O
the XXX O
same XXX O
period XXX O
we XXX O
pointed XXX O
out XXX O
an XXX O
increase XXX O
of XXX O
hematocrit XXX O
( XXX O
from XXX O
29% XXX O
to XXX O
35% XXX O
) XXX O
and XXX O
of XXX O
the XXX O
Hb XXX B-GENE
( XXX O
from XXX O
9 XXX O
. XXX O
3 XXX O
to XXX O
11 XXX O
. XXX O
2 XXX O
g XXX O
/ XXX O
dl XXX O
) XXX O
. XXX O

Rabbits XXX O
developed XXX O
profound XXX O
hypocalcemia XXX O
, XXX O
with XXX O
levels XXX O
falling XXX O
from XXX O
15 XXX O
. XXX O
5 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
2 XXX O
to XXX O
7 XXX O
. XXX O
6 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
4 XXX O
mg XXX O
/ XXX O
dl XXX O
under XXX O
the XXX O
influence XXX O
of XXX O
TSST-1 XXX O
. XXX O

Midge XXX O
control XXX O
in XXX O
flood XXX O
channels XXX O
. XXX O

Nuclear XXX B-GENE
factor XXX I-GENE
kappa XXX I-GENE
B XXX I-GENE
( XXX O
NF-kappaB XXX B-GENE
) XXX O
is XXX O
an XXX O
important XXX O
transcription XXX O
factor XXX O
for XXX O
the XXX O
genes XXX O
of XXX O
many XXX O
pro-inflammatory XXX O
proteins XXX O
and XXX O
is XXX O
strongly XXX O
activated XXX O
by XXX O
the XXX O
cytokines XXX O
interleukin-1 XXX B-GENE
and XXX O
tumor XXX B-GENE
necrosis XXX I-GENE
factor XXX I-GENE
( XXX I-GENE
TNF XXX I-GENE
) XXX I-GENE
alpha XXX I-GENE
under XXX O
various XXX O
pathological XXX O
conditions XXX O
. XXX O

Identification XXX O
of XXX O
pulmonary XXX O
vein XXX O
stenosis XXX O
after XXX O
radiofrequency XXX O
ablation XXX O
for XXX O
atrial XXX O
fibrillation XXX O
using XXX O
MRI XXX O
. XXX O

EMSA XXX O
with XXX O
crude XXX O
nuclear XXX O
extracts XXX O
demonstrated XXX O
that XXX O
stimulation XXX O
with XXX O
CD40L XXX B-GENE
results XXX O
in XXX O
the XXX O
induction XXX O
of XXX O
NF-kappaB XXX B-GENE
complexes XXX I-GENE
that XXX O
bind XXX O
to XXX O
each XXX O
of XXX O
the XXX O
three XXX O
NF-kappaB XXX B-GENE
sites XXX I-GENE
and XXX O
are XXX O
composed XXX O
mainly XXX O
of XXX O
p50 XXX B-GENE
and XXX O
RelB XXX B-GENE
, XXX O
but XXX O
also XXX O
include XXX O
c-Rel XXX B-GENE
and XXX O
p65 XXX B-GENE
. XXX O

Furthermore XXX O
, XXX O
heparin XXX B-GENE
lyase XXX I-GENE
treatment XXX O
of XXX O
extracts XXX O
of XXX O
cells XXX O
expressing XXX O
recombinant XXX B-GENE
YD-repeat XXX I-GENE
protein XXX I-GENE
releases XXX O
this XXX O
protein XXX O
from XXX O
high XXX O
molecular XXX O
mass XXX O
aggregates XXX O
. XXX O

Absorption XXX O
was XXX O
rapid XXX O
, XXX O
with XXX O
a XXX O
mean XXX O
time XXX O
to XXX O
peak XXX O
of XXX O
39 XXX O
min XXX O
. XXX O

Post-transcriptional XXX O
regulation XXX O
of XXX O
ribosomal XXX B-GENE
protein XXX I-GENE
gene XXX I-GENE
expression XXX O
during XXX O
development XXX O
in XXX O
Dictyostelium XXX O
discoideum XXX O
. XXX O

Myosin XXX B-GENE
light XXX I-GENE
chain XXX I-GENE
kinase XXX I-GENE
functions XXX O
downstream XXX O
of XXX O
Ras XXX B-GENE
/ XXX I-GENE
ERK XXX I-GENE
to XXX O
promote XXX O
migration XXX O
of XXX O
urokinase-type XXX O
plasminogen XXX O
activator-stimulated XXX O
cells XXX O
in XXX O
an XXX O
integrin-selective XXX O
manner XXX O
. XXX O

Thus XXX O
, XXX O
we XXX O
have XXX O
separated XXX O
the XXX O
signal XXX O
function XXX O
from XXX O
the XXX O
anchor XXX O
function XXX O
of XXX O
the XXX O
6 XXX O
. XXX O
7K XXX O
SA XXX O
domain XXX O
. XXX O

Studied XXX O
groups XXX O
were XXX O
( XXX O
1 XXX O
) XXX O
untreated XXX O
control XXX O
, XXX O
n XXX O
= XXX O
12 XXX O
; XXX O
( XXX O
2 XXX O
) XXX O
FK-1 XXX O
, XXX O
n XXX O
= XXX O
8 XXX O
; XXX O
( XXX O
3 XXX O
) XXX O
FK-3 XXX O
, XXX O
n XXX O
= XXX O
8 XXX O
. XXX O

Prevalence XXX O
of XXX O
sleep-disordered XXX O
breathing XXX O
( XXX O
SDB XXX O
) XXX O
is XXX O
reported XXX O
to XXX O
increase XXX O
in XXX O
menopausal XXX O
women XXX O
. XXX O

In XXX O
the XXX O
studies XXX O
described XXX O
in XXX O
this XXX O
report XXX O
, XXX O
we XXX O
have XXX O
investigated XXX O
the XXX O
signaling XXX O
pathway XXX O
( XXX O
s XXX O
) XXX O
that XXX O
are XXX O
responsible XXX O
for XXX O
CREB XXX B-GENE
activation XXX O
in XXX O
normal XXX O
T XXX O
cells XXX O
. XXX O

With XXX O
only XXX O
purified XXX O
T XXX B-GENE
antigen XXX I-GENE
in XXX O
the XXX O
presence XXX O
of XXX O
topoisomerase XXX B-GENE
I XXX I-GENE
to XXX O
unwind XXX O
purified XXX O
DNA XXX O
, XXX O
ori-auxiliary XXX O
sequences XXX O
strongly XXX O
facilitated XXX O
T-antigen-dependent XXX O
DNA XXX O
conformational XXX O
changes XXX O
consistent XXX O
with XXX O
melting XXX O
the XXX O
first XXX O
50 XXX O
base XXX O
pairs XXX O
. XXX O

CPDs XXX O
at XXX O
these XXX O
three XXX O
sites XXX O
may XXX O
partially XXX O
displace XXX O
TFIIIA XXX B-GENE
, XXX O
thereby XXX O
enabling XXX O
rapid XXX O
repair XXX O
. XXX O

This XXX O
interaction XXX O
occurs XXX O
over XXX O
a XXX O
wide XXX O
range XXX O
of XXX O
both XXX O
parameters XXX O
; XXX O
for XXX O
charge XXX O
density XXX O
from XXX O
at XXX O
least XXX O
10 XXX O
to XXX O
800 XXX O
microC XXX O
/ XXX O
cm2 XXX O
and XXX O
, XXX O
for XXX O
charge XXX O
per XXX O
phase XXX O
, XXX O
from XXX O
at XXX O
least XXX O
0 XXX O
. XXX O
05 XXX O
to XXX O
5 XXX O
. XXX O
0 XXX O
microC XXX O
per XXX O
phase XXX O
. XXX O

Inefficacy XXX O
of XXX O
phosphine XXX O
fumigation XXX O
against XXX O
ticks XXX O
. XXX O

Of XXX O
the XXX O
53 XXX O
units XXX O
tested XXX O
during XXX O
sinusoidal XXX O
motion XXX O
at XXX O
0 XXX O
. XXX O
05 XXX O
Hz XXX O
( XXX O
9 XXX O
. XXX O
1 XXX O
cm XXX O
/ XXX O
s XXX O
) XXX O
, XXX O
1 XXX O
( XXX O
1 XXX O
. XXX O
9% XXX O
) XXX O
was XXX O
responsive XXX O
to XXX O
the XXX O
otolith XXX O
input XXX O
only XXX O
, XXX O
13 XXX O
( XXX O
24 XXX O
. XXX O
5% XXX O
) XXX O
were XXX O
influenced XXX O
by XXX O
the XXX O
visual XXX O
input XXX O
only XXX O
and XXX O
23 XXX O
( XXX O
43 XXX O
. XXX O
4% XXX O
) XXX O
responded XXX O
to XXX O
both XXX O
modalities XXX O
. XXX O

In XXX O
Cd-spiked XXX O
OECD XXX O
soil XXX O
, XXX O
internal XXX O
Cd XXX O
levels XXX O
were XXX O
linearly XXX O
related XXX O
to XXX O
external XXX O
Cd XXX O
concentrations XXX O
, XXX O
whereas XXX O
the XXX O
springtails XXX O
maintained XXX O
fixed XXX O
internal XXX O
levels XXX O
of XXX O
Cu XXX O
and XXX O
Zn XXX O
regardless XXX O
of XXX O
spiked XXX O
concentrations XXX O
. XXX O

In XXX O
general XXX O
, XXX O
two XXX O
separate XXX O
high-performance XXX O
liquid XXX O
chromatographic XXX O
runs XXX O
were XXX O
performed XXX O
, XXX O
one XXX O
for XXX O
the XXX O
gamma-aminobutyric XXX O
acid XXX O
determination XXX O
and XXX O
one XXX O
for XXX O
the XXX O
determination XXX O
of XXX O
the XXX O
monoamines XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
26 XXX O
amino XXX O
acid XXX O
residues XXX O
, XXX O
K69 XXX O
, XXX O
D88 XXX O
, XXX O
E94 XXX O
, XXX O
D134 XXX O
, XXX O
R154 XXX O
, XXX O
K169 XXX O
, XXX O
H197 XXX O
, XXX O
D233 XXX O
, XXX O
G235 XXX O
, XXX O
G236 XXX O
, XXX O
G237 XXX O
, XXX O
F238 XXX O
, XXX O
E274 XXX O
, XXX O
G276 XXX O
, XXX O
R277 XXX O
, XXX O
Y278 XXX O
, XXX O
K294 XXX O
, XXX O
Y323 XXX O
, XXX O
Y331 XXX O
, XXX O
D332 XXX O
, XXX O
C360 XXX O
, XXX O
D361 XXX O
, XXX O
D364 XXX O
, XXX O
G387 XXX O
, XXX O
Y389 XXX O
, XXX O
and XXX O
F397 XXX O
( XXX O
mouse XXX O
ODC XXX B-GENE
numbering XXX O
) XXX O
, XXX O
all XXX O
of XXX O
which XXX O
are XXX O
implicated XXX O
in XXX O
the XXX O
formation XXX O
of XXX O
the XXX O
pyridoxal XXX O
phosphate-binding XXX O
domain XXX O
and XXX O
the XXX O
substrate-binding XXX O
domain XXX O
and XXX O
in XXX O
dimer XXX O
stabilization XXX O
with XXX O
the XXX O
eukaryotic XXX O
ODCs XXX B-GENE
, XXX O
were XXX O
also XXX O
conserved XXX O
in XXX O
S XXX O
. XXX O
ruminantium XXX O
LDC XXX B-GENE
. XXX O

Amikacin XXX O
was XXX O
the XXX O
most XXX O
stable XXX O
and XXX O
tobramycin XXX O
was XXX O
the XXX O
least XXX O
stable XXX O
aminoglycoside XXX O
under XXX O
the XXX O
conditions XXX O
tested XXX O
. XXX O

Sequence XXX O
analysis XXX O
indicates XXX O
that XXX O
RBP21 XXX B-GENE
shares XXX O
homology XXX O
with XXX O
other XXX O
retinoblastoma-binding XXX B-GENE
proteins XXX I-GENE
in XXX O
the XXX O
pRb-binding XXX O
motif XXX O
LxCxE XXX B-GENE
at XXX O
the XXX O
C-terminal XXX O
region XXX O
. XXX O

Rinit XXX O
reflects XXX O
the XXX O
Newtonian XXX O
resistances XXX O
and XXX O
Rdiff XXX O
represents XXX O
the XXX O
viscoelastic XXX O
/ XXX O
inhomogeneous XXX O
pressure XXX O
dissipations XXX O
in XXX O
the XXX O
system XXX O
. XXX O

The XXX O
role XXX O
of XXX O
intraoperative XXX O
echocardiography XXX O
in XXX O
surgery XXX O
of XXX O
the XXX O
heart XXX O
and XXX O
large XXX O
vessels XXX O
. XXX O

Recent XXX O
studies XXX O
have XXX O
suggested XXX O
that XXX O
Y319 XXX O
also XXX O
positively XXX O
regulate XXX O
ZAP-70 XXX B-GENE
function XXX O
. XXX O

As XXX O
the XXX O
length XXX O
of XXX O
the XXX O
fatty XXX O
acid XXX O
decreased XXX O
, XXX O
the XXX O
binding XXX O
affinity XXX O
was XXX O
reduced XXX O
; XXX O
myristic XXX O
acid XXX O
( XXX O
14 XXX O
: XXX O
0 XXX O
) XXX O
bound XXX O
with XXX O
a XXX O
K XXX O
( XXX O
d XXX O
) XXX O
of XXX O
1409 XXX O
+ XXX O
/ XXX O
- XXX O
423 XXX O
nM XXX O
, XXX O
but XXX O
medium-chain XXX O
( XXX O
decanoic XXX O
acid XXX O
, XXX O
10 XXX O
: XXX O
0 XXX O
) XXX O
and XXX O
short-chain XXX O
( XXX O
octanoic XXX O
acid XXX O
, XXX O
8 XXX O
: XXX O
0 XXX O
) XXX O
lipids XXX O
were XXX O
not XXX O
bound XXX O
at XXX O
all XXX O
. XXX O

The XXX O
sacT XXX B-GENE
gene XXX I-GENE
regulating XXX O
the XXX O
sacPA XXX B-GENE
operon XXX I-GENE
in XXX I-GENE
Bacillus XXX I-GENE
subtilis XXX I-GENE
shares XXX O
strong XXX O
homology XXX O
with XXX O
transcriptional XXX O
antiterminators XXX O
. XXX O

The XXX O
gene XXX O
encoding XXX O
the XXX O
receptor XXX O
for XXX O
macrophage XXX B-GENE
colony-stimulating XXX I-GENE
factor XXX I-GENE
1 XXX I-GENE
( XXX O
CSF-1 XXX B-GENE
) XXX O
, XXX O
the XXX O
c-fms XXX B-GENE
protooncogene XXX I-GENE
, XXX O
is XXX O
selectively XXX O
expressed XXX O
in XXX O
immature XXX O
and XXX O
mature XXX O
mononuclear XXX O
phagocytes XXX O
and XXX O
trophoblasts XXX O
. XXX O

They XXX O
are XXX O
subdivided XXX O
into XXX O
two XXX O
types XXX O
that XXX O
activate XXX O
transduction XXX O
pathways XXX O
via XXX O
different XXX O
cell XXX O
surface XXX O
receptors XXX O
. XXX O

Family XXX O
visits XXX O
and XXX O
involvement XXX O
in XXX O
treatment XXX O
of XXX O
patients XXX O
at XXX O
a XXX O
state XXX O
hospital XXX O
. XXX O

The XXX O
corticosterone XXX O
synthesis XXX O
inhibitor XXX O
metyrapone XXX O
( XXX O
75 XXX O
mg XXX O
/ XXX O
kg XXX O
i XXX O
. XXX O
p XXX O
. XXX O
) XXX O
was XXX O
given XXX O
to XXX O
attenuate XXX O
the XXX O
rise XXX O
of XXX O
corticosterone XXX O
to XXX O
a XXX O
level XXX O
typical XXX O
of XXX O
stressed XXX O
males XXX O
. XXX O

This XXX O
effect XXX O
and XXX O
the XXX O
fact XXX O
that XXX O
all XXX O
three XXX O
doses XXX O
were XXX O
toxic XXX O
to XXX O
the XXX O
dams XXX O
dictated XXX O
that XXX O
a XXX O
second XXX O
experiment XXX O
be XXX O
carried XXX O
out XXX O
at XXX O
lower XXX O
doses XXX O
. XXX O

Both XXX O
examinations XXX O
are XXX O
sensitive XXX O
indicators XXX O
of XXX O
CNS XXX O
abnormalities XXX O
associated XXX O
with XXX O
bacterial XXX O
meningeal XXX O
infections XXX O
and XXX O
are XXX O
important XXX O
determinants XXX O
of XXX O
the XXX O
therapy XXX O
and XXX O
ultimate XXX O
prognosis XXX O
of XXX O
such XXX O
complications XXX O
. XXX O

Some XXX O
of XXX O
them XXX O
produce XXX O
gigantic XXX O
sperm XXX O
several XXX O
times XXX O
the XXX O
total XXX O
male XXX O
body XXX O
length XXX O
. XXX O

A XXX O
cluster XXX O
of XXX O
basic XXX O
amino XXX O
acids XXX O
, XXX O
KKKR XXX B-GENE
, XXX O
generated XXX O
by XXX O
joining XXX O
of XXX O
the XXX O
sequences XXX O
encoded XXX O
by XXX O
the XXX O
constitutive XXX O
exon XXX O
13 XXX O
and XXX O
the XXX O
alternative XXX O
exon XXX O
16 XXX O
, XXX O
is XXX O
necessary XXX O
for XXX O
the XXX O
nuclear XXX O
targeting XXX O
of XXX O
4 XXX B-GENE
. XXX I-GENE
1H XXX I-GENE
, XXX O
as XXX O
demonstrated XXX O
by XXX O
site-directed XXX O
mutagenesis XXX O
analysis XXX O
. XXX O

Modulation XXX O
of XXX O
25-hydroxyvitamin XXX B-GENE
D3-24-hydroxylase XXX I-GENE
by XXX O
aminophylline XXX O
: XXX O
a XXX O
cytochrome XXX B-GENE
P-450 XXX I-GENE
monooxygenase XXX I-GENE
system XXX O
. XXX O

Plasma XXX O
ion XXX O
changes XXX O
in XXX O
venous XXX O
blood XXX O
incubated XXX O
with XXX O
beta XXX B-GENE
receptor XXX I-GENE
blockers XXX O
and XXX O
subjected XXX O
to XXX O
tonometry XXX O
in XXX O
vitro XXX O
. XXX O

Transcripts XXX O
characterized XXX O
include XXX O
( XXX O
i XXX O
) XXX O
abundant XXX O
monocistronic XXX O
L11e XXX B-GENE
and XXX O
tricistronic XXX O
L1e-L10e-L12e XXX B-GENE
transcripts XXX I-GENE
; XXX O
( XXX O
ii XXX O
) XXX O
less XXX O
abundant XXX O
bicistronic XXX O
NAB-L11e XXX B-GENE
and XXX O
monocistronic XXX O
NAB XXX B-GENE
transcripts XXX I-GENE
and XXX O
( XXX O
iii XXX O
) XXX O
a XXX O
very XXX O
rare XXX O
ORF XXX B-GENE
monocistronic XXX I-GENE
transcript XXX I-GENE
. XXX O

These XXX O
results XXX O
indicate XXX O
that XXX O
inhibition XXX O
of XXX O
Jun XXX B-GENE
kinase XXX I-GENE
activation XXX O
was XXX O
sufficient XXX O
to XXX O
inhibit XXX O
Ras XXX B-GENE
transformation XXX O
even XXX O
in XXX O
the XXX O
presence XXX O
of XXX O
activated XXX O
Erk-2 XXX B-GENE
. XXX O

Interaction XXX O
was XXX O
apparently XXX O
determined XXX O
by XXX O
the XXX O
N-terminal XXX O
splice XXX O
region XXX O
of XXX O
RPDE-6 XXX B-GENE
, XXX O
as XXX O
the XXX O
PDE4A XXX B-GENE
splice XXX O
variant XXX O
RPDE-39 XXX B-GENE
, XXX O
which XXX O
differs XXX O
from XXX O
RPDE-6 XXX B-GENE
at XXX O
the XXX O
extreme XXX O
N-terminus XXX O
, XXX O
failed XXX O
to XXX O
associate XXX O
with XXX O
v-Src-SH3 XXX B-GENE
; XXX O
met26RD1 XXX B-GENE
( XXX O
where XXX O
RD1 XXX B-GENE
is XXX O
rat XXX B-GENE
'dunc-like' XXX I-GENE
PDE XXX I-GENE
) XXX O
, XXX O
which XXX O
has XXX O
the XXX O
N-terminal XXX O
splice XXX O
region XXX O
deleted XXX O
, XXX O
failed XXX O
to XXX O
associate XXX O
with XXX O
v-Src-SH3 XXX B-GENE
, XXX O
and XXX O
the XXX O
association XXX O
of XXX O
RPDE-6 XXX B-GENE
and XXX O
v-Src-SH3 XXX B-GENE
was XXX O
blocked XXX O
by XXX O
a XXX O
fusion XXX O
protein XXX O
formed XXX O
from XXX O
the XXX O
N-terminal XXX O
splice XXX O
region XXX O
. XXX O

Plasma XXX O
was XXX O
tested XXX O
before XXX O
and XXX O
after XXX O
( XXX O
14 XXX O
+ XXX O
/ XXX O
- XXX O
7 XXX O
. XXX O
5 XXX O
[ XXX O
SD XXX O
] XXX O
days XXX O
) XXX O
surgery XXX O
for XXX O
IgG XXX B-GENE
antibodies XXX I-GENE
to XXX O
the XXX O
complex XXX O
of XXX O
heparin XXX B-GENE
/ XXX I-GENE
platelet XXX I-GENE
factor XXX I-GENE
4 XXX I-GENE
, XXX O
using XXX O
a XXX O
standardized XXX O
, XXX O
validated XXX O
enzyme-linked XXX O
immunosorbent XXX O
assay XXX O
( XXX O
ELISA XXX O
) XXX O
. XXX O

Necrosis XXX O
appears XXX O
6 XXX O
h XXX O
after XXX O
TA XXX O
infusion XXX O
, XXX O
being XXX O
5 XXX O
. XXX O
77% XXX O
in XXX O
extent XXX O
after XXX O
12 XXX O
h XXX O
, XXX O
14 XXX O
. XXX O
9% XXX O
after XXX O
24 XXX O
h XXX O
and XXX O
animals XXX O
die XXX O
with XXX O
an XXX O
area XXX O
of XXX O
29 XXX O
. XXX O
5% XXX O
necrosis XXX O
. XXX O

In XXX O
a XXX O
third XXX O
experiment XXX O
, XXX O
a XXX O
Chessmaster XXX O
gradually XXX O
increases XXX O
the XXX O
number XXX O
of XXX O
boards XXX O
he XXX O
can XXX O
reproduce XXX O
with XXX O
higher XXX O
than XXX O
70% XXX O
average XXX O
accuracy XXX O
to XXX O
nine XXX O
, XXX O
replacing XXX O
as XXX O
many XXX O
as XXX O
160 XXX O
pieces XXX O
correctly XXX O
. XXX O

In XXX O
Group XXX O
IV XXX O
dogs XXX O
that XXX O
received XXX O
alpha-MSH XXX B-GENE
only XXX O
during XXX O
reperfusion XXX O
, XXX O
BAEPs XXX O
were XXX O
increased XXX O
approximately XXX O
10 XXX O
to XXX O
14% XXX O
more XXX O
than XXX O
in XXX O
Group XXX O
II XXX O
during XXX O
the XXX O
late XXX O
reperfusion XXX O
period XXX O
. XXX O

For XXX O
smaller XXX O
vessels XXX O
up XXX O
to XXX O
a XXX O
diameter XXX O
of XXX O
0 XXX O
. XXX O
5 XXX O
mm XXX O
, XXX O
treatments XXX O
at XXX O
16 XXX O
and XXX O
18 XXX O
J XXX O
/ XXX O
cm2 XXX O
showed XXX O
good XXX O
results XXX O
in XXX O
60 XXX O
and XXX O
82% XXX O
respectively XXX O
; XXX O
for XXX O
vessels XXX O
up XXX O
to XXX O
1 XXX O
mm XXX O
in XXX O
27 XXX O
and XXX O
33% XXX O
. XXX O

Using XXX O
mutagenesis XXX O
, XXX O
we XXX O
have XXX O
identified XXX O
two XXX O
mutations XXX O
of XXX O
the XXX O
second XXX O
actin-binding XXX O
domain XXX O
that XXX O
can XXX O
also XXX O
suppress XXX O
the XXX O
act1 XXX B-GENE
mutations XXX O
of XXX O
interest XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
narZ XXX B-GENE
expression XXX O
was XXX O
induced XXX O
approximately XXX O
20-fold XXX O
intracellularly XXX O
in XXX O
Madin-Darby XXX O
canine XXX O
kidney XXX O
epithelial XXX O
cells XXX O
and XXX O
16-fold XXX O
in XXX O
intracellular XXX O
salts XXX O
medium XXX O
, XXX O
which XXX O
is XXX O
believed XXX O
to XXX O
mimic XXX O
the XXX O
intracellular XXX O
milieu XXX O
. XXX O

As XXX O
hGM-CSF XXX B-GENE
receptor XXX I-GENE
( XXX O
hGMR XXX B-GENE
) XXX O
does XXX O
not XXX O
contain XXX O
a XXX O
consensus XXX O
sequence XXX O
for XXX O
binding XXX O
of XXX O
PI XXX B-GENE
3-kinase XXX I-GENE
, XXX O
hGMR XXX B-GENE
must XXX O
use XXX O
a XXX O
distinct XXX O
mechanism XXX O
for XXX O
its XXX O
association XXX O
with XXX O
and XXX O
activation XXX O
of XXX O
PI XXX B-GENE
3-kinase XXX I-GENE
. XXX O

This XXX O
study XXX O
allows XXX O
us XXX O
to XXX O
draw XXX O
conclusions XXX O
about XXX O
the XXX O
identity XXX O
of XXX O
proteins XXX O
required XXX O
for XXX O
the XXX O
development XXX O
of XXX O
the XXX O
nervous XXX O
system XXX O
in XXX O
Drosophila XXX O
and XXX O
provides XXX O
an XXX O
example XXX O
of XXX O
a XXX O
molecular XXX O
approach XXX O
to XXX O
characterize XXX O
en XXX O
masse XXX O
transposon-tagged XXX O
mutations XXX O
identified XXX O
in XXX O
genetic XXX O
screens XXX O
. XXX O

Marker XXX O
rescue XXX O
analysis XXX O
has XXX O
localized XXX O
ts8 XXX B-GENE
to XXX O
a XXX O
910-bp XXX O
internal XXX O
segment XXX O
of XXX O
rpoB XXX B-GENE
that XXX O
encodes XXX O
the XXX O
Rif XXX B-GENE
domain XXX I-GENE
. XXX O

Pituitary XXX O
adenylate XXX B-GENE
cyclase-activating XXX I-GENE
polypeptide XXX I-GENE
regulates XXX O
prolactin XXX B-GENE
promoter XXX I-GENE
activity XXX O
via XXX O
a XXX O
protein XXX O
kinase XXX O
A-mediated XXX O
pathway XXX O
that XXX O
is XXX O
independent XXX O
of XXX O
the XXX O
transcriptional XXX O
pathway XXX O
employed XXX O
by XXX O
thyrotropin-releasing XXX B-GENE
hormone XXX I-GENE
. XXX O

A XXX O
full-length XXX O
cDNA XXX O
clone XXX O
isolated XXX O
from XXX O
a XXX O
rat XXX O
lung XXX O
library XXX O
was XXX O
predicted XXX O
to XXX O
encode XXX O
a XXX O
55-kDa XXX O
protein XXX O
containing XXX O
at XXX O
its XXX O
amino XXX O
terminus XXX O
a XXX O
targeting XXX O
domain XXX O
that XXX O
binds XXX O
to XXX O
the XXX O
ANP-receptor XXX B-GENE
kinase-like XXX I-GENE
domain XXX I-GENE
and XXX O
containing XXX O
at XXX O
its XXX O
carboxyl XXX O
terminus XXX O
a XXX O
putative XXX O
protein-serine XXX B-GENE
phosphatase XXX I-GENE
domain XXX O
. XXX O

It XXX O
has XXX O
been XXX O
shown XXX O
in XXX O
an XXX O
animal XXX O
experiment XXX O
that XXX O
alterations XXX O
of XXX O
the XXX O
renal XXX O
vasculature XXX O
and XXX O
parenchyma XXX O
after XXX O
hemostasis XXX O
performed XXX O
by XXX O
Infrared-Contact-Coagulation XXX O
are XXX O
best XXX O
shown XXX O
by XXX O
intravital XXX O
magnification XXX O
angiography XXX O
( XXX O
magnification XXX O
factor XXX O
2 XXX O
. XXX O
22 XXX O
) XXX O
. XXX O

Sensitization XXX O
to XXX O
hyperlactatemia XXX O
induced XXX O
by XXX O
phenformin XXX O
after XXX O
subtotal XXX O
ablation XXX O
of XXX O
the XXX O
pancreas XXX O
. XXX O

Partial XXX O
engorgement XXX O
was XXX O
higher XXX O
in XXX O
the XXX O
treatments XXX O
. XXX O

Nonlocal XXX O
approach XXX O
to XXX O
scattering XXX O
in XXX O
a XXX O
one-dimensional XXX O
problem XXX O
. XXX O

DAF XXX B-GENE
is XXX O
a XXX O
70 XXX O
kD XXX O
glycoprotein XXX O
containing XXX O
complement XXX O
regulatory XXX O
short XXX O
consensus XXX O
repeats XXX O
( XXX O
SCRs XXX O
) XXX O
; XXX O
its XXX O
gene XXX O
is XXX O
located XXX O
in XXX O
the XXX O
regulation XXX B-GENE
of XXX I-GENE
complement XXX I-GENE
activation XXX I-GENE
( XXX O
RCA XXX B-GENE
) XXX O
gene XXX O
cluster XXX O
on XXX O
chromosome XXX O
1 XXX O
and XXX O
is XXX O
about XXX O
40 XXX O
kb XXX O
in XXX O
size XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
the XXX O
calbindin-D28K XXX B-GENE
promoter XXX I-GENE
is XXX O
composed XXX O
of XXX O
a XXX O
variety XXX O
of XXX O
simple XXX O
repeated XXX O
sequences XXX O
, XXX O
some XXX O
of XXX O
which XXX O
are XXX O
components XXX O
of XXX O
putative XXX O
regulatory XXX O
signals XXX O
. XXX O

Chicken XXX B-GENE
sterol XXX I-GENE
carrier XXX I-GENE
protein XXX I-GENE
2 XXX I-GENE
/ XXX I-GENE
sterol XXX I-GENE
carrier XXX I-GENE
protein XXX I-GENE
x XXX I-GENE
: XXX O
cDNA XXX O
cloning XXX O
reveals XXX O
evolutionary XXX O
conservation XXX O
of XXX O
structure XXX O
and XXX O
regulated XXX O
expression XXX O
. XXX O

DR1 XXX B-GENE
molecules XXX I-GENE
purified XXX O
from XXX O
human XXX O
lymphoblastoid XXX O
cell XXX O
lines XXX O
could XXX O
specifically XXX O
bind XXX O
to XXX O
these XXX O
peptide XXX O
sequences XXX O
expressed XXX O
on XXX O
the XXX O
phage XXX O
surface XXX O
. XXX O

An XXX O
anchored XXX O
AFLP- XXX O
and XXX O
retrotransposon-based XXX O
map XXX O
of XXX O
diploid XXX O
Avena XXX O
. XXX O

Both XXX O
betaAPP XXX B-GENE
mRNA XXX I-GENE
and XXX O
Abeta XXX B-GENE
levels XXX O
are XXX O
increased XXX O
in XXX O
trisomy XXX O
21 XXX O
. XXX O

In XXX O
contrast XXX O
, XXX O
neither XXX O
I XXX O
. XXX O
argentina XXX O
nor XXX O
I XXX O
. XXX O
theezans XXX O
exerted XXX O
any XXX O
effect XXX O
on XXX O
BF XXX O
or XXX O
intestinal XXX O
propulsion XXX O
. XXX O

An XXX O
apparent XXX O
ufo XXX B-GENE
mRNA XXX I-GENE
overexpression XXX O
was XXX O
not XXX O
found XXX O
in XXX O
any XXX O
of XXX O
the XXX O
positive XXX O
leukemia XXX O
cell XXX O
lines XXX O
, XXX O
but XXX O
was XXX O
identified XXX O
in XXX O
the XXX O
drug-resistant XXX O
subclones XXX O
of XXX O
the XXX O
cervix XXX O
carcinoma XXX O
cell XXX O
line XXX O
HeLa XXX O
. XXX O

Recent XXX O
studies XXX O
have XXX O
demonstrated XXX O
that XXX O
Cbl XXX B-GENE
, XXX O
the XXX O
120-kDa XXX O
protein XXX O
product XXX O
of XXX O
the XXX O
c-cbl XXX B-GENE
proto-oncogene XXX I-GENE
, XXX O
serves XXX O
as XXX O
a XXX O
substrate XXX O
of XXX O
a XXX O
number XXX O
of XXX O
receptor-coupled XXX B-GENE
tyrosine XXX I-GENE
kinases XXX I-GENE
and XXX O
forms XXX O
complexes XXX O
with XXX O
SH3 XXX B-GENE
and XXX O
SH2 XXX B-GENE
domain-containing XXX O
proteins XXX O
, XXX O
pointing XXX O
to XXX O
its XXX O
role XXX O
in XXX O
signal XXX O
transduction XXX O
. XXX O

The XXX O
present XXX O
data XXX O
also XXX O
indicate XXX O
that XXX O
patients XXX O
with XXX O
TGBM XXX O
nephropathy XXX O
often XXX O
have XXX O
concomitant XXX O
IgA XXX B-GENE
nephropathy XXX O
and XXX O
mesangial XXX O
proliferative XXX O
glomerulonephritis XXX O
. XXX O

In XXX O
a XXX O
prospective XXX O
, XXX O
multicentre XXX O
trial XXX O
the XXX O
efficacy XXX O
of XXX O
an XXX O
Vitex XXX O
agnus XXX O
castus XXX O
L XXX O
extract XXX O
Ze XXX O
440 XXX O
was XXX O
investigated XXX O
in XXX O
50 XXX O
patients XXX O
with XXX O
pre-menstrual XXX O
syndrome XXX O
( XXX O
PMS XXX O
) XXX O
. XXX O

Among XXX O
known XXX O
flea XXX O
larvae XXX O
, XXX O
the XXX O
genus XXX O
Anomiopsyllus XXX O
( XXX O
Anomiopsyllinae XXX O
, XXX O
Anomiopsyllini XXX O
) XXX O
is XXX O
as XXX O
distinctive XXX O
in XXX O
larval XXX O
form XXX O
as XXX O
are XXX O
the XXX O
adults XXX O
. XXX O

Among XXX O
the XXX O
remaining XXX O
22 XXX O
sites XXX O
, XXX O
six XXX O
are XXX O
in XXX O
the XXX O
promoters XXX O
of XXX O
known XXX O
alpha-specific XXX O
genes XXX O
and XXX O
two XXX O
other XXX O
sites XXX O
have XXX O
an XXX O
alpha2-Mcm1-dependent XXX O
role XXX O
in XXX O
determining XXX O
the XXX O
direction XXX O
of XXX O
mating XXX O
type XXX O
switching XXX O
. XXX O

Acquired XXX O
factor XXX B-GENE
VIII XXX I-GENE
inhibitor XXX O
in XXX O
non-hemophilic XXX O
patients XXX O
. XXX O

Efferent XXX O
projections XXX O
of XXX O
the XXX O
ventral XXX O
portion XXX O
of XXX O
the XXX O
putamen XXX O
to XXX O
the XXX O
frontal XXX O
, XXX O
parietal XXX O
and XXX O
temporal XXX O
regions XXX O
of XXX O
the XXX O
cat XXX O
cerebral XXX O
cortex XXX O
. XXX O

A XXX O
high XXX O
mean XXX O
intensity XXX O
of XXX O
CLTPA XXX O
( XXX O
standardized XXX O
multivariate XXX O
regression XXX O
coefficient XXX O
beta XXX O
-0 XXX O
. XXX O
059 XXX O
, XXX O
p XXX O
= XXX O
0 XXX O
. XXX O
020 XXX O
) XXX O
and XXX O
a XXX O
high XXX O
maximal XXX O
oxygen XXX O
uptake XXX O
( XXX O
beta XXX O
-0 XXX O
. XXX O
163 XXX O
, XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
001 XXX O
) XXX O
were XXX O
associated XXX O
with XXX O
reduced XXX O
plasma XXX B-GENE
fibrinogen XXX I-GENE
when XXX O
adjusting XXX O
for XXX O
the XXX O
strongest XXX O
covariates XXX O
. XXX O

Demyelinating XXX O
diseases XXX O
involving XXX O
the XXX O
grey XXX O
matter XXX O
were XXX O
very XXX O
rare XXX O
, XXX O
but XXX O
we XXX O
must XXX O
consider XXX O
the XXX O
presence XXX O
of XXX O
symmetrical XXX O
thalamic XXX O
involvement XXX O
in XXX O
patients XXX O
with XXX O
ADEM XXX O
. XXX O

One XXX O
hundred XXX O
units XXX O
/ XXX O
kg XXX O
of XXX O
recombinant XXX B-GENE
human XXX I-GENE
erythropoietin XXX I-GENE
( XXX O
rhEPO XXX B-GENE
) XXX O
was XXX O
given XXX O
subcutaneously XXX O
3 XXX O
times XXX O
a XXX O
week XXX O
for XXX O
3 XXX O
weeks XXX O
. XXX O

Mild XXX O
orbital XXX O
discomfort XXX O
occurred XXX O
in XXX O
some XXX O
patients XXX O
. XXX O

This XXX O
growth XXX O
arrest XXX O
is XXX O
partly XXX O
suppressed XXX O
on XXX O
minimal XXX O
medium XXX O
or XXX O
under XXX O
conditions XXX O
in XXX O
which XXX O
the XXX O
cells XXX O
are XXX O
less XXX O
dependent XXX O
on XXX O
mitochondrial XXX O
metabolism XXX O
. XXX O

Removal XXX O
of XXX O
each XXX O
of XXX O
three XXX O
contiguous XXX O
segments XXX O
from XXX O
the XXX O
N-terminal XXX O
half XXX O
specifically XXX O
inhibits XXX O
the XXX O
formation XXX O
of XXX O
5 XXX B-GENE
. XXX I-GENE
8Ss XXX I-GENE
rRNA XXX I-GENE
, XXX O
whereas XXX O
deleting XXX O
part XXX O
of XXX O
the XXX O
C-terminal XXX O
region XXX O
of XXX O
the XXX O
protein XXX O
only XXX O
blocks XXX O
the XXX O
production XXX O
of XXX O
18S XXX B-GENE
rRNA XXX I-GENE
. XXX O

This XXX O
report XXX O
expands XXX O
on XXX O
previous XXX O
work XXX O
with XXX O
interferon XXX B-GENE
alfa-2b XXX I-GENE
( XXX I-GENE
Intron XXX I-GENE
A XXX I-GENE
; XXX I-GENE
Schering-Plough XXX I-GENE
) XXX I-GENE
in XXX O
the XXX O
treatment XXX O
of XXX O
hairy XXX O
cell XXX O
leukemia XXX O
( XXX O
HCL XXX O
) XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
a XXX O
microsatellite XXX O
repeat XXX O
polymorphism XXX O
with XXX O
a XXX O
heterozygosity XXX O
of XXX O
71% XXX O
at XXX O
the XXX O
RET XXX B-GENE
locus XXX I-GENE
and XXX O
a XXX O
restriction XXX O
fragment XXX O
length XXX O
polymorphism XXX O
with XXX O
a XXX O
heterozygosity XXX O
of XXX O
42% XXX O
detected XXX O
by XXX O
a XXX O
lambda XXX O
clone XXX O
from XXX O
the XXX O
D10S94 XXX B-GENE
locus XXX I-GENE
have XXX O
been XXX O
developed XXX O
for XXX O
high-resolution XXX O
genetic XXX O
linkage XXX O
mapping XXX O
and XXX O
predictive XXX O
diagnostic XXX O
testing XXX O
. XXX O

We XXX O
isolated XXX O
a XXX O
complementary XXX O
DNA XXX O
( XXX O
cDNA XXX O
) XXX O
clone XXX O
from XXX O
an XXX O
RL95-2 XXX O
expression XXX O
library XXX O
that XXX O
encodes XXX O
the XXX O
C1 XXX B-GENE
site-binding XXX I-GENE
protein XXX I-GENE
. XXX O

The XXX O
upTRE XXX B-GENE
binds XXX O
more XXX O
T3R XXX B-GENE
homodimers XXX I-GENE
and XXX O
less XXX O
T3R-RXR XXX B-GENE
heterodimers XXX I-GENE
than XXX O
the XXX O
dnTRE XXX B-GENE
, XXX O
and XXX O
T3 XXX B-GENE
more XXX O
readily XXX O
facilitates XXX O
heterodimer XXX O
binding XXX O
to XXX O
the XXX O
dn- XXX O
than XXX O
to XXX O
the XXX O
upTRE XXX B-GENE
. XXX O

Analysis XXX O
of XXX O
glucocorticoid XXX O
unresponsive XXX O
cell XXX O
variants XXX O
using XXX O
a XXX O
mouse XXX B-GENE
glucocorticoid XXX I-GENE
receptor XXX I-GENE
complementary XXX O
DNA XXX O
clone XXX O
. XXX O

Moreover XXX O
, XXX O
PTax XXX B-GENE
expressed XXX O
higher XXX O
background XXX O
activities XXX O
than XXX O
PTF XXX B-GENE
, XXX O
indicating XXX O
that XXX O
the XXX O
sequence XXX O
of XXX O
the XXX O
synthetic XXX O
regulatory XXX O
region XXX O
can XXX O
influence XXX O
background XXX O
levels XXX O
. XXX O

When XXX O
the XXX O
high XXX O
affinity XXX O
hnRNP XXX B-GENE
A1 XXX I-GENE
binding XXX I-GENE
site XXX I-GENE
was XXX O
inserted XXX O
into XXX O
the XXX O
beta-globin XXX B-GENE
reporter XXX I-GENE
, XXX O
Rev XXX B-GENE
was XXX O
able XXX O
to XXX O
increase XXX O
the XXX O
cytoplasmic XXX O
levels XXX O
of XXX O
unspliced XXX O
mRNAs XXX O
to XXX O
14% XXX O
. XXX O

Since XXX O
the XXX O
stability XXX O
of XXX O
TF1 XXX B-GENE
resides XXX O
in XXX O
its XXX O
primary XXX O
structure XXX O
, XXX O
we XXX O
cloned XXX O
a XXX O
gene XXX O
coding XXX O
for XXX O
TF1 XXX B-GENE
, XXX O
and XXX O
the XXX O
primary XXX O
structure XXX O
of XXX O
the XXX O
beta XXX O
subunit XXX O
was XXX O
deduced XXX O
from XXX O
the XXX O
nucleotide XXX O
sequence XXX O
of XXX O
the XXX O
gene XXX O
to XXX O
compare XXX O
the XXX O
sequence XXX O
with XXX O
those XXX O
of XXX O
beta's XXX O
of XXX O
three XXX O
major XXX O
categories XXX O
of XXX O
F1's XXX O
; XXX O
prokaryotic XXX O
membranes XXX O
, XXX O
chloroplasts XXX O
, XXX O
and XXX O
mitochondria XXX O
. XXX O

Intact XXX O
Flag-tagged XXX O
protein XXX O
products XXX O
from XXX O
all XXX O
six XXX O
were XXX O
produced XXX O
from XXX O
genomic XXX O
expression XXX O
vectors XXX O
, XXX O
although XXX O
the XXX O
ORF40 XXX B-GENE
/ XXX I-GENE
41 XXX I-GENE
transcript XXX I-GENE
encoding XXX O
a XXX O
primase-helicase XXX B-GENE
component XXX I-GENE
proved XXX O
to XXX O
be XXX O
spliced XXX O
with XXX O
a XXX O
127-bp XXX O
intron XXX O
. XXX O

With XXX O
both XXX O
wild-type XXX O
and XXX O
the XXX O
mutant XXX O
enzymes XXX O
, XXX O
ATP XXX O
activates XXX O
both XXX O
[ XXX O
14C XXX O
] XXX O
Asp XXX O
in XXX O
equilibrium XXX O
N-carbamyl-L-aspartate XXX O
( XXX O
C-Asp XXX O
) XXX O
and XXX O
the XXX O
[ XXX O
32P XXX O
] XXX O
carbamyl XXX O
phosphate XXX O
( XXX O
C-P XXX O
) XXX O
in XXX O
equilibrium XXX O
Pi XXX O
exchanges XXX O
. XXX O

The XXX O
effect XXX O
of XXX O
water XXX O
deprivation XXX O
for XXX O
19 XXX O
h XXX O
on XXX O
renal XXX O
Na XXX O
excretion XXX O
of XXX O
conscious XXX O
adrenalectomized XXX O
( XXX O
ADX XXX O
) XXX O
sheep XXX O
maintained XXX O
on XXX O
a XXX O
constant XXX O
intravenous XXX O
infusion XXX O
of XXX O
aldosterone XXX O
and XXX O
cortisol XXX O
( XXX O
ADX-constant XXX O
steroid XXX O
sheep XXX O
) XXX O
was XXX O
investigated XXX O
. XXX O

As XXX O
in XXX O
the XXX O
other XXX O
three XXX O
members XXX O
whose XXX O
gene XXX O
expression XXX O
is XXX O
altered XXX O
during XXX O
tumorigenesis XXX O
, XXX O
PI12 XXX B-GENE
expression XXX O
was XXX O
found XXX O
to XXX O
be XXX O
down-regulated XXX O
in XXX O
tumor XXX O
brain XXX O
tissues XXX O
and XXX O
in XXX O
two XXX O
brain XXX O
cancer XXX O
cell XXX O
lines XXX O
: XXX O
U-87 XXX O
MG XXX O
and XXX O
H4 XXX O
. XXX O

It XXX O
is XXX O
suggested XXX O
that XXX O
these XXX O
results XXX O
may XXX O
raise XXX O
the XXX O
interesting XXX O
possibility XXX O
of XXX O
providing XXX O
a XXX O
means XXX O
of XXX O
identifying XXX O
greater XXX O
or XXX O
lesser XXX O
susceptibility XXX O
to XXX O
the XXX O
coronary XXX O
effects XXX O
of XXX O
Type XXX O
A XXX O
behavior XXX O
. XXX O

Similarly XXX O
, XXX O
actuarial XXX O
interpretations XXX O
for XXX O
the XXX O
second XXX O
protocols XXX O
were XXX O
not XXX O
more XXX O
frequently XXX O
selected XXX O
by XXX O
therapists XXX O
as XXX O
more XXX O
valid XXX O
, XXX O
regardless XXX O
of XXX O
treatment XXX O
condition XXX O
and XXX O
elevation XXX O
of XXX O
the XXX O
F XXX O
and XXX O
F-K XXX O
indices XXX O
on XXX O
the XXX O
first XXX O
MMPI XXX O
profile XXX O
. XXX O

All XXX O
patients XXX O
received XXX O
VCR XXX O
1 XXX O
. XXX O
0 XXX O
mg XXX O
/ XXX O
m2 XXX O
weekly XXX O
for XXX O
6 XXX O
weeks XXX O
with XXX O
dose XXX O
modification XXX O
for XXX O
neurotoxicity XXX O
. XXX O

In XXX O
patients XXX O
who XXX O
respond XXX O
to XXX O
quetiapine XXX O
, XXX O
therapy XXX O
should XXX O
be XXX O
continued XXX O
at XXX O
the XXX O
optimal XXX O
dose XXX O
that XXX O
maintains XXX O
remission XXX O
, XXX O
within XXX O
the XXX O
range XXX O
of XXX O
150 XXX O
to XXX O
750 XXX O
mg XXX O
/ XXX O
d XXX O
. XXX O

The XXX O
construction XXX O
of XXX O
a XXX O
small XXX O
library XXX O
of XXX O
mouse XXX O
repetitive XXX O
DNA XXX O
has XXX O
been XXX O
previously XXX O
reported XXX O
( XXX O
Pietras XXX O
et XXX O
al XXX O
. XXX O
, XXX O
Nucleic XXX O
Acids XXX O
Res XXX O
. XXX O

This XXX O
suggests XXX O
that XXX O
the XXX O
DcuS-DcuR XXX B-GENE
system XXX I-GENE
responds XXX O
to XXX O
external XXX O
substrates XXX O
. XXX O

The XXX O
weak XXX O
relationships XXX O
between XXX O
F XXX O
and XXX O
Zn XXX O
to XXX O
Mg XXX O
clearly XXX O
have XXX O
no XXX O
significant XXX O
effect XXX O
on XXX O
the XXX O
contents XXX O
of XXX O
these XXX O
elements XXX O
in XXX O
bone XXX O
. XXX O

Deletion XXX O
analysis XXX O
showed XXX O
that XXX O
the XXX O
NF-4FA XXX B-GENE
, XXX O
NF-4FB XXX B-GENE
, XXX O
and XXX O
AP-1 XXX B-GENE
sequences XXX O
are XXX O
each XXX O
necessary XXX O
for XXX O
full XXX O
enhancer XXX O
activity XXX O
. XXX O

Serial XXX O
US XXX O
images XXX O
were XXX O
obtained XXX O
before XXX O
and XXX O
20 XXX O
, XXX O
30 XXX O
, XXX O
40 XXX O
, XXX O
50 XXX O
, XXX O
60 XXX O
, XXX O
90 XXX O
, XXX O
120 XXX O
, XXX O
150 XXX O
, XXX O
180 XXX O
, XXX O
240 XXX O
, XXX O
and XXX O
300 XXX O
s XXX O
after XXX O
intravenous XXX O
injection XXX O
of XXX O
2 XXX O
g XXX O
of XXX O
contrast XXX O
agent XXX O
using XXX O
conventional XXX O
and XXX O
harmonic XXX O
PD XXX O
US XXX O
. XXX O

The XXX O
catalytic XXX O
site XXX O
has XXX O
an XXX O
S1 XXX B-GENE
pocket XXX I-GENE
lined XXX O
with XXX O
conserved XXX O
hydrophobic XXX O
residues XXX O
to XXX O
accommodate XXX O
the XXX O
pyroglutamyl XXX O
residue XXX O
. XXX O

Coexpression XXX O
studies XXX O
indicate XXX O
that XXX O
insulin XXX B-GENE
and XXX O
PKB XXX B-GENE
suppress XXX O
transactivation XXX O
by XXX O
C XXX B-GENE
/ XXX I-GENE
EBPbeta XXX I-GENE
, XXX O
but XXX O
not XXX O
C XXX B-GENE
/ XXX I-GENE
EBPalpha XXX I-GENE
, XXX O
and XXX O
that XXX O
N-terminal XXX O
transactivation XXX O
domains XXX O
in XXX O
C XXX B-GENE
/ XXX I-GENE
EBPbeta XXX I-GENE
are XXX O
required XXX O
. XXX O

Thus XXX O
, XXX O
MKK7 XXX B-GENE
is XXX O
an XXX O
essential XXX O
and XXX O
specific XXX O
regulator XXX O
of XXX O
stress-induced XXX O
SAPK XXX B-GENE
/ XXX I-GENE
JNK XXX I-GENE
activation XXX O
in XXX O
mast XXX O
cells XXX O
and XXX O
MKK7 XXX B-GENE
negatively XXX O
regulates XXX O
growth XXX B-GENE
factor XXX I-GENE
and XXX O
antigen XXX O
receptor-driven XXX O
proliferation XXX O
in XXX O
hematopoietic XXX O
cells XXX O
. XXX O

Glucose XXX O
disappearance XXX O
rate XXX O
and XXX O
changes XXX O
in XXX O
plasma XXX O
nutrients XXX O
after XXX O
intravenouly XXX O
injected XXX O
glucose XXX O
in XXX O
normoglycaemic XXX O
and XXX O
hypoglycaemic XXX O
underweight XXX O
newborns XXX O
. XXX O

Albumin XXX B-GENE
dialysis XXX O
: XXX O
effective XXX O
removal XXX O
of XXX O
copper XXX O
in XXX O
a XXX O
patient XXX O
with XXX O
fulminant XXX O
Wilson XXX O
disease XXX O
and XXX O
successful XXX O
bridging XXX O
to XXX O
liver XXX O
transplantation XXX O
: XXX O
a XXX O
new XXX O
possibility XXX O
for XXX O
the XXX O
elimination XXX O
of XXX O
protein-bound XXX O
toxins XXX O
. XXX O

We XXX O
have XXX O
shown XXX O
previously XXX O
that XXX O
GH3 XXX O
cells XXX O
transfected XXX O
with XXX O
the XXX O
rat XXX B-GENE
GnRH XXX I-GENE
receptor XXX I-GENE
cDNA XXX I-GENE
( XXX O
GGH3-1' XXX O
cells XXX O
) XXX O
support XXX O
the XXX O
expression XXX O
of XXX O
a XXX O
cotransfected XXX O
fusion XXX O
gene XXX O
composed XXX O
of XXX O
797 XXX O
base XXX O
pairs XXX O
of XXX O
rat XXX B-GENE
LHbeta XXX I-GENE
gene XXX I-GENE
5'-flanking XXX I-GENE
sequence XXX I-GENE
and XXX O
the XXX O
first XXX O
5 XXX O
base XXX O
pairs XXX O
of XXX O
the XXX O
5'-untranslated XXX O
region XXX O
fused XXX O
to XXX O
a XXX O
luciferase XXX B-GENE
reporter XXX I-GENE
( XXX I-GENE
-797 XXX I-GENE
/ XXX I-GENE
+5LHbetaLUC XXX I-GENE
) XXX I-GENE
and XXX O
respond XXX O
to XXX O
a XXX O
GnRH XXX B-GENE
agonist XXX O
with XXX O
a XXX O
10-fold XXX O
stimulation XXX O
of XXX O
activity XXX O
. XXX O

However XXX O
, XXX O
a XXX O
surprisingly XXX O
high XXX O
degree XXX O
of XXX O
conservation XXX O
of XXX O
intron XXX O
sequences XXX O
was XXX O
observed XXX O
between XXX O
both XXX O
species XXX O
. XXX O

Here XXX O
we XXX O
describe XXX O
the XXX O
optimization XXX O
and XXX O
characterization XXX O
of XXX O
a XXX O
140-residue XXX O
fragment XXX O
, XXX O
containing XXX O
the XXX O
Runt XXX B-GENE
domain XXX I-GENE
of XXX O
AML1 XXX B-GENE
, XXX O
which XXX O
is XXX O
suitable XXX O
for XXX O
structural XXX O
studies XXX O
. XXX O

We XXX O
present XXX O
evidence XXX O
that XXX O
DNA XXX B-GENE
polymerase XXX I-GENE
delta XXX I-GENE
of XXX I-GENE
Saccharomyces XXX I-GENE
cerevisiae XXX I-GENE
, XXX O
an XXX O
enzyme XXX O
that XXX O
is XXX O
essential XXX O
for XXX O
viability XXX O
and XXX O
chromosomal XXX O
replication XXX O
, XXX O
is XXX O
also XXX O
required XXX O
for XXX O
base XXX O
excision XXX O
repair XXX O
of XXX O
exogenous XXX O
DNA XXX O
methylation XXX O
damage XXX O
. XXX O

The XXX O
behavior XXX O
of XXX O
suf12-null XXX B-GENE
/ XXX I-GENE
SUF12+ XXX I-GENE
heterozygotes XXX I-GENE
indicates XXX O
that XXX O
suf12 XXX B-GENE
is XXX O
co-dominantly XXX O
expressed XXX O
and XXX O
suggests XXX O
that XXX O
suf12 XXX B-GENE
allele-specific XXX O
suppression XXX O
may XXX O
result XXX O
from XXX O
functionally XXX O
distinct XXX O
mutant XXX O
proteins XXX O
rather XXX O
than XXX O
variation XXX O
in XXX O
residual XXX O
wild-type XXX B-GENE
SUF12+ XXX I-GENE
activity XXX O
. XXX O

The XXX O
4 XXX O
patients XXX O
with XXX O
carboxyhemoglobin XXX O
levels XXX O
in XXX O
excess XXX O
of XXX O
10% XXX O
may XXX O
represent XXX O
occult XXX O
carbon XXX O
monoxide XXX O
poisoning XXX O
in XXX O
this XXX O
population XXX O
. XXX O

The XXX O
7-kb XXX O
mRNA XXX O
differs XXX O
by XXX O
alternative XXX O
splicing XXX O
such XXX O
that XXX O
it XXX O
encodes XXX O
a XXX O
protein XXX O
with XXX O
a XXX O
distinct XXX O
amino XXX O
terminus XXX O
. XXX O

Risks XXX O
of XXX O
chronicity XXX O
following XXX O
acute XXX O
hepatitis XXX O
B XXX O
virus XXX O
infection XXX O
: XXX O
a XXX O
review XXX O
. XXX O

Folate XXX O
metabolism XXX O
in XXX O
the XXX O
human XXX O
malaria XXX O
parasite XXX O
Plasmodium XXX O
falciparum XXX O
is XXX O
an XXX O
essential XXX O
activity XXX O
for XXX O
cell XXX O
growth XXX O
and XXX O
replication XXX O
, XXX O
and XXX O
the XXX O
target XXX O
of XXX O
an XXX O
important XXX O
class XXX O
of XXX O
therapeutic XXX O
agents XXX O
in XXX O
widespread XXX O
use XXX O
. XXX O

The XXX O
decay XXX O
curves XXX O
of XXX O
chlorophyll XXX O
fluorescence XXX O
showed XXX O
a XXX O
superposition XXX O
of XXX O
three XXX O
exponentially XXX O
decaying XXX O
components XXX O
with XXX O
time XXX O
constants XXX O
of XXX O
T1 XXX O
= XXX O
100-200 XXX O
ps XXX O
, XXX O
T2 XXX O
= XXX O
300-500 XXX O
ps XXX O
and XXX O
T3 XXX O
= XXX O
2 XXX O
. XXX O
0-3 XXX O
. XXX O
5 XXX O
ns XXX O
. XXX O

IV XXX O
. XXX O
combined XXX O
sclerosis XXX O
and XXX O
resorption XXX O
of XXX O
the XXX O
skull XXX O
base XXX O
( XXX O
6 XXX O
cases XXX O
, XXX O
2 XXX O
group XXX O
I XXX O
lesions XXX O
and XXX O
4 XXX O
group XXX O
II XXX O
lesions XXX O
) XXX O
. XXX O

Tyrosine XXX O
phosphorylation XXX O
of XXX O
cellular XXX O
proteins XXX O
is XXX O
the XXX O
earliest XXX O
identifiable XXX O
event XXX O
following XXX O
T-cell XXX B-GENE
antigen XXX I-GENE
receptor XXX I-GENE
( XXX O
TCR XXX B-GENE
) XXX O
stimulation XXX O
and XXX O
is XXX O
essential XXX O
for XXX O
activating XXX O
downstream XXX O
signaling XXX O
machinery XXX O
. XXX O

Generally XXX O
, XXX O
a XXX O
correlation XXX O
was XXX O
observed XXX O
between XXX O
highest XXX O
concentrations XXX O
of XXX O
CSF XXX O
immunoglobulins XXX O
and XXX O
degree XXX O
of XXX O
meningeal XXX O
inflammatory XXX O
response XXX O
, XXX O
even XXX O
if XXX O
this XXX O
was XXX O
a XXX O
component XXX O
of XXX O
other XXX O
neurological XXX O
diseases XXX O
. XXX O

High-affinity XXX O
binding XXX O
of XXX O
NF-1 XXX B-GENE
to XXX O
PSE-B XXX B-GENE
, XXX O
but XXX O
not XXX O
to XXX O
PSE-A XXX B-GENE
, XXX O
was XXX O
confirmed XXX O
by XXX O
competition XXX O
of XXX O
DNA-protein XXX O
interactions XXX O
by XXX O
using XXX O
NF-1 XXX B-GENE
DNA XXX O
elements XXX O
and XXX O
antibodies XXX O
. XXX O

METHODS XXX O
: XXX O
TBN XXX O
measurements XXX O
were XXX O
performed XXX O
in XXX O
31 XXX O
female XXX O
outpatients XXX O
with XXX O
breast XXX O
carcinoma XXX O
who XXX O
were XXX O
undergoing XXX O
standard XXX O
cyclophosphamide XXX O
, XXX O
methotrexate XXX O
, XXX O
and XXX O
5-fluorouracil XXX O
( XXX O
CMF XXX O
) XXX O
-based XXX O
chemotherapy XXX O
( XXX O
median XXX O
age XXX O
, XXX O
48 XXX O
years XXX O
; XXX O
range XXX O
, XXX O
26- XXX O
77 XXX O
years XXX O
) XXX O
. XXX O

While XXX O
daily XXX O
food XXX O
intake XXX O
was XXX O
almost XXX O
constant XXX O
regardless XXX O
of XXX O
the XXX O
dietary XXX O
protein XXX O
level XXX O
, XXX O
water XXX O
intake XXX O
and XXX O
urine XXX O
volume XXX O
increased XXX O
with XXX O
increasing XXX O
the XXX O
dietary XXX O
protein XXX O
. XXX O

This XXX O
short XXX O
communication XXX O
compares XXX O
a XXX O
novel XXX O
fluorimetric XXX O
microplate XXX O
enzyme XXX O
immunoassay XXX O
( XXX O
FEIA XXX O
) XXX O
with XXX O
a XXX O
commercial XXX O
time-resolved XXX O
fluoroimmunoassay XXX O
for XXX O
the XXX O
determination XXX O
of XXX O
thyrotropin XXX B-GENE
in XXX O
dried XXX O
blood XXX O
spots XXX O
. XXX O

None XXX O
of XXX O
the XXX O
cystometrograms XXX O
showed XXX O
uninhibited XXX O
detrusor XXX O
contractions XXX O
. XXX O

CXC XXX B-GENE
chemokines XXX I-GENE
bind XXX O
to XXX O
unique XXX O
sets XXX O
of XXX O
selectivity XXX O
determinants XXX O
that XXX O
can XXX O
function XXX O
independently XXX O
and XXX O
are XXX O
broadly XXX O
distributed XXX O
on XXX O
multiple XXX O
domains XXX O
of XXX O
human XXX O
interleukin-8 XXX B-GENE
receptor XXX I-GENE
B XXX I-GENE
. XXX O

An XXX O
explanation XXX O
explored XXX O
for XXX O
this XXX O
lack XXX O
of XXX O
gene XXX O
expression XXX O
was XXX O
that XXX O
increased XXX O
levels XXX O
of XXX O
RAR XXX B-GENE
alpha XXX I-GENE
or XXX O
PML XXX B-GENE
might XXX O
suppress XXX O
APL XXX O
cell XXX O
growth XXX O
. XXX O

Transcription XXX O
initiation XXX O
occurred XXX O
predominantly XXX O
at XXX O
the XXX O
putative XXX O
sigmaA-dependent XXX B-GENE
promoter XXX I-GENE
in XXX O
exponentially XXX O
growing XXX O
cells XXX O
and XXX O
was XXX O
induced XXX O
under XXX O
stress XXX O
conditions XXX O
. XXX O

This XXX O
study XXX O
indicates XXX O
that XXX O
the XXX O
phenotype XXX O
of XXX O
myofibrillar XXX O
disarray XXX O
seen XXX O
in XXX O
HCM XXX O
patients XXX O
which XXX O
harbor XXX O
either XXX O
of XXX O
these XXX O
two XXX O
mutations XXX O
may XXX O
not XXX O
be XXX O
directly XXX O
due XXX O
to XXX O
the XXX O
failure XXX O
of XXX O
the XXX O
mutant XXX B-GENE
myosin XXX I-GENE
heavy XXX I-GENE
chain XXX I-GENE
protein XXX I-GENE
to XXX O
assemble XXX O
and XXX O
form XXX O
normal XXX O
sarcomeres XXX O
, XXX O
but XXX O
may XXX O
rather XXX O
be XXX O
a XXX O
secondary XXX O
effect XXX O
possibly XXX O
resulting XXX O
from XXX O
the XXX O
chronic XXX O
stress XXX O
of XXX O
decreased XXX O
beta XXX B-GENE
MHC XXX I-GENE
function XXX O
. XXX O

The XXX O
RFX XXX B-GENE
protein XXX I-GENE
family XXX I-GENE
includes XXX O
members XXX O
from XXX O
yeast XXX O
to XXX O
humans XXX O
, XXX O
which XXX O
function XXX O
in XXX O
various XXX O
biological XXX O
systems XXX O
, XXX O
and XXX O
share XXX O
a XXX O
DNA-binding XXX O
domain XXX O
and XXX O
a XXX O
conserved XXX O
C-terminal XXX O
region XXX O
. XXX O

In XXX O
this XXX O
article XXX O
we XXX O
propose XXX O
to XXX O
find XXX O
out XXX O
the XXX O
percentage XXX O
of XXX O
normal XXX O
occlusion XXX O
and XXX O
the XXX O
distribution XXX O
of XXX O
maloclusions XXX O
, XXX O
according XXX O
to XXX O
the XXX O
anteroposterior XXX O
relationship XXX O
between XXX O
the XXX O
dental XXX O
archs XXX O
( XXX O
following XXX O
the XXX O
ANGLE3 XXX O
classification XXX O
) XXX O
. XXX O

Some XXX O
research XXX O
studies XXX O
have XXX O
related XXX O
this XXX O
kind XXX O
of XXX O
tumors XXX O
with XXX O
prolonged XXX O
ingestion XXX O
of XXX O
H2 XXX O
inhibitors XXX O
and XXX O
others XXX O
antacid XXX O
. XXX O

Detailed XXX O
mutagenesis XXX O
of XXX O
the XXX O
element's XXX O
rare-codon XXX O
/ XXX O
AU-rich XXX O
sequence XXX O
boundary XXX O
revealed XXX O
that XXX O
the XXX O
destabilizing XXX O
activity XXX O
of XXX O
the XXX O
MATalpha1 XXX B-GENE
IE XXX I-GENE
is XXX O
observed XXX O
when XXX O
the XXX O
terminal XXX O
codon XXX O
of XXX O
the XXX O
element's XXX O
rare-codon XXX O
interval XXX O
is XXX O
translated XXX O
. XXX O

The XXX O
observed XXX O
incidence XXX O
rates XXX O
were XXX O
compared XXX O
to XXX O
expected XXX O
rates XXX O
in XXX O
the XXX O
general XXX O
population XXX O
. XXX O

Electromagnetic XXX O
blood XXX O
flow XXX O
( XXX O
BF XXX O
) XXX O
probe XXX O
was XXX O
applied XXX O
on XXX O
the XXX O
left XXX O
anterior XXX O
descending XXX O
artery XXX O
( XXX O
LAD XXX O
) XXX O
. XXX O

We XXX O
now XXX O
show XXX O
that XXX O
gp200-MR6 XXX B-GENE
ligation XXX O
can XXX O
also XXX O
mimic XXX O
IL-4 XXX B-GENE
and XXX O
have XXX O
an XXX O
anti-proliferative XXX O
pro-maturational XXX O
influence XXX O
within XXX O
the XXX O
immune XXX O
system XXX O
, XXX O
causing XXX O
up-regulation XXX O
of XXX O
co-stimulatory XXX O
molecules XXX O
on XXX O
B XXX O
lymphocytes XXX O
. XXX O

Iodine XXX O
deficiency XXX O
disorders XXX O
in XXX O
Bangladesh XXX O
. XXX O

Suppression XXX O
of XXX O
food XXX O
intake XXX O
in XXX O
the XXX O
rat XXX O
by XXX O
tung XXX O
oil XXX O
. XXX O

Similarities XXX O
between XXX O
the XXX O
hIGFBP-1 XXX B-GENE
and XXX O
phosphoenolpyruvate XXX B-GENE
kinase XXX I-GENE
( XXX O
PEPCK XXX B-GENE
) XXX O
promoters XXX O
, XXX O
including XXX O
regions XXX O
conferring XXX O
insulin XXX B-GENE
, XXX O
glucocorticoid XXX O
, XXX O
and XXX O
cyclic XXX O
adenosine-monophosphate XXX O
responses XXX O
, XXX O
are XXX O
consistent XXX O
with XXX O
our XXX O
previous XXX O
hypothesis XXX O
that XXX O
IGFBP-1 XXX B-GENE
is XXX O
involved XXX O
in XXX O
regulation XXX O
of XXX O
glucose XXX O
metabolism XXX O
. XXX O

A XXX O
genomic XXX O
clone XXX O
, XXX O
pTt21 XXX O
, XXX O
containing XXX O
DNA XXX O
apparently XXX O
transcribed XXX O
specifically XXX O
in XXX O
Trypanosoma XXX O
cruzi XXX O
trypomastigotes XXX O
, XXX O
was XXX O
obtained XXX O
by XXX O
differentially XXX O
screening XXX O
a XXX O
genomic XXX O
library XXX O
with XXX O
trypomastigote XXX O
and XXX O
epimastigote XXX O
cDNA XXX O
. XXX O

CONCLUSIONS XXX O
: XXX O
Using XXX O
icodextrin-based XXX O
instead XXX O
of XXX O
glucose-based XXX O
PD XXX O
fluids XXX O
can XXX O
largely XXX O
reduce XXX O
the XXX O
formation XXX O
of XXX O
Amadori XXX O
albumin XXX B-GENE
and XXX O
AGEs XXX O
. XXX O

Five XXX O
healthy XXX O
male XXX O
subjects XXX O
inspired XXX O
air XXX O
for XXX O
20 XXX O
min XXX O
and XXX O
then XXX O
5% XXX O
CO2 XXX O
/ XXX O
95% XXX O
O2 XXX O
for XXX O
30 XXX O
min XXX O
, XXX O
of XXX O
which XXX O
the XXX O
first XXX O
10 XXX O
min XXX O
was XXX O
used XXX O
to XXX O
achieve XXX O
a XXX O
steady-state XXX O
end-tidal XXX O
CO2 XXX O
measurement XXX O
. XXX O

Here XXX O
, XXX O
we XXX O
present XXX O
genetic XXX O
evidence XXX O
in XXX O
Saccharomyces XXX O
cerevisiae XXX O
for XXX O
a XXX O
functional XXX O
interaction XXX O
between XXX O
the XXX O
DEAH XXX B-GENE
protein XXX I-GENE
Prp16 XXX I-GENE
, XXX O
and XXX O
the XXX O
U6 XXX B-GENE
and XXX O
U2 XXX B-GENE
spliceosomal XXX I-GENE
snRNAs XXX I-GENE
. XXX O

Within XXX O
the XXX O
compartment XXX O
or XXX O
dimension XXX O
of XXX O
severity XXX O
of XXX O
depression XXX O
a XXX O
subscale XXX O
of XXX O
the XXX O
Hamilton XXX O
Depression XXX O
Scale XXX O
( XXX O
or XXX O
the XXX O
Melancholia XXX O
Scale XXX O
) XXX O
was XXX O
shown XXX O
to XXX O
have XXX O
reached XXX O
an XXX O
instrumental XXX O
perfection XXX O
, XXX O
e XXX O
. XXX O
g XXX O
. XXX O
as XXX O
an XXX O
outcome XXX O
measure XXX O
of XXX O
antidepressant XXX O
treatment XXX O
. XXX O

Although XXX O
within XXX O
normal XXX O
limits XXX O
, XXX O
latency XXX O
was XXX O
high XXX O
. XXX O

Since XXX O
the XXX O
early XXX O
1980s XXX O
there XXX O
has XXX O
been XXX O
increasing XXX O
awareness XXX O
of XXX O
the XXX O
importance XXX O
of XXX O
quantifying XXX O
health-related XXX O
quality XXX O
of XXX O
life XXX O
( XXX O
HRQL XXX O
) XXX O
in XXX O
patients XXX O
with XXX O
chronic XXX O
respiratory XXX O
disorders XXX O
included XXX O
in XXX O
clinical XXX O
trials XXX O
. XXX O

Previous XXX O
studies XXX O
have XXX O
suggested XXX O
that XXX O
the XXX O
616 XXX O
amino XXX O
acid XXX O
, XXX O
70-kDa XXX B-GENE
subunit XXX I-GENE
of XXX I-GENE
RPA XXX I-GENE
( XXX O
RPA XXX B-GENE
70 XXX I-GENE
) XXX O
is XXX O
composed XXX O
of XXX O
multiple XXX O
structural XXX O
/ XXX O
functional XXX O
domains XXX O
. XXX O

One XXX O
of XXX O
these XXX O
factors XXX O
, XXX O
HRF-1 XXX B-GENE
, XXX O
recognizes XXX O
a XXX O
cis XXX O
element XXX O
consisting XXX O
of XXX O
an XXX O
inverted XXX O
palindromic XXX O
motif XXX O
. XXX O

Adult XXX O
Amblyomma XXX O
lepidum XXX O
ticks XXX O
fed XXX O
as XXX O
nymphs XXX O
on XXX O
this XXX O
goat XXX O
transmitted XXX O
heartwater XXX O
to XXX O
a XXX O
Friesian XXX O
( XXX O
Bos XXX O
taurus XXX O
) XXX O
calf XXX O
. XXX O

The XXX O
N-terminal XXX O
domain XXX O
of XXX O
approximately XXX O
70 XXX O
kDa XXX O
exhibits XXX O
11 XXX O
imperfect XXX O
amino XXX O
acid XXX O
repeats XXX O
that XXX O
show XXX O
some XXX O
homology XXX O
to XXX O
promastigote XXX O
surface XXX O
glycoproteins XXX O
of XXX O
the XXX O
psa2 XXX B-GENE
/ XXX I-GENE
gp46 XXX I-GENE
complex XXX I-GENE
. XXX O

In XXX O
the XXX O
present XXX O
article XXX O
, XXX O
the XXX O
causes XXX O
of XXX O
death XXX O
or XXX O
ill-being XXX O
as XXX O
found XXX O
in XXX O
10 XXX O
consecutive XXX O
carcinogenicity XXX O
studies--5 XXX O
studies XXX O
with XXX O
2400 XXX O
OFA XXX O
( XXX O
Sprague-Dawley-derived XXX O
) XXX O
and XXX O
Wistar XXX O
rats XXX O
and XXX O
5 XXX O
studies XXX O
with XXX O
2400 XXX O
OF1 XXX O
and XXX O
NMRI XXX O
mice--were XXX O
re-examined XXX O
. XXX O

Whereas XXX O
both XXX O
MAP XXX O
and XXX O
MSNA XXX O
increase XXX O
during XXX O
SHG XXX O
, XXX O
the XXX O
transition XXX O
from XXX O
SHG XXX O
to XXX O
PHI XXX O
is XXX O
characterized XXX O
by XXX O
a XXX O
transient XXX O
reduction XXX O
in XXX O
MAP XXX O
but XXX O
sustained XXX O
elevation XXX O
in XXX O
MSNA XXX O
, XXX O
facilitating XXX O
separation XXX O
of XXX O
these XXX O
factors XXX O
in XXX O
vivo XXX O
. XXX O

The XXX O
SV40 XXX O
enhancer XXX O
augmented XXX O
replication XXX O
1 XXX O
. XXX O
5-10 XXX O
fold XXX O
. XXX O

Air XXX O
lead XXX O
was XXX O
not XXX O
a XXX O
significant XXX O
explanatory XXX O
variable XXX O
. XXX O

E3 XXX B-GENE
/ XXX I-GENE
19K XXX I-GENE
resides XXX O
in XXX O
the XXX O
endoplasmic XXX O
reticulum XXX O
where XXX O
it XXX O
binds XXX O
to XXX O
MHC XXX B-GENE
class XXX I-GENE
I XXX I-GENE
molecules XXX I-GENE
, XXX O
thereby XXX O
preventing XXX O
their XXX O
transport XXX O
to XXX O
the XXX O
cell XXX O
surface XXX O
. XXX O

Differential XXX O
drawing XXX O
size XXX O
associated XXX O
with XXX O
unilateral XXX O
brain XXX O
damage XXX O
. XXX O

The XXX O
pia XXX O
mater XXX O
at XXX O
the XXX O
site XXX O
of XXX O
the XXX O
entry XXX O
of XXX O
blood XXX O
vessels XXX O
into XXX O
the XXX O
central XXX O
nervous XXX O
system XXX O
. XXX O

The XXX O
optimum XXX O
technique XXX O
for XXX O
the XXX O
pathological XXX O
examination XXX O
of XXX O
sentinel XXX O
lymph XXX O
nodes XXX O
( XXX O
SLNs XXX O
) XXX O
is XXX O
still XXX O
under XXX O
debate XXX O
. XXX O

In XXX O
a XXX O
man XXX O
with XXX O
myelomonocytic XXX O
leukemia XXX O
, XXX O
the XXX O
association XXX O
of XXX O
increased XXX O
prostatic XXX B-GENE
acid XXX I-GENE
phosphatase XXX I-GENE
activity XXX O
in XXX O
serum XXX O
and XXX O
the XXX O
presence XXX O
of XXX O
typical XXX O
bone XXX O
lesions XXX O
on XXX O
roentgenography XXX O
suggested XXX O
the XXX O
existence XXX O
of XXX O
disseminated XXX O
prostatic XXX O
carcinoma XXX O
. XXX O

The XXX O
protein-tyrosine XXX B-GENE
kinase XXX I-GENE
fer XXX B-GENE
associates XXX O
with XXX O
signaling XXX O
complexes XXX O
containing XXX O
insulin XXX B-GENE
receptor XXX I-GENE
substrate-1 XXX I-GENE
and XXX O
phosphatidylinositol XXX B-GENE
3-kinase XXX I-GENE
. XXX O

The XXX O
degree XXX O
of XXX O
hypoperfusion XXX O
was XXX O
slightly XXX O
related XXX O
to XXX O
decrease XXX O
in XXX O
FEV1 XXX O
. XXX O
0% XXX O
, XXX O
V25 XXX O
and XXX O
PaO2 XXX O
and XXX O
increase XXX O
in XXX O
circulating XXX O
blood XXX O
volume XXX O
and XXX O
peripheral XXX O
red XXX O
blood XXX O
cell XXX O
counts XXX O
. XXX O

IMPLICATIONS XXX O
: XXX O
Given XXX O
the XXX O
small XXX O
size XXX O
of XXX O
this XXX O
study XXX O
and XXX O
the XXX O
inconsistency XXX O
of XXX O
results XXX O
among XXX O
the XXX O
few XXX O
prospective XXX O
studies XXX O
of XXX O
ovarian XXX O
cancer XXX O
conducted XXX O
to XXX O
test XXX O
these XXX O
associations XXX O
, XXX O
replications XXX O
of XXX O
these XXX O
findings XXX O
are XXX O
highly XXX O
desirable XXX O
. XXX O

Abnormal XXX O
urinary XXX B-GENE
coproporphyrin XXX I-GENE
levels XXX O
in XXX O
patients XXX O
infected XXX O
by XXX O
hepatitis XXX O
C XXX O
virus XXX O
with XXX O
or XXX O
without XXX O
human XXX O
immunodeficiency XXX O
virus XXX O
. XXX O

Here XXX O
we XXX O
describe XXX O
an XXX O
in XXX O
vitro XXX O
assay XXX O
where XXX O
the XXX O
NS3-4A XXX B-GENE
polyprotein XXX I-GENE
, XXX O
NS3 XXX B-GENE
, XXX O
the XXX O
serine XXX B-GENE
proteinase XXX I-GENE
domain XXX I-GENE
( XXX I-GENE
the XXX I-GENE
N-terminal XXX I-GENE
181 XXX I-GENE
residues XXX I-GENE
of XXX I-GENE
NS3 XXX I-GENE
) XXX I-GENE
, XXX O
and XXX O
the XXX O
NS4A XXX B-GENE
cofactor XXX I-GENE
were XXX O
produced XXX O
by XXX O
cell-free XXX O
translation XXX O
and XXX O
tested XXX O
for XXX O
trans-processing XXX O
of XXX O
radiolabeled XXX O
substrates XXX O
. XXX O

Previous XXX O
studies XXX O
demonstrated XXX O
that XXX O
the XXX O
flavin-containing XXX B-GENE
monooxygenases XXX I-GENE
( XXX O
FMO XXX B-GENE
) XXX O
are XXX O
expressed XXX O
in XXX O
a XXX O
tissue-specific XXX O
manner XXX O
. XXX O

A XXX O
comparison XXX O
of XXX O
the XXX O
duplicated XXX O
Vkappa XXX B-GENE
genes XXX I-GENE
suggests XXX O
positive XXX O
selection XXX O
on XXX O
the XXX O
complementarity-determining XXX O
regions XXX O
of XXX O
the XXX O
duplicated XXX O
genes XXX O
by XXX O
point XXX O
mutations XXX O
. XXX O

Concerted XXX O
transcriptional XXX O
activation XXX O
of XXX O
the XXX O
low XXX B-GENE
density XXX I-GENE
lipoprotein XXX I-GENE
receptor XXX I-GENE
gene XXX I-GENE
by XXX O
insulin XXX B-GENE
and XXX O
luteinizing XXX B-GENE
hormone XXX I-GENE
in XXX O
cultured XXX O
porcine XXX O
granulosa-luteal XXX O
cells XXX O
: XXX O
possible XXX O
convergence XXX O
of XXX O
protein XXX B-GENE
kinase XXX I-GENE
a XXX I-GENE
, XXX O
phosphatidylinositol XXX B-GENE
3-kinase XXX I-GENE
, XXX O
and XXX O
mitogen-activated XXX B-GENE
protein XXX I-GENE
kinase XXX I-GENE
signaling XXX O
pathways XXX O
. XXX O

Synthesis XXX O
of XXX O
( XXX O
+ XXX O
) XXX O
-lysergic XXX O
acid XXX O
diethylamide XXX O
tartrate XXX O
. XXX O

Stimulation XXX O
of XXX O
macrophage XXX O
function XXX O
by XXX O
killed XXX O
Bordetella XXX O
pertussis XXX O
cells XXX O
did XXX O
not XXX O
show XXX O
any XXX O
beneficial XXX O
effect XXX O
as XXX O
an XXX O
increased XXX O
susceptibility XXX O
became XXX O
apparent XXX O
. XXX O

RESULTS XXX O
: XXX O
Among XXX O
women XXX O
, XXX O
the XXX O
age-related XXX O
decline XXX O
in XXX O
BMD XXX O
at XXX O
all XXX O
non-spine XXX O
skeletal XXX O
sites XXX O
was XXX O
significantly XXX O
different XXX O
from XXX O
zero XXX O
, XXX O
with XXX O
the XXX O
largest XXX O
decline XXX O
seen XXX O
at XXX O
the XXX O
femoral XXX O
neck XXX O
( XXX O
- XXX O
. XXX O
0038 XXX O
g XXX O
/ XXX O
cm2 XXX O
/ XXX O
y XXX O
, XXX O
p XXX O
< XXX O
. XXX O
001 XXX O
) XXX O
and XXX O
the XXX O
smallest XXX O
at XXX O
the XXX O
trochanter XXX O
of XXX O
the XXX O
hip XXX O
( XXX O
- XXX O
. XXX O
0023 XXX O
g XXX O
/ XXX O
cm2 XXX O
/ XXX O
y XXX O
, XXX O
p XXX O
= XXX O
. XXX O
03 XXX O
) XXX O
. XXX O

A XXX O
raised XXX O
amplitude XXX O
of XXX O
the XXX O
aggregation XXX O
of XXX O
plates XXX O
and XXX O
a XXX O
decrease XXX O
in XXX O
the XXX O
threshold XXX O
of XXX O
their XXX O
sensitivity XXX O
to XXX O
ADP XXX O
were XXX O
established XXX O
in XXX O
the XXX O
persons XXX O
with XXX O
types XXX O
IIa XXX O
and XXX O
IIb XXX O
HLP XXX O
and XXX O
in XXX O
CHD XXX O
without XXX O
HLP XXX O
. XXX O

To XXX O
determine XXX O
the XXX O
genomic XXX O
complexity XXX O
of XXX O
the XXX O
deleted XXX O
region XXX O
shared XXX O
among XXX O
tumors XXX O
, XXX O
we XXX O
assembled XXX O
a XXX O
physical XXX O
map XXX O
of XXX O
the XXX O
I XXX O
Mbp XXX O
SRO XXX O
consisting XXX O
predominantly XXX O
of XXX O
bacteriophage XXX O
P1-derived XXX O
artificial XXX O
chromosome XXX O
( XXX O
PAC XXX O
) XXX O
clones XXX O
. XXX O

Chronotherapeutics XXX O
in XXX O
cardiovascular XXX O
disease XXX O
. XXX O

In XXX O
order XXX O
to XXX O
quantify XXX O
these XXX O
effects XXX O
, XXX O
tests XXX O
were XXX O
conducted XXX O
in XXX O
the XXX O
NASA XXX O
MSFC XXX O
Neutral XXX O
Buoyancy XXX O
Simulator XXX O
, XXX O
in XXX O
the XXX O
NASA XXX O
KC-135 XXX O
in XXX O
parabolic XXX O
flight XXX O
, XXX O
and XXX O
in XXX O
space XXX O
with XXX O
the XXX O
EASE XXX O
program XXX O
during XXX O
the XXX O
Shuttle XXX O
Atlantis XXX O
mission XXX O
61-B XXX O
. XXX O

Cycles XXX O
were XXX O
repeated XXX O
every XXX O
3 XXX O
weeks XXX O
. XXX O

Change XXX O
in XXX O
the XXX O
makeup XXX O
of XXX O
the XXX O
blood XXX O
following XXX O
a XXX O
short-term XXX O
local XXX O
action XXX O
of XXX O
a XXX O
permanent XXX O
magnetic XXX O
field XXX O
on XXX O
the XXX O
human XXX O
body XXX O
. XXX O

Tolerance XXX O
to XXX O
fenfluramine XXX O
anorexia XXX O
: XXX O
fact XXX O
or XXX O
fiction XXX O
? XXX O
Recent XXX O
findings XXX O
in XXX O
this XXX O
laboratory XXX O
with XXX O
regard XXX O
to XXX O
tolerance XXX O
to XXX O
fenfluramine XXX O
anorexia XXX O
are XXX O
reviewed XXX O
with XXX O
respect XXX O
to XXX O
generality XXX O
of XXX O
the XXX O
behavioural XXX O
phenomenon XXX O
. XXX O

Here XXX O
, XXX O
we XXX O
evidence XXX O
that XXX O
the XXX O
developmental XXX O
functions XXX O
of XXX O
the XXX O
family XXX O
of XXX O
transcription XXX O
factors XXX O
characterized XXX O
by XXX O
the XXX O
POU XXX B-GENE
DNA XXX I-GENE
binding XXX I-GENE
motif XXX I-GENE
exerts XXX O
roles XXX O
in XXX O
mammalian XXX O
development XXX O
. XXX O

The XXX O
absence XXX O
of XXX O
H4PteGlun XXX O
bound XXX O
to XXX O
the XXX O
T XXX B-GENE
protein XXX I-GENE
in XXX O
our XXX O
experimental XXX O
conditions XXX O
demonstrates XXX O
that XXX O
H4PteGlun XXX O
is XXX O
not XXX O
covalently XXX O
linked XXX O
to XXX O
the XXX O
T XXX B-GENE
protein XXX I-GENE
. XXX O

He XXX O
was XXX O
administered XXX O
recombinant XXX B-GENE
IFN XXX I-GENE
alpha-2b XXX I-GENE
under XXX O
the XXX O
diagnosis XXX O
of XXX O
chronic XXX O
hepatitis XXX O
C XXX O
. XXX O

74 XXX O
, XXX O
193-197 XXX O
) XXX O
. XXX O

Serum XXX O
ascorbic XXX O
acid XXX O
had XXX O
an XXX O
inverse XXX O
and XXX O
the XXX O
strongest XXX O
association XXX O
with XXX O
systolic XXX O
blood XXX O
pressure XXX O
among XXX O
the XXX O
risk XXX O
factors XXX O
including XXX O
blood XXX O
pressure XXX O
, XXX O
total XXX O
cholesterol XXX O
, XXX O
triglyceride XXX O
, XXX O
gamma-GTP XXX O
and XXX O
obesity XXX O
. XXX O

Discrepant XXX O
results XXX O
with XXX O
a XXX O
latex XXX O
agglutination XXX O
test XXX O
in XXX O
the XXX O
assessment XXX O
of XXX O
cytomegalovirus XXX B-GENE
antibody XXX I-GENE
status XXX O
of XXX O
cardiac XXX O
transplant XXX O
donors XXX O
. XXX O

Many XXX O
studies XXX O
have XXX O
pointed XXX O
out XXX O
the XXX O
possibility XXX O
of XXX O
"masked" XXX O
organic XXX O
factors XXX O
in XXX O
erectile XXX O
impotence XXX O
, XXX O
detectable XXX O
only XXX O
by XXX O
means XXX O
of XXX O
laboratory XXX O
investigations XXX O
: XXX O
mild XXX O
hypogonadism XXX O
, XXX O
hyperprolactinemia XXX O
, XXX O
occlusions XXX O
selectively XXX O
located XXX O
at XXX O
the XXX O
site XXX O
of XXX O
the XXX O
sexual XXX O
arteries XXX O
, XXX O
venous XXX O
incompetence XXX O
, XXX O
subclinical XXX O
neuropathies XXX O
. XXX O

MSSP XXX B-GENE
proteins XXX I-GENE
have XXX O
been XXX O
identified XXX O
by XXX O
their XXX O
binding XXX O
to XXX O
an XXX O
upstream XXX O
element XXX O
of XXX O
c-myc XXX B-GENE
. XXX O

Changes XXX O
in XXX O
stimulation XXX O
levels XXX O
over XXX O
time XXX O
in XXX O
nucleus XXX O
22 XXX O
cochlear XXX O
implant XXX O
users XXX O
. XXX O

A XXX O
given XXX O
standard XXX O
input XXX O
function XXX O
and XXX O
a XXX O
given XXX O
value XXX O
of XXX O
distribution XXX O
volume XXX O
( XXX O
Vd XXX O
) XXX O
used XXX O
for XXX O
the XXX O
rCBF XXX O
measurement XXX O
of XXX O
this XXX O
method XXX O
were XXX O
calculated XXX O
from XXX O
the XXX O
dynamic XXX O
study XXX O
by XXX O
six XXX O
normal XXX O
volunteers XXX O
. XXX O

The XXX O
solution XXX O
structure XXX O
of XXX O
the XXX O
adduct XXX O
derived XXX O
from XXX O
the XXX O
covalent XXX O
bonding XXX O
of XXX O
the XXX O
fjord XXX O
region XXX O
( XXX O
+ XXX O
) XXX O
- XXX O
( XXX O
11S XXX O
, XXX O
12R XXX O
, XXX O
13R XXX O
, XXX O
14S XXX O
) XXX O
stereoisomer XXX O
of XXX O
anti XXX O
-11 XXX O
, XXX O
12-dihydroxy-13 XXX O
, XXX O
14-epoxy-11 XXX O
, XXX O
12 XXX O
, XXX O
13 XXX O
, XXX O
14-tetrahydrobenzo XXX O
[ XXX O
g XXX O
] XXX O
chrysene XXX O
, XXX O
( XXX O
+ XXX O
) XXX O
- XXX O
anti XXX O
-B XXX O
[ XXX O
g XXX O
] XXX O
CDE XXX O
, XXX O
to XXX O
the XXX O
exocyclic XXX O
N XXX O
( XXX O
6 XXX O
) XXX O
amino XXX O
group XXX O
of XXX O
the XXX O
adenine XXX O
residue XXX O
dA6 XXX O
, XXX O
( XXX O
designated XXX O
( XXX O
+ XXX O
) XXX O
- XXX O
trans-anti XXX O
- XXX O
( XXX O
B XXX O
[ XXX O
g XXX O
] XXX O
C XXX O
) XXX O
dA6 XXX O
) XXX O
, XXX O
positioned XXX O
opposite XXX O
a XXX O
thymine XXX O
residue XXX O
dT17 XXX O
in XXX O
the XXX O
DNA XXX O
sequence XXX O
context XXX O
d XXX O
( XXX O
C1-T2-C3-T4-C5- XXX O
( XXX O
B XXX O
[ XXX O
g XXX O
] XXX O
C XXX O
) XXX O
A6-C7-T8-T9-C10-C11 XXX O
) XXX O
. XXX O
d XXX O
( XXX O
G12-G13-A14-A15-G16-T17-G18-A19-G20++ XXX O
+-A21-G22 XXX O
) XXX O
( XXX O
designated XXX O
( XXX O
B XXX O
[ XXX O
g XXX O
] XXX O
C XXX O
) XXX O
dA XXX O
. XXX O
dT XXX O
11-mer XXX O
duplex XXX O
) XXX O
, XXX O
has XXX O
been XXX O
studied XXX O
using XXX O
structural XXX O
information XXX O
derived XXX O
from XXX O
NMR XXX O
data XXX O
in XXX O
combination XXX O
with XXX O
molecular XXX O
dynamics XXX O
( XXX O
MD XXX O
) XXX O
calculations XXX O
. XXX O

Characterization XXX O
of XXX O
the XXX O
alpha XXX B-GENE
4 XXX I-GENE
integrin XXX I-GENE
gene XXX I-GENE
promoter XXX I-GENE
. XXX O

Uses XXX O
of XXX O
orthoclone XXX O
OKT3 XXX B-GENE
for XXX O
prophylaxis XXX O
of XXX O
rejection XXX O
and XXX O
induction XXX O
in XXX O
initial XXX O
nonfunction XXX O
in XXX O
kidney XXX O
transplantation XXX O
. XXX O

Relationship XXX O
between XXX O
gross XXX O
lesions XXX O
and XXX O
Escherichia XXX O
coli XXX O
serotypes XXX O
in XXX O
chronic XXX O
respiratory XXX O
disease XXX O
( XXX O
CRD XXX O
) XXX O
of XXX O
poultry XXX O
. XXX O

Furthermore XXX O
, XXX O
synergistic XXX O
activation XXX O
of XXX O
ERK2 XXX B-GENE
occurred XXX O
in XXX O
the XXX O
absence XXX O
of XXX O
changes XXX O
in XXX O
intracellular XXX O
Ca2+ XXX O
, XXX O
and XXX O
was XXX O
not XXX O
blocked XXX O
by XXX O
inhibition XXX O
of XXX O
protein XXX B-GENE
kinase XXX I-GENE
C XXX I-GENE
activity XXX O
and XXX O
represents XXX O
a XXX O
separate XXX O
pathway XXX O
by XXX O
which XXX O
CD19 XXX B-GENE
regulates XXX O
B XXX O
cell XXX O
function XXX O
. XXX O

Pancreatic XXX O
and XXX O
biliary XXX O
secretion XXX O
and XXX O
gastric XXX O
emptying XXX O
rates XXX O
of XXX O
a XXX O
liquid XXX O
test XXX O
meal XXX O
( XXX O
LTM XXX O
) XXX O
were XXX O
determined XXX O
in XXX O
normal XXX O
persons XXX O
, XXX O
in XXX O
patients XXX O
with XXX O
subtotal XXX O
gastrectomy XXX O
with XXX O
gastroduodenostomy XXX O
( XXX O
STG-BI XXX O
) XXX O
or XXX O
with XXX O
gastrojejunostomy XXX O
( XXX O
STG-BII XXX O
) XXX O
, XXX O
and XXX O
in XXX O
patients XXX O
with XXX O
truncal XXX O
vagotomy XXX O
and XXX O
pyloroplasty XXX O
( XXX O
V&P XXX O
) XXX O
. XXX O

Analysis XXX O
of XXX O
mRNA XXX O
expression XXX O
shows XXX O
that XXX O
AT-BP1 XXX B-GENE
and XXX O
AT-BP2 XXX B-GENE
are XXX O
expressed XXX O
in XXX O
all XXX O
the XXX O
tissues XXX O
examined XXX O
. XXX O

RNA XXX O
transcripts XXX O
that XXX O
hybridize XXX O
to XXX O
the XXX O
introduced XXX O
foreign XXX O
gene XXX O
have XXX O
been XXX O
identified XXX O
. XXX O

Transient XXX O
tyrosine XXX O
phosphorylation XXX O
of XXX O
Crk XXX B-GENE
in XXX O
fibroblast XXX O
growth XXX O
factor-2-stimulated XXX O
endothelial XXX O
cells XXX O
was XXX O
dependent XXX O
on XXX O
the XXX O
juxtamembrane XXX O
tyrosine XXX O
residue XXX O
463 XXX O
in XXX O
FGFR-1 XXX B-GENE
, XXX O
and XXX O
a XXX O
Crk XXX B-GENE
SH2 XXX B-GENE
domain XXX I-GENE
precipitated XXX O
FGFR-1 XXX B-GENE
via XXX O
phosphorylated XXX O
Tyr-463 XXX O
, XXX O
indicating XXX O
direct XXX O
complex XXX O
formation XXX O
between XXX O
Crk XXX B-GENE
and XXX O
FGFR-1 XXX B-GENE
. XXX O

Blood XXX O
pressure XXX O
also XXX O
was XXX O
increased XXX O
by XXX O
lidocaine XXX O
( XXX O
6 XXX O
mg XXX O
kg-1 XXX O
) XXX O
. XXX O

Multiple XXX O
SW16-dependent XXX O
cis-acting XXX O
elements XXX O
control XXX O
SWI4 XXX B-GENE
transcription XXX O
through XXX O
the XXX O
cell XXX O
cycle XXX O
. XXX O

We XXX O
conclude XXX O
that XXX O
the XXX O
beta-adrenergic XXX O
agonist XXX O
, XXX O
isoproterenol XXX O
, XXX O
has XXX O
little XXX O
influence XXX O
on XXX O
vascular XXX O
capacitance XXX O
or XXX O
liver XXX O
volume XXX O
of XXX O
dogs XXX O
, XXX O
unless XXX O
the XXX O
hepatic XXX O
outflow XXX O
resistance XXX O
is XXX O
elevated XXX O
by XXX O
agents XXX O
such XXX O
as XXX O
histamine XXX O
. XXX O

This XXX O
Mr XXX O
is XXX O
similar XXX O
to XXX O
those XXX O
of XXX O
the XXX O
purified XXX B-GENE
smg XXX I-GENE
p25A XXX I-GENE
GDI XXX B-GENE
estimated XXX O
by XXX O
sodium XXX O
dodecyl XXX O
sulfate-polyacrylamide XXX O
gel XXX O
electrophoresis XXX O
and XXX O
sucrose XXX O
density XXX O
gradient XXX O
ultracentrifugation XXX O
, XXX O
which XXX O
are XXX O
about XXX O
54 XXX O
, XXX O
000 XXX O
and XXX O
65 XXX O
, XXX O
000 XXX O
, XXX O
respectively XXX O
. XXX O

Measurement XXX O
of XXX O
SaO2 XXX O
at XXX O
moderate XXX O
altitude XXX O
can XXX O
be XXX O
helpful XXX O
in XXX O
the XXX O
care XXX O
of XXX O
both XXX O
healthy XXX O
and XXX O
ill XXX O
newborns XXX O
or XXX O
infants XXX O
. XXX O

In XXX O
co-transfection XXX O
studies XXX O
, XXX O
an XXX O
AP-2 XXX B-GENE
but XXX O
not XXX O
an XXX O
Egr-1 XXX B-GENE
expression XXX O
vector XXX O
activated XXX O
VPF XXX B-GENE
/ XXX I-GENE
VEGF XXX I-GENE
transcription XXX O
, XXX O
thus XXX O
indicating XXX O
that XXX O
AP-2 XXX B-GENE
protein XXX I-GENE
is XXX O
functionally XXX O
important XXX O
in XXX O
TGF XXX B-GENE
alpha-induced XXX I-GENE
VPF XXX I-GENE
/ XXX I-GENE
VEGF XXX I-GENE
gene XXX I-GENE
expression XXX O
. XXX O

Similarly XXX O
, XXX O
curcumin XXX O
( XXX O
diferuloylmethane XXX O
) XXX O
, XXX O
an XXX O
anti-inflammatory XXX O
agent XXX O
, XXX O
suppressed XXX O
OSM-stimulated XXX O
STAT1 XXX B-GENE
phosphorylation XXX O
, XXX O
DNA-binding XXX O
activity XXX O
of XXX O
STAT1 XXX B-GENE
, XXX O
and XXX O
c-Jun XXX B-GENE
N-terminal XXX I-GENE
kinase XXX I-GENE
activation XXX O
without XXX O
affecting XXX O
JAK1 XXX B-GENE
, XXX O
JAK2 XXX B-GENE
, XXX O
JAK3 XXX B-GENE
, XXX O
ERK1 XXX B-GENE
/ XXX I-GENE
2 XXX I-GENE
, XXX O
and XXX O
p38 XXX B-GENE
phosphorylation XXX O
. XXX O

The XXX O
reproductive XXX O
effects XXX O
of XXX O
the XXX O
administration XXX O
of XXX O
4-chloro-2-methylphenoxyacetic XXX O
acid XXX O
( XXX O
MCPA XXX O
) XXX O
to XXX O
rats XXX O
were XXX O
evaluated XXX O
through XXX O
two XXX O
generations XXX O
, XXX O
from XXX O
prior XXX O
to XXX O
mating XXX O
, XXX O
throughout XXX O
mating XXX O
, XXX O
to XXX O
gestation XXX O
and XXX O
lactation XXX O
. XXX O

The XXX O
rat XXX B-GENE
branched-chain-2-oxo-acid XXX I-GENE
dehydrogenase XXX I-GENE
( XXX I-GENE
BCOD XXX I-GENE
) XXX I-GENE
kinase XXX I-GENE
mRNA XXX I-GENE
is XXX O
transcribed XXX O
from XXX O
a XXX O
TATA-less XXX O
promoter XXX O
that XXX O
has XXX O
GC-rich XXX O
sequences XXX O
and XXX O
two XXX O
putative XXX O
Sp1 XXX B-GENE
binding XXX I-GENE
sites XXX I-GENE
near XXX O
the XXX O
transcription XXX O
start XXX O
site XXX O
. XXX O

67 XXX O
393 XXX O
bp XXX O
of XXX O
contiguous XXX O
DNA XXX O
located XXX O
between XXX O
markers XXX O
cdc18 XXX B-GENE
and XXX O
cdc14 XXX B-GENE
on XXX O
the XXX O
right XXX O
arm XXX O
of XXX O
fission XXX O
yeast XXX O
chromosome XXX O
II XXX O
has XXX O
been XXX O
sequenced XXX O
as XXX O
part XXX O
of XXX O
the XXX O
European XXX O
Union XXX O
Schizosaccharomyces XXX O
pombe XXX O
genome XXX O
sequencing XXX O
project XXX O
. XXX O

The XXX O
ability XXX O
of XXX O
rats XXX O
with XXX O
control XXX O
or XXX O
hippocampal XXX O
lesions XXX O
to XXX O
learn XXX O
an XXX O
object-place XXX O
, XXX O
odor-place XXX O
, XXX O
or XXX O
object-odor XXX O
paired-associate XXX O
task XXX O
was XXX O
assessed XXX O
in XXX O
a XXX O
cheeseboard XXX O
maze XXX O
apparatus XXX O
. XXX O

Gel XXX O
electrophoresis XXX O
and XXX O
Western XXX O
immunoblot XXX O
analyses XXX O
of XXX O
intracellular XXX O
fractions XXX O
derived XXX O
from XXX O
infected XXX O
cells XXX O
revealed XXX O
that XXX O
large XXX O
amounts XXX O
of XXX O
NS53 XXX B-GENE
were XXX O
present XXX O
in XXX O
the XXX O
cytosol XXX O
and XXX O
in XXX O
association XXX O
with XXX O
the XXX O
cytoskeletal XXX O
matrix XXX O
. XXX O

Structural XXX O
organization XXX O
of XXX O
the XXX O
gene XXX O
encoding XXX O
the XXX O
human XXX B-GENE
lipocalin XXX I-GENE
tear XXX I-GENE
prealbumin XXX I-GENE
and XXX O
synthesis XXX O
of XXX O
the XXX O
recombinant XXX O
protein XXX O
in XXX O
Escherichia XXX O
coli XXX O
. XXX O

Bacterial XXX O
meningitis XXX O
secondary XXX O
to XXX O
abscess XXX O
of XXX O
the XXX O
nasal XXX O
septum XXX O
. XXX O

On XXX O
the XXX O
basis XXX O
of XXX O
serological XXX O
studies XXX O
, XXX O
the XXX O
highly XXX O
conserved XXX O
A XXX O
domain XXX O
of XXX O
HspA XXX B-GENE
was XXX O
found XXX O
to XXX O
be XXX O
the XXX O
immunodominant XXX O
domain XXX O
. XXX O

In XXX O
PC12 XXX O
cells XXX O
, XXX O
nerve XXX B-GENE
growth XXX I-GENE
factor XXX I-GENE
induces XXX O
neuronal XXX O
differentiation XXX O
and XXX O
repressed XXX O
expression XXX O
of XXX O
nrg-1 XXX B-GENE
. XXX O

The XXX O
murine XXX B-GENE
facilitative XXX I-GENE
glucose XXX I-GENE
transporter XXX I-GENE
isoform XXX I-GENE
3 XXX I-GENE
( XXX O
Glut XXX B-GENE
3 XXX I-GENE
) XXX O
is XXX O
developmentally XXX O
regulated XXX O
and XXX O
is XXX O
predominantly XXX O
expressed XXX O
in XXX O
neurons XXX O
and XXX O
trophoblasts XXX O
. XXX O

It XXX O
has XXX O
been XXX O
proposed XXX O
that XXX O
insulin XXX B-GENE
resistance XXX O
( XXX O
IR XXX O
) XXX O
underlies XXX O
a XXX O
cluster XXX O
of XXX O
cardiovascular XXX O
disease XXX O
( XXX O
CVD XXX O
) XXX O
risk XXX O
factors XXX O
constituting XXX O
a XXX O
"metabolic XXX O
syndrome XXX O
. XXX O
" XXX O
CVD XXX O
is XXX O
a XXX O
leading XXX O
cause XXX O
of XXX O
premature XXX O
mortality XXX O
among XXX O
indigenous XXX O
Australians XXX O
. XXX O

To XXX O
investigate XXX O
the XXX O
regulation XXX O
of XXX O
expression XXX O
of XXX O
the XXX O
human XXX B-GENE
mdr1 XXX I-GENE
gene XXX I-GENE
, XXX O
the XXX O
response XXX O
of XXX O
the XXX O
mdr1 XXX B-GENE
promoter XXX I-GENE
to XXX O
signals XXX O
involved XXX O
in XXX O
cell XXX O
proliferation XXX O
was XXX O
examined XXX O
. XXX O

Increased XXX O
urinary XXX O
riboflavin XXX O
excretion XXX O
resulting XXX O
from XXX O
boric XXX O
acid XXX O
ingestion XXX O
. XXX O

The XXX O
adenovirus XXX B-GENE
E1A XXX I-GENE
gene XXX I-GENE
encodes XXX O
a XXX O
protein XXX O
that XXX O
transcriptionally XXX O
activates XXX O
viral XXX O
early XXX O
genes XXX O
. XXX O

This XXX O
compares XXX O
favorably XXX O
to XXX O
results XXX O
of XXX O
similarly XXX O
sized XXX O
melanomas XXX O
treated XXX O
by XXX O
enucleation XXX O
. XXX O

In XXX O
the XXX O
control XXX O
group XXX O
the XXX O
histological XXX O
picture XXX O
resembled XXX O
osteoarthritis XXX O
. XXX O

The XXX O
isolated XXX O
POT1 XXX B-GENE
clones XXX O
hybridized XXX O
to XXX O
a XXX O
1 XXX O
. XXX O
4 XXX O
kb XXX O
RNA XXX O
species XXX O
, XXX O
which XXX O
was XXX O
induced XXX O
approximately XXX O
30-fold XXX O
when XXX O
oleate XXX O
was XXX O
the XXX O
carbon XXX O
source XXX O
. XXX O

X-linked XXX O
liver XXX O
glycogenosis XXX O
: XXX O
localization XXX O
and XXX O
isolation XXX O
of XXX O
a XXX O
candidate XXX O
gene XXX O
. XXX O

Cell XXX O
lines XXX O
derived XXX O
from XXX O
the XXX O
tumors XXX O
were XXX O
examined XXX O
by XXX O
fluorescent XXX O
in XXX O
situ XXX O
hybridization XXX O
for XXX O
the XXX O
status XXX O
of XXX O
the XXX O
transferred XXX O
human XXX O
chromosome XXX O
and XXX O
by XXX O
PCR XXX O
for XXX O
marker XXX O
loss XXX O
. XXX O

Other XXX O
properties XXX O
of XXX O
Hg- XXX O
and XXX O
Cd-spores XXX O
were XXX O
similar XXX O
to XXX O
those XXX O
of XXX O
control XXX O
spores XXX O
. XXX O

During XXX O
coronary XXX O
stenosis XXX O
, XXX O
on XXX O
the XXX O
contrary XXX O
, XXX O
intracoronary XXX O
procaterol XXX O
at XXX O
the XXX O
same XXX O
dose XXX O
significantly XXX O
deteriorated XXX O
regional XXX O
myocardial XXX O
dysfunction XXX O
without XXX O
changing XXX O
LCX XXX O
flow XXX O
, XXX O
global XXX O
hemodynamics XXX O
and XXX O
cardiac XXX O
lactate XXX O
metabolism XXX O
. XXX O

Accumulation XXX O
of XXX O
the XXX O
U4 XXX B-GENE
/ XXX I-GENE
U6 XXX I-GENE
duplex XXX I-GENE
was XXX O
relieved XXX O
by XXX O
overexpression XXX O
of XXX O
wild-type XXX B-GENE
Prp44p XXX I-GENE
. XXX O

Its XXX O
transcription XXX O
has XXX O
been XXX O
shown XXX O
to XXX O
be XXX O
induced XXX O
40-50-fold XXX O
in XXX O
response XXX O
to XXX O
oxygen XXX O
or XXX O
heme XXX O
deficiency XXX O
, XXX O
in XXX O
part XXX O
through XXX O
relief XXX O
of XXX O
repression XXX O
exerted XXX O
by XXX O
Rox1p XXX B-GENE
and XXX O
in XXX O
part XXX O
by XXX O
activation XXX O
mediated XXX O
by XXX O
an XXX O
upstream XXX B-GENE
activation XXX I-GENE
sequence XXX I-GENE
( XXX O
UAS XXX B-GENE
) XXX O
. XXX O

Methods XXX O
used XXX O
include XXX O
Cobb XXX O
angle XXX O
and XXX O
a XXX O
segmental XXX O
evaluation XXX O
( XXX O
T7-T12 XXX O
) XXX O
of XXX O
each XXX O
of XXX O
convex XXX O
and XXX O
concave XXX O
rib-vertebra XXX O
angles XXX O
( XXX O
RVAs XXX O
) XXX O
, XXX O
rib-vertebra XXX O
angle XXX O
differences XXX O
( XXX O
RVADs XXX O
) XXX O
, XXX O
vertebral XXX O
rotation XXX O
, XXX O
tilt XXX O
and XXX O
displacement XXX O
. XXX O

The XXX O
exonic XXX O
sequence XXX O
encodes XXX O
a XXX O
protein XXX O
of XXX O
495 XXX O
amino XXX O
acids XXX O
that XXX O
is XXX O
nearly XXX O
identical XXX O
to XXX O
the XXX O
previously XXX O
reported XXX O
protein XXX O
sequence XXX O
of XXX O
human XXX B-GENE
GPT-1 XXX I-GENE
. XXX O

Endothelial XXX O
cell XXX O
seeding XXX O
. XXX O

EMBO XXX O
J XXX O
. XXX O

The XXX O
promoter XXX O
for XXX O
HMG-CoA XXX B-GENE
synthase XXX I-GENE
contains XXX O
two XXX O
binding XXX O
sites XXX O
for XXX O
the XXX O
sterol XXX B-GENE
regulatory XXX I-GENE
element-binding XXX I-GENE
proteins XXX I-GENE
( XXX O
SREBPs XXX B-GENE
) XXX O
. XXX O

U24 XXX B-GENE
has XXX O
two XXX O
separate XXX O
12 XXX O
nt XXX O
long XXX O
complementarities XXX O
to XXX O
a XXX O
highly XXX O
conserved XXX O
tract XXX O
of XXX O
28S XXX B-GENE
rRNA XXX I-GENE
. XXX O

Thus XXX O
, XXX O
IHHNV XXX O
is XXX O
closely XXX O
related XXX O
to XXX O
densoviruses XXX O
of XXX O
the XXX O
genus XXX O
Brevidensovirus XXX O
in XXX O
the XXX O
family XXX O
Parvoviridae XXX O
, XXX O
and XXX O
we XXX O
therefore XXX O
propose XXX O
to XXX O
rename XXX O
this XXX O
virus XXX O
Penaeus XXX O
stylirostris XXX O
densovirus XXX O
( XXX O
PstDNV XXX O
) XXX O
. XXX O

We XXX O
have XXX O
also XXX O
identified XXX O
a XXX O
functional XXX O
domain XXX O
in XXX O
the XXX O
ORF XXX B-GENE
50 XXX I-GENE
protein XXX I-GENE
, XXX O
an XXX O
immediate-early XXX B-GENE
gene XXX I-GENE
product XXX I-GENE
that XXX O
is XXX O
mainly XXX O
encoded XXX O
by XXX O
ORF XXX B-GENE
50 XXX I-GENE
. XXX O

Collectively XXX O
, XXX O
the XXX O
results XXX O
suggest XXX O
that XXX O
ARF XXX B-GENE
binding XXX O
to XXX O
Mdm2 XXX B-GENE
induces XXX O
a XXX O
conformational XXX O
change XXX O
that XXX O
facilitates XXX O
nucleolar XXX O
import XXX O
of XXX O
the XXX O
ARF-Mdm2 XXX B-GENE
complex XXX I-GENE
and XXX O
p53-dependent XXX O
cell XXX O
cycle XXX O
arrest XXX O
. XXX O

Inhibitor-1 XXX B-GENE
( XXX O
I-1 XXX B-GENE
) XXX O
and XXX O
inhibitor-2 XXX B-GENE
( XXX O
I-2 XXX B-GENE
) XXX O
selectively XXX O
inhibit XXX O
type XXX B-GENE
1 XXX I-GENE
protein XXX I-GENE
serine XXX I-GENE
/ XXX I-GENE
threonine XXX I-GENE
phosphatases XXX I-GENE
( XXX O
PP1 XXX B-GENE
) XXX O
. XXX O

Deregulation XXX O
of XXX O
their XXX O
expression XXX O
may XXX O
contribute XXX O
to XXX O
malignant XXX O
transformation XXX O
associated XXX O
with XXX O
HTLV-1 XXX O
infection XXX O
. XXX O

Thus XXX O
our XXX O
observations XXX O
establish XXX O
a XXX O
functional XXX O
link XXX O
between XXX O
the XXX O
PKC XXX B-GENE
and XXX O
retinoid XXX O
pathways XXX O
, XXX O
which XXX O
are XXX O
generally XXX O
considered XXX O
to XXX O
have XXX O
antagonistic XXX O
activities XXX O
on XXX O
differentiation XXX O
processes XXX O
. XXX O

A XXX O
preliminary XXX O
study XXX O
on XXX O
pyogenic XXX O
arthritis XXX O
. XXX O

In XXX O
several XXX O
studies XXX O
the XXX O
RDFS XXX O
has XXX O
shown XXX O
evidence XXX O
of XXX O
reliability XXX O
and XXX O
validity XXX O
. XXX O

We XXX O
mapped XXX O
the XXX O
DGCR6 XXX B-GENE
gene XXX I-GENE
to XXX O
chromosome XXX O
22q11 XXX O
within XXX O
a XXX O
low XXX O
copy XXX O
repeat XXX O
, XXX O
termed XXX O
sc11 XXX O
. XXX O
1a XXX O
, XXX O
and XXX O
identified XXX O
a XXX O
second XXX O
copy XXX O
of XXX O
the XXX O
gene XXX O
, XXX O
DGCR6L XXX B-GENE
, XXX O
within XXX O
the XXX O
duplicate XXX O
locus XXX O
, XXX O
termed XXX O
sc11 XXX O
. XXX O
1b XXX O
. XXX O

Pharmacological XXX O
action XXX O
of XXX O
eptazocine XXX O
( XXX O
l-1 XXX O
, XXX O
4-dimethyl-10-hydroxy-2 XXX O
, XXX O
3 XXX O
, XXX O
4 XXX O
, XXX O
5 XXX O
, XXX O
6 XXX O
, XXX O
7-hexahydro-1 XXX O
, XXX O
6-methano-1H-4-benz XXX O
azonine XXX O
) XXX O
. XXX O

We XXX O
have XXX O
elucidated XXX O
the XXX O
exon-intron XXX O
organization XXX O
of XXX O
the XXX O
entire XXX O
human XXX O
CD58 XXX B-GENE
gene XXX I-GENE
, XXX O
including XXX O
approximately XXX O
2 XXX O
. XXX O
5 XXX O
kilobases XXX O
( XXX O
kb XXX O
) XXX O
of XXX O
5'-flanking XXX O
DNA XXX O
. XXX O

This XXX O
may XXX O
account XXX O
, XXX O
at XXX O
least XXX O
in XXX O
part XXX O
, XXX O
for XXX O
the XXX O
ability XXX O
of XXX O
excess XXX O
wt XXX B-GENE
p53 XXX I-GENE
to XXX O
inhibit XXX O
cell XXX O
proliferation XXX O
and XXX O
to XXX O
interfere XXX O
with XXX O
neoplastic XXX O
processes XXX O
. XXX O

In XXX O
addition XXX O
to XXX O
the XXX O
significant XXX O
reduction XXX O
in XXX O
blood XXX O
pressure XXX O
, XXX O
the XXX O
angiotensin XXX B-GENE
converting XXX I-GENE
enzyme XXX I-GENE
( XXX O
ACE XXX B-GENE
) XXX O
inhibitor XXX O
ramipril XXX O
caused XXX O
a XXX O
significant XXX O
regression XXX O
of XXX O
pathologic XXX O
left XXX O
ventricular XXX O
hypertrophy XXX O
demonstrated XXX O
by XXX O
magnetic XXX O
resonance XXX O
imaging XXX O
and XXX O
echocardiography XXX O
. XXX O

We XXX O
show XXX O
that XXX O
the XXX O
5'UTR XXX O
characteristic XXX O
of XXX O
testis-specific XXX B-GENE
c-mos XXX I-GENE
mRNA XXX I-GENE
strongly XXX O
represses XXX O
translation XXX O
relative XXX O
to XXX O
the XXX O
translation XXX O
of XXX O
transcripts XXX O
that XXX O
contain XXX O
a XXX O
5'UTR XXX O
derived XXX O
from XXX O
beta-globin XXX B-GENE
mRNA XXX I-GENE
, XXX O
and XXX O
this XXX O
is XXX O
mainly XXX O
due XXX O
to XXX O
the XXX O
four XXX O
uORFs XXX O
. XXX O

In XXX O
regards XXX O
to XXX O
the XXX O
latter XXX O
activity XXX O
, XXX O
it XXX O
has XXX O
been XXX O
shown XXX O
that XXX O
S3 XXX B-GENE
contains XXX O
vigorous XXX O
N-glycosylase XXX B-GENE
activity XXX O
for XXX O
the XXX O
removal XXX O
of XXX O
8-oxoguanine XXX O
residues XXX O
in XXX O
DNA XXX O
that XXX O
leaves XXX O
baseless XXX O
sites XXX O
in XXX O
their XXX O
places XXX O
. XXX O

Analysis XXX O
of XXX O
proteins XXX O
synthesized XXX O
by XXX O
plasmids XXX O
containing XXX O
deleted XXX O
forms XXX O
of XXX O
the XXX O
trfA XXX B-GENE
region XXX I-GENE
indicates XXX O
that XXX O
the XXX O
A2 XXX B-GENE
protein XXX I-GENE
is XXX O
the XXX O
essential XXX O
trfA-encoded XXX B-GENE
replication XXX I-GENE
protein XXX I-GENE
of XXX O
plasmid XXX O
RK2 XXX O
. XXX O

When XXX O
the XXX O
first XXX O
twitch XXX O
of XXX O
TOF XXX O
spontaneously XXX O
recovered XXX O
to XXX O
10% XXX O
of XXX O
control XXX O
value XXX O
, XXX O
neostigmine XXX O
was XXX O
injected XXX O
( XXX O
40 XXX O
micrograms XXX O
/ XXX O
kg XXX O
in XXX O
adults XXX O
, XXX O
30 XXX O
micrograms XXX O
/ XXX O
kg XXX O
in XXX O
infants XXX O
and XXX O
children XXX O
) XXX O
. XXX O

16 XXX O
, XXX O
99-104 XXX O
) XXX O
. XXX O

In XXX O
conclusion XXX O
, XXX O
NF-Y XXX B-GENE
and XXX O
Sp1 XXX B-GENE
binding XXX O
sites XXX O
play XXX O
a XXX O
decisive XXX O
role XXX O
in XXX O
the XXX O
basal XXX O
expression XXX O
of XXX O
the XXX O
rat XXX B-GENE
mrp2 XXX I-GENE
gene XXX I-GENE
, XXX O
while XXX O
the XXX O
human XXX B-GENE
MRP2 XXX I-GENE
gene XXX I-GENE
is XXX O
regulated XXX O
differently XXX O
. XXX O

Minor XXX O
initiation XXX O
sites XXX O
were XXX O
found XXX O
at XXX O
positions XXX O
-128 XXX O
, XXX O
-111 XXX O
, XXX O
-91 XXX O
, XXX O
and XXX O
-74 XXX O
. XXX O

The XXX O
DNA XXX O
sequence XXX O
conferring XXX O
AP-1 XXX B-GENE
activity XXX O
was XXX O
located XXX O
in XXX O
the XXX O
proximal XXX O
promoter XXX O
region XXX O
. XXX O

Thus XXX O
, XXX O
SPECT XXX O
was XXX O
not XXX O
as XXX O
sensitive XXX O
as XXX O
PET XXX O
in XXX O
this XXX O
activation XXX O
task XXX O
. XXX O

In XXX O
both XXX O
experiments XXX O
, XXX O
average XXX O
daily XXX O
gain XXX O
and XXX O
gain-to-feed XXX O
ratio XXX O
were XXX O
similar XXX O
for XXX O
TR XXX O
and XXX O
CR XXX O
. XXX O

Molecular XXX O
cloning XXX O
, XXX O
genomic XXX O
mapping XXX O
, XXX O
and XXX O
expression XXX O
of XXX O
two XXX O
secretor XXX B-GENE
blood XXX I-GENE
group XXX I-GENE
alpha XXX I-GENE
( XXX I-GENE
1 XXX I-GENE
, XXX I-GENE
2 XXX I-GENE
) XXX I-GENE
fucosyltransferase XXX I-GENE
genes XXX I-GENE
differentially XXX O
regulated XXX O
in XXX O
mouse XXX O
uterine XXX O
epithelium XXX O
and XXX O
gastrointestinal XXX O
tract XXX O
. XXX O

The XXX O
afferents' XXX O
phase XXX O
of XXX O
response XXX O
was XXX O
unmodified XXX O
by XXX O
electrical XXX O
EVS XXX O
stimulation XXX O
. XXX O

A XXX O
log-linear XXX O
dose-response XXX O
was XXX O
obtained XXX O
for XXX O
the XXX O
average XXX O
increase XXX O
in XXX O
FEV1 XXX O
up XXX O
to XXX O
6 XXX O
h XXX O
( XXX O
AUC0-6 XXX O
h XXX O
) XXX O
and XXX O
peak XXX O
FEV1 XXX O
across XXX O
the XXX O
dose XXX O
range XXX O
administered XXX O
by XXX O
Respimat XXX O
. XXX O

The XXX O
glomerular XXX O
filtration XXX O
rate XXX O
did XXX O
not XXX O
change XXX O
but XXX O
lithium XXX O
clearance XXX O
fell XXX O
by XXX O
30% XXX O
. XXX O

Adipocyte XXX O
differentiation XXX O
of XXX O
nontransformed XXX O
cells XXX O
also XXX O
markedly XXX O
represses XXX O
the XXX O
ability XXX O
of XXX O
SRF XXX B-GENE
to XXX O
bind XXX O
to XXX O
the XXX O
junB XXX B-GENE
SRE XXX B-GENE
, XXX O
the XXX O
c-fos XXX B-GENE
SRE XXX B-GENE
, XXX O
and XXX O
other XXX O
SREs XXX B-GENE
, XXX O
as XXX O
determined XXX O
by XXX O
mobility XXX O
shift XXX O
and XXX O
gel XXX O
supershift XXX O
assays XXX O
, XXX O
without XXX O
affecting XXX O
the XXX O
DNA XXX O
binding XXX O
characteristics XXX O
of XXX O
the XXX O
nuclear XXX B-GENE
protein XXX I-GENE
SP-1 XXX I-GENE
. XXX O

The XXX O
PEBP2 XXX B-GENE
alpha XXX I-GENE
proteins XXX I-GENE
contain XXX O
a XXX O
128-amino-acid XXX O
( XXX O
aa XXX O
) XXX O
region XXX O
highly XXX O
homologous XXX O
to XXX O
the XXX O
Drosophila XXX B-GENE
melanogaster XXX I-GENE
segmentation XXX I-GENE
gene XXX I-GENE
runt XXX I-GENE
. XXX O

Consistent XXX O
with XXX O
our XXX O
model XXX O
, XXX O
CTCF XXX B-GENE
binding XXX O
is XXX O
abolished XXX O
by XXX O
DNA XXX O
methylation XXX O
. XXX O

Analysis XXX O
of XXX O
regulatory XXX O
regions XXX O
in XXX O
the XXX O
promoter XXX O
of XXX O
the XXX O
ctr4 XXX B-GENE
( XXX I-GENE
+ XXX I-GENE
) XXX I-GENE
copper XXX I-GENE
transporter XXX I-GENE
gene XXX I-GENE
in XXX O
fission XXX O
yeast XXX O
Schizosaccharomyces XXX O
pombe XXX O
reveals XXX O
the XXX O
identity XXX O
of XXX O
a XXX O
conserved XXX O
copper-signaling XXX B-GENE
element XXX I-GENE
( XXX O
CuSE XXX B-GENE
) XXX O
, XXX O
which XXX O
is XXX O
recognized XXX O
by XXX O
the XXX O
transcription XXX B-GENE
factor XXX I-GENE
Cuf1 XXX I-GENE
. XXX O

A XXX O
study XXX O
of XXX O
the XXX O
comparative XXX O
efficacy XXX O
of XXX O
diflucortolone XXX O
valerate XXX O
0 XXX O
. XXX O
3% XXX O
ointment XXX O
and XXX O
clobetasol XXX O
propionate XXX O
0 XXX O
. XXX O
05% XXX O
ointment XXX O
. XXX O

The XXX O
relative XXX O
risk XXX O
of XXX O
graft XXX O
loss XXX O
after XXX O
conversion XXX O
to XXX O
azathioprine XXX O
compared XXX O
with XXX O
graft XXX O
loss XXX O
after XXX O
conversion XXX O
to XXX O
azathioprine XXX O
compared XXX O
with XXX O
cyclosporin XXX O
maintenance XXX O
was XXX O
0 XXX O
. XXX O
71 XXX O
( XXX O
0 XXX O
. XXX O
37-1 XXX O
. XXX O
38 XXX O
) XXX O
and XXX O
the XXX O
relative XXX O
risk XXX O
of XXX O
patient XXX O
death XXX O
was XXX O
0 XXX O
. XXX O
57 XXX O
( XXX O
0 XXX O
. XXX O
23-1 XXX O
. XXX O
41 XXX O
) XXX O
. XXX O

Therefore XXX O
, XXX O
we XXX O
have XXX O
named XXX O
this XXX O
gene XXX O
UBP43 XXX B-GENE
. XXX O

Nucleotide XXX O
sequence XXX O
, XXX O
transcription XXX O
map XXX O
, XXX O
and XXX O
mutation XXX O
analysis XXX O
of XXX O
the XXX O
13q14 XXX O
chromosomal XXX O
region XXX O
deleted XXX O
in XXX O
B-cell XXX O
chronic XXX O
lymphocytic XXX O
leukemia XXX O
. XXX O

Practical XXX O
use XXX O
and XXX O
interpretation XXX O
of XXX O
viral XXX O
hepatitis XXX O
B XXX O
markers XXX O
and XXX O
hepatic XXX O
biopsy XXX O
in XXX O
HBs XXX B-GENE
Ag XXX I-GENE
carriers XXX O
and XXX O
at XXX O
the XXX O
chronic XXX O
hepatitis XXX O
stage XXX O
. XXX O

The XXX O
human XXX B-GENE
RAD30B XXX I-GENE
and XXX O
mouse XXX B-GENE
Rad30b XXX I-GENE
mRNA XXX I-GENE
transcripts XXX I-GENE
, XXX O
like XXX O
many XXX O
repair XXX O
proteins XXX O
, XXX O
are XXX O
highly XXX O
expressed XXX O
in XXX O
the XXX O
testis XXX O
. XXX O

HuEpo-R XXX B-GENE
Ab XXX I-GENE
inhibited XXX O
Epo-induced XXX O
parental XXX O
UT-7 XXX O
cell XXX O
growth XXX O
, XXX O
but XXX O
not XXX O
that XXX O
of XXX O
cells XXX O
of XXX O
clone XXX O
12 XXX O
, XXX O
suggesting XXX O
that XXX O
the XXX O
muEpo-R XXX B-GENE
is XXX O
able XXX O
to XXX O
induce XXX O
human XXX O
UT-7 XXX O
cell XXX O
proliferation XXX O
. XXX O

In XXX O
order XXX O
to XXX O
determine XXX O
which XXX O
sequences XXX O
in XXX O
the XXX O
GATA-1 XXX B-GENE
promoter XXX I-GENE
are XXX O
crucial XXX O
for XXX O
activation XXX O
by XXX O
the XXX O
ME26 XXX B-GENE
viral XXX I-GENE
protein XXX I-GENE
, XXX O
we XXX O
made XXX O
deletions XXX O
of XXX O
the XXX O
promoter XXX O
, XXX O
cloned XXX O
them XXX O
into XXX O
a XXX O
luciferase XXX B-GENE
expression XXX O
vector XXX O
and XXX O
tested XXX O
their XXX O
activity XXX O
in XXX O
mouse XXX O
fibroblasts XXX O
, XXX O
which XXX O
do XXX O
not XXX O
express XXX O
GATA-1 XXX B-GENE
. XXX O

The XXX O
effects XXX O
of XXX O
chlordiazepoxide XXX O
( XXX O
2 XXX O
. XXX O
5-15 XXX O
. XXX O
0mg XXX O
/ XXX O
kg XXX O
) XXX O
, XXX O
a XXX O
full XXX O
benzodiazepine XXX B-GENE
receptor XXX I-GENE
agonist XXX O
, XXX O
and XXX O
bretazenil XXX O
( XXX O
5 XXX O
. XXX O
0-30 XXX O
. XXX O
0mg XXX O
/ XXX O
kg XXX O
) XXX O
, XXX O
a XXX O
partial XXX O
benzodiazepine XXX B-GENE
receptor XXX I-GENE
agonist XXX O
, XXX O
were XXX O
examined XXX O
in XXX O
the XXX O
murine XXX O
elevated XXX O
plus-maze XXX O
paradigm XXX O
. XXX O

PMEK1 XXX B-GENE
displays XXX O
96 XXX O
and XXX O
80% XXX O
identity XXX O
respectively XXX O
with XXX O
the XXX O
tobacco XXX B-GENE
NTF3 XXX I-GENE
and XXX O
Arabidopsis XXX B-GENE
ATMPK1 XXX I-GENE
kinases XXX I-GENE
, XXX O
and XXX O
only XXX O
50% XXX O
to XXX O
the XXX O
more XXX O
distantly XXX O
related XXX O
plant XXX O
MAP XXX B-GENE
kinase XXX I-GENE
MsERK1 XXX I-GENE
from XXX O
alfalfa XXX O
. XXX O

IRF-1 XXX B-GENE
acts XXX O
as XXX O
a XXX O
transcriptional XXX O
activator XXX O
, XXX O
while XXX O
IRF-2 XXX B-GENE
acts XXX O
as XXX O
a XXX O
repressor XXX O
. XXX O

We XXX O
conclude XXX O
that XXX O
the XXX O
QLMI XXX O
questionnaire XXX O
has XXX O
good XXX O
potential XXX O
as XXX O
an XXX O
instrument XXX O
for XXX O
assessing XXX O
QL XXX O
in XXX O
post-AMI XXX O
patients XXX O
and XXX O
that XXX O
it XXX O
can XXX O
be XXX O
successfully XXX O
self-administered XXX O
. XXX O

Ca2+ XXX B-GENE
/ XXX I-GENE
calmodulin-dependent XXX I-GENE
protein XXX I-GENE
kinase XXX I-GENE
II XXX I-GENE
( XXX O
CaMK XXX B-GENE
II XXX I-GENE
) XXX O
is XXX O
a XXX O
multifunctional XXX O
serine XXX B-GENE
/ XXX I-GENE
threonine XXX I-GENE
protein XXX I-GENE
kinase XXX I-GENE
that XXX O
regulates XXX O
ion XXX O
channels XXX O
, XXX O
metabolic XXX O
enzymes XXX O
, XXX O
cytoskeletal XXX O
proteins XXX O
, XXX O
and XXX O
possibly XXX O
transcription XXX O
factors XXX O
. XXX O

We XXX O
studied XXX O
the XXX O
GR XXX B-GENE
in XXX O
DMS-79 XXX O
cells XXX O
derived XXX O
from XXX O
a XXX O
human XXX O
ACTH-secreting XXX O
small XXX O
cell XXX O
lung XXX O
cancer XXX O
. XXX O

However XXX O
, XXX O
we XXX O
were XXX O
unable XXX O
to XXX O
identify XXX O
a XXX O
p4 XXX B-GENE
molecule XXX O
. XXX O

Direct XXX O
approach XXX O
to XXX O
the XXX O
study XXX O
of XXX O
soliton XXX O
perturbations XXX O
. XXX O

To XXX O
define XXX O
the XXX O
minimal XXX O
VDRE XXX B-GENE
binding XXX O
domain XXX O
for XXX O
human XXX B-GENE
VDR XXX I-GENE
( XXX O
hVDR XXX B-GENE
) XXX O
, XXX O
a XXX O
series XXX O
of XXX O
C-terminally XXX O
truncated XXX O
hVDR XXX B-GENE
mutants XXX I-GENE
( XXX O
Delta134 XXX B-GENE
, XXX O
Delta113 XXX B-GENE
, XXX O
Delta102 XXX B-GENE
, XXX O
Delta90 XXX B-GENE
, XXX O
Delta84 XXX B-GENE
, XXX O
Delta80 XXX B-GENE
, XXX O
and XXX O
Delta60 XXX B-GENE
) XXX O
was XXX O
generated XXX O
and XXX O
expressed XXX O
in XXX O
bacteria XXX O
. XXX O

The XXX O
urinary XXX O
protein XXX O
, XXX O
serum XXX O
albumin XXX B-GENE
, XXX O
BUN XXX O
and XXX O
SCr XXX O
all XXX O
had XXX O
very XXX O
significant XXX O
improvement XXX O
. XXX O

Most XXX O
, XXX O
however XXX O
, XXX O
would XXX O
tell XXX O
the XXX O
spouse XXX O
the XXX O
full XXX O
truth XXX O
about XXX O
both XXX O
diagnosis XXX O
and XXX O
prognosis XXX O
. XXX O

The XXX O
combination XXX O
PIP XXX O
64 XXX O
micrograms XXX O
- XXX O
PEF XXX O
4 XXX O
micrograms XXX O
prevents XXX O
the XXX O
frequent XXX O
secondary XXX O
regrowth XXX O
seen XXX O
after XXX O
6 XXX O
hours XXX O
with XXX O
the XXX O
antibiotics XXX O
used XXX O
alone XXX O
. XXX O

The XXX O
second XXX O
and XXX O
third XXX O
responded XXX O
similarly XXX O
to XXX O
either XXX O
a XXX O
combined XXX O
cyclophosphamide XXX O
+ XXX O
antilymphocyte XXX B-GENE
globulin XXX I-GENE
( XXX O
ALG XXX B-GENE
) XXX O
treatment XXX O
or XXX O
to XXX O
ALG XXX B-GENE
administration XXX O
preceded XXX O
by XXX O
a XXX O
small XXX O
dosage XXX O
of XXX O
cyclophosphamide XXX O
, XXX O
which XXX O
had XXX O
proved XXX O
ineffective XXX O
when XXX O
administered XXX O
alone XXX O
. XXX O

These XXX O
and XXX O
other XXX O
comparisons XXX O
suggest XXX O
that XXX O
, XXX O
during XXX O
evolution XXX O
, XXX O
both XXX O
the XXX O
RNA-polymerase XXX B-GENE
specificity XXX O
of XXX O
telomerase XXX B-GENE
RNA-gene XXX I-GENE
promoters XXX I-GENE
and XXX O
, XXX O
more XXX O
recently XXX O
, XXX O
the XXX O
position XXX O
of XXX O
the XXX O
template XXX O
sequence XXX O
in XXX O
the XXX O
telomerase XXX B-GENE
RNA XXX I-GENE
changed XXX O
. XXX O

Importantly XXX O
, XXX O
in XXX O
HeLa XXX O
and XXX O
293 XXX O
cells XXX O
, XXX O
endogenous XXX O
and XXX O
transfected XXX O
I XXX B-GENE
kappaB XXX I-GENE
alpha XXX I-GENE
coimmunoprecipitated XXX O
with XXX O
Myc-tagged XXX O
or XXX O
endogenous XXX O
Dlc-1 XXX B-GENE
. XXX O

Estrus XXX O
and XXX O
copulative XXX O
abilities XXX O
of XXX O
androgen-sterilized XXX O
rats XXX O
. XXX O

Analysis XXX O
of XXX O
corticosteroids XXX O
. XXX O

Here XXX O
, XXX O
we XXX O
show XXX O
that XXX O
IRF-1 XXX B-GENE
is XXX O
degraded XXX O
via XXX O
the XXX O
ubiquitin-proteasome XXX B-GENE
pathway XXX O
. XXX O

That XXX O
sequence XXX O
strongly XXX O
promoted XXX O
the XXX O
transcription XXX O
of XXX O
the XXX O
promotorless XXX O
chloramphenicol XXX B-GENE
acetyltranferase XXX I-GENE
( XXX O
CAT XXX B-GENE
) XXX O
gene XXX O
in XXX O
cells XXX O
of XXX O
pancreatic XXX O
origin XXX O
( XXX O
AR-42J XXX O
) XXX O
but XXX O
not XXX O
in XXX O
cells XXX O
of XXX O
non-pancreatic XXX O
origin XXX O
( XXX O
Rat XXX O
2 XXX O
and XXX O
IEC XXX O
6 XXX O
) XXX O
. XXX O

We XXX O
report XXX O
the XXX O
molecular XXX O
cloning XXX O
and XXX O
functional XXX O
characterization XXX O
of XXX O
USF2 XXX B-GENE
isoforms XXX I-GENE
, XXX O
corresponding XXX O
to XXX O
a XXX O
44-kDa XXX O
subunit XXX O
, XXX O
USF2a XXX B-GENE
, XXX O
and XXX O
a XXX O
new XXX O
38-kDa XXX O
subunit XXX O
, XXX O
USF2b XXX B-GENE
, XXX O
generated XXX O
by XXX O
differential XXX O
splicing XXX O
. XXX O

These XXX O
issues XXX O
include XXX O
the XXX O
use XXX O
of XXX O
LMWHs XXX O
in XXX O
patients XXX O
with XXX O
arterial XXX O
thrombosis XXX O
or XXX O
myocardial XXX O
infarction XXX O
( XXX O
e XXX O
. XXX O
g XXX O
. XXX O
in XXX O
conjunction XXX O
with XXX O
thrombolytic XXX O
treatment XXX O
) XXX O
, XXX O
and XXX O
in XXX O
patients XXX O
with XXX O
pulmonary XXX O
embolism XXX O
. XXX O

The XXX O
protein XXX B-GENE
kinase XXX I-GENE
domains XXX I-GENE
of XXX O
LIMK1 XXX B-GENE
and XXX O
LIMK2 XXX B-GENE
are XXX O
unique XXX O
in XXX O
that XXX O
they XXX O
contain XXX O
an XXX O
unusual XXX O
sequence XXX B-GENE
motif XXX I-GENE
Asp-Leu-Asn-Ser-His-Asn XXX I-GENE
in XXX O
subdomain XXX B-GENE
VIB XXX I-GENE
and XXX O
a XXX O
highly XXX O
basic XXX O
insert XXX O
between XXX O
subdomains XXX B-GENE
VII XXX I-GENE
and XXX I-GENE
VIII XXX I-GENE
. XXX O

In XXX O
agreement XXX O
with XXX O
previous XXX O
in XXX O
vitro XXX O
data XXX O
, XXX O
we XXX O
have XXX O
shown XXX O
that XXX O
UmuD XXX B-GENE
and XXX O
UmuD' XXX B-GENE
are XXX O
able XXX O
to XXX O
form XXX O
both XXX O
homodimers XXX O
( XXX O
UmuD-UmuD XXX B-GENE
and XXX O
UmuD'-UmuD' XXX B-GENE
) XXX O
and XXX O
a XXX O
heterodimer XXX O
( XXX O
UmuD-UmuD' XXX B-GENE
) XXX O
. XXX O

In XXX O
Salmo XXX O
gairdneri XXX O
, XXX O
no XXX O
specialized XXX O
system XXX O
of XXX O
portal XXX O
vessels XXX O
appears XXX O
to XXX O
exist XXX O
between XXX O
the XXX O
pineal XXX O
organ XXX O
and XXX O
other XXX O
portions XXX O
of XXX O
the XXX O
brain XXX O
. XXX O

Diagnosis XXX O
and XXX O
treatment XXX O
planning XXX O
in XXX O
Class XXX O
II XXX O
, XXX O
division XXX O
2 XXX O
. XXX O

Peripheral XXX O
vitreochorioretinal XXX O
dystrophies XXX O
in XXX O
myopia XXX O
patients XXX O
. XXX O

ESS XXX O
type XXX O
1 XXX O
, XXX O
with XXX O
FT3 XXX O
low XXX O
and XXX O
FT4 XXX O
and XXX O
TSH XXX B-GENE
normal XXX O
, XXX O
is XXX O
the XXX O
most XXX O
frequent XXX O
form XXX O
. XXX O

Although XXX O
Grice's XXX O
operation XXX O
has XXX O
been XXX O
used XXX O
all XXX O
over XXX O
the XXX O
world XXX O
, XXX O
no XXX O
systematic XXX O
account XXX O
of XXX O
it XXX O
has XXX O
been XXX O
found XXX O
in XXX O
the XXX O
literature XXX O
( XXX O
including XXX O
publications XXX O
dealing XXX O
with XXX O
technique XXX O
) XXX O
, XXX O
which XXX O
presents XXX O
it XXX O
in XXX O
terms XXX O
related XXX O
to XXX O
the XXX O
basic XXX O
"classical" XXX O
principles XXX O
on XXX O
which XXX O
the XXX O
operation XXX O
was XXX O
conceived XXX O
. XXX O

Our XXX O
results XXX O
indicate XXX O
that XXX O
periseizure XXX O
lipid XXX O
accumulation XXX O
is XXX O
related XXX O
to XXX O
cortical XXX O
oxygenation XXX O
. XXX O

Serum XXX O
lactate XXX B-GENE
dehydrogenase XXX I-GENE
and XXX O
haptoglobin XXX B-GENE
levels XXX O
were XXX O
normal XXX O
, XXX O
and XXX O
total XXX O
bilirubin XXX O
was XXX O
only XXX O
slightly XXX O
elevated XXX O
. XXX O

During XXX O
the XXX O
cloning XXX O
by XXX O
reverse XXX O
transcriptase-polymerase XXX B-GENE
chain XXX O
reaction XXX O
of XXX O
the XXX O
human XXX B-GENE
HIF-1alpha XXX I-GENE
subunit XXX I-GENE
, XXX O
we XXX O
isolated XXX O
two XXX O
cDNA XXX O
clones XXX O
which XXX O
corresponded XXX O
to XXX O
alternative XXX O
splicing XXX O
of XXX O
the XXX O
HIF-1alpha XXX B-GENE
gene XXX I-GENE
. XXX O

With XXX O
a XXX O
GC XXX O
content XXX O
of XXX O
45% XXX O
the XXX O
one XXX O
segment XXX O
would XXX O
correspond XXX O
to XXX O
"isochore XXX B-GENE
H1" XXX I-GENE
and XXX O
the XXX O
other XXX O
segment XXX O
( XXX O
39% XXX O
GC XXX O
in XXX O
human XXX O
, XXX O
40% XXX O
GC XXX O
in XXX O
mouse XXX O
) XXX O
to XXX O
"isochore XXX B-GENE
L1 XXX I-GENE
/ XXX I-GENE
L2" XXX I-GENE
. XXX O

Sixty XXX O
months XXX O
after XXX O
the XXX O
initial XXX O
vaccination XXX O
, XXX O
all XXX O
vaccinees XXX O
who XXX O
received XXX O
annual XXX O
follow-up XXX O
still XXX O
had XXX O
protective XXX O
levels XXX O
of XXX O
anti-HAV XXX B-GENE
. XXX O

This XXX O
could XXX O
lead XXX O
to XXX O
subsequent XXX O
outbreaks XXX O
if XXX O
Babesia XXX O
carrier XXX O
animals XXX O
were XXX O
to XXX O
be XXX O
introduced XXX O
into XXX O
the XXX O
herd XXX O
. XXX O

Shear XXX O
bond XXX O
strength XXX O
of XXX O
a XXX O
composite XXX O
resin XXX O
to XXX O
an XXX O
etched XXX O
glass XXX O
ionomer XXX O
. XXX O

There XXX O
were XXX O
no XXX O
interfering XXX O
peaks XXX O
in XXX O
the XXX O
quantitation XXX O
of XXX O
sulbactam XXX O
. XXX O

Ultrasonic XXX O
evaluation XXX O
of XXX O
renal XXX O
calculi XXX O
. XXX O

Since XXX O
the XXX O
-172 XXX O
/ XXX O
-148 XXX O
element XXX O
also XXX O
conferred XXX O
estrogen XXX O
and XXX O
thyroid XXX O
hormone XXX O
responsiveness XXX O
, XXX O
it XXX O
can XXX O
be XXX O
considered XXX O
a XXX O
composite XXX O
hormone XXX B-GENE
response XXX I-GENE
element XXX I-GENE
. XXX O

Molecular XXX O
cloning XXX O
of XXX O
an XXX O
amphibian XXX B-GENE
insulin XXX I-GENE
receptor XXX I-GENE
substrate XXX I-GENE
1-like XXX I-GENE
cDNA XXX I-GENE
and XXX O
involvement XXX O
of XXX O
phosphatidylinositol XXX B-GENE
3-kinase XXX I-GENE
in XXX O
insulin-induced XXX O
Xenopus XXX O
oocyte XXX O
maturation XXX O
. XXX O

Hydrallazine XXX O
also XXX O
caused XXX O
a XXX O
slight XXX O
increase XXX O
in XXX O
plasma XXX B-GENE
renin XXX I-GENE
activity XXX O
and XXX O
urinary XXX O
excretion XXX O
of XXX O
noradrenaline XXX O
. XXX O

The XXX O
Delta6CCI XXX O
virus XXX O
was XXX O
extremely XXX O
attenuated XXX O
in XXX O
replication XXX O
capacity XXX O
yet XXX O
retained XXX O
infectiousness XXX O
for XXX O
CEMx174 XXX O
and XXX O
MT4 XXX O
cells XXX O
. XXX O

Tissue XXX O
necrosis XXX O
was XXX O
evaluated XXX O
using XXX O
triphenyltetrazolium XXX O
staining XXX O
and XXX O
was XXX O
related XXX O
to XXX O
two XXX O
major XXX O
baseline XXX O
predictors XXX O
of XXX O
infarct XXX O
size XXX O
: XXX O
anatomic XXX O
risk XXX O
zone XXX O
size XXX O
and XXX O
coronary XXX O
collateral XXX O
flow XXX O
. XXX O

Northern XXX O
blot XXX O
analysis XXX O
revealed XXX O
multiple XXX O
oIGF-I XXX B-GENE
transcripts XXX I-GENE
in XXX O
a XXX O
broad XXX O
band XXX O
at XXX O
800-1 XXX O
, XXX O
100 XXX O
nucleotides XXX O
and XXX O
other XXX O
transcripts XXX O
of XXX O
higher XXX O
molecular XXX O
weight XXX O
in XXX O
liver XXX O
. XXX O

Phenobarbital-induced XXX O
alterations XXX O
in XXX O
the XXX O
metabolism XXX O
of XXX O
[ XXX O
3H XXX O
] XXX O
vitamin XXX O
D3 XXX O
by XXX O
the XXX O
perfused XXX O
rachitic XXX O
rat XXX O
liver XXX O
in XXX O
vitro XXX O
. XXX O

Therefore XXX O
, XXX O
with XXX O
a XXX O
biopsy XXX O
from XXX O
the XXX O
stoma XXX O
site XXX O
there XXX O
is XXX O
a XXX O
risk XXX O
of XXX O
missing XXX O
early XXX O
rejection XXX O
. XXX O

Canalith XXX O
repositioning XXX O
is XXX O
the XXX O
mainstay XXX O
of XXX O
treatment XXX O
. XXX O

Further XXX O
, XXX O
the XXX O
reduction XXX O
in XXX O
5-hydroxytryptophan XXX O
( XXX O
5-HTP XXX O
) XXX O
accumulation XXX O
by XXX O
LSD XXX O
showed XXX O
regional XXX O
differences XXX O
in XXX O
inhibition XXX O
by XXX O
methiothepin XXX O
( XXX O
hypothalamus XXX O
greater XXX O
than XXX O
cortex XXX O
greater XXX O
than XXX O
striatum XXX O
) XXX O
which XXX O
paralleled XXX O
the XXX O
autoreceptor XXX O
antagonist XXX O
activity XXX O
of XXX O
methiothepin XXX O
in XXX O
vitro XXX O
. XXX O
( XXX O
ABSTRACT XXX O
TRUNCATED XXX O
AT XXX O
250 XXX O
WORDS XXX O
) XXX O

The XXX O
slower-electrophoretic-mobility XXX O
form XXX O
of XXX O
p68 XXX B-GENE
was XXX O
absent XXX O
in XXX O
human XXX O
cells XXX O
in XXX O
G1 XXX O
/ XXX O
S XXX O
and XXX O
appeared XXX O
as XXX O
the XXX O
cells XXX O
entered XXX O
G2 XXX O
/ XXX O
M XXX O
. XXX O

Fragments XXX O
containing XXX O
the XXX O
21-base-pair XXX O
repeat XXX O
region XXX O
, XXX O
the XXX O
enhancer XXX O
of XXX O
simian XXX O
virus XXX O
40 XXX O
or XXX O
both XXX O
strongly XXX O
stimulated XXX O
beta-galactosidase XXX B-GENE
synthesis XXX O
, XXX O
and XXX O
three XXX O
fragments XXX O
from XXX O
the XXX O
polyomavirus XXX O
enhancer XXX O
region XXX O
stimulated XXX O
moderate XXX O
levels XXX O
. XXX O

It XXX O
is XXX O
concluded XXX O
that XXX O
contact XXX O
allergy XXX O
to XXX O
K-CG XXX O
is XXX O
common XXX O
. XXX O

Characterization XXX O
of XXX O
LRP XXX B-GENE
, XXX O
a XXX O
leucine-rich XXX B-GENE
repeat XXX I-GENE
( XXX I-GENE
LRR XXX I-GENE
) XXX I-GENE
protein XXX I-GENE
from XXX I-GENE
tomato XXX I-GENE
plants XXX I-GENE
that XXX O
is XXX O
processed XXX O
during XXX O
pathogenesis XXX O
. XXX O

We XXX O
did XXX O
not XXX O
detect XXX O
p50 XXX B-GENE
in XXX O
association XXX O
with XXX O
native XXX B-GENE
glucocorticoid XXX I-GENE
receptor XXX I-GENE
in XXX O
L XXX O
cells XXX O
or XXX O
with XXX O
the XXX O
overexpressed XXX O
glucocorticoid XXX B-GENE
receptor XXX I-GENE
in XXX O
Chinese XXX O
hamster XXX O
ovary XXX O
cells XXX O
. XXX O

Hydrophobicity XXX O
analysis XXX O
indicated XXX O
that XXX O
the XXX O
KlaA XXX B-GENE
and XXX O
KlaB XXX B-GENE
polypeptides XXX I-GENE
are XXX O
likely XXX O
to XXX O
be XXX O
soluble XXX O
, XXX O
whereas XXX O
the XXX O
KlaC XXX B-GENE
polypeptide XXX I-GENE
was XXX O
predicted XXX O
to XXX O
have XXX O
four XXX O
potential XXX O
membrane-spanning XXX O
domains XXX O
. XXX O

Therefore XXX O
, XXX O
homozygous XXX O
co-deletions XXX O
of XXX O
CDKN2A XXX B-GENE
and XXX O
CDKN2B XXX B-GENE
rather XXX O
than XXX O
mutations XXX O
targeting XXX O
individual XXX O
transcripts XXX O
are XXX O
frequently XXX O
selected XXX O
for XXX O
in XXX O
these XXX O
tumors XXX O
. XXX O

To XXX O
test XXX O
the XXX O
hypothesis XXX O
that XXX O
progestin-mediated XXX O
increases XXX O
in XXX O
resting XXX O
core XXX O
temperature XXX O
and XXX O
the XXX O
core XXX O
temperature XXX O
threshold XXX O
for XXX O
sweating XXX O
onset XXX O
are XXX O
counteracted XXX O
by XXX O
estrogen XXX O
, XXX O
we XXX O
studied XXX O
eight XXX O
women XXX O
( XXX O
24 XXX O
+ XXX O
/ XXX O
- XXX O
2 XXX O
yr XXX O
) XXX O
at XXX O
27 XXX O
degrees XXX O
C XXX O
rest XXX O
, XXX O
during XXX O
20 XXX O
min XXX O
of XXX O
passive XXX O
heating XXX O
( XXX O
35 XXX O
degrees XXX O
C XXX O
) XXX O
, XXX O
and XXX O
during XXX O
40 XXX O
min XXX O
of XXX O
exercise XXX O
at XXX O
35 XXX O
degrees XXX O
C XXX O
. XXX O

CONCLUSION XXX O
: XXX O
Treatment XXX O
of XXX O
sepsis XXX O
with XXX O
the XXX O
platelet-activating XXX B-GENE
factor XXX I-GENE
antagonist XXX O
BB-882 XXX O
offers XXX O
no XXX O
advantage XXX O
over XXX O
placebo XXX O
on XXX O
survival XXX O
, XXX O
hemodynamic XXX O
status XXX O
, XXX O
respiratory XXX O
function XXX O
, XXX O
or XXX O
organ XXX O
failure XXX O
scores XXX O
. XXX O

No XXX O
differences XXX O
in XXX O
total XXX O
cholesterol XXX O
levels XXX O
were XXX O
observed XXX O
between XXX O
mapuches XXX O
and XXX O
aymaras XXX O
. XXX O

Scintigraphic XXX O
visualisation XXX O
of XXX O
Walker XXX O
carcinoma-256 XXX O
in XXX O
Sprague-Dawley XXX O
rats XXX O
by XXX O
means XXX O
of XXX O
99mTc-labelled XXX O
monocytes XXX O
. XXX O

The XXX O
recovery XXX O
rates XXX O
for XXX O
the XXX O
MB XXX O
/ XXX O
BacT XXX O
, XXX O
MGIT XXX O
960 XXX O
, XXX O
and XXX O
solid XXX O
media XXX O
were XXX O
91 XXX O
. XXX O
6 XXX O
, XXX O
87 XXX O
. XXX O
4 XXX O
, XXX O
and XXX O
54 XXX O
. XXX O
7% XXX O
, XXX O
respectively XXX O
, XXX O
for XXX O
all XXX O
mycobacteria XXX O
; XXX O
the XXX O
recovery XXX O
rates XXX O
were XXX O
93 XXX O
. XXX O
6 XXX O
, XXX O
88 XXX O
. XXX O
9 XXX O
, XXX O
and XXX O
63 XXX O
. XXX O
4% XXX O
, XXX O
respectively XXX O
, XXX O
for XXX O
M XXX O
. XXX O
tuberculosis XXX O
complex XXX O
alone XXX O
, XXX O
and XXX O
87 XXX O
. XXX O
5 XXX O
, XXX O
84 XXX O
. XXX O
4 XXX O
, XXX O
and XXX O
37 XXX O
. XXX O
5% XXX O
, XXX O
respectively XXX O
, XXX O
for XXX O
all XXX O
nontuberculous XXX O
mycobacteria XXX O
. XXX O

Ras XXX B-GENE
is XXX O
not XXX O
associated XXX O
with XXX O
the XXX O
tegument XXX O
. XXX O

In XXX O
293 XXX O
cells XXX O
, XXX O
expression XXX O
of XXX O
the XXX O
NF-kappa XXX B-GENE
B XXX I-GENE
inhibitor XXX O
, XXX O
I XXX B-GENE
kappa XXX I-GENE
B-alpha XXX I-GENE
, XXX O
reduced XXX O
the XXX O
stimulatory XXX O
activity XXX O
of XXX O
LMP XXX B-GENE
. XXX O

Studies XXX O
using XXX O
HLA-DR-B7-1-LFA-3 XXX B-GENE
triple XXX O
transfectants XXX O
showed XXX O
that XXX O
the XXX O
LFA-3-induced XXX O
NF-AT XXX B-GENE
DNA XXX O
binding XXX O
activity XXX O
was XXX O
negatively XXX O
regulated XXX O
by XXX O
B7-1 XXX B-GENE
costimulation XXX O
. XXX O

Icterus XXX O
and XXX O
beta-thalassemia XXX O
in XXX O
Congolese XXX O
children XXX O
in XXX O
Brazzaville XXX O
. XXX O

It XXX O
contains XXX O
binding XXX O
sites XXX O
for XXX O
several XXX O
transcription XXX O
factors XXX O
, XXX O
for XXX O
example XXX O
: XXX O
( XXX O
i XXX O
) XXX O
a XXX O
well-characterized XXX O
binding XXX O
site XXX O
for XXX O
rel XXX B-GENE
/ XXX I-GENE
NF-kappaB XXX I-GENE
transcription XXX I-GENE
factors XXX I-GENE
in XXX O
its XXX O
3'-end XXX O
( XXX O
the XXX O
H2TF1 XXX B-GENE
or XXX O
kappaB1 XXX B-GENE
element XXX I-GENE
) XXX O
, XXX O
( XXX O
ii XXX O
) XXX O
a XXX O
second XXX O
kappaB XXX B-GENE
site XXX I-GENE
( XXX O
the XXX O
kappaB2 XXX B-GENE
element XXX I-GENE
) XXX O
, XXX O
which XXX O
is XXX O
located XXX O
immediately XXX O
adjacent XXX O
5' XXX O
to XXX O
the XXX O
H2TF1 XXX B-GENE
element XXX I-GENE
and XXX O
which XXX O
is XXX O
recognized XXX O
by XXX O
p65 XXX B-GENE
/ XXX I-GENE
relA XXX I-GENE
in XXX O
the XXX O
human XXX B-GENE
HLA XXX I-GENE
system XXX O
, XXX O
and XXX O
( XXX O
iii XXX O
) XXX O
an XXX O
AP-1 XXX B-GENE
/ XXX I-GENE
ATF XXX I-GENE
recognition XXX I-GENE
sequence XXX I-GENE
in XXX O
the XXX O
5' XXX O
end XXX O
( XXX O
EnA-TRE XXX B-GENE
) XXX O
. XXX O

PURPOSE XXX O
: XXX O
The XXX O
purposes XXX O
of XXX O
the XXX O
present XXX O
study XXX O
were XXX O
to XXX O
assess XXX O
the XXX O
effects XXX O
of XXX O
a XXX O
12-wk XXX O
laboratory XXX O
based XXX O
aerobic XXX O
exercise XXX O
program XXX O
on XXX O
cardiopulmonary XXX O
function XXX O
, XXX O
CD4 XXX O
cell XXX O
count XXX O
, XXX O
and XXX O
physician-assessed XXX O
health XXX O
status XXX O
among XXX O
symptomatic XXX O
pre-AIDS XXX O
HIV-infected XXX O
individuals XXX O
( XXX O
N XXX O
= XXX O
28 XXX O
) XXX O
and XXX O
to XXX O
assess XXX O
the XXX O
degree XXX O
to XXX O
which XXX O
ill XXX O
health XXX O
was XXX O
associated XXX O
with XXX O
exercise XXX O
relapse XXX O
. XXX O

Ulcer XXX O
appeared XXX O
on XXX O
the XXX O
angulus XXX O
of XXX O
the XXX O
stomach XXX O
at XXX O
the XXX O
28th XXX O
week XXX O
and XXX O
resulted XXX O
in XXX O
ulcer XXX O
scar XXX O
at XXX O
the XXX O
42nd XXX O
week XXX O
. XXX O

These XXX O
similarities XXX O
suggest XXX O
that XXX O
these XXX O
E2 XXX B-GENE
proteins XXX I-GENE
are XXX O
structurally XXX O
and XXX O
evolutionarily XXX O
related XXX O
. XXX O

Treatment XXX O
and XXX O
staining XXX O
of XXX O
smears XXX O
and XXX O
sections XXX O
for XXX O
detection XXX O
of XXX O
microorganisms XXX O
. XXX O

Taxonomically XXX O
significant XXX O
colour XXX O
changes XXX O
in XXX O
Brevibacterium XXX O
linens XXX O
probably XXX O
associated XXX O
with XXX O
a XXX O
carotenoid-like XXX O
pigment XXX O
. XXX O

The XXX O
effect XXX O
of XXX O
a XXX O
tissue XXX O
emulsion XXX O
, XXX O
vitamin XXX O
A XXX O
and XXX O
nonspecific XXX O
gamma-globulin XXX B-GENE
on XXX O
the XXX O
blood XXX O
clearance XXX O
in XXX O
rabbits XXX O
. XXX O

The XXX O
enhanced XXX O
cysteine XXX O
formation XXX O
in XXX O
a XXX O
pCSK4F XXX O
plant XXX O
responding XXX O
to XXX O
sulfite XXX O
was XXX O
also XXX O
observed XXX O
in XXX O
leaf XXX O
discs XXX O
. XXX O

Examination XXX O
of XXX O
immediate-early XXX O
transcription XXX O
factor XXX O
expression XXX O
during XXX O
the XXX O
MDI XXX O
regimen XXX O
revealed XXX O
that XXX O
RA XXX O
mediated XXX O
an XXX O
elevated XXX O
, XXX O
prolonged XXX O
expression XXX O
of XXX O
c-Jun XXX B-GENE
mRNA XXX I-GENE
accompanied XXX O
by XXX O
diminished XXX O
expression XXX O
of XXX O
c-Fos XXX B-GENE
and XXX O
Jun-B XXX B-GENE
mRNAs XXX I-GENE
. XXX O

Consistent XXX O
with XXX O
the XXX O
in XXX O
vivo XXX O
result XXX O
, XXX O
the XXX O
pseudorevertant XXX O
endonucleases XXX B-GENE
in XXX O
the XXX O
crude XXX O
cell XXX O
extract XXX O
display XXX O
site-specific XXX O
partial XXX O
DNA XXX O
cleavage XXX O
activity XXX O
. XXX O

Six XXX O
of XXX O
them XXX O
, XXX O
NUC1 XXX B-GENE
, XXX O
PRP21 XXX B-GENE
( XXX O
also XXX O
called XXX O
SPP91 XXX B-GENE
) XXX O
, XXX O
CDC6 XXX B-GENE
, XXX O
CRY2 XXX B-GENE
, XXX O
the XXX O
gene XXX O
encoding XXX O
the XXX O
ribosomal XXX B-GENE
protein XXX I-GENE
S24 XXX I-GENE
and XXX O
the XXX O
gene XXX O
coding XXX O
for XXX O
a XXX O
hypothetical XXX O
protein XXX O
of XXX O
599 XXX O
amino XXX O
acids XXX O
, XXX O
have XXX O
been XXX O
sequenced XXX O
previously XXX O
. XXX O

The XXX O
spacing XXX O
of XXX O
the XXX O
essential XXX O
N-terminal XXX O
domain XXX O
( XXX O
END XXX O
) XXX O
relative XXX O
to XXX O
the XXX O
HFD XXX O
can XXX O
be XXX O
changed XXX O
significantly XXX O
without XXX O
an XXX O
apparent XXX O
effect XXX O
on XXX O
Cse4p XXX B-GENE
function XXX O
. XXX O

Vam7p XXX B-GENE
, XXX O
a XXX O
SNAP-25-like XXX B-GENE
molecule XXX I-GENE
, XXX O
and XXX O
Vam3p XXX B-GENE
, XXX O
a XXX O
syntaxin XXX B-GENE
homolog XXX I-GENE
, XXX O
function XXX O
together XXX O
in XXX O
yeast XXX O
vacuolar XXX O
protein XXX O
trafficking XXX O
. XXX O

A XXX O
potential XXX O
binding XXX O
site XXX O
for XXX O
the XXX O
dShc XXX B-GENE
PTB XXX B-GENE
domain XXX I-GENE
is XXX O
located XXX O
at XXX O
Tyr-1228 XXX O
of XXX O
DER XXX B-GENE
. XXX O

Chimeras XXX O
containing XXX O
IE1 XXX B-GENE
peptides XXX I-GENE
dramatically XXX O
activated XXX O
transcription XXX O
of XXX O
the XXX O
basal XXX O
promoter XXX O
only XXX O
when XXX O
lac XXX B-GENE
operator XXX I-GENE
sequences XXX I-GENE
were XXX O
present XXX O
. XXX O

After XXX O
10 XXX O
months XXX O
of XXX O
treatment XXX O
with XXX O
the XXX O
conjugated XXX O
estrogen XXX O
, XXX O
both XXX O
his XXX O
height XXX O
and XXX O
weight XXX O
showed XXX O
improvement XXX O
, XXX O
while XXX O
his XXX O
bone XXX O
mineral XXX O
density XXX O
and XXX O
bone XXX O
age XXX O
were XXX O
increased XXX O
. XXX O

Agranulocytosis XXX O
treatment XXX O
with XXX O
rhGM-CSF XXX B-GENE
. XXX O

This XXX O
sequence XXX O
is XXX O
very XXX O
similar XXX O
to XXX O
the XXX O
insulin XXX B-GENE
response XXX I-GENE
sequence XXX I-GENE
found XXX O
in XXX O
the XXX O
regulatory XXX O
region XXX O
of XXX O
other XXX O
genes XXX O
negatively XXX O
regulated XXX O
by XXX O
insulin XXX B-GENE
such XXX O
as XXX O
those XXX O
encoding XXX O
phosphoenolpyruvate XXX B-GENE
carboxykinase XXX I-GENE
, XXX O
tyrosine XXX B-GENE
aminotransferase XXX I-GENE
, XXX O
and XXX O
insulin-like XXX B-GENE
growth XXX I-GENE
factor-binding XXX I-GENE
protein XXX I-GENE
1 XXX I-GENE
. XXX O

Beyond XXX O
the XXX O
Tower XXX O
of XXX O
Babel XXX O
: XXX O
a XXX O
nomenclature XXX O
for XXX O
suicidology XXX O
. XXX O

Animal XXX O
experimental XXX O
and XXX O
clinical XXX O
applications XXX O
of XXX O
plates XXX O
, XXX O
screws XXX O
and XXX O
spinal XXX O
segmental XXX O
replacement XXX O
implants XXX O
made XXX O
of XXX O
this XXX O
composite XXX O
material XXX O
have XXX O
shown XXX O
good XXX O
results XXX O
so XXX O
far XXX O
. XXX O

Naltrexone XXX O
has XXX O
been XXX O
recently XXX O
approved XXX O
by XXX O
the XXX O
Food XXX O
and XXX O
Drug XXX O
Administration XXX O
for XXX O
the XXX O
treatment XXX O
of XXX O
alcohol XXX O
dependence XXX O
. XXX O

The XXX O
mean XXX O
weight XXX O
and XXX O
height XXX O
velocities XXX O
were XXX O
148% XXX O
and XXX O
122% XXX O
of XXX O
the XXX O
standard XXX O
, XXX O
respectively XXX O
. XXX O

Albumin XXX B-GENE
and XXX O
cyclic XXX O
AMP XXX O
levels XXX O
in XXX O
peritoneal XXX O
fluids XXX O
in XXX O
the XXX O
child XXX O
. XXX O

In XXX O
the XXX O
present XXX O
study XXX O
, XXX O
we XXX O
transiently XXX O
expressed XXX O
in XXX O
primary XXX O
cultures XXX O
of XXX O
rat XXX O
hepatocytes XXX O
plasmids XXX O
consisting XXX O
of XXX O
CYP3A1 XXX B-GENE
5'-flanking XXX I-GENE
sequences XXX I-GENE
fused XXX O
to XXX O
a XXX O
chloramphenicol XXX B-GENE
acetyltransferase XXX I-GENE
reporter XXX I-GENE
plasmid XXX O
. XXX O

A XXX O
cDNA XXX O
encoding XXX O
a XXX O
new XXX O
human XXX O
lymphocyte XXX O
cell XXX O
surface XXX O
molecule XXX O
has XXX O
been XXX O
isolated XXX O
and XXX O
shown XXX O
to XXX O
identify XXX O
a XXX O
fourth XXX O
member XXX O
of XXX O
a XXX O
recently XXX O
discovered XXX O
family XXX O
of XXX O
adhesion XXX O
proteins XXX O
. XXX O

Here XXX O
we XXX O
demonstrate XXX O
that XXX O
the XXX O
Ras-activated XXX O
Raf-MEK-extracellular XXX B-GENE
signal-regulated XXX I-GENE
kinase XXX I-GENE
( XXX O
ERK XXX B-GENE
) XXX O
signaling XXX O
pathway XXX O
can XXX O
specifically XXX O
control XXX O
the XXX O
expression XXX O
of XXX O
individual XXX O
integrin XXX B-GENE
subunits XXX I-GENE
in XXX O
a XXX O
variety XXX O
of XXX O
human XXX O
and XXX O
mouse XXX O
cell XXX O
lines XXX O
. XXX O

RESULTS XXX O
: XXX O
We XXX O
isolated XXX O
a XXX O
C XXX O
. XXX O
elegans XXX O
cDNA XXX O
that XXX O
encoded XXX O
a XXX O
protein XXX O
which XXX O
was XXX O
similar XXX O
to XXX O
, XXX O
but XXX O
not XXX O
exactly XXX O
homologous XXX O
with XXX O
mammalian XXX O
p120 XXX B-GENE
Ras-GAP XXX I-GENE
. XXX O

Petko XXX O
, XXX O
and XXX O
S XXX O
. XXX O

Among XXX O
82 XXX O
superficial XXX O
lesions XXX O
34 XXX O
were XXX O
classified XXX O
as XXX O
showing XXX O
CR XXX O
and XXX O
another XXX O
23 XXX O
as XXX O
showing XXX O
PR XXX O
, XXX O
with XXX O
a XXX O
response XXX O
rate XXX O
of XXX O
69 XXX O
. XXX O
5% XXX O
. XXX O

The XXX O
mammalian XXX B-GENE
phosphoinositide XXX I-GENE
3-kinases XXX I-GENE
( XXX O
PI3Ks XXX B-GENE
) XXX O
p110alpha XXX B-GENE
, XXX I-GENE
beta XXX I-GENE
, XXX I-GENE
and XXX I-GENE
delta XXX I-GENE
form XXX O
heterodimers XXX O
with XXX O
Src XXX B-GENE
homology XXX I-GENE
2 XXX I-GENE
( XXX I-GENE
SH2 XXX I-GENE
) XXX I-GENE
domain-containing XXX I-GENE
adaptors XXX I-GENE
such XXX O
as XXX O
p85alpha XXX B-GENE
or XXX O
p55 XXX B-GENE
( XXX I-GENE
PIK XXX I-GENE
) XXX I-GENE
. XXX O

Transformed XXX O
bacterial XXX O
colonies XXX O
were XXX O
screened XXX O
for XXX O
recombinant XXX O
plasmids XXX O
containing XXX O
cDNA XXX O
coding XXX O
for XXX O
BiP XXX B-GENE
by XXX O
hybrid-selected XXX O
mRNA XXX O
translation XXX O
. XXX O

Although XXX O
no XXX O
differences XXX O
were XXX O
noted XXX O
in XXX O
the XXX O
decrease XXX O
in XXX O
platelet XXX O
counts XXX O
between XXX O
the XXX O
two XXX O
groups XXX O
, XXX O
fibrinogen XXX B-GENE
levels XXX O
and XXX O
alpha XXX B-GENE
2-antiplasmin XXX I-GENE
levels XXX O
declined XXX O
less XXX O
drastically XXX O
in XXX O
the XXX O
antithrombin-treated XXX O
group XXX O
. XXX O

Using XXX O
an XXX O
RNase XXX O
H-mediated XXX O
mapping XXX O
technique XXX O
, XXX O
we XXX O
show XXX O
that XXX O
the XXX O
64-kDa XXX O
subunit XXX O
of XXX O
CstF XXX B-GENE
can XXX O
be XXX O
photo XXX O
cross-linked XXX O
to XXX O
pre-mRNAs XXX O
at XXX O
U-rich XXX O
regions XXX O
located XXX O
downstream XXX O
of XXX O
the XXX O
cleavage XXX O
site XXX O
of XXX O
the XXX O
simian XXX O
virus XXX O
40 XXX O
late XXX O
and XXX O
adenovirus XXX O
L3 XXX O
pre-mRNAs XXX O
. XXX O

Either XXX O
20 XXX O
mg XXX O
mitomycin XXX O
/ XXX O
20 XXX O
ml XXX O
distilled XXX O
water XXX O
or XXX O
40 XXX O
mg XXX O
/ XXX O
40 XXX O
ml XXX O
distilled XXX O
water XXX O
was XXX O
locally XXX O
instilled XXX O
into XXX O
the XXX O
bladder XXX O
with XXX O
a XXX O
catheter XXX O
after XXX O
emptying XXX O
it XXX O
and XXX O
was XXX O
left XXX O
for XXX O
about XXX O
25-l20 XXX O
min XXX O
. XXX O

Total XXX O
cholesterol XXX O
was XXX O
also XXX O
reduced XXX O
at XXX O
week XXX O
12 XXX O
by XXX O
17 XXX O
. XXX O
0% XXX O
( XXX O
20 XXX O
mg XXX O
/ XXX O
day XXX O
) XXX O
and XXX O
15 XXX O
. XXX O
7% XXX O
( XXX O
20-30 XXX O
mg XXX O
/ XXX O
day XXX O
) XXX O
, XXX O
and XXX O
at XXX O
week XXX O
52 XXX O
by XXX O
20 XXX O
. XXX O
4% XXX O
( XXX O
< XXX O
or XXX O
= XXX O
20 XXX O
mg XXX O
/ XXX O
day XXX O
) XXX O
and XXX O
19 XXX O
. XXX O
2% XXX O
( XXX O
> XXX O
or XXX O
= XXX O
30 XXX O
mg XXX O
/ XXX O
day XXX O
) XXX O
. XXX O

Saccharomyces XXX O
cerevisiae XXX O
has XXX O
been XXX O
used XXX O
widely XXX O
both XXX O
as XXX O
a XXX O
model XXX O
system XXX O
for XXX O
unraveling XXX O
the XXX O
biochemical XXX O
, XXX O
genetic XXX O
, XXX O
and XXX O
molecular XXX O
details XXX O
of XXX O
gene XXX O
expression XXX O
and XXX O
the XXX O
secretion XXX O
process XXX O
, XXX O
and XXX O
as XXX O
a XXX O
host XXX O
for XXX O
the XXX O
production XXX O
of XXX O
heterologous XXX O
proteins XXX O
of XXX O
biotechnological XXX O
interest XXX O
. XXX O

Giant XXX O
pilomatrix XXX O
carcinoma XXX O
: XXX O
report XXX O
and XXX O
review XXX O
of XXX O
the XXX O
literature XXX O
. XXX O

The XXX O
RI XXX B-GENE
alpha XXX I-GENE
gene XXX I-GENE
is XXX O
composed XXX O
of XXX O
nine XXX O
coding XXX O
exons XXX O
of XXX O
varying XXX O
lengths XXX O
, XXX O
separated XXX O
by XXX O
introns XXX O
, XXX O
giving XXX O
the XXX O
gene XXX O
a XXX O
total XXX O
length XXX O
of XXX O
at XXX O
least XXX O
21 XXX O
kb XXX O
. XXX O
our XXX O
recent XXX O
cloning XXX O
of XXX O
a XXX O
processed XXX O
RI XXX B-GENE
alpha XXX I-GENE
pseudogene XXX I-GENE
with XXX O
a XXX O
5'-noncoding XXX O
region XXX O
different XXX O
from XXX O
the XXX O
previously XXX O
reported XXX O
RI XXX B-GENE
alpha XXX I-GENE
complementary XXX I-GENE
RNA XXX I-GENE
indicated XXX O
that XXX O
the XXX O
RI XXX B-GENE
alpha XXX I-GENE
gene XXX I-GENE
may XXX O
have XXX O
multiple XXX O
leader XXX O
exons XXX O
giving XXX O
rise XXX O
to XXX O
alternately XXX O
spliced XXX O
messenger XXX O
RNAs XXX O
( XXX O
mRNAs XXX O
) XXX O
. XXX O

1 XXX O
in XXX O
Ho XXX O
Chi XXX O
Minh XXX O
City XXX O
was XXX O
studied XXX O
by XXX O
culture XXX O
and XXX O
latex XXX O
agglutination XXX O
of XXX O
blood XXX O
, XXX O
cerebrospinal XXX O
fluid XXX O
, XXX O
urine XXX O
and XXX O
pleural XXX O
fluid XXX O
. XXX O

Patients XXX O
underwent XXX O
pretreatment XXX O
cystoscopy XXX O
and XXX O
detailed XXX O
tumor XXX O
mapping XXX O
, XXX O
and XXX O
were XXX O
treated XXX O
with XXX O
75 XXX O
mg XXX O
. XXX O
/ XXX O
m XXX O
. XXX O
2 XXX O
cisplatin XXX O
on XXX O
day XXX O
1 XXX O
and XXX O
1 XXX O
gm XXX O
. XXX O
/ XXX O
m XXX O
. XXX O
2 XXX O
daily XXX O
, XXX O
5-fluorouracil XXX O
on XXX O
days XXX O
1 XXX O
to XXX O
4 XXX O
and XXX O
definitive XXX O
radiotherapy XXX O
. XXX O

Genomic XXX O
Southern XXX O
blot XXX O
analysis XXX O
and XXX O
chromosome XXX O
mapping XXX O
showed XXX O
that XXX O
GPRK6 XXX B-GENE
hybridizes XXX O
to XXX O
two XXX O
closely XXX O
related XXX O
genes XXX O
located XXX O
on XXX O
chromosomes XXX O
5 XXX O
and XXX O
13 XXX O
and XXX O
are XXX O
, XXX O
therefore XXX O
, XXX O
distinct XXX O
from XXX O
the XXX O
GPRK XXX B-GENE
located XXX O
near XXX O
the XXX O
Huntington XXX B-GENE
disease XXX I-GENE
locus XXX I-GENE
on XXX O
chromosome XXX O
4 XXX O
. XXX O

Candidate XXX O
tumor XXX O
suppressor XXX O
genes XXX O
, XXX O
Mts1 XXX B-GENE
( XXX O
p16INK4a XXX B-GENE
) XXX O
and XXX O
Mts2 XXX B-GENE
( XXX O
p15INK4b XXX B-GENE
) XXX O
, XXX O
have XXX O
been XXX O
mapped XXX O
to XXX O
this XXX O
region XXX O
, XXX O
but XXX O
by XXX O
Southern XXX O
blot XXX O
analysis XXX O
, XXX O
no XXX O
homozygous XXX O
deletions XXX O
were XXX O
detected XXX O
in XXX O
either XXX O
gene XXX O
. XXX O

The XXX O
effects XXX O
of XXX O
pharmacological XXX O
treatment XXX O
and XXX O
professional XXX O
care XXX O
and XXX O
support XXX O
may XXX O
improve XXX O
when XXX O
dementia XXX O
is XXX O
detected XXX O
in XXX O
an XXX O
early XXX O
stage XXX O
. XXX O

Apo XXX B-GENE
A-I XXX I-GENE
level XXX O
was XXX O
unrelated XXX O
to XXX O
age XXX O
, XXX O
but XXX O
increased XXX O
with XXX O
ethanol XXX O
consumption XXX O
and XXX O
decreased XXX O
with XXX O
adiposity XXX O
. XXX O

The XXX O
linear XXX O
plasmid XXX O
pDHL1 XXX O
from XXX O
Debaryomyces XXX O
hansenii XXX O
encodes XXX O
a XXX O
protein XXX O
highly XXX O
homologous XXX O
to XXX O
the XXX O
pGKL1-plasmid XXX B-GENE
DNA XXX I-GENE
polymerase XXX I-GENE
. XXX O

Paradoxically XXX O
, XXX O
coexpression XXX O
of XXX O
the XXX O
transcriptionally XXX O
inactive XXX O
, XXX O
amino-terminally XXX O
deleted XXX O
IDX-1 XXX B-GENE
mutant XXX I-GENE
proteins XXX I-GENE
, XXX O
either XXX O
with XXX O
the XXX O
wild-type XXX B-GENE
IDX-1 XXX I-GENE
or XXX O
with XXX O
themselves XXX O
, XXX O
results XXX O
in XXX O
a XXX O
marked XXX O
enhancement XXX O
of XXX O
transactivation XXX O
of XXX O
the XXX O
transcriptional XXX O
TAAT-1 XXX B-GENE
element XXX I-GENE
reporter XXX I-GENE
. XXX O

However XXX O
, XXX O
the XXX O
rtFc XXX B-GENE
gamma XXX I-GENE
R XXX I-GENE
alpha XXX I-GENE
cDNA XXX I-GENE
clone XXX O
is XXX O
complementary XXX O
to XXX O
at XXX O
least XXX O
two XXX O
different-sized XXX O
mRNAs XXX O
expressed XXX O
by XXX O
CRNK-16 XXX O
cells XXX O
, XXX O
contrasting XXX O
the XXX O
single XXX O
Fc XXX B-GENE
gamma XXX I-GENE
R-related XXX I-GENE
mRNA XXX I-GENE
species XXX O
expressed XXX O
by XXX O
human XXX O
and XXX O
mouse XXX O
natural XXX O
killer XXX O
cells XXX O
. XXX O

Flap XXX O
survival XXX O
depends XXX O
on XXX O
the XXX O
development XXX O
of XXX O
a XXX O
small XXX O
number XXX O
of XXX O
vascular XXX O
connections XXX O
between XXX O
vessels XXX O
arising XXX O
from XXX O
the XXX O
pedicle XXX O
and XXX O
preexisting XXX O
dermal XXX O
vessels XXX O
. XXX O

The XXX O
predicted XXX O
molecular XXX O
weight XXX O
of XXX O
the XXX O
polyprotein XXX O
encoded XXX O
by XXX O
ORF1 XXX O
is XXX O
33 XXX O
kilodaltons XXX O
( XXX O
kDa XXX O
) XXX O
. XXX O

After XXX O
a XXX O
year XXX O
of XXX O
planning XXX O
in XXX O
the XXX O
Laboratory XXX O
Assistants' XXX O
School XXX O
in XXX O
Stockholm XXX O
: XXX O
new XXX O
education XXX O
for XXX O
laboratory XXX O
assistants XXX O
is XXX O
now XXX O
arranged XXX O
. XXX O

These XXX O
regions XXX O
contain XXX O
inverted XXX O
E-box XXX O
palindromic XXX O
or XXX O
direct XXX O
repeat XXX O
motifs XXX O
and XXX O
bind XXX O
SREBP-1 XXX B-GENE
with XXX O
different XXX O
affinities XXX O
. XXX O

Electronic XXX O
data XXX O
processing XXX O
( XXX O
EDP XXX O
) XXX O
latex XXX O
immunoassay XXX O
using XXX O
anti-human XXX B-GENE
seminal XXX I-GENE
acid XXX I-GENE
phosphatase XXX I-GENE
( XXX O
anti-HSAP XXX B-GENE
) XXX O
immune XXX O
serum XXX O
was XXX O
applied XXX O
for XXX O
the XXX O
species XXX O
and XXX O
organ XXX O
identification XXX O
of XXX O
human XXX O
seminal XXX O
stains XXX O
. XXX O

The XXX O
author XXX O
provides XXX O
a XXX O
rationale XXX O
for XXX O
an XXX O
interactional XXX O
view XXX O
and XXX O
presents XXX O
a XXX O
case XXX O
in XXX O
which XXX O
post-surgical XXX O
hiccups XXX O
were XXX O
successfully XXX O
treated XXX O
, XXX O
using XXX O
principles XXX O
developed XXX O
by XXX O
the XXX O
Mental XXX O
Research XXX O
Institute XXX O
. XXX O

Near XXX O
a XXX O
third XXX O
( XXX O
31 XXX O
. XXX O
6% XXX O
) XXX O
of XXX O
Insulin XXX B-GENE
Dependent XXX O
and XXX O
a XXX O
third XXX O
( XXX O
33 XXX O
. XXX O
41% XXX O
) XXX O
for XXX O
Non XXX O
Insulin XXX B-GENE
Dependent XXX O
were XXX O
of XXX O
D XXX O
, XXX O
F XXX O
, XXX O
H XXX O
White's XXX O
Class XXX O
. XXX O

Subretinal XXX O
fluid XXX O
was XXX O
punctured XXX O
on XXX O
the XXX O
poorer XXX O
eye XXX O
in XXX O
19 XXX O
eyes XXX O
( XXX O
52 XXX O
. XXX O
7% XXX O
) XXX O
and XXX O
on XXX O
the XXX O
better XXX O
eye XXX O
in XXX O
7 XXX O
eyes XXX O
( XXX O
19 XXX O
. XXX O
4% XXX O
) XXX O
. XXX O

In XXX O
each XXX O
compartment XXX O
O2 XXX O
is XXX O
removed XXX O
by XXX O
the XXX O
tissues XXX O
as XXX O
a XXX O
chemical XXX O
reaction XXX O
takes XXX O
place XXX O
between XXX O
O2 XXX O
and XXX O
oxyhemoglobin XXX B-GENE
( XXX O
HbO2 XXX B-GENE
) XXX O
. XXX O

Additionally XXX O
, XXX O
the XXX O
enzyme XXX O
shows XXX O
activity XXX O
towards XXX O
triglycerides XXX O
such XXX O
as XXX O
olive XXX O
oil XXX O
and XXX O
tributyrin XXX O
and XXX O
towards XXX O
egg-yolk XXX O
emulsions XXX O
. XXX O

In XXX O
the XXX O
past XXX O
, XXX O
immunology XXX O
in XXX O
Singapore XXX O
was XXX O
mainly XXX O
confined XXX O
to XXX O
serology XXX O
for XXX O
the XXX O
diagnosis XXX O
of XXX O
certain XXX O
infectious XXX O
diseases XXX O
. XXX O

General XXX O
formulae XXX O
for XXX O
estimating XXX O
heritability XXX O
in XXX O
a XXX O
population XXX O
with XXX O
related XXX O
parents XXX O
. XXX O

Patients XXX O
with XXX O
psychotropic XXX O
drugs XXX O
showed XXX O
significantly XXX O
higher XXX O
PRL XXX B-GENE
levels XXX O
. XXX O

The XXX O
potency XXX O
of XXX O
the XXX O
effect XXX O
of XXX O
Nim XXX O
( XXX O
0 XXX O
. XXX O
5 XXX O
mg XXX O
. XXX O
kg-1 XXX O
i XXX O
. XXX O
p XXX O
. XXX O
) XXX O
was XXX O
similar XXX O
to XXX O
that XXX O
of XXX O
NBP XXX O
( XXX O
10 XXX O
mg XXX O
. XXX O
kg-1 XXX O
i XXX O
. XXX O
p XXX O
. XXX O
) XXX O
. XXX O

The XXX O
histamine XXX B-GENE
H1 XXX I-GENE
receptor XXX I-GENE
antagonists XXX O
( XXX O
antihistamines XXX O
) XXX O
are XXX O
an XXX O
important XXX O
class XXX O
of XXX O
medications XXX O
used XXX O
for XXX O
the XXX O
relief XXX O
of XXX O
common XXX O
symptoms XXX O
associated XXX O
with XXX O
hyperhistaminic XXX O
conditions XXX O
occurring XXX O
in XXX O
children XXX O
and XXX O
adults XXX O
. XXX O

Thalamotomy XXX O
aiming XXX O
at XXX O
the XXX O
CM-Pf XXX O
complex XXX O
and XXX O
using XXX O
stereotactic XXX O
gamma XXX O
irradiation XXX O
has XXX O
been XXX O
performed XXX O
in XXX O
a XXX O
series XXX O
of XXX O
52 XXX O
patients XXX O
with XXX O
severe XXX O
pain XXX O
due XXX O
to XXX O
malignancy XXX O
. XXX O

The XXX O
zona XXX O
pellucida XXX O
( XXX O
ZP XXX O
) XXX O
, XXX O
the XXX O
extracellular XXX O
glycocalyx XXX O
that XXX O
surrounds XXX O
the XXX O
oocyte XXX O
, XXX O
is XXX O
well XXX O
known XXX O
to XXX O
mediate XXX O
homologous XXX O
gamete XXX O
interaction XXX O
. XXX O

We XXX O
have XXX O
characterized XXX O
a XXX O
panel XXX O
of XXX O
6 XXX O
monoclonal XXX O
antibodies XXX O
raised XXX O
against XXX O
human XXX B-GENE
platelet XXX I-GENE
talin XXX I-GENE
by XXX O
Western XXX O
blotting XXX O
, XXX O
immune XXX O
precipitation XXX O
, XXX O
and XXX O
immunofluorescence XXX O
, XXX O
and XXX O
shown XXX O
that XXX O
antibodies XXX B-GENE
TA205 XXX I-GENE
and XXX O
TD77 XXX B-GENE
disrupt XXX O
actin XXX B-GENE
stress XXX O
fibers XXX O
and XXX O
focal XXX O
adhesions XXX O
, XXX O
and XXX O
inhibit XXX O
cell XXX O
motility XXX O
when XXX O
microinjected XXX O
into XXX O
human XXX O
fibroblasts XXX O
. XXX O

The XXX O
cell XXX O
cycle XXX O
and XXX O
transcriptional XXX O
defects XXX O
caused XXX O
by XXX O
taf17 XXX B-GENE
( XXX I-GENE
slm7-1 XXX I-GENE
) XXX I-GENE
are XXX O
consistent XXX O
with XXX O
the XXX O
role XXX O
of XXX O
TAF XXX B-GENE
( XXX I-GENE
II XXX I-GENE
) XXX I-GENE
s XXX I-GENE
as XXX O
modulators XXX O
of XXX O
transcriptional XXX O
activation XXX O
and XXX O
may XXX O
reflect XXX O
a XXX O
role XXX O
for XXX O
TAF17 XXX B-GENE
in XXX O
regulating XXX O
activation XXX O
by XXX O
SBF XXX B-GENE
and XXX O
MBF XXX B-GENE
. XXX O

These XXX O
data XXX O
will XXX O
help XXX O
us XXX O
to XXX O
better XXX O
detail XXX O
the XXX O
CXCR4 XXX B-GENE
structural XXX O
requirements XXX O
exhibited XXX O
by XXX O
different XXX O
HIV-1 XXX O
strains XXX O
and XXX O
will XXX O
direct XXX O
further XXX O
mutagenesis XXX O
efforts XXX O
aimed XXX O
at XXX O
better XXX O
defining XXX O
the XXX O
domains XXX O
in XXX O
CXCR4 XXX B-GENE
involved XXX O
in XXX O
the XXX O
HIV-1 XXX O
Env-mediated XXX O
fusion XXX O
process XXX O
. XXX O

There XXX O
was XXX O
no XXX O
apparent XXX O
effect XXX O
of XXX O
growth XXX O
temperature XXX O
on XXX O
the XXX O
steady-state XXX O
levels XXX O
of XXX O
fad7 XXX B-GENE
mRNA XXX I-GENE
in XXX O
wild XXX O
type XXX O
plants XXX O
. XXX O

Here XXX O
, XXX O
we XXX O
show XXX O
that XXX O
the XXX O
phorbol XXX O
ester XXX O
PMA XXX O
decreases XXX O
both XXX O
basal XXX O
and XXX O
dexamethasone XXX O
/ XXX O
cAMP-induced XXX O
expression XXX O
of XXX O
a XXX O
luciferase XXX B-GENE
gene XXX I-GENE
under XXX O
the XXX O
control XXX O
of XXX O
the XXX O
G6Pase XXX B-GENE
promoter XXX I-GENE
in XXX O
transiently XXX O
transfected XXX O
H4IIE XXX O
hepatoma XXX O
cells XXX O
. XXX O

They XXX O
are XXX O
present XXX O
in XXX O
many XXX O
kinds XXX O
of XXX O
living XXX O
things XXX O
, XXX O
but XXX O
their XXX O
functions XXX O
, XXX O
especially XXX O
those XXX O
in XXX O
humans XXX O
, XXX O
are XXX O
unclear XXX O
. XXX O

A511 XXX O
is XXX O
a XXX O
broad-host-range XXX O
, XXX O
virulent XXX O
myovirus XXX O
for XXX O
Listeria XXX O
monocytogenes XXX O
. XXX O

Regional XXX O
cerebral XXX O
blood XXX O
flow XXX O
was XXX O
measured XXX O
using XXX O
N-isopropyl-123I-iodoamphetamine XXX O
with XXX O
single-photon XXX O
emission XXX O
computed XXX O
tomography XXX O
( XXX O
CT XXX O
) XXX O
in XXX O
16 XXX O
aged XXX O
patients XXX O
with XXX O
noninsulin-dependent XXX O
diabetes XXX O
mellitus XXX O
( XXX O
NIDDM XXX O
, XXX O
average XXX O
age XXX O
72 XXX O
. XXX O
8 XXX O
years XXX O
, XXX O
average XXX O
fasting XXX O
plasma XXX O
glucose XXX O
7 XXX O
. XXX O
7 XXX O
mmol XXX O
/ XXX O
L XXX O
) XXX O
, XXX O
and XXX O
12 XXX O
nondiabetic XXX O
subjects XXX O
( XXX O
71 XXX O
. XXX O
6 XXX O
years XXX O
, XXX O
5 XXX O
. XXX O
3 XXX O
mmol XXX O
/ XXX O
L XXX O
) XXX O
. XXX O

The XXX O
role XXX O
of XXX O
transport XXX O
by XXX O
sea XXX O
ice XXX O
from XXX O
the XXX O
Kara XXX O
Sea XXX O
into XXX O
the XXX O
Arctic XXX O
Ocean XXX O
was XXX O
assessed XXX O
by XXX O
a XXX O
small XXX O
subgroup XXX O
at XXX O
GEOMAR XXX O
. XXX O

Inhibition XXX O
of XXX O
constitutive XXX O
NF-kappaB XXX B-GENE
activity XXX O
results XXX O
in XXX O
cell XXX O
death XXX O
of XXX O
TT XXX O
cells XXX O
and XXX O
blocks XXX O
focus XXX O
formation XXX O
induced XXX O
by XXX O
oncogenic XXX O
forms XXX O
of XXX O
RET XXX B-GENE
in XXX O
NIH XXX O
3T3 XXX O
cells XXX O
. XXX O

Codon XXX O
optimization XXX O
for XXX O
high-level XXX O
expression XXX O
of XXX O
human XXX B-GENE
erythropoietin XXX I-GENE
( XXX O
EPO XXX B-GENE
) XXX O
in XXX O
mammalian XXX O
cells XXX O
. XXX O

CD4 XXX B-GENE
lymphocyte XXX O
and XXX O
viral XXX O
load XXX O
levels XXX O
suggested XXX O
an XXX O
optimal XXX O
response XXX O
to XXX O
ARV XXX O
therapy XXX O
at XXX O
the XXX O
time XXX O
LD XXX O
developed XXX O
. XXX O

Central XXX O
venous XXX O
catheter XXX O
used XXX O
for XXX O
recording XXX O
intracardiac XXX O
electrocardiogram XXX O
. XXX O

The XXX O
receptor XXX B-GENE
for XXX I-GENE
hyaluronan XXX I-GENE
mediated XXX I-GENE
motility XXX I-GENE
( XXX B-GENE
RHAMM XXX I-GENE
) XXX I-GENE
gene XXX I-GENE
expression XXX O
is XXX O
markedly XXX O
elevated XXX O
in XXX O
fibrosarcomas XXX O
exposed XXX O
to XXX O
transforming XXX B-GENE
growth XXX I-GENE
factor-beta1 XXX I-GENE
( XXX O
TGF-beta1 XXX B-GENE
) XXX O
. XXX O

SECONDARY XXX O
OUTCOME XXX O
MEASURE--Double-blind XXX O
caffeine-withdrawal XXX O
evaluation XXX O
. XXX O

A XXX O
causal XXX O
analysis XXX O
of XXX O
secondary XXX O
variables XXX O
showed XXX O
that XXX O
the XXX O
formation XXX O
of XXX O
FB XXX O
memories XXX O
was XXX O
primarily XXX O
associated XXX O
with XXX O
the XXX O
level XXX O
of XXX O
importance XXX O
attached XXX O
to XXX O
the XXX O
event XXX O
and XXX O
level XXX O
of XXX O
affective XXX O
response XXX O
to XXX O
the XXX O
news XXX O
. XXX O

Plastic XXX O
solution XXX O
of XXX O
elbow XXX O
joint XXX O
ankylosis XXX O
with XXX O
a XXX O
decorticated XXX O
cylindrical XXX O
flap XXX O
. XXX O

This XXX O
study XXX O
underlines XXX O
the XXX O
importance XXX O
of XXX O
terminal XXX O
SC5b-9 XXX B-GENE
complement XXX I-GENE
complex XXX I-GENE
as XXX O
a XXX O
suitable XXX O
marker XXX O
in XXX O
the XXX O
evaluation XXX O
of XXX O
complement XXX O
activation XXX O
during XXX O
cardiopulmonary XXX O
bypass XXX O
. XXX O

Glucagon XXX O
also XXX O
induced XXX O
LUC XXX B-GENE
activity XXX O
very XXX O
strongly XXX O
when XXX O
the XXX O
CRE1 XXX B-GENE
and XXX O
CRE2 XXX B-GENE
sites XXX I-GENE
were XXX O
combined XXX O
; XXX O
induction XXX O
of XXX O
the XXX O
( XXX B-GENE
CRE1 XXX I-GENE
) XXX I-GENE
3 XXX I-GENE
( XXX I-GENE
CRE2 XXX I-GENE
) XXX I-GENE
2SV40-LUC XXX I-GENE
constructs XXX I-GENE
was XXX O
positively XXX O
modulated XXX O
by XXX O
the XXX O
pO2 XXX O
. XXX O

Problems XXX O
in XXX O
the XXX O
determination XXX O
of XXX O
the XXX O
antigenic XXX O
content XXX O
of XXX O
influenza XXX O
vaccines XXX O
. XXX O

The XXX O
role XXX O
of XXX O
protein XXX B-GENE
kinase XXX I-GENE
C XXX I-GENE
signaling XXX O
in XXX O
activated XXX O
DRA XXX B-GENE
transcription XXX O
. XXX O

It XXX O
is XXX O
concluded XXX O
that XXX O
the XXX O
unique XXX O
suppository XXX O
formulation XXX O
of XXX O
CZX-S XXX O
is XXX O
useful XXX O
in XXX O
the XXX O
treatment XXX O
of XXX O
infections XXX O
in XXX O
children XXX O
with XXX O
heavy XXX O
psychophysiologic XXX O
disorders XXX O
and XXX O
in XXX O
children XXX O
who XXX O
cannot XXX O
take XXX O
oral XXX O
drugs XXX O
because XXX O
of XXX O
severe XXX O
vomiting XXX O
. XXX O

Training XXX O
for XXX O
audit XXX O
. XXX O

Tyrosine XXX O
1356 XXX O
forms XXX O
a XXX O
multisubstrate XXX O
binding XXX O
site XXX O
for XXX O
the XXX O
Grb2 XXX B-GENE
and XXX O
Shc XXX B-GENE
adaptor XXX I-GENE
proteins XXX I-GENE
, XXX O
the XXX O
p85 XXX B-GENE
subunit XXX I-GENE
of XXX O
phosphatidylinositol XXX B-GENE
3'-kinase XXX I-GENE
, XXX O
phospholipase XXX B-GENE
Cgamma XXX I-GENE
, XXX O
and XXX O
a XXX O
phosphatase XXX B-GENE
, XXX O
SHP2 XXX B-GENE
. XXX O

In XXX O
the XXX O
case XXX O
of XXX O
the XXX O
unspliceable XXX O
intron XXX O
, XXX O
repression XXX O
of XXX O
luciferase XXX B-GENE
expression XXX O
likely XXX O
involved XXX O
two XXX O
AUF1-binding XXX B-GENE
sequences XXX I-GENE
, XXX O
since XXX O
luciferase XXX B-GENE
expression XXX O
was XXX O
increased XXX O
by XXX O
deletion XXX O
of XXX O
these XXX O
sites XXX O
. XXX O

Amongst XXX O
other XXX O
qualities XXX O
, XXX O
the XXX O
book's XXX O
importance XXX O
lies XXX O
in XXX O
the XXX O
fact XXX O
that XXX O
it XXX O
associates XXX O
an XXX O
elaborate XXX O
theoretical XXX O
construction XXX O
with XXX O
the XXX O
empirical XXX O
data XXX O
, XXX O
working XXX O
within XXX O
the XXX O
possibilities XXX O
provided XXX O
by XXX O
late XXX O
19th-century XXX O
moral XXX O
statistics XXX O
. XXX O

A XXX O
method XXX O
for XXX O
determining XXX O
optimal XXX O
development XXX O
conditions XXX O
by XXX O
summary XXX O
oxygen XXX O
consumption XXX O
. XXX O

The XXX O
lines XXX O
also XXX O
differed XXX O
in XXX O
postsynaptic XXX O
, XXX O
but XXX O
not XXX O
presynaptic XXX O
, XXX O
5-HT1A XXX B-GENE
receptors XXX I-GENE
. XXX O

This XXX O
apparently XXX O
anomalous XXX O
structure XXX O
/ XXX O
activity XXX O
relationship XXX O
raises XXX O
important XXX O
issues XXX O
for XXX O
understanding XXX O
the XXX O
evolution XXX O
of XXX O
regulatory XXX O
peptides XXX O
and XXX O
the XXX O
mechanisms XXX O
that XXX O
control XXX O
their XXX O
expression XXX O
. XXX O

Ultrastructural XXX O
study XXX O
of XXX O
polyarteritis XXX O
. XXX O

Osteosarcoma XXX O
caused XXX O
by XXX O
3 XXX O
, XXX O
4-benzopyrene XXX O
. XXX O

Dopamine XXX O
neurons XXX O
in XXX O
subjects XXX O
that XXX O
received XXX O
6-OHDA XXX O
were XXX O
protected XXX O
by XXX O
pre-treatment XXX O
with XXX O
GBR-12909 XXX O
. XXX O

E2 XXX B-GENE
point XXX O
mutants XXX O
unable XXX O
to XXX O
inhibit XXX O
cell XXX O
growth XXX O
did XXX O
not XXX O
repress XXX O
cdc25A XXX B-GENE
and XXX O
cdc25B XXX B-GENE
expression XXX O
, XXX O
nor XXX O
did XXX O
the XXX O
cell XXX O
cycle XXX O
inhibitors XXX O
hydroxyurea XXX O
and XXX O
mimosine XXX O
. XXX O

Lys XXX O
( XXX O
193 XXX O
) XXX O
and XXX O
Arg XXX O
( XXX O
194 XXX O
) XXX O
, XXX O
located XXX O
at XXX O
the XXX O
COOH-terminal XXX O
end XXX O
of XXX O
HD XXX B-GENE
, XXX O
are XXX O
essential XXX O
for XXX O
dimerization XXX O
. XXX O

Regression XXX O
line XXX O
slopes XXX O
of XXX O
IBDQ XXX O
scores XXX O
were XXX O
significantly XXX O
different XXX O
in XXX O
patients XXX O
who XXX O
deteriorated XXX O
from XXX O
those XXX O
who XXX O
remained XXX O
stable XXX O
( XXX O
[ XXX O
b XXX O
] XXX O
< XXX O
0 XXX O
. XXX O
15 XXX O
; XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
0001 XXX O
) XXX O
. XXX O

A XXX O
variety XXX O
of XXX O
nuclear XXX O
ribonucleoproteins XXX O
are XXX O
believed XXX O
to XXX O
associate XXX O
directly XXX O
with XXX O
nascent XXX O
RNA XXX B-GENE
polymerase XXX I-GENE
II XXX I-GENE
transcripts XXX I-GENE
and XXX O
remain XXX O
associated XXX O
during XXX O
subsequent XXX O
nuclear XXX O
RNA XXX O
processing XXX O
reactions XXX O
, XXX O
including XXX O
pre-mRNA XXX O
polyadenylation XXX O
and XXX O
splicing XXX O
as XXX O
well XXX O
as XXX O
nucleocytoplasmic XXX O
mRNA XXX O
transport XXX O
. XXX O

Inducible XXX O
VT XXX O
was XXX O
suppressed XXX O
entirely XXX O
in XXX O
one XXX O
patient XXX O
. XXX O

Electrophoretic XXX O
mobility XXX O
shift XXX O
assays XXX O
demonstrated XXX O
specific XXX O
nuclear XXX O
protein XXX O
binding XXX O
to XXX O
-85 XXX O
/ XXX O
-64 XXX O
, XXX O
and XXX O
single XXX O
point XXX O
mutations XXX O
suggested XXX O
important XXX O
binding XXX O
nucleotides XXX O
between XXX O
-79 XXX O
/ XXX O
-68 XXX O
with XXX O
five XXX O
critical XXX O
bases XXX O
between XXX O
-74 XXX O
/ XXX O
-70 XXX O
( XXX O
5'-CTCCT-3' XXX B-GENE
) XXX O
. XXX O

The XXX O
27-base XXX O
element XXX O
interacts XXX O
with XXX O
a XXX O
PDGF-activated XXX B-GENE
serine XXX I-GENE
/ XXX I-GENE
threonine XXX I-GENE
phosphoprotein XXX I-GENE
that XXX O
is XXX O
detected XXX O
only XXX O
within XXX O
the XXX O
nucleus XXX O
of XXX O
PDGF-treated XXX O
3T3 XXX O
cells XXX O
. XXX O

The XXX O
inflation XXX O
hub XXX O
of XXX O
the XXX O
probe XXX O
is XXX O
recreated XXX O
by XXX O
modifying XXX O
a XXX O
standard XXX O
USCI XXX O
Tuohy-Borst XXX O
Y XXX O
adaptor XXX O
and XXX O
attaching XXX O
this XXX O
to XXX O
the XXX O
transected XXX O
probe XXX O
hypotube XXX O
. XXX O

The XXX O
8 XXX O
patients XXX O
receiving XXX O
Ir192 XXX O
implant XXX O
in XXX O
addition XXX O
to XXX O
external XXX O
radiation XXX O
showed XXX O
improved XXX O
( XXX O
p XXX O
= XXX O
0 XXX O
. XXX O
06 XXX O
) XXX O
survival XXX O
compared XXX O
to XXX O
the XXX O
9 XXX O
receiving XXX O
external XXX O
only XXX O
: XXX O
median XXX O
15 XXX O
months XXX O
( XXX O
range XXX O
1 XXX O
. XXX O
5-34 XXX O
+ XXX O
months XXX O
) XXX O
versus XXX O
7 XXX O
months XXX O
( XXX O
range XXX O
2 XXX O
. XXX O
5-21 XXX O
months XXX O
) XXX O
. XXX O

The XXX O
detection XXX O
success XXX O
rate XXX O
was XXX O
determined XXX O
for XXX O
different XXX O
markers XXX O
using XXX O
this XXX O
MEK XXX B-GENE
. XXX O

Binding XXX O
of XXX O
NusA XXX B-GENE
to XXX O
RNA XXX O
in XXX O
the XXX O
presence XXX O
of XXX O
alpha XXX O
or XXX O
N XXX O
involves XXX O
an XXX O
amino-terminal XXX B-GENE
S1 XXX I-GENE
homology XXX I-GENE
region XXX I-GENE
that XXX O
is XXX O
otherwise XXX O
inactive XXX O
in XXX O
full-length XXX B-GENE
NusA XXX I-GENE
. XXX O

Diagnosis XXX O
of XXX O
phenylalanine XXX B-GENE
hydroxylase XXX I-GENE
deficiency XXX O
( XXX O
phenylketonuria XXX O
) XXX O
. XXX O

The XXX O
unique XXX O
nature XXX O
and XXX O
arrangement XXX O
of XXX O
the XXX O
ANT1 XXX B-GENE
transcriptional XXX I-GENE
control XXX I-GENE
elements XXX I-GENE
may XXX O
account XXX O
for XXX O
this XXX O
differential XXX O
expression XXX O
. XXX O

Max XXX B-GENE
was XXX O
constantly XXX O
transcribed XXX O
at XXX O
a XXX O
relatively XXX O
low XXX O
level XXX O
during XXX O
cell XXX O
cycle XXX O
progression XXX O
. XXX O

METHODS XXX O
: XXX O
The XXX O
former XXX O
group XXX O
included XXX O
patients XXX O
who XXX O
had XXX O
been XXX O
treated XXX O
with XXX O
at XXX O
least XXX O
four XXX O
PGE1 XXX O
alpha-ciclodestrina XXX O
, XXX O
short-term XXX O
treatment XXX O
cycles XXX O
per XXX O
year XXX O
while XXX O
the XXX O
latter XXX O
was XXX O
a XXX O
historical XXX O
reference XXX O
group XXX O
managed XXX O
without XXX O
prostaglandins XXX O
. XXX O

However XXX O
, XXX O
the XXX O
relative XXX O
binding XXX O
affinity XXX O
for XXX O
the XXX O
motifs XXX O
is XXX O
different XXX O
. XXX O

In XXX O
1993 XXX O
and XXX O
1994 XXX O
and XXX O
infection XXX O
with XXX O
body XXX O
lice XXX O
was XXX O
registered XXX O
41 XXX O
times XXX O
in XXX O
31 XXX O
patients XXX O
at XXX O
the XXX O
clinic XXX O
for XXX O
homeless XXX O
of XXX O
the XXX O
Community XXX O
Health XXX O
Service XXX O
of XXX O
Utrecht XXX O
. XXX O

In XXX O
this XXX O
paper XXX O
, XXX O
we XXX O
show XXX O
that XXX O
, XXX O
like XXX O
BAP2 XXX B-GENE
, XXX O
the XXX O
expression XXX O
of XXX O
the XXX O
BAP3 XXX B-GENE
gene XXX I-GENE
in XXX O
S XXX O
. XXX O
cerevisiae XXX O
is XXX O
induced XXX O
by XXX O
the XXX O
addition XXX O
of XXX O
branched-chain XXX O
amino XXX O
acids XXX O
to XXX O
the XXX O
medium XXX O
. XXX O

When XXX O
phencyclidine XXX O
was XXX O
administered XXX O
alone XXX O
, XXX O
overall XXX O
response XXX O
rate XXX O
decreased XXX O
and XXX O
percent XXX O
errors XXX O
increased XXX O
with XXX O
increasing XXX O
doses XXX O
. XXX O

The XXX O
number XXX O
of XXX O
lactotropes XXX O
, XXX O
somatotropes XXX O
, XXX O
thyrotropes XXX O
, XXX O
and XXX O
gonadotropes XXX O
was XXX O
not XXX O
altered XXX O
compared XXX O
with XXX O
controls XXX O
, XXX O
indicating XXX O
that XXX O
in XXX O
the XXX O
adult XXX O
pituitary XXX O
, XXX O
POMC XXX B-GENE
products XXX I-GENE
are XXX O
not XXX O
required XXX O
to XXX O
maintain XXX O
the XXX O
distribution XXX O
of XXX O
cell XXX O
types XXX O
. XXX O

A XXX O
Dictyostelium XXX O
transformant XXX O
overexpressing XXX O
DdPTPa XXX B-GENE
does XXX O
not XXX O
develop XXX O
normally XXX O
. XXX O

Using XXX O
the XXX O
balloon-gas XXX O
procedure XXX O
with XXX O
a XXX O
single XXX O
gas XXX O
injection XXX O
, XXX O
a XXX O
bubble XXX O
was XXX O
obtained XXX O
that XXX O
was XXX O
large XXX O
enough XXX O
to XXX O
tamponade XXX O
a XXX O
giant XXX O
tear XXX O
without XXX O
prior XXX O
drainage XXX O
of XXX O
subretinal XXX O
fluid XXX O
or XXX O
vitrectomy XXX O
. XXX O

Identification XXX O
and XXX O
nucleotide XXX O
sequence XXX O
of XXX O
Rhizobium XXX B-GENE
meliloti XXX I-GENE
insertion XXX I-GENE
sequence XXX I-GENE
ISRm3 XXX I-GENE
: XXX O
similarity XXX O
between XXX O
the XXX O
putative XXX O
transposase XXX B-GENE
encoded XXX O
by XXX O
ISRm3 XXX B-GENE
and XXX O
those XXX O
encoded XXX O
by XXX O
Staphylococcus XXX B-GENE
aureus XXX I-GENE
IS256 XXX I-GENE
and XXX O
Thiobacillus XXX B-GENE
ferrooxidans XXX I-GENE
IST2 XXX I-GENE
. XXX O

Lengthy XXX O
and XXX O
repeated XXX O
hemodialyses XXX O
were XXX O
required XXX O
to XXX O
lower XXX O
lithemia XXX O
to XXX O
nontoxic XXX O
ranges XXX O
. XXX O

The XXX O
protein XXX O
encoded XXX O
by XXX O
ORF113 XXX B-GENE
contains XXX O
a XXX O
transmembrane XXX O
domain XXX O
. XXX O

When XXX O
the XXX O
l-methadone-sensitive XXX O
, XXX O
opioid XXX B-GENE
receptor XXX I-GENE
is XXX O
blocked XXX O
by XXX O
naloxone XXX O
or XXX O
tolerance XXX O
has XXX O
developed XXX O
, XXX O
than XXX O
l-methadone XXX O
can XXX O
produce XXX O
behavioral XXX O
effects XXX O
by XXX O
a XXX O
nonopioid XXX O
mechanism XXX O
. XXX O

Two XXX O
new XXX O
temperature-sensitive XXX O
alleles XXX O
of XXX O
SEC3 XXX B-GENE
, XXX O
1 XXX O
of XXX O
10 XXX O
late-acting XXX O
SEC XXX B-GENE
genes XXX I-GENE
required XXX O
for XXX O
targeting XXX O
or XXX O
fusion XXX O
of XXX O
post-Golgi XXX O
secretory XXX O
vesicles XXX O
to XXX O
the XXX O
plasma XXX O
membrane XXX O
in XXX O
Saccharomyces XXX O
cerevisiae XXX O
, XXX O
were XXX O
isolated XXX O
in XXX O
a XXX O
screen XXX O
for XXX O
temperature-sensitive XXX O
secretory XXX O
mutants XXX O
that XXX O
are XXX O
synthetically XXX O
lethal XXX O
with XXX O
sec4-8 XXX B-GENE
. XXX O

The XXX O
hyperacute XXX O
phase XXX O
of XXX O
posterolateral XXX O
myocardial XXX O
infarction XXX O
. XXX O

Although XXX O
Micrococcus XXX B-GENE
luteus XXX I-GENE
UV XXX I-GENE
endonuclease XXX I-GENE
has XXX O
been XXX O
reported XXX O
to XXX O
be XXX O
an XXX O
18-kDa XXX O
enzyme XXX O
with XXX O
possible XXX O
homology XXX O
to XXX O
the XXX O
16-kDa XXX B-GENE
endonuclease XXX I-GENE
V XXX I-GENE
from XXX I-GENE
bacteriophage XXX I-GENE
T4 XXX I-GENE
( XXX O
Gordon XXX O
, XXX O
L XXX O
. XXX O

Endoscopic XXX O
transthoracic XXX O
sympathectomy XXX O
as XXX O
adjuvant XXX O
treatment XXX O
for XXX O
critical XXX O
upper-limb XXX O
ischaemia XXX O
. XXX O

Furthermore XXX O
, XXX O
this XXX O
kinase-deficient XXX O
mutant XXX O
inhibited XXX O
2-MeSADP-induced XXX O
caspase-3 XXX B-GENE
stimulation XXX O
and XXX O
the XXX O
associated XXX O
decrease XXX O
in XXX O
cell XXX O
number XXX O
. XXX O

Furthermore XXX O
, XXX O
freezing XXX O
in XXX O
the XXX O
presence XXX O
of XXX O
bovine XXX B-GENE
lactalbumin XXX I-GENE
resulted XXX O
in XXX O
a XXX O
good XXX O
maintenance XXX O
of XXX O
the XXX O
cellular XXX O
viability XXX O
and XXX O
of XXX O
the XXX O
CCCD XXX O
heterogeneity XXX O
in XXX O
respect XXX O
to XXX O
fresh XXX O
cells XXX O
. XXX O

Using XXX O
the XXX O
polymerase XXX B-GENE
chain XXX O
reaction XXX O
, XXX O
we XXX O
analyzed XXX O
the XXX O
U6 XXX B-GENE
RNA XXX I-GENE
genes XXX I-GENE
of XXX O
52 XXX O
organisms XXX O
. XXX O

Our XXX O
results XXX O
also XXX O
indicate XXX O
the XXX O
existence XXX O
of XXX O
sequences XXX O
downstream XXX O
of XXX O
-0 XXX O
. XXX O
11 XXX O
kb XXX O
which XXX O
can XXX O
influence XXX O
the XXX O
pattern XXX O
of XXX O
tissue-specific XXX O
expression XXX O
of XXX O
the XXX O
HLA-B7 XXX B-GENE
gene XXX I-GENE
and XXX O
the XXX O
ability XXX O
of XXX O
this XXX O
gene XXX O
to XXX O
respond XXX O
to XXX O
gamma XXX B-GENE
interferon XXX I-GENE
. XXX O

Additionally XXX O
, XXX O
putative XXX O
CF1 XXX B-GENE
/ XXX I-GENE
USP XXX I-GENE
and XXX O
Broad XXX B-GENE
Complex XXX I-GENE
Z2 XXX I-GENE
transcription XXX O
factor XXX O
elements XXX O
were XXX O
found XXX O
in XXX O
the XXX O
upstream XXX O
regions XXX O
of XXX O
MIH XXX B-GENE
and XXX O
MO-IH XXX B-GENE
genes XXX O
respectively XXX O
. XXX O

By XXX O
electrophoresis XXX O
mobility XXX O
shift XXX O
assays XXX O
using XXX O
probes XXX O
corresponding XXX O
to XXX O
different XXX O
segments XXX O
of XXX O
the XXX O
putative XXX O
human XXX B-GENE
c-myb XXX I-GENE
intron XXX I-GENE
1 XXX I-GENE
transcription XXX I-GENE
pause XXX I-GENE
region XXX I-GENE
and XXX O
nuclear XXX O
extracts XXX O
from XXX O
myeloid XXX O
leukemia XXX O
HL XXX O
60 XXX O
and XXX O
fibroblast XXX O
WI XXX O
38 XXX O
cells XXX O
, XXX O
we XXX O
detected XXX O
a XXX O
HL-60-specific XXX B-GENE
DNA-protein XXX I-GENE
complex XXX I-GENE
with XXX O
a XXX O
123-bp XXX O
fragment XXX O
containing XXX O
binding XXX O
sites XXX O
for XXX O
the XXX O
interferon XXX B-GENE
regulatory XXX I-GENE
factors XXX I-GENE
( XXX O
IRFs XXX B-GENE
) XXX O
nuclear XXX O
proteins XXX O
. XXX O

This XXX O
model XXX O
is XXX O
further XXX O
supported XXX O
by XXX O
binding XXX O
of XXX O
the XXX O
Fos-Jun XXX B-GENE
complex XXX I-GENE
at XXX O
an XXX O
AP-1 XXX B-GENE
site XXX I-GENE
in XXX O
the XXX O
type XXX B-GENE
alpha XXX I-GENE
I XXX I-GENE
collagen XXX I-GENE
promoter XXX I-GENE
that XXX O
is XXX O
contiguous XXX O
with XXX O
, XXX O
but XXX O
not XXX O
overlapping XXX O
, XXX O
the XXX O
VDRE XXX B-GENE
. XXX O

Alpha-1 XXX B-GENE
antitrypsin XXX I-GENE
and XXX O
Indian XXX O
childhood XXX O
cirrhosis XXX O
. XXX O

The XXX O
recombinant XXX B-GENE
vaccinia XXX I-GENE
virus-expressed XXX I-GENE
mutant XXX I-GENE
P1 XXX I-GENE
polyproteins XXX I-GENE
were XXX O
analyzed XXX O
for XXX O
proteolytic XXX O
processing XXX O
defects XXX O
in XXX O
cells XXX O
coinfected XXX O
with XXX O
a XXX O
recombinant XXX O
vaccinia XXX O
virus XXX O
( XXX O
VVP3 XXX O
) XXX O
that XXX O
expresses XXX O
the XXX O
poliovirus XXX B-GENE
3CD XXX I-GENE
protease XXX I-GENE
and XXX O
for XXX O
processing XXX O
and XXX O
assembly XXX O
defects XXX O
by XXX O
using XXX O
a XXX O
trans XXX O
complementation XXX O
system XXX O
in XXX O
which XXX O
P1-expressing XXX O
recombinant XXX O
vaccinia XXX O
viruses XXX O
provide XXX O
capsid XXX B-GENE
precursor XXX I-GENE
to XXX O
a XXX O
defective XXX O
poliovirus XXX O
genome XXX O
that XXX O
does XXX O
not XXX O
express XXX O
functional XXX O
capsid XXX B-GENE
proteins XXX I-GENE
( XXX O
D XXX O
. XXX O

The XXX O
AD XXX O
components XXX O
were XXX O
markedly XXX O
more XXX O
dependent XXX O
on XXX O
the XXX O
affective XXX O
state XXX O
of XXX O
the XXX O
rat XXX O
then XXX O
was XXX O
the XXX O
V1 XXX O
component XXX O
. XXX O

When XXX O
the XXX O
cervical XXX O
Pap XXX O
smear XXX O
is XXX O
positive XXX O
. XXX O

Causes XXX O
of XXX O
death XXX O
found XXX O
in XXX O
an XXX O
epidemiological XXX O
study XXX O
of XXX O
native XXX O
chickens XXX O
in XXX O
Thai XXX O
villages XXX O
. XXX O

To XXX O
study XXX O
the XXX O
origin XXX O
of XXX O
different XXX O
fMLF-R XXX B-GENE
transcripts XXX I-GENE
, XXX O
the XXX O
genetic XXX O
linkage XXX O
of XXX O
chemotactic XXX B-GENE
receptor XXX I-GENE
genes XXX O
, XXX O
and XXX O
the XXX O
regulation XXX O
of XXX O
fMLF-R XXX B-GENE
gene XXX I-GENE
expression XXX O
, XXX O
we XXX O
determined XXX O
the XXX O
copy XXX O
number XXX O
, XXX O
chromosomal XXX O
location XXX O
, XXX O
structural XXX O
organization XXX O
, XXX O
and XXX O
5'-flanking XXX O
sequence XXX O
of XXX O
the XXX O
human XXX B-GENE
fMLF-R XXX I-GENE
gene XXX I-GENE
. XXX O

We XXX O
had XXX O
previously XXX O
analyzed XXX O
repair XXX O
rates XXX O
of XXX O
cyclobutane XXX O
pyrimidine XXX O
dimers XXX O
at XXX O
nucleotide XXX O
resolution XXX O
along XXX O
the XXX O
human XXX B-GENE
JUN XXX I-GENE
gene XXX I-GENE
in XXX O
normal XXX O
fibroblasts XXX O
and XXX O
found XXX O
very XXX O
efficient XXX O
repair XXX O
of XXX O
sequences XXX O
near XXX O
the XXX O
transcription XXX O
initiation XXX O
site XXX O
but XXX O
slow XXX O
repair XXX O
along XXX O
the XXX O
promoter XXX O
. XXX O

A XXX O
canonical XXX O
TATA XXX O
box XXX O
was XXX O
not XXX O
detected XXX O
. XXX O

This XXX O
multimodality XXX O
treatment XXX O
for XXX O
locally XXX O
advanced XXX O
gynecologic XXX O
tumors XXX O
appears XXX O
feasible XXX O
with XXX O
modification XXX O
, XXX O
and XXX O
continued XXX O
work XXX O
exploring XXX O
this XXX O
approach XXX O
is XXX O
encouraged XXX O
. XXX O

Inactivation XXX O
of XXX O
Ulp2 XXX B-GENE
also XXX O
suppresses XXX O
several XXX O
ulp1 XXX B-GENE
( XXX I-GENE
ts XXX I-GENE
) XXX I-GENE
defects XXX O
, XXX O
and XXX O
the XXX O
double XXX O
mutant XXX O
accumulates XXX O
far XXX O
fewer XXX O
Smt3-protein XXX B-GENE
conjugates XXX O
than XXX O
either XXX O
single XXX O
mutant XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
our XXX O
results XXX O
show XXX O
that XXX O
ERKs XXX B-GENE
and XXX O
PI3Ks XXX B-GENE
can XXX O
synergise XXX O
to XXX O
convert XXX O
ectoderm XXX O
into XXX O
mesoderm XXX O
. XXX O

During XXX O
the XXX O
febrile XXX O
period XXX O
, XXX O
pleocytosis XXX O
was XXX O
associated XXX O
with XXX O
high XXX O
levels XXX O
of XXX O
IgG XXX B-GENE
, XXX O
IL-6 XXX B-GENE
, XXX O
TNF-alpha XXX B-GENE
, XXX O
and XXX O
PGE2 XXX B-GENE
in XXX O
the XXX O
cerebrospinal XXX O
fluid XXX O
. XXX O

Potential XXX O
indicators XXX O
were XXX O
assessed XXX O
for XXX O
the XXX O
two XXX O
classifications XXX O
of XXX O
protein-energy XXX O
malnutrition XXX O
in XXX O
the XXX O
guidelines XXX O
for XXX O
integrated XXX O
management XXX O
of XXX O
childhood XXX O
illness XXX O
: XXX O
severe XXX O
malnutrition XXX O
, XXX O
which XXX O
requires XXX O
immediate XXX O
referral XXX O
to XXX O
hospital XXX O
, XXX O
and XXX O
very XXX O
low XXX O
weight XXX O
, XXX O
which XXX O
calls XXX O
for XXX O
feeding XXX O
assessment XXX O
, XXX O
nutritional XXX O
counselling XXX O
and XXX O
follow-up XXX O
. XXX O

The XXX O
experimental XXX O
design XXX O
represents XXX O
a XXX O
2 XXX O
x XXX O
3 XXX O
factorial XXX O
arrangement XXX O
of XXX O
treatments XXX O
with XXX O
three XXX O
dietary XXX O
levels XXX O
of XXX O
incorporation XXX O
of XXX O
RSB XXX O
( XXX O
0 XXX O
, XXX O
50 XXX O
, XXX O
and XXX O
100% XXX O
) XXX O
, XXX O
and XXX O
chickens XXX O
either XXX O
infected XXX O
or XXX O
uninfected XXX O
. XXX O

Deletion XXX O
analyses XXX O
implicate XXX O
the XXX O
N-terminal XXX O
110 XXX O
amino XXX O
acids XXX O
of XXX O
Grb14 XXX B-GENE
and XXX O
ankyrin XXX B-GENE
repeats XXX O
10-19 XXX O
of XXX O
tankyrase XXX B-GENE
2 XXX I-GENE
in XXX O
mediating XXX O
this XXX O
interaction XXX O
. XXX O

Characterization XXX O
of XXX O
the XXX O
human XXX B-GENE
gene XXX I-GENE
encoding XXX I-GENE
cytokeratin XXX I-GENE
17 XXX I-GENE
and XXX O
its XXX O
expression XXX O
pattern XXX O
. XXX O

Sensitivities XXX O
of XXX O
thromboplastins XXX B-GENE
to XXX O
factor XXX B-GENE
VII XXX I-GENE
deficiency XXX O
. XXX O

In XXX O
an XXX O
effort XXX O
to XXX O
isolate XXX O
genes XXX O
with XXX O
down-regulated XXX O
expression XXX O
at XXX O
the XXX O
mRNA XXX O
level XXX O
during XXX O
oncogenic XXX O
transformation XXX O
of XXX O
human XXX O
mammary XXX O
epithelial XXX O
cells XXX O
( XXX O
MECs XXX O
) XXX O
, XXX O
we XXX O
performed XXX O
subtractive XXX O
hybridization XXX O
between XXX O
normal XXX O
MEC XXX O
strain XXX O
76N XXX O
and XXX O
its XXX O
radiation-transformed XXX O
tumorigenic XXX O
derivative XXX O
76R-30 XXX O
. XXX O

OKT3 XXX B-GENE
prophylaxis XXX O
improves XXX O
long-term XXX O
renal XXX O
graft XXX O
survival XXX O
in XXX O
high-risk XXX O
patients XXX O
as XXX O
compared XXX O
to XXX O
cyclosporine XXX O
: XXX O
combined XXX O
results XXX O
from XXX O
the XXX O
prospective XXX O
, XXX O
randomized XXX O
Belgian XXX O
and XXX O
US XXX O
studies XXX O
. XXX O

Intra-operative XXX O
ultrasound XXX O
( XXX O
IOUS XXX O
) XXX O
has XXX O
been XXX O
widely XXX O
used XXX O
in XXX O
an XXX O
attempt XXX O
to XXX O
overcome XXX O
these XXX O
difficulties XXX O
, XXX O
but XXX O
is XXX O
limited XXX O
by XXX O
its XXX O
two-dimensional XXX O
nature XXX O
, XXX O
inter-user XXX O
variability XXX O
, XXX O
and XXX O
image XXX O
obliteration XXX O
with XXX O
ablative XXX O
or XXX O
resectional XXX O
techniques XXX O
. XXX O

PATIENTS XXX O
AND XXX O
METHODS XXX O
: XXX O
Semen XXX O
analyses XXX O
were XXX O
performed XXX O
on XXX O
58 XXX O
patients XXX O
with XXX O
stages XXX O
I-III XXX O
HD XXX O
before XXX O
, XXX O
during XXX O
, XXX O
and XXX O
after XXX O
chemotherapy XXX O
and XXX O
after XXX O
the XXX O
sperm XXX O
count XXX O
recovered XXX O
from XXX O
the XXX O
effects XXX O
of XXX O
abdominal XXX O
radiotherapy XXX O
that XXX O
was XXX O
given XXX O
after XXX O
chemotherapy XXX O
. XXX O

We XXX O
did XXX O
not XXX O
observe XXX O
any XXX O
changes XXX O
in XXX O
Bcl-2 XXX B-GENE
or XXX O
Bcl-2-related XXX B-GENE
proteins XXX I-GENE
( XXX O
Bcl-x XXX B-GENE
, XXX O
Bax XXX B-GENE
, XXX O
and XXX O
Bad XXX B-GENE
) XXX O
in XXX O
control XXX O
or XXX O
KCREB-transfected XXX O
cells XXX O
before XXX O
or XXX O
after XXX O
treatment XXX O
with XXX O
Tg XXX O
. XXX O

An XXX O
evolutionary XXX O
conserved XXX O
element XXX O
is XXX O
essential XXX O
for XXX O
somite XXX O
and XXX O
adjacent XXX O
mesenchymal XXX O
expression XXX O
of XXX O
the XXX O
Hoxa1 XXX B-GENE
gene XXX I-GENE
. XXX O

The XXX O
minus-end-directed XXX O
microtubule XXX O
motors XXX O
, XXX O
the XXX O
dyneins XXX B-GENE
, XXX O
may XXX O
also XXX O
constitute XXX O
a XXX O
superfamily XXX O
of XXX O
force-generating XXX O
proteins XXX O
with XXX O
distinct XXX O
attachment XXX O
domains XXX O
. XXX O

Chronic XXX O
dose XXX O
effects XXX O
of XXX O
methyl XXX O
parathion XXX O
on XXX O
nuthatches XXX O
: XXX O
cholinesterase XXX B-GENE
and XXX O
ptilochronology XXX O
. XXX O

Several XXX O
PTPases XXX B-GENE
were XXX O
expressed XXX O
abundantly XXX O
in XXX O
the XXX O
5-FU-treated XXX O
bone XXX O
marrow XXX O
stem XXX O
cells XXX O
. XXX O

No XXX O
significant XXX O
differences XXX O
between XXX O
the XXX O
two XXX O
treatment XXX O
groups XXX O
were XXX O
found XXX O
, XXX O
but XXX O
rapid XXX O
responders XXX O
had XXX O
a XXX O
smaller XXX O
mean XXX O
initial XXX O
platelet-associated XXX B-GENE
IgG XXX I-GENE
index XXX O
which XXX O
returned XXX O
more XXX O
rapidly XXX O
and XXX O
more XXX O
permanently XXX O
to XXX O
normal XXX O
than XXX O
that XXX O
of XXX O
slow XXX O
responders XXX O
. XXX O

Decreased XXX O
cardiac XXX O
glycogen XXX O
following XXX O
phenformin XXX O
injection XXX O
in XXX O
hyperglycemic XXX O
, XXX O
hyperinsulinemic XXX O
anaesthetized XXX O
rats XXX O
. XXX O

Accordingly XXX O
, XXX O
we XXX O
designated XXX O
this XXX O
gene XXX B-GENE
CTL1 XXX I-GENE
( XXX O
capping XXX B-GENE
enzyme XXX I-GENE
RNAtriphosphatase-like XXX I-GENE
1 XXX I-GENE
) XXX O
. XXX O

Cyclosporine XXX O
treatment XXX O
for XXX O
intractable XXX O
polymyositis XXX O
. XXX O

Erythrocyte XXX B-GENE
delta-aminolevulinic XXX I-GENE
acid XXX I-GENE
dehydratase XXX I-GENE
( XXX O
ALAD XXX B-GENE
) XXX O
activity XXX O
, XXX O
erythrocyte XXX O
zinc XXX O
protoporphyrin XXX O
( XXX O
ZPP XXX O
) XXX O
/ XXX O
heme XXX O
ratio XXX O
, XXX O
and XXX O
urinary XXX O
coproporphyrin XXX O
( XXX O
UC XXX O
) XXX O
concentration XXX O
have XXX O
been XXX O
employed XXX O
as XXX O
biological XXX O
indicators XXX O
of XXX O
moderate-to XXX O
high-level XXX O
lead XXX O
exposure XXX O
, XXX O
corresponding XXX O
to XXX O
blood XXX O
levels XXX O
in XXX O
excess XXX O
of XXX O
50 XXX O
micrograms XXX O
/ XXX O
dl XXX O
, XXX O
in XXX O
human XXX O
subjects XXX O
. XXX O

A XXX O
38-bp XXX O
poly XXX O
( XXX O
dA-dT XXX O
) XXX O
region XXX O
was XXX O
found XXX O
to XXX O
be XXX O
a XXX O
positive XXX O
regulator XXX O
of XXX O
Act1 XXX B-GENE
promoter XXX I-GENE
activity XXX O
. XXX O

This XXX O
tendency XXX O
is XXX O
likely XXX O
due XXX O
to XXX O
the XXX O
biased XXX O
nucleotide XXX O
composition XXX O
of XXX O
the XXX O
asparagus XXX O
genome XXX O
, XXX O
rather XXX O
than XXX O
to XXX O
the XXX O
translational XXX O
selection XXX O
for XXX O
specific XXX O
codons XXX O
. XXX O

PATIENTS XXX O
AND XXX O
METHOD XXX O
: XXX O
Since XXX O
1986 XXX O
, XXX O
62 XXX O
patients XXX O
were XXX O
irradiated XXX O
stereotactically XXX O
. XXX O

Liver XXX O
transplantation XXX O
in XXX O
one XXX O
patient XXX O
resolved XXX O
metabolic XXX O
complications XXX O
but XXX O
did XXX O
not XXX O
improve XXX O
PMN XXX O
count XXX O
or XXX O
the XXX O
infectious XXX O
status XXX O
, XXX O
while XXX O
neutropenia XXX O
was XXX O
corrected XXX O
by XXX O
G-CSF XXX B-GENE
. XXX O

The XXX O
RING XXX O
finger XXX O
, XXX O
B2 XXX O
box XXX O
, XXX O
and XXX O
coiled-coil XXX O
region XXX O
are XXX O
required XXX O
for XXX O
oligomerization XXX O
of XXX O
KAP-1-RBCC XXX B-GENE
and XXX O
KRAB XXX B-GENE
binding XXX O
, XXX O
as XXX O
mutations XXX O
in XXX O
these XXX O
domains XXX O
concomitantly XXX O
abolished XXX O
these XXX O
functions XXX O
. XXX O

Injection XXX O
of XXX O
double-stranded XXX O
RNA XXX O
into XXX O
C XXX O
. XXX O
elegans XXX O
results XXX O
in XXX O
embryonic XXX O
lethality XXX O
; XXX O
thus XXX O
, XXX O
the XXX O
SF1 XXX B-GENE
gene XXX I-GENE
is XXX O
essential XXX O
not XXX O
only XXX O
in XXX O
yeast XXX O
but XXX O
also XXX O
in XXX O
at XXX O
least XXX O
one XXX O
metazoan XXX O
. XXX O

We XXX O
suggest XXX O
that XXX O
MotA XXX B-GENE
and XXX O
AsiA XXX B-GENE
may XXX O
function XXX O
like XXX O
certain XXX O
eukaryotic XXX B-GENE
TAFs XXX I-GENE
( XXX O
TATA XXX B-GENE
binding XXX I-GENE
protein XXX I-GENE
( XXX I-GENE
TBP XXX I-GENE
) XXX I-GENE
associated XXX I-GENE
factors XXX I-GENE
) XXX O
whose XXX O
binding XXX O
to XXX O
TBP XXX B-GENE
results XXX O
in XXX O
transcription XXX O
from XXX O
new XXX O
core XXX O
promoter XXX O
sequences XXX O
. XXX O

The XXX O
usefulness XXX O
of XXX O
the XXX O
lambda XXX O
PG15 XXX O
and XXX O
the XXX O
lambda XXX O
AD5 XXX O
cloning XXX O
vectors XXX O
was XXX O
demonstrated XXX O
by XXX O
constructing XXX O
large XXX O
Neurospora XXX O
crassa XXX O
cDNA XXX O
libraries XXX O
. XXX O

Manifest XXX O
anxiety XXX O
of XXX O
Vietnam XXX O
returnees XXX O
and XXX O
undergraduates XXX O
. XXX O

This XXX O
action XXX O
is XXX O
dependent XXX O
on XXX O
helix-loop-helix XXX O
factors XXX O
bound XXX O
to XXX O
the XXX O
E1 XXX B-GENE
element XXX I-GENE
. XXX O

The XXX O
use XXX O
of XXX O
the XXX O
PLCgamma XXX B-GENE
inhibitory XXX I-GENE
peptide XXX I-GENE
, XXX O
neomycin XXX O
and XXX O
the XXX O
calcium XXX O
chelator XXX O
BAPTA-AM XXX O
on XXX O
oocytes XXX O
expressing XXX O
FGFR1 XXX B-GENE
or XXX O
the XXX O
stimulation XXX O
by XXX O
PDGF-BB XXX B-GENE
of XXX O
oocytes XXX O
expressing XXX O
PDGFR-FGFR1 XXX B-GENE
mutated XXX O
on XXX O
the XXX O
PLCgamma XXX B-GENE
binding XXX I-GENE
site XXX I-GENE
, XXX O
prevented XXX O
GVBD XXX O
and XXX O
ERK2 XXX B-GENE
phosphorylation XXX O
. XXX O

The XXX O
pheromone XXX O
response XXX O
pathway XXX O
activates XXX O
transcription XXX O
of XXX O
Ty5 XXX B-GENE
retrotransposons XXX I-GENE
located XXX O
within XXX O
silent XXX O
chromatin XXX O
of XXX O
Saccharomyces XXX O
cerevisiae XXX O
. XXX O

Isopenicillin XXX B-GENE
N XXX I-GENE
isomerase XXX I-GENE
( XXX O
epimerase XXX B-GENE
) XXX O
has XXX O
been XXX O
purified XXX O
from XXX O
Streptomyces XXX O
clavuligerus XXX O
, XXX O
and XXX O
the XXX O
amino XXX O
acid XXX O
sequence XXX O
of XXX O
the XXX O
N-terminus XXX O
has XXX O
been XXX O
determined XXX O
. XXX O

Our XXX O
analysis XXX O
suggests XXX O
that XXX O
Upf1p XXX B-GENE
is XXX O
a XXX O
multifunctional XXX O
protein XXX O
with XXX O
separable XXX O
activities XXX O
that XXX O
can XXX O
affect XXX O
mRNA XXX O
turnover XXX O
and XXX O
nonsense XXX O
suppression XXX O
. XXX O

A XXX O
2 XXX O
kb XXX O
transcript XXX O
was XXX O
isolated XXX O
from XXX O
brain XXX O
that XXX O
encodes XXX O
a XXX O
approximately XXX O
57 XXX O
kDa XXX O
protein XXX O
; XXX O
the XXX O
predicted XXX O
protein XXX O
contains XXX O
the XXX O
known XXX O
N-terminal XXX B-GENE
Ets XXX I-GENE
domain XXX I-GENE
of XXX O
PE1 XXX B-GENE
and XXX O
a XXX O
novel XXX O
C-terminal XXX O
domain XXX O
with XXX O
signficant XXX O
homology XXX O
to XXX O
murine XXX B-GENE
ERF XXX I-GENE
. XXX O

Transcriptional XXX O
repression XXX O
mediated XXX O
by XXX O
LysR-type XXX B-GENE
regulator XXX I-GENE
CatR XXX I-GENE
bound XXX O
at XXX O
multiple XXX O
binding XXX O
sites XXX O
. XXX O

We XXX O
show XXX O
here XXX O
that XXX O
this XXX O
difference XXX O
is XXX O
due XXX O
to XXX O
the XXX O
presence XXX O
of XXX O
a XXX O
Mot3 XXX B-GENE
binding XXX I-GENE
site XXX I-GENE
in XXX O
OpA XXX B-GENE
. XXX O

Computer XXX O
analysis XXX O
included XXX O
digital XXX O
averaging XXX O
, XXX O
followed XXX O
by XXX O
digital XXX O
filtering XXX O
in XXX O
different XXX O
frequency XXX O
bands XXX O
in XXX O
order XXX O
to XXX O
determine XXX O
the XXX O
frequency XXX O
range XXX O
corresponding XXX O
to XXX O
notches XXX O
and XXX O
slurs XXX O
. XXX O

In XXX O
the XXX O
present XXX O
study XXX O
, XXX O
lesions XXX O
of XXX O
the XXX O
OPT XXX O
complex XXX O
( XXX O
the XXX O
thalamic XXX O
source XXX O
of XXX O
afferents XXX O
to XXX O
IHA XXX O
and XXX O
HD XXX O
) XXX O
were XXX O
found XXX O
to XXX O
have XXX O
no XXX O
effect XXX O
on XXX O
color-reversal XXX O
learning XXX O
performance XXX O
. XXX O

The XXX O
deduced XXX O
amino XXX O
acid XXX O
sequences XXX O
of XXX O
each XXX O
of XXX O
the XXX O
W3A1 XXX B-GENE
ETF XXX I-GENE
subunits XXX I-GENE
exhibit XXX O
only XXX O
approximately XXX O
30% XXX O
identity XXX O
with XXX O
the XXX O
corresponding XXX O
subunits XXX O
of XXX O
the XXX O
ETF XXX B-GENE
from XXX O
human XXX O
, XXX O
rat XXX O
, XXX O
and XXX O
Paracoccus XXX O
denitrificans XXX O
, XXX O
which XXX O
as XXX O
a XXX O
group XXX O
are XXX O
greater XXX O
than XXX O
50% XXX O
identical XXX O
. XXX O

These XXX O
results XXX O
suggest XXX O
that XXX O
XAB1 XXX B-GENE
is XXX O
a XXX O
novel XXX O
cytoplasmic XXX B-GENE
GTPase XXX I-GENE
involved XXX O
in XXX O
nuclear XXX O
localization XXX O
of XXX O
XPA XXX B-GENE
. XXX O

The XXX O
scores XXX O
are XXX O
dependent XXX O
in XXX O
part XXX O
on XXX O
the XXX O
reliability XXX O
of XXX O
faculty XXX O
evaluations XXX O
. XXX O

Thus XXX O
E14 XXX O
. XXX O
1TG3B1 XXX O
is XXX O
a XXX O
useful XXX O
ES XXX O
cell XXX O
line XXX O
for XXX O
modifying XXX O
the XXX O
mouse XXX O
genome XXX O
using XXX O
the XXX O
HPRT XXX B-GENE
gene XXX I-GENE
as XXX O
a XXX O
selection XXX O
marker XXX O
and XXX O
for XXX O
transmission XXX O
at XXX O
a XXX O
high XXX O
frequency XXX O
into XXX O
the XXX O
mouse XXX O
germ XXX O
line XXX O
. XXX O

This XXX O
virus XXX O
is XXX O
not XXX O
merely XXX O
a XXX O
South XXX O
African XXX O
strain XXX O
of XXX O
passion XXX O
fruit XXX O
woodiness XXX O
virus XXX O
( XXX O
PWV XXX O
) XXX O
: XXX O
the XXX O
deduced XXX O
CP XXX B-GENE
sequence XXX I-GENE
is XXX O
only XXX O
distantly XXX O
related XXX O
to XXX O
CPs XXX B-GENE
of XXX O
other XXX O
sequenced XXX O
strains XXX O
of XXX O
PWV XXX O
, XXX O
although XXX O
it XXX O
is XXX O
part XXX O
of XXX O
a XXX O
distinct XXX O
subgroup XXX O
of XXX O
potyviruses XXX O
related XXX O
to XXX O
PWV XXX O
. XXX O

In XXX O
serum-free XXX O
media XXX O
, XXX O
p50E4F XXX B-GENE
accelerated XXX O
E1A-induced XXX O
apoptosis XXX O
. XXX O

Sci XXX O
. XXX O

Morphological XXX O
features XXX O
of XXX O
Jat XXX O
dentition XXX O
. XXX O

The XXX O
TTG-2 XXX B-GENE
gene XXX I-GENE
has XXX O
been XXX O
identified XXX O
at XXX O
the XXX O
site XXX O
of XXX O
chromosomal XXX O
translocations XXX O
in XXX O
acute XXX O
T-cell XXX O
leukemia's XXX O
( XXX O
T-ALL XXX O
) XXX O
. XXX O

The XXX O
validity XXX O
of XXX O
the XXX O
FPS-R XXX O
was XXX O
further XXX O
supported XXX O
by XXX O
strong XXX O
positive XXX O
correlations XXX O
with XXX O
the XXX O
VAS XXX O
( XXX O
r XXX O
= XXX O
0 XXX O
. XXX O
92 XXX O
, XXX O
N XXX O
= XXX O
45 XXX O
) XXX O
and XXX O
the XXX O
CAS XXX O
( XXX O
r XXX O
= XXX O
0 XXX O
. XXX O
84 XXX O
, XXX O
N XXX O
= XXX O
45 XXX O
) XXX O
in XXX O
this XXX O
clinical XXX O
sample XXX O
. XXX O

The XXX O
abundance XXX O
of XXX O
transcripts XXX O
from XXX O
several XXX O
unrelated XXX O
genes XXX O
is XXX O
decreased XXX O
in XXX O
cdc68-1 XXX B-GENE
mutant XXX I-GENE
cells XXX O
after XXX O
transfer XXX O
to XXX O
the XXX O
restrictive XXX O
temperature XXX O
, XXX O
while XXX O
at XXX O
least XXX O
one XXX O
transcript XXX O
, XXX O
from XXX O
the XXX O
HSP82 XXX B-GENE
gene XXX I-GENE
, XXX O
persists XXX O
in XXX O
an XXX O
aberrant XXX O
fashion XXX O
. XXX O

Collectively XXX O
, XXX O
these XXX O
results XXX O
suggest XXX O
that XXX O
components XXX O
of XXX O
the XXX O
protein XXX B-GENE
kinase XXX I-GENE
A XXX I-GENE
signaling XXX O
pathway XXX O
are XXX O
recruited XXX O
by XXX O
mIg XXX B-GENE
to XXX O
induce XXX O
junB XXX B-GENE
transcription XXX O
. XXX O

Strikingly XXX O
, XXX O
stoichiometric XXX O
association XXX O
of XXX O
p107 XXX B-GENE
or XXX O
p130 XXX B-GENE
with XXX O
either XXX O
cyclin XXX B-GENE
E-cdk2 XXX I-GENE
or XXX O
cyclin XXX B-GENE
A-cdk2 XXX I-GENE
negated XXX O
the XXX O
activities XXX O
of XXX O
these XXX O
kinases XXX B-GENE
. XXX O

The XXX O
human XXX B-GENE
immunodeficiency XXX I-GENE
virus XXX I-GENE
type XXX I-GENE
1 XXX I-GENE
( XXX I-GENE
HIV-1 XXX I-GENE
) XXX I-GENE
Rev XXX I-GENE
protein XXX I-GENE
is XXX O
a XXX O
positive XXX O
posttranscriptional XXX O
regulator XXX O
of XXX O
viral XXX O
structural XXX O
gene XXX O
expression XXX O
and XXX O
essential XXX O
for XXX O
virus XXX O
replication XXX O
. XXX O

Wnt-1 XXX B-GENE
overexpression XXX O
in XXX O
mammary XXX O
epithelial XXX O
cells XXX O
induced XXX O
cyclin XXX B-GENE
D1 XXX I-GENE
mRNA XXX I-GENE
and XXX O
targeted XXX O
overexpression XXX O
of XXX O
Wnt-1 XXX B-GENE
in XXX O
the XXX O
mammary XXX O
gland XXX O
of XXX O
transgenic XXX O
mice XXX O
increased XXX O
both XXX O
ILK XXX B-GENE
activity XXX O
and XXX O
cyclin XXX B-GENE
D1 XXX I-GENE
levels XXX O
. XXX O

The XXX O
immune XXX O
system XXX O
is XXX O
closely XXX O
integrated XXX O
with XXX O
the XXX O
neuroendocrine XXX O
system XXX O
, XXX O
and XXX O
infection-induced XXX O
increases XXX O
in XXX O
cytokines XXX O
such XXX O
as XXX O
IL-1 XXX B-GENE
, XXX O
IL-6 XXX B-GENE
and XXX O
TNF XXX B-GENE
have XXX O
numerous XXX O
effects XXX O
on XXX O
the XXX O
central XXX O
nervous XXX O
system XXX O
. XXX O

Biological XXX O
activities XXX O
of XXX O
hematopoietic XXX B-GENE
growth XXX I-GENE
factors XXX I-GENE
that XXX O
lead XXX O
to XXX O
future XXX O
clinical XXX O
application XXX O
. XXX O

Mature XXX O
and XXX O
old XXX O
B6AF1 XXX O
and XXX O
B6D2F1 XXX O
mice XXX O
were XXX O
given XXX O
acidified XXX O
tap XXX O
water XXX O
or XXX O
promethazine XXX O
HCl XXX O
( XXX O
a XXX O
phenothiazine XXX O
with XXX O
H1 XXX B-GENE
receptor XXX I-GENE
blocking XXX O
activity XXX O
) XXX O
, XXX O
chlorpheniramine XXX O
( XXX O
an XXX O
H1 XXX B-GENE
blocker XXX O
) XXX O
or XXX O
trifluoperazine XXX O
( XXX O
a XXX O
phenothiazine XXX O
with XXX O
no XXX O
H1 XXX B-GENE
blocking XXX O
activity XXX O
) XXX O
in XXX O
their XXX O
drinking XXX O
water XXX O
, XXX O
and XXX O
the XXX O
effects XXX O
of XXX O
these XXX O
agents XXX O
on XXX O
bone XXX O
mineral XXX O
content XXX O
were XXX O
assessed XXX O
by XXX O
intermittently XXX O
measuring XXX O
the XXX O
24-h XXX O
whole XXX O
body XXX O
retention XXX O
of XXX O
Tc XXX O
99m XXX O
methylene XXX O
diphosphonate XXX O
( XXX O
Tc XXX O
99m XXX O
MDP XXX O
, XXX O
an XXX O
indicator XXX O
of XXX O
bone XXX O
metabolism XXX O
) XXX O
and XXX O
at XXX O
the XXX O
end XXX O
of XXX O
the XXX O
studies XXX O
by XXX O
determining XXX O
ash XXX O
weights XXX O
of XXX O
femur XXX O
, XXX O
ilium XXX O
and XXX O
sacrum XXX O
. XXX O

The XXX O
mechanism XXX O
of XXX O
the XXX O
induction XXX O
of XXX O
3beta-HSD XXX B-GENE
type XXX I-GENE
1 XXX I-GENE
gene XXX I-GENE
expression XXX O
was XXX O
further XXX O
characterized XXX O
in XXX O
ZR-75-1 XXX O
human XXX O
breast XXX O
cancer XXX O
cells XXX O
. XXX O

Analysis XXX O
of XXX O
strains XXX O
harboring XXX O
an XXX O
mds1 XXX B-GENE
null XXX I-GENE
mutation XXX I-GENE
demonstrates XXX O
that XXX O
MDS1 XXX B-GENE
is XXX O
not XXX O
essential XXX O
during XXX O
normal XXX O
vegetative XXX O
growth XXX O
but XXX O
appears XXX O
to XXX O
be XXX O
required XXX O
for XXX O
meiosis XXX O
. XXX O

Insert2 XXX O
contains XXX O
repetitive XXX O
non-Ig-related XXX O
sequences XXX O
and XXX O
a XXX O
small XXX O
Ig-related XXX O
sequence XXX O
. XXX O

The XXX O
primer XXX O
is XXX O
generated XXX O
by XXX O
a XXX O
cleavage XXX O
that XXX O
occurs XXX O
between XXX O
bases XXX O
11 XXX O
and XXX O
12 XXX O
of XXX O
the XXX O
Tf1 XXX B-GENE
mRNA XXX I-GENE
. XXX O

A XXX O
bacteriological XXX O
relapse XXX O
requiring XXX O
treatment XXX O
occurred XXX O
by XXX O
5 XXX O
years XXX O
in XXX O
16 XXX O
. XXX O
8% XXX O
of XXX O
113 XXX O
R3 XXX O
, XXX O
5 XXX O
. XXX O
2% XXX O
of XXX O
97 XXX O
R5 XXX O
, XXX O
and XXX O
20 XXX O
. XXX O
0% XXX O
of XXX O
115 XXX O
Z5 XXX O
patients XXX O
with XXX O
organisms XXX O
sensitive XXX O
to XXX O
streptomycin XXX O
and XXX O
isoniazid XXX O
initially XXX O
. XXX O

Deflunia XXX O
was XXX O
well XXX O
tolerated XXX O
by XXX O
25 XXX O
patients XXX O
, XXX O
very XXX O
well XXX O
tolerated XXX O
by XXX O
2 XXX O
. XXX O

In XXX O
a XXX O
model XXX O
of XXX O
the XXX O
ternary XXX O
complex XXX O
, XXX O
the XXX O
segment XXX O
of XXX O
NFAT XXX B-GENE
nearest XXX O
AP-1 XXX B-GENE
is XXX O
the XXX O
Rel XXX B-GENE
insert XXX I-GENE
region XXX I-GENE
( XXX O
RIR XXX B-GENE
) XXX O
, XXX O
a XXX O
feature XXX O
that XXX O
is XXX O
notable XXX O
for XXX O
its XXX O
hypervariability XXX O
in XXX O
size XXX O
and XXX O
in XXX O
sequence XXX O
amongst XXX O
members XXX O
of XXX O
the XXX O
Rel XXX B-GENE
transcription XXX I-GENE
factor XXX I-GENE
family XXX I-GENE
. XXX O

The XXX O
nucleotide XXX O
sequence XXX O
directly XXX O
upstream XXX O
of XXX O
fimA XXX B-GENE
contains XXX O
two XXX O
open XXX O
reading XXX O
frames XXX O
, XXX O
ORF5 XXX O
and XXX O
ORF1 XXX O
, XXX O
whose XXX O
deduced XXX O
protein XXX O
products XXX O
are XXX O
homologous XXX O
to XXX O
members XXX O
of XXX O
a XXX O
superfamily XXX O
of XXX O
ATP-binding XXX B-GENE
cassette XXX I-GENE
membrane XXX I-GENE
transport XXX I-GENE
proteins XXX I-GENE
, XXX O
including XXX O
both XXX O
prokaryotic XXX O
and XXX O
eukaryotic XXX O
uptake XXX O
and XXX O
export XXX O
systems XXX O
. XXX O

The XXX O
two XXX O
cysteine XXX O
residues XXX O
located XXX O
in XXX O
this XXX O
additional XXX O
region XXX O
may XXX O
be XXX O
involved XXX O
in XXX O
the XXX O
formation XXX O
of XXX O
a XXX O
disulfide XXX O
bridge XXX O
associated XXX O
with XXX O
the XXX O
activation XXX O
process XXX O
of XXX O
the XXX O
catalytic XXX O
activity XXX O
. XXX O

The XXX O
tissue-specific XXX O
expression XXX O
of XXX O
DP XXX B-GENE
family XXX I-GENE
members XXX I-GENE
suggests XXX O
that XXX O
the XXX O
combination XXX O
of XXX O
DP XXX B-GENE
/ XXX I-GENE
E2F XXX I-GENE
heterodimers XXX I-GENE
that XXX O
constitute XXX O
DRTF1 XXX B-GENE
/ XXX I-GENE
E2F XXX I-GENE
is XXX O
influenced XXX O
by XXX O
the XXX O
phenotype XXX O
of XXX O
the XXX O
cell XXX O
. XXX O

Recent XXX O
studies XXX O
have XXX O
suggested XXX O
that XXX O
SHP-1 XXX B-GENE
regulates XXX O
the XXX O
function XXX O
of XXX O
Jak XXX B-GENE
family XXX O
tyrosine XXX B-GENE
kinases XXX I-GENE
, XXX O
as XXX O
shown XXX O
by XXX O
its XXX O
constitutive XXX O
association XXX O
with XXX O
the XXX O
Tyk2 XXX B-GENE
kinase XXX I-GENE
and XXX O
the XXX O
hyperphosphorylation XXX O
of XXX O
Jak XXX B-GENE
kinases XXX I-GENE
in XXX O
the XXX O
motheaten XXX O
cells XXX O
that XXX O
lack XXX O
functional XXX O
SHP-1 XXX B-GENE
. XXX O

Clinico-physiological XXX O
experiment XXX O
. XXX O

These XXX O
results XXX O
suggested XXX O
a XXX O
critical XXX O
role XXX O
for XXX O
tyrosine XXX O
residue XXX O
1229 XXX O
in XXX O
the XXX O
regulation XXX O
of XXX O
L1 XXX B-GENE
endocytosis XXX O
. XXX O

Blood XXX O
GSH-Px XXX B-GENE
activity XXX O
was XXX O
measured XXX O
with XXX O
a XXX O
spectrophotometer XXX O
, XXX O
using XXX O
a XXX O
modification XXX O
of XXX O
a XXX O
previously XXX O
described XXX O
assay XXX O
. XXX O

Cleidocranial XXX O
dysostosis XXX O
. XXX O

The XXX O
partial XXX O
ORF XXX O
was XXX O
found XXX O
to XXX O
be XXX O
identical XXX O
to XXX O
the XXX O
C XXX O
terminus XXX O
of XXX O
HrpJ2 XXX B-GENE
. XXX O

The XXX O
Ras XXX B-GENE
guanine XXX I-GENE
nucleotide-binding XXX I-GENE
protein XXX I-GENE
functions XXX O
as XXX O
a XXX O
molecular XXX O
switch XXX O
in XXX O
signalling XXX O
downstream XXX O
of XXX O
protein-tyrosine XXX B-GENE
kinases XXX I-GENE
. XXX O

Isolation XXX O
of XXX O
a XXX O
novel XXX O
TP53 XXX B-GENE
target XXX I-GENE
gene XXX I-GENE
from XXX O
a XXX O
colon XXX O
cancer XXX O
cell XXX O
line XXX O
carrying XXX O
a XXX O
highly XXX O
regulated XXX O
wild-type XXX B-GENE
TP53 XXX I-GENE
expression XXX O
system XXX O
. XXX O

Tonsillectomy XXX O
is XXX O
an XXX O
effective XXX O
means XXX O
of XXX O
prophylaxis XXX O
for XXX O
upper XXX O
respiratory XXX O
infection XXX O
in XXX O
habitual XXX O
angina XXX O
patients XXX O
. XXX O

All XXX O
samples XXX O
exhibited XXX O
a XXX O
decline XXX O
in XXX O
ethanol XXX O
concentration XXX O
, XXX O
with XXX O
most XXX O
losses XXX O
falling XXX O
within XXX O
the XXX O
expected XXX O
20 XXX O
to XXX O
40 XXX O
mg% XXX O
range XXX O
. XXX O

MotA XXX B-GENE
also XXX O
binds XXX O
a XXX O
DNA XXX O
sequence XXX O
( XXX O
a XXX O
MotA XXX B-GENE
box XXX I-GENE
) XXX O
, XXX O
centered XXX O
at XXX O
position XXX O
-30 XXX O
. XXX O

However XXX O
, XXX O
C3 XXX B-GENE
toxin XXX I-GENE
alone XXX O
or XXX O
in XXX O
combination XXX O
with XXX O
growth XXX B-GENE
factors XXX I-GENE
did XXX O
not XXX O
stimulate XXX O
AP-1 XXX B-GENE
: XXX O
Luc XXX B-GENE
activity XXX O
and XXX O
actually XXX O
antagonized XXX O
the XXX O
synergistic XXX O
activation XXX O
of XXX O
AP-1 XXX B-GENE
: XXX O
Luc XXX B-GENE
observed XXX O
in XXX O
response XXX O
to XXX O
co-stimulation XXX O
with XXX O
growth XXX B-GENE
factors XXX I-GENE
and XXX O
Ro-31-8220 XXX O
. XXX O

Basal XXX O
midexpiratory XXX O
lower XXX O
esophageal XXX O
sphincter XXX O
pressure XXX O
was XXX O
similar XXX O
in XXX O
the XXX O
study XXX O
group XXX O
( XXX O
mean XXX O
[ XXX O
SD XXX O
] XXX O
20 XXX O
. XXX O
1 XXX O
[ XXX O
9 XXX O
. XXX O
1 XXX O
] XXX O
mmHg XXX O
) XXX O
and XXX O
controls XXX O
( XXX O
17 XXX O
. XXX O
6 XXX O
[ XXX O
6 XXX O
. XXX O
0 XXX O
] XXX O
mmHg XXX O
) XXX O
; XXX O
the XXX O
pressure XXX O
did XXX O
not XXX O
change XXX O
following XXX O
EVS XXX O
or XXX O
EVL XXX O
. XXX O

An XXX O
open XXX O
reading XXX O
frame XXX O
encoding XXX O
a XXX O
protein XXX O
which XXX O
shows XXX O
significant XXX O
similarity XXX O
to XXX O
invertases XXX B-GENE
and XXX O
resolvases XXX B-GENE
was XXX O
located XXX O
immediately XXX O
upstream XXX O
of XXX O
the XXX O
Pac25I XXX B-GENE
R-M XXX B-GENE
operon XXX I-GENE
. XXX O

Using XXX O
site-directed XXX O
mutagenesis XXX O
, XXX O
we XXX O
show XXX O
that XXX O
the XXX O
RAREoct XXX B-GENE
contributes XXX O
to XXX O
the XXX O
transcriptional XXX O
activation XXX O
of XXX O
Oct-3 XXX B-GENE
/ XXX I-GENE
4 XXX I-GENE
promoter XXX I-GENE
in XXX O
P19 XXX O
cells XXX O
and XXX O
, XXX O
most XXX O
interestingly XXX O
, XXX O
mediates XXX O
the XXX O
RA-induced XXX O
repression XXX O
in XXX O
RA-differentiated XXX O
EC XXX O
cells XXX O
. XXX O

Binding XXX O
of XXX O
U2 XXX B-GENE
small XXX I-GENE
nuclear XXX I-GENE
ribonucleoprotein XXX I-GENE
( XXX O
snRNP XXX B-GENE
) XXX O
to XXX O
the XXX O
pre-mRNA XXX O
is XXX O
an XXX O
early XXX O
and XXX O
important XXX O
step XXX O
in XXX O
spliceosome XXX O
assembly XXX O
. XXX O

Monitoring XXX O
of XXX O
rheumatoid XXX O
arthritis XXX O
. XXX O

Furthermore XXX O
, XXX O
the XXX O
initial XXX O
plasma XXX O
retinol XXX O
level XXX O
in XXX O
conjunction XXX O
with XXX O
RBP XXX B-GENE
was XXX O
found XXX O
to XXX O
be XXX O
even XXX O
lower XXX O
in XXX O
12 XXX O
patients XXX O
( XXX O
35 XXX O
. XXX O
1 XXX O
micrograms XXX O
dl-1 XXX O
, XXX O
3 XXX O
. XXX O
7 XXX O
mg XXX O
dl-1 XXX O
) XXX O
who XXX O
subsequently XXX O
had XXX O
cancer XXX O
recurrence XXX O
than XXX O
in XXX O
those XXX O
who XXX O
remained XXX O
free XXX O
of XXX O
apparent XXX O
cancer XXX O
( XXX O
44 XXX O
. XXX O
5 XXX O
micrograms XXX O
dl-1 XXX O
, XXX O
4 XXX O
. XXX O
6 XXX O
mg XXX O
dl-1 XXX O
) XXX O
. XXX O

WRN XXX B-GENE
helicase XXX I-GENE
resolves XXX O
alternate XXX O
DNA XXX O
structures XXX O
including XXX O
tetraplex XXX O
and XXX O
triplex XXX O
DNA XXX O
, XXX O
and XXX O
Holliday XXX O
junctions XXX O
. XXX O

Study XXX O
on XXX O
re-establishment XXX O
of XXX O
ovulation XXX O
after XXX O
termination XXX O
of XXX O
sex-steroidal XXX O
treatment XXX O
--compared XXX O
with XXX O
re-appearance XXX O
of XXX O
ovulation XXX O
after XXX O
abortion XXX O
and XXX O
premature XXX O
delivery XXX O
. XXX O

Most XXX O
pituitary XXX B-GENE
hormone-coding XXX I-GENE
gene XXX I-GENE
promoters XXX O
are XXX O
activated XXX O
by XXX O
Ptx1 XXX B-GENE
. XXX O

The XXX O
p97-depleted XXX O
nuclei XXX O
remained XXX O
largely XXX O
competent XXX O
for XXX O
nuclear XXX O
protein XXX O
import XXX O
. XXX O

BCR XXX B-GENE
cross-linking XXX O
also XXX O
led XXX O
to XXX O
increased XXX O
MAPK-activated XXX B-GENE
protein XXX I-GENE
kinase-2 XXX I-GENE
activity XXX O
, XXX O
an XXX O
enzyme XXX O
that XXX O
lies XXX O
immediately XXX O
downstream XXX O
from XXX O
p38 XXX B-GENE
MAPK XXX I-GENE
; XXX O
MAPK-activated XXX B-GENE
protein XXX I-GENE
kinase-2 XXX I-GENE
immune XXX O
complexes XXX O
phosphorylated XXX O
a XXX O
peptide XXX O
substrate XXX O
containing XXX O
the XXX O
CREB XXX B-GENE
serine XXX I-GENE
133 XXX I-GENE
phosphoacceptor XXX I-GENE
motif XXX I-GENE
. XXX O

It XXX O
bound XXX O
to XXX O
vitamin XXX B-GENE
D XXX I-GENE
receptor XXX I-GENE
( XXX O
VDR XXX B-GENE
) XXX O
but XXX O
not XXX O
retinoic XXX B-GENE
acid XXX I-GENE
Xalpha XXX I-GENE
receptor XXX I-GENE
( XXX O
RXRalpha XXX B-GENE
) XXX O
in XXX O
the XXX O
human XXX O
T XXX O
cell XXX O
line XXX O
MT2 XXX O
cells XXX O
. XXX O

Immunogenicity XXX O
of XXX O
various XXX O
mycobacteria XXX O
and XXX O
the XXX O
corresponding XXX O
levels XXX O
of XXX O
cross-protection XXX O
developed XXX O
between XXX O
species XXX O
. XXX O

Isomers XXX O
were XXX O
differentiated XXX O
based XXX O
on XXX O
the XXX O
MS-MS XXX O
data XXX O
of XXX O
the XXX O
trofluoroacetyl-biphenylol XXX O
derivatives XXX O
. XXX O

Most XXX O
importantly XXX O
, XXX O
the XXX O
addition XXX O
of XXX O
purified XXX O
17S XXX B-GENE
U2 XXX I-GENE
snRNPs XXX I-GENE
, XXX O
but XXX O
not XXX O
of XXX O
12S XXX B-GENE
U2 XXX I-GENE
snRNPs XXX I-GENE
, XXX O
to XXX O
HeLa XXX O
splicing XXX O
extracts XXX O
in XXX O
which XXX O
the XXX O
endogeneous XXX B-GENE
U2 XXX I-GENE
snRNPs XXX I-GENE
have XXX O
been XXX O
functionally XXX O
neutralized XXX O
with XXX O
anti-PRP9 XXX B-GENE
antibodies XXX I-GENE
fully XXX O
restores XXX O
the XXX O
mRNA-splicing XXX O
activity XXX O
of XXX O
the XXX O
extracts XXX O
. XXX O

Diuretics XXX O
: XXX O
basic XXX O
clinical XXX O
pharmacology XXX O
and XXX O
therapeutic XXX O
use XXX O
. XXX O

The XXX O
Cdk2-cyclin-D1 XXX B-GENE
complex XXX I-GENE
did XXX O
not XXX O
phosphorylate XXX O
any XXX O
tested XXX O
substrates XXX O
, XXX O
such XXX O
as XXX O
H1 XXX B-GENE
histone XXX I-GENE
, XXX O
pRB XXX B-GENE
, XXX O
SV40 XXX B-GENE
large XXX I-GENE
T XXX I-GENE
antigen XXX I-GENE
, XXX O
p53 XXX B-GENE
, XXX O
E2F-1 XXX B-GENE
or XXX O
a XXX O
preparation XXX O
of XXX O
nuclear XXX O
proteins XXX O
from XXX O
HeLa XXX O
cells XXX O
; XXX O
in XXX O
contrast XXX O
, XXX O
Cdk2-cyclin-E XXX B-GENE
and XXX O
Cdk2-cyclin-A XXX B-GENE
phosphorylated XXX O
these XXX O
proteins XXX O
. XXX O

The XXX O
December XXX O
armed XXX O
revolt XXX O
in XXX O
Moscow XXX O
and XXX O
the XXX O
paramedical XXX O
personnel XXX O
. XXX O

In XXX O
situ XXX O
hybridization XXX O
with XXX O
the XXX O
antisense XXX O
RNA XXX O
probes XXX O
further XXX O
supported XXX O
the XXX O
expression XXX O
changes XXX O
of XXX O
these XXX O
six XXX O
clones XXX O
and XXX O
localized XXX O
the XXX O
changes XXX O
in XXX O
multiple XXX O
germ XXX O
cell XXX O
stages XXX O
as XXX O
well XXX O
as XXX O
other XXX O
cell XXX O
types XXX O
( XXX O
Sertoli XXX O
, XXX O
interstitial XXX O
and XXX O
peritubular XXX O
cells XXX O
) XXX O
. XXX O

On XXX O
physical XXX O
examination XXX O
a XXX O
mild XXX O
symmetrical XXX O
polyarthritis XXX O
of XXX O
small XXX O
and XXX O
large XXX O
joints XXX O
was XXX O
seen XXX O
. XXX O

The XXX O
described XXX O
results XXX O
show XXX O
that XXX O
DTD XXX O
is XXX O
fast XXX O
, XXX O
simple XXX O
, XXX O
and XXX O
easy XXX O
to XXX O
automate XXX O
; XXX O
requires XXX O
only XXX O
a XXX O
small XXX O
amount XXX O
of XXX O
sample XXX O
( XXX O
approximately XXX O
50 XXX O
mg XXX O
) XXX O
; XXX O
and XXX O
affords XXX O
quantitative XXX O
information XXX O
about XXX O
the XXX O
main XXX O
groups XXX O
of XXX O
compounds XXX O
present XXX O
in XXX O
cheeses XXX O
. XXX O

With XXX O
a XXX O
cutoff XXX O
level XXX O
for XXX O
TSST-1 XXX B-GENE
of XXX O
less XXX O
than XXX O
100 XXX O
pg XXX O
/ XXX O
ml XXX O
, XXX O
28 XXX O
samples XXX O
obtained XXX O
from XXX O
12 XXX O
patients XXX O
were XXX O
positive XXX O
for XXX O
TSST-1 XXX B-GENE
. XXX O

The XXX O
elevation XXX O
of XXX O
cyclic XXX O
AMP XXX O
( XXX O
cAMP XXX O
) XXX O
levels XXX O
in XXX O
the XXX O
cell XXX O
downregulates XXX O
the XXX O
activity XXX O
of XXX O
the XXX O
Raf-1 XXX B-GENE
kinase XXX I-GENE
. XXX O

It XXX O
is XXX O
, XXX O
however XXX O
, XXX O
extremely XXX O
homologous XXX O
to XXX O
a XXX O
third XXX O
'non-classical' XXX O
gene XXX O
, XXX O
HLA-5 XXX B-GENE
. XXX I-GENE
4 XXX I-GENE
, XXX O
and XXX O
to XXX O
the XXX O
chimpanzee XXX O
gene XXX O
, XXX O
Ch28 XXX B-GENE
. XXX O

Twenty-five XXX O
patients XXX O
( XXX O
80 XXX O
, XXX O
6% XXX O
) XXX O
with XXX O
mixed XXX O
neoplasms XXX O
were XXX O
operated XXX O
on XXX O
by XXX O
total XXX O
conservative XXX O
parotidectomy XXX O
( XXX O
T XXX O
. XXX O
C XXX O
. XXX O
P XXX O
. XXX O
) XXX O
, XXX O
3 XXX O
( XXX O
9 XXX O
, XXX O
7% XXX O
) XXX O
by XXX O
S XXX O
. XXX O
P XXX O
. XXX O
and XXX O
3 XXX O
( XXX O
9 XXX O
, XXX O
7% XXX O
) XXX O
by XXX O
En XXX O
. XXX O

Karger XXX O
AG XXX O
, XXX O
Basel XXX O

Traditional XXX O
surgical XXX O
exploration XXX O
was XXX O
followed XXX O
by XXX O
survey XXX O
with XXX O
a XXX O
gamma-detecting XXX O
probe XXX O
. XXX O

Magnetic XXX O
resonance XXX O
imaging XXX O
( XXX O
MRI XXX O
) XXX O
has XXX O
enabled XXX O
us XXX O
to XXX O
see XXX O
the XXX O
spinal XXX O
intramedullary XXX O
pathology XXX O
as XXX O
differences XXX O
in XXX O
signal XXX O
intensity XXX O
. XXX O

As XXX O
high-speed XXX O
, XXX O
volumetric XXX O
imaging XXX O
, XXX O
computed XXX O
tomographic XXX O
scan XXX O
machines XXX O
such XXX O
as XXX O
the XXX O
Dynamic XXX O
Spatial XXX O
Reconstructor XXX O
become XXX O
available XXX O
with XXX O
higher XXX O
density XXX O
resolution XXX O
, XXX O
perhaps XXX O
a XXX O
single XXX O
injection XXX O
of XXX O
contrast XXX O
agent XXX O
into XXX O
the XXX O
right XXX O
atrium XXX O
or XXX O
even XXX O
a XXX O
peripheral XXX O
vein XXX O
may XXX O
be XXX O
adequate XXX O
to XXX O
obtain XXX O
all XXX O
these XXX O
measurements XXX O
. XXX O

We XXX O
demonstrate XXX O
that XXX O
the XXX O
protein XXX O
is XXX O
a XXX O
murine XXX B-GENE
homologue XXX I-GENE
of XXX I-GENE
SAF-A XXX I-GENE
which XXX O
has XXX O
been XXX O
shown XXX O
to XXX O
bind XXX O
selectively XXX O
to XXX O
MARs XXX O
and XXX O
is XXX O
responsible XXX O
for XXX O
the XXX O
satMa-binding XXX O
activity XXX O
in XXX O
the XXX O
chromatographic XXX O
fractions XXX O
. XXX O

The XXX O
extent XXX O
of XXX O
the XXX O
fbpA XXX B-GENE
operator XXX I-GENE
sequence XXX I-GENE
( XXX I-GENE
42 XXX I-GENE
bp XXX I-GENE
) XXX I-GENE
, XXX O
as XXX O
defined XXX O
by XXX O
our XXX O
footprinting XXX O
analysis XXX O
, XXX O
would XXX O
suggest XXX O
the XXX O
binding XXX O
of XXX O
two XXX O
Fur XXX B-GENE
repressor XXX I-GENE
dimers XXX I-GENE
. XXX O

According XXX O
to XXX O
the XXX O
published XXX O
sequence XXX O
of XXX O
the XXX O
CHS1 XXX B-GENE
gene XXX I-GENE
, XXX O
this XXX O
fragment XXX O
contains XXX O
four XXX O
repeats XXX O
of XXX O
a XXX O
TGAAACA XXX O
consensus XXX O
sequence XXX O
previously XXX O
identified XXX O
in XXX O
the XXX O
alpha-factor-inducible XXX O
BAR1 XXX B-GENE
promoter XXX I-GENE
[ XXX O
Kronstad XXX O
, XXX O
J XXX O
. XXX O

The XXX O
number XXX O
of XXX O
crystalline XXX O
deposits XXX O
is XXX O
less XXX O
in XXX O
the XXX O
advanced XXX O
atrophic XXX O
areas XXX O
of XXX O
the XXX O
RPE-choriocapillaris XXX O
complex XXX O
. XXX O

Peroxydase XXX B-GENE
reaction XXX O
stains XXX O
were XXX O
negative XXX O
, XXX O
chloroacetate XXX B-GENE
esterase XXX I-GENE
were XXX O
strongly XXX O
positive XXX O
. XXX O

Genesis XXX O
of XXX O
foam XXX O
cells XXX O
: XXX O
study XXX O
in XXX O
rats XXX O
after XXX O
administration XXX O
of XXX O
Cloforex XXX O
. XXX O

Risk XXX O
factors XXX O
associated XXX O
with XXX O
a XXX O
high XXX O
seroprevalence XXX O
of XXX O
hepatitis XXX O
C XXX O
virus XXX O
infection XXX O
in XXX O
Egyptian XXX O
blood XXX O
donors XXX O
. XXX O

In XXX O
contrast XXX O
, XXX O
the XXX O
ubiquitous XXX O
expression XXX O
of XXX O
p19 XXX B-GENE
( XXX I-GENE
INK4d XXX I-GENE
) XXX I-GENE
has XXX O
not XXX O
been XXX O
previously XXX O
described XXX O
in XXX O
human XXX O
or XXX O
murine XXX O
B-lineage XXX O
cells XXX O
. XXX O

These XXX O
findings XXX O
were XXX O
reinforced XXX O
by XXX O
an XXX O
analysis XXX O
that XXX O
was XXX O
restricted XXX O
to XXX O
living XXX O
donor XXX O
transplants XXX O
without XXX O
acute XXX O
rejection XXX O
. XXX O

There XXX O
is XXX O
general XXX O
agreement XXX O
that XXX O
the XXX O
hepatitis XXX O
C XXX O
virus XXX O
is XXX O
efficiently XXX O
transmitted XXX O
parenterally XXX O
, XXX O
while XXX O
data XXX O
on XXX O
viral XXX O
transmission XXX O
from XXX O
mothers XXX O
to XXX O
babies XXX O
or XXX O
by XXX O
sexual XXX O
or XXX O
non-sexual XXX O
household XXX O
contact XXX O
are XXX O
conflicting XXX O
. XXX O

Molecular XXX O
characterization XXX O
of XXX O
a XXX O
large XXX O
Borrelia XXX O
burgdorferi XXX O
motility XXX O
operon XXX O
which XXX O
is XXX O
initiated XXX O
by XXX O
a XXX O
consensus XXX O
sigma70 XXX B-GENE
promoter XXX I-GENE
. XXX O

Demographic XXX O
characteristics XXX O
and XXX O
risk XXX O
factor XXX O
data XXX O
for XXX O
76 XXX O
, XXX O
672 XXX O
clients XXX O
were XXX O
studied XXX O
to XXX O
characterize XXX O
the XXX O
distribution XXX O
of XXX O
infection XXX O
with XXX O
human XXX O
immunodeficiency XXX O
virus XXX O
( XXX O
HIV XXX O
) XXX O
and XXX O
the XXX O
use XXX O
of XXX O
counseling XXX O
and XXX O
testing XXX O
facilities XXX O
in XXX O
Houston XXX O
, XXX O
Tex XXX O
. XXX O

These XXX O
CTD XXX B-GENE
kinases XXX I-GENE
, XXX O
designated XXX O
CTDK1 XXX B-GENE
and XXX O
CTDK2 XXX B-GENE
, XXX O
are XXX O
fractionated XXX O
by XXX O
chromatography XXX O
on XXX O
Mono XXX O
Q XXX O
. XXX O

Anti-NPROSP-C XXX B-GENE
also XXX O
exclusively XXX O
detected XXX O
time-dependent XXX O
appearances XXX O
of XXX O
5-10-kDa XXX B-GENE
proSP-C XXX I-GENE
forms XXX O
in XXX O
lamellar XXX O
bodies XXX O
and XXX O
homogenates XXX O
. XXX O

The XXX O
ubiquitously XXX O
expressed XXX O
E12 XXX B-GENE
bHLH XXX I-GENE
protein XXX I-GENE
dimerizes XXX O
with XXX O
numerous XXX O
cell-specific XXX O
bHLH XXX B-GENE
factors XXX I-GENE
. XXX O

Epithelial XXX O
cytotoxicity XXX O
of XXX O
combined XXX O
antibiotics XXX O
was XXX O
additive XXX O
, XXX O
with XXX O
no XXX O
evidence XXX O
of XXX O
competition XXX O
or XXX O
synergism XXX O
. XXX O

In XXX O
vitro XXX O
antimalarial XXX O
activity XXX O
of XXX O
neem XXX O
( XXX O
Azadirachta XXX O
indica XXX O
A XXX O
. XXX O

DIBA XXX O
was XXX O
more XXX O
sensitive XXX O
and XXX O
had XXX O
a XXX O
better XXX O
negative XXX O
predictive XXX O
value XXX O
and XXX O
a XXX O
lower XXX O
false XXX O
negative XXX O
percentage XXX O
than XXX O
DFAT XXX O
. XXX O

Managing XXX O
dysphagia XXX O
in XXX O
a XXX O
chronic XXX O
care XXX O
setting XXX O
: XXX O
an XXX O
introduction XXX O
. XXX O

In XXX O
none XXX O
of XXX O
the XXX O
44 XXX O
type XXX O
I XXX O
attacks XXX O
and XXX O
29 XXX O
type XXX O
II XXX O
attacks XXX O
which XXX O
were XXX O
recorded XXX O
did XXX O
circulatory XXX O
changes XXX O
; XXX O
the XXX O
latter XXX O
were XXX O
different XXX O
in XXX O
the XXX O
two XXX O
groups XXX O
. XXX O

By XXX O
stepwise XXX O
linear XXX O
multiple XXX O
regression XXX O
analysis XXX O
, XXX O
ionized XXX O
magnesium XXX O
was XXX O
significantly XXX O
related XXX O
to XXX O
cyclosporin XXX O
trough XXX O
level XXX O
and XXX O
total XXX O
cholesterol XXX O
but XXX O
not XXX O
to XXX O
serum XXX O
creatinine XXX O
, XXX O
time XXX O
after XXX O
transplant XXX O
or XXX O
the XXX O
dose XXX O
of XXX O
cyclosporin XXX O
. XXX O

These XXX O
findings XXX O
indicate XXX O
the XXX O
involvement XXX O
of XXX O
Sp1 XXX B-GENE
and XXX O
an XXX O
Inr XXX O
in XXX O
non-cell-specific XXX O
regulation XXX O
and XXX O
a XXX O
Kruppel-like XXX B-GENE
transcription XXX I-GENE
factor XXX I-GENE
and XXX O
Sp1 XXX B-GENE
in XXX O
the XXX O
cell-specific XXX O
regulation XXX O
of XXX O
the XXX O
LTC XXX B-GENE
( XXX I-GENE
4 XXX I-GENE
) XXX I-GENE
S XXX I-GENE
gene XXX I-GENE
. XXX O

Primer XXX O
extension XXX O
analysis XXX O
and XXX O
RNA XXX O
sequencing XXX O
demonstrates XXX O
that XXX O
the XXX O
transcription XXX O
start XXX O
point XXX O
of XXX O
rat XXX B-GENE
ODC XXX I-GENE
mRNA XXX I-GENE
is XXX O
located XXX O
303 XXX O
nt XXX O
upstream XXX O
from XXX O
the XXX O
A XXX O
residue XXX O
in XXX O
the XXX O
start XXX O
codon XXX O
. XXX O

In XXX O
all XXX O
experimental XXX O
eyes XXX O
, XXX O
there XXX O
was XXX O
a XXX O
marked XXX O
reduction XXX O
, XXX O
but XXX O
never XXX O
a XXX O
complete XXX O
absence XXX O
of XXX O
adrenergic XXX O
nerves XXX O
in XXX O
the XXX O
iris XXX O
. XXX O

RNA XXX O
in XXX O
situ XXX O
hybridization XXX O
on XXX O
brain XXX O
sections XXX O
of XXX O
normal XXX O
human XXX O
embryos XXX O
revealed XXX O
a XXX O
strong XXX O
labeling XXX O
in XXX O
restricted XXX O
areas XXX O
of XXX O
the XXX O
cerebral XXX O
cortex XXX O
. XXX O

Individual XXX O
alcohol XXX O
reaction XXX O
profiles XXX O
. XXX O

Tobramycin-loaded XXX O
SLN XXX O
administered XXX O
i XXX O
. XXX O
v XXX O
. XXX O
showed XXX O
a XXX O
prolonged XXX O
circulation XXX O
time XXX O
compared XXX O
to XXX O
the XXX O
i XXX O
. XXX O
v XXX O
. XXX O
administered XXX O
tobramycin XXX O
solution XXX O
. XXX O

Mapping XXX O
of XXX O
the XXX O
mouse XXX B-GENE
ornithine XXX I-GENE
decarboxylase-related XXX I-GENE
sequence XXX I-GENE
family XXX I-GENE
. XXX O

Lithium XXX O
delays XXX O
the XXX O
circadian XXX O
rhythm XXX O
of XXX O
wheel-running XXX O
in XXX O
Syrian XXX O
hamsters XXX O
at XXX O
plasma XXX O
concentrations XXX O
( XXX O
0 XXX O
. XXX O
59-0 XXX O
. XXX O
74 XXX O
mM XXX O
) XXX O
that XXX O
also XXX O
cause XXX O
toxic XXX O
weight XXX O
loss XXX O
. XXX O

The XXX O
recombinant XXX O
contains XXX O
the XXX O
normal XXX O
beta XXX B-GENE
A-globin XXX I-GENE
gene XXX I-GENE
, XXX O
the XXX O
mutant XXX O
gene XXX O
and XXX O
Ylp XXX O
vector XXX O
sequences XXX O
between XXX O
the XXX O
two XXX O
copies XXX O
. XXX O

The XXX O
following XXX O
data XXX O
were XXX O
recorded XXX O
at XXX O
arrival XXX O
in XXX O
the XXX O
intensive XXX O
care XXX O
unit XXX O
6 XXX O
, XXX O
12 XXX O
, XXX O
24 XXX O
, XXX O
and XXX O
48 XXX O
hours XXX O
after XXX O
termination XXX O
of XXX O
CPB XXX O
: XXX O
heart XXX O
rate XXX O
, XXX O
blood XXX O
pressure XXX O
, XXX O
left XXX O
atrial XXX O
pressure XXX O
, XXX O
central-peripheral XXX O
temperature XXX O
difference XXX O
, XXX O
arterial-central XXX O
venous XXX O
oxygen XXX O
saturation XXX O
difference XXX O
, XXX O
urine XXX O
output XXX O
, XXX O
serum XXX O
creatinine XXX O
, XXX O
lactate XXX O
and XXX O
neutrophil XXX B-GENE
elastase XXX I-GENE
levels XXX O
, XXX O
the XXX O
Doppler XXX O
echocardiographic XXX O
factors XXX O
shortening XXX O
fraction XXX O
and XXX O
preejection XXX O
period XXX O
/ XXX O
left-ventricular XXX O
ejection XXX O
time XXX O
, XXX O
and XXX O
cumulative XXX O
doses XXX O
of XXX O
catecholamines XXX O
( XXX O
epinephrine XXX O
) XXX O
, XXX O
enoximone XXX O
, XXX O
and XXX O
furosemide XXX O
. XXX O

Deaths XXX O
stopped XXX O
11 XXX O
hours XXX O
after XXX O
copper XXX O
concentrations XXX O
decreased XXX O
below XXX O
0 XXX O
. XXX O
2 XXX O
ppm XXX O
and XXX O
signs XXX O
of XXX O
distress XXX O
stopped XXX O
in XXX O
surviving XXX O
pinfish XXX O
by XXX O
approximately XXX O
6 XXX O
hours XXX O
after XXX O
the XXX O
last XXX O
death XXX O
. XXX O

A XXX O
family XXX O
of XXX O
RNA XXX O
molecules XXX O
in XXX O
the XXX O
2 XXX O
. XXX O
0-2 XXX O
. XXX O
2-kilobase XXX O
range XXX O
identified XXX O
with XXX O
a XXX O
probe XXX O
from XXX O
this XXX O
gene XXX O
was XXX O
overexpressed XXX O
in XXX O
the XXX O
resistant XXX O
cells XXX O
. XXX O

Body XXX O
weight XXX O
reduction XXX O
increases XXX O
insulin XXX B-GENE
sensitivity XXX O
and XXX O
improves XXX O
both XXX O
blood XXX O
glucose XXX O
and XXX O
blood XXX O
pressure XXX O
control XXX O
. XXX O

Several XXX O
mutations XXX O
disrupted XXX O
the XXX O
endonuclease XXX B-GENE
and XXX O
helicase XXX B-GENE
activities XXX O
; XXX O
however XXX O
, XXX O
only XXX O
one XXX O
amino-terminal-charge XXX B-GENE
cluster XXX I-GENE
mutant XXX I-GENE
protein XXX I-GENE
( XXX O
D40A-D42A-D44A XXX B-GENE
) XXX O
completely XXX O
lost XXX O
AAV XXX O
hairpin XXX O
DNA XXX O
binding XXX O
activity XXX O
. XXX O

Gene XXX O
silencing XXX O
associated XXX O
with XXX O
repeated XXX O
DNA XXX O
sequences XXX O
has XXX O
been XXX O
reported XXX O
for XXX O
many XXX O
eukaryotes XXX O
, XXX O
including XXX O
plants XXX O
. XXX O

In XXX O
mammalian XXX O
cells XXX O
, XXX O
phosphorylation XXX O
of XXX O
eIF-2 XXX B-GENE
alpha XXX I-GENE
inhibits XXX O
the XXX O
activity XXX O
of XXX O
eIF-2B XXX B-GENE
, XXX O
the XXX O
GDP-GTP XXX B-GENE
exchange XXX I-GENE
factor XXX I-GENE
for XXX O
eIF-2 XXX B-GENE
. XXX O

These XXX O
clones XXX O
overlapped XXX O
and XXX O
contained XXX O
the XXX O
structural XXX O
gene XXX O
encoding XXX O
the XXX O
complete XXX O
C5 XXX B-GENE
alpha-chain XXX I-GENE
and XXX O
90% XXX O
of XXX O
the XXX O
beta-chain XXX O
. XXX O

Although XXX O
inactive XXX O
in XXX O
cells XXX O
under XXX O
normal XXX O
conditions XXX O
, XXX O
the XXX O
CHOP XXX B-GENE
gene XXX I-GENE
is XXX O
markedly XXX O
induced XXX O
by XXX O
a XXX O
variety XXX O
of XXX O
cellular XXX O
stresses XXX O
, XXX O
including XXX O
nutrient XXX O
deprivation XXX O
and XXX O
metabolic XXX O
perturbations XXX O
. XXX O

DNase XXX B-GENE
I XXX I-GENE
footprint XXX O
analysis XXX O
identified XXX O
a XXX O
protected XXX O
region XXX O
from XXX O
-37 XXX O
to XXX O
-53 XXX O
. XXX O

Fine XXX O
analysis XXX O
at XXX O
the XXX O
nucleotide XXX O
level XXX O
of XXX O
the XXX O
early XXX O
events XXX O
in XXX O
the XXX O
digestion XXX O
with XXX O
nuclease XXX B-GENE
S1 XXX I-GENE
shows XXX O
that XXX O
the XXX O
enzyme XXX O
attacks XXX O
preferentially XXX O
the XXX O
sequence XXX O
( XXX O
G-A XXX O
) XXX O
12 XXX O
on XXX O
the XXX O
message XXX O
complementary XXX O
strand XXX O
. XXX O

Parodoxical XXX O
rise XXX O
in XXX O
urinary XXX B-GENE
albumin XXX I-GENE
levels XXX O
after XXX O
treatment XXX O
of XXX O
essential XXX O
hypertension XXX O
. XXX O

These XXX O
latter XXX O
results XXX O
showed XXX O
that XXX O
the XXX O
ABFI XXX B-GENE
protein XXX I-GENE
, XXX O
like XXX O
the XXX O
RAP1 XXX B-GENE
protein XXX I-GENE
, XXX O
bound XXX O
sequences XXX O
required XXX O
for XXX O
positive XXX O
as XXX O
well XXX O
as XXX O
negative XXX O
regulation XXX O
of XXX O
gene XXX O
expression XXX O
. XXX O

Efficacy XXX O
of XXX O
cervical XXX O
spine XXX O
immobilization XXX O
methods XXX O
. XXX O

BACKGROUND XXX O
: XXX O
Dermoscopy XXX O
is XXX O
a XXX O
noninvasive XXX O
technique XXX O
that XXX O
increases XXX O
the XXX O
diagnostic XXX O
accuracy XXX O
of XXX O
pigmented XXX O
skin XXX O
lesions XXX O
, XXX O
particularly XXX O
improving XXX O
the XXX O
diagnosis XXX O
of XXX O
patients XXX O
with XXX O
cutaneous XXX O
melanoma XXX O
in XXX O
situ XXX O
( XXX O
CMIS XXX O
) XXX O
and XXX O
early XXX O
invasive XXX O
melanoma XXX O
. XXX O

3600-fold XXX O
to XXX O
apparent XXX O
homogeneity XXX O
with XXX O
a XXX O
41% XXX O
yield XXX O
by XXX O
affinity XXX O
chromatography XXX O
utilizing XXX O
DNA-cellulose XXX O
; XXX O
the XXX O
purity XXX O
of XXX O
the XXX O
final XXX O
preparation XXX O
was XXX O
assessed XXX O
by XXX O
SDS XXX O
/ XXX O
PAGE XXX O
, XXX O
lack XXX O
of XXX O
contamination XXX O
by XXX O
other XXX O
nucleases XXX B-GENE
and XXX O
production XXX O
of XXX O
a XXX O
monospecific XXX O
antibody XXX O
against XXX O
the XXX O
enzyme XXX O
. XXX O

Several XXX O
Src XXX B-GENE
SH3-binding XXX I-GENE
proteins XXX I-GENE
were XXX O
phosphorylated XXX O
in XXX O
Src-transformed XXX O
cells XXX O
. XXX O

Patients XXX O
enrolled XXX O
in XXX O
the XXX O
Integrilin XXX O
to XXX O
Minimize XXX O
Platelet XXX O
Aggregation XXX O
and XXX O
Coronary XXX O
Thrombosis-II XXX O
( XXX O
IMPACT-II XXX O
) XXX O
trial XXX O
were XXX O
analyzed XXX O
. XXX O

The XXX O
circadian XXX O
rhythmicity XXX O
of XXX O
sleep XXX O
was XXX O
pronounced XXX O
. XXX O

Sequence XXX O
analysis XXX O
reveals XXX O
that XXX O
the XXX O
DNA XXX O
binding XXX O
domain XXX O
of XXX O
ILF XXX B-GENE
has XXX O
strong XXX O
homology XXX O
to XXX O
the XXX O
recently XXX O
described XXX O
fork XXX B-GENE
head XXX I-GENE
DNA XXX I-GENE
binding XXX I-GENE
domain XXX I-GENE
found XXX O
in XXX O
the XXX O
Drosophila XXX B-GENE
homeotic XXX I-GENE
protein XXX I-GENE
fork XXX B-GENE
head XXX I-GENE
and XXX O
a XXX O
family XXX O
of XXX O
hepatocyte XXX B-GENE
nuclear XXX I-GENE
factors XXX I-GENE
, XXX O
HNF-3 XXX B-GENE
. XXX O

Plasma XXX B-GENE
lactoferrin XXX I-GENE
and XXX O
the XXX O
blood XXX O
count XXX O
of XXX O
polynuclear XXX O
neutrophils XXX O
. XXX O

Although XXX O
a XXX O
wide XXX O
range XXX O
of XXX O
cognitive XXX O
functions XXX O
had XXX O
been XXX O
tested XXX O
, XXX O
all XXX O
but XXX O
one XXX O
seizure XXX O
occurred XXX O
during XXX O
assessment XXX O
of XXX O
memory XXX O
performance XXX O
. XXX O

Because XXX O
results XXX O
of XXX O
recent XXX O
randomized XXX O
trials XXX O
indicate XXX O
minimal XXX O
efficacy XXX O
of XXX O
continuing XXX O
MAC XXX O
prophylaxis XXX O
in XXX O
patients XXX O
who XXX O
respond XXX O
to XXX O
potent XXX O
combination XXX O
antiretroviral XXX O
therapy XXX O
, XXX O
the XXX O
observed XXX O
high XXX O
incidence XXX O
of XXX O
macrolide-resistant XXX O
bacterial XXX O
colonization XXX O
of XXX O
the XXX O
respiratory XXX O
tract XXX O
in XXX O
this XXX O
trial XXX O
supports XXX O
the XXX O
discontinuation XXX O
of XXX O
macrolide XXX O
prophylaxis XXX O
in XXX O
all XXX O
AIDS XXX O
patients XXX O
whose XXX O
CD4 XXX O
counts XXX O
have XXX O
risen XXX O
above XXX O
100 XXX O
cells XXX O
/ XXX O
microL XXX O
. XXX O

Mean XXX O
weighted XXX O
skin XXX O
temperature XXX O
( XXX O
Tsk XXX O
) XXX O
was XXX O
lower XXX O
( XXX O
P XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
following XXX O
acclimation XXX O
than XXX O
before XXX O
, XXX O
and XXX O
acclimation XXX O
resulted XXX O
in XXX O
a XXX O
larger XXX O
( XXX O
P XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
02 XXX O
) XXX O
Tre-to-Tsk XXX O
gradient XXX O
. XXX O

Biol XXX O
. XXX O

Here XXX O
we XXX O
show XXX O
that XXX O
short XXX O
synthetic XXX O
peptides XXX O
containing XXX O
the XXX O
pRB-binding XXX B-GENE
sequences XXX I-GENE
of XXX O
E1A XXX B-GENE
are XXX O
sufficient XXX O
for XXX O
interaction XXX O
with XXX O
p107 XXX B-GENE
, XXX O
cyclin XXX B-GENE
A XXX I-GENE
, XXX O
and XXX O
p130 XXX B-GENE
. XXX O

Evidence XXX O
forthe XXX O
electroosmosis XXX O
theory XXX O
of XXX O
transport XXX O
in XXX O
the XXX O
phloem XXX O
. XXX O

Either XXX O
two XXX O
or XXX O
more XXX O
different XXX O
sequences XXX O
can XXX O
promote XXX O
cleavage XXX O
, XXX O
or XXX O
a XXX O
single XXX O
element XXX O
exists XXX O
which XXX O
is XXX O
long XXX O
and XXX O
diffuse XXX O
. XXX O

Paradoxically XXX O
, XXX O
however XXX O
, XXX O
the XXX O
GH XXX B-GENE
receptor XXX I-GENE
cloned XXX O
from XXX O
liver XXX O
exhibits XXX O
no XXX O
sequence XXX O
similarity XXX O
to XXX O
receptors XXX O
with XXX O
known XXX O
signal XXX O
transduction XXX O
mechanisms XXX O
, XXX O
including XXX O
those XXX O
exhibiting XXX O
ligand-activated XXX O
tyrosine XXX B-GENE
kinase XXX I-GENE
activity XXX O
. XXX O

RESULTS XXX O
: XXX O
Closure XXX O
time XXX O
of XXX O
fistulas XXX O
in XXX O
patients XXX O
receiving XXX O
TPN XXX O
+ XXX O
somatostatin XXX B-GENE
was XXX O
significantly XXX O
shorter XXX O
( XXX O
13 XXX O
. XXX O
86 XXX O
+ XXX O
/ XXX O
- XXX O
1 XXX O
. XXX O
84 XXX O
versus XXX O
20 XXX O
. XXX O
4 XXX O
+ XXX O
/ XXX O
- XXX O
2 XXX O
. XXX O
89 XXX O
days XXX O
) XXX O
than XXX O
in XXX O
those XXX O
receiving XXX O
TPN XXX O
alone XXX O
. XXX O

In XXX O
the XXX O
premating XXX O
period XXX O
male XXX O
rate XXX O
of XXX O
aggression XXX O
was XXX O
not XXX O
significantly XXX O
correlated XXX O
with XXX O
testosterone XXX O
level XXX O
. XXX O

Far-infrared XXX O
hopping XXX O
conductivity XXX O
in XXX O
the XXX O
CuO XXX O
chains XXX O
of XXX O
a XXX O
single-domain XXX O
YBa2Cu3O7- XXX O
delta XXX O
crystal XXX O
. XXX O

Factors XXX O
associated XXX O
with XXX O
afterdrop XXX O
included XXX O
age XXX O
, XXX O
end-of-surgery XXX O
temperature XXX O
( XXX O
both XXX O
positively XXX O
) XXX O
and XXX O
body XXX O
mass XXX O
( XXX O
negatively XXX O
) XXX O
. XXX O

Extracellular XXX O
fibril XXX O
formation XXX O
by XXX O
neuroglial XXX O
cells XXX O
at XXX O
the XXX O
vitreoretinal XXX O
junction XXX O
of XXX O
the XXX O
human XXX O
eye XXX O
. XXX O

The XXX O
site-specific XXX O
DNA XXX O
inversion XXX O
system XXX O
Cin XXX B-GENE
encoded XXX O
by XXX O
the XXX O
bacteriophage XXX O
P1 XXX O
consists XXX O
of XXX O
a XXX O
recombinase XXX B-GENE
, XXX O
two XXX O
inverted XXX O
crossing-over XXX O
sites XXX O
and XXX O
a XXX O
recombinational XXX O
enhancer XXX O
. XXX O

The XXX O
product XXX O
of XXX O
rat XXX B-GENE
gene XXX I-GENE
33 XXX I-GENE
was XXX O
identified XXX O
as XXX O
an XXX O
ErbB-2-interacting XXX B-GENE
protein XXX I-GENE
in XXX O
a XXX O
two-hybrid XXX O
screen XXX O
employing XXX O
the XXX O
ErbB-2 XXX B-GENE
juxtamembrane XXX I-GENE
and XXX I-GENE
kinase XXX I-GENE
domains XXX I-GENE
as XXX O
bait XXX O
. XXX O

Both XXX O
fusion XXX O
proteins XXX O
form XXX O
stable XXX O
specific XXX O
complexes XXX O
with XXX O
a XXX O
short XXX O
DNA XXX O
duplex XXX O
harboring XXX O
the XXX O
CTGT XXX B-GENE
( XXX I-GENE
at XXX I-GENE
) XXX I-GENE
4ACAG XXX I-GENE
consensus XXX I-GENE
sequence XXX I-GENE
of XXX O
the XXX O
LexA XXX B-GENE
repressor XXX I-GENE
. XXX O

The XXX O
ability XXX O
to XXX O
maintain XXX O
expression XXX O
of XXX O
FAS1 XXX B-GENE
in XXX O
nmt1-451Dino2 XXX B-GENE
Delta XXX I-GENE
cells XXX O
suggests XXX O
the XXX O
existence XXX O
of XXX O
another XXX O
transcription XXX O
factor XXX O
, XXX O
or XXX O
factors XXX O
, XXX O
whose XXX O
expression XXX O
/ XXX O
activity XXX O
is XXX O
inversely XXX O
related XXX O
to XXX O
overall XXX O
levels XXX O
of XXX O
cellular XXX O
protein XXX O
N-myristoy-lation XXX O
. XXX O

Thus XXX O
, XXX O
the XXX O
interaction XXX O
of XXX O
Tat XXX B-GENE
with XXX O
the XXX O
components XXX O
of XXX O
this XXX O
rel XXX B-GENE
/ XXX I-GENE
AP1 XXX I-GENE
cooperative XXX I-GENE
complex XXX I-GENE
seems XXX O
to XXX O
induce XXX O
quantitative XXX O
and XXX O
qualitative XXX O
alterations XXX O
of XXX O
this XXX O
complex XXX O
as XXX O
activation XXX O
progresses XXX O
, XXX O
resulting XXX O
in XXX O
a XXX O
decrease XXX O
of XXX O
IL-2 XXX B-GENE
gene XXX I-GENE
transcription XXX O
. XXX O

The XXX O
general XXX O
recombination XXX O
at XXX O
a XXX O
polarizing XXX O
voltage XXX O
of XXX O
300 XXX O
V XXX O
is XXX O
less XXX O
than XXX O
2% XXX O
for XXX O
dose-rates XXX O
up XXX O
to XXX O
about XXX O
100 XXX O
mGy XXX O
min-1 XXX O
. XXX O

The XXX O
3' XXX O
terminus XXX O
of XXX O
the XXX O
genome XXX O
can XXX O
be XXX O
folded XXX O
into XXX O
a XXX O
tRNA-like XXX B-GENE
secondary XXX O
structure XXX O
that XXX O
has XXX O
a XXX O
valine XXX O
anticodon XXX O
; XXX O
the XXX O
tRNA-like XXX B-GENE
structure XXX O
lacks XXX O
a XXX O
pseudoknot XXX O
in XXX O
the XXX O
aminoacyl XXX O
stem XXX O
, XXX O
a XXX O
feature XXX O
common XXX O
to XXX O
both XXX O
genera XXX O
of XXX O
tetraviruses XXX O
. XXX O

Comprising XXX O
a XXX O
126-nucleotide XXX O
5' XXX O
untranscribed XXX O
genomic XXX O
sequence XXX O
and XXX O
a XXX O
466-nucleotide XXX O
5' XXX O
noncoding XXX O
cDNA XXX O
sequence XXX O
, XXX O
the XXX O
592-nucleotide XXX O
5' XXX O
CpG XXX O
island XXX O
lacked XXX O
TATA XXX O
and XXX O
CAAT XXX O
boxes XXX O
but XXX O
displayed XXX O
a XXX O
high XXX O
G+C XXX O
content XXX O
, XXX O
was XXX O
enriched XXX O
for XXX O
CpG XXX O
dinucleotides XXX O
, XXX O
and XXX O
contained XXX O
a XXX O
potential XXX O
Sp1-binding XXX B-GENE
site XXX I-GENE
, XXX O
i XXX O
. XXX O
e XXX O
. XXX O
, XXX O
features XXX O
compatible XXX O
with XXX O
a XXX O
housekeeping XXX O
gene XXX O
. XXX O

Oligodeoxynucleotides XXX O
antisense XXX O
to XXX O
the XXX O
predicted XXX O
translation XXX O
initiation XXX O
regions XXX O
of XXX O
ICP4 XXX B-GENE
and XXX O
pp38 XXX B-GENE
mRNAs XXX I-GENE
inhibited XXX O
proliferation XXX O
of XXX O
MSB1 XXX O
cells XXX O
but XXX O
not XXX O
MDCC-CU91 XXX O
( XXX O
CU91 XXX O
) XXX O
reticuloendotheliosis XXX O
virus-transformed XXX O
cells XXX O
. XXX O

A XXX O
total XXX O
of XXX O
25 XXX O
patients XXX O
with XXX O
malignant XXX O
brain XXX O
tumours XXX O
were XXX O
investigated XXX O
. XXX O

Other XXX O
uncertainties XXX O
in XXX O
the XXX O
dosimetry XXX O
at XXX O
Y-12 XXX O
and XXX O
Vinca XXX O
are XXX O
unaltered XXX O
. XXX O

The XXX O
binding XXX O
site XXX O
for XXX O
OxyR XXX B-GENE
overlapped XXX O
P1oxyR XXX B-GENE
, XXX O
reminiscent XXX O
of XXX O
the XXX O
autoregulatory XXX O
loops XXX O
controlling XXX O
expression XXX O
of XXX O
oxyR XXX B-GENE
in XXX O
enteric XXX O
bacteria XXX O
and XXX O
characteristic XXX O
of XXX O
the XXX O
LysR XXX B-GENE
superfamily XXX I-GENE
in XXX O
general XXX O
. XXX O

Furthermore XXX O
, XXX O
the XXX O
UvrA XXX B-GENE
protein XXX I-GENE
interacts XXX O
with XXX O
the XXX O
UvrB XXX B-GENE
protein XXX I-GENE
to XXX O
modulate XXX O
its XXX O
activities XXX O
, XXX O
both XXX O
in XXX O
solution XXX O
and XXX O
in XXX O
association XXX O
with XXX O
DNA XXX O
, XXX O
where XXX O
the XXX O
UvrAB XXX B-GENE
complex XXX I-GENE
possesses XXX O
a XXX O
helicase XXX B-GENE
activity XXX O
. XXX O

Sputum XXX B-GENE
IL-8 XXX I-GENE
and XXX O
MPO XXX B-GENE
were XXX O
significantly XXX O
increased XXX O
after XXX O
BPT XXX O
in XXX O
both XXX O
TDI- XXX O
and XXX O
grain XXX O
dust-asthma XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
. XXX O

Crisis XXX O
of XXX O
the XXX O
therapeutic XXX O
community XXX O
in XXX O
Great XXX O
Britain XXX O
. XXX O

Two XXX O
of XXX O
these XXX O
resulted XXX O
in XXX O
increased XXX O
levels XXX O
of XXX O
the XXX O
alpha XXX O
subunit XXX O
, XXX O
and XXX O
one XXX O
caused XXX O
a XXX O
substitution XXX O
of XXX O
glycine XXX O
for XXX O
the XXX O
aspartic XXX O
acid XXX O
residue XXX O
at XXX O
position XXX O
171 XXX O
, XXX O
in XXX O
the XXX O
N-terminal XXX O
domain XXX O
. XXX O

Analysis XXX O
of XXX O
nucleotide XXX O
sequence XXX O
of XXX O
the XXX O
rightmost XXX O
43 XXX O
kbp XXX O
of XXX O
herpesvirus XXX O
saimiri XXX O
( XXX O
HVS XXX O
) XXX O
L-DNA XXX O
: XXX O
general XXX O
conservation XXX O
of XXX O
genetic XXX O
organization XXX O
between XXX O
HVS XXX O
and XXX O
Epstein-Barr XXX O
virus XXX O
. XXX O

Oncogenic XXX O
activation XXX O
of XXX O
the XXX O
tyrosine XXX B-GENE
kinase XXX I-GENE
domain XXX I-GENE
of XXX O
the XXX O
human XXX B-GENE
trk XXX I-GENE
proto-oncogene XXX I-GENE
by XXX O
fusion XXX O
to XXX O
a XXX O
cell XXX O
adhesion XXX O
molecule XXX O
. XXX O

In XXX O
unc-4 XXX B-GENE
mutants XXX I-GENE
, XXX O
VA XXX O
motor XXX O
neurons XXX O
assume XXX O
the XXX O
pattern XXX O
of XXX O
synaptic XXX O
input XXX O
normally XXX O
reserved XXX O
for XXX O
their XXX O
lineal XXX O
sister XXX O
cells XXX O
, XXX O
the XXX O
VB XXX O
motor XXX O
neurons XXX O
; XXX O
the XXX O
loss XXX O
of XXX O
normal XXX O
input XXX O
to XXX O
the XXX O
VAs XXX O
produces XXX O
a XXX O
distinctive XXX O
backward XXX O
movement XXX O
defect XXX O
. XXX O

With XXX O
regard XXX O
to XXX O
the XXX O
optimal XXX O
threshold XXX O
values XXX O
, XXX O
sensitivity XXX O
and XXX O
specificity XXX O
were XXX O
100% XXX O
/ XXX O
97% XXX O
and XXX O
95% XXX O
/ XXX O
95% XXX O
with XXX O
FDG XXX O
PET XXX O
, XXX O
compared XXX O
to XXX O
86% XXX O
/ XXX O
92% XXX O
and XXX O
77% XXX O
/ XXX O
82% XXX O
with XXX O
IS XXX O
, XXX O
respectively XXX O
. XXX O

Among XXX O
blood XXX O
donors XXX O
in XXX O
the XXX O
Republic XXX O
of XXX O
Serbia XXX O
, XXX O
regardless XXX O
the XXX O
number XXX O
of XXX O
blood XXX O
donations XXX O
, XXX O
the XXX O
percentage XXX O
of XXX O
female XXX O
donors XXX O
is XXX O
significantly XXX O
lower XXX O
compared XXX O
to XXX O
the XXX O
percentage XXX O
of XXX O
male XXX O
blood XXX O
donors XXX O
. XXX O

The XXX O
fragments XXX O
are XXX O
separated XXX O
and XXX O
directly XXX O
sized XXX O
by XXX O
agarose XXX O
gel XXX O
electrophoresis XXX O
. XXX O

In XXX O
Trial XXX O
1 XXX O
, XXX O
eight XXX O
sows XXX O
were XXX O
allowed XXX O
to XXX O
farrow XXX O
naturally XXX O
( XXX O
d XXX O
114 XXX O
, XXX O
NF XXX O
sows XXX O
) XXX O
and XXX O
eight XXX O
sows XXX O
were XXX O
induced XXX O
to XXX O
farrow XXX O
( XXX O
IF XXX O
sows XXX O
) XXX O
prematurely XXX O
by XXX O
injection XXX O
of XXX O
prostaglandin XXX O
F2 XXX O
alpha XXX O
on XXX O
d XXX O
112 XXX O
of XXX O
gestation XXX O
. XXX O

In XXX O
such XXX O
conditions XXX O
, XXX O
the XXX O
following XXX O
kinetic XXX O
reactions XXX O
have XXX O
been XXX O
studied XXX O
: XXX O
N2 XXX O
( XXX O
A XXX O
) XXX O
+ XXX O
N2 XXX O
( XXX O
A XXX O
) XXX O
-- XXX O
> XXX O
N2 XXX O
( XXX O
C XXX O
, XXX O
B XXX O
, XXX O
V' XXX O
) XXX O
+ XXX O
N2 XXX O
( XXX O
X XXX O
) XXX O
, XXX O
N2 XXX O
( XXX O
A XXX O
) XXX O
+ XXX O
N2 XXX O
( XXX O
X XXX O
, XXX O
V XXX O
> XXX O
5 XXX O
) XXX O
-- XXX O
> XXX O
N2 XXX O
( XXX O
X XXX O
) XXX O
+ XXX O
N2 XXX O
( XXX O
B XXX O
, XXX O
V' XXX O
) XXX O
in XXX O
pure XXX O
N2 XXX O
post-discharges XXX O
and XXX O
N2 XXX O
( XXX O
A XXX O
) XXX O
+ XXX O
CH4 XXX O
-- XXX O
> XXX O
products XXX O
, XXX O
C XXX O
+ XXX O
N XXX O
+ XXX O
M2 XXX O
-- XXX O
> XXX O
CN XXX O
( XXX O
B XXX O
, XXX O
V' XXX O
) XXX O
+ XXX O
M2 XXX O
, XXX O
N2 XXX O
( XXX O
X XXX O
, XXX O
V XXX O
> XXX O
4 XXX O
) XXX O
+ XXX O
CN XXX O
-- XXX O
> XXX O
N2 XXX O
( XXX O
X XXX O
) XXX O
+ XXX O
CN XXX O
( XXX O
B XXX O
, XXX O
A XXX O
, XXX O
V' XXX O
) XXX O
, XXX O
in XXX O
N2-1% XXX O
CH4 XXX O
post-discharges XXX O
. XXX O

Moreover XXX O
, XXX O
the XXX O
major XXX O
site XXX O
of XXX O
transcriptional XXX O
initiation XXX O
, XXX O
which XXX O
was XXX O
localized XXX O
by XXX O
primer XXX O
extension XXX O
250 XXX O
bp XXX O
upstream XXX O
of XXX O
the XXX O
5' XXX O
end XXX O
of XXX O
the XXX O
Ets-1 XXX B-GENE
cDNA XXX I-GENE
clone XXX I-GENE
, XXX O
was XXX O
shown XXX O
to XXX O
be XXX O
identical XXX O
in XXX O
normal XXX O
cells XXX O
and XXX O
tumors XXX O
carrying XXX O
a XXX O
provirus XXX O
in XXX O
the XXX O
Tpl-1 XXX B-GENE
locus XXX I-GENE
. XXX O

In XXX O
addition XXX O
, XXX O
using XXX O
biochemical XXX O
activity XXX O
assays XXX O
for XXX O
Rho-like XXX B-GENE
GTPases XXX I-GENE
, XXX O
we XXX O
show XXX O
that XXX O
the XXX O
expression XXX O
of XXX O
beta1A XXX B-GENE
, XXX O
beta1D XXX B-GENE
, XXX O
or XXX O
IL2R-beta1A XXX B-GENE
in XXX O
GE11 XXX O
or XXX O
GD25 XXX O
cells XXX O
triggers XXX O
activation XXX O
of XXX O
both XXX O
RhoA XXX B-GENE
and XXX O
Rac1 XXX B-GENE
, XXX O
but XXX O
not XXX O
of XXX O
Cdc42 XXX B-GENE
. XXX O

The XXX O
nucleotide XXX O
sequence XXX O
of XXX O
the XXX O
region XXX O
upstream XXX O
from XXX O
M XXX B-GENE
. XXX I-GENE
voltae XXX I-GENE
ORFtrpA XXX I-GENE
was XXX O
determined XXX O
and XXX O
revealed XXX O
the XXX O
presence XXX O
of XXX O
an XXX O
ORF XXX O
of XXX O
1227 XXX O
nucleotides XXX O
( XXX O
ORFtrpB XXX B-GENE
) XXX O
encoding XXX O
a XXX O
409 XXX O
amino XXX O
acid XXX O
polypeptide XXX O
of XXX O
mol XXX O
. XXX O
wt XXX O
. XXX O

The XXX O
present XXX O
study XXX O
describes XXX O
the XXX O
cell XXX O
volume XXX O
dynamics XXX O
in XXX O
intact XXX O
rat XXX O
hearts XXX O
, XXX O
during XXX O
ischemia XXX O
and XXX O
after XXX O
reperfusion XXX O
. XXX O

Analysis XXX O
of XXX O
Standard XXX O
Reference XXX O
Material XXX O
1846 XXX O
, XXX O
Infant XXX O
Formula XXX O
, XXX O
gave XXX O
a XXX O
mean XXX O
value XXX O
of XXX O
0 XXX O
. XXX O
95 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
088 XXX O
mg XXX O
vitamin XXX O
K XXX O
/ XXX O
kg XXX O
( XXX O
K XXX O
or XXX O
K1 XXX O
? XXX O
) XXX O
( XXX O
n XXX O
= XXX O
31 XXX O
) XXX O
with XXX O
a XXX O
coefficient XXX O
of XXX O
variation XXX O
of XXX O
9 XXX O
. XXX O
26 XXX O
. XXX O

When XXX O
expressed XXX O
in XXX O
COS-7 XXX O
cells XXX O
, XXX O
MKP-4 XXX B-GENE
blocks XXX O
activation XXX O
of XXX O
MAP XXX B-GENE
kinases XXX I-GENE
with XXX O
the XXX O
selectivity XXX O
ERK XXX B-GENE
> XXX O
p38 XXX B-GENE
= XXX O
JNK XXX B-GENE
/ XXX I-GENE
SAPK XXX I-GENE
. XXX O

Here XXX O
we XXX O
demonstrate XXX O
that XXX O
THOV XXX B-GENE
NP XXX I-GENE
contains XXX O
a XXX O
motif XXX O
( XXX O
KRxxxxxxxxxKTKK XXX B-GENE
) XXX O
at XXX O
amino XXX O
acid XXX O
positions XXX O
179-193 XXX O
that XXX O
represents XXX O
a XXX O
classical XXX O
bipartite XXX O
nuclear XXX O
localization XXX O
signal XXX O
( XXX O
NLS XXX O
) XXX O
. XXX O

Autotransfusion XXX O
was XXX O
performed XXX O
as XXX O
follows XXX O
: XXX O
Heparin-ACD-B- XXX O
Heparin-DPD- XXX O
Heparin-ACD-B XXX O
etc XXX O
. XXX O

Sterols XXX O
in XXX O
pollen XXX O
. XXX O

The XXX O
values XXX O
were XXX O
consistently XXX O
lower XXX O
( XXX O
P XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
during XXX O
summer XXX O
( XXX O
3 XXX O
. XXX O
79 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
13 XXX O
micrograms XXX O
/ XXX O
100 XXX O
ml XXX O
) XXX O
, XXX O
as XXX O
compared XXX O
to XXX O
winter XXX O
( XXX O
5 XXX O
. XXX O
06 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
27 XXX O
) XXX O
. XXX O

We XXX O
report XXX O
here XXX O
that XXX O
, XXX O
for XXX O
a XXX O
constant XXX O
amount XXX O
of XXX O
transfected XXX O
DNA XXX O
, XXX O
the XXX O
level XXX O
of XXX O
chloramphenicol XXX B-GENE
acetyltransferase XXX I-GENE
( XXX O
CAT XXX B-GENE
) XXX O
mRNA XXX O
is XXX O
increased XXX O
in XXX O
Vpr-expressing XXX O
cells XXX O
using XXX O
either XXX O
HIV-1 XXX O
or XXX O
a XXX O
murine XXX B-GENE
leukemia XXX I-GENE
virus XXX I-GENE
( XXX I-GENE
MLV XXX I-GENE
) XXX I-GENE
SL3-3 XXX I-GENE
LTR-CAT XXX I-GENE
reporter XXX I-GENE
construct XXX I-GENE
. XXX O

Gap1 XXX B-GENE
( XXX I-GENE
IP4BP XXX I-GENE
) XXX I-GENE
, XXX O
one XXX O
of XXX O
a XXX O
member XXX O
of XXX O
Ras XXX B-GENE
GTPase-activating XXX I-GENE
proteins XXX I-GENE
, XXX O
has XXX O
been XXX O
identified XXX O
as XXX O
a XXX O
specific XXX O
inositol XXX B-GENE
1 XXX I-GENE
, XXX I-GENE
3 XXX I-GENE
, XXX I-GENE
4 XXX I-GENE
, XXX I-GENE
5-tetrakisphosphate XXX I-GENE
( XXX I-GENE
IP4 XXX I-GENE
) XXX I-GENE
-binding XXX I-GENE
protein XXX I-GENE
( XXX O
Cullen XXX O
, XXX O
P XXX O
. XXX O

Activity XXX O
of XXX O
palgD XXX B-GENE
in XXX O
the XXX O
cysB XXX B-GENE
mutant XXX I-GENE
, XXX O
in XXX O
CHA XXX O
and XXX O
in XXX O
the XXX O
non-mucoid XXX O
strain XXX O
PAO XXX O
was XXX O
assessed XXX O
by XXX O
the XXX O
use XXX O
of XXX O
a XXX O
transcriptional XXX O
algD-xylE XXX B-GENE
fusion XXX I-GENE
. XXX O

These XXX O
results XXX O
indicate XXX O
that XXX O
ATF-2 XXX B-GENE
plays XXX O
a XXX O
central XXX O
role XXX O
in XXX O
TGF-beta XXX B-GENE
signaling XXX O
by XXX O
acting XXX O
as XXX O
a XXX O
common XXX O
nuclear XXX O
target XXX O
of XXX O
both XXX O
Smad XXX B-GENE
and XXX O
TAK1 XXX B-GENE
pathways XXX I-GENE
. XXX O

Proteinuria XXX O
in XXX O
a XXX O
young XXX O
man XXX O
. XXX O

Morphogenesis XXX O
of XXX O
the XXX O
trochanter XXX O
produced XXX O
by XXX O
femoral XXX O
regeneration XXX O
in XXX O
the XXX O
phasmid XXX O
Carausius XXX O
morosus XXX O
Br XXX O
. XXX O

Diagnosis XXX O
of XXX O
primary XXX O
sclerosing XXX O
cholangitis XXX O
in XXX O
a XXX O
blood XXX O
donor XXX O
with XXX O
elevated XXX O
serum XXX B-GENE
alanine XXX I-GENE
aminotransferase XXX I-GENE
. XXX O

Control XXX O
experiments XXX O
showed XXX O
that XXX O
each XXX O
fusion XXX O
protein XXX O
had XXX O
a XXX O
high XXX O
affinity XXX O
binding XXX O
site XXX O
for XXX O
estradiol-17 XXX O
beta XXX O
and XXX O
could XXX O
transactivate XXX O
an XXX O
ERE-LacZ XXX B-GENE
reporter XXX I-GENE
gene XXX I-GENE
in XXX O
yeast XXX O
similar XXX O
to XXX O
the XXX O
wild XXX O
type XXX O
ER XXX O
. XXX O

STUDY XXX O
DESIGN XXX O
AND XXX O
METHODS XXX O
: XXX O
A XXX O
study XXX O
was XXX O
initiated XXX O
to XXX O
compare XXX O
the XXX O
collection XXX O
of XXX O
PBPCs XXX O
with XXX O
the XXX O
new XXX O
device XXX O
, XXX O
the XXX O
AutoPBSC XXX O
( XXX O
version XXX O
[ XXX O
V XXX O
] XXX O
6 XXX O
. XXX O
0 XXX O
with XXX O
AutoPBSC XXX O
tubing XXX O
set XXX O
) XXX O
, XXX O
and XXX O
that XXX O
with XXX O
the XXX O
MNC XXX O
( XXX O
mononuclear XXX O
cell XXX O
) XXX O
procedure XXX O
( XXX O
V4 XXX O
. XXX O
7 XXX O
with XXX O
white XXX O
cell XXX O
tubing XXX O
set XXX O
) XXX O
, XXX O
for XXX O
patients XXX O
and XXX O
healthy XXX O
donors XXX O
. XXX O

Collectively XXX O
, XXX O
this XXX O
study XXX O
emphasizes XXX O
a XXX O
critical XXX O
role XXX O
of XXX O
Phox2a XXX B-GENE
as XXX O
well XXX O
as XXX O
its XXX O
functional XXX O
synergism XXX O
with XXX O
other XXX O
transcription XXX O
factors XXX O
( XXX O
e XXX O
. XXX O
g XXX O
. XXX O
, XXX O
CREB XXX B-GENE
, XXX O
AP2 XXX B-GENE
, XXX O
and XXX O
Sp1 XXX B-GENE
) XXX O
in XXX O
transcriptional XXX O
activation XXX O
of XXX O
the XXX O
DBH XXX B-GENE
gene XXX I-GENE
. XXX O

Studying XXX O
intracellular XXX O
signaling XXX O
pathways XXX O
, XXX O
which XXX O
may XXX O
be XXX O
involved XXX O
in XXX O
malignant XXX O
transformation XXX O
of XXX O
Ret-9bp XXX B-GENE
expressing XXX O
NIH3T3 XXX O
cells XXX O
, XXX O
we XXX O
could XXX O
demonstrate XXX O
Ret-9bp XXX B-GENE
dependent XXX O
phosphorylation XXX O
of XXX O
insulin XXX B-GENE
receptor XXX I-GENE
substrate-2 XXX I-GENE
( XXX O
IRS-2 XXX B-GENE
) XXX O
with XXX O
consecutive XXX O
activation XXX O
of XXX O
phosphatidylinositol XXX B-GENE
3-kinase XXX I-GENE
( XXX O
PI XXX B-GENE
3-kinase XXX I-GENE
) XXX O
and XXX O
protein XXX B-GENE
kinase XXX I-GENE
B XXX I-GENE
( XXX O
PKB XXX B-GENE
/ XXX I-GENE
AKT XXX I-GENE
) XXX O
. XXX O

The XXX O
duration XXX O
of XXX O
reactive XXX O
hyperemia XXX O
decreased XXX O
with XXX O
aging XXX O
, XXX O
but XXX O
the XXX O
difference XXX O
between XXX O
males XXX O
and XXX O
females XXX O
was XXX O
not XXX O
significant XXX O
at XXX O
any XXX O
age XXX O
. XXX O

The XXX O
P XXX B-GENE
mRNA XXX I-GENE
also XXX O
contains XXX O
a XXX O
third XXX O
ORF XXX O
for XXX O
the XXX O
V XXX B-GENE
protein XXX I-GENE
, XXX O
although XXX O
it XXX O
is XXX O
unclear XXX O
how XXX O
or XXX O
whether XXX O
this XXX O
ORF XXX O
is XXX O
accessed XXX O
. XXX O

Identification XXX O
of XXX O
p40x-responsive XXX O
regulatory XXX O
sequences XXX O
within XXX O
the XXX O
human XXX O
T-cell XXX O
leukemia XXX O
virus XXX O
type XXX O
I XXX O
long XXX O
terminal XXX O
repeat XXX O
. XXX O

A XXX O
cdc33-1 XXX B-GENE
strain XXX O
expressing XXX O
either XXX O
stable XXX O
Cln3p XXX B-GENE
( XXX O
Cln3-1p XXX B-GENE
) XXX O
or XXX O
a XXX O
hybrid XXX O
UBI4 XXX B-GENE
5'-CLN3 XXX I-GENE
mRNA XXX O
, XXX O
whose XXX O
translation XXX O
displays XXX O
decreased XXX O
dependence XXX O
on XXX O
eIF4E XXX B-GENE
, XXX O
arrested XXX O
randomly XXX O
in XXX O
the XXX O
cell XXX O
cycle XXX O
. XXX O

Cutaneous XXX O
necrosis XXX O
associated XXX O
with XXX O
protein XXX B-GENE
S XXX I-GENE
deficiency XXX O
. XXX O

Effects XXX O
of XXX O
early XXX O
monocular XXX O
deprivation XXX O
on XXX O
development XXX O
of XXX O
cortico-geniculate XXX O
projections XXX O
in XXX O
the XXX O
cat XXX O
. XXX O

The XXX O
nerve XXX B-GENE
growth XXX I-GENE
factor XXX I-GENE
beta XXX I-GENE
gene XXX I-GENE
( XXX O
NGFB XXX B-GENE
) XXX O
belongs XXX O
to XXX O
a XXX O
conserved XXX O
syntenic XXX O
group XXX O
on XXX O
human XXX O
chromosome XXX O
1 XXX O
and XXX O
mouse XXX O
Chromosome XXX O
3 XXX O
. XXX O

Studies XXX O
on XXX O
immunoglobulin XXX B-GENE
E XXX I-GENE
: XXX O
the XXX O
impact XXX O
of XXX O
a XXX O
sojourn XXX O
with XXX O
Professor XXX O
Dan XXX O
H XXX O
. XXX O

272 XXX O
, XXX O
1904 XXX O
] XXX O
. XXX O

Several XXX O
dozen XXX O
HIF-1 XXX B-GENE
targets XXX I-GENE
are XXX O
known XXX O
, XXX O
including XXX O
the XXX O
gene XXX O
encoding XXX O
vascular XXX B-GENE
endothelial XXX I-GENE
growth XXX I-GENE
factor XXX I-GENE
( XXX O
VEGF XXX B-GENE
) XXX O
. XXX O

The XXX O
pet56 XXX B-GENE
and XXX O
his3 XXX B-GENE
genes XXX I-GENE
are XXX O
transcribed XXX O
divergently XXX O
from XXX O
initiation XXX O
sites XXX O
that XXX O
are XXX O
separated XXX O
by XXX O
only XXX O
192 XXX O
bp XXX O
. XXX O

To XXX O
further XXX O
investigate XXX O
the XXX O
nature XXX O
of XXX O
the XXX O
site XXX O
specificity XXX O
a XXX O
set XXX O
of XXX O
deletion XXX O
mutants XXX O
of XXX O
the XXX O
160 XXX O
bp XXX O
sequence XXX O
were XXX O
analysed XXX O
. XXX O

Cataract XXX O
extraction XXX O
in XXX O
primary XXX O
glaucoma XXX O
. XXX O

WR-2721 XXX O
( XXX O
S-2- XXX O
( XXX O
3 XXX O
aminopropylamino XXX O
) XXX O
ethylphosphorothioic XXX O
acid XXX O
) XXX O
has XXX O
been XXX O
investigated XXX O
for XXX O
its XXX O
ability XXX O
to XXX O
protect XXX O
gut XXX O
, XXX O
lung XXX O
, XXX O
and XXX O
testis XXX O
, XXX O
as XXX O
well XXX O
as XXX O
fibrosarcoma XXX O
( XXX O
FSa XXX O
) XXX O
tumor XXX O
nodules XXX O
, XXX O
in XXX O
the XXX O
lungs XXX O
of XXX O
mice XXX O
from XXX O
gamma-radiation XXX O
injury XXX O
. XXX O

The XXX O
0 XXX B-GENE
. XXX I-GENE
22-kb XXX I-GENE
NheI XXX I-GENE
/ XXX I-GENE
BglII XXX I-GENE
promoter XXX I-GENE
exhibited XXX O
PMA XXX O
inducibility XXX O
in XXX O
myeloid XXX O
cells XXX O
and XXX O
contained XXX O
a XXX O
PMA-responsive XXX B-GENE
element XXX I-GENE
recognized XXX O
by XXX O
Sp1 XXX B-GENE
and XXX O
EGR-1 XXX B-GENE
transcription XXX I-GENE
factors XXX I-GENE
. XXX O

Both XXX O
mutations XXX O
confer XXX O
amino XXX O
acid XXX O
substitutions XXX O
in XXX O
the XXX O
viral XXX B-GENE
coat XXX I-GENE
protein XXX I-GENE
but XXX O
differ XXX O
in XXX O
their XXX O
relative XXX O
abilities XXX O
to XXX O
utilize XXX O
the XXX O
foreign XXX O
scaffolding XXX B-GENE
protein XXX I-GENE
. XXX O

Cell XXX O
adhesion XXX O
and XXX O
migration XXX O
assays XXX O
demonstrate XXX O
that XXX O
alpha XXX B-GENE
6 XXX I-GENE
beta XXX I-GENE
1 XXX I-GENE
is XXX O
the XXX O
major XXX O
laminin XXX B-GENE
receptor XXX I-GENE
in XXX O
undifferentiated XXX O
F9 XXX O
cells XXX O
as XXX O
well XXX O
as XXX O
F9-derived XXX O
PE XXX O
cells XXX O
. XXX O

Effects XXX O
of XXX O
a XXX O
low-energy XXX O
laser XXX O
beam XXX O
on XXX O
the XXX O
cells XXX O
of XXX O
the XXX O
newt XXX O
embryo XXX O
. XXX O

In XXX O
electrophoretic XXX O
mobility XXX O
shift XXX O
assays XXX O
, XXX O
the XXX O
PERE XXX B-GENE
formed XXX O
three XXX O
major XXX O
complexes XXX O
( XXX O
P1 XXX B-GENE
, XXX O
P2 XXX B-GENE
and XXX O
P3 XXX B-GENE
) XXX O
with XXX O
proteins XXX O
in XXX O
nuclear XXX O
extracts XXX O
from XXX O
HeLa XXX O
or XXX O
293 XXX O
cells XXX O
. XXX O

CCAAT XXX B-GENE
displacement XXX I-GENE
protein XXX I-GENE
binds XXX O
to XXX O
and XXX O
negatively XXX O
regulates XXX O
human XXX B-GENE
papillomavirus XXX I-GENE
type XXX I-GENE
6 XXX I-GENE
E6 XXX I-GENE
, XXX O
E7 XXX B-GENE
, XXX O
and XXX O
E1 XXX B-GENE
promoters XXX I-GENE
. XXX O

SUMMARY XXX O
OF XXX O
REVIEW XXX O
: XXX O
We XXX O
discuss XXX O
the XXX O
criteria XXX O
that XXX O
make XXX O
such XXX O
studies XXX O
comparable XXX O
, XXX O
drawing XXX O
on XXX O
the XXX O
experiences XXX O
of XXX O
recent XXX O
studies XXX O
performed XXX O
around XXX O
the XXX O
world XXX O
. XXX O

Multiple XXX O
copies XXX O
of XXX O
rsmB+ XXX B-GENE
DNA XXX I-GENE
, XXX O
on XXX O
the XXX O
other XXX O
hand XXX O
, XXX O
stimulate XXX O
exoenzyme XXX O
production XXX O
by XXX O
relieving XXX O
the XXX O
negative XXX O
effects XXX O
of XXX O
a XXX O
chromosomal XXX O
copy XXX O
of XXX O
hexA+ XXX B-GENE
. XXX O

Clones XXX O
that XXX O
expressed XXX O
DBD XXX O
exhibited XXX O
a XXX O
dominant XXX O
negative XXX O
phenotype XXX O
and XXX O
did XXX O
not XXX O
elicit XXX O
antiviral XXX O
activity XXX O
against XXX O
vesicular XXX O
stomatitis XXX O
virus XXX O
( XXX O
VSV XXX O
) XXX O
infection XXX O
upon XXX O
IFN XXX B-GENE
treatment XXX O
. XXX O

These XXX O
genes XXX O
may XXX O
represent XXX O
interesting XXX O
targets XXX O
for XXX O
new XXX O
therapeutic XXX O
strategies XXX O
. XXX O

Leukemia-inhibitory XXX B-GENE
factor XXX I-GENE
( XXX O
LIF XXX B-GENE
) XXX O
is XXX O
a XXX O
neuropoietin XXX B-GENE
able XXX O
to XXX O
regulate XXX O
the XXX O
differentiation XXX O
and XXX O
the XXX O
survival XXX O
of XXX O
many XXX O
cell XXX O
types XXX O
, XXX O
which XXX O
include XXX O
some XXX O
neuronal XXX O
populations XXX O
. XXX O

Groups XXX O
of XXX O
male XXX O
and XXX O
female XXX O
Fischer XXX O
344 XXX O
rats XXX O
, XXX O
B6C3F1 XXX O
mice XXX O
, XXX O
and XXX O
Hartley XXX O
guinea XXX O
pigs XXX O
were XXX O
exposed XXX O
once XXX O
for XXX O
6 XXX O
hr XXX O
to XXX O
mean XXX O
concentrations XXX O
of XXX O
10 XXX O
. XXX O
5 XXX O
, XXX O
5 XXX O
. XXX O
4 XXX O
, XXX O
2 XXX O
. XXX O
4 XXX O
, XXX O
1 XXX O
. XXX O
0 XXX O
, XXX O
or XXX O
0 XXX O
( XXX O
control XXX O
) XXX O
ppm XXX O
of XXX O
methyl XXX O
isocyanate XXX O
( XXX O
MIC XXX O
) XXX O
vapor XXX O
. XXX O

Here XXX O
we XXX O
demonstrate XXX O
that XXX O
Hh XXX B-GENE
and XXX O
Patched XXX B-GENE
( XXX O
Ptc XXX B-GENE
) XXX O
act XXX O
through XXX O
those XXX O
Ci XXX B-GENE
binding XXX O
sites XXX B-GENE
to XXX O
modulate XXX O
the XXX O
level XXX O
of XXX O
Ci-dependent XXX O
transcriptional XXX O
activation XXX O
in XXX O
S2 XXX O
cells XXX O
. XXX O

The XXX O
main XXX O
advantages XXX O
of XXX O
Multi-MUP XXX O
analysis XXX O
are XXX O
: XXX O
( XXX O
1 XXX O
) XXX O
quick XXX O
acquisition XXX O
of XXX O
many XXX O
MUPs XXX O
; XXX O
( XXX O
2 XXX O
) XXX O
simultaneous XXX O
collection XXX O
of XXX O
several XXX O
MUPs XXX O
at XXX O
one XXX O
recording XXX O
site XXX O
; XXX O
( XXX O
3 XXX O
) XXX O
possibility XXX O
to XXX O
analyze XXX O
not XXX O
only XXX O
low XXX O
threshold XXX O
MUPs XXX O
; XXX O
( XXX O
4 XXX O
) XXX O
less XXX O
bias XXX O
in XXX O
the XXX O
selection XXX O
of XXX O
MUPs XXX O
and XXX O
( XXX O
5 XXX O
) XXX O
the XXX O
reproducibility XXX O
of XXX O
the XXX O
results XXX O
that XXX O
allow XXX O
the XXX O
same XXX O
reference XXX O
values XXX O
to XXX O
be XXX O
used XXX O
in XXX O
different XXX O
laboratories XXX O
. XXX O

CONCLUSION XXX O
( XXX O
S XXX O
) XXX O
: XXX O
Measuring XXX O
urinary XXX O
LH XXX B-GENE
levels XXX O
is XXX O
an XXX O
excellent XXX O
method XXX O
for XXX O
determining XXX O
ovulation XXX O
. XXX O

Intraperitoneal XXX O
administration XXX O
of XXX O
L-5-hydroxytryptophan XXX O
( XXX O
L-5-HTP XXX O
) XXX O
at XXX O
doses XXX O
of XXX O
25 XXX O
to XXX O
100 XXX O
mg XXX O
/ XXX O
kg XXX O
dramatically XXX O
increase XXX O
defecation XXX O
in XXX O
mice XXX O
. XXX O

Copyright XXX O
1998 XXX O
Elsevier XXX O
Science XXX O
B XXX O
. XXX O
V XXX O
. XXX O

It XXX O
is XXX O
now XXX O
well XXX O
accepted XXX O
that XXX O
the XXX O
p53 XXX B-GENE
C-terminus XXX I-GENE
plays XXX O
a XXX O
central XXX O
role XXX O
in XXX O
controlling XXX O
the XXX O
activity XXX O
of XXX O
the XXX O
wild-type XXX O
molecule XXX O
. XXX O

We XXX O
have XXX O
previously XXX O
shown XXX O
that XXX O
the XXX O
adenoviral XXX B-GENE
12S XXX I-GENE
E1A XXX I-GENE
protein XXX I-GENE
modulates XXX O
the XXX O
phosphorylation XXX O
status XXX O
of XXX O
p130 XXX B-GENE
and XXX O
p107 XXX B-GENE
without XXX O
apparent XXX O
changes XXX O
in XXX O
the XXX O
cell XXX O
cycle XXX O
dependent XXX O
phosphorylation XXX O
of XXX O
the XXX O
retinoblastoma XXX B-GENE
protein XXX I-GENE
. XXX O

Endostatin XXX O
treatment XXX O
for XXX O
10 XXX O
minutes XXX O
or XXX O
24 XXX O
hours XXX O
induced XXX O
tyrosine XXX O
phosphorylation XXX O
of XXX O
Shb XXX B-GENE
and XXX O
formation XXX O
of XXX O
multiprotein XXX O
complexes XXX O
. XXX O

The XXX O
PSD2 XXX B-GENE
gene XXX I-GENE
was XXX O
heterologously XXX O
expressed XXX O
by XXX O
infection XXX O
of XXX O
Sf-9 XXX O
insect XXX O
cells XXX O
with XXX O
recombinant XXX O
baculovirus XXX O
, XXX O
resulting XXX O
in XXX O
a XXX O
10-fold XXX O
increase XXX O
in XXX O
PSD XXX B-GENE
activity XXX O
. XXX O

In XXX O
acute-phase XXX O
livers XXX O
, XXX O
we XXX O
observed XXX O
a XXX O
dramatic XXX O
reduction XXX O
in XXX O
HNF-3 XXX B-GENE
alpha XXX I-GENE
expression XXX O
which XXX O
correlates XXX O
with XXX O
a XXX O
decrease XXX O
in XXX O
the XXX O
expression XXX O
of XXX O
its XXX O
target XXX O
gene XXX O
, XXX O
the XXX O
TTR XXX B-GENE
gene XXX I-GENE
. XXX O

A XXX O
comparative XXX O
study XXX O
of XXX O
the XXX O
effects XXX O
of XXX O
carbamazepine XXX O
and XXX O
the XXX O
NMDA XXX B-GENE
receptor XXX I-GENE
antagonist XXX O
remacemide XXX O
on XXX O
road XXX O
tracking XXX O
and XXX O
car-following XXX O
performance XXX O
in XXX O
actual XXX O
traffic XXX O
. XXX O

All XXX O
mutant XXX B-GENE
JCV XXX I-GENE
T XXX I-GENE
antigens XXX I-GENE
bound XXX O
to XXX O
JCV XXX O
and XXX O
SV40 XXX O
origins XXX O
of XXX O
DNA XXX O
replication XXX O
. XXX O

The XXX O
git1 XXX B-GENE
, XXX O
git3 XXX B-GENE
, XXX O
git5 XXX B-GENE
, XXX O
git7 XXX B-GENE
, XXX O
git8 XXX B-GENE
and XXX O
git10 XXX B-GENE
genes XXX I-GENE
act XXX O
upstream XXX O
of XXX O
adenylate XXX B-GENE
cyclase XXX I-GENE
, XXX O
presumably XXX O
encoding XXX O
an XXX O
adenylate XXX B-GENE
cyclase XXX I-GENE
activation XXX O
pathway XXX O
. XXX O

EMSA XXX O
showed XXX O
that XXX O
nuclear XXX O
proteins XXX O
from XXX O
PC12 XXX O
but XXX O
not XXX O
C6 XXX O
or XXX O
Rat2 XXX O
cells XXX O
bind XXX O
the XXX O
CRE XXX B-GENE
as XXX O
a XXX O
complex XXX O
containing XXX O
activating XXX B-GENE
transcription XXX I-GENE
factor XXX I-GENE
( XXX I-GENE
ATF XXX I-GENE
) XXX I-GENE
-4 XXX I-GENE
and XXX O
CCAAT XXX B-GENE
enhancer-binding XXX I-GENE
protein XXX I-GENE
beta XXX I-GENE
, XXX O
while XXX O
both XXX O
PC12 XXX O
and XXX O
C6 XXX O
cell XXX O
nuclear XXX O
extracts XXX O
were XXX O
recruited XXX O
by XXX O
the XXX O
CCAAT-box XXX O
as XXX O
a XXX O
complex XXX O
containing XXX O
nuclear XXX B-GENE
factor XXX I-GENE
Y XXX O
. XXX O

The XXX O
disease XXX O
ran XXX O
an XXX O
atypical XXX O
course XXX O
; XXX O
with XXX O
early XXX O
jaundice XXX O
syndrome XXX O
, XXX O
severe XXX O
enterorrhagia XXX O
and XXX O
late XXX O
appearance XXX O
of XXX O
roseola XXX O
. XXX O

The XXX O
core XXX O
enzyme XXX O
is XXX O
homologous XXX O
to XXX O
those XXX O
of XXX O
bacteriophages XXX O
T3 XXX O
, XXX O
T7 XXX O
and XXX O
SP6 XXX O
whereas XXX O
the XXX O
specificity XXX O
factor XXX O
shows XXX O
similarities XXX O
with XXX O
bacterial XXX B-GENE
sigma XXX I-GENE
factors XXX I-GENE
. XXX O

The XXX O
binding XXX O
of XXX O
NF-ATp XXX B-GENE
, XXX O
although XXX O
not XXX O
NF-AT4 XXX B-GENE
, XXX O
to XXX O
this XXX O
enhancer XXX O
also XXX O
occurs XXX O
along XXX O
with XXX O
HTLV-I-mediated XXX O
infection XXX O
of XXX O
human XXX O
peripheral XXX O
blood XXX O
T-cells XXX O
. XXX O

The XXX O
serum XXX O
concentration XXX O
of XXX O
iP XXX O
before XXX O
dialysis XXX O
( XXX O
HD XXX O
) XXX O
was XXX O
on XXX O
average XXX O
3 XXX O
. XXX O
06 XXX O
( XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
81 XXX O
) XXX O
mmol XXX O
/ XXX O
l XXX O
and XXX O
D XXX O
was XXX O
on XXX O
average XXX O
55 XXX O
. XXX O
6 XXX O
( XXX O
+ XXX O
/ XXX O
- XXX O
10 XXX O
. XXX O
0 XXX O
) XXX O
mmol XXX O
. XXX O

Since XXX O
1968 XXX O
, XXX O
a XXX O
steep XXX O
decrease XXX O
in XXX O
the XXX O
number XXX O
of XXX O
strains XXX O
resistant XXX O
to XXX O
three XXX O
or XXX O
more XXX O
antibiotics XXX O
( XXX O
multiple-resistant XXX O
) XXX O
and XXX O
in XXX O
strains XXX O
of XXX O
the XXX O
83A XXX O
complex XXX O
was XXX O
noticed XXX O
. XXX O

An XXX O
int6 XXX B-GENE
deletion XXX I-GENE
( XXX O
int6Delta XXX B-GENE
) XXX O
mutant XXX O
was XXX O
viable XXX O
but XXX O
grew XXX O
slowly XXX O
in XXX O
minimal XXX O
medium XXX O
. XXX O

The XXX O
role XXX O
of XXX O
supercritical XXX O
fluid XXX O
chromatography XXX O
( XXX O
SFC XXX O
) XXX O
as XXX O
a XXX O
viable XXX O
technique XXX O
for XXX O
analyzing XXX O
agricultural XXX O
products XXX O
has XXX O
been XXX O
investigated XXX O
using XXX O
packed XXX O
and XXX O
capillary XXX O
column XXX O
methodology XXX O
. XXX O

Chronic XXX O
thyroiditis XXX O
as XXX O
a XXX O
risk XXX O
factor XXX O
of XXX O
B-cell XXX O
lymphoma XXX O
in XXX O
the XXX O
thyroid XXX O
gland XXX O
. XXX O

After XXX O
14 XXX O
d XXX O
of XXX O
overfeeding XXX O
, XXX O
hepatic XXX O
PL XXX O
profiles XXX O
were XXX O
identical XXX O
in XXX O
the XXX O
two XXX O
breeds XXX O
and XXX O
similar XXX O
to XXX O
that XXX O
in XXX O
control XXX O
livers XXX O
; XXX O
choline-containing XXX O
PL XXX O
accounted XXX O
for XXX O
95% XXX O
of XXX O
total XXX O
PL XXX O
. XXX O

Iodine-123 XXX O
was XXX O
satisfactorily XXX O
imaged XXX O
only XXX O
with XXX O
the XXX O
MEC XXX O
and XXX O
pinhole XXX O
collimators XXX O
, XXX O
which XXX O
in XXX O
turn XXX O
yielded XXX O
MTF XXX O
values XXX O
comparable XXX O
to XXX O
those XXX O
measured XXX O
for XXX O
99mTc XXX O
. XXX O

JNK XXX B-GENE
and XXX O
p38 XXX B-GENE
are XXX O
constitutively XXX O
present XXX O
in XXX O
the XXX O
nucleus XXX O
, XXX O
and XXX O
DNA-bound XXX O
c-JUN XXX B-GENE
and XXX O
ATF-2 XXX B-GENE
are XXX O
stably XXX O
contacted XXX O
by XXX O
JNK XXX B-GENE
and XXX O
p38 XXX B-GENE
, XXX O
respectively XXX O
. XXX O

The XXX O
mean XXX O
minimum XXX O
steady-state XXX O
concentration XXX O
after XXX O
the XXX O
oral XXX O
regimen XXX O
( XXX O
23 XXX O
micrograms XXX O
. XXX O
l-1 XXX O
) XXX O
was XXX O
78% XXX O
of XXX O
that XXX O
after XXX O
the XXX O
intramuscular XXX O
regime XXX O
( XXX O
29 XXX O
micrograms XXX O
. XXX O
l-1 XXX O
) XXX O
. XXX O

BACKGROUND XXX O
: XXX O
Previous XXX O
studies XXX O
have XXX O
indicated XXX O
that XXX O
the XXX O
60- XXX O
, XXX O
30- XXX O
, XXX O
28- XXX O
and XXX O
12-item XXX O
versions XXX O
of XXX O
the XXX O
General XXX O
Health XXX O
Questionnaire XXX O
( XXX O
GHQ XXX O
) XXX O
are XXX O
liable XXX O
to XXX O
retest XXX O
effects XXX O
, XXX O
especially XXX O
when XXX O
administered XXX O
multiple XXX O
times XXX O
with XXX O
short XXX O
intervals XXX O
. XXX O

Increasing XXX O
the XXX O
RH XXX O
beyond XXX O
32% XXX O
resulted XXX O
in XXX O
solvation XXX O
of XXX O
the XXX O
peroxy XXX O
radical XXX O
, XXX O
sterically XXX O
hindering XXX O
the XXX O
radical XXX O
from XXX O
entering XXX O
the XXX O
propagation XXX O
transition XXX O
state XXX O
. XXX O

Promoter XXX O
transcriptional XXX O
activity XXX O
was XXX O
determined XXX O
for XXX O
a XXX O
wide XXX O
5' XXX O
portion XXX O
of XXX O
the XXX O
human XXX O
annexin XXX B-GENE
A5 XXX I-GENE
gene XXX I-GENE
, XXX O
from XXX O
bp XXX O
-1275 XXX O
to XXX O
+79 XXX O
relative XXX O
to XXX O
the XXX O
most XXX O
5' XXX O
of XXX O
several XXX O
discrete XXX O
transcription XXX O
start XXX O
points XXX O
. XXX O

Depth-controlled XXX O
grazing-incidence XXX O
diffraction XXX O
of XXX O
synchrotron XXX O
x XXX O
radiation XXX O
. XXX O

Our XXX O
results XXX O
suggested XXX O
that XXX O
the XXX O
hexamer XXX O
and XXX O
the XXX O
octamer XXX O
motifs XXX O
may XXX O
play XXX O
important XXX O
role XXX O
( XXX O
s XXX O
) XXX O
in XXX O
regulation XXX O
of XXX O
replication-dependent XXX O
but XXX O
not XXX O
of XXX O
replication-independent XXX O
expression XXX O
of XXX O
the XXX O
wheat XXX B-GENE
histone XXX I-GENE
H3 XXX I-GENE
gene XXX I-GENE
. XXX O

These XXX O
results XXX O
indicate XXX O
that XXX O
ATF4 XXX B-GENE
regulates XXX O
basal XXX O
and XXX O
CdCl XXX O
( XXX O
2 XXX O
) XXX O
-induced XXX O
expression XXX O
of XXX O
the XXX O
ho-1 XXX B-GENE
gene XXX I-GENE
in XXX O
a XXX O
cell-specific XXX O
manner XXX O
and XXX O
possibly XXX O
in XXX O
a XXX O
complex XXX O
with XXX O
Nrf2 XXX B-GENE
. XXX O

Therefore XXX O
, XXX O
high XXX O
set-up XXX O
accuracy XXX O
and XXX O
reproducibility XXX O
are XXX O
mandatory XXX O
. XXX O

A XXX O
list XXX O
of XXX O
12 XXX O
names XXX O
for XXX O
the XXX O
disease XXX O
and XXX O
37 XXX O
diagnostic XXX O
criteria XXX O
were XXX O
proposed XXX O
to XXX O
a XXX O
Consensus XXX O
Panel XXX O
of XXX O
12 XXX O
Italian XXX O
experts XXX O
who XXX O
ranked XXX O
them XXX O
in XXX O
order XXX O
so XXX O
as XXX O
to XXX O
identify XXX O
a XXX O
core XXX O
set XXX O
of XXX O
criteria XXX O
. XXX O

As XXX O
well XXX O
, XXX O
mixtures XXX O
of XXX O
( XXX O
LA XXX O
) XXX O
( XXX O
12 XXX O
) XXX O
with XXX O
the XXX O
longer XXX O
chain XXX O
PEs XXX O
exhibit XXX O
unusual XXX O
biomodal XXX O
enthalpy XXX O
variations XXX O
, XXX O
suggesting XXX O
peptide XXX O
immiscibility XXX O
in XXX O
thicker XXX O
gel XXX O
state XXX O
bilayers XXX O
. XXX O

The XXX O
effects XXX O
of XXX O
contrast XXX O
media XXX O
on XXX O
coagulation XXX B-GENE
factor XXX I-GENE
XII XXX I-GENE
. XXX O

Evidence XXX O
from XXX O
a XXX O
Northern XXX O
hybridization XXX O
indicated XXX O
that XXX O
jadM XXX B-GENE
expression XXX O
is XXX O
correlated XXX O
with XXX O
jadomycin XXX B-GENE
B XXX I-GENE
synthesis XXX O
. XXX O

Two XXX O
experiments XXX O
investigating XXX O
the XXX O
effects XXX O
of XXX O
short-term XXX O
spaceflight XXX O
on XXX O
cancellous XXX O
bone XXX O
turnover XXX O
were XXX O
carried XXX O
out XXX O
: XXX O
Physiological XXX O
Systems XXX O
Experiment-1 XXX O
( XXX O
PSE-1 XXX O
) XXX O
( XXX O
a XXX O
4-d XXX O
orbital XXX O
spaceflight XXX O
) XXX O
and XXX O
PSE-2 XXX O
( XXX O
a XXX O
10-d XXX O
flight XXX O
) XXX O
. XXX O

Mutation XXX O
of XXX O
the XXX O
NF-kappaB XXX B-GENE
site XXX I-GENE
in XXX O
the XXX O
Mdr1b XXX B-GENE
promoter XXX I-GENE
prevents XXX O
its XXX O
induction XXX O
by XXX O
TNF-alpha XXX B-GENE
. XXX O

A XXX O
5 XXX O
. XXX O
0-kb XXX O
transcript XXX O
detected XXX O
by XXX O
the XXX O
differential XXX O
display XXX O
amplicon XXX O
3G1 XXX O
was XXX O
found XXX O
to XXX O
correlate XXX O
strongly XXX O
with XXX O
RAG1 XXX B-GENE
mRNA XXX I-GENE
expression XXX O
in XXX O
various XXX O
human XXX O
cell XXX O
lines XXX O
. XXX O

Post-translational XXX O
modifications XXX O
such XXX O
as XXX O
glycosylation XXX O
and XXX O
phosphorylation XXX O
could XXX O
be XXX O
excluded XXX O
as XXX O
potential XXX O
explanations XXX O
for XXX O
the XXX O
protein XXX O
heterogeneity XXX O
. XXX O

In XXX O
4 XXX O
spinalized XXX O
cats XXX O
, XXX O
the XXX O
effects XXX O
of XXX O
afferent XXX O
inputs XXX O
from XXX O
hindlimb XXX O
cutaneous XXX O
nerves XXX O
( XXX O
sural XXX O
cutaneous XXX O
nerve XXX O
: XXX O
Sur XXX O
) XXX O
on XXX O
mono-and XXX O
poly-synaptic XXX O
reflex XXX O
recorded XXX O
from XXX O
tail XXX O
muscle XXX O
motoneurons XXX O
were XXX O
studied XXX O
before XXX O
and XXX O
after XXX O
spinal XXX O
lesioning XXX O
at XXX O
S2-3 XXX O
level XXX O
. XXX O

One XXX O
unit XXX O
encodes XXX O
traA XXX B-GENE
, XXX O
traF XXX B-GENE
, XXX O
and XXX O
traB XXX B-GENE
, XXX O
while XXX O
the XXX O
second XXX O
encodes XXX O
traC XXX B-GENE
, XXX O
traD XXX B-GENE
, XXX O
and XXX O
traG XXX B-GENE
. XXX O

In XXX O
PB XXX O
mice XXX O
, XXX O
there XXX O
was XXX O
only XXX O
a XXX O
small XXX O
deficit XXX O
in XXX O
the XXX O
number XXX O
of XXX O
the XXX O
hippocampal XXX O
pyramidal XXX O
neurons XXX O
compared XXX O
to XXX O
controls XXX O
( XXX O
15% XXX O
, XXX O
p XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
, XXX O
and XXX O
no XXX O
deficit XXX O
in XXX O
the XXX O
granule XXX O
cells XXX O
. XXX O

In XXX O
the XXX O
Arithmetic XXX O
subtest XXX O
one XXX O
of XXX O
the XXX O
items XXX O
would XXX O
not XXX O
meet XXX O
the XXX O
difficulty XXX O
grading XXX O
shown XXX O
while XXX O
the XXX O
last XXX O
two XXX O
items XXX O
offer XXX O
very XXX O
little XXX O
possibility XXX O
of XXX O
success XXX O
for XXX O
all XXX O
subjects XXX O
. XXX O
( XXX O
ABSTRACT XXX O
TRUNCATED XXX O
AT XXX O
250 XXX O
WORDS XXX O
) XXX O

In XXX O
the XXX O
ileum XXX O
, XXX O
enterotoxin XXX B-GENE
increased XXX O
the XXX O
luminal XXX O
disappearance XXX O
( XXX O
P XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
and XXX O
peripheral XXX O
blood XXX O
appearance XXX O
( XXX O
P XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
001 XXX O
) XXX O
of XXX O
chloroquine XXX O
. XXX O

Both XXX O
Z XXX B-GENE
and XXX O
R XXX B-GENE
expression XXX O
resulted XXX O
in XXX O
PML XXX O
dispersion XXX O
in XXX O
EBV-positive XXX O
cells XXX O
. XXX O

Regulation XXX O
of XXX O
pituitary XXX O
vasopressin XXX B-GENE
V1b XXX I-GENE
receptors XXX I-GENE
plays XXX O
a XXX O
critical XXX O
role XXX O
in XXX O
regulating XXX O
pituitary XXX B-GENE
adrenocorticotropic XXX I-GENE
hormone XXX I-GENE
( XXX O
ACTH XXX B-GENE
) XXX O
secretion XXX O
during XXX O
adaptation XXX O
to XXX O
stress XXX O
. XXX O

Measurements XXX O
included XXX O
bone XXX O
mineral XXX O
density XXX O
of XXX O
the XXX O
lumbar XXX O
spine XXX O
and XXX O
proximal XXX O
femur XXX O
( XXX O
by XXX O
dual-energy XXX O
X-ray XXX O
absorptiometry XXX O
) XXX O
and XXX O
biochemical XXX O
markers XXX O
of XXX O
bone XXX O
remodeling XXX O
( XXX O
serum XXX O
bone-specific XXX O
alkaline XXX B-GENE
phosphatase XXX I-GENE
by XXX O
immunoassay XXX O
and XXX O
urine XXX O
deoxypyridinoline XXX O
by XXX O
high-pressure XXX O
liquid XXX O
chromatography XXX O
) XXX O
. XXX O

The XXX O
obvious XXX O
functional XXX O
necessity XXX O
for XXX O
editing XXX O
in XXX O
kinetoplastid XXX O
mitochondria XXX O
is XXX O
the XXX O
formation XXX O
of XXX O
translatable XXX O
mRNAs XXX O
. XXX O

The XXX O
mechanism XXX O
involves XXX O
Gbetagamma XXX B-GENE
subunit-mediated XXX O
increases XXX O
in XXX O
tyrosine XXX O
phosphorylation XXX O
of XXX O
the XXX O
Shc XXX B-GENE
adapter XXX I-GENE
protein XXX I-GENE
, XXX O
Shc*Grb2 XXX B-GENE
complex XXX I-GENE
formation XXX O
, XXX O
and XXX O
recruitment XXX O
of XXX O
Ras XXX B-GENE
guanine XXX I-GENE
nucleotide XXX I-GENE
exchange XXX I-GENE
factor XXX I-GENE
activity XXX O
. XXX O

The XXX O
Hagen-Poiseuille XXX O
equation XXX O
is XXX O
used XXX O
to XXX O
assess XXX O
the XXX O
effects XXX O
of XXX O
attached XXX O
parasites XXX O
in XXX O
the XXX O
foregut XXX O
of XXX O
Leishmania-infected XXX O
sandflies XXX O
on XXX O
blood XXX O
flow XXX O
. XXX O

Translation XXX O
of XXX O
specific XXX O
cellular XXX O
genes XXX O
from XXX O
the XXX O
chimeric XXX O
viral-cellular XXX O
transcripts XXX O
seems XXX O
to XXX O
be XXX O
unlikely XXX O
. XXX O

Recently XXX O
, XXX O
a XXX O
protein XXX O
designated XXX O
GF14 XXX B-GENE
has XXX O
been XXX O
isolated XXX O
that XXX O
is XXX O
associated XXX O
with XXX O
the XXX O
GBF XXX B-GENE
protein XXX I-GENE
complex XXX I-GENE
. XXX O

Diltiazem XXX O
caused XXX O
significant XXX O
decrease XXX O
in XXX O
the XXX O
ventricular XXX O
response XXX O
without XXX O
conversion XXX O
to XXX O
sinus XXX O
rhythm XXX O
. XXX O

Although XXX O
not XXX O
common XXX O
, XXX O
the XXX O
disorder XXX O
is XXX O
the XXX O
most XXX O
frequently XXX O
diagnosed XXX O
disturbance XXX O
of XXX O
porphyrin XXX O
metabolism XXX O
in XXX O
many XXX O
countries XXX O
, XXX O
and XXX O
further XXX O
insight XXX O
into XXX O
its XXX O
unusual XXX O
pathogenesis XXX O
may XXX O
clarify XXX O
the XXX O
hepatotoxic XXX O
effects XXX O
of XXX O
the XXX O
4 XXX O
etiologic XXX O
agents XXX O
. XXX O

Resistance XXX O
to XXX O
thyroid XXX O
hormone XXX O
: XXX O
implications XXX O
for XXX O
neurodevelopmental XXX O
research XXX O
on XXX O
the XXX O
effects XXX O
of XXX O
thyroid XXX O
hormone XXX O
disruptors XXX O
. XXX O

We XXX O
conclude XXX O
that XXX O
, XXX O
both XXX O
in XXX O
atrial XXX O
myocytes XXX O
and XXX O
in XXX O
Xenopus XXX O
oocytes XXX O
, XXX O
beta-adrenergic XXX O
stimulation XXX O
potentiates XXX O
the XXX O
ACh-evoked XXX O
GIRK XXX B-GENE
channels XXX I-GENE
via XXX O
a XXX O
pathway XXX O
that XXX O
involves XXX O
PKA-catalyzed XXX O
phosphorylation XXX O
downstream XXX O
from XXX O
beta XXX B-GENE
( XXX I-GENE
2 XXX I-GENE
) XXX I-GENE
AR XXX I-GENE
. XXX O

We XXX O
established XXX O
the XXX O
radiosensitive XXX O
cell XXX O
line XXX O
SX9 XXX O
from XXX O
mammary XXX O
carcinoma XXX O
cell XXX O
line XXX O
FM3A XXX O
. XXX O

CRS XXX B-GENE
function XXX O
in XXX O
a XXX O
5' XXX B-GENE
LTR-linked XXX I-GENE
gene XXX I-GENE
expression XXX O
assay XXX O
correlates XXX O
with XXX O
the XXX O
ability XXX O
of XXX O
both XXX O
p60CRS XXX B-GENE
and XXX O
p40CRS XXX B-GENE
to XXX O
interact XXX O
with XXX O
5' XXX B-GENE
LTR XXX I-GENE
RNA XXX I-GENE
in XXX O
vitro XXX O
. XXX O

Null XXX O
mutations XXX O
in XXX O
daf-3 XXX B-GENE
suppress XXX O
mutations XXX O
in XXX O
genes XXX O
encoding XXX O
this XXX O
TGF-beta XXX B-GENE
signal XXX O
, XXX O
its XXX O
receptors XXX O
, XXX O
and XXX O
associated XXX O
Smad XXX B-GENE
signal XXX I-GENE
transduction XXX I-GENE
proteins XXX I-GENE
. XXX O
daf-3 XXX B-GENE
encodes XXX O
a XXX O
Smad XXX B-GENE
protein XXX I-GENE
that XXX O
is XXX O
most XXX O
closely XXX O
related XXX O
to XXX O
mammalian XXX B-GENE
DPC4 XXX I-GENE
, XXX O
and XXX O
is XXX O
expressed XXX O
throughout XXX O
development XXX O
in XXX O
many XXX O
of XXX O
the XXX O
tissues XXX O
that XXX O
are XXX O
remodeled XXX O
during XXX O
dauer XXX O
development XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
the XXX O
R206S XXX B-GENE
HSF XXX I-GENE
substitution XXX O
exhibits XXX O
constitutive XXX O
transcriptional XXX O
activation XXX O
from XXX O
a XXX O
consensus XXX O
HSE XXX B-GENE
( XXX O
HSE2 XXX B-GENE
) XXX O
. XXX O

The XXX O
major XXX O
neurological XXX O
manifestations XXX O
of XXX O
brain XXX O
injury XXX O
in XXX O
these XXX O
babies XXX O
are XXX O
spastic XXX O
motor XXX O
deficits XXX O
. XXX O

The XXX O
IDF XXX O
standard XXX O
method XXX O
for XXX O
the XXX O
detection XXX O
of XXX O
penicillin XXX O
in XXX O
milk XXX O
is XXX O
not XXX O
suitable XXX O
for XXX O
the XXX O
detection XXX O
of XXX O
sulphonamide XXX O
residues XXX O
in XXX O
milk XXX O
. XXX O

Comparative XXX O
study XXX O
of XXX O
the XXX O
differential XXX O
white XXX O
blood XXX O
cell XXX O
count XXX O
using XXX O
three XXX O
automated XXX O
analyzers XXX O
: XXX O
Coulter XXX O
STKS XXX O
, XXX O
Sysmex XXX O
NE XXX O
8000 XXX O
and XXX O
Technicon XXX O
H-1 XXX O
. XXX O

This XXX O
sequence XXX O
similarity XXX O
raises XXX O
the XXX O
possibility XXX O
that XXX O
GCN1 XXX B-GENE
interacts XXX O
with XXX O
ribosomes XXX O
or XXX O
tRNA XXX O
molecules XXX O
and XXX O
functions XXX O
in XXX O
conjunction XXX O
with XXX O
GCN2 XXX B-GENE
in XXX O
monitoring XXX O
uncharged XXX O
tRNA XXX O
levels XXX O
during XXX O
the XXX O
process XXX O
of XXX O
translation XXX O
elongation XXX O
. XXX O

Moreover XXX O
, XXX O
xTAK1KN XXX B-GENE
could XXX O
block XXX O
the XXX O
expression XXX O
of XXX O
ventral XXX O
mesoderm XXX O
marker XXX O
genes XXX O
induced XXX O
by XXX O
Smad1 XXX B-GENE
or XXX I-GENE
5 XXX I-GENE
. XXX O

The XXX O
first XXX O
involved XXX O
measurements XXX O
of XXX O
the XXX O
steady XXX O
state XXX O
levels XXX O
of XXX O
mRNAs XXX O
for XXX O
subunit XXX O
5 XXX O
of XXX O
cytochrome XXX B-GENE
oxidase XXX I-GENE
and XXX O
the XXX O
beta XXX O
subunit XXX O
of XXX O
F1 XXX B-GENE
ATPase XXX I-GENE
in XXX O
wild XXX O
type XXX O
and XXX O
in XXX O
a XXX O
hem2 XXX B-GENE
mutant XXX I-GENE
. XXX O

In XXX O
2 XXX O
subjects XXX O
the XXX O
phytomitogen XXX O
reactivity XXX O
of XXX O
the XXX O
lymphocytes XXX O
was XXX O
improved XXX O
after XXX O
treatment XXX O
. XXX O

The XXX O
osmotic XXX O
diuretic XXX O
mannitol XXX O
was XXX O
administered XXX O
to XXX O
21 XXX O
patients XXX O
. XXX O

A XXX O
2 XXX B-GENE
. XXX I-GENE
4-kb XXX I-GENE
MAPKAPK-2 XXX I-GENE
message XXX I-GENE
is XXX O
expressed XXX O
throughout XXX O
development XXX O
, XXX O
while XXX O
two XXX O
shorter XXX O
transcripts XXX O
of XXX O
2 XXX O
. XXX O
3 XXX O
and XXX O
1 XXX O
. XXX O
8 XXX O
kb XXX O
appear XXX O
to XXX O
be XXX O
specifically XXX O
expressed XXX O
in XXX O
the XXX O
germline XXX O
. XXX O

Here XXX O
we XXX O
characterize XXX O
an XXX O
S XXX B-GENE
. XXX I-GENE
cerevisiae XXX I-GENE
Swi3 XXX I-GENE
homolog XXX I-GENE
( XXX O
Swh3 XXX B-GENE
) XXX O
and XXX O
present XXX O
evidence XXX O
that XXX O
it XXX O
associates XXX O
in XXX O
a XXX O
complex XXX O
with XXX O
a XXX O
Snf2 XXX B-GENE
homolog XXX I-GENE
, XXX O
Sthl XXX B-GENE
. XXX O

Phylogenetic XXX O
analysis XXX O
gave XXX O
evidence XXX O
for XXX O
a XXX O
close XXX O
evolutionary XXX O
relationship XXX O
between XXX O
PhHV-1 XXX O
and XXX O
members XXX O
of XXX O
the XXX O
Varicellovirus XXX O
genus XXX O
of XXX O
the XXX O
alpha-Herpesvirinae XXX O
and XXX O
canid XXX O
herpesvirus XXX O
in XXX O
particular XXX O
. XXX O

Both XXX O
EWS-FLI-1 XXX B-GENE
and XXX O
FLI-1 XXX B-GENE
proteins XXX I-GENE
function XXX O
as XXX O
transcription XXX O
factors XXX O
that XXX O
bind XXX O
specifically XXX O
to XXX O
ets XXX B-GENE
sequences XXX I-GENE
( XXX O
the XXX O
ets XXX B-GENE
boxes XXX I-GENE
) XXX O
present XXX O
in XXX O
promoter XXX O
elements XXX O
. XXX O

Changes XXX O
in XXX O
immunologic XXX O
reactivity XXX O
in XXX O
subjects XXX O
receiving XXX O
transfer XXX B-GENE
factor XXX I-GENE
could XXX O
not XXX O
be XXX O
distinguished XXX O
from XXX O
those XXX O
in XXX O
subjects XXX O
receiving XXX O
placebo XXX O
. XXX O

Transitory XXX O
subclinical XXX O
and XXX O
permanent XXX O
hypothyroidism XXX O
in XXX O
the XXX O
course XXX O
of XXX O
subacute XXX O
thyroiditis XXX O
( XXX O
de XXX O
Quervain XXX O
) XXX O
. XXX O

Transient XXX O
, XXX O
high-level XXX O
Ras-expression XXX O
induces XXX O
transcriptional XXX O
activation XXX O
of XXX O
p21 XXX B-GENE
mediated XXX O
by XXX O
a XXX O
GC-rich XXX O
region XXX O
in XXX O
p21 XXX B-GENE
promoter XXX I-GENE
-83-54 XXX O
bp XXX O
relative XXX O
to XXX O
the XXX O
transcription XXX O
initiation XXX O
site XXX O
containing XXX O
binding XXX O
sites XXX O
for XXX O
Sp1-family XXX B-GENE
transcription XXX I-GENE
factors XXX I-GENE
. XXX O

The XXX O
MICs XXX O
of XXX O
this XXX O
compound XXX O
against XXX O
90% XXX O
of XXX O
these XXX O
organisms XXX O
, XXX O
except XXX O
for XXX O
methicillin-resistant XXX O
S XXX O
. XXX O
aureus XXX O
, XXX O
ranged XXX O
from XXX O
less XXX O
than XXX O
or XXX O
equal XXX O
to XXX O
0 XXX O
. XXX O
006 XXX O
to XXX O
3 XXX O
. XXX O
13 XXX O
micrograms XXX O
/ XXX O
ml XXX O
. XXX O

Five XXX O
patients XXX O
with XXX O
type XXX O
III XXX O
musculoskeletal XXX O
infection XXX O
from XXX O
nongonococcal XXX O
Neisseria XXX O
species XXX O
were XXX O
examined XXX O
during XXX O
a XXX O
13-month XXX O
period XXX O
. XXX O

A XXX O
large XXX O
increase XXX O
of XXX O
serum XXX O
ketones XXX O
occurred XXX O
under XXX O
all XXX O
conditions XXX O
, XXX O
and XXX O
the XXX O
exercise XXX O
respiratory XXX O
quotient XXX O
suggested XXX O
some XXX O
increase XXX O
of XXX O
fat XXX O
utilization XXX O
, XXX O
WW XXX O
( XXX O
0 XXX O
. XXX O
85 XXX O
) XXX O
through XXX O
CW XXX O
( XXX O
0 XXX O
. XXX O
84 XXX O
) XXX O
to XXX O
CC XXX O
( XXX O
0 XXX O
. XXX O
83 XXX O
) XXX O
. XXX O

The XXX O
current XXX O
study XXX O
demonstrates XXX O
that XXX O
T3-activated XXX O
transcription XXX O
of XXX O
the XXX O
NADPH XXX O
: XXX O
cytochrome XXX B-GENE
P450 XXX I-GENE
oxidoreductase XXX I-GENE
( XXX O
P450R XXX B-GENE
) XXX O
gene XXX O
is XXX O
dependent XXX O
on XXX O
the XXX O
thyroid XXX O
hormonal XXX O
status XXX O
of XXX O
the XXX O
animal XXX O
, XXX O
with XXX O
both XXX O
transcriptional XXX O
and XXX O
post-transcriptional XXX O
pathways XXX O
being XXX O
important XXX O
in XXX O
regulating XXX O
the XXX O
cellular XXX O
P450R XXX B-GENE
mRNA XXX I-GENE
level XXX O
. XXX O

From XXX O
this XXX O
library XXX O
, XXX O
LEU2 XXX B-GENE
and XXX O
HIS3 XXX B-GENE
cDNAs XXX O
were XXX O
recovered XXX O
at XXX O
a XXX O
frequency XXX O
of XXX O
about XXX O
1 XXX O
in XXX O
10 XXX O
( XXX O
4 XXX O
) XXX O
and XXX O
in XXX O
12 XXX O
out XXX O
of XXX O
13 XXX O
cases XXX O
these XXX O
were XXX O
expressed XXX O
in XXX O
a XXX O
galactose-dependent XXX O
manner XXX O
. XXX O

However XXX O
, XXX O
as XXX O
determined XXX O
by XXX O
PCR XXX O
with XXX O
primers XXX O
specific XXX O
for XXX O
the XXX O
26-kDa XXX O
product XXX O
, XXX O
the XXX O
majority XXX O
of XXX O
cats XXX O
at XXX O
2 XXX O
and XXX O
4 XXX O
weeks XXX O
p XXX O
. XXX O
t XXX O
. XXX O
had XXX O
gastric XXX O
fluid XXX O
samples XXX O
which XXX O
were XXX O
positive XXX O
for XXX O
H XXX O
. XXX O
pylori XXX O
and XXX O
three XXX O
of XXX O
three XXX O
cats XXX O
at XXX O
2 XXX O
weeks XXX O
p XXX O
. XXX O
t XXX O
. XXX O
had XXX O
dental XXX O
plaque XXX O
which XXX O
was XXX O
positive XXX O
for XXX O
H XXX O
. XXX O
pylori XXX O
. XXX O

Functional XXX B-GENE
rearranged XXX I-GENE
antibody XXX I-GENE
genes XXX I-GENE
were XXX O
detected XXX O
with XXX O
JH XXX B-GENE
and XXX O
VH XXX B-GENE
heavy XXX I-GENE
chain XXX I-GENE
probes XXX O
and XXX O
with XXX O
Jk XXX B-GENE
and XXX O
Vk XXX B-GENE
light XXX I-GENE
chain XXX I-GENE
probes XXX O
. XXX O

A XXX O
. XXX O

Sweet XXX O
oranges XXX O
, XXX O
mandarin XXX O
, XXX O
grapefruit XXX O
, XXX O
lemon XXX O
, XXX O
and XXX O
lime XXX O
are XXX O
generally XXX O
used XXX O
for XXX O
processing XXX O
. XXX O

Drug-drug XXX O
interactions XXX O
are XXX O
most XXX O
likely XXX O
to XXX O
occur XXX O
in XXX O
patients XXX O
receiving XXX O
multiple XXX O
medications XXX O
and XXX O
with XXX O
drugs XXX O
that XXX O
have XXX O
a XXX O
narrow XXX O
therapeutic XXX O
window XXX O
. XXX O

Protein XXX B-GENE
phosphatases XXX I-GENE
play XXX O
a XXX O
critical XXX O
role XXX O
in XXX O
the XXX O
regulation XXX O
of XXX O
the XXX O
eukaryotic XXX O
cell XXX O
cycle XXX O
and XXX O
signal XXX O
transduction XXX O
. XXX O

Gag XXX B-GENE
protein XXX O
sequence XXX O
motifs XXX O
of XXX O
the XXX O
NC XXX B-GENE
domain XXX I-GENE
of XXX O
primate XXX O
foamy XXX O
viruses XXX O
assumed XXX O
to XXX O
be XXX O
involved XXX O
in XXX O
genome XXX O
encapsidation XXX O
are XXX O
not XXX O
conserved XXX O
in XXX O
FeFV XXX O
. XXX O

The XXX O
requirement XXX O
of XXX O
Tyr-19 XXX O
dephosphorylation XXX O
for XXX O
spindle XXX O
assembly XXX O
is XXX O
also XXX O
observed XXX O
under XXX O
conditions XXX O
in XXX O
which XXX O
spindle XXX O
formation XXX O
is XXX O
independent XXX O
of XXX O
mitosis XXX O
, XXX O
suggesting XXX O
that XXX O
the XXX O
involvement XXX O
of XXX O
Cdc28 XXX B-GENE
/ XXX I-GENE
Clb XXX I-GENE
kinase XXX I-GENE
in XXX O
SPB XXX O
separation XXX O
is XXX O
direct XXX O
. XXX O

The XXX O
neuroprotective XXX O
efficacy XXX O
of XXX O
the XXX O
selective XXX O
N-type XXX O
voltage-sensitive XXX O
calcium XXX O
channel XXX O
blocker XXX O
, XXX O
SNX-111 XXX O
, XXX O
was XXX O
evaluated XXX O
in XXX O
spontaneously XXX O
hypertensive XXX O
rats XXX O
subjected XXX O
to XXX O
60 XXX O
min XXX O
of XXX O
focal XXX O
cerebral XXX O
ischemia XXX O
by XXX O
permanent XXX O
ligation XXX O
of XXX O
the XXX O
right XXX O
common XXX O
carotid XXX O
artery XXX O
and XXX O
temporary XXX O
occlusion XXX O
of XXX O
the XXX O
right XXX O
middle XXX O
cerebral XXX O
artery XXX O
. XXX O

Further XXX O
, XXX O
Tax-mediated XXX O
apoptosis XXX O
was XXX O
effectively XXX O
prevented XXX O
by XXX O
ectopic XXX O
expression XXX O
of XXX O
the XXX O
p300 XXX B-GENE
coactivator XXX I-GENE
. XXX O

Comparison XXX O
of XXX O
frequencies XXX O
of XXX O
atrial XXX O
fibrillation XXX O
after XXX O
coronary XXX O
artery XXX O
bypass XXX O
grafting XXX O
with XXX O
and XXX O
without XXX O
the XXX O
use XXX O
of XXX O
cardiopulmonary XXX O
bypass XXX O
. XXX O

Aspirin XXX O
causes XXX O
peptic XXX O
ulcers XXX O
predominately XXX O
by XXX O
reducing XXX O
gastric XXX B-GENE
mucosal XXX I-GENE
cyclooxygenase XXX I-GENE
( XXX O
COX XXX B-GENE
) XXX O
activity XXX O
and XXX O
prostaglandin XXX O
synthesis XXX O
. XXX O

The XXX O
mEmBP-1 XXX B-GENE
protein XXX I-GENE
can XXX O
activate XXX O
transcription XXX O
from XXX O
a XXX O
truncated XXX O
promoter XXX O
containing XXX O
a XXX O
pentamer XXX O
of XXX O
the XXX O
O2 XXX B-GENE
site XXX I-GENE
in XXX O
yeast XXX O
cells XXX O
; XXX O
however XXX O
, XXX O
it XXX O
inhibited XXX O
regulated XXX O
transcription XXX O
of XXX O
a XXX O
22 XXX B-GENE
kDa XXX I-GENE
zein XXX I-GENE
promoter XXX I-GENE
in XXX O
a XXX O
transient XXX O
expression XXX O
assay XXX O
using XXX O
cultured XXX O
maize XXX O
endosperm XXX O
cells XXX O
. XXX O

Partial XXX O
sequencing XXX O
of XXX O
the XXX O
region XXX O
downstream XXX O
of XXX O
ORF-Pto XXX O
revealed XXX O
homology XXX O
to XXX O
the XXX O
ru XXX B-GENE
/ XXX I-GENE
AB XXX I-GENE
genes XXX I-GENE
, XXX O
involved XXX O
in XXX O
UV XXX O
resistance XXX O
, XXX O
from XXX O
plasmid XXX O
pPSR1 XXX O
. XXX O

The XXX O
manifestations XXX O
often XXX O
include XXX O
a XXX O
moderate XXX O
thrombocytopenia XXX O
and XXX O
, XXX O
less XXX O
commonly XXX O
, XXX O
hemolysis XXX O
. XXX O

During XXX O
a XXX O
disease XXX O
remission XXX O
there XXX O
was XXX O
an XXX O
increase XXX O
in XXX O
GAG XXX O
secretion XXX O
with XXX O
urine XXX O
, XXX O
linked XXX O
with XXX O
hyperheparinuria XXX O
( XXX O
13 XXX O
. XXX O
1-fold XXX O
, XXX O
P XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
001 XXX O
) XXX O
. XXX O

Liquid XXX O
chromatographic XXX O
method XXX O
for XXX O
determination XXX O
of XXX O
citreoviridin XXX O
in XXX O
corn XXX O
and XXX O
rice XXX O
. XXX O

Effects XXX O
of XXX O
moderate XXX O
hypercapnia XXX O
on XXX O
hypothermia XXX O
induced XXX O
by XXX O
cold XXX O
He-O2 XXX O
in XXX O
rats XXX O
. XXX O

Solitary XXX O
thyroid XXX O
nodule XXX O
. XXX O

The XXX O
antioxidant XXX O
agent XXX O
pyrrolidine XXX O
dithiocarbamate XXX O
( XXX O
PDTC XXX O
) XXX O
has XXX O
been XXX O
shown XXX O
to XXX O
protect XXX O
endothelial XXX O
cells XXX O
( XXX O
EC XXX O
) XXX O
from XXX O
pro-inflammatory-induced XXX O
and XXX O
pro-oxidant-induced XXX O
NF-kappaB XXX B-GENE
activation XXX O
. XXX O

The XXX O
interaction XXX O
of XXX O
zf4-6 XXX B-GENE
with XXX O
full-length XXX B-GENE
5 XXX I-GENE
S XXX I-GENE
RNA XXX I-GENE
was XXX O
far XXX O
more XXX O
sensitive XXX O
to XXX O
non-specific XXX O
competitor XXX O
concentration XXX O
than XXX O
was XXX O
the XXX O
zf4-7 XXX B-GENE
: XXX O
5 XXX B-GENE
S XXX I-GENE
RNA XXX I-GENE
interaction XXX O
, XXX O
suggesting XXX O
that XXX O
finger XXX O
seven XXX O
contributes XXX O
to XXX O
both XXX O
affinity XXX O
and XXX O
specificity XXX O
in XXX O
this XXX O
protein XXX O
: XXX O
RNA XXX O
interaction XXX O
. XXX O

It XXX O
was XXX O
found XXX O
that XXX O
the XXX O
disappearance XXX O
of XXX O
BOD5 XXX O
and XXX O
NH3-N XXX O
could XXX O
be XXX O
approximated XXX O
using XXX O
first-order XXX O
kinetics XXX O
, XXX O
but XXX O
the XXX O
kinetics XXX O
of XXX O
TP XXX O
removal XXX O
were XXX O
unclear XXX O
. XXX O

A XXX O
great XXX O
deal XXX O
of XXX O
information XXX O
is XXX O
available XXX O
on XXX O
the XXX O
morphology XXX O
of XXX O
the XXX O
claustrum XXX O
in XXX O
various XXX O
animal XXX O
species XXX O
, XXX O
as XXX O
well XXX O
as XXX O
on XXX O
its XXX O
neuronal XXX O
distribution XXX O
and XXX O
relationships XXX O
with XXX O
the XXX O
cerebral XXX O
cortex XXX O
and XXX O
other XXX O
nuclei XXX O
. XXX O

These XXX O
results XXX O
suggest XXX O
that XXX O
the XXX O
M XXX O
. XXX O
jannaschii XXX O
as XXX O
well XXX O
as XXX O
related XXX O
archaeal XXX O
20S XXX O
proteasomes XXX O
require XXX O
a XXX O
nucleotidase XXX B-GENE
complex XXX I-GENE
such XXX O
as XXX O
PAN XXX B-GENE
to XXX O
mediate XXX O
the XXX O
energy-dependent XXX O
hydrolysis XXX O
of XXX O
folded-substrate XXX O
proteins XXX O
and XXX O
that XXX O
the XXX O
N-terminal XXX O
73 XXX O
amino XXX O
acid XXX O
residues XXX O
of XXX O
PAN XXX B-GENE
are XXX O
not XXX O
absolutely XXX O
required XXX O
for XXX O
this XXX O
reaction XXX O
. XXX O

This XXX O
stimulatory XXX O
effect XXX O
could XXX O
also XXX O
be XXX O
elicited XXX O
by XXX O
c-Jun XXX B-GENE
, XXX O
which XXX O
interacts XXX O
with XXX O
topo XXX B-GENE
II XXX I-GENE
, XXX O
but XXX O
not XXX O
by XXX O
c-Fos XXX B-GENE
, XXX O
which XXX O
does XXX O
not XXX O
bind XXX O
topo XXX B-GENE
II XXX I-GENE
in XXX O
our XXX O
in XXX O
vitro XXX O
assay XXX O
. XXX O

Here XXX O
we XXX O
examine XXX O
the XXX O
potential XXX O
for XXX O
VP16 XXX B-GENE
protein-protein XXX O
interactions XXX O
specific XXX O
to XXX O
virus-infected XXX O
cells XXX O
and XXX O
show XXX O
that XXX O
VP16 XXX B-GENE
copurifies XXX O
in XXX O
a XXX O
highly XXX O
enriched XXX O
fraction XXX O
with XXX O
a XXX O
single XXX O
major XXX O
polypeptide XXX O
which XXX O
we XXX O
identify XXX O
as XXX O
the XXX O
virus-encoded XXX O
structural XXX O
protein XXX O
VP22 XXX B-GENE
. XXX O

Abstracts XXX O
. XXX O

A XXX O
simple XXX O
analytical XXX O
method XXX O
for XXX O
l-menthol XXX O
by XXX O
high-performance XXX O
liquid XXX O
chromatography XXX O
with XXX O
a XXX O
polarized XXX O
photometric XXX O
detector XXX O
was XXX O
established XXX O
. XXX O

Multistage XXX O
models XXX O
and XXX O
the XXX O
A-bomb XXX O
survivor XXX O
data XXX O
: XXX O
implications XXX O
for XXX O
carcinogenic XXX O
mechanisms XXX O
? XXX O

The XXX O
best XXX O
endometrial XXX O
ablation XXX O
was XXX O
seen XXX O
when XXX O
SnET2 XXX O
was XXX O
given XXX O
by XXX O
intrauterine XXX O
administration XXX O
with XXX O
light XXX O
treatment XXX O
at XXX O
150 XXX O
J XXX O
/ XXX O
cm XXX O
24 XXX O
hours XXX O
later XXX O
. XXX O

After XXX O
recovery XXX O
, XXX O
a XXX O
hypertonic XXX O
saline XXX O
challenge XXX O
was XXX O
performed XXX O
. XXX O

We XXX O
also XXX O
discovered XXX O
a XXX O
V XXX B-GENE
lambda XXX I-GENE
pseudogene XXX I-GENE
, XXX O
called XXX O
psi XXX B-GENE
V XXX I-GENE
lambda XXX I-GENE
1 XXX I-GENE
, XXX O
3 XXX O
kb XXX O
upstream XXX O
of XXX O
the XXX O
U266 XXX B-GENE
lambda XXX I-GENE
gene XXX I-GENE
. XXX O

These XXX O
results XXX O
indicate XXX O
that XXX O
cynomolgus XXX O
monkeys XXX O
are XXX O
either XXX O
less XXX O
sensitive XXX O
or XXX O
respond XXX O
differently XXX O
than XXX O
rhesus XXX O
monkeys XXX O
to XXX O
some XXX O
of XXX O
the XXX O
pharmacological XXX O
effects XXX O
of XXX O
norcocaine XXX O
. XXX O

Experimental XXX O
cardiotoxicity XXX O
of XXX O
adriamycin XXX O
. XXX O

The XXX O
present XXX O
study XXX O
examined XXX O
the XXX O
effect XXX O
of XXX O
intensity XXX O
, XXX O
rate XXX O
, XXX O
and XXX O
polarity XXX O
on XXX O
the XXX O
spectral XXX O
content XXX O
of XXX O
ABRs XXX O
of XXX O
15 XXX O
normal-hearing XXX O
subjects XXX O
. XXX O

Its XXX O
hydropathy XXX O
profile XXX O
predicts XXX O
seven XXX O
transmembrane XXX O
spans XXX O
and XXX O
a XXX O
hydrophilic XXX O
amino XXX O
terminus XXX O
of XXX O
approximately XXX O
100 XXX O
residues XXX O
, XXX O
and XXX O
it XXX O
suggests XXX O
the XXX O
presence XXX O
of XXX O
an XXX O
amphiphilic XXX O
alpha-helix XXX O
( XXX O
L-61 XXX O
to XXX O
F-97 XXX O
) XXX O
in XXX O
close XXX O
proximity XXX O
to XXX O
the XXX O
first XXX O
strongly XXX O
hydrophobic XXX O
segment XXX O
of XXX O
ProW XXX B-GENE
. XXX O

The XXX O
applicability XXX O
of XXX O
laparoscopic XXX O
donor XXX O
nephrectomy XXX O
( XXX O
LDN XXX O
) XXX O
has XXX O
not XXX O
been XXX O
assessed XXX O
in XXX O
the XXX O
obese XXX O
donor XXX O
. XXX O

ERK XXX B-GENE
MAP XXX B-GENE
kinase XXX I-GENE
links XXX O
cytokine XXX O
signals XXX O
to XXX O
activation XXX O
of XXX O
latent XXX O
HIV-1 XXX O
infection XXX O
by XXX O
stimulating XXX O
a XXX O
cooperative XXX O
interaction XXX O
of XXX O
AP-1 XXX B-GENE
and XXX O
NF-kappaB XXX B-GENE
. XXX O

Neural-specific XXX O
expression XXX O
, XXX O
genomic XXX O
structure XXX O
, XXX O
and XXX O
chromosomal XXX O
localization XXX O
of XXX O
the XXX O
gene XXX O
encoding XXX O
the XXX O
zinc-finger XXX B-GENE
transcription XXX I-GENE
factor XXX I-GENE
NGFI-C XXX I-GENE
. XXX O

The XXX O
skin XXX O
site XXX O
, XXX O
6-cm-distal XXX O
and XXX O
-proximal XXX O
subcutaneous XXX O
segments XXX O
of XXX O
the XXX O
catheter XXX O
, XXX O
exudates XXX O
, XXX O
and XXX O
blood XXX O
were XXX O
cultured XXX O
. XXX O

A XXX O
brief XXX O
discussion XXX O
of XXX O
color XXX O
deficiencies XXX O
. XXX O

A XXX O
human XXX O
nuclear-localized XXX O
chaperone XXX O
that XXX O
regulates XXX O
dimerization XXX O
, XXX O
DNA XXX O
binding XXX O
, XXX O
and XXX O
transcriptional XXX O
activity XXX O
of XXX O
bZIP XXX B-GENE
proteins XXX I-GENE
. XXX O

The XXX O
inhibition XXX O
by XXX O
cytosolic XXX O
Ca2+ XXX O
was XXX O
caused XXX O
by XXX O
a XXX O
decrease XXX O
in XXX O
cooperativity XXX O
and XXX O
by XXX O
a XXX O
shift XXX O
in XXX O
EC50 XXX O
toward XXX O
higher XXX O
InsP3 XXX O
concentrations XXX O
. XXX O

Some XXX O
studies XXX O
of XXX O
exercise XXX O
have XXX O
associated XXX O
beta-endorphin XXX B-GENE
release XXX O
with XXX O
increased XXX O
exertion XXX O
levels XXX O
, XXX O
but XXX O
other XXX O
evidence XXX O
suggests XXX O
that XXX O
acidosis XXX O
may XXX O
stimulate XXX O
the XXX O
release XXX O
of XXX O
beta-endorphin XXX B-GENE
. XXX O

The XXX O
event XXX O
rate XXX O
in XXX O
patients XXX O
with XXX O
chronic XXX O
Irr-rMFP XXX O
or XXX O
Un-nrMFP XXX O
was XXX O
markedly XXX O
higher XXX O
than XXX O
it XXX O
was XXX O
in XXX O
those XXX O
with XXX O
Rev-rMFP XXX O
or XXX O
Sta-nrMFP XXX O
. XXX O

Krox-24 XXX B-GENE
is XXX O
therefore XXX O
a XXX O
sequence-specific XXX O
transcriptional XXX O
activator XXX O
. XXX O

In XXX O
wandering XXX O
stage XXX O
larvae XXX O
, XXX O
the XXX O
OBP XXX B-GENE
transcript XXX I-GENE
appeared XXX O
to XXX O
be XXX O
at XXX O
least XXX O
250-fold XXX O
less XXX O
abundant XXX O
than XXX O
ribosomal XXX B-GENE
RNA XXX I-GENE
. XXX O

A XXX O
sheep XXX O
testicular XXX O
cDNA XXX O
library XXX O
constructed XXX O
in XXX O
pcDNA1 XXX O
vector XXX O
was XXX O
screened XXX O
with XXX O
a XXX O
probe XXX O
generated XXX O
by XXX O
polymerase XXX O
chain XXX O
reaction XXX O
( XXX O
PCR XXX O
) XXX O
and XXX O
corresponding XXX O
to XXX O
a XXX O
1 XXX O
. XXX O
6 XXX O
kb XXX O
fragment XXX O
of XXX O
the XXX O
rat XXX B-GENE
luteinizing XXX I-GENE
hormone XXX I-GENE
receptor XXX I-GENE
cDNA XXX I-GENE
. XXX O

Plethysmographic XXX O
technique XXX O
and XXX O
indirect XXX O
blood XXX O
pressure XXX O
recordings XXX O
were XXX O
used XXX O
. XXX O

Dissipation XXX O
of XXX O
claudication XXX O
pain XXX O
after XXX O
walking XXX O
: XXX O
implications XXX O
for XXX O
endurance XXX O
training XXX O
. XXX O

This XXX O
is XXX O
necessary XXX O
if XXX O
psychiatric XXX O
diagnoses XXX O
are XXX O
ultimately XXX O
going XXX O
to XXX O
be XXX O
refined XXX O
and XXX O
validated XXX O
against XXX O
biological XXX O
criteria XXX O
. XXX O

Furthermore XXX O
, XXX O
we XXX O
demonstrated XXX O
that XXX O
Galpha11 XXX B-GENE
Q209L XXX I-GENE
stimulated XXX O
Src XXX B-GENE
family XXX I-GENE
kinase XXX B-GENE
activity XXX O
and XXX O
induced XXX O
tyrosine XXX O
phosphorylation XXX O
of XXX O
several XXX O
proteins XXX O
in XXX O
HEK-293 XXX O
cells XXX O
. XXX O

The XXX O
percentages XXX O
of XXX O
recovery XXX O
decreased XXX O
with XXX O
storage XXX O
time XXX O
, XXX O
although XXX O
the XXX O
addition XXX O
of XXX O
dispersant XXX O
( XXX O
Tris-Tween XXX O
80 XXX O
) XXX O
before XXX O
storage XXX O
appeared XXX O
to XXX O
partially XXX O
prevent XXX O
adhesion XXX O
. XXX O

The XXX O
results XXX O
are XXX O
given XXX O
as XXX O
: XXX O
flux XXX O
, XXX O
number XXX O
of XXX O
stars XXX O
per XXX O
CM3 XXX O
, XXX O
charge XXX O
of XXX O
the XXX O
ions XXX O
, XXX O
comparison XXX O
with XXX O
other XXX O
detectors XXX O
( XXX O
plastics XXX O
, XXX O
AgCl XXX O
crystals XXX O
, XXX O
LiF XXX O
) XXX O
, XXX O
energy XXX O
loss XXX O
, XXX O
hit XXX O
region XXX O
in XXX O
the XXX O
biological XXX O
objects XXX O
. XXX O

Ultrasonography XXX O
provides XXX O
excellent XXX O
intraoperative XXX O
evaluation XXX O
of XXX O
spinal XXX O
cord XXX O
injury XXX O
. XXX O

This XXX O
paper XXX O
summarises XXX O
the XXX O
experimental XXX O
evidence XXX O
upon XXX O
which XXX O
the XXX O
clinical XXX O
trials XXX O
of XXX O
aldose XXX B-GENE
reductase XXX I-GENE
inhibitors XXX O
in XXX O
diabetic XXX O
patients XXX O
have XXX O
been XXX O
initiated XXX O
and XXX O
the XXX O
results XXX O
of XXX O
published XXX O
drug XXX O
trials XXX O
in XXX O
these XXX O
patients XXX O
. XXX O

At XXX O
least XXX O
some XXX O
of XXX O
the XXX O
difference XXX O
in XXX O
stability XXX O
of XXX O
the XXX O
two XXX O
kinds XXX O
of XXX O
complexes XXX O
was XXX O
due XXX O
to XXX O
the XXX O
fact XXX O
that XXX O
the XXX O
dissociation XXX O
rate XXX O
of XXX O
the XXX O
A XXX O
stem XXX O
substrate XXX O
from XXX O
the XXX O
protein-DNA XXX O
complexes XXX O
was XXX O
approximately XXX O
fourfold XXX O
faster XXX O
than XXX O
that XXX O
of XXX O
the XXX O
complete XXX O
TR XXX O
. XXX O

Disruption XXX O
mutations XXX O
have XXX O
been XXX O
constructed XXX O
in XXX O
the XXX O
SLK1 XXX B-GENE
gene XXX I-GENE
. XXX O
slk1 XXX B-GENE
null XXX I-GENE
mutants XXX I-GENE
cannot XXX O
grow XXX O
at XXX O
37 XXX O
degrees XXX O
C XXX O
, XXX O
but XXX O
many XXX O
cells XXX O
can XXX O
grow XXX O
at XXX O
30 XXX O
, XXX O
24 XXX O
, XXX O
and XXX O
17 XXX O
degrees XXX O
C XXX O
. XXX O

As XXX O
an XXX O
application XXX O
of XXX O
reverse XXX O
genetics XXX O
, XXX O
we XXX O
introduced XXX O
one XXX O
nucleotide XXX O
change XXX O
( XXX O
UCU XXX O
to XXX O
ACU XXX O
) XXX O
to XXX O
immediate XXX O
downstream XXX O
of XXX O
the XXX O
RNA-editing XXX O
site XXX O
of XXX O
the XXX O
V XXX B-GENE
gene XXX I-GENE
in XXX O
the XXX O
full-length XXX B-GENE
hPIV2 XXX I-GENE
cDNA XXX I-GENE
and XXX O
were XXX O
able XXX O
to XXX O
obtain XXX O
infectious XXX O
viruses XXX O
[ XXX O
rPIV2V XXX O
( XXX O
- XXX O
) XXX O
] XXX O
from XXX O
the XXX O
cDNA XXX O
. XXX O

ARPIA XXX O
has XXX O
been XXX O
implemented XXX O
by XXX O
using XXX O
a XXX O
relational XXX O
DBMS XXX O
, XXX O
very XXX O
cheap XXX O
and XXX O
highly XXX O
diffused XXX O
on XXX O
personal XXX O
computers XXX O
. XXX O

Combined XXX O
intravenous XXX O
and XXX O
intra-arterial XXX O
recombinant XXX O
tissue XXX B-GENE
plasminogen XXX I-GENE
activator XXX I-GENE
in XXX O
acute XXX O
ischemic XXX O
stroke XXX O
. XXX O

Stimulation XXX O
with XXX O
MCh XXX O
produced XXX O
a XXX O
Ca-dependent XXX O
transient XXX O
elevation XXX O
of XXX O
cGMP XXX O
level XXX O
from XXX O
10 XXX O
to XXX O
80 XXX O
fmol XXX O
/ XXX O
gland XXX O
, XXX O
peaking XXX O
at XXX O
1-2 XXX O
min XXX O
but XXX O
returning XXX O
to XXX O
the XXX O
basal XXX O
level XXX O
by XXX O
5 XXX O
min XXX O
. XXX O

Courses XXX O
were XXX O
repeated XXX O
monthly XXX O
upon XXX O
recovery XXX O
of XXX O
myelosuppression XXX O
. XXX O

To XXX O
study XXX O
the XXX O
regulation XXX O
of XXX O
mdr2 XXX B-GENE
expression XXX O
, XXX O
the XXX O
promoter XXX O
of XXX O
the XXX O
mdr2 XXX B-GENE
gene XXX I-GENE
has XXX O
been XXX O
isolated XXX O
from XXX O
a XXX O
murine XXX O
vinblastine-resistant XXX O
cell XXX O
line XXX O
, XXX O
J7 XXX O
. XXX O
V2-1 XXX O
, XXX O
and XXX O
characterized XXX O
. XXX O

The XXX O
MABP XXX O
and XXX O
MCBFV XXX O
signals XXX O
were XXX O
bandpass XXX O
filtered XXX O
in XXX O
the XXX O
very XXX O
low-frequency XXX O
range XXX O
( XXX O
VLF XXX O
, XXX O
0 XXX O
. XXX O
015-0 XXX O
. XXX O
07 XXX O
Hz XXX O
) XXX O
, XXX O
low-frequency XXX O
range XXX O
( XXX O
LF XXX O
, XXX O
0 XXX O
. XXX O
07-0 XXX O
. XXX O
15 XXX O
Hz XXX O
) XXX O
and XXX O
high-frequency XXX O
range XXX O
( XXX O
HF XXX O
, XXX O
0 XXX O
. XXX O
15-0 XXX O
. XXX O
40 XXX O
Hz XXX O
) XXX O
before XXX O
applying XXX O
CCF XXX O
for XXX O
the XXX O
purpose XXX O
of XXX O
studying XXX O
the XXX O
effect XXX O
of XXX O
different XXX O
bandwidths XXX O
on XXX O
the XXX O
resulting XXX O
mean XXX O
CCFs XXX O
. XXX O

Delayed XXX O
hypersensitivity XXX O
in XXX O
man XXX O
: XXX O
effects XXX O
of XXX O
systemic XXX O
anticoagulation XXX O
. XXX O

The XXX O
elm1 XXX B-GENE
kinase XXX I-GENE
functions XXX O
in XXX O
a XXX O
mitotic XXX O
signaling XXX O
network XXX O
in XXX O
budding XXX O
yeast XXX O
. XXX O

We XXX O
have XXX O
mutated XXX O
to XXX O
cysteine XXX O
, XXX O
one XXX O
at XXX O
a XXX O
time XXX O
, XXX O
21 XXX O
consecutive XXX O
residues XXX O
in XXX O
the XXX O
fourth XXX O
TMS XXX O
( XXX O
TM4 XXX O
) XXX O
. XXX O

D XXX O
. XXX O
melanogaster XXX O
HeT-A XXX B-GENE
coding XXX O
sequences XXX O
have XXX O
a XXX O
polymorphic XXX O
region XXX O
with XXX O
insertions XXX O
/ XXX O
deletions XXX O
of XXX O
1-31 XXX O
codons XXX O
and XXX O
many XXX O
nucleotide XXX O
changes XXX O
. XXX O

Although XXX O
no XXX O
Rh-antibodies XXX B-GENE
were XXX O
demonstrable XXX O
, XXX O
a XXX O
similar XXX O
mechanism XXX O
can XXX O
be XXX O
postulated XXX O
for XXX O
the XXX O
Rh-system XXX O
. XXX O

The XXX O
predicted XXX O
amino XXX O
acid XXX O
sequence XXX O
contains XXX O
regions XXX O
identical XXX O
to XXX O
the XXX O
sequences XXX O
of XXX O
peptides XXX O
derived XXX O
from XXX O
bovine XXX B-GENE
liver XXX I-GENE
eIF-2B XXX I-GENE
alpha XXX I-GENE
subunit XXX I-GENE
. XXX O

These XXX O
REPs XXX B-GENE
, XXX O
or XXX O
clusters XXX O
of XXX O
paralogous XXX O
loci XXX O
, XXX O
are XXX O
15-100 XXX O
kb XXX O
and XXX O
harbor XXX O
at XXX O
least XXX O
four XXX O
ESTs XXX O
and XXX O
an XXX O
expressed XXX O
SH3GL XXX B-GENE
pseudogene XXX I-GENE
. XXX O

The XXX O
N XXX B-GENE
terminus XXX I-GENE
of XXX I-GENE
beta XXX I-GENE
( XXX I-GENE
95 XXX I-GENE
kDa XXX I-GENE
) XXX I-GENE
corresponds XXX O
to XXX O
alpha XXX B-GENE
with XXX O
the XXX O
integrase XXX B-GENE
domain XXX I-GENE
attached XXX O
to XXX O
the XXX O
C XXX O
terminus XXX O
( XXX O
32 XXX O
kDa XXX O
) XXX O
. XXX O

Eukaryotic XXX B-GENE
translation XXX I-GENE
initiation XXX I-GENE
factor XXX I-GENE
4GI XXX I-GENE
is XXX O
a XXX O
cellular XXX O
target XXX O
for XXX O
NS1 XXX B-GENE
protein XXX I-GENE
, XXX O
a XXX O
translational XXX O
activator XXX O
of XXX O
influenza XXX O
virus XXX O
. XXX O

Various XXX O
assays XXX O
demonstrate XXX O
promoter XXX O
activity XXX O
in XXX O
this XXX O
sequence XXX O
that XXX O
reproduces XXX O
the XXX O
normal XXX O
control XXX O
of XXX O
E2F2 XXX B-GENE
expression XXX O
during XXX O
a XXX O
growth XXX O
stimulation XXX O
. XXX O

This XXX O
activation XXX O
was XXX O
then XXX O
blocked XXX O
by XXX O
CGS XXX O
12066A XXX O
. XXX O

A XXX O
complete XXX O
drug XXX O
history XXX O
was XXX O
compiled XXX O
, XXX O
specifying XXX O
the XXX O
amount XXX O
and XXX O
duration XXX O
of XXX O
VGB XXX O
medication XXX O
. XXX O

Thus XXX O
, XXX O
unlike XXX O
other XXX O
proteins XXX O
reported XXX O
to XXX O
inhibit XXX O
SRF XXX B-GENE
activity XXX O
, XXX O
the XXX O
repressor XXX O
activity XXX O
associated XXX O
with XXX O
the XXX O
GC-rich XXX O
element XXX O
does XXX O
not XXX O
appear XXX O
to XXX O
function XXX O
through XXX O
direct XXX O
inhibition XXX O
of XXX O
SRF XXX B-GENE
binding XXX O
. XXX O

The XXX O
concomitant XXX O
interaction XXX O
of XXX O
mSTI1 XXX B-GENE
with XXX O
hsp70 XXX B-GENE
and XXX O
hsp90 XXX B-GENE
at XXX O
its XXX O
N- XXX O
and XXX O
C-termini XXX O
respectively XXX O
is XXX O
mediated XXX O
by XXX O
the XXX O
tetratricopeptide XXX O
repeat XXX O
( XXX O
TPR XXX O
) XXX O
motifs XXX O
in XXX O
these XXX O
regions XXX O
. XXX O

The XXX O
5' XXX O
regions XXX O
of XXX O
these XXX O
two XXX O
soybean XXX B-GENE
actin XXX I-GENE
genes XXX I-GENE
contain XXX O
many XXX O
unusual XXX O
features XXX O
including XXX O
( XXX O
CT XXX O
) XXX O
repeats XXX O
and XXX O
long XXX O
stretches XXX O
of XXX O
pyrimidine-rich XXX O
DNA XXX O
. XXX O

A XXX O
new XXX O
technique XXX O
to XXX O
create XXX O
an XXX O
artificial XXX O
stenosis XXX O
in XXX O
the XXX O
native XXX O
LAD XXX O
using XXX O
a XXX O
hemoclip XXX O
. XXX O

The XXX O
effectiveness XXX O
of XXX O
NRT XXX O
appears XXX O
to XXX O
be XXX O
largely XXX O
independent XXX O
of XXX O
the XXX O
intensity XXX O
of XXX O
additional XXX O
support XXX O
provided XXX O
to XXX O
the XXX O
smoker XXX O
. XXX O

ROCK-I XXX B-GENE
, XXX O
Kinectin XXX B-GENE
, XXX O
and XXX O
mDia2 XXX B-GENE
can XXX O
bind XXX O
the XXX O
wild XXX O
type XXX O
forms XXX O
of XXX O
both XXX O
RhoA XXX B-GENE
and XXX O
Cdc42 XXX B-GENE
in XXX O
a XXX O
GTP-dependent XXX O
manner XXX O
in XXX O
vitro XXX O
. XXX O

A XXX O
. XXX O
, XXX O
Bowers XXX O
, XXX O
K XXX O
. XXX O
E XXX O
, XXX O
and XXX O
Matthews XXX O
, XXX O
C XXX O
. XXX O

The XXX O
customary XXX O
coupling XXX O
reagent XXX O
sulfanilic XXX O
acid XXX O
has XXX O
been XXX O
replaced XXX O
by XXX O
1 XXX O
, XXX O
3-dimethylbarbituric XXX O
acid XXX O
; XXX O
CNCl XXX O
is XXX O
produced XXX O
in XXX O
the XXX O
flow XXX O
through XXX O
system XXX O
directly XXX O
from XXX O
KCN XXX O
and XXX O
chloramine XXX O
T XXX O
. XXX O

Of XXX O
848 XXX O
patients XXX O
, XXX O
819 XXX O
cases XXX O
with XXX O
complete XXX O
description XXX O
of XXX O
patient's XXX O
background XXX O
were XXX O
evaluable XXX O
: XXX O
Group XXX O
A XXX O
( XXX O
surgery XXX O
+ XXX O
MMC XXX O
+ XXX O
5-FU XXX O
: XXX O
chemotherapy XXX O
) XXX O
253 XXX O
cases XXX O
, XXX O
group XXX O
B XXX O
( XXX O
surgery XXX O
+ XXX O
MMC XXX O
+ XXX O
5-FU XXX O
+ XXX O
OK-432 XXX O
or XXX O
PSK XXX O
: XXX O
immunochemotherapy XXX O
) XXX O
282 XXX O
and XXX O
group XXX O
C XXX O
( XXX O
surgery XXX O
alone XXX O
) XXX O
284 XXX O
. XXX O

A--A XXX O
natural XXX O
hydrostatic XXX O
phenomenon XXX O
, XXX O
at XXX O
the XXX O
level XXX O
of XXX O
the XXX O
ends XXX O
of XXX O
the XXX O
plantar XXX O
arcs XXX O
, XXX O
diffuses XXX O
body XXX O
weight XXX O
, XXX O
as XXX O
PAIN XXX O
plays XXX O
the XXX O
role XXX O
of XXX O
outsentry XXX O
( XXX O
fig XXX O
. XXX O
--1 XXX O
) XXX O
( XXX O
5 XXX O
) XXX O
; XXX O
B--Plantar XXX O
perforating XXX O
ulceration XXX O
( XXX O
PPU XXX O
) XXX O
is XXX O
caused XXX O
by XXX O
a XXX O
combination XXX O
of XXX O
INSENSITIVITY XXX O
and XXX O
TRAUMATIS XXX O
( XXX O
1 XXX O
) XXX O
; XXX O
C--The XXX O
patient XXX O
reposing XXX O
, XXX O
as XXX O
body XXX O
weight XXX O
( XXX O
traumatism XXX O
) XXX O
effects XXX O
disappear XXX O
, XXX O
cicatrization XXX O
process XXX O
can XXX O
be XXX O
easily XXX O
observed XXX O
; XXX O
D--PNEUMATIC XXX O
INSOLE XXX O
, XXX O
being XXX O
elastic XXX O
, XXX O
diffuses XXX O
localized XXX O
compression XXX O
at XXX O
the XXX O
ends XXX O
of XXX O
the XXX O
plantar XXX O
arcs XXX O
, XXX O
reduces XXX O
attrition XXX O
, XXX O
makes XXX O
easier XXX O
blood XXX O
circulation XXX O
, XXX O
as XXX O
well XXX O
as XXX O
cure XXX O
and XXX O
prophylaxis XXX O
of XXX O
PPU XXX O
( XXX O
fig XXX O
. XXX O
--6 XXX O
) XXX O
( XXX O
3 XXX O
) XXX O
. XXX O

Equine XXX O
amnion XXX O
and XXX O
live XXX O
yeast XXX O
cell XXX O
derivative XXX O
were XXX O
evaluated XXX O
as XXX O
a XXX O
biological XXX O
dressing XXX O
and XXX O
as XXX O
a XXX O
topical XXX O
wound XXX O
medicament XXX O
respectively XXX O
, XXX O
in XXX O
the XXX O
treatment XXX O
of XXX O
granulating XXX O
wounds XXX O
of XXX O
the XXX O
distal XXX O
portion XXX O
of XXX O
the XXX O
limbs XXX O
of XXX O
horses XXX O
. XXX O

Osteocalcin XXX B-GENE
( XXX O
OC XXX B-GENE
) XXX O
is XXX O
a XXX O
matrix XXX O
calcium-binding XXX O
protein XXX O
expressed XXX O
in XXX O
osteoblasts XXX O
and XXX O
odontoblasts XXX O
undergoing XXX O
mineralization XXX O
. XXX O

A XXX O
computerized XXX O
method XXX O
of XXX O
determining XXX O
the XXX O
focal XXX O
point XXX O
of XXX O
electrical XXX O
activity XXX O
in XXX O
the XXX O
pallidum XXX O
of XXX O
parkinsonian XXX O
patients XXX O
was XXX O
developed XXX O
using XXX O
on-line XXX O
quantitative XXX O
physiological XXX O
data XXX O
analysis XXX O
. XXX O

Third XXX O
, XXX O
consistent XXX O
with XXX O
these XXX O
data XXX O
, XXX O
N-acetylcysteine XXX O
reduced XXX O
the XXX O
stimulatory XXX O
effect XXX O
of XXX O
HGF XXX B-GENE
on XXX O
stress XXX B-GENE
kinase XXX I-GENE
activities XXX O
, XXX O
while XXX O
p42 XXX B-GENE
/ XXX I-GENE
44 XXX I-GENE
mitogen XXX B-GENE
activated XXX I-GENE
kinase XXX I-GENE
( XXX O
MAPK XXX B-GENE
) XXX O
was XXX O
unmodified XXX O
, XXX O
suggesting XXX O
an XXX O
involvement XXX O
of XXX O
c-Jun-N-terminal XXX B-GENE
kinase XXX I-GENE
( XXX O
JNK XXX B-GENE
) XXX O
and XXX O
p38 XXX B-GENE
MAPK XXX I-GENE
in XXX O
HIF-1 XXX B-GENE
activation XXX O
. XXX O

( XXX O
iv XXX O
) XXX O
The XXX O
accumulation XXX O
of XXX O
cyclin XXX B-GENE
D3 XXX I-GENE
protein XXX I-GENE
in XXX O
Vero XXX O
cells XXX O
infected XXX O
with XXX O
an XXX O
alpha0 XXX B-GENE
deletion XXX I-GENE
mutant XXX I-GENE
was XXX O
reduced XXX O
relative XXX O
to XXX O
that XXX O
of XXX O
cells XXX O
infected XXX O
with XXX O
wild-type XXX O
virus XXX O
or XXX O
a XXX O
recombinant XXX O
virus XXX O
in XXX O
which XXX O
the XXX O
deleted XXX O
alpha0 XXX B-GENE
sequences XXX I-GENE
were XXX O
restored XXX O
. XXX O

The XXX O
DAP5 XXX B-GENE
/ XXX I-GENE
p86 XXX I-GENE
apoptotic XXX O
form XXX O
was XXX O
more XXX O
potent XXX O
than XXX O
DAP5 XXX B-GENE
/ XXX I-GENE
p97 XXX I-GENE
in XXX O
these XXX O
functional XXX O
assays XXX O
. XXX O

Factor XXX O
V XXX O
Leiden XXX O
is XXX O
a XXX O
genetic XXX O
disorder XXX O
associated XXX O
with XXX O
an XXX O
increased XXX O
risk XXX O
of XXX O
venous XXX O
thrombosis XXX O
. XXX O

The XXX O
interferon-induced XXX O
RNA-dependent XXX B-GENE
protein XXX I-GENE
kinase XXX I-GENE
( XXX O
PKR XXX B-GENE
) XXX O
is XXX O
considered XXX O
to XXX O
play XXX O
an XXX O
important XXX O
role XXX O
in XXX O
the XXX O
cellular XXX O
defense XXX O
against XXX O
viral XXX O
infection XXX O
and XXX O
, XXX O
in XXX O
addition XXX O
, XXX O
has XXX O
been XXX O
suggested XXX O
to XXX O
be XXX O
a XXX O
tumor XXX O
suppressor XXX O
gene XXX O
because XXX O
of XXX O
its XXX O
growth-suppressive XXX O
properties XXX O
. XXX O

Egd1p XXX B-GENE
is XXX O
homologous XXX O
to XXX O
human XXX B-GENE
BTF3b XXX I-GENE
, XXX O
recently XXX O
identified XXX O
as XXX O
the XXX O
beta XXX O
subunit XXX O
of XXX O
the XXX O
heterodimeric XXX B-GENE
nascent-polypeptide-associated XXX I-GENE
complex XXX I-GENE
( XXX O
NAC XXX B-GENE
) XXX O
involved XXX O
in XXX O
ensuring XXX O
signal-sequence-specific XXX O
protein XXX O
sorting XXX O
and XXX O
translocation XXX O
[ XXX O
Wiedmann XXX O
et XXX O
al XXX O
. XXX O
, XXX O
Nature XXX O
370 XXX O
( XXX O
1994 XXX O
) XXX O
434-440 XXX O
] XXX O
. XXX O

Energy XXX O
expenditure XXX O
was XXX O
obtained XXX O
using XXX O
a XXX O
primed XXX O
, XXX O
3-hour XXX O
infusion XXX O
of XXX O
NaH XXX O
( XXX O
13 XXX O
) XXX O
CO XXX O
( XXX O
3' XXX O
) XXX O
, XXX O
breath XXX O
( XXX O
13 XXX O
) XXX O
CO XXX O
( XXX O
2 XXX O
) XXX O
enrichment XXX O
determination XXX O
by XXX O
isotope XXX O
ratio XXX O
mass XXX O
spectroscopy XXX O
, XXX O
and XXX O
the XXX O
application XXX O
of XXX O
a XXX O
standard XXX O
regression XXX O
equation XXX O
. XXX O

We XXX O
have XXX O
found XXX O
that XXX O
the XXX O
expression XXX O
of XXX O
GTPase-deficient XXX O
mutants XXX O
of XXX O
alpha XXX B-GENE
12 XXX I-GENE
( XXX O
alpha XXX B-GENE
12Q229L XXX I-GENE
) XXX O
or XXX O
alpha XXX B-GENE
13 XXX I-GENE
( XXX O
alpha XXX B-GENE
13Q226L XXX I-GENE
) XXX O
leads XXX O
to XXX O
robust XXX O
activation XXX O
of XXX O
the XXX O
Jun XXX B-GENE
kinase XXX I-GENE
/ XXX I-GENE
stress-activated XXX I-GENE
protein XXX I-GENE
kinase XXX I-GENE
( XXX O
JNK XXX B-GENE
/ XXX I-GENE
SAPK XXX I-GENE
) XXX O
pathway XXX O
. XXX O

Tissues XXX O
and XXX O
exudates XXX O
contain XXX O
sufficient XXX O
thymidine XXX O
for XXX O
growth XXX O
of XXX O
anaerobic XXX O
bacteria XXX O
in XXX O
the XXX O
presence XXX O
of XXX O
inhibitory XXX O
levels XXX O
of XXX O
trimethoprim-sulfamethoxazole XXX O
. XXX O

Two XXX O
of XXX O
these XXX O
motifs XXX O
are XXX O
part XXX O
of XXX O
a XXX O
highly XXX O
conserved XXX O
and XXX O
inducible XXX O
dyad XXX O
symmetry XXX O
element XXX O
shown XXX O
previously XXX O
to XXX O
control XXX O
a XXX O
remote XXX O
IL-2 XXX B-GENE
enhancer XXX I-GENE
and XXX O
the XXX O
CD18 XXX B-GENE
promoter XXX I-GENE
. XXX O

Specific XXX O
binding XXX O
was XXX O
not XXX O
observed XXX O
with XXX O
either XXX O
the XXX O
orthologous XXX O
rat XXX O
or XXX O
mouse XXX O
fragments XXX O
using XXX O
human XXX O
or XXX O
rodent XXX O
extracts XXX O
. XXX O

Spliced XXX O
exons XXX O
of XXX O
adenovirus XXX O
late XXX O
RNAs XXX O
colocalize XXX O
with XXX O
snRNP XXX B-GENE
in XXX O
a XXX O
specific XXX O
nuclear XXX O
domain XXX O
. XXX O

Degradation XXX O
of XXX O
the XXX O
soybean XXX B-GENE
ribulose-1 XXX I-GENE
, XXX I-GENE
5-bisphosphate XXX I-GENE
carboxylase XXX I-GENE
small-subunit XXX I-GENE
mRNA XXX I-GENE
, XXX O
SRS4 XXX B-GENE
, XXX O
initiates XXX O
with XXX O
endonucleolytic XXX O
cleavage XXX O
. XXX O

Results XXX O
of XXX O
a XXX O
controlled XXX O
study XXX O
. XXX O

How XXX O
many XXX O
embryos XXX O
to XXX O
transfer XXX O
in XXX O
patients XXX O
undergoing XXX O
IVF XXX O
? XXX O

Legionella XXX O
, XXX O
microbial XXX O
ecology XXX O
, XXX O
and XXX O
inconspicuous XXX O
consumption XXX O
. XXX O

The XXX O
structure XXX O
of XXX O
these XXX O
genes XXX O
suggests XXX O
a XXX O
common XXX O
ancestor XXX O
for XXX O
all XXX O
viperid XXX B-GENE
PLA2 XXX I-GENE
genes XXX I-GENE
. XXX O

CSF XXX O
adenosine XXX B-GENE
deaminase XXX I-GENE
activity XXX O
( XXX O
ADA XXX O
) XXX O
was XXX O
measured XXX O
at XXX O
the XXX O
same XXX O
time XXX O
. XXX O

The XXX O
Dox-A2 XXX B-GENE
locus XXX I-GENE
is XXX O
within XXX O
3 XXX O
. XXX O
4 XXX O
to XXX O
4 XXX O
. XXX O
4 XXX O
kb XXX O
of XXX O
the XXX O
Df XXX B-GENE
( XXX I-GENE
2L XXX I-GENE
) XXX I-GENE
OD15 XXX I-GENE
breakpoint XXX I-GENE
, XXX O
placing XXX O
four XXX O
of XXX O
the XXX O
vital XXX O
loci XXX O
within XXX O
a XXX O
maximum XXX O
of XXX O
15 XXX O
. XXX O
5 XXX O
kb XXX O
. XXX O

99Tcm-DMP-HSA XXX B-GENE
showed XXX O
an XXX O
almost XXX O
identical XXX O
behaviour XXX O
to XXX O
in XXX O
vitro XXX O
labelled XXX O
red XXX O
blood XXX O
cells XXX O
( XXX O
RBCs XXX O
) XXX O
, XXX O
which XXX O
are XXX O
generally XXX O
considered XXX O
the XXX O
reference XXX O
standard XXX O
for XXX O
blood XXX O
pool XXX O
agents XXX O
. XXX O

One-third XXX O
of XXX O
the XXX O
men XXX O
with XXX O
azoospermia XXX O
and XXX O
with XXX O
sperm XXX O
density XXX O
of XXX O
less XXX O
than XXX O
10 XXX O
million XXX O
had XXX O
marked XXX O
FSH XXX B-GENE
elevation XXX O
and XXX O
our XXX O
experience XXX O
confirms XXX O
the XXX O
work XXX O
of XXX O
others XXX O
that XXX O
this XXX O
indicates XXX O
a XXX O
poor XXX O
prognosis XXX O
. XXX O

The XXX O
previously XXX O
described XXX O
four XXX O
sets XXX O
of XXX O
13- XXX O
to XXX O
18-base-pair XXX O
interspersed XXX O
repeat XXX O
elements XXX O
between XXX O
-55 XXX O
and XXX O
-580 XXX O
provide XXX O
most XXX O
of XXX O
the XXX O
high XXX O
basal XXX O
transcriptional XXX O
strength XXX O
, XXX O
whereas XXX O
the XXX O
arrangement XXX O
of XXX O
further XXX O
upstream XXX O
tandemly XXX O
repeated XXX O
NF1-binding XXX B-GENE
sites XXX I-GENE
may XXX O
contribute XXX O
significantly XXX O
to XXX O
the XXX O
expanded XXX O
biological XXX O
host XXX O
range XXX O
for XXX O
expression XXX O
of XXX O
SCMV XXX B-GENE
IE94 XXX I-GENE
compared XXX O
with XXX O
HCMV XXX B-GENE
IE68 XXX I-GENE
. XXX O

These XXX O
characteristics XXX O
of XXX O
N22 XXX O
/ XXX O
P22 XXX O
indicate XXX O
that XXX O
it XXX O
is XXX O
a XXX O
localized XXX O
synaptically XXX O
dependent XXX O
event XXX O
conforming XXX O
to XXX O
a XXX O
transverse XXX O
dipole XXX O
with XXX O
dorsal XXX O
negativity XXX O
and XXX O
a XXX O
simultaneous XXX O
anterior XXX O
positivity XXX O
. XXX O

Heterozygous XXX O
mutation XXX O
in XXX O
the XXX O
G+5 XXX O
position XXX O
of XXX O
intron XXX O
33 XXX O
of XXX O
the XXX O
pro-alpha XXX B-GENE
2 XXX I-GENE
( XXX I-GENE
I XXX I-GENE
) XXX I-GENE
gene XXX I-GENE
( XXX O
COL1A2 XXX B-GENE
) XXX O
that XXX O
causes XXX O
aberrant XXX O
RNA XXX O
splicing XXX O
and XXX O
lethal XXX O
osteogenesis XXX O
imperfecta XXX O
. XXX O

Evidence XXX O
that XXX O
opiate XXX O
addiction XXX O
is XXX O
in XXX O
part XXX O
an XXX O
immune XXX O
response XXX O
. XXX O

These XXX O
widely XXX O
expressed XXX O
proteins XXX O
share XXX O
a XXX O
C-terminal XXX O
region XXX O
that XXX O
bears XXX O
significant XXX O
sequence XXX O
homology XXX O
to XXX O
a XXX O
group XXX O
of XXX O
GDP XXX B-GENE
/ XXX I-GENE
GTP XXX I-GENE
exchange XXX I-GENE
proteins XXX I-GENE
for XXX O
the XXX O
Rab3 XXX B-GENE
family XXX I-GENE
of XXX O
small XXX B-GENE
GTP XXX I-GENE
binding XXX I-GENE
proteins XXX I-GENE
. XXX O

On XXX O
cessation XXX O
of XXX O
steroid XXX O
therapy XXX O
the XXX O
patient XXX O
was XXX O
noted XXX O
to XXX O
have XXX O
radiologic XXX O
manifestations XXX O
of XXX O
hypertrophic XXX O
osteoarthropathy XXX O
( XXX O
HOA XXX O
) XXX O
as XXX O
well XXX O
as XXX O
clinical XXX O
and XXX O
laboratory XXX O
features XXX O
of XXX O
rheumatoid XXX O
arthritis XXX O
( XXX O
RA XXX O
) XXX O
. XXX O

Specifically XXX O
, XXX O
this XXX O
study XXX O
determined XXX O
the XXX O
influence XXX O
of XXX O
: XXX O
( XXX O
1 XXX O
) XXX O
an XXX O
awareness XXX O
strategy XXX O
, XXX O
( XXX O
2 XXX O
) XXX O
a XXX O
non-awareness XXX O
strategy XXX O
, XXX O
( XXX O
3 XXX O
) XXX O
a XXX O
Five-Step XXX O
Approach XXX O
strategy XXX O
and XXX O
( XXX O
4 XXX O
) XXX O
a XXX O
control XXX O
condition XXX O
. XXX O

ISIS XXX O
5 XXX O
possibilities XXX O
. XXX O

These XXX O
effects XXX O
were XXX O
abrogated XXX O
by XXX O
co-expression XXX O
of XXX O
kinase-deficient XXX B-GENE
PKC XXX I-GENE
zeta XXX I-GENE
and XXX O
inhibition XXX O
of XXX O
phosphatidylinositol XXX B-GENE
3-kinase XXX I-GENE
p85alpha-p110 XXX B-GENE
by XXX O
wortmannin XXX O
, XXX O
LY294002 XXX O
and XXX O
a XXX O
dominant-negative XXX O
mutant XXX O
of XXX O
p85alpha XXX B-GENE
. XXX O

The XXX O
H2 XXX B-GENE
receptor XXX I-GENE
antagonists XXX O
and XXX O
sucralfate XXX O
cost XXX O
about XXX O
the XXX O
same XXX O
and XXX O
have XXX O
few XXX O
side XXX O
effects XXX O
. XXX O

A XXX O
cDNA XXX O
clone XXX O
was XXX O
identified XXX O
encoding XXX O
a XXX O
second XXX O
GHS-R-related XXX B-GENE
gene XXX I-GENE
( XXX O
GPR39 XXX B-GENE
) XXX O
. XXX O

A XXX O
mutation XXX O
linked XXX O
to XXX O
the XXX O
SOC1 XXX B-GENE
gene XXX I-GENE
, XXX O
previously XXX O
defined XXX O
by XXX O
recessive XXX O
mutations XXX O
that XXX O
suppress XXX O
cbp1 XXX B-GENE
ts XXX I-GENE
alleles XXX I-GENE
and XXX O
stabilize XXX O
many XXX O
mitochondrial XXX O
mRNAs XXX O
, XXX O
was XXX O
also XXX O
isolated XXX O
. XXX O

Intravenous XXX O
amine XXX O
pressor XXX O
tests XXX O
in XXX O
healthy XXX O
volunteers XXX O
. XXX O

During XXX O
transcript XXX O
elongation XXX O
, XXX O
the XXX O
sizes XXX O
of XXX O
the XXX O
DNA XXX O
footprint XXX O
and XXX O
the XXX O
single-stranded XXX O
transcription XXX O
bubble XXX O
vary XXX O
markedly XXX O
among XXX O
transcription XXX O
complexes XXX O
halted XXX O
at XXX O
different XXX O
template XXX O
positions XXX O
. XXX O

Furthermore XXX O
, XXX O
we XXX O
showed XXX O
that XXX O
the XXX O
IL-6 XXX B-GENE
/ XXX I-GENE
interferon XXX I-GENE
gamma XXX I-GENE
( XXX O
IFN XXX B-GENE
gamma XXX I-GENE
) XXX O
response XXX O
element XXX O
in XXX O
the XXX O
IRF-1 XXX B-GENE
promoter XXX I-GENE
( XXX O
IR XXX B-GENE
/ XXX I-GENE
IRF-1 XXX I-GENE
) XXX O
, XXX O
which XXX O
contains XXX O
a XXX O
Stat-binding XXX B-GENE
site XXX I-GENE
and XXX O
an XXX O
adjacent XXX O
CRE-like XXX B-GENE
site XXX I-GENE
, XXX O
also XXX O
makes XXX O
IL-6-induced XXX O
binding XXX O
complexes XXX O
similar XXX O
to XXX O
JRE-IL6-BCs XXX B-GENE
. XXX O

Blood XXX O
glucose XXX O
and XXX O
plasma XXX O
insulin XXX B-GENE
were XXX O
measured XXX O
at XXX O
zero XXX O
time XXX O
and XXX O
then XXX O
at XXX O
15 XXX O
, XXX O
30 XXX O
, XXX O
60 XXX O
, XXX O
90 XXX O
and XXX O
120 XXX O
min XXX O
after XXX O
ingestion XXX O
of XXX O
25 XXX O
g XXX O
glucose XXX O
, XXX O
fructose XXX O
or XXX O
lactose XXX O
, XXX O
or XXX O
30 XXX O
g XXX O
honey XXX O
, XXX O
50 XXX O
g XXX O
white XXX O
bread XXX O
, XXX O
125 XXX O
g XXX O
white XXX O
rice XXX O
or XXX O
potatoes XXX O
, XXX O
150 XXX O
g XXX O
apples XXX O
or XXX O
260 XXX O
g XXX O
carrots XXX O
. XXX O

A XXX O
total XXX O
of XXX O
1060 XXX O
clones XXX O
were XXX O
randomly XXX O
selected XXX O
for XXX O
sequencing XXX O
of XXX O
one XXX O
end XXX O
. XXX O

The XXX O
5' XXX O
region XXX O
shows XXX O
strong XXX O
sequence XXX O
similarity XXX O
to XXX O
Escherichia XXX O
coli XXX O
consensus XXX O
promoters XXX O
and XXX O
ribosome-binding XXX O
sequences XXX O
and XXX O
allows XXX O
high XXX O
levels XXX O
of XXX O
expression XXX O
in XXX O
E XXX O
. XXX O
coli XXX O
. XXX O

This XXX O
DNA XXX O
containing XXX O
promoter XXX O
activity XXX O
has XXX O
been XXX O
sequenced XXX O
in XXX O
its XXX O
entirety XXX O
and XXX O
found XXX O
to XXX O
contain XXX O
multiple XXX O
putative XXX O
regulatory XXX O
sites XXX O
. XXX O

MEF XXX B-GENE
and XXX O
AML1B XXX B-GENE
synergistically XXX O
transactivated XXX O
an XXX O
interleukin XXX B-GENE
3 XXX I-GENE
promoter XXX I-GENE
reporter XXX I-GENE
gene XXX I-GENE
construct XXX I-GENE
, XXX O
yet XXX O
the XXX O
activating XXX O
activity XXX O
of XXX O
MEF XXX B-GENE
was XXX O
abolished XXX O
when XXX O
MEF XXX B-GENE
was XXX O
coexpressed XXX O
with XXX O
AML1 XXX B-GENE
/ XXX I-GENE
ETO XXX I-GENE
. XXX O

Alanine XXX O
substitution XXX O
mutations XXX O
in XXX O
the XXX O
Zta XXX B-GENE
activation XXX I-GENE
domain XXX I-GENE
which XXX O
eliminate XXX O
the XXX O
ability XXX O
of XXX O
Zta XXX B-GENE
to XXX O
stimulate XXX O
the XXX O
D-A XXX B-GENE
complex XXX I-GENE
were XXX O
examined XXX O
. XXX O

MpB XXX B-GENE
GroEL XXX I-GENE
has XXX O
extensive XXX O
sequence XXX O
similarity XXX O
( XXX O
92% XXX O
) XXX O
with XXX O
Escherichia XXX B-GENE
coli XXX I-GENE
GroEL XXX I-GENE
and XXX O
other XXX O
members XXX O
of XXX O
the XXX O
chaperonin-60 XXX B-GENE
family XXX I-GENE
. XXX O

GRP78 XXX B-GENE
, XXX O
a XXX O
molecular XXX O
chaperone XXX O
expressed XXX O
in XXX O
the XXX O
endoplasmic XXX O
reticulum XXX O
, XXX O
is XXX O
a XXX O
"glucose-regulated XXX O
protein" XXX O
induced XXX O
by XXX O
stress XXX O
responses XXX O
that XXX O
deplete XXX O
glucose XXX O
or XXX O
intracisternal XXX O
calcium XXX O
or XXX O
otherwise XXX O
disrupt XXX O
glycoprotein XXX O
trafficking XXX O
. XXX O

A XXX O
highly XXX O
hydrophobic XXX O
sequence XXX O
located XXX O
near XXX O
the XXX O
carboxyl-terminal XXX O
extremity XXX O
of XXX O
the XXX O
molecule XXX O
most XXX O
likely XXX O
constitutes XXX O
the XXX O
anchor XXX O
to XXX O
the XXX O
plasma XXX O
membrane XXX O
. XXX O

Protein XXX B-GENE
C XXX I-GENE
deficiency XXX O
or XXX O
protein XXX B-GENE
S XXX I-GENE
deficiency XXX O
was XXX O
the XXX O
only XXX O
identified XXX O
risk XXX O
factor XXX O
for XXX O
5 XXX O
. XXX O
4% XXX O
( XXX O
2 XXX O
patients XXX O
) XXX O
and XXX O
13 XXX O
. XXX O
5% XXX O
( XXX O
5 XXX O
patients XXX O
) XXX O
, XXX O
respectively XXX O
, XXX O
of XXX O
these XXX O
37 XXX O
children XXX O
. XXX O

The XXX O
results XXX O
showed XXX O
that XXX O
fog XXX O
, XXX O
up XXX O
to XXX O
a XXX O
level XXX O
of XXX O
base XXX O
plus XXX O
fog XXX O
of XXX O
0 XXX O
. XXX O
6 XXX O
optical XXX O
density XXX O
units XXX O
, XXX O
had XXX O
no XXX O
influence XXX O
on XXX O
the XXX O
diagnostic XXX O
accuracy XXX O
in XXX O
the XXX O
absence XXX O
of XXX O
any XXX O
compensation XXX O
. XXX O

Theories XXX O
proffered XXX O
to XXX O
account XXX O
for XXX O
the XXX O
modality XXX O
shift XXX O
effect XXX O
are XXX O
critically XXX O
evaluated XXX O
. XXX O

Conversely XXX O
, XXX O
activated XXX O
glucocorticoid XXX B-GENE
receptors XXX I-GENE
suppressed XXX O
the XXX O
transactivation XXX O
function XXX O
of XXX O
p53 XXX B-GENE
, XXX O
while XXX O
transrepression XXX O
by XXX O
p53 XXX B-GENE
was XXX O
largely XXX O
unaffected XXX O
. XXX O

Molecular XXX O
cloning XXX O
, XXX O
expression XXX O
pattern XXX O
, XXX O
and XXX O
chromosomal XXX O
localization XXX O
of XXX O
human XXX B-GENE
CDKN2D XXX I-GENE
/ XXX I-GENE
INK4d XXX I-GENE
, XXX O
an XXX O
inhibitor XXX O
of XXX O
cyclin XXX B-GENE
D-dependent XXX I-GENE
kinases XXX I-GENE
. XXX O

She XXX O
drank XXX O
alcohol XXX O
once XXX O
or XXX O
twice XXX O
a XXX O
week XXX O
and XXX O
regularly XXX O
took XXX O
an XXX O
analgesic XXX O
preparation XXX O
, XXX O
containing XXX O
aspirin XXX O
and XXX O
acetaminophen XXX O
, XXX O
for XXX O
alleviation XXX O
of XXX O
headaches XXX O
. XXX O

Mutants XXX O
lacking XXX O
the XXX O
3' XXX O
stem-loop XXX O
exhibited XXX O
a XXX O
75% XXX O
reduction XXX O
in XXX O
the XXX O
level XXX O
of XXX O
psaB XXX B-GENE
mRNA XXX O
. XXX O

In XXX O
the XXX O
intact XXX O
animal XXX O
, XXX O
postextrasystolic XXX O
potentiation XXX O
depended XXX O
on XXX O
the XXX O
basic XXX O
pacing XXX O
interval XXX O
, XXX O
t0 XXX O
, XXX O
and XXX O
the XXX O
timing XXX O
of XXX O
the XXX O
extrasystole XXX O
, XXX O
t1 XXX O
: XXX O
when XXX O
t0 XXX O
was XXX O
held XXX O
constant XXX O
and XXX O
t1 XXX O
was XXX O
increased XXX O
, XXX O
potentiation XXX O
decreased XXX O
; XXX O
when XXX O
t1 XXX O
was XXX O
held XXX O
constant XXX O
and XXX O
t0 XXX O
was XXX O
increased XXX O
, XXX O
potentiation XXX O
increased XXX O
. XXX O

We XXX O
have XXX O
cloned XXX O
and XXX O
characterized XXX O
a XXX O
55-kb XXX O
region XXX O
of XXX O
DNA XXX O
surrounding XXX O
HRAS1 XXX B-GENE
. XXX O

The XXX O
most XXX O
striking XXX O
difference XXX O
in XXX O
the XXX O
birch XXX B-GENE
NAD XXX I-GENE
( XXX I-GENE
P XXX I-GENE
) XXX I-GENE
H-NR XXX I-GENE
sequence XXX I-GENE
in XXX O
comparison XXX O
to XXX O
NADH-NR XXX B-GENE
sequences XXX I-GENE
was XXX O
found XXX O
at XXX O
the XXX O
putative XXX O
pyridine XXX O
nucleotide XXX O
binding XXX O
site XXX O
. XXX O

Paxillin XXX B-GENE
acts XXX O
as XXX O
an XXX O
adaptor XXX O
molecule XXX O
in XXX O
integrin XXX B-GENE
signaling XXX O
. XXX O

Two XXX O
rare XXX O
novel XXX O
mutations XXX O
, XXX O
D811N XXX O
in XXX O
exon XXX O
20 XXX O
and XXX O
R835C XXX O
in XXX O
exon XXX O
21 XXX O
, XXX O
were XXX O
identified XXX O
in XXX O
the XXX O
first XXX O
nucleotide-binding XXX O
fold XXX O
( XXX O
NBF XXX O
) XXX O
, XXX O
a XXX O
functionally XXX O
important XXX O
region XXX O
of XXX O
SUR1 XXX B-GENE
, XXX O
in XXX O
one XXX O
patient XXX O
each XXX O
, XXX O
both XXX O
heterozygotes XXX O
. XXX O

Overexpression XXX O
of XXX O
c-Myc XXX B-GENE
in XXX O
serum-starved XXX O
human XXX O
or XXX O
mouse XXX O
embryonic XXX O
cells XXX O
leads XXX O
to XXX O
apoptosis XXX O
which XXX O
is XXX O
significantly XXX O
reduced XXX O
in XXX O
the XXX O
presence XXX O
of XXX O
growth XXX O
factor-containing XXX O
serum XXX O
. XXX O
c-Myc-induced XXX O
apoptosis XXX O
appears XXX O
to XXX O
be XXX O
deficient XXX O
in XXX O
bax-null XXX O
as XXX O
compared XXX O
with XXX O
bax-wild-type XXX B-GENE
mouse XXX O
embryonic XXX O
fibroblasts XXX O
. XXX O

Accurate XXX O
evaluation XXX O
of XXX O
the XXX O
treatment XXX O
results XXX O
in XXX O
unresectable XXX O
lung XXX O
cancer XXX O
patients XXX O
must XXX O
take XXX O
the XXX O
strong XXX O
prognostic XXX O
factors XXX O
into XXX O
account XXX O
. XXX O

Specifically XXX O
, XXX O
they XXX O
were XXX O
performed XXX O
to XXX O
determine XXX O
whether XXX O
detection XXX O
of XXX O
envelope XXX O
phase XXX O
disparity XXX O
was XXX O
consistent XXX O
with XXX O
processing XXX O
within XXX O
a XXX O
single XXX O
channel XXX O
in XXX O
which XXX O
the XXX O
AM XXX O
tones XXX O
were XXX O
simply XXX O
added XXX O
. XXX O

These XXX O
results XXX O
suggested XXX O
that XXX O
BACH1t XXX B-GENE
recruits XXX O
BACH1 XXX B-GENE
to XXX O
the XXX O
nucleus XXX O
through XXX O
BTB XXX B-GENE
domain-mediated XXX O
interaction XXX O
. XXX O

Unilateral XXX O
naris XXX O
occlusion XXX O
and XXX O
the XXX O
rat XXX O
accessory XXX O
olfactory XXX O
bulb XXX O
. XXX O

Acoustic XXX O
transmission XXX O
spectra XXX O
in XXX O
the XXX O
Penrose XXX O
lattice XXX O
. XXX O

The XXX O
latter XXX O
domain XXX O
appears XXX O
to XXX O
be XXX O
involved XXX O
in XXX O
targeting XXX O
Num1p XXX B-GENE
to XXX O
the XXX O
mother XXX O
cell XXX O
cortex XXX O
. XXX O

Carbohydrate XXX O
metabolism XXX O
and XXX O
the XXX O
semen XXX O
profile XXX O
: XXX O
glucose XXX O
, XXX O
insulin XXX B-GENE
, XXX O
and XXX O
sperm XXX O
studies XXX O
. XXX O

The XXX O
active XXX O
open XXX O
reading XXX O
frame XXX O
in XXX O
the XXX O
clone XXX O
maps XXX O
at XXX O
27 XXX O
min XXX O
on XXX O
the XXX O
E XXX O
. XXX O
coli XXX O
chromosome XXX O
and XXX O
is XXX O
identical XXX O
in XXX O
sequence XXX O
to XXX O
a XXX O
wild XXX O
type XXX O
counterpart XXX O
. XXX O

Childhood XXX O
misbehavior XXX O
and XXX O
the XXX O
risk XXX O
of XXX O
injecting XXX O
drug XXX O
use XXX O
. XXX O

Visual XXX O
acuity XXX O
may XXX O
be XXX O
decreased XXX O
by XXX O
transient XXX O
changes XXX O
in XXX O
refractive XXX O
error XXX O
caused XXX O
by XXX O
sulfonamides XXX O
, XXX O
the XXX O
antifungal XXX O
agent XXX O
metronidazole XXX O
, XXX O
thiazide XXX O
diuretics XXX O
, XXX O
and XXX O
carbonic XXX B-GENE
anhydrase XXX I-GENE
inhibitors XXX O
. XXX O

Transcriptional XXX O
analysis XXX O
of XXX O
a XXX O
series XXX O
of XXX O
deletion XXX O
mutants XXX O
of XXX O
the XXX O
gene XXX O
in XXX O
the XXX O
nuclear XXX O
extracts XXX O
prepared XXX O
from XXX O
the XXX O
middle XXX O
silk XXX O
gland XXX O
of XXX O
2-day-old XXX O
fifth XXX O
instar XXX O
larvae XXX O
revealed XXX O
the XXX O
presence XXX O
of XXX O
multiple XXX O
cis-regulatory XXX O
elements XXX O
located XXX O
both XXX O
upstream XXX O
and XXX O
downstream XXX O
of XXX O
the XXX O
initiation XXX O
site XXX O
. XXX O

This XXX O
study XXX O
provides XXX O
direct XXX O
evidence XXX O
that XXX O
USF XXX B-GENE
, XXX O
a XXX O
member XXX O
of XXX O
the XXX O
basic XXX B-GENE
helix-loop-helix XXX I-GENE
leucine XXX I-GENE
zipper XXX I-GENE
family XXX I-GENE
, XXX O
binds XXX O
to XXX O
MLE1 XXX B-GENE
, XXX O
HF-1a XXX B-GENE
, XXX O
and XXX O
PRE XXX B-GENE
B XXX I-GENE
sites XXX I-GENE
and XXX O
suggests XXX O
that XXX O
it XXX O
is XXX O
a XXX O
component XXX O
of XXX O
protein XXX O
complexes XXX O
that XXX O
may XXX O
coordinately XXX O
control XXX O
the XXX O
expression XXX O
of XXX O
MLC-2v XXX B-GENE
and XXX O
alpha-myosin XXX B-GENE
heavy-chain XXX I-GENE
genes XXX I-GENE
. XXX O

We XXX O
report XXX O
a XXX O
case XXX O
of XXX O
pheochromocytoma XXX O
manifesting XXX O
during XXX O
the XXX O
third XXX O
trimester XXX O
of XXX O
pregnancy XXX O
. XXX O

The XXX O
pp90rsk-protein XXX B-GENE
kinase XXX I-GENE
activity XXX O
( XXX O
referred XXX O
to XXX O
as XXX O
rsk-kinase XXX B-GENE
) XXX O
is XXX O
also XXX O
not XXX O
related XXX O
to XXX O
cofactor-dependent XXX O
signal XXX O
transducing XXX O
protein XXX B-GENE
kinases XXX I-GENE
such XXX O
as XXX O
the XXX O
cyclic XXX B-GENE
AMP-dependent XXX I-GENE
protein XXX I-GENE
kinases XXX I-GENE
, XXX O
members XXX O
of XXX O
the XXX O
protein XXX B-GENE
kinase XXX I-GENE
C XXX I-GENE
family XXX I-GENE
, XXX O
or XXX O
other XXX O
Ca2 XXX B-GENE
( XXX I-GENE
+ XXX I-GENE
) XXX I-GENE
-dependent XXX I-GENE
protein XXX I-GENE
kinases XXX I-GENE
. XXX O

The XXX O
beta XXX O
subunit XXX O
of XXX O
the XXX O
Fc XXX B-GENE
epsilon XXX I-GENE
R1 XXX I-GENE
is XXX O
a XXX O
33-kDa XXX O
tyrosine XXX O
phosphoprotein XXX O
, XXX O
but XXX O
the XXX O
p33 XXX B-GENE
Grb2-binding XXX I-GENE
protein XXX I-GENE
described XXX O
in XXX O
the XXX O
present XXX O
report XXX O
is XXX O
not XXX O
the XXX O
Fc XXX B-GENE
epsilon XXX I-GENE
R1 XXX I-GENE
beta XXX I-GENE
chain XXX I-GENE
and XXX O
its XXX O
identity XXX O
is XXX O
unknown XXX O
. XXX O

We XXX O
also XXX O
identify XXX O
several XXX O
regulatory XXX O
domain XXX O
mutants XXX O
in XXX O
which XXX O
Cd XXX O
( XXX O
2+ XXX O
) XXX O
tolerance XXX O
of XXX O
the XXX O
mutant XXX O
strain XXX O
and XXX O
transport XXX O
activity XXX O
of XXX O
the XXX O
protein XXX O
are XXX O
dissociated XXX O
. XXX O

ATX XXX B-GENE
, XXX O
like XXX O
PC-1 XXX B-GENE
, XXX O
was XXX O
found XXX O
to XXX O
hydrolyze XXX O
the XXX O
type XXX B-GENE
I XXX I-GENE
phosphodiesterase XXX I-GENE
substrate XXX O
p-nitrophenyl XXX O
thymidine-5'-monophosphate XXX O
. XXX O

The XXX O
two XXX O
ParA XXX B-GENE
proteins XXX I-GENE
that XXX O
are XXX O
produced XXX O
as XXX O
a XXX O
result XXX O
of XXX O
independent XXX O
translation XXX O
initiation XXX O
at XXX O
two XXX O
different XXX O
start XXX O
codons XXX O
within XXX O
the XXX O
same XXX O
open XXX O
reading XXX O
frame XXX O
were XXX O
overexpressed XXX O
in XXX O
Escherichia XXX O
coli XXX O
and XXX O
partially XXX O
purified XXX O
. XXX O

A XXX O
36-kDa XXX O
protein XXX O
that XXX O
was XXX O
localized XXX O
to XXX O
the XXX O
membrane XXX O
fraction XXX O
was XXX O
detected XXX O
in XXX O
minicells XXX O
containing XXX O
plasmids XXX O
with XXX O
the XXX O
ftsN XXX B-GENE
gene XXX I-GENE
, XXX O
confirming XXX O
that XXX O
FtsN XXX B-GENE
was XXX O
a XXX O
membrane XXX O
protein XXX O
. XXX O

Mutations XXX O
in XXX O
the XXX O
yeast XXX B-GENE
RNA14 XXX I-GENE
and XXX O
RNA15 XXX B-GENE
genes XXX I-GENE
result XXX O
in XXX O
an XXX O
abnormal XXX O
mRNA XXX O
decay XXX O
rate XXX O
; XXX O
sequence XXX O
analysis XXX O
reveals XXX O
an XXX O
RNA-binding XXX O
domain XXX O
in XXX O
the XXX O
RNA15 XXX B-GENE
protein XXX I-GENE
. XXX O

Online XXX O
LATCH XXX O
demonstrates XXX O
a XXX O
shift XXX O
in XXX O
identification XXX O
of XXX O
the XXX O
library XXX O
as XXX O
an XXX O
isolated XXX O
unit XXX O
to XXX O
an XXX O
interactive XXX O
resource XXX O
center XXX O
. XXX O

The XXX O
initial XXX O
translation XXX O
protein XXX O
encoded XXX O
by XXX O
the XXX O
cDNA XXX O
is XXX O
53 XXX O
, XXX O
932 XXX O
kDa XXX O
and XXX O
possesses XXX O
a XXX O
hydrophilic XXX O
amino XXX O
acid XXX O
composition XXX O
with XXX O
glutamic XXX O
acid XXX O
comprising XXX O
22% XXX O
of XXX O
the XXX O
total XXX O
amino XXX O
acid XXX O
residues XXX O
. XXX O

With XXX O
stepwise XXX O
reductions XXX O
in XXX O
flow XXX O
, XXX O
the XXX O
peak XXX O
( XXX O
S XXX O
) XXX O
and XXX O
trough XXX O
( XXX O
D XXX O
) XXX O
points XXX O
of XXX O
the XXX O
maximum XXX O
shifted-frequency XXX O
envelope XXX O
fell XXX O
in XXX O
parallel XXX O
in XXX O
a XXX O
linear XXX O
fashion XXX O
until XXX O
D XXX O
reached XXX O
zero XXX O
. XXX O

Kinetic XXX O
coupling XXX O
and XXX O
requirement XXX O
for XXX O
ATP XXX O
hydrolysis XXX O
. XXX O

Northern XXX O
blot XXX O
analysis XXX O
of XXX O
RNAs XXX O
from XXX O
a XXX O
number XXX O
of XXX O
mouse XXX O
tissues XXX O
reveals XXX O
that XXX O
Atp6i XXX B-GENE
is XXX O
expressed XXX O
predominantly XXX O
in XXX O
osteoclasts XXX O
, XXX O
and XXX O
this XXX O
predominant XXX O
expression XXX O
was XXX O
confirmed XXX O
by XXX O
reverse-transcription XXX O
polymerase XXX O
chain XXX O
reaction XXX O
( XXX O
RT-PCR XXX O
) XXX O
assay XXX O
and XXX O
immunohistochemical XXX O
analysis XXX O
. XXX O

We XXX O
found XXX O
a XXX O
direct XXX O
correlation XXX O
between XXX O
the XXX O
levels XXX O
of XXX O
transcription XXX O
of XXX O
the XXX O
acc XXX B-GENE
genes XXX I-GENE
and XXX O
the XXX O
rate XXX O
of XXX O
cellular XXX O
growth XXX O
. XXX O

A XXX O
lambda XXX O
gt10 XXX O
cDNA XXX O
library XXX O
was XXX O
constructed XXX O
from XXX O
poly XXX O
( XXX O
A+ XXX O
) XXX O
RNA XXX O
of XXX O
young XXX O
green XXX O
leaves XXX O
of XXX O
spinach XXX O
. XXX O

MICs XXX O
of XXX O
four XXX O
antifungal XXX O
agents XXX O
( XXX O
5-fluorocytosine XXX O
, XXX O
miconazole XXX O
, XXX O
ketoconazole XXX O
, XXX O
and XXX O
amphotericin XXX O
B XXX O
) XXX O
for XXX O
84 XXX O
clinical XXX O
isolates XXX O
of XXX O
various XXX O
Candida XXX O
species XXX O
were XXX O
then XXX O
determined XXX O
with XXX O
both XXX O
media XXX O
in XXX O
agar XXX O
dilution XXX O
and XXX O
microtiter XXX O
broth XXX O
dilution XXX O
systems XXX O
. XXX O

Foreign XXX O
profiles XXX O
in XXX O
air XXX O
pollution XXX O
control XXX O
activities XXX O
. XXX O

Release XXX O
of XXX O
this XXX O
selective XXX O
pressure XXX O
, XXX O
however XXX O
, XXX O
gave XXX O
way XXX O
to XXX O
homologous XXX O
resolution XXX O
of XXX O
the XXX O
cointegrate XXX O
structures XXX O
. XXX O

Therefore XXX O
the XXX O
prevalences XXX O
of XXX O
total XXX O
diabetes XXX O
and XXX O
GDM XXX O
were XXX O
1 XXX O
. XXX O
19% XXX O
and XXX O
0 XXX O
. XXX O
56% XXX O
, XXX O
respectively XXX O
. XXX O

These XXX O
introns XXX O
contain XXX O
only XXX O
single XXX O
snoRNA XXX B-GENE
genes XXX I-GENE
and XXX O
their XXX O
processing XXX O
involves XXX O
exonucleolytic XXX O
release XXX O
of XXX O
the XXX O
snoRNA XXX B-GENE
from XXX O
debranched XXX O
intron XXX O
lariats XXX O
. XXX O

Symptoms XXX O
, XXX O
however XXX O
, XXX O
appear XXX O
to XXX O
correlate XXX O
poorly XXX O
with XXX O
oesophagitis XXX O
; XXX O
hence XXX O
, XXX O
severe XXX O
symptoms XXX O
do XXX O
not XXX O
indicate XXX O
there XXX O
is XXX O
greater XXX O
oesophageal XXX O
damage XXX O
. XXX O

Activation XXX O
of XXX O
the XXX O
aboral XXX O
ectoderm-specific XXX B-GENE
Spec2a XXX I-GENE
gene XXX I-GENE
in XXX O
blastula-stage XXX O
sea XXX O
urchin XXX O
embryos XXX O
requires XXX O
an XXX O
upstream XXX O
regulatory XXX O
region XXX O
that XXX O
is XXX O
part XXX O
of XXX O
a XXX O
repetitive XXX O
sequence XXX O
element XXX O
( XXX O
RSR XXX B-GENE
) XXX O
associated XXX O
with XXX O
all XXX O
Spec1 XXX B-GENE
/ XXX I-GENE
Spec2 XXX I-GENE
genes XXX I-GENE
. XXX O

These XXX O
findings XXX O
suggest XXX O
that XXX O
the XXX O
MAP XXX B-GENE
kinase XXX I-GENE
activator XXX I-GENE
/ XXX I-GENE
MAP XXX I-GENE
kinase XXX I-GENE
system XXX I-GENE
may XXX O
be XXX O
the XXX O
downstream XXX O
components XXX O
of XXX O
ras XXX B-GENE
signal XXX I-GENE
transduction XXX I-GENE
pathways XXX I-GENE
. XXX O

The XXX O
present XXX O
research XXX O
evaluated XXX O
the XXX O
possibility XXX O
that XXX O
polyethylene XXX O
glycol XXX O
400 XXX O
( XXX O
PEG XXX O
400 XXX O
) XXX O
might XXX O
be XXX O
efficacious XXX O
, XXX O
toxic XXX O
, XXX O
or XXX O
both XXX O
. XXX O

Keeping XXX O
in XXX O
mind XXX O
the XXX O
limited XXX O
range XXX O
of XXX O
age XXX O
and XXX O
dosages XXX O
, XXX O
advantages XXX O
and XXX O
disadvantages XXX O
of XXX O
the XXX O
drug XXX O
are XXX O
discussed XXX O
, XXX O
comparing XXX O
the XXX O
experimental XXX O
results XXX O
with XXX O
those XXX O
derived XXX O
from XXX O
the XXX O
literature XXX O
. XXX O

Here XXX O
we XXX O
show XXX O
that XXX O
PKC XXX B-GENE
and XXX O
p44 XXX B-GENE
/ XXX I-GENE
p42MAPK XXX I-GENE
signalings XXX O
are XXX O
required XXX O
for XXX O
the XXX O
HBx-induced XXX O
Sp1-mediated XXX O
IGF-II XXX B-GENE
P4 XXX I-GENE
transcriptional XXX O
activity XXX O
since XXX O
( XXX O
i XXX O
) XXX O
PKC XXX B-GENE
activation XXX O
by XXX O
PMA XXX O
or XXX O
PKC XXX B-GENE
expression XXX O
vector XXX O
increases XXX O
Sp1 XXX B-GENE
phosphorylation XXX O
and XXX O
P4 XXX B-GENE
activity XXX O
in XXX O
HBx-transfected XXX O
HepG2 XXX O
cells XXX O
; XXX O
( XXX O
ii XXX O
) XXX O
PKC XXX B-GENE
inhibition XXX O
by XXX O
PKC XXX B-GENE
inhibitor XXX O
Go6976 XXX O
reduces XXX O
Sp1 XXX B-GENE
phosphorylation XXX O
, XXX O
P4 XXX B-GENE
activity XXX O
, XXX O
and XXX O
IGF-II XXX B-GENE
mRNA XXX I-GENE
in XXX O
HBx-transfected XXX O
HepG2 XXX O
cells XXX O
; XXX O
and XXX O
( XXX O
iii XXX O
) XXX O
the XXX O
inhibition XXX O
of XXX O
MEK XXX B-GENE
activation XXX O
by XXX O
U0126 XXX O
reduces XXX O
Sp1 XXX B-GENE
phosphorylation XXX O
, XXX O
P4 XXX B-GENE
activity XXX O
and XXX O
IGF-II XXX B-GENE
mRNA XXX I-GENE
in XXX O
HBx-transfected XXX O
HepG2 XXX O
cells XXX O
. XXX O

We XXX O
evaluated XXX O
the XXX O
likelihood XXX O
of XXX O
tissues XXX O
to XXX O
be XXX O
positive XXX O
for XXX O
carcinoembryonic XXX B-GENE
antigen XXX I-GENE
and XXX O
the XXX O
intensity XXX O
of XXX O
carcinoembryonic XXX B-GENE
antigen XXX I-GENE
staining XXX O
in XXX O
specimens XXX O
of XXX O
villous XXX O
adenomas XXX O
, XXX O
mixed XXX O
polypoid XXX O
villous XXX O
adenomas XXX O
, XXX O
polypoid XXX O
adenomas XXX O
, XXX O
and XXX O
diverticulitis XXX O
using XXX O
the XXX O
peroxidase-antiperoxidase XXX B-GENE
technique XXX O
. XXX O

Serine XXX O
528 XXX O
is XXX O
phosphorylated XXX O
in XXX O
vivo XXX O
in XXX O
several XXX O
cell XXX O
lines XXX O
, XXX O
and XXX O
substitution XXX O
of XXX O
serine XXX O
528 XXX O
to XXX O
alanine XXX O
( XXX O
S528A XXX O
) XXX O
resulted XXX O
in XXX O
an XXX O
increased XXX O
ability XXX O
of XXX O
Myb XXX B-GENE
to XXX O
transactivate XXX O
a XXX O
synthetic XXX O
promoter XXX O
containing XXX O
five XXX O
copies XXX O
of XXX O
the XXX O
mim-1A XXX B-GENE
Myb-responsive XXX I-GENE
element XXX I-GENE
and XXX O
a XXX O
minimal XXX O
herpes XXX B-GENE
tk XXX I-GENE
promoter XXX I-GENE
. XXX O

Teratogenic XXX O
effects XXX O
of XXX O
actinomycin XXX O
D XXX O
in XXX O
rats XXX O
. XXX O

To XXX O
determine XXX O
whether XXX O
food XXX O
and XXX O
/ XXX O
or XXX O
water XXX O
in XXX O
the XXX O
gastrointestinal XXX O
tract XXX O
affects XXX O
restitution XXX O
of XXX O
blood XXX O
volume XXX O
and XXX O
plasma XXX O
protein XXX O
after XXX O
hemorrhage XXX O
, XXX O
fed XXX O
and XXX O
24-h-fasted XXX O
awake XXX O
rats XXX O
received XXX O
a XXX O
20 XXX O
ml XXX O
. XXX O
kg-1 XXX O
x XXX O
3 XXX O
min-1 XXX O
hemorrhage XXX O
, XXX O
and XXX O
restitution XXX O
of XXX O
blood XXX O
volume XXX O
was XXX O
measured XXX O
by XXX O
Evans XXX O
blue XXX O
dye XXX O
and XXX O
dilution XXX O
of XXX O
hematocrit XXX O
. XXX O

Children XXX O
with XXX O
ADD XXX O
showed XXX O
an XXX O
attenuated XXX O
frontal XXX O
CNV-1 XXX O
amplitude XXX O
and XXX O
a XXX O
trend XXX O
towards XXX O
increased XXX O
CNV-1 XXX O
and XXX O
CNV-2 XXX O
occipital XXX O
amplitudes XXX O
. XXX O

This XXX O
study XXX O
confirms XXX O
, XXX O
although XXX O
individual XXX O
reaction XXX O
is XXX O
remarkably XXX O
different XXX O
, XXX O
transportation XXX O
as XXX O
a XXX O
potent XXX O
stressor XXX O
for XXX O
Beagle XXX O
dogs XXX O
. XXX O

Sequence XXX O
analysis XXX O
identified XXX O
some XXX O
of XXX O
these XXX O
cDNA XXX O
clones XXX O
as XXX O
Dlc-1 XXX B-GENE
, XXX O
a XXX O
sequence XXX O
encoding XXX O
a XXX O
small XXX O
, XXX O
9-kDa XXX B-GENE
human XXX I-GENE
homolog XXX I-GENE
of XXX I-GENE
the XXX I-GENE
outer-arm XXX I-GENE
dynein XXX I-GENE
light-chain XXX I-GENE
protein XXX O
. XXX O

The XXX O
ratio XXX O
of XXX O
radioactivity XXX O
in XXX O
tumour XXX O
compared XXX O
with XXX O
normal XXX O
tissue XXX O
( XXX O
T XXX O
: XXX O
N XXX O
ratio XXX O
) XXX O
was XXX O
determined XXX O
after XXX O
simultaneously XXX O
injecting XXX O
microspheres XXX O
into XXX O
the XXX O
portal XXX O
and XXX O
arterial XXX O
circulation XXX O
of XXX O
each XXX O
animal XXX O
. XXX O

Five XXX O
cell XXX O
strains XXX O
of XXX O
human XXX O
dermal XXX O
fibroblasts XXX O
were XXX O
each XXX O
treated XXX O
with XXX O
three XXX O
samples XXX O
of XXX O
burn XXX O
blister XXX O
fluid XXX O
and XXX O
the XXX O
effect XXX O
compared XXX O
with XXX O
the XXX O
rate XXX O
of XXX O
contraction XXX O
of XXX O
free XXX O
floating XXX O
fibroblast XXX O
populated XXX O
collagen XXX B-GENE
lattices XXX O
( XXX O
FPCL XXX O
) XXX O
. XXX O

Infants XXX O
of XXX O
this XXX O
sample XXX O
had XXX O
monocular XXX O
PL XXX O
visual XXX O
acuities XXX O
similar XXX O
to XXX O
those XXX O
established XXX O
by XXX O
McDonald XXX O
et XXX O
al XXX O
. XXX O
in XXX O
a XXX O
laboratory XXX O
setting XXX O
. XXX O

The XXX O
cDNA XXX O
segment XXX O
is XXX O
flanked XXX O
by XXX O
the XXX O
immunoglobulin XXX B-GENE
gene XXX I-GENE
recombination XXX I-GENE
signal XXX I-GENE
sequences XXX I-GENE
so XXX O
that XXX O
the XXX O
cDNA XXX O
segment XXX O
can XXX O
invert XXX O
and XXX O
the XXX O
human XXX B-GENE
IL-2R XXX I-GENE
L XXX I-GENE
chain XXX I-GENE
is XXX O
subsequently XXX O
expressed XXX O
under XXX O
the XXX O
control XXX O
of XXX O
the XXX O
SV40 XXX O
promoter XXX O
. XXX O

Evaluation XXX O
of XXX O
left XXX O
ventricular XXX O
function XXX O
using XXX O
gated XXX O
planar XXX O
myocardial XXX O
imaging XXX O
with XXX O
Tc-99m-MIBI XXX O
. XXX O

Panlobular XXX O
emphysema XXX O
. XXX O

Mutating XXX O
the XXX O
Fcp1p-binding XXX O
motif XXX O
KEFGK XXX B-GENE
in XXX O
the XXX O
RAP74 XXX B-GENE
( XXX O
Tfg1p XXX B-GENE
) XXX O
subunit XXX O
of XXX O
TFIIF XXX B-GENE
to XXX O
EEFGE XXX O
led XXX O
to XXX O
both XXX O
synthetic XXX O
phenotypes XXX O
in XXX O
certain XXX O
fcp1 XXX B-GENE
tfg1 XXX B-GENE
double XXX O
mutants XXX O
and XXX O
a XXX O
reduced XXX O
ability XXX O
of XXX O
Fcp1p XXX B-GENE
to XXX O
activate XXX O
transcription XXX O
when XXX O
it XXX O
is XXX O
artificially XXX O
tethered XXX O
to XXX O
a XXX O
promoter XXX O
. XXX O

Anesthesia XXX O
was XXX O
maintained XXX O
with XXX O
isoflurane XXX O
( XXX O
ISO XXX O
) XXX O
/ XXX O
N2O XXX O
/ XXX O
O2 XXX O
inhalation XXX O
. XXX O

The XXX O
v-Src XXX B-GENE
SH3 XXX B-GENE
domain XXX I-GENE
facilitates XXX O
a XXX O
cell XXX O
adhesion-independent XXX O
association XXX O
with XXX O
focal XXX B-GENE
adhesion XXX I-GENE
kinase XXX I-GENE
. XXX O

In XXX O
both XXX O
cases XXX O
, XXX O
at XXX O
the XXX O
end XXX O
of XXX O
exposure XXX O
the XXX O
same XXX O
level XXX O
of XXX O
blood XXX B-GENE
carboxyhemoglobin XXX I-GENE
( XXX O
COHb XXX B-GENE
) XXX O
( XXX O
about XXX O
50% XXX O
) XXX O
was XXX O
reached XXX O
. XXX O

We XXX O
conclude XXX O
that XXX O
the XXX O
SIMV XXX O
is XXX O
useful XXX O
in XXX O
weaning XXX O
neonates XXX O
from XXX O
the XXX O
ventilator XXX O
. XXX O

Identification XXX O
of XXX O
the XXX O
region XXX O
in XXX O
actin-binding XXX B-GENE
protein XXX I-GENE
that XXX O
binds XXX O
to XXX O
the XXX O
cytoplasmic XXX O
domain XXX O
of XXX O
glycoprotein XXX B-GENE
IBalpha XXX I-GENE
. XXX O

Simple XXX O
models XXX O
of XXX O
bimolecular XXX O
interaction XXX O
did XXX O
not XXX O
fully XXX O
account XXX O
for XXX O
the XXX O
kinetic XXX O
profiles XXX O
obtained XXX O
with XXX O
the XXX O
parental XXX O
antibodies XXX O
and XXX O
the XXX O
hybrids XXX O
, XXX O
and XXX O
this XXX O
complexity XXX O
suggested XXX O
the XXX O
existence XXX O
of XXX O
a XXX O
conformational XXX O
heterogeneity XXX O
in XXX O
these XXX O
molecules XXX O
. XXX O

Histopathological XXX O
examination XXX O
revealed XXX O
dose-related XXX O
proliferation XXX O
of XXX O
type XXX O
II XXX O
pneumocytes XXX O
in XXX O
dams XXX O
and XXX O
proliferation XXX O
of XXX O
interstitial XXX O
cells XXX O
and XXX O
delayed XXX O
septal XXX O
/ XXX O
capillary XXX O
development XXX O
in XXX O
neonates XXX O
. XXX O
( XXX O
ABSTRACT XXX O
TRUNCATED XXX O
AT XXX O
250 XXX O
WORDS XXX O
) XXX O

Little XXX O
is XXX O
known XXX O
about XXX O
the XXX O
mechanism XXX O
, XXX O
but XXX O
the XXX O
availability XXX O
of XXX O
rapid XXX O
facile XXX O
assays XXX O
for XXX O
monitoring XXX O
immunoglobulin XXX B-GENE
hypermutation XXX O
would XXX O
greatly XXX O
aid XXX O
the XXX O
development XXX O
of XXX O
culture XXX O
systems XXX O
for XXX O
hypermutating XXX O
B XXX O
cells XXX O
as XXX O
well XXX O
as XXX O
the XXX O
screening XXX O
for XXX O
individuals XXX O
deficient XXX O
in XXX O
the XXX O
process XXX O
. XXX O

Xenopus XXX B-GENE
Ran-binding XXX I-GENE
protein XXX I-GENE
1 XXX I-GENE
: XXX O
molecular XXX O
interactions XXX O
and XXX O
effects XXX O
on XXX O
nuclear XXX O
assembly XXX O
in XXX O
Xenopus XXX O
egg XXX O
extracts XXX O
. XXX O

Thus XXX O
, XXX O
both XXX O
the XXX O
hyperplasia XXX O
and XXX O
thrombotic XXX O
complications XXX O
which XXX O
often XXX O
follow XXX O
stenting XXX O
might XXX O
be XXX O
minimized XXX O
by XXX O
employing XXX O
gold XXX O
stents XXX O
, XXX O
which XXX O
have XXX O
a XXX O
greater XXX O
capacity XXX O
than XXX O
steel XXX O
in XXX O
supporting XXX O
a XXX O
functional XXX O
neo-endothelium XXX O
. XXX O

The XXX O
Van XXX O
der XXX O
Hoeve's XXX O
syndrome XXX O
lesions XXX O
as XXX O
poorly XXX O
mineralized XXX O
, XXX O
with XXX O
low XXX O
calcium XXX O
salt XXX O
and XXX O
apparent XXX O
increase XXX O
of XXX O
phosphates XXX O
. XXX O

Native XXX O
human XXX B-GENE
fibrinogen XXX I-GENE
was XXX O
brought XXX O
to XXX O
coagulation XXX O
by XXX O
adding XXX O
thrombin XXX B-GENE
. XXX O

Fission XXX B-GENE
yeast XXX I-GENE
mal2+ XXX I-GENE
is XXX O
required XXX O
for XXX O
chromosome XXX O
segregation XXX O
. XXX O

Surprisingly XXX O
, XXX O
the XXX O
Xenopus XXX B-GENE
U7 XXX I-GENE
gene XXX I-GENE
contains XXX O
two XXX O
adjacent XXX O
octamer-binding XXX O
motifs XXX O
located XXX O
only XXX O
12 XXX O
and XXX O
24 XXX O
bp XXX O
upstream XXX O
from XXX O
the XXX O
PSE XXX B-GENE
, XXX O
instead XXX O
of XXX O
the XXX O
usual XXX O
location XXX O
around XXX O
150-200 XXX O
bp XXX O
upstream XXX O
. XXX O

Insulin XXX B-GENE
regulation XXX O
of XXX O
mitogen-activated XXX B-GENE
protein XXX I-GENE
kinase XXX I-GENE
kinase XXX I-GENE
( XXX O
MEK XXX B-GENE
) XXX O
, XXX O
mitogen-activated XXX B-GENE
protein XXX I-GENE
kinase XXX I-GENE
and XXX O
casein XXX B-GENE
kinase XXX I-GENE
in XXX O
the XXX O
cell XXX O
nucleus XXX O
: XXX O
a XXX O
possible XXX O
role XXX O
in XXX O
the XXX O
regulation XXX O
of XXX O
gene XXX O
expression XXX O
. XXX O

Functional XXX O
domains XXX O
of XXX O
c-myc XXX B-GENE
promoter XXX I-GENE
binding XXX I-GENE
protein XXX I-GENE
1 XXX I-GENE
involved XXX O
in XXX O
transcriptional XXX O
repression XXX O
and XXX O
cell XXX O
growth XXX O
regulation XXX O
. XXX O

Our XXX O
results XXX O
indicate XXX O
that XXX O
interaction XXX O
between XXX O
Jak2 XXX B-GENE
and XXX O
PRLR XXX B-GENE
requires XXX O
a XXX O
proline-rich XXX O
sequence XXX O
in XXX O
the XXX O
membrane XXX O
proximal XXX O
region XXX O
of XXX O
the XXX O
receptor XXX O
, XXX O
which XXX O
is XXX O
conserved XXX O
among XXX O
the XXX O
different XXX O
members XXX O
of XXX O
the XXX O
cytokine XXX B-GENE
receptor XXX I-GENE
superfamily XXX I-GENE
. XXX O

Mouse XXX B-GENE
mast XXX I-GENE
cell XXX I-GENE
protease XXX I-GENE
9 XXX I-GENE
, XXX O
a XXX O
novel XXX O
member XXX O
of XXX O
the XXX O
chromosome XXX O
14 XXX O
family XXX O
of XXX O
serine XXX B-GENE
proteases XXX I-GENE
that XXX O
is XXX O
selectively XXX O
expressed XXX O
in XXX O
uterine XXX O
mast XXX O
cells XXX O
. XXX O

Inhibition XXX O
of XXX O
Fusarium XXX O
moniliforme XXX O
var XXX O
. XXX O
subglutinans XXX O
, XXX O
the XXX O
causal XXX O
agent XXX O
of XXX O
pine XXX O
pitch XXX O
canker XXX O
, XXX O
by XXX O
the XXX O
soil XXX O
bacterium XXX O
Arthrobacter XXX O
sp XXX O
. XXX O

We XXX O
conclude XXX O
from XXX O
these XXX O
studies XXX O
that XXX O
CKII XXX B-GENE
may XXX O
act XXX O
as XXX O
a XXX O
positive XXX O
regulator XXX O
of XXX O
myogenesis XXX O
by XXX O
preventing XXX O
E XXX B-GENE
protein XXX I-GENE
homodimers XXX I-GENE
from XXX O
binding XXX O
to XXX O
muscle XXX O
gene XXX O
regulatory XXX O
elements XXX O
. XXX O

We XXX O
have XXX O
cloned XXX O
and XXX O
sequenced XXX O
a XXX O
3574-bp XXX O
Bacillus XXX O
subtilis XXX O
( XXX O
Bs XXX O
) XXX O
DNA XXX O
fragment XXX O
located XXX O
between XXX O
the XXX O
nrdA XXX B-GENE
and XXX O
citB XXX B-GENE
genes XXX I-GENE
at XXX O
about XXX O
169 XXX O
degrees XXX O
on XXX O
the XXX O
chromosome XXX O
. XXX O

At XXX O
the XXX O
basal XXX O
unstimulated XXX O
condition XXX O
, XXX O
Ren1d XXX B-GENE
5' XXX I-GENE
flanking XXX I-GENE
sequence XXX I-GENE
in XXX O
the XXX O
sense XXX O
orientation XXX O
inhibited XXX O
basal XXX O
CAT XXX B-GENE
expression XXX O
from XXX O
the XXX O
TK XXX B-GENE
promoter XXX I-GENE
of XXX O
pUTKAT1 XXX O
, XXX O
whereas XXX O
the XXX O
same XXX O
sequence XXX O
in XXX O
the XXX O
antisense XXX O
orientation XXX O
did XXX O
not XXX O
. XXX O

The XXX O
adeno-associated XXX B-GENE
virus XXX I-GENE
( XXX I-GENE
AAV XXX I-GENE
) XXX I-GENE
rep XXX I-GENE
gene XXX I-GENE
encodes XXX O
four XXX O
proteins XXX O
( XXX O
Rep78 XXX B-GENE
, XXX O
Rep68 XXX B-GENE
, XXX O
Rep52 XXX B-GENE
, XXX O
and XXX O
Rep40 XXX B-GENE
) XXX O
required XXX O
for XXX O
AAV XXX O
DNA XXX O
replication XXX O
and XXX O
AAV XXX O
gene XXX O
regulation XXX O
. XXX O

Patients XXX O
with XXX O
types XXX O
I XXX O
and XXX O
III XXX O
MPGN XXX O
did XXX O
not XXX O
differ XXX O
in XXX O
age XXX O
at XXX O
apparent XXX O
onset XXX O
, XXX O
age XXX O
at XXX O
diagnosis XXX O
, XXX O
or XXX O
interval XXX O
from XXX O
apparent XXX O
onset XXX O
of XXX O
symptoms XXX O
to XXX O
diagnosis XXX O
( XXX O
biopsy XXX O
) XXX O
. XXX O

The XXX O
dnaQ-lacZ XXX B-GENE
and XXX O
the XXX O
rnh-lacZ XXX B-GENE
fused XXX I-GENE
genes XXX I-GENE
were XXX O
constructed XXX O
and XXX O
hybrid XXX O
proteins XXX O
with XXX O
beta-galactosidase XXX B-GENE
activity XXX O
were XXX O
produced XXX O
. XXX O

We XXX O
identified XXX O
a XXX O
protein XXX O
, XXX O
termed XXX O
NFIL-1 XXX B-GENE
beta XXX I-GENE
A XXX I-GENE
( XXX O
NF XXX B-GENE
beta XXX I-GENE
A XXX I-GENE
) XXX O
, XXX O
that XXX O
binds XXX O
to XXX O
a XXX O
highly XXX O
conserved XXX O
12-bp XXX O
DNA XXX O
sequence XXX O
( XXX O
-49 XXX O
to XXX O
-38 XXX O
) XXX O
located XXX O
upstream XXX O
of XXX O
the XXX O
TATA XXX O
box XXX O
motif XXX O
in XXX O
both XXX O
the XXX O
human XXX B-GENE
and XXX I-GENE
murine XXX I-GENE
IL-1 XXX I-GENE
beta XXX I-GENE
genes XXX I-GENE
. XXX O

The XXX O
preferential XXX O
heterodimerization XXX O
of XXX O
USF XXX B-GENE
subunits XXX I-GENE
was XXX O
reproduced XXX O
ex XXX O
vivo XXX O
, XXX O
while XXX O
the XXX O
in XXX O
vitro XXX O
association XXX O
of XXX O
cotranslated XXX O
subunits XXX O
, XXX O
or XXX O
recombinant XXX B-GENE
USF XXX I-GENE
proteins XXX I-GENE
, XXX O
appeared XXX O
to XXX O
be XXX O
random XXX O
. XXX O

In XXX O
all XXX O
trials XXX O
, XXX O
antigen XXX O
challenge XXX O
followed XXX O
1 XXX O
h XXX O
after XXX O
the XXX O
last XXX O
treatment XXX O
. XXX O

Since XXX O
considerable XXX O
variations XXX O
in XXX O
length XXX O
and XXX O
primary XXX O
sequence XXX O
in XXX O
the XXX O
CDR3 XXX B-GENE
( XXX O
complementarity XXX B-GENE
determining XXX I-GENE
region XXX I-GENE
) XXX O
peptides XXX O
of XXX O
all XXX O
the XXX O
H-chains XXX B-GENE
are XXX O
evident XXX O
, XXX O
conservation XXX O
of XXX O
the XXX O
D-region XXX B-GENE
structure XXX O
does XXX O
not XXX O
appear XXX O
to XXX O
be XXX O
necessary XXX O
for XXX O
effective XXX O
hapten XXX O
binding XXX O
. XXX O

The XXX O
sequence XXX O
of XXX O
four XXX O
clones XXX O
was XXX O
sufficient XXX O
to XXX O
construct XXX O
a XXX O
3018-bp XXX B-GENE
BAL XXX I-GENE
cDNA XXX I-GENE
structure XXX O
. XXX O

New-onset XXX O
angina XXX O
preceding XXX O
acute XXX O
myocardial XXX O
infarction XXX O
is XXX O
associated XXX O
with XXX O
improved XXX O
contractile XXX O
recovery XXX O
after XXX O
thrombolysis XXX O
. XXX O

This XXX O
agent XXX O
, XXX O
isolated XXX O
from XXX O
the XXX O
fungus XXX O
Streptomyces XXX O
tsukubaensis XXX O
, XXX O
has XXX O
a XXX O
mechanism XXX O
of XXX O
action XXX O
similar XXX O
to XXX O
that XXX O
of XXX O
cyclosporine XXX O
. XXX O

Arnt3 XXX B-GENE
mRNA XXX I-GENE
was XXX O
expressed XXX O
in XXX O
brain XXX O
, XXX O
skeletal XXX O
muscle XXX O
, XXX O
13 XXX O
. XXX O
5-day XXX O
embryos XXX O
, XXX O
and XXX O
P19 XXX O
cells XXX O
treated XXX O
with XXX O
retinoic XXX O
acid XXX O
. XXX O

Neither XXX O
RD19 XXX B-GENE
nor XXX O
RD21 XXX B-GENE
mRNA XXX I-GENE
synthesis XXX O
was XXX O
responsive XXX O
to XXX O
cold XXX O
or XXX O
to XXX O
heat XXX O
stress XXX O
. XXX O

Diagnostic XXX O
importance XXX O
of XXX O
determining XXX O
the XXX O
complement XXX O
constituents XXX O
in XXX O
children XXX O
with XXX O
autoimmune XXX O
thyroiditis XXX O
. XXX O

Because XXX O
of XXX O
the XXX O
functional XXX O
conservation XXX O
of XXX O
cell XXX O
cycle XXX O
control XXX O
elements XXX O
, XXX O
the XXX O
expression XXX O
of XXX O
a XXX O
vertebrate XXX B-GENE
wee1 XXX I-GENE
or XXX O
mik1 XXX B-GENE
homolog XXX I-GENE
would XXX O
be XXX O
expected XXX O
to XXX O
rescue XXX O
such XXX O
lethal XXX O
mutations XXX O
in XXX O
yeast XXX O
. XXX O

Supplementary XXX O
Phase XXX O
Contraste XXX O
RSE XXX O
( XXX O
"Rapid XXX O
Sequential XXX O
Excitation" XXX O
) XXX O
sequences XXX O
were XXX O
carried XXX O
out XXX O
in XXX O
29 XXX O
patients XXX O
. XXX O

PATIENTS XXX O
AND XXX O
METHODS XXX O
: XXX O
Between XXX O
January XXX O
1992 XXX O
and XXX O
June XXX O
1994 XXX O
at XXX O
St XXX O
. XXX O

It XXX O
is XXX O
concluded XXX O
that XXX O
in XXX O
patients XXX O
with XXX O
first-attack XXX O
genital XXX O
herpes XXX O
, XXX O
the XXX O
type XXX O
of XXX O
HSV XXX O
is XXX O
the XXX O
most XXX O
important XXX O
determinant XXX O
of XXX O
subsequent XXX O
recurrences XXX O
and XXX O
that XXX O
intravenous XXX O
acyclovir XXX O
has XXX O
little XXX O
effect XXX O
on XXX O
subsequent XXX O
recurrences XXX O
. XXX O

The XXX O
amino XXX O
acid XXX O
sequences XXX O
of XXX O
the XXX O
known XXX O
largest XXX O
subunits XXX O
of XXX O
DdRPs XXX B-GENE
from XXX O
different XXX O
species XXX O
contain XXX O
highly XXX O
conserved XXX O
regions XXX O
. XXX O

All XXX O
three XXX O
NR XXX B-GENE
isoforms XXX I-GENE
are XXX O
expressed XXX O
in XXX O
cv XXX O
. XXX O

Facioscapulohumeral XXX O
muscular XXX O
dystrophy XXX O
( XXX O
FSHD XXX O
) XXX O
is XXX O
an XXX O
autosomal XXX O
dominant XXX O
, XXX O
neuromuscular XXX O
disorder XXX O
characterized XXX O
by XXX O
progressive XXX O
weakness XXX O
of XXX O
muscles XXX O
in XXX O
the XXX O
face XXX O
, XXX O
shoulder XXX O
and XXX O
upper XXX O
arm XXX O
. XXX O

Significantly XXX O
lower XXX O
heart XXX O
rate XXX O
reactivity XXX O
and XXX O
significantly XXX O
less XXX O
pronounced XXX O
left XXX O
temporal XXX O
artery XXX O
pulse XXX O
amplitude XXX O
responses XXX O
were XXX O
found XXX O
in XXX O
non-medicated XXX O
TH XXX O
subjects XXX O
than XXX O
in XXX O
controls XXX O
. XXX O

MATERIALS XXX O
AND XXX O
METHODS XXX O
: XXX O
Coronal XXX O
3D XXX O
GRE XXX O
imaging XXX O
was XXX O
used XXX O
to XXX O
study XXX O
the XXX O
volar XXX O
, XXX O
middle XXX O
, XXX O
and XXX O
dorsal XXX O
portions XXX O
of XXX O
the XXX O
SLL XXX O
in XXX O
14 XXX O
patients XXX O
with XXX O
an XXX O
arthroscopically XXX O
normal XXX O
SLL XXX O
and XXX O
in XXX O
five XXX O
cadaveric XXX O
wrists XXX O
that XXX O
had XXX O
a XXX O
normal XXX O
SLL XXX O
proved XXX O
with XXX O
dissection XXX O
. XXX O

Rex-1 XXX B-GENE
, XXX O
a XXX O
gene XXX O
encoding XXX O
a XXX O
transcription XXX O
factor XXX O
expressed XXX O
in XXX O
the XXX O
early XXX O
embryo XXX O
, XXX O
is XXX O
regulated XXX O
via XXX O
Oct-3 XXX B-GENE
/ XXX I-GENE
4 XXX I-GENE
and XXX O
Oct-6 XXX B-GENE
binding XXX O
to XXX O
an XXX O
octamer XXX O
site XXX O
and XXX O
a XXX O
novel XXX O
protein XXX O
, XXX O
Rox-1 XXX B-GENE
, XXX O
binding XXX O
to XXX O
an XXX O
adjacent XXX O
site XXX O
. XXX O

The XXX O
13 XXX O
, XXX O
14-dihydro-15-keto-metabolites XXX O
of XXX O
PGE2 XXX B-GENE
and XXX O
PGF2 XXX B-GENE
alpha XXX I-GENE
had XXX O
no XXX O
statistically XXX O
significant XXX O
antiarrhythmic XXX O
effect XXX O
. XXX O

The XXX O
imino XXX O
proton XXX O
of XXX O
T3 XXX O
in XXX O
the XXX O
O6meG XXX O
. XXX O
T XXX O
12-mer XXX O
and XXX O
G3 XXX O
in XXX O
the XXX O
O6meG XXX O
. XXX O
N XXX O
12-mer XXX O
helix XXX O
, XXX O
which XXX O
are XXX O
associated XXX O
with XXX O
the XXX O
modification XXX O
site XXX O
, XXX O
resonate XXX O
at XXX O
unusually XXX O
high XXX O
field XXX O
( XXX O
8 XXX O
. XXX O
5 XXX O
to XXX O
9 XXX O
. XXX O
0 XXX O
ppm XXX O
) XXX O
compared XXX O
to XXX O
imino XXX O
protons XXX O
in XXX O
Watson-Crick XXX O
base XXX O
pairs XXX O
( XXX O
12 XXX O
. XXX O
5 XXX O
to XXX O
14 XXX O
. XXX O
5 XXX O
ppm XXX O
) XXX O
. XXX O

Update XXX O
: XXX O
diphtheria XXX O
epidemic XXX O
in XXX O
the XXX O
newly XXX O
independent XXX O
states XXX O
of XXX O
the XXX O
former XXX O
USSR XXX O
, XXX O
January XXX O
1995-March XXX O
1996 XXX O
. XXX O

The XXX O
glomerular XXX O
filtration XXX O
rate XXX O
and XXX O
effective XXX O
renal XXX O
plasma XXX O
flow XXX O
were XXX O
determined XXX O
by XXX O
a XXX O
standard XXX O
clearance XXX O
method XXX O
, XXX O
employing XXX O
continuous XXX O
infusion XXX O
of XXX O
inulin XXX O
and XXX O
para-aminohippuric XXX O
acid XXX O
. XXX O

A XXX O
TATA-less XXX O
promoter XXX O
containing XXX O
binding XXX O
sites XXX O
for XXX O
ubiquitous XXX O
transcription XXX O
factors XXX O
mediates XXX O
cell XXX O
type-specific XXX O
regulation XXX O
of XXX O
the XXX O
gene XXX O
for XXX O
transcription XXX B-GENE
enhancer XXX I-GENE
factor-1 XXX I-GENE
( XXX O
TEF-1 XXX B-GENE
) XXX O
. XXX O

Chimeric XXX O
phage-plasmid XXX O
expression XXX O
vectors XXX O
were XXX O
constructed XXX O
from XXX O
pUC18 XXX O
/ XXX O
19 XXX O
plasmids XXX O
by XXX O
cloning XXX O
a XXX O
single-stranded XXX O
DNA XXX O
( XXX O
ssDNA XXX O
) XXX O
origin XXX O
of XXX O
replication XXX O
from XXX O
bacteriophage XXX O
f1 XXX O
and XXX O
inserting XXX O
a XXX O
bacteriophage XXX O
T7 XXX O
promoter XXX O
within XXX O
the XXX O
beta-galactosidase XXX B-GENE
gene XXX I-GENE
. XXX O

Analysis XXX O
of XXX O
the XXX O
E2F1 XXX B-GENE
gene XXX I-GENE
promoter XXX I-GENE
showed XXX O
that XXX O
the XXX O
-146 XXX O
to XXX O
-54 XXX O
region XXX O
was XXX O
required XXX O
for XXX O
E2-responsiveness XXX O
in XXX O
transient XXX O
transfection XXX O
assays XXX O
, XXX O
and XXX O
subsequent XXX O
deletion XXX O
/ XXX O
mutation XXX O
analysis XXX O
showed XXX O
that XXX O
a XXX O
single XXX O
upstream XXX O
GC-rich XXX O
and XXX O
two XXX O
downstream XXX O
CCAAT-binding XXX O
sites XXX O
were XXX O
required XXX O
for XXX O
transactivation XXX O
by XXX O
E2 XXX B-GENE
. XXX O

Most XXX O
smokers XXX O
would XXX O
prefer XXX O
to XXX O
quit XXX O
smoking XXX O
on XXX O
their XXX O
own XXX O
. XXX O

Effect XXX O
of XXX O
separate XXX O
and XXX O
combined XXX O
effects XXX O
of XXX O
plutonium-239 XXX O
, XXX O
hexachlorobutadiene XXX O
and XXX O
tributyl XXX O
phosphate XXX O
on XXX O
the XXX O
thymus XXX O
gland XXX O
of XXX O
rats XXX O
. XXX O

However XXX O
, XXX O
the XXX O
range XXX O
of XXX O
values XXX O
observed XXX O
is XXX O
suggestive XXX O
of XXX O
the XXX O
need XXX O
to XXX O
investigate XXX O
districts XXX O
with XXX O
contrasting XXX O
values XXX O
of XXX O
SYPLR XXX O
with XXX O
respect XXX O
to XXX O
the XXX O
inter-relationships XXX O
between XXX O
sociodemographic XXX O
characteristics XXX O
, XXX O
duration XXX O
of XXX O
symptoms XXX O
, XXX O
clinical XXX O
presentation XXX O
and XXX O
treatment XXX O
efficacy XXX O
. XXX O

Because XXX O
there XXX O
is XXX O
great XXX O
need XXX O
for XXX O
iron XXX O
in XXX O
the XXX O
EPO-stimulated XXX O
erythroid XXX O
progenitors XXX O
, XXX O
it XXX O
is XXX O
essential XXX O
that XXX O
serum XXX B-GENE
ferritin XXX I-GENE
and XXX O
transferrin XXX B-GENE
saturation XXX O
levels XXX O
should XXX O
be XXX O
maintained XXX O
over XXX O
300 XXX O
microg XXX O
/ XXX O
liter XXX O
and XXX O
30% XXX O
, XXX O
respectively XXX O
. XXX O

IST XXX B-GENE
is XXX O
not XXX O
the XXX O
RNA XXX O
target XXX O
( XXX O
TAR XXX O
) XXX O
for XXX O
Tat XXX B-GENE
trans-activation XXX O
; XXX O
however XXX O
, XXX O
because XXX O
it XXX O
relies XXX O
entirely XXX O
on XXX O
cellular XXX O
factors XXX O
for XXX O
activity XXX O
, XXX O
IST XXX B-GENE
may XXX O
serve XXX O
to XXX O
provide XXX O
abundant XXX O
RNA XXX O
targets XXX O
for XXX O
Tat XXX B-GENE
trans-activation XXX O
without XXX O
a XXX O
requirement XXX O
for XXX O
full-length XXX O
viral XXX O
mRNA XXX O
expression XXX O
. XXX O

Immunocytochemical XXX O
analysis XXX O
demonstrated XXX O
the XXX O
presence XXX O
of XXX O
DREF XXX B-GENE
polypeptide XXX I-GENE
in XXX O
nuclei XXX O
after XXX O
the XXX O
eighth XXX O
nuclear XXX O
division XXX O
cycle XXX O
, XXX O
suggesting XXX O
that XXX O
nuclear XXX O
accumulation XXX O
of XXX O
DREF XXX B-GENE
is XXX O
important XXX O
for XXX O
the XXX O
coordinate XXX O
zygotic XXX O
expression XXX O
of XXX O
DNA XXX O
replication-related XXX O
genes XXX O
carrying XXX O
DRE XXX B-GENE
sequences XXX I-GENE
. XXX O

Mean XXX O
growth XXX O
changes XXX O
in XXX O
this XXX O
Class XXX O
II XXX O
sample XXX O
were XXX O
comparable XXX O
to XXX O
those XXX O
previously XXX O
reported XXX O
for XXX O
male XXX O
subjects XXX O
with XXX O
Class XXX O
I XXX O
malocclusions XXX O
over XXX O
the XXX O
same XXX O
age XXX O
period XXX O
, XXX O
suggesting XXX O
a XXX O
similarity XXX O
in XXX O
postpubertal XXX O
development XXX O
between XXX O
these XXX O
two XXX O
groups XXX O
. XXX O

Large XXX O
genomic XXX O
constructs XXX O
integrate XXX O
at XXX O
the XXX O
endogenous XXX O
locus XXX O
by XXX O
homologous XXX O
recombination XXX O
, XXX O
but XXX O
cDNA-derived XXX O
sequences XXX O
lacking XXX O
long XXX O
stretches XXX O
of XXX O
contiguous XXX O
genomic XXX O
DNA XXX O
( XXX O
due XXX O
to XXX O
intron XXX O
excision XXX O
) XXX O
typically XXX O
integrate XXX O
into XXX O
chromosomal XXX O
DNA XXX O
by XXX O
nonhomologous XXX O
recombination XXX O
. XXX O

DNA XXX O
sequencing XXX O
of XXX O
the XXX O
DPM1 XXX B-GENE
gene XXX I-GENE
revealed XXX O
an XXX O
open XXX O
reading XXX O
frame XXX O
of XXX O
801 XXX O
bases XXX O
. XXX O

Unlike XXX O
most XXX O
other XXX O
members XXX O
of XXX O
the XXX O
Bcl-2 XXX B-GENE
family XXX I-GENE
, XXX O
BAD XXX B-GENE
( XXX O
Bcl-xL XXX B-GENE
/ XXX I-GENE
Bcl-2 XXX I-GENE
associated XXX I-GENE
death XXX I-GENE
promoter XXX I-GENE
) XXX O
, XXX O
a XXX O
death XXX B-GENE
enhancer XXX I-GENE
, XXX O
has XXX O
no XXX O
C-terminal XXX O
transmembrane XXX O
domain XXX O
for XXX O
targeting XXX O
to XXX O
the XXX O
outer XXX O
mitochondrial XXX O
membrane XXX O
and XXX O
nuclear XXX O
envelope XXX O
. XXX O

Analysis XXX O
of XXX O
promoter XXX O
and XXX O
androgen XXX O
regulatory XXX O
sequences XXX O
required XXX O
for XXX O
optimal XXX O
transcription XXX O
of XXX O
the XXX O
rat XXX O
androgen-binding XXX B-GENE
protein XXX I-GENE
gene XXX O
. XXX O

These XXX O
results XXX O
suggest XXX O
that XXX O
the XXX O
negative XXX O
inotropic XXX O
action XXX O
of XXX O
nicorandil XXX O
is XXX O
caused XXX O
by XXX O
inhibition XXX O
of XXX O
Ca XXX O
influx XXX O
and XXX O
intracellular XXX O
mobilization XXX O
of XXX O
Ca XXX O
. XXX O

Plasma XXX O
membranes XXX O
of XXX O
cultured XXX O
cells XXX O
contain XXX O
high XXX O
affinity XXX O
receptors XXX O
for XXX O
high XXX O
density XXX O
lipoprotein XXX O
( XXX O
HDL XXX O
) XXX O
that XXX O
appear XXX O
to XXX O
mediate XXX O
removal XXX O
of XXX O
excess XXX O
intracellular XXX O
cholesterol XXX O
. XXX O

We XXX O
have XXX O
addressed XXX O
these XXX O
issues XXX O
by XXX O
reconstituting XXX O
and XXX O
characterizing XXX O
the XXX O
KRAB XXX B-GENE
: XXX O
KAP-1-RBCC XXX B-GENE
interaction XXX O
using XXX O
purified XXX O
components XXX O
. XXX O

Interventions XXX O
aimed XXX O
at XXX O
these XXX O
specific XXX O
mediators XXX O
and XXX O
processes XXX O
may XXX O
be XXX O
successful XXX O
in XXX O
reducing XXX O
the XXX O
very XXX O
significant XXX O
human XXX O
and XXX O
economic XXX O
costs XXX O
of XXX O
vascular XXX O
access XXX O
dysfunction XXX O
. XXX O

Despite XXX O
the XXX O
high XXX O
frequency XXX O
of XXX O
natural XXX O
infection XXX O
, XXX O
the XXX O
seropositive XXX O
rates XXX O
of XXX O
JEV XXX O
antibody XXX O
still XXX O
correlated XXX O
well XXX O
with XXX O
the XXX O
dose XXX O
of XXX O
vaccine XXX O
received XXX O
, XXX O
i XXX O
. XXX O
e XXX O
. XXX O
, XXX O
67% XXX O
( XXX O
1122 XXX O
/ XXX O
1664 XXX O
) XXX O
, XXX O
66% XXX O
( XXX O
65 XXX O
/ XXX O
97 XXX O
) XXX O
, XXX O
33% XXX O
( XXX O
4 XXX O
/ XXX O
12 XXX O
) XXX O
and XXX O
40% XXX O
( XXX O
19 XXX O
/ XXX O
47 XXX O
) XXX O
for XXX O
children XXX O
receiving XXX O
3 XXX O
, XXX O
2 XXX O
, XXX O
1 XXX O
, XXX O
and XXX O
0 XXX O
dose XXX O
of XXX O
JE XXX O
vaccines XXX O
, XXX O
respectively XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
0001 XXX O
Chi-square XXX O
for XXX O
trend XXX O
test XXX O
) XXX O
. XXX O

Isolated XXX O
proteinuria XXX O
( XXX O
i XXX O
. XXX O
e XXX O
. XXX O
without XXX O
hematuria XXX O
and XXX O
/ XXX O
or XXX O
pyuria XXX O
) XXX O
is XXX O
a XXX O
frequent XXX O
finding XXX O
. XXX O

Concomitantly XXX O
, XXX O
p34CDC2 XXX B-GENE
histone XXX B-GENE
H1 XXX I-GENE
kinase XXX B-GENE
activity XXX O
increases XXX O
in XXX O
the XXX O
former XXX O
, XXX O
but XXX O
not XXX O
in XXX O
the XXX O
latter XXX O
cell XXX O
lines XXX O
, XXX O
hence XXX O
suggesting XXX O
a XXX O
role XXX O
for XXX O
this XXX O
protein XXX O
in XXX O
radiation-induced XXX O
cell XXX O
death XXX O
. XXX O

These XXX O
studies XXX O
suggest XXX O
that XXX O
MAPK XXX B-GENE
acts XXX O
by XXX O
stimulating XXX O
AP-1 XXX B-GENE
and XXX O
a XXX O
subsequent XXX O
physical XXX O
and XXX O
functional XXX O
interaction XXX O
of XXX O
AP-1 XXX B-GENE
with XXX O
NF-kappaB XXX B-GENE
, XXX O
resulting XXX O
in XXX O
a XXX O
complex XXX O
that XXX O
synergistically XXX O
transactivates XXX O
the XXX O
HIV-1 XXX B-GENE
LTR XXX I-GENE
. XXX O

Although XXX O
the XXX O
fertility XXX O
decline XXX O
in XXX O
the XXX O
black XXX O
population XXX O
in XXX O
the XXX O
Mississippi XXX O
Delta XXX O
between XXX O
the XXX O
late XXX O
1870's XXX O
and XXX O
early XXX O
1930's XXX O
closely XXX O
paralleled XXX O
that XXX O
of XXX O
the XXX O
national XXX O
black XXX O
population XXX O
, XXX O
it XXX O
rose XXX O
much XXX O
more XXX O
dramatically XXX O
in XXX O
the XXX O
1940's XXX O
and XXX O
1950's XXX O
to XXX O
almost XXX O
1880 XXX O
levels XXX O
. XXX O

During XXX O
a XXX O
28-week XXX O
promotion XXX O
bioassay XXX O
, XXX O
groups XXX O
of XXX O
30 XXX O
male XXX O
CD-1 XXX B-GENE
mice XXX O
were XXX O
treated XXX O
once XXX O
with XXX O
50 XXX O
microliter XXX O
of XXX O
either XXX O
DMBA XXX O
( XXX O
1 XXX O
. XXX O
0 XXX O
mg XXX O
/ XXX O
ml XXX O
) XXX O
or XXX O
acetone XXX O
, XXX O
rested XXX O
for XXX O
2 XXX O
weeks XXX O
, XXX O
and XXX O
then XXX O
treated XXX O
twice XXX O
per XXX O
week XXX O
with XXX O
test XXX O
material XXX O
for XXX O
the XXX O
remaining XXX O
25 XXX O
weeks XXX O
. XXX O

Retransformation XXX O
of XXX O
uvsH77 XXX B-GENE
mutants XXX I-GENE
with XXX O
the XXX O
rescued XXX O
cosmids XXX O
from XXX O
the XXX O
MMS-resistant XXX O
transformants XXX O
resulted XXX O
in XXX O
restoration XXX O
of XXX O
both XXX O
UV XXX O
and XXX O
MMS XXX O
resistance XXX O
to XXX O
wild-type XXX O
levels XXX O
. XXX O

Similar XXX O
mechanisms XXX O
leading XXX O
to XXX O
deregulation XXX O
of XXX O
Tcf XXX B-GENE
target XXX I-GENE
gene XXX I-GENE
activity XXX O
are XXX O
likely XXX O
to XXX O
be XXX O
involved XXX O
in XXX O
melanoma XXX O
and XXX O
other XXX O
forms XXX O
of XXX O
cancer XXX O
. XXX O

In XXX O
the XXX O
United XXX O
States XXX O
high-MW XXX O
HES XXX O
480 XXX O
which XXX O
is XXX O
difficult XXX O
to XXX O
degrade XXX O
is XXX O
most XXX O
frequently XXX O
used XXX O
and XXX O
results XXX O
in XXX O
a XXX O
larger XXX O
in XXX O
vivo XXX O
MW XXX O
and XXX O
subsequent XXX O
decrease XXX O
in XXX O
factor XXX B-GENE
VIII XXX I-GENE
/ XXX I-GENE
von XXX I-GENE
Willebrand XXX I-GENE
factor XXX I-GENE
levels XXX O
. XXX O

However XXX O
, XXX O
there XXX O
was XXX O
a XXX O
difference XXX O
in XXX O
the XXX O
quality XXX O
of XXX O
immunity XXX O
: XXX O
fever XXX O
and XXX O
body XXX O
weight XXX O
loss XXX O
were XXX O
seen XXX O
in XXX O
hamsters XXX O
vaccinated XXX O
with XXX O
the XXX O
killed-toxoplasma XXX O
vaccine XXX O
after XXX O
they XXX O
were XXX O
challenge XXX O
exposed XXX O
with XXX O
T-1 XXX O
strain XXX O
, XXX O
whereas XXX O
these XXX O
changes XXX O
were XXX O
rarely XXX O
seen XXX O
in XXX O
hamsters XXX O
given XXX O
the XXX O
live-toxoplasma XXX O
vaccine XXX O
and XXX O
then XXX O
challenge XXX O
exposed XXX O
with XXX O
RH XXX O
strain XXX O
. XXX O

We XXX O
analyzed XXX O
serial XXX O
biopsy XXX O
specimens XXX O
from XXX O
eight XXX O
patients XXX O
with XXX O
FL XXX O
for XXX O
secondary XXX O
alterations XXX O
of XXX O
the XXX O
rearranged XXX B-GENE
bcl-2 XXX I-GENE
gene XXX I-GENE
in XXX O
the XXX O
breakpoint XXX O
and XXX O
open XXX O
reading XXX O
frame XXX O
( XXX O
ORF XXX O
) XXX O
regions XXX O
. XXX O

Eight XXX O
of XXX O
14 XXX O
infectious XXX O
or XXX O
inflammatory XXX O
lesions XXX O
could XXX O
be XXX O
detected XXX O
in XXX O
the XXX O
early XXX O
scan XXX O
( XXX O
4-6 XXX O
h XXX O
p XXX O
. XXX O
i XXX O
. XXX O
) XXX O
. XXX O

In XXX O
the XXX O
adult XXX O
mouse XXX O
, XXX O
ERR XXX B-GENE
alpha XXX I-GENE
is XXX O
most XXX O
highly XXX O
expressed XXX O
in XXX O
kidney XXX O
, XXX O
heart XXX O
, XXX O
and XXX O
brown XXX O
adipocytes XXX O
, XXX O
tissues XXX O
which XXX O
preferentially XXX O
metabolize XXX O
fatty XXX O
acids XXX O
. XXX O

Antithrombin XXX B-GENE
III XXX I-GENE
in XXX O
hip XXX O
surgery XXX O
. XXX O

The XXX O
pentafluorobenzyl XXX O
derivative XXX O
of XXX O
clonidine XXX O
yields XXX O
an XXX O
intense XXX O
ion XXX O
fragment XXX O
at XXX O
m XXX O
/ XXX O
z XXX O
354 XXX O
, XXX O
and XXX O
the XXX O
lower XXX O
limit XXX O
of XXX O
detection XXX O
is XXX O
0 XXX O
. XXX O
025 XXX O
ng XXX O
/ XXX O
ml XXX O
for XXX O
a XXX O
1-ml XXX O
plasma XXX O
sample XXX O
. XXX O

We XXX O
recently XXX O
reported XXX O
the XXX O
molecular XXX O
cloning XXX O
of XXX O
a XXX O
PL XXX B-GENE
scramblase XXX I-GENE
of XXX O
human XXX O
( XXX O
HuPLSCR1 XXX B-GENE
) XXX O
and XXX O
mouse XXX O
origin XXX O
, XXX O
respectively XXX O
. XXX O

However XXX O
, XXX O
unlike XXX O
Bcl-2 XXX B-GENE
and XXX O
the XXX O
E1B XXX B-GENE
19K XXX I-GENE
proteins XXX I-GENE
, XXX O
which XXX O
completely XXX O
block XXX O
apoptosis XXX O
but XXX O
not XXX O
p53-dependent XXX O
growth XXX O
arrest XXX O
, XXX O
H-ras XXX B-GENE
expression XXX O
permitted XXX O
DNA XXX O
synthesis XXX O
and XXX O
cell XXX O
proliferation XXX O
in XXX O
the XXX O
presence XXX O
of XXX O
high XXX O
levels XXX O
of XXX O
wild-type XXX B-GENE
p53 XXX I-GENE
. XXX O

Of XXX O
these XXX O
proteins XXX O
, XXX O
five XXX O
have XXX O
previously XXX O
been XXX O
shown XXX O
to XXX O
be XXX O
phosphorylated XXX O
during XXX O
mitosis XXX O
( XXX O
epithelial-microtubule XXX B-GENE
associated XXX I-GENE
protein-115 XXX I-GENE
, XXX O
Oct91 XXX B-GENE
, XXX O
Elongation XXX B-GENE
factor XXX I-GENE
1gamma XXX I-GENE
, XXX O
BRG1 XXX B-GENE
and XXX O
Ribosomal XXX B-GENE
protein XXX I-GENE
L18A XXX I-GENE
) XXX O
, XXX O
five XXX O
are XXX O
related XXX O
to XXX O
proteins XXX O
postulated XXX O
to XXX O
have XXX O
roles XXX O
in XXX O
mitosis XXX O
( XXX O
epithelial-microtubule XXX B-GENE
associated XXX I-GENE
protein-115 XXX I-GENE
, XXX O
Schizosaccharomyces XXX B-GENE
pombe XXX I-GENE
Cdc5 XXX I-GENE
, XXX O
innercentrosome XXX B-GENE
protein XXX I-GENE
, XXX O
BRG1 XXX B-GENE
and XXX O
the XXX O
RNA XXX B-GENE
helicase XXX I-GENE
WM6 XXX I-GENE
) XXX O
, XXX O
and XXX O
nine XXX O
are XXX O
related XXX O
to XXX O
transcription XXX O
factors XXX O
( XXX O
BRG1 XXX B-GENE
, XXX O
negative XXX B-GENE
co-factor XXX I-GENE
2alpha XXX I-GENE
, XXX O
Oct91 XXX B-GENE
, XXX O
S XXX O
. XXX O
pombe XXX O
Cdc5 XXX B-GENE
, XXX O
HoxD1 XXX B-GENE
, XXX O
Sox3 XXX B-GENE
, XXX O
Vent2 XXX B-GENE
, XXX O
and XXX O
two XXX O
isoforms XXX O
of XXX O
Xbr1b XXX B-GENE
) XXX O
. XXX O

For XXX O
the XXX O
present XXX O
work XXX O
we XXX O
used XXX O
water XXX O
saturated XXX O
with XXX O
a XXX O
50 XXX O
/ XXX O
50 XXX O
mixture XXX O
of XXX O
H2 XXX O
and XXX O
O2 XXX O
gases XXX O
, XXX O
for XXX O
which XXX O
the XXX O
heat XXX O
defect XXX O
is XXX O
calculated XXX O
to XXX O
be XXX O
-2 XXX O
. XXX O
1% XXX O
. XXX O

Caution XXX O
should XXX O
be XXX O
exercised XXX O
in XXX O
the XXX O
use XXX O
of XXX O
these XXX O
dyes XXX O
for XXX O
lymphograms XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
mutation XXX O
of XXX O
the XXX O
Sp1 XXX B-GENE
site XXX I-GENE
also XXX O
significantly XXX O
reduced XXX O
promoter XXX O
activity XXX O
. XXX O

This XXX O
conclusion XXX O
is XXX O
based XXX O
on XXX O
the XXX O
observations XXX O
of XXX O
the XXX O
immunologic XXX O
changes XXX O
that XXX O
characterize XXX O
the XXX O
acute XXX O
stages XXX O
of XXX O
illness XXX O
as XXX O
well XXX O
as XXX O
on XXX O
the XXX O
demonstrated XXX O
association XXX O
with XXX O
toxin-producing XXX O
bacteria XXX O
in XXX O
the XXX O
pharynx XXX O
and XXX O
gastrointestinal XXX O
tract XXX O
. XXX O

RESULTS XXX O
: XXX O
Sixty XXX O
per XXX O
cent XXX O
of XXX O
African XXX O
Americans XXX O
exposed XXX O
in XXX O
26 XXX O
community XXX O
outbreaks XXX O
were XXX O
TST XXX O
positive XXX O
compared XXX O
to XXX O
only XXX O
40% XXX O
of XXX O
whites XXX O
following XXX O
comparable XXX O
exposures XXX O
. XXX O

To XXX O
address XXX O
mechanisms XXX O
that XXX O
define XXX O
interactions XXX O
of XXX O
Site XXX B-GENE
II XXX I-GENE
regulatory XXX I-GENE
factors XXX I-GENE
with XXX O
this XXX O
cell XXX O
cycle XXX O
control XXX O
element XXX O
, XXX O
we XXX O
have XXX O
investigated XXX O
these XXX O
determinants XXX O
of XXX O
transcriptional XXX O
regulation XXX O
at XXX O
the XXX O
G1 XXX O
/ XXX O
S XXX O
phase XXX O
transition XXX O
in XXX O
FDC-P1 XXX O
hematopoietic XXX O
progenitor XXX O
cells XXX O
. XXX O

Botulinum XXX B-GENE
toxin XXX I-GENE
: XXX O
preferred XXX O
treatment XXX O
for XXX O
hemifacial XXX O
spasm XXX O
. XXX O

Objective XXX O
: XXX O
To XXX O
evaluate XXX O
endometrial XXX O
thickness XXX O
and XXX O
the XXX O
incidence XXX O
of XXX O
uterine XXX O
bleeding XXX O
in XXX O
postmenopausal XXX O
women XXX O
using XXX O
either XXX O
tibolone XXX O
2 XXX O
. XXX O
5 XXX O
mg XXX O
or XXX O
continuous XXX O
combined XXX O
2 XXX O
mg XXX O
estradiol XXX O
and XXX O
1 XXX O
mg XXX O
norethisterone XXX O
acetate XXX O
( XXX O
E+NETA XXX O
) XXX O
daily XXX O
as XXX O
hormone XXX O
replacement XXX O
therapy XXX O
. XXX O

Nerve XXX O
stimulation XXX O
( XXX O
1 XXX O
. XXX O
5-12 XXX O
cycles XXX O
/ XXX O
s XXX O
) XXX O
produced XXX O
frequency-dependent XXX O
reductions XXX O
in XXX O
CBF XXX O
, XXX O
a XXX O
decrease XXX O
of XXX O
50 XXX O
percent XXX O
occurring XXX O
with XXX O
the XXX O
highest XXX O
frequency XXX O
. XXX O

Sibling XXX O
aggregation XXX O
of XXX O
low- XXX O
and XXX O
high-density XXX O
lipoprotein XXX O
cholesterol XXX O
and XXX O
apolipoproteins XXX B-GENE
B XXX I-GENE
and XXX O
A-I XXX B-GENE
levels XXX O
in XXX O
black XXX O
and XXX O
white XXX O
children XXX O
: XXX O
the XXX O
Bogalusa XXX O
Heart XXX O
Study XXX O
. XXX O

Dilutions XXX O
of XXX O
H-2b XXX B-GENE
or XXX O
H-2d XXX B-GENE
NP XXX B-GENE
peptides XXX I-GENE
indicated XXX O
that XXX O
3-4 XXX O
logs XXX O
less XXX O
H-2b XXX B-GENE
NP XXX B-GENE
peptide XXX I-GENE
was XXX O
required XXX O
to XXX O
sensitize XXX O
syngeneic XXX O
target XXX O
cells XXX O
for XXX O
CTL-specific XXX O
lysis XXX O
, XXX O
suggesting XXX O
that XXX O
the XXX O
differing XXX O
affinities XXX O
of XXX O
H-2b XXX B-GENE
and XXX O
H-2d XXX B-GENE
major XXX B-GENE
histocompatibility XXX I-GENE
complex XXX I-GENE
molecules XXX I-GENE
for XXX O
their XXX O
peptides XXX O
likely XXX O
account XXX O
for XXX O
the XXX O
total XXX O
removal XXX O
of XXX O
NP XXX B-GENE
CTL XXX O
in XXX O
the XXX O
H-2b XXX B-GENE
mice XXX O
but XXX O
only XXX O
partial XXX O
removal XXX O
in XXX O
H-2d XXX B-GENE
mice XXX O
made XXX O
to XXX O
express XXX O
thymic XXX B-GENE
NP XXX O
. XXX O

EMSA XXX O
showed XXX O
that XXX O
nuclear XXX O
proteins XXX O
from XXX O
PC12 XXX O
but XXX O
not XXX O
C6 XXX O
or XXX O
Rat2 XXX O
cells XXX O
bind XXX O
the XXX O
CRE XXX B-GENE
as XXX O
a XXX O
complex XXX O
containing XXX O
activating XXX B-GENE
transcription XXX I-GENE
factor XXX I-GENE
( XXX I-GENE
ATF XXX I-GENE
) XXX I-GENE
-4 XXX I-GENE
and XXX O
CCAAT XXX B-GENE
enhancer-binding XXX I-GENE
protein XXX I-GENE
beta XXX I-GENE
, XXX O
while XXX O
both XXX O
PC12 XXX O
and XXX O
C6 XXX O
cell XXX O
nuclear XXX O
extracts XXX O
were XXX O
recruited XXX O
by XXX O
the XXX O
CCAAT-box XXX O
as XXX O
a XXX O
complex XXX O
containing XXX O
nuclear XXX B-GENE
factor XXX I-GENE
Y XXX I-GENE
. XXX O

Auditory-visual XXX O
interaction XXX O
in XXX O
the XXX O
generation XXX O
of XXX O
saccades XXX O
in XXX O
man XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
a XXX O
noncanonical XXX O
C XXX B-GENE
/ XXX I-GENE
EBP-binding XXX I-GENE
site XXX I-GENE
within XXX O
the XXX O
Gadd45gamma XXX B-GENE
promoter XXX I-GENE
where XXX O
C XXX B-GENE
/ XXX I-GENE
EBPbeta XXX I-GENE
and XXX O
C XXX B-GENE
/ XXX I-GENE
EBPdelta XXX I-GENE
could XXX O
bind XXX O
, XXX O
was XXX O
identified XXX O
by XXX O
electrophoretic XXX O
mobility XXX O
shift XXX O
assay XXX O
( XXX O
EMSA XXX O
) XXX O
and XXX O
reporter XXX O
gene XXX O
analysis XXX O
. XXX O

BCR-ABL XXX B-GENE
and XXX O
v-abl XXX B-GENE
oncogenes XXX I-GENE
induce XXX O
distinct XXX O
patterns XXX O
of XXX O
thymic XXX O
lymphoma XXX O
involving XXX O
different XXX O
lymphocyte XXX O
subsets XXX O
. XXX O

DNA XXX O
sequence XXX O
analysis XXX O
has XXX O
confirmed XXX O
that XXX O
this XXX O
mutation XXX O
affects XXX O
the XXX O
C-terminal XXX O
region XXX O
of XXX O
the XXX O
alpha XXX O
subunit XXX O
, XXX O
changing XXX O
a XXX O
leucine XXX O
residue XXX O
at XXX O
position XXX O
290 XXX O
to XXX O
a XXX O
histidine XXX O
( XXX O
rpoAL290H XXX B-GENE
) XXX O
. XXX O

Biometric XXX O
analysis XXX O
of XXX O
intraocular XXX O
lens XXX O
power XXX O
required XXX O
to XXX O
produce XXX O
emmetropia XXX O
: XXX O
results XXX O
of XXX O
450 XXX O
implants XXX O
. XXX O

There XXX O
was XXX O
a XXX O
trend XXX O
toward XXX O
an XXX O
association XXX O
between XXX O
IENF XXX O
and XXX O
sural XXX O
nerve XXX O
unmyelinated XXX O
fiber XXX O
densities XXX O
( XXX O
r XXX O
= XXX O
0 XXX O
. XXX O
32 XXX O
, XXX O
p XXX O
= XXX O
0 XXX O
. XXX O
054 XXX O
) XXX O
. XXX O

CDNA XXX O
cloning XXX O
of XXX O
chick XXX B-GENE
brain XXX I-GENE
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic XXX I-GENE
acid XXX I-GENE
receptors XXX I-GENE
reveals XXX O
conservation XXX O
of XXX O
structure XXX O
, XXX O
function XXX O
and XXX O
post-transcriptional XXX O
processes XXX O
with XXX O
mammalian XXX O
receptors XXX O
. XXX O

The XXX O
apparent XXX O
Kd XXX O
of XXX O
the XXX O
MetRS XXX B-GENE
/ XXX I-GENE
CAU XXX I-GENE
operator XXX I-GENE
complex XXX I-GENE
is XXX O
one XXX O
order XXX O
magnitude XXX O
higher XXX O
than XXX O
that XXX O
of XXX O
the XXX O
ThrRS XXX B-GENE
/ XXX I-GENE
CGU XXX I-GENE
operator XXX I-GENE
complex XXX I-GENE
. XXX O

Bipolarity XXX O
in XXX O
Jungian XXX O
type XXX O
theory XXX O
and XXX O
the XXX O
Myers-Briggs XXX O
Type XXX O
Indicator XXX O
. XXX O

Deletional XXX O
analyses XXX O
of XXX O
VDR XXX B-GENE
indicated XXX O
that XXX O
GRIP1 XXX B-GENE
and XXX O
RAC3 XXX B-GENE
required XXX O
an XXX O
intact XXX O
VDR XXX B-GENE
activation XXX B-GENE
function XXX I-GENE
( XXX I-GENE
AF-2 XXX I-GENE
) XXX I-GENE
domain XXX I-GENE
for XXX O
efficient XXX O
interaction XXX O
as XXX O
well XXX O
as XXX O
additional XXX O
but XXX O
distinct XXX O
regions XXX O
of XXX O
the XXX O
VDR XXX B-GENE
. XXX O

Sequence XXX O
comparisons XXX O
strongly XXX O
suggest XXX O
that XXX O
the XXX O
S27a XXX B-GENE
and XXX O
the XXX O
ubiquitin XXX B-GENE
coding XXX O
sequences XXX O
found XXX O
in XXX O
the XXX O
genome XXX O
of XXX O
CP XXX O
Rit XXX O
were XXX O
both XXX O
derived XXX O
from XXX O
a XXX O
bovine XXX O
mRNA XXX O
encoding XXX O
a XXX O
hybrid XXX O
protein XXX O
with XXX O
the XXX O
structure XXX O
NH2-ubiquitin-S27a-COOH XXX B-GENE
. XXX O

Kinetics XXX O
of XXX O
the XXX O
inhibition XXX O
indicated XXX O
that XXX O
this XXX O
polymerase XXX B-GENE
domain XXX I-GENE
can XXX O
inhibit XXX O
viral XXX O
replication XXX O
only XXX O
during XXX O
the XXX O
preinitiation XXX O
stage XXX O
. XXX O

The XXX O
reduced XXX O
NO XXX O
production XXX O
in XXX O
these XXX O
cells XXX O
was XXX O
associated XXX O
with XXX O
low XXX O
levels XXX O
of XXX O
mRNA XXX O
of XXX O
inducible XXX B-GENE
NO XXX I-GENE
synthetase XXX I-GENE
. XXX O

A XXX O
diagnosis XXX O
of XXX O
MS XXX O
was XXX O
made XXX O
based XXX O
on XXX O
subtle XXX O
neurologic XXX O
signs XXX O
, XXX O
spinal XXX O
fluid XXX O
gamma XXX B-GENE
globulin XXX I-GENE
elevations XXX O
, XXX O
and XXX O
abnormalities XXX O
in XXX O
neuropsychological XXX O
testing XXX O
. XXX O

We XXX O
found XXX O
that XXX O
virulent XXX O
Ngo XXX O
strains XXX O
induce XXX O
phosphorylation XXX O
and XXX O
activation XXX O
of XXX O
JNK XXX B-GENE
but XXX O
not XXX O
of XXX O
p38 XXX B-GENE
kinase XXX I-GENE
. XXX O

In XXX O
terms XXX O
of XXX O
sequence XXX O
repetitions XXX O
, XXX O
seven XXX O
tandemly XXX O
repeated XXX O
copies XXX O
of XXX O
the XXX O
hexanucleotide XXX B-GENE
ATTGTT XXX I-GENE
and XXX O
three XXX O
flanking XXX O
regions XXX O
of XXX O
dyad XXX O
symmetry XXX O
were XXX O
detected XXX O
, XXX O
all XXX O
in XXX O
ORF XXX B-GENE
T3C XXX I-GENE
. XXX O

The XXX O
cDNA XXX O
encoded XXX O
a XXX O
mature XXX O
protein XXX O
of XXX O
240 XXX O
amino XXX O
acids XXX O
, XXX O
including XXX O
a XXX O
29-amino XXX O
acid XXX O
signal XXX O
sequence XXX O
. XXX O

Cdk2 XXX B-GENE
formed XXX O
a XXX O
complex XXX O
with XXX O
cyclin XXX B-GENE
D1 XXX I-GENE
in XXX O
this XXX O
system XXX O
. XXX O

However XXX O
, XXX O
when XXX O
domain XXX O
I XXX O
and XXX O
domain XXX O
II XXX O
were XXX O
linked XXX O
on XXX O
the XXX O
same XXX O
plasmid XXX O
, XXX O
high XXX O
levels XXX O
of XXX O
replication XXX O
were XXX O
observed XXX O
. XXX O

Biological XXX O
properties XXX O
of XXX O
sumithion XXX O
. XXX O

These XXX O
results XXX O
suggest XXX O
that XXX O
different XXX O
models XXX O
of XXX O
intestinal XXX O
ischemia XXX O
have XXX O
different XXX O
cytokine XXX O
profiles XXX O
and XXX O
that XXX O
the XXX O
early XXX O
TNF XXX B-GENE
response XXX O
associated XXX O
with XXX O
SMA XXX O
occlusion XXX O
model XXX O
is XXX O
primarily XXX O
due XXX O
to XXX O
the XXX O
laparotomy XXX O
. XXX O

An XXX O
in XXX O
vitro XXX O
binding XXX O
site XXX O
selection XXX O
procedure XXX O
was XXX O
used XXX O
to XXX O
determine XXX O
DNA XXX O
sequences XXX O
preferentially XXX O
bound XXX O
by XXX O
wild-type XXX B-GENE
HLF XXX I-GENE
and XXX O
chimeric XXX B-GENE
E2A-HLF XXX I-GENE
proteins XXX I-GENE
isolated XXX O
from XXX O
various XXX O
t XXX O
( XXX O
17 XXX O
; XXX O
19 XXX O
) XXX O
-bearing XXX O
leukemias XXX O
. XXX O

The XXX O
science XXX O
of XXX O
tissue XXX O
engineering XXX O
. XXX O

The XXX O
structural XXX O
similarity XXX O
between XXX O
Vav XXX B-GENE
and XXX O
other XXX O
guanine XXX B-GENE
nucleotide XXX I-GENE
exchange XXX I-GENE
factors XXX I-GENE
for XXX O
small XXX B-GENE
GTP-binding XXX I-GENE
proteins XXX I-GENE
, XXX O
together XXX O
with XXX O
the XXX O
recent XXX O
identification XXX O
of XXX O
biochemical XXX O
routes XXX O
specific XXX O
for XXX O
members XXX O
of XXX O
the XXX O
Ras XXX B-GENE
and XXX O
Rho XXX B-GENE
family XXX I-GENE
of XXX O
GTPases XXX B-GENE
, XXX O
prompted XXX O
us XXX O
to XXX O
explore XXX O
whether XXX O
MAPK XXX B-GENE
or XXX O
JNK XXX B-GENE
are XXX O
downstream XXX O
components XXX O
of XXX O
the XXX O
Vav XXX B-GENE
signaling XXX O
pathways XXX O
. XXX O

The XXX O
inferred XXX O
amino XXX O
acid XXX O
sequence XXX O
of XXX O
the XXX O
cyanobacterial XXX B-GENE
HemB XXX I-GENE
protein XXX I-GENE
indicates XXX O
a XXX O
significant XXX O
difference XXX O
in XXX O
the XXX O
metal XXX O
cofactor XXX O
requirement XXX O
from XXX O
the XXX O
higher-plant XXX O
enzymes XXX O
, XXX O
which XXX O
was XXX O
confirmed XXX O
by XXX O
overexpression XXX O
and XXX O
biochemical XXX O
analysis XXX O
. XXX O

Besides XXX O
, XXX O
it XXX O
was XXX O
considered XXX O
that XXX O
the XXX O
NPF XXX O
was XXX O
a XXX O
useful XXX O
tool XXX O
for XXX O
activation XXX O
of XXX O
velopharyngeal XXX O
activity XXX O
by XXX O
way XXX O
of XXX O
visual XXX O
feed-back XXX O
control XXX O
. XXX O

Using XXX O
these XXX O
antibodies XXX O
, XXX O
we XXX O
were XXX O
able XXX O
to XXX O
define XXX O
the XXX O
conditions XXX O
to XXX O
completely XXX O
solubilize XXX O
the XXX O
Cdc25 XXX B-GENE
protein XXX I-GENE
. XXX O

Here XXX O
, XXX O
we XXX O
report XXX O
the XXX O
characterization XXX O
of XXX O
an XXX O
alternatively XXX O
processed XXX O
form XXX O
of XXX O
AFAP-110 XXX B-GENE
that XXX O
encodes XXX O
an XXX O
additional XXX O
258 XXX O
base XXX O
pair XXX O
( XXX O
bp XXX O
) XXX O
of XXX O
open XXX O
reading XXX O
frame XXX O
. XXX O

Dry XXX O
matter XXX O
intake XXX O
, XXX O
apparent XXX O
nutrient XXX O
digestibilities XXX O
, XXX O
serum XXX O
chemistry XXX O
profiles XXX O
, XXX O
sphingolipid XXX O
concentrations XXX O
, XXX O
and XXX O
persistency XXX O
of XXX O
FB1 XXX O
in XXX O
tissues XXX O
were XXX O
evaluated XXX O
. XXX O

2 XXX O
Silastic XXX O
capsules XXX O
, XXX O
each XXX O
containing XXX O
22-23 XXX O
mg XXX O
of XXX O
ethinyl XXX O
estradiol XXX O
, XXX O
were XXX O
inserted XXX O
subcutaneously XXX O
in XXX O
5 XXX O
men XXX O
with XXX O
benign XXX O
prostatic XXX O
hypertrophy XXX O
. XXX O

Sixty-one XXX O
cases XXX O
of XXX O
cholera XXX O
, XXX O
all XXX O
caused XXX O
by XXX O
V XXX O
. XXX O
cholerae XXX O
O1 XXX O
, XXX O
were XXX O
reported XXX O
. XXX O

Multiple XXX O
chemical XXX O
sensitivity XXX O
( XXX O
MCS XXX O
) XXX O
is XXX O
a XXX O
syndrome XXX O
in XXX O
which XXX O
multiple XXX O
symptoms XXX O
reportedly XXX O
occur XXX O
with XXX O
low-level XXX O
chemical XXX O
exposure XXX O
. XXX O

The XXX O
minimum XXX O
and XXX O
essential XXX O
subunits XXX O
for XXX O
RNA XXX O
synthesis XXX O
have XXX O
not XXX O
yet XXX O
been XXX O
identified XXX O
. XXX O

Behind XXX O
the XXX O
ATPase XXX B-GENE
cluster XXX I-GENE
, XXX O
two XXX O
open XXX O
reading XXX O
frames XXX O
were XXX O
detected XXX O
that XXX O
are XXX O
not XXX O
homologous XXX O
to XXX O
any XXX O
known XXX O
chloroplast XXX O
gene XXX O
. XXX O

Induced XXX O
gamma-ray XXX O
spectroscopy XXX O
. XXX O

We XXX O
compared XXX O
the XXX O
efficacy XXX O
and XXX O
costs XXX O
of XXX O
valacyclovir XXX O
in XXX O
preventing XXX O
HSV XXX O
reactivation XXX O
among XXX O
HSV XXX O
seropositive XXX O
autologous XXX O
progenitor XXX O
cell XXX O
transplantation XXX O
( XXX O
APCT XXX O
) XXX O
patients XXX O
with XXX O
historical XXX O
controls XXX O
in XXX O
whom XXX O
intravenous XXX O
acyclovir XXX O
or XXX O
no XXX O
HSV XXX O
prophylaxis XXX O
were XXX O
used XXX O
. XXX O

Frozen XXX O
/ XXX O
thawed XXX O
extensor XXX O
digitorum XXX O
longus XXX O
muscle XXX O
tendon XXX O
units XXX O
had XXX O
significantly XXX O
lower XXX O
values XXX O
for XXX O
load XXX O
to XXX O
failure XXX O
( XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
, XXX O
energy XXX O
absorbed XXX O
to XXX O
failure XXX O
( XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
, XXX O
and XXX O
strain XXX O
at XXX O
failure XXX O
( XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
, XXX O
and XXX O
they XXX O
tended XXX O
to XXX O
fail XXX O
at XXX O
a XXX O
different XXX O
anatomic XXX O
location XXX O
( XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
( XXX O
broadly XXX O
at XXX O
the XXX O
fascia-muscle XXX O
interface XXX O
as XXX O
compared XXX O
with XXX O
horizontally XXX O
at XXX O
the XXX O
musculotendinous XXX O
junction XXX O
) XXX O
than XXX O
fresh XXX O
units XXX O
. XXX O

Latexin XXX B-GENE
, XXX O
a XXX O
carboxypeptidase XXX B-GENE
A XXX I-GENE
inhibitor XXX O
, XXX O
is XXX O
expressed XXX O
in XXX O
a XXX O
cell XXX O
type-specific XXX O
manner XXX O
in XXX O
both XXX O
central XXX O
and XXX O
peripheral XXX O
nervous XXX O
systems XXX O
in XXX O
the XXX O
rat XXX O
. XXX O

The XXX O
Sarns XXX O
51F XXX O
cavoatrial XXX O
cannula XXX O
decompressed XXX O
the XXX O
venous XXX O
system XXX O
as XXX O
efficiently XXX O
as XXX O
the XXX O
double XXX O
caval XXX O
cannulas XXX O
. XXX O

We XXX O
show XXX O
here XXX O
that XXX O
the XXX O
protein XXX B-GENE
kinase XXX I-GENE
MEKK1 XXX B-GENE
can XXX O
induce XXX O
reporter XXX O
gene XXX O
expression XXX O
from XXX O
the XXX O
atrial XXX B-GENE
natriuretic XXX I-GENE
factor XXX I-GENE
( XXX O
ANF XXX B-GENE
) XXX O
promoter XXX O
, XXX O
a XXX O
genetic XXX O
marker XXX O
that XXX O
is XXX O
activated XXX O
during XXX O
in XXX O
vivo XXX O
hypertrophy XXX O
. XXX O

The XXX O
other XXX O
hypoglycaemic XXX O
patient XXX O
showed XXX O
an XXX O
exaggerated XXX O
insulin XXX B-GENE
release XXX O
in XXX O
response XXX O
to XXX O
tolbutamide XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
the XXX O
regulation XXX O
of XXX O
Glvr-1 XXX B-GENE
gene XXX I-GENE
expression XXX O
also XXX O
has XXX O
potential XXX O
applications XXX O
to XXX O
gene XXX O
therapy XXX O
, XXX O
since XXX O
retroviral XXX O
vectors XXX O
carrying XXX O
gibbon XXX B-GENE
ape XXX I-GENE
leukemia XXX I-GENE
virus XXX I-GENE
envelope XXX I-GENE
proteins XXX I-GENE
are XXX O
used XXX O
for XXX O
gene XXX O
delivery XXX O
into XXX O
different XXX O
cell XXX O
types XXX O
. XXX O

The XXX O
motor XXX O
unit XXX O
viewed XXX O
from XXX O
above XXX O
. XXX O
pp XXX O
. XXX O

Thus XXX O
, XXX O
the XXX O
nematode XXX O
genes XXX O
could XXX O
be XXX O
the XXX O
homologs XXX B-GENE
of XXX I-GENE
Hh XXX I-GENE
molecules XXX I-GENE
in XXX O
other XXX O
phyla XXX O
. XXX O

The XXX O
method XXX O
also XXX O
eliminates XXX O
tagging XXX O
of XXX O
venous XXX O
spins XXX O
and XXX O
concern XXX O
about XXX O
asymmetric XXX O
magnetization XXX O
transfer XXX O
effects XXX O
. XXX O

MDS1 XXX B-GENE
/ XXX I-GENE
EVI1 XXX I-GENE
, XXX O
located XXX O
on XXX O
chromosome XXX O
3 XXX O
band XXX O
q26 XXX O
, XXX O
encodes XXX O
a XXX O
zinc-finger XXX O
DNA-binding XXX O
transcription XXX O
activator XXX O
not XXX O
detected XXX O
in XXX O
normal XXX O
hematopoietic XXX O
cells XXX O
but XXX O
expressed XXX O
in XXX O
several XXX O
normal XXX O
tissues XXX O
. XXX O

We XXX O
have XXX O
now XXX O
shown XXX O
that XXX O
in XXX O
vivo XXX O
phosphorylation XXX O
of XXX O
14-3-3 XXX B-GENE
zeta XXX I-GENE
at XXX O
the XXX O
CKIalpha XXX B-GENE
site XXX I-GENE
( XXX I-GENE
Thr-233 XXX I-GENE
) XXX I-GENE
negatively XXX O
regulates XXX O
its XXX O
binding XXX O
to XXX O
c-Raf XXX B-GENE
, XXX O
and XXX O
may XXX O
be XXX O
important XXX O
in XXX O
Raf-mediated XXX O
signal XXX O
transduction XXX O
. XXX O

Fusion XXX O
of XXX O
ubiquitin XXX B-GENE
to XXX O
pADPRP XXX B-GENE
increased XXX O
the XXX O
yield XXX O
of XXX O
pADPRP XXX B-GENE
approximately XXX O
10-fold XXX O
compared XXX O
to XXX O
that XXX O
of XXX O
the XXX O
unfused XXX O
enzyme XXX O
. XXX O

Radiation XXX O
decreased XXX O
the XXX O
levels XXX O
of XXX O
T4 XXX O
and XXX O
T3 XXX O
6 XXX O
h XXX O
and XXX O
72 XXX O
h XXX O
in XXX O
group XXX O
C XXX O
, XXX O
in XXX O
group XXX O
A XXX O
at XXX O
72 XXX O
h XXX O
, XXX O
in XXX O
group XXX O
B XXX O
at XXX O
24 XXX O
h XXX O
postexposure XXX O
. XXX O

Reciprocally XXX O
, XXX O
HMGI-C XXX B-GENE
expression XXX O
also XXX O
coordinately XXX O
enhances XXX O
PIAS3-mediated XXX O
repression XXX O
of XXX O
STAT3-dependent XXX O
transactivation XXX O
. XXX O

The XXX O
determination XXX O
of XXX O
immunoglobulin XXX B-GENE
E XXX I-GENE
( XXX O
IgE XXX B-GENE
) XXX O
antibodies XXX O
by XXX O
one XXX O
of XXX O
several XXX O
laboratory XXX O
tests XXX O
, XXX O
by XXX O
skin-prick XXX O
tests XXX O
or XXX O
by XXX O
appropriate XXX O
challenge XXX O
procedures XXX O
is XXX O
useful XXX O
either XXX O
to XXX O
identify XXX O
atopic XXX O
individuals XXX O
or XXX O
as XXX O
outcome XXX O
predictors XXX O
in XXX O
wheezy XXX O
children XXX O
. XXX O

A XXX O
P22 XXX B-GENE
R17 XXX I-GENE
derivative XXX I-GENE
with XXX O
an XXX O
OcRNA XXX B-GENE
site XXX I-GENE
( XXX O
P22 XXX B-GENE
R17 XXX I-GENE
[ XXX I-GENE
A XXX I-GENE
( XXX I-GENE
-10 XXX I-GENE
) XXX I-GENE
U XXX I-GENE
] XXX I-GENE
) XXX I-GENE
develops XXX O
lytically XXX O
following XXX O
infection XXX O
of XXX O
these XXX O
strains XXX O
. XXX O

Determinants XXX O
of XXX O
recurrent XXX O
ischaemia XXX O
and XXX O
revascularisation XXX O
procedures XXX O
after XXX O
thrombolysis XXX O
with XXX O
recombinant XXX O
tissue XXX B-GENE
plasminogen XXX I-GENE
activator XXX I-GENE
in XXX O
primary XXX O
coronary XXX O
occlusion XXX O
. XXX O

The XXX O
major XXX O
49-kDa XXX O
core XXX O
protein XXX O
in XXX O
the XXX O
liver XXX O
HSPG XXX O
preparation XXX O
was XXX O
found XXX O
to XXX O
be XXX O
reactive XXX O
to XXX O
an XXX O
antibody XXX O
that XXX O
specifically XXX O
recognizes XXX O
the XXX O
cytoplasmic XXX O
domain XXX O
of XXX O
fibroglycan XXX B-GENE
. XXX O

Tumor XXX O
cell XXX O
lines XXX O
transduced XXX O
at XXX O
an XXX O
MOI XXX O
of XXX O
8 XXX O
for XXX O
3 XXX O
days XXX O
led XXX O
to XXX O
> XXX O
90% XXX O
gene XXX O
transfer XXX O
efficiency XXX O
. XXX O

It XXX O
may XXX O
also XXX O
be XXX O
suggested XXX O
that XXX O
particular XXX O
care XXX O
should XXX O
be XXX O
taken XXX O
when XXX O
such XXX O
a XXX O
trans-dominant XXX O
Rev XXX B-GENE
mutant XXX I-GENE
is XXX O
considered XXX O
to XXX O
be XXX O
used XXX O
as XXX O
a XXX O
genetic XXX O
therapy XXX O
against XXX O
HIV-I XXX O
infection XXX O
, XXX O
in XXX O
individuals XXX O
infected XXX O
with XXX O
both XXX O
HIV-I XXX O
and XXX O
HTLV-1 XXX O
. XXX O

These XXX O
results XXX O
provide XXX O
direct XXX O
evidence XXX O
for XXX O
differential XXX O
susceptibility XXX O
to XXX O
endonuclease-mediated XXX O
mRNA XXX O
decay XXX O
resulting XXX O
from XXX O
the XXX O
differential XXX O
affinity XXX O
of XXX O
a XXX O
RNA-binding XXX O
protein XXX O
for XXX O
cis-acting XXX O
stability XXX O
determinants XXX O
. XXX O

LH XXX B-GENE
/ XXX I-GENE
CG XXX I-GENE
receptor XXX I-GENE
activation XXX O
of XXX O
ARNO XXX B-GENE
is XXX O
not XXX O
mediated XXX O
by XXX O
activation XXX O
of XXX O
phosphatidylinositol XXX B-GENE
3-kinase XXX I-GENE
( XXX O
PI XXX B-GENE
3-kinase XXX I-GENE
) XXX O
or XXX O
by XXX O
G XXX B-GENE
protein XXX I-GENE
beta XXX I-GENE
gamma XXX I-GENE
subunits XXX I-GENE
. XXX O

Modulation XXX O
of XXX O
human XXX B-GENE
heat XXX I-GENE
shock XXX I-GENE
factor XXX I-GENE
trimerization XXX O
by XXX O
the XXX O
linker XXX O
domain XXX O
. XXX O

A XXX O
much XXX O
less XXX O
expensive XXX O
solution XXX O
than XXX O
UW XXX O
, XXX O
containing XXX O
only XXX O
K XXX O
( XXX O
+ XXX O
) XXX O
-lactobionate XXX O
, XXX O
KH2PO4 XXX O
, XXX O
MgSO4 XXX O
and XXX O
raffinose XXX O
, XXX O
can XXX O
be XXX O
used XXX O
successfully XXX O
for XXX O
preservation XXX O
of XXX O
rat XXX O
hepatocytes XXX O
for XXX O
24 XXX O
hr XXX O
for XXX O
drug XXX O
transport XXX O
studies XXX O
. XXX O

Rss1p XXX B-GENE
encodes XXX O
a XXX O
novel XXX O
essential XXX O
protein XXX O
of XXX O
538 XXX O
amino XXX O
acids XXX O
, XXX O
which XXX O
contains XXX O
an XXX O
extended XXX O
predicted XXX O
coiled-coil XXX O
domain XXX O
and XXX O
is XXX O
located XXX O
both XXX O
at XXX O
nuclear XXX O
pore XXX O
complexes XXX O
( XXX O
NPCs XXX O
) XXX O
and XXX O
in XXX O
the XXX O
cytoplasm XXX O
. XXX O

In XXX O
the XXX O
absence XXX O
of XXX O
enhancer XXX O
sequences XXX O
, XXX O
the XXX O
adenovirus XXX B-GENE
E1A XXX I-GENE
gene XXX I-GENE
can XXX O
not XXX O
stimulate XXX O
CATase XXX B-GENE
synthesis XXX O
. XXX O

To XXX O
characterize XXX O
the XXX O
gene XXX O
products XXX O
, XXX O
the XXX O
cvaA XXX B-GENE
gene XXX I-GENE
was XXX O
subcloned XXX O
and XXX O
expressed XXX O
under XXX O
the XXX O
control XXX O
of XXX O
T7 XXX B-GENE
RNA XXX I-GENE
polymerase XXX I-GENE
promoter XXX I-GENE
. XXX O

Delayed XXX O
mortality XXX O
of XXX O
mice XXX O
following XXX O
inhalation XXX O
of XXX O
acute XXX O
doses XXX O
of XXX O
CH2O XXX O
, XXX O
SO2Cl2 XXX O
, XXX O
and XXX O
Br2 XXX O
. XXX O

Three XXX O
FGF-AS XXX B-GENE
cDNAs XXX I-GENE
were XXX O
isolated XXX O
; XXX O
the XXX O
full-length XXX B-GENE
FGF-AS XXX I-GENE
mRNA XXX I-GENE
and XXX O
two XXX O
alternative XXX O
splice XXX O
variants XXX O
lacking XXX O
exon XXX O
2 XXX O
or XXX O
exons XXX O
2 XXX O
and XXX O
3 XXX O
of XXX O
the XXX O
FGF-AS XXX B-GENE
sequence XXX I-GENE
. XXX O

The XXX O
authors XXX O
did XXX O
not XXX O
detect XXX O
any XXX O
significant XXX O
correlations XXX O
between XXX O
parameters XXX O
of XXX O
the XXX O
lipids XXX O
of XXX O
bone XXX O
marrow XXX O
and XXX O
leptin XXX B-GENE
levels XXX O
in XXX O
serum XXX O
and XXX O
bone XXX O
marrow XXX O
. XXX O

We XXX O
inserted XXX O
genes XXX O
or XXX O
gene XXX O
segments XXX O
, XXX O
that XXX O
code XXX O
for XXX O
the XXX O
bacterial XXX B-GENE
chloramphenicol XXX I-GENE
acetyltransferase XXX I-GENE
, XXX O
the XXX O
bacterial XXX O
gene XXX O
conferring XXX O
resistance XXX O
against XXX O
hygromycin XXX O
, XXX O
and XXX O
the XXX O
ORF XXX O
E7 XXX B-GENE
of XXX O
the XXX O
human XXX O
papillomavirus XXX O
type XXX O
18 XXX O
into XXX O
these XXX O
vectors XXX O
. XXX O

Troglitazone XXX O
also XXX O
induced XXX O
an XXX O
endogenous XXX B-GENE
PPARgamma XXX I-GENE
target XXX I-GENE
gene XXX I-GENE
in XXX O
T24 XXX O
cells XXX O
, XXX O
adipocyte-type XXX B-GENE
fatty XXX I-GENE
acid XXX I-GENE
binding XXX I-GENE
protein XXX I-GENE
( XXX O
A-FABP XXX B-GENE
) XXX O
, XXX O
the XXX O
expression XXX O
of XXX O
which XXX O
correlates XXX O
with XXX O
bladder XXX O
cancer XXX O
differentiation XXX O
. XXX O

The XXX O
temporal XXX O
and XXX O
static XXX O
plasma XXX O
concentration-effect XXX O
relationships XXX O
were XXX O
evaluated XXX O
by XXX O
pharmacodynamic XXX O
modeling XXX O
and XXX O
linear XXX O
regression XXX O
. XXX O

Bertioga XXX O
( XXX O
Guama XXX O
group XXX O
) XXX O
and XXX O
Anhembi XXX O
( XXX O
Bunyamwera XXX O
group XXX O
) XXX O
, XXX O
two XXX O
new XXX O
arboviruses XXX O
isolated XXX O
in XXX O
Sao XXX O
Paulo XXX O
, XXX O
Brazil XXX O
. XXX O

The XXX O
ADP-ribosylation XXX B-GENE
factor XXX I-GENE
( XXX O
ARF XXX B-GENE
) XXX O
family XXX O
is XXX O
one XXX O
of XXX O
four XXX O
subfamilies XXX O
of XXX O
the XXX O
RAS XXX B-GENE
superfamily XXX I-GENE
of XXX O
low XXX B-GENE
molecular XXX I-GENE
weight XXX I-GENE
GTP-binding XXX I-GENE
proteins XXX I-GENE
( XXX O
G XXX B-GENE
proteins XXX I-GENE
) XXX O
. XXX O

We XXX O
found XXX O
that XXX O
both XXX O
the XXX O
E26 XXX O
virus-encoded XXX O
v-ets XXX B-GENE
and XXX O
the XXX O
myeloid XXX B-GENE
/ XXX I-GENE
B-cell-specific XXX I-GENE
factor XXX I-GENE
PU XXX I-GENE
. XXX I-GENE
1 XXX I-GENE
bind XXX O
efficiently XXX O
to XXX O
this XXX O
site XXX O
in XXX O
vitro XXX O
. XXX O

Cimetidine XXX O
800 XXX O
mg XXX O
given XXX O
at XXX O
night XXX O
is XXX O
as XXX O
effective XXX O
as XXX O
400 XXX O
mg XXX O
twice XXX O
daily XXX O
; XXX O
the XXX O
single XXX O
dose XXX O
regimen XXX O
may XXX O
improve XXX O
patient XXX O
compliance XXX O
, XXX O
thus XXX O
facilitating XXX O
treatment XXX O
. XXX O

A XXX O
developmentally XXX O
modulated XXX O
chromatin XXX O
structure XXX O
at XXX O
the XXX O
mouse XXX B-GENE
immunoglobulin XXX I-GENE
kappa XXX I-GENE
3' XXX I-GENE
enhancer XXX I-GENE
. XXX O

Quantitative XXX O
evaluation XXX O
of XXX O
magneto-optical XXX O
parameters XXX O
is XXX O
necessary XXX O
in XXX O
order XXX O
to XXX O
apply XXX O
scanning XXX O
near-field XXX O
optical XXX O
microscope XXX O
( XXX O
SNOM XXX O
) XXX O
technology XXX O
to XXX O
the XXX O
study XXX O
of XXX O
magnetism XXX O
on XXX O
the XXX O
mesoscopic XXX O
scale XXX O
. XXX O

Identification XXX O
of XXX O
five XXX O
new XXX O
genes XXX O
, XXX O
closely XXX O
related XXX O
to XXX O
the XXX O
interleukin-1beta XXX B-GENE
converting XXX I-GENE
enzyme XXX I-GENE
gene XXX I-GENE
, XXX O
that XXX O
do XXX O
not XXX O
encode XXX O
functional XXX O
proteases XXX B-GENE
. XXX O

Colorectal XXX O
polyps XXX O
should XXX O
be XXX O
removed XXX O
endoscopically XXX O
whenever XXX O
possible XXX O
. XXX O

The XXX O
architecture XXX O
of XXX O
microvasculature XXX O
in XXX O
these XXX O
two XXX O
regions XXX O
was XXX O
also XXX O
examined XXX O
by XXX O
scanning XXX O
electron XXX O
microscopy XXX O
, XXX O
using XXX O
the XXX O
resin XXX O
casting XXX O
method XXX O
. XXX O

Baseline XXX O
measurements XXX O
of XXX O
forced XXX O
expiratory XXX O
volume XXX O
in XXX O
1 XXX O
s XXX O
( XXX O
FEV1 XXX O
) XXX O
, XXX O
specific XXX O
airway XXX O
conductance XXX O
( XXX O
SGaw XXX O
) XXX O
and XXX O
the XXX O
provocative XXX O
dose XXX O
of XXX O
carbachol XXX O
causing XXX O
a XXX O
35% XXX O
reduction XXX O
in XXX O
SGaw XXX O
( XXX O
PD35 XXX O
) XXX O
, XXX O
and XXX O
a XXX O
20% XXX O
reduction XXX O
in XXX O
FEV1 XXX O
( XXX O
PD20 XXX O
) XXX O
were XXX O
established XXX O
on XXX O
entry XXX O
while XXX O
each XXX O
subject XXX O
was XXX O
still XXX O
smoking XXX O
. XXX O

Thus XXX O
, XXX O
the XXX O
screen XXX O
for XXX O
toxic XXX O
p53 XXX B-GENE
mutants XXX I-GENE
in XXX O
yeast XXX O
can XXX O
identify XXX O
novel XXX O
p53 XXX B-GENE
variants XXX O
that XXX O
may XXX O
be XXX O
useful XXX O
in XXX O
dissecting XXX O
p53 XXX B-GENE
regulated XXX O
cellular XXX O
responses XXX O
and XXX O
in XXX O
developing XXX O
p53-based XXX O
cancer XXX O
therapies XXX O
. XXX O

Cases XXX O
of XXX O
lung XXX O
cancer XXX O
with XXX O
intramedullary XXX O
metastasis XXX O
are XXX O
rare XXX O
, XXX O
especially XXX O
those XXX O
diagnosed XXX O
before XXX O
death XXX O
. XXX O

The XXX O
new XXX O
algorithm XXX O
, XXX O
called XXX O
RBI-MAP XXX O
, XXX O
is XXX O
based XXX O
on XXX O
the XXX O
rescaled XXX O
block XXX O
iterative XXX O
EM XXX O
( XXX O
RBI-EM XXX O
) XXX O
algorithm XXX O
. XXX O

These XXX O
results XXX O
suggested XXX O
the XXX O
possibility XXX O
that XXX O
the XXX O
fetus XXX O
played XXX O
some XXX O
role XXX O
in XXX O
the XXX O
production XXX O
of XXX O
E3-16-G XXX O
in XXX O
early XXX O
pregnancy XXX O
. XXX O

PARTICIPANTS XXX O
: XXX O
Convenience XXX O
sample XXX O
of XXX O
ambulatory XXX O
outpatients XXX O
with XXX O
hereditary XXX O
motor XXX O
and XXX O
sensory XXX O
neuropathy XXX O
, XXX O
type XXX O
I XXX O
( XXX O
n XXX O
= XXX O
9 XXX O
) XXX O
, XXX O
myotonic XXX O
muscular XXX O
dystrophy XXX O
( XXX O
n XXX O
= XXX O
10 XXX O
) XXX O
, XXX O
and XXX O
able-bodied XXX O
controls XXX O
( XXX O
n XXX O
= XXX O
11 XXX O
) XXX O
. XXX O

Respiratory XXX O
interaction XXX O
after XXX O
spinal XXX O
anesthesia XXX O
and XXX O
sedation XXX O
with XXX O
midazolam XXX O
. XXX O

The XXX O
percentages XXX O
of XXX O
formed XXX O
cysts XXX O
and XXX O
growth XXX O
rates XXX O
were XXX O
monthly XXX O
estimated XXX O
and XXX O
analyzed XXX O
rhythmometrically XXX O
by XXX O
cosinor XXX O
for XXX O
5 XXX O
clonal XXX O
cultures XXX O
of XXX O
Scripsiella XXX O
trochoidea XXX O
Stein XXX O
grown XXX O
for XXX O
2 XXX O
years XXX O
under XXX O
laboratory XXX O
conditions XXX O
, XXX O
rended XXX O
as XXX O
constant XXX O
as XXX O
possible XXX O
from XXX O
the XXX O
view XXX O
point XXX O
of XXX O
environmental XXX O
temperature XXX O
( XXX O
24 XXX O
+ XXX O
/ XXX O
- XXX O
1 XXX O
degree XXX O
C XXX O
) XXX O
, XXX O
lighting XXX O
( XXX O
25 XXX O
microEin XXX O
m-2 XXX O
s-1 XXX O
) XXX O
, XXX O
and XXX O
artificial XXX O
seawater XXX O
. XXX O

Antenatal XXX O
diagnosis XXX O
of XXX O
haematological XXX O
disorders--'1978' XXX O
. XXX O

The XXX O
results XXX O
point XXX O
to XXX O
the XXX O
effectiveness XXX O
of XXX O
the XXX O
educational XXX O
intervention XXX O
. XXX O

The XXX O
novel XXX O
protein XXX B-GENE
kinases XXX I-GENE
, XXX O
c-Jun XXX B-GENE
NH2-terminal XXX I-GENE
kinases XXX I-GENE
( XXX O
JNKs XXX B-GENE
) XXX O
/ XXX B-GENE
stress-activated XXX I-GENE
protein XXX I-GENE
kinases XXX I-GENE
, XXX O
are XXX O
also XXX O
activated XXX O
by XXX O
TNF-alpha XXX B-GENE
, XXX O
IL-1 XXX B-GENE
, XXX O
and XXX O
CD28 XXX B-GENE
costimulation XXX O
. XXX O

Descriptions XXX O
of XXX O
this XXX O
locus XXX O
would XXX O
allow XXX O
comparison XXX O
with XXX O
functionally XXX O
relevant XXX O
molecular XXX O
genetic XXX O
features XXX O
of XXX O
other XXX O
species' XXX O
homologous XXX O
loci XXX O
including XXX O
the XXX O
single-copy XXX O
equid XXX B-GENE
LH XXX I-GENE
/ XXX I-GENE
CGbeta XXX I-GENE
gene XXX I-GENE
and XXX O
the XXX O
primate XXX B-GENE
LHbeta-CGbeta XXX I-GENE
gene XXX I-GENE
cluster XXX I-GENE
locus XXX I-GENE
. XXX O

In XXX O
contrast XXX O
to XXX O
the XXX O
morphological XXX O
criteria XXX O
, XXX O
the XXX O
few XXX O
data XXX O
available XXX O
from XXX O
recent XXX O
studies XXX O
at XXX O
the XXX O
genetic XXX O
level XXX O
have XXX O
suggested XXX O
that XXX O
EPVs XXX O
infecting XXX O
different XXX O
insect XXX O
orders XXX O
are XXX O
phylogenetically XXX O
distant XXX O
. XXX O

To XXX O
assess XXX O
the XXX O
effects XXX O
of XXX O
alveolar XXX O
hypoxia XXX O
and XXX O
angiotensin XXX B-GENE
II XXX I-GENE
infusion XXX O
on XXX O
distribution XXX O
of XXX O
blood XXX O
flow XXX O
to XXX O
the XXX O
lung XXX O
we XXX O
performed XXX O
perfusion XXX O
lung XXX O
scans XXX O
on XXX O
anesthetized XXX O
mechanically XXX O
ventilated XXX O
lambs XXX O
. XXX O

Its XXX O
clinical XXX O
and XXX O
histopathologic XXX O
characteristics XXX O
. XXX O

Both XXX O
promoters XXX O
lack XXX O
a XXX O
TATA XXX O
box XXX O
, XXX O
and XXX O
Pint XXX B-GENE
belongs XXX O
to XXX O
the XXX O
MED-1 XXX B-GENE
class XXX O
of XXX O
promoters XXX O
, XXX O
which XXX O
initiate XXX O
transcription XXX O
at XXX O
multiple XXX O
sites XXX O
. XXX O

A XXX O
1 XXX B-GENE
. XXX I-GENE
5-kb XXX I-GENE
HindIII XXX I-GENE
genomic XXX I-GENE
fragment XXX I-GENE
carrying XXX I-GENE
the XXX I-GENE
vspA XXX I-GENE
gene XXX I-GENE
from XXX O
M XXX O
. XXX O
bovis XXX O
PG45 XXX O
was XXX O
cloned XXX O
and XXX O
sequenced XXX O
. XXX O

Cerebrospinal XXX O
fluid XXX O
transferrin XXX B-GENE
II XXX I-GENE
studies XXX O
in XXX O
ischemic XXX O
disorders XXX O
of XXX O
the XXX O
central XXX O
nervous XXX O
system XXX O
. XXX O

These XXX O
results XXX O
suggest XXX O
that XXX O
Cdc42p XXX B-GENE
is XXX O
in XXX O
fact XXX O
required XXX O
for XXX O
pheromone XXX O
response XXX O
and XXX O
that XXX O
interaction XXX O
with XXX O
the XXX O
PAK XXX B-GENE
Ste20p XXX B-GENE
is XXX O
critical XXX O
for XXX O
that XXX O
role XXX O
. XXX O

C XXX O
. XXX O
elegans XXX O
embryogenesis XXX O
begins XXX O
with XXX O
a XXX O
stereotyped XXX O
sequence XXX O
of XXX O
asymmetric XXX O
cell XXX O
divisions XXX O
that XXX O
are XXX O
largely XXX O
responsible XXX O
for XXX O
establishing XXX O
the XXX O
nematode XXX O
body XXX O
plan XXX O
. XXX O

The XXX O
gene XXX O
encoding XXX O
IFN-gamma XXX B-GENE
was XXX O
previously XXX O
found XXX O
to XXX O
contain XXX O
an XXX O
intronic XXX O
enhancer XXX O
element XXX O
that XXX O
was XXX O
not XXX O
tissue-specific XXX O
in XXX O
its XXX O
activity XXX O
, XXX O
despite XXX O
the XXX O
restricted XXX O
expression XXX O
of XXX O
the XXX O
intact XXX O
IFN-gamma-encoding XXX B-GENE
gene XXX I-GENE
. XXX O

The XXX O
HBP XXX B-GENE
gene XXX I-GENE
is XXX O
composed XXX O
of XXX O
eight XXX O
exons XXX O
covering XXX O
19 XXX O
. XXX O
5 XXX O
kb XXX O
on XXX O
the XXX O
short XXX O
arm XXX O
of XXX O
chromosome XXX O
4 XXX O
. XXX O

Bilateral XXX O
Charnley XXX O
arthroplasty XXX O
as XXX O
a XXX O
single XXX O
procedure XXX O
. XXX O

It XXX O
is XXX O
likely XXX O
that XXX O
the XXX O
sequence XXX O
similarities XXX O
reflect XXX O
a XXX O
common XXX O
molecular XXX O
architecture XXX O
of XXX O
the XXX O
two XXX O
heme XXX O
binding XXX O
sites XXX O
and XXX O
of XXX O
a XXX O
copper XXX O
binding XXX O
site XXX O
in XXX O
these XXX O
enzymes XXX O
. XXX O

Five XXX O
of XXX O
the XXX O
PDP1 XXX B-GENE
isoforms XXX I-GENE
differ XXX O
by XXX O
the XXX O
substitution XXX O
or XXX O
insertion XXX O
of XXX O
amino XXX O
acids XXX O
at XXX O
or XXX O
near XXX O
the XXX O
N-terminal XXX O
of XXX O
the XXX O
protein XXX O
. XXX O

However XXX O
, XXX O
reoperation XXX O
for XXX O
bulky XXX O
cervical XXX O
disease XXX O
( XXX O
group XXX O
3 XXX O
) XXX O
rarely XXX O
results XXX O
in XXX O
normal XXX O
calcitonin XXX B-GENE
levels XXX O
and XXX O
is XXX O
associated XXX O
with XXX O
a XXX O
high XXX O
incidence XXX O
of XXX O
permanent XXX O
hypoparathyroidism XXX O
. XXX O

In XXX O
the XXX O
long XXX O
term XXX O
, XXX O
questions XXX O
still XXX O
remain XXX O
about XXX O
whether XXX O
pre-dialysis XXX O
rHu XXX B-GENE
EPO XXX I-GENE
either XXX O
speeds XXX O
up XXX O
or XXX O
delays XXX O
the XXX O
onset XXX O
of XXX O
dialysis XXX O
. XXX O

T XXX O
. XXX O
, XXX O
Mahasneh XXX O
, XXX O
A XXX O
. XXX O
, XXX O
and XXX O
Cote XXX O
, XXX O
G XXX O
. XXX O

In XXX O
both XXX O
cities XXX O
, XXX O
HTLV-I XXX O
/ XXX O
II XXX O
prevalence XXX O
increased XXX O
significantly XXX O
with XXX O
age XXX O
, XXX O
and XXX O
the XXX O
New XXX O
Orleans XXX O
age- XXX O
and XXX O
sex-adjusted XXX O
HTLV-I XXX O
/ XXX O
II XXX O
prevalence XXX O
was XXX O
significantly XXX O
higher XXX O
than XXX O
that XXX O
of XXX O
Baltimore XXX O
( XXX O
P XXX O
less XXX O
than XXX O
. XXX O
001 XXX O
) XXX O
. XXX O

As XXX O
well XXX O
, XXX O
further XXX O
deletion XXX O
of XXX O
the XXX O
promoter XXX O
region XXX O
to XXX O
nucleotide XXX O
-110 XXX O
, XXX O
which XXX O
contains XXX O
only XXX O
one XXX O
SF-1 XXX B-GENE
binding XXX I-GENE
site XXX I-GENE
, XXX O
still XXX O
retained XXX O
the XXX O
ability XXX O
to XXX O
respond XXX O
to XXX O
exogenous XXX O
SF-1 XXX B-GENE
. XXX O

Integrin XXX B-GENE
adhesion XXX I-GENE
receptors XXX I-GENE
transduce XXX O
signals XXX O
that XXX O
control XXX O
complex XXX O
cell XXX O
functions XXX O
which XXX O
require XXX O
the XXX O
regulation XXX O
of XXX O
gene XXX O
expression XXX O
, XXX O
such XXX O
as XXX O
proliferation XXX O
, XXX O
differentiation XXX O
and XXX O
survival XXX O
. XXX O

Structural XXX O
characteristics XXX O
of XXX O
the XXX O
erythrocyte XXX O
membrane XXX O
, XXX O
peroxidation XXX O
processes XXX O
and XXX O
antioxidant XXX O
function XXX O
in XXX O
children XXX O
with XXX O
diffuse XXX O
glomerulonephritis XXX O
. XXX O

In XXX O
the XXX O
tissues XXX O
tested XXX O
, XXX O
except XXX O
brain XXX O
, XXX O
the XXX O
message XXX O
for XXX O
CLIP-170 XXX B-GENE
was XXX O
more XXX O
abundant XXX O
than XXX O
that XXX O
for XXX O
Restin XXX B-GENE
. XXX O

Promoter XXX O
elements XXX O
include XXX O
an XXX O
atypical XXX O
TATA XXX O
box XXX O
( XXX O
GTTA XXX O
) XXX O
, XXX O
one XXX O
CCAAT XXX O
box XXX O
much XXX O
further XXX O
from XXX O
the XXX O
initiation XXX O
site XXX O
, XXX O
three XXX O
reverse XXX O
compliments XXX O
of XXX O
CCAAT XXX O
( XXX O
ATTGG XXX O
) XXX O
, XXX O
and XXX O
two XXX O
pyrimidine-rich XXX O
nucleotide XXX O
stretches XXX O
. XXX O

M XXX O
. XXX O
M XXX O
. XXX O
C XXX O
. XXX O
was XXX O
used XXX O
for XXX O
2 XXX O
. XXX O
5 XXX O
minutes XXX O
in XXX O
44 XXX O
cases XXX O
( XXX O
20 XXX O
HR XXX O
patients XXX O
, XXX O
24 XXX O
LR XXX O
patients XXX O
) XXX O
, XXX O
and XXX O
for XXX O
5 XXX O
minutes XXX O
in XXX O
66 XXX O
cases XXX O
( XXX O
46 XXX O
HR XXX O
patients XXX O
, XXX O
20 XXX O
LR XXX O
patients XXX O
) XXX O
. XXX O

Transcription XXX O
of XXX O
the XXX O
vascular XXX B-GENE
cell XXX I-GENE
adhesion XXX I-GENE
molecule XXX I-GENE
1 XXX I-GENE
( XXX O
VCAM-1 XXX B-GENE
) XXX O
gene XXX O
in XXX O
endothelial XXX O
cells XXX O
is XXX O
induced XXX O
by XXX O
lipopolysaccharide XXX O
and XXX O
the XXX O
inflammatory XXX O
cytokines XXX B-GENE
interleukin-1 XXX I-GENE
beta XXX I-GENE
and XXX O
tumor XXX B-GENE
necrosis XXX I-GENE
factor XXX I-GENE
alpha XXX I-GENE
( XXX O
TNF-alpha XXX B-GENE
) XXX O
. XXX O

In XXX O
HCMV XXX O
( XXX O
Towne XXX O
) XXX O
-infected XXX O
HF XXX O
cells XXX O
at XXX O
24 XXX O
to XXX O
48 XXX O
h XXX O
, XXX O
IE2 XXX B-GENE
also XXX O
accumulated XXX O
in XXX O
newly XXX O
formed XXX O
viral XXX O
DNA XXX O
replication XXX O
compartments XXX O
containing XXX O
the XXX O
polymerase XXX B-GENE
processivity XXX I-GENE
factor XXX I-GENE
( XXX O
UL44 XXX B-GENE
) XXX O
, XXX O
the XXX O
single-stranded XXX B-GENE
DNA XXX I-GENE
binding XXX I-GENE
protein XXX I-GENE
( XXX O
SSB XXX B-GENE
; XXX O
UL57 XXX B-GENE
) XXX O
, XXX O
the XXX O
UL112-113 XXX B-GENE
accessory XXX I-GENE
protein XXX I-GENE
, XXX O
and XXX O
newly XXX O
incorporated XXX O
bromodeoxyuridine XXX O
( XXX O
BrdU XXX O
) XXX O
. XXX O

A XXX O
preoperative XXX O
teaching XXX O
booklet XXX O
for XXX O
pediatric XXX O
patients XXX O
. XXX O

These XXX O
kinases XXX B-GENE
belong XXX O
to XXX O
a XXX O
new XXX O
subfamily XXX O
related XXX O
to XXX O
the XXX O
Trk XXX B-GENE
subfamily XXX I-GENE
. XXX O

Substitutions XXX O
in XXX O
the XXX O
YFV XXX B-GENE
Ag-binding XXX B-GENE
region XXX I-GENE
( XXX O
ABR XXX B-GENE
) XXX O
occur XXX O
at XXX O
four XXX O
of XXX O
the XXX O
eight XXX O
highly XXX O
conserved XXX O
residues XXX O
that XXX O
are XXX O
essential XXX O
for XXX O
binding XXX O
of XXX O
peptide-Ag XXX O
in XXX O
the XXX O
class XXX B-GENE
Ia XXX I-GENE
molecules XXX I-GENE
. XXX O

Furthermore XXX O
, XXX O
the XXX O
striking XXX O
ability XXX O
of XXX O
polyoma XXX B-GENE
middle XXX I-GENE
T XXX I-GENE
antigens XXX I-GENE
to XXX O
promote XXX O
retinoic XXX O
acid-induced XXX O
differentiation XXX O
appears XXX O
to XXX O
utilize XXX O
ERK XXX B-GENE
, XXX O
but XXX O
not XXX O
JNK XXX B-GENE
/ XXX I-GENE
SPK XXX I-GENE
or XXX O
p38 XXX B-GENE
signaling XXX O
. XXX O

This XXX O
paper XXX O
reports XXX O
the XXX O
results XXX O
of XXX O
a XXX O
laboratory XXX O
study XXX O
on XXX O
aldicarb XXX O
and XXX O
its XXX O
main XXX O
metabolites XXX O
, XXX O
aldicarb XXX O
sulfone XXX O
and XXX O
aldicarb XXX O
sulfoxide XXX O
. XXX O

In XXX O
comparison XXX O
with XXX O
the XXX O
16 XXX O
introns XXX O
reported XXX O
in XXX O
AHA3 XXX B-GENE
, XXX O
AHA2 XXX B-GENE
is XXX O
missing XXX O
one XXX O
intron XXX O
in XXX O
the XXX O
5'-untranslated XXX O
region XXX O
and XXX O
a XXX O
second XXX O
intron XXX O
in XXX O
the XXX O
C-terminal XXX O
coding XXX O
region XXX O
. XXX O

The XXX O
data XXX O
provide XXX O
evidence XXX O
both XXX O
for XXX O
a XXX O
signal XXX O
transduction XXX O
pathway XXX O
independent XXX O
of XXX O
JNK XXX B-GENE
, XXX O
ERK XXX B-GENE
, XXX O
and XXX O
p38 XXX B-GENE
MAP XXX I-GENE
kinase XXX I-GENE
to XXX O
be XXX O
involved XXX O
in XXX O
the XXX O
induction XXX O
of XXX O
rhoB XXX B-GENE
by XXX O
genotoxic XXX O
stress XXX O
, XXX O
and XXX O
furthermore XXX O
, XXX O
indicate XXX O
autoregulation XXX O
of XXX O
rhoB XXX B-GENE
. XXX O

Gel-mobility-shift XXX O
assays XXX O
confirmed XXX O
that XXX O
the XXX O
Raji XXX B-GENE
nuclear XXX I-GENE
proteins XXX I-GENE
that XXX O
bound XXX O
to XXX O
W XXX B-GENE
and XXX I-GENE
V XXX I-GENE
elements XXX I-GENE
were XXX O
competed XXX O
with XXX O
by XXX O
an XXX O
HLA-DRA XXX B-GENE
X-box XXX I-GENE
oligonucleotide XXX I-GENE
. XXX O

The XXX O
median XXX O
survival XXX O
is XXX O
not XXX O
reached XXX O
with XXX O
a XXX O
median XXX O
follow-up XXX O
time XXX O
of XXX O
9 XXX O
. XXX O
6 XXX O
years XXX O
. XXX O

Slap XXX B-GENE
negatively XXX O
regulates XXX O
Src XXX B-GENE
mitogenic XXX O
function XXX O
but XXX O
does XXX O
not XXX O
revert XXX O
Src-induced XXX O
cell XXX O
morphology XXX O
changes XXX O
. XXX O

Twelve XXX O
patients XXX O
without XXX O
abnormalities XXX O
in XXX O
the XXX O
PTT XXX O
are XXX O
assumed XXX O
to XXX O
harbor XXX O
missense XXX O
mutations XXX O
, XXX O
probably XXX O
in XXX O
TSC2 XXX B-GENE
. XXX O

These XXX O
include XXX O
NPF XXX B-GENE
repeats XXX I-GENE
, XXX O
a XXX O
leucine XXX O
heptad XXX O
repeat XXX O
enriched XXX O
in XXX O
charged XXX O
residues XXX O
, XXX O
and XXX O
a XXX O
proline-rich XXX O
SH3-like XXX B-GENE
and XXX O
/ XXX O
or XXX O
WW XXX B-GENE
domain-binding XXX I-GENE
site XXX I-GENE
in XXX O
the XXX O
N-terminal XXX O
domain XXX O
, XXX O
which XXX O
is XXX O
followed XXX O
by XXX O
a XXX O
membrane XXX O
core XXX O
containing XXX O
four XXX O
putative XXX O
transmembrane XXX O
spans XXX O
and XXX O
three XXX O
amphiphilic XXX O
segments XXX O
that XXX O
are XXX O
the XXX O
most XXX O
highly XXX O
conserved XXX O
structural XXX O
elements XXX O
. XXX O

At XXX O
maximum XXX O
photosensitivity XXX O
the XXX O
inhibitory XXX O
amino XXX O
acids XXX O
gamma-aminobutyric XXX O
acid XXX O
and XXX O
taurine XXX O
were XXX O
lower XXX O
, XXX O
and XXX O
those XXX O
of XXX O
asparagine XXX O
( XXX O
metabolite XXX O
of XXX O
the XXX O
excitatory XXX O
amino XXX O
acid XXX O
aspartate XXX O
) XXX O
were XXX O
higher XXX O
, XXX O
than XXX O
when XXX O
the XXX O
animals XXX O
were XXX O
not XXX O
photosensitive XXX O
. XXX O

Cat-1 XXX B-GENE
is XXX O
identical XXX O
to XXX O
the XXX O
recently XXX O
identified XXX O
binding XXX O
partner XXX O
for XXX O
the XXX O
beta-adrenergic XXX B-GENE
receptor XXX I-GENE
kinase XXX I-GENE
( XXX O
betaARK XXX B-GENE
or XXX O
GRK-2 XXX B-GENE
) XXX O
, XXX O
which XXX O
was XXX O
shown XXX O
to XXX O
have XXX O
Arf-GAP XXX B-GENE
activity XXX O
. XXX O

RESULTS XXX O
: XXX O
The XXX O
introduction XXX O
of XXX O
the XXX O
PAIP XXX O
resulted XXX O
in XXX O
a XXX O
significant XXX O
( XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
001 XXX O
) XXX O
reduction XXX O
in XXX O
contaminating XXX O
WBCs XXX O
( XXX O
median XXX O
, XXX O
30 XXX O
, XXX O
000 XXX O
) XXX O
from XXX O
the XXX O
numbers XXX O
seen XXX O
with XXX O
FIP XXX O
( XXX O
median XXX O
, XXX O
2 XXX O
, XXX O
300 XXX O
, XXX O
000 XXX O
) XXX O
while XXX O
maintaining XXX O
the XXX O
separation XXX O
efficacy XXX O
( XXX O
47% XXX O
) XXX O
and XXX O
separation XXX O
time XXX O
. XXX O

We XXX O
then XXX O
studied XXX O
four XXX O
unrelated XXX O
Japanese XXX O
families XXX O
with XXX O
GSD-Ib XXX O
, XXX O
and XXX O
found XXX O
three XXX O
novel XXX O
mutations XXX O
: XXX O
a XXX O
four-base XXX O
deletion XXX O
/ XXX O
two-base XXX O
insertion XXX O
, XXX O
a XXX O
point XXX O
mutation XXX O
within XXX O
a XXX O
consensus XXX O
splicing XXX O
donor XXX O
site XXX O
, XXX O
and XXX O
a XXX O
missense XXX O
mutation XXX O
( XXX O
W118R XXX O
) XXX O
. XXX O

Human XXX B-GENE
immunodeficiency XXX I-GENE
virus XXX I-GENE
type XXX I-GENE
1 XXX I-GENE
( XXX I-GENE
HIV-1 XXX I-GENE
) XXX I-GENE
IN XXX I-GENE
, XXX O
expressed XXX O
in XXX O
Escherichia XXX O
coli XXX O
, XXX O
was XXX O
purified XXX O
to XXX O
near XXX O
homogeneity XXX O
. XXX O

The XXX O
other XXX O
inhibitor XXX O
was XXX O
a XXX O
single XXX O
TAR XXX B-GENE
decoy XXX O
, XXX O
driven XXX O
by XXX O
the XXX O
U6 XXX B-GENE
small XXX I-GENE
nuclear XXX I-GENE
RNA XXX I-GENE
promoter XXX I-GENE
( XXX O
U6-P XXX B-GENE
) XXX O
. XXX O

5 XXX O
) XXX O
We've XXX O
noticed XXX O
that XXX O
the XXX O
mean XXX O
value XXX O
of XXX O
the XXX O
cost XXX O
for XXX O
episode XXX O
of XXX O
pnx XXX O
s XXX O
. XXX O
in XXX O
class XXX O
A XXX O
was XXX O
more XXX O
than XXX O
15% XXX O
compared XXX O
to XXX O
class XXX O
B XXX O
and XXX O
the XXX O
cost XXX O
for XXX O
patient XXX O
in XXX O
class XXX O
A XXX O
was XXX O
nearly XXX O
double XXX O
than XXX O
in XXX O
class XXX O
B XXX O
. XXX O

Hailey-Hailey XXX O
disease XXX O
is XXX O
caused XXX O
by XXX O
mutations XXX O
in XXX O
ATP2C1 XXX B-GENE
encoding XXX O
a XXX O
novel XXX O
Ca XXX O
( XXX O
2+ XXX O
) XXX O
pump XXX O
. XXX O

Thus XXX O
, XXX O
the XXX O
absence XXX O
of XXX O
residual XXX O
infarct-zone XXX O
viability XXX O
discriminates XXX O
patients XXX O
who XXX O
develop XXX O
progressive XXX O
left XXX O
ventricular XXX O
dilation XXX O
after XXX O
reperfused XXX O
AMI XXX O
from XXX O
those XXX O
who XXX O
maintain XXX O
normal XXX O
left XXX O
ventricular XXX O
geometry XXX O
. XXX O

Furthermore XXX O
, XXX O
deletion XXX O
and XXX O
mutation XXX O
analyses XXX O
of XXX O
the XXX O
VCAM-1 XXX B-GENE
promoter XXX I-GENE
performed XXX O
with XXX O
chloramphenicol XXX B-GENE
acetyltransferase XXX I-GENE
constructs XXX I-GENE
revealed XXX O
that XXX O
Tax XXX B-GENE
was XXX O
trans XXX O
activating XXX O
the XXX O
VCAM-1 XXX B-GENE
promoter XXX I-GENE
via XXX O
two XXX O
NF-kappaB XXX B-GENE
sites XXX I-GENE
present XXX O
at XXX O
bp XXX O
-72 XXX O
and XXX O
-57 XXX O
in XXX O
the XXX O
VCAM-1 XXX B-GENE
gene XXX I-GENE
promoter XXX I-GENE
, XXX O
with XXX O
both XXX O
of XXX O
them XXX O
being XXX O
required XXX O
for XXX O
the XXX O
Tax-induced XXX O
expression XXX O
of XXX O
this XXX O
adhesion XXX O
molecule XXX O
. XXX O

These XXX O
data XXX O
suggest XXX O
that XXX O
RPF-1 XXX B-GENE
is XXX O
likely XXX O
to XXX O
be XXX O
involved XXX O
in XXX O
early XXX O
steps XXX O
in XXX O
the XXX O
differentiation XXX O
of XXX O
amacrine XXX O
and XXX O
ganglion XXX O
cells XXX O
. XXX O

The XXX O
data XXX O
indicate XXX O
that XXX O
the XXX O
five XXX O
different XXX O
( XXX O
and XXX O
partially XXX O
overlapping XXX O
) XXX O
sry XXX B-GENE
messenger XXX I-GENE
RNAs XXX I-GENE
detectable XXX O
in XXX O
early XXX O
embryos XXX O
are XXX O
initiated XXX O
at XXX O
three XXX O
separate XXX O
sites XXX O
, XXX O
each XXX O
directly XXX O
upstream XXX O
from XXX O
one XXX O
of XXX O
the XXX O
three XXX O
protein-coding XXX O
regions XXX O
, XXX O
designated XXX O
( XXX O
in XXX O
5' XXX O
to XXX O
3' XXX O
order XXX O
) XXX O
beta XXX O
, XXX O
alpha XXX O
and XXX O
delta XXX O
. XXX O

Paper XXX O
alert XXX O
. XXX O

Recurrence XXX O
of XXX O
bladder XXX O
tumors XXX O
among XXX O
the XXX O
original XXX O
9 XXX O
cases XXX O
has XXX O
occurred XXX O
only XXX O
among XXX O
the XXX O
5 XXX O
whose XXX O
properdin XXX B-GENE
levels XXX O
remained XXX O
below XXX O
the XXX O
median XXX O
. XXX O

CONCLUSIONS XXX O
: XXX O
The XXX O
methodology XXX O
of XXX O
LHR XXX O
measurement XXX O
significantly XXX O
influences XXX O
the XXX O
clinical XXX O
contribution XXX O
of XXX O
Tl-201 XXX O
lung XXX O
uptake XXX O
evaluation XXX O
. XXX O

This XXX O
failure XXX O
to XXX O
execute XXX O
regulated XXX O
G1 XXX O
/ XXX O
S XXX O
arrest XXX O
is XXX O
correlated XXX O
with XXX O
enhanced XXX O
thermosensitivity XXX O
of XXX O
colony-forming XXX O
ability XXX O
. XXX O

One XXX O
cDNA XXX O
clone XXX O
designated XXX O
NCoA-62 XXX O
, XXX O
encoded XXX O
a XXX O
62 XXX O
, XXX O
000-Da XXX O
protein XXX O
that XXX O
is XXX O
highly XXX O
related XXX O
to XXX O
BX42 XXX B-GENE
, XXX O
a XXX O
Drosophila XXX O
melanogaster XXX O
nuclear XXX O
protein XXX O
involved XXX O
in XXX O
ecdysone-stimulated XXX O
gene XXX O
expression XXX O
. XXX O

Atomic XXX O
absorption XXX O
spectrophotometry XXX O
applied XXX O
to XXX O
bacterially XXX O
expressed XXX O
E1A XXX B-GENE
proteins XXX I-GENE
revealed XXX O
that XXX O
the XXX O
289-amino XXX O
acid XXX O
protein XXX O
binds XXX O
one XXX O
zinc XXX O
ion XXX O
, XXX O
whereas XXX O
the XXX O
243-amino XXX O
acid XXX O
protein XXX O
binds XXX O
no XXX O
zinc XXX O
. XXX O

Using XXX O
the XXX O
presented XXX O
categorical XXX O
structure XXX O
as XXX O
domain XXX O
model XXX O
a XXX O
prototype XXX O
DSS XXX O
for XXX O
dipslide XXX O
urine XXX O
cultures XXX O
has XXX O
been XXX O
developed XXX O
. XXX O

Nip7p-depleted XXX O
cells XXX O
exhibited XXX O
the XXX O
same XXX O
defects XXX O
as XXX O
Nop8p-depleted XXX O
cells XXX O
, XXX O
except XXX O
that XXX O
they XXX O
accumulated XXX O
27S XXX B-GENE
precursors XXX I-GENE
. XXX O

Discordance XXX O
on XXX O
the XXX O
cost XXX O
dimension XXX O
correlated XXX O
negatively XXX O
with XXX O
G XXX B-GENE
Hb XXX I-GENE
, XXX O
suggesting XXX O
better XXX O
glycemic XXX O
control XXX O
with XXX O
greater XXX O
disagreement XXX O
. XXX O

RESULTS XXX O
: XXX O
A XXX O
significant XXX O
correlation XXX O
( XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
001 XXX O
) XXX O
was XXX O
observed XXX O
for XXX O
mean XXX O
wall XXX O
thickness XXX O
and XXX O
vessel XXX O
wall XXX O
area XXX O
between XXX O
MRI XXX O
and XXX O
histopathology XXX O
( XXX O
r XXX O
= XXX O
0 XXX O
. XXX O
87 XXX O
and XXX O
r XXX O
= XXX O
0 XXX O
. XXX O
85 XXX O
, XXX O
respectively XXX O
) XXX O
. XXX O

In XXX O
this XXX O
paper XXX O
the XXX O
tyrosine XXX O
dephosphorylating XXX O
enzymes XXX O
, XXX O
the XXX O
protein-tyrosine XXX B-GENE
phosphatases XXX I-GENE
( XXX O
PTPs XXX B-GENE
) XXX O
, XXX O
are XXX O
studied XXX O
which XXX O
can XXX O
be XXX O
grouped XXX O
into XXX O
two XXX O
subfamilies XXX O
, XXX O
the XXX O
soluble XXX B-GENE
PTPs XXX I-GENE
and XXX O
the XXX O
receptor XXX B-GENE
PTPs XXX I-GENE
( XXX O
RPTPs XXX B-GENE
) XXX O
. XXX O

We XXX O
report XXX O
here XXX O
that XXX O
microinjection XXX O
of XXX O
an XXX O
anti-CBP XXX B-GENE
antiserum XXX I-GENE
into XXX O
fibroblasts XXX O
can XXX O
inhibit XXX O
transcription XXX O
from XXX O
a XXX O
cAMP XXX B-GENE
responsive XXX I-GENE
promoter XXX I-GENE
. XXX O

Relatively XXX O
little XXX O
is XXX O
known XXX O
regarding XXX O
the XXX O
role XXX O
of XXX O
5-HT2 XXX B-GENE
receptor XXX I-GENE
activity XXX O
in XXX O
male XXX O
rat XXX O
sexual XXX O
behavior XXX O
. XXX O

S2F XXX B-GENE
, XXX O
a XXX O
leaf-specific XXX O
trans-acting XXX O
factor XXX O
, XXX O
binds XXX O
to XXX O
a XXX O
novel XXX O
cis-acting XXX O
element XXX O
and XXX O
differentially XXX O
activates XXX O
the XXX O
RPL21 XXX B-GENE
gene XXX I-GENE
. XXX O

Among XXX O
three XXX O
isoforms XXX O
, XXX O
the XXX O
beta XXX O
isoform XXX O
has XXX O
the XXX O
greatest XXX O
Vmax XXX O
value XXX O
for XXX O
the XXX O
PtdIns XXX B-GENE
( XXX I-GENE
4 XXX I-GENE
) XXX I-GENE
P XXX I-GENE
kinase XXX I-GENE
activity XXX O
and XXX O
the XXX O
gamma XXX O
isoform XXX O
is XXX O
most XXX O
markedly XXX O
stimulated XXX O
by XXX O
phosphatidic XXX O
acid XXX O
. XXX O

The XXX O
overall XXX O
results XXX O
of XXX O
this XXX O
paper XXX O
are XXX O
consistent XXX O
with XXX O
the XXX O
conclusion XXX O
that XXX O
the XXX O
carboxyl-terminal XXX O
LBD XXX O
is XXX O
not XXX O
sufficient XXX O
for XXX O
mediating XXX O
PR XXX B-GENE
dimerization XXX O
and XXX O
that XXX O
multiple XXX O
regions XXX O
, XXX O
including XXX O
the XXX O
hinge XXX O
and XXX O
amino-terminal XXX O
sequences XXX O
, XXX O
contribute XXX O
either XXX O
directly XXX O
or XXX O
indirectly XXX O
to XXX O
homodimerization XXX O
of XXX O
PR XXX B-GENE
. XXX O

A XXX O
water-vapour XXX O
giga-maser XXX O
in XXX O
the XXX O
active XXX O
galaxy XXX O
TXFS2226-184 XXX O
. XXX O

A XXX O
potential XXX O
outcome XXX O
of XXX O
these XXX O
biochemical XXX O
effects XXX O
may XXX O
include XXX O
the XXX O
limited XXX O
responsiveness XXX O
of XXX O
infected XXX O
T XXX O
cells XXX O
to XXX O
antigenic XXX O
stimulation XXX O
observed XXX O
during XXX O
HIV-1 XXX O
infection XXX O
. XXX O

Analysis XXX O
by XXX O
cell XXX O
surface XXX O
immunofluorescence XXX O
showed XXX O
that XXX O
the XXX O
UL28 XXX B-GENE
gene XXX I-GENE
is XXX O
not XXX O
required XXX O
for XXX O
expression XXX O
of XXX O
viral XXX O
glycoproteins XXX O
on XXX O
the XXX O
surface XXX O
of XXX O
infected XXX O
cells XXX O
. XXX O

Based XXX O
on XXX O
these XXX O
data XXX O
, XXX O
we XXX O
conclude XXX O
that XXX O
transcription XXX O
of XXX O
prgX XXX B-GENE
is XXX O
initiated XXX O
from XXX O
the XXX O
Qa XXX B-GENE
promoter XXX I-GENE
in XXX O
prgQ XXX B-GENE
, XXX O
and XXX O
PrgX XXX B-GENE
autoregulates XXX O
its XXX O
transcription XXX O
either XXX O
by XXX O
mediating XXX O
transcriptional XXX O
readthrough XXX O
or XXX O
increasing XXX O
mRNA XXX O
stability XXX O
. XXX O

Secretory XXX B-GENE
IgA XXX I-GENE
and XXX O
serum XXX B-GENE
immunoglobulins XXX I-GENE
as XXX O
indices XXX O
of XXX O
the XXX O
local XXX O
immunity XXX O
of XXX O
the XXX O
intestinal XXX O
mucosa XXX O
in XXX O
acute XXX O
leukemias XXX O
. XXX O

Digitalis XXX O
glycosides XXX O
or XXX O
beta-receptor XXX B-GENE
antagonists XXX O
are XXX O
not XXX O
helpful XXX O
in XXX O
the XXX O
therapy XXX O
of XXX O
this XXX O
form XXX O
of XXX O
atrial XXX O
fibrillation XXX O
whereas XXX O
class XXX O
I XXX O
antiarrhythmic XXX O
drugs XXX O
have XXX O
been XXX O
shown XXX O
to XXX O
be XXX O
more XXX O
effective XXX O
. XXX O

Our XXX O
data XXX O
show XXX O
that XXX O
multiple XXX O
MLSN1 XXX B-GENE
transcripts XXX I-GENE
, XXX O
both XXX O
constitutively XXX O
expressed XXX O
and XXX O
inducible XXX O
, XXX O
are XXX O
present XXX O
in XXX O
cultured XXX O
pigmented XXX O
melanoma XXX O
cells XXX O
, XXX O
and XXX O
suggest XXX O
that XXX O
MLSN1 XXX B-GENE
expression XXX O
can XXX O
be XXX O
regulated XXX O
at XXX O
the XXX O
level XXX O
of XXX O
both XXX O
transcription XXX O
and XXX O
mRNA XXX O
processing XXX O
. XXX O

Both XXX O
classes XXX O
of XXX O
MHBst XXX B-GENE
proteins XXX I-GENE
were XXX O
found XXX O
to XXX O
form XXX O
dimers XXX O
; XXX O
an XXX O
which XXX O
is XXX O
involved XXX O
in XXX O
mediating XXX O
the XXX O
dimerization XXX O
. XXX O

After XXX O
the XXX O
first XXX O
28 XXX O
patients XXX O
vincristine XXX O
was XXX O
replaced XXX O
by XXX O
teniposide XXX O
( XXX O
VM-26 XXX O
) XXX O
due XXX O
to XXX O
neurotoxicity XXX O
. XXX O

The XXX O
specificity XXX O
of XXX O
action XXX O
of XXX O
C XXX B-GENE
/ XXX I-GENE
EBP XXX I-GENE
family XXX I-GENE
members XXX I-GENE
may XXX O
be XXX O
derived XXX O
from XXX O
the XXX O
characteristics XXX O
of XXX O
each XXX O
factor XXX O
, XXX O
including XXX O
the XXX O
expression XXX O
profiles XXX O
, XXX O
the XXX O
DNA XXX O
binding XXX O
affinities XXX O
, XXX O
the XXX O
cofactors XXX O
, XXX O
and XXX O
so XXX O
on XXX O
, XXX O
in XXX O
addition XXX O
to XXX O
the XXX O
DNA XXX O
binding XXX O
specificities XXX O
. XXX O

We XXX O
have XXX O
performed XXX O
toeprinting XXX O
analyses XXX O
on XXX O
repA XXX B-GENE
mRNA XXX I-GENE
of XXX O
plasmid XXX O
R1 XXX O
, XXX O
both XXX O
free XXX O
and XXX O
in XXX O
duplex XXX O
with XXX O
the XXX O
antisense XXX O
RNA XXX O
, XXX O
CopA XXX B-GENE
. XXX O

The XXX O
yeast XXX B-GENE
LPD1 XXX I-GENE
gene XXX I-GENE
encoding XXX O
lipoamide XXX B-GENE
dehydrogenase XXX I-GENE
is XXX O
subject XXX O
to XXX O
the XXX O
general XXX O
control XXX O
of XXX O
amino XXX O
acid XXX O
biosynthesis XXX O
mediated XXX O
by XXX O
the XXX O
GCN4 XXX B-GENE
transcription XXX I-GENE
factor XXX I-GENE
. XXX O

Either XXX O
a XXX O
UV XXX O
detector XXX O
set XXX O
at XXX O
268 XXX O
nm XXX O
or XXX O
an XXX O
electrochemical XXX O
( XXX O
EC XXX O
) XXX O
detector XXX O
set XXX O
at XXX O
a XXX O
potential XXX O
of XXX O
+0 XXX O
. XXX O
9 XXX O
V XXX O
( XXX O
versus XXX O
Ag XXX O
/ XXX O
AgCl XXX O
/ XXX O
3 XXX O
M XXX O
NaCl XXX O
) XXX O
was XXX O
used XXX O
to XXX O
monitor XXX O
the XXX O
drug XXX O
. XXX O

Apparent XXX O
loss XXX O
of XXX O
differentiation XXX O
markers XXX O
characterizes XXX O
advanced XXX O
malignant XXX O
neoplasms XXX O
. XXX O

The XXX O
most XXX O
common XXX O
grade XXX O
3 XXX O
toxicity XXX O
was XXX O
neutropenia XXX O
, XXX O
thrombocytopenia XXX O
, XXX O
and XXX O
parasthesias XXX O
( XXX O
observed XXX O
in XXX O
< XXX O
10% XXX O
of XXX O
cycles XXX O
) XXX O
. XXX O

Mitogen-induced XXX O
lymphocyte XXX O
proliferation XXX O
was XXX O
diminished XXX O
. XXX O

A XXX O
striking XXX O
feature XXX O
of XXX O
the XXX O
recombinant XXX B-GENE
H19 XXX I-GENE
allele XXX I-GENE
is XXX O
the XXX O
occurrence XXX O
of XXX O
a XXX O
parental XXX O
imprint XXX O
set XXX O
on XXX O
the XXX O
neo XXX B-GENE
replacement XXX I-GENE
cassette XXX I-GENE
. XXX O

The XXX O
yeast XXX B-GENE
C-type XXX I-GENE
cyclin XXX I-GENE
Ume3p XXX I-GENE
/ XXX I-GENE
Srb11p XXX I-GENE
and XXX O
its XXX O
cyclin-dependent XXX B-GENE
kinase XXX I-GENE
( XXX O
Cdk XXX B-GENE
) XXX O
Ume5p XXX B-GENE
are XXX O
required XXX O
for XXX O
the XXX O
full XXX O
repression XXX O
of XXX O
genes XXX O
involved XXX O
in XXX O
the XXX O
stress XXX O
response XXX O
or XXX O
meiosis XXX O
. XXX O

Coimmunoprecipitation XXX O
experiments XXX O
performed XXX O
in XXX O
transfected XXX O
cells XXX O
showed XXX O
that XXX O
BCMA XXX B-GENE
associates XXX O
with XXX O
TNFR-associated XXX B-GENE
factor XXX I-GENE
( XXX I-GENE
TRAF XXX I-GENE
) XXX I-GENE
1 XXX I-GENE
, XXX O
TRAF2 XXX B-GENE
, XXX O
and XXX O
TRAF3 XXX B-GENE
adaptor XXX I-GENE
proteins XXX I-GENE
. XXX O

Except XXX O
for XXX O
nonperfusion XXX O
of XXX O
neurosensory XXX O
retinal XXX O
vessels XXX O
at XXX O
a XXX O
light XXX O
dose XXX O
of XXX O
150 XXX O
J XXX O
/ XXX O
cm2 XXX O
, XXX O
no XXX O
other XXX O
adverse XXX O
events XXX O
were XXX O
of XXX O
concern XXX O
. XXX O

Interlimb XXX O
coordination XXX O
during XXX O
fictive XXX O
locomotion XXX O
in XXX O
the XXX O
thalamic XXX O
cat XXX O
. XXX O

Restriction XXX O
enzyme XXX O
mapping XXX O
, XXX O
subcloning XXX O
, XXX O
and XXX O
DNA XXX O
sequencing XXX O
analysis XXX O
of XXX O
recombinant XXX O
phage XXX O
lambda XXX O
and XXX O
P1 XXX O
clones XXX O
revealed XXX O
that XXX O
exons XXX O
encoding XXX O
the XXX O
1 XXX O
. XXX O
9-kb XXX O
mouse XXX B-GENE
TS XXX I-GENE
mRNA XXX I-GENE
are XXX O
dispersed XXX O
over XXX O
> XXX O
150 XXX O
kb XXX O
genomic XXX O
DNA XXX O
. XXX O

However XXX O
, XXX O
butyrate XXX O
was XXX O
at XXX O
least XXX O
2-fold XXX O
more XXX O
effective XXX O
in XXX O
stimulating XXX O
CAT XXX B-GENE
activity XXX O
of XXX O
fusion XXX O
genes XXX O
containing XXX O
upstream XXX O
sequences XXX O
( XXX O
-834 XXX O
to XXX O
-576 XXX O
) XXX O
than XXX O
those XXX O
containing XXX O
proximal XXX O
sequences XXX O
( XXX O
-456 XXX O
to XXX O
-172 XXX O
) XXX O
, XXX O
suggesting XXX O
two XXX O
regions XXX O
in XXX O
the XXX O
PSG1-I XXX B-GENE
gene XXX I-GENE
that XXX O
mediate XXX O
the XXX O
butyrate XXX O
response XXX O
. XXX O

Effects XXX O
of XXX O
temperature XXX O
and XXX O
moulting XXX O
cycle XXX O
on XXX O
melanin XXX O
synthesis XXX O
in XXX O
the XXX O
newt XXX O
, XXX O
Triturus XXX O
cristatus XXX O
. XXX O

The XXX O
murine XXX B-GENE
int-6 XXX I-GENE
locus XXX I-GENE
, XXX O
identified XXX O
as XXX O
a XXX O
frequent XXX O
integration XXX O
site XXX O
of XXX O
mouse XXX O
mammary XXX O
tumor XXX O
viruses XXX O
, XXX O
encodes XXX O
the XXX O
48-kDa XXX B-GENE
eIF3e XXX I-GENE
subunit XXX I-GENE
of XXX I-GENE
translation XXX I-GENE
initiation XXX I-GENE
factor XXX I-GENE
eIF3 XXX I-GENE
. XXX O

In XXX O
30 XXX O
dogs XXX O
the XXX O
left XXX O
limb XXX O
( XXX O
tail XXX O
) XXX O
of XXX O
the XXX O
pancreas XXX O
was XXX O
removed XXX O
but XXX O
left XXX O
in XXX O
the XXX O
abdominal XXX O
cavity XXX O
after XXX O
cessation XXX O
of XXX O
blood XXX O
flow XXX O
to XXX O
produce XXX O
warm XXX O
ischemia XXX O
for XXX O
30 XXX O
, XXX O
60 XXX O
, XXX O
and XXX O
120 XXX O
min XXX O
( XXX O
10 XXX O
dogs XXX O
at XXX O
each XXX O
time XXX O
point XXX O
) XXX O
, XXX O
and XXX O
then XXX O
was XXX O
flushed XXX O
with XXX O
cold XXX O
Ringers' XXX O
lactate XXX O
and XXX O
transplanted XXX O
to XXX O
the XXX O
iliac XXX O
vessels XXX O
. XXX O

The XXX O
core XXX O
of XXX O
this XXX O
enhancer XXX O
contains XXX O
two XXX O
evolutionarily XXX O
conserved XXX O
binding XXX O
sites XXX O
for XXX O
the XXX O
homeodomain XXX B-GENE
protein XXX I-GENE
Tinman XXX B-GENE
( XXX O
Tin XXX B-GENE
) XXX O
, XXX O
expressed XXX O
in XXX O
developing XXX O
cardiac XXX O
, XXX O
somatic XXX O
, XXX O
and XXX O
visceral XXX O
muscle XXX O
lineages XXX O
. XXX O

The XXX O
por XXX B-GENE
gene XXX I-GENE
has XXX O
been XXX O
expressed XXX O
, XXX O
for XXX O
the XXX O
first XXX O
time XXX O
, XXX O
in XXX O
anaerobically XXX O
grown XXX O
Escherichia XXX O
coli XXX O
behind XXX O
the XXX O
isopropyl-beta-D-thiogalactopyranoside-inducible XXX O
tac XXX B-GENE
promoter XXX I-GENE
, XXX O
resulting XXX O
in XXX O
the XXX O
production XXX O
of XXX O
POR XXX B-GENE
in XXX O
its XXX O
active XXX O
form XXX O
. XXX O

Marrow XXX O
dysplasia XXX O
is XXX O
a XXX O
major XXX O
characteristic XXX O
of XXX O
patients XXX O
with XXX O
myelodysplastic XXX O
syndrome XXX O
( XXX O
MDS XXX O
) XXX O
, XXX O
along XXX O
with XXX O
marrow XXX O
blastosis XXX O
, XXX O
cytopenia XXX O
and XXX O
cytogenetic XXX O
anomalies XXX O
. XXX O

Proximal XXX O
CBD XXX O
was XXX O
inversely XXX O
correlated XXX O
with XXX O
bone XXX B-GENE
alkaline XXX I-GENE
phosphatase XXX I-GENE
( XXX O
r XXX O
= XXX O
-0 XXX O
. XXX O
71 XXX O
, XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
and XXX O
intact XXX O
PTH XXX O
( XXX O
r XXX O
= XXX O
-0 XXX O
. XXX O
59 XXX O
, XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
. XXX O

Recombinant XXX B-GENE
BRI1-KD XXX I-GENE
autophosphorylated XXX O
on XXX O
serine XXX O
( XXX O
Ser XXX O
) XXX O
and XXX O
threonine XXX O
( XXX O
Thr XXX O
) XXX O
residues XXX O
with XXX O
p-Ser XXX O
predominating XXX O
. XXX O

The XXX O
C XXX O
terminus XXX O
of XXX O
TRBP XXX B-GENE
binds XXX O
to XXX O
CBP XXX B-GENE
/ XXX I-GENE
p300 XXX I-GENE
and XXX O
DRIP130 XXX B-GENE
, XXX O
a XXX O
component XXX O
of XXX O
the XXX O
DRIP XXX B-GENE
/ XXX I-GENE
TRAP XXX I-GENE
/ XXX I-GENE
ARC XXX I-GENE
complex XXX I-GENE
, XXX O
which XXX O
suggests XXX O
that XXX O
TRBP XXX B-GENE
may XXX O
activate XXX O
transcription XXX O
by XXX O
means XXX O
of XXX O
such XXX O
interactions XXX O
. XXX O

FISH XXX O
using XXX O
a XXX O
whole XXX O
chromosome XXX O
4 XXX O
paint XXX O
demonstrated XXX O
multiple XXX O
rearrangements XXX O
involving XXX O
chromosome XXX O
4 XXX O
in XXX O
MCF-7 XXX O
AdVp3000 XXX O
and XXX O
MCF-7 XXX O
MX XXX O
, XXX O
while XXX O
S1-M1-80 XXX O
contained XXX O
only XXX O
a XXX O
simple XXX O
reciprocal XXX O
translocation XXX O
. XXX O

In XXX O
ICE XXX B-GENE
gamma XXX I-GENE
, XXX O
most XXX O
of XXX O
the XXX O
propeptide XXX O
( XXX O
amino XXX O
acids XXX O
20-112 XXX O
) XXX O
is XXX O
deleted XXX O
, XXX O
which XXX O
suggests XXX O
that XXX O
it XXX O
may XXX O
function XXX O
as XXX O
a XXX O
catalyst XXX O
for XXX O
ICE XXX B-GENE
autoprocessing XXX O
in XXX O
vivo XXX O
. XXX O

Schistosoma XXX O
mansoni XXX O
schistosomiasis XXX O
Schistosomosis XXX O
are XXX O
parasitic XXX O
diseases XXX O
caused XXX O
by XXX O
blood XXX O
flukes XXX O
of XXX O
the XXX O
Schistosoma XXX O
genus XXX O
. XXX O

They XXX O
contrast XXX O
trends XXX O
in XXX O
fertility XXX O
, XXX O
life XXX O
expectancy XXX O
ratios XXX O
, XXX O
and XXX O
gender XXX O
differences XXX O
in XXX O
these XXX O
countries XXX O
with XXX O
the XXX O
Hispanic XXX O
population XXX O
of XXX O
the XXX O
United XXX O
States XXX O
. XXX O

These XXX O
results XXX O
imply XXX O
that XXX O
the XXX O
GCN3 XXX B-GENE
product XXX I-GENE
can XXX O
promote XXX O
either XXX O
repression XXX O
or XXX O
activation XXX O
of XXX O
GCN4 XXX B-GENE
expression XXX O
depending XXX O
on XXX O
amino XXX O
acid XXX O
availability XXX O
. XXX O

Twenty-two XXX O
consecutive XXX O
patients XXX O
with XXX O
ischaemic XXX O
ulcers XXX O
had XXX O
tcPO2 XXX O
measured XXX O
and XXX O
the XXX O
ankle XXX O
/ XXX O
brachial XXX O
( XXX O
ABI XXX O
) XXX O
and XXX O
toe XXX O
/ XXX O
brachial XXX O
( XXX O
TBI XXX O
) XXX O
indices XXX O
calculated XXX O
. XXX O

John XXX O
leonard XXX O
dawson XXX O
. XXX O

In XXX O
order XXX O
to XXX O
better XXX O
characterize XXX O
the XXX O
distribution XXX O
of XXX O
ML XXX O
and XXX O
MAP XXX O
estimates XXX O
under XXX O
these XXX O
conditions XXX O
, XXX O
we XXX O
derive XXX O
a XXX O
point XXX O
approximation XXX O
to XXX O
density XXX O
values XXX O
of XXX O
the XXX O
conditional XXX O
distribution XXX O
of XXX O
such XXX O
estimates XXX O
. XXX O

We XXX O
conclude XXX O
that XXX O
cAMP XXX O
, XXX O
acting XXX O
through XXX O
PKA XXX B-GENE
, XXX O
is XXX O
an XXX O
essential XXX O
regulator XXX O
of XXX O
basal XXX O
CFTR XXX B-GENE
gene XXX I-GENE
expression XXX O
and XXX O
may XXX O
mediate XXX O
an XXX O
induction XXX O
of XXX O
CFTR XXX B-GENE
in XXX O
responsive XXX O
cell XXX O
types XXX O
. XXX O

We XXX O
have XXX O
demonstrated XXX O
that XXX O
the XXX O
activity XXX O
of XXX O
ILK XXX B-GENE
is XXX O
constitutively XXX O
elevated XXX O
in XXX O
PTEN XXX B-GENE
mutant XXX I-GENE
cells XXX O
. XXX O

A XXX O
normal XXX O
systemic XXX O
response XXX O
was XXX O
obtained XXX O
after XXX O
IF XXX O
, XXX O
indicating XXX O
that XXX O
rhG-CSF XXX B-GENE
retains XXX O
activity XXX O
in XXX O
the XXX O
solid XXX O
state XXX O
. XXX O

In XXX O
Saccharomyces XXX O
cerevisiae XXX O
, XXX O
eIF6 XXX B-GENE
is XXX O
encoded XXX O
by XXX O
a XXX O
single-copy XXX O
essential XXX O
gene XXX O
. XXX O

METHODS XXX O
: XXX O
Thyroid XXX O
status XXX O
was XXX O
measured XXX O
at XXX O
baseline XXX O
( XXX O
1990-93 XXX O
) XXX O
, XXX O
through XXX O
assessment XXX O
of XXX O
serum XXX O
antibodies XXX O
to XXX O
thyroid XXX B-GENE
peroxidase XXX I-GENE
( XXX O
TPO-Abs XXX B-GENE
, XXX O
positive XXX O
: XXX O
> XXX O
10 XXX O
IU XXX O
/ XXX O
ml XXX O
) XXX O
, XXX O
serum XXX B-GENE
TSH XXX I-GENE
levels XXX O
, XXX O
and XXX O
when XXX O
TSH XXX B-GENE
was XXX O
abnormal XXX O
( XXX O
< XXX O
0 XXX O
. XXX O
4 XXX O
or XXX O
> XXX O
4 XXX O
. XXX O
0 XXX O
mU XXX O
/ XXX O
l XXX O
) XXX O
, XXX O
serum XXX B-GENE
thyroxin XXX I-GENE
levels XXX O
( XXX O
T4 XXX O
) XXX O
. XXX O

Two XXX O
hundred XXX O
forty-three XXX O
patients XXX O
have XXX O
received XXX O
WR-2721 XXX O
in XXX O
Phase XXX O
I-II XXX O
studies XXX O
. XXX O

All XXX O
three XXX O
NR XXX B-GENE
isoforms XXX O
are XXX O
expressed XXX O
in XXX O
cv XXX O
. XXX O

These XXX O
results XXX O
demonstrate XXX O
that XXX O
a XXX O
diverse XXX O
set XXX O
of XXX O
carboxyl-terminal XXX O
sequence XXX O
motifs XXX O
and XXX O
posttranslational XXX O
modifications XXX O
lead XXX O
to XXX O
functional XXX O
Ras XXX B-GENE
proteins XXX I-GENE
in XXX O
yeast XXX O
. XXX O

Epithelial XXX O
and XXX O
corneal XXX O
thickness XXX O
measurements XXX O
by XXX O
in XXX O
vivo XXX O
confocal XXX O
microscopy XXX O
through XXX O
focusing XXX O
( XXX O
CMTF XXX O
) XXX O
. XXX O

Five-year XXX O
survivals XXX O
amounted XXX O
to XXX O
100% XXX O
, XXX O
86 XXX O
. XXX O
2% XXX O
, XXX O
59 XXX O
. XXX O
4% XXX O
, XXX O
29 XXX O
. XXX O
8% XXX O
, XXX O
and XXX O
20% XXX O
for XXX O
stages XXX O
I XXX O
, XXX O
II XXX O
, XXX O
III XXX O
, XXX O
IVA XXX O
and XXX O
IVB XXX O
respectively XXX O
. XXX O

In XXX O
biopsies XXX O
CK-MB XXX B-GENE
fraction XXX O
of XXX O
total XXX O
myocardial XXX O
CPK XXX B-GENE
was XXX O
37% XXX O
, XXX O
the XXX O
total-CPK XXX B-GENE
activity XXX O
of XXX O
human XXX O
skeletal XXX O
muscles XXX O
still XXX O
shows XXX O
a XXX O
5% XXX O
fraction XXX O
of XXX O
CK-MB XXX B-GENE
. XXX O

Measurements XXX O
were XXX O
obtained XXX O
: XXX O
( XXX O
i XXX O
) XXX O
just XXX O
after XXX O
the XXX O
traumatic XXX O
exposure XXX O
( XXX O
D0 XXX O
) XXX O
; XXX O
( XXX O
ii XXX O
) XXX O
3 XXX O
days XXX O
after XXX O
this XXX O
first XXX O
measurement XXX O
( XXX O
D3 XXX O
) XXX O
; XXX O
and XXX O
( XXX O
iii XXX O
) XXX O
30 XXX O
days XXX O
after XXX O
( XXX O
D30 XXX O
) XXX O
. XXX O

The XXX O
results XXX O
of XXX O
our XXX O
ten-fold XXX O
cross-validation XXX O
experiments XXX O
show XXX O
that XXX O
, XXX O
on XXX O
the XXX O
average XXX O
, XXX O
the XXX O
system XXX O
increases XXX O
the XXX O
specificity XXX O
from XXX O
0 XXX O
. XXX O
19 XXX O
( XXX O
0 XXX O
. XXX O
35 XXX O
) XXX O
to XXX O
0 XXX O
. XXX O
69 XXX O
( XXX O
0 XXX O
. XXX O
74 XXX O
) XXX O
at XXX O
a XXX O
sensitivity XXX O
level XXX O
of XXX O
1 XXX O
. XXX O
0 XXX O
( XXX O
0 XXX O
. XXX O
95 XXX O
) XXX O
. XXX O

In XXX O
the XXX O
case XXX O
of XXX O
congenital XXX O
protein XXX B-GENE
C XXX I-GENE
deficiency XXX O
, XXX O
vitamin XXX O
K XXX O
antagonists XXX O
must XXX O
be XXX O
started XXX O
cautiously XXX O
due XXX O
to XXX O
the XXX O
risk XXX O
of XXX O
skin XXX O
necrosis XXX O
. XXX O

HTLV-1 XXX O
gene XXX O
expression XXX O
by XXX O
defective XXX O
proviruses XXX O
in XXX O
an XXX O
infected XXX O
T-cell XXX O
line XXX O
. XXX O

The XXX O
structural XXX O
analysis XXX O
also XXX O
demonstrated XXX O
that XXX O
the XXX O
heterogeneity XXX O
of XXX O
the XXX O
HDC XXX B-GENE
mRNA XXX I-GENE
is XXX O
caused XXX O
by XXX O
an XXX O
insertion XXX O
of XXX O
the XXX O
seventh XXX O
intron XXX O
sequence XXX O
and XXX O
alternative XXX O
use XXX O
of XXX O
the XXX O
splicing XXX O
acceptor XXX O
site XXX O
at XXX O
the XXX O
12th XXX O
exon XXX O
. XXX O

Thus XXX O
, XXX O
ZNF74 XXX B-GENE
sublocalization XXX O
in XXX O
nuclear XXX O
domains XXX O
enriched XXX O
in XXX O
pre-mRNA XXX O
maturating XXX O
factors XXX O
, XXX O
its XXX O
RNA XXX O
binding XXX O
activity XXX O
, XXX O
and XXX O
its XXX O
direct XXX O
phosphodependent XXX O
interaction XXX O
with XXX O
the XXX O
pol XXX B-GENE
IIo XXX I-GENE
, XXX O
a XXX O
form XXX O
of XXX O
the XXX O
RNA XXX B-GENE
polymerase XXX I-GENE
functionally XXX O
associated XXX O
with XXX O
pre- XXX O
mRNA XXX O
processing XXX O
, XXX O
suggest XXX O
a XXX O
role XXX O
for XXX O
this XXX O
member XXX O
of XXX O
the XXX O
KRAB XXX B-GENE
multifinger XXX I-GENE
protein XXX I-GENE
family XXX I-GENE
in XXX O
RNA XXX O
processing XXX O
. XXX O

The XXX O
blood XXX O
levels XXX O
of XXX O
lactate XXX O
, XXX O
pyruvate XXX O
and XXX O
amino XXX O
acids XXX O
were XXX O
not XXX O
elevated XXX O
. XXX O

Isolation XXX O
of XXX O
a XXX O
near XXX O
full-length XXX O
cDNA XXX O
from XXX O
a XXX O
human XXX O
fetal XXX O
brain XXX O
cDNA XXX O
library XXX O
revealed XXX O
a XXX O
protein XXX B-GENE
serine-threonine XXX I-GENE
phosphatase XXX I-GENE
with XXX O
a XXX O
tetratricopeptide XXX B-GENE
motif XXX I-GENE
, XXX O
almost XXX O
identical XXX O
to XXX O
human XXX B-GENE
PPP5C XXX I-GENE
( XXX O
PP5 XXX B-GENE
) XXX O
and XXX O
highly XXX O
homologous XXX O
to XXX O
rat XXX B-GENE
PPT XXX I-GENE
. XXX O

This XXX O
element XXX O
was XXX O
used XXX O
to XXX O
screen XXX O
an XXX O
EMBL3 XXX O
mouse XXX O
genomic XXX O
library XXX O
. XXX O

The XXX O
nucleotide XXX O
sequence XXX O
consists XXX O
of XXX O
48 XXX O
bp XXX O
of XXX O
5'-end XXX O
non-coding XXX O
region XXX O
, XXX O
1695 XXX O
bp XXX O
of XXX O
coding XXX O
region XXX O
and XXX O
212 XXX O
bp XXX O
of XXX O
3'-end XXX O
non-coding XXX O
region XXX O
including XXX O
a XXX O
20 XXX O
bp XXX O
poly XXX O
( XXX O
A XXX O
) XXX O
tail XXX O
. XXX O

Effects XXX O
of XXX O
a XXX O
new XXX O
antihypertensive XXX O
agent XXX O
, XXX O
SGB-1534 XXX O
, XXX O
on XXX O
rat XXX O
platelet XXX O
aggregation XXX O
. XXX O

Plasma XXX O
levels XXX O
of XXX O
protein XXX B-GENE
C XXX I-GENE
, XXX O
protein XXX B-GENE
S XXX I-GENE
, XXX O
and XXX O
antithrombin XXX B-GENE
III XXX I-GENE
in XXX O
patients XXX O
with XXX O
subarachnoid XXX O
haemorrhage XXX O
. XXX O

Two XXX O
BASIC XXX O
computer XXX O
programs XXX O
using XXX O
logit XXX O
transformation XXX O
for XXX O
the XXX O
analysis XXX O
of XXX O
S-shaped XXX O
curves XXX O
are XXX O
presented XXX O
. XXX O

Among XXX O
9 XXX O
group XXX O
I XXX O
patients XXX O
with XXX O
a XXX O
positive XXX O
result XXX O
on XXX O
head-up XXX O
tilt-table XXX O
testing XXX O
and XXX O
no XXX O
evidence XXX O
of XXX O
structural XXX O
heart XXX O
disease XXX O
( XXX O
mean XXX O
follow-up XXX O
4 XXX O
. XXX O
3 XXX O
years XXX O
) XXX O
, XXX O
7 XXX O
are XXX O
without XXX O
further XXX O
episodes XXX O
of XXX O
syncope XXX O
; XXX O
3 XXX O
have XXX O
discontinued XXX O
medication XXX O
and XXX O
5 XXX O
have XXX O
resumed XXX O
at XXX O
least XXX O
limited XXX O
exercise XXX O
. XXX O

In XXX O
contrast XXX O
, XXX O
COUP-TF XXX B-GENE
alone XXX O
had XXX O
no XXX O
effect XXX O
on XXX O
repCRS2-dependent XXX O
reporter XXX O
gene XXX O
activity XXX O
. XXX O

Pups XXX O
placed XXX O
into XXX O
the XXX O
novel XXX O
environment XXX O
with XXX O
their XXX O
mothers XXX O
exhibited XXX O
an XXX O
intermediate XXX O
level XXX O
of XXX O
DA XXX O
turnover XXX O
. XXX O

With XXX O
this XXX O
bisected XXX O
diastolic XXX O
driving XXX O
, XXX O
the XXX O
abnormal XXX O
echo XXX O
disappeared XXX O
completely XXX O
. XXX O

This XXX O
report XXX O
focused XXX O
on XXX O
the XXX O
relationship XXX O
between XXX O
Type XXX O
A XXX O
behavior XXX O
and XXX O
eight XXX O
basic XXX O
emotion XXX O
dimensions XXX O
. XXX O

Using XXX O
either XXX O
a XXX O
p50- XXX O
or XXX O
p65-selected XXX B-GENE
kappa XXX I-GENE
B XXX I-GENE
motif XXX I-GENE
, XXX O
which XXX O
displayed XXX O
differential XXX O
binding XXX O
with XXX O
respect XXX O
to XXX O
the XXX O
other XXX O
protein XXX O
, XXX O
little XXX O
to XXX O
no XXX O
binding XXX O
was XXX O
observed XXX O
with XXX O
the XXX O
heterodimeric XXX B-GENE
NF-kappa XXX I-GENE
B XXX I-GENE
complex XXX I-GENE
. XXX O

We XXX O
have XXX O
isolated XXX O
a XXX O
novel XXX O
human XXX B-GENE
cyclin XXX I-GENE
, XXX O
cyclin XXX B-GENE
E2 XXX I-GENE
, XXX O
that XXX O
contains XXX O
significant XXX O
homology XXX O
to XXX O
cyclin XXX B-GENE
E XXX I-GENE
. XXX O

He XXX O
is XXX O
well XXX O
, XXX O
five XXX O
years XXX O
after XXX O
relapse XXX O
. XXX O

The XXX O
concentration XXX O
of XXX O
alpha XXX B-GENE
2-macroglobulin XXX I-GENE
, XXX O
alpha XXX B-GENE
1-antitrypsin XXX I-GENE
, XXX O
plasminogen XXX B-GENE
, XXX O
C3-complement XXX B-GENE
, XXX O
fibrinogen XXX B-GENE
degradation XXX O
products XXX O
( XXX O
FDP XXX O
) XXX O
and XXX O
fibrinolytic XXX O
activity XXX O
, XXX O
were XXX O
studied XXX O
in XXX O
the XXX O
aqueous XXX O
humour XXX O
and XXX O
serum XXX O
from XXX O
nine XXX O
patients XXX O
with XXX O
Fuchs' XXX O
endothelial XXX O
dystrophy XXX O
, XXX O
17 XXX O
patients XXX O
with XXX O
uncomplicated XXX O
senile XXX O
cataract XXX O
and XXX O
in XXX O
the XXX O
secondary XXX O
aqueous XXX O
from XXX O
six XXX O
cataract XXX O
patients XXX O
. XXX O

Significant XXX O
clinical XXX O
differences XXX O
between XXX O
the XXX O
patients XXX O
treated XXX O
with XXX O
and XXX O
without XXX O
AMB XXX O
were XXX O
longer XXX O
survival XXX O
time XXX O
following XXX O
diagnosis XXX O
of XXX O
illness XXX O
( XXX O
P XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
and XXX O
more XXX O
frequent XXX O
cranial XXX O
nerve XXX O
signs XXX O
in XXX O
the XXX O
treated XXX O
patients XXX O
( XXX O
P XXX O
= XXX O
0 XXX O
. XXX O
089 XXX O
) XXX O
. XXX O

However XXX O
, XXX O
mandibular XXX O
position XXX O
( XXX O
S-N-B XXX O
and XXX O
S-N-Pog XXX O
) XXX O
was XXX O
found XXX O
to XXX O
be XXX O
significantly XXX O
more XXX O
retrusive XXX O
in XXX O
Class XXX O
II XXX O
when XXX O
compared XXX O
with XXX O
Class XXX O
I XXX O
subjects XXX O
. XXX O

State-approved XXX O
schools XXX O
of XXX O
nursing XXX O
R XXX O
. XXX O
N XXX O
. XXX O

B XXX B-GENE
cell XXX I-GENE
antigen XXX I-GENE
receptor XXX I-GENE
( XXX O
BCR XXX B-GENE
) XXX O
-mediated XXX O
formation XXX O
of XXX O
a XXX O
SHP-2-pp120 XXX B-GENE
complex XXX I-GENE
and XXX O
its XXX O
inhibition XXX O
by XXX O
Fc XXX B-GENE
gamma XXX I-GENE
RIIB1-BCR XXX I-GENE
coligation XXX O
. XXX O

The XXX O
method XXX O
involves XXX O
preliminary XXX O
isolation XXX O
of XXX O
oxiracetam XXX O
and XXX O
internal XXX O
standard XXX O
from XXX O
plasma XXX O
by XXX O
solid-phase XXX O
extraction XXX O
prior XXX O
to XXX O
the XXX O
formation XXX O
of XXX O
their XXX O
n-propyl XXX O
carbamate XXX O
derivatives XXX O
. XXX O

The XXX O
alternative XXX O
splice XXX O
sites XXX O
for XXX O
the XXX O
smallest XXX O
adducin XXX B-GENE
isoform XXX O
, XXX O
beta-3 XXX B-GENE
, XXX O
are XXX O
alternative XXX O
donor XXX O
and XXX O
acceptor XXX O
sites XXX O
within XXX O
exons XXX O
7 XXX O
and XXX O
12 XXX O
. XXX O

The XXX O
patient XXX O
was XXX O
a XXX O
78-year-old XXX O
male XXX O
in XXX O
whom XXX O
skin XXX O
lesions XXX O
preceded XXX O
the XXX O
diagnosis XXX O
of XXX O
myelofibrosis XXX O
. XXX O

Isolation XXX O
of XXX O
Weeksella XXX O
virosa XXX O
( XXX O
formerly XXX O
CDC XXX O
group XXX O
IIf XXX O
) XXX O
from XXX O
a XXX O
vaginal XXX O
sample XXX O
. XXX O

Biochemical XXX O
analysis XXX O
demonstrates XXX O
that XXX O
the XXX O
BJ1 XXX B-GENE
protein XXX I-GENE
is XXX O
associated XXX O
with XXX O
nucleosomes XXX O
and XXX O
is XXX O
released XXX O
from XXX O
chromatin XXX O
by XXX O
agents XXX O
which XXX O
intercalate XXX O
into XXX O
DNA XXX O
, XXX O
as XXX O
previously XXX O
shown XXX O
for XXX O
the XXX O
high XXX B-GENE
mobility XXX I-GENE
group XXX I-GENE
proteins XXX I-GENE
( XXX O
HMGs XXX B-GENE
) XXX O
. XXX O

Overexpression XXX O
of XXX O
Trdpm1 XXX B-GENE
in XXX O
a XXX O
dpm1 XXX B-GENE
( XXX I-GENE
+ XXX I-GENE
) XXX I-GENE
: XXX O
: XXX O
his7 XXX B-GENE
/ XXX I-GENE
dpm1 XXX I-GENE
( XXX I-GENE
+ XXX I-GENE
) XXX I-GENE
S XXX O
. XXX O
pombe XXX O
diploid XXX O
resulted XXX O
in XXX O
a XXX O
4-fold XXX O
increase XXX O
in XXX O
specific XXX O
DPM XXX B-GENE
synthase XXX I-GENE
activity XXX O
. XXX O

The XXX O
average XXX O
deviations XXX O
in XXX O
the XXX O
X-ray XXX O
counts XXX O
of XXX O
the XXX O
constant XXX O
elements XXX O
from XXX O
the XXX O
series XXX O
means XXX O
were XXX O
used XXX O
to XXX O
correct XXX O
the XXX O
recorded XXX O
count XXX O
of XXX O
the XXX O
variable XXX O
element XXX O
in XXX O
each XXX O
block XXX O
. XXX O

The XXX O
proposed XXX O
mechanism XXX O
of XXX O
effect XXX O
states XXX O
that XXX O
mono XXX O
( XXX O
2-ethylhexyl XXX O
) XXX O
phthalate XXX O
( XXX O
MEHP XXX O
) XXX O
, XXX O
the XXX O
primary XXX O
hydrolysis XXX O
product XXX O
of XXX O
DEHP XXX O
, XXX O
mimics XXX O
the XXX O
inducing XXX O
prostaglandins XXX O
( XXX O
PG XXX O
) XXX O
PGD XXX O
( XXX O
2 XXX O
) XXX O
, XXX O
9alpha XXX O
, XXX O
11betaPGF2 XXX O
, XXX O
and XXX O
PGF2alpha XXX O
, XXX O
and XXX O
thromboxanes XXX O
in XXX O
the XXX O
lungs XXX O
, XXX O
thereby XXX O
increasing XXX O
the XXX O
risk XXX O
of XXX O
inducing XXX O
inflammation XXX O
in XXX O
the XXX O
airways XXX O
, XXX O
which XXX O
is XXX O
a XXX O
characteristic XXX O
of XXX O
asthma XXX O
. XXX O

Effect XXX O
of XXX O
the XXX O
methods XXX O
of XXX O
cutaneous XXX O
administration XXX O
of XXX O
methyl XXX O
isobutyl XXX O
ketone XXX O
on XXX O
its XXX O
toxicity XXX O
. XXX O

TIP30 XXX B-GENE
has XXX O
an XXX O
intrinsic XXX O
kinase XXX B-GENE
activity XXX O
required XXX O
for XXX O
up-regulation XXX O
of XXX O
a XXX O
subset XXX O
of XXX O
apoptotic XXX O
genes XXX O
. XXX O

The XXX O
optimal XXX O
care XXX O
of XXX O
CHF XXX O
patient XXX O
includes XXX O
the XXX O
recognition XXX O
and XXX O
management XXX O
of XXX O
these XXX O
electrolyte XXX O
disturbances XXX O
. XXX O

However XXX O
, XXX O
laparoscopy XXX O
failed XXX O
to XXX O
establish XXX O
inoperability XXX O
in XXX O
any XXX O
cases XXX O
of XXX O
carcinoma XXX O
spread XXX O
to XXX O
areas XXX O
not XXX O
accessible XXX O
to XXX O
laparoscopic XXX O
visualization XXX O
. XXX O

Randomised XXX O
comparison XXX O
of XXX O
addition XXX O
of XXX O
autologous XXX O
bone-marrow XXX O
transplantation XXX O
to XXX O
intensive XXX O
chemotherapy XXX O
for XXX O
acute XXX O
myeloid XXX O
leukaemia XXX O
in XXX O
first XXX O
remission XXX O
: XXX O
results XXX O
of XXX O
MRC XXX O
AML XXX O
10 XXX O
trial XXX O
. XXX O

The XXX O
organization XXX O
of XXX O
SPP1 XXX B-GENE
genes XXX I-GENE
involved XXX O
in XXX O
the XXX O
replication XXX O
, XXX O
DNA XXX O
packaging XXX O
and XXX O
phage XXX O
assembly XXX O
proteins XXX O
resembles XXX O
the XXX O
organization XXX O
of XXX O
genes XXX O
of XXX O
equivalent XXX O
regions XXX O
of XXX O
different XXX O
E XXX O
. XXX O
coli XXX O
double-stranded XXX O
DNA XXX O
phages XXX O
. XXX O

The XXX O
retention XXX O
index XXX O
of XXX O
201Tl XXX O
SPECT XXX O
is XXX O
a XXX O
useful XXX O
indicator XXX O
of XXX O
metastatic XXX O
potential XXX O
, XXX O
thereby XXX O
facilitating XXX O
the XXX O
prediction XXX O
of XXX O
prognosis XXX O
, XXX O
and XXX O
provides XXX O
insight XXX O
into XXX O
the XXX O
relationship XXX O
between XXX O
201Tl XXX O
uptake XXX O
and XXX O
malignancy XXX O
. XXX O

The XXX O
gene XXX O
organization XXX O
of XXX O
CRSV XXX B-GENE
RNA-1 XXX I-GENE
is XXX O
similar XXX O
to XXX O
those XXX O
of XXX O
red XXX O
clover XXX O
necrotic XXX O
mosaic XXX O
( XXX O
RCNMV XXX O
) XXX O
and XXX O
sweet XXX O
clover XXX O
necrotic XXX O
mosaic XXX O
( XXX O
SCNMV XXX O
) XXX O
dianthoviruses XXX O
with XXX O
the XXX O
exception XXX O
that XXX O
CRSV XXX B-GENE
RNA-1 XXX I-GENE
contains XXX O
the XXX O
additional XXX O
3'-terminal XXX O
ORF XXX O
. XXX O

All XXX O
anti-I XXX B-GENE
and XXX I-GENE
anti-i XXX I-GENE
CA XXX I-GENE
were XXX O
shown XXX O
to XXX O
express XXX O
VH4 XXX B-GENE
heavy XXX I-GENE
chains XXX I-GENE
, XXX O
and XXX O
14 XXX O
of XXX O
17 XXX O
CA XXX O
expressed XXX O
a XXX O
previously XXX O
described XXX O
VH4 XXX B-GENE
second XXX O
hypervariable XXX O
region XXX O
determinant XXX O
, XXX O
termed XXX O
VH4-HV2a XXX B-GENE
. XXX O

The XXX O
data XXX O
indicate XXX O
a XXX O
three-phase XXX O
reaction XXX O
after XXX O
B1 XXX O
injection XXX O
: XXX O
Phase XXX O
1--shortly XXX O
after XXX O
injection XXX O
there XXX O
is XXX O
a XXX O
drop XXX O
of XXX O
all XXX O
parameters XXX O
lasting XXX O
for XXX O
30 XXX O
sec XXX O
. XXX O

A XXX O
secondary XXX O
phosphorylation XXX O
of XXX O
CREB341 XXX B-GENE
at XXX O
Ser129 XXX O
is XXX O
required XXX O
for XXX O
the XXX O
cAMP-mediated XXX O
control XXX O
of XXX O
gene XXX O
expression XXX O
. XXX O

After XXX O
declamping XXX O
of XXX O
the XXX O
aorta XXX O
, XXX O
there XXX O
were XXX O
also XXX O
severe XXX O
edema XXX O
, XXX O
local XXX O
fibre XXX O
necrosis XXX O
, XXX O
and XXX O
adhesion XXX O
of XXX O
leucocytes XXX O
, XXX O
whereas XXX O
muscle XXX O
fibre XXX O
areas XXX O
became XXX O
3 XXX O
, XXX O
935 XXX O
. XXX O
18 XXX O
&mgr XXX O
; XXX O
531 XXX O
&mgr XXX O
; XXX O
m XXX O
( XXX O
2 XXX O
) XXX O
for XXX O
type XXX O
I XXX O
and XXX O
5 XXX O
, XXX O
804 XXX O
+ XXX O
/ XXX O
- XXX O
1 XXX O
, XXX O
075 XXX O
&mgr XXX O
; XXX O
m XXX O
( XXX O
2 XXX O
) XXX O
for XXX O
type XXX O
II XXX O
. XXX O

RNase XXX B-GENE
MRP XXX I-GENE
is XXX O
a XXX O
ribonucleoprotein XXX O
endoribonuclease XXX O
that XXX O
has XXX O
been XXX O
shown XXX O
to XXX O
have XXX O
roles XXX O
in XXX O
both XXX O
mitochondrial XXX O
DNA XXX O
replication XXX O
and XXX O
nuclear XXX B-GENE
5 XXX I-GENE
. XXX I-GENE
8S XXX I-GENE
rRNA XXX I-GENE
processing XXX O
. XXX O

In XXX O
the XXX O
present XXX O
study XXX O
, XXX O
we XXX O
have XXX O
determined XXX O
the XXX O
ICBP90 XXX B-GENE
gene XXX I-GENE
structure XXX O
by XXX O
screening XXX O
of XXX O
a XXX O
human XXX O
placenta XXX O
genomic XXX O
library XXX O
and XXX O
PCR XXX O
analysis XXX O
. XXX O

The XXX O
method XXX O
is XXX O
accurate XXX O
, XXX O
with XXX O
good XXX O
precision XXX O
and XXX O
adequate XXX O
sensitivity XXX O
. XXX O

Tyrosine XXX B-GENE
kinase XXX I-GENE
oncogenes XXX O
abrogate XXX O
interleukin-3 XXX B-GENE
dependence XXX O
of XXX O
murine XXX O
myeloid XXX O
cells XXX O
through XXX O
signaling XXX O
pathways XXX O
involving XXX O
c-myc XXX B-GENE
: XXX O
conditional XXX O
regulation XXX O
of XXX O
c-myc XXX B-GENE
transcription XXX O
by XXX O
temperature-sensitive XXX O
v-abl XXX B-GENE
. XXX O

In XXX O
mice XXX O
, XXX O
three XXX O
major XXX O
families XXX O
of XXX O
L1 XXX B-GENE
elements XXX I-GENE
, XXX O
termed XXX O
"A XXX B-GENE
, XXX I-GENE
" XXX I-GENE
"F XXX B-GENE
, XXX I-GENE
" XXX I-GENE
and XXX O
"V XXX B-GENE
, XXX I-GENE
" XXX I-GENE
have XXX O
been XXX O
defined XXX O
on XXX O
the XXX O
basis XXX O
of XXX O
the XXX O
sequence XXX O
found XXX O
at XXX O
the XXX O
5' XXX O
terminus XXX O
. XXX O

ST XXX O
elevation XXX O
occurs XXX O
in XXX O
5 XXX O
patients XXX O
( XXX O
55 XXX O
. XXX O
5% XXX O
) XXX O
of XXX O
subgroup XXX O
A XXX O
and XXX O
in XXX O
no XXX O
patient XXX O
of XXX O
the XXX O
subgroup XXX O
B XXX O
. XXX O

Co-transfection XXX O
of XXX O
expression XXX O
vectors XXX O
for XXX O
CCAAT XXX B-GENE
/ XXX I-GENE
enhancer XXX I-GENE
binding XXX I-GENE
protein XXX I-GENE
( XXX I-GENE
C XXX I-GENE
/ XXX I-GENE
EBP XXX I-GENE
) XXX I-GENE
alpha XXX I-GENE
and XXX O
C XXX B-GENE
/ XXX I-GENE
EBP XXX I-GENE
beta XXX I-GENE
trans-activated XXX O
the XXX O
rat XXX B-GENE
uncoupling XXX I-GENE
protein XXX I-GENE
gene XXX I-GENE
promoter XXX I-GENE
due XXX O
to XXX O
sequences XXX O
in XXX O
the XXX O
5' XXX O
proximal XXX O
region XXX O
. XXX O

Of XXX O
49 XXX O
receptors XXX O
which XXX O
fired XXX O
in XXX O
phase XXX O
with XXX O
ventilation XXX O
, XXX O
13 XXX O
behaved XXX O
like XXX O
mammalian XXX O
rapidly XXX O
adapting XXX O
pulmonary XXX O
stretch XXX O
receptors XXX O
, XXX O
19 XXX O
like XXX O
mammalian XXX O
slowly XXX O
adapting XXX O
pulmonary XXX O
stretch XXX O
receptors XXX O
( XXX O
PSR XXX O
) XXX O
, XXX O
and XXX O
17 XXX O
like XXX O
avian XXX O
intrapulmonary XXX O
CO2-sensitive XXX O
chemoreceptors XXX O
( XXX O
IPC XXX O
) XXX O
. XXX O

Our XXX O
results XXX O
, XXX O
when XXX O
combined XXX O
with XXX O
previously XXX O
published XXX O
in XXX O
vitro XXX O
results XXX O
, XXX O
support XXX O
a XXX O
direct XXX O
role XXX O
for XXX O
Prp44p XXX B-GENE
in XXX O
unwinding XXX O
of XXX O
the XXX O
U4 XXX B-GENE
/ XXX I-GENE
U6 XXX I-GENE
helix XXX O
. XXX O

Tryptic XXX O
cleavage XXX O
and XXX O
peptide XXX O
sequence XXX O
analysis XXX O
demonstrated XXX O
that XXX O
the XXX O
98-kD XXX O
protein XXX O
is XXX O
identical XXX O
to XXX O
a XXX O
recently XXX O
cloned XXX O
protein XXX O
, XXX O
special XXX B-GENE
A-T-rich XXX I-GENE
binding XXX I-GENE
protein XXX I-GENE
1 XXX I-GENE
( XXX O
SATB1 XXX B-GENE
) XXX O
, XXX O
that XXX O
binds XXX O
selectively XXX O
to XXX O
nuclear XXX O
matrix XXX O
/ XXX O
scaffold-associated XXX O
regions XXX O
of XXX O
DNA XXX O
( XXX O
MARs XXX O
/ XXX O
SARs XXX O
) XXX O
. XXX O

Conversely XXX O
, XXX O
E1A XXX B-GENE
binding XXX O
to XXX O
only XXX O
p300 XXX B-GENE
/ XXX I-GENE
CBP XXX I-GENE
results XXX O
in XXX O
an XXX O
increase XXX O
in XXX O
PARP XXX B-GENE
enzyme XXX I-GENE
activity XXX O
and XXX O
consequently XXX O
in XXX O
cell XXX O
death XXX O
susceptibility XXX O
to XXX O
irradiation XXX O
, XXX O
which XXX O
is XXX O
effectively XXX O
counteracted XXX O
by XXX O
the XXX O
PARP XXX B-GENE
chemical XXX O
inhibitor XXX O
3-aminobenzamide XXX O
. XXX O

The XXX O
N-syndecan-dependent XXX O
neurite XXX O
outgrowth XXX O
is XXX O
inhibited XXX O
by XXX O
the XXX O
tyrosine XXX B-GENE
kinase XXX I-GENE
inhibitors XXX O
herbimycin XXX O
A XXX O
and XXX O
PP1 XXX B-GENE
. XXX O

We XXX O
reviewed XXX O
the XXX O
records XXX O
of XXX O
151 XXX O
patients XXX O
with XXX O
optic XXX O
neuritis XXX O
examined XXX O
over XXX O
an XXX O
eight-year XXX O
period XXX O
. XXX O

Contributions XXX O
from XXX O
pairs XXX O
of XXX O
source XXX O
and XXX O
target XXX O
volume XXX O
elements XXX O
are XXX O
summed XXX O
for XXX O
the XXX O
S XXX O
values XXX O
between XXX O
the XXX O
tumor XXX O
and XXX O
itself XXX O
, XXX O
between XXX O
the XXX O
remaining XXX O
healthy XXX O
host XXX O
organ XXX O
and XXX O
itself XXX O
, XXX O
and XXX O
between XXX O
the XXX O
tumor XXX O
and XXX O
the XXX O
remaining XXX O
healthy XXX O
host XXX O
organ XXX O
, XXX O
with XXX O
the XXX O
reciprocity XXX O
theorem XXX O
assumed XXX O
for XXX O
the XXX O
last XXX O
. XXX O

Transfection XXX O
studies XXX O
also XXX O
showed XXX O
that XXX O
3'-deletion XXX O
of XXX O
sequences XXX O
downstream XXX O
of XXX O
the XXX O
transcriptional XXX O
start XXX O
site XXX O
( XXX O
+1 XXX O
/ XXX O
+47 XXX O
) XXX O
markedly XXX O
reduced XXX O
OSM XXX O
-fold XXX O
induction XXX O
. XXX O

Indeed XXX O
, XXX O
mutation XXX O
of XXX O
two XXX O
of XXX O
these XXX O
motifs XXX O
, XXX O
known XXX O
to XXX O
be XXX O
important XXX O
to XXX O
regulation XXX O
of XXX O
sid1 XXX B-GENE
, XXX O
altered XXX O
the XXX O
differential XXX O
regulation XXX O
of XXX O
sid2 XXX B-GENE
by XXX O
iron XXX O
. XXX O

Like XXX O
DNA XXX O
binding XXX O
, XXX O
transcriptional XXX O
enhancement XXX O
required XXX O
amino-terminally XXX O
located XXX O
basic XXX O
amino XXX O
acid XXX O
residues XXX O
but XXX O
not XXX O
the XXX O
carboxyl-terminal XXX O
portion XXX O
of XXX O
Hap46 XXX B-GENE
known XXX O
to XXX O
participate XXX O
in XXX O
hsp70 XXX B-GENE
interaction XXX O
. XXX O

Pet-1 XXX B-GENE
can XXX O
bind XXX O
specifically XXX O
to XXX O
a XXX O
PEA3 XXX B-GENE
ETS XXX I-GENE
DNA-binding XXX I-GENE
motif XXX I-GENE
and XXX O
can XXX O
modulate XXX O
transcription XXX O
of XXX O
synthetic XXX O
promoter XXX O
constructs XXX O
in XXX O
a XXX O
sequence-specific XXX O
manner XXX O
. XXX O

In XXX O
conclusion XXX O
, XXX O
our XXX O
data XXX O
do XXX O
not XXX O
support XXX O
a XXX O
role XXX O
for XXX O
IVIg XXX O
in XXX O
the XXX O
remyelination XXX O
of XXX O
stable XXX O
multiple XXX O
sclerosis XXX O
lesions XXX O
as XXX O
measured XXX O
by XXX O
central XXX O
conduction XXX O
time XXX O
. XXX O

Isolation XXX O
of XXX O
tha XXX O
avian XXX O
reticuloendothelial XXX O
virus XXX O
( XXX O
strain XXX O
T XXX O
) XXX O
. XXX O

To XXX O
explore XXX O
the XXX O
mechanism XXX O
of XXX O
RSK XXX B-GENE
activation XXX O
, XXX O
a XXX O
cloned XXX O
human XXX O
RSK XXX B-GENE
cDNA XXX O
( XXX O
RSK3 XXX B-GENE
) XXX O
was XXX O
used XXX O
to XXX O
generate XXX O
and XXX O
characterize XXX O
several XXX O
site-directed XXX O
RSK XXX B-GENE
mutants XXX I-GENE
; XXX O
K91A XXX O
( XXX O
N-Lys XXX O
, XXX O
NH2-terminal XXX O
ATP-binding XXX O
mutant XXX O
) XXX O
, XXX O
K444A XXX O
( XXX O
C-Lys XXX O
, XXX O
COOH-terminal XXX O
ATP-binding XXX O
mutant XXX O
) XXX O
, XXX O
N XXX O
/ XXX O
C-Lys XXX O
( XXX O
double XXX O
ATP-binding XXX O
mutant XXX O
) XXX O
T570A XXX O
( XXX O
C-Thr XXX O
, XXX O
mutant XXX O
of XXX O
the XXX O
putative XXX O
MAPK XXX B-GENE
phosphorylation XXX O
site XXX O
in XXX O
subdomain XXX O
VIII XXX O
of XXX O
the XXX O
C-domain XXX O
) XXX O
, XXX O
S218A XXX O
( XXX O
N-Ser XXX O
, XXX O
mutant XXX O
of XXX O
the XXX O
corresponding XXX O
NH2-terminal XXX O
residue XXX O
) XXX O
. XXX O

Since XXX O
MEK XXX B-GENE
acts XXX O
as XXX O
a XXX O
cytoplasmic XXX O
anchor XXX O
for XXX O
the XXX O
ERKs XXX B-GENE
, XXX O
the XXX O
lack XXX O
of XXX O
a XXX O
MEK XXX B-GENE
interaction XXX O
resulted XXX O
in XXX O
the XXX O
aberrant XXX O
nuclear XXX O
localization XXX O
of XXX O
ERK2-Delta19-25 XXX B-GENE
mutants XXX I-GENE
in XXX O
serum-starved XXX O
cells XXX O
. XXX O

When XXX O
two XXX O
determinations XXX O
were XXX O
performed XXX O
on XXX O
12 XXX O
samples XXX O
of XXX O
plasma XXX O
taken XXX O
from XXX O
normal XXX O
adults XXX O
in XXX O
October XXX O
, XXX O
the XXX O
values XXX O
were XXX O
22 XXX O
. XXX O
6 XXX O
+ XXX O
/ XXX O
- XXX O
4 XXX O
. XXX O
8 XXX O
and XXX O
21 XXX O
. XXX O
0 XXX O
+ XXX O
/ XXX O
- XXX O
3 XXX O
. XXX O
6 XXX O
( XXX O
mean XXX O
+ XXX O
/ XXX O
- XXX O
SD XXX O
) XXX O
ng XXX O
/ XXX O
ml XXX O
, XXX O
respectively XXX O
. XXX O

Based XXX O
on XXX O
peptide XXX O
map XXX O
similarities XXX O
, XXX O
partial XXX O
amino-terminal XXX O
sequence XXX O
data XXX O
, XXX O
and XXX O
common XXX O
genetic XXX O
origin XXX O
, XXX O
it XXX O
is XXX O
suggested XXX O
that XXX O
p60 XXX B-GENE
and XXX O
p62 XXX B-GENE
have XXX O
identical XXX O
amino XXX O
acid XXX O
sequences XXX O
carboxy-terminal XXX O
to XXX O
the XXX O
p60 XXX B-GENE
initiator XXX O
methionine XXX O
( XXX O
residue XXX O
21 XXX O
of XXX O
p62 XXX B-GENE
) XXX O
. XXX O

Overexpression XXX O
of XXX O
ICBP90 XXX B-GENE
in XXX O
COS-1-transfected XXX O
cells XXX O
induced XXX O
an XXX O
enhanced XXX O
expression XXX O
of XXX O
endogenous XXX B-GENE
topoisomerase XXX I-GENE
IIalpha XXX I-GENE
. XXX O

The XXX O
latter XXX O
method XXX O
adds XXX O
clamping XXX O
of XXX O
the XXX O
inferior XXX O
vena XXX O
cava XXX O
, XXX O
which XXX O
results XXX O
in XXX O
hypotension XXX O
, XXX O
requiring XXX O
invasive XXX O
anesthetic XXX O
management XXX O
. XXX O

We XXX O
conclude XXX O
that XXX O
transcription XXX O
activation XXX O
by XXX O
LEF-1 XXX B-GENE
in XXX O
vitro XXX O
is XXX O
a XXX O
chromatin-dependent XXX O
process XXX O
that XXX O
requires XXX O
a XXX O
functional XXX O
trans-activation XXX O
domain XXX O
in XXX O
addition XXX O
to XXX O
the XXX O
HMG XXX B-GENE
domain XXX I-GENE
. XXX O

313 XXX O
, XXX O
98-102 XXX O
) XXX O
. XXX O

These XXX O
primers XXX O
yielded XXX O
a XXX O
PCR XXX O
product XXX O
of XXX O
a XXX O
characteristic XXX O
length XXX O
within XXX O
most XXX O
Xanthomonas XXX O
species XXX O
and XXX O
pathovars XXX O
tested XXX O
. XXX O

We XXX O
have XXX O
thus XXX O
identified XXX O
the XXX O
first XXX O
mammalian XXX B-GENE
homolog XXX I-GENE
of XXX I-GENE
yeast XXX I-GENE
UPF1 XXX I-GENE
, XXX O
a XXX O
protein XXX O
that XXX O
regulates XXX O
levels XXX O
of XXX O
nonsense XXX O
mRNA XXX O
, XXX O
and XXX O
we XXX O
tentatively XXX O
name XXX O
this XXX O
protein XXX O
human XXX B-GENE
HUPF1 XXX I-GENE
( XXX O
for XXX O
human XXX B-GENE
homolog XXX I-GENE
of XXX I-GENE
UPF1 XXX I-GENE
) XXX O
. XXX O

Of XXX O
the XXX O
three XXX O
known XXX O
C XXX B-GENE
/ XXX I-GENE
EBP XXX I-GENE
family XXX I-GENE
inhibitors XXX O
, XXX O
Ig XXX B-GENE
/ XXX I-GENE
EBP XXX I-GENE
, XXX O
LIP XXX B-GENE
and XXX O
CHOP-10 XXX B-GENE
, XXX O
only XXX O
Ig XXX B-GENE
/ XXX I-GENE
EBP XXX I-GENE
is XXX O
ubiquitously XXX O
expressed XXX O
. XXX O

BACKGROUND XXX O
: XXX O
The XXX O
MAZE-III XXX O
is XXX O
the XXX O
surgical XXX O
treatment XXX O
of XXX O
choice XXX O
for XXX O
medically XXX O
refractory XXX O
atrial XXX O
fibrillation XXX O
. XXX O

Failures XXX O
of XXX O
colorimetric XXX O
additivity XXX O
under XXX O
these XXX O
experimental XXX O
conditions XXX O
are XXX O
discussed XXX O
. XXX O

0% XXX O
) XXX O
and XXX O
IL-12 XXX B-GENE
( XXX O
42 XXX O
. XXX O
6% XXX O
vs XXX O
. XXX O

[ XXX O
Diabetologia XXX O
( XXX O
2001 XXX O
) XXX O
44 XXX O
[ XXX O
Suppl XXX O
3 XXX O
] XXX O
: XXX O
B XXX O
37-B XXX O
44 XXX O
] XXX O

The XXX O
Cox XXX O
proportional XXX O
hazards XXX O
model XXX O
was XXX O
applied XXX O
to XXX O
the XXX O
data XXX O
in XXX O
order XXX O
to XXX O
determine XXX O
the XXX O
prognostic XXX O
factors XXX O
for XXX O
long-term XXX O
survival XXX O
. XXX O

Atopic XXX O
dermatitis XXX O
is XXX O
an XXX O
"itch XXX O
which XXX O
rashes XXX O
and XXX O
not XXX O
a XXX O
rash XXX O
which XXX O
itches" XXX O
and XXX O
therefore XXX O
, XXX O
any XXX O
patient XXX O
treatment XXX O
program XXX O
should XXX O
address XXX O
the XXX O
multiplicity XXX O
of XXX O
potential XXX O
trigger XXX O
factors XXX O
that XXX O
provoke XXX O
this XXX O
itching XXX O
. XXX O

This XXX O
protein XXX O
can XXX O
bind XXX O
to XXX O
a XXX O
region XXX O
of XXX O
the XXX O
promoter XXX O
of XXX O
an XXX O
Arabidopsis XXX B-GENE
light-harvesting XXX I-GENE
chlorophyll XXX I-GENE
a XXX I-GENE
/ XXX I-GENE
b XXX I-GENE
protein XXX I-GENE
gene XXX I-GENE
, XXX O
Lhcb1*3 XXX B-GENE
, XXX O
which XXX O
is XXX O
necessary XXX O
for XXX O
its XXX O
regulation XXX O
by XXX O
phytochrome XXX O
. XXX O

The XXX O
metabolic XXX O
events XXX O
occurring XXX O
at XXX O
or XXX O
near XXX O
that XXX O
structure XXX O
and XXX O
involving XXX O
cyclin XXX B-GENE
D3 XXX I-GENE
cause XXX O
the XXX O
translocation XXX O
of XXX O
ICP0 XXX B-GENE
to XXX O
the XXX O
cytoplasm XXX O
. XXX O

The XXX O
PDGFR XXX B-GENE
mutants XXX I-GENE
that XXX O
failed XXX O
to XXX O
associate XXX O
with XXX O
PLC XXX B-GENE
gamma XXX I-GENE
were XXX O
not XXX O
able XXX O
to XXX O
mediate XXX O
the XXX O
PDGF-dependent XXX O
production XXX O
of XXX O
inositol XXX O
phosphates XXX O
. XXX O

There XXX O
were XXX O
3 XXX O
/ XXX O
32 XXX O
( XXX O
9 XXX O
. XXX O
4 XXX O
per XXX O
cent XXX O
) XXX O
adverse XXX O
reactions XXX O
( XXX O
ADRs XXX O
) XXX O
, XXX O
and XXX O
one XXX O
case XXX O
each XXX O
of XXX O
nausea XXX O
, XXX O
dizziness XXX O
and XXX O
increased XXX O
menstrual XXX O
flow XXX O
. XXX O

Moreover XXX O
, XXX O
when XXX O
added XXX O
to XXX O
the XXX O
osteoclast XXX O
cultures XXX O
, XXX O
mrIhh-N XXX B-GENE
markedly XXX O
stimulated XXX O
the XXX O
formation XXX O
of XXX O
resorption XXX O
pits XXX O
on XXX O
dentine XXX O
slices XXX O
. XXX O

II XXX O
. XXX O

Sex XXX O
selection XXX O
via XXX O
albumin XXX B-GENE
columns XXX O
: XXX O
20 XXX O
years XXX O
of XXX O
results XXX O
. XXX O

Tl-201 XXX O
uptake XXX O
ratio XXX O
of XXX O
the XXX O
right XXX O
ventricle XXX O
, XXX O
which XXX O
represents XXX O
the XXX O
ratio XXX O
of XXX O
total XXX O
counts XXX O
of XXX O
the XXX O
right XXX O
ventricle XXX O
to XXX O
counts XXX O
of XXX O
the XXX O
administered XXX O
dose XXX O
of XXX O
Tl-201 XXX O
, XXX O
was XXX O
higher XXX O
in XXX O
COPD XXX O
, XXX O
especially XXX O
in XXX O
pulmonary XXX O
emphysema XXX O
and XXX O
B XXX O
type XXX O
COPD XXX O
by XXX O
Burrows XXX O
classification XXX O
than XXX O
in XXX O
controls XXX O
. XXX O

Substantial XXX O
amounts XXX O
of XXX O
liposomal XXX O
ampicillin XXX O
were XXX O
recovered XXX O
from XXX O
isolated XXX O
Kupffer XXX O
cells XXX O
, XXX O
the XXX O
target XXX O
cells XXX O
of XXX O
L XXX O
. XXX O
monocytogenes XXX O
after XXX O
intravenous XXX O
inoculation XXX O
. XXX O

Val-- XXX O
> XXX O
Ala XXX O
mutations XXX O
selectively XXX O
alter XXX O
helix-helix XXX O
packing XXX O
in XXX O
the XXX O
transmembrane XXX O
segment XXX O
of XXX O
phage XXX B-GENE
M13 XXX I-GENE
coat XXX I-GENE
protein XXX I-GENE
. XXX O

The XXX O
preferential XXX O
serum XXX B-GENE
IgA XXX I-GENE
response XXX O
observed XXX O
in XXX O
the XXX O
patient XXX O
population XXX O
suggests XXX O
that XXX O
bronchial XXX O
associated XXX O
lymphoid XXX O
tissue XXX O
in XXX O
the XXX O
diseased XXX O
lung XXX O
is XXX O
an XXX O
important XXX O
source XXX O
of XXX O
circulating XXX O
IgA XXX B-GENE
. XXX O

Indium-111 XXX O
OncoScint XXX O
CR XXX O
/ XXX O
OV XXX O
and XXX O
F-18 XXX O
FDG XXX O
in XXX O
colorectal XXX O
and XXX O
ovarian XXX O
carcinoma XXX O
recurrences XXX O
. XXX O

Possible XXX O
pathogenetic XXX O
mechanisms XXX O
of XXX O
hemopoietic XXX O
changes XXX O
in XXX O
response XXX O
to XXX O
space XXX O
flight XXX O
effects XXX O
are XXX O
described XXX O
. XXX O

One XXX O
such XXX O
mutant XXX O
also XXX O
affects XXX O
the XXX O
overlapping XXX O
-10 XXX O
hexamer XXX O
of XXX O
PR XXX O
and XXX O
results XXX O
in XXX O
reduced XXX O
occupancy XXX O
by XXX O
both XXX O
MerR XXX B-GENE
and XXX O
RNA XXX B-GENE
polymerase XXX I-GENE
, XXX O
likely XXX O
as XXX O
a XXX O
result XXX O
of XXX O
inefficient XXX O
transcriptional XXX O
initiation XXX O
of XXX O
merR XXX B-GENE
mRNA XXX I-GENE
. XXX O

All XXX O
groups XXX O
were XXX O
tested XXX O
in XXX O
a XXX O
Hebb-Williams XXX O
maze XXX O
at XXX O
100 XXX O
approximately XXX O
10 XXX O
days XXX O
of XXX O
age XXX O
. XXX O

Complete XXX O
sequences XXX O
were XXX O
obtained XXX O
for XXX O
the XXX O
three XXX O
large XXX O
thrombic XXX O
peptides XXX O
, XXX O
and XXX O
these XXX O
were XXX O
aligned XXX O
by XXX O
using XXX O
peptides XXX O
from XXX O
the XXX O
V8 XXX B-GENE
protease XXX I-GENE
digest XXX O
. XXX O

Mutation XXX O
of XXX O
the XXX O
presumptive XXX O
phosphorylated XXX O
tyrosine XXX O
and XXX O
threonine XXX O
residues XXX O
of XXX O
Mpk1p XXX B-GENE
individually XXX O
to XXX O
phenylalanine XXX O
and XXX O
alanine XXX O
, XXX O
respectively XXX O
, XXX O
severely XXX O
impaired XXX O
Mpk1p XXX B-GENE
function XXX O
. XXX O
( XXX O
ABSTRACT XXX O
TRUNCATED XXX O
AT XXX O
250 XXX O
WORDS XXX O
) XXX O

Using XXX O
Southern XXX O
blot XXX O
analysis XXX O
and XXX O
restriction XXX O
mapping XXX O
of XXX O
genomic XXX O
YAC XXX O
( XXX O
yeast XXX O
artificial XXX O
chromosome XXX O
) XXX O
and XXX O
cosmid XXX O
clones XXX O
, XXX O
we XXX O
located XXX O
the XXX O
human XXX B-GENE
RIL XXX I-GENE
gene XXX I-GENE
240-260 XXX O
kb XXX O
telomeric XXX O
to XXX O
the XXX O
IRF1 XXX B-GENE
gene XXX I-GENE
and XXX O
characterized XXX O
its XXX O
genomic XXX O
structure XXX O
. XXX O

In XXX O
49 XXX O
patients XXX O
in XXX O
whom XXX O
gated XXX O
equilibrium XXX O
ventriculography XXX O
and XXX O
cardiac XXX O
catheterization XXX O
were XXX O
performed XXX O
within XXX O
a XXX O
6 XXX O
day XXX O
interval XXX O
, XXX O
total XXX O
and XXX O
fractional XXX O
portions XXX O
of XXX O
global XXX O
and XXX O
regional XXX O
right XXX O
ventricular XXX O
ejection XXX O
fraction XXX O
( XXX O
RVEF XXX O
) XXX O
were XXX O
correlated XXX O
with XXX O
pulmonary XXX O
arterial XXX O
systolic XXX O
pressure XXX O
. XXX O

( XXX O
1980 XXX O
) XXX O
: XXX O
Science XXX O
210 XXX O
, XXX O
77-72 XXX O
) XXX O
that XXX O
stimulating XXX O
the XXX O
crossed XXX O
olivocochlear XXX O
bundle XXX O
( XXX O
COCB XXX O
) XXX O
can XXX O
change XXX O
the XXX O
magnitude XXX O
of XXX O
the XXX O
distortion XXX O
product XXX O
( XXX O
f2-f1 XXX O
) XXX O
in XXX O
the XXX O
ear-canal XXX O
sound XXX O
pressure XXX O
. XXX O

METHODS XXX O
: XXX O
302 XXX O
consecutive XXX O
patients XXX O
with XXX O
BS XXX O
and XXX O
438 XXX O
patients XXX O
with XXX O
other XXX O
rheumatological XXX O
conditions XXX O
were XXX O
surveyed XXX O
for XXX O
the XXX O
presence XXX O
or XXX O
absence XXX O
of XXX O
the XXX O
features XXX O
of XXX O
BS XXX O
by XXX O
means XXX O
of XXX O
a XXX O
standard XXX O
form XXX O
which XXX O
had XXX O
been XXX O
prepared XXX O
according XXX O
to XXX O
ISG XXX O
criteria XXX O
. XXX O

In XXX O
general XXX O
, XXX O
however XXX O
, XXX O
this XXX O
study XXX O
provided XXX O
little XXX O
evidence XXX O
of XXX O
any XXX O
effect XXX O
of XXX O
supplementation XXX O
to XXX O
athletic XXX O
performance XXX O
for XXX O
athletes XXX O
consuming XXX O
the XXX O
dietary XXX O
RDIs XXX O
. XXX O

In XXX O
contrast XXX O
, XXX O
AP-2 XXX B-GENE
binding XXX O
activity XXX O
was XXX O
significantly XXX O
greater XXX O
in XXX O
T47D XXX O
cells XXX O
, XXX O
and XXX O
Western XXX O
blots XXX O
confirmed XXX O
increased XXX O
AP-2 XXX B-GENE
protein XXX I-GENE
levels XXX O
in XXX O
these XXX O
cells XXX O
. XXX O

Deletion XXX O
of XXX O
the XXX O
last XXX O
two XXX O
Ser XXX O
residues XXX O
, XXX O
including XXX O
one XXX O
PKC XXX B-GENE
consensus XXX O
site XXX O
in XXX O
the XXX O
receptor XXX O
tail XXX O
, XXX O
prevented XXX O
only XXX O
phorbol XXX O
12-myristate XXX O
13-acetate-induced XXX O
desensitization XXX O
by XXX O
30% XXX O
. XXX O

Competitive XXX O
reverse XXX O
transcription-polymerase XXX O
chain XXX O
reaction XXX O
and XXX O
HPLC XXX O
analysis XXX O
showed XXX O
that XXX O
RUSH-1alpha XXX B-GENE
is XXX O
the XXX O
progesterone-dependent XXX O
splice XXX O
variant XXX O
. XXX O

This XXX O
was XXX O
performed XXX O
in XXX O
a XXX O
double XXX O
blinded XXX O
, XXX O
randomized XXX O
, XXX O
placebo-controlled XXX O
study XXX O
. XXX O

E2F-6 XXX B-GENE
shares XXX O
significant XXX O
homology XXX O
with XXX O
E2Fs XXX B-GENE
1-5 XXX I-GENE
, XXX O
especially XXX O
within XXX O
the XXX O
DNA XXX O
binding XXX O
, XXX O
heterodimerization XXX O
and XXX O
marked XXX O
box XXX O
domains XXX O
. XXX O

Pharmacoeconomic XXX O
assessment XXX O
of XXX O
HMG-CoA XXX B-GENE
reductase XXX I-GENE
inhibitor XXX O
therapy XXX O
: XXX O
an XXX O
analysis XXX O
based XXX O
on XXX O
the XXX O
CURVES XXX O
study XXX O
. XXX O

A XXX O
quantitative XXX O
analysis XXX O
of XXX O
the XXX O
diffraction XXX O
intensity XXX O
as XXX O
function XXX O
of XXX O
the XXX O
accumulated XXX O
electron XXX O
dose XXX O
suggests XXX O
the XXX O
possibility XXX O
of XXX O
recording XXX O
up XXX O
to XXX O
250 XXX O
diffraction XXX O
patterns XXX O
with XXX O
3 XXX O
. XXX O
5 XXX O
A XXX O
resolution XXX O
from XXX O
a XXX O
single XXX O
crotoxin XXX O
complex XXX O
crystal XXX O
128 XXX O
A XXX O
thick XXX O
. XXX O

Consequently XXX O
functional XXX O
mRNAs XXX O
can XXX O
be XXX O
produced XXX O
by XXX O
endogenous XXX B-GENE
RNA XXX I-GENE
polymerase XXX I-GENE
I XXX O
. XXX O

Essential XXX O
features XXX O
of XXX O
this XXX O
model XXX O
are XXX O
bending XXX O
of XXX O
the XXX O
DNA XXX O
double XXX O
helix XXX O
and XXX O
contact XXX O
of XXX O
operator XXX O
sites XXX O
with XXX O
repressor XXX O
domains XXX O
bearing XXX O
sequence XXX O
homologies XXX O
with XXX O
the XXX O
helix-turn-helix XXX O
( XXX O
HTH XXX O
) XXX O
motifs XXX O
of XXX O
other XXX O
DNA-binding XXX O
proteins XXX O
. XXX O

Organisms XXX O
were XXX O
recovered XXX O
from XXX O
the XXX O
conjunctiva XXX O
for XXX O
several XXX O
weeks XXX O
, XXX O
and XXX O
persistent XXX O
genital XXX O
and XXX O
gastrointestinal XXX O
infection XXX O
also XXX O
resulted XXX O
from XXX O
the XXX O
ocular XXX O
infection XXX O
in XXX O
some XXX O
cats XXX O
. XXX O

Mean XXX O
rCBF XXX O
increased XXX O
in XXX O
some XXX O
patients XXX O
4-8 XXX O
weeks XXX O
after XXX O
surgery XXX O
on XXX O
the XXX O
ipsilateral XXX O
side XXX O
. XXX O

The XXX O
first XXX O
exon XXX O
encodes XXX O
66 XXX O
bp XXX O
of XXX O
the XXX O
5'-untranslated XXX O
sequence XXX O
, XXX O
while XXX O
exon XXX O
2 XXX O
encodes XXX O
the XXX O
coding XXX O
and XXX O
3'-untranslated XXX O
sequences XXX O
. XXX O

Clinical XXX O
method XXX O
for XXX O
the XXX O
treatment XXX O
of XXX O
Class XXX O
II XXX O
occlusal XXX O
anomalies XXX O
with XXX O
open XXX O
bite XXX O
. XXX O

A XXX O
key XXX O
event XXX O
in XXX O
this XXX O
process XXX O
is XXX O
the XXX O
selective XXX O
recognition XXX O
of XXX O
the XXX O
target XXX O
membrane XXX O
by XXX O
the XXX O
vesicle XXX O
and XXX O
the XXX O
current XXX O
view XXX O
is XXX O
that XXX O
SNARE XXX B-GENE
protein XXX I-GENE
interactions XXX O
likely XXX O
play XXX O
a XXX O
central XXX O
role XXX O
in XXX O
vesicle-target XXX O
recognition XXX O
and XXX O
or XXX O
membrane XXX O
fusion XXX O
. XXX O

This XXX O
site XXX O
acts XXX O
as XXX O
a XXX O
negative XXX O
element XXX O
when XXX O
transferred XXX O
to XXX O
the XXX O
thymidine XXX B-GENE
kinase XXX I-GENE
promoter XXX I-GENE
, XXX O
but XXX O
does XXX O
not XXX O
confer XXX O
inducibility XXX O
. XXX O

CONCLUSION XXX O
: XXX O
Vitrectomy XXX O
for XXX O
vitreous XXX O
hemorrhage XXX O
in XXX O
Terson XXX O
syndrome XXX O
is XXX O
a XXX O
safe XXX O
and XXX O
effective XXX O
procedure XXX O
, XXX O
offering XXX O
a XXX O
rapid XXX O
and XXX O
prolonged XXX O
improvement XXX O
in XXX O
vision XXX O
. XXX O

Mouse XXX B-GENE
growth XXX I-GENE
hormone XXX I-GENE
transcription XXX I-GENE
factor XXX I-GENE
Zn-16 XXX I-GENE
: XXX O
unique XXX O
bipartite XXX O
structure XXX O
containing XXX O
tandemly XXX O
repeated XXX O
zinc XXX O
finger XXX O
domains XXX O
not XXX O
reported XXX O
in XXX O
rat XXX B-GENE
Zn-15 XXX I-GENE
. XXX O

Early XXX O
infection XXX O
was XXX O
detected XXX O
in XXX O
one XXX O
of XXX O
50 XXX O
control XXX O
women XXX O
who XXX O
gave XXX O
birth XXX O
to XXX O
a XXX O
healthy XXX O
infant XXX O
. XXX O

By XXX O
screening XXX O
a XXX O
Y1 XXX O
cell XXX O
cDNA XXX O
library XXX O
with XXX O
the XXX O
DNA-binding XXX O
region XXX O
of XXX O
the XXX O
H-2RIIBP XXX B-GENE
nuclear XXX I-GENE
hormone XXX I-GENE
receptor XXX I-GENE
cDNA XXX I-GENE
, XXX O
we XXX O
isolated XXX O
a XXX O
cDNA XXX O
that XXX O
is XXX O
selectively XXX O
expressed XXX O
in XXX O
steroidogenic XXX O
cells XXX O
. XXX O

Pentachlorophenol XXX O
accelerates XXX O
the XXX O
onset XXX O
of XXX O
HCB XXX O
porphyria XXX O
, XXX O
in XXX O
other XXX O
words XXX O
it XXX O
increases XXX O
the XXX O
total XXX O
urinary XXX B-GENE
porphyrin XXX I-GENE
excretion XXX O
and XXX O
causes XXX O
an XXX O
earlier XXX O
disturbance XXX O
of XXX O
the XXX O
porphyrin XXX B-GENE
pattern XXX O
. XXX O

A XXX O
cDNA XXX O
clone XXX O
encoding XXX O
C2H2-type XXX B-GENE
zinc XXX I-GENE
finger XXX I-GENE
protein XXX I-GENE
, XXX O
SCOF-1 XXX B-GENE
, XXX O
was XXX O
isolated XXX O
from XXX O
soybean XXX O
. XXX O

EGV XXX O
had XXX O
no XXX O
detectable XXX O
effect XXX O
on XXX O
PP XXX B-GENE
secretion XXX O
under XXX O
basal XXX O
or XXX O
stimulated XXX O
conditions XXX O
. XXX O

Intrapocket XXX O
chemotherapy XXX O
in XXX O
adult XXX O
periodontitis XXX O
using XXX O
a XXX O
new XXX O
controlled-release XXX O
insert XXX O
containing XXX O
ofloxacin XXX O
( XXX O
PT-01 XXX O
) XXX O
. XXX O

Linearized XXX O
overall XXX O
infection XXX O
rates XXX O
( XXX O
events XXX O
/ XXX O
100 XXX O
patient-days XXX O
) XXX O
were XXX O
2 XXX O
. XXX O
05 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
33 XXX O
( XXX O
heart-lung XXX O
) XXX O
and XXX O
2 XXX O
. XXX O
34 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
34 XXX O
( XXX O
double-lung XXX O
; XXX O
P XXX O
= XXX O
NS XXX O
) XXX O
at XXX O
3 XXX O
months XXX O
. XXX O

Hepatitis XXX O
B XXX O
and XXX O
C XXX O
seroprevalence XXX O
rates XXX O
among XXX O
high-risk XXX O
adolescents XXX O
are XXX O
lower XXX O
in XXX O
El XXX O
Paso XXX O
than XXX O
in XXX O
other XXX O
similar XXX O
US XXX O
populations XXX O
, XXX O
presenting XXX O
an XXX O
ideal XXX O
climate XXX O
for XXX O
prevention XXX O
programs XXX O
. XXX O

The XXX O
results XXX O
suggest XXX O
that XXX O
the XXX O
presence XXX O
or XXX O
absence XXX O
per XXX O
se XXX O
of XXX O
keratan XXX O
sulfate XXX O
on XXX O
native XXX O
G1-G2 XXX O
does XXX O
not XXX O
affect XXX O
the XXX O
activity XXX O
of XXX O
atrolysin XXX O
C XXX O
toward XXX O
the XXX O
two XXX O
sites XXX O
. XXX O

Charcoal-facilitated XXX O
dialysis XXX O
. XXX O

Pseudomonas XXX B-GENE
aeruginosa XXX I-GENE
exotoxin XXX I-GENE
A XXX I-GENE
: XXX O
its XXX O
role XXX O
in XXX O
retardation XXX O
of XXX O
wound XXX O
healing XXX O
: XXX O
the XXX O
1992 XXX O
Lindberg XXX O
Award XXX O
. XXX O

This XXX O
means XXX O
that XXX O
the XXX O
loss XXX O
of XXX O
recessives XXX O
must XXX O
be XXX O
calculated XXX O
by XXX O
using XXX O
a XXX O
hypergeometric XXX O
and XXX O
not XXX O
a XXX O
binomial XXX O
model XXX O
as XXX O
Fisher XXX O
did XXX O
. XXX O

We XXX O
have XXX O
cloned XXX O
a XXX O
novel XXX O
100-kDa XXX O
mammalian XXX O
protein XXX O
, XXX O
which XXX O
was XXX O
recognized XXX O
by XXX O
an XXX O
anti-peptide XXX O
antibody XXX O
against XXX O
an XXX O
epitope-containing XXX O
nuclear XXX O
localization XXX O
signal XXX O
of XXX O
NF-kappaB XXX B-GENE
p65 XXX B-GENE
subunit XXX I-GENE
. XXX O

The XXX O
U14 XXX B-GENE
genes XXX I-GENE
of XXX O
mouse XXX O
as XXX O
well XXX O
as XXX O
rat XXX O
, XXX O
hamster XXX O
, XXX O
human XXX O
, XXX O
Xenopus XXX O
and XXX O
trout XXX O
are XXX O
encoded XXX O
within XXX O
introns XXX O
of XXX O
the XXX O
constitutively XXX O
expressed XXX O
70-kDa-cognate-heat-shock XXX B-GENE
protein XXX I-GENE
gene XXX I-GENE
( XXX O
hsc70 XXX B-GENE
) XXX O
. XXX O

Presidential XXX O
address XXX O
1990--coming XXX O
in XXX O
from XXX O
the XXX O
cold XXX O
. XXX O

However XXX O
, XXX O
we XXX O
could XXX O
not XXX O
find XXX O
the XXX O
homologous XXX O
regions XXX O
with XXX O
guanine XXX B-GENE
nucleotide XXX I-GENE
exchange XXX I-GENE
factors XXX I-GENE
or XXX O
GTPase-activating XXX B-GENE
proteins XXX I-GENE
in XXX O
the XXX O
c-cbl XXX B-GENE
gene XXX I-GENE
. XXX O

The XXX O
control XXX O
group XXX O
included XXX O
8 XXX O
afterbirth XXX O
samples XXX O
from XXX O
physiological XXX O
full-term XXX O
pregnancies XXX O
. XXX O

Scalp XXX O
flaps XXX O
can XXX O
be XXX O
expanded XXX O
just XXX O
to XXX O
the XXX O
point XXX O
of XXX O
becoming XXX O
noticeable XXX O
over XXX O
4 XXX O
to XXX O
6 XXX O
weeks XXX O
followed XXX O
by XXX O
scalp XXX O
flap XXX O
transposition XXX O
and XXX O
easy XXX O
closure XXX O
of XXX O
the XXX O
donor XXX O
site XXX O
. XXX O

The XXX O
negative XXX O
calcium XXX O
balance XXX O
with XXX O
hyperparathyroidemia XXX O
occurred XXX O
after XXX O
continuous XXX O
oral XXX O
administration XXX O
of XXX O
Cd XXX O
and XXX O
developed XXX O
via XXX O
increased XXX O
urinary XXX O
excretion XXX O
of XXX O
calcium XXX O
. XXX O

Wild XXX B-GENE
type XXX I-GENE
and XXX I-GENE
mutant XXX I-GENE
Epo XXX I-GENE
cDNAs XXX I-GENE
were XXX O
transiently XXX O
expressed XXX O
at XXX O
high XXX O
levels XXX O
in XXX O
COS1 XXX O
and XXX O
COS7 XXX O
cells XXX O
. XXX O

The XXX O
inhibition XXX O
by XXX O
the XXX O
RIalpha XXX B-GENE
subunit XXX I-GENE
is XXX O
reversed XXX O
by XXX O
addition XXX O
of XXX O
nanomolar XXX O
concentrations XXX O
of XXX O
cAMP XXX O
( XXX O
Ka XXX O
= XXX O
40 XXX O
nM XXX O
) XXX O
, XXX O
thus XXX O
demonstrating XXX O
that XXX O
PrKX XXX B-GENE
is XXX O
a XXX O
novel XXX O
, XXX O
type XXX B-GENE
I XXX I-GENE
cAMP-dependent XXX I-GENE
protein XXX I-GENE
kinase XXX I-GENE
that XXX O
is XXX O
activated XXX O
at XXX O
lower XXX O
cAMP XXX O
concentrations XXX O
than XXX O
the XXX O
holoenzyme XXX O
with XXX O
the XXX O
Calpha XXX B-GENE
subunit XXX I-GENE
of XXX O
cAMP-dependent XXX B-GENE
protein XXX I-GENE
kinase XXX I-GENE
. XXX O

This XXX O
technique XXX O
was XXX O
employed XXX O
in XXX O
12 XXX O
patients XXX O
with XXX O
a XXX O
unicameral XXX O
bone XXX O
cyst XXX O
. XXX O

Studies XXX O
of XXX O
MPO XXX B-GENE
gene XXX I-GENE
regulation XXX O
can XXX O
help XXX O
to XXX O
elucidate XXX O
the XXX O
mechanism XXX O
of XXX O
normal XXX O
and XXX O
abnormal XXX O
myeloid XXX O
differentiation XXX O
. XXX O

The XXX O
sympathetic XXX O
neuroeffector XXX O
influence XXX O
on XXX O
the XXX O
myocardium XXX O
with XXX O
ATCI XXX O
depends XXX O
to XXX O
a XXX O
large XXX O
measure XXX O
on XXX O
the XXX O
intensity XXX O
of XXX O
the XXX O
neurotransmitter XXX O
biosynthesis XXX O
and XXX O
function XXX O
of XXX O
cardiomyocyte XXX O
adrenoreceptors XXX B-GENE
. XXX O

Oncological XXX O
, XXX O
clinical XXX O
and XXX O
psychological XXX O
aspects XXX O
are XXX O
evaluated XXX O
according XXX O
to XXX O
experience XXX O
accumulated XXX O
in XXX O
recent XXX O
years XXX O
, XXX O
with XXX O
immediate XXX O
and XXX O
delayed XXX O
reconstruction XXX O
, XXX O
carried XXX O
out XXX O
in XXX O
the XXX O
most XXX O
diverse XXX O
specialized XXX O
centers XXX O
. XXX O

Moreover XXX O
, XXX O
an XXX O
in XXX O
vitro XXX O
pull-down XXX O
assay XXX O
showed XXX O
that XXX O
Os XXX B-GENE
; XXX I-GENE
CycH XXX I-GENE
; XXX I-GENE
1 XXX I-GENE
specifically XXX O
bound XXX O
to XXX O
R2 XXX B-GENE
but XXX O
not XXX O
to XXX O
other XXX O
rice XXX B-GENE
CDKs XXX I-GENE
. XXX O

All XXX O
of XXX O
the XXX O
elements XXX O
exhibited XXX O
a XXX O
uniform XXX O
structure XXX O
. XXX O

Vivid XXX O
visual XXX O
hallucinations XXX O
without XXX O
other XXX O
psychopathology XXX O
have XXX O
been XXX O
reported XXX O
for XXX O
several XXX O
hundred XXX O
years XXX O
. XXX O

Sequencing XXX O
of XXX O
the XXX O
facB XXX B-GENE
gene XXX I-GENE
revealed XXX O
that XXX O
it XXX O
encodes XXX O
a XXX O
protein XXX O
that XXX O
contains XXX O
an XXX O
N-terminal XXX B-GENE
GAL4-like XXX I-GENE
Zn XXX I-GENE
( XXX I-GENE
II XXX I-GENE
) XXX I-GENE
2Cys6 XXX I-GENE
( XXX I-GENE
or XXX I-GENE
C6 XXX I-GENE
zinc XXX I-GENE
) XXX I-GENE
binuclear XXX I-GENE
cluster XXX I-GENE
for XXX O
DNA XXX O
binding XXX O
, XXX O
leucine XXX O
zipper-like XXX O
heptad XXX O
repeat XXX O
motifs XXX O
and XXX O
central XXX O
and XXX O
C-terminal XXX O
acidic XXX O
alpha-helical XXX O
regions XXX O
, XXX O
consistent XXX O
with XXX O
a XXX O
function XXX O
as XXX O
a XXX O
DNA-binding XXX O
transcriptional XXX O
activator XXX O
. XXX O

The XXX O
previously XXX O
described XXX O
enhanced XXX O
translation XXX O
of XXX O
spinach XXX O
L12 XXX B-GENE
mRNA XXX I-GENE
from XXX O
its XXX O
two XXX O
tandem XXX O
AUG XXX O
codons XXX O
and XXX O
the XXX O
two XXX O
functional XXX O
rpl12 XXX B-GENE
genes XXX I-GENE
in XXX O
Arabidopsis XXX O
probably XXX O
provide XXX O
two XXX O
mechanisms XXX O
for XXX O
generating XXX O
the XXX O
four XXX O
copies XXX O
of XXX O
L12 XXX B-GENE
/ XXX I-GENE
chloroplast XXX I-GENE
ribosome XXX I-GENE
, XXX O
qualitatively XXX O
different XXX O
from XXX O
those XXX O
attempted XXX O
in XXX O
eubacteria XXX O
. XXX O

An XXX O
18-kb XXX O
genomic XXX O
clone XXX O
including XXX O
sequences XXX O
encoding XXX O
for XXX O
the XXX O
two XXX O
GHS-R XXX B-GENE
variants XXX I-GENE
was XXX O
isolated XXX O
. XXX O

We XXX O
report XXX O
a XXX O
patient XXX O
developing XXX O
factor XXX B-GENE
VII XXX I-GENE
inhibitor XXX I-GENE
possibly XXX O
as XXX O
a XXX O
reaction XXX O
to XXX O
penicillin XXX O
administration XXX O
; XXX O
it XXX O
gave XXX O
rise XXX O
to XXX O
fatal XXX O
haemorrhage XXX O
. XXX O

Both XXX O
inserts XXX O
are XXX O
larger XXX O
than XXX O
their XXX O
homologues XXX O
in XXX O
eIF-2alpha XXX B-GENE
kinases XXX I-GENE
. XXX O

Wnt-1 XXX B-GENE
( XXX O
int-1 XXX B-GENE
) XXX O
is XXX O
a XXX O
cellular XXX O
oncogene XXX O
often XXX O
activated XXX O
by XXX O
insertion XXX O
of XXX O
proviral XXX O
DNA XXX O
of XXX O
the XXX O
mouse XXX O
mammary XXX O
tumor XXX O
virus XXX O
. XXX O

Effects XXX O
of XXX O
ketamine XXX O
on XXX O
the XXX O
circulatory XXX O
functions XXX O
and XXX O
body XXX O
tissue XXX O
oxygenation XXX O
in XXX O
dogs XXX O
under XXX O
normal XXX O
and XXX O
hypovolemic XXX O
conditions XXX O
. XXX O

To XXX O
date XXX O
, XXX O
two XXX O
such XXX O
proteins XXX O
, XXX O
PLZF XXX B-GENE
and XXX O
LAZ-3 XXX B-GENE
/ XXX I-GENE
BCL-6 XXX I-GENE
, XXX O
have XXX O
been XXX O
implicated XXX O
in XXX O
oncogenesis XXX O
. XXX O

Polymerization XXX O
of XXX O
neurofilament XXX B-GENE
L XXX I-GENE
protein XXX I-GENE
in XXX O
vitro XXX O
was XXX O
inhibited XXX O
by XXX O
phosphorylation XXX O
of XXX O
neurofilament XXX B-GENE
L XXX I-GENE
protein XXX I-GENE
by XXX O
PKN XXX B-GENE
. XXX O

Repair XXX O
of XXX O
this XXX O
insertion XXX O
by XXX O
homologous XXX O
recombination XXX O
restores XXX O
the XXX O
activity XXX O
of XXX O
the XXX O
hprt XXX B-GENE
locus XXX I-GENE
, XXX O
thus XXX O
confirming XXX O
the XXX O
site XXX O
of XXX O
mutation XXX O
. XXX O

Ten XXX O
selenocysteine XXX O
residues XXX O
( XXX O
deduced XXX O
) XXX O
are XXX O
present XXX O
. XXX O

Recent XXX O
studies XXX O
have XXX O
revealed XXX O
unconventional XXX O
myosin XXX B-GENE
V XXX I-GENE
to XXX O
be XXX O
an XXX O
important XXX O
actin-based XXX O
molecular XXX O
motor XXX O
involved XXX O
in XXX O
vesicular XXX O
movement XXX O
. XXX O

When XXX O
expressed XXX O
in XXX O
and XXX O
purified XXX O
from XXX O
Escherichia XXX O
coli XXX O
, XXX O
both XXX O
full-length XXX B-GENE
Fpr3 XXX I-GENE
and XXX O
its XXX O
isolated XXX O
COOH-terminal XXX O
domain XXX O
exhibit XXX O
readily XXX O
detectable XXX O
PPIase XXX B-GENE
activity XXX O
. XXX O

Hepatitis-B XXX O
vaccination XXX O
in XXX O
the XXX O
elderly XXX O
. XXX O

No XXX O
evidence XXX O
of XXX O
either XXX O
positive XXX O
or XXX O
negative XXX O
chemography XXX O
was XXX O
found XXX O
. XXX O

A XXX O
third XXX O
series XXX O
of XXX O
mice XXX O
were XXX O
given XXX O
a XXX O
single XXX O
injection XXX O
of XXX O
5-OH-DA XXX O
, XXX O
sacrificed XXX O
, XXX O
and XXX O
prepared XXX O
for XXX O
ultrastructural XXX O
study XXX O
. XXX O

We XXX O
also XXX O
present XXX O
evidence XXX O
for XXX O
a XXX O
negative XXX O
regulatory XXX O
element XXX O
in XXX O
the XXX O
5' XXX O
flanking XXX O
region XXX O
of XXX O
the XXX O
Mlu XXX B-GENE
I XXX I-GENE
upstream XXX I-GENE
activation XXX I-GENE
sequence XXX I-GENE
. XXX O

This XXX O
is XXX O
the XXX O
first XXX O
determination XXX O
of XXX O
the XXX O
complete XXX O
secondary XXX O
structure XXX O
of XXX O
an XXX O
RNA XXX O
spliced XXX O
in XXX O
a XXX O
spliceosome XXX O
. XXX O

No XXX O
causal XXX O
relations XXX O
may XXX O
be XXX O
inferred XXX O
from XXX O
the XXX O
correlation XXX O
between XXX O
the XXX O
level XXX O
of XXX O
trapezius XXX O
activity XXX O
and XXX O
complaints XXX O
, XXX O
though XXX O
it XXX O
indicates XXX O
that XXX O
individual XXX O
, XXX O
inexpedient XXX O
muscle XXX O
activity XXX O
patterns XXX O
may XXX O
constitute XXX O
an XXX O
important XXX O
risk XXX O
factor XXX O
for XXX O
development XXX O
of XXX O
musculo-skeletal XXX O
complaints XXX O
. XXX O

Finally XXX O
, XXX O
the XXX O
C-terminal XXX O
region XXX O
of XXX O
ENBP1 XXX B-GENE
shows XXX O
strong XXX O
homology XXX O
to XXX O
a XXX O
protein XXX O
from XXX O
rat XXX O
that XXX O
is XXX O
specifically XXX O
expressed XXX O
in XXX O
testis XXX O
tissue XXX O
. XXX O

Modality-specific XXX O
areas XXX O
( XXX O
e XXX O
. XXX O
g XXX O
. XXX O
, XXX O
right XXX O
Wernicke XXX O
, XXX O
left XXX O
fusiform XXX O
gyrus XXX O
, XXX O
Broca XXX O
BA44 XXX O
, XXX O
supramarginal XXX O
gyrus XXX O
) XXX O
, XXX O
appear XXX O
to XXX O
cope XXX O
with XXX O
the XXX O
computations XXX O
relevant XXX O
to XXX O
making XXX O
contact XXX O
with XXX O
these XXX O
more XXX O
abstract XXX O
dimensions XXX O
. XXX O

The XXX O
promoter XXX O
mutation XXX O
is XXX O
complemented XXX O
in XXX O
trans XXX O
by XXX O
E1A XXX B-GENE
products XXX O
of XXX O
the XXX O
heterologous XXX O
helper XXX O
adenovirus XXX O
type XXX O
5 XXX O
( XXX O
Ad5 XXX O
) XXX O
. XXX O

Deletion XXX O
of XXX O
fdsR XXX B-GENE
revealed XXX O
a XXX O
dual XXX O
regulatory XXX O
effect XXX O
of XXX O
FdsR XXX B-GENE
on XXX O
the XXX O
fds XXX B-GENE
operon XXX I-GENE
by XXX O
acting XXX O
as XXX O
transcriptional XXX O
activator XXX O
in XXX O
the XXX O
presence XXX O
of XXX O
formate XXX O
or XXX O
as XXX O
repressor XXX O
in XXX O
the XXX O
absence XXX O
of XXX O
formate XXX O
. XXX O

The XXX O
predictive XXX O
value XXX O
of XXX O
a XXX O
positive XXX O
flag XXX O
was XXX O
77 XXX O
. XXX O
7% XXX O
. XXX O

Significance XXX O
of XXX O
cytokine XXX O
production XXX O
and XXX O
adhesion XXX O
molecules XXX O
in XXX O
malarial XXX O
immunopathology XXX O
. XXX O

Myocardial XXX O
interstitial XXX O
edema XXX O
is XXX O
more XXX O
likely XXX O
a XXX O
potential XXX O
mechanism XXX O
of XXX O
diastolic XXX O
dysfunction XXX O
after XXX O
DC XXX O
shocks XXX O
. XXX O

All XXX O
loci XXX O
have XXX O
a XXX O
similar XXX O
organization XXX O
, XXX O
except XXX O
for XXX O
H1 XXX B-GENE
. XXX I-GENE
8 XXX I-GENE
that XXX O
harbors XXX O
two XXX O
TcP2beta XXX B-GENE
genes XXX I-GENE
arranged XXX O
in XXX O
tandem XXX O
and XXX O
separated XXX O
by XXX O
a XXX O
short XXX O
repetitive XXX O
sequence XXX O
, XXX O
named XXX O
SIRE XXX B-GENE
( XXX O
short XXX B-GENE
interspersed XXX I-GENE
repetitive XXX I-GENE
element XXX I-GENE
) XXX O
, XXX O
which XXX O
is XXX O
also XXX O
found XXX O
upstream XXX O
of XXX O
the XXX O
first XXX O
gene XXX O
of XXX O
the XXX O
tandem XXX O
and XXX O
downstream XXX O
of XXX O
the XXX O
second XXX O
. XXX O

5 XXX O
. XXX O

Statins XXX B-GENE
: XXX O
lower XXX O
lipids XXX O
and XXX O
better XXX O
bones XXX O
? XXX O
Although XXX O
statins XXX O
are XXX O
widely XXX O
used XXX O
as XXX O
cholesterol-lowering XXX O
drugs XXX O
, XXX O
a XXX O
recent XXX O
study XXX O
suggests XXX O
that XXX O
these XXX O
compounds XXX O
have XXX O
anabolic XXX O
effects XXX O
on XXX O
bone XXX O
and XXX O
could XXX O
be XXX O
developed XXX O
into XXX O
new XXX O
treatments XXX O
for XXX O
common XXX O
metabolic XXX O
bone XXX O
diseases XXX O
such XXX O
as XXX O
osteoporosis XXX O

Campomelic XXX O
dysplasia XXX O
translocation XXX O
breakpoints XXX O
are XXX O
scattered XXX O
over XXX O
1 XXX O
Mb XXX O
proximal XXX O
to XXX O
SOX9 XXX B-GENE
: XXX O
evidence XXX O
for XXX O
an XXX O
extended XXX O
control XXX O
region XXX O
. XXX O

It XXX O
was XXX O
found XXX O
that XXX O
intrathecal XXX O
administration XXX O
( XXX O
i XXX O
. XXX O
t XXX O
. XXX O
) XXX O
of XXX O
D2 XXX B-GENE
receptor XXX I-GENE
agonist XXX O
LY171555 XXX O
or XXX O
D1 XXX B-GENE
/ XXX I-GENE
D2 XXX I-GENE
receptor XXX I-GENE
agonist XXX O
apomorphine XXX O
increased XXX O
pain XXX O
threshold XXX O
and XXX O
had XXX O
a XXX O
potentiating XXX O
effect XXX O
on XXX O
AA XXX O
. XXX O

The XXX O
Babcock XXX O
Surgical XXX O
Clinic XXX O
. XXX O

However XXX O
, XXX O
at XXX O
lower XXX O
temperature XXX O
the XXX O
positive XXX O
staircase XXX O
was XXX O
not XXX O
clear XXX O
and XXX O
rather XXX O
negative XXX O
staircase XXX O
appeared XXX O
( XXX O
1--3 XXX O
Hz XXX O
) XXX O
. XXX O

Internal XXX O
biliary XXX O
drainage XXX O
, XXX O
unlike XXX O
external XXX O
drainage XXX O
, XXX O
does XXX O
not XXX O
suppress XXX O
the XXX O
regeneration XXX O
of XXX O
cholestatic XXX O
rat XXX O
liver XXX O
after XXX O
partial XXX O
hepatectomy XXX O
. XXX O

Induced XXX O
expression XXX O
of XXX O
c-myc XXX B-GENE
is XXX O
likely XXX O
to XXX O
contribute XXX O
to XXX O
the XXX O
proliferation XXX O
of XXX O
Stat1-null XXX O
cells XXX O
in XXX O
response XXX O
to XXX O
IFNs XXX B-GENE
. XXX O

Further XXX O
experiments XXX O
will XXX O
be XXX O
required XXX O
to XXX O
highlight XXX O
the XXX O
in XXX O
vivo XXX O
role XXX O
of XXX O
ELE1 XXX B-GENE
in XXX O
nuclear XXX O
receptor XXX O
functioning XXX O
. XXX O

The XXX O
incidence XXX O
of XXX O
early XXX O
neonatal XXX O
convulsions XXX O
for XXX O
inborn XXX O
babies XXX O
was XXX O
3 XXX O
. XXX O
0 XXX O
/ XXX O
1000 XXX O
live XXX O
births XXX O
. XXX O

In XXX O
vitro XXX O
studies XXX O
with XXX O
blood XXX O
cells XXX O
incubated XXX O
with XXX O
acetate XXX O
or XXX O
bicarbonate XXX O
ions XXX O
in XXX O
concentrations XXX O
, XXX O
which XXX O
are XXX O
observed XXX O
in XXX O
vivo XXX O
during XXX O
hemodialysis XXX O
, XXX O
suggest XXX O
that XXX O
probably XXX O
these XXX O
ions XXX O
do XXX O
not XXX O
directly XXX O
affect XXX O
superoxide XXX O
anions XXX O
generation XXX O
, XXX O
erythrocyte XXX O
SOD-1 XXX B-GENE
and XXX O
catalase XXX B-GENE
activities XXX O
and XXX O
erythrocyte XXX O
membrane XXX O
lipid XXX O
peroxidation XXX O
. XXX O

A XXX O
comprehensive XXX O
neuropsychological XXX O
battery XXX O
was XXX O
administered XXX O
to XXX O
48 XXX O
veterans XXX O
with XXX O
Gulf XXX O
War XXX O
Illness XXX O
( XXX O
GWI XXX O
) XXX O
characterized XXX O
by XXX O
severe XXX O
fatigue XXX O
( XXX O
GV-F XXX O
) XXX O
and XXX O
39 XXX O
healthy XXX O
veterans XXX O
( XXX O
GV-H XXX O
) XXX O
. XXX O

Comparison XXX O
of XXX O
propofol XXX O
and XXX O
thiopentone XXX O
as XXX O
anaesthetic XXX O
agents XXX O
for XXX O
electroconvulsive XXX O
therapy XXX O
. XXX O

It XXX O
is XXX O
suggested XXX O
that XXX O
the XXX O
use XXX O
of XXX O
endogenous XXX O
creatinine XXX O
clearance XXX O
to XXX O
estimate XXX O
the XXX O
glomerular XXX O
filtration XXX O
rate XXX O
( XXX O
GFR XXX O
) XXX O
requires XXX O
caution XXX O
and XXX O
the XXX O
recognition XXX O
of XXX O
the XXX O
limitations XXX O
of XXX O
the XXX O
method XXX O
, XXX O
and XXX O
that XXX O
simpler XXX O
techniques XXX O
( XXX O
serum XXX O
creatinine XXX O
or XXX O
estimated XXX O
endogenous XXX O
creatinine XXX O
clearance XXX O
) XXX O
are XXX O
preferable XXX O
in XXX O
routine XXX O
practice XXX O
. XXX O

PURPOSE XXX O
/ XXX O
OBJECTIVES XXX O
: XXX O
To XXX O
examine XXX O
the XXX O
question XXX O
of XXX O
whether XXX O
an XXX O
early XXX O
first XXX O
full-term XXX O
pregnancy XXX O
( XXX O
FFTP XXX O
) XXX O
protects XXX O
against XXX O
breast XXX O
cancer XXX O
and XXX O
whether XXX O
interruption XXX O
of XXX O
the XXX O
pregnancy XXX O
with XXX O
an XXX O
induced XXX O
abortion XXX O
increases XXX O
breast XXX O
cancer XXX O
risk XXX O
. XXX O

The XXX O
loop XXX O
domain XXX O
of XXX O
heat XXX B-GENE
shock XXX I-GENE
transcription XXX I-GENE
factor XXX I-GENE
1 XXX I-GENE
dictates XXX O
DNA-binding XXX O
specificity XXX O
and XXX O
responses XXX O
to XXX O
heat XXX O
stress XXX O
. XXX O

The XXX O
hypBFCDE XXX B-GENE
operon XXX I-GENE
from XXX O
Rhizobium XXX O
leguminosarum XXX O
biovar XXX O
viciae XXX O
is XXX O
expressed XXX O
from XXX O
an XXX O
Fnr-type XXX B-GENE
promoter XXX I-GENE
that XXX O
escapes XXX O
mutagenesis XXX O
of XXX O
the XXX O
fnrN XXX B-GENE
gene XXX I-GENE
. XXX O

This XXX O
interaction XXX O
inhibits XXX O
the XXX O
histone XXX B-GENE
acetyltransferase XXX I-GENE
activity XXX O
of XXX O
p300 XXX B-GENE
, XXX O
resulting XXX O
in XXX O
drastic XXX O
reduction XXX O
of XXX O
nucleosomal XXX O
histone XXX B-GENE
acetylation XXX O
and XXX O
alteration XXX O
of XXX O
chromatin XXX O
structure XXX O
. XXX O

Unlike XXX O
the XXX O
MAR-binding XXX O
domain XXX O
, XXX O
the XXX O
homeodomain XXX O
when XXX O
isolated XXX O
binds XXX O
poorly XXX O
and XXX O
with XXX O
low XXX O
specificity XXX O
to XXX O
DNA XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
severe XXX O
vision XXX O
loss XXX O
can XXX O
be XXX O
seen XXX O
with XXX O
interferon XXX B-GENE
alfa-2b-associated XXX O
retinopathy XXX O
. XXX O

Here XXX O
, XXX O
we XXX O
report XXX O
theoretical XXX O
models XXX O
for XXX O
the XXX O
Gla XXX B-GENE
and XXX O
EGF-1 XXX B-GENE
modules XXX I-GENE
of XXX O
human XXX B-GENE
PS XXX I-GENE
constructed XXX O
using XXX O
prothrombin XXX B-GENE
and XXX O
factor XXX B-GENE
X XXX I-GENE
experimental XXX O
structures XXX O
. XXX O

Previous XXX O
investigators XXX O
have XXX O
suggested XXX O
that XXX O
subretinal XXX O
blood XXX O
damages XXX O
the XXX O
retina XXX O
in XXX O
part XXX O
because XXX O
of XXX O
its XXX O
solid XXX O
fibrin XXX B-GENE
meshwork XXX O
. XXX O

High XXX O
expression XXX O
of XXX O
the XXX O
peroxisome XXX B-GENE
proliferator-activated XXX I-GENE
receptor XXX I-GENE
alpha XXX I-GENE
( XXX O
PPARalpha XXX B-GENE
) XXX O
differentiates XXX O
brown XXX O
fat XXX O
from XXX O
white XXX O
, XXX O
and XXX O
is XXX O
related XXX O
to XXX O
its XXX O
high XXX O
capacity XXX O
of XXX O
lipid XXX O
oxidation XXX O
. XXX O

In XXX O
vitro XXX O
translation XXX O
and XXX O
in XXX O
vivo XXX O
polysome XXX O
profile XXX O
analysis XXX O
indicated XXX O
that XXX O
transcripts XXX B-GENE
C XXX I-GENE
and XXX I-GENE
E XXX I-GENE
were XXX O
translated XXX O
with XXX O
similar XXX O
translational XXX O
efficiencies XXX O
that XXX O
are XXX O
substantially XXX O
greater XXX O
than XXX O
that XXX O
of XXX O
transcript XXX B-GENE
D XXX I-GENE
, XXX O
suggesting XXX O
that XXX O
5'-untranslated XXX O
regions XXX O
play XXX O
a XXX O
role XXX O
in XXX O
translational XXX O
control XXX O
. XXX O

RNase XXX B-GENE
protection XXX O
analyses XXX O
indicate XXX O
that XXX O
either XXX O
61-kDa XXX B-GENE
CaM XXX I-GENE
PDE XXX I-GENE
mRNA XXX I-GENE
or XXX O
structurally XXX O
related XXX O
transcripts XXX O
encoding XXX O
different XXX O
CaM XXX B-GENE
PDE XXX I-GENE
isoforms XXX I-GENE
are XXX O
expressed XXX O
in XXX O
a XXX O
tissue-specific XXX O
manner XXX O
. XXX O

Attitudes XXX O
were XXX O
found XXX O
to XXX O
be XXX O
multidimensional XXX O
, XXX O
with XXX O
similar XXX O
dimensions XXX O
being XXX O
identified XXX O
in XXX O
both XXX O
samples XXX O
. XXX O

The XXX O
5' XXX O
end XXX O
of XXX O
the XXX O
coding XXX O
region XXX O
was XXX O
located XXX O
precisely XXX O
by XXX O
comparing XXX O
the XXX O
deduced XXX O
amino XXX O
acid XXX O
sequence XXX O
to XXX O
the XXX O
actual XXX O
N-terminal XXX O
amino XXX O
acid XXX O
sequence XXX O
of XXX O
IHF XXX B-GENE
. XXX O

The XXX O
missing XXX O
5' XXX O
sequences XXX O
were XXX O
obtained XXX O
by XXX O
5'-rapid XXX O
amplification XXX O
of XXX O
cDNA XXX O
ends XXX O
and XXX O
by XXX O
analysis XXX O
of XXX O
an XXX O
NHE5 XXX B-GENE
genomic XXX I-GENE
clone XXX I-GENE
, XXX O
and XXX O
the XXX O
missing XXX O
3' XXX O
sequences XXX O
were XXX O
obtained XXX O
by XXX O
3'-rapid XXX O
amplification XXX O
of XXX O
cDNA XXX O
ends XXX O
. XXX O

We XXX O
showed XXX O
that XXX O
Stat3 XXX B-GENE
and XXX O
Stat3beta XXX B-GENE
were XXX O
affinity XXX O
purified XXX O
using XXX O
phosphopeptides XXX O
containing XXX O
Y704 XXX O
and XXX O
Y744 XXX O
but XXX O
not XXX O
by XXX O
nonphosphorylated XXX O
peptide XXX O
analogues XXX O
or XXX O
by XXX O
phosphopeptides XXX O
containing XXX O
Y729 XXX O
and XXX O
Y764 XXX O
. XXX O

Brain XXX B-GENE
cholinesterase XXX I-GENE
activity XXX O
of XXX O
nestling XXX O
great XXX O
egrets XXX O
, XXX O
snowy XXX O
egrets XXX O
and XXX O
black-crowned XXX O
night-herons XXX O
. XXX O
inhibition XXX O
of XXX O
brain XXX B-GENE
cholinesterase XXX I-GENE
( XXX O
ChE XXX B-GENE
) XXX O
activity XXX O
in XXX O
birds XXX O
is XXX O
often XXX O
used XXX O
to XXX O
diagnose XXX O
exposure XXX O
or XXX O
death XXX O
from XXX O
organophosphorus XXX O
or XXX O
carbamate XXX O
pesticides XXX O
. XXX O

Three XXX O
cases XXX O
of XXX O
primary XXX O
signet-ring XXX O
cell XXX O
carcinoma XXX O
of XXX O
the XXX O
rectum XXX O
are XXX O
described XXX O
. XXX O

Furthermore XXX O
, XXX O
competitor XXX O
containing XXX O
the XXX O
YY1 XXX B-GENE
consensus XXX I-GENE
sequence XXX I-GENE
competed XXX O
for XXX O
protein XXX B-GENE
B XXX I-GENE
binding XXX O
, XXX O
whereas XXX O
competitor XXX O
containing XXX O
a XXX O
perfect XXX O
yeast XXX B-GENE
ABF-1 XXX I-GENE
consensus XXX I-GENE
sequence XXX I-GENE
did XXX O
not XXX O
. XXX O
( XXX O
ABSTRACT XXX O
TRUNCATED XXX O
AT XXX O
400 XXX O
WORDS XXX O
) XXX O

VaI XXX B-GENE
and XXX O
VaII XXX B-GENE
co-immunoprecipitated XXX O
with XXX O
ErbB2 XXX B-GENE
, XXX O
but XXX O
not XXX O
with XXX O
ErbB1 XXX B-GENE
, XXX O
ErbB3 XXX B-GENE
, XXX O
or XXX O
ErbB4 XXX B-GENE
. XXX O

ELISA XXX O
was XXX O
found XXX O
to XXX O
make XXX O
a XXX O
contribution XXX O
to XXX O
the XXX O
diagnosis XXX O
of XXX O
tuberculosis XXX O
similar XXX O
to XXX O
that XXX O
of XXX O
sputum XXX O
smear XXX O
. XXX O

The XXX O
levels XXX O
of XXX O
both XXX O
MAP1-specific XXX B-GENE
and XXX O
MAP2-specific XXX B-GENE
mRNAs XXX I-GENE
decline XXX O
in XXX O
the XXX O
postnatal XXX O
developing XXX O
brain XXX O
; XXX O
the XXX O
level XXX O
of XXX O
MAP1-specific XXX B-GENE
mRNA XXX I-GENE
also XXX O
increases XXX O
slightly XXX O
in XXX O
rat XXX O
PC12 XXX O
cells XXX O
upon XXX O
exposure XXX O
to XXX O
nerve XXX B-GENE
growth XXX I-GENE
factor XXX I-GENE
. XXX O

This XXX O
is XXX O
based XXX O
on XXX O
partitioning XXX O
an XXX O
underlying XXX O
multivariate XXX O
normal XXX O
distribution XXX O
. XXX O

Human XXX O
SRF-related XXX B-GENE
proteins XXX I-GENE
: XXX O
DNA-binding XXX O
properties XXX O
and XXX O
potential XXX O
regulatory XXX O
targets XXX O
. XXX O

Comparison XXX O
of XXX O
transmembrane XXX O
and XXX O
cytoplasmic XXX O
domains XXX O
to XXX O
a XXX O
third XXX O
cell-surface XXX O
proteoglycan XXX O
, XXX O
48K5 XXX B-GENE
from XXX O
human XXX O
lung XXX O
fibroblasts XXX O
( XXX O
Marynen XXX O
, XXX O
P XXX O
. XXX O
, XXX O
Zhang XXX O
, XXX O
J XXX O
. XXX O
, XXX O
Cassiman XXX O
, XXX O
J XXX O
. XXX O
, XXX O
Vanden XXX O
Berghe XXX O
, XXX O
H XXX O
. XXX O
, XXX O
and XXX O
David XXX O
, XXX O
C XXX O
. XXX O

Heterodimers XXX O
of XXX O
myogenin XXX B-GENE
and XXX O
E12 XXX B-GENE
( XXX O
or XXX O
MyoD XXX B-GENE
and XXX O
E12 XXX B-GENE
) XXX O
specifically XXX O
bound XXX O
a XXX O
restriction XXX O
fragment XXX O
extending XXX O
from XXX O
-200 XXX O
to XXX O
-103 XXX O
relative XXX O
to XXX O
the XXX O
start XXX O
of XXX O
cardiac XXX B-GENE
alpha-actin XXX I-GENE
transcription XXX O
. XXX O

Regulation XXX O
of XXX O
irgA XXX B-GENE
by XXX O
iron XXX O
in XXX O
V XXX O
. XXX O
cholerae XXX O
occurs XXX O
at XXX O
the XXX O
transcriptional XXX O
level XXX O
, XXX O
and XXX O
there XXX O
is XXX O
an XXX O
interrupted XXX O
dyad XXX O
symmetric XXX O
sequence XXX O
in XXX O
the XXX O
vicinity XXX O
of XXX O
the XXX O
promoter XXX O
that XXX O
is XXX O
homologous XXX O
to XXX O
Fur XXX B-GENE
binding XXX I-GENE
sites XXX I-GENE
of XXX O
E XXX O
. XXX O
coli XXX O
. XXX O

To XXX O
study XXX O
the XXX O
retinal XXX O
surface XXX O
in XXX O
the XXX O
human XXX O
eye XXX O
in XXX O
normal XXX O
and XXX O
diseased XXX O
states XXX O
we XXX O
used XXX O
laser XXX O
scanning XXX O
tomography XXX O
. XXX O

Intravenous XXX O
L-carnitine XXX O
treatment XXX O
increased XXX O
plasma XXX O
carnitine XXX O
concentrations XXX O
, XXX O
improved XXX O
patient-assessed XXX O
fatigue XXX O
, XXX O
and XXX O
may XXX O
prevent XXX O
the XXX O
decline XXX O
in XXX O
peak XXX O
exercise XXX O
capacity XXX O
in XXX O
hemodialysis XXX O
patients XXX O
. XXX O

Dose XXX O
of XXX O
20 XXX O
ig XXX O
were XXX O
administered XXX O
within XXX O
a XXX O
scheme XXX O
from XXX O
0 XXX O
. XXX O
1 XXX O
to XXX O
6 XXX O
months XXX O
in XXX O
order XXX O
to XXX O
study XXX O
its XXX O
immunogenicity XXX O
, XXX O
which XXX O
was XXX O
evaluated XXX O
at XXX O
2 XXX O
, XXX O
7 XXX O
, XXX O
and XXX O
12 XXX O
months XXX O
after XXX O
the XXX O
first XXX O
dose XXX O
. XXX O

Initiation XXX O
of XXX O
translation XXX O
of XXX O
the XXX O
human XXX O
hepatitis XXX O
C XXX O
virus XXX O
( XXX O
HCV XXX O
) XXX O
RNA XXX O
genome XXX O
occurs XXX O
by XXX O
internal XXX O
ribosome XXX O
entry XXX O
into XXX O
the XXX O
5' XXX O
noncoding XXX O
region XXX O
( XXX O
5'NCR XXX O
) XXX O
in XXX O
a XXX O
cap-independent XXX O
manner XXX O
. XXX O

Appl XXX O
. XXX O

These XXX O
observations XXX O
have XXX O
led XXX O
us XXX O
to XXX O
conclude XXX O
that XXX O
an XXX O
elevated XXX O
VIII-ratio XXX O
is XXX O
a XXX O
very XXX O
sensitive XXX O
indicator XXX O
of XXX O
intravascular XXX O
coagulation XXX O
. XXX O

The XXX O
effect XXX O
of XXX O
nitric XXX B-GENE
oxide XXX I-GENE
synthase XXX I-GENE
inhibitor XXX O
on XXX O
reperfusion XXX O
injury XXX O
of XXX O
the XXX O
brain XXX O
under XXX O
hypothermic XXX O
circulatory XXX O
arrest XXX O
. XXX O

The XXX O
c-myc XXX B-GENE
and XXX O
skeletal XXX B-GENE
alpha-actin XXX I-GENE
gene XXX I-GENE
promoters XXX I-GENE
contain XXX O
YY1 XXX B-GENE
binding XXX I-GENE
sites XXX I-GENE
thought XXX O
to XXX O
act XXX O
either XXX O
as XXX O
positive XXX O
or XXX O
negative XXX O
cis-acting XXX O
elements XXX O
. XXX O

Sixteen XXX O
other XXX O
normal XXX O
subjects XXX O
with XXX O
2 XXX O
g XXX O
of XXX O
Metyrapone XXX O
are XXX O
best XXX O
responses XXX O
. XXX O

cDNA XXX O
cloning XXX O
, XXX O
expression XXX O
analysis XXX O
, XXX O
and XXX O
chromosomal XXX O
localization XXX O
of XXX O
a XXX O
gene XXX O
with XXX O
high XXX O
homology XXX O
to XXX O
wheat XXX B-GENE
eIF- XXX I-GENE
( XXX I-GENE
iso XXX I-GENE
) XXX I-GENE
4F XXX I-GENE
and XXX O
mammalian XXX B-GENE
eIF-4G XXX I-GENE
. XXX O

Creutzfeldt-Jakob XXX O
disease XXX O
and XXX O
lyophilised XXX O
dura XXX O
mater XXX O
grafts XXX O
: XXX O
report XXX O
of XXX O
two XXX O
cases XXX O
. XXX O

We XXX O
used XXX O
oligonucleotide-directed XXX O
mutagenesis XXX O
to XXX O
alter XXX O
a XXX O
site XXX O
in XXX O
MucA XXX B-GENE
homologous XXX O
to XXX O
the XXX O
Ala-Gly XXX O
cleavage XXX O
site XXX O
of XXX O
LexA XXX B-GENE
. XXX O

The XXX O
C-terminal XXX O
peptide XXX O
sequences XXX O
of XXX O
the XXX O
human XXX B-GENE
lymphocyte-specific XXX I-GENE
high XXX I-GENE
mobility XXX I-GENE
group XXX I-GENE
( XXX I-GENE
HMG XXX I-GENE
) XXX I-GENE
-box XXX I-GENE
transcription XXX I-GENE
factor XXX I-GENE
TCF-1 XXX I-GENE
are XXX O
determined XXX O
by XXX O
alternative XXX O
splice XXX O
mechanisms XXX O
affecting XXX O
the XXX O
exons XXX O
VIII XXX O
to XXX O
X XXX O
. XXX O

Five XXX O
concensus XXX O
poly XXX O
A XXX O
addition XXX O
sites XXX O
are XXX O
located XXX O
in XXX O
the XXX O
350 XXX O
base XXX O
pairs XXX O
immediately XXX O
following XXX O
the XXX O
protein XXX B-GENE
IX XXX I-GENE
coding XXX O
region XXX O
. XXX O

Colorimetric XXX O
method XXX O
of XXX O
determining XXX O
glycerin XXX O
in XXX O
the XXX O
blood XXX O
. XXX O

The XXX O
tyrosine-phosphorylated XXX O
state XXX O
of XXX O
CAK XXX B-GENE
beta XXX I-GENE
was XXX O
not XXX O
reduced XXX O
on XXX O
trypsinization XXX O
, XXX O
nor XXX O
enhanced XXX O
in XXX O
response XXX O
to XXX O
plating XXX O
3Y1 XXX O
cells XXX O
onto XXX O
fibronectin XXX B-GENE
. XXX O

Comparison XXX O
of XXX O
Tc-99m XXX O
sestamibi XXX O
perfusion XXX O
imaging XXX O
and XXX O
echocardiography XXX O
using XXX O
an XXX O
arbutamine XXX O
infusion XXX O
for XXX O
the XXX O
detection XXX O
of XXX O
coronary XXX O
artery XXX O
disease XXX O
. XXX O

These XXX O
sequences XXX O
were XXX O
then XXX O
used XXX O
to XXX O
clone XXX O
the XXX O
full-length XXX O
genes XXX O
from XXX O
a XXX O
yeast XXX O
genomic XXX O
library XXX O
. XXX O

This XXX O
gave XXX O
rise XXX O
to XXX O
RNA XXX O
molecules XXX O
with XXX O
3'-untranslated XXX O
regions XXX O
of XXX O
roughly XXX O
375 XXX O
, XXX O
655 XXX O
, XXX O
and XXX O
945 XXX O
base XXX O
pairs XXX O
. XXX O

Organ XXX O
transplantation XXX O
in XXX O
Denmark XXX O
. XXX O

Transfection XXX O
of XXX O
EGFP-tagged XXX B-GENE
DENTT XXX I-GENE
NLS XXX I-GENE
deletion XXX I-GENE
constructs XXX I-GENE
lacking XXX O
the XXX O
bipartite XXX O
NLS-1 XXX B-GENE
were XXX O
excluded XXX O
from XXX O
the XXX O
nucleolus XXX O
. XXX O

We XXX O
conclude XXX O
that XXX O
at XXX O
steady XXX O
state XXX O
the XXX O
timing XXX O
of XXX O
a XXX O
light XXX O
meal XXX O
is XXX O
unlikely XXX O
to XXX O
alter XXX O
in XXX O
any XXX O
clinically XXX O
important XXX O
manner XXX O
the XXX O
pharmacokinetics XXX O
of XXX O
nifedipine XXX O
released XXX O
from XXX O
'biphasic' XXX O
tablets XXX O
. XXX O

Family XXX O
planning XXX O
continues XXX O
to XXX O
play XXX O
a XXX O
minor XXX O
role XXX O
, XXX O
and XXX O
only XXX O
25 XXX O
. XXX O
3 XXX O
per XXX O
cent XXX O
of XXX O
all XXX O
patients XXX O
reviewed XXX O
took XXX O
to XXX O
oral XXX O
contraceptives XXX O
for XXX O
shorter XXX O
or XXX O
longer XXX O
periods XXX O
of XXX O
time XXX O
. XXX O
- XXX O
The XXX O
percentages XXX O
of XXX O
primiparae XXX O
and XXX O
secundiparae XXX O
in XXX O
all XXX O
births XXX O
as XXX O
well XXX O
as XXX O
the XXX O
high XXX O
percentage XXX O
of XXX O
multigravidity XXX O
are XXX O
parameters XXX O
by XXX O
which XXX O
the XXX O
approach XXX O
to XXX O
reproduction XXX O
differs XXX O
substantively XXX O
from XXX O
behaviour XXX O
patterns XXX O
in XXX O
Europe XXX O
. XXX O

The XXX O
double-stranded XXX O
RNA XXX O
binding XXX O
domain XXX O
( XXX O
dsRBD XXX O
) XXX O
is XXX O
an XXX O
approximately XXX O
65 XXX O
amino XXX O
acid XXX O
motif XXX O
that XXX O
is XXX O
found XXX O
in XXX O
a XXX O
variety XXX O
of XXX O
proteins XXX O
that XXX O
interact XXX O
with XXX O
double-stranded XXX O
( XXX O
ds XXX O
) XXX O
RNA XXX O
, XXX O
such XXX O
as XXX O
Escherichia XXX O
coli XXX O
RNase XXX B-GENE
III XXX I-GENE
and XXX O
the XXX O
dsRNA-dependent XXX B-GENE
kinase XXX I-GENE
, XXX O
PKR XXX B-GENE
. XXX O

Sexually XXX O
conditioned XXX O
incentives XXX O
: XXX O
Attenuation XXX O
of XXX O
motivational XXX O
impact XXX O
during XXX O
dopamine XXX B-GENE
receptor XXX I-GENE
antagonism XXX O
. XXX O

Ophthalmosonographic XXX O
evaluation XXX O
of XXX O
blood XXX O
flow XXX O
velocity XXX O
in XXX O
arteriocavernous XXX O
fistula XXX O
. XXX O

Of XXX O
the XXX O
serum XXX B-GENE
neutralizing XXX I-GENE
( XXX I-GENE
SN XXX I-GENE
) XXX I-GENE
antibody XXX I-GENE
negative XXX O
calves XXX O
89 XXX O
. XXX O
7% XXX O
( XXX O
26 XXX O
/ XXX O
29 XXX O
) XXX O
and XXX O
92 XXX O
. XXX O
8% XXX O
( XXX O
90 XXX O
/ XXX O
97 XXX O
) XXX O
developed XXX O
SN XXX B-GENE
antibody XXX I-GENE
1 XXX O
month XXX O
after XXX O
intranasal XXX O
and XXX O
intramuscular XXX O
vaccination XXX O
, XXX O
respectively XXX O
. XXX O

Direct XXX O
binding XXX O
and XXX O
competition XXX O
assays XXX O
using XXX O
30-mer XXX O
oligonucleotide XXX O
probes XXX O
representing XXX O
the XXX O
individual XXX O
CBF1 XXX B-GENE
binding XXX I-GENE
sites XXX I-GENE
indicated XXX O
that XXX O
CBF1 XXX B-GENE
bound XXX O
less XXX O
efficiently XXX O
to XXX O
the XXX O
CD23 XXX B-GENE
promoter XXX I-GENE
and XXX O
the XXX O
EBV XXX B-GENE
LMP-1 XXX I-GENE
promoter XXX I-GENE
sites XXX I-GENE
than XXX O
to XXX O
the XXX O
Cp XXX B-GENE
site XXX I-GENE
. XXX O

The XXX O
present XXX O
study XXX O
investigates XXX O
whether XXX O
prostaglandins XXX O
"cytoprotect" XXX O
the XXX O
gastric XXX O
mucosa XXX O
against XXX O
hemorrhage-induced XXX O
stress XXX O
ulceration XXX O
by XXX O
assessing XXX O
the XXX O
influence XXX O
of XXX O
16 XXX O
, XXX O
16-dimethyl XXX O
prostaglandin XXX O
E2 XXX O
( XXX O
16 XXX O
, XXX O
16-dm XXX O
PGE2 XXX O
) XXX O
on XXX O
gross XXX O
and XXX O
microscopic XXX O
lesion XXX O
formation XXX O
, XXX O
intramucosal XXX O
tissue XXX O
pH XXX O
, XXX O
H+ XXX O
back-diffusion XXX O
, XXX O
and XXX O
mucosal XXX O
blood XXX O
flow XXX O
in XXX O
rat XXX O
gastric XXX O
mucosa XXX O
exposed XXX O
to XXX O
luminal XXX O
acid XXX O
( XXX O
100 XXX O
mM XXX O
HCl XXX O
) XXX O
during XXX O
hemorrhagic XXX O
shock XXX O
( XXX O
13 XXX O
ml XXX O
/ XXX O
kg XXX O
for XXX O
20 XXX O
min XXX O
) XXX O
. XXX O

In XXX O
the XXX O
yeast XXX O
Saccharomyces XXX O
cerevisiae XXX O
, XXX O
copper XXX O
levels XXX O
exert XXX O
some XXX O
control XXX O
over XXX O
the XXX O
level XXX O
of XXX O
SOD1 XXX B-GENE
expression XXX O
. XXX O

The XXX O
state XXX O
of XXX O
the XXX O
liver XXX O
in XXX O
generalized XXX O
forms XXX O
of XXX O
meningococcal XXX O
infection XXX O
. XXX O

Human XXX B-GENE
homologue XXX I-GENE
of XXX I-GENE
yeast XXX I-GENE
Rad23 XXX I-GENE
protein XXX I-GENE
A XXX I-GENE
interacts XXX O
with XXX O
p300 XXX B-GENE
/ XXX I-GENE
cyclic XXX I-GENE
AMP-responsive XXX I-GENE
element XXX I-GENE
binding XXX I-GENE
( XXX I-GENE
CREB XXX I-GENE
) XXX I-GENE
-binding XXX I-GENE
protein XXX I-GENE
to XXX O
down-regulate XXX O
transcriptional XXX O
activity XXX O
of XXX O
p53 XXX B-GENE
. XXX O

They XXX O
consisted XXX O
of XXX O
behavioural XXX O
disorders XXX O
, XXX O
tetraparesis XXX O
, XXX O
incontinence XXX O
and XXX O
oculomotor XXX O
paralysis XXX O
. XXX O

Structural XXX O
features XXX O
of XXX O
the XXX O
minimal XXX O
DNA XXX O
binding XXX O
domain XXX O
( XXX O
M98-F219 XXX B-GENE
) XXX O
of XXX O
human XXX B-GENE
nucleotide XXX I-GENE
excision XXX I-GENE
repair XXX I-GENE
protein XXX I-GENE
XPA XXX I-GENE
. XXX O

Mining XXX O
the XXX O
diagnostic XXX O
iron XXX O
ore XXX O
. XXX O

RU486 XXX O
and XXX O
ONO XXX O
802 XXX O
in XXX O
combination XXX O
have XXX O
been XXX O
shown XXX O
to XXX O
be XXX O
effective XXX O
in XXX O
early XXX O
termination XXX O
of XXX O
pregnancy XXX O
. XXX O

We XXX O
report XXX O
the XXX O
successful XXX O
use XXX O
of XXX O
electroconvulsive XXX O
therapy XXX O
for XXX O
treatment XXX O
of XXX O
severe XXX O
depression XXX O
in XXX O
a XXX O
young XXX O
man XXX O
with XXX O
adult XXX O
GM2 XXX O
gangliosidosis XXX O
. XXX O

The XXX O
transmembrane XXX O
topology XXX O
of XXX O
Na XXX O
( XXX O
+ XXX O
) XXX O
/ XXX O
H XXX O
( XXX O
+ XXX O
) XXX O
exchanger XXX O
NHE3 XXX B-GENE
has XXX O
been XXX O
studied XXX O
using XXX O
in XXX O
vitro XXX O
transcription XXX O
/ XXX O
translation XXX O
of XXX O
two XXX O
types XXX O
of XXX O
fusion XXX O
vectors XXX O
designed XXX O
to XXX O
test XXX O
membrane XXX O
insertion XXX O
properties XXX O
of XXX O
cDNA XXX O
sequences XXX O
encoding XXX O
putative XXX O
NHE3 XXX B-GENE
membrane XXX O
spanning XXX O
domains XXX O
( XXX O
msds XXX O
) XXX O
. XXX O

Stress-activated XXX B-GENE
protein XXX I-GENE
kinase XXX I-GENE
1 XXX I-GENE
( XXX O
SAPK1 XXX B-GENE
) XXX O
, XXX O
also XXX O
called XXX O
c-Jun XXX B-GENE
N-terminal XXX I-GENE
kinase XXX I-GENE
( XXX O
JNK XXX B-GENE
) XXX O
, XXX O
becomes XXX O
activated XXX O
in XXX O
vivo XXX O
in XXX O
response XXX O
to XXX O
pro-inflammatory XXX O
cytokines XXX O
or XXX O
cellular XXX O
stresses XXX O
. XXX O

The XXX O
therapeutic XXX O
use XXX O
of XXX O
botulinum XXX B-GENE
toxin XXX I-GENE
( XXX O
Botox XXX B-GENE
) XXX O
is XXX O
increasing XXX O
in XXX O
popularity XXX O
. XXX O

Methylation XXX O
at XXX O
both XXX O
cytosine XXX O
residues XXX O
in XXX O
the XXX O
E2F XXX B-GENE
element XXX I-GENE
( XXX I-GENE
( XXX I-GENE
m XXX I-GENE
) XXX I-GENE
CG XXX I-GENE
( XXX I-GENE
m XXX I-GENE
) XXX I-GENE
CG XXX I-GENE
) XXX I-GENE
generated XXX O
a XXX O
new XXX O
methylcytosine-specific XXX O
DNA-protein XXX O
complex XXX O
. XXX O

Skin XXX O
pH XXX O
changes XXX O
associated XXX O
with XXX O
iontophoresis XXX O
. XXX O

METHODS XXX O
: XXX O
We XXX O
retrospectively XXX O
selected XXX O
13 XXX O
TFCD XXX O
patients XXX O
who XXX O
underwent XXX O
surgery XXX O
for XXX O
intractable XXX O
epilepsy XXX O
with XXX O
the XXX O
aim XXX O
of XXX O
removing XXX O
the XXX O
magnetic XXX O
resonance XXX O
( XXX O
MR XXX O
) XXX O
-detectable XXX O
lesion XXX O
and XXX O
/ XXX O
or XXX O
the XXX O
epileptogenic XXX O
zone XXX O
defined XXX O
by XXX O
stereoelectroencephalographic XXX O
recordings XXX O
. XXX O

Isoform XXX B-GENE
C XXX I-GENE
beta XXX I-GENE
2 XXX I-GENE
, XXX O
an XXX O
unusual XXX O
form XXX O
of XXX O
the XXX O
bovine XXX O
catalytic XXX O
subunit XXX O
of XXX O
cAMP-dependent XXX B-GENE
protein XXX I-GENE
kinase XXX I-GENE
. XXX O

The XXX O
C-LIP XXX O
also XXX O
was XXX O
compared XXX O
with XXX O
transcather XXX O
arterial XXX O
embolization XXX O
( XXX O
TAE XXX O
; XXX O
C-LIP XXX O
followed XXX O
by XXX O
gelatin XXX O
sponge XXX O
) XXX O
and XXX O
percutaneous XXX O
ethanol XXX O
injection XXX O
therapy XXX O
( XXX O
PEIT XXX O
) XXX O
. XXX O

The XXX O
authors XXX O
found XXX O
that XXX O
except XXX O
for XXX O
fear XXX O
and XXX O
pugnacity XXX O
all XXX O
husband-wife XXX O
trait XXX O
correlations XXX O
were XXX O
positive XXX O
, XXX O
in XXX O
contrast XXX O
to XXX O
Winch's XXX O
principle XXX O
of XXX O
type XXX O
I XXX O
complementarity XXX O
. XXX O

In XXX O
metastasis-free XXX O
patients XXX O
, XXX O
the XXX O
best XXX O
results XXX O
were XXX O
obtained XXX O
with XXX O
tumor XXX O
diameters XXX O
under XXX O
2 XXX O
cm XXX O
regardless XXX O
of XXX O
their XXX O
localization XXX O
in XXX O
lung XXX O
tissue XXX O
and XXX O
with XXX O
2--4 XXX O
. XXX O
9 XXX O
cm XXX O
tumors XXX O
embedded XXX O
in XXX O
lung XXX O
parenchyma XXX O
. XXX O

In XXX O
vitro XXX O
assessment XXX O
of XXX O
the XXX O
biocompatibility XXX O
of XXX O
dental XXX O
materials--the XXX O
millipore XXX O
filter XXX O
method XXX O
. XXX O

The XXX O
N3 XXX O
wave XXX O
of XXX O
the XXX O
SSEP's XXX O
, XXX O
which XXX O
has XXX O
been XXX O
found XXX O
to XXX O
correlate XXX O
best XXX O
with XXX O
neurological XXX O
recovery XXX O
, XXX O
returned XXX O
to XXX O
65% XXX O
+ XXX O
/ XXX O
- XXX O
48% XXX O
of XXX O
the XXX O
preischemia XXX O
amplitude XXX O
in XXX O
the XXX O
insulin-treated XXX O
animals XXX O
, XXX O
compared XXX O
to XXX O
40% XXX O
+ XXX O
/ XXX O
- XXX O
34% XXX O
in XXX O
the XXX O
fasted XXX O
group XXX O
and XXX O
26% XXX O
+ XXX O
/ XXX O
- XXX O
24% XXX O
in XXX O
the XXX O
control XXX O
animals XXX O
. XXX O

Out XXX O
of XXX O
40 XXX O
patients XXX O
, XXX O
who XXX O
initially XXX O
did XXX O
not XXX O
show XXX O
eye XXX O
complications XXX O
due XXX O
to XXX O
leprosy XXX O
, XXX O
37 XXX O
patients XXX O
were XXX O
essentially XXX O
the XXX O
same XXX O
10 XXX O
years XXX O
later XXX O
. XXX O

The XXX O
value XXX O
of XXX O
different XXX O
sources XXX O
of XXX O
nitrogen XXX O
in XXX O
diets XXX O
for XXX O
the XXX O
early-weaned XXX O
calf XXX O
. XXX O

Data XXX O
were XXX O
obtained XXX O
from XXX O
2 XXX O
undergraduate XXX O
student XXX O
samples XXX O
, XXX O
a XXX O
self-report XXX O
group XXX O
( XXX O
n XXX O
= XXX O
132 XXX O
) XXX O
who XXX O
provided XXX O
NEO-PI-R XXX O
self-ratings XXX O
on XXX O
2 XXX O
occasions XXX O
separated XXX O
by XXX O
a XXX O
7- XXX O
to XXX O
14-day XXX O
interval XXX O
and XXX O
an XXX O
informant XXX O
group XXX O
( XXX O
n XXX O
= XXX O
109 XXX O
) XXX O
who XXX O
provided XXX O
ratings XXX O
of XXX O
well-known XXX O
friends XXX O
or XXX O
relatives XXX O
on XXX O
2 XXX O
occasions XXX O
separated XXX O
by XXX O
a XXX O
6 XXX O
month XXX O
interval XXX O
. XXX O

These XXX O
are XXX O
two XXX O
regions XXX O
of XXX O
known XXX O
conserved XXX O
synteny XXX O
, XXX O
providing XXX O
further XXX O
evidence XXX O
that XXX O
the XXX O
human XXX B-GENE
STEP XXX I-GENE
is XXX O
a XXX O
true XXX O
homolog XXX O
of XXX O
the XXX O
murine XXX B-GENE
STEP XXX I-GENE
gene XXX I-GENE
. XXX O

However XXX O
, XXX O
the XXX O
presence XXX O
of XXX O
Tax XXX B-GENE
I XXX I-GENE
increased XXX O
the XXX O
extent XXX O
and XXX O
altered XXX O
the XXX O
profile XXX O
of XXX O
proteins XXX O
binding XXX O
TRE-2 XXX B-GENE
in XXX O
vivo XXX O
. XXX O

The XXX O
FCMS XXX O
conditions XXX O
were XXX O
as XXX O
follows XXX O
: XXX O
2 XXX O
kW XXX O
maximum XXX O
electrical XXX O
power XXX O
consumption XXX O
, XXX O
800 XXX O
V XXX O
maximum XXX O
capacitor XXX O
voltage XXX O
, XXX O
720 XXX O
microseconds XXX O
pulsewidth XXX O
( XXX O
180 XXX O
microseconds XXX O
rise XXX O
time XXX O
) XXX O
, XXX O
and XXX O
5-30 XXX O
Hz XXX O
frequency XXX O
. XXX O

The XXX O
3ASubE XXX O
cells XXX O
expressing XXX O
CXCR2 XXX B-GENE
with XXX O
mutation XXX O
of XXX O
Ser-346 XXX O
, XXX O
-347 XXX O
, XXX O
and XXX O
-348 XXX O
to XXX O
alanine XXX O
, XXX O
or XXX O
with XXX O
mutation XXX O
of XXX O
only XXX O
one XXX O
serine XXX O
in XXX O
this XXX O
domain XXX O
, XXX O
continue XXX O
to XXX O
be XXX O
phosphorylated XXX O
in XXX O
response XXX O
to XXX O
ligand XXX O
and XXX O
are XXX O
60-70% XXX O
desensitized XXX O
following XXX O
the XXX O
initial XXX O
ligand XXX O
challenge XXX O
. XXX O

The XXX O
study XXX O
goals XXX O
were XXX O
to XXX O
isolate XXX O
a XXX O
full-length XXX O
clone XXX O
encoding XXX O
CO-Ag XXX B-GENE
from XXX O
a XXX O
bovine XXX O
corneal XXX O
cDNA XXX O
library XXX O
and XXX O
to XXX O
express XXX O
this XXX O
clone XXX O
in XXX O
Escherichia XXX O
coli XXX O
( XXX O
E XXX O
. XXX O
coli XXX O
) XXX O
. XXX O

The XXX O
promoter XXX O
activity XXX O
was XXX O
measured XXX O
by XXX O
a XXX O
transient XXX O
expression XXX O
of XXX O
a XXX O
chloramphenicol XXX B-GENE
acetyltransferase XXX I-GENE
( XXX O
CAT XXX B-GENE
) XXX O
gene XXX O
connected XXX O
with XXX O
various XXX O
5'-deletion XXX O
mutants XXX O
of XXX O
the XXX O
5'-flanking XXX O
region XXX O
. XXX O

To XXX O
further XXX O
our XXX O
knowledge XXX O
about XXX O
the XXX O
systemic XXX O
humoral XXX O
immune XXX O
system XXX O
response XXX O
to XXX O
weak XXX O
hapten-syngeneic XXX O
or XXX O
allogeneic XXX O
protein XXX O
conjugates XXX O
( XXX O
corrosion XXX O
and XXX O
wear XXX O
products XXX O
of XXX O
metallic XXX O
orthopedic XXX O
devices XXX O
) XXX O
, XXX O
a XXX O
sensitive XXX O
enzyme-linked XXX O
immunosorbent XXX O
assay XXX O
( XXX O
ELISA XXX O
) XXX O
method XXX O
for XXX O
testing XXX O
for XXX O
antibody XXX O
( XXX O
humoral XXX O
immunity XXX O
) XXX O
to XXX O
metals XXX O
was XXX O
developed XXX O
. XXX O

Single-photon XXX O
emission XXX O
computed XXX O
tomography XXX O
( XXX O
SPECT XXX O
) XXX O
with XXX O
99mTc-hexamethylpropyleneamine XXX O
oxime XXX O
( XXX O
HMPAO XXX O
) XXX O
was XXX O
used XXX O
to XXX O
investigate XXX O
changes XXX O
in XXX O
cerebral XXX O
blood XXX O
flow XXX O
in XXX O
seven XXX O
patients XXX O
with XXX O
cortical XXX O
visual XXX O
impairment XXX O
. XXX O

100 XXX O
more XXX O
than XXX O
in XXX O
the XXX O
summer XXX O
coat XXX O
) XXX O
. XXX O

Post XXX O
and XXX O
core XXX O
fabrication XXX O
for XXX O
divergent XXX O
canals XXX O
with XXX O
a XXX O
cast XXX O
post XXX O
and XXX O
core XXX O
and XXX O
a XXX O
prefabricated XXX O
dowel XXX O
. XXX O

Alison XXX O
Bell XXX O
Memorial XXX O
Award XXX O
. XXX O

Menetrier XXX O
disease XXX O
in XXX O
a XXX O
child XXX O
. XXX O

The XXX O
population XXX O
of XXX O
between XXX O
75 XXX O
, XXX O
000 XXX O
and XXX O
100 XXX O
, XXX O
000 XXX O
was XXX O
largely XXX O
unstable XXX O
, XXX O
and XXX O
cost XXX O
per XXX O
capita XXX O
was XXX O
$0 XXX O
. XXX O
95 XXX O
to XXX O
$1 XXX O
. XXX O
21 XXX O
. XXX O

This XXX O
is XXX O
consistent XXX O
with XXX O
a XXX O
model XXX O
proposing XXX O
that XXX O
SSV XXX O
was XXX O
generated XXX O
by XXX O
recombination XXX O
between XXX O
proviral XXX O
DNA XXX O
of XXX O
a XXX O
simian XXX O
sarcoma XXX O
associated XXX O
virus XXX O
and XXX O
proto-sis XXX B-GENE
and XXX O
that XXX O
introns XXX O
were XXX O
spliced XXX O
out XXX O
subsequently XXX O
from XXX O
a XXX O
fused XXX O
viral-sis XXX B-GENE
messenger XXX I-GENE
RNA XXX I-GENE
. XXX O

Mutations XXX O
at XXX O
the XXX O
suf12 XXX B-GENE
locus XXX I-GENE
were XXX O
isolated XXX O
in XXX O
Saccharomyces XXX O
cerevisiae XXX O
as XXX O
extragenic XXX O
suppressors XXX O
of XXX O
+1 XXX O
frameshift XXX O
mutations XXX O
in XXX O
glycine XXX O
( XXX O
GGX XXX O
) XXX O
and XXX O
proline XXX O
( XXX O
CCX XXX O
) XXX O
codons XXX O
, XXX O
as XXX O
well XXX O
as XXX O
UGA XXX O
and XXX O
UAG XXX O
nonsense XXX O
mutations XXX O
. XXX O

Absence XXX O
of XXX O
action XXX O
potentials XXX O
in XXX O
frog XXX O
slow XXX O
muscle XXX O
fibres XXX O
paralysed XXX O
by XXX O
botulinum XXX B-GENE
toxin XXX I-GENE
. XXX O

Pronounced XXX O
microangiopathy XXX O
characterized XXX O
by XXX O
avascular XXX O
fields XXX O
, XXX O
enlarged XXX O
and XXX O
tortuous XXX O
capillaries XXX O
and XXX O
increased XXX O
transcapillary XXX O
diffusion XXX O
of XXX O
sodium XXX O
fluorescein XXX O
, XXX O
was XXX O
clearly XXX O
demonstrable XXX O
in XXX O
the XXX O
area XXX O
of XXX O
the XXX O
nodules XXX O
. XXX O

Logistic XXX O
regression XXX O
analysis XXX O
revealed XXX O
that XXX O
physicians XXX O
were XXX O
3 XXX O
. XXX O
6 XXX O
times XXX O
more XXX O
likely XXX O
to XXX O
detect XXX O
thin XXX O
lesions XXX O
( XXX O
< XXX O
/ XXX O
= XXX O
0 XXX O
. XXX O
75 XXX O
mm XXX O
) XXX O
compared XXX O
with XXX O
nonphysician XXX O
detectors XXX O
( XXX O
95% XXX O
confidence XXX O
interval XXX O
[ XXX O
95% XXX O
CI XXX O
] XXX O
, XXX O
2 XXX O
. XXX O
1 XXX O
, XXX O
6 XXX O
. XXX O
5 XXX O
; XXX O
P XXX O
= XXX O
0 XXX O
. XXX O
0001 XXX O
) XXX O
. XXX O

GW XXX O
Gamma XXX O
approximation XXX O
for XXX O
electron XXX O
self-energies XXX O
in XXX O
semiconductors XXX O
and XXX O
insulators XXX O
. XXX O

Relationships XXX O
with XXX O
the XXX O
acquired XXX O
immune XXX O
deficiency XXX O
syndrome XXX O
. XXX O

The XXX O
results XXX O
of XXX O
the XXX O
ISIS-2 XXX O
trial XXX O
and XXX O
the XXX O
data XXX O
from XXX O
the XXX O
Antiplatelet XXX O
Trialists' XXX O
Collaboration XXX O
indicated XXX O
that XXX O
aspirin XXX O
is XXX O
mandatory XXX O
in XXX O
patients XXX O
with XXX O
acute XXX O
myocardial XXX O
infarction XXX O
and XXX O
for XXX O
secondary XXX O
prevention XXX O
. XXX O

This XXX O
paper XXX O
reviews XXX O
the XXX O
middleware-based XXX O
approach XXX O
adopted XXX O
by XXX O
CEN XXX O
ENV XXX O
12967-1 XXX O
and XXX O
the XXX O
specialisation XXX O
necessary XXX O
for XXX O
the XXX O
healthcare XXX O
record XXX O
based XXX O
on XXX O
CEN XXX O
ENV XXX O
12265 XXX O
'Electronic XXX O
Healthcare XXX O
Record XXX O
Architecture' XXX O
. XXX O

Double XXX O
mutant XXX O
analysis XXX O
suggests XXX O
that XXX O
Rad54p XXX B-GENE
and XXX O
Mus81p XXX B-GENE
act XXX O
in XXX O
one XXX O
pathway XXX O
for XXX O
the XXX O
repair XXX O
of XXX O
, XXX O
or XXX O
tolerance XXX O
to XXX O
, XXX O
UV-induced XXX O
DNA XXX O
damage XXX O
. XXX O

Contrary XXX O
to XXX O
the XXX O
observation XXX O
made XXX O
with XXX O
other XXX O
S XXX O
. XXX O
pombe XXX O
genes XXX O
transcribed XXX O
in XXX O
the XXX O
budding XXX O
yeast XXX O
, XXX O
the XXX O
heterologous XXX O
actin XXX B-GENE
gene XXX I-GENE
transcript XXX I-GENE
is XXX O
initiated XXX O
39 XXX O
nucleotides XXX O
upstream XXX O
of XXX O
the XXX O
initiation XXX O
start XXX O
site XXX O
used XXX O
in XXX O
the XXX O
homologous XXX O
yeast XXX O
. XXX O

Furthermore XXX O
, XXX O
early- XXX O
and XXX O
late-firing XXX O
origins XXX O
differ XXX O
not XXX O
in XXX O
the XXX O
timing XXX O
of XXX O
their XXX O
recruitment XXX O
of XXX O
an XXX O
Mcm XXX B-GENE
protein XXX I-GENE
, XXX O
but XXX O
in XXX O
the XXX O
timing XXX O
of XXX O
RPA's XXX B-GENE
recruitment XXX O
. XXX O

All XXX O
Cu XXX O
values XXX O
obtained XXX O
from XXX O
the XXX O
organs XXX O
investigated XXX O
had XXX O
reached XXX O
a XXX O
saturation XXX O
level XXX O
at XXX O
8 XXX O
mug XXX O
Cu XXX O
/ XXX O
g XXX O
diet XXX O
with XXX O
the XXX O
exception XXX O
of XXX O
the XXX O
values XXX O
for XXX O
body XXX O
Cu XXX O
found XXX O
in XXX O
the XXX O
dams XXX O
that XXX O
were XXX O
killed XXX O
on XXX O
the XXX O
day XXX O
of XXX O
delivery XXX O
. XXX O

The XXX O
CEM XXX O
receives XXX O
registration XXX O
updates XXX O
via XXX O
an XXX O
HL7 XXX O
message XXX O
and XXX O
evaluates XXX O
data XXX O
dependencies XXX O
in XXX O
rules XXX O
via XXX O
an XXX O
interface XXX O
to XXX O
the XXX O
relational XXX O
database XXX O
. XXX O

Since XXX O
only XXX O
58% XXX O
of XXX O
our XXX O
sample XXX O
could XXX O
be XXX O
adequately XXX O
classified XXX O
with XXX O
one XXX O
diagnosis XXX O
, XXX O
we XXX O
expect XXX O
that XXX O
the XXX O
ASDC XXX O
nosology XXX O
will XXX O
need XXX O
to XXX O
evolve XXX O
further XXX O
. XXX O

Furthermore XXX O
, XXX O
a XXX O
mutant XXX O
receptor XXX O
( XXX O
Y977F XXX B-GENE
/ XXX I-GENE
Y989F XXX I-GENE
[ XXX I-GENE
PLC XXX I-GENE
gamma-binding XXX I-GENE
sites XXX I-GENE
] XXX I-GENE
) XXX O
could XXX O
fully XXX O
activate XXX O
Ras XXX B-GENE
, XXX O
and XXX O
the XXX O
direct XXX O
activation XXX O
of XXX O
protein XXX B-GENE
kinase XXX I-GENE
C XXX I-GENE
and XXX O
calcium XXX O
mobilization XXX O
had XXX O
almost XXX O
no XXX O
effect XXX O
on XXX O
the XXX O
GDP XXX O
/ XXX O
GTP XXX O
state XXX O
of XXX O
Ras XXX B-GENE
in XXX O
this XXX O
cell XXX O
line XXX O
. XXX O
( XXX O
ABSTRACT XXX O
TRUNCATED XXX O
AT XXX O
250 XXX O
WORDS XXX O
) XXX O

The XXX O
treatments XXX O
were XXX O
60 XXX O
mg XXX O
t XXX O
. XXX O
i XXX O
. XXX O
d XXX O
. XXX O
and XXX O
120 XXX O
mg XXX O
t XXX O
. XXX O
i XXX O
. XXX O
d XXX O
. XXX O
during XXX O
14 XXX O
days' XXX O
treatment XXX O
, XXX O
with XXX O
the XXX O
last XXX O
dose XXX O
pulsed XXX O
with XXX O
1 XXX O
. XXX O
85 XXX O
MBq XXX O
[ XXX O
14C XXX O
] XXX O
diltiazem XXX O
. XXX O

We XXX O
have XXX O
identified XXX O
amino XXX O
acid XXX O
sequences XXX O
in XXX O
mammalian XXX B-GENE
and XXX I-GENE
Xenopus XXX I-GENE
NeuroD1 XXX I-GENE
/ XXX I-GENE
BETA2 XXX I-GENE
that XXX O
are XXX O
necessary XXX O
for XXX O
insulin XXX B-GENE
gene XXX I-GENE
expression XXX O
and XXX O
ectopic XXX O
neurogenesis XXX O
. XXX O

For XXX O
the XXX O
2 XXX O
. XXX O
5 XXX O
to XXX O
4 XXX O
ng XXX O
/ XXX O
mL XXX O
model XXX O
, XXX O
the XXX O
AUC XXX O
of XXX O
the XXX O
ANN XXX O
ROC XXX O
curve XXX O
was XXX O
significantly XXX O
higher XXX O
than XXX O
the XXX O
AUCs XXX O
for XXX O
percentage XXX O
of XXX O
free XXX O
PSA XXX B-GENE
( XXX O
P XXX O
= XXX O
. XXX O
0239 XXX O
) XXX O
, XXX O
PSA-TZ XXX O
( XXX O
P XXX O
= XXX O
. XXX O
0204 XXX O
) XXX O
, XXX O
and XXX O
PSA XXX B-GENE
density XXX O
and XXX O
total XXX O
prostate XXX O
volume XXX O
( XXX O
P XXX O
< XXX O
. XXX O
01 XXX O
for XXX O
both XXX O
) XXX O
. XXX O

Mechanisms XXX O
of XXX O
visible-light XXX O
emission XXX O
from XXX O
electro-oxidized XXX O
porous XXX O
silicon XXX O
. XXX O

Ovarian XXX O
allotransplantation XXX O
in XXX O
human XXX O
. XXX O

A XXX O
17-mer XXX O
oligodeoxynucleotide XXX O
, XXX O
corresponding XXX O
to XXX O
a XXX O
region XXX O
of XXX O
the XXX O
VtHb XXX B-GENE
amino XXX I-GENE
acid XXX I-GENE
sequence XXX I-GENE
was XXX O
used XXX O
as XXX O
a XXX O
hybridization XXX O
probe XXX O
to XXX O
screen XXX O
a XXX O
Vitreoscilla XXX O
genomic XXX O
library XXX O
constructed XXX O
in XXX O
broad-host-range XXX O
cosmid XXX O
vector XXX O
pVK102 XXX O
. XXX O

The XXX O
results XXX O
suggest XXX O
that XXX O
, XXX O
although XXX O
both XXX O
the XXX O
N- XXX O
and XXX O
C-terminal XXX O
regions XXX O
of XXX O
talin XXX B-GENE
bind XXX O
actin XXX B-GENE
, XXX O
the XXX O
properties XXX O
of XXX O
these XXX O
two XXX O
regions XXX O
of XXX O
the XXX O
protein XXX O
are XXX O
distinct XXX O
. XXX O

Cam XXX B-GENE
kinase XXX I-GENE
II XXX I-GENE
induces XXX O
in XXX O
vivo XXX O
phosphorylation XXX O
of XXX O
Smad2 XXX B-GENE
and XXX O
Smad4 XXX B-GENE
and XXX O
, XXX O
to XXX O
a XXX O
lesser XXX O
extent XXX O
, XXX O
Smad3 XXX B-GENE
. XXX O

The XXX O
predicted XXX O
amino XXX O
acid XXX O
sequence XXX O
of XXX O
the XXX O
SAP-1 XXX B-GENE
cDNA XXX I-GENE
showed XXX O
that XXX O
mature XXX B-GENE
SAP-1 XXX I-GENE
consisted XXX O
of XXX O
1093 XXX O
amino XXX O
acids XXX O
and XXX O
a XXX O
transmembrane-type XXX B-GENE
PTP XXX I-GENE
, XXX O
which XXX O
possessed XXX O
a XXX O
single XXX O
PTP-conserved XXX B-GENE
domain XXX I-GENE
in XXX O
the XXX O
cytoplasmic XXX O
region XXX O
. XXX O

RESULTS XXX O
: XXX O
During XXX O
the XXX O
stabilization XXX O
period XXX O
, XXX O
PaCO2 XXX O
( XXX O
mean XXX O
+ XXX O
/ XXX O
- XXX O
SD XXX O
) XXX O
was XXX O
33 XXX O
+ XXX O
/ XXX O
- XXX O
5 XXX O
mm XXX O
Hg XXX O
, XXX O
and XXX O
arrhythmias XXX O
were XXX O
not XXX O
detected XXX O
. XXX O

However XXX O
, XXX O
the XXX O
promoter XXX O
region XXX O
contains XXX O
several XXX O
potential XXX O
cis-regulatory XXX O
elements XXX O
such XXX O
as XXX O
Sp1 XXX B-GENE
, XXX O
early XXX B-GENE
growth XXX I-GENE
response-1 XXX I-GENE
, XXX O
activator XXX B-GENE
protein-2 XXX I-GENE
, XXX O
MyoD XXX B-GENE
, XXX O
p300 XXX B-GENE
, XXX O
nuclear XXX B-GENE
factor-kappaB XXX I-GENE
, XXX O
myeloid XXX B-GENE
zinc XXX I-GENE
finger XXX I-GENE
protein-1 XXX I-GENE
, XXX O
caudal-related XXX B-GENE
homeobox XXX I-GENE
( XXX I-GENE
Cdx XXX I-GENE
) XXX I-GENE
gene XXX I-GENE
A XXX I-GENE
, XXX O
and XXX O
Cdx XXX B-GENE
protein-2 XXX I-GENE
binding XXX I-GENE
sites XXX I-GENE
. XXX O

Functional XXX O
analysis XXX O
of XXX O
the XXX O
mutant XXX B-GENE
desmin XXX I-GENE
in XXX O
SW13 XXX O
( XXX O
vim- XXX O
) XXX O
cells XXX O
showed XXX O
aggregation XXX O
of XXX O
abnormal XXX O
coarse XXX O
clumps XXX O
of XXX O
desmin XXX B-GENE
positive XXX O
material XXX O
dispersed XXX O
throughout XXX O
the XXX O
cytoplasm XXX O
. XXX O

Cleavage XXX O
by XXX O
the XXX O
intron-encoded XXX O
enzyme XXX O
( XXX O
I-CreI XXX B-GENE
) XXX O
occurs XXX O
5 XXX O
bp XXX O
and XXX O
1 XXX O
bp XXX O
3' XXX O
to XXX O
the XXX O
intron XXX O
insertion XXX O
site XXX O
( XXX O
in XXX O
the XXX O
3'-exon XXX O
) XXX O
in XXX O
the XXX O
top XXX O
( XXX O
/ XXX O
) XXX O
and XXX O
bottom XXX O
( XXX O
, XXX O
) XXX O
strands XXX O
, XXX O
respectively XXX O
, XXX O
resulting XXX O
in XXX O
4-nt XXX O
single-stranded XXX O
overhangs XXX O
with XXX O
3'-OH XXX O
termini XXX O
. XXX O

Based XXX O
on XXX O
the XXX O
sequence XXX O
of XXX O
the XXX O
conRTRE XXX B-GENE
, XXX O
we XXX O
located XXX O
a XXX O
putative XXX O
RTRE XXX B-GENE
, XXX O
referred XXX O
to XXX O
as XXX O
P2-RE XXX B-GENE
, XXX O
in XXX O
the XXX O
5' XXX O
promoter-flanking XXX O
region XXX O
of XXX O
the XXX O
mouse XXX B-GENE
protamine XXX I-GENE
2 XXX I-GENE
gene XXX I-GENE
, XXX O
which XXX O
is XXX O
induced XXX O
during XXX O
the XXX O
same XXX O
stage XXX O
of XXX O
spermatogenesis XXX O
as XXX O
RTR XXX B-GENE
. XXX O

Osteoadherin XXX B-GENE
is XXX O
a XXX O
recently XXX O
described XXX O
bone XXX O
proteoglycan XXX O
containing XXX O
keratan XXX O
sulfate XXX O
. XXX O

Possibly XXX O
, XXX O
the XXX O
scr1-1 XXX B-GENE
mutation XXX I-GENE
does XXX O
not XXX O
affect XXX O
signal XXX O
recognition XXX O
or XXX O
translational XXX O
arrest XXX O
but XXX O
instead XXX O
results XXX O
in XXX O
maintenance XXX O
of XXX O
translational XXX O
arrest XXX O
of XXX O
AEP XXX B-GENE
synthesis XXX O
. XXX O

A XXX O
recombinant XXX O
vector XXX O
, XXX O
p410+ XXX O
, XXX O
was XXX O
constructed XXX O
which XXX O
carried XXX O
the XXX O
BamHI-K XXX B-GENE
fragment XXX I-GENE
( XXX O
nucleotides XXX O
107565 XXX O
to XXX O
112625 XXX O
of XXX O
the XXX O
B95-8 XXX O
strain XXX O
, XXX O
encoding XXX O
the XXX O
EBV-associated XXX B-GENE
nuclear XXX I-GENE
antigen XXX I-GENE
EBNA-1 XXX I-GENE
) XXX O
, XXX O
the XXX O
cis-acting XXX O
sequence XXX O
from XXX O
the XXX O
BamHI-C XXX B-GENE
fragment XXX I-GENE
, XXX O
and XXX O
a XXX O
dominant XXX O
selectable XXX O
marker XXX O
gene XXX O
encoding XXX O
G-418 XXX O
resistance XXX O
in XXX O
animal XXX O
cells XXX O
. XXX O

When XXX O
this XXX O
CCAAT XXX O
box XXX O
was XXX O
inserted XXX O
into XXX O
a XXX O
heterologous XXX O
promoter XXX O
construct XXX O
, XXX O
OA XXX O
induction XXX O
was XXX O
dependent XXX O
on XXX O
an XXX O
intact XXX O
CCAAT XXX O
box XXX O
. XXX O

Radioimmunoassays XXX O
of XXX O
pregnenolone XXX O
, XXX O
progesterone XXX O
, XXX O
dehydroepiandrosterone XXX O
( XXX O
DHA XXX O
) XXX O
16 XXX O
alpha-hydroxy-DHA XXX O
, XXX O
estriol XXX O
, XXX O
and XXX O
cortisol XXX O
were XXX O
performed XXX O
on XXX O
a XXX O
total XXX O
of XXX O
0 XXX O
; XXX O
1 XXX O
ml XXX O
; XXX O
of XXX O
fetal XXX O
plasma XXX O
, XXX O
collected XXX O
during XXX O
the XXX O
course XXX O
of XXX O
normal XXX O
vaginal XXX O
delivery XXX O
. XXX O

DNA XXX O
sequencing XXX O
and XXX O
Southern XXX O
blot XXX O
analyses XXX O
established XXX O
that XXX O
the XXX O
cDNA XXX O
clones XXX O
are XXX O
derived XXX O
from XXX O
two XXX O
different XXX O
genes XXX O
. XXX O

The XXX O
transcription XXX O
initiation XXX O
site XXX O
was XXX O
determined XXX O
by XXX O
S1 XXX B-GENE
nuclease XXX I-GENE
mapping XXX O
. XXX O

Ivermectin XXX O
uptake XXX O
and XXX O
distribution XXX O
in XXX O
the XXX O
plasma XXX O
and XXX O
tissue XXX O
of XXX O
Sudanese XXX O
and XXX O
Mexican XXX O
patients XXX O
infected XXX O
with XXX O
Onchocerca XXX O
volvulus XXX O
. XXX O

Total XXX O
cumulative XXX O
doses XXX O
of XXX O
doxorubicin XXX O
ranged XXX O
from XXX O
145 XXX O
to XXX O
625 XXX O
mg XXX O
. XXX O
/ XXX O
m XXX O
. XXX O
2 XXX O
. XXX O

Using XXX O
PRL-R XXX B-GENE
tagged XXX O
both XXX O
in XXX O
the XXX O
N-terminal XXX O
or XXX O
C-terminal XXX O
regions XXX O
of XXX O
the XXX O
mature XXX O
receptor XXX O
excludes XXX O
the XXX O
possibility XXX O
of XXX O
a XXX O
cleaved XXX O
fragment XXX O
which XXX O
could XXX O
have XXX O
been XXX O
subsequently XXX O
imported XXX O
into XXX O
the XXX O
nucleus XXX O
. XXX O

Response XXX O
was XXX O
extremely XXX O
poor XXX O
in XXX O
African XXX O
Americans XXX O
and XXX O
those XXX O
with XXX O
HCV XXX O
genotype XXX O
1 XXX O
. XXX O

Analysis XXX O
of XXX O
the XXX O
5' XXX O
end XXX O
of XXX O
the XXX O
mouse XXX B-GENE
Elavl1 XXX I-GENE
( XXX O
mHuA XXX B-GENE
) XXX O
gene XXX O
reveals XXX O
a XXX O
transcriptional XXX O
regulatory XXX O
element XXX O
and XXX O
evidence XXX O
for XXX O
conserved XXX O
genomic XXX O
organization XXX O
. XXX O
mHuA XXX B-GENE
( XXX O
Elavl1 XXX B-GENE
) XXX O
belongs XXX O
to XXX O
a XXX O
highly XXX O
conserved XXX O
family XXX O
of XXX O
genes XXX O
encoding XXX O
RNA-binding XXX O
proteins XXX O
and XXX O
has XXX O
been XXX O
linked XXX O
to XXX O
cell XXX O
growth XXX O
and XXX O
proliferation XXX O
through XXX O
its XXX O
regulation XXX O
of XXX O
mRNA XXX O
stability XXX O
. XXX O

The XXX O
results XXX O
indicate XXX O
that XXX O
a XXX O
more XXX O
differentiated XXX O
diagnosis XXX O
of XXX O
the XXX O
molar XXX O
relationship XXX O
will XXX O
allow XXX O
for XXX O
a XXX O
more XXX O
causally XXX O
directed XXX O
correction XXX O
of XXX O
Class XXX O
II XXX O
molar XXX O
relationship XXX O
. XXX O

After XXX O
i XXX O
. XXX O
v XXX O
. XXX O

Splice-junction XXX O
elements XXX O
and XXX O
intronic XXX O
sequences XXX O
regulate XXX O
alternative XXX O
splicing XXX O
of XXX O
the XXX O
Drosophila XXX O
myosin XXX B-GENE
heavy XXX I-GENE
chain XXX I-GENE
gene XXX I-GENE
transcript XXX O
. XXX O

Competitionsupershift XXX O
EMSA XXX O
assays XXX O
revealed XXX O
that XXX O
multiple XXX O
proteins XXX O
were XXX O
involved XXX O
in XXX O
bandshift XXX O
complex XXX O
formation XXX O
with XXX O
KCS XXX B-GENE
, XXX O
one XXX O
of XXX O
which XXX O
was XXX O
identified XXX O
as XXX O
factor XXX B-GENE
Sp1 XXX I-GENE
. XXX O

Some XXX O
of XXX O
these XXX O
targets XXX O
were XXX O
reported XXX O
to XXX O
code XXX O
for XXX O
molecules XXX O
involved XXX O
in XXX O
cell-cell XXX O
interactions XXX O
, XXX O
whereas XXX O
no XXX O
relationship XXX O
has XXX O
yet XXX O
been XXX O
demonstrated XXX O
between XXX O
Hox XXX B-GENE
genes XXX I-GENE
and XXX O
other XXX O
transcription XXX O
factors XXX O
involved XXX O
in XXX O
determining XXX O
and XXX O
/ XXX O
or XXX O
maintaining XXX O
tissue XXX O
specificity XXX O
. XXX O

Upstream XXX O
activation XXX O
sites XXX O
of XXX O
the XXX O
CYC1 XXX B-GENE
gene XXX I-GENE
of XXX O
Saccharomyces XXX O
cerevisiae XXX O
are XXX O
active XXX O
when XXX O
inverted XXX O
but XXX O
not XXX O
when XXX O
placed XXX O
downstream XXX O
of XXX O
the XXX O
"TATA XXX O
box" XXX O
. XXX O

The XXX O
relative XXX O
R- XXX O
and XXX O
L-brain XXX O
weights XXX O
were XXX O
found XXX O
to XXX O
be XXX O
inversely XXX O
related XXX O
to XXX O
the XXX O
relative XXX O
R-L XXX O
brain XXX O
weight XXX O
only XXX O
in XXX O
the XXX O
RH XXX O
female XXX O
cats XXX O
with XXX O
R-L XXX O
brain XXX O
weight XXX O
smaller XXX O
than XXX O
zero XXX O
( XXX O
testosterone XXX O
in XXX O
males XXX O
, XXX O
estrogen XXX O
in XXX O
females XXX O
) XXX O
. XXX O

Chemotherapy XXX O
was XXX O
administered XXX O
without XXX O
altering XXX O
the XXX O
course XXX O
of XXX O
the XXX O
disorder XXX O
. XXX O

Furthermore XXX O
, XXX O
the XXX O
use XXX O
of XXX O
zero-loss XXX O
filtering XXX O
in XXX O
combination XXX O
with XXX O
exit XXX O
wavefront XXX O
reconstruction XXX O
is XXX O
considerably XXX O
more XXX O
effective XXX O
at XXX O
removing XXX O
the XXX O
effects XXX O
of XXX O
multiple XXX O
elastic XXX O
and XXX O
inelastic XXX O
scattering XXX O
and XXX O
microscope XXX O
objective XXX O
lens XXX O
aberrations XXX O
than XXX O
either XXX O
technique XXX O
by XXX O
itself XXX O
. XXX O

Our XXX O
studies XXX O
also XXX O
excluded XXX O
the XXX O
possibility XXX O
that XXX O
the XXX O
phosphorylation XXX O
of XXX O
Ser-2 XXX B-GENE
, XXX O
Ser-123 XXX B-GENE
, XXX O
or XXX O
Ser-210 XXX B-GENE
, XXX O
had XXX O
roles XXX O
in XXX O
the XXX O
trans-suppression XXX O
activity XXX O
of XXX O
the XXX O
large XXX B-GENE
HDAg XXX I-GENE
, XXX O
in XXX O
the XXX O
assembly XXX O
of XXX O
empty XXX O
virus-like XXX B-GENE
HDAg XXX I-GENE
particle XXX I-GENE
, XXX O
and XXX O
in XXX O
the XXX O
nuclear XXX O
transport XXX O
of XXX O
HDAgs XXX B-GENE
. XXX O

Workplace XXX O
violence--nurses XXX O
at XXX O
risk XXX O
. XXX O

Effect XXX O
of XXX O
noise XXX O
on XXX O
CO-induced XXX O
increases XXX O
of XXX O
LAP XXX B-GENE
and XXX O
GPT XXX B-GENE
activity XXX O
in XXX O
the XXX O
plasma XXX O
of XXX O
rats XXX O
. XXX O

It XXX O
contains XXX O
three XXX O
putative XXX O
TATA XXX O
boxes XXX O
far XXX O
upstream XXX O
of XXX O
the XXX O
main XXX O
start XXX O
sites XXX O
region XXX O
, XXX O
one XXX O
AP-1 XXX B-GENE
box XXX I-GENE
, XXX O
one XXX O
AP-2 XXX B-GENE
box XXX I-GENE
, XXX O
one XXX O
Malt XXX B-GENE
box XXX I-GENE
, XXX O
one XXX O
GAGA XXX O
box XXX O
, XXX O
one XXX O
half XXX O
serum-responsive XXX B-GENE
element XXX I-GENE
, XXX O
and XXX O
putative XXX O
binding XXX O
sites XXX O
for XXX O
Sp1 XXX B-GENE
( XXX O
five XXX O
) XXX O
, XXX O
GC-rich XXX B-GENE
binding XXX I-GENE
factor XXX I-GENE
( XXX O
five XXX O
) XXX O
, XXX O
CTF-NF1 XXX B-GENE
( XXX O
one XXX O
) XXX O
, XXX O
Myb XXX B-GENE
( XXX O
one XXX O
) XXX O
, XXX O
p53 XXX B-GENE
( XXX O
two XXX O
) XXX O
, XXX O
Ets-1 XXX B-GENE
( XXX O
one XXX O
) XXX O
, XXX O
NF-IL6 XXX B-GENE
( XXX O
two XXX O
) XXX O
, XXX O
MyoD XXX B-GENE
( XXX O
two XXX O
) XXX O
, XXX O
Zeste XXX B-GENE
( XXX O
one XXX O
) XXX O
, XXX O
and XXX O
hepatocyte XXX B-GENE
nuclear XXX I-GENE
factor-5 XXX I-GENE
( XXX O
one XXX O
) XXX O
. XXX O

Postoperative XXX O
serum XXX O
ACTH XXX B-GENE
levels XXX O
were XXX O
normal XXX O
. XXX O

MBI XXX O
and XXX O
MMBI XXX O
showed XXX O
similar XXX O
Cmax XXX O
values XXX O
, XXX O
but XXX O
the XXX O
former XXX O
disappeared XXX O
slower XXX O
in XXX O
the XXX O
serum XXX O
than XXX O
the XXX O
latter XXX O
and XXX O
resulted XXX O
in XXX O
its XXX O
larger XXX O
AUC XXX O
values XXX O
. XXX O

Both XXX O
4 XXX O
, XXX O
8-DiMeIQx XXX O
and XXX O
A XXX O
alpha XXX O
C XXX O
were XXX O
found XXX O
at XXX O
< XXX O
1 XXX O
p XXX O
. XXX O
p XXX O
. XXX O
b XXX O
. XXX O

Epitope XXX O
mapping XXX O
revealed XXX O
that XXX O
these XXX O
three XXX O
clones XXX O
appear XXX O
to XXX O
recognize XXX O
an XXX O
identical XXX O
epitope XXX O
domain XXX O
present XXX O
on XXX O
the XXX O
C-terminal XXX O
RNP XXX B-GENE
motif XXX I-GENE
of XXX O
the XXX O
U1A XXX B-GENE
protein XXX I-GENE
. XXX O

Emphysematous XXX O
cholecystitis XXX O
: XXX O
sonographic XXX O
findings XXX O
. XXX O

Cyclin XXX B-GENE
G2 XXX I-GENE
is XXX O
highly XXX O
expressed XXX O
in XXX O
the XXX O
immune XXX O
system XXX O
where XXX O
immunologic XXX O
tolerance XXX O
subjects XXX O
self-reactive XXX O
lymphocytes XXX O
to XXX O
negative XXX O
selection XXX O
and XXX O
clonal XXX O
deletion XXX O
via XXX O
apoptosis XXX O
. XXX O

Nevertheless XXX O
, XXX O
they XXX O
are XXX O
functionally XXX O
distinct XXX O
in XXX O
that XXX O
FcalphaRI XXX B-GENE
binds XXX O
human XXX B-GENE
IgA XXX I-GENE
( XXX O
hIgA XXX B-GENE
) XXX O
but XXX O
not XXX O
bovine XXX B-GENE
IgG2 XXX I-GENE
( XXX O
bIgG2 XXX B-GENE
) XXX O
, XXX O
whereas XXX O
bFcgamma2R XXX B-GENE
binds XXX O
bIgG2 XXX B-GENE
but XXX O
not XXX O
hIgA XXX B-GENE
. XXX O

CD3 XXX B-GENE
cross-linking XXX O
induced XXX O
tyrosine XXX O
phosphorylation XXX O
of XXX O
Sam68 XXX B-GENE
in XXX O
uninfected XXX O
T XXX O
cells XXX O
. XXX O

Another XXX O
long XXX O
insertion XXX O
in XXX O
the XXX O
cathepsin XXX B-GENE
X XXX I-GENE
amino XXX I-GENE
acid XXX I-GENE
sequence XXX O
forms XXX O
a XXX O
beta-hairpin XXX O
pointing XXX O
away XXX O
from XXX O
the XXX O
active XXX O
site XXX O
. XXX O

One XXX O
chimpanzee XXX O
reliably XXX O
selected XXX O
the XXX O
larger XXX O
numeral XXX O
4 XXX O
during XXX O
testing XXX O
with XXX O
a XXX O
nonadjacent XXX O
pair XXX O
( XXX O
2-4 XXX O
) XXX O
, XXX O
and XXX O
2 XXX O
chimps XXX O
showed XXX O
no XXX O
preference XXX O
. XXX O

We XXX O
determined XXX O
how XXX O
DNA XXX O
repair XXX O
is XXX O
affected XXX O
by XXX O
TFA1 XXX B-GENE
conditional XXX O
mutations XXX O
. XXX O

Analysis XXX O
of XXX O
cell XXX O
cycle XXX O
proteins XXX O
showed XXX O
that XXX O
24 XXX O
h XXX O
of XXX O
lovastatin XXX O
treatment XXX O
in XXX O
the XXX O
control XXX O
cells XXX O
caused XXX O
an XXX O
elevation XXX O
in XXX O
the XXX O
levels XXX O
of XXX O
the XXX O
cyclin-dependent XXX B-GENE
kinase XXX I-GENE
inhibitor XXX I-GENE
p27 XXX I-GENE
( XXX I-GENE
kip1 XXX I-GENE
) XXX I-GENE
, XXX O
inhibition XXX O
of XXX O
both XXX O
cyclin XXX B-GENE
E- XXX I-GENE
and XXX O
cyclin XXX B-GENE
A-dependent XXX I-GENE
kinase XXX I-GENE
activity XXX O
, XXX O
and XXX O
decreased XXX O
levels XXX O
of XXX O
hyperphosphorylated XXX O
retinoblastoma XXX B-GENE
protein XXX I-GENE
( XXX O
pRb XXX B-GENE
) XXX O
. XXX O

Urease XXX B-GENE
activity XXX O
of XXX O
97% XXX O
of XXX O
these XXX O
organisms XXX O
became XXX O
evident XXX O
within XXX O
30 XXX O
min XXX O
. XXX O

Structure XXX O
and XXX O
regulation XXX O
of XXX O
a XXX O
nuclear XXX O
gene XXX O
in XXX O
Saccharomyces XXX O
cerevisiae XXX O
that XXX O
specifies XXX O
MRP13 XXX B-GENE
, XXX O
a XXX O
protein XXX O
of XXX O
the XXX O
small XXX O
subunit XXX O
of XXX O
the XXX O
mitochondrial XXX O
ribosome XXX O
. XXX O

Nuclear-encoded XXX B-GENE
chloroplast XXX I-GENE
ribosomal XXX I-GENE
protein XXX I-GENE
L12 XXX I-GENE
of XXX O
Nicotiana XXX O
tabacum XXX O
: XXX O
characterization XXX O
of XXX O
mature XXX O
protein XXX O
and XXX O
isolation XXX O
and XXX O
sequence XXX O
analysis XXX O
of XXX O
cDNA XXX O
clones XXX O
encoding XXX O
its XXX O
cytoplasmic XXX O
precursor XXX O
. XXX O

The XXX O
amino-terminal XXX O
DNA-binding XXX O
domain XXX O
of XXX O
Pip XXX B-GENE
exhibits XXX O
a XXX O
high XXX O
degree XXX O
of XXX O
homology XXX O
to XXX O
the XXX O
DNA-binding XXX O
domains XXX O
of XXX O
members XXX O
of XXX O
the XXX O
interferon XXX B-GENE
regulatory XXX I-GENE
factor XXX I-GENE
( XXX O
IRF XXX B-GENE
) XXX O
family XXX O
, XXX O
which XXX O
includes XXX O
IRF-1 XXX B-GENE
, XXX O
IRF-2 XXX B-GENE
, XXX O
ICSBP XXX B-GENE
, XXX O
and XXX O
ISGF3 XXX B-GENE
gamma XXX I-GENE
. XXX O

Resting XXX O
plasma XXX O
norepinephrine XXX O
( XXX O
NE XXX O
) XXX O
and XXX O
epinephrine XXX O
( XXX O
E XXX O
) XXX O
levels XXX O
were XXX O
lower XXX O
during XXX O
active XXX O
therapy XXX O
than XXX O
2 XXX O
wk XXX O
after XXX O
withdrawal XXX O
( XXX O
guanfacine XXX O
and XXX O
control XXX O
: XXX O
plasma XXX O
NE XXX O
, XXX O
0 XXX O
. XXX O
27 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
03 XXX O
/ XXX O
0 XXX O
. XXX O
64 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
13 XXX O
ng XXX O
/ XXX O
ml XXX O
; XXX O
plasma XXX O
E XXX O
, XXX O
0 XXX O
. XXX O
09 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
02 XXX O
/ XXX O
0 XXX O
. XXX O
17 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
05 XXX O
ng XXX O
/ XXX O
ml XXX O
) XXX O
. XXX O

A XXX O
diagnosis XXX O
of XXX O
IgA XXX B-GENE
lambda XXX I-GENE
multiple XXX O
myeloma XXX O
with XXX O
peritoneal XXX O
involvement XXX O
was XXX O
made XXX O
. XXX O

After XXX O
90 XXX O
d XXX O
a XXX O
subsurface XXX O
, XXX O
radiolucent XXX O
caries-like XXX O
lesion XXX O
was XXX O
observed XXX O
in XXX O
two XXX O
specimens XXX O
only XXX O
. XXX O

In XXX O
all XXX O
tissues XXX O
examined XXX O
only XXX O
transcripts XXX O
positive XXX O
for XXX O
insert XXX O
3 XXX O
, XXX O
an XXX O
18 XXX O
bp XXX O
insertion XXX O
in XXX O
repeat XXX O
21 XXX O
, XXX O
were XXX O
amplified XXX O
, XXX O
even XXX O
under XXX O
conditions XXX O
in XXX O
which XXX O
a XXX O
30% XXX O
level XXX O
of XXX O
insert XXX O
3 XXX O
negative XXX O
transcript XXX O
could XXX O
be XXX O
easily XXX O
detected XXX O
in XXX O
artificially XXX O
prepared XXX O
control XXX O
samples XXX O
. XXX O

The XXX O
background XXX O
processes XXX O
depending XXX O
on XXX O
the XXX O
etiological XXX O
factor XXX O
and XXX O
the XXX O
character XXX O
of XXX O
lesion XXX O
of XXX O
the XXX O
epithelium XXX O
are XXX O
divided XXX O
into XXX O
dyshormonal XXX O
, XXX O
inflammatory XXX O
, XXX O
and XXX O
posttraumatic XXX O
. XXX O

Purple XXX O
photosynthetic XXX O
bacteria XXX O
are XXX O
capable XXX O
of XXX O
generating XXX O
cellular XXX O
energy XXX O
from XXX O
several XXX O
sources XXX O
, XXX O
including XXX O
photosynthesis XXX O
, XXX O
respiration XXX O
, XXX O
and XXX O
H XXX O
( XXX O
2 XXX O
) XXX O
oxidation XXX O
. XXX O

Effect XXX O
of XXX O
Azadirachta XXX O
indica XXX O
hydroalcoholic XXX O
leaf XXX O
extract XXX O
on XXX O
the XXX O
cardiovascular XXX O
system XXX O
. XXX O

Hepatitis XXX O
B XXX O
virus XXX O
and XXX O
hepatoma XXX O
. XXX O

All XXX O
groups XXX O
were XXX O
challenged XXX O
subsequently XXX O
with XXX O
naloxone XXX O
( XXX O
0 XXX O
. XXX O
4 XXX O
mg XXX O
/ XXX O
kg XXX O
) XXX O
in XXX O
the XXX O
distinctive XXX O
environment XXX O
and XXX O
then XXX O
observed XXX O
for XXX O
signs XXX O
of XXX O
opiate XXX O
withdrawal XXX O
. XXX O

No XXX O
difference XXX O
in XXX O
percentage XXX O
of XXX O
males XXX O
in XXX O
semen XXX O
production XXX O
was XXX O
noted XXX O
between XXX O
strains XXX O
, XXX O
CP XXX O
levels XXX O
, XXX O
or XXX O
feeding XXX O
regimens XXX O
. XXX O

The XXX O
heterogeneity XXX O
of XXX O
bovine XXX B-GENE
IgG2--VIII XXX I-GENE
. XXX O

Erythromycin XXX O
and XXX O
clindamycin XXX O
resistance XXX O
in XXX O
Corynebacterium XXX O
diphtheriae XXX O
from XXX O
skin XXX O
lesions XXX O
. XXX O

MRI XXX O
disclosed XXX O
one XXX O
or XXX O
more XXX O
of XXX O
the XXX O
following XXX O
abnormalities XXX O
in XXX O
24 XXX O
( XXX O
63% XXX O
) XXX O
of XXX O
38 XXX O
treated XXX O
kidneys XXX O
: XXX O
( XXX O
1 XXX O
) XXX O
loss XXX O
of XXX O
corticomedullary XXX O
differentiation XXX O
, XXX O
( XXX O
2 XXX O
) XXX O
perirenal XXX O
fluid XXX O
, XXX O
( XXX O
3 XXX O
) XXX O
subcapsular XXX O
hematoma XXX O
, XXX O
( XXX O
4 XXX O
) XXX O
hemorrhage XXX O
into XXX O
a XXX O
renal XXX O
cyst XXX O
, XXX O
and XXX O
( XXX O
5 XXX O
) XXX O
unexplained XXX O
abnormalities XXX O
. XXX O

As XXX O
was XXX O
observed XXX O
previously XXX O
for XXX O
MATa XXX B-GENE
cna1 XXX B-GENE
cna2 XXX B-GENE
double XXX O
mutants XXX O
, XXX O
MATa XXX B-GENE
cnb1 XXX B-GENE
mutants XXX I-GENE
were XXX O
defective XXX O
in XXX O
their XXX O
ability XXX O
to XXX O
recover XXX O
from XXX O
alpha-factor-induced XXX O
growth XXX O
arrest XXX O
. XXX O

Lithium XXX O
phthalocyanine XXX O
( XXX O
LiPc XXX O
) XXX O
is XXX O
a XXX O
prototype XXX O
of XXX O
another XXX O
generation XXX O
of XXX O
synthetic XXX O
, XXX O
metallic-organic XXX O
, XXX O
paramagnetic XXX O
crystallites XXX O
that XXX O
appear XXX O
very XXX O
useful XXX O
for XXX O
in XXX O
vitro XXX O
and XXX O
in XXX O
vivo XXX O
electron XXX O
paramagnetic XXX O
resonance XXX O
oximetry XXX O
. XXX O

In XXX O
transient XXX O
assays XXX O
, XXX O
using XXX O
rice XXX O
suspension-cultured XXX O
cells XXX O
transformed XXX O
by XXX O
particle XXX O
bombardment XXX O
, XXX O
we XXX O
showed XXX O
previously XXX O
that XXX O
Oshox1 XXX B-GENE
can XXX O
transcriptionally XXX O
repress XXX O
the XXX O
activity XXX O
of XXX O
reporter XXX O
gene XXX O
constructs XXX O
with XXX O
upstream XXX O
HD-Zip XXX B-GENE
binding XXX I-GENE
sites XXX I-GENE
. XXX O

A XXX O
mutation XXX O
in XXX O
the XXX O
5' XXX B-GENE
C2U4 XXX I-GENE
repeat XXX I-GENE
causes XXX O
underaccumulation XXX O
of XXX O
snR13F XXX B-GENE
, XXX O
whereas XXX O
mutations XXX O
in XXX O
the XXX O
3' XXX B-GENE
C2U4 XXX I-GENE
repeat XXX I-GENE
cause XXX O
the XXX O
accumulation XXX O
of XXX O
two XXX O
novel XXX O
RNAs XXX O
that XXX O
migrate XXX O
in XXX O
the XXX O
500-nt XXX O
range XXX O
. XXX O

Atorvastatin XXX O
was XXX O
the XXX O
most XXX O
cost-effective XXX O
HMG-CoA XXX B-GENE
reductase XXX I-GENE
inhibitor XXX O
. XXX O

Slp1 XXX B-GENE
represses XXX O
transcription XXX O
via XXX O
this XXX O
binding XXX O
site XXX O
in XXX O
yeast XXX O
cells XXX O
, XXX O
consistent XXX O
with XXX O
its XXX O
role XXX O
as XXX O
a XXX O
direct XXX O
repressor XXX O
of XXX O
ftz XXX B-GENE
stripes XXX O
in XXX O
interstripe XXX O
regions XXX O
during XXX O
late XXX O
stages XXX O
of XXX O
embryogenesis XXX O
. XXX O

Comparisons XXX O
of XXX O
rrnB XXX B-GENE
P1-lacZ XXX I-GENE
expression XXX O
at XXX O
different XXX O
ppGpp XXX O
levels XXX O
is XXX O
interpreted XXX O
for XXX O
the XXX O
rpoD XXX B-GENE
( XXX I-GENE
P504L XXX I-GENE
) XXX I-GENE
mutant XXX I-GENE
as XXX O
resulting XXX O
from XXX O
a XXX O
hypersensitivity XXX O
to XXX O
ppGpp XXX O
. XXX O

In XXX O
addition XXX O
to XXX O
targeting XXX O
partially XXX O
assembled XXX O
Ti XXX B-GENE
alpha-beta XXX I-GENE
CD3 XXX B-GENE
gamma XXX I-GENE
delta XXX I-GENE
epsilon XXX I-GENE
TCR XXX B-GENE
complexes XXX I-GENE
to XXX O
the XXX O
cell XXX O
surface XXX O
, XXX O
CD3 XXX B-GENE
zeta XXX I-GENE
appears XXX O
to XXX O
be XXX O
essential XXX O
for XXX O
interleukin-2 XXX B-GENE
production XXX O
after XXX O
TCR XXX B-GENE
stimulation XXX O
with XXX O
antigen XXX B-GENE
/ XXX I-GENE
major XXX I-GENE
histocompatibility XXX I-GENE
complex XXX I-GENE
. XXX O

Quantitative XXX O
predictions XXX O
are XXX O
confirmed XXX O
for XXX O
the XXX O
positive XXX O
responses XXX O
, XXX O
but XXX O
not XXX O
for XXX O
the XXX O
negatives XXX O
, XXX O
suggesting XXX O
that XXX O
the XXX O
SSTS XXX O
model XXX O
is XXX O
incorrect XXX O
. XXX O

Bimodal XXX O
cochlear XXX O
response XXX O
curves XXX O
in XXX O
rodents XXX O
. XXX O

Structure XXX O
of XXX O
the XXX O
gene XXX O
encoding XXX O
the XXX O
human XXX B-GENE
cyclin-dependent XXX I-GENE
kinase XXX I-GENE
inhibitor XXX I-GENE
p18 XXX I-GENE
and XXX O
mutational XXX O
analysis XXX O
in XXX O
breast XXX O
cancer XXX O
. XXX O

Human XXX B-GENE
MN XXX I-GENE
/ XXX I-GENE
CA9 XXX I-GENE
gene XXX I-GENE
, XXX O
a XXX O
novel XXX O
member XXX O
of XXX O
the XXX O
carbonic XXX B-GENE
anhydrase XXX I-GENE
family XXX I-GENE
: XXX O
structure XXX O
and XXX O
exon XXX O
to XXX O
protein XXX O
domain XXX O
relationships XXX O
. XXX O

However XXX O
, XXX O
when XXX O
, XXX O
where XXX O
and XXX O
how XXX O
the XXX O
DSPP XXX B-GENE
is XXX O
cleaved XXX O
into XXX O
DSP XXX B-GENE
and XXX O
DPP XXX B-GENE
is XXX O
not XXX O
clear XXX O
. XXX O

Low-dose XXX O
D XXX O
( XXX O
0 XXX O
. XXX O
4-0 XXX O
. XXX O
8 XXX O
mg XXX O
) XXX O
and XXX O
DB XXX O
( XXX O
1 XXX O
. XXX O
0-5 XXX O
. XXX O
0 XXX O
mg XXX O
) XXX O
did XXX O
not XXX O
significantly XXX O
alter XXX O
any XXX O
parameter XXX O
from XXX O
control XXX O
. XXX O

We XXX O
have XXX O
investigated XXX O
the XXX O
influence XXX O
of XXX O
NaFe3+EDTA XXX O
, XXX O
and XXX O
of XXX O
increasing XXX O
dietary XXX O
levels XXX O
of XXX O
Na2EDTA XXX O
, XXX O
on XXX O
Zn XXX O
, XXX O
Cu XXX O
and XXX O
Ca XXX O
metabolism XXX O
in XXX O
rats XXX O
fed XXX O
on XXX O
Zn-sufficient XXX O
and XXX O
Zn-deficient XXX O
soya-bean-isolate-based XXX O
diets XXX O
. XXX O

Further XXX O
evidence XXX O
for XXX O
a XXX O
clustered XXX O
organization XXX O
of XXX O
FAX-ZFP XXX B-GENE
transcription XXX I-GENE
units XXX I-GENE
is XXX O
provided XXX O
by XXX O
Southern XXX O
blot XXX O
analysis XXX O
of XXX O
large XXX O
genomic XXX O
restriction XXX O
fragments XXX O
separated XXX O
by XXX O
transverse XXX O
field XXX O
gel XXX O
electrophoresis XXX O
, XXX O
and XXX O
by XXX O
in XXX O
situ XXX O
hybridization XXX O
on XXX O
intact XXX O
chromosomes XXX O
. XXX O

Here XXX O
, XXX O
we XXX O
show XXX O
that XXX O
aortic XXX O
explants XXX O
isolated XXX O
from XXX O
PPARalpha-null XXX O
mice XXX O
display XXX O
an XXX O
exacerbated XXX O
response XXX O
to XXX O
inflammatory XXX O
stimuli XXX O
, XXX O
such XXX O
as XXX O
lipopolysaccharide XXX O
( XXX O
LPS XXX O
) XXX O
, XXX O
as XXX O
demonstrated XXX O
by XXX O
increased XXX O
IL-6 XXX B-GENE
secretion XXX O
. XXX O

Metastasis XXX O
of XXX O
colon XXX O
carcinoma XXX O
to XXX O
the XXX O
lip XXX O
. XXX O

During XXX O
heat XXX O
exposure XXX O
, XXX O
chicks XXX O
that XXX O
had XXX O
been XXX O
subjected XXX O
to XXX O
early XXX O
60% XXX O
restriction XXX O
with XXX O
non-metyrapone-treated XXX O
food XXX O
had XXX O
lower XXX O
H XXX O
/ XXX O
L XXX O
ratios XXX O
and XXX O
improved XXX O
resistance XXX O
to XXX O
marble XXX O
spleen XXX O
disease XXX O
infection XXX O
. XXX O

No XXX O
recombination XXX O
signal XXX O
sequences XXX O
have XXX O
been XXX O
found XXX O
contiguous XXX O
to XXX O
the XXX O
recombination XXX O
point XXX O
. XXX O

Abnormal XXX O
intrapulmonary XXX O
shunting XXX O
( XXX O
IPS XXX O
) XXX O
, XXX O
which XXX O
was XXX O
proved XXX O
in XXX O
4 XXX O
cases XXX O
by XXX O
whole-body XXX O
radionuclide XXX O
scanning XXX O
with XXX O
99mTc-MAA XXX O
, XXX O
is XXX O
suggested XXX O
as XXX O
the XXX O
major XXX O
cause XXX O
of XXX O
cyanosis XXX O
in XXX O
liver XXX O
cirrhosis XXX O
. XXX O

Organization XXX O
of XXX O
the XXX O
bovine XXX O
gene XXX O
encoding XXX O
the XXX O
endothelial XXX B-GENE
nitric XXX I-GENE
oxide XXX I-GENE
synthase XXX I-GENE
. XXX O

The XXX O
5'-nontranslated XXX O
sequences XXX O
and XXX O
parts XXX O
of XXX O
the XXX O
coding XXX O
sequences XXX O
of XXX O
various XXX O
yeast XXX O
genes XXX O
have XXX O
been XXX O
cloned XXX O
into XXX O
representative XXX O
lacZ XXX B-GENE
fusion XXX O
vectors XXX O
. XXX O

In XXX O
this XXX O
study XXX O
we XXX O
provide XXX O
evidence XXX O
that XXX O
B-Myb XXX B-GENE
is XXX O
a XXX O
direct XXX O
physiological XXX O
target XXX O
for XXX O
cyclin XXX B-GENE
A XXX I-GENE
/ XXX I-GENE
Cdk2 XXX I-GENE
. XXX O

Thus XXX O
, XXX O
while XXX O
the XXX O
genomic XXX O
organization XXX O
of XXX O
mHuA XXX B-GENE
is XXX O
similar XXX O
to XXX O
the XXX O
neural-restricted XXX O
members XXX O
of XXX O
the XXX O
Elav XXX B-GENE
family XXX I-GENE
, XXX O
the XXX O
promoter XXX O
element XXX O
differs XXX O
substantially XXX O
both XXX O
by XXX O
sequence XXX O
analysis XXX O
and XXX O
transcriptional XXX O
activity XXX O
in XXX O
non-neural XXX O
cell XXX O
types XXX O
. XXX O

A XXX O
total XXX O
of XXX O
90 XXX O
patients XXX O
were XXX O
randomly XXX O
allocated XXX O
either XXX O
to XXX O
an XXX O
MY-1 XXX O
treated XXX O
or XXX O
an XXX O
untreated XXX O
group XXX O
. XXX O

Using XXX O
an XXX O
image-processing XXX O
computer XXX O
, XXX O
regional XXX O
LV XXX O
time-density XXX O
curves XXX O
were XXX O
constructed XXX O
for XXX O
one XXX O
cardiac XXX O
cycle XXX O
. XXX O

A XXX O
chicken XXX B-GENE
paxillin XXX I-GENE
cDNA XXX I-GENE
was XXX O
also XXX O
cloned XXX O
and XXX O
is XXX O
predicted XXX O
to XXX O
encode XXX O
a XXX O
protein XXX O
approximately XXX O
90% XXX O
identical XXX O
to XXX O
human XXX B-GENE
paxil-lin XXX I-GENE
. XXX O

In XXX O
the XXX O
normal XXX O
, XXX O
basal XXX O
( XXX O
unstimulated XXX O
) XXX O
condition XXX O
there XXX O
were XXX O
no XXX O
significant XXX O
correlations XXX O
( XXX O
p XXX O
greater XXX O
than XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
between XXX O
the XXX O
systolic XXX O
blood XXX O
pressure XXX O
and XXX O
dopamine XXX O
( XXX O
r XXX O
= XXX O
0 XXX O
. XXX O
09 XXX O
) XXX O
, XXX O
norepinephrine XXX O
( XXX O
r XXX O
= XXX O
0 XXX O
. XXX O
26 XXX O
) XXX O
, XXX O
or XXX O
epinephrine XXX O
( XXX O
r XXX O
= XXX O
0 XXX O
. XXX O
27 XXX O
) XXX O
, XXX O
nor XXX O
were XXX O
there XXX O
significant XXX O
correlations XXX O
between XXX O
melatonin XXX O
and XXX O
dopamine XXX O
( XXX O
r XXX O
= XXX O
-0 XXX O
. XXX O
01 XXX O
) XXX O
, XXX O
norepinephrine XXX O
( XXX O
r XXX O
= XXX O
-0 XXX O
. XXX O
26 XXX O
) XXX O
, XXX O
or XXX O
growth XXX B-GENE
hormone XXX I-GENE
( XXX O
r XXX O
= XXX O
0 XXX O
. XXX O
17 XXX O
) XXX O
. XXX O

Transition XXX O
between XXX O
P- XXX O
and XXX O
H-BPPV XXX O
was XXX O
found XXX O
in XXX O
6 XXX O
cases XXX O
. XXX O

The XXX O
study XXX O
suggests XXX O
the XXX O
presence XXX O
of XXX O
an XXX O
anatomical XXX O
sphincter XXX O
at XXX O
the XXX O
RSJ XXX O
which XXX O
seems XXX O
to XXX O
regulate XXX O
the XXX O
passage XXX O
of XXX O
stools XXX O
from XXX O
the XXX O
sigmoid XXX O
colon XXX O
to XXX O
the XXX O
rectum XXX O
. XXX O

No XXX O
correlation XXX O
between XXX O
the XXX O
age XXX O
of XXX O
the XXX O
horses XXX O
and XXX O
the XXX O
antibody XXX O
level XXX O
could XXX O
be XXX O
found XXX O
. XXX O

In XXX O
the XXX O
ISO XXX O
group XXX O
, XXX O
at XXX O
pre-DEX XXX O
, XXX O
CBF XXX O
increased XXX O
from XXX O
86 XXX O
+ XXX O
/ XXX O
- XXX O
8 XXX O
to XXX O
166 XXX O
+ XXX O
/ XXX O
- XXX O
19 XXX O
mL XXX O
. XXX O
min-1 XXX O
. XXX O
100 XXX O
g-1 XXX O
in XXX O
response XXX O
to XXX O
hypercapnia XXX O
( XXX O
PCO2 XXX O
approximately XXX O
90 XXX O
mmHg XXX O
) XXX O
. XXX O
( XXX O
ABSTRACT XXX O
TRUNCATED XXX O
AT XXX O
250 XXX O
WORDS XXX O
) XXX O

Maximum XXX O
induction XXX O
of XXX O
AP-1 XXX B-GENE
was XXX O
reached XXX O
at XXX O
a XXX O
concentration XXX O
of XXX O
250 XXX O
nmol XXX O
/ XXX O
L XXX O
of XXX O
CalC XXX O
. XXX O

Pregnancy XXX O
screening XXX O
by XXX O
uterine XXX O
artery XXX O
Doppler XXX O
velocimetry--which XXX O
criterion XXX O
performs XXX O
best XXX O
? XXX O
OBJECTIVE XXX O
: XXX O
To XXX O
test XXX O
whether XXX O
repeating XXX O
Doppler XXX O
studies XXX O
of XXX O
the XXX O
uteroplacental XXX O
circulation XXX O
late XXX O
in XXX O
gestation XXX O
will XXX O
improve XXX O
the XXX O
test's XXX O
power XXX O
for XXX O
predicting XXX O
pregnancy-induced XXX O
hypertension XXX O
and XXX O
fetal XXX O
growth XXX O
restriction XXX O
( XXX O
FGR XXX O
) XXX O
, XXX O
and XXX O
whether XXX O
analysis XXX O
based XXX O
on XXX O
a XXX O
combination XXX O
of XXX O
quantitative XXX O
and XXX O
qualitative XXX O
assessments XXX O
of XXX O
the XXX O
uterine XXX O
arterial XXX O
waveforms XXX O
will XXX O
yield XXX O
better XXX O
results XXX O
than XXX O
analysis XXX O
based XXX O
on XXX O
either XXX O
alone XXX O
. XXX O

The XXX O
relationships XXX O
among XXX O
blood XXX O
concentrations XXX O
of XXX O
thyroid XXX O
hormones XXX O
and XXX O
selenium XXX O
, XXX O
zinc XXX O
, XXX O
retinol XXX O
, XXX O
and XXX O
alpha-tocopherol XXX O
were XXX O
studied XXX O
in XXX O
44 XXX O
healthy XXX O
Northern XXX O
Italian XXX O
oldest-old XXX O
subjects XXX O
( XXX O
age XXX O
range XXX O
, XXX O
90-107 XXX O
yr XXX O
) XXX O
, XXX O
selected XXX O
by XXX O
the XXX O
criteria XXX O
of XXX O
the XXX O
SENIEUR XXX O
protocol XXX O
. XXX O

[ XXX O
14C XXX O
] XXX O
-beta-phenethylamine XXX O
, XXX O
its XXX O
distribution XXX O
after XXX O
administration XXX O
by XXX O
various XXX O
routes XXX O
to XXX O
cats XXX O
, XXX O
and XXX O
the XXX O
effects XXX O
of XXX O
monoamine XXX B-GENE
oxidase XXX I-GENE
inhibitors XXX O
. XXX O

The XXX O
intrapancreatic XXX O
spread XXX O
of XXX O
the XXX O
carcinoma XXX O
correlated XXX O
with XXX O
portal XXX O
invasion XXX O
of XXX O
carcinoma XXX O
, XXX O
hardness XXX O
of XXX O
the XXX O
body XXX O
and XXX O
tail XXX O
, XXX O
obstruction XXX O
of XXX O
main XXX O
pancreatic XXX O
duct XXX O
and XXX O
irregular XXX O
pancreaticogram XXX O
. XXX O

The XXX O
content XXX O
of XXX O
glucosamine XXX O
and XXX O
galactosamine XXX O
in XXX O
tartar XXX O
. XXX O

The XXX O
two XXX O
bases XXX O
immediately XXX O
flanking XXX O
the XXX O
5' XXX O
end XXX O
of XXX O
the XXX O
element XXX O
proved XXX O
to XXX O
be XXX O
very XXX O
important XXX O
to XXX O
its XXX O
function XXX O
as XXX O
a XXX O
UAS XXX B-GENE
element XXX I-GENE
as XXX O
did XXX O
the XXX O
two XXX O
bases XXX O
immediately XXX O
3' XXX O
of XXX O
the XXX O
bHLH XXX O
core XXX O
motif XXX O
. XXX O

2 XXX O
. XXX O

Moreover XXX O
, XXX O
radiolabeled XXX O
EFI XXX B-GENE
, XXX O
NF-Y XXX B-GENE
, XXX O
or XXX O
CBF XXX B-GENE
DNAs XXX I-GENE
give XXX O
rise XXX O
to XXX O
identical XXX O
gel XXX O
retardation XXX O
patterns XXX O
in XXX O
extracts XXX O
from XXX O
a XXX O
variety XXX O
of XXX O
different XXX O
cell XXX O
types XXX O
. XXX O

Issues XXX O
of XXX O
distribution XXX O
of XXX O
kinetic XXX O
energy XXX O
of XXX O
traumatizing XXX O
object XXX O
in XXX O
direct XXX O
contact XXX O
interaction XXX O
with XXX O
head XXX O
during XXX O
impact XXX O
are XXX O
discussed XXX O
from XXX O
position XXX O
of XXX O
biomechanics XXX O
. XXX O

Urine XXX O
antibodies XXX O
could XXX O
not XXX O
be XXX O
demonstrated XXX O
in XXX O
any XXX O
other XXX O
cases XXX O
. XXX O

Glutamyl-tRNA XXX B-GENE
synthetase XXX I-GENE
and XXX O
prolyl-tRNA XXX B-GENE
synthetase XXX I-GENE
belong XXX O
to XXX O
different XXX O
classes XXX O
of XXX O
aminoacyl-tRNA XXX B-GENE
synthetases XXX I-GENE
that XXX O
are XXX O
thought XXX O
to XXX O
have XXX O
evolved XXX O
along XXX O
independent XXX O
evolutionary XXX O
pathways XXX O
. XXX O

This XXX O
soluble XXX O
form XXX O
of XXX O
the XXX O
HGFr XXX B-GENE
( XXX O
sHGFr XXX B-GENE
) XXX O
bound XXX O
HGF XXX B-GENE
with XXX O
an XXX O
affinity XXX O
similar XXX O
to XXX O
that XXX O
of XXX O
the XXX O
authentic XXX O
, XXX O
membrane-associated XXX O
receptor XXX O
. XXX O

Single XXX O
photon XXX O
emission XXX O
computerized XXX O
tomography XXX O
( XXX O
SPECT XXX O
) XXX O
, XXX O
by XXX O
providing XXX O
three-dimensional XXX O
representation XXX O
of XXX O
myocardial XXX O
Tl-201 XXX O
, XXX O
offers XXX O
promise XXX O
for XXX O
improved XXX O
localization XXX O
of XXX O
CAD XXX O
. XXX O

Functional XXX O
analysis XXX O
of XXX O
promoter XXX O
activity XXX O
of XXX O
the XXX O
5'-flanking XXX O
region XXX O
of XXX O
cyclin XXX B-GENE
D2 XXX I-GENE
suggested XXX O
that XXX O
the XXX O
region XXX O
- XXX O
1 XXX O
, XXX O
100 XXX O
to XXX O
- XXX O
805 XXX O
including XXX O
C XXX B-GENE
/ XXX I-GENE
EBP XXX I-GENE
, XXX O
PEA3 XXX B-GENE
, XXX O
AP2 XXX B-GENE
, XXX O
NF-Y XXX B-GENE
, XXX O
c-Myc XXX B-GENE
, XXX O
and XXX O
Sp1 XXX B-GENE
may XXX O
have XXX O
a XXX O
major XXX O
positive XXX O
regulatory XXX O
activity XXX O
for XXX O
expression XXX O
of XXX O
cyclin XXX B-GENE
D2 XXX I-GENE
. XXX O

Technetium-99m XXX O
stannous XXX O
pyrophosphate XXX O
myocardial XXX O
scintigrams XXX O
were XXX O
obtained XXX O
in XXX O
138 XXX O
clinically XXX O
stable XXX O
patients XXX O
32 XXX O
. XXX O
7 XXX O
+ XXX O
/ XXX O
- XXX O
47 XXX O
. XXX O
3 XXX O
weeks XXX O
( XXX O
range XXX O
6 XXX O
to XXX O
260 XXX O
) XXX O
after XXX O
acute XXX O
myocardial XXX O
infarction XXX O
. XXX O

By XXX O
Caveman XXX O
. XXX O

Identification XXX O
of XXX O
this XXX O
region XXX O
as XXX O
the XXX O
E XXX B-GENE
. XXX I-GENE
coli XXX I-GENE
tmk XXX I-GENE
gene XXX I-GENE
was XXX O
confirmed XXX O
by XXX O
functional XXX O
complementation XXX O
of XXX O
a XXX O
yeast XXX B-GENE
dTMP XXX I-GENE
kinase XXX I-GENE
temperature-sensitive XXX O
mutant XXX O
and XXX O
by XXX O
in XXX O
vitro XXX O
enzyme XXX O
assay XXX O
of XXX O
the XXX O
thymidylate XXX B-GENE
kinase XXX I-GENE
activity XXX O
in XXX O
cell XXX O
extracts XXX O
of XXX O
E XXX O
. XXX O
coli XXX O
by XXX O
use XXX O
of XXX O
tmk-overproducing XXX O
plasmids XXX O
. XXX O

Wherever XXX O
the XXX O
site XXX O
of XXX O
the XXX O
conditioning XXX O
stimulation XXX O
, XXX O
these XXX O
modifications XXX O
disappeared XXX O
after XXX O
ischaemia XXX O
of XXX O
the XXX O
leg XXX O
. XXX O

62 XXX O
: XXX O
2491-2499 XXX O
, XXX O
1987 XXX O
) XXX O
. XXX O

These XXX O
results XXX O
further XXX O
support XXX O
an XXX O
important XXX O
role XXX O
for XXX O
CBF2 XXX B-GENE
in XXX O
mediating XXX O
EBNA2 XXX B-GENE
transactivation XXX O
; XXX O
they XXX O
identify XXX O
the XXX O
hnRNP XXX B-GENE
protein XXX I-GENE
AUF1 XXX I-GENE
as XXX O
a XXX O
major XXX O
component XXX O
of XXX O
CBF2 XXX B-GENE
and XXX O
are XXX O
also XXX O
the XXX O
first XXX O
evidence XXX O
of XXX O
a XXX O
cis-acting XXX O
sequence XXX O
other XXX O
than XXX O
a XXX O
CBF1 XXX B-GENE
binding XXX I-GENE
element XXX I-GENE
that XXX O
is XXX O
able XXX O
to XXX O
confer XXX O
responsiveness XXX O
to XXX O
EBNA2 XXX B-GENE
. XXX O

The XXX O
Twentieth XXX O
Anniversary XXX O
of XXX O
the XXX O
Pomeranian XXX O
Medical XXX O
Academy XXX O
. XXX O

We XXX O
have XXX O
developed XXX O
a XXX O
new XXX O
method XXX O
for XXX O
estimation XXX O
of XXX O
regional XXX O
CBF XXX O
( XXX O
rCBF XXX O
) XXX O
and XXX O
cerebrovascular XXX O
reserve XXX O
capacity XXX O
on XXX O
a XXX O
pixel-by-pixel XXX O
basis XXX O
by XXX O
means XXX O
of XXX O
dynamic XXX O
magnetic XXX O
resonance XXX O
imaging XXX O
( XXX O
MRI XXX O
) XXX O
. XXX O

AF154055 XXX B-GENE
. XXX O

The XXX O
epidermal XXX B-GENE
growth XXX I-GENE
factor XXX I-GENE
( XXX I-GENE
EGF XXX I-GENE
) XXX I-GENE
receptor XXX I-GENE
, XXX O
which XXX O
exhibits XXX O
intrinsic XXX O
protein XXX B-GENE
tyrosine XXX I-GENE
kinase XXX I-GENE
activity XXX O
, XXX O
undergoes XXX O
a XXX O
rapid XXX O
, XXX O
intramolecular XXX O
self-phosphorylation XXX O
reaction XXX O
following XXX O
EGF XXX B-GENE
activation XXX O
. XXX O

These XXX O
results XXX O
suggest XXX O
that XXX O
N-nitroso XXX O
compounds XXX O
can XXX O
be XXX O
formed XXX O
in XXX O
vivo XXX O
in XXX O
the XXX O
infected XXX O
bladder XXX O
, XXX O
which XXX O
could XXX O
explain XXX O
the XXX O
association XXX O
between XXX O
urinary-tract XXX O
infections XXX O
and XXX O
increased XXX O
risk XXX O
for XXX O
bladder XXX O
cancer XXX O
. XXX O

The XXX O
effects XXX O
of XXX O
high XXX O
intensity XXX O
light XXX O
emissions XXX O
, XXX O
produced XXX O
by XXX O
a XXX O
novel XXX O
pulsed XXX O
power XXX O
energization XXX O
technique XXX O
( XXX O
PPET XXX O
) XXX O
, XXX O
on XXX O
the XXX O
survival XXX O
of XXX O
bacterial XXX O
populations XXX O
of XXX O
verocytotoxigenic XXX O
Escherichia XXX O
coli XXX O
( XXX O
serotype XXX O
0157 XXX O
: XXX O
H7 XXX O
) XXX O
and XXX O
Listeria XXX O
monocytogenes XXX O
( XXX O
serotype XXX O
4b XXX O
) XXX O
were XXX O
investigated XXX O
. XXX O

Bilateral XXX O
basal XXX O
arteries XXX O
were XXX O
measured XXX O
by XXX O
the XXX O
transtemporal XXX O
approach XXX O
with XXX O
a XXX O
2 XXX O
MHz XXX O
pulsed XXX O
Doppler XXX O
instrument XXX O
( XXX O
TC-2 XXX O
64B XXX O
EME XXX O
) XXX O
. XXX O

TDEYA XXX O
at XXX O
doses XXX O
of XXX O
200 XXX O
to XXX O
500 XXX O
mg XXX O
/ XXX O
kg XXX O
significantly XXX O
suppressed XXX O
xanthine XXX B-GENE
oxidase XXX I-GENE
( XXX O
XO XXX B-GENE
) XXX O
activity XXX O
in XXX O
the XXX O
stomach XXX O
tissue XXX O
following XXX O
its XXX O
oral XXX O
administration XXX O
. XXX O

Southern XXX O
blot XXX O
analysis XXX O
of XXX O
genomic XXX O
DNA XXX O
from XXX O
somatic XXX O
cell XXX O
hybrids XXX O
showed XXX O
that XXX O
endothelial-TACC-related XXX B-GENE
cDNA XXX I-GENE
maps XXX O
to XXX O
chromosome XXX O
10 XXX O
. XXX O

We XXX O
have XXX O
tested XXX O
this XXX O
proposal XXX O
by XXX O
carrying XXX O
out XXX O
circular XXX O
dichroism XXX O
( XXX O
CD XXX O
) XXX O
and XXX O
NMR XXX O
experiments XXX O
on XXX O
the XXX O
Skn XXX B-GENE
domain XXX I-GENE
and XXX O
five XXX O
truncated XXX O
proteins XXX O
. XXX O

We XXX O
show XXX O
here XXX O
that XXX O
these XXX O
Jun XXX B-GENE
/ XXX I-GENE
eb1 XXX I-GENE
chimeras XXX I-GENE
are XXX O
potent XXX O
transactivators XXX O
of XXX O
AP1 XXX B-GENE
sites XXX I-GENE
and XXX O
that XXX O
they XXX O
can XXX O
cooperate XXX O
with XXX O
c-Ha-Ras XXX B-GENE
to XXX O
induce XXX O
foci XXX O
. XXX O

Visual XXX O
response XXX O
properties XXX O
of XXX O
neurons XXX O
in XXX O
four XXX O
extrastriate XXX O
visual XXX O
areas XXX O
of XXX O
the XXX O
owl XXX O
monkey XXX O
( XXX O
Aotus XXX O
trivirgatus XXX O
) XXX O
: XXX O
a XXX O
quantitative XXX O
comparison XXX O
of XXX O
medial XXX O
, XXX O
dorsomedial XXX O
, XXX O
dorsolateral XXX O
, XXX O
and XXX O
middle XXX O
temporal XXX O
areas XXX O
. XXX O

An XXX O
interatrial XXX O
communication XXX O
mitigates XXX O
the XXX O
impairment XXX O
of XXX O
LV XXX O
function XXX O
after XXX O
an XXX O
acute XXX O
and XXX O
sustained XXX O
drop XXX O
of XXX O
intrathoracic XXX O
pressure XXX O
. XXX O

The XXX O
former XXX O
group XXX O
did XXX O
excrete XXX O
less XXX O
dry XXX O
fecal XXX O
material XXX O
compared XXX O
to XXX O
both XXX O
other XXX O
groups XXX O
. XXX O

Domains XXX O
I XXX O
and XXX O
II XXX O
of XXX O
B" XXX B-GENE
are XXX O
buried XXX O
upon XXX O
assembly XXX O
of XXX O
the XXX O
TFIIIB-DNA XXX B-GENE
complex XXX I-GENE
, XXX O
as XXX O
determined XXX O
by XXX O
protein XXX O
footprinting XXX O
. XXX O

We XXX O
have XXX O
found XXX O
a XXX O
satisfactory XXX O
reproducibility XXX O
in XXX O
vitro XXX O
( XXX O
T1 XXX O
: XXX O
1 XXX O
. XXX O
9% XXX O
; XXX O
T2 XXX O
: XXX O
6 XXX O
. XXX O
2% XXX O
) XXX O
, XXX O
while XXX O
the XXX O
reproducibility XXX O
was XXX O
less XXX O
satisfactory XXX O
in XXX O
vivo XXX O
( XXX O
T1 XXX O
: XXX O
16 XXX O
. XXX O
4% XXX O
; XXX O
T2 XXX O
: XXX O
13 XXX O
. XXX O
4% XXX O
) XXX O
. XXX O

This XXX O
test XXX O
should XXX O
provide XXX O
another XXX O
practical XXX O
means XXX O
to XXX O
study XXX O
leprosy XXX O
. XXX O

The XXX O
smallest XXX O
active XXX B-GENE
FecR XXX I-GENE
derivative XXX I-GENE
contained XXX O
59 XXX O
amino XXX O
acid XXX O
residues XXX O
as XXX O
compared XXX O
to XXX O
the XXX O
317 XXX O
residues XXX O
of XXX O
wild-type XXX B-GENE
FecR XXX I-GENE
. XXX O

The XXX O
non-role XXX O
of XXX O
fluoride XXX O
in XXX O
the XXX O
control XXX O
of XXX O
plasma XXX O
calcium XXX O
in XXX O
the XXX O
parathyroidectomized XXX O
rat XXX O
. XXX O

The XXX O
nucleotide XXX O
sequence XXX O
of XXX O
the XXX O
chloroplast XXX O
( XXX O
cp XXX O
) XXX O
DNA XXX O
from XXX O
maize XXX O
( XXX O
Zea XXX O
mays XXX O
) XXX O
has XXX O
been XXX O
completed XXX O
. XXX O

Although XXX O
basal XXX O
vessels XXX O
may XXX O
constrict XXX O
distal XXX O
parenchymal XXX O
vessels XXX O
tend XXX O
to XXX O
dilate XXX O
after XXX O
SAH XXX O
. XXX O

Exchange XXX O
of XXX O
the XXX O
LPL XXX B-GENE
and XXX O
HL XXX B-GENE
lids XXX O
resulted XXX O
in XXX O
a XXX O
reversal XXX O
of XXX O
the XXX O
phospholipase XXX O
/ XXX O
neutral XXX O
lipase XXX B-GENE
ratio XXX O
, XXX O
establishing XXX O
the XXX O
important XXX O
role XXX O
of XXX O
this XXX O
region XXX O
in XXX O
mediating XXX O
substrate XXX O
specificity XXX O
. XXX O

Frog XXX O
type XXX O
I XXX O
( XXX O
Ft XXX O
I XXX O
) XXX O
and XXX O
frog XXX O
type XXX O
II XXX O
( XXX O
Ft XXX O
II XXX O
) XXX O
slowly XXX O
adapting XXX O
( XXX O
SA XXX O
) XXX O
units XXX O
produced XXX O
spikes XXX O
only XXX O
at XXX O
the XXX O
indentation XXX O
phase XXX O
, XXX O
and XXX O
the XXX O
threshold XXX O
response XXX O
phase XXX O
( XXX O
TRP XXX O
) XXX O
, XXX O
i XXX O
. XXX O
e XXX O
. XXX O
. XXX O
the XXX O
phase XXX O
of XXX O
the XXX O
first XXX O
spike XXX O
was XXX O
for XXX O
ca XXX O
. XXX O

A XXX O
new XXX O
hemagglutination XXX O
test XXX O
for XXX O
the XXX O
on-slide XXX O
assay XXX O
of XXX O
rheumatoid XXX B-GENE
factor XXX I-GENE
. XXX O

Through XXX O
transient XXX O
transfection XXX O
of XXX O
NIH3T3 XXX O
fibroblast XXX O
cells XXX O
and XXX O
gel XXX O
mobility XXX O
shift XXX O
assays XXX O
, XXX O
the XXX O
functional XXX O
binding XXX O
site XXX O
was XXX O
localized XXX O
to XXX O
a XXX O
short XXX O
region XXX O
( XXX O
-318 XXX O
to XXX O
-303 XXX O
bp XXX O
from XXX O
the XXX O
transcription XXX O
start XXX O
site XXX O
) XXX O
which XXX O
has XXX O
a XXX O
CTCCC XXX B-GENE
sequence XXX I-GENE
. XXX O

The XXX O
DHEAS XXX O
levels XXX O
in XXX O
all XXX O
stages XXX O
of XXX O
decreased XXX O
BMD XXX O
were XXX O
significantly XXX O
lower XXX O
than XXX O
those XXX O
in XXX O
the XXX O
group XXX O
with XXX O
normal XXX O
BMD XXX O
. XXX O

Most XXX O
apneic XXX O
events XXX O
occurred XXX O
during XXX O
Stages XXX O
I XXX O
and XXX O
II XXX O
, XXX O
and XXX O
REM XXX O
, XXX O
but XXX O
this XXX O
proportion XXX O
was XXX O
less XXX O
during XXX O
the XXX O
gamma XXX O
OH XXX O
study XXX O
( XXX O
77 XXX O
. XXX O
9 XXX O
+ XXX O
/ XXX O
- XXX O
8 XXX O
. XXX O
9% XXX O
) XXX O
than XXX O
during XXX O
the XXX O
control XXX O
studies XXX O
( XXX O
92 XXX O
. XXX O
3 XXX O
+ XXX O
/ XXX O
- XXX O
1 XXX O
. XXX O
9 XXX O
and XXX O
95 XXX O
. XXX O
9 XXX O
+ XXX O
/ XXX O
- XXX O
2 XXX O
. XXX O
2% XXX O
) XXX O
, XXX O
apneas XXX O
occurring XXX O
even XXX O
during XXX O
SWS XXX O
with XXX O
gamma XXX O
OH XXX O
. XXX O
( XXX O
ABSTRACT XXX O
TRUNCATED XXX O
AT XXX O
250 XXX O
WORDS XXX O
) XXX O

10 XXX O
. XXX O
0 XXX O
+ XXX O
/ XXX O
- XXX O
2 XXX O
. XXX O
0 XXX O
pmol XXX O
/ XXX O
24 XXX O
h XXX O
, XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
and XXX O
remained XXX O
elevated XXX O
. XXX O

Is XXX O
leishmaniasis XXX O
endemic XXX O
on XXX O
the XXX O
island XXX O
of XXX O
Minorca XXX O
( XXX O
Spain XXX O
) XXX O
? XXX O
A XXX O
human XXX O
visceral XXX O
case XXX O
after XXX O
living XXX O
13 XXX O
years XXX O
in XXX O
Minorca XXX O
. XXX O

Interferon XXX B-GENE
Regulatory XXX I-GENE
Factor XXX I-GENE
( XXX I-GENE
IRF XXX I-GENE
) XXX I-GENE
-1 XXX I-GENE
has XXX O
been XXX O
characterized XXX O
as XXX O
an XXX O
important XXX O
growth XXX O
regulatory XXX O
and XXX O
immunomodulatory XXX O
transcription XXX O
factor XXX O
. XXX O

A XXX O
genomic XXX O
clone XXX O
for XXX O
the XXX O
cyc07 XXX B-GENE
gene XXX I-GENE
, XXX O
which XXX O
is XXX O
expressed XXX O
specifically XXX O
at XXX O
the XXX O
S XXX O
phase XXX O
during XXX O
the XXX O
cell XXX O
cycle XXX O
in XXX O
synchronous XXX O
cultures XXX O
of XXX O
periwinkle XXX O
( XXX O
Catharanthus XXX O
roseus XXX O
) XXX O
cells XXX O
, XXX O
was XXX O
isolated XXX O
. XXX O

BACKGROUND XXX O
: XXX O
To XXX O
determine XXX O
the XXX O
predictors XXX O
of XXX O
desipramine-refractory XXX O
depression XXX O
, XXX O
the XXX O
authors XXX O
examined XXX O
the XXX O
outcome XXX O
in XXX O
patients XXX O
with XXX O
major XXX O
depression XXX O
who XXX O
were XXX O
admitted XXX O
to XXX O
a XXX O
general XXX O
hospital XXX O
and XXX O
treated XXX O
with XXX O
desipramine XXX O
adjusted XXX O
to XXX O
an XXX O
adequate XXX O
blood XXX O
level XXX O
. XXX O

It XXX O
is XXX O
present XXX O
in XXX O
the XXX O
nucleus XXX O
of XXX O
the XXX O
cells XXX O
in XXX O
which XXX O
it XXX O
is XXX O
expressed XXX O
and XXX O
can XXX O
phosphorylate XXX O
and XXX O
activate XXX O
the XXX O
cyclic XXX B-GENE
AMP XXX I-GENE
response XXX I-GENE
element XXX I-GENE
binding XXX I-GENE
proteins XXX I-GENE
CREB XXX B-GENE
and XXX O
CREM XXX B-GENE
tau XXX I-GENE
in XXX O
a XXX O
manner XXX O
analogous XXX O
to XXX O
protein XXX B-GENE
kinase XXX I-GENE
A XXX I-GENE
. XXX O

Herceptin XXX O
, XXX O
which XXX O
recognizes XXX O
the XXX O
HER-2 XXX B-GENE
/ XXX I-GENE
neu XXX I-GENE
antigen XXX I-GENE
and XXX O
has XXX O
similar XXX O
size XXX O
( XXX O
10 XXX O
nm XXX O
) XXX O
to XXX O
G6- XXX O
( XXX O
1B4M-Gd XXX O
) XXX O
( XXX O
256 XXX O
) XXX O
, XXX O
accumulated XXX O
and XXX O
internalized XXX O
in XXX O
the XXX O
WIBC-9 XXX O
tumors XXX O
more XXX O
quickly XXX O
than XXX O
in XXX O
the XXX O
control XXX O
MC-5 XXX O
tumors XXX O
that XXX O
progress XXX O
with XXX O
normal XXX O
angiogenesis XXX O
. XXX O

This XXX O
intron XXX O
occupies XXX O
a XXX O
conserved XXX O
position XXX O
corresponding XXX O
to XXX O
that XXX O
of XXX O
intron XXX O
1 XXX O
in XXX O
the XXX O
transit XXX O
peptide XXX O
region XXX O
of XXX O
chloroplast XXX B-GENE
GAPDH XXX I-GENE
genes XXX I-GENE
( XXX O
GapA XXX B-GENE
and XXX O
GapB XXX B-GENE
) XXX O
of XXX O
higher XXX O
plants XXX O
. XXX O

We XXX O
conclude XXX O
that XXX O
TA XXX O
caused XXX O
a XXX O
specific XXX O
decrease XXX O
in XXX O
AGD XXX O
on XXX O
GD XXX O
20 XXX O
that XXX O
was XXX O
largely XXX O
reversed XXX O
by XXX O
PCD XXX O
23 XXX O
. XXX O

Peripheral XXX O
visual XXX O
stimuli XXX O
and XXX O
monoaural XXX O
auditory XXX O
stimuli XXX O
were XXX O
used XXX O
as XXX O
targets XXX O
. XXX O

The XXX O
interaction XXX O
does XXX O
not XXX O
depend XXX O
on XXX O
the XXX O
presence XXX O
of XXX O
the XXX O
correct XXX O
amino-terminal XXX O
DNA XXX O
binding XXX O
domain XXX O
or XXX O
the XXX O
amino XXX O
acid XXX O
sequences XXX O
between XXX O
the XXX O
DNA XXX O
binding XXX O
domain XXX O
and XXX O
the XXX O
last XXX O
ten XXX O
amino XXX O
acids XXX O
. XXX O

Electrochemical XXX O
detection XXX O
of XXX O
depressed XXX O
circulating XXX O
levels XXX O
of XXX O
vitamin XXX O
K1 XXX O
in XXX O
osteoporosis XXX O
. XXX O

Conversely XXX O
, XXX O
the XXX O
inactive XXX O
dAK XXX B-GENE
subunit XXX I-GENE
is XXX O
progressively XXX O
activated XXX O
by XXX O
1 XXX O
) XXX O
association XXX O
with XXX O
a XXX O
dGK XXX B-GENE
or XXX O
dCK XXX B-GENE
subunit XXX I-GENE
and XXX O
2 XXX O
) XXX O
the XXX O
conformationally XXX O
driven XXX O
heterotropic XXX O
affect XXX O
of XXX O
dGuo XXX B-GENE
or XXX O
dCyd XXX B-GENE
bound XXX O
to XXX O
the XXX O
opposing XXX O
subunit XXX O
. XXX O

Mutation XXX O
of XXX O
TTF-1-binding XXX B-GENE
sites XXX I-GENE
( XXX I-GENE
TBE XXX I-GENE
) XXX I-GENE
1 XXX I-GENE
, XXX I-GENE
3 XXX I-GENE
, XXX I-GENE
and XXX I-GENE
4 XXX I-GENE
in XXX O
combination XXX O
markedly XXX O
decreased XXX O
transcriptional XXX O
activity XXX O
of XXX O
SP-A XXX B-GENE
promoter-chloramphenicol XXX I-GENE
acetyltransferase XXX I-GENE
constructs XXX O
containing XXX O
SP-A XXX B-GENE
gene XXX I-GENE
sequences XXX O
from XXX O
-256 XXX O
to XXX O
+45 XXX O
. XXX O

Unrecognized XXX O
amnionitis XXX O
and XXX O
prematurity XXX O
: XXX O
a XXX O
preliminary XXX O
report XXX O
. XXX O

A XXX O
patient XXX O
matches XXX O
a XXX O
PIC XXX O
patient XXX O
if XXX O
both XXX O
have XXX O
the XXX O
same XXX O
mechanism XXX O
of XXX O
injury XXX O
, XXX O
the XXX O
same XXX O
coding XXX O
of XXX O
Revised XXX O
Trauma XXX O
Score XXX O
variables XXX O
( XXX O
Glascow XXX O
Coma XXX O
Scale XXX O
score XXX O
, XXX O
systolic XXX O
blood XXX O
pressure XXX O
, XXX O
respiratory XXX O
rate XXX O
) XXX O
, XXX O
the XXX O
same XXX O
coded XXX O
age XXX O
per XXX O
A XXX O
Severity XXX O
Characterization XXX O
of XXX O
Trauma XXX O
) XXX O
( XXX O
ASCOT XXX O
) XXX O
, XXX O
and XXX O
if XXX O
they XXX O
differ XXX O
by XXX O
no XXX O
more XXX O
than XXX O
0 XXX O
. XXX O
5 XXX O
for XXX O
A XXX O
, XXX O
B XXX O
, XXX O
and XXX O
C XXX O
( XXX O
the XXX O
ASCOT XXX O
components XXX O
for XXX O
serious XXX O
injuries XXX O
) XXX O
. XXX O

Although XXX O
the XXX O
RAD23 XXX B-GENE
equivalents XXX O
are XXX O
well XXX O
conserved XXX O
during XXX O
evolution XXX O
, XXX O
the XXX O
mammalian XXX O
genes XXX O
did XXX O
not XXX O
express XXX O
the XXX O
UV-inducible XXX O
phenotype XXX O
of XXX O
their XXX O
yeast XXX O
counterpart XXX O
. XXX O

Measurement XXX O
of XXX O
gastric XXX O
acid XXX O
secretion XXX O
by XXX O
conductivity XXX O
. XXX O

Routine XXX O
clinical XXX O
analysis XXX O
revealed XXX O
lower XXX O
hematocrit XXX O
and XXX O
hemoglobin XXX B-GENE
, XXX O
and XXX O
elevated XXX O
BUN XXX O
and XXX O
alkaline XXX B-GENE
phosphatase XXX I-GENE
in XXX O
the XXX O
treated XXX O
group XXX O
. XXX O

The XXX O
C-terminal XXX O
region XXX O
of XXX O
the XXX O
150-kDa XXX O
protein XXX O
contains XXX O
an XXX O
NTP-binding XXX O
helicase XXX B-GENE
motif XXX I-GENE
and XXX O
the XXX O
readthrough XXX O
region XXX O
, XXX O
an XXX O
RNA XXX B-GENE
polymerase XXX I-GENE
motif XXX I-GENE
, XXX O
indicating XXX O
that XXX O
these XXX O
two XXX O
overlapping XXX O
proteins XXX O
may XXX O
form XXX O
an XXX O
RNA XXX O
replication XXX O
complex XXX O
similar XXX O
to XXX O
those XXX O
of XXX O
tobamo- XXX O
and XXX O
tobraviruses XXX O
. XXX O

Comparable XXX O
amounts XXX O
of XXX O
alpha XXX B-GENE
5 XXX I-GENE
beta XXX I-GENE
1 XXX I-GENE
integrin XXX I-GENE
were XXX O
isolated XXX O
from XXX O
these XXX O
cells XXX O
by XXX O
chromatography XXX O
of XXX O
detergent XXX O
extracts XXX O
on XXX O
a XXX O
fibronectin XXX B-GENE
cell-binding XXX O
fragment XXX O
affinity XXX O
column XXX O
and XXX O
elution XXX O
with XXX O
EDTA XXX O
. XXX O

In XXX O
the XXX O
course XXX O
of XXX O
Hepatitis XXX B-GENE
A XXX I-GENE
HBs- XXX I-GENE
and XXX I-GENE
HBe-antigen XXX I-GENE
as XXX O
well XXX O
as XXX O
HBc XXX B-GENE
( XXX I-GENE
IgM XXX I-GENE
and XXX I-GENE
IgG XXX I-GENE
) XXX I-GENE
- XXX I-GENE
, XXX O
HBs- XXX B-GENE
and XXX I-GENE
HBe-antibodies XXX I-GENE
can XXX O
be XXX O
detected XXX O
. XXX O

The XXX O
high XXX O
density XXX O
of XXX O
tegumental XXX O
spines XXX O
on XXX O
posterior XXX O
half XXX O
of XXX O
the XXX O
body XXX O
and XXX O
the XXX O
distribution XXX O
of XXX O
type XXX O
II XXX O
papillae XXX O
on XXX O
dorsal XXX O
surface XXX O
are XXX O
considered XXX O
to XXX O
be XXX O
characteristic XXX O
of XXX O
C XXX O
. XXX O
armatus XXX O
. XXX O

It XXX O
could XXX O
be XXX O
detected XXX O
exclusively XXX O
in XXX O
the XXX O
culture XXX O
medium XXX O
of XXX O
cDNA-transfected XXX O
COS XXX O
cells XXX O
. XXX O

Two XXX O
classes XXX O
of XXX O
Xanthomonas XXX O
pathogens XXX O
evading XXX O
Bs2 XXX O
host XXX O
resistance XXX O
and XXX O
displaying XXX O
reduced XXX O
fitness XXX O
were XXX O
found XXX O
to XXX O
be XXX O
specifically XXX O
mutated XXX O
in XXX O
avrBs2 XXX B-GENE
. XXX O

Our XXX O
findings XXX O
suggest XXX O
that XXX O
the XXX O
mtr XXX B-GENE
product XXX I-GENE
causes XXX O
both XXX O
transcription XXX O
attenuation XXX O
and XXX O
inhibition XXX O
of XXX O
translation XXX O
of XXX O
trpE XXX B-GENE
mRNA XXX I-GENE
. XXX O

At XXX O
the XXX O
same XXX O
time XXX O
we XXX O
obtained XXX O
easily XXX O
understandable XXX O
EEG-information XXX O
which XXX O
has XXX O
never XXX O
previously XXX O
been XXX O
available XXX O
to XXX O
us XXX O
. XXX O

Air XXX O
ion XXX O
action XXX O
on XXX O
bacteria XXX O
. XXX O

Induction XXX O
of XXX O
the XXX O
urokinase XXX B-GENE
promoter XXX I-GENE
by XXX O
HGF XXX B-GENE
/ XXX I-GENE
SF XXX I-GENE
via XXX O
the XXX O
Met XXX B-GENE
receptor XXX I-GENE
was XXX O
blocked XXX O
by XXX O
co-expression XXX O
of XXX O
a XXX O
dominant-negative XXX O
Grb2 XXX B-GENE
and XXX O
Sos1 XXX B-GENE
expression XXX O
construct XXX O
. XXX O

The XXX O
Harleco XXX O
apparatus XXX O
is XXX O
a XXX O
simple XXX O
, XXX O
useful XXX O
, XXX O
cost-effective XXX O
adjunct XXX O
to XXX O
the XXX O
diagnosis XXX O
and XXX O
treatment XXX O
of XXX O
this XXX O
life-threatening XXX O
condition XXX O
. XXX O

The XXX O
average XXX O
annual XXX O
cost XXX O
per XXX O
head XXX O
of XXX O
population XXX O
was XXX O
US+0 XXX O
X XXX O
46 XXX O
. XXX O

A XXX O
patient XXX O
suffering XXX O
from XXX O
heparin-associated XXX O
thrombocytopenia XXX O
( XXX O
HAT XXX O
) XXX O
, XXX O
recurrent XXX O
arteriothromboses XXX O
, XXX O
and XXX O
acute XXX O
renal XXX O
failure XXX O
after XXX O
treatment XXX O
with XXX O
standard XXX O
heparin XXX O
is XXX O
described XXX O
. XXX O

However XXX O
, XXX O
conversions XXX O
of XXX O
12 XXX O
mm XXX O
or XXX O
more XXX O
from XXX O
a XXX O
documented XXX O
negative XXX O
result XXX O
indicated XXX O
spread XXX O
of XXX O
infection XXX O
. XXX O

In XXX O
a XXX O
series XXX O
of XXX O
patients XXX O
with XXX O
neuroinfection XXX O
, XXX O
Lyme XXX O
disease XXX O
, XXX O
Guillain XXX O
Barre XXX O
syndrome XXX O
, XXX O
demyelinization XXX O
, XXX O
partial XXX O
or XXX O
generalized XXX O
, XXX O
epilepsy XXX O
, XXX O
we XXX O
have XXX O
investigated XXX O
antiphospholipid XXX O
antibodies XXX O
of XXX O
IgG XXX B-GENE
and XXX O
IgM XXX B-GENE
subtypes XXX O
, XXX O
together XXX O
with XXX O
anticoagulant XXX O
factors XXX O
, XXX O
member XXX O
of XXX O
thrombocytes XXX O
, XXX O
sedimentation XXX O
rate XXX O
of XXX O
erythrocytes XXX O
. XXX O

Inclusion XXX O
in XXX O
this XXX O
family XXX O
of XXX O
proteins XXX O
suggests XXX O
that XXX O
FliQ XXX B-GENE
and XXX O
FliR XXX B-GENE
may XXX O
participate XXX O
in XXX O
an XXX O
export XXX O
pathway XXX O
required XXX O
for XXX O
flagellum XXX O
assembly XXX O
. XXX O

For XXX O
pressure XXX O
greater XXX O
than XXX O
121 XXX O
atm XXX O
abs XXX O
, XXX O
an XXX O
increased XXX O
excitability XXX O
of XXX O
the XXX O
tadpoles XXX O
made XXX O
it XXX O
difficult XXX O
to XXX O
distinguish XXX O
the XXX O
righting XXX O
reflex XXX O
from XXX O
involuntary XXX O
movements XXX O
. XXX O

The XXX O
duration XXX O
and XXX O
the XXX O
amplitude XXX O
of XXX O
the XXX O
negative XXX O
potential XXX O
were XXX O
greatest XXX O
for XXX O
completely XXX O
regenerating XXX O
ears XXX O
with XXX O
overgrowth XXX O
, XXX O
smaller XXX O
for XXX O
partially XXX O
regenerating XXX O
ears XXX O
, XXX O
and XXX O
smallest XXX O
for XXX O
the XXX O
nonregenerating XXX O
ears XXX O
. XXX O

Ozagrel XXX O
, XXX O
ifenprodil XXX O
, XXX O
cinnarizine XXX O
and XXX O
dilazep XXX O
were XXX O
more XXX O
effective XXX O
than XXX O
pentoxifylline XXX O
in XXX O
increasing XXX O
rCBF XXX O
at XXX O
the XXX O
HPC XXX O
. XXX O

Scapulae XXX O
with XXX O
a XXX O
Type XXX O
I XXX O
configuration XXX O
were XXX O
found XXX O
to XXX O
have XXX O
low XXX O
values XXX O
for XXX O
the XXX O
coraco-glenoid XXX O
angle XXX O
and XXX O
coracoid XXX O
overlap XXX O
, XXX O
which XXX O
are XXX O
known XXX O
to XXX O
be XXX O
associated XXX O
with XXX O
a XXX O
short XXX O
coraco-humeral XXX O
distance XXX O
. XXX O

Addition XXX O
of XXX O
sucralfate XXX O
or XXX O
De-Nol XXX O
resulted XXX O
in XXX O
increments XXX O
of XXX O
gastric XXX O
HCO3 XXX O
secretion XXX O
, XXX O
reaching XXX O
about XXX O
45% XXX O
and XXX O
59% XXX O
, XXX O
respectively XXX O
, XXX O
of XXX O
the XXX O
maximal XXX O
HCO3 XXX O
response XXX O
to XXX O
16 XXX O
, XXX O
16-dimethyl XXX O
PGE2 XXX O
( XXX O
dmPGE2 XXX O
) XXX O
. XXX O

The XXX O
encoded XXX O
protein XXX O
has XXX O
a XXX O
leader XXX O
sequence XXX O
of XXX O
27 XXX O
amino XXX O
acids XXX O
. XXX O

Factors XXX O
involved XXX O
in XXX O
specific XXX O
transcription XXX O
by XXX O
mammalian XXX O
RNA XXX B-GENE
polymerase XXX I-GENE
II XXX I-GENE
: XXX O
purification XXX O
, XXX O
genetic XXX O
specificity XXX O
, XXX O
and XXX O
TATA XXX O
box-promoter XXX O
interactions XXX O
of XXX O
TFIID XXX B-GENE
. XXX O

Aplastic XXX O
crisis XXX O
in XXX O
sickle XXX O
cell XXX O
disorders XXX O
: XXX O
bone XXX O
marrow XXX O
necrosis XXX O
and XXX O
human XXX O
parvovirus XXX O
infection XXX O
. XXX O

K XXX O
. XXX O

This XXX O
sensitivity XXX O
analysis XXX O
showed XXX O
that XXX O
the XXX O
practical XXX O
limits XXX O
of XXX O
the XXX O
accuracy XXX O
of XXX O
the XXX O
used XXX O
screening XXX O
test XXX O
jeopardize XXX O
the XXX O
estimation XXX O
of XXX O
the XXX O
true XXX O
herd XXX O
prevalence XXX O
within XXX O
reasonable XXX O
confidence XXX O
limits XXX O
, XXX O
because XXX O
the XXX O
within-herd XXX O
PTB XXX O
true XXX O
prevalence XXX O
was XXX O
low XXX O
. XXX O
For XXX O
this XXX O
reason XXX O
we XXX O
augmented XXX O
the XXX O
herd XXX O
specificity XXX O
for XXX O
herds XXX O
with XXX O
larger XXX O
adult XXX O
herd XXX O
size XXX O
( XXX O
> XXX O
5 XXX O
) XXX O
. XXX O

Poliomyelitis XXX O
from XXX O
a XXX O
vaccine XXX O
. XXX O

HNF-3 XXX B-GENE
beta XXX I-GENE
amino-terminal XXX I-GENE
sequences XXX I-GENE
defined XXX O
by XXX O
conserved XXX B-GENE
region XXX I-GENE
IV XXX I-GENE
also XXX O
contributed XXX O
to XXX O
transactivation XXX O
, XXX O
but XXX O
region XXX B-GENE
IV XXX I-GENE
activity XXX O
required XXX O
the XXX O
participation XXX O
of XXX O
the XXX O
region XXX B-GENE
II-III XXX I-GENE
domain XXX I-GENE
. XXX O

PURPOSE XXX O
: XXX O
To XXX O
evaluate XXX O
the XXX O
disease-free XXX O
survival XXX O
( XXX O
DFS XXX O
) XXX O
and XXX O
overall XXX O
survival XXX O
( XXX O
OS XXX O
) XXX O
, XXX O
prognostic XXX O
factors XXX O
, XXX O
and XXX O
treatment-related XXX O
mortality XXX O
of XXX O
women XXX O
with XXX O
stage XXX O
IIIB XXX O
inflammatory XXX O
breast XXX O
cancer XXX O
( XXX O
IBC XXX O
) XXX O
treated XXX O
with XXX O
combined XXX O
modality XXX O
therapy XXX O
( XXX O
CMT XXX O
) XXX O
and XXX O
high-dose XXX O
chemotherapy XXX O
( XXX O
HDCT XXX O
) XXX O
with XXX O
autologous XXX O
stem-cell XXX O
transplantation XXX O
. XXX O

CONCLUSIONS XXX O
: XXX O
These XXX O
findings XXX O
indicate XXX O
a XXX O
physical XXX O
barrier XXX O
of XXX O
oesophageal XXX O
surfactant XXX O
which XXX O
could XXX O
offer XXX O
some XXX O
degree XXX O
of XXX O
protection XXX O
against XXX O
gastro-oesophageal XXX O
reflux XXX O
but XXX O
one XXX O
which XXX O
is XXX O
particularly XXX O
prone XXX O
to XXX O
attack XXX O
by XXX O
bile XXX O
. XXX O

In XXX O
this XXX O
study XXX O
, XXX O
the XXX O
effect XXX O
of XXX O
acute XXX O
administration XXX O
of XXX O
various XXX O
doses XXX O
of XXX O
malathion XXX O
via XXX O
oral XXX O
and XXX O
dermal XXX O
routes XXX O
to XXX O
mice XXX O
and XXX O
rats XXX O
on XXX O
serum XXX O
levels XXX O
of XXX O
histamine XXX O
was XXX O
evaluated XXX O
. XXX O

In XXX O
this XXX O
study XXX O
, XXX O
we XXX O
tested XXX O
this XXX O
notion XXX O
by XXX O
using XXX O
ligation-mediated XXX O
PCR XXX O
to XXX O
assess XXX O
the XXX O
formation XXX O
of XXX O
recombination-activating XXX B-GENE
gene XXX I-GENE
( XXX O
RAG XXX B-GENE
) XXX O
-dependent XXX O
double-strand XXX O
breaks XXX O
( XXX O
DSBs XXX O
) XXX O
at XXX O
RSSs XXX O
3' XXX O
of XXX O
Ddelta3 XXX B-GENE
and XXX O
5' XXX O
of XXX O
Jdelta1 XXX B-GENE
. XXX O

At XXX O
the XXX O
MTD XXX O
( XXX O
8 XXX O
mg XXX O
/ XXX O
m2 XXX O
/ XXX O
day XXX O
) XXX O
, XXX O
the XXX O
dose-limiting XXX O
toxicity XXX O
of XXX O
this XXX O
agent XXX O
is XXX O
myelosuppression XXX O
. XXX O

All XXX O
control XXX O
persons XXX O
had XXX O
a XXX O
normal XXX O
reaction XXX O
to XXX O
DNFB XXX O
. XXX O

Therapeutic XXX O
action XXX O
of XXX O
a XXX O
new XXX O
antibiotic-corticoid XXX O
association XXX O
used XXX O
for XXX O
instillations XXX O
in XXX O
otology XXX O
. XXX O

Small XXX B-GENE
GTPases XXX I-GENE
of XXX O
the XXX O
Ypt XXX B-GENE
/ XXX I-GENE
Rab XXX I-GENE
family XXX I-GENE
are XXX O
involved XXX O
in XXX O
the XXX O
regulation XXX O
of XXX O
vesicular XXX O
transport XXX O
. XXX O

SRFDelta5 XXX B-GENE
acts XXX O
as XXX O
a XXX O
naturally XXX O
occurring XXX O
dominant XXX O
negative XXX O
regulatory XXX O
mutant XXX O
that XXX O
blocks XXX O
SRF-dependent XXX B-GENE
skeletal XXX I-GENE
alpha-actin XXX I-GENE
, XXX O
cardiac XXX B-GENE
alpha-actin XXX I-GENE
, XXX O
smooth XXX B-GENE
alpha-actin XXX I-GENE
, XXX O
SM22alpha XXX B-GENE
, XXX O
and XXX O
SRF XXX B-GENE
promoter-luciferase XXX I-GENE
reporter XXX I-GENE
activities XXX O
. XXX O

Renin XXX B-GENE
secretion XXX O
in XXX O
essential XXX O
and XXX O
accelerated XXX O
hypertension XXX O
. XXX O

These XXX O
findings XXX O
suggest XXX O
that XXX O
there XXX O
may XXX O
be XXX O
a XXX O
relationship XXX O
between XXX O
the XXX O
pathogenesis XXX O
of XXX O
MAL XXX O
, XXX O
narcolepsy XXX O
, XXX O
and XXX O
OSA XXX O
. XXX O

An XXX O
N-terminal XXX O
arm XXX O
from XXX O
each XXX O
subunit XXX O
wraps XXX O
around XXX O
the XXX O
dinucleotide-binding XXX O
domain XXX O
of XXX O
an XXX O
adjacent XXX O
subunit XXX O
, XXX O
covering XXX O
the XXX O
adenine XXX O
ring XXX O
of XXX O
NADP XXX O
. XXX O

At XXX O
rest XXX O
AFF XXX O
was XXX O
significantly XXX O
higher XXX O
in XXX O
UT XXX O
( XXX O
29% XXX O
) XXX O
as XXX O
compared XXX O
to XXX O
AT XXX O
( XXX O
25% XXX O
) XXX O
and XXX O
UEA XXX O
( XXX O
25% XXX O
) XXX O
. XXX O

Recombinant XXX O
plasmids XXX O
containing XXX O
the XXX O
entire XXX O
322 XXX O
nt XXX O
5' XXX O
UTR XXX O
of XXX O
exon XXX O
1 XXX O
and XXX O
a XXX O
1630 XXX O
nt XXX O
segment XXX O
of XXX O
5' XXX O
flanking XXX O
sequence XXX O
stimulated XXX O
luciferase XXX B-GENE
activity XXX O
nearly XXX O
70 XXX O
times XXX O
higher XXX O
than XXX O
a XXX O
promoterless XXX O
control XXX O
plasmid XXX O
. XXX O

In XXX O
concept XXX O
II XXX O
62 XXX O
patients XXX O
were XXX O
treated XXX O
with XXX O
selective XXX O
vagotomy XXX O
and XXX O
pyloroplasty XXX O
. XXX O

Abnormal XXX O
characteristics XXX O
and XXX O
verticillation XXX O
in XXX O
Platynothrus XXX O
peltifer XXX O
. XXX O

Next XXX O
, XXX O
with XXX O
carcinoma XXX O
presenting XXX O
a XXX O
leather XXX O
bottle XXX O
( XXX O
linitis XXX O
plastica XXX O
type XXX O
) XXX O
of XXX O
the XXX O
stomach XXX O
itself XXX O
, XXX O
the XXX O
II XXX O
c XXX O
portion XXX O
of XXX O
the XXX O
stomach XXX O
consisted XXX O
of XXX O
fundic XXX O
glands XXX O
( XXX O
undifferentiated XXX O
carcinoma XXX O
) XXX O
shall XXX O
become XXX O
the XXX O
primary XXX O
focus XXX O
supporting XXX O
Nakamura's XXX O
theory XXX O
. XXX O

The XXX O
abluminal XXX O
surface XXX O
is XXX O
often XXX O
almost XXX O
entirely XXX O
encircled XXX O
by XXX O
a XXX O
thick XXX O
layer XXX O
of XXX O
fibrillary XXX O
connective XXX O
tissue XXX O
. XXX O

Thus XXX O
, XXX O
an XXX O
increase XXX O
in XXX O
plasma XXX B-GENE
TBG XXX I-GENE
and XXX O
a XXX O
shift XXX O
from XXX O
adrenal XXX O
androgen XXX O
and XXX O
mineralocorticoid XXX O
steroid XXX O
secretion XXX O
towards XXX O
cortisol XXX O
secretion XXX O
may XXX O
be XXX O
endocrine XXX O
markers XXX O
for XXX O
progression XXX O
of XXX O
the XXX O
disease XXX O
in XXX O
patients XXX O
with XXX O
HIV-infection XXX O
. XXX O

By XXX O
150 XXX O
minutes XXX O
after XXX O
Cr2O3 XXX O
inhalation XXX O
, XXX O
FEV1 XXX O
. XXX O
0 XXX O
had XXX O
decreased XXX O
by XXX O
32% XXX O
. XXX O

A XXX O
deletion XXX O
mutation XXX O
analysis XXX O
of XXX O
the XXX O
recombinant XXX O
protein XXX O
has XXX O
shown XXX O
that XXX O
the XXX O
N-terminal XXX O
region XXX O
and XXX O
the XXX O
two XXX O
leucine XXX O
zippers XXX O
are XXX O
necessary XXX O
for XXX O
the XXX O
binding XXX O
. XXX O

The XXX O
influence XXX O
of XXX O
a XXX O
mobile XXX O
pupil XXX O
on XXX O
the XXX O
response XXX O
in XXX O
the XXX O
DC-ERG XXX O
is XXX O
demonstrated XXX O
. XXX O

On XXX O
the XXX O
basis XXX O
of XXX O
a XXX O
global XXX O
assessment XXX O
patients XXX O
showed XXX O
a XXX O
highly XXX O
significant XXX O
preference XXX O
for XXX O
imipramine XXX O
compared XXX O
with XXX O
placebo XXX O
as XXX O
adjunctive XXX O
therapy XXX O
. XXX O

The XXX O
growing XXX O
drug XXX O
problem XXX O
is XXX O
also XXX O
reflected XXX O
in XXX O
the XXX O
increasing XXX O
number XXX O
of XXX O
cases XXX O
of XXX O
hepatitis XXX O
B XXX O
and XXX O
of XXX O
drug-related XXX O
deaths XXX O
. XXX O

Many XXX O
human XXX O
viruses XXX O
are XXX O
able XXX O
to XXX O
develop XXX O
suitable XXX O
strategies XXX O
for XXX O
modifying XXX O
apoptosis XXX O
in XXX O
virus-infected XXX O
cells XXX O
and XXX O
in XXX O
virus-primed XXX O
T XXX O
cells XXX O
. XXX O

This XXX O
motif XXX O
is XXX O
similar XXX O
to XXX O
but XXX O
distinct XXX O
from XXX O
the XXX O
LIM XXX B-GENE
domain XXX I-GENE
and XXX O
the XXX O
RING XXX B-GENE
finger XXX I-GENE
family XXX I-GENE
, XXX O
and XXX O
is XXX O
reminiscent XXX O
of XXX O
known XXX O
metal-binding XXX O
regions XXX O
. XXX O

The XXX O
femoroarterial XXX O
coronary XXX O
sinus XXX O
difference XXX O
in XXX O
lactate XXX O
turned XXX O
negative XXX O
, XXX O
and XXX O
pH XXX O
, XXX O
PCO2 XXX O
and XXX O
potassium XXX O
differences XXX O
increased XXX O
in XXX O
group XXX O
2 XXX O
during XXX O
pacing XXX O
. XXX O

T XXX B-GENE
antigen XXX I-GENE
contains XXX O
four XXX O
H-2Db-restricted XXX B-GENE
cytotoxic XXX I-GENE
T XXX I-GENE
lymphocyte XXX I-GENE
( XXX I-GENE
CTL XXX I-GENE
) XXX I-GENE
recognition XXX I-GENE
epitopes XXX I-GENE
that XXX O
are XXX O
targets XXX O
for XXX O
CTL XXX O
clones XXX O
Y-1 XXX O
, XXX O
Y-2 XXX O
, XXX O
Y-3 XXX O
, XXX O
and XXX O
Y-5 XXX O
. XXX O

Combined XXX O
therapy XXX O
with XXX O
MK-801 XXX O
and XXX O
nimodipine XXX O
for XXX O
protection XXX O
of XXX O
ischemic XXX O
brain XXX O
damage XXX O
. XXX O

Histopathological XXX O
features XXX O
of XXX O
relapsed XXX O
leprosy XXX O
. XXX O

Intracellular XXX O
activity XXX O
studies XXX O
indicated XXX O
that XXX O
, XXX O
at XXX O
ten XXX O
times XXX O
MBC XXX O
, XXX O
only XXX O
penicillin XXX O
had XXX O
any XXX O
significant XXX O
activity XXX O
against XXX O
intracellular XXX O
staphylococci XXX O
, XXX O
reducing XXX O
survival XXX O
by XXX O
28% XXX O
. XXX O

Regulators XXX O
of XXX O
G XXX B-GENE
protein XXX I-GENE
signaling XXX I-GENE
( XXX I-GENE
RGS XXX I-GENE
) XXX I-GENE
proteins XXX I-GENE
that XXX O
contain XXX O
DEP XXX B-GENE
( XXX O
disheveled XXX B-GENE
, XXX O
EGL-10 XXX B-GENE
, XXX O
pleckstrin XXX B-GENE
) XXX O
and XXX O
GGL XXX B-GENE
( XXX O
G XXX B-GENE
protein XXX I-GENE
gamma XXX I-GENE
subunit-like XXX I-GENE
) XXX O
domains XXX O
form XXX O
a XXX O
subfamily XXX O
that XXX O
includes XXX O
the XXX O
mammalian XXX B-GENE
RGS XXX I-GENE
proteins XXX I-GENE
RGS6 XXX B-GENE
, XXX O
RGS7 XXX B-GENE
, XXX O
RGS9 XXX B-GENE
, XXX O
and XXX O
RGS11 XXX B-GENE
. XXX O

The XXX O
results XXX O
demonstrate XXX O
( XXX O
i XXX O
) XXX O
that XXX O
the XXX O
selenocysteine-specific XXX O
UGA XXX O
codon XXX O
is XXX O
readily XXX O
suppressed XXX O
under XXX O
conditions XXX O
where XXX O
the XXX O
homologous XXX B-GENE
SelB XXX I-GENE
protein XXX I-GENE
is XXX O
absent XXX O
and XXX O
( XXX O
ii XXX O
) XXX O
that XXX O
apart XXX O
from XXX O
the XXX O
specificity XXX O
of XXX O
the XXX O
SelB-mRNA XXX B-GENE
interaction XXX O
, XXX O
a XXX O
structural XXX O
compatibility XXX O
of XXX O
the XXX O
quaternary XXX O
complex XXX O
with XXX O
the XXX O
ribosome XXX O
is XXX O
required XXX O
. XXX O

Genomic XXX O
and XXX O
cDNA XXX O
clones XXX O
homologous XXX O
to XXX O
the XXX O
yeast XXX B-GENE
GCN2 XXX I-GENE
eIF-2alpha XXX I-GENE
kinase XXX I-GENE
( XXX O
yGCN2 XXX B-GENE
) XXX O
were XXX O
isolated XXX O
from XXX O
Drosophila XXX O
melanogaster XXX O
. XXX O

Chem XXX O
. XXX O

Later XXX O
in XXX O
development XXX O
, XXX O
Tbx6 XXX B-GENE
expression XXX O
is XXX O
restricted XXX O
to XXX O
presomitic XXX O
, XXX O
paraxial XXX O
mesoderm XXX O
and XXX O
to XXX O
the XXX O
tail XXX O
bud XXX O
, XXX O
which XXX O
replaces XXX O
the XXX O
streak XXX O
as XXX O
the XXX O
source XXX O
of XXX O
mesoderm XXX O
. XXX O

RAS2val19 XXX B-GENE
, XXX O
a XXX O
dominant XXX O
activated XXX O
form XXX O
of XXX O
Saccharomyces XXX B-GENE
cerevisiae XXX I-GENE
Ras2 XXX I-GENE
, XXX O
stimulates XXX O
both XXX O
filamentous XXX O
growth XXX O
and XXX O
expression XXX O
of XXX O
a XXX O
transcriptional XXX B-GENE
reporter XXX I-GENE
FG XXX I-GENE
( XXX I-GENE
TyA XXX I-GENE
) XXX I-GENE
: XXX O
: XXX O
lacZ XXX B-GENE
but XXX O
does XXX O
not XXX O
induce XXX O
the XXX O
mating XXX B-GENE
pathway XXX I-GENE
reporter XXX I-GENE
FUS1 XXX I-GENE
: XXX O
: XXX O
lacZ XXX B-GENE
. XXX O

The XXX O
eluent XXX O
from XXX O
the XXX O
column XXX O
was XXX O
mixed XXX O
with XXX O
the XXX O
chemiluminescent XXX O
solution XXX O
containing XXX O
lucigenin XXX O
and XXX O
Triton XXX O
X-100 XXX O
and XXX O
a XXX O
0 XXX O
. XXX O
28 XXX O
M XXX O
KOH XXX O
solution XXX O
by XXX O
pumps XXX O
and XXX O
monitored XXX O
by XXX O
a XXX O
chemiluminescence XXX O
detector XXX O
. XXX O

Prevalence XXX O
of XXX O
rheumatoid XXX O
arthritis XXX O
and XXX O
rheumatoid XXX B-GENE
factor XXX I-GENE
in XXX O
women XXX O
: XXX O
evidence XXX O
for XXX O
a XXX O
secular XXX O
decline XXX O
. XXX O

The XXX O
Ng XXX B-GENE
/ XXX I-GENE
RC3 XXX I-GENE
and XXX O
PKC-gamma XXX B-GENE
genes XXX I-GENE
have XXX O
a XXX O
similar XXX O
expression XXX O
pattern XXX O
in XXX O
the XXX O
brain XXX O
during XXX O
development XXX O
. XXX O

RESULTS XXX O
: XXX O
In XXX O
vivo XXX O
, XXX O
there XXX O
was XXX O
a XXX O
wide XXX O
distribution XXX O
with XXX O
the XXX O
coefficient XXX O
of XXX O
variation XXX O
( XXX O
SD XXX O
/ XXX O
mean XXX O
x XXX O
100% XXX O
) XXX O
for XXX O
different XXX O
valve XXX O
sizes XXX O
ranging XXX O
from XXX O
21% XXX O
to XXX O
39% XXX O
in XXX O
the XXX O
St XXX O
Jude XXX O
Medical XXX O
valve XXX O
and XXX O
from XXX O
25% XXX O
to XXX O
33% XXX O
in XXX O
the XXX O
Omnicarbon XXX O
valve XXX O
. XXX O

CONCLUSIONS XXX O
: XXX O
This XXX O
retrospective XXX O
uncontrolled XXX O
study XXX O
shows XXX O
that XXX O
in XXX O
patients XXX O
with XXX O
type XXX O
1 XXX O
HRS XXX O
, XXX O
terlipressin-induced XXX O
improved XXX O
renal XXX O
function XXX O
is XXX O
associated XXX O
with XXX O
an XXX O
increase XXX O
in XXX O
survival XXX O
. XXX O

HRES XXX O
has XXX O
been XXX O
found XXX O
to XXX O
be XXX O
clinically XXX O
useful XXX O
in XXX O
assessing XXX O
histologic XXX O
damage XXX O
following XXX O
pneumatic XXX O
dilatation XXX O
and XXX O
in XXX O
localizing XXX O
the XXX O
LES XXX O
during XXX O
the XXX O
administration XXX O
of XXX O
intrasphincter XXX O
botulinum XXX B-GENE
toxin XXX I-GENE
injection XXX O
in XXX O
the XXX O
treatment XXX O
of XXX O
achalasia XXX O
. XXX O

Evaluation XXX O
of XXX O
1 XXX O
, XXX O
10-phenanthroline XXX O
as XXX O
a XXX O
reagent XXX O
for XXX O
sialic XXX O
acid XXX O
determinations XXX O
. XXX O

On XXX O
parents XXX O
. XXX O

Relationship XXX O
of XXX O
mast XXX O
cells XXX O
to XXX O
sarcoidosis XXX O
granuloma XXX O
of XXX O
the XXX O
skin XXX O
. XXX O

In XXX O
6 XXX O
of XXX O
24 XXX O
infants XXX O
studied XXX O
( XXX O
27th-40th XXX O
weeks XXX O
of XXX O
gestation XXX O
) XXX O
, XXX O
acquired XXX O
and XXX O
congenital XXX O
structural XXX O
anomalies XXX O
of XXX O
the XXX O
airways XXX O
were XXX O
detected XXX O
with XXX O
an XXX O
ultrathin XXX O
flexible XXX O
fiberscope XXX O
( XXX O
Olympus XXX O
PF18 XXX O
S XXX O
, XXX O
1 XXX O
. XXX O
8 XXX O
mm XXX O
) XXX O
. XXX O

The XXX O
cellular XXX O
rate XXX O
of XXX O
anticoagulant XXX O
heparan XXX O
sulfate XXX O
proteoglycan XXX O
( XXX O
HSPGact XXX O
) XXX O
generation XXX O
is XXX O
determined XXX O
by XXX O
the XXX O
level XXX O
of XXX O
a XXX O
kinetically XXX O
limiting XXX O
microsomal XXX O
activity XXX O
, XXX O
HSact XXX O
conversion XXX O
activity XXX O
, XXX O
which XXX O
is XXX O
predominantly XXX O
composed XXX O
of XXX O
the XXX O
long XXX O
sought XXX O
heparan XXX B-GENE
sulfate XXX I-GENE
D-glucosaminyl XXX I-GENE
3-O-sulfotransferase XXX I-GENE
( XXX O
3-OST XXX B-GENE
) XXX O
( XXX O
Shworak XXX O
, XXX O
N XXX O
. XXX O

Basal XXX O
FVR XXX O
was XXX O
reduced XXX O
by XXX O
approximately XXX O
18% XXX O
by XXX O
ERT XXX O
and XXX O
HRT XXX O
, XXX O
but XXX O
FVR XXX O
responses XXX O
to XXX O
noradrenaline XXX O
, XXX O
angiotensin XXX B-GENE
II XXX I-GENE
, XXX O
acetylcholine XXX O
and XXX O
nitroprusside XXX O
were XXX O
unaffected XXX O
. XXX O

Molecular XXX O
cloning XXX O
of XXX O
a XXX O
novel XXX O
human XXX B-GENE
I-mfa XXX I-GENE
domain-containing XXX I-GENE
protein XXX I-GENE
that XXX O
differently XXX O
regulates XXX O
human XXX O
T-cell XXX O
leukemia XXX O
virus XXX O
type XXX O
I XXX O
and XXX O
HIV-1 XXX O
expression XXX O
. XXX O

Aluminium XXX O
resin XXX O
for XXX O
the XXX O
treatment XXX O
of XXX O
the XXX O
hyperkalamia XXX O
of XXX O
renal XXX O
failure XXX O
. XXX O

Strategic XXX O
change XXX O
in XXX O
the XXX O
NHS XXX O
. XXX O

Interestingly XXX O
, XXX O
PKA XXX B-GENE
activity XXX O
is XXX O
dispensable XXX O
in XXX O
a XXX O
strain XXX O
lacking XXX O
Msn2p XXX B-GENE
and XXX O
Msn4p XXX B-GENE
activity XXX O
. XXX O

The XXX O
homologous XXX O
active-site XXX O
framework XXX O
of XXX O
these XXX O
enzymes XXX O
with XXX O
distinct XXX O
structures XXX O
suggests XXX O
convergent XXX O
evolution XXX O
of XXX O
a XXX O
common XXX O
catalytic XXX O
mechanism XXX O
. XXX O

In XXX O
addition XXX O
to XXX O
its XXX O
elongation XXX O
activity XXX O
, XXX O
ELL XXX B-GENE
contains XXX O
a XXX O
novel XXX O
type XXX O
of XXX O
RNA XXX B-GENE
polymerase XXX I-GENE
II XXX I-GENE
interaction XXX I-GENE
domain XXX I-GENE
that XXX O
is XXX O
capable XXX O
of XXX O
repressing XXX O
polymerase XXX B-GENE
activity XXX O
in XXX O
promoter-specific XXX O
transcription XXX O
. XXX O

In XXX O
contrast XXX O
, XXX O
we XXX O
observed XXX O
high XXX O
concentrations XXX O
in XXX O
29 XXX O
of XXX O
75 XXX O
patients XXX O
with XXX O
tumors XXX O
of XXX O
the XXX O
central XXX O
nervous XXX O
system XXX O
, XXX O
especially XXX O
in XXX O
meningioma XXX O
( XXX O
6 XXX O
/ XXX O
9 XXX O
) XXX O
, XXX O
glioblastoma XXX O
( XXX O
9 XXX O
/ XXX O
23 XXX O
) XXX O
, XXX O
and XXX O
neurinoma XXX O
( XXX O
5 XXX O
/ XXX O
5 XXX O
) XXX O
. XXX O

We XXX O
present XXX O
evidence XXX O
that XXX O
YY1 XXX B-GENE
, XXX O
a XXX O
ubiquitously XXX O
expressed XXX O
DNA-binding XXX O
protein XXX O
, XXX O
regulates XXX O
the XXX O
activity XXX O
of XXX O
the XXX O
c-fos XXX B-GENE
promoter XXX I-GENE
primarily XXX O
through XXX O
an XXX O
effect XXX O
on XXX O
DNA XXX O
structure XXX O
. XXX O

DNase XXX B-GENE
I XXX I-GENE
genomic XXX O
footprinting XXX O
revealed XXX O
that XXX O
the XXX O
c-Myb XXX B-GENE
site XXX I-GENE
is XXX O
occupied XXX O
in XXX O
a XXX O
tissue-specific XXX O
fashion XXX O
in XXX O
vivo XXX O
. XXX O

Regulators XXX O
responsible XXX O
for XXX O
the XXX O
pervasive XXX O
, XXX O
nonsex-specific XXX O
alternative XXX O
pre-mRNA XXX O
splicing XXX O
characteristic XXX O
of XXX O
metazoans XXX O
are XXX O
almost XXX O
entirely XXX O
unknown XXX O
or XXX O
uncertain XXX O
. XXX O

Cystatin XXX B-GENE
A XXX I-GENE
, XXX O
a XXX O
cysteine XXX B-GENE
proteinase XXX I-GENE
inhibitor XXX O
, XXX O
is XXX O
one XXX O
of XXX O
the XXX O
precursor XXX O
proteins XXX O
of XXX O
cornified XXX O
cell XXX O
envelope XXX O
of XXX O
keratinocytes XXX O
and XXX O
is XXX O
expressed XXX O
during XXX O
the XXX O
late XXX O
stage XXX O
of XXX O
keratinocyte XXX O
differentiation XXX O
. XXX O

Emergency XXX O
treatment XXX O
of XXX O
facial XXX O
and XXX O
maxillary XXX O
/ XXX O
mandibular XXX O
injuries XXX O
. XXX O

A XXX O
rare XXX O
chronic XXX O
course XXX O
of XXX O
Budd-Chiari XXX O
syndrome XXX O
associated XXX O
with XXX O
thrombosis XXX O
of XXX O
the XXX O
portal XXX O
vein XXX O
was XXX O
observed XXX O
in XXX O
a XXX O
30-year-old XXX O
male XXX O
patient XXX O
suffering XXX O
from XXX O
postmyocarditic XXX O
cardiosclerosis XXX O
. XXX O

The XXX O
contribution XXX O
that XXX O
alternative XXX O
splicing XXX O
events XXX O
in XXX O
c-myb XXX B-GENE
expression XXX O
may XXX O
make XXX O
on XXX O
c-myb XXX B-GENE
function XXX O
remains XXX O
to XXX O
be XXX O
elucidated XXX O
. XXX O

In XXX O
vivo XXX O
, XXX O
CARbeta XXX B-GENE
/ XXX I-GENE
RXRalpha XXX I-GENE
activated XXX O
transcription XXX O
from XXX O
an XXX O
HD-PPRE XXX B-GENE
luciferase XXX B-GENE
reporter XXX I-GENE
construct XXX I-GENE
. XXX O

We XXX O
report XXX O
the XXX O
results XXX O
of XXX O
a XXX O
detailed XXX O
policy XXX O
analysis XXX O
comparing XXX O
2 XXX O
CJD-related XXX O
decisions XXX O
: XXX O
a XXX O
1995 XXX O
recall XXX O
of XXX O
blood XXX O
from XXX O
a XXX O
donor XXX O
with XXX O
classic XXX O
CJD XXX O
and XXX O
the XXX O
1999 XXX O
decision XXX O
to XXX O
defer XXX O
donations XXX O
from XXX O
individuals XXX O
with XXX O
a XXX O
6-month XXX O
travel XXX O
history XXX O
to XXX O
the XXX O
UK XXX O
between XXX O
1980 XXX O
and XXX O
1996 XXX O
due XXX O
to XXX O
concerns XXX O
related XXX O
to XXX O
variant XXX O
CJD XXX O
. XXX O

Identification XXX O
of XXX O
a XXX O
cis-acting XXX O
element XXX O
in XXX O
the XXX O
class XXX B-GENE
I XXX I-GENE
major XXX I-GENE
histocompatibility XXX I-GENE
complex XXX I-GENE
gene XXX I-GENE
promoter XXX I-GENE
responsive XXX O
to XXX O
activation XXX O
by XXX O
retroviral XXX O
sequences XXX O
. XXX O

DESIGN XXX O
: XXX O
Comparison XXX O
of XXX O
number XXX O
of XXX O
women XXX O
with XXX O
PKU XXX O
aged XXX O
15-44 XXX O
years XXX O
on XXX O
the XXX O
NSW XXX O
PKU XXX O
database XXX O
( XXX O
observed XXX O
number XXX O
) XXX O
with XXX O
expected XXX O
number XXX O
derived XXX O
from XXX O
population XXX O
data XXX O
. XXX O

Most XXX O
strains XXX O
( XXX O
95% XXX O
) XXX O
of XXX O
S XXX O
. XXX O
lugdunensis XXX O
produced XXX O
a XXX O
delta XXX B-GENE
hemolysin XXX I-GENE
like XXX O
that XXX O
seen XXX O
with XXX O
nine XXX O
other XXX O
species XXX O
of XXX O
CNS XXX O
. XXX O

Longitudinal XXX O
force-length XXX O
relationships XXX O
of XXX O
guinea XXX O
pig XXX O
ureter XXX O
were XXX O
studied XXX O
in XXX O
vitro XXX O
in XXX O
animals XXX O
3 XXX O
weeks XXX O
, XXX O
3 XXX O
months XXX O
, XXX O
and XXX O
3 XXX O
years XXX O
of XXX O
age XXX O
. XXX O

Aggregation XXX O
of XXX O
vHnf1-deficient XXX O
embryonic XXX O
stem XXX O
cells XXX O
with XXX O
wild-type XXX O
tetraploid XXX O
embryos XXX O
, XXX O
which XXX O
contribute XXX O
exclusively XXX O
to XXX O
extraembryonic XXX O
tissues XXX O
, XXX O
rescues XXX O
periimplantation XXX O
lethality XXX O
and XXX O
allows XXX O
development XXX O
to XXX O
progress XXX O
to XXX O
early XXX O
organogenesis XXX O
. XXX O

Endogenous XXX O
release XXX O
of XXX O
neuronal XXX O
serotonin XXX O
and XXX O
5-hydroxyindoleacetic XXX O
acid XXX O
in XXX O
the XXX O
caudate-putamen XXX O
of XXX O
the XXX O
rat XXX O
as XXX O
revealed XXX O
by XXX O
intracerebral XXX O
dialysis XXX O
coupled XXX O
to XXX O
high-performance XXX O
liquid XXX O
chromatography XXX O
with XXX O
fluorimetric XXX O
detection XXX O
. XXX O

The XXX O
use XXX O
of XXX O
primary XXX O
GE XXX O
cells XXX O
thus XXX O
provides XXX O
a XXX O
convenient XXX O
in XXX O
vitro XXX O
system XXX O
for XXX O
further XXX O
study XXX O
of XXX O
the XXX O
endocrine XXX O
, XXX O
paracrine XXX O
, XXX O
and XXX O
autocrine XXX O
factors XXX O
regulating XXX O
endometrial XXX O
gene XXX O
expression XXX O
during XXX O
pregnancy XXX O
. XXX O

We XXX O
found XXX O
14 XXX O
protein XXX O
binding XXX O
sites XXX O
that XXX O
were XXX O
occupied XXX O
in XXX O
vivo XXX O
. XXX O

The XXX O
pulpal XXX O
tissues XXX O
of XXX O
the XXX O
permanent XXX O
mandibular XXX O
molars XXX O
were XXX O
amputated XXX O
and XXX O
then XXX O
dressed XXX O
with XXX O
calcium XXX O
hydrate XXX O
. XXX O

CPAP XXX O
reduced XXX O
isotime XXX O
( XXX O
defined XXX O
as XXX O
the XXX O
last XXX O
common XXX O
minute XXX O
of XXX O
exercise XXX O
) XXX O
VO2 XXX O
and XXX O
dyspnea XXX O
in XXX O
those XXX O
patients XXX O
with XXX O
more XXX O
severe XXX O
lung XXX O
disease XXX O
, XXX O
but XXX O
these XXX O
values XXX O
tended XXX O
to XXX O
increase XXX O
slightly XXX O
in XXX O
the XXX O
patients XXX O
with XXX O
only XXX O
mild XXX O
lung XXX O
disease XXX O
. XXX O

High-frequency XXX O
electrical XXX O
stimulation XXX O
in XXX O
the XXX O
hippocampus XXX O
leads XXX O
to XXX O
an XXX O
increase XXX O
in XXX O
synaptic XXX O
efficacy XXX O
that XXX O
lasts XXX O
for XXX O
many XXX O
hours XXX O
. XXX O

The XXX O
histologic XXX O
grade XXX O
for XXX O
the XXX O
same XXX O
anatomic XXX O
site XXX O
varied XXX O
among XXX O
hearts XXX O
and XXX O
among XXX O
different XXX O
anatomic XXX O
sites XXX O
in XXX O
the XXX O
same XXX O
heart XXX O
. XXX O

The XXX O
RanQ69L XXX B-GENE
preincubation XXX O
leads XXX O
to XXX O
accumulation XXX O
of XXX O
CRM1 XXX B-GENE
at XXX O
the XXX O
cytoplasmic XXX O
periphery XXX O
of XXX O
the XXX O
nuclear XXX B-GENE
pore XXX I-GENE
complex XXX I-GENE
( XXX O
NPC XXX B-GENE
) XXX O
in XXX O
association XXX O
with XXX O
the XXX O
p62 XXX B-GENE
complex XXX I-GENE
and XXX O
Can XXX B-GENE
/ XXX I-GENE
Nup214 XXX I-GENE
. XXX O

This XXX O
generalization XXX O
of XXX O
MFP XXX O
involves XXX O
defining XXX O
an XXX O
appropriate XXX O
high-resolution XXX O
cost XXX O
function XXX O
, XXX O
parametrizing XXX O
the XXX O
search XXX O
space XXX O
of XXX O
the XXX O
environment XXX O
and XXX O
source XXX O
, XXX O
constructing XXX O
solutions XXX O
of XXX O
the XXX O
wave XXX O
equation XXX O
, XXX O
and XXX O
utilizing XXX O
a XXX O
nonlinear XXX O
optimization XXX O
method XXX O
to XXX O
search XXX O
the XXX O
parameter XXX O
landscape XXX O
for XXX O
the XXX O
global XXX O
minimum XXX O
of XXX O
the XXX O
cost XXX O
function XXX O
. XXX O

This XXX O
domain XXX O
without XXX O
the XXX O
canonical XXX O
anticodon XXX O
loop XXX O
or XXX O
the XXX O
tyrosine XXX O
anticodon XXX O
acts XXX O
as XXX O
an XXX O
anchor XXX O
for XXX O
TyrRS XXX B-GENE
interaction XXX O
leading XXX O
to XXX O
a XXX O
better XXX O
efficiency XXX O
of XXX O
tyrosylation XXX O
. XXX O

Static XXX O
orthoses XXX O
for XXX O
the XXX O
management XXX O
of XXX O
microstomia XXX O
. XXX O

Value XXX O
of XXX O
urine XXX O
glucose XXX O
tests XXX O
in XXX O
the XXX O
management XXX O
of XXX O
type XXX O
II XXX O
diabetes XXX O
mellitus XXX O
. XXX O

Two XXX O
US XXX O
commercial XXX O
cultivars XXX O
( XXX O
Tehama XXX O
and XXX O
Vina XXX O
) XXX O
, XXX O
three XXX O
European XXX O
commercial XXX O
cultivars XXX O
( XXX O
Esterhazy XXX O
, XXX O
139 XXX O
, XXX O
G120 XXX O
) XXX O
and XXX O
five XXX O
New XXX O
Zealand XXX O
selections XXX O
( XXX O
Rex XXX O
, XXX O
Dublin's XXX O
Glory XXX O
, XXX O
Meyric XXX O
, XXX O
McKinster XXX O
, XXX O
Stanley XXX O
) XXX O
were XXX O
evaluated XXX O
. XXX O

This XXX O
review XXX O
seeks XXX O
to XXX O
summarize XXX O
the XXX O
disease XXX O
, XXX O
to XXX O
propose XXX O
pathways XXX O
of XXX O
carcinogenesis XXX O
and XXX O
to XXX O
suggest XXX O
ways XXX O
in XXX O
which XXX O
the XXX O
"traditional" XXX O
risk XXX O
factors XXX O
may XXX O
be XXX O
interpreted XXX O
on XXX O
the XXX O
basis XXX O
of XXX O
evolving XXX O
knowledge XXX O
. XXX O

Twenty-eight XXX O
( XXX O
7 XXX O
. XXX O
0% XXX O
) XXX O
infants XXX O
without XXX O
periventricular XXX O
hemorrhage XXX O
were XXX O
revealed XXX O
as XXX O
having XXX O
spastic XXX O
cerebral XXX O
palsy XXX O
by XXX O
neurodevelopmental XXX O
evaluation XXX O
in XXX O
later XXX O
infancy XXX O
. XXX O

The XXX O
statistical XXX O
analysis XXX O
of XXX O
data XXX O
of XXX O
TRH XXX B-GENE
test XXX O
on XXX O
a XXX O
sample XXX O
of XXX O
57 XXX O
healthy XXX O
volunteers XXX O
has XXX O
permitted XXX O
an XXX O
evaluation XXX O
of XXX O
the XXX O
upper XXX O
limits XXX O
of XXX O
the XXX O
normal XXX O
thyrotropin XXX B-GENE
response XXX O
; XXX O
the XXX O
secretory XXX O
area XXX O
( XXX O
As XXX O
) XXX O
was XXX O
shown XXX O
to XXX O
be XXX O
more XXX O
discriminating XXX O
. XXX O

The XXX O
alpha XXX B-GENE
2A-adrenergic XXX I-GENE
receptor XXX I-GENE
( XXX O
alpha XXX B-GENE
2AAR XXX I-GENE
) XXX O
is XXX O
coupled XXX O
to XXX O
a XXX O
variety XXX O
of XXX O
effectors XXX O
via XXX O
pertussis XXX O
toxin-sensitive XXX O
GTP-binding XXX B-GENE
proteins XXX I-GENE
. XXX O

Cardiac XXX B-GENE
endothelin XXX I-GENE
release XXX O
and XXX O
infarct XXX O
size XXX O
, XXX O
myocardial XXX O
blood XXX O
flow XXX O
, XXX O
and XXX O
ventricular XXX O
function XXX O
in XXX O
canine XXX O
infarction XXX O
and XXX O
reperfusion XXX O
. XXX O

This XXX O
association XXX O
was XXX O
independently XXX O
significant XXX O
for XXX O
patients XXX O
treated XXX O
primarily XXX O
( XXX O
not XXX O
for XXX O
recurrence XXX O
) XXX O
. XXX O

The XXX O
effects XXX O
of XXX O
L655 XXX O
, XXX O
240 XXX O
, XXX O
a XXX O
selective XXX O
thromboxane XXX O
and XXX O
prostaglandin XXX O
endoperoxide XXX O
antagonist XXX O
, XXX O
on XXX O
ischemia- XXX O
and XXX O
reperfusion-induced XXX O
cardiac XXX O
arrhythmias XXX O
. XXX O

However XXX O
, XXX O
in XXX O
TF-1 XXX O
cells XXX O
grown XXX O
on XXX O
GM-CSF XXX B-GENE
before XXX O
starvation XXX O
, XXX O
CREB XXX B-GENE
phosphorylation XXX O
was XXX O
observed XXX O
10 XXX O
minutes XXX O
after XXX O
PIXY321 XXX B-GENE
stimulation XXX O
. XXX O

The XXX O
Cr XXX B-GENE
. XXX I-GENE
psbA-4 XXX I-GENE
ORF XXX I-GENE
contains XXX O
an XXX O
H-N-H XXX B-GENE
motif XXX I-GENE
, XXX O
and XXX O
possibly XXX O
a XXX O
GIY-YIG XXX B-GENE
motif XXX I-GENE
. XXX O

The XXX O
promoter XXX O
and XXX O
upstream XXX O
region XXX O
of XXX O
the XXX O
Brassica XXX B-GENE
napus XXX I-GENE
2S XXX I-GENE
storage XXX I-GENE
protein XXX I-GENE
napA XXX I-GENE
gene XXX I-GENE
were XXX O
studied XXX O
to XXX O
identify XXX O
cis-acting XXX O
sequences XXX O
involved XXX O
in XXX O
developmental XXX O
seed-specific XXX O
expression XXX O
. XXX O

Antibodies XXX O
raised XXX O
against XXX O
GST XXX B-GENE
mSH2-B XXX I-GENE
identified XXX O
a XXX O
cellular XXX O
protein XXX O
of XXX O
92 XXX O
kDa XXX O
that XXX O
was XXX O
not XXX O
found XXX O
to XXX O
be XXX O
phosphorylated XXX O
on XXX O
Tyr XXX O
. XXX O

The XXX O
diagnosis XXX O
of XXX O
metachromatic XXX O
leukodystrophy XXX O
( XXX O
MLD XXX O
) XXX O
was XXX O
confirmed XXX O
by XXX O
the XXX O
finding XXX O
of XXX O
low XXX O
arylsulfatase XXX B-GENE
A XXX I-GENE
( XXX O
ASA XXX B-GENE
) XXX O
levels XXX O
in XXX O
cultured XXX O
fibroblasts XXX O
in XXX O
both XXX O
sisters XXX O
. XXX O

Once XXX O
more XXX O
Hong XXX O
Kong XXX O
influenza XXX O
in XXX O
the XXX O
Netherlands XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
this XXX O
kinase XXX O
is XXX O
well XXX O
conserved XXX O
evolutionarily XXX O
, XXX O
ubiquitously XXX O
expressed XXX O
, XXX O
and XXX O
its XXX O
genes XXX O
map XXX O
to XXX O
a XXX O
position XXX O
on XXX O
human XXX O
chromosome XXX O
1 XXX O
frequently XXX O
deleted XXX O
in XXX O
the XXX O
late XXX O
stages XXX O
of XXX O
tumorigenesis XXX O
. XXX O

Deletions XXX O
in XXX O
each XXX O
of XXX O
these XXX O
regions XXX O
abolish XXX O
membrane XXX O
localization XXX O
of XXX O
Tiam1 XXX B-GENE
and XXX O
membrane XXX O
ruffling XXX O
, XXX O
suggesting XXX O
that XXX O
they XXX O
function XXX O
cooperatively XXX O
. XXX O

In XXX O
contrast XXX O
, XXX O
the XXX O
xtRNA XXX B-GENE
( XXX I-GENE
Sec XXX I-GENE
) XXX I-GENE
gene XXX I-GENE
needs XXX O
the XXX O
binding XXX O
of XXX O
the XXX O
seven XXX O
Staf XXX B-GENE
zinc XXX I-GENE
fingers XXX I-GENE
, XXX O
but XXX O
not XXX O
Oct-1 XXX B-GENE
, XXX O
for XXX O
optimal XXX O
transcriptional XXX O
capacity XXX O
. XXX O

During XXX O
IC XXX O
breaths XXX O
and XXX O
following XXX O
EC XXX O
and XXX O
VC XXX O
breaths XXX O
at XXX O
rest XXX O
, XXX O
end-tidal XXX O
CO2 XXX O
pressure XXX O
( XXX O
PET XXX O
, XXX O
CO2 XXX O
) XXX O
fell XXX O
by XXX O
7 XXX O
. XXX O
5 XXX O
, XXX O
8 XXX O
. XXX O
5 XXX O
and XXX O
9 XXX O
. XXX O
5 XXX O
mmHg XXX O
, XXX O
respectively XXX O
. XXX O

It XXX O
is XXX O
postulated XXX O
that XXX O
altered XXX O
blood XXX O
flow XXX O
, XXX O
mediated XXX O
through XXX O
the XXX O
well-known XXX O
prostaglandin XXX B-GENE
synthetase XXX I-GENE
inhibitory XXX O
effects XXX O
of XXX O
ibuprofen XXX O
, XXX O
resulted XXX O
in XXX O
tubular XXX O
necrosis XXX O
. XXX O

Mitochondrial XXX B-GENE
Mas70p XXX I-GENE
signal XXX I-GENE
anchor XXX I-GENE
sequence XXX I-GENE
. XXX O

Genetic XXX O
and XXX O
phenotypic XXX O
analysis XXX O
indicates XXX O
that XXX O
NHP6A XXX B-GENE
and XXX O
NHP6B XXX B-GENE
function XXX O
downstream XXX O
of XXX O
SLT2 XXX B-GENE
. XXX O

The XXX O
use XXX O
of XXX O
an XXX O
appropriate XXX O
solution XXX O
of XXX O
methylene XXX O
blue XXX O
( XXX O
0 XXX O
. XXX O
2% XXX O
in XXX O
0 XXX O
. XXX O
9 XXX O
M XXX O
NaCl XXX O
for XXX O
15 XXX O
min XXX O
) XXX O
permits XXX O
the XXX O
staining XXX O
of XXX O
premalignant XXX O
areas XXX O
and XXX O
CIS XXX O
, XXX O
and XXX O
their XXX O
early XXX O
diagnosis XXX O
. XXX O

BACKGROUND XXX O
: XXX O
Studies XXX O
in XXX O
lean XXX O
men XXX O
show XXX O
poor XXX O
regulation XXX O
of XXX O
energy XXX O
( XXX O
EB XXX O
) XXX O
and XXX O
fat XXX O
balance XXX O
( XXX O
FB XXX O
) XXX O
during XXX O
manipulation XXX O
of XXX O
dietary XXX O
ratios XXX O
of XXX O
fat XXX O
to XXX O
carbohydrate XXX O
. XXX O

TCR XXX B-GENE
alpha XXX I-GENE
( XXX O
TCRA XXX B-GENE
) XXX O
expression XXX O
was XXX O
examined XXX O
in XXX O
RNA XXX O
samples XXX O
from XXX O
PBMC XXX O
and XXX O
isolated XXX O
populations XXX O
of XXX O
CD4+ XXX B-GENE
, XXX O
CD8+ XXX B-GENE
, XXX O
and XXX O
DN XXX B-GENE
T XXX O
cells XXX O
from XXX O
15 XXX O
healthy XXX O
individuals XXX O
. XXX O

The XXX O
long XXX O
terminal XXX O
repeat XXX O
( XXX O
LTR XXX O
) XXX O
of XXX O
the XXX O
human XXX O
immunodeficiency XXX O
virus XXX O
( XXX O
HIV XXX O
) XXX O
contains XXX O
three XXX O
binding XXX O
sites XXX O
for XXX O
the XXX O
transcriptional XXX O
factor XXX O
Sp1 XXX B-GENE
. XXX O

The XXX O
used XXX O
expression XXX O
system XXX O
could XXX O
allow XXX O
to XXX O
produce XXX O
mutated XXX O
forms XXX O
of XXX O
SsEF-2 XXX B-GENE
obtained XXX O
by XXX O
mutagenesis XXX O
of XXX O
the XXX O
corresponding XXX O
gene XXX O
. XXX O

Ileal XXX O
digestibilities XXX O
of XXX O
DM XXX O
, XXX O
OM XXX O
, XXX O
CP XXX O
, XXX O
total XXX O
dietary XXX O
fiber XXX O
( XXX O
TDF XXX O
) XXX O
, XXX O
fat XXX O
and XXX O
gross XXX O
energy XXX O
( XXX O
GE XXX O
) XXX O
were XXX O
lower XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
for XXX O
dogs XXX O
fed XXX O
diets XXX O
containing XXX O
supplemental XXX O
fiber XXX O
compared XXX O
with XXX O
dogs XXX O
fed XXX O
the XXX O
control XXX O
diet XXX O
. XXX O

This XXX O
model XXX O
is XXX O
supported XXX O
by XXX O
experiments XXX O
showing XXX O
that XXX O
Cdr2 XXX B-GENE
associates XXX O
with XXX O
the XXX O
N-terminal XXX B-GENE
regulatory XXX I-GENE
domain XXX I-GENE
of XXX I-GENE
Wee1 XXX I-GENE
in XXX O
cell XXX O
lysates XXX O
and XXX O
phosphorylates XXX O
Wee1 XXX B-GENE
in XXX O
vitro XXX O
. XXX O

Greek XXX O
classicism XXX O
in XXX O
living XXX O
structure XXX O
? XXX O
Some XXX O
deductive XXX O
pathways XXX O
in XXX O
animal XXX O
morphology XXX O
. XXX O

We XXX O
linked XXX O
a XXX O
4 XXX O
. XXX O
1-kilobase XXX O
pair XXX O
HindIII XXX B-GENE
DNA XXX I-GENE
fragment XXX I-GENE
from XXX O
the XXX O
region XXX O
upstream XXX O
of XXX O
the XXX O
human XXX B-GENE
AP XXX I-GENE
endonuclease XXX I-GENE
gene XXX I-GENE
( XXX O
APE XXX B-GENE
) XXX O
to XXX O
the XXX O
chloramphenicol XXX B-GENE
acetyltransferase XXX I-GENE
( XXX O
CAT XXX B-GENE
) XXX O
gene XXX O
. XXX O

It XXX O
was XXX O
concluded XXX O
that XXX O
patients XXX O
with XXX O
acute XXX O
respiratory XXX O
failure XXX O
requiring XXX O
artificial XXX O
ventilation XXX O
have XXX O
two XXX O
componenents XXX O
of XXX O
the XXX O
pulmonary XXX O
shunt XXX O
, XXX O
one XXX O
parallel XXX O
with XXX O
and XXX O
the XXX O
other XXX O
inversely XXX O
related XXX O
with XXX O
the XXX O
PAO2 XXX O
. XXX O

Recent XXX O
studies XXX O
have XXX O
demonstrated XXX O
that XXX O
the XXX O
U1 XXX B-GENE
snRNP XXX I-GENE
is XXX O
recruited XXX O
to XXX O
the XXX O
5' XXX O
splice XXX O
site XXX O
by XXX O
protein XXX O
/ XXX O
protein XXX O
interactions XXX O
involving XXX O
the XXX O
SR XXX B-GENE
domains XXX O
of XXX O
the XXX O
U1-70K XXX B-GENE
protein XXX I-GENE
and XXX O
SF2 XXX B-GENE
/ XXX I-GENE
ASF XXX I-GENE
. XXX O

The XXX O
control XXX O
group XXX O
revealed XXX O
significantly XXX O
higher XXX O
levels XXX O
of XXX O
coagulation XXX B-GENE
factors XXX I-GENE
II XXX I-GENE
, XXX O
V XXX B-GENE
and XXX O
VIII XXX B-GENE
, XXX O
compared XXX O
to XXX O
the XXX O
index XXX O
group XXX O
. XXX O

Whereas XXX O
, XXX O
in XXX O
the XXX O
single-chambered XXX O
body XXX O
box XXX O
, XXX O
PenH XXX O
units XXX O
( XXX O
Enhanced XXX O
Pause XXX O
) XXX O
reflect XXX O
"effort XXX O
of XXX O
breathing XXX O
. XXX O
" XXX O
This XXX O
is XXX O
measured XXX O
as XXX O
the XXX O
pause XXX O
between XXX O
inspiration XXX O
and XXX O
expiration XXX O
. XXX O

These XXX O
thyroid XXX O
hormone XXX O
changes XXX O
may XXX O
be XXX O
mediated XXX O
in XXX O
part XXX O
by XXX O
cytokines XXX O
or XXX O
other XXX O
inflammatory XXX O
mediators XXX O
, XXX O
acting XXX O
at XXX O
the XXX O
level XXX O
of XXX O
the XXX O
hypothalamus XXX O
and XXX O
pituitary XXX O
gland XXX O
, XXX O
the XXX O
thyroid XXX O
gland XXX O
, XXX O
and XXX O
the XXX O
hepatic XXX B-GENE
deiodinase XXX I-GENE
system XXX I-GENE
. XXX O

Compared XXX O
with XXX O
normal XXX O
control XXX O
subjects XXX O
, XXX O
all XXX O
74 XXX O
TOF XXX O
patients XXX O
had XXX O
decreased XXX O
systolic XXX O
and XXX O
diastolic XXX O
myocardial XXX O
velocities XXX O
and XXX O
a XXX O
longer XXX O
isovolumic XXX O
relaxation XXX O
time XXX O
. XXX O

The XXX O
ability XXX O
of XXX O
A20 XXX B-GENE
to XXX O
block XXX O
NF-kappaB XXX B-GENE
activation XXX O
was XXX O
mapped XXX O
to XXX O
its XXX O
C-terminal XXX O
zinc XXX O
finger XXX O
domain XXX O
. XXX O

The XXX O
cyclins XXX B-GENE
bind XXX O
to XXX O
and XXX O
activate XXX O
the XXX O
CDK XXX B-GENE
, XXX O
which XXX O
leads XXX O
to XXX O
phosphorylation XXX O
( XXX O
and XXX O
then XXX O
inhibition XXX O
) XXX O
of XXX O
the XXX O
tumor XXX O
suppressor XXX O
protein XXX O
, XXX O
pRb XXX B-GENE
. XXX O
pRb XXX B-GENE
controls XXX O
commitment XXX O
to XXX O
progress XXX O
from XXX O
the XXX O
G1 XXX O
to XXX O
S XXX O
phase XXX O
, XXX O
at XXX O
least XXX O
in XXX O
part XXX O
by XXX O
repressing XXX O
the XXX O
activity XXX O
of XXX O
the XXX O
E2F XXX B-GENE
transcription XXX I-GENE
factors XXX I-GENE
known XXX O
to XXX O
promote XXX O
cell XXX O
proliferation XXX O
. XXX O

Snail XXX B-GENE
family XXX I-GENE
proteins XXX I-GENE
are XXX O
zinc XXX O
finger XXX O
transcriptional XXX O
regulators XXX O
first XXX O
identified XXX O
in XXX O
Drosophila XXX O
which XXX O
play XXX O
critical XXX O
roles XXX O
in XXX O
cell XXX O
fate XXX O
determination XXX O
. XXX O

When XXX O
tethered XXX O
to XXX O
a XXX O
heterologous XXX O
DNA-binding XXX O
domain XXX O
, XXX O
PSU1 XXX B-GENE
can XXX O
activate XXX O
transcription XXX O
on XXX O
its XXX O
own XXX O
. XXX O

The XXX O
promoter XXX O
of XXX O
the XXX O
first XXX O
gene XXX O
, XXX O
epiF XXX B-GENE
, XXX O
responded XXX O
to XXX O
the XXX O
activator XXX B-GENE
protein XXX I-GENE
EpiQ XXX I-GENE
and XXX O
contained XXX O
a XXX O
palindromic XXX O
sequence XXX O
similar XXX O
to XXX O
the XXX O
EpiQ XXX B-GENE
binding XXX I-GENE
site XXX I-GENE
of XXX O
the XXX O
epiA XXX B-GENE
promoter XXX I-GENE
, XXX O
which XXX O
is XXX O
also XXX O
activated XXX O
by XXX O
EpiQ XXX B-GENE
. XXX O

We XXX O
have XXX O
used XXX O
a XXX O
site-directed XXX O
mutagenesis XXX O
approach XXX O
to XXX O
examine XXX O
how XXX O
the XXX O
Xaa XXX O
and XXX O
hydroxy XXX O
( XXX O
Ser XXX O
/ XXX O
Thr XXX O
) XXX O
amino XXX O
acid XXX O
residues XXX O
in XXX O
sequons XXX O
influence XXX O
core-glycosylation XXX O
efficiency XXX O
. XXX O

Lastly XXX O
, XXX O
there XXX O
are XXX O
multiple XXX O
instances XXX O
in XXX O
which XXX O
short XXX O
oligonucleotide XXX O
direct XXX O
repeats XXX O
flank XXX O
a XXX O
region XXX O
absent XXX O
from XXX O
either XXX O
variola XXX O
or XXX O
vaccinia XXX O
virus XXX O
. XXX O

The XXX O
attainment XXX O
of XXX O
sexual XXX O
maturity XXX O
in XXX O
terms XXX O
of XXX O
secondary XXX O
sexual XXX O
characteristics XXX O
, XXX O
the XXX O
production XXX O
of XXX O
spermatozoa XXX O
in XXX O
the XXX O
male XXX O
, XXX O
and XXX O
the XXX O
cyclical XXX O
female XXX O
pattern XXX O
with XXX O
release XXX O
of XXX O
ova XXX O
are XXX O
end-points XXX O
of XXX O
the XXX O
developmental XXX O
process XXX O
. XXX O

CONCLUSIONS XXX O
: XXX O
Free XXX O
protein XXX B-GENE
S XXX I-GENE
deficiency XXX O
is XXX O
common XXX O
among XXX O
hospitalized XXX O
patients XXX O
, XXX O
even XXX O
in XXX O
the XXX O
absence XXX O
of XXX O
a XXX O
recognized XXX O
predisposing XXX O
condition XXX O
. XXX O

She XXX O
had XXX O
been XXX O
receiving XXX O
MTX XXX O
7 XXX O
. XXX O
5 XXX O
mg XXX O
/ XXX O
week XXX O
for XXX O
2 XXX O
. XXX O
5 XXX O
months XXX O
because XXX O
of XXX O
her XXX O
vasculitis XXX O
symptoms XXX O
. XXX O

We XXX O
interpret XXX O
these XXX O
data XXX O
as XXX O
further XXX O
evidence XXX O
that XXX O
interaction XXX O
with XXX O
a XXX O
small XXX B-GENE
GTPase XXX I-GENE
is XXX O
the XXX O
main XXX O
regulatory XXX O
function XXX O
of XXX O
the XXX O
C1 XXX B-GENE
domain XXX I-GENE
in XXX O
yeast XXX O
. XXX O

Type XXX O
IV XXX O
splice XXX O
pattern XXX O
, XXX O
containing XXX O
exon XXX B-GENE
U3 XXX I-GENE
and XXX I-GENE
S XXX I-GENE
was XXX O
found XXX O
both XXX O
in XXX O
kidney XXX O
and XXX O
ovary XXX O
. XXX O

Sestamibi XXX O
scintigraphy XXX O
, XXX O
performed XXX O
in XXX O
70 XXX O
patients XXX O
, XXX O
was XXX O
less XXX O
sensitive XXX O
than XXX O
ultrasonography XXX O
( XXX O
80% XXX O
) XXX O
. XXX O

Neither XXX O
clone XXX O
encoded XXX O
the XXX O
cognate XXX O
endonuclease XXX B-GENE
. XXX O

Clinical XXX O
nutrition XXX O
of XXX O
adult XXX O
horses XXX O
. XXX O

To XXX O
determine XXX O
if XXX O
CYC2 XXX B-GENE
is XXX O
found XXX O
in XXX O
a XXX O
complex XXX O
with XXX O
previously XXX O
identified XXX O
trypanosome XXX B-GENE
cdc2-related XXX I-GENE
kinases XXX I-GENE
( XXX O
CRKs XXX B-GENE
) XXX O
, XXX O
the XXX O
CYC2 XXX B-GENE
gene XXX I-GENE
was XXX O
fused XXX O
to XXX O
the XXX O
TY XXX B-GENE
epitope XXX I-GENE
tag XXX O
, XXX O
integrated XXX O
into XXX O
the XXX O
trypanosome XXX O
genome XXX O
, XXX O
and XXX O
expressed XXX O
under XXX O
inducible XXX O
control XXX O
. XXX O

Dll3 XXX B-GENE
is XXX O
mutated XXX O
in XXX O
the XXX O
X-ray-induced XXX O
mouse XXX B-GENE
mutant XXX I-GENE
pudgy XXX I-GENE
( XXX O
pu XXX B-GENE
) XXX O
, XXX O
causing XXX O
a XXX O
variety XXX O
of XXX O
vertebrocostal XXX O
defects XXX O
similar XXX O
to XXX O
SD XXX O
phenotypes XXX O
. XXX O

The XXX O
junctions XXX O
between XXX O
viral XXX O
and XXX O
cellular XXX O
sequences XXX O
were XXX O
determined XXX O
by XXX O
DNA XXX O
sequence XXX O
analysis XXX O
to XXX O
be XXX O
517 XXX O
nucleotides XXX O
into XXX O
the XXX O
p30 XXX B-GENE
sequence XXX I-GENE
and XXX O
1 XXX O
, XXX O
920 XXX O
nucleotides XXX O
into XXX O
the XXX O
polymerase XXX B-GENE
sequence XXX I-GENE
. XXX O

In XXX O
this XXX O
study XXX O
we XXX O
describe XXX O
that XXX O
platelet-derived XXX B-GENE
growth XXX I-GENE
factor XXX I-GENE
( XXX O
PDGF XXX B-GENE
) XXX O
, XXX O
12-O-tetradecanoyl-phorbol-acetate XXX O
( XXX O
TPA XXX O
) XXX O
, XXX O
and XXX O
forskolin XXX O
induced XXX O
CREB XXX B-GENE
( XXX O
cAMP-responsive XXX B-GENE
element-binding XXX I-GENE
protein XXX I-GENE
) XXX O
Ser-133 XXX O
phosphorylation XXX O
with XXX O
comparable XXX O
magnitude XXX O
and XXX O
kinetics XXX O
in XXX O
NIH XXX O
3T3 XXX O
cells XXX O
. XXX O

On XXX O
the XXX O
other XXX O
hand XXX O
factor XXX B-GENE
IX XXX I-GENE
activity XXX O
is XXX O
decreased XXX O
in XXX O
coumarin XXX O
treatment XXX O
with XXX O
factor XXX B-GENE
IX XXX I-GENE
antigen XXX O
remaining XXX O
normal XXX O
. XXX O

In XXX O
this XXX O
report XXX O
, XXX O
we XXX O
focus XXX O
on XXX O
the XXX O
genetics XXX O
of XXX O
the XXX O
region XXX O
of XXX O
the XXX O
17 XXX B-GENE
hep XXX I-GENE
syn XXX I-GENE
gB XXX I-GENE
gene XXX I-GENE
that XXX O
conferred XXX O
both XXX O
the XXX O
syncytial XXX O
and XXX O
pathogenic XXX O
phenotypes XXX O
to XXX O
17 XXX O
syn+ XXX O
. XXX O

The XXX O
coding XXX O
sequence XXX O
for XXX O
a XXX O
260-amino-acid XXX O
residue XXX O
polypeptide XXX O
was XXX O
interrupted XXX O
by XXX O
a XXX O
single XXX O
short XXX O
intron XXX O
of XXX O
60 XXX O
base XXX O
pairs XXX O
( XXX O
bp XXX O
) XXX O
, XXX O
and XXX O
about XXX O
70% XXX O
of XXX O
the XXX O
deduced XXX O
amino XXX O
acid XXX O
sequence XXX O
of XXX O
the XXX O
Drosophila XXX B-GENE
PCNA XXX I-GENE
was XXX O
identical XXX O
to XXX O
the XXX O
rat XXX O
and XXX O
human XXX B-GENE
PCNA XXX I-GENE
polypeptides XXX I-GENE
, XXX O
with XXX O
conserved XXX O
unique XXX O
repeats XXX O
of XXX O
leucine XXX O
in XXX O
the XXX O
C-terminal XXX O
region XXX O
. XXX O

No XXX O
homology XXX O
was XXX O
found XXX O
between XXX O
the XXX O
36K XXX O
protein XXX O
and XXX O
known XXX O
structures XXX O
of XXX O
proteins XXX O
. XXX O

Nursing XXX O
education--the XXX O
computer XXX O
obligation XXX O
. XXX O

Plasma XXX O
fibrinogen XXX B-GENE
was XXX O
measured XXX O
by XXX O
the XXX O
turbidimetric XXX O
method XXX O
in XXX O
timol XXX O
turbidimetric XXX O
units XXX O
. XXX O

SUMMARY XXX O
BACKGROUND XXX O
DATA XXX O
: XXX O
Melanoma XXX O
care XXX O
has XXX O
not XXX O
changed XXX O
significantly XXX O
in XXX O
the XXX O
last XXX O
20 XXX O
years XXX O
, XXX O
and XXX O
the XXX O
controversy XXX O
of XXX O
elective XXX O
lymph XXX O
node XXX O
dissections XXX O
in XXX O
this XXX O
disease XXX O
continues XXX O
to XXX O
be XXX O
discussed XXX O
. XXX O

The XXX O
results XXX O
indicate XXX O
that XXX O
: XXX O
1 XXX O
) XXX O
the XXX O
initial XXX O
response XXX O
to XXX O
tethering XXX O
varies XXX O
according XXX O
to XXX O
previous XXX O
penning XXX O
and XXX O
handling XXX O
experience XXX O
, XXX O
2 XXX O
) XXX O
although XXX O
the XXX O
circadian XXX O
rhythm XXX O
of XXX O
cortisol XXX O
was XXX O
either XXX O
altered XXX O
or XXX O
disrupted XXX O
during XXX O
estrus XXX O
, XXX O
such XXX O
disruptions XXX O
were XXX O
not XXX O
influenced XXX O
by XXX O
type XXX O
of XXX O
penning XXX O
and XXX O
3 XXX O
) XXX O
tether XXX O
stalls XXX O
may XXX O
chronically XXX O
increase XXX O
cortisol XXX O
concentrations XXX O
in XXX O
gilts XXX O
. XXX O

This XXX O
unique XXX O
work XXX O
needs XXX O
to XXX O
be XXX O
edited XXX O
critically XXX O
and XXX O
afterwards XXX O
translated XXX O
into XXX O
Urdu XXX O
and XXX O
other XXX O
languages XXX O
for XXX O
the XXX O
benefit XXX O
of XXX O
the XXX O
present XXX O
day XXX O
students XXX O
and XXX O
scholars XXX O
. XXX O

Macroscopic XXX O
researches XXX O
on XXX O
heart XXX O
vascularization XXX O
have XXX O
indicated XXX O
that XXX O
the XXX O
angioarchitecture XXX O
of XXX O
the XXX O
conducting XXX O
system XXX O
differs XXX O
from XXX O
that XXX O
of XXX O
the XXX O
normal XXX O
myocardium XXX O
. XXX O

Key XXX O
areas XXX O
of XXX O
the XXX O
selection XXX O
process XXX O
including XXX O
medical XXX O
and XXX O
surgical XXX O
alternatives XXX O
to XXX O
transplantation XXX O
, XXX O
the XXX O
composition XXX O
of XXX O
the XXX O
transplant XXX O
work-up XXX O
, XXX O
specific XXX O
inclusion XXX O
criteria XXX O
as XXX O
well XXX O
as XXX O
specific XXX O
psychosocial XXX O
factors XXX O
and XXX O
specific XXX O
disease XXX O
etiologies XXX O
and XXX O
co-morbidities XXX O
that XXX O
might XXX O
represent XXX O
contraindications XXX O
were XXX O
extensively XXX O
reviewed XXX O
. XXX O

The XXX O
diagnosis XXX O
of XXX O
HCV XXX O
arthritis XXX O
in XXX O
patients XXX O
with XXX O
positive XXX O
rheumatoid XXX B-GENE
factor XXX I-GENE
and XXX O
chronic XXX O
inflammatory XXX O
polyarthritis XXX O
may XXX O
be XXX O
difficult XXX O
. XXX O

Adapromine XXX O
was XXX O
established XXX O
to XXX O
evoke XXX O
a XXX O
decrease XXX O
of XXX O
the XXX O
amplitude XXX O
of XXX O
the XXX O
dominant XXX O
peak XXX O
and XXX O
dominant XXX O
theta-activity XXX O
in XXX O
power XXX O
spectra XXX O
of XXX O
the XXX O
EEG XXX O
in XXX O
the XXX O
cortex XXX O
and XXX O
hippocamp XXX O
, XXX O
with XXX O
an XXX O
increase XXX O
of XXX O
rapid XXX O
wave XXX O
activity XXX O
in XXX O
the XXX O
beta XXX O
2 XXX O
range XXX O
in XXX O
the XXX O
right XXX O
cortex XXX O
and XXX O
hippocamp XXX O
. XXX O

Although XXX O
no XXX O
statistical XXX O
significance XXX O
was XXX O
achieved XXX O
, XXX O
it XXX O
is XXX O
remarkable XXX O
that XXX O
there XXX O
was XXX O
a XXX O
clear XXX O
trend XXX O
for XXX O
the XXX O
superiority XXX O
of XXX O
Galphimia XXX O
D6 XXX O
while XXX O
the XXX O
Galphimia XXX O
dilution XXX O
10 XXX O
( XXX O
-6 XXX O
) XXX O
was XXX O
about XXX O
equally XXX O
effective XXX O
compared XXX O
with XXX O
placebo XXX O
. XXX O

Definite XXX O
JPsA XXX O
( XXX O
24 XXX O
patients XXX O
) XXX O
was XXX O
defined XXX O
as XXX O
arthritis XXX O
associated XXX O
, XXX O
but XXX O
not XXX O
necessarily XXX O
coincident XXX O
, XXX O
with XXX O
a XXX O
typical XXX O
psoriatic XXX O
rash XXX O
, XXX O
or XXX O
arthritis XXX O
plus XXX O
at XXX O
least XXX O
3 XXX O
of XXX O
4 XXX O
minor XXX O
criteria XXX O
: XXX O
dactylitis XXX O
, XXX O
nail XXX O
pitting XXX O
, XXX O
psoriasis-like XXX O
rash XXX O
, XXX O
or XXX O
family XXX O
history XXX O
of XXX O
psoriasis XXX O
. XXX O

Hprp3p XXX B-GENE
is XXX O
a XXX O
77 XXX O
kDa XXX O
protein XXX O
, XXX O
which XXX O
is XXX O
homologous XXX O
to XXX O
the XXX O
Saccharomyces XXX B-GENE
cerevisiae XXX I-GENE
splicing XXX I-GENE
factor XXX I-GENE
Prp3p XXX I-GENE
. XXX O

PTP-S3 XXX B-GENE
differs XXX O
from XXX O
PTP-S4 XXX B-GENE
in XXX O
having XXX O
a XXX O
deletion XXX O
of XXX O
19 XXX O
amino XXX O
acids XXX O
corresponding XXX O
to XXX O
exon XXX O
E1 XXX O
. XXX O

For XXX O
monocytes XXX O
, XXX O
as XXX O
measured XXX O
on XXX O
the XXX O
Hematrak XXX O
, XXX O
it XXX O
was XXX O
13 XXX O
. XXX O
4% XXX O
. XXX O

Absorption XXX O
varied XXX O
between XXX O
65 XXX O
and XXX O
95 XXX O
per XXX O
cent XXX O
, XXX O
with XXX O
a XXX O
mean XXX O
absorption XXX O
of XXX O
80 XXX O
per XXX O
cent XXX O
, XXX O
in XXX O
both XXX O
pregnant XXX O
and XXX O
non-pregnant XXX O
subjects XXX O
. XXX O

In XXX O
contrast XXX O
, XXX O
extracts XXX O
of XXX O
the XXX O
mutant XXX O
virions XXX O
catalyze XXX O
the XXX O
wild-type XXX O
level XXX O
of XXX O
transcription XXX O
from XXX O
an XXX O
exogenous XXX O
template XXX O
containing XXX O
an XXX O
early XXX O
promoter XXX O
. XXX O

Influence XXX O
of XXX O
diet XXX O
on XXX O
urinary XXX O
VMA XXX O
excretion XXX O
. XXX O

We XXX O
also XXX O
examined XXX O
the XXX O
effect XXX O
of XXX O
proteolytic XXX O
processing XXX O
in XXX O
the XXX O
MVE XXX O
nonstructural XXX O
polyprotein XXX O
segment XXX O
mediated XXX O
by XXX O
the XXX O
viral XXX B-GENE
proteinase XXX I-GENE
NS3 XXX I-GENE
on XXX O
antigen XXX O
processing XXX O
and XXX O
presentation XXX O
of XXX O
the XXX O
MVE XXX O
H-2Kk-restricted XXX O
T XXX O
cell XXX O
determinant XXX O
. XXX O

BACKGROUND XXX O
: XXX O
Hepatic XXX O
encephalopathy XXX O
is XXX O
a XXX O
neuropsychiatric XXX O
syndrome XXX O
associated XXX O
with XXX O
acute XXX O
liver XXX O
failure XXX O
, XXX O
chronic XXX O
parenchymal XXX O
liver XXX O
disease XXX O
or XXX O
portal XXX O
systemic XXX O
anastomosis XXX O
. XXX O

METHODS XXX O
: XXX O
Between XXX O
August XXX O
1991 XXX O
and XXX O
June XXX O
1994 XXX O
, XXX O
198 XXX O
men XXX O
with XXX O
clinical XXX O
T2 XXX O
or XXX O
T3 XXX O
classified XXX O
( XXX O
TNM XXX O
) XXX O
prostate XXX O
carcinoma XXX O
( XXX O
bone XXX O
scan XXX O
negative XXX O
) XXX O
who XXX O
were XXX O
at XXX O
high XXX O
risk XXX O
of XXX O
lymph XXX O
node XXX O
involvement XXX O
underwent XXX O
a XXX O
111In-capromab XXX O
pendetide XXX O
scan XXX O
prior XXX O
to XXX O
staging XXX O
lymphadenectomy XXX O
. XXX O

Organisms XXX O
were XXX O
not XXX O
observed XXX O
in XXX O
the XXX O
5 XXX O
bobcats XXX O
trapped XXX O
in XXX O
2 XXX O
other XXX O
counties XXX O
. XXX O

However XXX O
, XXX O
expression XXX O
of XXX O
sigma XXX B-GENE
3 XXX I-GENE
from XXX O
S4 XXX B-GENE
( XXX O
3'UTR XXX B-GENE
/ XXX I-GENE
S1 XXX I-GENE
) XXX O
, XXX O
which XXX O
included XXX O
the XXX O
PKR XXX B-GENE
activator XXX I-GENE
sequence XXX I-GENE
from XXX O
S1 XXX B-GENE
within XXX O
the XXX O
3'-UTR XXX B-GENE
of XXX I-GENE
S4 XXX I-GENE
, XXX O
was XXX O
comparable XXX O
to XXX O
that XXX O
from XXX O
wild-type XXX B-GENE
S4 XXX I-GENE
. XXX O

Each XXX O
type XXX O
was XXX O
divided XXX O
into XXX O
two XXX O
subgroups XXX O
on XXX O
the XXX O
basis XXX O
of XXX O
whether XXX O
the XXX O
body XXX O
and XXX O
tail XXX O
of XXX O
the XXX O
pancreas XXX O
showed XXX O
intense XXX O
fatty XXX O
replacement XXX O
( XXX O
type XXX O
a XXX O
= XXX O
negative XXX O
for XXX O
intense XXX O
fatty XXX O
replacement XXX O
, XXX O
type XXX O
b XXX O
= XXX O
positive XXX O
for XXX O
intense XXX O
fatty XXX O
replacement XXX O
) XXX O
. XXX O

These XXX O
data XXX O
support XXX O
a XXX O
possible XXX O
biological XXX O
significance XXX O
of XXX O
the XXX O
frameshift XXX O
to XXX O
occur XXX O
at XXX O
this XXX O
position XXX O
of XXX O
the XXX O
large XXX O
overlap XXX O
by XXX O
including XXX O
the XXX O
putative XXX O
RNA XXX O
template-binding XXX O
site XXX O
of XXX O
the XXX O
PLRV XXX B-GENE
replicase XXX I-GENE
in XXX O
the XXX O
ORF2a XXX B-GENE
/ XXX I-GENE
ORF2b XXX I-GENE
transframe XXX I-GENE
protein XXX I-GENE
. XXX O

Hepatitis XXX O
B XXX O
vaccine XXX O
. XXX O

A XXX O
new XXX O
method XXX O
for XXX O
the XXX O
quantitative XXX O
analysis XXX O
of XXX O
sleep XXX O
spindles XXX O
during XXX O
continuous XXX O
overnight XXX O
EEG XXX O
recordings XXX O
. XXX O

The XXX O
cDNA XXX O
of XXX O
cpm7 XXX B-GENE
encodes XXX O
a XXX O
closely XXX O
related XXX O
protein XXX O
of XXX O
36 XXX O
. XXX O
8 XXX O
kDa XXX O
. XXX O

The XXX O
COD XXX O
and XXX O
color XXX O
removals XXX O
were XXX O
both XXX O
more XXX O
than XXX O
90% XXX O
when XXX O
FeCl3 XXX O
was XXX O
used XXX O
as XXX O
the XXX O
coagulation XXX O
( XXX O
dosages XXX O
of XXX O
two-step XXX O
coagulation XXX O
were XXX O
0 XXX O
. XXX O
031 XXX O
and XXX O
0 XXX O
. XXX O
012 XXX O
mol XXX O
/ XXX O
L XXX O
respectively XXX O
) XXX O
after XXX O
a XXX O
ferrous XXX O
hydrogen XXX O
peroxide XXX O
oxidation XXX O
pretreatment XXX O
at XXX O
a XXX O
H2O2 XXX O
dosage XXX O
of XXX O
0 XXX O
. XXX O
06 XXX O
mol XXX O
/ XXX O
L XXX O
. XXX O

Utilizing XXX O
transient XXX O
transfection XXX O
studies XXX O
in XXX O
HepG2 XXX O
cells XXX O
, XXX O
we XXX O
have XXX O
shown XXX O
that XXX O
deletion XXX O
of XXX O
the XXX O
factor XXX B-GENE
VIII XXX I-GENE
promoter XXX I-GENE
sequences XXX I-GENE
distal XXX O
to XXX O
nucleotide XXX O
-44 XXX O
results XXX O
in XXX O
a XXX O
significant XXX O
but XXX O
small XXX O
increase XXX O
in XXX O
promoter XXX O
activity XXX O
. XXX O

Clinical XXX O
findings XXX O
were XXX O
: XXX O
height XXX O
183 XXX O
cm XXX O
, XXX O
weight XXX O
62 XXX O
kg XXX O
, XXX O
increased XXX O
length XXX O
of XXX O
lower XXX O
limbs XXX O
, XXX O
P2-A2 XXX O
pilosity XXX O
and XXX O
micropenis XXX O
. XXX O

Moreover XXX O
, XXX O
a XXX O
recombinant XXX O
Ad XXX O
expressing XXX O
Ad5 XXX B-GENE
E4orf6 XXX I-GENE
/ XXX I-GENE
7 XXX I-GENE
induced XXX O
apoptosis XXX O
in XXX O
rat XXX O
cells XXX O
when XXX O
coinfected XXX O
with XXX O
wild-type XXX O
p53-expressing XXX O
Ad XXX O
. XXX O

Hyperthyroidism XXX O
is XXX O
one XXX O
of XXX O
the XXX O
numerous XXX O
causes XXX O
of XXX O
infertility XXX O
and XXX O
recurrent XXX O
abortion XXX O
. XXX O

An XXX O
extensive XXX O
inverted XXX O
repeat XXX O
is XXX O
present XXX O
3' XXX O
of XXX O
rpeA XXX B-GENE
; XXX O
inverted XXX O
repeats XXX O
are XXX O
found XXX O
downstream XXX O
of XXX O
all XXX O
PE XXX B-GENE
operons XXX I-GENE
sequenced XXX O
to XXX O
date XXX O
, XXX O
although XXX O
the XXX O
sequence XXX O
is XXX O
not XXX O
conserved XXX O
. XXX O

Recent XXX O
studies XXX O
have XXX O
shown XXX O
that XXX O
the XXX O
Src XXX B-GENE
homology-2 XXX I-GENE
( XXX O
SH2 XXX B-GENE
) XXX O
domain-containing XXX O
protein-tyrosine XXX B-GENE
phosphatase XXX I-GENE
, XXX O
SHP-2 XXX B-GENE
, XXX O
associates XXX O
with XXX O
the XXX O
cytoplasmic XXX O
domain XXX O
of XXX O
PECAM-1 XXX B-GENE
as XXX O
it XXX O
becomes XXX O
tyrosine-phosphorylated XXX O
during XXX O
platelet XXX O
aggregation XXX O
: XXX O
a XXX O
process XXX O
that XXX O
can XXX O
be XXX O
mimicked XXX O
in XXX O
part XXX O
by XXX O
small XXX O
synthetic XXX O
phosphopeptides XXX O
corresponding XXX O
to XXX O
the XXX O
cytoplasmic XXX O
domain XXX O
of XXX O
PECAM-1 XXX B-GENE
encompassing XXX O
tyrosine XXX O
residues XXX O
Tyr-663 XXX O
or XXX O
Tyr-686 XXX O
. XXX O

All XXX O
8 XXX O
( XXX O
100% XXX O
) XXX O
patients XXX O
with XXX O
fulminant XXX O
hepatic XXX O
failure XXX O
who XXX O
received XXX O
grafts XXX O
survived XXX O
, XXX O
including XXX O
3 XXX O
who XXX O
received XXX O
ABO-incompatible XXX O
grafts XXX O
, XXX O
though XXX O
2 XXX O
of XXX O
these XXX O
subsequently XXX O
required XXX O
retransplantation XXX O
. XXX O

High XXX O
dosages XXX O
of XXX O
D-penicillamine XXX O
in XXX O
pulmonary XXX O
fibroses XXX O
. XXX O

MAIN XXX O
OUTCOME XXX O
MEASURES XXX O
: XXX O
Percentage XXX O
change XXX O
in XXX O
the XXX O
apnea-hypopnea XXX O
index XXX O
( XXX O
AHI XXX O
; XXX O
apnea XXX O
events XXX O
+ XXX O
hypopnea XXX O
events XXX O
per XXX O
hour XXX O
of XXX O
sleep XXX O
) XXX O
and XXX O
odds XXX O
of XXX O
developing XXX O
moderate-to-severe XXX O
SDB XXX O
( XXX O
defined XXX O
by XXX O
an XXX O
AHI XXX O
> XXX O
or XXX O
= XXX O
15 XXX O
events XXX O
per XXX O
hour XXX O
of XXX O
sleep XXX O
) XXX O
, XXX O
with XXX O
respect XXX O
to XXX O
change XXX O
in XXX O
weight XXX O
. XXX O

The XXX O
paramyxovirus XXX B-GENE
fusion XXX I-GENE
( XXX I-GENE
F XXX I-GENE
) XXX I-GENE
protein XXX I-GENE
mediates XXX O
membrane XXX O
fusion XXX O
. XXX O

Expression XXX O
in XXX O
early XXX O
postnatal XXX O
pituitary XXX O
and XXX O
in XXX O
pre-somatotrophic XXX O
cells XXX O
suggests XXX O
that XXX O
Zn-16 XXX B-GENE
could XXX O
play XXX O
a XXX O
role XXX O
in XXX O
pituitary XXX O
development XXX O
prior XXX O
to XXX O
somatotroph XXX O
differentiation XXX O
. XXX O

The XXX O
repetitive XXX O
ETn XXX B-GENE
( XXX O
early XXX B-GENE
transposon XXX I-GENE
) XXX O
family XXX O
of XXX O
sequences XXX O
represents XXX O
an XXX O
active XXX O
"mobile XXX O
mutagen" XXX O
in XXX O
the XXX O
mouse XXX O
genome XXX O
. XXX O

Ume6p XXX B-GENE
, XXX O
which XXX O
also XXX O
controls XXX O
the XXX O
expression XXX O
of XXX O
early XXX O
meiotic XXX O
genes XXX O
, XXX O
represses XXX O
CAR1 XXX B-GENE
expression XXX O
through XXX O
a XXX O
sequence XXX O
called XXX O
URS XXX B-GENE
, XXX O
as XXX O
a XXX O
function XXX O
of XXX O
nitrogen XXX O
availability XXX O
. XXX O

Slowed XXX O
lysosomal XXX B-GENE
enzyme XXX I-GENE
release XXX O
and XXX O
its XXX O
normalization XXX O
by XXX O
drugs XXX O
in XXX O
adjuvant-induced XXX O
polyarthritis XXX O
. XXX O

The XXX O
pharmacology XXX O
of XXX O
carnitine XXX O
. XXX O

I XXX O
. XXX O

Nitrogen-hydrogen XXX O
tautomerism XXX O
in XXX O
porphyrins XXX O
and XXX O
chlorins XXX O
. XXX O

Interspecific XXX O
mouse XXX O
back-cross XXX O
analysis XXX O
identified XXX O
the XXX O
loci XXX O
for XXX O
mouse XXX B-GENE
3Ost XXX I-GENE
genes XXX I-GENE
and XXX O
syntenic XXX O
assignments XXX O
of XXX O
corresponding XXX O
human XXX O
isologs XXX O
were XXX O
confirmed XXX O
by XXX O
the XXX O
identification XXX O
of XXX O
mapped XXX O
sequence-tagged XXX O
site XXX O
markers XXX O
. XXX O

Two XXX O
closely XXX O
related XXX O
IgH XXX B-GENE
constant XXX B-GENE
region XXX I-GENE
genes XXX I-GENE
, XXX O
CHA XXX B-GENE
and XXX O
CHB XXX B-GENE
, XXX O
have XXX O
been XXX O
sequenced XXX O
completely XXX O
. XXX O

The XXX O
uteroglobin XXX B-GENE
promoter XXX I-GENE
contains XXX O
a XXX O
noncanonical XXX O
estrogen XXX B-GENE
responsive XXX I-GENE
element XXX I-GENE
. XXX O

Fraction XXX O
2 XXX O
contains XXX O
1 XXX O
, XXX O
25 XXX O
( XXX O
OH XXX O
) XXX O
2-vitamin XXX O
D3 XXX O
, XXX O
vitamin XXX O
D3 XXX O
, XXX O
25 XXX O
( XXX O
OH XXX O
) XXX O
-vitamin XXX O
D3 XXX O
and XXX O
1 XXX O
, XXX O
24 XXX O
, XXX O
25 XXX O
( XXX O
OH XXX O
) XXX O
3-vitamin XXX O
D3 XXX O
. XXX O

The XXX O
healing XXX O
rate XXX O
in XXX O
HIV-positive XXX O
patients XXX O
was XXX O
66 XXX O
percent XXX O
after XXX O
14 XXX O
weeks XXX O
and XXX O
100 XXX O
percent XXX O
after XXX O
32 XXX O
weeks XXX O
; XXX O
the XXX O
corresponding XXX O
figures XXX O
for XXX O
patients XXX O
with XXX O
acquired XXX O
immunodeficiency XXX O
syndrome XXX O
were XXX O
0 XXX O
and XXX O
50 XXX O
percent XXX O
. XXX O

Regional XXX O
CBF XXX O
was XXX O
determined XXX O
by XXX O
clearance XXX O
of XXX O
xenon XXX O
133 XXX O
in XXX O
67 XXX O
patients XXX O
undergoing XXX O
coronary XXX O
bypass XXX O
grafting XXX O
procedures XXX O
. XXX O

RVEF XXX O
and XXX O
LVEF XXX O
both XXX O
increased XXX O
by XXX O
about XXX O
14% XXX O
( XXX O
p XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
05 XXX O
and XXX O
p XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
. XXX O

Early XXX O
cirrhosis XXX O
, XXX O
an XXX O
early XXX O
modality XXX O
of XXX O
the XXX O
evolution XXX O
of XXX O
acute XXX O
hepatitis XXX O
. XXX O

Among XXX O
the XXX O
few XXX O
proteins XXX O
of XXX O
the XXX O
eukaryotic XXX O
nucleolus XXX O
that XXX O
have XXX O
been XXX O
characterized XXX O
, XXX O
four XXX O
proteins XXX O
, XXX O
nucleolin XXX B-GENE
, XXX O
fibrillarin XXX B-GENE
, XXX O
SSB1 XXX B-GENE
and XXX O
NSR1 XXX B-GENE
, XXX O
possess XXX O
a XXX O
common XXX O
structural XXX O
motif XXX O
, XXX O
the XXX O
GAR XXX B-GENE
domain XXX I-GENE
, XXX O
which XXX O
is XXX O
rich XXX O
in XXX O
glycine XXX O
and XXX O
arginine XXX O
residues XXX O
. XXX O

Cross XXX O
reactivity XXX O
in XXX O
theophylline XXX O
RIA XXX O
kit XXX O
decreased XXX O
. XXX O

In XXX O
particular XXX O
, XXX O
changes XXX O
in XXX O
intracellular XXX O
Ca2+ XXX O
have XXX O
the XXX O
potential XXX O
to XXX O
either XXX O
inhibit XXX O
or XXX O
augment XXX O
the XXX O
ability XXX O
of XXX O
cAMP XXX O
to XXX O
stimulate XXX O
transcription XXX O
, XXX O
depending XXX O
on XXX O
the XXX O
presence XXX O
of XXX O
specific XXX O
forms XXX O
of XXX O
Ca2+ XXX B-GENE
/ XXX I-GENE
calmodulin-dependent XXX I-GENE
protein XXX I-GENE
kinases XXX I-GENE
. XXX O

In XXX O
contrast XXX O
, XXX O
injection XXX O
of XXX O
a XXX O
plasmid XXX O
encoding XXX O
simian XXX B-GENE
virus XXX I-GENE
40 XXX I-GENE
small XXX I-GENE
t XXX I-GENE
antigen XXX I-GENE
, XXX O
which XXX O
interacts XXX O
with XXX O
PP2A XXX B-GENE
to XXX O
inhibit XXX O
its XXX O
activity XXX O
towards XXX O
several XXX O
phosphoprotein XXX O
substrates XXX O
, XXX O
had XXX O
no XXX O
effect XXX O
on XXX O
the XXX O
phosphorylation XXX O
state XXX O
of XXX O
CREB XXX B-GENE
in XXX O
stimulated XXX O
or XXX O
unstimulated XXX O
NIH XXX O
3T3 XXX O
cells XXX O
. XXX O

Eight XXX O
hours XXX O
after XXX O
the XXX O
administration XXX O
of XXX O
colchicine XXX O
, XXX O
the XXX O
serum XXX B-GENE
ceruloplasmin XXX I-GENE
level XXX O
began XXX O
to XXX O
rise XXX O
again XXX O
in XXX O
female XXX O
rats XXX O
, XXX O
but XXX O
not XXX O
in XXX O
male XXX O
rats XXX O
. XXX O

Primary XXX O
amenorrhoea XXX O
in XXX O
a XXX O
phenotypically XXX O
female XXX O
individual XXX O
with XXX O
a XXX O
karyotype XXX O
46 XXX O
, XXX O
xy XXX O
and XXX O
bilateral XXX O
gonadoblastoma XXX O
. XXX O

Vimentin XXX B-GENE
positivity XXX O
was XXX O
noted XXX O
in XXX O
the XXX O
undifferentiated XXX O
and XXX O
fibroblastic XXX O
components XXX O
. XXX O

This XXX O
fraction XXX O
is XXX O
resistant XXX O
to XXX O
digestions XXX O
by XXX O
DNase XXX B-GENE
I XXX I-GENE
and XXX O
RNase XXX B-GENE
T1 XXX I-GENE
and XXX O
disappears XXX O
completely XXX O
upon XXX O
alkali XXX O
hydrolysis XXX O
. XXX O

SCID XXX O
V XXX B-GENE
( XXX I-GENE
D XXX I-GENE
) XXX I-GENE
J XXX I-GENE
recombination XXX O
can XXX O
be XXX O
partly XXX O
rescued XXX O
in XXX O
T-lymphocytes XXX O
by XXX O
either XXX O
DNA-damaging XXX O
agents XXX O
( XXX O
gamma-irradiation XXX O
and XXX O
bieomycin XXX O
) XXX O
or XXX O
a XXX O
null XXX O
mutation XXX O
of XXX O
the XXX O
p53 XXX B-GENE
gene XXX I-GENE
, XXX O
possibly XXX O
because XXX O
of XXX O
transiently XXX O
elevated XXX O
DNA XXX O
repair XXX O
activity XXX O
in XXX O
response XXX O
to XXX O
DNA XXX O
damage XXX O
or XXX O
to XXX O
delayed XXX O
apoptosis XXX O
in XXX O
the XXX O
absence XXX O
of XXX O
p53 XXX B-GENE
. XXX O

Thus XXX O
, XXX O
Fis XXX B-GENE
acts XXX O
as XXX O
an XXX O
accessory XXX O
transcriptional XXX O
activator XXX O
at XXX O
the XXX O
mar XXX B-GENE
promoter XXX I-GENE
. XXX O

A XXX O
larval XXX B-GENE
albumin-like XXX I-GENE
protein XXX I-GENE
was XXX O
not XXX O
detectable XXX O
by XXX O
silver XXX O
staining XXX O
in XXX O
serum XXX O
of XXX O
tadpoles XXX O
before XXX O
the XXX O
beginning XXX O
of XXX O
metamorphosis XXX O
at XXX O
stage XXX O
48 XXX O
. XXX O

All XXX O
these XXX O
processes XXX O
were XXX O
fully XXX O
developed XXX O
during XXX O
the XXX O
last XXX O
month XXX O
of XXX O
pregnancy XXX O
, XXX O
offering XXX O
the XXX O
same XXX O
picture XXX O
as XXX O
the XXX O
controls XXX O
. XXX O

It XXX O
has XXX O
been XXX O
previously XXX O
shown XXX O
that XXX O
genes XXX O
transcribed XXX O
by XXX O
RNA XXX B-GENE
polymerase XXX I-GENE
II XXX I-GENE
( XXX O
RNAP XXX B-GENE
II XXX I-GENE
) XXX O
are XXX O
subject XXX O
to XXX O
position XXX O
effect XXX O
variegation XXX O
when XXX O
located XXX O
near XXX O
yeast XXX O
telomeres XXX O
. XXX O

Alignment XXX O
of XXX O
different XXX O
cDNAs XXX O
of XXX O
the XXX O
NR5A2 XXX B-GENE
( XXX O
hB1F XXX B-GENE
) XXX O
gene XXX O
with XXX O
the XXX O
genomic XXX O
sequence XXX O
facilitated XXX O
the XXX O
delineation XXX O
of XXX O
its XXX O
structural XXX O
organization XXX O
, XXX O
which XXX O
spans XXX O
over XXX O
150 XXX O
kb XXX O
and XXX O
consists XXX O
of XXX O
eight XXX O
exons XXX O
interrupted XXX O
by XXX O
seven XXX O
introns XXX O
. XXX O

Conventionally XXX O
, XXX O
four XXX O
nominal XXX O
allotypic XXX O
variants XXX O
, XXX O
b4 XXX B-GENE
, XXX O
b5 XXX B-GENE
, XXX O
b6 XXX B-GENE
and XXX O
b9 XXX B-GENE
have XXX O
been XXX O
shown XXX O
to XXX O
be XXX O
co-dominantly XXX O
expressed XXX O
at XXX O
the XXX O
Ckappa1 XXX B-GENE
gene XXX I-GENE
locus XXX I-GENE
. XXX O

Genetic XXX O
interactions XXX O
between XXX O
BCK2 XXX B-GENE
and XXX O
other XXX O
pathway XXX O
components XXX O
suggested XXX O
that XXX O
BCK2 XXX B-GENE
functions XXX O
on XXX O
a XXX O
common XXX O
pathway XXX O
branch XXX O
with XXX O
PPZ1 XXX B-GENE
and XXX O
PPZ2 XXX B-GENE
. XXX O

Trial XXX O
3 XXX O
broiler XXX O
chickens XXX O
were XXX O
maintained XXX O
on XXX O
control XXX O
feed XXX O
until XXX O
they XXX O
reached XXX O
3 XXX O
weeks XXX O
of XXX O
age XXX O
at XXX O
which XXX O
time XXX O
they XXX O
were XXX O
taken XXX O
off XXX O
of XXX O
feed XXX O
for XXX O
2 XXX O
. XXX O
5 XXX O
hr XXX O
and XXX O
then XXX O
placed XXX O
on XXX O
either XXX O
control XXX O
feed XXX O
or XXX O
feed XXX O
containing XXX O
4 XXX O
. XXX O
0 XXX O
ppm XXX O
ochratoxin XXX O
A XXX O
, XXX O
and XXX O
heart XXX O
rate XXX O
and XXX O
blood XXX O
pressure XXX O
were XXX O
measured XXX O
every XXX O
half XXX O
hour XXX O
through XXX O
7 XXX O
hr XXX O
. XXX O

We XXX O
also XXX O
provide XXX O
evidence XXX O
that XXX O
neither XXX O
the XXX O
lambda XXX B-GENE
O XXX I-GENE
and XXX O
P XXX B-GENE
initiators XXX I-GENE
nor XXX O
the XXX O
E XXX B-GENE
. XXX I-GENE
coli XXX I-GENE
DnaJ XXX I-GENE
and XXX O
DnaK XXX B-GENE
heat XXX B-GENE
shock XXX I-GENE
proteins XXX I-GENE
play XXX O
a XXX O
direct XXX O
role XXX O
in XXX O
the XXX O
propagation XXX O
of XXX O
lambda XXX O
replication XXX O
forks XXX O
in XXX O
vitro XXX O
. XXX O

Limited XXX O
role XXX O
for XXX O
PCR-based XXX O
diagnosis XXX O
of XXX O
Whipple's XXX O
disease XXX O
from XXX O
peripheral XXX O
blood XXX O
mononuclear XXX O
cells XXX O
. XXX O

Neuro-otological XXX O
examinations XXX O
revealed XXX O
spontaneous XXX O
downbeat XXX O
nystagmus XXX O
, XXX O
bilateral XXX O
gaze XXX O
nystagmus XXX O
and XXX O
rebound XXX O
nystagmus XXX O
. XXX O

Study XXX O
of XXX O
the XXX O
physico-chemical XXX O
state XXX O
of XXX O
plutonium-239 XXX O
in XXX O
a XXX O
citrate XXX O
solution-blood XXX O
system XXX O
. XXX O

Insertion XXX O
of XXX O
short XXX O
oligonucleotides XXX O
encoding XXX O
the XXX O
basic XXX O
amino XXX O
acid XXX O
motifs XXX O
726-GRKRKSP-732 XXX B-GENE
from XXX O
IE175 XXX B-GENE
and XXX O
500-VRPRKRR-506 XXX B-GENE
from XXX O
IE110 XXX B-GENE
into XXX O
deleted XXX O
cytoplasmic XXX O
forms XXX O
of XXX O
the XXX O
two XXX O
proteins XXX O
restored XXX O
the XXX O
karyophilic XXX O
phenotype XXX O
and XXX O
confirmed XXX O
that XXX O
these XXX O
motifs XXX O
are XXX O
both XXX O
necessary XXX O
and XXX O
sufficient XXX O
for XXX O
proper XXX O
nuclear XXX O
localization XXX O
. XXX O

This XXX O
negative XXX O
element XXX O
may XXX O
, XXX O
at XXX O
least XXX O
in XXX O
part XXX O
, XXX O
be XXX O
responsible XXX O
for XXX O
the XXX O
cell XXX O
type-specific XXX O
expression XXX O
of XXX O
the XXX O
DGK XXX B-GENE
gene XXX I-GENE
. XXX O

A XXX O
case XXX O
of XXX O
anterior XXX O
cleavage XXX O
syndrome XXX O
in XXX O
a XXX O
27-year-old XXX O
female XXX O
patient XXX O
is XXX O
described XXX O
. XXX O

Responses XXX O
of XXX O
single-unit XXX O
carotid XXX O
body XXX O
chemoreceptors XXX O
in XXX O
adult XXX O
rats XXX O
. XXX O

Mutations XXX O
that XXX O
alter XXX O
photoreceptor XXX O
cell XXX O
structure XXX O
and XXX O
development XXX O
were XXX O
isolated XXX O
that XXX O
fail XXX O
to XXX O
complement XXX O
these XXX O
deletions XXX O
. XXX O

In XXX O
that XXX O
case XXX O
, XXX O
the XXX O
ratio XXX O
of XXX O
brush XXX O
abrasion XXX O
was XXX O
0 XXX O
. XXX O
268 XXX O
, XXX O
compressive XXX O
and XXX O
transverse XXX O
strength XXX O
, XXX O
124 XXX O
. XXX O
3 XXX O
and XXX O
86 XXX O
. XXX O
3 XXX O
MPa XXX O
respectively XXX O
, XXX O
hardness XXX O
, XXX O
43 XXX O
. XXX O
2 XXX O
Hk XXX O
, XXX O
water XXX O
absorption XXX O
14 XXX O
. XXX O
2 XXX O
micrograms XXX O
/ XXX O
mm3 XXX O
and XXX O
thermal XXX O
expansion XXX O
coefficient XXX O
, XXX O
47 XXX O
. XXX O
4 XXX O
x XXX O
10 XXX O
( XXX O
-6 XXX O
) XXX O
/ XXX O
degrees XXX O
C XXX O
. XXX O

A XXX O
proportion XXX O
of XXX O
APC XXX B-GENE
wild-type XXX O
colon XXX O
carcinomas XXX O
and XXX O
melanomas XXX O
also XXX O
contains XXX O
constitutive XXX O
nuclear XXX B-GENE
Tcf-4 XXX I-GENE
/ XXX I-GENE
beta-catenin XXX I-GENE
complexes XXX I-GENE
as XXX O
a XXX O
result XXX O
of XXX O
dominant XXX O
mutations XXX O
in XXX O
the XXX O
N XXX O
terminus XXX O
of XXX O
beta-catenin XXX B-GENE
that XXX O
render XXX O
it XXX O
insensitive XXX O
to XXX O
downregulation XXX O
by XXX O
APC XXX B-GENE
, XXX O
GSK3 XXX B-GENE
beta XXX I-GENE
, XXX O
and XXX O
Axin XXX B-GENE
/ XXX I-GENE
Conductin XXX I-GENE
. XXX O

Hydrogels XXX O
for XXX O
tissue XXX O
engineering XXX O
. XXX O

Here XXX O
, XXX O
we XXX O
demonstrate XXX O
that XXX O
kinase-dead XXX O
but XXX O
not XXX O
wild-type XXX O
forms XXX O
of XXX O
Fyn XXX B-GENE
, XXX O
Lck XXX B-GENE
, XXX O
and XXX O
ZAP-70 XXX B-GENE
block XXX O
70Z XXX O
Cbl-mediated XXX O
NFAT XXX B-GENE
activation XXX O
. XXX O

In XXX O
a XXX O
country XXX O
where XXX O
general XXX O
HIV XXX O
prevalence XXX O
is XXX O
low XXX O
, XXX O
the XXX O
strategy XXX O
is XXX O
cost-effective XXX O
for XXX O
location XXX O
and XXX O
counselling XXX O
of XXX O
unknowingly XXX O
seropositive XXX O
individuals XXX O
. XXX O

CONCLUSIONS XXX O
: XXX O
Serum XXX O
levels XXX O
of XXX O
S-100beta XXX B-GENE
are XXX O
reliable XXX O
markers XXX O
for XXX O
adverse XXX O
neurologic XXX O
outcomes XXX O
after XXX O
cardiac XXX O
surgery XXX O
. XXX O

If XXX O
, XXX O
however XXX O
, XXX O
the XXX O
mean XXX O
temperature XXX O
rise XXX O
was XXX O
higher XXX O
( XXX O
0 XXX O
. XXX O
57 XXX O
degrees XXX O
C XXX O
or XXX O
0 XXX O
. XXX O
69 XXX O
degrees XXX O
C XXX O
) XXX O
, XXX O
such XXX O
a XXX O
selection XXX O
practically XXX O
resulted XXX O
in XXX O
the XXX O
disappearance XXX O
of XXX O
'passable' XXX O
qualifications XXX O
in XXX O
the XXX O
triplet XXX O
groups XXX O
and XXX O
a XXX O
great XXX O
predominance XXX O
of XXX O
'to XXX O
be XXX O
rejected' XXX O
qualifications XXX O
in XXX O
the XXX O
large XXX O
groups XXX O
. XXX O

These XXX O
regions XXX O
overlap XXX O
with XXX O
the XXX O
HIT XXX B-GENE
protein XXX I-GENE
similarity XXX I-GENE
regions XXX I-GENE
. XXX O

This XXX O
alternatively XXX O
spliced XXX O
transcript XXX O
contained XXX O
an XXX O
open XXX O
reading XXX O
frame XXX O
extending XXX O
from XXX O
the XXX O
upstream XXX O
J XXX B-GENE
alpha XXX I-GENE
11-2 XXX I-GENE
region XXX I-GENE
to XXX O
82 XXX O
nucleotides XXX O
downstream XXX O
of XXX O
the XXX O
beginning XXX O
of XXX O
the XXX O
TCR XXX B-GENE
C XXX I-GENE
alpha XXX I-GENE
region XXX I-GENE
, XXX O
and XXX O
potentially XXX O
encoded XXX O
a XXX O
36 XXX O
amino XXX O
acid XXX O
polypeptide XXX O
. XXX O

Critical XXX O
evaluation XXX O
of XXX O
various XXX O
methods XXX O
of XXX O
determining XXX O
markers XXX O
of XXX O
fetal XXX O
maturity XXX O
in XXX O
amniotic XXX O
fluid XXX O
. XXX O

This XXX O
review XXX O
summarizes XXX O
the XXX O
clinical XXX O
evidence XXX O
to XXX O
support XXX O
current XXX O
therapies XXX O
in XXX O
irritable XXX O
bowel XXX O
syndrome XXX O
( XXX O
IBS XXX O
) XXX O
. XXX O

The XXX O
technical XXX O
construction XXX O
of XXX O
the XXX O
mouth XXX O
protectors XXX O
is XXX O
illustrated XXX O
, XXX O
as XXX O
is XXX O
the XXX O
need XXX O
for XXX O
instrumentation XXX O
and XXX O
its XXX O
costs XXX O
and XXX O
the XXX O
materials XXX O
required XXX O
to XXX O
manufacture XXX O
these XXX O
mouth XXX O
protectors XXX O
. XXX O

The XXX O
same XXX O
ligands XXX O
also XXX O
exhibit XXX O
a XXX O
similar XXX O
inhibitory XXX O
effect XXX O
on XXX O
PDGF-BB-dependent XXX O
[ XXX O
3H XXX O
] XXX O
thymidine XXX O
incorporation XXX O
in XXX O
PAE XXX O
cells XXX O
expressing XXX O
the XXX O
PDGF XXX B-GENE
beta-receptors XXX I-GENE
. XXX O

In XXX O
epithelial XXX O
cells XXX O
, XXX O
the XXX O
PH XXX B-GENE
domain XXX I-GENE
of XXX O
Akt XXX B-GENE
/ XXX I-GENE
PKB XXX I-GENE
localised XXX O
to XXX O
sites XXX O
of XXX O
cell-cell XXX O
and XXX O
cell-matrix XXX O
contact XXX O
, XXX O
distinct XXX O
from XXX O
focal XXX O
contacts XXX O
, XXX O
even XXX O
in XXX O
the XXX O
absence XXX O
of XXX O
serum XXX O
. XXX O

The XXX O
plant XXX O
hormone XXX O
auxin XXX O
transcriptionally XXX O
activates XXX O
early XXX O
genes XXX O
. XXX O

Oxygen XXX O
delivery XXX O
and XXX O
base XXX O
excess XXX O
decreased XXX O
significantly XXX O
and XXX O
four XXX O
pigs XXX O
died XXX O
. XXX O

The XXX O
P69 XXX O
cell XXX O
line XXX O
was XXX O
derived XXX O
by XXX O
immortalization XXX O
of XXX O
human XXX O
primary XXX O
prostate XXX O
epithelial XXX O
cells XXX O
with XXX O
simian XXX B-GENE
virus-40 XXX I-GENE
T XXX I-GENE
antigen XXX I-GENE
and XXX O
is XXX O
rarely XXX O
tumorigenic XXX O
. XXX O

It XXX O
was XXX O
also XXX O
found XXX O
that XXX O
there XXX O
is XXX O
no XXX O
significant XXX O
difference XXX O
between XXX O
the XXX O
prevalence XXX O
of XXX O
nasal XXX O
carriage XXX O
of XXX O
S XXX O
. XXX O
aureus XXX O
amongst XXX O
the XXX O
hospital XXX O
staff XXX O
and XXX O
the XXX O
patients XXX O
. XXX O

Quantitative XXX O
analysis XXX O
of XXX O
plasmid XXX O
loss XXX O
rates XXX O
in XXX O
cdc28-1N XXX B-GENE
strains XXX O
carrying XXX O
plasmids XXX O
with XXX O
multiple XXX O
replication XXX O
origins XXX O
suggests XXX O
that XXX O
a XXX O
defect XXX O
in XXX O
initiating XXX O
DNA XXX O
replication XXX O
probably XXX O
causes XXX O
this XXX O
plasmid XXX O
loss XXX O
phenotype XXX O
. XXX O

The XXX O
application XXX O
of XXX O
ISH XXX O
and XXX O
IHC XXX O
did XXX O
not XXX O
change XXX O
significantly XXX O
the XXX O
routine XXX O
histologic XXX O
classification XXX O
of XXX O
pneumonias XXX O
into XXX O
CMV-IP XXX O
and XXX O
IIP XXX O
. XXX O

The XXX O
most XXX O
common XXX O
types XXX O
of XXX O
malformations XXX O
were XXX O
eye XXX O
defects XXX O
and XXX O
open XXX O
coeloms XXX O
. XXX O

Our XXX O
findings XXX O
further XXX O
our XXX O
understanding XXX O
of XXX O
how XXX O
ZBP-89 XXX B-GENE
modulates XXX O
cell XXX O
proliferation XXX O
and XXX O
reveals XXX O
a XXX O
novel XXX O
mechanism XXX O
by XXX O
which XXX O
the XXX O
p53 XXX B-GENE
protein XXX I-GENE
is XXX O
stabilized XXX O
. XXX O

This XXX O
study XXX O
investigated XXX O
whether XXX O
boron XXX O
would XXX O
enhance XXX O
the XXX O
ability XXX O
of XXX O
17beta-estradiol XXX O
( XXX O
E2 XXX O
) XXX O
or XXX O
parathyroid XXX B-GENE
hormone XXX I-GENE
( XXX O
PTH XXX B-GENE
) XXX O
to XXX O
improve XXX O
bone XXX O
quality XXX O
in XXX O
ovariectomized XXX O
OVX XXX O
rats XXX O
. XXX O

The XXX O
absorbed XXX O
dose XXX O
was XXX O
measured XXX O
by XXX O
combination XXX O
of XXX O
two XXX O
integrating XXX O
detectors XXX O
: XXX O
thermo- XXX O
luminescent XXX O
dosemeter XXX O
of XXX O
Mg2SiO4 XXX O
: XXX O
Tb XXX O
( XXX O
TDMS XXX O
) XXX O
and XXX O
plastic XXX O
nuclear XXX O
track XXX O
detector XXX O
( XXX O
PNTD XXX O
) XXX O
. XXX O

Weight XXX O
and XXX O
height XXX O
z-scores XXX O
were XXX O
significantly XXX O
associated XXX O
with XXX O
BMD XXX O
z-scores XXX O
. XXX O

DDP1 XXX B-GENE
also XXX O
localizes XXX O
to XXX O
heterochromatin XXX O
in XXX O
interphase XXX O
nuclei XXX O
of XXX O
larval XXX O
neuroblasts XXX O
. XXX O

Moreover XXX O
, XXX O
in XXX O
transient XXX O
transfection XXX O
assays XXX O
, XXX O
PU XXX B-GENE
. XXX I-GENE
1 XXX I-GENE
alone XXX O
activated XXX O
reporter XXX O
constructs XXX O
containing XXX O
the XXX O
JB XXX B-GENE
cis-element XXX I-GENE
, XXX O
and XXX O
the XXX O
activation XXX O
was XXX O
shown XXX O
to XXX O
be XXX O
dependent XXX O
on XXX O
a XXX O
glutamine-rich XXX O
sequence XXX O
in XXX O
the XXX O
amino-terminal XXX O
portion XXX O
of XXX O
PU XXX B-GENE
. XXX I-GENE
1 XXX I-GENE
. XXX O

It XXX O
is XXX O
reported XXX O
that XXX O
, XXX O
at XXX O
present XXX O
, XXX O
most XXX O
of XXX O
the XXX O
MRSAs XXX O
spreading XXX O
in XXX O
Japan XXX O
are XXX O
acceleratedly XXX O
acquiring XXX O
resistance XXX O
to XXX O
many XXX O
drugs XXX O
, XXX O
and XXX O
especially XXX O
, XXX O
they XXX O
are XXX O
developing XXX O
high XXX O
resistance XXX O
against XXX O
beta-lactams XXX O
. XXX O

The XXX O
mean XXX O
day XXX O
of XXX O
diagnosis XXX O
of XXX O
periventricular XXX O
echodensities XXX O
was XXX O
3 XXX O
+ XXX O
/ XXX O
- XXX O
2 XXX O
days XXX O
( XXX O
range XXX O
1-11 XXX O
days XXX O
) XXX O
, XXX O
and XXX O
of XXX O
cystic XXX O
PVL XXX O
21 XXX O
+ XXX O
/ XXX O
- XXX O
8 XXX O
days XXX O
( XXX O
range XXX O
2-47 XXX O
days XXX O
) XXX O
. XXX O

The XXX O
integrity XXX O
of XXX O
the XXX O
cDNA XXX O
sequence XXX O
was XXX O
confirmed XXX O
by XXX O
analysis XXX O
of XXX O
several XXX O
overlapping XXX O
genomic XXX O
clones XXX O
that XXX O
span XXX O
the XXX O
GAR1 XXX B-GENE
gene XXX I-GENE
. XXX O

In XXX O
one XXX O
patient XXX O
with XXX O
severe XXX O
diarrhea XXX O
the XXX O
estriol XXX O
concentration XXX O
in XXX O
serum XXX O
was XXX O
low XXX O
until XXX O
the XXX O
intestinal XXX O
function XXX O
normalised XXX O
and XXX O
the XXX O
estriol XXX O
concentration XXX O
went XXX O
up XXX O
exactly XXX O
when XXX O
the XXX O
diarrhea XXX O
stopped XXX O
. XXX O

We XXX O
conclude XXX O
that XXX O
c-Myb XXX B-GENE
regulates XXX O
the XXX O
RAG-2 XXX B-GENE
promoter XXX I-GENE
in XXX O
T XXX O
cells XXX O
by XXX O
binding XXX O
to XXX O
this XXX O
consensus XXX B-GENE
c-Myb XXX I-GENE
binding XXX I-GENE
site XXX I-GENE
. XXX O

The XXX O
deduced XXX O
amino XXX O
acid XXX O
sequence XXX O
of XXX O
CBP90 XXX B-GENE
had XXX O
no XXX O
significant XXX O
similarity XXX O
to XXX O
any XXX O
other XXX O
protein XXX O
, XXX O
but XXX O
it XXX O
had XXX O
a XXX O
proline-rich XXX O
domain XXX O
at XXX O
the XXX O
C-terminal XXX O
region XXX O
. XXX O

The XXX O
structural XXX O
gene XXX O
for XXX O
hydrogenase XXX B-GENE
encodes XXX O
a XXX O
protein XXX O
product XXX O
of XXX O
molecular XXX O
mass XXX O
45820 XXX O
Da XXX O
. XXX O

Children XXX O
born XXX O
from XXX O
chronic XXX O
alcoholic XXX O
mothers XXX O
have XXX O
shown XXX O
behavioral XXX O
teratogenic XXX O
effects XXX O
more XXX O
frequently XXX O
than XXX O
morphological XXX O
malformations XXX O
. XXX O

CONCLUSIONS XXX O
: XXX O
These XXX O
results XXX O
show XXX O
that XXX O
once XXX O
daily XXX O
oral XXX O
valganciclovir XXX O
can XXX O
produce XXX O
exposures XXX O
of XXX O
ganciclovir XXX O
( XXX O
AUC24 XXX O
) XXX O
exceeding XXX O
those XXX O
attained XXX O
using XXX O
intravenous XXX O
ganciclovir XXX O
10 XXX O
mg XXX O
/ XXX O
kg XXX O
. XXX O

Copyright XXX O
2000 XXX O
The XXX O
Royal XXX O
College XXX O
of XXX O
Radiologists XXX O
. XXX O

A XXX O
rise XXX O
of XXX O
hemoglobin XXX B-GENE
concentration XXX O
accompanied XXX O
by XXX O
an XXX O
increase XXX O
of XXX O
the XXX O
total XXX O
iron XXX O
in XXX O
the XXX O
blood XXX O
serum XXX O
of XXX O
white XXX O
mice XXX O
was XXX O
found XXX O
under XXX O
oxygen XXX O
pressure XXX O
of XXX O
4 XXX O
atm XXX O
for XXX O
an XXX O
hour XXX O
( XXX O
preconvulsive XXX O
state XXX O
) XXX O
and XXX O
6 XXX O
atm XXX O
( XXX O
convulsive XXX O
state XXX O
) XXX O
. XXX O

Antithrombin XXX B-GENE
III XXX I-GENE
prevents XXX O
60 XXX O
min XXX O
warm XXX O
intestinal XXX O
ischemia XXX O
reperfusion XXX O
injury XXX O
in XXX O
rats XXX O
. XXX O

This XXX O
regulation XXX O
requires XXX O
two XXX O
HMG-box XXX B-GENE
proteins XXX I-GENE
: XXX O
the XXX O
ubiquitous XXX O
Ste11 XXX B-GENE
transcription XXX I-GENE
factor XXX I-GENE
and XXX O
the XXX O
M XXX O
cell-controlling XXX O
protein XXX O
Mat1-Mc XXX B-GENE
. XXX O

Two XXX O
related XXX O
studies XXX O
conducted XXX O
over XXX O
a XXX O
five XXX O
week XXX O
period XXX O
measured XXX O
and XXX O
typed XXX O
HLA-DQA1 XXX B-GENE
from XXX O
accumulated XXX O
DNA XXX O
on XXX O
autopsy XXX O
room XXX O
and XXX O
Forensic XXX O
DNA XXX O
Laboratory XXX O
structures XXX O
. XXX O

In XXX O
the XXX O
p51 XXX B-GENE
subunit XXX I-GENE
, XXX O
the XXX O
Cys181 XXX O
side-chain XXX O
is XXX O
oriented XXX O
in XXX O
a XXX O
similar XXX O
direction XXX O
to XXX O
the XXX O
Tyr181 XXX O
side-chain XXX O
in XXX O
the XXX O
wild-type XXX O
complex XXX O
. XXX O

The XXX O
pyrR XXX B-GENE
and XXX O
pyrP XXX B-GENE
genes XXX I-GENE
encoded XXX O
polypeptides XXX O
with XXX O
calculated XXX O
molecular XXX O
masses XXX O
of XXX O
19 XXX O
. XXX O
9 XXX O
and XXX O
45 XXX O
. XXX O
2 XXX O
kDa XXX O
, XXX O
respectively XXX O
. XXX O

In XXX O
contrast XXX O
, XXX O
the XXX O
insulin XXX B-GENE
response XXX O
had XXX O
returned XXX O
to XXX O
the XXX O
non-pregnant XXX O
value XXX O
by XXX O
the XXX O
second XXX O
day XXX O
of XXX O
the XXX O
puerperium XXX O
. XXX O

Therapy XXX O
with XXX O
dietary XXX O
modification XXX O
and XXX O
triglyceride XXX O
lowering XXX O
drugs XXX O
resulted XXX O
in XXX O
resolution XXX O
of XXX O
symptoms XXX O
and XXX O
parotid XXX O
swelling XXX O
in XXX O
one XXX O
patient XXX O
. XXX O

Further XXX O
outbreaks XXX O
of XXX O
ocular XXX O
disease XXX O
in XXX O
farmed XXX O
red XXX O
deer XXX O
calves XXX O
caused XXX O
by XXX O
HVC-1 XXX O
were XXX O
investigated XXX O
. XXX O

Expression XXX O
of XXX O
a XXX O
novel XXX O
murine XXX B-GENE
phospholipase XXX I-GENE
D XXX I-GENE
homolog XXX I-GENE
coincides XXX O
with XXX O
late XXX O
neuronal XXX O
development XXX O
in XXX O
the XXX O
forebrain XXX O
. XXX O

These XXX O
results XXX O
suggest XXX O
that XXX O
VP1 XXX B-GENE
was XXX O
efficiently XXX O
transported XXX O
to XXX O
the XXX O
nucleus XXX O
and XXX O
localized XXX O
in XXX O
the XXX O
discrete XXX O
subnuclear XXX O
regions XXX O
, XXX O
possibly XXX O
with XXX O
VP2 XXX B-GENE
and XXX O
VP3 XXX B-GENE
. XXX O

Moreover XXX O
, XXX O
following XXX O
a XXX O
single XXX O
intravenous XXX O
injection XXX O
of XXX O
the XXX O
bicistronic XXX O
vector XXX O
complexed XXX O
to XXX O
cationic XXX O
liposomes XXX O
into XXX O
recipient XXX O
mice XXX O
, XXX O
delivery XXX O
of XXX O
MDR1 XXX B-GENE
and XXX O
GC XXX B-GENE
cDNAs XXX I-GENE
was XXX O
achieved XXX O
in XXX O
all XXX O
the XXX O
organs XXX O
we XXX O
tested XXX O
. XXX O

To XXX O
avoid XXX O
misinterpretations XXX O
, XXX O
special XXX O
reference XXX O
values XXX O
should XXX O
be XXX O
applied XXX O
for XXX O
preadolescents XXX O
, XXX O
at XXX O
least XXX O
with XXX O
regard XXX O
to XXX O
FVC XXX O
and XXX O
FEV1 XXX O
. XXX O

Utilization XXX O
of XXX O
alternative XXX O
polyadenylation XXX O
signals XXX O
was XXX O
previously XXX O
shown XXX O
to XXX O
generate XXX O
two XXX O
sialophorin XXX B-GENE
mRNAs XXX I-GENE
of XXX I-GENE
1 XXX I-GENE
. XXX I-GENE
9 XXX I-GENE
and XXX I-GENE
4 XXX I-GENE
. XXX I-GENE
3 XXX I-GENE
kb XXX I-GENE
, XXX O
which XXX O
differ XXX O
in XXX O
the XXX O
length XXX O
of XXX O
their XXX O
3' XXX O
untranslated XXX O
regions XXX O
. XXX O

Moreover XXX O
, XXX O
we XXX O
observed XXX O
that XXX O
the XXX O
function XXX O
of XXX O
T3R-RXR XXX B-GENE
heterodimers XXX I-GENE
on XXX O
response XXX O
elements XXX O
composed XXX O
of XXX O
two XXX O
half-sites XXX O
in XXX O
a XXX O
directly XXX O
repeated XXX O
orientation XXX O
spaced XXX O
by XXX O
4 XXX O
nucleotides XXX O
is XXX O
determined XXX O
in XXX O
major XXX O
parts XXX O
by XXX O
the XXX O
5'-flanking XXX O
sequence XXX O
of XXX O
the XXX O
upstream XXX O
half-site XXX O
. XXX O

Magnetotherapy XXX O
of XXX O
hepatitis XXX O
A XXX O
and XXX O
B XXX O
in XXX O
children XXX O
. XXX O

Point XXX O
mutations XXX O
of XXX O
the XXX O
five XXX O
tyrosine XXX O
residues XXX O
in XXX O
the XXX O
cytoplasmic XXX O
domain XXX O
of XXX O
the XXX O
receptor XXX O
were XXX O
subsequently XXX O
used XXX O
to XXX O
confirm XXX O
our XXX O
conclusions XXX O
. XXX O

Volume XXX O
of XXX O
distribution XXX O
of XXX O
total XXX O
DMDZ XXX O
( XXX O
range XXX O
, XXX O
1 XXX O
. XXX O
33 XXX O
to XXX O
6 XXX O
. XXX O
30 XXX O
l XXX O
/ XXX O
kg XXX O
) XXX O
and XXX O
of XXX O
unbound XXX O
DMDZ XXX O
after XXX O
correction XXX O
for XXX O
protein XXX O
binding XXX O
( XXX O
range XXX O
, XXX O
43 XXX O
to XXX O
243 XXX O
l XXX O
/ XXX O
kg XXX O
) XXX O
was XXX O
larger XXX O
in XXX O
women XXX O
than XXX O
in XXX O
men XXX O
of XXX O
all XXX O
ages XXX O
, XXX O
and XXX O
in XXX O
the XXX O
elderly XXX O
as XXX O
opposed XXX O
to XXX O
the XXX O
young XXX O
. XXX O

Finally XXX O
, XXX O
a XXX O
chromogenic XXX O
method XXX O
was XXX O
used XXX O
, XXX O
based XXX O
on XXX O
thrombin XXX B-GENE
inhibition XXX O
and XXX O
the XXX O
substrate XXX O
S-2238 XXX O
. XXX O

It XXX O
is XXX O
now XXX O
well XXX O
established XXX O
that XXX O
progression XXX O
through XXX O
the XXX O
eukaryotic XXX O
cell XXX O
cycle XXX O
is XXX O
controlled XXX O
by XXX O
oscillations XXX O
in XXX O
the XXX O
activity XXX O
of XXX O
cyclin- XXX B-GENE
dependent XXX I-GENE
kinases XXX I-GENE
( XXX O
CDKs XXX B-GENE
) XXX O
. XXX O

No XXX O
drop XXX O
in XXX O
oxygen XXX O
saturation XXX O
( XXX O
SaO2 XXX O
) XXX O
or XXX O
visual XXX O
evidence XXX O
of XXX O
transient XXX O
electroencephalographic XXX O
( XXX O
EEG XXX O
) XXX O
arousals XXX O
can XXX O
be XXX O
found XXX O
at XXX O
repeat XXX O
polysomnography XXX O
. XXX O

The XXX O
mechanism XXX O
whereby XXX O
zeta XXX B-GENE
PKC XXX I-GENE
regulates XXX O
NF-kappa XXX B-GENE
B XXX I-GENE
most XXX O
probably XXX O
involves XXX O
the XXX O
activation XXX O
of XXX O
a XXX O
putative XXX O
I XXX B-GENE
kappa XXX I-GENE
B XXX I-GENE
kinase XXX I-GENE
of XXX O
molecular XXX O
mass XXX O
approximately XXX O
50 XXX O
kDa XXX O
, XXX O
which XXX O
phosphorylates XXX O
and XXX O
inactivates XXX O
I XXX B-GENE
kappa XXX I-GENE
B XXX O
. XXX O

Sequencing XXX O
analysis XXX O
revealed XXX O
that XXX O
the XXX O
0 XXX O
. XXX O
54- XXX O
and XXX O
0 XXX O
. XXX O
4-kb XXX O
fragments XXX O
are XXX O
identical XXX O
except XXX O
for XXX O
150 XXX O
nucleotides XXX O
missing XXX O
at XXX O
the XXX O
5' XXX O
region XXX O
of XXX O
the XXX O
0 XXX O
. XXX O
4-kb XXX O
fragment XXX O
. XXX O

Instead XXX O
, XXX O
they XXX O
contained XXX O
dendritic XXX O
cells XXX O
that XXX O
express XXX O
melanogenic XXX O
marker XXX O
proteins XXX O
such XXX O
as XXX O
tyrosinase XXX B-GENE
and XXX O
tyrosinase-related XXX B-GENE
protein XXX I-GENE
1 XXX O
. XXX O

A XXX O
double-blind XXX O
trial XXX O
of XXX O
half-strength XXX O
Polybactrin XXX O
Soluble XXX O
GU XXX O
bladder XXX O
irrigation XXX O
in XXX O
cystoscopy XXX O
. XXX O

In XXX O
the XXX O
next XXX O
week XXX O
, XXX O
the XXX O
beta-adrenergic XXX O
antagonist XXX O
atenolol XXX O
was XXX O
added XXX O
at XXX O
an XXX O
initial XXX O
dose XXX O
of XXX O
25 XXX O
mg XXX O
/ XXX O
day XXX O
and XXX O
titrated XXX O
to XXX O
50 XXX O
mg XXX O
/ XXX O
day XXX O
within XXX O
1 XXX O
week XXX O
. XXX O

To XXX O
assess XXX O
the XXX O
maximum XXX O
oxygen XXX O
uptake XXX O
( XXX O
V'O2 XXX O
max XXX O
) XXX O
of XXX O
Hong XXX O
Kong XXX O
Chinese XXX O
children XXX O
and XXX O
to XXX O
explore XXX O
its XXX O
association XXX O
with XXX O
respiratory XXX O
illnesses XXX O
, XXX O
we XXX O
conducted XXX O
the XXX O
Multistage XXX O
Fitness XXX O
Test XXX O
( XXX O
MFT XXX O
) XXX O
, XXX O
a XXX O
20-m XXX O
shuttle XXX O
run XXX O
test XXX O
, XXX O
in XXX O
1 XXX O
, XXX O
427 XXX O
schoolchildren XXX O
aged XXX O
between XXX O
8-12 XXX O
years XXX O
. XXX O

A XXX O
second XXX O
hydrophobic XXX O
domain XXX O
, XXX O
bordered XXX O
by XXX O
two XXX O
hydrophilic XXX O
regions XXX O
strongly XXX O
suggests XXX O
a XXX O
transmembrane XXX O
region XXX O
. XXX O

The XXX O
insulin-induced XXX O
DNA-binding XXX O
complex XXX O
was XXX O
identified XXX O
as XXX O
the XXX O
p50 XXX B-GENE
/ XXX I-GENE
p65 XXX I-GENE
heterodimer XXX I-GENE
. XXX O

It XXX O
is XXX O
concluded XXX O
that XXX O
attention XXX O
to XXX O
these XXX O
issues XXX O
can XXX O
substantially XXX O
improve XXX O
the XXX O
quality XXX O
of XXX O
research XXX O
on XXX O
AIDS XXX O
related XXX O
behaviors XXX O
on XXX O
Black XXX O
communities XXX O
. XXX O

2 XXX O
patients XXX O
( XXX O
11% XXX O
) XXX O
had XXX O
significant XXX O
morbidity XXX O
502 XXX O
and XXX O
529 XXX O
days XXX O
respectively XXX O
after XXX O
transplantation XXX O
. XXX O

This XXX O
study XXX O
was XXX O
undertaken XXX O
to XXX O
assess XXX O
the XXX O
effects XXX O
of XXX O
hypothermia XXX O
and XXX O
chemical XXX O
cardioplegia XXX O
on XXX O
the XXX O
functional XXX O
recovery XXX O
of XXX O
hypertrophied XXX O
non-failing XXX O
rat XXX O
hearts XXX O
subjected XXX O
to XXX O
an XXX O
extended XXX O
period XXX O
of XXX O
global XXX O
ischaemia XXX O
. XXX O

The XXX O
SCH9 XXX B-GENE
protein XXX I-GENE
kinase XXX I-GENE
mRNA XXX I-GENE
contains XXX O
a XXX O
long XXX O
5' XXX O
leader XXX O
with XXX O
a XXX O
small XXX O
open XXX O
reading XXX O
frame XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
the XXX O
affinities XXX O
of XXX O
CBF2 XXX B-GENE
for XXX O
binding XXX O
to XXX O
the XXX O
LMP-1 XXX B-GENE
, XXX O
LMP-2 XXX B-GENE
, XXX O
and XXX O
CD23 XXX B-GENE
promoters XXX I-GENE
were XXX O
also XXX O
measured XXX O
. XXX O

Multilayer-relaxation XXX O
geometry XXX O
and XXX O
electronic XXX O
structure XXX O
of XXX O
a XXX O
W XXX O
( XXX O
111 XXX O
) XXX O
surface XXX O
. XXX O

Conditions XXX O
influencing XXX O
inhibitors XXX O
of XXX O
the XXX O
colony-stimulating XXX B-GENE
factor XXX I-GENE
( XXX O
CSF XXX B-GENE
) XXX O
. XXX O

Spatial XXX O
zones XXX O
for XXX O
muscle XXX O
coactivation XXX O
and XXX O
the XXX O
control XXX O
of XXX O
postural XXX O
stability XXX O
. XXX O

In XXX O
one XXX O
glioblastoma XXX O
cell XXX O
line XXX O
, XXX O
a XXX O
Shc-associated XXX O
p190 XXX B-GENE
was XXX O
identified XXX O
as XXX O
the XXX O
activated XXX O
PDGFR XXX B-GENE
. XXX O

The XXX O
expression XXX O
of XXX O
the XXX O
gene XXX O
encoding XXX O
the XXX O
enzyme XXX O
( XXX O
CYP19 XXX B-GENE
) XXX O
is XXX O
regulated XXX O
, XXX O
in XXX O
part XXX O
, XXX O
by XXX O
tissue-specific XXX O
promoters XXX O
through XXX O
the XXX O
use XXX O
of XXX O
alternative-splicing XXX O
mechanisms XXX O
. XXX O

The XXX O
role XXX O
of XXX O
negative XXX O
regulators XXX O
such XXX O
as XXX O
NCE3 XXX B-GENE
, XXX O
as XXX O
well XXX O
as XXX O
the XXX O
previously XXX O
described XXX O
SIN5 XXX B-GENE
gene XXX I-GENE
, XXX O
in XXX O
determining XXX O
the XXX O
promoter XXX O
specificity XXX O
of XXX O
homologous XXX O
activators XXX O
is XXX O
discussed XXX O
. XXX O

By XXX O
contrast XXX O
, XXX O
mTRAP100 XXX B-GENE
coprecipitates XXX O
in XXX O
vivo XXX O
with XXX O
another XXX O
component XXX O
of XXX O
the XXX O
TRAP XXX B-GENE
complex XXX I-GENE
( XXX O
TRAP220 XXX B-GENE
) XXX O
, XXX O
which XXX O
directly XXX O
contacts XXX O
TR XXX B-GENE
and XXX O
the XXX O
vitamin XXX B-GENE
D XXX I-GENE
receptor XXX I-GENE
in XXX O
a XXX O
ligand-dependent XXX O
manner XXX O
. XXX O

These XXX O
observations XXX O
lead XXX O
to XXX O
the XXX O
proposal XXX O
that XXX O
the XXX O
RNAP XXX B-GENE
II XXX I-GENE
CTD XXX I-GENE
might XXX O
be XXX O
an XXX O
in XXX O
vivo XXX O
target XXX O
for XXX O
the XXX O
activated XXX O
p42mapk XXX B-GENE
and XXX O
p44mapk XXX B-GENE
MAP XXX I-GENE
kinases XXX I-GENE
. XXX O

Study XXX O
on XXX O
distribution XXX O
of XXX O
metal XXX O
in XXX O
the XXX O
teeth XXX O
treated XXX O
by XXX O
iontophoresis XXX O
with XXX O
transparent XXX O
specimens XXX O
. XXX O

Regulation XXX O
of XXX O
Gax XXX B-GENE
homeobox XXX B-GENE
gene XXX I-GENE
transcription XXX O
by XXX O
a XXX O
combination XXX O
of XXX O
positive XXX O
factors XXX O
including XXX O
myocyte-specific XXX B-GENE
enhancer XXX I-GENE
factor XXX I-GENE
2 XXX I-GENE
. XXX O

The XXX O
genomic XXX O
structure XXX O
of XXX O
the XXX O
human XXX B-GENE
SPEC1 XXX I-GENE
gene XXX I-GENE
reveals XXX O
complex XXX O
splicing XXX O
and XXX O
close XXX O
promoter XXX O
proximity XXX O
to XXX O
the XXX O
AF1q XXX B-GENE
translocation XXX I-GENE
gene XXX I-GENE
. XXX O

Quantitative XXX O
PCR XXX O
studies XXX O
indicated XXX O
that XXX O
synthesis XXX O
and XXX O
transport XXX O
of XXX O
vector XXX O
DNA XXX O
into XXX O
the XXX O
nucleus XXX O
were XXX O
similar XXX O
for XXX O
macrophages XXX O
infected XXX O
with XXX O
the XXX O
clone XXX O
239 XXX O
and XXX O
316 XXX O
pseudotypes XXX O
, XXX O
suggesting XXX O
that XXX O
the XXX O
restriction XXX O
for XXX O
SIVmac239 XXX O
infection XXX O
is XXX O
after XXX O
reverse XXX O
transcription XXX O
and XXX O
nuclear XXX O
import XXX O
of XXX O
viral XXX O
DNA XXX O
. XXX O

The XXX O
various XXX O
muscles XXX O
of XXX O
the XXX O
pelvic XXX O
floor XXX O
region XXX O
could XXX O
be XXX O
reflexly XXX O
activated XXX O
either XXX O
individually XXX O
or XXX O
as XXX O
a XXX O
mass XXX O
unit XXX O
depending XXX O
on XXX O
the XXX O
intensity XXX O
of XXX O
stimulation XXX O
. XXX O

ECG-gated XXX O
myocardial XXX O
Technetium-99m XXX O
sestamibi XXX O
SPECT XXX O
is XXX O
a XXX O
useful XXX O
technique XXX O
to XXX O
measure XXX O
myocardial XXX O
perfusion XXX O
and XXX O
function XXX O
simultaneously XXX O
. XXX O

This XXX O
suggests XXX O
that XXX O
cardiovascular XXX O
magnetic XXX O
resonance XXX O
is XXX O
the XXX O
preferred XXX O
technique XXX O
for XXX O
volume XXX O
and XXX O
ejection XXX O
fraction XXX O
estimation XXX O
in XXX O
heart XXX O
failure XXX O
patients XXX O
, XXX O
because XXX O
of XXX O
its XXX O
3D XXX O
approach XXX O
for XXX O
non-symmetric XXX O
ventricles XXX O
and XXX O
superior XXX O
image XXX O
quality XXX O
. XXX O

No XXX O
symptoms XXX O
other XXX O
than XXX O
hot XXX O
flush XXX O
showed XXX O
such XXX O
significant XXX O
correlation XXX O
with XXX O
plasma XXX O
epinephrine XXX O
or XXX O
norepinephrine XXX O
levels XXX O
. XXX O

Ti XXX O
exhibited XXX O
a XXX O
feather-like XXX O
morphology XXX O
. XXX O

To XXX O
search XXX O
for XXX O
transcriptional XXX O
regulators XXX O
, XXX O
we XXX O
used XXX O
a XXX O
fragment XXX O
of XXX O
the XXX O
SpHE XXX B-GENE
promoter XXX I-GENE
containing XXX O
several XXX O
individual XXX O
elements XXX O
instead XXX O
of XXX O
the XXX O
conventional XXX O
bait XXX O
that XXX O
contains XXX O
a XXX O
multimerized XXX O
cis XXX O
element XXX O
. XXX O

The XXX O
gene XXX O
encoding XXX O
the XXX O
105-kDa XXX B-GENE
protein XXX I-GENE
( XXX I-GENE
p105 XXX I-GENE
) XXX I-GENE
precursor XXX I-GENE
of XXX O
the XXX O
p50 XXX B-GENE
subunit XXX I-GENE
of XXX O
transcription XXX O
factor XXX O
NF-kappa XXX B-GENE
B XXX I-GENE
also XXX O
encodes XXX O
a XXX O
p70 XXX B-GENE
I XXX I-GENE
kappa XXX I-GENE
B XXX I-GENE
protein XXX I-GENE
, XXX O
I XXX B-GENE
kappa XXX I-GENE
B XXX I-GENE
gamma XXX I-GENE
, XXX O
which XXX O
is XXX O
identical XXX O
to XXX O
the XXX O
C-terminal XXX O
607 XXX O
amino XXX O
acids XXX O
of XXX O
p105 XXX B-GENE
. XXX O

Though XXX O
hepatomegaly XXX O
and XXX O
mild XXX O
elevation XXX O
of XXX O
enzymes XXX O
can XXX O
be XXX O
observed XXX O
in XXX O
a XXX O
significant XXX O
proportion XXX O
of XXX O
patients XXX O
, XXX O
involvement XXX O
of XXX O
liver XXX O
leading XXX O
to XXX O
acute XXX O
hepatitis XXX O
or XXX O
liver XXX O
cell XXX O
necrosis XXX O
is XXX O
a XXX O
relatively XXX O
uncommon XXX O
complication XXX O
in XXX O
P XXX O
. XXX O
falciparum XXX O
malaria XXX O
. XXX O

Serotonin XXX B-GENE
receptors XXX I-GENE
in XXX O
suicide XXX O
victims XXX O
with XXX O
major XXX O
depression XXX O
. XXX O

The XXX O
volume XXX O
fraction XXX O
( XXX O
Vv XXX O
) XXX O
and XXX O
number XXX O
/ XXX O
mm2 XXX O
( XXX O
Na XXX O
) XXX O
of XXX O
all XXX O
capillaries XXX O
( XXX O
perfused XXX O
and XXX O
nonperfused XXX O
) XXX O
in XXX O
a XXX O
given XXX O
area XXX O
of XXX O
brain XXX O
were XXX O
determined XXX O
after XXX O
staining XXX O
for XXX O
alkaline XXX B-GENE
phosphatase XXX I-GENE
. XXX O

A XXX O
second XXX O
important XXX O
molecule XXX O
in XXX O
TCR XXX B-GENE
signal XXX O
transduction XXX O
is XXX O
the XXX O
guanine XXX B-GENE
nucleotide XXX I-GENE
binding XXX I-GENE
protein XXX I-GENE
, XXX O
p21ras XXX B-GENE
, XXX O
which XXX O
is XXX O
coupled XXX O
to XXX O
the XXX O
TCR XXX B-GENE
by XXX O
a XXX O
protein XXX B-GENE
tyrosine XXX I-GENE
kinase XXX I-GENE
dependent XXX O
mechanism XXX O
. XXX O

Local XXX O
control XXX O
rates XXX O
were XXX O
91% XXX O
for XXX O
metastatic XXX O
lung XXX O
cancer XXX O
, XXX O
89% XXX O
for XXX O
primary XXX O
lung XXX O
cancer XXX O
and XXX O
85% XXX O
for XXX O
T1 XXX O
, XXX O
2N0M0 XXX O
cases XXX O
. XXX O

Here XXX O
the XXX O
conventional XXX O
tests XXX O
clearly XXX O
pointed XXX O
to XXX O
the XXX O
presence XXX O
of XXX O
retrocochlear XXX O
disease XXX O
. XXX O

A XXX B-GENE
further XXX O
mechanism XXX O
increasing XXX O
specific XXX O
activation XXX O
was XXX O
cooperation XXX O
of XXX O
receptors XXX O
at XXX O
multiple XXX O
and XXX O
weak XXX O
HREs XXX B-GENE
, XXX O
which XXX O
was XXX O
accentuated XXX O
in XXX O
the XXX O
presence XXX O
of XXX O
both XXX O
the XXX O
AR XXX B-GENE
N XXX O
terminus XXX O
and XXX O
ligand XXX O
binding XXX O
domain XXX O
. XXX O

Estimation XXX O
of XXX O
renin XXX B-GENE
secretion XXX O
rate XXX O
and XXX O
renal XXX O
plasma XXX O
flow XXX O
from XXX O
peripheral XXX O
and XXX O
renal XXX B-GENE
vein XXX I-GENE
renin XXX I-GENE
levels XXX O
. XXX O

Other XXX O
parameters XXX O
of XXX O
iron XXX O
metabolism XXX O
, XXX O
including XXX O
ferritin XXX B-GENE
, XXX O
were XXX O
not XXX O
found XXX O
to XXX O
contribute XXX O
to XXX O
the XXX O
risk XXX O
. XXX O

PAS1 XXX B-GENE
, XXX O
a XXX O
yeast XXX O
gene XXX O
required XXX O
for XXX O
peroxisome XXX O
biogenesis XXX O
, XXX O
encodes XXX O
a XXX O
member XXX O
of XXX O
a XXX O
novel XXX O
family XXX O
of XXX O
putative XXX O
ATPases XXX B-GENE
. XXX O

However XXX O
, XXX O
ICK1 XXX B-GENE
was XXX O
induced XXX O
by XXX O
ABA XXX O
, XXX O
and XXX O
along XXX O
with XXX O
ICK1 XXX B-GENE
induction XXX O
there XXX O
was XXX O
a XXX O
decrease XXX O
in XXX O
Cdc2-like XXX B-GENE
histone XXX B-GENE
H1 XXX I-GENE
kinase XXX I-GENE
activity XXX O
. XXX O

The XXX O
models XXX O
were XXX O
tested XXX O
by XXX O
studying XXX O
their XXX O
response XXX O
to XXX O
disturbances XXX O
of XXX O
the XXX O
afferent XXX O
signal XXX O
from XXX O
the XXX O
bladder XXX O
. XXX O

Functional XXX O
analysis XXX O
of XXX O
the XXX O
sGTH XXX B-GENE
alpha XXX I-GENE
subunit XXX I-GENE
promoter XXX I-GENE
by XXX O
the XXX O
transient XXX O
transfection XXX O
of XXX O
several XXX O
sGTH XXX B-GENE
alpha XXX I-GENE
/ XXX I-GENE
CAT XXX I-GENE
chimeric XXX O
plasmids XXX O
into XXX O
rainbow XXX O
trout XXX O
pituitary XXX O
cells XXX O
suggests XXX O
that XXX O
its XXX O
pituitary-specific XXX O
expression XXX O
is XXX O
GSE-dependent XXX O
. XXX O

Domain XXX O
switch XXX O
experiments XXX O
reveal XXX O
that XXX O
C XXX B-GENE
/ XXX I-GENE
EBP XXX I-GENE
beta XXX I-GENE
proteins XXX I-GENE
containing XXX O
either XXX O
the XXX O
leucine XXX O
zipper XXX O
or XXX O
the XXX O
activation XXX O
domain XXX O
of XXX O
C XXX B-GENE
/ XXX I-GENE
EBP XXX I-GENE
alpha XXX I-GENE
are XXX O
unable XXX O
to XXX O
stimulate XXX O
the XXX O
2D5 XXX B-GENE
promoter XXX I-GENE
yet XXX O
are XXX O
fully XXX O
capable XXX O
of XXX O
transactivating XXX O
an XXX O
artificial XXX O
promoter XXX O
bearing XXX O
a XXX O
high-affinity XXX O
C XXX B-GENE
/ XXX I-GENE
EBP XXX I-GENE
site XXX I-GENE
. XXX O

In XXX O
addition XXX O
, XXX O
we XXX O
demonstrate XXX O
that XXX O
the XXX O
production XXX O
of XXX O
active XXX B-GENE
recombinant XXX I-GENE
telomerase XXX I-GENE
requires XXX O
a XXX O
factor XXX O
in XXX O
rabbit XXX O
reticulocyte XXX O
lysate XXX O
that XXX O
promotes XXX O
ribonucleoprotein XXX O
assembly XXX O
. XXX O

A XXX O
simple XXX O
method XXX O
for XXX O
measuring XXX O
urinary XXX O
iron XXX O
following XXX O
the XXX O
administration XXX O
of XXX O
desferrioxamine XXX O
( XXX O
DF XXX O
) XXX O
is XXX O
described XXX O
. XXX O

Recent XXX O
studies XXX O
using XXX O
isolated XXX O
rat XXX O
adipocytes XXX O
and XXX O
chemically XXX O
synthesized XXX O
PIG XXX O
compounds XXX O
point XXX O
to XXX O
IRS1 XXX B-GENE
/ XXX I-GENE
3 XXX I-GENE
tyrosine XXX O
phosphorylation XXX O
by XXX O
p59Lyn XXX B-GENE
kinase XXX I-GENE
as XXX O
the XXX O
site XXX O
of XXX O
cross-talk XXX O
, XXX O
the XXX O
negative XXX O
regulation XXX O
of XXX O
which XXX O
by XXX O
interaction XXX O
with XXX O
caveolin XXX B-GENE
is XXX O
apparently XXX O
abrogated XXX O
by XXX O
PIG XXX O
. XXX O

Thus XXX O
, XXX O
the XXX O
P XXX O
. XXX O
aeruginosa XXX O
orfX XXX B-GENE
and XXX O
vfr XXX B-GENE
promoters XXX I-GENE
are XXX O
arranged XXX O
in XXX O
a XXX O
back-to-back XXX O
orientation XXX O
rather XXX O
than XXX O
the XXX O
face-to-face XXX O
orientation XXX O
of XXX O
the XXX O
dorf XXX B-GENE
and XXX O
crp XXX B-GENE
promoters XXX I-GENE
. XXX O

A XXX O
rare XXX O
case XXX O
of XXX O
primary XXX O
group XXX O
A XXX O
streptococcal XXX O
peritonitis XXX O
. XXX O

Fourteen XXX O
patients XXX O
were XXX O
in XXX O
the XXX O
multifocal XXX O
disease XXX O
group XXX O
; XXX O
13 XXX O
were XXX O
detected XXX O
by XXX O
SPECT XXX O
and XXX O
10 XXX O
by XXX O
TCT XXX O
. XXX O

High XXX O
ADR1 XXX B-GENE
gene XXX I-GENE
dosage XXX O
increased XXX O
the XXX O
transcription XXX O
of XXX O
genes XXX O
encoding XXX O
peroxisomal XXX O
proteins XXX O
as XXX O
compared XXX O
to XXX O
one XXX O
copy XXX O
of XXX O
the XXX O
ADR1 XXX B-GENE
gene XXX I-GENE
. XXX O

The XXX O
65-bp XXX O
sequence XXX O
contains XXX O
the XXX O
octameric XXX O
cAMP-responsive XXX B-GENE
enhancer XXX I-GENE
( XXX O
CRE XXX B-GENE
) XXX O
TGACGTCA XXX B-GENE
( XXX O
nucleotides XXX O
-48 XXX O
to XXX O
-41 XXX O
) XXX O
. XXX O

The XXX O
bioavailability XXX O
of XXX O
etodolac XXX O
from XXX O
capsules XXX O
exposed XXX O
to XXX O
stressed XXX O
conditions XXX O
was XXX O
compared XXX O
in XXX O
both XXX O
dogs XXX O
and XXX O
humans XXX O
to XXX O
capsules XXX O
stored XXX O
at XXX O
RT XXX O
conditions XXX O
. XXX O

Scmh1 XXX B-GENE
maps XXX O
to XXX O
4D1-D2 XXX O
. XXX O
1 XXX O
in XXX O
mice XXX O
. XXX O

In XXX O
this XXX O
paper XXX O
, XXX O
an XXX O
analysis XXX O
of XXX O
the XXX O
dynamics XXX O
in XXX O
the XXX O
closing XXX O
phase XXX O
of XXX O
the XXX O
occluder XXX O
of XXX O
a XXX O
mechanical XXX O
monoleaflet XXX O
heart XXX O
valve XXX O
prosthesis XXX O
is XXX O
presented XXX O
. XXX O

Investigation XXX O
of XXX O
the XXX O
structural XXX O
basis XXX O
of XXX O
the XXX O
interaction XXX O
between XXX O
human XXX B-GENE
Igs XXX I-GENE
and XXX O
gp120 XXX B-GENE
shows XXX O
that XXX O
the XXX O
viral XXX B-GENE
gp120 XXX I-GENE
SAg XXX I-GENE
can XXX O
interact XXX O
only XXX O
with XXX O
a XXX O
subset XXX O
of XXX O
human XXX B-GENE
V XXX I-GENE
( XXX I-GENE
H XXX I-GENE
) XXX I-GENE
3+ XXX I-GENE
Igs XXX I-GENE
. XXX O

JPEG XXX O
53 XXX O
, XXX O
resulting XXX O
in XXX O
a XXX O
compression XXX O
ratio XXX O
of XXX O
1 XXX O
: XXX O
21 XXX O
, XXX O
does XXX O
not XXX O
compromise XXX O
the XXX O
diagnostic XXX O
performance XXX O
in XXX O
general XXX O
. XXX O

The XXX O
presence XXX O
of XXX O
the XXX O
corresponding XXX O
mature XXX O
mRNA XXX O
transcripts XXX O
( XXX O
3 XXX O
. XXX O
2-3 XXX O
. XXX O
5 XXX O
kilobase XXX O
pairs XXX O
( XXX O
kb XXX O
] XXX O
in XXX O
human XXX O
fibroblasts XXX O
was XXX O
shown XXX O
by XXX O
Northern XXX O
blot XXX O
hybridization XXX O
, XXX O
S1 XXX B-GENE
nuclease XXX I-GENE
protection XXX O
assay XXX O
, XXX O
and XXX O
the XXX O
polymerase XXX B-GENE
chain XXX O
reaction XXX O
. XXX O

In XXX O
case XXX O
of XXX O
a XXX O
pathologically XXX O
convoluted XXX O
internal XXX O
carotid XXX O
the XXX O
common XXX O
carotid XXX O
artery XXX O
was XXX O
resected XXX O
with XXX O
an XXX O
end-to-end XXX O
anastomosis XXX O
. XXX O

However XXX O
, XXX O
mean XXX O
food XXX O
intake XXX O
in XXX O
the XXX O
40% XXX O
group XXX O
was XXX O
half XXX O
that XXX O
of XXX O
the XXX O
ACT XXX O
group XXX O
( XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
001 XXX O
) XXX O
and XXX O
significantly XXX O
less XXX O
( XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
than XXX O
the XXX O
SEP XXX O
group XXX O
, XXX O
which XXX O
consumed XXX O
amounts XXX O
equivalent XXX O
to XXX O
65% XXX O
of XXX O
daily XXX O
requirement XXX O
. XXX O

Wrist XXX O
measurement XXX O
of XXX O
blood XXX O
pressure XXX O
: XXX O
some XXX O
critical XXX O
remarks XXX O
to XXX O
oscillometry XXX O
. XXX O

The XXX O
effects XXX O
of XXX O
the XXX O
transfected XXX O
receptors XXX O
were XXX O
associated XXX O
with XXX O
antagonism XXX O
of XXX O
activator XXX B-GENE
protein XXX I-GENE
1 XXX I-GENE
( XXX O
AP-1 XXX B-GENE
) XXX O
activity XXX O
. XXX O

In XXX O
the XXX O
COPD XXX O
patients XXX O
, XXX O
the XXX O
variability XXX O
of XXX O
Delta-inst XXX O
Rrs XXX O
( XXX O
30% XXX O
) XXX O
was XXX O
greater XXX O
than XXX O
that XXX O
of XXX O
FOT XXX O
Rrs XXX O
( XXX O
21% XXX O
) XXX O
. XXX O

The XXX O
"cracked-tooth" XXX O
syndrome XXX O
. XXX O

Regression XXX O
analyses XXX O
identified XXX O
7 XXX O
risk XXX O
and XXX O
7 XXX O
protective XXX O
factors XXX O
with XXX O
minimal XXX O
overlap XXX O
. XXX O

However XXX O
, XXX O
multiple XXX O
alanine XXX O
substitutions XXX O
or XXX O
proline XXX O
( XXX O
helix-destabilizing XXX O
) XXX O
substitutions XXX O
disrupted XXX O
both XXX O
oligomerization XXX O
and XXX O
transport XXX O
of XXX O
GP64 XXX B-GENE
EFP XXX I-GENE
. XXX O

The XXX O
hepatocyte XXX B-GENE
nuclear XXX I-GENE
factor-3 XXX I-GENE
( XXX O
HNF-3 XXX B-GENE
) XXX O
/ XXX B-GENE
orkhead XXX I-GENE
( XXX O
fkh XXX B-GENE
) XXX O
proteins XXX O
consist XXX O
of XXX O
an XXX O
extensive XXX O
family XXX O
of XXX O
tissue-specific XXX O
and XXX O
developmental XXX O
gene XXX O
regulators XXX O
which XXX O
share XXX O
homology XXX O
within XXX O
the XXX O
winged XXX B-GENE
helix XXX I-GENE
DNA XXX I-GENE
binding XXX I-GENE
motif XXX I-GENE
. XXX O

Nucleotide XXX O
sequences XXX O
of XXX O
the XXX O
clones XXX O
revealed XXX O
that XXX O
one XXX O
clone XXX O
, XXX O
cap3 XXX B-GENE
, XXX O
contained XXX O
an XXX O
open XXX O
reading XXX O
frame XXX O
( XXX O
ORF XXX O
) XXX O
that XXX O
would XXX O
code XXX O
for XXX O
a XXX O
26-amino XXX O
acid XXX O
, XXX O
cysteine-rich XXX O
peptide XXX O
with XXX O
significant XXX O
homology XXX O
to XXX O
Neurospora XXX B-GENE
crassa XXX I-GENE
copper XXX I-GENE
metallothionein XXX I-GENE
. XXX O

In XXX O
treated XXX O
herds XXX O
, XXX O
cows XXX O
more XXX O
than XXX O
40 XXX O
d XXX O
postpartum XXX O
with XXX O
a XXX O
corpus XXX O
luteum XXX O
received XXX O
prostaglandin XXX O
F2 XXX O
alpha XXX O
. XXX O

Immunohistochemical XXX O
analysis XXX O
of XXX O
several XXX O
rat XXX O
organs XXX O
also XXX O
showed XXX O
staining XXX O
in XXX O
epithelial XXX O
cells XXX O
. XXX O

CONCLUSION XXX O
: XXX O
Twice XXX O
daily XXX O
treatment XXX O
with XXX O
inhaled XXX O
fluticasone XXX O
propionate XXX O
50 XXX O
micrograms XXX O
or XXX O
100 XXX O
micrograms XXX O
was XXX O
significantly XXX O
more XXX O
effective XXX O
than XXX O
theophylline XXX O
in XXX O
the XXX O
treatment XXX O
of XXX O
mild-to-moderate XXX O
asthma XXX O
. XXX O

The XXX O
elevated XXX O
Viso XXX O
V XXX O
in XXX O
the XXX O
RDS XXX O
group XXX O
suggests XXX O
an XXX O
increase XXX O
in XXX O
small XXX O
airway XXX O
resistance XXX O
secondary XXX O
to XXX O
the XXX O
disease XXX O
or XXX O
to XXX O
its XXX O
therapy XXX O
. XXX O

The XXX O
GEF XXX B-GENE
and XXX O
GAP XXX B-GENE
activities XXX O
for XXX O
Ypt1p XXX B-GENE
localize XXX O
to XXX O
particulate XXX O
cellular XXX O
fractions XXX O
. XXX O

DNA-dependent XXX B-GENE
protein XXX I-GENE
kinase XXX I-GENE
( XXX O
DNA-PK XXX B-GENE
) XXX O
consists XXX O
of XXX O
a XXX O
heterodimeric XXX O
protein XXX O
( XXX O
Ku XXX B-GENE
) XXX O
and XXX O
a XXX O
large XXX O
catalytic XXX O
subunit XXX O
( XXX O
DNA-PKcs XXX B-GENE
) XXX O
. XXX O

Our XXX O
results XXX O
demonstrate XXX O
that XXX O
cis XXX O
elements XXX O
positioned XXX O
between XXX O
the XXX O
alpha XXX B-GENE
3 XXX I-GENE
and XXX O
beta XXX B-GENE
4 XXX I-GENE
coding XXX O
regions XXX O
are XXX O
important XXX O
for XXX O
establishing XXX O
part XXX O
of XXX O
the XXX O
restricted XXX O
CNS XXX O
patterns XXX O
of XXX O
beta XXX B-GENE
4 XXX I-GENE
, XXX O
alpha XXX B-GENE
3 XXX I-GENE
, XXX O
and XXX O
alpha XXX B-GENE
5 XXX I-GENE
gene XXX I-GENE
transcription XXX O
. XXX O

However XXX O
, XXX O
no XXX O
genetic XXX O
alteration XXX O
was XXX O
detected XXX O
in XXX O
any XXX O
of XXX O
the XXX O
cancers XXX O
examined XXX O
. XXX O

Although XXX O
RAD17 XXX B-GENE
, XXX O
RAD24 XXX B-GENE
and XXX O
MEC3 XXX B-GENE
are XXX O
not XXX O
required XXX O
for XXX O
cell XXX O
cycle XXX O
arrest XXX O
when XXX O
S XXX O
phase XXX O
is XXX O
inhibited XXX O
by XXX O
hydroxyurea XXX O
( XXX O
HU XXX O
) XXX O
, XXX O
they XXX O
do XXX O
contribute XXX O
to XXX O
the XXX O
viability XXX O
of XXX O
yeast XXX O
cells XXX O
grown XXX O
in XXX O
the XXX O
presence XXX O
of XXX O
HU XXX O
, XXX O
possibly XXX O
because XXX O
they XXX O
are XXX O
required XXX O
for XXX O
the XXX O
repair XXX O
of XXX O
HU-induced XXX O
DNA XXX O
damage XXX O
. XXX O

D5 XXX B-GENE
/ XXX I-GENE
D1 XXX I-GENE
( XXX I-GENE
CT XXX I-GENE
) XXX I-GENE
or XXX O
D5 XXX B-GENE
/ XXX I-GENE
D1D XXX I-GENE
( XXX I-GENE
CT XXX I-GENE
) XXX I-GENE
tail XXX O
substitution XXX O
mutants XXX O
displayed XXX O
a XXX O
rank XXX O
order XXX O
of XXX O
potency XXX O
and XXX O
agonist XXX O
affinities XXX O
virtually XXX O
mimicking XXX O
wild-type XXX B-GENE
( XXX I-GENE
wt XXX I-GENE
) XXX I-GENE
D1 XXX I-GENE
receptors XXX I-GENE
, XXX O
as XXX O
indexed XXX O
by XXX O
both XXX O
ligand XXX O
binding XXX O
and XXX O
dopamine-stimulated XXX O
cAMP XXX O
accumulation XXX O
assays XXX O
, XXX O
and XXX O
, XXX O
similar XXX O
to XXX O
wt XXX O
D1 XXX B-GENE
receptors XXX I-GENE
, XXX O
did XXX O
not XXX O
exhibit XXX O
receptor XXX O
constitutive XXX O
activity XXX O
or XXX O
responsiveness XXX O
to XXX O
inverse XXX O
agonists XXX O
. XXX O

When XXX O
examined XXX O
as XXX O
adults XXX O
( XXX O
8 XXX O
weeks XXX O
old XXX O
) XXX O
, XXX O
the XXX O
external XXX O
genitalia XXX O
of XXX O
TA-exposed XXX O
offspring XXX O
were XXX O
normal XXX O
. XXX O

Doppler XXX O
echo XXX O
in XXX O
evaluating XXX O
arteriovenous XXX O
fistulae XXX O
for XXX O
dialysis XXX O
. XXX O

GTPase XXX B-GENE
activating XXX O
specificity XXX O
of XXX O
RGS12 XXX B-GENE
and XXX O
binding XXX O
specificity XXX O
of XXX O
an XXX O
alternatively XXX O
spliced XXX O
PDZ XXX B-GENE
( XXX O
PSD-95 XXX B-GENE
/ XXX I-GENE
Dlg XXX I-GENE
/ XXX I-GENE
ZO-1 XXX I-GENE
) XXX O
domain XXX O
. XXX O

The XXX O
non-homologous XXX O
sequences XXX O
in XXX O
the XXX O
5' XXX O
untranslated XXX O
regions XXX O
might XXX O
be XXX O
acquired XXX O
at XXX O
or XXX O
after XXX O
transcription XXX O
during XXX O
retrotransposition XXX O
of XXX O
the XXX O
ATLN XXX B-GENE
elements XXX I-GENE
. XXX O

Chem XXX O
. XXX O

Twelve XXX O
out XXX O
of XXX O
43 XXX O
renal XXX O
failure XXX O
patients XXX O
had XXX O
troponin XXX B-GENE
I XXX I-GENE
0 XXX O
. XXX O
13-0 XXX O
. XXX O
9 XXX O
microg XXX O
/ XXX O
l XXX O
using XXX O
Axsym XXX O
method XXX O
and XXX O
4 XXX O
had XXX O
levels XXX O
of XXX O
0 XXX O
. XXX O
07-0 XXX O
. XXX O
13 XXX O
microg XXX O
/ XXX O
l XXX O
using XXX O
Immuno XXX O
1 XXX O
. XXX O

Pitfalls XXX O
in XXX O
the XXX O
use XXX O
of XXX O
chromosome XXX O
aberration XXX O
analysis XXX O
for XXX O
biological XXX O
radiation XXX O
dosimetry XXX O
. XXX O

Both XXX O
GH XXX B-GENE
deficiency XXX O
and XXX O
impaired XXX O
spinal XXX O
growth XXX O
may XXX O
result XXX O
in XXX O
short XXX O
stature XXX O
, XXX O
whereas XXX O
the XXX O
occurrence XXX O
of XXX O
early XXX O
puberty XXX O
in XXX O
association XXX O
with XXX O
GH XXX B-GENE
deficiency XXX O
reduces XXX O
the XXX O
time XXX O
available XXX O
for XXX O
GH XXX B-GENE
therapy XXX O
. XXX O

The XXX O
DNA XXX O
sequences XXX O
upstream XXX O
of XXX O
these XXX O
termini XXX O
exhibit XXX O
homology XXX O
to XXX O
plant XXX O
mitochondrial-processing XXX O
sites XXX O
, XXX O
therefore XXX O
the XXX O
proximal XXX O
5' XXX O
ends XXX O
are XXX O
most XXX O
probably XXX O
generated XXX O
by XXX O
RNA XXX O
processing XXX O
. XXX O

Brief XXX O
report XXX O
. XXX O

After XXX O
6 XXX O
h XXX O
of XXX O
reperfusion XXX O
, XXX O
PO2 XXX O
/ XXX O
FlO2 XXX O
ratio XXX O
was XXX O
significantly XXX O
better XXX O
after XXX O
Combined XXX O
Therapy XXX O
( XXX O
372 XXX O
+ XXX O
/ XXX O
- XXX O
52 XXX O
mm XXX O
Hg XXX O
) XXX O
than XXX O
in XXX O
the XXX O
Recipient XXX O
Instilled XXX O
( XXX O
117 XXX O
+ XXX O
/ XXX O
- XXX O
47 XXX O
mm XXX O
Hg XXX O
) XXX O
and XXX O
Control XXX O
groups XXX O
( XXX O
87 XXX O
+ XXX O
/ XXX O
- XXX O
26 XXX O
mm XXX O
Hg XXX O
) XXX O
, XXX O
with XXX O
intermediate XXX O
values XXX O
in XXX O
Donor XXX O
Aerosol XXX O
dogs XXX O
( XXX O
232 XXX O
+ XXX O
/ XXX O
- XXX O
64 XXX O
mm XXX O
Hg XXX O
) XXX O
. XXX O

But XXX O
, XXX O
as XXX O
Theriault XXX O
explains XXX O
, XXX O
improvements XXX O
in XXX O
assessing XXX O
exposure XXX O
have XXX O
not XXX O
yet XXX O
translated XXX O
into XXX O
clear XXX O
and XXX O
consistent XXX O
findings XXX O
. XXX O

Concomitantly XXX O
, XXX O
the XXX O
total XXX O
cellular XXX O
level XXX O
of XXX O
p21 XXX B-GENE
increased XXX O
severalfold XXX O
via XXX O
a XXX O
posttranscriptional XXX O
mechanism XXX O
. XXX O

BACKGROUND XXX O
: XXX O
The XXX O
Bazett-corrected XXX O
QT XXX O
( XXX O
QTc XXX O
) XXX O
interval XXX O
during XXX O
exercise XXX O
has XXX O
been XXX O
used XXX O
as XXX O
a XXX O
marker XXX O
for XXX O
ischemic XXX O
disease XXX O
, XXX O
arrhythmogenic XXX O
substrate XXX O
and XXX O
the XXX O
long XXX O
QT XXX O
syndrome XXX O
. XXX O

The XXX O
data XXX O
suggest XXX O
that XXX O
ICP10 XXX B-GENE
constitutively XXX O
increases XXX O
ras XXX B-GENE
activity XXX O
, XXX O
and XXX O
its XXX O
TM XXX O
segment XXX O
plays XXX O
a XXX O
critical XXX O
role XXX O
in XXX O
transformation-related XXX O
signaling XXX O
pathways XXX O
. XXX O

Behavioural XXX O
tests XXX O
with XXX O
192 XXX O
specimen XXX O
of XXX O
the XXX O
roman XXX O
garden XXX O
snail XXX O
Helix XXX O
pomatia XXX O
L XXX O
. XXX O
were XXX O
performed XXX O
in XXX O
order XXX O
to XXX O
clarify XXX O
whether XXX O
the XXX O
thermopreferendum XXX O
of XXX O
this XXX O
pulmonate XXX O
is XXX O
influenced XXX O
not XXX O
only XXX O
by XXX O
the XXX O
temperature XXX O
of XXX O
the XXX O
substratum XXX O
but XXX O
also XXX O
by XXX O
air XXX O
temperature XXX O
. XXX O

In XXX O
a XXX O
retrospective XXX O
analysis XXX O
of XXX O
first-time XXX O
total XXX O
colonoscopies XXX O
in XXX O
685 XXX O
patients XXX O
, XXX O
we XXX O
investigated XXX O
the XXX O
relationship XXX O
between XXX O
hyperplastic XXX O
and XXX O
adenomatous XXX O
polyps XXX O
. XXX O

The XXX O
TIMP XXX B-GENE
( XXX I-GENE
-59 XXX I-GENE
/ XXX I-GENE
-53 XXX I-GENE
) XXX I-GENE
AP1 XXX I-GENE
site XXX I-GENE
is XXX O
a XXX O
promiscuous XXX O
motif XXX O
that XXX O
binds XXX O
c-Fos XXX B-GENE
/ XXX I-GENE
c-Jun XXX I-GENE
AP1 XXX B-GENE
translated XXX O
in XXX O
vitro XXX O
and XXX O
is XXX O
an XXX O
effective XXX O
competitor XXX O
for XXX O
binding XXX O
of XXX O
nuclear XXX B-GENE
AP1 XXX I-GENE
factors XXX I-GENE
to XXX O
the XXX O
consensus XXX B-GENE
TRE XXX I-GENE
, XXX O
but XXX O
in XXX O
addition XXX O
it XXX O
binds XXX O
factors XXX O
that XXX O
do XXX O
not XXX O
associate XXX O
with XXX O
the XXX O
consensus XXX B-GENE
TRE XXX I-GENE
. XXX O

These XXX O
data XXX O
indicate XXX O
that XXX O
the XXX O
SmSmad2 XXX B-GENE
responds XXX O
to XXX O
the XXX O
TGF-beta XXX B-GENE
signals XXX O
by XXX O
interaction XXX O
with XXX O
receptor XXX B-GENE
I XXX I-GENE
, XXX O
which XXX O
phosphorylates XXX O
it XXX O
, XXX O
whereupon XXX O
it XXX O
translocates XXX O
into XXX O
the XXX O
nucleus XXX O
presumably XXX O
to XXX O
regulate XXX O
target XXX O
gene XXX O
transcription XXX O
and XXX O
consequently XXX O
elicit XXX O
a XXX O
specific XXX O
TGF-beta XXX B-GENE
effect XXX O
. XXX O

Hence XXX O
, XXX O
scs32 XXX B-GENE
only XXX O
partially XXX O
suppressed XXX O
the XXX O
ts XXX O
phenotype XXX O
and XXX O
was XXX O
unable XXX O
to XXX O
suppress XXX O
the XXX O
Ino-phenotype XXX O
of XXX O
rpo26-31 XXX B-GENE
. XXX O

Using XXX O
avidin-biotin XXX O
complex XXX O
DNA XXX O
binding XXX O
assays XXX O
, XXX O
a XXX O
series XXX O
of XXX O
overlapping XXX O
alpha XXX B-GENE
promoter XXX I-GENE
DNA XXX I-GENE
sequences XXX I-GENE
between XXX O
-170 XXX O
to XXX O
29 XXX O
basepairs XXX O
were XXX O
tested XXX O
, XXX O
but XXX O
each XXX O
failed XXX O
to XXX O
bind XXX O
GR XXX B-GENE
, XXX O
whereas XXX O
a XXX O
control XXX O
GRE XXX B-GENE
avidly XXX O
bound XXX O
receptor XXX O
. XXX O

An XXX O
expression XXX O
library XXX O
was XXX O
constructed XXX O
by XXX O
inserting XXX O
5' XXX O
portion-enriched XXX O
cDNAs XXX O
from XXX O
phytohemagglutinin-stimulated XXX O
peripheral XXX O
blood XXX O
mononuclear XXX O
cells XXX O
into XXX O
upstream XXX O
of XXX O
signal XXX B-GENE
sequence-deleted XXX I-GENE
CD4 XXX I-GENE
cDNA XXX I-GENE
in XXX O
an XXX O
Epstein-Barr XXX O
virus XXX O
shuttle XXX O
vector XXX O
. XXX O

The XXX O
finding XXX O
that XXX O
the XXX O
chimeric XXX B-GENE
TdT XXX I-GENE
: XXX O
: XXX O
Pol XXX B-GENE
beta XXX I-GENE
protein XXX I-GENE
possessed XXX O
significant XXX O
template-dependent XXX O
polymerase XXX B-GENE
activity XXX O
suggests XXX O
that XXX O
aa XXX O
1-60 XXX O
of XXX O
Pol XXX B-GENE
beta XXX I-GENE
are XXX O
involved XXX O
in XXX O
template XXX O
utilization XXX O
during XXX O
the XXX O
polymerization XXX O
reaction XXX O
, XXX O
as XXX O
suggested XXX O
by XXX O
the XXX O
previous XXX O
finding XXX O
that XXX O
the XXX O
8-kDa XXX O
N-terminal XXX O
domain XXX O
of XXX O
Pol XXX B-GENE
beta XXX I-GENE
possesses XXX O
ssDNA-binding XXX O
activity XXX O
[ XXX O
Kumar XXX O
et XXX O
al XXX O
. XXX O
, XXX O
J XXX O
. XXX O

When XXX O
extracorporeal XXX O
CO2 XXX O
removal XXX O
approximated XXX O
CO2 XXX O
production XXX O
( XXX O
VCO2 XXX O
) XXX O
, XXX O
alveolar XXX O
ventilation XXX O
almost XXX O
ceased XXX O
. XXX O

This XXX O
result XXX O
supports XXX O
the XXX O
argument XXX O
that XXX O
the XXX O
beta' XXX B-GENE
subunit XXX I-GENE
plays XXX O
an XXX O
essential XXX O
role XXX O
in XXX O
determining XXX O
the XXX O
progress XXX O
of XXX O
transcription XXX O
elongation XXX O
. XXX O

Because XXX O
decreases XXX O
in XXX O
the XXX O
disfluency XXX O
rates XXX O
of XXX O
stutterers XXX O
were XXX O
observed XXX O
during XXX O
the XXX O
presentation XXX O
of XXX O
all XXX O
three XXX O
stimulus XXX O
words XXX O
, XXX O
the XXX O
data XXX O
failed XXX O
to XXX O
support XXX O
the XXX O
operant XXX O
model XXX O
. XXX O

The XXX O
calculated XXX O
values XXX O
of XXX O
lambda XXX O
tb XXX O
at XXX O
37 XXX O
degrees XXX O
C XXX O
and XXX O
50 XXX O
per XXX O
cent XXX O
haematocrit XXX O
were XXX O
0 XXX O
. XXX O
650 XXX O
for XXX O
the XXX O
pulp XXX O
, XXX O
0 XXX O
. XXX O
674 XXX O
for XXX O
the XXX O
tongue XXX O
, XXX O
0 XXX O
. XXX O
828 XXX O
for XXX O
the XXX O
submandibular XXX O
gland XXX O
and XXX O
0 XXX O
. XXX O
881 XXX O
for XXX O
the XXX O
gingiva XXX O
of XXX O
the XXX O
dog XXX O
. XXX O
lambda XXX O
cp XXX O
increased XXX O
and XXX O
lambda XXX O
tp XXX O
decreased XXX O
as XXX O
the XXX O
temperature XXX O
was XXX O
reduced XXX O
from XXX O
37 XXX O
to XXX O
4 XXX O
degrees XXX O
C XXX O
. XXX O

The XXX O
sequence XXX O
has XXX O
a XXX O
1092-bp XXX O
open XXX O
reading XXX O
frame XXX O
encoding XXX O
a XXX O
protein XXX O
of XXX O
364 XXX O
amino XXX O
acids XXX O
. XXX O

Bacterial XXX O
recovery XXX O
of XXX O
SA XXX O
from XXX O
the XXX O
liver XXX O
/ XXX O
spleen XXX O
and XXX O
the XXX O
cecal XXX O
tonsil XXX O
in XXX O
contact XXX O
poults XXX O
and XXX O
SG XXX O
from XXX O
contact XXX O
chicks XXX O
treated XXX O
with XXX O
ILK XXX B-GENE
was XXX O
dramatically XXX O
reduced XXX O
when XXX O
compared XXX O
to XXX O
non-treated XXX O
contact XXX O
poults XXX O
and XXX O
chicks XXX O
. XXX O

Absorption XXX O
of XXX O
electrolytes XXX O
from XXX O
the XXX O
colon XXX O
in XXX O
cases XXX O
of XXX O
ulcerative XXX O
colitis XXX O
and XXX O
in XXX O
control XXX O
subjects XXX O
. XXX O

OBJECTIVE XXX O
: XXX O
To XXX O
investigate XXX O
the XXX O
incidence XXX O
and XXX O
presentation XXX O
of XXX O
acute XXX O
pernicious XXX O
or XXX O
fulminating XXX O
beriberi XXX O
in XXX O
a XXX O
general XXX O
district XXX O
hospital XXX O
. XXX O

This XXX O
article XXX O
reports XXX O
the XXX O
design XXX O
and XXX O
development XXX O
of XXX O
an XXX O
ECG XXX O
simulator XXX O
intended XXX O
for XXX O
use XXX O
in XXX O
the XXX O
testing XXX O
, XXX O
calibration XXX O
and XXX O
maintenance XXX O
of XXX O
electrocardiographic XXX O
equipment XXX O
. XXX O

Allergy XXX O
and XXX O
Tourette's XXX O
syndrome XXX O
. XXX O

Gel XXX O
mobility XXX O
shift XXX O
assays XXX O
indicated XXX O
that XXX O
at XXX O
least XXX O
four XXX O
nuclear XXX O
proteins XXX O
with XXX O
distinct XXX O
biochemical XXX O
and XXX O
binding XXX O
properties XXX O
possess XXX O
the XXX O
ability XXX O
to XXX O
bind XXX O
the XXX O
3 XXX B-GENE
beta XXX I-GENE
I-A XXX I-GENE
element XXX I-GENE
to XXX O
produce XXX O
four XXX O
DNA-protein XXX O
complexes XXX O
( XXX O
R1 XXX O
to XXX O
R4 XXX O
) XXX O
. XXX O

Workers XXX O
with XXX O
"sensitivity" XXX O
to XXX O
toluene XXX O
diisocyanate XXX O
( XXX O
TDI XXX O
) XXX O
studied XXX O
in XXX O
depth XXX O
in XXX O
an XXX O
attempt XXX O
to XXX O
determine XXX O
mechanisms XXX O
of XXX O
bronchial XXX O
hyperreactivity XXX O
. XXX O

Characterization XXX O
of XXX O
the XXX O
regulon XXX O
controlled XXX O
by XXX O
the XXX O
leucine-responsive XXX O
regulatory XXX O
protein XXX O
in XXX O
Escherichia XXX O
coli XXX O
. XXX O

Calcinosis XXX O
cutis XXX O
following XXX O
intravenous XXX O
infusion XXX O
of XXX O
calcium XXX O
gluconate XXX O
. XXX O

Inhibition XXX O
of XXX O
JNK1 XXX B-GENE
and XXX O
ERK XXX B-GENE
kinase XXX O
activities XXX O
either XXX O
by XXX O
expression XXX O
of XXX O
the XXX O
dominant XXX O
negative XXX O
mutant XXX O
JNK1 XXX B-GENE
or XXX O
by XXX O
treatment XXX O
with XXX O
a XXX O
selective XXX O
chemical XXX O
inhibitor XXX O
of XXX O
ERK XXX B-GENE
( XXX O
PD098059 XXX O
) XXX O
substantially XXX O
abrogates XXX O
the XXX O
UV XXX O
induction XXX O
of XXX O
the XXX O
GADD45 XXX B-GENE
promoter XXX I-GENE
. XXX O

Transforming XXX B-GENE
growth XXX I-GENE
factor-beta1 XXX I-GENE
( XXX O
TGF-beta1 XXX B-GENE
) XXX O
can XXX O
act XXX O
as XXX O
a XXX O
tumor XXX O
suppressor XXX O
or XXX O
a XXX O
tumor XXX O
promoter XXX O
depending XXX O
on XXX O
the XXX O
characteristics XXX O
of XXX O
the XXX O
malignant XXX O
cell XXX O
. XXX O

Nor XXX O
is XXX O
such XXX O
adjustment XXX O
possible XXX O
unless XXX O
one XXX O
posits XXX O
a XXX O
model XXX O
that XXX O
relates XXX O
the XXX O
missing XXX O
observations XXX O
to XXX O
other XXX O
observed XXX O
information XXX O
for XXX O
each XXX O
subject-models XXX O
that XXX O
are XXX O
inherently XXX O
untestable XXX O
. XXX O

Multiple XXX O
transcription XXX O
start XXX O
sites XXX O
were XXX O
revealed XXX O
by XXX O
primer XXX O
extension XXX O
analysis XXX O
of XXX O
the XXX O
mouse XXX O
gene XXX O
, XXX O
and XXX O
transfection XXX O
constructs XXX O
containing XXX O
the XXX O
prospective XXX O
promoter XXX O
generated XXX O
transcriptional XXX O
activity XXX O
comparable XXX O
to XXX O
that XXX O
of XXX O
the XXX O
SV40 XXX B-GENE
promoter XXX I-GENE
. XXX O

A XXX O
mail XXX O
survey XXX O
of XXX O
Georgia XXX O
members XXX O
of XXX O
the XXX O
American XXX O
College XXX O
of XXX O
Obstetricians XXX O
and XXX O
Gynecologists XXX O
was XXX O
conducted XXX O
. XXX O

Subacute XXX O
diencephalic XXX O
angioencephalopathy XXX O
( XXX O
SDAE XXX O
) XXX O
is XXX O
a XXX O
rare XXX O
and XXX O
fatal XXX O
disease XXX O
of XXX O
unknown XXX O
etiology XXX O
that XXX O
involves XXX O
the XXX O
thalami XXX O
bilaterally XXX O
. XXX O

We XXX O
estimate XXX O
that XXX O
the XXX O
protease XXX B-GENE
activity XXX O
is XXX O
at XXX O
least XXX O
35-fold XXX O
greater XXX O
in XXX O
mature XXX O
B XXX O
cells XXX O
than XXX O
in XXX O
pre-B XXX O
cells XXX O
. XXX O
( XXX O
ABSTRACT XXX O
TRUNCATED XXX O
AT XXX O
250 XXX O
WORDS XXX O
) XXX O

Plectin XXX B-GENE
and XXX O
desmoplakin XXX B-GENE
have XXX O
GSR-containing XXX O
domains XXX O
at XXX O
their XXX O
C-termini XXX O
and XXX O
we XXX O
further XXX O
demonstrate XXX O
that XXX O
the XXX O
GSR-containing XXX O
domain XXX O
of XXX O
plectin XXX B-GENE
, XXX O
but XXX O
not XXX O
desmoplakin XXX B-GENE
, XXX O
can XXX O
bind XXX O
to XXX O
MTs XXX O
in XXX O
vivo XXX O
. XXX O

Vacuolar XXX O
membrane XXX O
vesicles XXX O
from XXX O
hum1 XXX B-GENE
mutants XXX I-GENE
lack XXX O
all XXX O
Ca2+ XXX O
/ XXX O
H+ XXX O
antiport XXX O
activity XXX O
, XXX O
demonstrating XXX O
that XXX O
Hum1p XXX B-GENE
catalyzes XXX O
the XXX O
exchange XXX O
of XXX O
Ca2+ XXX O
for XXX O
H+ XXX O
across XXX O
the XXX O
yeast XXX O
vacuolar XXX O
membrane XXX O
. XXX O

During XXX O
the XXX O
years XXX O
1980-87 XXX O
a XXX O
total XXX O
of XXX O
287 XXX O
persons XXX O
received XXX O
disability XXX O
pensions XXX O
in XXX O
the XXX O
municipality XXX O
of XXX O
Nordreisa XXX O
in XXX O
northern XXX O
Norway XXX O
. XXX O

This XXX O
article XXX O
will XXX O
briefly XXX O
review XXX O
the XXX O
published XXX O
data XXX O
on XXX O
the XXX O
morphology XXX O
, XXX O
function XXX O
, XXX O
and XXX O
biochemistry XXX O
of XXX O
the XXX O
normal XXX O
renal XXX O
medulla XXX O
and XXX O
the XXX O
pathology XXX O
associated XXX O
with XXX O
RPN XXX O
, XXX O
together XXX O
with XXX O
the XXX O
secondary XXX O
changes XXX O
which XXX O
give XXX O
rise XXX O
to XXX O
cortical XXX O
degeneration XXX O
or XXX O
epithelial XXX O
carcinoma XXX O
. XXX O

Novel XXX O
multigene XXX O
families XXX O
encoding XXX O
highly XXX O
repetitive XXX O
peptide XXX O
sequences XXX O
. XXX O

The XXX O
STAT-1 XXX B-GENE
signaling XXX O
pathway XXX O
provides XXX O
at XXX O
least XXX O
one XXX O
mechanism XXX O
for XXX O
activation XXX O
of XXX O
the XXX O
CAEV XXX B-GENE
LTR XXX I-GENE
by XXX O
IFN-gamma XXX B-GENE
in XXX O
monocytes XXX O
. XXX O

A XXX O
single XXX O
1 XXX O
. XXX O
8-kb XXX O
transcript XXX O
mRNA XXX O
was XXX O
detected XXX O
by XXX O
Northern XXX O
( XXX O
RNA XXX O
) XXX O
blot XXX O
analysis XXX O
, XXX O
and XXX O
its XXX O
5' XXX O
end XXX O
maps XXX O
to XXX O
a XXX O
position XXX O
51 XXX O
bp XXX O
upstream XXX O
from XXX O
the XXX O
site XXX O
of XXX O
initiation XXX O
of XXX O
protein XXX O
synthesis XXX O
. XXX O

Patient XXX O
characteristics XXX O
associated XXX O
with XXX O
deep XXX O
wounds XXX O
as XXX O
well XXX O
as XXX O
patient XXX O
and XXX O
wound XXX O
characteristics XXX O
predictive XXX O
of XXX O
the XXX O
extent XXX O
of XXX O
healing XXX O
and XXX O
time XXX O
required XXX O
for XXX O
healing XXX O
were XXX O
identified XXX O
. XXX O

The XXX O
retention XXX O
of XXX O
75SeHCAT XXX O
was XXX O
low XXX O
. XXX O

When XXX O
the XXX O
PHT XXX O
and XXX O
CSA XXX O
groups XXX O
were XXX O
compared XXX O
, XXX O
Hyp XXX O
levels XXX O
were XXX O
significantly XXX O
higher XXX O
in XXX O
the XXX O
PHT-GO+ XXX O
group XXX O
than XXX O
in XXX O
the XXX O
CSA-GO+ XXX O
group XXX O
. XXX O

Sequence XXX O
of XXX O
10q24 XXX B-GENE
locus XXX I-GENE
surrounding XXX O
the XXX O
HOX11 XXX B-GENE
oncogene XXX I-GENE
reveals XXX O
a XXX O
new XXX O
gene XXX O
HUG1 XXX B-GENE
expressed XXX O
in XXX O
a XXX O
T-ALL XXX O
cell XXX O
line XXX O
. XXX O

Using XXX O
in XXX O
organello XXX O
footprint XXX O
analysis XXX O
, XXX O
we XXX O
demonstrate XXX O
that XXX O
within XXX O
human XXX O
placental XXX O
mitochondria XXX O
there XXX O
is XXX O
a XXX O
high XXX O
level XXX O
of XXX O
protein-DNA XXX O
binding XXX O
at XXX O
regularly XXX O
phased XXX O
intervals XXX O
throughout XXX O
a XXX O
500-bp XXX O
region XXX O
encompassing XXX O
the XXX O
D-loop XXX O
DNA XXX O
origins XXX O
and XXX O
two XXX O
promoter XXX O
regions XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
TRP1 XXX O
RI XXX O
Circle XXX O
DNA XXX O
is XXX O
organized XXX O
into XXX O
nucleosomes XXX O
whose XXX O
size XXX O
and XXX O
spacing XXX O
are XXX O
indistinguishable XXX O
from XXX O
that XXX O
of XXX O
bulk XXX O
yeast XXX O
chromatin XXX O
. XXX O

Surprisingly XXX O
, XXX O
the XXX O
CSF1R XXX B-GENE
/ XXX I-GENE
IRDelta960 XXX I-GENE
was XXX O
as XXX O
effective XXX O
as XXX O
the XXX O
CSF1R XXX B-GENE
/ XXX I-GENE
IR XXX I-GENE
in XXX O
mediating XXX O
CSF-1 XXX B-GENE
protection XXX O
of XXX O
cells XXX O
from XXX O
staurosporine-induced XXX O
apoptosis XXX O
. XXX O

Therefore XXX O
, XXX O
we XXX O
suggested XXX O
that XXX O
both XXX O
proteins XXX O
might XXX O
belong XXX O
to XXX O
the XXX O
PLTP XXX B-GENE
family XXX I-GENE
. XXX O

These XXX O
tumors XXX O
were XXX O
classified XXX O
into XXX O
three XXX O
broad XXX O
groups XXX O
: XXX O
I XXX O
, XXX O
cystadenoma XXX O
; XXX O
II XXX O
, XXX O
cystadenocarcinoma XXX O
; XXX O
and XXX O
III XXX O
, XXX O
adenocarcinoma XXX O
with XXX O
mucin XXX O
production XXX O
or XXX O
an XXX O
associated XXX O
cyst XXX O
. XXX O

They XXX O
were XXX O
almost XXX O
regularly XXX O
excited XXX O
by XXX O
pressure XXX O
to XXX O
the XXX O
ipsilateral XXX O
cornea XXX O
or XXX O
to XXX O
both XXX O
corneas XXX O
at XXX O
a XXX O
strength XXX O
well XXX O
above XXX O
the XXX O
human XXX O
corneal XXX O
pain XXX O
threshold XXX O
. XXX O

26 XXX O
micrograms XXX O
PAF XXX B-GENE
or XXX O
placebo XXX O
was XXX O
sprayed XXX O
into XXX O
each XXX O
nasal XXX O
cavity XXX O
8 XXX O
h XXX O
and XXX O
1 XXX O
h XXX O
before XXX O
a XXX O
nasal XXX O
allergen XXX O
challenge XXX O
. XXX O

In XXX O
contrast XXX O
, XXX O
Y239 XXX B-GENE
/ XXX I-GENE
240F XXX I-GENE
Shc XXX I-GENE
, XXX O
but XXX O
not XXX O
Y317F XXX B-GENE
Shc XXX I-GENE
, XXX O
reduced XXX O
the XXX O
EGF-induced XXX O
c-myc XXX B-GENE
message XXX O
. XXX O

The XXX O
wavenumbers XXX O
corresponding XXX O
to XXX O
the XXX O
normal XXX O
modes XXX O
of XXX O
vibration XXX O
were XXX O
calculated XXX O
using XXX O
the XXX O
DFT XXX O
( XXX O
B3LYP XXX O
/ XXX O
6-31G** XXX O
) XXX O
approximation XXX O
and XXX O
their XXX O
agreement XXX O
with XXX O
the XXX O
measured XXX O
values XXX O
improved XXX O
after XXX O
scaling XXX O
of XXX O
the XXX O
associated XXX O
force XXX O
field XXX O
. XXX O

A XXX O
total XXX O
number XXX O
of XXX O
1628 XXX O
cases XXX O
were XXX O
collected XXX O
from XXX O
135 XXX O
medical XXX O
institutions XXX O
. XXX O

The XXX O
small XXX B-GENE
IGF-binding XXX I-GENE
protein XXX I-GENE
is XXX O
abundant XXX O
in XXX O
human XXX O
amniotic XXX O
fluid XXX O
. XXX O

By XXX O
adapting XXX O
a XXX O
method XXX O
for XXX O
DNA-footprinting XXX O
using XXX O
impure XXX O
extracts XXX O
of XXX O
ner XXX B-GENE
overproducing XXX O
cells XXX O
, XXX O
we XXX O
were XXX O
able XXX O
to XXX O
determine XXX O
that XXX O
the XXX O
ner-binding XXX B-GENE
sites XXX I-GENE
are XXX O
located XXX O
between XXX O
nucleotides XXX O
1026 XXX O
and XXX O
1058 XXX O
from XXX O
the XXX O
Mu XXX O
left XXX O
end XXX O
. XXX O

After XXX O
dopamine XXX O
infusion XXX O
in XXX O
women XXX O
with XXX O
polycystic XXX O
ovary XXX O
syndrome XXX O
and XXX O
in XXX O
matched XXX O
controls XXX O
, XXX O
steady XXX O
state XXX O
levels XXX O
of XXX O
plasma XXX O
dopamine XXX O
, XXX O
norepinephrine XXX O
, XXX O
and XXX O
the XXX O
ratio XXX O
of XXX O
dopamine XXX O
/ XXX O
norepinephrine XXX O
were XXX O
similar XXX O
in XXX O
the XXX O
two XXX O
groups XXX O
. XXX O

Delta-aminolevulinic XXX O
acid XXX O
in XXX O
physiological XXX O
conditions XXX O
and XXX O
some XXX O
diseases XXX O
in XXX O
children XXX O
. XXX O

Cloning XXX O
and XXX O
sequencing XXX O
revealed XXX O
that XXX O
dMax XXX B-GENE
contains XXX O
a XXX O
deletion XXX O
spanning XXX O
the XXX O
basic XXX O
region XXX O
and XXX O
helix XXX O
1 XXX O
and XXX O
the XXX O
loop XXX O
of XXX O
the XXX O
helix-loop-helix XXX O
region XXX O
, XXX O
presumably XXX O
as XXX O
a XXX O
result XXX O
of XXX O
alternative XXX O
splicing XXX O
of XXX O
max XXX B-GENE
RNA XXX I-GENE
. XXX O

Mesial XXX O
temporal XXX O
sclerosis XXX O
was XXX O
characterized XXX O
by XXX O
severe XXX O
neuronal XXX O
loss XXX O
accompanied XXX O
by XXX O
gliosis XXX O
occurring XXX O
in XXX O
the XXX O
CA1 XXX O
/ XXX O
prosubiculum XXX O
( XXX O
27 XXX O
patients XXX O
, XXX O
100% XXX O
) XXX O
, XXX O
focally XXX O
in XXX O
the XXX O
dentate XXX O
gyrus XXX O
( XXX O
12 XXX O
patients XXX O
, XXX O
44% XXX O
) XXX O
, XXX O
and XXX O
in XXX O
the XXX O
CA4 XXX O
region XXX O
( XXX O
11 XXX O
patients XXX O
, XXX O
41% XXX O
) XXX O
. XXX O

To XXX O
quantify XXX O
any XXX O
mechanical XXX O
inhibitory XXX O
effect XXX O
of XXX O
nasal XXX O
intermittent XXX O
positive XXX O
pressure XXX O
ventilation XXX O
( XXX O
IPPV XXX O
) XXX O
on XXX O
inspiratory XXX O
activity XXX O
of XXX O
the XXX O
diaphragm XXX O
we XXX O
ventilated XXX O
five XXX O
conscious XXX O
relaxed XXX O
subjects XXX O
on XXX O
two XXX O
occasions XXX O
at XXX O
respiratory XXX O
rates XXX O
similar XXX O
to XXX O
quiet XXX O
breathing XXX O
( XXX O
QB XXX O
) XXX O
and XXX O
at XXX O
three XXX O
levels XXX O
of XXX O
applied XXX O
pressure XXX O
( XXX O
Pappl XXX O
) XXX O
--6 XXX O
, XXX O
9 XXX O
and XXX O
12 XXX O
cmH2O XXX O
, XXX O
each XXX O
during XXX O
hypocapnia XXX O
( XXX O
P XXX O
( XXX O
CO2 XXX O
) XXX O
allowed XXX O
to XXX O
decrease XXX O
) XXX O
and XXX O
eucapnia XXX O
( XXX O
CO2 XXX O
added XXX O
to XXX O
inspired XXX O
gas XXX O
) XXX O
. XXX O

In XXX O
the XXX O
multivariate XXX O
analysis XXX O
, XXX O
six XXX O
variables XXX O
were XXX O
independently XXX O
correlated XXX O
with XXX O
survival XXX O
: XXX O
blood XXX O
urea XXX O
nitrogen XXX O
level XXX O
, XXX O
serum XXX B-GENE
aspartate XXX I-GENE
aminotransferase XXX I-GENE
level XXX O
, XXX O
community-acquired XXX O
vs XXX O
. XXX O
hospital-acquired XXX O
peritonitis XXX O
, XXX O
age XXX O
, XXX O
Child-Pugh XXX O
score XXX O
and XXX O
ileus XXX O
. XXX O

X2 XXX O
test XXX O
, XXX O
with XXX O
Yates XXX O
correction XXX O
if XXX O
need XXX O
, XXX O
was XXX O
used XXX O
as XXX O
statistical XXX O
. XXX O
method XXX O
. XXX O

Carboxy-terminal XXX O
Spc110p XXX B-GENE
truncations XXX O
lacking XXX O
the XXX O
calmodulin XXX B-GENE
binding XXX O
site XXX O
can XXX O
support XXX O
growth XXX O
and XXX O
are XXX O
also XXX O
phosphorylated XXX O
in XXX O
a XXX O
cell XXX O
cycle-specific XXX O
manner XXX O
. XXX O

The XXX O
study XXX O
disclosed XXX O
generalized XXX O
atrophy XXX O
and XXX O
diffuse XXX O
symmetric XXX O
white XXX O
matter XXX O
hypodensities XXX O
. XXX O

Biol XXX O
. XXX O

The XXX O
Penn XXX O
State XXX O
Worry XXX O
Questionnaire XXX O
for XXX O
Children XXX O
( XXX O
PSWQ-C XXX O
) XXX O
is XXX O
a XXX O
14-item XXX O
self-report XXX O
questionnaire XXX O
that XXX O
intends XXX O
to XXX O
measure XXX O
the XXX O
tendency XXX O
of XXX O
children XXX O
to XXX O
engage XXX O
in XXX O
excessive XXX O
, XXX O
generalized XXX O
, XXX O
and XXX O
uncontrollable XXX O
worry XXX O
( XXX O
Chorpita XXX O
et XXX O
al XXX O
. XXX O
, XXX O
Behav XXX O
. XXX O

In XXX O
contrast XXX O
to XXX O
previously XXX O
characterized XXX O
proteophosphoglycans XXX O
, XXX O
the XXX O
ppg1 XXX B-GENE
gene XXX O
product XXX O
is XXX O
predominantly XXX O
membrane-associated XXX O
and XXX O
it XXX O
is XXX O
expressed XXX O
on XXX O
the XXX O
promastigote XXX O
cell XXX O
surface XXX O
. XXX O

The XXX O
greatest XXX O
difference XXX O
between XXX O
the XXX O
Ad7 XXX B-GENE
and XXX I-GENE
Ad5 XXX I-GENE
DBPs XXX I-GENE
is XXX O
the XXX O
absence XXX O
, XXX O
in XXX O
the XXX O
Ad7 XXX O
protein XXX O
, XXX O
of XXX O
12 XXX O
amino XXX O
acids XXX O
located XXX O
between XXX O
the XXX O
two XXX O
functional XXX O
domains XXX O
in XXX O
the XXX O
Ad5 XXX O
protein XXX O
( XXX O
amino XXX O
acids XXX O
151-162 XXX O
) XXX O
. XXX O

Compared XXX O
to XXX O
white-on-white XXX O
( XXX O
W-W XXX O
) XXX O
perimetry XXX O
, XXX O
SWAP XXX O
is XXX O
limited XXX O
clinically XXX O
by XXX O
: XXX O
greater XXX O
variability XXX O
associated XXX O
with XXX O
the XXX O
estimation XXX O
of XXX O
threshold XXX O
, XXX O
ocular XXX O
media XXX O
absorption XXX O
, XXX O
increased XXX O
examination XXX O
duration XXX O
and XXX O
an XXX O
additional XXX O
learning XXX O
effect XXX O
. XXX O

Characteristics XXX O
of XXX O
anesthesia XXX O
and XXX O
resuscitation XXX O
in XXX O
emergency XXX O
lung XXX O
surgery XXX O
. XXX O

Northern XXX O
and XXX O
RT-PCR XXX O
analysis XXX O
of XXX O
Ube3a XXX B-GENE
expression XXX O
in XXX O
mouse XXX O
tissues XXX O
from XXX O
animals XXX O
with XXX O
segmental XXX O
, XXX O
paternal XXX O
uniparental XXX O
disomy XXX O
failed XXX O
to XXX O
detect XXX O
substantially XXX O
reduced XXX O
or XXX O
absent XXX O
expression XXX O
compared XXX O
to XXX O
control XXX O
animals XXX O
, XXX O
failing XXX O
to XXX O
provide XXX O
any XXX O
evidence XXX O
for XXX O
maternal-specific XXX O
expression XXX O
from XXX O
this XXX O
locus XXX O
. XXX O

Age XXX O
and XXX O
sex XXX O
structure XXX O
of XXX O
the XXX O
natural XXX O
population XXX O
of XXX O
Ornithodoros XXX O
tatarovski XXX O
Ol XXX O
. XXX O

Over XXX O
a XXX O
period XXX O
of XXX O
15 XXX O
days XXX O
16% XXX O
of XXX O
the XXX O
dose XXX O
administered XXX O
was XXX O
excreted XXX O
with XXX O
faeces XXX O
and XXX O
0 XXX O
. XXX O
9% XXX O
in XXX O
the XXX O
urine XXX O
. XXX O

Proteolysis XXX O
of XXX O
Mbp1 XXX B-GENE
and XXX O
Swi4 XXX B-GENE
DNA-protein XXX I-GENE
complexes XXX I-GENE
has XXX O
revealed XXX O
the XXX O
extent XXX O
of XXX O
these XXX O
sequences XXX O
, XXX O
and XXX O
C-terminally XXX O
extended XXX O
molecules XXX O
with XXX O
substantially XXX O
enhanced XXX O
DNA XXX O
binding XXX O
activity XXX O
compared XXX O
to XXX O
the XXX O
core XXX O
domains XXX O
alone XXX O
have XXX O
been XXX O
produced XXX O
. XXX O

The XXX O
fourth XXX O
dose XXX O
produced XXX O
favorable XXX O
results XXX O
( XXX O
66 XXX O
. XXX O
7% XXX O
) XXX O
in XXX O
individuals XXX O
with XXX O
HB XXX B-GENE
antibodies XXX I-GENE
between XXX O
10 XXX O
and XXX O
100 XXX O
IU XXX O
/ XXX O
ml XXX O
and XXX O
unfavorable XXX O
ones XXX O
( XXX O
3 XXX O
. XXX O
8% XXX O
) XXX O
where XXX O
the XXX O
HB XXX B-GENE
antibodies XXX I-GENE
were XXX O
below XXX O
10 XXX O
IU XXX O
/ XXX O
ml XXX O
. XXX O

Employing XXX O
this XXX O
sequence XXX O
information XXX O
from XXX O
c11 XXX O
/ XXX O
1 XXX O
, XXX O
the XXX O
c11 XXX O
/ XXX O
1-specific XXX O
cDNA XXX O
was XXX O
generated XXX O
from XXX O
poly XXX O
( XXX O
A XXX O
) XXX O
+RNA XXX O
of XXX O
bovine XXX O
PMNLs XXX O
by XXX O
reverse XXX O
transcription XXX O
and XXX O
a XXX O
combination XXX O
of XXX O
polymerase XXX B-GENE
chain XXX O
reaction XXX O
( XXX O
PCR XXX O
) XXX O
methods XXX O
. XXX O

Cyclophilins XXX B-GENE
are XXX O
cis-trans-peptidyl-prolyl XXX B-GENE
isomerases XXX I-GENE
that XXX O
bind XXX O
to XXX O
and XXX O
are XXX O
inhibited XXX O
by XXX O
the XXX O
immunosuppressant XXX O
cyclosporin XXX O
A XXX O
( XXX O
CsA XXX O
) XXX O
. XXX O

The XXX O
17-kDa XXX O
protein XXX O
is XXX O
required XXX O
for XXX O
the XXX O
systemic XXX O
infection XXX O
of XXX O
plants XXX O
. XXX O

The XXX O
defined XXX O
length XXX O
of XXX O
the XXX O
mRNA XXX O
, XXX O
1 XXX O
, XXX O
838 XXX O
nucleotides XXX O
, XXX O
was XXX O
in XXX O
agreement XXX O
with XXX O
that XXX O
of XXX O
a XXX O
1 XXX O
. XXX O
9-kb XXX O
RNA XXX O
expressed XXX O
throughout XXX O
the XXX O
replication XXX O
cycle XXX O
, XXX O
starting XXX O
at XXX O
the XXX O
early XXX O
stages XXX O
of XXX O
infection XXX O
. XXX O

Consumption XXX O
of XXX O
4% XXX O
sucrose XXX O
was XXX O
not XXX O
affected XXX O
by XXX O
excitotoxic XXX O
lesions XXX O
of XXX O
the XXX O
PPTg XXX O
, XXX O
but XXX O
PPTg XXX O
lesioned XXX O
rats XXX O
consumed XXX O
significantly XXX O
more XXX O
12% XXX O
and XXX O
20% XXX O
sucrose XXX O
than XXX O
sham XXX O
controls XXX O
. XXX O

The XXX O
presence XXX O
in XXX O
such XXX O
patients XXX O
of XXX O
antibodies XXX O
to XXX O
adrenaline XXX O
and XXX O
noradrenaline XXX O
is XXX O
indicative XXX O
of XXX O
considerable XXX O
disruption XXX O
of XXX O
catecholamine XXX O
biotransformation XXX O
. XXX O

Low XXX O
molecular XXX O
weight XXX O
heparins XXX O
have XXX O
stimulated XXX O
much XXX O
interest XXX O
because XXX O
of XXX O
their XXX O
supposedly XXX O
more XXX O
selective XXX O
action XXX O
on XXX O
Xa XXX B-GENE
factor XXX I-GENE
. XXX O

In XXX O
all XXX O
of XXX O
these XXX O
cases XXX O
, XXX O
expression XXX O
of XXX O
the XXX O
implicated XXX O
genes XXX O
was XXX O
absent XXX O
. XXX O

Letter XXX O
: XXX O
Lactose XXX O
tolerance XXX O
tests XXX O
as XXX O
a XXX O
predictor XXX O
of XXX O
milk XXX O
tolerance XXX O
. XXX O

Anastrozole XXX O
is XXX O
the XXX O
first XXX O
aromatase XXX B-GENE
inhibitor XXX O
to XXX O
show XXX O
a XXX O
significant XXX O
survival XXX O
advantage XXX O
over XXX O
megestrol XXX O
acetate XXX O
in XXX O
post-menopausal XXX O
women XXX O
with XXX O
advanced XXX O
breast XXX O
cancer XXX O
. XXX O

These XXX O
genes XXX O
are XXX O
expressed XXX O
within XXX O
a XXX O
few XXX O
hours XXX O
of XXX O
the XXX O
initiation XXX O
of XXX O
development XXX O
; XXX O
their XXX O
mRNAs XXX O
accumulate XXX O
to XXX O
a XXX O
peak XXX O
at XXX O
12 XXX O
hr XXX O
and XXX O
persist XXX O
until XXX O
culmination XXX O
. XXX O

Fourteen XXX O
patients XXX O
with XXX O
New XXX O
York XXX O
Heart XXX O
Association XXX O
class XXX O
II XXX O
congestive XXX O
heart XXX O
failure XXX O
were XXX O
enrolled XXX O
in XXX O
a XXX O
double-blind XXX O
, XXX O
cross-over XXX O
study XXX O
. XXX O

Doxorubicin XXX O
( XXX O
DOX XXX O
) XXX O
is XXX O
commonly XXX O
used XXX O
for XXX O
the XXX O
treatment XXX O
of XXX O
hematological XXX O
and XXX O
solid XXX O
tumors XXX O
. XXX O

The XXX O
third XXX O
domain XXX O
had XXX O
the XXX O
motif XXX O
of XXX O
a XXX O
cAMP XXX B-GENE
response XXX I-GENE
element XXX I-GENE
( XXX O
CRE XXX B-GENE
) XXX O
. XXX O

It XXX O
was XXX O
found XXX O
that XXX O
the XXX O
primary XXX O
visual XXX O
cortex XXX O
of XXX O
the XXX O
rat XXX O
is XXX O
asymmetrical XXX O
in XXX O
volume XXX O
, XXX O
and XXX O
that XXX O
the XXX O
asymmetry XXX O
reflects XXX O
side XXX O
differences XXX O
in XXX O
the XXX O
number XXX O
of XXX O
neurons XXX O
. XXX O

Using XXX O
Spurr's XXX O
resin XXX O
as XXX O
a XXX O
mounting XXX O
medium XXX O
, XXX O
we XXX O
could XXX O
observe XXX O
thick XXX O
specimens XXX O
with XXX O
oil XXX O
immersion XXX O
objective XXX O
lens XXX O
without XXX O
the XXX O
use XXX O
of XXX O
coverslips XXX O
, XXX O
then XXX O
avoid XXX O
air XXX O
bubbles XXX O
near XXX O
the XXX O
specimen XXX O
. XXX O

Mutations XXX O
within XXX O
conserved XXX B-GENE
region XXX I-GENE
2 XXX I-GENE
( XXX O
CR2 XXX B-GENE
) XXX O
of XXX O
E1A XXX B-GENE
that XXX O
inhibit XXX O
the XXX O
binding XXX O
of XXX O
E1A XXX B-GENE
to XXX O
the XXX O
retinoblastoma XXX B-GENE
gene XXX I-GENE
product XXX I-GENE
( XXX O
pRb XXX B-GENE
) XXX O
further XXX O
enhanced XXX O
the XXX O
stimulation XXX O
of XXX O
transcription XXX O
from XXX O
the XXX O
PEPCK XXX B-GENE
promoter XXX I-GENE
by XXX O
2 XXX O
3-fold XXX O
compared XXX O
with XXX O
wild XXX B-GENE
type XXX I-GENE
E1A XXX I-GENE
. XXX O

Factor XXX B-GENE
VIII XXX I-GENE
procoagulant XXX O
activity XXX O
, XXX O
antigen XXX O
concentration XXX O
and XXX O
von XXX O
Willebrand XXX O
activity XXX O
as XXX O
ristocetin XXX B-GENE
cofactor XXX I-GENE
were XXX O
determined XXX O
several XXX O
times XXX O
in XXX O
10 XXX O
patients XXX O
with XXX O
DIC XXX O
. XXX O

In XXX O
the XXX O
presence XXX O
of XXX O
inositol XXX O
and XXX O
choline XXX O
( XXX O
repressing XXX O
) XXX O
, XXX O
the XXX O
product XXX O
of XXX O
the XXX O
OPI1 XXX B-GENE
gene XXX I-GENE
represses XXX O
transcription XXX O
dictated XXX O
by XXX O
the XXX O
UASINO XXX B-GENE
element XXX I-GENE
. XXX O

In XXX O
vitro XXX O
, XXX O
Arix XXX B-GENE
and XXX O
NBPhox XXX B-GENE
form XXX O
DNA-independent XXX O
multimers XXX O
and XXX O
exhibit XXX O
cooperative XXX O
binding XXX O
to XXX O
the XXX O
DB1 XXX B-GENE
regulatory XXX I-GENE
element XXX I-GENE
, XXX O
which XXX O
contains XXX O
two XXX O
homeodomain XXX B-GENE
recognition XXX O
sites XXX O
. XXX O

These XXX O
findings XXX O
suggest XXX O
that XXX O
fodrin XXX B-GENE
proteolysis XXX O
in XXX O
vivo XXX O
may XXX O
reflect XXX O
the XXX O
activity XXX O
of XXX O
multiple XXX O
ICE XXX B-GENE
/ XXX I-GENE
Ced-3 XXX I-GENE
proteases XXX I-GENE
whose XXX O
partial XXX O
sensitivity XXX O
to XXX O
DEVD-CHO XXX O
reflects XXX O
a XXX O
limited XXX O
contribution XXX O
from XXX O
CPP32 XXX B-GENE
, XXX O
or XXX O
an XXX O
ICE XXX B-GENE
/ XXX I-GENE
Ced-3 XXX I-GENE
protease XXX I-GENE
less XXX O
sensitive XXX O
than XXX O
CPP32 XXX B-GENE
to XXX O
DEVD-CHO XXX O
inhibition XXX O
. XXX O

Molecular XXX O
cloning XXX O
of XXX O
the XXX O
human XXX O
homolog XXX O
of XXX O
a XXX O
striatum-enriched XXX B-GENE
phosphatase XXX I-GENE
( XXX B-GENE
STEP XXX I-GENE
) XXX I-GENE
gene XXX I-GENE
and XXX O
chromosomal XXX O
mapping XXX O
of XXX O
the XXX O
human XXX O
and XXX O
murine XXX O
loci XXX O
. XXX O

According XXX O
to XXX O
the XXX O
investigation XXX O
, XXX O
the XXX O
recent XXX O
burst XXX O
of XXX O
pseudoterranovosis XXX O
in XXX O
this XXX O
area XXX O
can XXX O
be XXX O
attributed XXX O
to XXX O
the XXX O
increased XXX O
presence XXX O
of XXX O
sea XXX O
lions XXX O
, XXX O
which XXX O
proliferate XXX O
in XXX O
the XXX O
Arctic XXX O
region XXX O
, XXX O
then XXX O
migrate XXX O
to XXX O
the XXX O
northern XXX O
Japan XXX O
Sea XXX O
and XXX O
eat XXX O
the XXX O
intermediate XXX O
host XXX O
fish XXX O
. XXX O

Flow XXX O
cytomery XXX O
was XXX O
used XXX O
for XXX O
cell XXX O
cycle XXX O
analysis XXX O
. XXX O

Mutations XXX O
in XXX O
seven XXX O
other XXX O
lts XXX B-GENE
genes XXX I-GENE
do XXX O
not XXX O
result XXX O
in XXX O
the XXX O
mak- XXX B-GENE
phenotype XXX I-GENE
. XXX O

The XXX O
tramtrack XXX B-GENE
( XXX O
ttk XXX B-GENE
) XXX O
gene XXX O
of XXX O
Drosophila XXX O
encodes XXX O
69-kDa XXX O
and XXX O
88-kDa XXX O
proteins XXX O
through XXX O
alternative XXX O
splicing XXX O
of XXX O
the XXX O
primary XXX O
ttk XXX B-GENE
transcript XXX I-GENE
. XXX O

The XXX O
lowest XXX O
detectable XXX O
concentration XXX O
was XXX O
1 XXX O
. XXX O
0 XXX O
ng XXX O
/ XXX O
ml XXX O
in XXX O
the XXX O
serum XXX O
. XXX O

The XXX O
examination XXX O
was XXX O
focused XXX O
on XXX O
assessment XXX O
of XXX O
different XXX O
types XXX O
of XXX O
drusen XXX O
, XXX O
on XXX O
evaluation XXX O
of XXX O
the XXX O
development XXX O
and XXX O
incidence XXX O
of XXX O
risk XXX O
factors XXX O
leading XXX O
to XXX O
complications XXX O
and XXX O
loss XXX O
of XXX O
central XXX O
vision XXX O
. XXX O

In XXX O
spite XXX O
of XXX O
much XXX O
effort XXX O
, XXX O
no XXX O
one XXX O
has XXX O
succeeded XXX O
in XXX O
isolating XXX O
and XXX O
characterizing XXX O
the XXX O
enzyme XXX O
( XXX O
s XXX O
) XXX O
responsible XXX O
for XXX O
synthesis XXX O
of XXX O
cellulose XXX B-GENE
, XXX O
the XXX O
major XXX O
cell XXX O
wall XXX O
polymer XXX O
of XXX O
plants XXX O
. XXX O

Clinical XXX O
value XXX O
of XXX O
the XXX O
estimation XXX O
of XXX O
growth XXX O
kinetics XXX O
of XXX O
primary XXX O
ovarian XXX O
cancer XXX O
recurrences XXX O
by XXX O
CA125 XXX B-GENE
doubling XXX O
time XXX O
. XXX O

Dystonic XXX O
movement XXX O
of XXX O
the XXX O
left XXX O
upper XXX O
limb XXX O
in XXX O
a XXX O
case XXX O
of XXX O
the XXX O
right XXX O
pontine XXX O
hemorrhage XXX O
. XXX O

TNF-alpha XXX B-GENE
induced XXX O
a XXX O
dose- XXX O
and XXX O
time-dependent XXX O
increase XXX O
in XXX O
cyclooxygenase-2 XXX B-GENE
( XXX O
COX-2 XXX B-GENE
) XXX O
expression XXX O
and XXX O
PGE2 XXX O
formation XXX O
in XXX O
human XXX O
NCI-H292 XXX O
epithelial XXX O
cells XXX O
. XXX O

After XXX O
a XXX O
survey XXX O
of XXX O
the XXX O
anatomical XXX O
and XXX O
physiological XXX O
basis XXX O
of XXX O
operative XXX O
treatment XXX O
of XXX O
behaviour XXX O
disorders XXX O
by XXX O
stereotactic XXX O
lesions XXX O
in XXX O
the XXX O
amygdala XXX O
and XXX O
the XXX O
posterior XXX O
medial XXX O
hypothalamus XXX O
the XXX O
author XXX O
describes XXX O
his XXX O
own XXX O
experiences XXX O
with XXX O
603 XXX O
operations XXX O
for XXX O
control XXX O
of XXX O
conservatively XXX O
untreatable XXX O
aggressiveness XXX O
. XXX O

Although XXX O
most XXX O
SFV XXX B-GENE
genes XXX I-GENE
have XXX O
homologs XXX O
encoded XXX O
by XXX O
other XXX O
Chordopoxvirinae XXX O
, XXX O
the XXX O
SFV XXX O
genome XXX O
lacks XXX O
a XXX O
key XXX O
gene XXX O
required XXX O
for XXX O
the XXX O
production XXX O
of XXX O
extracellular XXX O
enveloped XXX O
virus XXX O
. XXX O

Interleukin-6 XXX B-GENE
may XXX O
possibly XXX O
potentiate XXX O
metastasis XXX O
of XXX O
cardiac XXX O
myxoma XXX O
. XXX O

We XXX O
have XXX O
determined XXX O
that XXX O
several XXX O
E1 XXX B-GENE
mutants XXX I-GENE
mapping XXX O
in XXX O
both XXX O
the XXX O
M XXX O
and XXX O
R XXX O
regions XXX O
and XXX O
a XXX O
single XXX O
mutant XXX O
of XXX O
the XXX O
upstream XXX O
regulatory XXX O
region XXX O
have XXX O
a XXX O
higher XXX O
transforming XXX O
activity XXX O
on XXX O
mouse XXX O
C127 XXX O
cells XXX O
than XXX O
the XXX O
wild-type XXX O
genome XXX O
does XXX O
. XXX O

Antimicrobial XXX O
substance XXX O
isolated XXX O
from XXX O
an XXX O
acorn XXX O
extract XXX O
. XXX O

Army XXX O
veterans XXX O
given XXX O
yellow XXX O
fever XXX O
vaccine XXX O
contaminated XXX O
with XXX O
hepatitis XXX O
B XXX O
virus XXX O
in XXX O
1942 XXX O
and XXX O
controls XXX O
and XXX O
( XXX O
b XXX O
) XXX O
a XXX O
case-control XXX O
study XXX O
comparing XXX O
veterans XXX O
with XXX O
hepatocellular XXX O
carcinoma XXX O
in XXX O
Veterans XXX O
Affairs XXX O
hospitals XXX O
with XXX O
matched XXX O
controls XXX O
with XXX O
respect XXX O
to XXX O
receipt XXX O
of XXX O
contaminated XXX O
vaccine XXX O
in XXX O
1942 XXX O
. XXX O

The XXX O
IA4 XXX B-GENE
mAb XXX I-GENE
was XXX O
identified XXX O
among XXX O
a XXX O
series XXX O
of XXX O
antibodies XXX O
raised XXX O
in XXX O
BALB XXX O
/ XXX O
c XXX O
mice XXX O
after XXX O
immunization XXX O
against XXX O
a XXX O
HLA XXX B-GENE
class XXX O
I-deficient XXX O
, XXX O
lymphokine-activated XXX O
killer XXX O
( XXX O
LAK XXX O
) XXX O
-susceptible XXX O
EBV-B XXX O
lymphocyte XXX O
line XXX O
. XXX O

This XXX O
is XXX O
the XXX O
first XXX O
description XXX O
, XXX O
to XXX O
our XXX O
knowledge XXX O
, XXX O
of XXX O
regulatory XXX O
elements XXX O
that XXX O
control XXX O
expression XXX O
of XXX O
a XXX O
gene XXX O
encoding XXX O
a XXX O
B7 XXX B-GENE
costimulatory XXX I-GENE
molecule XXX I-GENE
. XXX O

Particularly XXX O
striking XXX O
was XXX O
the XXX O
conservation XXX O
of XXX O
an XXX O
AP-4 XXX B-GENE
binding XXX I-GENE
site XXX I-GENE
within XXX O
100 XXX O
nucleotides XXX O
upstream XXX O
of XXX O
the XXX O
transcription XXX O
initiation XXX O
site XXX O
in XXX O
both XXX O
Aal-rpL34 XXX B-GENE
and XXX O
Aal-rpL8 XXX B-GENE
genes XXX I-GENE
. XXX O

We XXX O
find XXX O
that XXX O
beta XXX B-GENE
II XXX I-GENE
PKC XXX I-GENE
phosphorylates XXX O
nuclear XXX B-GENE
envelope XXX I-GENE
lamin XXX I-GENE
B XXX I-GENE
at XXX O
10-20 XXX O
times XXX O
the XXX O
rate XXX O
of XXX O
alpha XXX B-GENE
PKC XXX I-GENE
, XXX O
whereas XXX O
both XXX O
kinases XXX B-GENE
phosphorylate XXX O
soluble XXX B-GENE
lamin XXX I-GENE
B XXX I-GENE
at XXX O
similar XXX O
rates XXX O
. XXX O

Gel XXX O
route XXX O
preparation XXX O
of XXX O
low XXX O
fusing XXX O
dental XXX O
porcelain XXX O
frit XXX O
. XXX O

The XXX O
Aa-Pri2 XXX B-GENE
gene XXX I-GENE
, XXX O
specifically XXX O
expressed XXX O
during XXX O
basidiocarp XXX O
differentiation XXX O
of XXX O
the XXX O
mushroom XXX O
Agrocybe XXX O
aegerita XXX O
, XXX O
was XXX O
cloned XXX O
. XXX O

Even XXX O
when XXX O
the XXX O
inoculum XXX O
size XXX O
was XXX O
reduced XXX O
sixfold XXX O
( XXX O
i XXX O
. XXX O
e XXX O
. XXX O
, XXX O
6 XXX O
x XXX O
10 XXX O
( XXX O
6 XXX O
) XXX O
CFU XXX O
/ XXX O
mouse XXX O
) XXX O
, XXX O
50% XXX O
of XXX O
the XXX O
RB6-8C5-treated XXX O
animals XXX O
died XXX O
within XXX O
6 XXX O
days XXX O
. XXX O

YAC XXX O
and XXX O
cosmid XXX O
contigs XXX O
spanning XXX O
the XXX O
BRCA1 XXX B-GENE
region XXX I-GENE
were XXX O
used XXX O
to XXX O
select XXX O
cDNA XXX O
clones XXX O
from XXX O
pools XXX O
of XXX O
cDNAs XXX O
derived XXX O
from XXX O
human XXX O
placenta XXX O
, XXX O
HeLa XXX O
cells XXX O
, XXX O
activated XXX O
T XXX O
cells XXX O
, XXX O
and XXX O
fetal XXX O
head XXX O
. XXX O

These XXX O
results XXX O
illuminate XXX O
a XXX O
hitherto XXX O
unanticipated XXX O
function XXX O
of XXX O
U6 XXX B-GENE
RNA XXX I-GENE
: XXX O
the XXX O
modulation XXX O
of XXX O
a XXX O
phosphorylation-dephosphorylation XXX O
cycle XXX O
of XXX O
C1 XXX B-GENE
hnRNP XXX I-GENE
protein XXX I-GENE
that XXX O
influences XXX O
the XXX O
binding XXX O
affinity XXX O
of XXX O
this XXX O
protein XXX O
for XXX O
pre-mRNA XXX O
. XXX O

The XXX O
interaction XXX O
between XXX O
DDB XXX B-GENE
and XXX O
E2F1 XXX B-GENE
can XXX O
also XXX O
be XXX O
detected XXX O
by XXX O
coimmunoprecipitation XXX O
experiments XXX O
. XXX O

Differentiation XXX O
was XXX O
not XXX O
observed XXX O
after XXX O
cellular XXX O
expression XXX O
of XXX O
GTPase-deficient XXX O
forms XXX O
of XXX O
alpha XXX B-GENE
i2 XXX I-GENE
or XXX O
alpha XXX B-GENE
0 XXX I-GENE
, XXX O
indicating XXX O
selectivity XXX O
for XXX O
the XXX O
Gq XXX B-GENE
family XXX I-GENE
of XXX O
G XXX B-GENE
proteins XXX I-GENE
. XXX O

In XXX O
most XXX O
cases XXX O
of XXX O
acute XXX O
transmural XXX O
infarction XXX O
, XXX O
the XXX O
reciprocal XXX O
ST XXX O
segment XXX O
depressions XXX O
observed XXX O
in XXX O
contralateral XXX O
leads XXX O
are XXX O
less XXX O
marked XXX O
than XXX O
the XXX O
primary XXX O
ST XXX O
segment XXX O
elevations XXX O
. XXX O

This XXX O
expression XXX O
assumes XXX O
: XXX O
( XXX O
1 XXX O
) XXX O
a XXX O
laminar XXX O
flow XXX O
regimen XXX O
during XXX O
expiration XXX O
, XXX O
and XXX O
( XXX O
2 XXX O
) XXX O
a XXX O
constant XXX O
CT XXX O
value XXX O
over XXX O
the XXX O
range XXX O
of XXX O
VT XXX O
. XXX O

Mutation XXX O
of XXX O
the XXX O
central XXX O
Tyr497 XXX O
to XXX O
Phe XXX O
blocks XXX O
the XXX O
tyrosine XXX O
phosphorylation XXX O
of XXX O
the XXX O
insulin XXX B-GENE
receptor XXX I-GENE
substrate XXX I-GENE
1 XXX I-GENE
( XXX O
IRS1 XXX B-GENE
) XXX O
and XXX O
diminishes XXX O
proliferation XXX O
in XXX O
response XXX O
to XXX O
IL-4 XXX B-GENE
. XXX O

ULKs XXX B-GENE
and XXX O
UNC-51 XXX B-GENE
share XXX O
a XXX O
typical XXX O
domain XXX O
structure XXX O
of XXX O
an XXX O
amino-terminal XXX B-GENE
kinase XXX I-GENE
domain XXX I-GENE
, XXX O
a XXX O
central XXX O
proline XXX O
/ XXX O
serine XXX O
rich XXX O
( XXX O
PS XXX O
) XXX O
domain XXX O
, XXX O
and XXX O
a XXX O
carboxy-terminal XXX O
( XXX O
C XXX O
) XXX O
domain XXX O
. XXX O

The XXX O
pathophysiology XXX O
and XXX O
clinical XXX O
management XXX O
of XXX O
acute XXX O
brain XXX O
injury XXX O
in XXX O
infancy XXX O
and XXX O
childhood XXX O
are XXX O
presented XXX O
using XXX O
acute XXX O
traumatic XXX O
brain XXX O
injury XXX O
as XXX O
a XXX O
model XXX O
. XXX O

Comparison XXX O
of XXX O
German XXX O
language XXX O
versions XXX O
of XXX O
the XXX O
QWB-SA XXX O
and XXX O
SF-36 XXX O
evaluating XXX O
outcomes XXX O
for XXX O
patients XXX O
with XXX O
prostate XXX O
disease XXX O
. XXX O

RBP56 XXX B-GENE
protein XXX I-GENE
turned XXX O
out XXX O
to XXX O
be XXX O
hTAFII68 XXX B-GENE
which XXX O
was XXX O
isolated XXX O
as XXX O
a XXX O
TATA-binding XXX B-GENE
protein XXX I-GENE
associated XXX I-GENE
factor XXX I-GENE
( XXX O
TAF XXX B-GENE
) XXX O
from XXX O
a XXX O
sub-population XXX O
of XXX O
TFIID XXX B-GENE
complexes XXX I-GENE
( XXX O
Bertolotti XXX O
A XXX O
. XXX O
, XXX O
Lutz XXX O
, XXX O
Y XXX O
. XXX O
, XXX O
Heard XXX O
, XXX O
D XXX O
. XXX O
J XXX O
. XXX O
, XXX O
Chambon XXX O
, XXX O
P XXX O
. XXX O
, XXX O
Tora XXX O
, XXX O
L XXX O
. XXX O
, XXX O
1996 XXX O
. XXX O
hTAFII68 XXX B-GENE
, XXX O
a XXX O
novel XXX O
RNA XXX B-GENE
/ XXX I-GENE
ssDNA-binding XXX I-GENE
protein XXX I-GENE
with XXX O
homology XXX O
to XXX O
the XXX O
proto-oncoproteins XXX B-GENE
TLS XXX I-GENE
/ XXX I-GENE
FUS XXX I-GENE
and XXX O
EWS XXX B-GENE
is XXX O
associated XXX O
with XXX O
both XXX O
TFIID XXX B-GENE
and XXX O
RNA XXX B-GENE
polymerase XXX I-GENE
II XXX I-GENE
. XXX O

Effect XXX O
of XXX O
acute XXX O
and XXX O
chronic XXX O
psychogenic XXX O
stress XXX O
on XXX O
corticoadrenal XXX O
and XXX O
pituitary-thyroid XXX O
hormones XXX O
in XXX O
male XXX O
rats XXX O
. XXX O

Capnography XXX O
curves XXX O
of XXX O
40 XXX O
HVS XXX O
patients XXX O
, XXX O
40 XXX O
non-HVS XXX O
patients XXX O
with XXX O
psycho-somatic XXX O
complaints XXX O
and XXX O
26 XXX O
healthy XXX O
controls XXX O
were XXX O
analyzed XXX O
. XXX O

The XXX O
majority XXX O
of XXX O
tumors XXX O
occurred XXX O
in XXX O
the XXX O
nasal XXX O
cavities XXX O
, XXX O
although XXX O
significant XXX O
incidences XXX O
were XXX O
also XXX O
found XXX O
in XXX O
the XXX O
larynx XXX O
, XXX O
trachea XXX O
and XXX O
stem XXX O
bronchi XXX O
. XXX O

Human XXX B-GENE
LTBP-1 XXX I-GENE
is XXX O
known XXX O
to XXX O
exist XXX O
in XXX O
different XXX O
forms XXX O
. XXX O

In XXX O
contrast XXX O
, XXX O
the XXX O
lumenal XXX O
domains XXX O
of XXX O
Sec12p XXX B-GENE
, XXX O
Stl1p XXX B-GENE
and XXX O
Stl2p XXX B-GENE
are XXX O
very XXX O
different XXX O
in XXX O
size XXX O
and XXX O
do XXX O
not XXX O
show XXX O
any XXX O
appreciable XXX O
homology XXX O
. XXX O

Our XXX O
results XXX O
suggest XXX O
that XXX O
the XXX O
central XXX O
role XXX O
of XXX O
the XXX O
Notch-CBF1 XXX B-GENE
/ XXX I-GENE
RBP-Jkappa XXX I-GENE
signaling XXX I-GENE
pathway XXX I-GENE
in XXX O
cell XXX O
fate XXX O
decisions XXX O
renders XXX O
it XXX O
susceptible XXX O
to XXX O
pathways XXX O
of XXX O
viral XXX O
replication XXX O
and XXX O
oncogenic XXX O
conversion XXX O
. XXX O

The XXX O
possibility XXX O
of XXX O
selective XXX O
chemotherapy XXX O
of XXX O
progressive XXX O
recurring XXX O
ovarian XXX O
carcinoma XXX O
with XXX O
the XXX O
aid XXX O
of XXX O
cytodiagnosis XXX O
and XXX O
incorporation XXX O
of XXX O
tagged XXX O
idoxuridine XXX O
. XXX O

Well-visualised XXX O
arteriograms XXX O
of XXX O
the XXX O
limbs XXX O
can XXX O
be XXX O
obtained XXX O
by XXX O
xeroradiography XXX O
after XXX O
rapid XXX O
manual XXX O
injection XXX O
of XXX O
contrast-medium XXX O
into XXX O
an XXX O
arm XXX O
vein XXX O
, XXX O
as XXX O
demonstrated XXX O
in XXX O
28 XXX O
patients XXX O
. XXX O

To XXX O
determine XXX O
the XXX O
genetic XXX O
basis XXX O
for XXX O
the XXX O
differences XXX O
between XXX O
the XXX O
cardiac XXX O
and XXX O
brain XXX B-GENE
AE3 XXX I-GENE
variants XXX I-GENE
, XXX O
we XXX O
isolated XXX O
and XXX O
characterized XXX O
the XXX O
rat XXX O
gene XXX O
. XXX O

All XXX O
ABFI-binding XXX B-GENE
sites XXX I-GENE
, XXX O
regardless XXX O
of XXX O
origin XXX O
, XXX O
provided XXX O
weak XXX O
UAS XXX O
function XXX O
in XXX O
vivo XXX O
when XXX O
examined XXX O
in XXX O
test XXX O
plasmids XXX O
. XXX O

Patterns XXX O
of XXX O
connections XXX O
underlying XXX O
cross-modality XXX O
integration XXX O
were XXX O
studied XXX O
by XXX O
injecting XXX O
distinguishable XXX O
, XXX O
retrograde XXX O
tracers XXX O
( XXX O
Fluoro-Gold XXX O
and XXX O
diamidino XXX O
yellow XXX O
) XXX O
in XXX O
pairwise XXX O
manner XXX O
into XXX O
different XXX O
sensory XXX O
representations XXX O
( XXX O
visual XXX O
, XXX O
somatosensory XXX O
, XXX O
and XXX O
auditory XXX O
) XXX O
in XXX O
the XXX O
cerebral XXX O
cortex XXX O
of XXX O
the XXX O
rat XXX O
. XXX O

In XXX O
this XXX O
study XXX O
we XXX O
have XXX O
investigated XXX O
the XXX O
role XXX O
of XXX O
C XXX B-GENE
/ XXX I-GENE
EBP XXX I-GENE
beta XXX I-GENE
in XXX O
initiating XXX O
the XXX O
adipogenic XXX O
program XXX O
by XXX O
overexpressing XXX O
C XXX B-GENE
/ XXX I-GENE
EBP XXX I-GENE
beta XXX I-GENE
in XXX O
multipotential XXX O
NIH-3T3 XXX O
fibroblasts XXX O
. XXX O

Peripheral XXX O
polyneuropathy XXX O
associated XXX O
with XXX O
multiple XXX O
myeloma XXX O
. XXX O

As XXX O
hypothesized XXX O
, XXX O
believers XXX O
showed XXX O
relatively XXX O
higher XXX O
right XXX O
hemispheric XXX O
activation XXX O
and XXX O
reduced XXX O
hemispheric XXX O
asymmetry XXX O
of XXX O
functional XXX O
complexity XXX O
. XXX O

In XXX O
the XXX O
whole XXX O
group XXX O
, XXX O
basal XXX O
GH XXX B-GENE
and XXX O
somatomedin-C XXX B-GENE
levels XXX O
decreased XXX O
from XXX O
a XXX O
mean XXX O
( XXX O
+ XXX O
/ XXX O
- XXX O
standard XXX O
error XXX O
of XXX O
the XXX O
mean XXX O
) XXX O
of XXX O
52 XXX O
. XXX O
3 XXX O
+ XXX O
/ XXX O
- XXX O
12 XXX O
. XXX O
7 XXX O
to XXX O
11 XXX O
. XXX O
1 XXX O
+ XXX O
/ XXX O
- XXX O
6 XXX O
. XXX O
3 XXX O
ng XXX O
/ XXX O
ml XXX O
and XXX O
from XXX O
7 XXX O
. XXX O
6 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
7 XXX O
to XXX O
2 XXX O
. XXX O
5 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
5 XXX O
U XXX O
/ XXX O
ml XXX O
, XXX O
respectively XXX O
. XXX O

We XXX O
describe XXX O
49 XXX O
cases XXX O
with XXX O
papillary XXX O
tumor XXX O
< XXX O
1 XXX O
cm XXX O
. XXX O

Structure XXX O
and XXX O
regulation XXX O
of XXX O
the XXX O
gene XXX O
encoding XXX O
the XXX O
neuron-specific XXX O
protein XXX B-GENE
kinase XXX I-GENE
C XXX I-GENE
substrate XXX O
neurogranin XXX B-GENE
( XXX O
RC3 XXX B-GENE
protein XXX I-GENE
) XXX O
. XXX O

In XXX O
group XXX O
I XXX O
, XXX O
Paw XXX O
, XXX O
delta XXX O
V XXX O
, XXX O
PaO2 XXX O
, XXX O
Vinj XXX O
and XXX O
VT XXX O
significantly XXX O
decreased XXX O
whereas XXX O
operating XXX O
pressure XXX O
and XXX O
E XXX O
significantly XXX O
increased XXX O
when XXX O
the XXX O
internal XXX O
diameter XXX O
of XXX O
the XXX O
injector XXX O
cannula XXX O
was XXX O
reduced XXX O
. XXX O

Transient XXX O
hyperammonaemia XXX O
in XXX O
an XXX O
adult XXX O
German XXX O
shepherd XXX O
dog XXX O
. XXX O

Because XXX O
of XXX O
concerns XXX O
regarding XXX O
blood XXX O
transfusion-related XXX O
communicable XXX O
disease XXX O
( XXX O
eg XXX O
, XXX O
acquired XXX O
immune XXX O
deficiency XXX O
syndrome XXX O
and XXX O
non-A XXX O
, XXX O
non-B XXX O
hepatitis XXX O
) XXX O
, XXX O
there XXX O
has XXX O
been XXX O
increasing XXX O
research XXX O
effort XXX O
into XXX O
postoperative XXX O
hemorrhage XXX O
related XXX O
to XXX O
cardiopulmonary XXX O
bypass XXX O
with XXX O
extracorporeal XXX O
circulation XXX O
. XXX O

Inhibition XXX O
of XXX O
the XXX O
Raf-1 XXX B-GENE
kinase XXX I-GENE
by XXX O
cyclic XXX O
AMP XXX O
agonists XXX O
causes XXX O
apoptosis XXX O
of XXX O
v-abl-transformed XXX O
cells XXX O
. XXX O

CREB XXX B-GENE
was XXX O
identified XXX O
as XXX O
one XXX O
of XXX O
the XXX O
protein XXX O
components XXX O
in XXX O
several XXX O
of XXX O
the XXX O
gel XXX O
shift XXX O
complexes XXX O
formed XXX O
with XXX O
the XXX O
variant XXX O
CRE XXX B-GENE
. XXX O

About XXX O
20% XXX O
of XXX O
single-stranded XXX O
DNA XXX O
binding XXX O
was XXX O
observed XXX O
in XXX O
the XXX O
presence XXX O
of XXX O
MgdTDP XXX O
, XXX O
but XXX O
none XXX O
was XXX O
detectable XXX O
in XXX O
the XXX O
absence XXX O
of XXX O
nucleotides XXX O
. XXX O

Biol XXX O
. XXX O

Mammalian XXX O
sperm XXX O
motility XXX O
is XXX O
regulated XXX O
by XXX O
a XXX O
cascade XXX O
of XXX O
cAMP-dependent XXX O
protein XXX O
phosphorylation XXX O
events XXX O
mediated XXX O
by XXX O
protein XXX B-GENE
kinase XXX I-GENE
A XXX O
. XXX O

The XXX O
"tobacco XXX O
issue" XXX O
. XXX O

Diltiazem XXX O
resulted XXX O
in XXX O
a XXX O
significant XXX O
increase XXX O
in XXX O
epicardial XXX O
diameter XXX O
( XXX O
+10% XXX O
; XXX O
p XXX O
= XXX O
0 XXX O
. XXX O
001 XXX O
) XXX O
and XXX O
in XXX O
coronary XXX O
blood XXX O
flow XXX O
( XXX O
CBF XXX O
) XXX O
( XXX O
+30% XXX O
; XXX O
p XXX O
= XXX O
0 XXX O
. XXX O
0001 XXX O
) XXX O
. XXX O

Myelomatous XXX O
pleural XXX O
effusion XXX O
as XXX O
presentation XXX O
form XXX O
of XXX O
multiple XXX O
myeloma XXX O
. XXX O

These XXX O
results XXX O
establish XXX O
that XXX O
hydroquinones XXX O
lead XXX O
to XXX O
mutagenicity XXX O
and XXX O
carcinogenicity XXX O
. XXX O

Glutamic XXX O
acid XXX O
in XXX O
a XXX O
dose XXX O
of XXX O
1 XXX O
/ XXX O
100 XXX O
of XXX O
the XXX O
LD50 XXX O
was XXX O
injected XXX O
in XXX O
the XXX O
form XXX O
of XXX O
sodium XXX O
salt XXX O
into XXX O
male XXX O
and XXX O
female XXX O
Wistar XXX O
rats XXX O
for XXX O
7 XXX O
days XXX O
after XXX O
8- XXX O
and XXX O
12-day XXX O
injections XXX O
of XXX O
dexazone XXX O
. XXX O

Members XXX O
of XXX O
the XXX O
JAK XXX B-GENE
/ XXX I-GENE
Tyk XXX I-GENE
family XXX I-GENE
of XXX O
tyrosine XXX B-GENE
kinases XXX I-GENE
mediate XXX O
phosphorylation XXX O
of XXX O
STAT3 XXX B-GENE
at XXX O
Tyr705 XXX O
during XXX O
CNTF XXX B-GENE
signaling XXX O
; XXX O
however XXX O
, XXX O
the XXX O
kinase XXX B-GENE
responsible XXX O
for XXX O
phosphorylation XXX O
at XXX O
STAT3 XXX B-GENE
Tyr727 XXX O
appears XXX O
to XXX O
depend XXX O
on XXX O
both XXX O
the XXX O
extracellular XXX O
stimulus XXX O
and XXX O
the XXX O
cellular XXX O
context XXX O
. XXX O

Also XXX O
, XXX O
HR21ap XXX B-GENE
as XXX O
well XXX O
as XXX O
HR21Xap XXX B-GENE
are XXX O
specific XXX O
in XXX O
their XXX O
inhibition XXX O
of XXX O
Sp1 XXX B-GENE
binding XXX O
. XXX O

This XXX O
promoter XXX O
segment XXX O
could XXX O
drive XXX O
expression XXX O
of XXX O
a XXX O
luciferase XXX B-GENE
reporter XXX I-GENE
gene XXX I-GENE
, XXX O
could XXX O
confer XXX O
correct XXX O
transcriptional XXX O
initiation XXX O
to XXX O
the XXX O
reporter XXX O
and XXX O
could XXX O
confer XXX O
the XXX O
EGF-responsiveness XXX O
previously XXX O
observed XXX O
in XXX O
the XXX O
native XXX O
gene XXX O
. XXX O

Isolation XXX O
and XXX O
identification XXX O
of XXX O
genes XXX O
activating XXX O
UAS2-dependent XXX B-GENE
ADH2 XXX I-GENE
expression XXX O
in XXX O
Saccharomyces XXX O
cerevisiae XXX O
. XXX O

Methisergide XXX O
( XXX O
0 XXX O
. XXX O
5 XXX O
mg XXX O
/ XXX O
kg XXX O
, XXX O
i XXX O
. XXX O
p XXX O
. XXX O
) XXX O
, XXX O
a XXX O
blocker XXX O
of XXX O
serotonin XXX B-GENE
receptors XXX I-GENE
, XXX O
prevented XXX O
the XXX O
development XXX O
of XXX O
the XXX O
antinociceptive XXX O
effect XXX O
of XXX O
serotonin XXX O
. XXX O

Although XXX O
the XXX O
binding XXX O
of XXX O
IE2 XXX B-GENE
86 XXX I-GENE
to XXX O
nonphosphorylated XXX O
full-length XXX B-GENE
CREB XXX I-GENE
or XXX O
deltaCREB XXX B-GENE
is XXX O
minimal XXX O
, XXX O
IE2 XXX B-GENE
86 XXX I-GENE
does XXX O
form XXX O
complexes XXX O
with XXX O
p300 XXX B-GENE
and XXX O
the XXX O
CREB-binding XXX B-GENE
protein XXX I-GENE
( XXX O
CBP XXX B-GENE
) XXX O
, XXX O
which XXX O
in XXX O
turn XXX O
bind XXX O
to XXX O
CREB XXX B-GENE
and XXX O
can XXX O
serve XXX O
as XXX O
adaptor XXX O
proteins XXX O
for XXX O
CREB XXX B-GENE
function XXX O
. XXX O

These XXX O
results XXX O
demonstrate XXX O
that XXX O
endogenous XXX O
N-methylation XXX O
of XXX O
salsolinol XXX O
into XXX O
N-methylsalsolinol XXX O
occurs XXX O
in XXX O
the XXX O
brain XXX O
in XXX O
vivo XXX O
. XXX O

The XXX O
peptide XXX O
sequence XXX O
contains XXX O
a XXX O
region XXX O
of XXX O
80 XXX O
amino XXX O
acids XXX O
that XXX O
shows XXX O
similarity XXX O
to XXX O
bcl-2 XXX B-GENE
and XXX O
to XXX O
the XXX O
recently XXX O
described XXX O
bcl-2-related XXX B-GENE
gene XXX I-GENE
, XXX O
MCL1 XXX B-GENE
. XXX O

Survival XXX O
was XXX O
calculated XXX O
both XXX O
from XXX O
the XXX O
date XXX O
of XXX O
onset XXX O
and XXX O
from XXX O
the XXX O
date XXX O
of XXX O
diagnosis XXX O
. XXX O

Reverse XXX O
transcription-PCR XXX O
analysis XXX O
of XXX O
mRNA XXX O
from XXX O
patients XXX O
shows XXX O
that XXX O
each XXX O
of XXX O
these XXX O
five XXX O
mutations XXX O
results XXX O
in XXX O
aberrant XXX O
splicing XXX O
. XXX O

Acute XXX O
inhalation XXX O
toxicity XXX O
of XXX O
T-2 XXX O
mycotoxin XXX O
in XXX O
mice XXX O
. XXX O

Envelope-function XXX O
matching XXX O
conditions XXX O
for XXX O
GaAs XXX B-GENE
/ XXX I-GENE
( XXX I-GENE
Al XXX I-GENE
, XXX I-GENE
Ga XXX I-GENE
) XXX I-GENE
As XXX I-GENE
heterojunctions XXX I-GENE
. XXX O

Disrupted XXX O
vaccines XXX O
and XXX O
whole-virus XXX O
vaccines XXX O
containing XXX O
type XXX B-GENE
B XXX I-GENE
antigen XXX I-GENE
only XXX O
did XXX O
not XXX O
cause XXX O
significant XXX O
reactivity XXX O
. XXX O

The XXX O
ubiquitously XXX O
expressed XXX O
hypoxia-inducible XXX B-GENE
factor-1 XXX I-GENE
( XXX O
HIF-1 XXX B-GENE
) XXX O
is XXX O
involved XXX O
in XXX O
expression XXX O
of XXX O
a XXX O
large XXX O
number XXX O
of XXX O
oxygen-regulated XXX O
genes XXX O
. XXX O

Because XXX O
ATF-1 XXX B-GENE
and XXX O
CREM XXX B-GENE
are XXX O
known XXX O
to XXX O
bind XXX O
to XXX O
cAMP XXX B-GENE
response XXX I-GENE
elements XXX I-GENE
( XXX O
CRE XXX B-GENE
) XXX O
, XXX O
this XXX O
functional XXX O
sequence XXX O
was XXX O
named XXX O
the XXX O
kappa XXX B-GENE
E3'-CRE XXX I-GENE
. XXX O

INTERVENTIONS XXX O
: XXX O
Patients XXX O
received XXX O
rt-PA XXX B-GENE
, XXX O
heparin XXX O
, XXX O
and XXX O
aspirin XXX O
. XXX O

The XXX O
incidence XXX O
of XXX O
tumours XXX O
in XXX O
young XXX O
chickens XXX O
. XXX O

These XXX O
results XXX O
demonstrate XXX O
that XXX O
dopamine XXX B-GENE
receptor XXX I-GENE
stimulation XXX O
by XXX O
different XXX O
dopamine XXX O
agonists XXX O
produces XXX O
a XXX O
different XXX O
pattern XXX O
of XXX O
effects XXX O
on XXX O
the XXX O
characteristics XXX O
of XXX O
the XXX O
reaction XXX O
time XXX O
response XXX O
. XXX O

In XXX O
the XXX O
matched XXX O
control XXX O
group XXX O
the XXX O
acquisition-rate XXX O
of XXX O
both XXX O
symptomatic XXX O
and XXX O
asymptomatic XXX O
0acteriuria XXX O
was XXX O
over XXX O
12% XXX O
, XXX O
a XXX O
figure XXX O
similar XXX O
to XXX O
the XXX O
percentage XXX O
of XXX O
women XXX O
present XXX O
in XXX O
the XXX O
practice XXX O
population XXX O
during XXX O
one XXX O
year XXX O
with XXX O
transient XXX O
, XXX O
symptomatic XXX O
, XXX O
and XXX O
persistent XXX O
A XXX O
. XXX O
B XXX O
. XXX O

We XXX O
identified XXX O
telSMN XXX B-GENE
mutations XXX O
in XXX O
11 XXX O
of XXX O
these XXX O
unrelated XXX O
SMA-like XXX O
individuals XXX O
who XXX O
carry XXX O
a XXX O
single XXX O
copy XXX O
of XXX O
telSMN XXX B-GENE
: XXX O
these XXX O
include XXX O
two XXX O
frameshift XXX O
mutations XXX O
( XXX O
800ins11 XXX O
and XXX O
542delGT XXX O
) XXX O
and XXX O
three XXX O
missense XXX O
mutations XXX O
( XXX O
A2G XXX O
, XXX O
S262I XXX O
, XXX O
and XXX O
T274I XXX O
) XXX O
. XXX O

The XXX O
presence XXX O
of XXX O
an XXX O
additional XXX O
sequence XXX O
of XXX O
nucleotides XXX O
145-165 XXX O
from XXX O
the XXX O
3' XXX O
end XXX O
of XXX O
RNA3 XXX B-GENE
enhanced XXX O
template XXX O
recognition XXX O
by XXX O
RdRp XXX B-GENE
in XXX O
vitro XXX O
and XXX O
accumulation XXX O
of XXX O
RNA3 XXX B-GENE
in XXX O
vivo XXX O
to XXX O
wild-type XXX O
levels XXX O
. XXX O

At XXX O
visit XXX O
5 XXX O
, XXX O
the XXX O
isokinetic XXX O
test XXX O
showed XXX O
impaired XXX O
muscle XXX O
function XXX O
recovery XXX O
from XXX O
23% XXX O
to XXX O
32% XXX O
, XXX O
while XXX O
the XXX O
manual XXX O
test XXX O
showed XXX O
almost XXX O
full XXX O
recovery XXX O
. XXX O

In XXX O
situ XXX O
hybridization XXX O
analysis XXX O
in XXX O
adult XXX O
rat XXX O
tissue XXX O
reveals XXX O
good XXX O
correlation XXX O
with XXX O
this XXX O
pattern XXX O
and XXX O
indicates XXX O
that XXX O
drm XXX B-GENE
mRNA XXX I-GENE
is XXX O
most XXX O
highly XXX O
expressed XXX O
in XXX O
nondividing XXX O
and XXX O
terminally XXX O
differentiated XXX O
cells XXX O
, XXX O
such XXX O
as XXX O
neurons XXX O
, XXX O
type XXX O
1 XXX O
lung XXX O
cells XXX O
, XXX O
and XXX O
goblet XXX O
cells XXX O
. XXX O

Folded XXX O
tissue XXX O
and XXX O
crimped XXX O
collagen XXX B-GENE
fibers XXX O
in XXX O
the XXX O
tunica XXX O
albuginea XXX O
permit XXX O
its XXX O
expansion XXX O
during XXX O
erection XXX O
. XXX O

12-O-Tetradecanoylphorbol XXX O
13-acetate XXX O
was XXX O
found XXX O
to XXX O
inhibit XXX O
rapidly XXX O
and XXX O
potently XXX O
the XXX O
expression XXX O
of XXX O
mRNAs XXX O
coding XXX O
for XXX O
the XXX O
myogenic XXX O
regulators XXX O
CMD1 XXX B-GENE
and XXX O
myogenin XXX B-GENE
. XXX O

The XXX O
XS2 XXX B-GENE
gene XXX I-GENE
down-regulates XXX O
but XXX O
does XXX O
not XXX O
abolish XXX O
expression XXX O
of XXX O
LU XXX B-GENE
genes XXX I-GENE
and XXX O
does XXX O
not XXX O
affect XXX O
expression XXX O
of XXX O
CD44 XXX B-GENE
. XXX O

Additionally XXX O
, XXX O
a XXX O
variety XXX O
of XXX O
regulatory XXX O
schemes XXX O
contribute XXX O
temporal XXX O
and XXX O
/ XXX O
or XXX O
spatial XXX O
restriction XXX O
to XXX O
TGF-beta XXX B-GENE
responses XXX O
. XXX O

These XXX O
data XXX O
support XXX O
the XXX O
idea XXX O
that XXX O
the XXX O
repression XXX O
activity XXX O
of XXX O
NRSF XXX B-GENE
/ XXX I-GENE
REST XXX I-GENE
depends XXX O
upon XXX O
the XXX O
species XXX O
of XXX O
promoter XXX O
to XXX O
which XXX O
it XXX O
is XXX O
linked XXX O
and XXX O
upon XXX O
the XXX O
proteins XXX O
that XXX O
bind XXX O
to XXX O
those XXX O
promoters XXX O
. XXX O

This XXX O
information XXX O
, XXX O
together XXX O
with XXX O
estimation XXX O
of XXX O
the XXX O
size XXX O
of XXX O
the XXX O
deglycosylated XXX O
A XXX O
subunit XXX O
relative XXX O
to XXX O
a XXX O
series XXX O
of XXX O
C-terminal XXX B-GENE
truncated XXX I-GENE
TSHR XXX I-GENE
ectodomain XXX I-GENE
variants XXX I-GENE
, XXX O
places XXX O
cleavage XXX O
Site XXX O
1 XXX O
in XXX O
the XXX O
vicinity XXX O
of XXX O
, XXX O
or XXX O
closely XXX O
upstream XXX O
to XXX O
, XXX O
residue XXX O
317 XXX O
. XXX O

MAIN XXX O
OUTCOME XXX O
MEASURE XXX O
( XXX O
S XXX O
) XXX O
: XXX O
Serum XXX O
levels XXX O
of XXX O
FSH XXX B-GENE
, XXX O
LH XXX B-GENE
, XXX O
and XXX O
inhibin XXX B-GENE
A XXX I-GENE
and XXX I-GENE
B XXX I-GENE
. XXX O

We XXX O
generated XXX O
transformed XXX O
B XXX O
lymphoblast XXX O
cell XXX O
lines XXX O
from XXX O
controls XXX O
, XXX O
from XXX O
four XXX O
patients XXX O
with XXX O
p47-phox-deficient XXX O
chronic XXX O
granulomatous XXX O
disease XXX O
, XXX O
and XXX O
from XXX O
three XXX O
parents XXX O
. XXX O

In XXX O
a XXX O
blind XXX O
controlled XXX O
trial XXX O
, XXX O
15 XXX O
patients XXX O
with XXX O
COCM XXX O
( XXX O
NYHA XXX O
II-III XXX O
) XXX O
with XXX O
sinus XXX O
rhythm XXX O
and XXX O
a XXX O
left XXX O
ventricular XXX O
ejection XXX O
fraction XXX O
( XXX O
LV-EF XXX O
) XXX O
of XXX O
34 XXX O
. XXX O
5 XXX O
+ XXX O
/ XXX O
- XXX O
2 XXX O
. XXX O
6% XXX O
received XXX O
consecutively XXX O
D XXX O
( XXX O
0 XXX O
. XXX O
25-0 XXX O
. XXX O
5 XXX O
mg XXX O
/ XXX O
d XXX O
) XXX O
, XXX O
placebo XXX O
( XXX O
PLAC XXX O
) XXX O
, XXX O
P XXX O
( XXX O
slow XXX O
releases XXX O
= XXX O
SR XXX O
) XXX O
( XXX O
80 XXX O
mg XXX O
/ XXX O
d XXX O
SR XXX O
) XXX O
and XXX O
both XXX O
drugs XXX O
combined XXX O
in XXX O
respective XXX O
doses XXX O
. XXX O

Examination XXX O
of XXX O
nuclear XXX O
magnetic XXX O
resonance XXX O
( XXX O
NMR XXX O
) XXX O
spectra XXX O
of XXX O
a XXX O
series XXX O
of XXX O
N-terminally XXX B-GENE
truncated XXX I-GENE
MIP-1 XXX I-GENE
beta XXX I-GENE
variants XXX I-GENE
reveals XXX O
that XXX O
these XXX O
proteins XXX O
possess XXX O
a XXX O
range XXX O
of XXX O
ability XXX O
to XXX O
dimerize XXX O
. XXX O

Vitrectomy XXX O
in XXX O
ocular XXX O
traumatology XXX O
. XXX O

We XXX O
further XXX O
demonstrate XXX O
that XXX O
RU486-PR-B XXX O
interacts XXX O
physically XXX O
with XXX O
NCoR XXX B-GENE
in XXX O
vitro XXX O
. XXX O

We XXX O
have XXX O
isolated XXX O
and XXX O
sequenced XXX O
two XXX O
overlapping XXX O
cDNA XXX O
fragments XXX O
which XXX O
could XXX O
encode XXX O
the XXX O
complete XXX O
amino XXX O
acid XXX O
sequence XXX O
of XXX O
rat XXX B-GENE
testis XXX I-GENE
fructose-6-phosphate XXX I-GENE
, XXX I-GENE
2-kinase XXX I-GENE
: XXX I-GENE
fructose-2 XXX I-GENE
, XXX I-GENE
6-bisphosphatase XXX I-GENE
. XXX O

One XXX O
site XXX O
, XXX O
PAL XXX B-GENE
, XXX O
occurs XXX O
within XXX O
the XXX O
10 XXX B-GENE
bp XXX I-GENE
sequence XXX I-GENE
GGGGAGGAGG XXX I-GENE
. XXX O

We XXX O
emphasize XXX O
that XXX O
ANCA-associated XXX O
vasculitis XXX O
is XXX O
another XXX O
important XXX O
complication XXX O
of XXX O
RA XXX O
. XXX O

Replacement XXX O
of XXX O
the XXX O
spacer XXX O
sequence XXX O
between XXX O
the XXX O
two XXX O
ARMs XXX O
with XXX O
a XXX O
shorter XXX O
stretch XXX O
of XXX O
sequence XXX O
also XXX O
reduced XXX O
RNA XXX O
binding XXX O
in XXX O
vitro XXX O
. XXX O

It XXX O
is XXX O
possible XXX O
that XXX O
the XXX O
patch XXX O
determines XXX O
the XXX O
proper XXX O
conformation XXX O
of XXX O
the XXX O
site XXX O
and XXX O
thereby XXX O
contributes XXX O
to XXX O
recognition XXX O
indirectly XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
another XXX O
derivative XXX O
of XXX O
pCMVJS21 XXX O
( XXX O
pCMVJS21DeltaGP XXX O
) XXX O
in XXX O
which XXX O
the XXX O
gag XXX B-GENE
, XXX O
pol XXX B-GENE
( XXX O
and XXX O
orf-x XXX B-GENE
) XXX O
coding XXX O
sequences XXX O
were XXX O
deleted XXX O
also XXX O
gave XXX O
transformed XXX O
foci XXX O
. XXX O

In XXX O
ferrets XXX O
naturally XXX O
infected XXX O
with XXX O
H XXX O
. XXX O
mustelae XXX O
, XXX O
a XXX O
single XXX O
dose XXX O
( XXX O
50 XXX O
mg XXX O
/ XXX O
kg XXX O
, XXX O
per XXX O
os XXX O
) XXX O
of XXX O
fluorofamide XXX O
completely XXX O
inhibited XXX O
bacterial XXX B-GENE
urease XXX I-GENE
. XXX O

Petrous XXX O
meningioma XXX O
en XXX O
plaque XXX O
presenting XXX O
as XXX O
a XXX O
right XXX O
middle XXX O
ear XXX O
tumor XXX O
. XXX O

We XXX O
show XXX O
that XXX O
the XXX O
surfaces XXX O
of XXX O
tracheal XXX O
cartilage XXX O
matrix XXX O
are XXX O
collagen-rich XXX O
and XXX O
surround XXX O
a XXX O
proteoglycan-rich XXX O
core XXX O
. XXX O

Haemodilution XXX O
in XXX O
cardiopulmonary XXX O
bypass XXX O
using XXX O
a XXX O
gelatine XXX O
derivative XXX O
for XXX O
priming XXX O
. XXX O

The XXX O
Jenkins XXX O
Activity XXX O
Survey XXX O
and XXX O
the XXX O
CPI-revised XXX O
: XXX O
further XXX O
evidence XXX O
of XXX O
adaptive XXX O
and XXX O
maladaptive XXX O
type XXX O
A XXX O
traits XXX O
. XXX O

Irmiere XXX O
, XXX O
and XXX O
W XXX O
. XXX O

Segments XXX O
with XXX O
more XXX O
reduced XXX O
BMIPP XXX O
uptake XXX O
than XXX O
MIBI XXX O
uptake XXX O
( XXX O
mismatching XXX O
) XXX O
showed XXX O
either XXX O
normal XXX O
wall XXX O
motion XXX O
or XXX O
demonstrated XXX O
inotropic XXX O
reserve XXX O
during XXX O
dobutamine XXX O
stimulation XXX O
. XXX O

Two XXX O
copies XXX O
of XXX O
the XXX O
72-bp XXX O
repeat XXX O
provided XXX O
efficient XXX O
activation XXX O
of XXX O
gene XXX O
expression XXX O
. XXX O

Consistent XXX O
with XXX O
this XXX O
prediction XXX O
, XXX O
transfections XXX O
into XXX O
the XXX O
hematopoietic XXX O
cell XXX O
line XXX O
Jurkat XXX O
showed XXX O
a XXX O
9 XXX O
. XXX O
0- XXX O
and XXX O
2 XXX O
. XXX O
5-fold XXX O
activation XXX O
of XXX O
the XXX O
mim-1 XXX B-GENE
promoter XXX I-GENE
by XXX O
the XXX O
p32 XXX B-GENE
and XXX O
p30 XXX B-GENE
isoforms XXX I-GENE
, XXX O
respectively XXX O
. XXX O

In XXX O
our XXX O
previous XXX O
studies XXX O
, XXX O
transcriptional XXX O
activation XXX O
was XXX O
shown XXX O
to XXX O
correlate XXX O
with XXX O
IEP86 XXX B-GENE
binding XXX O
to XXX O
both XXX O
the XXX O
TATA-box XXX B-GENE
binding XXX I-GENE
protein XXX I-GENE
( XXX O
TBP XXX B-GENE
) XXX O
and XXX O
the XXX O
transcription XXX O
factor XXX O
bound XXX O
upstream XXX O
. XXX O

Two XXX O
siblings XXX O
with XXX O
hemolytic XXX O
anemia XXX O
caused XXX O
by XXX O
triosephosphate XXX B-GENE
isomerase XXX I-GENE
deficiency XXX O
developed XXX O
a XXX O
progressive XXX O
neurological XXX O
syndrome XXX O
featuring XXX O
dystonic XXX O
movements XXX O
, XXX O
tremor XXX O
, XXX O
pyramidal XXX O
tract XXX O
signs XXX O
, XXX O
and XXX O
evidence XXX O
of XXX O
spinal XXX O
motor XXX O
neuron XXX O
involvement XXX O
. XXX O

The XXX O
target XXX O
contained XXX O
between XXX O
positions XXX O
-403 XXX O
and XXX O
-125 XXX O
acts XXX O
independently XXX O
of XXX O
orientation XXX O
, XXX O
in XXX O
different XXX O
cell XXX O
types XXX O
and XXX O
species XXX O
, XXX O
and XXX O
in XXX O
the XXX O
context XXX O
of XXX O
a XXX O
heterologous XXX O
promoter XXX O
. XXX O

Female XXX O
subjects XXX O
, XXX O
including XXX O
both XXX O
normal XXX O
subjects XXX O
and XXX O
idiopathic XXX O
calcium XXX O
stone-formers XXX O
, XXX O
have XXX O
higher XXX O
urinary XXX O
cyclic XXX O
AMP XXX O
levels XXX O
than XXX O
their XXX O
male XXX O
counterparts XXX O
, XXX O
and XXX O
this XXX O
difference XXX O
is XXX O
significant XXX O
when XXX O
urinary XXX O
cyclic XXX O
AMP XXX O
is XXX O
expressed XXX O
in XXX O
the XXX O
units XXX O
mumol XXX O
/ XXX O
g XXX O
of XXX O
creatinine XXX O
. XXX O

He XXX O
visited XXX O
our XXX O
hospital XXX O
and XXX O
left XXX O
solitary XXX O
renal XXX O
cyst XXX O
was XXX O
suspected XXX O
. XXX O

The XXX O
effect XXX O
of XXX O
maternal XXX O
ingestion XXX O
of XXX O
the XXX O
reduced XXX O
energy XXX O
sweetener XXX O
erythritol XXX O
was XXX O
investigated XXX O
in XXX O
KBL XXX O
: XXX O
JW XXX O
strain XXX O
pregnant XXX O
rabbits XXX O
. XXX O

Our XXX O
results XXX O
concluded XXX O
that XXX O
1 XXX O
) XXX O
the XXX O
two XXX O
inhibin XXX B-GENE
/ XXX I-GENE
activin XXX I-GENE
beta XXX I-GENE
B-subunit XXX B-GENE
mRNAs XXX I-GENE
were XXX O
transcribed XXX O
from XXX O
different XXX O
initiation XXX O
sites XXX O
; XXX O
2 XXX O
) XXX O
both XXX O
promoters XXX O
may XXX O
be XXX O
controlled XXX O
by XXX O
up-stream XXX O
negative XXX O
regulatory XXX O
elements XXX O
; XXX O
and XXX O
3 XXX O
) XXX O
neither XXX O
of XXX O
these XXX O
promoters XXX O
is XXX O
responsive XXX O
to XXX O
cAMP XXX O
and XXX O
/ XXX O
or XXX O
phorbol XXX O
esters XXX O
under XXX O
the XXX O
conditions XXX O
employed XXX O
. XXX O

TE-671 XXX O
cells XXX O
that XXX O
were XXX O
transfected XXX O
with XXX O
cAMP XXX B-GENE
response XXX I-GENE
element XXX I-GENE
mutant XXX O
constructs XXX O
demonstrated XXX O
a XXX O
diminished XXX O
basal XXX O
activity XXX O
of XXX O
the XXX O
GnRH-II XXX B-GENE
promoter XXX I-GENE
. XXX O

The XXX O
HSD3B1 XXX B-GENE
and XXX O
HSD3B2 XXX B-GENE
genes XXX I-GENE
encoding XXX O
the XXX O
types XXX B-GENE
I XXX I-GENE
and XXX I-GENE
II XXX I-GENE
3 XXX I-GENE
beta-HSD XXX I-GENE
isoenzymes XXX I-GENE
, XXX O
respectively XXX O
, XXX O
have XXX O
been XXX O
previously XXX O
assigned XXX O
by XXX O
in XXX O
situ XXX O
hybridization XXX O
to XXX O
the XXX O
chromosome XXX O
1p13 XXX O
. XXX O
1 XXX O
region XXX O
. XXX O

Effect XXX O
of XXX O
enteral XXX O
nutritional XXX O
products XXX O
differing XXX O
in XXX O
carbohydrate XXX O
and XXX O
fat XXX O
on XXX O
indices XXX O
of XXX O
carbohydrate XXX O
and XXX O
lipid XXX O
metabolism XXX O
in XXX O
patients XXX O
with XXX O
NIDDM XXX O
. XXX O

A XXX O
study XXX O
was XXX O
performed XXX O
to XXX O
compare XXX O
the XXX O
ONLINE XXX O
and XXX O
EMIT XXX O
II XXX O
immunoassays XXX O
with XXX O
gas XXX O
chromatographic XXX O
/ XXX O
mass XXX O
spectrometric XXX O
( XXX O
GC XXX O
/ XXX O
MS XXX O
) XXX O
analysis XXX O
of XXX O
methaqualone XXX O
metabolites XXX O
on XXX O
urine XXX O
using XXX O
samples XXX O
obtained XXX O
from XXX O
a XXX O
clinical XXX O
study XXX O
. XXX O

Functional XXX O
analysis XXX O
of XXX O
aryl XXX B-GENE
hydrocarbon XXX I-GENE
receptor XXX I-GENE
nuclear XXX I-GENE
translocator XXX I-GENE
interactions XXX O
with XXX O
aryl XXX B-GENE
hydrocarbon XXX I-GENE
receptor XXX I-GENE
in XXX O
the XXX O
yeast XXX O
two-hybrid XXX O
system XXX O
. XXX O

The XXX O
5'-terminus XXX O
of XXX O
the XXX O
p-gvpF-M XXX B-GENE
mRNA XXX I-GENE
was XXX O
located XXX O
169 XXX O
nucleotides XXX O
upstream XXX O
of XXX O
p-gvpF XXX B-GENE
within XXX O
p-gvpE XXX B-GENE
. XXX O

Alternatively XXX O
, XXX O
loss-of-function XXX O
alleles XXX O
of XXX O
genes XXX O
that XXX O
inhibit XXX O
cAPK XXX B-GENE
lead XXX O
to XXX O
the XXX O
inability XXX O
to XXX O
undergo XXX O
sexual XXX O
differentiation XXX O
. XXX O

These XXX O
different XXX O
observations XXX O
exclude XXX O
a XXX O
heterozygosity XXX O
of XXX O
the XXX O
A XXX O
-- XXX O
> XXX O
G XXX O
mutation XXX O
at XXX O
codon XXX O
beta XXX O
77 XXX O
, XXX O
as XXX O
well XXX O
as XXX O
a XXX O
deletion XXX O
comparable XXX O
to XXX O
that XXX O
of XXX O
Hbs XXX B-GENE
Lepore XXX I-GENE
or XXX I-GENE
Kenya XXX I-GENE
, XXX O
or XXX O
a XXX O
beta-globin XXX B-GENE
gene XXX I-GENE
duplication XXX O
, XXX O
and XXX O
point XXX O
to XXX O
a XXX O
nontraditional XXX O
inheritance XXX O
of XXX O
Hb XXX B-GENE
Costa XXX I-GENE
Rica XXX I-GENE
. XXX O

Remarkably XXX O
, XXX O
a XXX O
construct XXX O
corresponding XXX O
to XXX O
residues XXX O
631 XXX O
to XXX O
970 XXX O
, XXX O
which XXX O
contains XXX O
only XXX O
the XXX O
LXXLL XXX B-GENE
motifs XXX I-GENE
and XXX O
the XXX O
AD1 XXX B-GENE
region XXX I-GENE
of XXX O
SRC1 XXX B-GENE
, XXX O
retained XXX O
strong XXX O
coactivator XXX O
activity XXX O
in XXX O
our XXX O
assays XXX O
. XXX O

The XXX O
alternative XXX O
sigma XXX B-GENE
factor XXX I-GENE
sigmaB XXX I-GENE
in XXX I-GENE
Staphylococcus XXX I-GENE
aureus XXX I-GENE
: XXX O
regulation XXX O
of XXX O
the XXX O
sigB XXX B-GENE
operon XXX I-GENE
in XXX O
response XXX O
to XXX O
growth XXX O
phase XXX O
and XXX O
heat XXX O
shock XXX O
. XXX O

The XXX O
serum XXX O
erythropoietin XXX B-GENE
( XXX O
EPO XXX B-GENE
) XXX O
concentrations XXX O
of XXX O
15 XXX O
male XXX O
triathletes XXX O
( XXX O
26 XXX O
. XXX O
3 XXX O
U XXX O
. XXX O
ml-1 XXX O
) XXX O
were XXX O
significantly XXX O
lower XXX O
than XXX O
those XXX O
of XXX O
45 XXX O
male XXX O
distance XXX O
runners XXX O
( XXX O
31 XXX O
. XXX O
6 XXX O
U XXX O
. XXX O
ml-1 XXX O
; XXX O
P XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
. XXX O

Endorphins XXX B-GENE
at XXX O
the XXX O
approach XXX O
of XXX O
death XXX O
. XXX O

UDP-Gal XXX B-GENE
: XXX I-GENE
Gal XXX I-GENE
beta XXX I-GENE
1----4GlcNAc XXX I-GENE
alpha XXX I-GENE
1----3-galactosyltransferase XXX I-GENE
is XXX O
a XXX O
terminal XXX B-GENE
glycosyltransferase XXX I-GENE
that XXX O
is XXX O
widely XXX O
expressed XXX O
in XXX O
a XXX O
variety XXX O
of XXX O
mammalian XXX O
species XXX O
, XXX O
with XXX O
the XXX O
notable XXX O
exception XXX O
of XXX O
man XXX O
, XXX O
apes XXX O
, XXX O
and XXX O
Old XXX O
World XXX O
monkeys XXX O
. XXX O

The XXX O
underlying XXX O
cirrhosis XXX O
was XXX O
alcoholic XXX O
in XXX O
11 XXX O
( XXX O
53 XXX O
. XXX O
3% XXX O
) XXX O
, XXX O
cryptogenic XXX O
in XXX O
5 XXX O
( XXX O
23 XXX O
. XXX O
8% XXX O
) XXX O
, XXX O
and XXX O
hepatitis XXX O
B XXX O
chronic XXX O
infection XXX O
related XXX O
in XXX O
5 XXX O
( XXX O
23 XXX O
. XXX O
8% XXX O
) XXX O
. XXX O

The XXX O
model XXX O
captures XXX O
the XXX O
essence XXX O
of XXX O
predator-prey XXX O
dynamics XXX O
to XXX O
provide XXX O
reasonable XXX O
predictions XXX O
of XXX O
population XXX O
patterns XXX O
. XXX O

Forty-eight XXX O
sequences XXX O
, XXX O
30 XXX O
not XXX O
previously XXX O
identified XXX O
as XXX O
IR-responsive XXX O
, XXX O
were XXX O
significantly XXX O
regulated XXX O
by XXX O
IR XXX O
. XXX O

The XXX O
bases XXX O
of XXX O
this XXX O
comparison XXX O
are XXX O
reviewed XXX O
and XXX O
discussed XXX O
. XXX O

In XXX O
the XXX O
TVD-patients XXX O
decreases XXX O
in XXX O
skin XXX O
blood XXX O
flow XXX O
were XXX O
similar XXX O
compared XXX O
with XXX O
the XXX O
healthy XXX O
controls XXX O
. XXX O

The XXX O
cpc-1-encoded XXX O
transcript XXX O
contains XXX O
three XXX O
open XXX O
reading XXX O
frames XXX O
, XXX O
two XXX O
of XXX O
which XXX O
are XXX O
located XXX O
in XXX O
the XXX O
720-nucleotide XXX O
leader XXX O
segment XXX O
preceding XXX O
the XXX O
cpc-1 XXX B-GENE
coding XXX I-GENE
region XXX I-GENE
. XXX O

The XXX O
complete XXX O
exon-intron XXX O
organization XXX O
of XXX O
the XXX O
murine XXX O
gene XXX O
encoding XXX O
M-protein XXX B-GENE
, XXX O
a XXX O
structural XXX O
protein XXX O
of XXX O
sarcomeric XXX O
myofibrils XXX O
, XXX O
was XXX O
determined XXX O
. XXX O

Functional XXX O
studies XXX O
which XXX O
introduced XXX O
a XXX O
mutation XXX O
in XXX O
the XXX O
AP2 XXX B-GENE
core XXX I-GENE
binding XXX I-GENE
region XXX I-GENE
as XXX O
well XXX O
as XXX O
cotransfection XXX O
experiments XXX O
using XXX O
an XXX O
AP2 XXX B-GENE
expression XXX O
vector XXX O
revealed XXX O
that XXX O
AP2 XXX B-GENE
exerts XXX O
a XXX O
repressive XXX O
role XXX O
on XXX O
the XXX O
HGF XXX B-GENE
gene XXX I-GENE
promoter XXX I-GENE
activity XXX O
. XXX O

Pigmentary XXX O
rhythms XXX O
as XXX O
indicators XXX O
of XXX O
neurosecretion XXX O
. XXX O

Deadenylation XXX O
and XXX O
decay XXX O
of XXX O
beta-globin XXX B-GENE
mRNA XXX I-GENE
in XXX O
K562 XXX O
cells XXX O
is XXX O
extraordinarily XXX O
slow XXX O
compared XXX O
with XXX O
NIH XXX O
3T3 XXX O
cells XXX O
, XXX O
suggesting XXX O
that XXX O
the XXX O
increased XXX O
stability XXX O
gained XXX O
by XXX O
beta-globin XXX B-GENE
mRNA XXX I-GENE
in XXX O
K562 XXX O
cells XXX O
is XXX O
mainly XXX O
controlled XXX O
at XXX O
the XXX O
deadenylation XXX O
step XXX O
. XXX O

Role XXX O
of XXX O
NH XXX O
( XXX O
2 XXX O
) XXX O
- XXX O
and XXX O
COOH-terminal XXX O
domains XXX O
of XXX O
the XXX O
P XXX B-GENE
protein XXX I-GENE
of XXX O
human XXX O
parainfluenza XXX O
virus XXX O
type XXX O
3 XXX O
in XXX O
transcription XXX O
and XXX O
replication XXX O
. XXX O

Otte XXX O
, XXX O
Mol XXX O
. XXX O

Transactivation XXX O
of XXX O
the XXX O
HIV-1 XXX B-GENE
LTR XXX I-GENE
by XXX O
T3R XXX B-GENE
alpha XXX I-GENE
and XXX O
several XXX O
receptor XXX O
mutants XXX O
revealed XXX O
that XXX O
the XXX O
50-amino-acid XXX O
N-terminal XXX O
A XXX B-GENE
/ XXX I-GENE
B XXX I-GENE
region XXX I-GENE
of XXX O
T3R XXX B-GENE
alpha XXX I-GENE
, XXX O
known XXX O
to XXX O
interact XXX O
with XXX O
the XXX O
basal XXX B-GENE
transcription XXX I-GENE
factor XXX I-GENE
TFIIB XXX I-GENE
, XXX O
is XXX O
critical XXX O
for XXX O
activation XXX O
of XXX O
both XXX O
Tat-dependent XXX O
and XXX O
Tat-independent XXX B-GENE
responsive XXX I-GENE
sequences XXX I-GENE
of XXX O
the XXX O
LTR XXX B-GENE
. XXX O

Ste18p XXX B-GENE
was XXX O
targeted XXX O
to XXX O
the XXX O
plasma XXX O
membrane XXX O
even XXX O
in XXX O
the XXX O
absence XXX O
of XXX O
prenylation XXX O
or XXX O
thioacylation XXX O
. XXX O

81 XXX O
milk XXX O
samples XXX O
collected XXX O
from XXX O
35 XXX O
donors XXX O
3 XXX O
days XXX O
to XXX O
7 XXX O
months XXX O
after XXX O
delivery XXX O
were XXX O
examined XXX O
for XXX O
the XXX O
occurrence XXX O
of XXX O
cytomegalovirus XXX O
( XXX O
CMV XXX O
) XXX O
. XXX O

A XXX O
novel XXX O
gene XXX O
designated XXX O
cmr XXX B-GENE
, XXX O
which XXX O
mapped XXX O
to XXX O
18 XXX O
. XXX O
8 XXX O
min XXX O
of XXX O
the XXX O
Escherichia XXX O
coli XXX O
K-12 XXX O
genome XXX O
, XXX O
was XXX O
shown XXX O
to XXX O
mediate XXX O
resistance XXX O
to XXX O
chloramphenicol XXX O
when XXX O
it XXX O
was XXX O
expressed XXX O
from XXX O
a XXX O
multicopy XXX O
vector XXX O
. XXX O

Neither XXX O
the XXX O
reaction XXX O
of XXX O
monosaccharides XXX O
nor XXX O
the XXX O
disaccharides XXX O
with XXX O
beta-alanine XXX O
resulted XXX O
in XXX O
the XXX O
formation XXX O
of XXX O
maltol XXX O
. XXX O

Amikacin XXX O
was XXX O
used XXX O
in XXX O
the XXX O
treatment XXX O
of XXX O
56 XXX O
serious XXX O
gram-negative XXX O
infections XXX O
in XXX O
54 XXX O
patients XXX O
of XXX O
whom XXX O
47 XXX O
survived XXX O
. XXX O

Transplantation XXX O
of XXX O
kidneys XXX O
of XXX O
juvenile XXX O
donors XXX O
in XXX O
adult XXX O
recipients XXX O
. XXX O

The XXX O
role XXX O
of XXX O
saliva XXX O
in XXX O
sour XXX O
taste XXX O
perception XXX O
was XXX O
investigated XXX O
in XXX O
a XXX O
series XXX O
of XXX O
4 XXX O
experiments XXX O
. XXX O

Ventral XXX O
rhinotomy XXX O
is XXX O
no XXX O
more XXX O
difficult XXX O
than XXX O
dorsal XXX O
rhinotomy XXX O
, XXX O
has XXX O
less XXX O
patient XXX O
morbidity XXX O
and XXX O
fewer XXX O
postoperative XXX O
complications XXX O
, XXX O
and XXX O
is XXX O
more XXX O
cosmetically XXX O
acceptable XXX O
. XXX O

The XXX O
financial XXX O
impact XXX O
of XXX O
childhood XXX O
asthma XXX O
has XXX O
not XXX O
been XXX O
assessed XXX O
since XXX O
Vance XXX O
and XXX O
Taylor XXX O
reported XXX O
their XXX O
data XXX O
in XXX O
Annals XXX O
of XXX O
Allergy XXX O
13 XXX O
years XXX O
ago XXX O
. XXX O

447 XXX O
microns XXX O
for XXX O
A XXX O
. XXX O
microcephalum XXX O
and XXX O
350 XXX O
microns XXX O
for XXX O
A XXX O
. XXX O
wedli XXX O
) XXX O
, XXX O
and XXX O
fewer XXX O
testes XXX O
per XXX O
proglottis XXX O
( XXX O
44-73 XXX O
vs XXX O
. XXX O

Primary XXX O
infection XXX O
is XXX O
usually XXX O
managed XXX O
conservatively XXX O
. XXX O

In XXX O
addition XXX O
to XXX O
DNA-protein XXX O
interactions XXX O
, XXX O
protein-protein XXX O
interactions XXX O
with XXX O
partner XXX O
proteins XXX O
often XXX O
play XXX O
major XXX O
roles XXX O
in XXX O
targeting XXX O
ETS-domain XXX B-GENE
proteins XXX I-GENE
to XXX O
specific XXX O
promoters XXX O
. XXX O

Alignment XXX O
of XXX O
the XXX O
selected XXX O
sequences XXX O
allowed XXX O
us XXX O
to XXX O
predict XXX O
a XXX O
consensus XXX O
sequence XXX O
for XXX O
binding XXX O
of XXX O
the XXX O
individual XXX O
homodimeric XXX O
Rel-related XXX B-GENE
proteins XXX I-GENE
, XXX O
and XXX O
DNA-protein XXX O
binding XXX O
analysis XXX O
of XXX O
the XXX O
selected XXX O
DNA XXX O
sequences XXX O
revealed XXX O
sequence XXX O
specificity XXX O
of XXX O
the XXX O
proteins XXX O
. XXX O

In XXX O
diethyl XXX O
ether XXX O
solution XXX O
the XXX O
main XXX O
peak XXX O
is XXX O
that XXX O
of XXX O
2-benzylidenamio-1-phenylpropane XXX O
, XXX O
which XXX O
has XXX O
a XXX O
retention XXX O
time XXX O
of XXX O
23 XXX O
, XXX O
2 XXX O
minutes XXX O
under XXX O
the XXX O
condition XXX O
delineated XXX O
. XXX O

On-line XXX O
angioscopic XXX O
images XXX O
of XXX O
tissue XXX O
flaps XXX O
floating XXX O
in XXX O
the XXX O
lumen XXX O
, XXX O
recent XXX O
or XXX O
structured XXX O
thrombi XXX O
, XXX O
artery XXX O
wall XXX O
dissections XXX O
, XXX O
plaque XXX O
ruptures XXX O
, XXX O
deep XXX O
fissurations XXX O
and XXX O
sub-intimal XXX O
haemorrhages XXX O
demonstrate XXX O
, XXX O
in XXX O
live XXX O
colour XXX O
, XXX O
the XXX O
pathophysiological XXX O
mechanisms XXX O
of XXX O
coronary XXX O
artery XXX O
stenosis XXX O
. XXX O

Area XXX O
under XXX O
the XXX O
drug XXX O
concentration-time XXX O
curves XXX O
( XXX O
AUC0-24 XXX O
hr XXX O
) XXX O
for XXX O
MTX XXX O
were XXX O
2379 XXX O
and XXX O
3534 XXX O
ng*hr XXX O
/ XXX O
ml XXX O
from XXX O
PG-2 XXX O
. XXX O
5% XXX O
Azone XXX O
and XXX O
PG-7 XXX O
. XXX O
5% XXX O
Azone XXX O
systems XXX O
respectively XXX O
. XXX O

From XXX O
S3 XXX O
( XXX O
CBF XXX O
: XXX O
79-60% XXX O
) XXX O
to XXX O
S5 XXX O
( XXX O
CBF XXX O
: XXX O
39-0% XXX O
) XXX O
, XXX O
%WTh XXX O
, XXX O
1 XXX O
/ XXX O
TPC XXX O
and XXX O
1 XXX O
/ XXX O
T XXX O
were XXX O
significantly XXX O
decreased XXX O
from XXX O
those XXX O
of XXX O
the XXX O
control XXX O
levels XXX O
( XXX O
all XXX O
p XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
. XXX O

One XXX O
complex XXX O
appears XXX O
to XXX O
be XXX O
ubiquitous XXX O
but XXX O
enriched XXX O
in XXX O
lymphoid XXX O
cells XXX O
and XXX O
represents XXX O
the XXX O
binding XXX O
of XXX O
a XXX O
potentially XXX O
novel XXX O
factor XXX O
with XXX O
an XXX O
apparent XXX O
molecular XXX O
mass XXX O
of XXX O
approximately XXX O
50 XXX O
kDa XXX O
. XXX O

With XXX O
a XXX O
view XXX O
to XXX O
identifying XXX O
other XXX O
important XXX O
U14 XXX B-GENE
interactions XXX O
, XXX O
a XXX O
stem-loop XXX O
domain XXX O
required XXX O
for XXX O
activity XXX O
of XXX O
Saccharomyces XXX B-GENE
cerevisiae XXX I-GENE
U14 XXX I-GENE
RNAs XXX I-GENE
( XXX O
the XXX O
Y XXX B-GENE
domain XXX I-GENE
) XXX O
was XXX O
first XXX O
subjected XXX O
to XXX O
detailed XXX O
mutational XXX O
analysis XXX O
. XXX O

The XXX O
newly XXX O
devised XXX O
DCT XXX O
method XXX O
yields XXX O
reliable XXX O
data XXX O
in XXX O
measuring XXX O
TBF XXX O
. XXX O

Pre-beta-1 XXX B-GENE
lipoprotein XXX I-GENE
and XXX O
early XXX O
detection XXX O
of XXX O
risk XXX O
factors XXX O
for XXX O
coronary XXX O
heart XXX O
disease XXX O
. XXX O

We XXX O
conclude XXX O
that XXX O
androgenic XXX O
hormones XXX O
reduce XXX O
HDL-cholesterol XXX O
concentrations XXX O
and XXX O
the XXX O
HDL2-cholesterol XXX O
subfraction XXX O
, XXX O
possibly XXX O
by XXX O
enhancing XXX O
hepatic XXX B-GENE
triglyceride XXX I-GENE
lipase XXX I-GENE
activity XXX O
. XXX O

Thus XXX O
, XXX O
prostacyclin XXX O
enhanced XXX O
the XXX O
autoregulative XXX O
property XXX O
of XXX O
the XXX O
inner XXX O
ear XXX O
vessels XXX O
. XXX O

In XXX O
addition XXX O
to XXX O
the XXX O
nine XXX O
and XXX O
51 XXX O
terminal XXX O
amino XXX O
acid XXX O
forms XXX O
already XXX O
known XXX O
, XXX O
we XXX O
identified XXX O
a XXX O
third XXX O
with XXX O
43 XXX O
terminal XXX O
amino XXX O
acids XXX O
predicted XXX O
to XXX O
encode XXX O
a XXX O
novel XXX O
RET XXX B-GENE
protein XXX I-GENE
isoform XXX I-GENE
. XXX O

Here XXX O
we XXX O
demonstrate XXX O
that XXX O
another XXX O
cellular XXX O
protein XXX O
linked XXX O
to XXX O
BCR XXX B-GENE
/ XXX I-GENE
ABL XXX I-GENE
through XXX O
the XXX O
CRKL-SH2 XXX B-GENE
domain XXX I-GENE
is XXX O
p130 XXX B-GENE
( XXX I-GENE
CAS XXX I-GENE
) XXX I-GENE
. XXX O
p130 XXX B-GENE
( XXX I-GENE
CAS XXX I-GENE
) XXX I-GENE
was XXX O
found XXX O
to XXX O
be XXX O
tyrosine XXX O
phosphorylated XXX O
and XXX O
associated XXX O
with XXX O
CRKL XXX B-GENE
in XXX O
BCR XXX B-GENE
/ XXX I-GENE
ABL XXX I-GENE
expressing XXX O
cell XXX O
lines XXX O
and XXX O
in XXX O
samples XXX O
obtained XXX O
from XXX O
CML XXX O
and XXX O
ALL XXX O
patients XXX O
, XXX O
but XXX O
not XXX O
in XXX O
samples XXX O
from XXX O
controls XXX O
. XXX O

Embryo XXX O
coculture XXX O
system XXX O
may XXX O
contribute XXX O
to XXX O
understand XXX O
the XXX O
mechanisms XXX O
underlying XXX O
the XXX O
decrease XXX O
of XXX O
fertility XXX O
with XXX O
aging XXX O
. XXX O

METHODS XXX O
: XXX O
The XXX O
responses XXX O
of XXX O
a XXX O
31-year-old XXX O
woman XXX O
with XXX O
complex XXX O
regional XXX O
pain XXX O
syndrome XXX O
type XXX O
I XXX O
( XXX O
reflex XXX O
sympathetic XXX O
dystrophy XXX O
) XXX O
to XXX O
a XXX O
thermal XXX O
grill XXX O
were XXX O
evaluated XXX O
before XXX O
and XXX O
after XXX O
stellate XXX O
ganglion XXX O
block XXX O
. XXX O

Ultrastructure XXX O
of XXX O
the XXX O
tumor XXX O
in XXX O
1 XXX O
patient XXX O
in XXX O
whom XXX O
transurethral XXX O
resection XXX O
was XXX O
performed XXX O
2 XXX O
weeks XXX O
after XXX O
alum XXX O
irrigation XXX O
revealed XXX O
well XXX O
preserved XXX O
nuclear XXX O
chromatin XXX O
, XXX O
thus XXX O
, XXX O
suggesting XXX O
that XXX O
whatever XXX O
changes XXX O
occur XXX O
after XXX O
alum XXX O
irrigation XXX O
are XXX O
short-lived XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
we XXX O
sought XXX O
to XXX O
test XXX O
the XXX O
hypothesis XXX O
that XXX O
, XXX O
when XXX O
equal XXX O
volumes XXX O
are XXX O
administered XXX O
intrathecally XXX O
, XXX O
significant XXX O
differences XXX O
exist XXX O
in XXX O
the XXX O
potential XXX O
to XXX O
three XXX O
commonly XXX O
used XXX O
anesthetic XXX O
solutions XXX O
to XXX O
induce XXX O
sensory XXX O
impairment XXX O
. XXX O

In XXX O
vitro XXX O
interaction XXX O
studies XXX O
, XXX O
using XXX O
proteins XXX O
fused XXX O
to XXX O
glutathione-S-transferase XXX B-GENE
, XXX O
showed XXX O
that XXX O
RBP-J XXX B-GENE
kappa XXX I-GENE
and XXX O
Su XXX B-GENE
( XXX I-GENE
H XXX I-GENE
) XXX I-GENE
bind XXX O
directly XXX O
to XXX O
the XXX O
RAM23 XXX B-GENE
regions XXX I-GENE
of XXX O
mouse XXX B-GENE
Notch1 XXX I-GENE
and XXX O
Drosophila XXX B-GENE
Notch XXX I-GENE
, XXX O
respectively XXX O
. XXX O

It XXX O
is XXX O
concluded XXX O
that XXX O
CT XXX O
should XXX O
be XXX O
routinely XXX O
employed XXX O
in XXX O
patients XXX O
with XXX O
N1-N3 XXX O
neck XXX O
disease XXX O
to XXX O
determine XXX O
the XXX O
proper XXX O
electron-energy XXX O
prescription XXX O
. XXX O

The XXX O
management XXX O
of XXX O
the XXX O
"chronic" XXX O
patient XXX O
. XXX O

In XXX O
agreement XXX O
with XXX O
this XXX O
southern XXX O
blotting XXX O
of XXX O
mouse XXX O
DNA XXX O
with XXX O
SmN XXX B-GENE
probes XXX O
reveals XXX O
bands XXX O
, XXX O
additional XXX O
to XXX O
those XXX O
derived XXX O
from XXX O
the XXX O
pseudogene XXX O
, XXX O
which XXX O
are XXX O
characteristic XXX O
of XXX O
an XXX O
intron-containing XXX O
SmN XXX B-GENE
gene XXX I-GENE
. XXX O

Interestingly XXX O
, XXX O
disruption XXX O
of XXX O
the XXX O
VPS34 XXX B-GENE
locus XXX I-GENE
resulted XXX O
in XXX O
a XXX O
temperature-sensitive XXX O
growth XXX O
defect XXX O
, XXX O
indicating XXX O
that XXX O
the XXX O
VPS34 XXX B-GENE
gene XXX I-GENE
is XXX O
essential XXX O
for XXX O
vegetative XXX O
growth XXX O
only XXX O
at XXX O
elevated XXX O
growth XXX O
temperatures XXX O
. XXX O

Derivation XXX O
and XXX O
initial XXX O
characterization XXX O
of XXX O
a XXX O
mouse XXX O
mammary XXX O
tumor XXX O
cell XXX O
line XXX O
carrying XXX O
the XXX O
polyomavirus XXX B-GENE
middle XXX I-GENE
T XXX I-GENE
antigen XXX I-GENE
: XXX O
utility XXX O
in XXX O
the XXX O
development XXX O
of XXX O
novel XXX O
cancer XXX O
therapeutics XXX O
. XXX O

Regulation XXX O
of XXX O
the XXX O
alpha XXX B-GENE
inhibin XXX I-GENE
gene XXX I-GENE
by XXX O
cyclic XXX O
adenosine XXX O
3' XXX O
, XXX O
5'-monophosphate XXX O
after XXX O
transfection XXX O
into XXX O
rat XXX O
granulosa XXX O
cells XXX O
. XXX O

Multiparity XXX O
had XXX O
a XXX O
protective XXX O
effect XXX O
with XXX O
0 XXX O
. XXX O
66 XXX O
less XXX O
risk XXX O
( XXX O
95% XXX O
CI XXX O
0 XXX O
. XXX O
44-0 XXX O
. XXX O
99 XXX O
) XXX O
. XXX O

Renal XXX O
pathology XXX O
and XXX O
long-term XXX O
outcome XXX O
in XXX O
childhood XXX O
SLE XXX O
. XXX O

Amino XXX O
acid XXX O
sequence XXX O
comparisons XXX O
of XXX O
the XXX O
E74A XXX B-GENE
protein XXX I-GENE
reveal XXX O
a XXX O
highly XXX O
conserved XXX O
C-terminal XXX O
region XXX O
that XXX O
is XXX O
rich XXX O
in XXX O
basic XXX O
amino XXX O
acid XXX O
residues XXX O
and XXX O
which XXX O
has XXX O
been XXX O
proposed XXX O
to XXX O
possess XXX O
sequence-specific XXX O
DNA XXX O
binding XXX O
activity XXX O
. XXX O

Conservative XXX O
treatment XXX O
of XXX O
central XXX O
nervous XXX O
system XXX O
injuries XXX O
. XXX O

Alkoxymetgyl-3 XXX O
, XXX O
4-dimethylpyridinium XXX O
chlorides XXX O
were XXX O
synthetized XXX O
by XXX O
reacting XXX O
3 XXX O
, XXX O
4-dimethylpyridine XXX O
with XXX O
chloromethyl XXX O
alkyl XXX O
ethers XXX O
, XXX O
while XXX O
1-ethyloxymethyl-3-alkylthiomethylimidazolium XXX O
chlorides XXX O
were XXX O
obtained XXX O
in XXX O
reactions XXX O
of XXX O
1-ethyloxymethylimidazol XXX O
with XXX O
chloromethyl XXX O
alkyl XXX O
sulfides XXX O
. XXX O

Thirty-five XXX O
patients XXX O
were XXX O
included XXX O
. XXX O

Polyglactin XXX O
910 XXX O
suture XXX O
absorption XXX O
and XXX O
the XXX O
role XXX O
of XXX O
cellular XXX O
enzymes XXX O
. XXX O

A XXX O
human XXX O
cytoplasmic XXX O
signaling XXX O
protein XXX O
has XXX O
been XXX O
cloned XXX O
that XXX O
possesses XXX O
the XXX O
same XXX O
structural XXX O
arrangement XXX O
of XXX O
SH3-SH2-SH3 XXX B-GENE
domains XXX I-GENE
as XXX O
Grb2 XXX B-GENE
. XXX O

The XXX O
Genescan XXX O
program XXX O
predicted XXX O
an XXX O
open XXX O
reading XXX O
frame XXX O
of XXX O
a XXX O
novel XXX O
, XXX O
intron-less XXX O
gene XXX O
adjacent XXX O
to XXX O
the XXX O
B236 XXX O
spot XXX O
that XXX O
encodes XXX O
a XXX O
putative XXX O
493-amino XXX O
acid XXX O
protein XXX O
containing XXX O
the XXX O
SNAG XXX B-GENE
repressor XXX I-GENE
motif XXX I-GENE
in XXX O
the XXX O
NH2-terminal XXX O
region XXX O
and XXX O
five XXX O
C2H2-type XXX B-GENE
zinc XXX I-GENE
finger XXX I-GENE
motifs XXX I-GENE
in XXX O
the XXX O
COOH-terminal XXX O
half XXX O
. XXX O

The XXX O
transcription XXX O
initiation XXX O
site XXX O
was XXX O
determined XXX O
to XXX O
occur XXX O
66 XXX O
bp XXX O
upstream XXX O
of XXX O
the XXX O
initiating XXX O
Met XXX O
. XXX O

The XXX O
importance XXX O
of XXX O
these XXX O
sites XXX O
for XXX O
transcriptional XXX O
activation XXX O
was XXX O
studied XXX O
by XXX O
site-directed XXX O
mutagenesis XXX O
followed XXX O
by XXX O
promoter XXX O
function XXX O
analysis XXX O
of XXX O
the XXX O
mutants XXX O
with XXX O
a XXX O
chloramphenicol XXX B-GENE
acetyltransferase XXX I-GENE
reporter XXX I-GENE
system XXX O
. XXX O

After XXX O
selection XXX O
and XXX O
conversion XXX O
to XXX O
adipocytes XXX O
, XXX O
the XXX O
level XXX O
of XXX O
EGFR XXX B-GENE
expression XXX O
was XXX O
retained XXX O
in XXX O
infectant XXX O
adipocytes XXX O
( XXX O
150 XXX O
, XXX O
000 XXX O
and XXX O
250 XXX O
, XXX O
000 XXX O
/ XXX O
cell XXX O
, XXX O
respectively XXX O
) XXX O
, XXX O
but XXX O
not XXX O
in XXX O
the XXX O
parental XXX O
3T3-L1 XXX O
adipocytes XXX O
( XXX O
< XXX O
5000 XXX O
/ XXX O
cell XXX O
) XXX O
. XXX O

CONCLUSIONS XXX O
: XXX O
Serum XXX B-GENE
prolactin XXX I-GENE
concentrations XXX O
show XXX O
age XXX O
related XXX O
variations XXX O
in XXX O
presumably XXX O
fertile XXX O
men XXX O
. XXX O

To XXX O
gain XXX O
further XXX O
insight XXX O
into XXX O
the XXX O
pathogenesis XXX O
of XXX O
the XXX O
adult XXX O
respiratory XXX O
distress XXX O
syndrome XXX O
( XXX O
ARDS XXX O
) XXX O
, XXX O
the XXX O
authors XXX O
studied XXX O
possible XXX O
relationships XXX O
among XXX O
the XXX O
activation XXX O
status XXX O
of XXX O
circulating XXX O
polymorphonuclear XXX O
neutrophils XXX O
( XXX O
PMN XXX O
) XXX O
, XXX O
cytokine XXX B-GENE
levels XXX O
, XXX O
and XXX O
the XXX O
severity XXX O
of XXX O
lung XXX O
injury XXX O
in XXX O
31 XXX O
patients XXX O
: XXX O
15 XXX O
with XXX O
ARDS XXX O
, XXX O
9 XXX O
with XXX O
severe XXX O
pneumonia XXX O
uncomplicated XXX O
by XXX O
ARDS XXX O
, XXX O
and XXX O
7 XXX O
mechanically XXX O
ventilated XXX O
patients XXX O
with XXX O
neither XXX O
ARDS XXX O
nor XXX O
pneumonia XXX O
. XXX O

There XXX O
is XXX O
a XXX O
national XXX O
effort XXX O
to XXX O
begin XXX O
to XXX O
ask XXX O
all XXX O
female XXX O
patients XXX O
about XXX O
family XXX O
violence XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
we XXX O
found XXX O
differences XXX O
in XXX O
the XXX O
binding XXX O
of XXX O
nuclear XXX O
factors XXX O
from XXX O
shoots XXX O
versus XXX O
from XXX O
roots XXX O
, XXX O
in XXX O
agreement XXX O
with XXX O
the XXX O
different XXX O
activities XXX O
of XXX O
the XXX O
promoter XXX O
in XXX O
these XXX O
two XXX O
organs XXX O
. XXX O

( XXX O
3 XXX O
) XXX O
. XXX O

Interestingly XXX O
, XXX O
this XXX O
activation XXX O
occurred XXX O
only XXX O
when XXX O
the XXX O
regions XXX O
were XXX O
cloned XXX O
in XXX O
the XXX O
same XXX O
relative XXX O
orientation XXX O
in XXX O
which XXX O
they XXX O
exist XXX O
on XXX O
wild-type XXX O
pCF10 XXX O
. XXX O

When XXX O
both XXX O
lesions XXX O
were XXX O
complete XXX O
lateral XXX O
hemisections XXX O
in XXX O
weanling XXX O
operates XXX O
, XXX O
little XXX O
behavioral XXX O
recovery XXX O
was XXX O
observed XXX O
, XXX O
similar XXX O
to XXX O
complete XXX O
spinal XXX O
cord XXX O
transection XXX O
( XXX O
N XXX O
= XXX O
3 XXX O
) XXX O
. XXX O

Exon-intron XXX O
junctions XXX O
in XXX O
the XXX O
human XXX O
and XXX O
rat XXX B-GENE
AdoMet XXX I-GENE
decarboxylase XXX I-GENE
genes XXX I-GENE
were XXX O
in XXX O
identical XXX O
positions XXX O
except XXX O
that XXX O
exons XXX O
6 XXX O
and XXX O
7 XXX O
of XXX O
the XXX O
human XXX O
gene XXX O
formed XXX O
a XXX O
single XXX O
exon XXX O
in XXX O
the XXX O
rat XXX O
gene XXX O
. XXX O

Multiresistant XXX O
strains XXX O
isolated XXX O
from XXX O
humans XXX O
in XXX O
enteral XXX O
toxico-infections XXX O
kill XXX O
orally XXX O
infected XXX O
mice XXX O
more XXX O
frequently XXX O
than XXX O
strains XXX O
isolated XXX O
in XXX O
hospital XXX O
infections XXX O
. XXX O

Pharmacodynamic XXX O
studies XXX O
on XXX O
the XXX O
cardiovascular XXX O
system XXX O
of XXX O
spontaneously XXX O
hypertensive XXX O
rats XXX O
. XXX O

Is XXX O
clopidogrel XXX O
superior XXX O
to XXX O
aspirin XXX O
in XXX O
secondary XXX O
prevention XXX O
of XXX O
vascular XXX O
disease XXX O
? XXX O
The XXX O
cornerstone XXX O
in XXX O
clinical XXX O
evidence XXX O
of XXX O
the XXX O
relative XXX O
efficacy XXX O
of XXX O
thienopyridines XXX O
( XXX O
clopidogrel XXX O
, XXX O
ticlopidine XXX O
) XXX O
versus XXX O
aspirin XXX O
in XXX O
the XXX O
secondary XXX O
prevention XXX O
of XXX O
vascular XXX O
disease XXX O
is XXX O
the XXX O
Clopidogrel XXX O
versus XXX O
Aspirin XXX O
in XXX O
Patients XXX O
at XXX O
Risk XXX O
of XXX O
Ischaemic XXX O
Events XXX O
trial XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
a XXX O
catalytically XXX O
inactive XXX O
version XXX O
of XXX O
the XXX O
Src XXX B-GENE
family XXX I-GENE
member XXX O
, XXX O
Lck XXX B-GENE
( XXX O
lymphoid XXX B-GENE
cell XXX I-GENE
kinase XXX I-GENE
) XXX O
, XXX O
was XXX O
expressed XXX O
, XXX O
purified XXX O
, XXX O
and XXX O
evaluated XXX O
as XXX O
a XXX O
Csk XXX B-GENE
substrate XXX O
. XXX O

The XXX O
N-terminal XXX O
sequence XXX O
of XXX O
one XXX O
hydrophilic XXX O
peptide XXX O
of XXX O
the XXX O
FeS XXX B-GENE
protein XXX I-GENE
has XXX O
been XXX O
also XXX O
obtained XXX O
confirming XXX O
the XXX O
fbcF XXX B-GENE
reading XXX O
frame XXX O
. XXX O

The XXX O
mutant XXX O
protein XXX O
is XXX O
present XXX O
at XXX O
levels XXX O
slightly XXX O
greater XXX O
than XXX O
wild-type XXX O
, XXX O
but XXX O
exhibits XXX O
the XXX O
same XXX O
tissue XXX O
distribution XXX O
as XXX O
wild-type XXX O
protein XXX O
, XXX O
and XXX O
has XXX O
approximately XXX O
normal XXX O
affinity XXX O
for XXX O
known XXX O
target XXX O
sequences XXX O
( XXX O
though XXX O
no XXX O
DNA XXX O
targets XXX O
identified XXX O
to XXX O
date XXX O
require XXX O
the XXX O
first XXX O
cut XXX O
repeat XXX O
for XXX O
binding XXX O
) XXX O
. XXX O

13 XXX O
men XXX O
with XXX O
a XXX O
history XXX O
of XXX O
recurrent XXX O
genital XXX O
herpes XXX O
simplex XXX O
virus XXX O
type XXX O
2 XXX O
( XXX O
HSV-2 XXX O
) XXX O
infection XXX O
were XXX O
followed XXX O
daily XXX O
for XXX O
4 XXX O
weeks XXX O
with XXX O
samples XXX O
taken XXX O
from XXX O
the XXX O
urethra XXX O
for XXX O
virus XXX O
isolation XXX O
. XXX O

Furthermore XXX O
, XXX O
DNA-bound XXX O
LAZ3 XXX B-GENE
/ XXX I-GENE
BCL6 XXX I-GENE
recruits XXX O
SMRT XXX B-GENE
in XXX O
vivo XXX O
, XXX O
and XXX O
both XXX O
overexpressed XXX O
proteins XXX O
completely XXX O
colocalize XXX O
in XXX O
nuclear XXX O
dots XXX O
. XXX O

Serum XXX O
concentrations XXX O
of XXX O
bone XXX B-GENE
specific XXX I-GENE
alkaline XXX I-GENE
phosphatase XXX I-GENE
( XXX O
BALP XXX B-GENE
) XXX O
and XXX O
osteocalcin XXX B-GENE
( XXX O
bone XXX B-GENE
Gla XXX I-GENE
protein XXX I-GENE
, XXX O
BGP XXX B-GENE
) XXX O
, XXX O
urinary XXX O
levels XXX O
of XXX O
pyridinoline XXX O
( XXX O
Pyr XXX O
) XXX O
and XXX O
deoxypyridinoline XXX O
( XXX O
Dpyr XXX O
) XXX O
and XXX O
computed XXX O
tomography XXX O
( XXX O
CT XXX O
) XXX O
measurements XXX O
of XXX O
the XXX O
cross-sectional XXX O
areas XXX O
of XXX O
the XXX O
vertebrae XXX O
and XXX O
the XXX O
femurs XXX O
, XXX O
the XXX O
apparent XXX O
density XXX O
of XXX O
cancellous XXX O
bone XXX O
in XXX O
the XXX O
vertebrae XXX O
, XXX O
and XXX O
the XXX O
volume XXX O
and XXX O
the XXX O
material XXX O
density XXX O
of XXX O
cortical XXX O
bone XXX O
in XXX O
the XXX O
femurs XXX O
were XXX O
determined XXX O
in XXX O
126 XXX O
boys XXX O
and XXX O
143 XXX O
girls XXX O
, XXX O
ages XXX O
7-18 XXX O
years XXX O
. XXX O

Such XXX O
an XXX O
hemoglobin XXX B-GENE
solution XXX O
was XXX O
shown XXX O
to XXX O
exhibit XXX O
a XXX O
high XXX O
affinity XXX O
for XXX O
oxygen XXX O
and XXX O
a XXX O
low XXX O
Bohr XXX O
effect XXX O
( XXX O
assessed XXX O
from XXX O
the XXX O
delta XXX O
log XXX O
Po2 XXX O
/ XXX O
delta XXX O
pH XXX O
ratio XXX O
) XXX O
. XXX O

The XXX O
latent XXX O
periods XXX O
from XXX O
the XXX O
antral XXX O
exclusion XXX O
to XXX O
the XXX O
occurrence XXX O
of XXX O
anastomotic XXX O
ulcers XXX O
after XXX O
a XXX O
subtotal XXX O
gastrectomy XXX O
with XXX O
Billroth's XXX O
type XXX O
II XXX O
reconstruction XXX O
varied XXX O
from XXX O
a XXX O
few XXX O
days XXX O
to XXX O
19 XXX O
years XXX O
, XXX O
with XXX O
an XXX O
average XXX O
of XXX O
2 XXX O
. XXX O
8 XXX O
years XXX O
. XXX O

Consistent XXX O
with XXX O
this XXX O
interpretation XXX O
, XXX O
recombinant XXX B-GENE
CREB XXX I-GENE
and XXX O
activating XXX O
transcription XXX O
factor XXX O
proteins XXX O
bound XXX O
the XXX O
junB XXX B-GENE
CRE-like XXX B-GENE
site XXX I-GENE
, XXX O
but XXX O
did XXX O
not XXX O
interact XXX O
with XXX O
a XXX O
mutant XXX B-GENE
CRE-like XXX I-GENE
site XXX I-GENE
. XXX O

However XXX O
, XXX O
a XXX O
clear XXX O
difference XXX O
exists XXX O
between XXX O
myoblasts XXX O
and XXX O
10T1 XXX O
/ XXX O
2 XXX O
cells XXX O
( XXX O
and XXX O
other XXX O
non-muscle XXX O
cell XXX O
types XXX O
) XXX O
in XXX O
the XXX O
chromatin XXX O
structure XXX O
of XXX O
the XXX O
chromosomal XXX O
myoD XXX B-GENE
core XXX I-GENE
enhancer XXX I-GENE
, XXX O
suggesting XXX O
that XXX O
the XXX O
myoD XXX B-GENE
enhancer XXX I-GENE
is XXX O
repressed XXX O
by XXX O
epigenetic XXX O
mechanisms XXX O
in XXX O
10T1 XXX O
/ XXX O
2 XXX O
cells XXX O
. XXX O

Nuclear XXX O
spin XXX O
of XXX O
249Bk XXX O
from XXX O
the XXX O
hyperfine XXX O
structure XXX O
in XXX O
its XXX O
emission XXX O
spectrum XXX O
. XXX O

Mammalian XXX B-GENE
Ras XXX I-GENE
GTPase-activating XXX I-GENE
protein XXX I-GENE
( XXX O
GAP XXX B-GENE
) XXX O
, XXX O
p120 XXX B-GENE
Ras-GAP XXX I-GENE
, XXX O
has XXX O
been XXX O
implicated XXX O
as XXX O
both XXX O
a XXX O
downregulator XXX O
and XXX O
effector XXX O
of XXX O
Ras XXX B-GENE
proteins XXX I-GENE
, XXX O
but XXX O
its XXX O
precise XXX O
role XXX O
in XXX O
Ras-mediated XXX O
signal XXX O
transduction XXX O
pathways XXX O
is XXX O
unclear XXX O
. XXX O

A XXX O
further XXX O
analysis XXX O
has XXX O
been XXX O
performed XXX O
using XXX O
the XXX O
series XXX O
of XXX O
maximum XXX O
intensity XXX O
for XXX O
fixed XXX O
duration XXX O
( XXX O
1 XXX O
, XXX O
3 XXX O
, XXX O
6 XXX O
, XXX O
12 XXX O
, XXX O
24 XXX O
hrs XXX O
) XXX O
and XXX O
annual XXX O
daily XXX O
maxima XXX O
. XXX O

ACE-2 XXX B-GENE
has XXX O
a XXX O
hydrophobic XXX O
C XXX O
terminus XXX O
of XXX O
H XXX O
type XXX O
. XXX O

The XXX O
coexpression XXX O
of XXX O
full-length XXX O
expression XXX O
constructs XXX O
for XXX O
both XXX O
DBP XXX B-GENE
and XXX O
hepatic XXX B-GENE
leukemia XXX I-GENE
factor XXX I-GENE
resulted XXX O
in XXX O
a XXX O
dramatic XXX O
increase XXX O
in XXX O
activation XXX O
mediated XXX O
by XXX O
the XXX O
GAL4-DBP XXX B-GENE
fusion XXX I-GENE
proteins XXX I-GENE
, XXX O
suggesting XXX O
the XXX O
involvement XXX O
of XXX O
a XXX O
regulated XXX O
coactivator XXX O
in XXX O
this XXX O
process XXX O
. XXX O

These XXX O
data XXX O
indicate XXX O
that XXX O
expansion XXX O
of XXX O
the XXX O
dodecamer XXX O
repeat XXX O
located XXX O
in XXX O
the XXX O
proximal XXX O
promoter XXX O
of XXX O
CSTB XXX B-GENE
severely XXX O
disrupts XXX O
the XXX O
function XXX O
of XXX O
the XXX O
promoter XXX O
and XXX O
thereby XXX O
reduces XXX O
transcription XXX O
of XXX O
CSTB XXX B-GENE
. XXX O

Rheumatoid XXX B-GENE
factor XXX I-GENE
and XXX O
antinuclear XXX O
antibody XXX O
tests XXX O
were XXX O
frequently XXX O
positive XXX O
, XXX O
and XXX O
reactions XXX O
to XXX O
gold XXX O
therapy XXX O
were XXX O
more XXX O
frequent XXX O
than XXX O
in XXX O
other XXX O
rheumatoid XXX O
populations XXX O
. XXX O

Moreover XXX O
, XXX O
moderate XXX O
overexpression XXX O
of XXX O
Chk1 XXX B-GENE
suppresses XXX O
the XXX O
phenotypes XXX O
of XXX O
cut5 XXX B-GENE
and XXX O
crb2 XXX B-GENE
mutants XXX I-GENE
. XXX O

Solution XXX O
structure XXX O
of XXX O
the XXX O
IRF-2 XXX B-GENE
DNA-binding XXX I-GENE
domain XXX O
: XXX O
a XXX O
novel XXX O
subgroup XXX O
of XXX O
the XXX O
winged XXX B-GENE
helix-turn-helix XXX I-GENE
family XXX I-GENE
. XXX O

Vancomycin XXX O
data XXX O
were XXX O
analyzed XXX O
according XXX O
to XXX O
a XXX O
one-compartment XXX O
open XXX O
model XXX O
with XXX O
use XXX O
of XXX O
NONMEM XXX O
population XXX O
pharmacokinetic XXX O
software XXX O
. XXX O

Addition XXX O
of XXX O
phalloidin-stabilized XXX O
F-actin XXX B-GENE
nuclei XXX O
and XXX O
phalloidin XXX O
restored XXX O
L266D XXX O
actin's XXX O
ability XXX O
to XXX O
polymerize XXX O
at XXX O
4 XXX O
degrees XXX O
C XXX O
. XXX O

Addition XXX O
of XXX O
synthetic XXX O
tyrosine-phosphorylated XXX O
peptides XXX O
derived XXX O
from XXX O
betac XXX O
cytoplasmic XXX O
tyrosines XXX O
prior XXX O
to XXX O
GM-CSF XXX B-GENE
stimulation XXX O
inhibited XXX O
the XXX O
in XXX O
vitro XXX O
activation XXX O
of XXX O
STAT5 XXX B-GENE
. XXX O

Thus XXX O
, XXX O
while XXX O
the XXX O
folds XXX O
of XXX O
all XXX O
Myb XXX B-GENE
domains XXX I-GENE
resemble XXX O
each XXX O
other XXX O
closely XXX O
, XXX O
the XXX O
function XXX O
of XXX O
each XXX O
Myb XXX B-GENE
domain XXX I-GENE
depends XXX O
on XXX O
the XXX O
amino XXX O
acid XXX O
residues XXX O
that XXX O
are XXX O
located XXX O
on XXX O
the XXX O
surface XXX O
of XXX O
each XXX O
protein XXX O
. XXX O

The XXX O
Ets-1 XXX B-GENE
binding XXX I-GENE
site XXX I-GENE
was XXX O
localized XXX O
to XXX O
a XXX O
17-base XXX O
pair XXX O
( XXX O
bp XXX O
) XXX O
region XXX O
from XXX O
the XXX O
3' XXX O
end XXX O
of XXX O
T XXX B-GENE
alpha XXX I-GENE
2 XXX I-GENE
. XXX O

Northern XXX O
blot XXX O
analyses XXX O
show XXX O
that XXX O
the XXX O
hBub1 XXX B-GENE
mRNA XXX I-GENE
level XXX O
is XXX O
abundantly XXX O
expressed XXX O
in XXX O
tissues XXX O
or XXX O
cells XXX O
with XXX O
a XXX O
high XXX O
mitotic XXX O
index XXX O
. XXX O

A XXX O
novel XXX O
pleckstrin XXX B-GENE
homology-related XXX I-GENE
gene XXX I-GENE
family XXX I-GENE
defined XXX O
by XXX O
Ipl XXX B-GENE
/ XXX I-GENE
Tssc3 XXX I-GENE
, XXX O
TDAG51 XXX B-GENE
, XXX O
and XXX O
Tih1 XXX B-GENE
: XXX O
tissue-specific XXX O
expression XXX O
, XXX O
chromosomal XXX O
location XXX O
, XXX O
and XXX O
parental XXX O
imprinting XXX O
. XXX O

Sak XXX B-GENE
kinase XXX I-GENE
gene XXX O
structure XXX O
and XXX O
transcriptional XXX O
regulation XXX O
. XXX O

Two XXX O
mutants XXX O
, XXX O
each XXX O
representative XXX O
of XXX O
a XXX O
separate XXX O
pet XXX O
complementation XXX O
group XXX O
, XXX O
have XXX O
been XXX O
analyzed XXX O
. XXX O

The XXX O
cloned XXX O
genes XXX O
were XXX O
identified XXX O
in XXX O
genetic XXX O
libraries XXX O
by XXX O
hybridization XXX O
screening XXX O
using XXX O
four XXX O
deoxyoligonucleotide XXX O
probes XXX O
which XXX O
corresponded XXX O
to XXX O
the XXX O
partial XXX O
amino XXX O
acid XXX O
sequence XXX O
of XXX O
the XXX O
purified XXX O
enzyme XXX O
. XXX O

The XXX O
objectives XXX O
of XXX O
the XXX O
present XXX O
study XXX O
were XXX O
to XXX O
evaluate XXX O
the XXX O
effects XXX O
of XXX O
adding XXX O
Equex XXX O
to XXX O
a XXX O
TRIS-extender XXX O
, XXX O
diluting XXX O
the XXX O
semen XXX O
in XXX O
1 XXX O
or XXX O
2 XXX O
steps XXX O
, XXX O
freezing XXX O
according XXX O
to XXX O
2 XXX O
methods XXX O
, XXX O
thawing XXX O
at XXX O
2 XXX O
rates XXX O
, XXX O
and XXX O
the XXX O
interactions XXX O
between XXX O
these XXX O
treatments XXX O
, XXX O
on XXX O
the XXX O
post-thaw XXX O
survival XXX O
of XXX O
dog XXX O
spermatozoa XXX O
at XXX O
38 XXX O
degrees XXX O
C XXX O
. XXX O

Stylohyoid XXX O
chain XXX O
ossification XXX O
: XXX O
choice XXX O
of XXX O
the XXX O
surgical XXX O
approach XXX O
. XXX O

The XXX O
region XXX O
that XXX O
imparts XXX O
inducibility XXX O
by XXX O
IL-1 XXX B-GENE
or XXX O
TNF XXX B-GENE
( XXX O
positions XXX O
-165 XXX O
to XXX O
-58 XXX O
) XXX O
contains XXX O
potential XXX O
binding XXX O
sites XXX O
for XXX O
IRF-1 XXX B-GENE
and XXX I-GENE
-2 XXX I-GENE
, XXX O
AP-1 XXX B-GENE
, XXX O
and XXX O
NF-IL-6 XXX B-GENE
. XXX O

To XXX O
avoid XXX O
complications XXX O
, XXX O
accurate XXX O
quantitative XXX O
analysis XXX O
of XXX O
NO XXX O
and XXX O
NO2 XXX O
is XXX O
necessary XXX O
during XXX O
this XXX O
therapy XXX O
. XXX O

RNA XXX O
of XXX O
GBV-C XXX O
was XXX O
detected XXX O
in XXX O
14 XXX O
( XXX O
18% XXX O
) XXX O
patients XXX O
before XXX O
BMT XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
we XXX O
also XXX O
constructed XXX O
and XXX O
expressed XXX O
chimeric XXX O
fusion XXX O
protein XXX O
that XXX O
contains XXX O
HIV-2 XXX B-GENE
gag XXX I-GENE
with XXX O
V3 XXX B-GENE
domains XXX I-GENE
of XXX O
HIV-1IIIB XXX O
, XXX O
HIV-1MN XXX O
, XXX O
HIV-1SF2 XXX O
and XXX O
HIV-1RF XXX O
. XXX O

Study XXX O
groups XXX O
were XXX O
control XXX O
, XXX O
and XXX O
those XXX O
treated XXX O
with XXX O
the XXX O
alpha1-adrenoceptor-subtype XXX B-GENE
blockers XXX O
WB4101 XXX O
( XXX O
0 XXX O
. XXX O
5 XXX O
mg XXX O
/ XXX O
kg XXX O
i XXX O
. XXX O
v XXX O
. XXX O
) XXX O
or XXX O
chloroethylclonidine XXX O
( XXX O
1 XXX O
. XXX O
9 XXX O
mg XXX O
/ XXX O
kg XXX O
i XXX O
. XXX O
v XXX O
. XXX O
) XXX O
. XXX O

These XXX O
observations XXX O
link XXX O
actin XXX B-GENE
plaque XXX O
assembly XXX O
to XXX O
increased XXX O
cell XXX O
substrate XXX O
adhesion XXX O
. XXX O

These XXX O
mutations XXX O
are XXX O
localized XXX O
in XXX O
the XXX O
same XXX O
region XXX O
where XXX O
the XXX O
HSV XXX B-GENE
transactivator XXX I-GENE
VP16 XXX I-GENE
binds XXX O
, XXX O
but XXX O
did XXX O
not XXX O
coincide XXX O
with XXX O
the XXX O
VP16 XXX B-GENE
contacts XXX O
. XXX O

Statokinesimetric XXX O
recording XXX O
in XXX O
Huntington XXX O
choreas XXX O
. XXX O

An XXX O
experiment XXX O
was XXX O
carried XXX O
on XXX O
133 XXX O
grown XXX O
up XXX O
fowls XXX O
and XXX O
broilers XXX O
from XXX O
4 XXX O
industrial XXX O
farms XXX O
, XXX O
vaccinated XXX O
with XXX O
spray XXX O
lento XXX O
and XXX O
mesogenic XXX O
vaccines XXX O
for XXX O
straining XXX O
the XXX O
immunity XXX O
against XXX O
pseodopest XXX O
through XXX O
RIHA XXX O
and XXX O
provoking XXX O
pseudoplague XXX O
with XXX O
a XXX O
pathogenic XXX O
virus XXX O
. XXX O

This XXX O
-2485 XXX O
/ XXX O
-2458 XXX O
element XXX O
bound XXX O
PPARalpha XXX B-GENE
and XXX O
PPARgamma XXX B-GENE
from XXX O
brown XXX O
fat XXX O
nuclei XXX O
. XXX O

The XXX O
results XXX O
showed XXX O
that XXX O
the XXX O
sensitivity XXX O
of XXX O
the XXX O
3 XXX O
given XXX O
guinea XXX O
pig XXX O
strains XXX O
was XXX O
comparable XXX O
. XXX O

Plasma XXX B-GENE
thromboxane XXX I-GENE
B2 XXX I-GENE
levels XXX O
in XXX O
the XXX O
older XXX O
group XXX O
were XXX O
about XXX O
double XXX O
those XXX O
in XXX O
younger XXX O
piglets XXX O
. XXX O

However XXX O
, XXX O
one XXX O
3' XXX O
splice XXX O
site XXX O
, XXX O
located XXX O
at XXX O
nucleotide XXX O
( XXX O
nt XXX O
) XXX O
3225 XXX O
, XXX O
is XXX O
used XXX O
for XXX O
the XXX O
processing XXX O
of XXX O
most XXX O
BPV-1 XXX O
pre-mRNAs XXX O
in XXX O
BPV-1-transformed XXX O
C127 XXX O
cells XXX O
and XXX O
at XXX O
early XXX O
to XXX O
intermediate XXX O
times XXX O
in XXX O
productively XXX O
infected XXX O
warts XXX O
. XXX O

Particles XXX O
resembling XXX O
microbodies XXX O
in XXX O
normal XXX O
and XXX O
neoplastic XXX O
perianal XXX O
glands XXX O
of XXX O
dogs XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
all XXX O
three XXX O
Opa XXX B-GENE
proteins XXX I-GENE
of XXX O
C751 XXX O
bind XXX O
equally XXX O
well XXX O
to XXX O
HeLa XXX O
cells XXX O
transfected XXX O
with XXX O
cDNA XXX O
encoding XXX O
the XXX O
carcinoembryonic XXX B-GENE
antigen XXX I-GENE
[ XXX I-GENE
CEA XXX I-GENE
( XXX I-GENE
CD66e XXX I-GENE
) XXX I-GENE
] XXX I-GENE
subgroup XXX O
of XXX O
the XXX O
CD66 XXX B-GENE
family XXX I-GENE
, XXX O
but XXX O
show XXX O
distinct XXX O
tropism XXX O
for XXX O
CGM1- XXX O
( XXX O
CD66d XXX B-GENE
) XXX O
and XXX O
NCA XXX B-GENE
( XXX O
CD66c XXX B-GENE
) XXX O
-expressing XXX O
cells XXX O
. XXX O

The XXX O
differential XXX O
diagnosis XXX O
of XXX O
both XXX O
affections XXX O
is XXX O
based XXX O
on XXX O
the XXX O
clinical XXX O
course XXX O
, XXX O
sialography XXX O
and XXX O
CT XXX O
examination XXX O
which XXX O
along XXX O
with XXX O
modern XXX O
ATB XXX O
treatment XXX O
significantly XXX O
modify XXX O
hitherto XXX O
used XXX O
surgical XXX O
therapy XXX O
. XXX O

The XXX O
pre- XXX O
and XXX O
postoperative XXX O
haemoglobin XXX B-GENE
concentrations XXX O
in XXX O
the XXX O
autologous XXX O
group XXX O
were XXX O
lower XXX O
by XXX O
15 XXX O
and XXX O
10 XXX O
g XXX O
/ XXX O
L XXX O
, XXX O
respectively XXX O
, XXX O
after XXX O
primary XXX O
THR XXX O
and XXX O
by XXX O
10 XXX O
g XXX O
/ XXX O
L XXX O
in XXX O
both XXX O
instances XXX O
after XXX O
revision XXX O
THR XXX O
. XXX O

The XXX O
same XXX O
IL-4-inducible XXX O
reporter XXX O
gene XXX O
is XXX O
also XXX O
synergistically XXX O
activated XXX O
by XXX O
the XXX O
endogenous XXX B-GENE
Stat6 XXX I-GENE
and XXX O
NF-kappaB XXX B-GENE
proteins XXX I-GENE
in XXX O
IL-4-stimulated XXX O
I XXX O
. XXX O
29mu XXX O
B XXX O
lymphoma XXX O
cells XXX O
. XXX O

The XXX O
odds XXX O
ratio XXX O
for XXX O
CHD XXX O
was XXX O
1 XXX O
. XXX O
21 XXX O
( XXX O
95% XXX O
confidence XXX O
interval XXX O
, XXX O
0 XXX O
. XXX O
84-1 XXX O
. XXX O
75 XXX O
) XXX O
given XXX O
a XXX O
positive XXX O
serostatus XXX O
of XXX O
specific XXX O
IgG XXX B-GENE
antibodies XXX O
after XXX O
adjustment XXX O
for XXX O
covariates XXX O
. XXX O

Taken XXX O
together XXX O
, XXX O
these XXX O
results XXX O
indicate XXX O
that XXX O
MAP XXX B-GENE
kinase XXX I-GENE
stimulates XXX O
the XXX O
hPL-B XXX B-GENE
enhancer XXX I-GENE
by XXX O
an XXX O
NF-IL-6-dependent XXX O
pathway XXX O
. XXX O

This XXX O
report XXX O
presents XXX O
state-specific XXX O
MMRs XXX O
for XXX O
1987-1996 XXX O
, XXX O
focusing XXX O
on XXX O
persistent XXX O
disparities XXX O
in XXX O
maternal XXX O
mortality XXX O
between XXX O
black XXX O
and XXX O
white XXX O
women XXX O
. XXX O

The XXX O
results XXX O
indicate XXX O
considerable XXX O
flexibility XXX O
in XXX O
the XXX O
spacing XXX O
between XXX O
DH XXX O
regulatory XXX O
sites XXX O
. XXX O

The XXX O
utility XXX O
of XXX O
such XXX O
analyses XXX O
in XXX O
the XXX O
design XXX O
of XXX O
ceramic XXX O
/ XXX O
substrate XXX O
bilayer XXX O
systems XXX O
for XXX O
optimal XXX O
resistance XXX O
to XXX O
lifetime-threatening XXX O
damage XXX O
is XXX O
discussed XXX O
. XXX O

Each XXX O
parent XXX O
interacted XXX O
with XXX O
their XXX O
4- XXX O
or XXX O
5-year-old XXX O
son XXX O
or XXX O
daughter XXX O
in XXX O
each XXX O
of XXX O
two XXX O
conversations--unstructured XXX O
( XXX O
social XXX O
conversation XXX O
) XXX O
and XXX O
structured XXX O
( XXX O
task XXX O
activity XXX O
) XXX O
. XXX O

Investigation XXX O
of XXX O
the XXX O
control XXX O
of XXX O
coronavirus XXX O
subgenomic XXX O
mRNA XXX O
transcription XXX O
by XXX O
using XXX O
T7-generated XXX O
negative-sense XXX O
RNA XXX O
transcripts XXX O
. XXX O

The XXX O
Saccharomyces XXX B-GENE
cerevisiae XXX I-GENE
14DM XXX I-GENE
gene XXX I-GENE
, XXX O
encoding XXX O
cytochrome XXX B-GENE
P450 XXX I-GENE
lanosterol XXX I-GENE
14 XXX I-GENE
alpha-demethylase XXX I-GENE
( XXX O
14DM XXX B-GENE
) XXX O
, XXX O
was XXX O
overexpressed XXX O
in XXX O
various XXX O
S XXX O
. XXX O
cerevisiae XXX O
strains XXX O
under XXX O
the XXX O
control XXX O
of XXX O
three XXX O
strong XXX O
heterologous XXX O
yeast XXX O
transcription XXX O
promoters XXX O
( XXX O
pADC1 XXX B-GENE
, XXX O
pGPD XXX B-GENE
, XXX O
pPHO5 XXX B-GENE
) XXX O
and XXX O
under XXX O
the XXX O
control XXX O
of XXX O
its XXX O
own XXX O
promoter XXX O
. XXX O

Previously XXX O
, XXX O
we XXX O
showed XXX O
that XXX O
the XXX O
APRE XXX B-GENE
is XXX O
a XXX O
cytokine XXX O
[ XXX O
tumor XXX B-GENE
necrosis XXX I-GENE
factor-alpha XXX I-GENE
( XXX O
TNFalpha XXX B-GENE
) XXX O
] XXX O
- XXX O
inducible XXX O
enhancer XXX O
by XXX O
binding XXX O
the XXX O
heterodimeric XXX B-GENE
nuclear XXX I-GENE
factor-kappaB XXX I-GENE
( XXX O
NF-kappaB XXX B-GENE
) XXX O
complex XXX O
Rel XXX B-GENE
A XXX I-GENE
x XXX O
NF-kappaB1 XXX B-GENE
. XXX O

Marked XXX O
thrombocytopenia XXX O
, XXX O
depletion XXX O
of XXX O
serum XXX B-GENE
fibrinogen XXX I-GENE
and XXX O
prolonged XXX O
prothrombin XXX B-GENE
and XXX O
activated XXX O
partial XXX O
thromboplastin XXX B-GENE
time XXX O
, XXX O
were XXX O
recorded XXX O
at XXX O
5 XXX O
to XXX O
10 XXX O
and XXX O
30 XXX O
to XXX O
40 XXX O
minutes XXX O
after XXX O
intravenous XXX O
envenomation XXX O
. XXX O

Stroop XXX O
interference XXX O
: XXX O
aging XXX O
effects XXX O
assessed XXX O
with XXX O
the XXX O
Stroop XXX O
Color-Word XXX O
Test XXX O
. XXX O

A XXX O
novel XXX O
approach XXX O
was XXX O
developed XXX O
for XXX O
identifying XXX O
transcription XXX O
factor XXX O
activities XXX O
associated XXX O
with XXX O
NGF-activated XXX O
, XXX O
but XXX O
not XXX O
EGF-activated XXX O
, XXX O
signaling XXX O
, XXX O
using XXX O
random XXX O
oligonucleotide XXX O
clones XXX O
from XXX O
a XXX O
DNA XXX O
recognition XXX O
library XXX O
to XXX O
isolate XXX O
specific XXX O
DNA XXX O
binding XXX O
proteins XXX O
from XXX O
PC12 XXX O
nuclear XXX O
extracts XXX O
. XXX O

The XXX O
partial XXX O
categories XXX O
of XXX O
the XXX O
SIP XXX O
that XXX O
were XXX O
more XXX O
affected XXX O
were XXX O
work XXX O
, XXX O
recreation XXX O
and XXX O
pastimes XXX O
, XXX O
home XXX O
management XXX O
, XXX O
and XXX O
sleep XXX O
and XXX O
rest XXX O
. XXX O

Patients XXX O
with XXX O
Parkinson's XXX O
disease XXX O
showed XXX O
a XXX O
relatively XXX O
high XXX O
incidence XXX O
to XXX O
psychoses XXX O
during XXX O
drug XXX O
treatment XXX O
( XXX O
51 XXX O
. XXX O
47% XXX O
) XXX O
. XXX O

Thus XXX O
, XXX O
patients XXX O
with XXX O
metastatic XXX O
melanoma XXX O
are XXX O
not XXX O
tolerant XXX O
to XXX O
gp100 XXX B-GENE
Ag XXX I-GENE
based XXX O
on XXX O
the XXX O
detection XXX O
of XXX O
CD8+ XXX B-GENE
T XXX O
cells XXX O
specific XXX O
for XXX O
multiple XXX O
HLA-A*0201-restricted XXX O
, XXX O
gp100-derived XXX O
epitopes XXX O
. XXX O

Despite XXX O
the XXX O
small XXX O
number XXX O
of XXX O
patients XXX O
, XXX O
on XXX O
the XXX O
basis XXX O
of XXX O
this XXX O
report XXX O
, XXX O
we XXX O
can XXX O
confirm XXX O
that XXX O
1 XXX O
. XXX O
5 XXX O
MU XXX O
/ XXX O
day XXX O
of XXX O
alpha-IFN XXX B-GENE
is XXX O
an XXX O
adequate XXX O
treatment XXX O
for XXX O
patients XXX O
with XXX O
hairy XXX O
cell XXX O
leukemia XXX O
. XXX O

Overall XXX O
, XXX O
lesions XXX O
infiltrating XXX O
the XXX O
deep XXX O
lamina XXX O
propria XXX O
do XXX O
not XXX O
exhibit XXX O
a XXX O
reduced XXX O
frequency XXX O
of XXX O
occurrence XXX O
compared XXX O
to XXX O
lesions XXX O
infiltrating XXX O
the XXX O
skeletal XXX O
muscle XXX O
; XXX O
however XXX O
, XXX O
carcinomas XXX O
affecting XXX O
other XXX O
oral XXX O
sites XXX O
showed XXX O
a XXX O
reduced XXX O
frequency XXX O
of XXX O
deeply XXX O
infiltrating XXX O
lesions XXX O
in XXX O
comparison XXX O
to XXX O
more XXX O
superficial XXX O
lesions XXX O
. XXX O

All XXX O
subjects XXX O
were XXX O
submitted XXX O
to XXX O
ECG XXX O
and XXX O
arterial XXX O
blood XXX O
pressure XXX O
determination XXX O
and XXX O
were XXX O
assayed XXX O
for XXX O
TSH XXX B-GENE
, XXX O
thyroid XXX O
hormone XXX O
, XXX O
PRL XXX B-GENE
, XXX O
glucose XXX O
, XXX O
creatinine XXX O
, XXX O
nitrogen XXX O
, XXX O
glutamine XXX B-GENE
transaminase XXX I-GENE
, XXX O
cholesterol XXX O
and XXX O
triglycerides XXX O
plasma XXX O
levels XXX O
before XXX O
therapy XXX O
( XXX O
T0 XXX O
) XXX O
, XXX O
after XXX O
30 XXX O
treatment XXX O
days XXX O
( XXX O
T30 XXX O
) XXX O
and XXX O
after XXX O
a XXX O
15 XXX O
days XXX O
washout XXX O
( XXX O
T45 XXX O
) XXX O
. XXX O

This XXX O
may XXX O
explain XXX O
in XXX O
part XXX O
a XXX O
secular XXX O
trend XXX O
towards XXX O
reduced XXX O
birthweight XXX O
for XXX O
gestation XXX O
in XXX O
preterm XXX O
infants XXX O
. XXX O

The XXX O
utilities XXX O
measured XXX O
in XXX O
our XXX O
study XXX O
can XXX O
be XXX O
applied XXX O
directly XXX O
to XXX O
quality-of-life XXX O
determinations XXX O
in XXX O
clinical XXX O
trials XXX O
of XXX O
adjuvant XXX O
IFN XXX B-GENE
alpha-2b XXX I-GENE
to XXX O
measure XXX O
the XXX O
net XXX O
benefit XXX O
of XXX O
therapy XXX O
. XXX O

Effect XXX O
of XXX O
castration XXX O
on XXX O
pituitary XXX B-GENE
and XXX I-GENE
serum XXX I-GENE
LH XXX I-GENE
and XXX O
FSH XXX B-GENE
in XXX O
testosterone-sterilized XXX O
rats XXX O
. XXX O

In XXX O
the XXX O
former XXX O
instance XXX O
, XXX O
in XXX O
addition XXX O
to XXX O
serum XXX O
calcium XXX O
and XXX O
phosphorous XXX O
ion XXX O
concentrations XXX O
, XXX O
tissue XXX O
pH XXX O
, XXX O
blood XXX O
supply XXX O
, XXX O
hormones XXX O
, XXX O
i XXX O
. XXX O
e XXX O
. XXX O
, XXX O
vitamin XXX O
D XXX O
, XXX O
vitamin XXX O
A XXX O
, XXX O
and XXX O
various XXX O
enzymes XXX O
( XXX O
e XXX O
. XXX O
g XXX O
. XXX O
, XXX O
alkaline XXX B-GENE
phosphatase XXX I-GENE
and XXX O
pyrophosphatase XXX B-GENE
) XXX O
may XXX O
all XXX O
play XXX O
significant XXX O
, XXX O
ancillary XXX O
, XXX O
time-dependent XXX O
, XXX O
but XXX O
as XXX O
yet XXX O
undetermined XXX O
roles XXX O
. XXX O

PURPOSE XXX O
: XXX O
The XXX O
role XXX O
interleukin-6 XXX B-GENE
( XXX O
IL-6 XXX B-GENE
) XXX O
in XXX O
the XXX O
treatment XXX O
of XXX O
congenital XXX O
thrombocytopenias XXX O
is XXX O
unknown XXX O
. XXX O

Truncated XXX B-GENE
ICSBP XXX I-GENE
lacking XXX O
the XXX O
first XXX O
33 XXX O
amino-terminal XXX O
amino XXX O
acids XXX O
fails XXX O
to XXX O
bind XXX O
to XXX O
the XXX O
ICS XXX O
, XXX O
indicating XXX O
that XXX O
at XXX O
least XXX O
part XXX O
of XXX O
the XXX O
DNA XXX O
binding XXX O
domain XXX O
is XXX O
located XXX O
within XXX O
the XXX O
well XXX O
conserved XXX O
amino XXX O
terminus XXX O
. XXX O

DNA XXX O
sequence XXX O
and XXX O
functions XXX O
of XXX O
the XXX O
actVI XXX B-GENE
region XXX I-GENE
of XXX O
the XXX O
actinorhodin XXX B-GENE
biosynthetic XXX I-GENE
gene XXX I-GENE
cluster XXX I-GENE
of XXX I-GENE
Streptomyces XXX I-GENE
coelicolor XXX I-GENE
A3 XXX I-GENE
( XXX I-GENE
2 XXX I-GENE
) XXX I-GENE
. XXX O

Leads XXX O
from XXX O
the XXX O
MMWR XXX O
. XXX O

At XXX O
cross XXX O
purposes XXX O
. XXX O

Using XXX O
a XXX O
natural XXX O
dominant XXX O
negative XXX O
for XXX O
AP-1 XXX B-GENE
transcriptional XXX O
activity XXX O
in XXX O
ROS XXX O
17 XXX O
/ XXX O
2 XXX O
. XXX O
8 XXX O
cells XXX O
, XXX O
we XXX O
then XXX O
showed XXX O
that XXX O
AP-1 XXX B-GENE
transcription XXX I-GENE
factors XXX I-GENE
mediated XXX O
TGF-beta1- XXX O
and XXX O
BMP-2-regulated XXX O
expression XXX O
of XXX O
the XXX O
( XXX B-GENE
alpha1 XXX I-GENE
) XXX I-GENE
collagen XXX I-GENE
I XXX I-GENE
gene XXX I-GENE
as XXX O
well XXX O
as XXX O
TGF-beta1-regulated XXX O
expression XXX O
of XXX O
the XXX O
parathyroid XXX B-GENE
hormone XXX I-GENE
( XXX I-GENE
PTH XXX I-GENE
) XXX I-GENE
/ XXX I-GENE
PTH-related XXX I-GENE
peptide XXX I-GENE
( XXX I-GENE
PTHrP XXX I-GENE
) XXX I-GENE
receptor XXX I-GENE
. XXX O

The XXX O
physicians XXX O
in XXX O
charge XXX O
of XXX O
all XXX O
patients XXX O
with XXX O
evidence XXX O
of XXX O
acute XXX O
Q XXX O
fever XXX O
( XXX O
seroconversion XXX O
and XXX O
/ XXX O
or XXX O
presence XXX O
of XXX O
IgM XXX B-GENE
) XXX O
or XXX O
chronic XXX O
Q XXX O
fever XXX O
( XXX O
prolonged XXX O
disease XXX O
and XXX O
/ XXX O
or XXX O
IgG XXX B-GENE
antibody XXX I-GENE
titer XXX O
to XXX O
phase XXX O
I XXX O
of XXX O
Coxiella XXX O
burnetii XXX O
> XXX O
or XXX O
= XXX O
800 XXX O
) XXX O
were XXX O
asked XXX O
to XXX O
complete XXX O
a XXX O
questionnaire XXX O
, XXX O
which XXX O
was XXX O
computerized XXX O
. XXX O

Furthermore XXX O
, XXX O
the XXX O
wide XXX O
distribution XXX O
of XXX O
the XXX O
GFP-POLO XXX B-GENE
protein XXX I-GENE
to XXX O
all XXX O
compartments XXX O
of XXX O
the XXX O
mitotic XXX O
apparatus XXX O
provides XXX O
a XXX O
valuable XXX O
tool XXX O
for XXX O
future XXX O
studies XXX O
on XXX O
cell XXX O
cycle XXX O
during XXX O
development XXX O
. XXX O

Liquid XXX O
chromatography XXX O
with XXX O
amperometric XXX O
detection XXX O
( XXX O
LC XXX O
/ XXX O
AD XXX O
) XXX O
is XXX O
used XXX O
to XXX O
determine XXX O
fluazifop XXX O
acid XXX O
produced XXX O
from XXX O
the XXX O
metabolism XXX O
or XXX O
base XXX O
hydrolysis XXX O
of XXX O
fluazifop-butyl XXX O
in XXX O
soybeans XXX O
and XXX O
soybean XXX O
oil XXX O
. XXX O

Flavonoids XXX O
from XXX O
Brosimum XXX O
acutifolium XXX O
. XXX O

Sequence XXX O
analysis XXX O
reveals XXX O
that XXX O
the XXX O
newly XXX O
discovered XXX O
oasA2 XXX B-GENE
gene XXX I-GENE
represents XXX O
a XXX O
pseudogene XXX O
that XXX O
is XXX O
still XXX O
transcribed XXX O
, XXX O
but XXX O
is XXX O
not XXX O
functionally XXX O
translated XXX O
. XXX O

Our XXX O
findings XXX O
provide XXX O
the XXX O
first XXX O
evidence XXX O
that XXX O
the XXX O
function XXX O
of XXX O
WT1 XXX B-GENE
can XXX O
be XXX O
modulated XXX O
by XXX O
its XXX O
phosphorylation XXX O
in XXX O
vivo XXX O
. XXX O

Genomic XXX O
Southern XXX O
blot XXX O
analysis XXX O
of XXX O
rat XXX B-GENE
EFIA XXX I-GENE
( XXX O
gene XXX O
encoding XXX O
enhancer XXX B-GENE
factor XXX I-GENE
I XXX I-GENE
subunit XXX I-GENE
A XXX I-GENE
) XXX O
reveals XXX O
a XXX O
complex XXX O
band XXX O
pattern XXX O
when XXX O
cDNA XXX O
subfragment XXX O
probes XXX O
are XXX O
used XXX O
. XXX O

To XXX O
study XXX O
the XXX O
sensitivity XXX O
of XXX O
some XXX O
central XXX O
brain XXX O
structures XXX O
to XXX O
the XXX O
action XXX O
of XXX O
an XXX O
electromagnetic XXX O
field XXX O
of XXX O
decimeter XXX O
waves XXX O
( XXX O
EMF XXX O
of XXX O
DW XXX O
) XXX O
a XXX O
dynamic XXX O
investigation XXX O
of XXX O
single XXX O
unit XXX O
activity XXX O
was XXX O
undertaken XXX O
. XXX O

Overproduction XXX O
, XXX O
purification XXX O
and XXX O
characterization XXX O
of XXX O
M XXX B-GENE
. XXX I-GENE
HinfI XXX I-GENE
methyltransferase XXX I-GENE
and XXX O
its XXX O
deletion XXX O
mutant XXX O
. XXX O

In XXX O
all XXX O
other XXX O
cases XXX O
, XXX O
vestibular XXX O
neurectomy XXX O
or XXX O
chemical XXX O
vestibular XXX O
labyrinthectomy XXX O
, XXX O
by XXX O
means XXX O
of XXX O
intratympanic XXX O
low XXX O
concentration XXX O
gentamicin XXX O
( XXX O
20 XXX O
mg XXX O
/ XXX O
mL XXX O
) XXX O
, XXX O
are XXX O
indicated XXX O
. XXX O

This XXX O
region XXX O
constitutes XXX O
the XXX O
DNA-binding XXX O
domain XXX O
with XXX O
basic-helix-loop-helix XXX O
and XXX O
leucine-zipper XXX O
motifs XXX O
, XXX O
features XXX O
common XXX O
to XXX O
the XXX O
myc-related XXX B-GENE
transcription XXX I-GENE
factor XXX I-GENE
family XXX I-GENE
. XXX O

Consistent XXX O
with XXX O
this XXX O
model XXX O
, XXX O
a XXX O
synthetic XXX O
construct XXX O
containing XXX O
three XXX O
tandem XXX O
copies XXX O
of XXX O
the XXX O
native XXX O
LDL XXX B-GENE
receptor XXX I-GENE
SREBP XXX B-GENE
site XXX O
linked XXX O
to XXX O
a XXX O
single XXX O
Sp1 XXX B-GENE
site XXX I-GENE
was XXX O
also XXX O
significantly XXX O
activated XXX O
in XXX O
a XXX O
buttonhead-independent XXX O
fashion XXX O
. XXX O

Heat-labile-like XXX O
enterotoxin XXX B-GENE
( XXX O
LT XXX B-GENE
) XXX O
was XXX O
produced XXX O
by XXX O
26 XXX O
of XXX O
42 XXX O
stool XXX O
isolates XXX O
( XXX O
62% XXX O
) XXX O
, XXX O
while XXX O
only XXX O
1 XXX O
of XXX O
the XXX O
42 XXX O
isolates XXX O
( XXX O
2% XXX O
) XXX O
produced XXX O
enterotoxinlike XXX O
activity XXX O
in XXX O
suckling XXX O
mice XXX O
; XXX O
65% XXX O
of XXX O
the XXX O
cytotoxin-producing XXX O
strains XXX O
also XXX O
produced XXX O
an XXX O
LT-like XXX O
material XXX O
. XXX O

The XXX O
hatcher XXX O
incubators XXX O
of XXX O
both XXX O
companies XXX O
were XXX O
also XXX O
persistently XXX O
contaminated XXX O
with XXX O
Salmonella XXX O
livingstone XXX O
and XXX O
Salmonella XXX O
thomasville XXX O
in XXX O
company XXX O
A XXX O
and XXX O
with XXX O
Salmonella XXX O
senftenberg XXX O
in XXX O
company XXX O
B XXX O
. XXX O

Oncogenic XXX B-GENE
Raf-1 XXX I-GENE
activates XXX O
p70 XXX B-GENE
S6 XXX I-GENE
kinase XXX I-GENE
via XXX O
a XXX O
mitogen-activated XXX O
protein XXX O
kinase-independent XXX O
pathway XXX O
. XXX O

Long-latency XXX O
: XXX O
locked XXX O
units XXX O
responded XXX O
to XXX O
shocks XXX O
with XXX O
little XXX O
jitter XXX O
and XXX O
long XXX O
latency XXX O
( XXX O
4-11 XXX O
ms XXX O
) XXX O
. XXX O

CCAAT XXX B-GENE
/ XXX I-GENE
enhancer-binding XXX I-GENE
protein XXX I-GENE
isoforms XXX I-GENE
beta XXX I-GENE
and XXX I-GENE
delta XXX I-GENE
are XXX O
expressed XXX O
in XXX O
mammary XXX O
epithelial XXX O
cells XXX O
and XXX O
bind XXX O
to XXX O
multiple XXX O
sites XXX O
in XXX O
the XXX O
beta-casein XXX B-GENE
gene XXX I-GENE
promoter XXX I-GENE
. XXX O

The XXX O
pel XXX B-GENE
gene XXX I-GENE
from XXX O
an XXX O
Amycolata XXX O
sp XXX O
. XXX O
encoding XXX O
a XXX O
pectate XXX B-GENE
lyase XXX I-GENE
( XXX O
EC XXX B-GENE
4 XXX I-GENE
. XXX I-GENE
2 XXX I-GENE
. XXX I-GENE
2 XXX I-GENE
. XXX I-GENE
2 XXX I-GENE
) XXX O
was XXX O
isolated XXX O
by XXX O
activity XXX O
screening XXX O
a XXX O
genomic XXX O
DNA XXX O
library XXX O
in XXX O
Streptomyces XXX O
lividans XXX O
TK24 XXX O
. XXX O

On XXX O
the XXX O
other XXX O
hand XXX O
, XXX O
subjects XXX O
with XXX O
air XXX O
trapping XXX O
( XXX O
residual XXX O
volume XXX O
( XXX O
RV XXX O
) XXX O
/ XXX O
total XXX O
lung XXX O
capacity XXX O
( XXX O
TLC XXX O
) XXX O
> XXX O
37% XXX O
) XXX O
disclosed XXX O
not XXX O
only XXX O
a XXX O
higher XXX O
n XXX O
( XXX O
mit XXX O
) XXX O
( XXX O
0 XXX O
. XXX O
63+ XXX O
/ XXX O
-0 XXX O
. XXX O
17 XXX O
versus XXX O
0 XXX O
. XXX O
43+ XXX O
/ XXX O
-0 XXX O
. XXX O
07 XXX O
mt XXX O
x XXX O
microm XXX O
( XXX O
-2 XXX O
) XXX O
, XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
but XXX O
shorter XXX O
sarcomeres XXX O
( XXX O
L XXX O
( XXX O
sar XXX O
) XXX O
) XXX O
than XXX O
subjects XXX O
without XXX O
this XXX O
functional XXX O
abnormality XXX O
( XXX O
2 XXX O
. XXX O
08+ XXX O
/ XXX O
-0 XXX O
. XXX O
16 XXX O
to XXX O
2 XXX O
. XXX O
27+ XXX O
/ XXX O
-0 XXX O
. XXX O
15 XXX O
microm XXX O
, XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
. XXX O

The XXX O
high XXX O
sequence XXX O
homology XXX O
, XXX O
similar XXX O
genomic XXX O
structure XXX O
, XXX O
and XXX O
identical XXX O
chromosomal XXX O
loci XXX O
of XXX O
hKID XXX B-GENE
, XXX O
MIP XXX B-GENE
, XXX O
and XXX O
AQP-2 XXX B-GENE
suggest XXX O
a XXX O
MIP XXX B-GENE
family XXX I-GENE
gene XXX I-GENE
cluster XXX I-GENE
at XXX O
chromosome XXX O
locus XXX O
12q13 XXX O
. XXX O

As XXX O
is XXX O
deduced XXX O
from XXX O
the XXX O
nucleotide XXX O
sequence XXX O
of XXX O
the XXX O
cDNA XXX O
, XXX O
CBS-1 XXX B-GENE
contains XXX O
an XXX O
open XXX O
reading XXX O
frame XXX O
consisting XXX O
of XXX O
182 XXX O
amino XXX O
acids XXX O
, XXX O
with XXX O
a XXX O
molecular XXX O
weight XXX O
of XXX O
19 XXX O
. XXX O
5kDa XXX O
. XXX O

The XXX O
mean XXX O
duration XXX O
of XXX O
pain XXX O
relief XXX O
was XXX O
4-6 XXX O
weeks XXX O
. XXX O

The XXX O
serine-threonine XXX B-GENE
kinase XXX I-GENE
gene XXX I-GENE
is XXX O
likely XXX O
functional XXX O
, XXX O
whereas XXX O
the XXX O
zinc XXX O
finger XXX O
motif XXX O
is XXX O
likely XXX O
nonfunctional XXX O
. XXX O

Modeling XXX O
also XXX O
revealed XXX O
a XXX O
very XXX O
hydrophobic XXX O
surface XXX O
due XXX O
to XXX O
the XXX O
absence XXX O
of XXX O
H12 XXX B-GENE
, XXX O
exposing XXX O
residues XXX O
from XXX O
H3 XXX B-GENE
, XXX O
loop XXX B-GENE
3-4 XXX I-GENE
, XXX O
H4 XXX B-GENE
, XXX O
and XXX O
H11 XXX B-GENE
. XXX O

Genetic XXX O
abnormalities XXX O
that XXX O
could XXX O
lead XXX O
to XXX O
mutagenesis XXX O
include XXX O
chromosomal XXX O
abnormalities XXX O
and XXX O
single-gene XXX O
mutations XXX O
. XXX O

Based XXX O
on XXX O
these XXX O
results XXX O
, XXX O
a XXX O
new XXX O
model XXX O
for XXX O
the XXX O
regulation XXX O
of XXX O
nif XXX B-GENE
/ XXX I-GENE
fix XXX I-GENE
gene XXX I-GENE
expression XXX O
in XXX O
A XXX O
. XXX O
caulinodans XXX O
is XXX O
proposed XXX O
. XXX O

However XXX O
, XXX O
a XXX O
> XXX O
10-fold XXX O
increase XXX O
in XXX O
ERK3 XXX B-GENE
activity XXX O
in XXX O
each XXX O
PKC XXX B-GENE
beta XXX I-GENE
transfectant XXX O
was XXX O
shown XXX O
by XXX O
immunoprecipitation XXX O
with XXX O
anti-ERK3 XXX B-GENE
monoclonal XXX I-GENE
antibody XXX I-GENE
followed XXX O
by XXX O
either XXX O
immune XXX O
complex XXX O
kinase XXX O
assay XXX O
or XXX O
by XXX O
in XXX O
gel XXX O
kinase XXX B-GENE
assay XXX O
. XXX O

The XXX O
residue XXX O
functions XXX O
, XXX O
R XXX O
( XXX O
t XXX O
) XXX O
, XXX O
for XXX O
C-11 XXX O
CPZ XXX O
and XXX O
In-113m XXX O
transferrin XXX O
were XXX O
plotted XXX O
against XXX O
time XXX O
for XXX O
selected XXX O
areas XXX O
of XXX O
interest XXX O
, XXX O
and XXX O
the XXX O
CPZ XXX O
area-weighted XXX O
extraction XXX O
, XXX O
E XXX O
( XXX O
t XXX O
) XXX O
, XXX O
was XXX O
computed XXX O
for XXX O
the XXX O
same XXX O
areas XXX O
every XXX O
250 XXX O
msec XXX O
using XXX O
the XXX O
formula XXX O
: XXX O
E XXX O
( XXX O
t XXX O
) XXX O
= XXX O
[ XXX O
RT XXX O
( XXX O
t XXX O
) XXX O
- XXX O
RR XXX O
( XXX O
t XXX O
) XXX O
] XXX O
/ XXX O
[ XXX O
1 XXX O
- XXX O
RR XXX O
( XXX O
t XXX O
) XXX O
] XXX O
, XXX O
where XXX O
RT XXX O
and XXX O
RR XXX O
are XXX O
the XXX O
normalized XXX O
residue XXX O
functions XXX O
for XXX O
CPZ XXX O
and XXX O
transferrin XXX B-GENE
, XXX O
respectively XXX O
. XXX O

Furthermore XXX O
, XXX O
Zelen's XXX O
method XXX O
is XXX O
used XXX O
to XXX O
balance XXX O
the XXX O
number XXX O
of XXX O
patients XXX O
allocated XXX O
to XXX O
the XXX O
two XXX O
groups XXX O
within XXX O
each XXX O
institution XXX O
( XXX O
M XXX O
. XXX O

In XXX O
contrast XXX O
, XXX O
deletion XXX O
of XXX O
the XXX O
upstream XXX O
portion XXX O
of XXX O
the XXX O
delta XXX B-GENE
promoter XXX I-GENE
led XXX O
to XXX O
a XXX O
10 XXX O
fold XXX O
decrease XXX O
in XXX O
expression XXX O
. XXX O

The XXX O
clinical XXX O
stage XXX O
was XXX O
I XXX O
( XXX O
T1N0M0 XXX O
) XXX O
, XXX O
and XXX O
S2 XXX O
sleeve XXX O
segmentectomy XXX O
with XXX O
lymph XXX O
node XXX O
dissection XXX O
( XXX O
R XXX O
2 XXX O
b XXX O
) XXX O
was XXX O
performed XXX O
. XXX O

Expression XXX O
of XXX O
ME31B XXX B-GENE
cDNA XXX I-GENE
in XXX O
S XXX O
. XXX O
pombe XXX O
suppresses XXX O
the XXX O
ste13 XXX B-GENE
mutation XXX O
. XXX O

Transduction XXX O
of XXX O
the XXX O
human XXX O
leukemic XXX O
cell XXX O
line XXX O
K562 XXX O
showed XXX O
that XXX O
viral XXX O
MRP1-PG13 XXX O
supernatants XXX O
routinely XXX O
transfer XXX O
the XXX O
MRP1 XXX B-GENE
gene XXX I-GENE
to XXX O
approximately XXX O
35% XXX O
of XXX O
target XXX O
K562 XXX O
cells XXX O
, XXX O
of XXX O
which XXX O
at XXX O
least XXX O
one XXX O
third XXX O
are XXX O
capable XXX O
of XXX O
proliferating XXX O
in XXX O
the XXX O
presence XXX O
of XXX O
otherwise XXX O
toxic XXX O
concentrations XXX O
of XXX O
etoposide XXX O
. XXX O

The XXX O
cytogenetic XXX O
expression XXX O
of XXX O
the XXX O
folate XXX O
sensitive XXX O
fragile XXX O
site XXX O
, XXX O
FRAXE XXX B-GENE
, XXX O
is XXX O
due XXX O
to XXX O
the XXX O
expansion XXX O
of XXX O
a XXX O
GCC XXX O
repeat XXX O
in XXX O
proximal XXX O
Xq28 XXX O
of XXX O
the XXX O
human XXX O
X XXX O
chromosome XXX O
and XXX O
is XXX O
associated XXX O
with XXX O
a XXX O
mild XXX O
form XXX O
of XXX O
mental XXX O
handicap XXX O
. XXX O

33 XXX O
out XXX O
of XXX O
90 XXX O
neurons XXX O
of XXX O
the XXX O
cat XXX O
medial XXX O
geniculate XXX O
body XXX O
revealed XXX O
the XXX O
selectivity XXX O
of XXX O
their XXX O
afterdischarges XXX O
to XXX O
movement XXX O
of XXX O
sound XXX O
when XXX O
velocity XXX O
of XXX O
the XXX O
movement XXX O
changed XXX O
from XXX O
30 XXX O
to XXX O
180 XXX O
deg XXX O
/ XXX O
s XXX O
. XXX O

Ampicillin XXX O
( XXX O
AMP XXX O
) XXX O
alone XXX O
or XXX O
with XXX O
an XXX O
aminoglycoside XXX O
( XXX O
AMI XXX O
) XXX O
was XXX O
the XXX O
treatment XXX O
in XXX O
9 XXX O
and XXX O
16 XXX O
cases XXX O
, XXX O
respectively XXX O
. XXX O

These XXX O
results XXX O
were XXX O
compared XXX O
with XXX O
those XXX O
obtained XXX O
in XXX O
-D XXX O
mothers XXX O
and XXX O
pups XXX O
, XXX O
after XXX O
giving XXX O
the XXX O
mothers XXX O
an XXX O
oral XXX O
supplement XXX O
( XXX O
10 XXX O
i XXX O
. XXX O
u XXX O
. XXX O
vitamin XXX O
D3 XXX O
/ XXX O
day XXX O
) XXX O
during XXX O
the XXX O
period XXX O
of XXX O
lactation XXX O
( XXX O
20 XXX O
days XXX O
) XXX O
. XXX O

The XXX O
most XXX O
common XXX O
risk XXX O
factor XXX O
reported XXX O
for XXX O
both XXX O
recent XXX O
and XXX O
all XXX O
other XXX O
hepatitis XXX O
C XXX O
cases XXX O
was XXX O
a XXX O
history XXX O
of XXX O
injecting XXX O
drug XXX O
use XXX O
, XXX O
although XXX O
the XXX O
proportion XXX O
of XXX O
cases XXX O
with XXX O
that XXX O
history XXX O
was XXX O
different XXX O
in XXX O
NT XXX O
from XXX O
ACT XXX O
and XXX O
Queensland XXX O
. XXX O

This XXX O
TC-II XXX B-GENE
enhanson XXX I-GENE
, XXX O
which XXX O
is XXX O
identical XXX O
to XXX O
the XXX O
kappa XXX B-GENE
B XXX I-GENE
motif XXX I-GENE
from XXX O
the XXX O
kappa XXX B-GENE
chain XXX I-GENE
enhancer XXX I-GENE
, XXX O
was XXX O
active XXX O
in XXX O
both XXX O
lymphoid XXX O
and XXX O
non-lymphoid XXX O
cells XXX O
, XXX O
which XXX O
contrasts XXX O
with XXX O
the XXX O
previously XXX O
reported XXX O
lymphoid XXX O
cell XXX O
specificity XXX O
of XXX O
the XXX O
kappa XXX B-GENE
B XXX I-GENE
motif XXX I-GENE
. XXX O

ATF1 XXX B-GENE
transcription XXX O
is XXX O
negatively XXX O
regulated XXX O
by XXX O
unsaturated XXX O
fatty XXX O
acids XXX O
and XXX O
oxygen XXX O
. XXX O

Rats XXX O
treated XXX O
with XXX O
8-OH-DPAT XXX O
were XXX O
not XXX O
impaired XXX O
in XXX O
their XXX O
ability XXX O
to XXX O
learn XXX O
a XXX O
visual XXX O
discrimination XXX O
in XXX O
a XXX O
water XXX O
maze XXX O
. XXX O

An XXX O
immunologic XXX O
test XXX O
using XXX O
stomach XXX B-GENE
and XXX I-GENE
tumor XXX I-GENE
antigens XXX I-GENE
for XXX O
screening XXX O
of XXX O
those XXX O
at XXX O
high XXX O
risk XXX O
for XXX O
stomach XXX O
cancer XXX O
is XXX O
suggested XXX O
. XXX O

Independent XXX O
protrudor XXX O
muscle XXX O
stimulation XXX O
increased XXX O
VI XXX O
, XXX O
max XXX O
( XXX O
peak XXX O
increase XXX O
61 XXX O
% XXX O
, XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
, XXX O
did XXX O
not XXX O
change XXX O
Pcrit XXX O
, XXX O
and XXX O
decreased XXX O
Rn XXX O
( XXX O
peak XXX O
decrease XXX O
of XXX O
41 XXX O
% XXX O
, XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
. XXX O

Sequence XXX O
comparison XXX O
indicates XXX O
that XXX O
exons XXX O
5' XXX O
/ XXX O
L XXX O
and XXX O
L XXX O
/ XXX O
N XXX O
in XXX O
PSG12 XXX B-GENE
and XXX O
PSG12 XXX B-GENE
psi XXX I-GENE
are XXX O
99% XXX O
identical XXX O
, XXX O
except XXX O
that XXX O
the XXX O
L XXX O
/ XXX O
N XXX O
exon XXX O
in XXX O
the XXX O
PSG12 XXX B-GENE
psi XXX I-GENE
gene XXX I-GENE
contains XXX O
a XXX O
stop XXX O
codon XXX O
. XXX O

The XXX O
individual XXX O
subunits XXX O
of XXX O
Ku XXX B-GENE
have XXX O
been XXX O
difficult XXX O
to XXX O
isolate XXX O
from XXX O
human XXX O
cells XXX O
without XXX O
denaturation XXX O
and XXX O
attempts XXX O
to XXX O
produce XXX O
functional XXX B-GENE
recombinant XXX I-GENE
Ku XXX I-GENE
have XXX O
been XXX O
largely XXX O
unsuccessful XXX O
. XXX O

Role XXX O
of XXX O
the XXX O
infectious-disease XXX O
specialist XXX O
of XXX O
a XXX O
polyclinic XXX O
in XXX O
reducing XXX O
the XXX O
incidence XXX O
of XXX O
communicable XXX O
diseases XXX O
. XXX O

CONCLUSIONS XXX O
: XXX O
Valproate XXX O
appears XXX O
to XXX O
inhibit XXX O
the XXX O
glucuronidation XXX O
of XXX O
carbamazepine-10 XXX O
, XXX O
11-trans-diol XXX O
, XXX O
and XXX O
probably XXX O
also XXX O
inhibits XXX O
the XXX O
conversion XXX O
of XXX O
carbamazepine-10 XXX O
, XXX O
11-epoxide XXX O
to XXX O
this XXX O
trans-diol XXX O
derivative XXX O
, XXX O
rather XXX O
than XXX O
simply XXX O
inhibiting XXX O
the XXX O
latter XXX O
reaction XXX O
only XXX O
. XXX O

IgE XXX B-GENE
levels XXX O
showed XXX O
higher XXX O
values XXX O
compared XXX O
to XXX O
normal XXX O
individuals XXX O
and XXX O
IgE XXX B-GENE
levels XXX O
were XXX O
higher XXX O
in XXX O
children XXX O
groups XXX O
than XXX O
in XXX O
adults XXX O
regardless XXX O
of XXX O
the XXX O
intensity XXX O
of XXX O
infection XXX O
. XXX O

Penicillin-G XXX O
degradation XXX O
products XXX O
inhibit XXX O
in XXX O
vitro XXX O
granulopoiesis XXX O
. XXX O

Removal XXX O
of XXX O
the XXX O
GST XXX B-GENE
domain XXX I-GENE
from XXX O
GST-Tax XXX B-GENE
by XXX O
thrombin XXX B-GENE
restores XXX O
Tax's XXX B-GENE
ability XXX O
to XXX O
assemble XXX O
a XXX O
ternary XXX O
Tax-CREB-21-bp-repeat XXX B-GENE
complex XXX I-GENE
. XXX I-GENE
( XXX I-GENE
ABSTRACT XXX I-GENE
TRUNCATED XXX O
AT XXX O
400 XXX O
WORDS XXX O
) XXX O

Saccharomyces XXX O
cerevisiae XXX O
contains XXX O
a XXX O
genetically XXX O
and XXX O
biochemically XXX O
proven XXX O
CAK XXX B-GENE
gene XXX I-GENE
, XXX O
CAK1 XXX B-GENE
, XXX O
that XXX O
encodes XXX O
a XXX O
monomeric XXX O
44-kDa XXX B-GENE
Cak1p XXX I-GENE
protein XXX I-GENE
unrelated XXX O
to XXX O
Cdk7 XXX B-GENE
. XXX O

R XXX O
. XXX O

The XXX O
majority XXX O
of XXX O
the XXX O
cases XXX O
with XXX O
0-I XXX O
or XXX O
0-III XXX O
components XXX O
were XXX O
sm XXX O
. XXX O
cancer XXX O
. XXX O

The XXX O
major XXX O
PKC XXX B-GENE
beta XXX I-GENE
transcription XXX O
initiation XXX O
site XXX O
was XXX O
identified XXX O
by XXX O
primer XXX O
extension XXX O
and XXX O
S1 XXX B-GENE
nuclease XXX I-GENE
protection XXX O
. XXX O

TAR XXX O
and XXX O
Sp1-independent XXX O
transactivation XXX O
of XXX O
HIV XXX B-GENE
long XXX I-GENE
terminal XXX I-GENE
repeat XXX I-GENE
by XXX O
the XXX O
Tat XXX B-GENE
protein XXX I-GENE
in XXX O
the XXX O
presence XXX O
of XXX O
human XXX B-GENE
cytomegalovirus XXX I-GENE
IE1 XXX I-GENE
/ XXX I-GENE
IE2 XXX I-GENE
. XXX O

Ectopic XXX O
expression XXX O
of XXX O
d-axin XXX B-GENE
inhibited XXX O
Wingless XXX B-GENE
signaling XXX O
. XXX O

In XXX O
11 XXX O
eyes XXX O
that XXX O
had XXX O
been XXX O
selected XXX O
at XXX O
random XXX O
10 XXX O
micrograms XXX O
of XXX O
recombinant XXX B-GENE
tissue XXX I-GENE
plasminogen XXX I-GENE
activator XXX I-GENE
were XXX O
injected XXX O
midvitreally XXX O
24 XXX O
hrs XXX O
later XXX O
. XXX O

Our XXX O
study XXX O
cohorts XXX O
consisted XXX O
of XXX O
15 XXX O
patients XXX O
who XXX O
received XXX O
SC XXX O
rIL-2 XXX B-GENE
at XXX O
doses XXX O
of XXX O
4 XXX O
. XXX O
8-14 XXX O
. XXX O
4 XXX O
million XXX O
IU XXX O
/ XXX O
m2 XXX O
/ XXX O
day XXX O
on XXX O
5 XXX O
days XXX O
per XXX O
week XXX O
for XXX O
a XXX O
total XXX O
of XXX O
8 XXX O
weeks XXX O
, XXX O
20 XXX O
patients XXX O
who XXX O
received XXX O
rIFN-alpha XXX B-GENE
2b XXX I-GENE
at XXX O
3 XXX O
. XXX O
0-6 XXX O
. XXX O
0 XXX O
million XXX O
U XXX O
/ XXX O
m2 XXX O
/ XXX O
day XXX O
thrice XXX O
weekly XXX O
for XXX O
a XXX O
total XXX O
of XXX O
6 XXX O
weeks XXX O
, XXX O
and XXX O
72 XXX O
patients XXX O
who XXX O
were XXX O
given XXX O
SC XXX O
rIFN-alpha XXX B-GENE
2b XXX I-GENE
at XXX O
6 XXX O
. XXX O
0 XXX O
million XXX O
U XXX O
/ XXX O
m2 XXX O
/ XXX O
day XXX O
thrice XXX O
weekly XXX O
plus XXX O
SC XXX O
rIL-2 XXX B-GENE
at XXX O
14 XXX O
. XXX O
4-18 XXX O
. XXX O
0 XXX O
million XXX O
IU XXX O
/ XXX O
m2 XXX O
/ XXX O
day XXX O
on XXX O
days XXX O
1 XXX O
and XXX O
2 XXX O
, XXX O
followed XXX O
by XXX O
4 XXX O
. XXX O
8 XXX O
million XXX O
IU XXX O
/ XXX O
m2 XXX O
/ XXX O
day XXX O
, XXX O
5 XXX O
days XXX O
per XXX O
week XXX O
for XXX O
6 XXX O
consecutive XXX O
weeks XXX O
. XXX O

This XXX O
specific XXX O
methylation XXX O
pattern XXX O
caused XXX O
inactivation XXX O
of XXX O
the XXX O
HSV XXX B-GENE
tk XXX I-GENE
gene XXX I-GENE
, XXX O
while XXX O
methylation XXX O
of XXX O
the XXX O
cytosine XXX O
residues XXX O
within XXX O
the XXX O
nucleotide XXX O
sequence XXX O
from XXX O
+811 XXX O
to XXX O
+1309 XXX O
had XXX O
no XXX O
effect XXX O
on XXX O
HSV XXX B-GENE
tk XXX I-GENE
gene XXX I-GENE
activity XXX O
. XXX O

Personal XXX O
satisfaction XXX O
in XXX O
nursing XXX O
: XXX O
an XXX O
encounter XXX O
with XXX O
extremely XXX O
hostile XXX O
patients XXX O
. XXX O

Determination XXX O
of XXX O
three-dimensional XXX O
imaging XXX O
properties XXX O
of XXX O
a XXX O
light XXX O
microscope XXX O
system XXX O
. XXX O

Mutation XXX O
of XXX O
the XXX O
P450BM-3 XXX B-GENE
Barbie XXX I-GENE
box XXX I-GENE
significantly XXX O
increased XXX O
the XXX O
expression XXX O
of XXX O
both XXX O
P450BM-3 XXX B-GENE
and XXX O
Bm3P1 XXX B-GENE
( XXX O
another XXX O
small XXX O
gene XXX O
located XXX O
upstream XXX O
of XXX O
the XXX O
P450BM-3 XXX B-GENE
gene XXX I-GENE
that XXX O
encodes XXX O
a XXX O
second XXX O
putative XXX O
regulatory XXX O
protein XXX O
) XXX O
in XXX O
response XXX O
to XXX O
pentobarbital XXX O
induction XXX O
but XXX O
left XXX O
the XXX O
basal XXX O
levels XXX O
unaffected XXX O
. XXX O

This XXX O
function XXX O
requires XXX O
not XXX O
only XXX O
the XXX O
kinase XXX O
domain XXX O
of XXX O
Csk XXX B-GENE
, XXX O
but XXX O
also XXX O
its XXX O
Src XXX B-GENE
homology XXX I-GENE
3 XXX I-GENE
( XXX O
SH3 XXX B-GENE
) XXX O
and XXX O
SH2 XXX B-GENE
regions XXX O
. XXX O

To XXX O
accomplish XXX O
this XXX O
, XXX O
actin XXX B-GENE
cables XXX O
and XXX O
patches XXX O
are XXX O
redistributed XXX O
during XXX O
the XXX O
cell XXX O
cycle XXX O
to XXX O
direct XXX O
secretory XXX O
components XXX O
to XXX O
appropriate XXX O
sites XXX O
for XXX O
cell XXX O
growth XXX O
. XXX O

Association XXX O
of XXX O
human XXX B-GENE
Pur XXX I-GENE
alpha XXX I-GENE
with XXX O
the XXX O
retinoblastoma XXX B-GENE
protein XXX I-GENE
, XXX O
Rb XXX B-GENE
, XXX O
regulates XXX O
binding XXX O
to XXX O
the XXX O
single-stranded XXX O
DNA XXX O
Pur XXX B-GENE
alpha XXX I-GENE
recognition XXX I-GENE
element XXX I-GENE
. XXX O

A XXX O
cDNA XXX O
encoding XXX O
a XXX O
putative XXX O
RNA XXX B-GENE
and XXX I-GENE
/ XXX I-GENE
or XXX I-GENE
DNA XXX I-GENE
helicase XXX I-GENE
has XXX O
been XXX O
isolated XXX O
from XXX O
Arabidopsis XXX O
thaliana XXX O
cDNA XXX O
libraries XXX O
. XXX O

By XXX O
analyzing XXX O
5'-deletion XXX O
insulin XXX B-GENE
promoter-reporter XXX I-GENE
constructs XXX I-GENE
in XXX O
transient XXX O
transfections XXX O
of XXX O
clonal XXX O
INS-1 XXX B-GENE
beta-cells XXX O
, XXX O
we XXX O
located XXX O
activating XXX O
Hh-responsive XXX B-GENE
regions XXX I-GENE
within XXX O
the XXX O
rat XXX B-GENE
insulin XXX I-GENE
I XXX I-GENE
promoter XXX I-GENE
that XXX O
include XXX O
the XXX O
glucose-response XXX B-GENE
elements XXX I-GENE
Far XXX B-GENE
( XXX O
E2 XXX B-GENE
) XXX O
and XXX O
Flat XXX B-GENE
( XXX O
A2 XXX B-GENE
/ XXX I-GENE
A3 XXX I-GENE
) XXX O
. XXX O

Human XXX O
and XXX O
Chinese XXX B-GENE
hamster XXX I-GENE
S14 XXX I-GENE
protein XXX I-GENE
sequences XXX I-GENE
deduced XXX O
from XXX O
the XXX O
cDNAs XXX O
are XXX O
identical XXX O
. XXX O

In XXX O
AcMNPV-infected XXX O
Sf9 XXX O
cells XXX O
, XXX O
late XXX O
transcription XXX O
initiation XXX O
is XXX O
detected XXX O
from XXX O
only XXX O
two XXX O
upstream XXX O
TAAG XXX B-GENE
sites XXX I-GENE
and XXX O
not XXX O
from XXX O
three XXX O
downstream XXX O
TAAG XXX B-GENE
sites XXX I-GENE
. XXX O

These XXX O
transcripts XXX O
contain XXX O
the XXX O
5' XXX O
ends XXX O
of XXX O
mature XXX O
UbCRBP XXX B-GENE
mRNAs XXX I-GENE
; XXX O
extend XXX O
through XXX O
UbCRBP XXX B-GENE
, XXX O
across XXX O
the XXX O
intergenic XXX O
region XXX O
, XXX O
and XXX O
a XXX O
significant XXX O
distance XXX O
3' XXX O
into XXX O
the XXX O
enolase XXX B-GENE
gene XXX I-GENE
. XXX O

Courses XXX O
were XXX O
repeated XXX O
every XXX O
four XXX O
weeks XXX O
. XXX O

Medicare XXX O
SNF XXX O
benefits XXX O
revised--again XXX O
. XXX O

There XXX O
were XXX O
no XXX O
significant XXX O
differences XXX O
in XXX O
graft XXX O
survival XXX O
between XXX O
groups XXX O
with XXX O
early XXX O
graft XXX O
function XXX O
( XXX O
EGF XXX O
) XXX O
and XXX O
DGF XXX O
, XXX O
either XXX O
in XXX O
first XXX O
transplantations XXX O
or XXX O
retransplantations XXX O
. XXX O

Copyright XXX O
2000 XXX O
Academic XXX O
Press XXX O
. XXX O

One XXX O
of XXX O
the XXX O
conserved XXX O
RNA XXX O
subdomains XXX O
, XXX O
designated XXX O
P3 XXX B-GENE
, XXX O
has XXX O
previously XXX O
been XXX O
shown XXX O
to XXX O
be XXX O
required XXX O
for XXX O
nucleolar XXX O
localization XXX O
. XXX O

Consistent XXX O
with XXX O
effects XXX O
on XXX O
STAT XXX B-GENE
activation XXX O
, XXX O
altered XXX O
SHP-1 XXX B-GENE
expression XXX O
also XXX O
affected XXX O
EGF-induced XXX O
activation XXX O
of XXX O
the XXX O
mitogen-activated XXX B-GENE
protein XXX I-GENE
kinase XXX I-GENE
pathway XXX I-GENE
; XXX O
expression XXX O
of XXX O
SHP-1- XXX B-GENE
( XXX I-GENE
Cys XXX I-GENE
-- XXX I-GENE
> XXX I-GENE
Ser XXX I-GENE
) XXX I-GENE
inhibited XXX O
activity XXX O
of XXX O
MEK XXX B-GENE
by XXX O
approximately XXX O
25% XXX O
, XXX O
whereas XXX O
expression XXX O
of XXX O
SHP-1 XXX B-GENE
resulted XXX O
in XXX O
a XXX O
approximately XXX O
25% XXX O
increase XXX O
. XXX O

Myasthenia XXX O
gravis XXX O
is XXX O
an XXX O
autoimmune XXX O
disease XXX O
resulting XXX O
from XXX O
the XXX O
production XXX O
of XXX O
antibodies XXX O
against XXX O
the XXX O
ACh XXX B-GENE
receptors XXX I-GENE
of XXX O
the XXX O
neuromuscular XXX O
synapse XXX O
. XXX O

Raf XXX B-GENE
is XXX O
a XXX O
key XXX O
serine-threonine XXX B-GENE
protein XXX I-GENE
kinase XXX I-GENE
which XXX O
participates XXX O
in XXX O
the XXX O
transmission XXX O
of XXX O
growth XXX O
, XXX O
anti-apoptotic XXX O
and XXX O
differentiation XXX O
messages XXX O
. XXX O

During XXX O
the XXX O
dose-finding XXX O
, XXX O
two XXX O
patients XXX O
were XXX O
temporarily XXX O
withdrawn XXX O
from XXX O
medication XXX O
and XXX O
one XXX O
patient XXX O
was XXX O
excluded XXX O
because XXX O
of XXX O
elevated XXX O
levels XXX O
of XXX O
liver XXX O
enzymes XXX O
. XXX O

Terminal XXX O
deoxynucleotidyl XXX O
transferase-mediated XXX O
nick XXX O
end XXX O
labeling XXX O
assays XXX O
revealed XXX O
that XXX O
hormonal XXX O
activation XXX O
of XXX O
the XXX O
PAX3 XXX B-GENE
repressors XXX I-GENE
induced XXX O
extensive XXX O
apoptosis XXX O
that XXX O
correlated XXX O
with XXX O
down-regulation XXX O
of XXX O
BCL-X XXX B-GENE
( XXX I-GENE
L XXX I-GENE
) XXX I-GENE
expression XXX O
. XXX O

It XXX O
was XXX O
found XXX O
that XXX O
the XXX O
disappearance XXX O
of XXX O
BOD5 XXX O
and XXX O
NH3-N XXX O
could XXX O
be XXX O
approximated XXX O
using XXX O
first-order XXX O
kinetics XXX O
, XXX O
but XXX O
the XXX O
kinetics XXX O
of XXX O
TP XXX O
removal XXX O
were XXX O
unclear XXX O
. XXX O

Differential XXX O
sensitivity XXX O
of XXX O
the XXX O
MMPI-2 XXX O
depression XXX O
scales XXX O
and XXX O
subscales XXX O
. XXX O

The XXX O
two XXX O
most XXX O
recent XXX O
patients XXX O
( XXX O
35 XXX O
and XXX O
132 XXX O
days XXX O
) XXX O
received XXX O
only XXX O
oral XXX O
dipyridamole XXX O
( XXX O
75 XXX O
mg XXX O
X XXX O
3 XXX O
/ XXX O
day XXX O
) XXX O
and XXX O
aspirin XXX O
( XXX O
80 XXX O
mg XXX O
/ XXX O
day XXX O
) XXX O
after XXX O
the XXX O
early XXX O
recovery XXX O
period XXX O
( XXX O
four-six XXX O
days XXX O
) XXX O
, XXX O
resulting XXX O
in XXX O
normal XXX O
prothrombin XXX B-GENE
and XXX O
partial XXX O
thromboplastin XXX B-GENE
times XXX O
. XXX O

The XXX O
purpose XXX O
of XXX O
the XXX O
study XXX O
reported XXX O
here XXX O
was XXX O
to XXX O
investigate XXX O
whether XXX O
differences XXX O
in XXX O
T1 XXX O
and XXX O
T2 XXX O
between XXX O
tumors XXX O
are XXX O
mainly XXX O
a XXX O
consequence XXX O
of XXX O
differences XXX O
in XXX O
the XXX O
fractional XXX O
volume XXX O
of XXX O
the XXX O
extracellular XXX O
compartment XXX O
. XXX O

Neuromyelitis XXX O
optica XXX O
( XXX O
Devic's XXX O
syndrome XXX O
) XXX O
: XXX O
not XXX O
always XXX O
multiple XXX O
sclerosis XXX O
. XXX O

Cytological XXX O
data XXX O
suggest XXX O
that XXX O
the XXX O
transgenes XXX O
associate XXX O
with XXX O
a XXX O
nucleolus XXX O
. XXX O

Aeromonas XXX O
salmonicida XXX O
possesses XXX O
two XXX O
genes XXX O
encoding XXX O
homologs XXX O
of XXX O
the XXX O
major XXX B-GENE
outer XXX I-GENE
membrane XXX I-GENE
protein XXX I-GENE
, XXX O
OmpA XXX B-GENE
. XXX O

PO2 XXX O
measurements XXX O
using XXX O
a XXX O
double XXX O
barrelled XXX O
recess XXX O
type XXX O
microelectrodes XXX O
were XXX O
measured XXX O
in XXX O
the XXX O
optic XXX O
nerve XXX O
head XXX O
of XXX O
miniature XXX O
pigs XXX O
in XXX O
normoxia XXX O
and XXX O
hyperoxia XXX O
. XXX O

In XXX O
this XXX O
study XXX O
, XXX O
we XXX O
have XXX O
examined XXX O
the XXX O
regulation XXX O
of XXX O
B-Myb XXX B-GENE
activity XXX O
by XXX O
cyclin-Cdks XXX B-GENE
. XXX O

Since XXX O
AP-1 XXX B-GENE
is XXX O
an XXX O
important XXX O
mediator XXX O
of XXX O
tumor XXX O
promoter XXX O
action XXX O
, XXX O
these XXX O
findings XXX O
may XXX O
explain XXX O
the XXX O
anti-tumor-promoting XXX O
activity XXX O
of XXX O
phenolic XXX O
antioxidants XXX O
. XXX O

Interestingly XXX O
, XXX O
virions XXX O
also XXX O
contained XXX O
smaller XXX O
proteins XXX O
that XXX O
reacted XXX O
with XXX O
antibodies XXX O
specific XXX O
for XXX O
the XXX O
accessory XXX O
proteins XXX O
as XXX O
well XXX O
as XXX O
SN XXX B-GENE
and XXX O
CAT XXX B-GENE
fusion XXX I-GENE
partners XXX O
. XXX O

Propagation XXX O
and XXX O
hormone XXX O
production XXX O
by XXX O
human XXX O
normal XXX O
and XXX O
malignant XXX O
trophoblast XXX O
in XXX O
rats XXX O
. XXX O

These XXX O
results XXX O
demonstrate XXX O
that XXX O
tip XXX B-GENE
acts XXX O
at XXX O
an XXX O
early XXX O
stage XXX O
of XXX O
the XXX O
T-cell XXX O
signal XXX O
transduction XXX O
cascade XXX O
by XXX O
associating XXX O
with XXX O
Lck XXX B-GENE
and XXX O
downregulating XXX O
Lck-mediated XXX O
activation XXX O
. XXX O

The XXX O
electrically XXX O
induced XXX O
motile XXX O
responses XXX O
were XXX O
not XXX O
suppressed XXX O
in XXX O
the XXX O
presence XXX O
of XXX O
dinitrophenol XXX O
or XXX O
cytochalasin XXX O
B XXX O
. XXX O

For XXX O
comparison XXX O
conventional XXX O
heparin XXX O
was XXX O
used XXX O
during XXX O
18 XXX O
dialyses XXX O
in XXX O
the XXX O
same XXX O
patients XXX O
. XXX O

F-box XXX B-GENE
proteins XXX I-GENE
are XXX O
receptors XXX O
that XXX O
recruit XXX O
phosphorylated XXX O
substrates XXX O
to XXX O
the XXX O
SCF XXX B-GENE
ubiquitin-ligase XXX I-GENE
complex XXX I-GENE
. XXX O

ERV1 XXX B-GENE
is XXX O
involved XXX O
in XXX O
the XXX O
cell-division XXX O
cycle XXX O
and XXX O
the XXX O
maintenance XXX O
of XXX O
mitochondrial XXX O
genomes XXX O
in XXX O
Saccharomyces XXX O
cerevisiae XXX O
. XXX O

This XXX O
protein XXX O
, XXX O
designated XXX O
p532 XXX B-GENE
based XXX O
on XXX O
its XXX O
predicted XXX O
molecular XXX O
weight XXX O
( XXX O
EMBO XXX O
J XXX O
15 XXX O
: XXX O
5738 XXX O
, XXX O
1996 XXX O
) XXX O
, XXX O
contains XXX O
multiple XXX O
structural XXX O
domains XXX O
including XXX O
two XXX O
regions XXX O
of XXX O
seven XXX O
internal XXX O
repeats XXX O
highly XXX O
related XXX O
to XXX O
the XXX O
cell XXX O
cycle XXX O
regulator XXX O
RCC1 XXX B-GENE
, XXX O
a XXX O
guanine XXX B-GENE
nucleotide XXX I-GENE
exchange XXX I-GENE
factor XXX I-GENE
for XXX O
the XXX O
small XXX B-GENE
GTP-binding XXX I-GENE
protein XXX I-GENE
Ran XXX B-GENE
, XXX O
seven XXX O
beta-repeat XXX O
domains XXX O
characteristic XXX O
of XXX O
the XXX O
beta XXX O
subunit XXX O
of XXX O
heterotrimeric XXX B-GENE
G XXX I-GENE
proteins XXX I-GENE
, XXX O
three XXX O
putative XXX O
SH3 XXX B-GENE
binding XXX I-GENE
sites XXX I-GENE
, XXX O
a XXX O
putative XXX O
leucine-zipper XXX O
and XXX O
a XXX O
carboxy-terminal XXX B-GENE
HECT XXX I-GENE
domain XXX I-GENE
characteristic XXX O
of XXX O
E3 XXX B-GENE
ubiquitin-protein XXX I-GENE
ligases XXX I-GENE
. XXX O

Northern XXX O
blotting XXX O
with XXX O
a XXX O
unique XXX O
17-mer XXX O
oligonucleotide XXX O
demonstrated XXX O
the XXX O
absence XXX O
of XXX O
the XXX O
mutant XXX O
sequence XXX O
in XXX O
the XXX O
mRNA XXX O
from XXX O
which XXX O
the XXX O
cDNA XXX O
library XXX O
giving XXX O
rise XXX O
to XXX O
the XXX O
mutant XXX O
cDNA XXX O
was XXX O
constructed XXX O
. XXX O

For XXX O
wild XXX O
type XXX O
MutT XXX B-GENE
and XXX O
its XXX O
E53D XXX B-GENE
and XXX O
E44D XXX B-GENE
mutants XXX I-GENE
, XXX O
plots XXX O
of XXX O
log XXX O
( XXX O
k XXX O
( XXX O
cat XXX O
) XXX O
) XXX O
versus XXX O
pH XXX O
exhibited XXX O
a XXX O
limiting XXX O
slope XXX O
of XXX O
1 XXX O
on XXX O
the XXX O
ascending XXX O
limb XXX O
and XXX O
then XXX O
a XXX O
hump XXX O
, XXX O
i XXX O
. XXX O
e XXX O
. XXX O
, XXX O
a XXX O
sharply XXX O
defined XXX O
maximum XXX O
near XXX O
pH XXX O
8 XXX O
followed XXX O
by XXX O
a XXX O
plateau XXX O
, XXX O
yielding XXX O
apparent XXX O
pK XXX O
( XXX O
a XXX O
) XXX O
values XXX O
of XXX O
7 XXX O
. XXX O
6 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
3 XXX O
and XXX O
8 XXX O
. XXX O
4 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
4 XXX O
for XXX O
an XXX O
essential XXX O
base XXX O
and XXX O
a XXX O
nonessential XXX O
acid XXX O
catalyst XXX O
, XXX O
respectively XXX O
, XXX O
in XXX O
the XXX O
active XXX O
quaternary XXX O
MutT-Mg XXX B-GENE
( XXX I-GENE
2+ XXX I-GENE
) XXX I-GENE
-dGTP-Mg XXX I-GENE
( XXX I-GENE
2+ XXX I-GENE
) XXX I-GENE
complex XXX I-GENE
. XXX O

Arm XXX O
function XXX O
tests XXX O
. XXX O

Groups XXX O
dicker XXX O
for XXX O
price XXX O
breaks XXX O
as XXX O
anesthetic XXX O
gas XXX O
goes XXX O
multi-source XXX O
. XXX O

Research XXX O
on XXX O
ethylene XXX O
glycol XXX O
and XXX O
diethylene XXX O
glycol XXX O
for XXX O
carcinogenic XXX O
effects XXX O
. XXX O

Diallylnitrosamine XXX O
( XXX O
DAN XXX O
) XXX O
, XXX O
one XXX O
of XXX O
the XXX O
few XXX O
nitrosamines XXX O
tested XXX O
thus XXX O
far XXX O
that XXX O
has XXX O
not XXX O
induced XXX O
neoplasms XXX O
in XXX O
rats XXX O
, XXX O
caused XXX O
a XXX O
high XXX O
incidence XXX O
of XXX O
respiratory XXX O
tract XXX O
tumors XXX O
in XXX O
Syrian XXX O
golden XXX O
hamsters XXX O
treated XXX O
sc XXX O
with XXX O
single XXX O
or XXX O
weekly XXX O
doses XXX O
of XXX O
the XXX O
compound XXX O
. XXX O

Cytogenetic XXX O
studies XXX O
were XXX O
performed XXX O
in XXX O
lymphocytes XXX O
from XXX O
hospital XXX O
workers XXX O
exposed XXX O
to XXX O
low XXX O
doses XXX O
of XXX O
radiation XXX O
( XXX O
1 XXX O
. XXX O
6-42 XXX O
. XXX O
71 XXX O
mSv XXX O
) XXX O
. XXX O

According XXX O
to XXX O
the XXX O
laboratory XXX O
results XXX O
, XXX O
the XXX O
application XXX O
of XXX O
neural XXX O
network XXX O
can XXX O
solve XXX O
the XXX O
problem XXX O
successfully XXX O
. XXX O

Upon XXX O
induction XXX O
of XXX O
SOS XXX O
, XXX O
viability XXX O
increased XXX O
2-6-fold XXX O
. XXX O

Processing XXX O
, XXX O
secretion XXX O
, XXX O
and XXX O
immunoreactivity XXX O
of XXX O
carboxy XXX B-GENE
terminally XXX I-GENE
truncated XXX I-GENE
dengue-2 XXX I-GENE
virus XXX I-GENE
envelope XXX I-GENE
proteins XXX I-GENE
expressed XXX O
in XXX O
insect XXX O
cells XXX O
by XXX O
recombinant XXX O
baculoviruses XXX O
. XXX O

Despite XXX O
i XXX O
. XXX O
v XXX O
. XXX O
steroid XXX O
therapy XXX O
, XXX O
[ XXX O
NOexh XXX O
] XXX O
remained XXX O
elevated XXX O
throughout XXX O
recovery XXX O
( XXX O
37 XXX O
. XXX O
9+ XXX O
/ XXX O
-4 XXX O
. XXX O
8 XXX O
ppb XXX O
, XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
001 XXX O
) XXX O
until XXX O
discharge XXX O
( XXX O
40 XXX O
. XXX O
9+ XXX O
/ XXX O
-4 XXX O
. XXX O
3 XXX O
ppb XXX O
, XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
001 XXX O
) XXX O
. XXX O

Similarly XXX O
, XXX O
supraventricular XXX O
tachycaydia XXX O
following XXX O
resuscitative XXX O
efforts XXX O
appeared XXX O
to XXX O
be XXX O
associated XXX O
with XXX O
a XXX O
negative XXX O
outcome XXX O
. XXX O

Abnormalities XXX O
of XXX O
plasma XXX B-GENE
cholecystokinin XXX I-GENE
were XXX O
observed XXX O
only XXX O
in XXX O
patients XXX O
with XXX O
delayed XXX O
gastric XXX O
emptying XXX O
. XXX O

Reaction XXX O
of XXX O
human XXX O
organism XXX O
to XXX O
exercise XXX O
. XXX O

In XXX O
sixteen XXX O
patients XXX O
with XXX O
moderate XXX O
essential XXX O
hypertension XXX O
the XXX O
effects XXX O
of XXX O
10-day XXX O
nifedipine XXX O
treatment XXX O
on XXX O
serum XXX O
uric XXX O
acid XXX O
and XXX O
renal XXX O
excretion XXX O
of XXX O
uric XXX O
acid XXX O
were XXX O
evaluated XXX O
. XXX O

We XXX O
now XXX O
demonstrate XXX O
that XXX O
CCAAT XXX B-GENE
/ XXX I-GENE
enhancer-binding XXX I-GENE
protein XXX I-GENE
( XXX I-GENE
C XXX I-GENE
/ XXX I-GENE
EBP XXX I-GENE
) XXX I-GENE
delta XXX I-GENE
is XXX O
a XXX O
major XXX O
component XXX O
of XXX O
a XXX O
PGE2-stimulated XXX B-GENE
DNA-protein XXX I-GENE
complex XXX I-GENE
involving XXX O
HS3D XXX B-GENE
and XXX O
find XXX O
that XXX O
C XXX B-GENE
/ XXX I-GENE
EBPdelta XXX I-GENE
transactivates XXX O
IGF-I XXX B-GENE
promoter XXX I-GENE
1 XXX I-GENE
through XXX O
this XXX O
site XXX O
. XXX O

To XXX O
characterize XXX O
the XXX O
O7-LPS XXX B-GENE
region XXX I-GENE
, XXX O
the XXX O
recombinant XXX O
cosmids XXX O
pJHCV31 XXX O
and XXX O
pJHCV32 XXX O
were XXX O
mutagenized XXX O
by XXX O
transposon XXX O
mutagenesis XXX O
with XXX O
Tn3HoHo1 XXX B-GENE
, XXX O
which XXX O
carries XXX O
a XXX O
promoterless XXX O
lac XXX B-GENE
operon XXX I-GENE
and XXX O
can XXX O
therefore XXX O
generate XXX O
lacZ XXX B-GENE
transcriptional XXX O
fusions XXX O
with XXX O
target XXX O
DNA XXX O
sequences XXX O
. XXX O

The XXX O
only XXX O
abundant XXX O
viral XXX O
transcript XXX O
expressed XXX O
during XXX O
latency XXX O
is XXX O
the XXX O
latency-related XXX B-GENE
( XXX I-GENE
LR XXX I-GENE
) XXX I-GENE
RNA XXX I-GENE
. XXX O

The XXX O
influence XXX O
of XXX O
adrenergic XXX O
nerves XXX O
of XXX O
the XXX O
response XXX O
of XXX O
blood XXX O
vessels XXX O
in XXX O
the XXX O
rabbit XXX O
ear XXX O
to XXX O
2--phenylalanine-8-lysine XXX B-GENE
vasopressin XXX I-GENE
( XXX O
Octapressin XXX B-GENE
) XXX O
. XXX O

Following XXX O
conditioning XXX O
, XXX O
a XXX O
single XXX O
coat XXX O
of XXX O
adhesive XXX O
was XXX O
applied XXX O
and XXX O
light-cured XXX O
. XXX O

In XXX O
transient XXX O
analysis XXX O
using XXX O
particle XXX O
bombardment XXX O
of XXX O
tobacco XXX O
leaf XXX O
sections XXX O
, XXX O
a XXX O
tetramer XXX O
of XXX O
the XXX O
distB XXX B-GENE
ABRE XXX I-GENE
( XXX O
abscisic XXX B-GENE
acid-responsive XXX I-GENE
element XXX I-GENE
) XXX O
mediated XXX O
transactivation XXX O
by XXX O
ABI3 XXX B-GENE
and XXX O
ABI3-dependent XXX O
response XXX O
to XXX O
ABA XXX O
, XXX O
whereas XXX O
a XXX O
tetramer XXX O
of XXX O
the XXX O
composite XXX O
RY XXX O
/ XXX O
G XXX O
complex XXX O
, XXX O
containing XXX O
RY XXX O
repeats XXX O
and XXX O
a XXX O
G-box XXX O
, XXX O
mediated XXX O
only XXX O
ABA-independent XXX O
transactivation XXX O
by XXX O
ABI3 XXX B-GENE
. XXX O

The XXX O
gene XXX O
pairs XXX O
psbB-psbT XXX B-GENE
and XXX O
psbH-psbN XXX B-GENE
are XXX O
cotranscribed XXX O
from XXX O
opposite XXX O
strands XXX O
. XXX O

About XXX O
20 XXX O
kb XXX O
upstream XXX O
of XXX O
LAMB2 XXX B-GENE
we XXX O
found XXX O
a XXX O
gene XXX O
encoding XXX O
a XXX O
transcribed XXX O
, XXX O
non-processed XXX O
LAMB2-like XXX B-GENE
pseudogene XXX I-GENE
( XXX O
LAMB2L XXX B-GENE
) XXX O
. XXX O

Site XXX B-GENE
S-II XXX I-GENE
also XXX O
spans XXX O
a XXX O
23 XXX O
bp XXX O
sequence XXX O
containing XXX O
two XXX O
tandem XXX O
consensus XXX O
binding XXX O
sites XXX O
with XXX O
three XXX O
base XXX O
pair XXX O
mismatches XXX O
in XXX O
each XXX O
and XXX O
a XXX O
one XXX O
base XXX O
pair XXX O
deletion XXX O
. XXX O

FZD4 XXX B-GENE
is XXX O
homologous XXX O
to XXX O
FZD9 XXX B-GENE
and XXX O
FZD10 XXX B-GENE
, XXX O
and XXX O
overall XXX O
amino XXX O
acid XXX O
identity XXX O
is XXX O
as XXX O
follows XXX O
: XXX O
FZD4 XXX B-GENE
vs XXX O
FZD9 XXX B-GENE
, XXX O
51 XXX O
. XXX O
6% XXX O
; XXX O
FZD4 XXX B-GENE
vs XXX O
FZD10 XXX B-GENE
, XXX O
51 XXX O
. XXX O
2% XXX O
; XXX O
FZD9 XXX B-GENE
vs XXX O
FZD10 XXX B-GENE
, XXX O
65 XXX O
. XXX O
7% XXX O
. XXX O

E2F1-mediated XXX O
transcriptional XXX O
inhibition XXX O
of XXX O
the XXX O
plasminogen XXX B-GENE
activator XXX I-GENE
inhibitor XXX I-GENE
type XXX I-GENE
1 XXX I-GENE
gene XXX I-GENE
. XXX O

The XXX O
mustard XXX B-GENE
chloroplast XXX I-GENE
gene XXX I-GENE
rps16 XXX I-GENE
is XXX O
split XXX O
by XXX O
an XXX O
887 XXX O
bp XXX O
group XXX O
II XXX O
( XXX O
or XXX O
III XXX O
) XXX O
intron XXX O
. XXX O

Armed XXX O
with XXX O
a XXX O
clear XXX O
understanding XXX O
of XXX O
the XXX O
pathophysiologic XXX O
pathways XXX O
that XXX O
may XXX O
cause XXX O
and XXX O
/ XXX O
or XXX O
contribute XXX O
to XXX O
the XXX O
development XXX O
of XXX O
unconjugated XXX O
hyperbilirubinemia XXX O
and XXX O
the XXX O
associated XXX O
jaundice XXX O
, XXX O
the XXX O
practitioner XXX O
will XXX O
be XXX O
successful XXX O
in XXX O
helping XXX O
the XXX O
family XXX O
understand XXX O
their XXX O
child's XXX O
illness XXX O
. XXX O

Twenty-five XXX O
patients XXX O
also XXX O
received XXX O
PET XXX O
examinations XXX O
during XXX O
the XXX O
staging XXX O
procedures XXX O
. XXX O

Reward XXX O
value XXX O
of XXX O
prosodic XXX O
features XXX O
of XXX O
language XXX O
for XXX O
autistic XXX O
, XXX O
mentally XXX O
retarded XXX O
, XXX O
and XXX O
normal XXX O
children XXX O
. XXX O

In XXX O
this XXX O
report XXX O
we XXX O
describe XXX O
for XXX O
the XXX O
first XXX O
time XXX O
the XXX O
complete XXX O
primary XXX O
structure XXX O
of XXX O
type XXX B-GENE
X XXX I-GENE
collagen XXX I-GENE
, XXX O
based XXX O
on XXX O
cloning XXX O
and XXX O
sequencing XXX O
of XXX O
cDNA XXX O
and XXX O
genomic XXX O
DNA XXX O
. XXX O

An XXX O
infectious XXX O
origin XXX O
should XXX O
always XXX O
be XXX O
excluded XXX O
since XXX O
specific XXX O
etiologic XXX O
therapy XXX O
may XXX O
be XXX O
implemented XXX O
. XXX O

We XXX O
have XXX O
mapped XXX O
the XXX O
human XXX B-GENE
STAG3 XXX I-GENE
gene XXX I-GENE
to XXX O
the XXX O
7q22 XXX O
region XXX O
of XXX O
chromosome XXX O
7 XXX O
; XXX O
six XXX O
human XXX B-GENE
STAG3-related XXX I-GENE
genes XXX I-GENE
have XXX O
also XXX O
been XXX O
mapped XXX O
: XXX O
two XXX O
at XXX O
7q22 XXX O
near XXX O
the XXX O
functional XXX O
gene XXX O
, XXX O
one XXX O
at XXX O
7q11 XXX O
. XXX O
22 XXX O
, XXX O
and XXX O
three XXX O
at XXX O
7q11 XXX O
. XXX O
23 XXX O
, XXX O
two XXX O
of XXX O
them XXX O
flanking XXX O
the XXX O
breakpoints XXX O
commonly XXX O
associated XXX O
with XXX O
the XXX O
Williams-Beuren XXX B-GENE
syndrome XXX I-GENE
( XXX I-GENE
WBS XXX I-GENE
) XXX I-GENE
deletion XXX I-GENE
. XXX O

Surprisingly XXX O
, XXX O
3 XXX O
full-length XXX B-GENE
murine XXX I-GENE
survivin XXX I-GENE
cDNA XXX I-GENE
clones XXX O
were XXX O
isolated XXX O
, XXX O
predicting XXX O
the XXX O
existence XXX O
of XXX O
3 XXX O
distinct XXX O
survivin XXX B-GENE
proteins XXX I-GENE
. XXX O

A XXX O
data XXX O
base XXX O
homology XXX O
search XXX O
revealed XXX O
that XXX O
the XXX O
predicted XXX O
ER1 XXX B-GENE
amino XXX O
acid XXX O
sequence XXX O
contains XXX O
three XXX O
regions XXX O
of XXX O
similarity XXX O
to XXX O
the XXX O
rat XXX O
and XXX O
human XXX O
proteins XXX O
encoded XXX O
by XXX O
the XXX O
metastasis-associated XXX B-GENE
gene XXX I-GENE
, XXX O
mta1 XXX B-GENE
, XXX O
and XXX O
two XXX O
regions XXX O
of XXX O
similarity XXX O
to XXX O
the XXX O
Caenorhabditis XXX O
elegans XXX O
sequence XXX O
that XXX O
is XXX O
similar XXX O
to XXX O
mta1 XXX B-GENE
. XXX O

The XXX O
modalities XXX O
for XXX O
using XXX O
reference XXX O
values XXX O
for XXX O
individual XXX O
subjects XXX O
as XXX O
well XXX O
as XXX O
for XXX O
groups XXX O
are XXX O
then XXX O
discussed XXX O
and XXX O
the XXX O
main XXX O
points XXX O
of XXX O
research XXX O
which XXX O
must XXX O
be XXX O
faced XXX O
in XXX O
the XXX O
near XXX O
future XXX O
regarding XXX O
reference XXX O
values XXX O
are XXX O
highlighted XXX O
. XXX O

Cross-linking XXX O
the XXX O
B XXX B-GENE
cell XXX I-GENE
Ag XXX I-GENE
receptor XXX I-GENE
( XXX O
BCR XXX B-GENE
) XXX O
to XXX O
surface XXX B-GENE
Fc XXX I-GENE
receptors XXX I-GENE
for XXX O
IgG XXX B-GENE
( XXX O
Fc XXX B-GENE
gamma XXX I-GENE
R XXX I-GENE
) XXX O
inhibits XXX O
G1-to-S XXX O
progression XXX O
; XXX O
the XXX O
mechanism XXX O
by XXX O
which XXX O
this XXX O
occurs XXX O
is XXX O
not XXX O
completely XXX O
known XXX O
. XXX O

The XXX O
DSF XXX O
regimen XXX O
appears XXX O
to XXX O
have XXX O
significant XXX O
activity XXX O
in XXX O
patients XXX O
who XXX O
have XXX O
metastatic XXX O
pancreatic XXX O
islet-cell XXX O
carcinoma XXX O
, XXX O
and XXX O
patient XXX O
tolerance XXX O
of XXX O
the XXX O
regimen XXX O
is XXX O
excellent XXX O
, XXX O
thus XXX O
warranting XXX O
further XXX O
investigation XXX O
. XXX O

A XXX O
comparative XXX O
study XXX O
by XXX O
holographic XXX O
interferometry XXX O
of XXX O
ten XXX O
porcine XXX O
bioprosthetic XXX O
valves XXX O
( XXX O
seven XXX O
Carpentier-Edwards XXX O
SAV XXX O
, XXX O
two XXX O
BioImplant XXX O
and XXX O
one XXX O
Valcor XXX O
) XXX O
with XXX O
five XXX O
human XXX O
aortic XXX O
valves XXX O
before XXX O
and XXX O
after XXX O
glutaraldehyde XXX O
treatment XXX O
is XXX O
presented XXX O
. XXX O

In XXX O
contrast XXX O
, XXX O
the XXX O
failure XXX O
of XXX O
the XXX O
QKTT XXX B-GENE
motif XXX I-GENE
and XXX O
TGN46 XXX B-GENE
cytoplasmic XXX O
tail XXX O
to XXX O
induce XXX O
steady-state XXX O
ER XXX O
localization XXX O
of XXX O
vesicular XXX B-GENE
stomatitis XXX I-GENE
virus XXX I-GENE
glycoprotein XXX I-GENE
( XXX O
VSVG XXX B-GENE
) XXX O
chimeras XXX O
in XXX O
HeLa XXX O
and XXX O
NRK XXX O
cells XXX O
indicates XXX O
that XXX O
significant XXX O
differences XXX O
in XXX O
early XXX O
secretory XXX O
trafficking XXX O
also XXX O
exist XXX O
. XXX O

The XXX O
incidence XXX O
of XXX O
fetal XXX O
breathing XXX O
movements XXX O
( XXX O
06 XXX O
. XXX O
00-10 XXX O
. XXX O
00 XXX O
h XXX O
) XXX O
decreased XXX O
with XXX O
increasing XXX O
gestational XXX O
age XXX O
while XXX O
fetal XXX O
arterial XXX O
concentrations XXX O
of XXX O
plasma XXX O
PGE XXX O
increased XXX O
significantly XXX O
over XXX O
the XXX O
same XXX O
period XXX O
of XXX O
gestation XXX O
. XXX O

Two XXX O
episodes XXX O
of XXX O
peritonitis XXX O
occurred XXX O
while XXX O
the XXX O
patient XXX O
received XXX O
CAPD XXX O
( XXX O
1 XXX O
episode XXX O
/ XXX O
3 XXX O
. XXX O
5 XXX O
patient-months XXX O
) XXX O
. XXX O

Potential XXX O
translational XXX O
start XXX O
signals XXX O
are XXX O
upstream XXX O
of XXX O
ORF1 XXX O
and XXX O
ORF2 XXX O
. XXX O

The XXX O
recombinant XXX O
protein XXX O
was XXX O
purified XXX O
to XXX O
homogeneity XXX O
by XXX O
( XXX O
NH4 XXX O
) XXX O
2SO4-precipitation XXX O
and XXX O
affinity XXX O
chromatography XXX O
on XXX O
5' XXX O
AMP-Sepharose XXX O
. XXX O

Here XXX O
we XXX O
show XXX O
that XXX O
IIIa XXX O
pre-mRNA XXX O
splicing XXX O
is XXX O
activated XXX O
more XXX O
than XXX O
200-fold XXX O
in XXX O
nuclear XXX O
extracts XXX O
prepared XXX O
from XXX O
late XXX O
adenovirus-infected XXX O
cells XXX O
( XXX O
Ad-NE XXX O
) XXX O
compared XXX O
to XXX O
uninfected XXX O
HeLa XXX O
cell XXX O
nuclear XXX O
extracts XXX O
( XXX O
HeLa-NE XXX O
) XXX O
. XXX O

Diuresis XXX O
was XXX O
induced XXX O
by XXX O
scheduled XXX O
drinking XXX O
of XXX O
tea XXX O
( XXX O
150 XXX O
ml XXX O
/ XXX O
h XXX O
) XXX O
. XXX O

In XXX O
these XXX O
cells XXX O
, XXX O
ras-induced XXX O
transition XXX O
is XXX O
accompanied XXX O
by XXX O
a XXX O
strong XXX O
induction XXX O
of XXX O
AP-1-binding XXX O
activity XXX O
along XXX O
with XXX O
increased XXX O
expression XXX O
of XXX O
CD44 XXX B-GENE
mRNA XXX I-GENE
and XXX O
protein XXX O
. XXX O

Structural XXX O
analysis XXX O
of XXX O
the XXX O
5'-regulatory XXX O
region XXX O
reveals XXX O
that XXX O
the XXX O
c-met XXX B-GENE
promoter XXX I-GENE
lacks XXX O
TATA XXX O
or XXX O
CAAT XXX O
elements XXX O
but XXX O
has XXX O
an XXX O
extremely XXX O
high XXX O
G-C XXX O
content XXX O
and XXX O
multiple XXX O
Sp1 XXX B-GENE
binding XXX I-GENE
sites XXX I-GENE
. XXX O

In XXX O
the XXX O
last XXX O
case XXX O
, XXX O
both XXX O
hydroxychloroquine XXX O
, XXX O
carbamazepine XXX O
and XXX O
fluvoxamine XXX O
had XXX O
a XXX O
common XXX O
imputability XXX O
which XXX O
was XXX O
plausible XXX O
. XXX O

Perceptions XXX O
of XXX O
illness XXX O
intrusiveness XXX O
were XXX O
significantly XXX O
higher XXX O
when XXX O
both XXX O
muscle XXX O
cramp XXX O
and XXX O
headache XXX O
symptoms XXX O
occurred XXX O
during XXX O
one XXX O
or XXX O
more XXX O
assessment XXX O
intervals XXX O
as XXX O
compared XXX O
to XXX O
when XXX O
muscle XXX O
cramps XXX O
or XXX O
headaches XXX O
, XXX O
only XXX O
, XXX O
occurred XXX O
. XXX O

Abp1 XXX B-GENE
preferentially XXX O
binds XXX O
to XXX O
multiple XXX O
sites XXX O
in XXX O
ARS XXX O
3002 XXX O
and XXX O
to XXX O
the XXX O
DNA XXX O
polymer XXX O
poly XXX O
[ XXX O
d XXX O
( XXX O
A XXX O
. XXX O
T XXX O
) XXX O
] XXX O
. XXX O

Neither XXX O
of XXX O
these XXX O
proteins XXX O
, XXX O
individually XXX O
or XXX O
as XXX O
a XXX O
pair XXX O
, XXX O
can XXX O
bind XXX O
the XXX O
alpha-globin XXX B-GENE
3'UTR XXX I-GENE
unless XXX O
they XXX O
are XXX O
complexed XXX O
with XXX O
the XXX O
remaining XXX O
non-poly XXX O
( XXX O
C XXX O
) XXX O
binding XXX O
proteins XXX O
of XXX O
the XXX O
alpha-complex XXX B-GENE
. XXX O

This XXX O
is XXX O
the XXX O
first XXX O
report XXX O
that XXX O
an XXX O
in XXX O
vitro-synthesized XXX O
alphavirus XXX O
RNA XXX O
lacking XXX O
a XXX O
poly XXX O
( XXX O
A XXX O
) XXX O
tail XXX O
can XXX O
initiate XXX O
infection XXX O
and XXX O
produce XXX O
3' XXX O
polyadenylated XXX O
viral XXX O
genome XXX O
in XXX O
vivo XXX O
. XXX O

Groups XXX O
of XXX O
ten XXX O
dependent XXX O
and XXX O
ten XXX O
saline XXX O
mice XXX O
were XXX O
singly XXX O
tested XXX O
in XXX O
both XXX O
light XXX O
and XXX O
dark XXX O
conditions XXX O
in XXX O
each XXX O
of XXX O
five XXX O
covered XXX O
cylinders XXX O
( XXX O
2-23 XXX O
in XXX O
high XXX O
) XXX O
. XXX O

Mapping XXX O
of XXX O
the XXX O
DNA XXX O
binding XXX O
domain XXX O
of XXX O
the XXX O
copper-responsive XXX O
transcription XXX O
factor XXX O
Mac1 XXX B-GENE
from XXX I-GENE
Saccharomyces XXX I-GENE
cerevisiae XXX I-GENE
. XXX O

Hence XXX O
follows XXX O
Kurti's XXX O
demand XXX O
to XXX O
mete XXX O
out XXX O
appropriate XXX O
importance XXX O
to XXX O
the XXX O
arguments XXX O
. XXX O

Nitrogen XXX O
balance XXX O
was XXX O
compared XXX O
, XXX O
and XXX O
metabolic XXX O
complications XXX O
were XXX O
monitored XXX O
by XXX O
evaluating XXX O
BUN XXX O
, XXX O
serum XXX O
creatinine XXX O
, XXX O
creatinine XXX O
clearance XXX O
, XXX O
serum XXX O
CO2 XXX O
, XXX O
SGOT XXX O
, XXX O
SGPT XXX O
, XXX O
serum XXX B-GENE
LDH XXX I-GENE
, XXX O
and XXX O
serum XXX B-GENE
alkaline XXX I-GENE
phosphatase XXX I-GENE
. XXX O

The XXX O
drug XXX O
was XXX O
given XXX O
in XXX O
a XXX O
daily XXX O
oral XXX O
dose XXX O
of XXX O
0 XXX O
. XXX O
5 XXX O
g XXX O
/ XXX O
m2 XXX O
, XXX O
3 XXX O
. XXX O
5 XXX O
h XXX O
prior XXX O
to XXX O
each XXX O
radiation XXX O
treatment XXX O
. XXX O

Because XXX O
the XXX O
biosynthetic XXX O
pathway XXX O
to XXX O
the XXX O
vacuole XXX O
intersects XXX O
with XXX O
the XXX O
endocytic XXX O
pathway XXX O
, XXX O
internalization XXX O
of XXX O
a XXX O
bulk XXX O
membrane XXX O
endocytic XXX O
marker XXX O
FM XXX O
4-64 XXX O
was XXX O
assayed XXX O
in XXX O
the XXX O
sop XXX B-GENE
mutants XXX I-GENE
. XXX O

RESULTS XXX O
: XXX O
256 XXX O
Periods XXX O
of XXX O
TTP XXX O
or XXX O
PUNP XXX O
were XXX O
reported XXX O
by XXX O
men XXX O
and XXX O
174 XXX O
by XXX O
women XXX O
. XXX O

The XXX O
protector XXX O
doubled XXX O
the XXX O
estimated XXX O
fall XXX O
distance XXX O
for XXX O
fracture XXX O
of XXX O
the XXX O
trochanter XXX O
. XXX O

The XXX O
remaining XXX O
80 XXX O
patients XXX O
underwent XXX O
recordings XXX O
of XXX O
ECG XXX O
, XXX O
beat-to-beat XXX O
arterial XXX O
oxygen XXX O
saturation XXX O
( XXX O
SaO2 XXX O
) XXX O
, XXX O
and XXX O
respiration XXX O
during XXX O
both XXX O
spontaneous XXX O
and XXX O
controlled XXX O
breathing XXX O
. XXX O

The XXX O
SH2-containing XXX O
adapter XXX O
protein XXX O
GRB10 XXX B-GENE
interacts XXX O
with XXX O
BCR-ABL XXX B-GENE
. XXX O

Controlled XXX O
versus XXX O
uncontrolled XXX O
reperfusion XXX O
of XXX O
ischemic XXX O
myocardium XXX O
after XXX O
experimental XXX O
coronary XXX O
artery XXX O
occlusion XXX O
was XXX O
studied XXX O
to XXX O
determine XXX O
the XXX O
effect XXX O
on XXX O
regional XXX O
ventricular XXX O
wall XXX O
motion XXX O
and XXX O
associated XXX O
biochemical XXX O
alterations XXX O
. XXX O

No XXX O
somatic XXX O
mutations XXX O
were XXX O
found XXX O
in XXX O
any XXX O
of XXX O
the XXX O
samples XXX O
, XXX O
suggesting XXX O
that XXX O
ING1 XXX B-GENE
is XXX O
not XXX O
a XXX O
tumor XXX O
suppressor XXX O
gene XXX O
target XXX O
in XXX O
head XXX O
and XXX O
neck XXX O
cancer XXX O
. XXX O

In XXX O
electrophoretic XXX O
mobility XXX O
shift XXX O
assay XXX O
( XXX O
EMSA XXX O
) XXX O
, XXX O
this XXX O
GLUT4 XXX B-GENE
repressor XXX I-GENE
element XXX I-GENE
( XXX O
G4RE XXX B-GENE
) XXX O
generated XXX O
specific XXX O
bands XXX O
with XXX O
nuclear XXX O
extracts XXX O
from XXX O
preadipocytes XXX O
, XXX O
but XXX O
not XXX O
from XXX O
adipocytes XXX O
. XXX O

The XXX O
report XXX O
highlights XXX O
the XXX O
possible XXX O
contribution XXX O
of XXX O
stress XXX O
factors XXX O
in XXX O
the XXX O
context XXX O
of XXX O
therapy XXX O
resistant XXX O
periodontal XXX O
disease XXX O
, XXX O
and XXX O
the XXX O
results XXX O
seem XXX O
to XXX O
be XXX O
understandable XXX O
within XXX O
the XXX O
context XXX O
of XXX O
a XXX O
stress XXX O
system XXX O
disorder XXX O
perspective XXX O
. XXX O

Four XXX O
putative XXX O
positive XXX O
cDNA XXX O
clones XXX O
were XXX O
isolated XXX O
, XXX O
and XXX O
the XXX O
largest XXX O
insert XXX O
( XXX O
pASB-1 XXX B-GENE
) XXX O
was XXX O
sequenced XXX O
in XXX O
both XXX O
orientations XXX O
. XXX O

DNA-protein XXX O
UV XXX O
cross-linking XXX O
studies XXX O
indicated XXX O
that XXX O
UHF-1 XXX B-GENE
has XXX O
an XXX O
electrophoretic XXX O
mobility XXX O
on XXX O
sodium XXX O
dodecyl XXX O
sulfate-acrylamide XXX O
gels XXX O
of XXX O
approximately XXX O
85 XXX O
kDa XXX O
and XXX O
suggested XXX O
that XXX O
additional XXX O
proteins XXX O
, XXX O
specific XXX O
to XXX O
each XXX O
promoter XXX O
, XXX O
bind XXX O
to XXX O
each XXX O
site XXX O
. XXX O

In XXX O
myometrial XXX O
SMC XXX O
, XXX O
both XXX O
isoforms XXX O
of XXX O
the XXX O
progesterone XXX B-GENE
receptor XXX I-GENE
, XXX O
PR-B XXX B-GENE
and XXX O
PR-A XXX B-GENE
, XXX O
caused XXX O
a XXX O
ligand-dependent XXX O
activation XXX O
of XXX O
PGDH-2368 XXX B-GENE
/ XXX I-GENE
luc3 XXX I-GENE
. XXX O

Further XXX O
analysis XXX O
of XXX O
this XXX O
domain XXX O
by XXX O
in XXX O
vitro XXX O
mutagenesis XXX O
pointed XXX O
to XXX O
a XXX O
core XXX O
of XXX O
hydrophobic XXX O
and XXX O
acidic XXX O
residues XXX O
as XXX O
critical XXX O
for XXX O
the XXX O
activity XXX O
. XXX O

Methods XXX O
of XXX O
clinical XXX O
and XXX O
experimental XXX O
algesimetry XXX O
are XXX O
described XXX O
that XXX O
have XXX O
been XXX O
used XXX O
to XXX O
evaluate XXX O
effects XXX O
of XXX O
peripherally XXX O
and XXX O
centrally XXX O
acting XXX O
analgesics XXX O
. XXX O

Facts XXX O
on XXX O
the XXX O
Economic XXX O
Recovery XXX O
Tax XXX O
Act XXX O
of XXX O
1981 XXX O
for XXX O
speech-language XXX O
pathologists XXX O
and XXX O
audiologists XXX O
. XXX O

However XXX O
, XXX O
Cbf5p XXX B-GENE
was XXX O
found XXX O
to XXX O
be XXX O
nucleolar XXX O
and XXX O
is XXX O
highly XXX O
homologous XXX O
to XXX O
the XXX O
rat XXX B-GENE
nucleolar XXX I-GENE
protein XXX I-GENE
NAP57 XXX I-GENE
, XXX O
which XXX O
coimmunoprecipitates XXX O
with XXX O
Nopp140 XXX B-GENE
and XXX O
which XXX O
is XXX O
postulated XXX O
to XXX O
be XXX O
involved XXX O
in XXX O
nucleolar-cytoplasmic XXX O
shuttling XXX O
( XXX O
U XXX O
. XXX O

RESULTS XXX O
: XXX O
Horses XXX O
with XXX O
colic XXX O
had XXX O
significantly XXX O
higher XXX O
fibrinogen XXX B-GENE
concentration XXX O
, XXX O
greater XXX O
alpha XXX B-GENE
2AP XXX I-GENE
and XXX O
protein XXX B-GENE
C XXX I-GENE
activities XXX O
, XXX O
and XXX O
longer XXX O
PT XXX O
and XXX O
APTT XXX O
than XXX O
did XXX O
healthy XXX O
horses XXX O
. XXX O

Trial XXX O
treatment XXX O
of XXX O
schizophrenia XXX O
with XXX O
des-Tyr-gamma-endorphin XXX B-GENE
. XXX O

The XXX O
Myc XXX B-GENE
LZ XXX I-GENE
was XXX O
found XXX O
to XXX O
prevent XXX O
homodimeric XXX O
interactions XXX O
, XXX O
thus XXX O
explaining XXX O
Myc XXX B-GENE
inability XXX O
to XXX O
homodimerize XXX O
efficiently XXX O
. XXX O

A XXX O
major XXX O
pool XXX O
of XXX O
Dsg-plakoglobin XXX B-GENE
complexes XXX I-GENE
sedimented XXX O
at XXX O
8S XXX O
and XXX O
exhibited XXX O
a XXX O
1 XXX O
: XXX O
1 XXX O
stoichiometry XXX O
. XXX O

Conclusion XXX O
: XXX O
The XXX O
Lp XXX B-GENE
( XXX I-GENE
a XXX I-GENE
) XXX I-GENE
levels XXX O
in XXX O
these XXX O
children XXX O
were XXX O
the XXX O
lower XXX O
ever XXX O
reported XXX O
. XXX O

In XXX O
vitro XXX O
translation XXX O
experiments XXX O
show XXX O
that XXX O
human XXX O
cDNA XXX O
derived XXX O
RNA XXX O
translates XXX O
into XXX O
a XXX O
protein XXX O
with XXX O
a XXX O
mobility XXX O
of XXX O
44-46 XXX O
kD XXX O
on XXX O
SDS XXX O
polyacrylamide XXX O
gels XXX O
. XXX O

Antibodies XXX O
raised XXX O
to XXX O
the XXX O
expressed XXX O
NS3 XXX B-GENE
by XXX O
immunization XXX O
of XXX O
mice XXX O
detected XXX O
both XXX O
NS3 XXX B-GENE
and XXX O
NS3A XXX B-GENE
in XXX O
BTV-10-infected XXX O
BHK XXX O
cells XXX O
but XXX O
not XXX O
in XXX O
purified XXX O
BTV-10 XXX O
virus XXX O
particles XXX O
. XXX O

There XXX O
is XXX O
a XXX O
cysteine XXX O
clustering XXX O
region XXX O
in XXX O
an XXX O
N-terminal XXX O
region XXX O
of XXX O
the XXX O
c-raf XXX B-GENE
( XXX I-GENE
-1 XXX I-GENE
) XXX I-GENE
product XXX I-GENE
deduced XXX O
from XXX O
the XXX O
nucleotide XXX O
sequence XXX O
, XXX O
and XXX O
this XXX O
cysteine XXX O
clustering XXX O
region XXX O
was XXX O
found XXX O
to XXX O
be XXX O
highly XXX O
homologous XXX O
to XXX O
that XXX O
present XXX O
in XXX O
an XXX O
N-terminal XXX O
region XXX O
of XXX O
protein XXX B-GENE
kinase XXX I-GENE
C XXX I-GENE
, XXX O
although XXX O
, XXX O
in XXX O
the XXX O
latter XXX O
cysteine XXX O
clusters XXX O
are XXX O
present XXX O
in XXX O
duplicate XXX O
. XXX O

In XXX O
transient XXX O
cotransfections XXX O
E1A XXX B-GENE
could XXX O
induce XXX O
the XXX O
activity XXX O
of XXX O
the XXX O
p53 XXX B-GENE
promoter XXX I-GENE
to XXX O
a XXX O
high XXX O
level XXX O
; XXX O
12S XXX B-GENE
E1A XXX I-GENE
was XXX O
threefold XXX O
as XXX O
efficient XXX O
as XXX O
13S XXX B-GENE
E1A XXX I-GENE
in XXX O
this XXX O
activity XXX O
, XXX O
and XXX O
YY1 XXX B-GENE
bound XXX O
to XXX O
the XXX O
composite XXX O
element XXX O
was XXX O
shown XXX O
to XXX O
mediate XXX O
55% XXX O
of XXX O
this XXX O
induction XXX O
. XXX O

Two XXX O
variant XXX O
PRP-precursor XXX B-GENE
alleles XXX I-GENE
occur XXX O
which XXX O
slightly XXX O
differ XXX O
in XXX O
the XXX O
number XXX O
of XXX O
repeats XXX O
in XXX O
domain XXX B-GENE
C XXX I-GENE
. XXX O

The XXX O
first XXX O
open XXX O
reading XXX O
frame XXX O
of XXX O
the XXX O
blueberry XXX O
scorch XXX O
carlavirus XXX O
( XXX O
BBScV XXX O
) XXX O
genome XXX O
encodes XXX O
a XXX O
putative XXX O
replication-associated XXX O
protein XXX O
of XXX O
223 XXX O
kDa XXX O
( XXX O
p223 XXX B-GENE
) XXX O
. XXX O

Hence XXX O
, XXX O
the XXX O
uPA XXX B-GENE
promoter XXX I-GENE
contains XXX O
multiple XXX O
weak XXX O
cis-acting XXX O
elements XXX O
distributed XXX O
over XXX O
7 XXX O
. XXX O
0 XXX O
kb XXX O
5' XXX O
to XXX O
the XXX O
translation XXX O
start XXX O
site XXX O
. XXX O

An XXX O
evolutionary XXX O
comparison XXX O
of XXX O
amino XXX O
acid XXX O
sequences XXX O
of XXX O
34 XXX O
HSP70 XXX B-GENE
proteins XXX I-GENE
from XXX O
17 XXX O
species XXX O
suggests XXX O
that XXX O
BiP XXX B-GENE
genes XXX I-GENE
share XXX O
a XXX O
common XXX O
ancestor XXX O
, XXX O
which XXX O
diverged XXX O
from XXX O
other XXX O
HSP70 XXX B-GENE
genes XXX I-GENE
near XXX O
the XXX O
time XXX O
when XXX O
eukaryotes XXX O
first XXX O
appeared XXX O
. XXX O

To XXX O
understand XXX O
whether XXX O
Shc XXX B-GENE
localization XXX O
in XXX O
membrane XXX O
rafts XXX O
is XXX O
sufficient XXX O
to XXX O
regulate XXX O
Shc XXX B-GENE
function XXX O
, XXX O
we XXX O
constructed XXX O
a XXX O
Shc XXX B-GENE
chimera XXX I-GENE
containing XXX O
the XXX O
Ras XXX B-GENE
membrane XXX I-GENE
localization XXX I-GENE
motif XXX I-GENE
at XXX O
the XXX O
C-terminus XXX O
. XXX O

On XXX O
the XXX O
other XXX O
hand XXX O
, XXX O
cells XXX O
containing XXX O
a XXX O
PTP1C XXX B-GENE
in XXX O
which XXX O
the XXX O
catalytic XXX O
site XXX O
had XXX O
been XXX O
inactivated XXX O
through XXX O
mutagenesis XXX O
, XXX O
stably XXX O
phosphorylated XXX O
the XXX O
phosphatase XXX B-GENE
. XXX O

Haemodynamic XXX O
responses XXX O
to XXX O
antagonism XXX O
of XXX O
bocurarine XXX O
block XXX O
with XXX O
atropine-neostigmine XXX O
mixture XXX O
in XXX O
children XXX O
. XXX O

Retrospective XXX O
analyses XXX O
of XXX O
this XXX O
death XXX O
revealed XXX O
a XXX O
significant XXX O
decrease XXX O
of XXX O
the XXX O
left XXX O
ventricular XXX O
( XXX O
LV XXX O
) XXX O
end-diastolic XXX O
volume XXX O
index XXX O
( XXX O
EDVI XXX O
) XXX O
of XXX O
21 XXX O
ml XXX O
/ XXX O
m2 XXX O
( XXX O
36% XXX O
of XXX O
normal XXX O
) XXX O
. XXX O

METHODS XXX O
AND XXX O
RESULTS XXX O
: XXX O
We XXX O
prospectively XXX O
compared XXX O
the XXX O
automated XXX O
measurements XXX O
of XXX O
left XXX O
ventricular XXX O
ejection XXX O
fraction XXX O
( XXX O
LVEF XXX O
) XXX O
and XXX O
volumes XXX O
from XXX O
rest-injected XXX O
gated XXX O
Technetium XXX O
99m XXX O
( XXX O
Tc99m XXX O
) XXX O
perfusion XXX O
SPECT XXX O
with XXX O
equilibrium XXX O
radionuclide XXX O
angiocardiography XXX O
( XXX O
ERNA XXX O
) XXX O
in XXX O
62 XXX O
patients XXX O
and XXX O
the XXX O
assessment XXX O
of XXX O
regional XXX O
function XXX O
with XXX O
echocardiography XXX O
in XXX O
22 XXX O
patients XXX O
. XXX O

The XXX O
DNA XXX O
helix XXX O
at XXX O
the XXX O
tandemly XXX O
repeated XXX O
, XXX O
13mer XXX O
sequence XXX O
is XXX O
thermodynamically XXX O
unstable XXX O
, XXX O
as XXX O
evidenced XXX O
by XXX O
hypersensitivity XXX O
to XXX O
single-strand-specific XXX B-GENE
nuclease XXX I-GENE
in XXX O
a XXX O
negatively XXX O
supercoiled XXX O
plasmid XXX O
, XXX O
and XXX O
demonstrated XXX O
by XXX O
stable XXX O
DNA XXX O
unwinding XXX O
seen XXX O
after XXX O
two-dimensional XXX O
gel XXX O
electrophoresis XXX O
of XXX O
topoisomers XXX O
. XXX O

Here XXX O
, XXX O
we XXX O
present XXX O
evidence XXX O
for XXX O
a XXX O
model XXX O
in XXX O
which XXX O
mRNA XXX O
sequences XXX O
up XXX O
to XXX O
around XXX O
100 XXX O
nucleotides XXX O
downstream XXX O
from XXX O
the XXX O
start XXX O
codon XXX O
of XXX O
21K XXX O
fold XXX O
back XXX O
and XXX O
base-pair XXX O
to XXX O
the XXX O
21K XXX O
translation XXX O
initiation XXX O
region XXX O
, XXX O
thereby XXX O
decreasing XXX O
the XXX O
translation XXX O
initiation XXX O
frequency XXX O
. XXX O

Consistent XXX O
effects XXX O
on XXX O
pVHL XXX B-GENE
function XXX O
were XXX O
observed XXX O
for XXX O
all XXX O
mutations XXX O
within XXX O
each XXX O
subclass XXX O
. XXX O

In XXX O
HeLa XXX O
x XXX O
fibroblast XXX O
cell XXX O
hybrids XXX O
its XXX O
expression XXX O
correlates XXX O
with XXX O
tumorigenicity XXX O
. XXX O

Furthermore XXX O
, XXX O
our XXX O
data XXX O
also XXX O
show XXX O
that XXX O
, XXX O
in XXX O
addition XXX O
to XXX O
TEF-1 XXX B-GENE
, XXX O
another XXX O
HF-1a-related XXX B-GENE
factor XXX I-GENE
may XXX O
be XXX O
recognized XXX O
by XXX O
the XXX O
alpha-MHC XXX B-GENE
gene XXX I-GENE
EM XXX B-GENE
element XXX I-GENE
. XXX O

In XXX O
this XXX O
way XXX O
it XXX O
is XXX O
possible XXX O
to XXX O
simulate XXX O
the XXX O
growth XXX O
function XXX O
of XXX O
the XXX O
embryofetal XXX O
curve XXX O
of XXX O
the XXX O
length' XXX O
increase XXX O
of XXX O
man XXX O
and XXX O
the XXX O
curve XXX O
of XXX O
the XXX O
mass' XXX O
increase XXX O
of XXX O
rat XXX O
. XXX O

The XXX O
use XXX O
of XXX O
this XXX O
model XXX O
for XXX O
investigating XXX O
pathophysiologically XXX O
significant XXX O
issues XXX O
in XXX O
denervating XXX O
diseases XXX O
is XXX O
illustrated XXX O
with XXX O
five XXX O
different XXX O
sets XXX O
of XXX O
parameters XXX O
. XXX O

The XXX O
14 XXX B-GENE
. XXX I-GENE
1 XXX I-GENE
( XXX I-GENE
IGLL1 XXX I-GENE
) XXX I-GENE
gene XXX I-GENE
is XXX O
expressed XXX O
in XXX O
a XXX O
lineage- XXX O
and XXX O
stage-restricted XXX O
manner XXX O
. XXX O

Determined XXX O
as XXX O
migration XXX O
differentials XXX O
, XXX O
chemotactic XXX O
and XXX O
chemokinetic XXX O
responsiveness XXX O
tended XXX O
to XXX O
be XXX O
higher XXX O
in XXX O
the XXX O
neutropenic XXX O
group XXX O
. XXX O

IA-CT XXX O
with XXX O
cisplatin XXX O
50 XXX O
mg XXX O
and XXX O
doxorubicin XXX O
30 XXX O
mg XXX O
was XXX O
administered XXX O
by XXX O
one XXX O
shot XXX O
method XXX O
in XXX O
bilateral XXX O
internal XXX O
iliac XXX O
arteries XXX O
. XXX O

Greater XXX O
attenuation XXX O
of XXX O
the XXX O
N1-P2 XXX O
and XXX O
baseline-P2 XXX O
amplitude XXX O
of XXX O
the XXX O
probe XXX O
EPs XXX O
was XXX O
observed XXX O
when XXX O
the XXX O
probe XXX O
stimulus XXX O
was XXX O
presented XXX O
to XXX O
the XXX O
right XXX O
ear XXX O
and XXX O
the XXX O
verbal XXX O
material XXX O
presented XXX O
to XXX O
the XXX O
left XXX O
ear XXX O
than XXX O
when XXX O
the XXX O
opposite XXX O
stimulation XXX O
arrangement XXX O
was XXX O
used XXX O
. XXX O

The XXX O
upstream XXX O
promoter XXX O
is XXX O
located XXX O
within XXX O
the XXX O
coding XXX O
sequence XXX O
of XXX O
a XXX O
divergent XXX O
gene XXX O
expressing XXX O
a XXX O
protein XXX O
of XXX O
Mr XXX O
39 XXX O
kDa XXX O
of XXX O
unknown XXX O
function XXX O
. XXX O

METHODS XXX O
: XXX O
All XXX O
these XXX O
30 XXX O
non-responders XXX O
received XXX O
an XXX O
extra XXX O
dose XXX O
of XXX O
the XXX O
same XXX O
vaccine XXX O
2 XXX O
months XXX O
after XXX O
primary XXX O
immunization XXX O
and XXX O
a XXX O
booster XXX O
dose XXX O
with XXX O
a XXX O
yeast-derived XXX O
vaccine XXX O
6 XXX O
years XXX O
later XXX O
. XXX O

In XXX O
sterilized XXX O
milk XXX O
there XXX O
was XXX O
a XXX O
slight XXX O
decrease XXX O
of XXX O
linoleic XXX O
acid XXX O
( XXX O
C18 XXX O
: XXX O
2n6 XXX O
; XXX O
-0 XXX O
. XXX O
7% XXX O
vs XXX O
. XXX O
fresh XXX O
; XXX O
P XXX O
= XXX O
0 XXX O
. XXX O
006 XXX O
) XXX O
and XXX O
arachidonic XXX O
acid XXX O
( XXX O
C20 XXX O
: XXX O
4n6 XXX O
; XXX O
-2 XXX O
. XXX O
5% XXX O
; XXX O
P XXX O
= XXX O
0 XXX O
. XXX O
045 XXX O
) XXX O
. XXX O

The XXX O
interrelation XXX O
of XXX O
the XXX O
levels XXX O
of XXX O
glucocorticoids XXX O
and XXX O
insulin XXX B-GENE
in XXX O
the XXX O
blood XXX O
of XXX O
irradiated XXX O
animals XXX O
. XXX O

CYP2C19 XXX B-GENE
genotype XXX I-GENE
was XXX O
determined XXX O
by XXX O
the XXX O
polymerase XXX O
chain XXX O
reaction-restriction XXX O
fragment XXX O
length XXX O
polymorphism XXX O
method XXX O
. XXX O

The XXX O
results XXX O
demonstrate XXX O
that XXX O
the XXX O
Glc7 XXX B-GENE
phosphatase XXX I-GENE
and XXX O
its XXX O
Gac1 XXX B-GENE
regulatory XXX O
subunit XXX O
play XXX O
positive XXX O
roles XXX O
in XXX O
HSF XXX B-GENE
activation XXX O
of XXX O
CUP1 XXX B-GENE
transcription XXX O
. XXX O

Most XXX O
of XXX O
them XXX O
were XXX O
situated XXX O
at XXX O
Sylvius XXX O
fissure XXX O
( XXX O
13 XXX O
cases XXX O
) XXX O
. XXX O

This XXX O
inhibition XXX O
can XXX O
be XXX O
overcome XXX O
by XXX O
mutating XXX O
either XXX O
the XXX O
exon's XXX O
5' XXX O
or XXX O
3' XXX O
splice XXX O
site XXX O
to XXX O
make XXX O
it XXX O
correspond XXX O
more XXX O
closely XXX O
to XXX O
the XXX O
relevant XXX O
consensus XXX O
sequence XXX O
. XXX O

A XXX O
database XXX O
search XXX O
has XXX O
revealed XXX O
as XXX O
the XXX O
most XXX O
significative XXX O
homology XXX O
a XXX O
match XXX O
with XXX O
the XXX O
human XXX B-GENE
mitochondrial XXX I-GENE
transcription XXX I-GENE
termination XXX I-GENE
factor XXX I-GENE
( XXX O
mTERF XXX B-GENE
) XXX O
, XXX O
a XXX O
protein XXX O
that XXX O
also XXX O
binds XXX O
DNA XXX O
as XXX O
a XXX O
monomer XXX O
and XXX O
contains XXX O
three XXX O
leucine XXX O
zippers XXX O
forming XXX O
intramolecular XXX O
interactions XXX O
. XXX O

PRH75 XXX B-GENE
, XXX O
a XXX O
new XXX O
nucleus-localized XXX O
member XXX O
of XXX O
the XXX O
DEAD-box XXX B-GENE
protein XXX I-GENE
family XXX I-GENE
from XXX O
higher XXX O
plants XXX O
. XXX O

Furthermore XXX O
, XXX O
the XXX O
negative XXX O
transcriptional XXX O
effect XXX O
of XXX O
COUP-TFs XXX B-GENE
is XXX O
dominant XXX O
over XXX O
the XXX O
activating XXX O
effect XXX O
of XXX O
the XXX O
Oct4 XXX B-GENE
embryonic XXX I-GENE
stem XXX I-GENE
cell-specific XXX I-GENE
enhancer XXX I-GENE
. XXX O

Point XXX O
mutations XXX O
in XXX O
the XXX O
third XXX O
SH3 XXX B-GENE
domain XXX I-GENE
abolished XXX O
the XXX O
vinexin-Sos XXX B-GENE
interaction XXX O
. XXX O

We XXX O
have XXX O
isolated XXX O
a XXX O
new XXX O
, XXX O
larger XXX O
rat XXX B-GENE
B-myc XXX I-GENE
genomic XXX I-GENE
clone XXX I-GENE
. XXX O

Cholesterol XXX B-GENE
side-chain XXX I-GENE
cleavage XXX I-GENE
cytochrome XXX I-GENE
P450 XXX I-GENE
( XXX O
CYP11A XXX B-GENE
; XXX O
P450scc XXX B-GENE
) XXX O
gene XXX O
expression XXX O
is XXX O
regulated XXX O
by XXX O
gonadotropins XXX B-GENE
via XXX O
cAMP XXX O
in XXX O
the XXX O
ovary XXX O
and XXX O
by XXX O
ACTH XXX B-GENE
via XXX O
cAMP XXX O
in XXX O
adrenal XXX O
cortical XXX O
cells XXX O
. XXX O

Stable XXX O
patients XXX O
have XXX O
mucous XXX O
hypersecretion XXX O
and XXX O
little XXX O
evidence XXX O
of XXX O
acute XXX O
inflammation XXX O
. XXX O

Selenium XXX O
status XXX O
of XXX O
thoroughbreds XXX O
in XXX O
the XXX O
United XXX O
Kingdom XXX O
. XXX O

The XXX O
carcinoma XXX O
was XXX O
restricted XXX O
within XXX O
the XXX O
epithelium XXX O
in XXX O
one XXX O
, XXX O
the XXX O
mucosal XXX O
layer XXX O
in XXX O
five XXX O
, XXX O
and XXX O
the XXX O
submucosal XXX O
layer XXX O
in XXX O
two XXX O
. XXX O

During XXX O
the XXX O
last XXX O
6 XXX O
months XXX O
of XXX O
the XXX O
study XXX O
a XXX O
striking XXX O
change XXX O
in XXX O
epidemiology XXX O
concerning XXX O
hepatitis XXX O
A XXX O
was XXX O
seen XXX O
, XXX O
apparently XXX O
caused XXX O
by XXX O
a XXX O
steep XXX O
increase XXX O
in XXX O
the XXX O
incidence XXX O
of XXX O
this XXX O
type XXX O
of XXX O
hepatitis XXX O
among XXX O
drug XXX O
addicts XXX O
. XXX O

In XXX O
two-field XXX O
nodal XXX O
dissection XXX O
, XXX O
two XXX O
components XXX O
are XXX O
included XXX O
with XXX O
( XXX O
modern XXX O
two-field XXX O
) XXX O
or XXX O
without XXX O
( XXX O
traditional XXX O
two-field XXX O
) XXX O
nodal XXX O
dissection XXX O
around XXX O
both XXX O
recurrent XXX O
laryngeal XXX O
nerve XXX O
chains XXX O
in XXX O
the XXX O
upper XXX O
mediastinum XXX O
. XXX O

Comparison XXX O
of XXX O
the XXX O
p50 XXX B-GENE
sequence XXX I-GENE
to XXX O
other XXX O
cloned XXX O
proteins XXX O
revealed XXX O
89% XXX O
homology XXX O
with XXX O
a XXX O
glycosaminoglycan-binding XXX O
protein XXX O
and XXX O
54% XXX O
homology XXX O
with XXX O
Drosophila XXX B-GENE
cell XXX I-GENE
cycle XXX I-GENE
control XXX I-GENE
protein XXX I-GENE
( XXX I-GENE
cdc XXX I-GENE
) XXX I-GENE
37 XXX O
. XXX O

The XXX O
metabolism XXX O
and XXX O
pharmacology XXX O
of XXX O
5-fluorouracil XXX O
. XXX O

Structure-function XXX O
analysis XXX O
of XXX O
the XXX O
Z-DNA-binding XXX O
domain XXX O
Zalpha XXX O
of XXX O
dsRNA XXX B-GENE
adenosine XXX I-GENE
deaminase XXX I-GENE
type XXX I-GENE
I XXX I-GENE
reveals XXX O
similarity XXX O
to XXX O
the XXX O
( XXX O
alpha XXX O
+ XXX O
beta XXX O
) XXX O
family XXX O
of XXX O
helix-turn-helix XXX O
proteins XXX O
. XXX O

L XXX O
. XXX O
, XXX O
Stange XXX O
, XXX O
G XXX O
. XXX O
, XXX O
Markovich XXX O
, XXX O
D XXX O
. XXX O
, XXX O
Biber XXX O
, XXX O
J XXX O
. XXX O
, XXX O
Testar XXX O
, XXX O
X XXX O
. XXX O
, XXX O
Zorzano XXX O
, XXX O
A XXX O
. XXX O
, XXX O
Palacin XXX O
, XXX O
M XXX O
. XXX O
, XXX O
and XXX O
Murer XXX O
, XXX O
H XXX O
. XXX O

The XXX O
GRE XXX B-GENE
at XXX O
nucleotide XXX O
7640 XXX O
is XXX O
a XXX O
composite XXX B-GENE
GRE XXX I-GENE
( XXX O
cGRE XXX B-GENE
) XXX O
containing XXX O
an XXX O
overlapping XXX O
activator XXX B-GENE
protein-1 XXX I-GENE
( XXX O
AP-1 XXX B-GENE
) XXX O
motif XXX O
for XXX O
the XXX O
c-jun XXX B-GENE
homodimer XXX I-GENE
and XXX O
c-jun XXX B-GENE
/ XXX I-GENE
c-fos XXX I-GENE
heterodimer XXX I-GENE
. XXX O

Feline XXX O
leukemia XXX O
viruses XXX O
( XXX O
FeLVs XXX O
) XXX O
, XXX O
which XXX O
are XXX O
replication-competent XXX O
oncoretroviruses XXX O
of XXX O
the XXX O
domestic XXX O
cat XXX O
species XXX O
, XXX O
are XXX O
contagiously XXX O
transmitted XXX O
in XXX O
natural XXX O
environments XXX O
. XXX O

Altogether XXX O
our XXX O
data XXX O
indicate XXX O
that XXX O
PEDF XXX B-GENE
belongs XXX O
to XXX O
the XXX O
subgroup XXX O
of XXX O
noninhibitory XXX O
serpins XXX B-GENE
and XXX O
that XXX O
its XXX O
N-terminal XXX O
region XXX O
confers XXX O
a XXX O
neurite-promoting XXX O
activity XXX O
to XXX O
the XXX O
protein XXX O
. XXX O

Our XXX O
data XXX O
suggest XXX O
that XXX O
, XXX O
at XXX O
least XXX O
at XXX O
high XXX O
temperature XXX O
, XXX O
a XXX O
critical XXX O
minimal XXX O
level XXX O
of XXX O
Ypt XXX B-GENE
protein XXX I-GENE
prenylation XXX O
is XXX O
required XXX O
for XXX O
maintaining XXX O
vesicle XXX O
polarization XXX O
. XXX O

We XXX O
have XXX O
constructed XXX O
, XXX O
using XXX O
synthetic XXX O
DNA XXX O
oligonucleotides XXX O
, XXX O
a XXX O
U14 XXX B-GENE
snRNA XXX I-GENE
gene XXX I-GENE
which XXX O
has XXX O
been XXX O
positioned XXX O
behind XXX O
a XXX O
T7 XXX B-GENE
RNA XXX I-GENE
polymerase XXX I-GENE
promoter XXX I-GENE
site XXX I-GENE
and XXX O
then XXX O
inserted XXX O
into XXX O
a XXX O
plasmid XXX O
. XXX O

On XXX O
T2 XXX O
weighted XXX O
images XXX O
, XXX O
low XXX O
intensity XXX O
areas XXX O
in XXX O
the XXX O
thalamus XXX O
, XXX O
the XXX O
striatum XXX O
, XXX O
the XXX O
anterior XXX O
limb XXX O
of XXX O
the XXX O
internal XXX O
capsule XXX O
, XXX O
the XXX O
tegmentum XXX O
of XXX O
midbrain XXX O
, XXX O
high XXX O
intensity XXX O
areas XXX O
in XXX O
middle XXX O
cerebellar XXX O
peduncle XXX O
, XXX O
the XXX O
posterior XXX O
limb XXX O
of XXX O
the XXX O
internal XXX O
capsule XXX O
, XXX O
the XXX O
lateral XXX O
part XXX O
of XXX O
the XXX O
cerebral XXX O
peduncle XXX O
, XXX O
and XXX O
the XXX O
cerebral XXX O
white XXX O
matter XXX O
were XXX O
noted XXX O
. XXX O

Northern XXX O
blot XXX O
hybridization XXX O
demonstrated XXX O
that XXX O
HEP-COP XXX B-GENE
was XXX O
expressed XXX O
in XXX O
a XXX O
wide XXX O
range XXX O
of XXX O
human XXX O
adult XXX O
and XXX O
fetal XXX O
tissues XXX O
. XXX O

We XXX O
have XXX O
isolated XXX O
a XXX O
cosmid XXX O
containing XXX O
DNA XXX O
that XXX O
corresponds XXX O
to XXX O
the XXX O
site XXX O
of XXX O
transposon XXX O
insertion XXX O
in XXX O
257DH4 XXX O
and XXX O
have XXX O
localized XXX O
Tn5 XXX B-GENE
on XXX O
an XXX O
8 XXX B-GENE
. XXX I-GENE
0 XXX I-GENE
kb XXX I-GENE
EcoRI XXX I-GENE
fragment XXX I-GENE
. XXX O

A XXX O
complementary XXX O
DNA XXX O
was XXX O
isolated XXX O
from XXX O
Caenorhabditis XXX O
elegans XXX O
that XXX O
encoded XXX O
a XXX O
polypeptide XXX O
of XXX O
1438 XXX O
amino XXX O
acid XXX O
residues XXX O
, XXX O
CeGAP XXX B-GENE
, XXX O
which XXX O
contains XXX O
a XXX O
domain XXX O
with XXX O
sequence XXX O
similarity XXX O
to XXX O
the XXX O
COOH-terminal XXX B-GENE
segment XXX I-GENE
( XXX I-GENE
GTPase-activating XXX I-GENE
protein XXX I-GENE
region XXX I-GENE
) XXX I-GENE
of XXX O
Bcr XXX B-GENE
and XXX O
other XXX O
known XXX O
GTPase-activating XXX B-GENE
proteins XXX I-GENE
of XXX O
the XXX O
Rho XXX B-GENE
subfamily XXX I-GENE
. XXX O

PaO2 XXX O
threshold XXX O
was XXX O
determined XXX O
through XXX O
an XXX O
indwelling XXX O
O2 XXX O
sensor XXX O
catheter XXX O
. XXX O

The XXX O
results XXX O
of XXX O
a XXX O
quantitative XXX O
study XXX O
of XXX O
vasculosyncytial XXX O
membranes XXX O
in XXX O
123 XXX O
placentas XXX O
are XXX O
presented XXX O
. XXX O

The XXX O
Stryker XXX O
frame XXX O
modification XXX O
to XXX O
the XXX O
standard XXX O
Dornier XXX O
HM3 XXX O
lithotriptor XXX O
allows XXX O
for XXX O
improved XXX O
visualization XXX O
and XXX O
easier XXX O
localization XXX O
of XXX O
distal XXX O
ureteral XXX O
calculi XXX O
compared XXX O
to XXX O
the XXX O
standard XXX O
gantry XXX O
. XXX O

The XXX O
Ishasha XXX O
samples XXX O
show XXX O
a XXX O
range XXX O
encompassing XXX O
three XXX O
trophic XXX O
levels XXX O
. XXX O

Transfection XXX O
experiments XXX O
demonstrated XXX O
that XXX O
the XXX O
5'-flanking XXX O
region XXX O
( XXX O
-1894 XXX O
to XXX O
+37 XXX O
) XXX O
of XXX O
the XXX O
mStaf XXX B-GENE
gene XXX I-GENE
drives XXX O
transcription XXX O
in XXX O
mouse XXX O
NMuMG XXX O
cells XXX O
and XXX O
that XXX O
a XXX O
construct XXX O
containing XXX O
a XXX O
fragment XXX O
from XXX O
-387 XXX O
to XXX O
+37 XXX O
showed XXX O
the XXX O
highest XXX O
transcriptional XXX O
activity XXX O
. XXX O

A XXX O
DNase XXX B-GENE
I-hypersensitive XXX I-GENE
site XXX I-GENE
has XXX O
also XXX O
been XXX O
mapped XXX O
in XXX O
the XXX O
258-base XXX O
pair XXX O
enhancer XXX O
region XXX O
. XXX O

Human XXX B-GENE
PDK1 XXX I-GENE
is XXX O
homologous XXX O
to XXX O
the XXX O
Drosophila XXX B-GENE
protein XXX I-GENE
kinase XXX I-GENE
DSTPK61 XXX I-GENE
, XXX O
which XXX O
has XXX O
been XXX O
implicated XXX O
in XXX O
the XXX O
regulation XXX O
of XXX O
sex XXX O
differentiation XXX O
, XXX O
oogenesis XXX O
and XXX O
spermatogenesis XXX O
. XXX O

Phylogenetic XXX O
position XXX O
of XXX O
the XXX O
Phacotaceae XXX O
within XXX O
the XXX O
Chlamydophyceaeas XXX O
revealed XXX O
by XXX O
analysis XXX O
of XXX O
18S XXX B-GENE
rDNA XXX I-GENE
and XXX O
rbcL XXX B-GENE
sequences XXX I-GENE
. XXX O

Additional XXX O
studies XXX O
with XXX O
new XXX O
and XXX O
reprocessed XXX O
regenerated XXX O
cellulose XXX O
dialyzers XXX O
comparing XXX O
450 XXX O
and XXX O
220 XXX O
mL XXX O
/ XXX O
min XXX O
blood XXX O
flow XXX O
rates XXX O
at XXX O
10 XXX O
minutes XXX O
showed XXX O
no XXX O
change XXX O
in XXX O
BTG XXX O
. XXX O

S XXX O
. XXX O
, XXX O
and XXX O
Walter XXX O
, XXX O
P XXX O
. XXX O

M-66 XXX B-GENE
identified XXX O
the XXX O
14-kDa XXX O
protein XXX O
in XXX O
another XXX O
MMTV XXX O
bearing XXX O
T-cell XXX O
lymphoma XXX O
, XXX O
EL-4 XXX O
. XXX O

A XXX O
significant XXX O
correlation XXX O
between XXX O
a XXX O
number XXX O
of XXX O
functional XXX O
parameters XXX O
of XXX O
gastric XXX O
secretion XXX O
, XXX O
incretion XXX O
and XXX O
histological XXX O
changes XXX O
of XXX O
gastric XXX O
mucosa XXX O
was XXX O
found XXX O
in XXX O
patients XXX O
with XXX O
chronic XXX O
gastritis XXX O
. XXX O

These XXX O
mutations XXX O
, XXX O
when XXX O
placed XXX O
in XXX O
a XXX O
wild-type XXX B-GENE
fliF XXX I-GENE
background XXX O
, XXX O
had XXX O
no XXX O
mutant XXX O
phenotype XXX O
. XXX O

65 XXX O
, XXX O
3829-3838 XXX O
, XXX O
1991 XXX O
) XXX O
, XXX O
a XXX O
truncated XXX O
form XXX O
of XXX O
the XXX O
IE XXX B-GENE
polypeptide XXX I-GENE
lacking XXX O
IE XXX B-GENE
amino XXX I-GENE
acid XXX I-GENE
residues XXX I-GENE
1-322 XXX I-GENE
( XXX O
and XXX O
, XXX O
therefore XXX O
lacks XXX O
the XXX O
deduced XXX O
transcriptional XXX O
activation XXX O
domain XXX O
) XXX O
, XXX O
fails XXX O
to XXX O
transactivate XXX O
the XXX O
EHV-1 XXX B-GENE
tk XXX I-GENE
promoter XXX I-GENE
, XXX O
but XXX O
retains XXX O
the XXX O
ability XXX O
to XXX O
down-regulate XXX O
the XXX O
EHV-1 XXX B-GENE
IE XXX I-GENE
promoter XXX I-GENE
. XXX O

Seven XXX O
out XXX O
of XXX O
34 XXX O
patients XXX O
died XXX O
, XXX O
giving XXX O
a XXX O
mortality XXX O
rate XXX O
of XXX O
21% XXX O
. XXX O

The XXX O
pseudolymphoma XXX O
syndrome XXX O
is XXX O
a XXX O
reversible XXX O
reactive XXX O
condition XXX O
consisting XXX O
of XXX O
fever XXX O
, XXX O
lymphadenopathy XXX O
and XXX O
generalized XXX O
rash XXX O
. XXX O

Large XXX O
interpatient XXX O
variation XXX O
in XXX O
peak XXX O
PCZ XXX O
plasma XXX O
levels XXX O
( XXX O
91-3215 XXX O
ng XXX O
/ XXX O
ml XXX O
) XXX O
was XXX O
seen XXX O
, XXX O
with XXX O
the XXX O
plasma XXX O
half-life XXX O
( XXX O
t1 XXX O
/ XXX O
2 XXX O
alpha XXX O
) XXX O
being XXX O
approximately XXX O
57 XXX O
min XXX O
in XXX O
patients XXX O
given XXX O
135-180 XXX O
mg XXX O
/ XXX O
m2 XXX O
PCZ XXX O
. XXX O

Intravenous XXX O
gamma XXX B-GENE
globulins XXX I-GENE
. XXX O

G-CSF XXX B-GENE
was XXX O
started XXX O
on XXX O
day XXX O
3 XXX O
of XXX O
each XXX O
cycle XXX O
( XXX O
5 XXX O
microg XXX O
/ XXX O
kg XXX O
/ XXX O
day XXX O
) XXX O
and XXX O
was XXX O
stopped XXX O
the XXX O
day XXX O
before XXX O
the XXX O
last XXX O
apheresis XXX O
or XXX O
when XXX O
absolute XXX O
neutrophil XXX O
count XXX O
was XXX O
above XXX O
0 XXX O
. XXX O
5 XXX O
x XXX O
10 XXX O
( XXX O
9 XXX O
) XXX O
/ XXX O
l XXX O
. XXX O

Experiment XXX O
3 XXX O
showed XXX O
that XXX O
the XXX O
long-term XXX O
analgesic XXX O
reaction XXX O
could XXX O
also XXX O
be XXX O
reduced XXX O
by XXX O
administration XXX O
of XXX O
naltrexone XXX O
prior XXX O
to XXX O
reexposure XXX O
to XXX O
shock XXX O
. XXX O

The XXX O
protein XXX O
expressed XXX O
from XXX O
the XXX O
cloned XXX O
cDNA XXX O
is XXX O
secreted XXX O
into XXX O
the XXX O
culture XXX O
medium XXX O
and XXX O
yields XXX O
of XXX O
up XXX O
to XXX O
40 XXX O
mg XXX O
per XXX O
litre XXX O
have XXX O
been XXX O
obtained XXX O
. XXX O

Acetoin-dependent XXX O
expression XXX O
of XXX O
the XXX O
acoABCD XXX B-GENE
operon XXX I-GENE
could XXX O
be XXX O
restored XXX O
in XXX O
the XXX O
E XXX B-GENE
. XXX I-GENE
coli XXX I-GENE
acoK XXX I-GENE
mutants XXX I-GENE
by XXX O
supplying XXX O
a XXX O
plasmid XXX O
carrying XXX O
an XXX O
intact XXX O
acoK XXX B-GENE
, XXX O
suggesting XXX O
a XXX O
transactivating XXX O
function XXX O
of XXX O
the XXX O
gene XXX O
product XXX O
. XXX O

Activation XXX O
of XXX O
transcription XXX O
through XXX O
the XXX O
AP-1 XXX B-GENE
site XXX I-GENE
in XXX O
Jurkat XXX O
cells XXX O
by XXX O
JunD XXX B-GENE
and XXX O
/ XXX O
or XXX O
Fra-2 XXX B-GENE
was XXX O
weak XXX O
. XXX O
c-Jun XXX B-GENE
, XXX O
JunB XXX B-GENE
, XXX O
and XXX O
c-Fos XXX B-GENE
activation XXX O
was XXX O
greater XXX O
, XXX O
although XXX O
the XXX O
level XXX O
was XXX O
still XXX O
less XXX O
than XXX O
that XXX O
with XXX O
Tax XXX B-GENE
. XXX O

Frequency XXX O
of XXX O
seeing XXX O
curves XXX O
were XXX O
examined XXX O
for XXX O
the XXX O
method XXX O
most XXX O
similar XXX O
to XXX O
FDT XXX O
. XXX O

Estradiol XXX O
is XXX O
known XXX O
to XXX O
induce XXX O
expression XXX O
of XXX O
certain XXX O
proto-oncogenes XXX O
, XXX O
and XXX O
this XXX O
led XXX O
us XXX O
to XXX O
examine XXX O
potential XXX O
regulatory XXX O
regions XXX O
of XXX O
the XXX O
cellular XXX B-GENE
c-fos XXX I-GENE
oncogene XXX I-GENE
. XXX O

Also XXX O
, XXX O
the XXX O
deduced XXX O
amino XXX O
acids XXX O
of XXX O
the XXX O
antigenic XXX B-GENE
regions XXX I-GENE
A XXX I-GENE
, XXX I-GENE
B XXX I-GENE
and XXX I-GENE
C XXX I-GENE
of XXX I-GENE
VP7 XXX I-GENE
were XXX O
nearly XXX O
conserved XXX O
within XXX O
the XXX O
phylogenetic XXX O
lineages XXX O
. XXX O

The XXX O
MMA XXX B-GENE
, XXX I-GENE
DMA XXX I-GENE
, XXX I-GENE
and XXX I-GENE
TMA XXX I-GENE
methyltransferases XXX I-GENE
are XXX O
not XXX O
homologs XXX O
; XXX O
however XXX O
, XXX O
like XXX O
the XXX O
MMA XXX B-GENE
methyltransferase XXX I-GENE
gene XXX I-GENE
, XXX O
the XXX O
genes XXX O
encoding XXX O
the XXX O
DMA XXX B-GENE
and XXX I-GENE
TMA XXX I-GENE
methyltransferases XXX I-GENE
each XXX O
contain XXX O
a XXX O
single XXX O
in-frame XXX O
amber XXX O
codon XXX O
. XXX O

Mutational XXX O
analysis XXX O
of XXX O
mammalian XXX B-GENE
translation XXX I-GENE
initiation XXX I-GENE
factor XXX I-GENE
5 XXX I-GENE
( XXX O
eIF5 XXX B-GENE
) XXX O
: XXX O
role XXX O
of XXX O
interaction XXX O
between XXX O
the XXX O
beta XXX O
subunit XXX O
of XXX O
eIF2 XXX B-GENE
and XXX O
eIF5 XXX B-GENE
in XXX O
eIF5 XXX B-GENE
function XXX O
in XXX O
vitro XXX O
and XXX O
in XXX O
vivo XXX O
. XXX O

DNA XXX O
methylation XXX O
, XXX O
especially XXX O
of XXX O
either XXX O
one XXX O
or XXX O
both XXX O
of XXX O
the XXX O
deoxyadenosines XXX O
at XXX O
the XXX O
two XXX O
GATC XXX B-GENE
motifs XXX I-GENE
( XXX O
one XXX O
in XXX O
the XXX O
first XXX O
exon XXX O
and XXX O
the XXX O
other XXX O
in XXX O
the XXX O
first XXX O
intron XXX O
of XXX O
the XXX O
rice XXX O
CatA XXX B-GENE
gene XXX I-GENE
) XXX O
, XXX O
appeared XXX O
to XXX O
be XXX O
responsible XXX O
for XXX O
the XXX O
CatA XXX B-GENE
promoter XXX I-GENE
activity XXX O
identified XXX O
in XXX O
the XXX O
transient XXX O
assay XXX O
. XXX O

Genetic XXX O
studies XXX O
in XXX O
Drosophila XXX O
have XXX O
led XXX O
to XXX O
the XXX O
identification XXX O
of XXX O
several XXX O
components XXX O
of XXX O
the XXX O
Notch XXX B-GENE
pathway XXX I-GENE
. XXX O

The XXX O
grandfather XXX O
and XXX O
the XXX O
granddaughter XXX O
both XXX O
had XXX O
microtia XXX O
and XXX O
meatal XXX O
atresia XXX O
, XXX O
whereas XXX O
the XXX O
daughter XXX O
had XXX O
a XXX O
normal XXX O
outer XXX O
ear XXX O
except XXX O
for XXX O
a XXX O
narrow XXX O
meatus XXX O
and XXX O
auricular XXX O
appendages XXX O
. XXX O

No XXX O
significant XXX O
differences XXX O
between XXX O
the XXX O
substituted XXX O
and XXX O
wild XXX O
type XXX O
peptides XXX O
were XXX O
observed XXX O
, XXX O
suggesting XXX O
that XXX O
this XXX O
substitution XXX O
in XXX O
the XXX O
intact XXX O
protein XXX O
may XXX O
cause XXX O
disruption XXX O
of XXX O
global XXX O
rather XXX O
than XXX O
local XXX O
structures XXX O
. XXX O

Competition XXX O
experiments XXX O
demonstrate XXX O
a XXX O
negative XXX O
allosteric XXX O
relationship XXX O
between XXX O
these XXX O
RGD XXX B-GENE
recognition XXX I-GENE
sites XXX I-GENE
. XXX O

The XXX O
favourable XXX O
effect XXX O
of XXX O
thymic XXX O
shielding XXX O
was XXX O
also XXX O
reflected XXX O
in XXX O
a XXX O
significant XXX O
increase XXX O
of XXX O
LD50 XXX O
/ XXX O
30 XXX O
, XXX O
and XXX O
the XXX O
dose XXX O
reduction XXX O
factor XXX O
was XXX O
equal XXX O
to XXX O
2 XXX O
. XXX O

As XXX O
shown XXX O
previously XXX O
, XXX O
EBNA2 XXX B-GENE
transactivates XXX O
the XXX O
promoters XXX O
of XXX O
the XXX O
viral XXX B-GENE
latent XXX I-GENE
membrane XXX I-GENE
proteins XXX I-GENE
. XXX O

Likewise XXX O
, XXX O
whether XXX O
or XXX O
not XXX O
the XXX O
hypotensive XXX O
action XXX O
of XXX O
converting XXX O
enzyme XXX O
inhibitors XXX O
is XXX O
age-related XXX O
is XXX O
as XXX O
yet XXX O
unknown XXX O
. XXX O

The XXX O
B XXX B-GENE
. XXX I-GENE
germanica XXX I-GENE
cyclophilin XXX I-GENE
amino XXX I-GENE
acid XXX I-GENE
sequence XXX I-GENE
shares XXX O
83% XXX O
identity XXX O
with XXX O
the XXX O
cytosolic XXX B-GENE
cyclophilin XXX I-GENE
isoform XXX I-GENE
from XXX I-GENE
Drosophila XXX I-GENE
melanogaster XXX I-GENE
( XXX O
Cyp-1 XXX B-GENE
) XXX O
. XXX O

First XXX O
, XXX O
two XXX O
MCTs XXX O
using XXX O
a XXX O
long XXX O
electrode XXX O
, XXX O
3 XXX O
cm XXX O
in XXX O
size XXX O
, XXX O
were XXX O
performed XXX O
in XXX O
the XXX O
central XXX O
area XXX O
of XXX O
the XXX O
tumor XXX O
, XXX O
and XXX O
eight XXX O
MCTs XXX O
by XXX O
a XXX O
short XXX O
electrode XXX O
, XXX O
2 XXX O
cm XXX O
in XXX O
size XXX O
, XXX O
were XXX O
done XXX O
in XXX O
the XXX O
peripheral XXX O
and XXX O
surrounding XXX O
area XXX O
of XXX O
the XXX O
tumor XXX O
. XXX O

Factors XXX O
influencing XXX O
direct-immersion XXX O
( XXX O
DI XXX O
) XXX O
-SPME XXX O
process XXX O
were XXX O
also XXX O
checked XXX O
and XXX O
chosen XXX O
experimentally XXX O
. XXX O

Argatroban XXX O
may XXX O
be XXX O
more XXX O
effective XXX O
under XXX O
low XXX O
HC XXX B-GENE
II XXX I-GENE
conditions XXX O
because XXX O
of XXX O
its XXX O
potent XXX O
inhibition XXX O
of XXX O
thrombin XXX B-GENE
activity XXX O
at XXX O
sites XXX O
of XXX O
vascular XXX O
wall XXX O
damage XXX O
. XXX O

CONCLUSION XXX O
: XXX O
These XXX O
results XXX O
suggest XXX O
that XXX O
vibration-induced XXX O
neural XXX O
involvement XXX O
can XXX O
be XXX O
considered XXX O
neither XXX O
pure XXX O
digital XXX O
neuropathy XXX O
, XXX O
nor XXX O
definite XXX O
CTS XXX O
, XXX O
as XXX O
previously XXX O
described XXX O
. XXX O

Salivary XXX O
estradiol XXX O
17 XXX O
beta XXX O
( XXX O
E2-17 XXX O
beta XXX O
) XXX O
and XXX O
progesterone XXX O
( XXX O
P XXX O
) XXX O
were XXX O
determined XXX O
by XXX O
using XXX O
radioimmunoassay XXX O
techniques XXX O
in XXX O
30 XXX O
pregnant XXX O
females XXX O
in XXX O
the XXX O
first XXX O
, XXX O
second XXX O
and XXX O
third XXX O
trimesters XXX O
as XXX O
well XXX O
as XXX O
in XXX O
10 XXX O
non-pregnant XXX O
controls XXX O
during XXX O
the XXX O
luteal XXX O
phase XXX O
of XXX O
the XXX O
menstrual XXX O
cycle XXX O
. XXX O

Triton-disrupted XXX O
cells XXX O
retained XXX O
capacity XXX O
for XXX O
activation XXX O
of XXX O
the XXX O
pathway XXX O
by XXX O
both XXX O
peptide XXX B-GENE
growth XXX I-GENE
factors XXX I-GENE
and XXX O
by XXX O
addition XXX O
of XXX O
GTP-loaded XXX O
p21 XXX B-GENE
rasVal12 XXX I-GENE
. XXX O

In XXX O
vitro XXX O
transcription XXX O
extracts XXX O
from XXX O
ret1-1 XXX B-GENE
cells XXX O
terminate XXX O
less XXX O
efficiently XXX O
at XXX O
weak XXX O
transcription XXX O
termination XXX O
signals XXX O
than XXX O
those XXX O
from XXX O
RET1 XXX B-GENE
cells XXX O
, XXX O
using XXX O
a XXX O
variety XXX O
of XXX O
tRNA XXX O
templates XXX O
. XXX O

Liu XXX O
, XXX O
B XXX O
. XXX O

Strain XXX O
CFN037 XXX O
is XXX O
an XXX O
R XXX O
. XXX O
etli XXX O
mutant XXX O
induced XXX O
by XXX O
a XXX O
single XXX O
Tn5mob XXX B-GENE
insertion XXX O
in XXX O
the XXX O
promoter XXX O
region XXX O
of XXX O
the XXX O
thiCOGE XXX B-GENE
gene XXX I-GENE
cluster XXX I-GENE
. XXX O

The XXX O
gene XXX O
is XXX O
1 XXX O
, XXX O
139 XXX O
base XXX O
pairs XXX O
( XXX O
bp XXX O
) XXX O
long XXX O
, XXX O
and XXX O
, XXX O
like XXX O
other XXX O
members XXX O
of XXX O
the XXX O
SIG XXX B-GENE
family XXX I-GENE
, XXX O
the XXX O
beta XXX B-GENE
TG XXX I-GENE
gene XXX I-GENE
is XXX O
divided XXX O
into XXX O
3 XXX O
exons XXX O
. XXX O

The XXX O
rCBF XXX O
and XXX O
vasomotion XXX O
were XXX O
recorded XXX O
by XXX O
laser-doppler XXX O
fluxmetry XXX O
. XXX O

None XXX O
of XXX O
these XXX O
organic XXX O
manifestations XXX O
was XXX O
discovered XXX O
by XXX O
scintigraphic XXX O
means XXX O
. XXX O

TCZ XXX O
provides XXX O
quick XXX O
, XXX O
inexpensive XXX O
, XXX O
noninvasive XXX O
indication XXX O
of XXX O
tissue XXX O
necrosis XXX O
, XXX O
moderate-to-severe XXX O
intracranial XXX O
hemorrhage XXX O
, XXX O
and XXX O
delayed XXX O
brain XXX O
maturation XXX O
. XXX O

A XXX O
novel XXX O
myeloid-restricted XXX O
zebrafish XXX O
CCAAT XXX B-GENE
/ XXX I-GENE
enhancer-binding XXX I-GENE
protein XXX I-GENE
with XXX O
a XXX O
potent XXX O
transcriptional XXX O
activation XXX O
domain XXX O
. XXX O

The XXX O
alpha XXX O
T3-1 XXX O
cell XXX O
line XXX O
, XXX O
a XXX O
GnRH-responsive XXX O
gonadotroph XXX O
cell XXX O
line XXX O
developed XXX O
by XXX O
targeted XXX O
oncogenesis XXX O
in XXX O
transgenic XXX O
mice XXX O
, XXX O
was XXX O
used XXX O
to XXX O
study XXX O
regulation XXX O
of XXX O
the XXX O
glycoprotein XXX B-GENE
hormone XXX I-GENE
alpha-subunit XXX I-GENE
by XXX O
activin XXX B-GENE
. XXX O

The XXX O
therapy XXX O
with XXX O
a XXX O
H2-receptor XXX B-GENE
antagonist XXX O
is XXX O
less XXX O
effective XXX O
than XXX O
the XXX O
triple XXX O
therapies XXX O
with XXX O
omeprazole XXX O
or XXX O
lansoprazole XXX O
. XXX O

Finally XXX O
, XXX O
we XXX O
show XXX O
that XXX O
PhLP XXX B-GENE
complexes XXX O
, XXX O
at XXX O
least XXX O
partially XXX O
, XXX O
with XXX O
Gbetagamma XXX B-GENE
in XXX O
vivo XXX O
. XXX O

The XXX O
rhabdomyosarcoma XXX O
R1H XXX O
growing XXX O
on XXX O
the XXX O
right XXX O
flank XXX O
of XXX O
male XXX O
WAG XXX O
/ XXX O
Rij XXX O
rats XXX O
was XXX O
clamped XXX O
for XXX O
2 XXX O
or XXX O
4 XXX O
h XXX O
at XXX O
20 XXX O
degrees XXX O
C XXX O
or XXX O
37 XXX O
degrees XXX O
C XXX O
. XXX O

However XXX O
, XXX O
F-SRC-1 XXX B-GENE
mutant XXX I-GENE
lacking XXX O
CBP-interacting XXX B-GENE
domain XXX I-GENE
still XXX O
preserved XXX O
enhancing XXX O
activity XXX O
. XXX O

The XXX O
electrocardiogram XXX O
. XXX O

PAI-1 XXX B-GENE
levels XXX O
increased XXX O
significantly XXX O
in XXX O
patients XXX O
who XXX O
received XXX O
iohexol XXX O
but XXX O
not XXX O
in XXX O
those XXX O
who XXX O
received XXX O
ioxaglate XXX O
. XXX O

Development XXX O
of XXX O
basophilic XXX O
leukemia XXX O
with XXX O
trisomy XXX O
8 XXX O
and XXX O
atypical XXX O
erythroblastosis XXX O
in XXX O
a XXX O
patient XXX O
with XXX O
a XXX O
history XXX O
of XXX O
aplastic XXX O
anemia XXX O
22 XXX O
years XXX O
earlier XXX O
. XXX O

A XXX O
polypeptide XXX O
encoded XXX O
by XXX O
the XXX O
NTS XXX O
16 XXX O
open XXX O
reading XXX O
frame XXX O
has XXX O
sequence XXX O
similarity XXX O
to XXX O
the XXX O
catalytic XXX O
domain XXX O
of XXX O
several XXX O
receptor XXX B-GENE
protein XXX I-GENE
kinases XXX I-GENE
from XXX I-GENE
plants XXX I-GENE
including XXX O
the XXX O
S-receptor XXX B-GENE
kinases XXX I-GENE
implicated XXX O
in XXX O
the XXX O
rejection XXX O
of XXX O
self-pollen XXX O
in XXX O
Brassica XXX O
species XXX O
and XXX O
the XXX O
Pto XXX B-GENE
gene XXX I-GENE
product XXX I-GENE
of XXX I-GENE
tomato XXX I-GENE
which XXX O
confers XXX O
resistance XXX O
to XXX O
a XXX O
bacterial XXX O
pathogen XXX O
. XXX O

Spontaneous XXX O
sensitization XXX O
to XXX O
cross-reacting XXX O
chemicals XXX O
in XXX O
a XXX O
proportion XXX O
of XXX O
control XXX O
animals XXX O
is XXX O
strongly XXX O
suggested XXX O
, XXX O
somewhat XXX O
akin XXX O
to XXX O
spontaneous XXX O
sensitization XXX O
in XXX O
patients XXX O
with XXX O
anaphylactoid XXX O
reactions XXX O
to XXX O
neuromuscular XXX O
blockers XXX O
on XXX O
first XXX O
exposure XXX O
, XXX O
and XXX O
in XXX O
whom XXX O
IgE XXX B-GENE
antibodies XXX I-GENE
are XXX O
detected XXX O
. XXX O

Improving XXX O
fissure XXX O
sealant XXX O
quality XXX O
: XXX O
mechanical XXX O
preparation XXX O
and XXX O
filling XXX O
level XXX O
. XXX O

Do XXX O
overall XXX O
treatment XXX O
time XXX O
, XXX O
field XXX O
size XXX O
, XXX O
and XXX O
treatment XXX O
energy XXX O
influence XXX O
local XXX O
control XXX O
of XXX O
T1-T2 XXX O
squamous XXX O
cell XXX O
carcinomas XXX O
of XXX O
the XXX O
glottic XXX O
larynx XXX O
? XXX O
PURPOSE XXX O
: XXX O
To XXX O
evaluate XXX O
treatment XXX O
and XXX O
patient XXX O
related XXX O
prognostic XXX O
factors XXX O
that XXX O
may XXX O
influence XXX O
local XXX O
control XXX O
in XXX O
the XXX O
treatment XXX O
of XXX O
T1-T2 XXX O
squamous XXX O
cell XXX O
carcinoma XXX O
of XXX O
the XXX O
glottic XXX O
larynx XXX O
. XXX O

These XXX O
results XXX O
demonstrate XXX O
the XXX O
existence XXX O
of XXX O
different XXX O
PI XXX B-GENE
3-kinase XXX I-GENE
isoforms XXX I-GENE
and XXX O
define XXX O
a XXX O
family XXX O
of XXX O
genes XXX O
encoding XXX O
distinct XXX O
PI XXX B-GENE
3-kinase XXX I-GENE
catalytic XXX I-GENE
subunits XXX I-GENE
that XXX O
can XXX O
associate XXX O
with XXX O
p85 XXX B-GENE
. XXX O

Cognate XXX O
promoter XXX O
elements XXX O
implicated XXX O
in XXX O
glucocorticoid- XXX O
and XXX O
cAMP-mediated XXX O
regulation XXX O
as XXX O
well XXX O
as XXX O
in XXX O
liver- XXX O
, XXX O
myeloid- XXX O
, XXX O
and XXX O
lymphocyte-specific XXX O
expression XXX O
are XXX O
located XXX O
within XXX O
the XXX O
5' XXX O
flanking XXX O
sequence XXX O
. XXX O

Residues XXX O
removed XXX O
from XXX O
transcripts XXX O
by XXX O
splicing XXX O
were XXX O
identified XXX O
. XXX O

An XXX O
outbreak XXX O
of XXX O
hepatitis XXX O
A XXX O
among XXX O
homosexual XXX O
men XXX O
in XXX O
Amsterdam XXX O
, XXX O
1991-1993 XXX O
. XXX O

The XXX O
differential XXX O
investigation XXX O
of XXX O
lipoproteins XXX O
, XXX O
however XXX O
, XXX O
showed XXX O
that XXX O
the XXX O
high-density XXX O
lipoprotein XXX O
( XXX O
HDL XXX O
) XXX O
fractions XXX O
are XXX O
absolutely XXX O
or XXX O
relatively XXX O
decreased XXX O
with XXX O
respect XXX O
to XXX O
low-density XXX B-GENE
lipoproteins XXX I-GENE
( XXX O
LDL XXX B-GENE
) XXX O
in XXX O
cerebral XXX O
infarcts XXX O
and XXX O
in XXX O
transient XXX O
ischaemic XXX O
attacks XXX O
. XXX O

Auto- XXX O
and XXX O
isotopy XXX O
of XXX O
the XXX O
conjunctiva XXX O
. XXX O

Prazosin XXX O
alone XXX O
was XXX O
effective XXX O
in XXX O
volume XXX O
responsive XXX O
patients XXX O
at XXX O
a XXX O
dose XXX O
of XXX O
5 XXX O
+ XXX O
/ XXX O
- XXX O
1 XXX O
. XXX O
0 XXX O
mg XXX O
daily XXX O
. XXX O

Diethylene XXX O
benzene XXX O
. XXX O

Coexisting XXX O
vertical XXX O
and XXX O
horizontal XXX O
one XXX O
and XXX O
a XXX O
half XXX O
syndromes XXX O
. XXX O

Recently XXX O
, XXX O
studies XXX O
of XXX O
agents XXX O
that XXX O
disrupt XXX O
collagen XXX B-GENE
synthesis XXX O
and XXX O
deposition XXX O
have XXX O
yielded XXX O
several XXX O
new XXX O
angiogenesis XXX O
inhibitors XXX O
. XXX O

A XXX O
single XXX O
exon XXX O
encodes XXX O
the XXX O
carboxyl-terminal XXX O
26 XXX O
amino XXX O
acids XXX O
of XXX O
the XXX O
ssd XXX B-GENE
chain XXX I-GENE
and XXX O
the XXX O
3' XXX O
untranslated XXX O
region XXX O
of XXX O
its XXX O
mRNA XXX O
, XXX O
ending XXX O
with XXX O
a XXX O
poly XXX O
( XXX O
A XXX O
) XXX O
-addition XXX O
site XXX O
. XXX O

Mutational XXX O
analysis XXX O
of XXX O
the XXX O
-84 XXX O
/ XXX O
-55 XXX O
DNA XXX O
showed XXX O
that XXX O
JEG-3 XXX B-GENE
nuclear XXX I-GENE
proteins XXX I-GENE
bound XXX O
to XXX O
a XXX O
site XXX O
containing XXX O
, XXX O
but XXX O
not XXX O
identical XXX O
to XXX O
, XXX O
the XXX O
SF-1 XXX B-GENE
sequence XXX I-GENE
. XXX O

The XXX O
sequenced XXX O
cDNA XXX O
predicts XXX O
a XXX O
704-amino XXX O
acid XXX O
protein XXX O
80% XXX O
identical XXX O
to XXX O
human XXX B-GENE
progelatinase XXX I-GENE
B XXX I-GENE
. XXX O

RESULT XXX O
( XXX O
S XXX O
) XXX O
: XXX O
In XXX O
patients XXX O
with XXX O
elevated XXX O
FSH XXX B-GENE
levels XXX O
on XXX O
cycle XXX O
day XXX O
3 XXX O
, XXX O
a XXX O
low XXX O
oocyte XXX O
yield XXX O
was XXX O
achieved XXX O
( XXX O
7 XXX O
versus XXX O
11 XXX O
) XXX O
and XXX O
a XXX O
high XXX O
number XXX O
of XXX O
ampules XXX O
of XXX O
hMG XXX O
was XXX O
necessary XXX O
( XXX O
56 XXX O
versus XXX O
33 XXX O
) XXX O
. XXX O

Nrf2 XXX B-GENE
regulates XXX O
expression XXX O
of XXX O
genes XXX O
encoding XXX O
enzymes XXX O
with XXX O
antioxidant XXX O
( XXX O
e XXX O
. XXX O
g XXX O
. XXX O
heme XXX B-GENE
oxygenase-1 XXX I-GENE
( XXX O
HO-1 XXX B-GENE
) XXX O
) XXX O
or XXX O
xenobiotic XXX O
detoxification XXX O
( XXX O
e XXX O
. XXX O
g XXX O
. XXX O

Cardiovascular XXX O
and XXX O
adrenal XXX O
medullo-sympathetic XXX O
reactions XXX O
to XXX O
acute XXX O
tobacco XXX O
poisoning XXX O
. XXX O

This XXX O
in XXX O
turn XXX O
will XXX O
further XXX O
enhance XXX O
the XXX O
role XXX O
of XXX O
meta-analysis XXX O
in XXX O
helping XXX O
clinicians XXX O
and XXX O
policy XXX O
makers XXX O
answer XXX O
clinical XXX O
questions XXX O
. XXX O

Serum XXX B-GENE
response XXX I-GENE
factor XXX I-GENE
( XXX O
SRF XXX B-GENE
) XXX O
, XXX O
a XXX O
member XXX O
of XXX O
an XXX O
ancient XXX O
family XXX O
of XXX O
DNA-binding XXX O
proteins XXX O
, XXX O
is XXX O
generally XXX O
assumed XXX O
to XXX O
be XXX O
a XXX O
ubiquitous XXX O
transcription XXX O
factor XXX O
involved XXX O
in XXX O
regulating XXX O
growth XXX B-GENE
factor-responsive XXX I-GENE
genes XXX I-GENE
. XXX O

Proctoscopy XXX O
and XXX O
roentgenographic XXX O
studies XXX O
may XXX O
be XXX O
an XXX O
important XXX O
part XXX O
of XXX O
evaluation XXX O
, XXX O
especially XXX O
in XXX O
patients XXX O
who XXX O
present XXX O
with XXX O
perianal XXX O
suppuration XXX O
, XXX O
masses XXX O
, XXX O
or XXX O
anal XXX O
fissures XXX O
. XXX O

Human XXX B-GENE
MGP XXX I-GENE
is XXX O
a XXX O
10-kD XXX B-GENE
skeletal XXX I-GENE
extracellular XXX I-GENE
matrix XXX I-GENE
( XXX I-GENE
ECM XXX I-GENE
) XXX I-GENE
protein XXX I-GENE
that XXX O
consists XXX O
of XXX O
an XXX O
84-aa XXX O
mature XXX O
protein XXX O
and XXX O
a XXX O
19-aa XXX O
transmembrane XXX O
signal XXX O
peptide XXX O
. XXX O

By XXX O
directly XXX O
interacting XXX O
with XXX O
both XXX O
Arfs XXX B-GENE
and XXX O
tyrosine XXX B-GENE
kinases XXX I-GENE
involved XXX O
in XXX O
regulating XXX O
cell XXX O
growth XXX O
and XXX O
cytoskeletal XXX O
organization XXX O
, XXX O
ASAP1 XXX B-GENE
could XXX O
coordinate XXX O
membrane XXX O
remodeling XXX O
events XXX O
with XXX O
these XXX O
processes XXX O
. XXX O

In XXX O
cells XXX O
limited XXX O
for XXX O
His XXX O
, XXX O
increased XXX O
expression XXX O
of XXX O
arg-2 XXX B-GENE
and XXX O
cpc-1 XXX B-GENE
, XXX O
and XXX O
decreased XXX O
expression XXX O
of XXX O
cox-5 XXX B-GENE
, XXX O
also XXX O
had XXX O
translational XXX O
and XXX O
transcriptional XXX O
components XXX O
. XXX O

Review XXX O
: XXX O
deterioration XXX O
of XXX O
glucose XXX O
tolerance XXX O
with XXX O
age XXX O
: XXX O
the XXX O
role XXX O
of XXX O
insulin XXX B-GENE
resistance XXX O
. XXX O

Resistance XXX O
pattern XXX O
of XXX O
Mycobacterium XXX O
tuberculosis XXX O
( XXX O
H XXX O
37 XXX O
Rv XXX O
) XXX O
to XXX O
a XXX O
new XXX O
antibiotic XXX O
, XXX O
lividomycin XXX O
. XXX O

Subsequent XXX O
experiments XXX O
showed XXX O
that XXX O
motoric XXX O
tasks XXX O
rather XXX O
than XXX O
cognitive XXX O
aspects XXX O
of XXX O
the XXX O
COWA XXX O
task XXX O
were XXX O
critical XXX O
in XXX O
potentiating XXX O
finger-tapping XXX O
performance XXX O
. XXX O

Mutational XXX O
studies XXX O
provide XXX O
evidence XXX O
to XXX O
this XXX O
end XXX O
and XXX O
indicate XXX O
that XXX O
the XXX O
side XXX O
chains XXX O
of XXX O
subdomain XXX O
4 XXX O
. XXX O
2 XXX O
make XXX O
specific XXX O
contacts XXX O
with XXX O
the XXX O
nucleotides XXX O
at XXX O
-35 XXX O
. XXX O

These XXX O
data XXX O
reveal XXX O
a XXX O
complex XXX O
network XXX O
of XXX O
interactions XXX O
between XXX O
GTPases XXX B-GENE
in XXX O
the XXX O
ARF XXX B-GENE
family XXX I-GENE
and XXX O
their XXX O
effectors XXX O
and XXX O
reveal XXX O
a XXX O
potential XXX O
for XXX O
cross-talk XXX O
not XXX O
demonstrated XXX O
previously XXX O
. XXX O

Sex XXX O
ratio XXX O
at XXX O
birth XXX O
. XXX O

I XXX O
. XXX O

Using XXX O
mutated XXX B-GENE
IL2R XXX I-GENE
alpha XXX I-GENE
promoter XXX I-GENE
constructs XXX I-GENE
in XXX O
transient XXX O
transfection XXX O
and XXX O
DNA XXX O
binding XXX O
assays XXX O
, XXX O
we XXX O
now XXX O
demonstrate XXX O
that XXX O
sequences XXX O
located XXX O
immediately XXX O
upstream XXX O
and XXX O
downstream XXX O
of XXX O
the XXX O
kappa XXX B-GENE
B XXX I-GENE
enhancer XXX I-GENE
also XXX O
contribute XXX O
to XXX O
the XXX O
regulation XXX O
of XXX O
IL2R XXX B-GENE
alpha XXX I-GENE
gene XXX I-GENE
expression XXX O
. XXX O

A XXX O
single XXX O
case XXX O
of XXX O
an XXX O
adenocarcinoma XXX O
, XXX O
arising XXX O
in XXX O
a XXX O
retroperitoneal XXX O
enterogenous XXX O
cyst XXX O
and XXX O
which XXX O
presented XXX O
as XXX O
a XXX O
left XXX O
renal XXX O
cyst XXX O
, XXX O
is XXX O
reported XXX O
. XXX O

On XXX O
the XXX O
other XXX O
hand XXX O
, XXX O
the XXX O
structures XXX O
of XXX O
the XXX O
b-Zip XXX O
domain XXX O
are XXX O
well XXX O
conserved XXX O
among XXX O
these XXX O
Maf-related XXX B-GENE
proteins XXX I-GENE
. XXX O

On XXX O
line XXX O
calculation XXX O
of XXX O
steroid XXX O
concentrations XXX O
by XXX O
radioimmunoassay XXX O
. XXX O

At XXX O
each XXX O
level XXX O
of XXX O
PaO2 XXX O
we XXX O
obtained XXX O
simultaneous XXX O
measures XXX O
of XXX O
arterial XXX O
and XXX O
venous XXX O
blood XXX O
gases XXX O
, XXX O
venous XXX O
lactate XXX O
concentration XXX O
, XXX O
and XXX O
changes XXX O
in XXX O
the XXX O
relative XXX O
concentrations XXX O
of XXX O
inorganic XXX O
phosphate XXX O
, XXX O
phosphocreatine XXX O
, XXX O
and XXX O
ATP XXX O
measured XXX O
with XXX O
31P XXX O
magnetic XXX O
resonance XXX O
spectroscopy XXX O
. XXX O

Truncated XXX O
mammalian XXX B-GENE
Notch1 XXX I-GENE
activates XXX O
CBF1 XXX B-GENE
/ XXX I-GENE
RBPJk-repressed XXX I-GENE
genes XXX I-GENE
by XXX O
a XXX O
mechanism XXX O
resembling XXX O
that XXX O
of XXX O
Epstein-Barr XXX B-GENE
virus XXX I-GENE
EBNA2 XXX I-GENE
. XXX O

Immunohistochemically XXX O
, XXX O
anticytokeratin XXX B-GENE
19 XXX I-GENE
antibody XXX I-GENE
revealed XXX O
strong XXX O
staining XXX O
in XXX O
both XXX O
epithelial XXX O
and XXX O
sarcomatous XXX O
MPM XXX O
tissues XXX O
. XXX O

Lack XXX O
of XXX O
controlled XXX O
prospective XXX O
studies XXX O
of XXX O
sleep XXX O
electroencephalograms XXX O
( XXX O
EEG XXX O
) XXX O
, XXX O
and XXX O
the XXX O
use XXX O
of XXX O
medication XXX O
, XXX O
in XXX O
children XXX O
with XXX O
developmental XXX O
dysphasia XXX O
, XXX O
may XXX O
deny XXX O
appropriate XXX O
treatment XXX O
strategies XXX O
to XXX O
children XXX O
with XXX O
severe XXX O
developmental XXX O
speech XXX O
and XXX O
language XXX O
disorders XXX O
. XXX O

The XXX O
position XXX O
of XXX O
the XXX O
analyst XXX O
as XXX O
expert XXX O
: XXX O
yesterday XXX O
and XXX O
today XXX O
. XXX O

Nuclease XXX O
footprinting XXX O
revealed XXX O
that XXX O
purified XXX B-GENE
glucocorticoid XXX I-GENE
receptor XXX I-GENE
bound XXX O
at XXX O
multiple XXX O
discrete XXX O
sites XXX O
within XXX O
and XXX O
at XXX O
the XXX O
borders XXX O
of XXX O
the XXX O
tandemly XXX O
repeated XXX O
sequence XXX O
motif XXX O
that XXX O
defines XXX O
Sa XXX B-GENE
. XXX O

A XXX O
medical-geographical XXX O
review XXX O
. XXX O

Topical XXX O
L-NNA XXX O
attenuated XXX O
the XXX O
hypercapnic XXX O
increase XXX O
of XXX O
CoBF XXX O
by XXX O
52 XXX O
+ XXX O
/ XXX O
- XXX O
6% XXX O
and XXX O
CeBF XXX O
by XXX O
29 XXX O
+ XXX O
/ XXX O
- XXX O
5% XXX O
after XXX O
45-min XXX O
exposure XXX O
. XXX O

In XXX O
contrast XXX O
with XXX O
the XXX O
previously XXX O
reported XXX O
HMGR1 XXX B-GENE
mRNA XXX I-GENE
( XXX O
HMGR1S XXX B-GENE
mRNA XXX I-GENE
) XXX O
, XXX O
which XXX O
is XXX O
detected XXX O
at XXX O
high XXX O
levels XXX O
in XXX O
all XXX O
tissues XXX O
of XXX O
the XXX O
plant XXX O
, XXX O
HMGR1L XXX B-GENE
mRNA XXX I-GENE
is XXX O
present XXX O
at XXX O
relatively XXX O
low XXX O
levels XXX O
and XXX O
its XXX O
expression XXX O
is XXX O
restricted XXX O
mostly XXX O
to XXX O
seedlings XXX O
, XXX O
roots XXX O
and XXX O
inflorescences XXX O
. XXX O

This XXX O
study XXX O
provides XXX O
a XXX O
direct XXX O
demonstration XXX O
of XXX O
a XXX O
role XXX O
for XXX O
G XXX B-GENE
betagamma XXX I-GENE
in XXX O
mediating XXX O
the XXX O
agonist-stimulated XXX O
translocation XXX O
of XXX O
GRK2 XXX B-GENE
and XXX O
GRK3 XXX B-GENE
in XXX O
an XXX O
intact XXX O
cellular XXX O
system XXX O
and XXX O
demonstrates XXX O
isoform XXX O
specificity XXX O
in XXX O
the XXX O
interaction XXX O
of XXX O
these XXX O
components XXX O
. XXX O

The XXX O
sequences XXX O
following XXX O
the XXX O
X XXX O
. XXX O
borealis XXX O
oocyte XXX O
and XXX O
somatic XXX O
5S XXX B-GENE
genes XXX I-GENE
are XXX O
identical XXX O
in XXX O
12 XXX O
of XXX O
the XXX O
first XXX O
14 XXX O
residues XXX O
and XXX O
contain XXX O
two XXX O
or XXX O
more XXX O
T XXX O
clusters XXX O
, XXX O
as XXX O
does XXX O
the XXX O
corresponding XXX O
region XXX O
of XXX O
X XXX B-GENE
. XXX I-GENE
laevis XXX I-GENE
oocyte XXX I-GENE
5S XXX I-GENE
DNA XXX I-GENE
. XXX O

The XXX O
aim XXX O
of XXX O
this XXX O
study XXX O
was XXX O
to XXX O
find XXX O
out XXX O
whether XXX O
it XXX O
was XXX O
possible XXX O
to XXX O
detect XXX O
normal XXX O
lymph XXX O
nodes XXX O
by XXX O
high-resolution XXX O
mediastinal XXX O
US XXX O
. XXX O

While XXX O
mutations XXX O
in XXX O
K-Rev XXX B-GENE
that XXX O
inactivate XXX O
any XXX O
one XXX O
of XXX O
these XXX O
properties XXX O
also XXX O
blocked XXX O
K-Rev-dependent XXX O
nuclear XXX O
RNA XXX O
export XXX O
, XXX O
several XXX O
K-Rev XXX B-GENE
mutants XXX I-GENE
were XXX O
comparable XXX O
to XXX O
wild XXX O
type XXX O
when XXX O
assayed XXX O
for XXX O
any XXX O
of XXX O
these XXX O
individual XXX O
activities XXX O
yet XXX O
nevertheless XXX O
defective XXX O
for XXX O
RNA XXX O
export XXX O
. XXX O

A XXX O
randomized XXX O
, XXX O
prospective XXX O
study XXX O
was XXX O
conducted XXX O
to XXX O
compare XXX O
ovarian XXX O
stimulation XXX O
with XXX O
human XXX B-GENE
menopausal XXX I-GENE
gonadotropin XXX I-GENE
( XXX O
hMG XXX B-GENE
) XXX O
and XXX O
human XXX B-GENE
follicle-stimulating XXX I-GENE
hormone XXX I-GENE
( XXX O
hFSH XXX B-GENE
) XXX O
in XXX O
an XXX O
in XXX O
vitro XXX O
fertilization XXX O
and XXX O
embryo XXX O
transfer XXX O
( XXX O
IVF-ET XXX O
) XXX O
program XXX O
. XXX O

This XXX O
study XXX O
demonstrated XXX O
that XXX O
the XXX O
PFA-100 XXX O
analyzer XXX O
can XXX O
accurately XXX O
assess XXX O
vWF-dependent XXX O
platelet XXX O
function XXX O
and XXX O
detect XXX O
other XXX O
platelet XXX O
defects XXX O
under XXX O
high XXX O
shear XXX O
stress XXX O
in XXX O
complex XXX O
patient XXX O
populations XXX O
. XXX O

We XXX O
conducted XXX O
a XXX O
clinical XXX O
and XXX O
pathologic XXX O
review XXX O
of XXX O
nine XXX O
patients XXX O
with XXX O
immature XXX O
ovarian XXX O
teratoma XXX O
. XXX O

Approximately XXX O
60% XXX O
of XXX O
cell XXX O
bodies XXX O
of XXX O
primary XXX O
neurons XXX O
innervating XXX O
the XXX O
intra XXX O
and XXX O
perioral XXX O
structures XXX O
through XXX O
the XXX O
inferior XXX O
alveolar XXX O
, XXX O
lingual XXX O
, XXX O
mental XXX O
, XXX O
and XXX O
buccal XXX O
nerves XXX O
were XXX O
in XXX O
the XXX O
range XXX O
between XXX O
300 XXX O
and XXX O
600 XXX O
micron XXX O
2 XXX O
in XXX O
cross-sectional XXX O
area XXX O
: XXX O
mean XXX O
+ XXX O
/ XXX O
- XXX O
SD XXX O
509 XXX O
+ XXX O
/ XXX O
- XXX O
243 XXX O
micron XXX O
2 XXX O
, XXX O
420 XXX O
+ XXX O
/ XXX O
- XXX O
181 XXX O
micron XXX O
2 XXX O
, XXX O
469 XXX O
+ XXX O
/ XXX O
- XXX O
200 XXX O
micron XXX O
2 XXX O
, XXX O
and XXX O
444 XXX O
+ XXX O
/ XXX O
- XXX O
186 XXX O
micron XXX O
2 XXX O
, XXX O
respectively XXX O
. XXX O

ASL-8123 XXX O
demonstrated XXX O
weak XXX O
competitive XXX O
beta-adrenoreceptor XXX B-GENE
blocking XXX O
activity XXX O
in XXX O
isolated XXX O
guinea XXX O
pig XXX O
right XXX O
atria XXX O
with XXX O
a XXX O
pA2 XXX O
of XXX O
3 XXX O
. XXX O
73 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
07 XXX O
; XXX O
no XXX O
agonist-like XXX O
activity XXX O
was XXX O
observed XXX O
in XXX O
this XXX O
tissue XXX O
at XXX O
concentrations XXX O
of XXX O
ASL-8123 XXX O
from XXX O
3 XXX O
X XXX O
10 XXX O
( XXX O
-5 XXX O
) XXX O
to XXX O
1 XXX O
X XXX O
10 XXX O
( XXX O
-2 XXX O
) XXX O
M XXX O
. XXX O

As XXX O
with XXX O
the XXX O
heterologous XXX O
DNA XXX O
binding XXX O
domain XXX O
, XXX O
MZF-1 XXX B-GENE
represses XXX O
reporter XXX O
gene XXX O
expression XXX O
in XXX O
nonhematopoietic XXX O
cell XXX O
lines XXX O
and XXX O
activates XXX O
expression XXX O
in XXX O
hematopoietic XXX O
cell XXX O
lines XXX O
. XXX O

The XXX O
present XXX O
study XXX O
highlights XXX O
the XXX O
improvement XXX O
in XXX O
sputum XXX O
amoxycillin XXX O
( XXX O
amoxy XXX O
) XXX O
levels XXX O
when XXX O
a XXX O
combination XXX O
tablet XXX O
, XXX O
amoxy XXX O
500 XXX O
mg XXX O
plus XXX O
bromhexeine XXX O
8 XXX O
mg XXX O
, XXX O
is XXX O
administered XXX O
as XXX O
compared XXX O
to XXX O
plain XXX O
amoxy XXX O
500 XXX O
mg XXX O
. XXX O

Clin XXX O
. XXX O

Recovery XXX O
was XXX O
characterized XXX O
by XXX O
rapid XXX O
improvement XXX O
such XXX O
that XXX O
all XXX O
measured XXX O
parameters XXX O
normalized XXX O
by XXX O
1 XXX O
week XXX O
, XXX O
except XXX O
for XXX O
cross-sectional XXX O
cardiac XXX O
area XXX O
which XXX O
remained XXX O
dilated XXX O
up XXX O
to XXX O
4 XXX O
weeks XXX O
( XXX O
14 XXX O
+ XXX O
/ XXX O
- XXX O
3 XXX O
cm2 XXX O
, XXX O
p XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
05 XXX O
versus XXX O
control XXX O
) XXX O
. XXX O
( XXX O
ABSTRACT XXX O
TRUNCATED XXX O
AT XXX O
250 XXX O
WORDS XXX O
) XXX O

Harmful XXX O
effects XXX O
in XXX O
animals XXX O
and XXX O
man XXX O
may XXX O
result XXX O
from XXX O
both XXX O
deficient XXX O
or XXX O
excessive XXX O
amounts XXX O
of XXX O
intake XXX O
. XXX O

In XXX O
the XXX O
course XXX O
of XXX O
a XXX O
study XXX O
of XXX O
low XXX O
dose XXX O
X-rays XXX O
effects XXX O
, XXX O
we XXX O
found XXX O
that XXX O
male XXX O
ICR XXX O
white XXX O
Swiss XXX O
mice XXX O
showed XXX O
remarkable XXX O
suppression XXX O
of XXX O
mounting XXX O
behavior XXX O
after XXX O
whole XXX O
body XXX O
irradiation XXX O
by XXX O
5 XXX O
to XXX O
15 XXX O
cGy XXX O
X-rays XXX O
. XXX O

Three XXX O
sequence XXX O
elements XXX O
are XXX O
shown XXX O
to XXX O
be XXX O
required XXX O
for XXX O
accurate XXX O
and XXX O
efficient XXX O
transcription XXX O
termination XXX O
by XXX O
RNA XXX B-GENE
polymerase XXX I-GENE
I XXX I-GENE
( XXX O
pol XXX B-GENE
I XXX I-GENE
) XXX O
assayed XXX O
both XXX O
in XXX O
a XXX O
cell-free XXX O
transcription XXX O
system XXX O
and XXX O
in XXX O
vivo XXX O
after XXX O
transfection XXX O
of XXX O
rDNA XXX O
minigene XXX O
constructs XXX O
into XXX O
3T6 XXX O
cells XXX O
. XXX O

Simultaneous XXX O
determination XXX O
of XXX O
theophylline XXX O
and XXX O
its XXX O
metabolites XXX O
by XXX O
HPLC XXX O
A XXX O
high XXX O
performance XXX O
liquid XXX O
chromatography XXX O
( XXX O
HPLC XXX O
) XXX O
method XXX O
has XXX O
been XXX O
developed XXX O
for XXX O
the XXX O
simultaneous XXX O
determination XXX O
of XXX O
theophylline XXX O
and XXX O
its XXX O
metabolites XXX O
, XXX O
with XXX O
caffeine XXX O
and XXX O
its XXX O
metabolites XXX O
. XXX O

RESULTS XXX O
: XXX O
Glaucoma XXX O
suspects XXX O
were XXX O
divided XXX O
into XXX O
two XXX O
groups XXX O
according XXX O
to XXX O
their XXX O
SWAP XXX O
results XXX O
: XXX O
high XXX O
risk XXX O
( XXX O
with XXX O
SWAP XXX O
abnormalities XXX O
) XXX O
and XXX O
low XXX O
risk XXX O
( XXX O
with XXX O
normal XXX O
SWAP XXX O
result XXX O
) XXX O
. XXX O

Encompassing XXX O
tamponade XXX O
and XXX O
pericardiocentesis XXX O
data XXX O
, XXX O
left XXX O
ventricular XXX O
stroke XXX O
work XXX O
index XXX O
showed XXX O
positive XXX O
correlation XXX O
with XXX O
TMFP1 XXX O
( XXX O
r XXX O
= XXX O
. XXX O
59 XXX O
) XXX O
and XXX O
TMFP2 XXX O
( XXX O
r XXX O
= XXX O
. XXX O
52 XXX O
) XXX O
but XXX O
not XXX O
with XXX O
TMFP3 XXX O
. XXX O

Serum XXX B-GENE
alkaline XXX I-GENE
phosphatase XXX I-GENE
activity XXX O
, XXX O
bone XXX O
mass XXX O
measurements XXX O
, XXX O
dual XXX O
energy XXX O
x-ray XXX O
absortiometric XXX O
analysis XXX O
of XXX O
mineral XXX O
density XXX O
, XXX O
and XXX O
mechanical XXX O
testing XXX O
values XXX O
in XXX O
vertebrae XXX O
and XXX O
femora XXX O
of XXX O
the XXX O
-D XXX O
Sal XXX O
animals XXX O
did XXX O
not XXX O
significantly XXX O
differ XXX O
from XXX O
those XXX O
in XXX O
+D XXX O
Sal XXX O
animals XXX O
. XXX O

We XXX O
have XXX O
developed XXX O
a XXX O
rAAV-mediated XXX O
gene XXX O
transfer XXX O
system XXX O
for XXX O
the XXX O
rat XXX B-GENE
preproinsulin XXX I-GENE
II XXX I-GENE
gene XXX I-GENE
. XXX O

We XXX O
used XXX O
expression XXX O
cloning XXX O
to XXX O
identify XXX O
interleukin-6 XXX B-GENE
( XXX O
IL-6 XXX B-GENE
) XXX O
as XXX O
one XXX O
factor XXX O
that XXX O
suppressed XXX O
growth XXX O
of XXX O
a XXX O
pre-B-cell XXX O
variant XXX O
line XXX O
, XXX O
1A9-M XXX O
. XXX O

( XXX O
anti-IIa XXX O
) XXX O
and XXX O
Holmer XXX O
et XXX O
al XXX O
. XXX O

Using XXX O
5 XXX O
ng XXX O
/ XXX O
mL XXX O
as XXX O
the XXX O
cutoff XXX O
, XXX O
the XXX O
sensitivity XXX O
of XXX O
CEA XXX O
was XXX O
68% XXX O
. XXX O

APETALA3 XXX B-GENE
transcripts XXX I-GENE
are XXX O
first XXX O
detected XXX O
in XXX O
a XXX O
meristematic XXX O
region XXX O
that XXX O
will XXX O
give XXX O
rise XXX O
to XXX O
the XXX O
petal XXX O
and XXX O
stamen XXX O
primordia XXX O
, XXX O
and XXX O
expression XXX O
is XXX O
maintained XXX O
in XXX O
this XXX O
region XXX O
during XXX O
subsequent XXX O
development XXX O
of XXX O
these XXX O
organs XXX O
. XXX O

Primer XXX O
extension XXX O
experiments XXX O
showed XXX O
that XXX O
there XXX O
are XXX O
two XXX O
transcription XXX O
initiation XXX O
sites XXX O
16 XXX O
bp XXX O
apart XXX O
in XXX O
the XXX O
mouse XXX B-GENE
type XXX I-GENE
2 XXX I-GENE
receptor XXX I-GENE
gene XXX I-GENE
. XXX O

In XXX O
a XXX O
randomized XXX O
single-blind XXX O
3 XXX O
x XXX O
3 XXX O
Latin-square XXX O
study XXX O
with XXX O
corrections XXX O
for XXX O
any XXX O
carryover XXX O
effects XXX O
, XXX O
27 XXX O
males XXX O
and XXX O
30 XXX O
females XXX O
consumed XXX O
supplements XXX O
containing XXX O
glucose XXX O
or XXX O
resistant XXX O
starch XXX O
( XXX O
RS XXX O
) XXX O
from XXX O
raw XXX O
high-amylose XXX O
cornstarch XXX O
( XXX O
RS2 XXX O
) XXX O
or XXX O
from XXX O
retrograded XXX O
high-amylose XXX O
cornstarch XXX O
( XXX O
RS3 XXX O
) XXX O
. XXX O

Biliary-enteric XXX O
fistulas XXX O
. XXX O

Both XXX O
domains XXX O
were XXX O
required XXX O
for XXX O
specific XXX O
DNA XXX O
binding XXX O
to XXX O
the XXX O
beta-retinoic XXX B-GENE
acid XXX I-GENE
receptor XXX I-GENE
element XXX I-GENE
, XXX O
producing XXX O
a XXX O
DNase XXX B-GENE
I XXX I-GENE
footprint XXX O
covering XXX O
predominantly XXX O
one XXX O
strand XXX O
. XXX O

The XXX O
results XXX O
indicate XXX O
that XXX O
the XXX O
bradycardic XXX O
agents XXX O
alinidine XXX O
and XXX O
zatebradine XXX O
do XXX O
not XXX O
exert XXX O
antiarrhythmic XXX O
efficacy XXX O
against XXX O
SVT XXX O
induced XXX O
during XXX O
subacute XXX O
myocardial XXX O
infarction XXX O
in XXX O
conscious XXX O
dogs XXX O
. XXX O

Ligation XXX O
of XXX O
CD40 XXX B-GENE
rescues XXX O
Ramos-Burkitt XXX O
lymphoma XXX O
B XXX O
cells XXX O
from XXX O
calcium XXX O
ionophore- XXX O
and XXX O
antigen XXX O
receptor-triggered XXX O
apoptosis XXX O
by XXX O
inhibiting XXX O
activation XXX O
of XXX O
the XXX O
cysteine XXX B-GENE
protease XXX I-GENE
CPP32 XXX I-GENE
/ XXX I-GENE
Yama XXX I-GENE
and XXX O
cleavage XXX O
of XXX O
its XXX O
substrate XXX O
PARP XXX B-GENE
. XXX O

Further XXX O
, XXX O
mutational XXX O
analysis XXX O
of XXX O
NS5A XXX B-GENE
assigned XXX O
the XXX O
SH3-binding XXX B-GENE
region XXX I-GENE
to XXX O
a XXX O
proline-rich XXX O
motif XXX O
that XXX O
is XXX O
highly XXX O
conserved XXX O
among XXX O
HCV XXX O
genotypes XXX O
. XXX O

Dotarizine XXX O
produced XXX O
arterial XXX O
dilation XXX O
in XXX O
both XXX O
systemic XXX O
and XXX O
pulmonary XXX O
circulation XXX O
: XXX O
the XXX O
total XXX O
peripheral XXX O
resistance XXX O
dropped XXX O
, XXX O
and XXX O
femoral XXX O
artery XXX O
flow XXX O
rose XXX O
; XXX O
aortic XXX O
and XXX O
pulmonary XXX O
artery XXX O
mean XXX O
and XXX O
diastolic XXX O
pressures XXX O
declined XXX O
, XXX O
and XXX O
systolic XXX O
pressures XXX O
remained XXX O
almost XXX O
stable XXX O
. XXX O

We XXX O
analyzed XXX O
the XXX O
P-SAECG XXX O
in XXX O
the XXX O
time XXX O
and XXX O
frequency XXX O
domain XXX O
in XXX O
23 XXX O
patients XXX O
with XXX O
Paf XXX O
and XXX O
19 XXX O
controls XXX O
. XXX O

Rolandic XXX O
spikes XXX O
and XXX O
cognitive XXX O
function XXX O
. XXX O

Methyllevamisole XXX O
was XXX O
used XXX O
as XXX O
the XXX O
internal XXX O
standard XXX O
. XXX O

Adduction XXX O
of XXX O
the XXX O
human XXX B-GENE
N-ras XXX I-GENE
codon XXX I-GENE
61 XXX I-GENE
sequence XXX I-GENE
with XXX O
( XXX O
- XXX O
) XXX O
- XXX O
( XXX O
7S XXX O
, XXX O
8R XXX O
, XXX O
9R XXX O
, XXX O
10S XXX O
) XXX O
-7 XXX O
, XXX O
8-dihydroxy-9 XXX O
, XXX O
10-epoxy-7 XXX O
, XXX O
8 XXX O
, XXX O
9 XXX O
, XXX O
10-tetrahydrobenzo XXX O
[ XXX O
a XXX O
] XXX O
pyrene XXX O
: XXX O
structural XXX O
refinement XXX O
of XXX O
the XXX O
intercalated XXX O
SRSR XXX O
( XXX O
61 XXX O
, XXX O
2 XXX O
) XXX O
( XXX O
- XXX O
) XXX O
- XXX O
( XXX O
7S XXX O
, XXX O
8R XXX O
, XXX O
9S XXX O
, XXX O
10R XXX O
) XXX O
-N6- XXX O
[ XXX O
10- XXX O
( XXX O
7 XXX O
, XXX O
8 XXX O
, XXX O
9 XXX O
, XXX O
10- XXX O
tetrahydrobenzo XXX O
[ XXX O
a XXX O
] XXX O
pyrenyl XXX O
) XXX O
] XXX O
-2'-deoxyadenosyl XXX O
adduct XXX O
from XXX O
1H XXX O
NMR XXX O
. XXX O

Histological XXX O
observations XXX O
on XXX O
the XXX O
decidua XXX O
in XXX O
the XXX O
second XXX O
half XXX O
of XXX O
pregnancy XXX O
. XXX O

The XXX O
effect XXX O
of XXX O
desipramine XXX O
probably XXX O
represents XXX O
inhibition XXX O
of XXX O
neuronal XXX O
uptake XXX O
and XXX O
that XXX O
of XXX O
amitriptyline XXX O
and XXX O
mianserin XXX O
blockade XXX O
of XXX O
neuronal XXX O
uptake XXX O
and XXX O
prejunctional XXX O
alpha XXX B-GENE
2-adrenoreceptors XXX I-GENE
. XXX O

Scaling XXX O
of XXX O
fluctuations XXX O
in XXX O
one-dimensional XXX O
interface XXX O
and XXX O
hopping XXX O
models XXX O
. XXX O

Thus XXX O
, XXX O
the XXX O
multidomained XXX O
ROK XXX B-GENE
alpha XXX I-GENE
appears XXX O
to XXX O
be XXX O
involved XXX O
in XXX O
reorganization XXX O
of XXX O
the XXX O
cytoskeleton XXX O
, XXX O
with XXX O
the XXX O
N XXX O
and XXX O
C XXX O
termini XXX O
acting XXX O
as XXX O
positive XXX O
and XXX O
negative XXX O
regulators XXX O
, XXX O
respectively XXX O
, XXX O
of XXX O
the XXX O
kinase XXX O
domain XXX O
whose XXX O
activity XXX O
is XXX O
crucial XXX O
for XXX O
formation XXX O
of XXX O
stress XXX O
fibers XXX O
and XXX O
focal XXX B-GENE
adhesion XXX I-GENE
complexes XXX I-GENE
. XXX O

RESULTS XXX O
: XXX O
No XXX O
significant XXX O
deformation XXX O
in XXX O
vertebral XXX O
artery XXX O
flow XXX O
was XXX O
noted XXX O
in XXX O
the XXX O
flexion-distraction XXX O
Stage XXX O
I XXX O
injuries XXX O
within XXX O
the XXX O
physiologic XXX O
range XXX O
of XXX O
cervical XXX O
flexion XXX O
. XXX O

The XXX O
poly XXX O
( XXX O
A XXX O
) XXX O
segment XXX O
of XXX O
the XXX O
RNA XXX O
was XXX O
selectively XXX O
cross-linked XXX O
to XXX O
the XXX O
72 XXX O
, XXX O
000-molecular-weight XXX O
protein XXX O
( XXX O
72K XXX O
protein XXX O
) XXX O
. XXX O

Interspecific XXX O
backcross XXX O
analysis XXX O
using XXX O
progeny XXX O
derived XXX O
from XXX O
matings XXX O
of XXX O
( XXX O
C57BL XXX O
/ XXX O
6J XXX O
x XXX O
Mus XXX O
spretus XXX O
) XXX O
F1 XXX O
x XXX O
C57BL XXX O
/ XXX O
6J XXX O
mice XXX O
indicates XXX O
that XXX O
the XXX O
thrombospondin XXX B-GENE
gene XXX I-GENE
is XXX O
tightly XXX O
linked XXX O
to XXX O
the XXX O
Fshb XXX B-GENE
, XXX O
Actcl XXX B-GENE
, XXX O
Ltk XXX B-GENE
, XXX O
and XXX O
B2M XXX B-GENE
loci XXX I-GENE
on XXX O
murine XXX O
chromosome XXX O
2 XXX O
. XXX O

However XXX O
, XXX O
primary XXX O
transcripts XXX O
of XXX O
a XXX O
variant XXX B-GENE
tRNA XXX I-GENE
( XXX I-GENE
Val XXX I-GENE
) XXX I-GENE
( XXX I-GENE
UAC XXX I-GENE
) XXX I-GENE
gene XXX I-GENE
are XXX O
processing XXX O
deficient XXX O
under XXX O
standard XXX O
growth XXX O
conditions XXX O
( XXX O
30 XXX O
degrees XXX O
C XXX O
) XXX O
, XXX O
due XXX O
to XXX O
a XXX O
slightly XXX O
altered XXX O
5' XXX O
flanking XXX O
region XXX O
. XXX O

On XXX O
long-term XXX O
follow-up XXX O
, XXX O
there XXX O
was XXX O
no XXX O
significant XXX O
difference XXX O
in XXX O
the XXX O
incidence XXX O
of XXX O
hospitalizations XXX O
( XXX O
1 XXX O
per XXX O
2 XXX O
. XXX O
1 XXX O
vs XXX O
. XXX O

Furthermore XXX O
, XXX O
addition XXX O
of XXX O
B-Myb-glutathionine XXX B-GENE
S-transferase XXX I-GENE
fusion XXX I-GENE
protein XXX I-GENE
inhibited XXX O
complex XXX O
formation XXX O
. XXX O

Neomycin XXX O
is XXX O
fairly XXX O
effective XXX O
against XXX O
staphylococci XXX O
, XXX O
less XXX O
effective XXX O
against XXX O
streptococci XXX O
, XXX O
and XXX O
fairly XXX O
effective XXX O
against XXX O
gram-negative XXX O
intestinal XXX O
organisms XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
REP21 XXX O
plants XXX O
were XXX O
resistant XXX O
to XXX O
an XXX O
unusually XXX O
broad XXX O
range XXX O
of XXX O
tobamoviruses XXX O
including XXX O
tomato XXX O
mosaic XXX O
virus XXX O
, XXX O
tobacco XXX O
mild XXX O
green XXX O
mosaic XXX O
virus XXX O
, XXX O
TMV-U5 XXX O
, XXX O
green XXX O
tomato XXX O
atypical XXX O
mosaic XXX O
virus XXX O
, XXX O
and XXX O
ribgrass XXX O
mosaic XXX O
virus XXX O
. XXX O

Three XXX O
cDNAs XXX O
encoding XXX O
basic XXX B-GENE
leucine XXX I-GENE
zipper XXX I-GENE
( XXX I-GENE
bZIP XXX I-GENE
) XXX I-GENE
-type XXX I-GENE
ABRE-binding XXX I-GENE
proteins XXX I-GENE
were XXX O
isolated XXX O
by XXX O
using XXX O
the XXX O
yeast XXX O
one-hybrid XXX O
system XXX O
and XXX O
were XXX O
designated XXX O
AREB1 XXX B-GENE
, XXX O
AREB2 XXX B-GENE
, XXX O
and XXX O
AREB3 XXX B-GENE
( XXX O
ABA-responsive XXX B-GENE
element XXX I-GENE
binding XXX I-GENE
protein XXX I-GENE
) XXX O
. XXX O

The XXX O
mean XXX O
( XXX O
+ XXX O
/ XXX O
- XXX O
SD XXX O
) XXX O
PaO2 XXX O
increased XXX O
from XXX O
80 XXX O
. XXX O
8 XXX O
+ XXX O
/ XXX O
- XXX O
26 XXX O
. XXX O
9 XXX O
mmHg XXX O
before XXX O
to XXX O
89 XXX O
. XXX O
8 XXX O
+ XXX O
/ XXX O
- XXX O
27 XXX O
. XXX O
3 XXX O
mmHg XXX O
after XXX O
the XXX O
infusion XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
and XXX O
the XXX O
PaCO2 XXX O
decreased XXX O
from XXX O
42 XXX O
. XXX O
4 XXX O
+ XXX O
/ XXX O
- XXX O
8 XXX O
. XXX O
3 XXX O
to XXX O
39 XXX O
. XXX O
6 XXX O
+ XXX O
/ XXX O
- XXX O
7 XXX O
. XXX O
9 XXX O
mmHg XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
. XXX O

Twenty-four XXX O
hours XXX O
later XXX O
, XXX O
the XXX O
animals XXX O
were XXX O
randomized XXX O
to XXX O
subretinal XXX O
treatment XXX O
with XXX O
2 XXX O
. XXX O
5 XXX O
micrograms XXX O
of XXX O
tissue XXX B-GENE
plasminogen XXX I-GENE
activator XXX I-GENE
or XXX O
a XXX O
similar XXX O
volume XXX O
of XXX O
physiologic XXX O
saline XXX O
. XXX O

Junctions XXX O
between XXX O
cells XXX O
of XXX O
the XXX O
human XXX B-GENE
enamel XXX I-GENE
organ XXX O
. XXX O

These XXX O
studies XXX O
demonstrate XXX O
that XXX O
both XXX O
G XXX B-GENE
alpha XXX I-GENE
i XXX I-GENE
genes XXX I-GENE
are XXX O
dynamically XXX O
regulated XXX O
in XXX O
LLC-PK1 XXX O
cells XXX O
by XXX O
both XXX O
growth XXX O
, XXX O
differentiation XXX O
, XXX O
and XXX O
hormone XXX O
signals XXX O
. XXX O

The XXX O
Nostoc XXX O
petBD XXX B-GENE
genes XXX I-GENE
are XXX O
not XXX O
closely XXX O
linked XXX O
to XXX O
the XXX O
psbB XXX B-GENE
gene XXX I-GENE
( XXX O
encoding XXX O
the XXX O
51-kDa XXX O
photosystem XXX B-GENE
II XXX I-GENE
polypeptide XXX I-GENE
) XXX O
and XXX O
do XXX O
not XXX O
contain XXX O
introns XXX O
as XXX O
do XXX O
the XXX O
closely XXX O
related XXX O
chloroplast XXX B-GENE
genes XXX I-GENE
. XXX O

OBJECTIVE XXX O
: XXX O
The XXX O
purpose XXX O
of XXX O
this XXX O
article XXX O
is XXX O
to XXX O
review XXX O
balance XXX O
instruments XXX O
developed XXX O
within XXX O
the XXX O
past XXX O
10 XXX O
years XXX O
that XXX O
can XXX O
be XXX O
used XXX O
in XXX O
the XXX O
clinic XXX O
or XXX O
home XXX O
environment XXX O
. XXX O

Mutations XXX O
of XXX O
the XXX O
AP-1 XXX B-GENE
site XXX I-GENE
of XXX O
the XXX O
TIMP-1 XXX B-GENE
promoter XXX I-GENE
that XXX O
prevented XXX O
formation XXX O
of XXX O
HMAP-1 XXX B-GENE
caused XXX O
a XXX O
70% XXX O
loss XXX O
of XXX O
activity XXX O
in XXX O
transfected XXX O
activated XXX O
HSCs XXX O
. XXX O

Sera XXX O
from XXX O
euthyroid XXX O
post-menopausal XXX O
or XXX O
pregnant XXX O
women XXX O
yielded XXX O
TSH XXX B-GENE
levels XXX O
within XXX O
the XXX O
normal XXX O
range XXX O
. XXX O

Expense XXX O
limits XXX O
the XXX O
use XXX O
of XXX O
hepatitis XXX O
B XXX O
vaccines XXX O
, XXX O
but XXX O
low-dose XXX O
intradermal XXX O
immunization XXX O
has XXX O
been XXX O
evaluated XXX O
as XXX O
a XXX O
cost-saving XXX O
strategy XXX O
in XXX O
numerous XXX O
studies XXX O
. XXX O

It XXX O
is XXX O
now XXX O
estimated XXX O
that XXX O
inactivation XXX O
mutants XXX O
of XXX O
PTEN XXX B-GENE
exist XXX O
in XXX O
60% XXX O
of XXX O
all XXX O
forms XXX O
of XXX O
solid XXX O
tumors XXX O
. XXX O

Ten-year XXX O
experience XXX O
with XXX O
one-stage XXX O
proctocolectomy XXX O
and XXX O
anal XXX O
ileostomy XXX O
. XXX O

In XXX O
the XXX O
TLE XXX O
patients XXX O
the XXX O
NAA XXX O
: XXX O
Cr XXX O
ratios XXX O
were XXX O
reduced XXX O
in XXX O
the XXX O
seizure XXX O
focus XXX O
, XXX O
while XXX O
in XXX O
the XXX O
FLE XXX O
patients XXX O
they XXX O
were XXX O
not XXX O
always XXX O
reduced XXX O
in XXX O
the XXX O
seizure XXX O
focus XXX O
. XXX O

Element XXX B-GENE
B XXX I-GENE
( XXX O
-249 XXX O
/ XXX O
-229 XXX O
) XXX O
shows XXX O
more XXX O
than XXX O
80% XXX O
homology XXX O
to XXX O
a XXX O
consensus XXX B-GENE
c-myb XXX I-GENE
element XXX I-GENE
, XXX O
but XXX O
formed XXX O
two XXX O
specific XXX O
complexes XXX O
that XXX O
differed XXX O
from XXX O
that XXX O
of XXX O
c-myb XXX B-GENE
in XXX O
the XXX O
electrophoretic XXX O
mobility XXX O
shift XXX O
assay XXX O
. XXX O

These XXX O
results XXX O
demonstrate XXX O
that XXX O
N-glycans XXX O
flanking XXX O
the XXX O
receptor-binding XXX O
site XXX O
of XXX O
the XXX O
HA XXX B-GENE
molecule XXX I-GENE
are XXX O
potent XXX O
regulators XXX O
of XXX O
influenza XXX O
virus XXX O
growth XXX O
, XXX O
with XXX O
the XXX O
glycan XXX O
at XXX O
Asn149 XXX O
being XXX O
dominant XXX O
and XXX O
that XXX O
at XXX O
Asn123 XXX O
being XXX O
less XXX O
effective XXX O
. XXX O

These XXX O
data XXX O
show XXX O
that XXX O
the XXX O
alpha-helix XXX O
domain XXX O
of XXX O
p57 XXX B-GENE
( XXX I-GENE
Kip2 XXX I-GENE
) XXX I-GENE
, XXX O
which XXX O
is XXX O
conserved XXX O
in XXX O
the XXX O
Cip XXX B-GENE
/ XXX I-GENE
Kip XXX I-GENE
proteins XXX I-GENE
, XXX O
is XXX O
implicated XXX O
in XXX O
protein-protein XXX O
interaction XXX O
and XXX O
confers XXX O
a XXX O
specific XXX O
regulatory XXX O
mechanism XXX O
, XXX O
outside XXX O
of XXX O
their XXX O
Cdk-inhibitory XXX O
activity XXX O
, XXX O
by XXX O
which XXX O
the XXX O
p57 XXX B-GENE
( XXX I-GENE
Kip2 XXX I-GENE
) XXX I-GENE
family XXX O
members XXX O
positively XXX O
act XXX O
on XXX O
myogenic XXX O
differentiation XXX O
. XXX O

Three XXX O
experiments XXX O
contrasted XXX O
the XXX O
effects XXX O
of XXX O
6-hydroxydopamine-induced XXX O
lesions XXX O
of XXX O
the XXX O
ventral XXX O
noradrenergic XXX O
and XXX O
dorsal XXX O
noradrenergic XXX O
projections XXX O
, XXX O
predominantly XXX O
to XXX O
hypothalamus XXX O
and XXX O
cortex XXX O
, XXX O
respectively XXX O
, XXX O
upon XXX O
body XXX O
weight XXX O
changes XXX O
and XXX O
food-related XXX O
behaviour XXX O
in XXX O
the XXX O
rat XXX O
. XXX O

Replacement XXX O
of XXX O
residues XXX O
in XXX O
positions XXX O
+3 XXX O
( XXX O
His128Asn XXX O
) XXX O
and XXX O
+2 XXX O
( XXX O
Gln155Lys XXX O
) XXX O
of XXX O
the XXX O
reading XXX O
helices XXX O
of XXX O
fingers XXX O
2 XXX O
and XXX O
3 XXX O
, XXX O
respectively XXX O
, XXX O
prevented XXX O
binding XXX O
. XXX O

Diagnostic XXX O
value XXX O
of XXX O
adenosine XXX B-GENE
deaminase XXX I-GENE
activity XXX O
in XXX O
tuberculous XXX O
effusions XXX O
. XXX O

Modern XXX O
studies XXX O
, XXX O
conducted XXX O
with XXX O
Delta-9-THC XXX O
, XXX O
in XXX O
healthy XXX O
voluntaries XXX O
, XXX O
again XXX O
suggest XXX O
the XXX O
comparison XXX O
or XXX O
even XXX O
the XXX O
identity XXX O
of XXX O
the XXX O
modifications XXX O
caused XXX O
by XXX O
cannabis XXX O
with XXX O
sleep XXX O
and XXX O
dream XXX O
. XXX O

To XXX O
determine XXX O
the XXX O
effects XXX O
on XXX O
the XXX O
pulmonary XXX O
barrier XXX O
of XXX O
several XXX O
surface XXX O
active XXX O
agents XXX O
, XXX O
a XXX O
series XXX O
of XXX O
metered XXX O
dose XXX O
inhalers XXX O
( XXX O
MDIs XXX O
) XXX O
was XXX O
prepared XXX O
and XXX O
used XXX O
to XXX O
dose XXX O
aerosolized XXX O
surfactant XXX O
to XXX O
the XXX O
airways XXX O
of XXX O
isolated XXX O
perfused XXX O
rat XXX O
lungs XXX O
. XXX O

These XXX O
data XXX O
provide XXX O
evidence XXX O
that XXX O
the XXX O
2 XXX B-GENE
. XXX I-GENE
0-kb XXX I-GENE
LAT XXX I-GENE
is XXX O
an XXX O
intron XXX O
of XXX O
the XXX O
mLAT XXX B-GENE
pre-mRNA XXX I-GENE
with XXX O
a XXX O
unique XXX O
branch XXX O
point XXX O
. XXX O

With XXX O
NEU XXX B-GENE
overexpression XXX O
, XXX O
nodal XXX O
control XXX O
decreased XXX O
from XXX O
72% XXX O
to XXX O
34% XXX O
( XXX O
p XXX O
= XXX O
. XXX O
008 XXX O
) XXX O
. XXX O

The XXX O
solitary XXX O
kidney XXX O
: XXX O
a XXX O
model XXX O
of XXX O
chronic XXX O
hyperfiltration XXX O
in XXX O
humans XXX O
. XXX O

Mutagenesis XXX O
of XXX O
the XXX O
pecT XXX B-GENE
regulatory XXX O
region XXX O
revealed XXX O
the XXX O
presence XXX O
of XXX O
two XXX O
sites XXX O
in XXX O
which XXX O
insertions XXX O
reproduced XXX O
the XXX O
pec-1 XXX B-GENE
phenotype XXX O
. XXX O

Overexpression XXX O
of XXX O
MDR1 XXX B-GENE
has XXX O
been XXX O
demonstrated XXX O
in XXX O
many XXX O
cancers XXX O
, XXX O
both XXX O
in XXX O
patient XXX O
tumors XXX O
and XXX O
in XXX O
cell XXX O
lines XXX O
selected XXX O
with XXX O
a XXX O
variety XXX O
of XXX O
chemotherapeutic XXX O
agents XXX O
. XXX O

The XXX O
number XXX O
of XXX O
muricidal XXX O
rats XXX O
increased XXX O
with XXX O
increase XXX O
in XXX O
the XXX O
duration XXX O
of XXX O
Cd XXX O
administration XXX O
in XXX O
association XXX O
with XXX O
greater XXX O
accumulation XXX O
of XXX O
Cd XXX O
in XXX O
the XXX O
olfactory XXX O
bulb XXX O
than XXX O
in XXX O
any XXX O
other XXX O
region XXX O
of XXX O
the XXX O
brain XXX O
. XXX O

These XXX O
studies XXX O
support XXX O
the XXX O
view XXX O
that XXX O
HMG XXX B-GENE
I XXX I-GENE
( XXX I-GENE
Y XXX I-GENE
) XXX I-GENE
is XXX O
an XXX O
important XXX O
cofactor XXX O
for XXX O
HLA-DRA XXX B-GENE
gene XXX I-GENE
activation XXX O
by XXX O
Oct-2A XXX B-GENE
and XXX O
provide XXX O
insights XXX O
into XXX O
its XXX O
mechanism XXX O
of XXX O
action XXX O
. XXX O

Down-regulation XXX O
of XXX O
IRS-1 XXX B-GENE
is XXX O
linked XXX O
to XXX O
its XXX O
serine XXX O
phosphorylation XXX O
dependent XXX O
on XXX O
PI XXX B-GENE
3-kinase XXX I-GENE
activity XXX O
and XXX O
appears XXX O
required XXX O
for XXX O
differentiation XXX O
to XXX O
occur XXX O
, XXX O
as XXX O
IRS-1 XXX B-GENE
is XXX O
not XXX O
modified XXX O
and XXX O
continues XXX O
to XXX O
accumulate XXX O
in XXX O
a XXX O
nondifferentiating XXX O
myoblast XXX O
cell XXX O
line XXX O
. XXX O

As XXX O
pleural XXX O
thickening XXX O
is XXX O
seen XXX O
commonly XXX O
in XXX O
asbestosis XXX O
and XXX O
may XXX O
influence XXX O
lung XXX O
volumes XXX O
and XXX O
the XXX O
ratio XXX O
of XXX O
transfer XXX O
factor XXX O
to XXX O
effective XXX O
alveolar XXX O
volume XXX O
, XXX O
the XXX O
results XXX O
of XXX O
these XXX O
measurements XXX O
were XXX O
compared XXX O
only XXX O
in XXX O
the XXX O
cases XXX O
showing XXX O
absent XXX O
or XXX O
minimal XXX O
pleural XXX O
thickening XXX O
. XXX O

The XXX O
protein XXX B-GENE
ELT-1 XXX I-GENE
, XXX O
encoded XXX O
by XXX O
a XXX O
single-copy XXX O
gene XXX O
homologous XXX O
to XXX O
the XXX O
GATA XXX B-GENE
family XXX I-GENE
of XXX I-GENE
vertebrate XXX I-GENE
transcription XXX I-GENE
factors XXX I-GENE
, XXX O
is XXX O
potentially XXX O
capable XXX O
of XXX O
interacting XXX O
with XXX O
this XXX O
element XXX O
. XXX O

Dr XXX O
. XXX O

The XXX O
increase XXX O
in XXX O
number XXX O
of XXX O
terminal XXX O
hairs XXX O
, XXX O
which XXX O
are XXX O
defined XXX O
as XXX O
hairs XXX O
more XXX O
than XXX O
60 XXX O
microm XXX O
in XXX O
diameter XXX O
, XXX O
in XXX O
the XXX O
designated XXX O
area XXX O
( XXX O
0 XXX O
. XXX O
5 XXX O
cm XXX O
square XXX O
= XXX O
0 XXX O
. XXX O
25 XXX O
cm2 XXX O
area XXX O
) XXX O
of XXX O
the XXX O
procyanidin XXX O
B-2 XXX O
group XXX O
subjects XXX O
after XXX O
the XXX O
6-month XXX O
trial XXX O
was XXX O
significantly XXX O
greater XXX O
than XXX O
that XXX O
of XXX O
the XXX O
placebo XXX O
control XXX O
group XXX O
subjects XXX O
( XXX O
procyanidin XXX O
B-2 XXX O
, XXX O
1 XXX O
. XXX O
99 XXX O
+ XXX O
/ XXX O
- XXX O
2 XXX O
. XXX O
58 XXX O
( XXX O
mean XXX O
+ XXX O
/ XXX O
- XXX O
SD XXX O
) XXX O
/ XXX O
0 XXX O
. XXX O
25 XXX O
cm2 XXX O
; XXX O
placebo XXX O
, XXX O
-0 XXX O
. XXX O
82 XXX O
+ XXX O
/ XXX O
- XXX O
3 XXX O
. XXX O
40 XXX O
( XXX O
mean XXX O
+ XXX O
/ XXX O
- XXX O
SD XXX O
) XXX O
/ XXX O
0 XXX O
. XXX O
25 XXX O
cm2 XXX O
; XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
02 XXX O
, XXX O
two-sample XXX O
t XXX O
test XXX O
) XXX O
. XXX O

CONCLUSION XXX O
: XXX O
The XXX O
training XXX O
of XXX O
novices XXX O
using XXX O
MIST-VR XXX O
yields XXX O
quantifiable XXX O
changes XXX O
in XXX O
skill XXX O
that XXX O
are XXX O
transferable XXX O
to XXX O
a XXX O
simple XXX O
real XXX O
task XXX O
and XXX O
are XXX O
similar XXX O
to XXX O
the XXX O
results XXX O
achieved XXX O
with XXX O
conventional XXX O
training XXX O
. XXX O

Within XXX O
a XXX O
135-bp XXX O
core XXX O
homology XXX O
region XXX O
, XXX O
the XXX O
human XXX B-GENE
HS12 XXX I-GENE
enhancers XXX I-GENE
are XXX O
approximately XXX O
90% XXX O
identical XXX O
to XXX O
the XXX O
murine XXX O
homolog XXX O
and XXX O
include XXX O
several XXX O
motifs XXX O
previously XXX O
demonstrated XXX O
to XXX O
be XXX O
important XXX O
for XXX O
function XXX O
of XXX O
the XXX O
murine XXX O
enhancer XXX O
; XXX O
additional XXX O
segments XXX O
of XXX O
high XXX O
sequence XXX O
conservation XXX O
suggest XXX O
the XXX O
possibility XXX O
of XXX O
previously XXX O
unrecognized XXX O
functional XXX O
motifs XXX O
. XXX O

The XXX O
detection XXX O
of XXX O
ORF-1 XXX O
sequences XXX O
in XXX O
human XXX O
tumors XXX O
, XXX O
while XXX O
not XXX O
proof XXX O
per XXX O
se XXX O
, XXX O
is XXX O
a XXX O
prerequisite XXX O
for XXX O
establishing XXX O
its XXX O
role XXX O
in XXX O
tumor XXX O
development XXX O
. XXX O

Moreover XXX O
, XXX O
by XXX O
complementation XXX O
of XXX O
the XXX O
WA XXX B-GENE
fyuA XXX I-GENE
mutant XXX I-GENE
by XXX O
the XXX O
cloned XXX O
fyuA XXX B-GENE
gene XXX I-GENE
, XXX O
yersiniabactin XXX O
uptake XXX O
and XXX O
mouse XXX O
virulence XXX O
were XXX O
restored XXX O
. XXX O

Roentgenographically XXX O
, XXX O
the XXX O
lesion XXX O
was XXX O
usually XXX O
a XXX O
well-defined XXX O
and XXX O
benign XXX O
appearing XXX O
one XXX O
, XXX O
either XXX O
purely XXX O
lytic XXX O
( XXX O
3 XXX O
cases XXX O
) XXX O
or XXX O
with XXX O
central XXX O
radiodensity XXX O
( XXX O
2 XXX O
cases XXX O
) XXX O
. XXX O

The XXX O
use XXX O
of XXX O
CRF-41 XXX O
in XXX O
the XXX O
differential XXX O
diagnosis XXX O
of XXX O
Cushing's XXX O
syndrome XXX O
and XXX O
obesity XXX O
. XXX O

A XXX O
novel XXX O
phosphotyrosine-binding XXX O
domain XXX O
in XXX O
the XXX O
N-terminal XXX O
transforming XXX O
region XXX O
of XXX O
Cbl XXX B-GENE
interacts XXX O
directly XXX O
and XXX O
selectively XXX O
with XXX O
ZAP-70 XXX B-GENE
in XXX O
T XXX O
cells XXX O
. XXX O

Ischemic XXX O
heart XXX O
disease XXX O
evaluated XXX O
by XXX O
exercise XXX O
stress XXX O
thallium-201 XXX O
myocardial XXX O
scintigraphy XXX O
: XXX O
a XXX O
comparison XXX O
of XXX O
SPECT XXX O
and XXX O
bull's XXX O
eye XXX O
display XXX O
. XXX O

Heart XXX O
rate XXX O
( XXX O
HR XXX O
) XXX O
, XXX O
rectal XXX O
temperature XXX O
( XXX O
Tre XXX O
) XXX O
, XXX O
blood XXX O
pressure XXX O
, XXX O
temperature XXX O
and XXX O
relative XXX O
humidity XXX O
changes XXX O
inside XXX O
clothing XXX O
were XXX O
measured XXX O
on XXX O
18 XXX O
professional XXX O
firemen XXX O
( XXX O
mean XXX O
age XXX O
29 XXX O
. XXX O
4 XXX O
+ XXX O
/ XXX O
- XXX O
7 XXX O
. XXX O
4 XXX O
yr XXX O
, XXX O
VO2 XXX O
max XXX O
41 XXX O
. XXX O
4 XXX O
+ XXX O
8 XXX O
. XXX O
8 XXX O
ml XXX O
kg-1 XXX O
min-1 XXX O
) XXX O
wearing XXX O
fire XXX O
fighter's XXX O
uniforms XXX O
( XXX O
SU XXX O
) XXX O
or XXX O
aluminized XXX O
, XXX O
fire XXX O
resistant XXX O
, XXX O
impermeable XXX O
clothing XXX O
with XXX O
self XXX O
contained XXX O
breathing XXX O
apparatus XXX O
( XXX O
FE XXX O
) XXX O
. XXX O

Both XXX O
mu XXX B-GENE
and XXX O
gamma XXX B-GENE
2b XXX I-GENE
heavy XXX B-GENE
chain XXX I-GENE
genes XXX I-GENE
cause XXX O
this XXX O
feedback XXX O
inhibition XXX O
of XXX O
heavy XXX B-GENE
chain XXX I-GENE
gene XXX I-GENE
rearrangement XXX O
. XXX O

KRN2391 XXX O
and XXX O
cromakalim XXX O
produced XXX O
a XXX O
dose-dependent XXX O
increase XXX O
in XXX O
aortic XXX O
and XXX O
coronary XXX O
blood XXX O
flow XXX O
. XXX O

The XXX O
prevalence XXX O
of XXX O
opportunistic XXX O
infection XXX O
among XXX O
surviving XXX O
AIDS XXX O
patients XXX O
and XXX O
the XXX O
probability XXX O
of XXX O
being XXX O
in XXX O
tumour XXX O
response XXX O
following XXX O
cancer XXX O
therapy XXX O
conditional XXX O
on XXX O
being XXX O
alive XXX O
are XXX O
two XXX O
examples XXX O
of XXX O
such XXX O
functions XXX O
. XXX O

The XXX O
interpretation XXX O
of XXX O
antibiotic XXX O
disc XXX O
sensitivities XXX O
. XXX O

RANTES XXX B-GENE
( XXX O
regulated XXX B-GENE
upon XXX I-GENE
activation XXX I-GENE
, XXX I-GENE
normally XXX I-GENE
T-cell XXX I-GENE
expressed XXX I-GENE
and XXX I-GENE
presumably XXX I-GENE
secreted XXX I-GENE
) XXX O
is XXX O
a XXX O
CC XXX B-GENE
chemokine XXX I-GENE
which XXX O
recruits XXX O
and XXX O
activates XXX O
monocytes XXX O
, XXX O
lymphocytes XXX O
, XXX O
and XXX O
eosinophils XXX O
, XXX O
all XXX O
cell XXX O
types XXX O
present XXX O
in XXX O
the XXX O
lung XXX O
inflammatory XXX O
infiltrate XXX O
induced XXX O
by XXX O
RSV XXX O
infection XXX O
. XXX O

The XXX O
ultrastructure XXX O
of XXX O
retinal XXX O
vessels XXX O
was XXX O
examined XXX O
in XXX O
three XXX O
eyes XXX O
from XXX O
diabetic XXX O
patients XXX O
and XXX O
two XXX O
eyes XXX O
from XXX O
control XXX O
subjects XXX O
. XXX O

Enzyme XXX B-GENE
I XXX I-GENE
of XXX I-GENE
the XXX I-GENE
phosphoenolpyruvate XXX I-GENE
: XXX I-GENE
sugar XXX I-GENE
phosphotransferase XXX I-GENE
system XXX I-GENE
. XXX O

Rainbow XXX O
trout XXX O
were XXX O
obtained XXX O
from XXX O
a XXX O
commercial XXX O
trout XXX O
farm XXX O
, XXX O
kept XXX O
in XXX O
running XXX O
water XXX O
and XXX O
feeding XXX O
in XXX O
experimental XXX O
pellets XXX O
for XXX O
4 XXX O
to XXX O
8 XXX O
weeks XXX O
. XXX O

The XXX O
effect XXX O
of XXX O
hydrostatic XXX O
pressure XXX O
on XXX O
the XXX O
swimming XXX O
activity XXX O
of XXX O
three XXX O
hyponeustonic XXX O
crustacea XXX O
, XXX O
Anomalocera XXX O
patersoni XXX O
, XXX O
Pontella XXX O
mediterranea XXX O
, XXX O
Labidocera XXX O
wollastoni XXX O
. XXX O

The XXX O
EPO XXX B-GENE
levels XXX O
were XXX O
distinctly XXX O
increased XXX O
before XXX O
transfusion XXX O
; XXX O
they XXX O
did XXX O
not XXX O
significantly XXX O
change XXX O
just XXX O
after XXX O
transfusion XXX O
, XXX O
but XXX O
subsequently XXX O
decreased XXX O
. XXX O

Taken XXX O
together XXX O
, XXX O
they XXX O
uphold XXX O
the XXX O
emerging XXX O
concern XXX O
that XXX O
women XXX O
with XXX O
ER XXX B-GENE
( XXX I-GENE
+ XXX I-GENE
) XXX I-GENE
cancers XXX O
may XXX O
not XXX O
benefit XXX O
significantly XXX O
from XXX O
endocrine XXX O
treatment XXX O
if XXX O
the XXX O
tumors XXX O
also XXX O
overexpress XXX O
HER-2 XXX B-GENE
. XXX O

Because XXX O
of XXX O
a XXX O
rapid XXX O
development XXX O
of XXX O
the XXX O
connective XXX O
tissue XXX O
scars XXX O
, XXX O
however XXX O
, XXX O
at XXX O
the XXX O
place XXX O
of XXX O
the XXX O
destroyed XXX O
glandular XXX O
parenchyma XXX O
areas XXX O
, XXX O
there XXX O
is XXX O
no XXX O
normalization XXX O
of XXX O
the XXX O
organ's XXX O
structure XXX O
and XXX O
function XXX O
by XXX O
the XXX O
42d XXX O
day XXX O
. XXX O

In XXX O
silicosis XXX O
, XXX O
significant XXX O
relationships XXX O
between XXX O
patients XXX O
and XXX O
sons XXX O
were XXX O
not XXX O
seen XXX O
with XXX O
respect XXX O
to XXX O
arterial XXX O
blood XXX O
gas XXX O
determinations XXX O
and XXX O
ventilatory XXX O
responses XXX O
except XXX O
for XXX O
Paco2 XXX O
of XXX O
patients XXX O
and XXX O
hypercapnic XXX O
ventilatory XXX O
responses XXX O
of XXX O
sons XXX O
. XXX O

The XXX O
above XXX O
results XXX O
mean XXX O
that XXX O
the XXX O
increase XXX O
in XXX O
alpha-adrenergic XXX B-GENE
receptors XXX I-GENE
makes XXX O
the XXX O
prostate XXX O
, XXX O
which XXX O
has XXX O
been XXX O
already XXX O
hypertrophied XXX O
, XXX O
less XXX O
elastic XXX O
, XXX O
inhibiting XXX O
external XXX O
urinary XXX O
sphincter XXX O
function XXX O
. XXX O

The XXX O
PAC XXX O
clone XXX O
with XXX O
an XXX O
insert XXX O
size XXX O
of XXX O
120kb XXX O
was XXX O
isolated XXX O
and XXX O
mapped XXX O
by XXX O
restriction XXX O
analysis XXX O
. XXX O

MAIN XXX O
OUTCOME XXX O
MEASURES XXX O
: XXX O
Systemic XXX O
and XXX O
pulmonary XXX O
hemodynamics XXX O
, XXX O
arterial XXX O
blood XXX O
gas XXX O
determination XXX O
, XXX O
bronchoalveolar XXX O
lavage XXX O
protein XXX O
and XXX O
neutrophil XXX O
content XXX O
, XXX O
neutrophil XXX O
oxidant XXX O
burst XXX O
, XXX O
lung XXX B-GENE
myeloperoxidase XXX I-GENE
content XXX O
, XXX O
and XXX O
scanning XXX O
electron XXX O
micrographic XXX O
studies XXX O
. XXX O

Benign XXX O
intramural XXX O
tumors XXX O
of XXX O
the XXX O
esophagus XXX O
. XXX O

Gal4-Eed XXX B-GENE
fusion XXX I-GENE
protein XXX I-GENE
represses XXX O
transcription XXX O
of XXX O
a XXX O
reporter XXX O
gene XXX O
driven XXX O
by XXX O
a XXX O
promoter XXX O
that XXX O
contains XXX O
Gal4-binding XXX B-GENE
DNA XXX I-GENE
elements XXX I-GENE
. XXX O

A XXX O
method XXX O
is XXX O
described XXX O
for XXX O
detecting XXX O
targeted XXX O
events XXX O
at XXX O
the XXX O
mu XXX B-GENE
heavy XXX I-GENE
chain XXX I-GENE
gene XXX I-GENE
which XXX O
relies XXX O
on XXX O
co-conversion XXX O
( XXX O
or XXX O
co-exchange XXX O
) XXX O
of XXX O
a XXX O
point XXX O
mutation XXX O
with XXX O
a XXX O
selectable XXX O
marker XXX O
contained XXX O
on XXX O
a XXX O
replacement XXX O
vector XXX O
. XXX O

For XXX O
E2 XXX O
, XXX O
each XXX O
cat XXX O
was XXX O
given XXX O
either XXX O
5 XXX O
( XXX O
group XXX O
[ XXX O
G XXX O
] XXX O
1 XXX O
) XXX O
or XXX O
10 XXX O
( XXX O
G2 XXX O
) XXX O
mg XXX O
of XXX O
itraconazole XXX O
/ XXX O
kg XXX O
( XXX O
capsules XXX O
) XXX O
twice XXX O
daily XXX O
for XXX O
6 XXX O
weeks XXX O
. XXX O

As XXX O
a XXX O
last XXX O
resort XXX O
, XXX O
it XXX O
may XXX O
be XXX O
possible XXX O
to XXX O
maintain XXX O
a XXX O
patient XXX O
on XXX O
dialysis XXX O
in XXX O
reasonable XXX O
health XXX O
with XXX O
a XXX O
DiaTAP XXX O
button XXX O
graft XXX O
complex XXX O
infected XXX O
with XXX O
Staphylococcus XXX O
epidermidis XXX O
and XXX O
intermittent XXX O
positive XXX O
blood XXX O
cultures XXX O
using XXX O
long XXX O
term XXX O
vancomycin XXX O
therapy XXX O
. XXX O

Using XXX O
an XXX O
RNase XXX B-GENE
H XXX I-GENE
protection XXX O
assay XXX O
and XXX O
specific XXX O
blocking XXX O
oligonucleotides XXX O
, XXX O
we XXX O
find XXX O
that XXX O
recognition XXX O
of XXX O
the XXX O
5' XXX O
splice-site XXX O
( XXX O
5'ss XXX O
) XXX O
and XXX O
branchpoint XXX B-GENE
sequence XXX I-GENE
( XXX I-GENE
BPS XXX I-GENE
) XXX I-GENE
elements XXX I-GENE
by XXX O
U11 XXX B-GENE
and XXX O
U12 XXX B-GENE
snRNPs XXX I-GENE
, XXX O
respectively XXX O
, XXX O
displays XXX O
strong XXX O
cooperativity XXX O
, XXX O
requiring XXX O
both XXX O
sites XXX O
in XXX O
the XXX O
pre-mRNA XXX O
substrate XXX O
for XXX O
efficient XXX O
complex XXX O
formation XXX O
. XXX O

Point XXX O
mutations XXX O
of XXX O
the XXX O
site XXX O
that XXX O
suppressed XXX O
Pit-1 XXX B-GENE
binding XXX O
in XXX O
vitro XXX O
restored XXX O
full XXX O
tiGH XXX B-GENE
promoter XXX I-GENE
activity XXX O
. XXX O

A XXX O
review XXX O
of XXX O
the XXX O
literature XXX O
identified XXX O
8 XXX O
comprehensive XXX O
clinical XXX O
studies XXX O
, XXX O
all XXX O
of XXX O
which XXX O
failed XXX O
to XXX O
document XXX O
any XXX O
relationship XXX O
between XXX O
NF1 XXX B-GENE
and XXX O
intracranial XXX O
aneurysms XXX O
. XXX O

In XXX O
order XXX O
to XXX O
study XXX O
the XXX O
influence XXX O
of XXX O
iron XXX O
overload XXX O
on XXX O
the XXX O
polymorphonuclear XXX O
leucocyte XXX O
( XXX O
PMN XXX O
) XXX O
metabolism XXX O
of XXX O
patients XXX O
on XXX O
chronic XXX O
hemodialysis XXX O
, XXX O
generation XXX O
of XXX O
superoxide XXX O
anion XXX O
( XXX O
O2- XXX O
) XXX O
by XXX O
PMN XXX O
in XXX O
whole XXX O
blood XXX O
was XXX O
compared XXX O
in XXX O
two XXX O
groups XXX O
of XXX O
hemodialyzed XXX O
patients XXX O
: XXX O
group XXX O
A XXX O
consisted XXX O
of XXX O
twenty-one XXX O
individuals XXX O
with XXX O
serum XXX O
ferritin XXX B-GENE
levels XXX O
above XXX O
1000 XXX O
ng XXX O
/ XXX O
ml XXX O
and XXX O
group XXX O
B XXX O
of XXX O
nineteen XXX O
individuals XXX O
with XXX O
serum XXX O
ferritin XXX B-GENE
levels XXX O
below XXX O
1000 XXX O
ng XXX O
/ XXX O
ml XXX O
. XXX O

LD50 XXX O
values XXX O
of XXX O
terms XXX O
of XXX O
KP XXX O
were XXX O
84 XXX O
mg XXX O
/ XXX O
kg XXX O
in XXX O
male XXX O
rats XXX O
and XXX O
122 XXX O
mg XXX O
/ XXX O
kg XXX O
in XXX O
female XXX O
rats XXX O
when XXX O
KP-CMC XXX O
was XXX O
administered XXX O
intrarectally XXX O
, XXX O
and XXX O
117 XXX O
mg XXX O
/ XXX O
kg XXX O
in XXX O
male XXX O
and XXX O
92 XXX O
mg XXX O
/ XXX O
kg XXX O
in XXX O
female XXX O
when XXX O
KP-T10 XXX O
was XXX O
administered XXX O
intrarectally XXX O
. XXX O
, XXX O
while XXX O
peroral XXX O
administration XXX O
of XXX O
KP-CMC XXX O
showed XXX O
LD50 XXX O
values XXX O
of XXX O
68 XXX O
mg XXX O
/ XXX O
kg XXX O
in XXX O
males XXX O
and XXX O
78 XXX O
mg XXX O
/ XXX O
kg XXX O
in XXX O
females XXX O
in XXX O
terms XXX O
of XXX O
KP XXX O
. XXX O

Blood XXX O
platelets XXX O
, XXX O
coagulation XXX O
factors XXX O
and XXX O
morphologic XXX O
organ XXX O
changes XXX O
following XXX O
scadling XXX O
shock XXX O
in XXX O
rhesus XXX O
monkeys XXX O
. XXX O

Sequencing XXX O
revealed XXX O
one XXX O
large XXX O
open XXX O
reading XXX O
frame XXX O
encoding XXX O
a XXX O
39-kDa XXX O
protein XXX O
. XXX O

Tumor XXX B-GENE
necrosis XXX I-GENE
factor-alpha XXX I-GENE
( XXX O
TNF XXX B-GENE
alpha XXX I-GENE
) XXX O
is XXX O
one XXX O
of XXX O
several XXX O
autocrine XXX O
/ XXX O
paracrine XXX O
factors XXX O
known XXX O
to XXX O
exert XXX O
potent XXX O
inhibitory XXX O
effects XXX O
on XXX O
bone XXX O
. XXX O

The XXX O
TB XXX O
incidence XXX O
in XXX O
the XXX O
"AIRIN" XXX O
area XXX O
, XXX O
where XXX O
about XXX O
20% XXX O
TB XXX O
patients XXX O
are XXX O
homeless XXX O
, XXX O
shows XXX O
highest XXX O
rate XXX O
of XXX O
above XXX O
1 XXX O
, XXX O
000 XXX O
/ XXX O
100 XXX O
, XXX O
000 XXX O
. XXX O

For XXX O
functional XXX O
studies XXX O
, XXX O
two XXX O
promoter XXX O
regions XXX O
were XXX O
cloned XXX O
upstream XXX O
of XXX O
the XXX O
reporter XXX O
gene XXX O
, XXX O
chloramphenicol XXX B-GENE
acetyl XXX I-GENE
transferase XXX I-GENE
( XXX O
CAT XXX B-GENE
) XXX O
: XXX O
( XXX O
i XXX O
) XXX O
phbetaE-B XXX O
- XXX O
the XXX O
plasmid XXX O
that XXX O
contains XXX O
the XXX O
human XXX O
( XXX O
h XXX O
) XXX O
promoter XXX O
region XXX O
( XXX O
-2832 XXX O
to XXX O
+101 XXX O
) XXX O
including XXX O
URE XXX B-GENE
, XXX O
and XXX O
( XXX O
ii XXX O
) XXX O
prhbetaE-B XXX O
- XXX O
the XXX O
plasmid XXX O
that XXX O
contains XXX O
the XXX O
rhesus XXX O
( XXX O
rh XXX O
) XXX O
promoter XXX O
region XXX O
excluding XXX O
URE XXX B-GENE
as XXX O
it XXX O
lacks XXX O
a XXX O
270 XXX O
bp XXX O
region XXX O
of XXX O
the XXX O
hbetaAPP XXX B-GENE
promoter XXX I-GENE
( XXX O
-2435 XXX O
to XXX O
-2165 XXX O
) XXX O
. XXX O

SIM1 XXX B-GENE
and XXX O
SIM2 XXX B-GENE
do XXX O
not XXX O
form XXX O
homodimers XXX O
, XXX O
and XXX O
they XXX O
do XXX O
not XXX O
interact XXX O
with XXX O
AHR XXX B-GENE
. XXX O

Our XXX O
results XXX O
indicate XXX O
that XXX O
serum XXX B-GENE
BGP XXX I-GENE
is XXX O
a XXX O
valuable XXX O
measurement XXX O
of XXX O
bone XXX O
metabolism XXX O
. XXX O

National XXX O
Institutes XXX O
of XXX O
Health XXX O
Consensus XXX O
Development XXX O
Conference XXX O
Statement XXX O
. XXX O

Reviewing XXX O
manuscripts XXX O
: XXX O
developing XXX O
an XXX O
efficient XXX O
system XXX O
. XXX O

The XXX O
Oct XXX B-GENE
and XXX O
HMG2 XXX B-GENE
proteins XXX I-GENE
also XXX O
interact XXX O
in XXX O
vivo XXX O
. XXX O

Voluntary XXX O
wheel XXX O
running XXX O
did XXX O
not XXX O
significantly XXX O
increase XXX O
estimated XXX O
alanine XXX O
or XXX O
pyruvate XXX O
Gneo XXX O
or XXX O
absolute XXX O
glycerol XXX O
Ra XXX O
. XXX O

End XXX O
points XXX O
measured XXX O
were XXX O
perioperative XXX O
( XXX O
30-day XXX O
) XXX O
myocardial XXX O
infarction XXX O
( XXX O
MI XXX O
) XXX O
rate XXX O
and XXX O
death XXX O
. XXX O

Surprisingly XXX O
, XXX O
nuclear XXX O
forms XXX O
of XXX O
IE110 XXX B-GENE
were XXX O
found XXX O
to XXX O
move XXX O
a XXX O
cytoplasmic XXX O
form XXX O
of XXX O
IE175 XXX B-GENE
into XXX O
nuclear XXX O
punctate XXX O
structures XXX O
, XXX O
and XXX O
a XXX O
cytoplasmic XXX O
form XXX O
of XXX O
IE110 XXX B-GENE
was XXX O
able XXX O
to XXX O
retain XXX O
nuclear XXX O
forms XXX O
of XXX O
IE175 XXX B-GENE
in XXX O
cytoplasmic XXX O
punctate XXX O
structures XXX O
. XXX O

The XXX O
enhanced XXX O
binding XXX O
of XXX O
c-Abl XXX B-GENE
to XXX O
DNA XXX O
containing XXX O
5-methylcytosine XXX O
residues XXX O
may XXX O
result XXX O
from XXX O
an XXX O
increased XXX O
propensity XXX O
of XXX O
the XXX O
double XXX O
helix XXX O
to XXX O
denature XXX O
locally XXX O
coupled XXX O
with XXX O
a XXX O
protein-induced XXX O
reduction XXX O
in XXX O
the XXX O
base XXX O
stacking XXX O
interaction XXX O
. XXX O

Sequence XXX O
analysis XXX O
revealed XXX O
that XXX O
in XXX O
addition XXX O
to XXX O
the XXX O
non-spliced XXX O
variant XXX O
, XXX O
multiple XXX O
mRNA XXX O
species XXX O
were XXX O
generated XXX O
by XXX O
alternative XXX O
splicing XXX O
resulting XXX O
in XXX O
the XXX O
exclusion XXX O
of XXX O
92 XXX O
, XXX O
166 XXX O
, XXX O
170 XXX O
, XXX O
174 XXX O
and XXX O
263 XXX O
nucleotides XXX O
( XXX O
nt XXX O
) XXX O
, XXX O
respectively XXX O
, XXX O
from XXX O
exon XXX O
1 XXX O
. XXX O

Cp XXX O
is XXX O
normally XXX O
the XXX O
main XXX O
promoter XXX O
for XXX O
EBNA XXX B-GENE
mRNA XXX I-GENE
initiation XXX O
, XXX O
so XXX O
it XXX O
appears XXX O
that XXX O
EBNA3C XXX B-GENE
contributes XXX O
to XXX O
a XXX O
negative XXX O
autoregulatory XXX O
control XXX O
loop XXX O
. XXX O

Using XXX O
a XXX O
v-erbA XXX B-GENE
probe XXX O
, XXX O
we XXX O
obtained XXX O
a XXX O
cDNA XXX O
which XXX O
encodes XXX O
a XXX O
novel XXX O
445-amino-acid XXX O
protein XXX O
, XXX O
RLD-1 XXX B-GENE
, XXX O
that XXX O
contains XXX O
the XXX O
characteristic XXX O
domains XXX O
of XXX O
nuclear XXX O
receptors XXX O
. XXX O

The XXX O
solubility XXX O
of XXX O
all XXX O
the XXX O
mutated XXX O
proteins XXX O
was XXX O
remarkably XXX O
reduced XXX O
. XXX O

Peter XXX O
Elfer XXX O
explores XXX O
the XXX O
implications XXX O
of XXX O
the XXX O
ruling XXX O
. XXX O

Synthesis XXX O
of XXX O
antisense XXX O
RNA XXX O
and XXX O
S XXX O
phase-dependent XXX O
binding XXX O
of XXX O
E2F XXX B-GENE
complexes XXX I-GENE
in XXX O
intron XXX O
1 XXX O
. XXX O

ORFA XXX O
and XXX O
ccdA XXX B-GENE
were XXX O
constitutively XXX O
cotranscribed XXX O
as XXX O
determined XXX O
by XXX O
primer XXX O
extension XXX O
analysis XXX O
. XXX O

Commercially XXX O
available XXX O
formulations XXX O
of XXX O
2 XXX O
. XXX O
5% XXX O
and XXX O
5% XXX O
lambdacyhalothrin XXX O
can XXX O
be XXX O
diluted XXX O
either XXX O
with XXX O
water XXX O
for XXX O
ULV XXX O
cold XXX O
aerosol XXX O
space-spraying XXX O
or XXX O
with XXX O
diesel XXX O
/ XXX O
kerosene XXX O
for XXX O
thermal XXX O
fogging XXX O
at XXX O
recommended XXX O
application XXX O
rates XXX O
of XXX O
0 XXX O
. XXX O
5-1 XXX O
g XXX O
ai XXX O
/ XXX O
ha XXX O
for XXX O
mosquito XXX O
control XXX O
and XXX O
2 XXX O
g XXX O
ai XXX O
/ XXX O
ha XXX O
for XXX O
housefly XXX O
control XXX O
. XXX O

Confocal XXX O
fluorescence XXX O
microscopy XXX O
in XXX O
modern XXX O
cell XXX O
biology XXX O
. XXX O

Stable XXX O
transfection XXX O
of XXX O
human XXX B-GENE
CHOP XXX I-GENE
cDNA XXX I-GENE
into XXX O
mammary XXX O
carcinoma XXX O
cells XXX O
demonstrated XXX O
that XXX O
CHOP XXX B-GENE
functioned XXX O
not XXX O
as XXX O
a XXX O
mediator XXX O
of XXX O
hGH-stimulated XXX O
mitogenesis XXX O
but XXX O
rather XXX O
enhanced XXX O
the XXX O
protection XXX O
from XXX O
apoptosis XXX O
afforded XXX O
by XXX O
hGH XXX B-GENE
in XXX O
a XXX O
p38 XXX B-GENE
MAPK-dependent XXX O
manner XXX O
. XXX O

All XXX O
other XXX O
ejaculate XXX O
parameters XXX O
( XXX O
density XXX O
, XXX O
motility XXX O
, XXX O
swelling XXX O
test XXX O
, XXX O
penetration XXX O
test XXX O
) XXX O
remained XXX O
unchanged XXX O
, XXX O
and XXX O
there XXX O
was XXX O
only XXX O
one XXX O
post-therapeutic XXX O
pregnancy XXX O
. XXX O

Other XXX O
than XXX O
d XXX O
7 XXX O
, XXX O
there XXX O
was XXX O
no XXX O
significant XXX O
effect XXX O
on XXX O
the XXX O
number XXX O
of XXX O
implants XXX O
. XXX O

However XXX O
, XXX O
further XXX O
analyses XXX O
of XXX O
the XXX O
data XXX O
indicate XXX O
that XXX O
increasing XXX O
VO2 XXX O
AT XXX O
( XXX O
r XXX O
= XXX O
-0 XXX O
. XXX O
63 XXX O
, XXX O
P XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
rather XXX O
than XXX O
VO2max XXX O
( XXX O
r XXX O
= XXX O
-0 XXX O
. XXX O
15 XXX O
) XXX O
could XXX O
result XXX O
in XXX O
improving XXX O
the XXX O
10 XXX O
, XXX O
000 XXX O
m XXX O
race XXX O
performance XXX O
to XXX O
a XXX O
larger XXX O
extent XXX O
, XXX O
and XXX O
that XXX O
the XXX O
absolute XXX O
amount XXX O
of XXX O
change XXX O
( XXX O
delta XXX O
) XXX O
in XXX O
the XXX O
10 XXX O
, XXX O
000 XXX O
m XXX O
run XXX O
time XXX O
is XXX O
best XXX O
accounted XXX O
for XXX O
by XXX O
a XXX O
combination XXX O
of XXX O
delta XXX O
VO2 XXX O
AT XXX O
and XXX O
delta XXX O
5 XXX O
, XXX O
000 XXX O
m XXX O
run XXX O
time XXX O
. XXX O

For XXX O
instance XXX O
, XXX O
a XXX O
total XXX O
SIP XXX O
score XXX O
of XXX O
an XXX O
individual XXX O
patient XXX O
of XXX O
28 XXX O
. XXX O
3% XXX O
( XXX O
which XXX O
is XXX O
taken XXX O
as XXX O
an XXX O
example XXX O
, XXX O
being XXX O
the XXX O
mean XXX O
score XXX O
in XXX O
the XXX O
study XXX O
population XXX O
) XXX O
should XXX O
decrease XXX O
by XXX O
at XXX O
least XXX O
9 XXX O
. XXX O
26% XXX O
or XXX O
approximately XXX O
13 XXX O
items XXX O
, XXX O
before XXX O
any XXX O
improvement XXX O
beyond XXX O
reproducibility XXX O
noise XXX O
can XXX O
be XXX O
detected XXX O
. XXX O

We XXX O
conclude XXX O
that XXX O
, XXX O
in XXX O
comparison XXX O
to XXX O
reports XXX O
from XXX O
other XXX O
regions XXX O
, XXX O
Scandinavian XXX O
renal XXX O
transplant XXX O
recipients XXX O
are XXX O
at XXX O
high XXX O
risk XXX O
of XXX O
dying XXX O
of XXX O
IHD XXX O
. XXX O

Double-staining XXX O
confirmed XXX O
that XXX O
there XXX O
were XXX O
separate XXX O
populations XXX O
of XXX O
CD68-positive XXX O
macrophages XXX O
and XXX O
XIIIa-positive XXX O
dendrocytes XXX O
. XXX O

Managing XXX O
HIV XXX O
. XXX O

Deleting XXX O
SNF1 XXX B-GENE
repressed XXX O
meiosis XXX O
at XXX O
the XXX O
same XXX O
three XXX O
steps XXX O
that XXX O
were XXX O
inhibited XXX O
by XXX O
glucose XXX O
, XXX O
suggesting XXX O
that XXX O
glucose XXX O
blocks XXX O
meiosis XXX O
by XXX O
inhibiting XXX O
Snf1 XXX B-GENE
. XXX O

Gel XXX O
shift XXX O
analysis XXX O
indicates XXX O
that XXX O
the XXX O
full-length XXX B-GENE
ERM XXX I-GENE
protein XXX I-GENE
is XXX O
able XXX O
to XXX O
bind XXX O
specifically XXX O
to XXX O
an XXX O
oligonucleotide XXX O
containing XXX O
the XXX O
consensus XXX O
nucleotide XXX O
core XXX O
sequence XXX O
GGAA XXX O
recognized XXX O
by XXX O
the XXX O
Ets XXX O
proteins XXX O
. XXX O

Treatment XXX O
is XXX O
instituted XXX O
with XXX O
prednisone XXX O
and XXX O
cyclophosphamide XXX O
. XXX O

This XXX O
paper XXX O
describes XXX O
the XXX O
advantages XXX O
and XXX O
limitations XXX O
of XXX O
the XXX O
main XXX O
study XXX O
approaches XXX O
used XXX O
. XXX O

Directives XXX O
concerning XXX O
medical XXX O
care XXX O
. XXX O

Whole XXX O
blood XXX O
serotonin XXX O
levels XXX O
were XXX O
investigated XXX O
in XXX O
a XXX O
control XXX O
group XXX O
( XXX O
n XXX O
= XXX O
35 XXX O
) XXX O
and XXX O
in XXX O
a XXX O
group XXX O
of XXX O
chronic XXX O
renal XXX O
failure XXX O
patients XXX O
( XXX O
n XXX O
= XXX O
127 XXX O
) XXX O
on XXX O
various XXX O
treatment XXX O
regimen XXX O
i XXX O
. XXX O
e XXX O
. XXX O
conservative XXX O
treatment XXX O
( XXX O
n XXX O
= XXX O
39 XXX O
) XXX O
, XXX O
maintenance XXX O
haemodialysis XXX O
( XXX O
n XXX O
= XXX O
35 XXX O
) XXX O
and XXX O
after XXX O
renal XXX O
transplantation XXX O
( XXX O
n XXX O
= XXX O
53 XXX O
) XXX O
. XXX O

These XXX O
responses XXX O
were XXX O
compared XXX O
with XXX O
others XXX O
in XXX O
the XXX O
same XXX O
subjects XXX O
under XXX O
the XXX O
same XXX O
conditions XXX O
and XXX O
it XXX O
was XXX O
concluded XXX O
that XXX O
the XXX O
antihypertensive XXX O
effect XXX O
of XXX O
labetalol XXX O
is XXX O
explained XXX O
by XXX O
concurrent XXX O
blockade XXX O
of XXX O
alpha-and XXX B-GENE
beta-adrenoceptors XXX I-GENE
. XXX O

Of XXX O
115 XXX O
hepatitis XXX O
B XXX O
patients XXX O
seen XXX O
at XXX O
12 XXX O
months XXX O
, XXX O
6% XXX O
had XXX O
chronic XXX O
hepatitis XXX O
Bs XXX O
antigenaemia XXX O
, XXX O
60% XXX O
had XXX O
developed XXX O
anti-HBs XXX B-GENE
antibodies XXX I-GENE
, XXX O
and XXX O
7 XXX O
. XXX O
3% XXX O
still XXX O
had XXX O
abnormal XXX O
liver XXX O
function XXX O
. XXX O

In XXX O
the XXX O
artificial XXX O
lung XXX O
, XXX O
like XXX O
in XXX O
the XXX O
natural XXX O
lung XXX O
and XXX O
peripheral XXX O
tissues XXX O
, XXX O
gas XXX O
exchanges XXX O
depend XXX O
on XXX O
several XXX O
parameters XXX O
: XXX O
blood XXX O
inlet XXX O
conditions XXX O
, XXX O
blood XXX O
flow XXX O
rate XXX O
, XXX O
temperature XXX O
, XXX O
composition XXX O
of XXX O
the XXX O
gas XXX O
mixture XXX O
used XXX O
for XXX O
ventilation XXX O
, XXX O
blood XXX O
tissue XXX O
perfusion XXX O
, XXX O
O2 XXX O
consumption XXX O
, XXX O
etc XXX O
. XXX O

Confirmatory XXX O
statistics XXX O
included XXX O
item XXX O
2 XXX O
of XXX O
the XXX O
Clinical XXX O
Global XXX O
Impression XXX O
( XXX O
CGI XXX O
) XXX O
, XXX O
the XXX O
total XXX O
score XXX O
of XXX O
the XXX O
Sandoz XXX O
Clinical XXX O
Assessment XXX O
Geriatric XXX O
( XXX O
SCAG XXX O
) XXX O
scale XXX O
, XXX O
the XXX O
subscale XXX O
'need XXX O
for XXX O
help' XXX O
of XXX O
the XXX O
nurse's XXX O
rating XXX O
of XXX O
geriatric XXX O
patients XXX O
( XXX O
Beurteilungsskala XXX O
fur XXX O
geriatrische XXX O
Patienten XXX O
; XXX O
BGP XXX O
) XXX O
and XXX O
the XXX O
total XXX O
score XXX O
of XXX O
the XXX O
Short XXX O
Cognitive XXX O
Performance XXX O
Test XXX O
( XXX O
Syndrom-Kurztest XXX O
; XXX O
SKT XXX O
) XXX O
. XXX O

Cotransfection XXX O
with XXX O
the XXX O
ie1 XXX B-GENE
gene XXX I-GENE
resulted XXX O
in XXX O
a XXX O
dramatic XXX O
increase XXX O
in XXX O
the XXX O
amount XXX O
of XXX O
the XXX O
two XXX O
enzymes XXX O
expressed XXX O
in XXX O
the XXX O
transfected XXX O
cells XXX O
. XXX O

Our XXX O
previous XXX O
study XXX O
suggested XXX O
that XXX O
pertussis XXX B-GENE
toxin XXX I-GENE
( XXX O
IAP XXX B-GENE
) XXX O
-sensitive XXX O
GTP-binding XXX B-GENE
protein XXX I-GENE
( XXX I-GENE
s XXX I-GENE
) XXX I-GENE
( XXX O
G-protein XXX B-GENE
) XXX O
is XXX O
involved XXX O
in XXX O
the XXX O
process XXX O
of XXX O
differentiation XXX O
by XXX O
hormones XXX O
/ XXX O
IBMX XXX O
, XXX O
accompanied XXX O
by XXX O
c-fos XXX B-GENE
induction XXX O
. XXX O

Jembrana XXX O
disease XXX O
virus XXX O
( XXX O
JDV XXX O
) XXX O
is XXX O
a XXX O
newly XXX O
identified XXX O
bovine XXX O
lentivirus XXX O
that XXX O
is XXX O
closely XXX O
related XXX O
to XXX O
the XXX O
bovine XXX O
immunodeficiency XXX O
virus XXX O
( XXX O
BIV XXX O
) XXX O
. XXX O

Insulin XXX B-GENE
receptor XXX I-GENE
substrate-1-mediated XXX O
enhancement XXX O
of XXX O
growth XXX O
hormone-induced XXX O
mitogen-activated XXX B-GENE
protein XXX I-GENE
kinase XXX I-GENE
activation XXX O
. XXX O

The XXX O
pea XXX B-GENE
rps10 XXX I-GENE
intron XXX I-GENE
is XXX O
homologous XXX O
to XXX O
introns XXX O
in XXX O
rrn26 XXX B-GENE
and XXX O
cox3 XXX B-GENE
in XXX O
the XXX O
Marchantia XXX O
mitochondrial XXX O
genome XXX O
, XXX O
while XXX O
the XXX O
Marchantia XXX B-GENE
rps10 XXX I-GENE
gene XXX I-GENE
lacks XXX O
an XXX O
intron XXX O
. XXX O

Rip1p XXX B-GENE
is XXX O
inessential XXX O
, XXX O
associated XXX O
with XXX O
nuclear XXX B-GENE
pore XXX I-GENE
complexes XXX I-GENE
, XXX O
and XXX O
structurally XXX O
related XXX O
to XXX O
the XXX O
FG-nucleoporin XXX B-GENE
family XXX I-GENE
of XXX O
pore XXX B-GENE
proteins XXX I-GENE
. XXX O

Homodimers XXX O
of XXX O
the XXX O
three XXX O
proteins XXX O
specifically XXX O
recognize XXX O
the XXX O
G-box XXX O
motif XXX O
, XXX O
with XXX O
GBF1 XXX B-GENE
and XXX O
GBF3 XXX B-GENE
binding XXX O
symmetrically XXX O
to XXX O
this XXX O
palindromic XXX O
sequence XXX O
. XXX O

First XXX O
, XXX O
a XXX O
pet54 XXX B-GENE
: XXX O
: XXX O
LEU2 XXX B-GENE
cytoductant XXX O
bearing XXX O
the XXX O
'short' XXX O
mitochondrial XXX O
genome XXX O
that XXX O
lacks XXX O
both XXX O
COX1 XXX B-GENE
introns XXX I-GENE
aI5 XXX B-GENE
alpha XXX I-GENE
and XXX O
aI5 XXX B-GENE
beta XXX I-GENE
is XXX O
defective XXX O
only XXX O
in XXX O
COX3 XXX B-GENE
gene XXX I-GENE
expression XXX O
and XXX O
not XXX O
in XXX O
COX1 XXX B-GENE
mRNA XXX I-GENE
splicing XXX O
or XXX O
mRNA XXX O
translation XXX O
. XXX O

Stable XXX O
transfection XXX O
of XXX O
the XXX O
BL XXX O
cell XXX O
line XXX O
Raji XXX O
with XXX O
constructs XXX O
containing XXX O
core XXX O
promoter XXX O
mutations XXX O
confirmed XXX O
that XXX O
the XXX O
proximal XXX O
Sp1 XXX B-GENE
site XXX I-GENE
and XXX O
the XXX O
TATA XXX O
box XXX O
are XXX O
essential XXX O
for XXX O
the XXX O
activation XXX O
of XXX O
promoter XXX B-GENE
P1 XXX I-GENE
by XXX O
the XXX O
Ig XXX B-GENE
kappa XXX I-GENE
enhancers XXX I-GENE
. XXX O

Patients XXX O
were XXX O
subclassified XXX O
into XXX O
age-matched XXX O
groups XXX O
of XXX O
primary XXX O
untreated XXX O
cancer XXX O
( XXX O
21 XXX O
) XXX O
, XXX O
recurrent XXX O
cancer XXX O
( XXX O
18 XXX O
) XXX O
, XXX O
and XXX O
"cured" XXX O
patients XXX O
who XXX O
had XXX O
been XXX O
free XXX O
of XXX O
disease XXX O
for XXX O
at XXX O
least XXX O
9 XXX O
months XXX O
( XXX O
16 XXX O
) XXX O
. XXX O

Histiocytic XXX O
panniculitis XXX O
was XXX O
observed XXX O
in XXX O
biopsy XXX O
specimens XXX O
with XXX O
cytophagocytosis XXX O
. XXX O

With XXX O
each XXX O
of XXX O
the XXX O
three XXX O
pairs XXX O
of XXX O
isolates XXX O
( XXX O
case XXX O
and XXX O
suspicious XXX O
case XXX O
) XXX O
, XXX O
identical XXX O
IS6110 XXX O
banding XXX O
patterns XXX O
were XXX O
found XXX O
suggesting XXX O
identical XXX O
MTB XXX O
strains XXX O
. XXX O

Retroviral XXX O
replication XXX O
requires XXX O
that XXX O
a XXX O
portion XXX O
of XXX O
the XXX O
primary XXX O
transcripts XXX O
generated XXX O
from XXX O
proviral XXX O
DNA XXX O
be XXX O
spliced XXX O
to XXX O
serve XXX O
as XXX O
mRNA XXX O
for XXX O
the XXX O
envelope XXX B-GENE
protein XXX I-GENE
and XXX O
in XXX O
Rous XXX O
sarcoma XXX O
virus XXX O
as XXX O
src XXX B-GENE
mRNA XXX I-GENE
. XXX O

( XXX O
1995 XXX O
) XXX O
J XXX O
. XXX O

In XXX O
the XXX O
chicken XXX O
liver XXX O
, XXX O
levels XXX O
of XXX O
chicken XXX B-GENE
MT XXX I-GENE
mRNA XXX I-GENE
were XXX O
rapidly XXX O
induced XXX O
by XXX O
metals XXX O
( XXX O
Cd2+ XXX O
, XXX O
Zn2+ XXX O
, XXX O
Cu2+ XXX O
) XXX O
, XXX O
glucocorticoids XXX O
and XXX O
lipopolysaccharide XXX O
. XXX O

Tendon XXX O
also XXX O
shows XXX O
a XXX O
degree XXX O
of XXX O
extensibility XXX O
. XXX O

Molecular XXX O
cloning XXX O
of XXX O
Elk-3 XXX B-GENE
, XXX O
a XXX O
new XXX O
member XXX O
of XXX O
the XXX O
Ets XXX B-GENE
family XXX I-GENE
expressed XXX O
during XXX O
mouse XXX O
embryogenesis XXX O
and XXX O
analysis XXX O
of XXX O
its XXX O
transcriptional XXX O
repression XXX O
activity XXX O
. XXX O

Cord XXX O
swelling XXX O
was XXX O
observed XXX O
in XXX O
2 XXX O
patients XXX O
who XXX O
developed XXX O
complete XXX O
lesions XXX O
. XXX O

These XXX O
modifications XXX O
may XXX O
improve XXX O
the XXX O
interlaboratory XXX O
reproducibility XXX O
of XXX O
CD34 XXX B-GENE
determinations XXX O
due XXX O
to XXX O
the XXX O
reduction XXX O
in XXX O
sample XXX O
handling XXX O
and XXX O
calculation XXX O
of XXX O
results XXX O
. XXX O

Evaluation XXX O
of XXX O
automatic XXX O
blood XXX O
cell XXX O
counters XXX O
. XXX O

The XXX O
region XXX O
of XXX O
plasmid XXX O
pCM2 XXX O
encoding XXX O
the XXX O
pathogenicity XXX B-GENE
locus XXX I-GENE
pat-1 XXX I-GENE
was XXX O
mapped XXX O
by XXX O
deletion XXX O
analysis XXX O
and XXX O
complementation XXX O
studies XXX O
to XXX O
a XXX O
1 XXX B-GENE
. XXX I-GENE
5-kb XXX I-GENE
Bg XXX I-GENE
/ XXX I-GENE
II XXX I-GENE
/ XXX I-GENE
SmaI XXX I-GENE
DNA XXX I-GENE
fragment XXX I-GENE
. XXX O

The XXX O
pathogenicity XXX O
of XXX O
Achromobacter XXX O
puntatum XXX O
for XXX O
cold XXX O
blooded XXX O
and XXX O
warm XXX O
blooded XXX O
animals XXX O
. XXX O

This XXX O
plus XXX O
the XXX O
reduced XXX O
phosphorylation XXX O
of XXX O
p27 XXX B-GENE
by XXX O
MAPK XXX B-GENE
enhanced XXX O
the XXX O
stability XXX O
of XXX O
p27 XXX B-GENE
that XXX O
associated XXX O
with XXX O
nuclear XXX B-GENE
Cdk2 XXX I-GENE
at XXX O
high XXX O
stoichiometry XXX O
and XXX O
inhibited XXX O
its XXX O
kinase XXX O
activity XXX O
. XXX O

The XXX O
Trx-CT XXX B-GENE
fusion XXX I-GENE
protein XXX I-GENE
was XXX O
produced XXX O
less XXX O
efficiently XXX O
( XXX O
20% XXX O
of XXX O
total XXX O
soluble XXX O
cellular XXX O
protein XXX O
) XXX O
. XXX O

The XXX O
elements XXX O
responsible XXX O
for XXX O
glucocorticoid XXX O
stimulation XXX O
of XXX O
ADH XXX B-GENE
gene XXX I-GENE
transcription XXX O
appear XXX O
to XXX O
reside XXX O
outside XXX O
of XXX O
this XXX O
region XXX O
. XXX O

Early XXX O
treatment XXX O
mechanics XXX O
of XXX O
the XXX O
Class XXX O
II XXX O
division XXX O
2 XXX O
malocclusion XXX O
. XXX O

With XXX O
the XXX O
human XXX B-GENE
Rhotekin XXX I-GENE
cDNA XXX I-GENE
as XXX O
a XXX O
probe XXX O
, XXX O
Northern XXX O
hybridization XXX O
revealed XXX O
that XXX O
a XXX O
4 XXX O
. XXX O
0-kb XXX O
transcript XXX O
was XXX O
expressed XXX O
at XXX O
a XXX O
high XXX O
level XXX O
in XXX O
prostate XXX O
and XXX O
at XXX O
a XXX O
middle XXX O
level XXX O
in XXX O
13 XXX O
of XXX O
16 XXX O
tissues XXX O
examined XXX O
, XXX O
but XXX O
it XXX O
cannot XXX O
be XXX O
detected XXX O
in XXX O
liver XXX O
and XXX O
lung XXX O
tissues XXX O
. XXX O

When XXX O
the XXX O
promoter XXX O
region XXX O
was XXX O
linked XXX O
with XXX O
a XXX O
heterologous XXX O
reporter XXX O
gene XXX O
, XXX O
we XXX O
found XXX O
that XXX O
the XXX O
promoter XXX O
region XXX O
is XXX O
inducible XXX O
by XXX O
both XXX O
interferons XXX B-GENE
( XXX O
interferon-alpha XXX B-GENE
and XXX O
-gamma XXX B-GENE
) XXX O
and XXX O
interferon XXX B-GENE
regulatory XXX I-GENE
factor XXX I-GENE
1 XXX I-GENE
. XXX O

A XXX O
recent XXX O
index XXX O
( XXX O
Fluorosis XXX O
Risk XXX O
Index XXX O
) XXX O
developed XXX O
by XXX O
Pendrys XXX O
( XXX O
1990 XXX O
) XXX O
is XXX O
also XXX O
included XXX O
in XXX O
this XXX O
review XXX O
. XXX O

However XXX O
, XXX O
study XXX O
of XXX O
the XXX O
productive XXX O
gamma XXX B-GENE
gene XXX I-GENE
showed XXX O
that XXX O
the XXX O
skipped XXX O
variable XXX O
exon XXX O
was XXX O
bounded XXX O
by XXX O
normal XXX O
splicing XXX O
signals XXX O
and XXX O
that XXX O
the XXX O
adjacent XXX O
intron XXX O
organization XXX O
was XXX O
not XXX O
altered XXX O
. XXX O

Because XXX O
a XXX O
close XXX O
correlation XXX O
between XXX O
regional XXX O
decreases XXX O
in XXX O
FMZ XXX O
binding XXX O
and XXX O
spiking XXX O
activity XXX O
was XXX O
recently XXX O
demonstrated XXX O
in XXX O
neocortical XXX O
epilepsies XXX O
, XXX O
abnormal XXX O
peri-lesional XXX O
FMZ XXX O
binding XXX O
may XXX O
bear XXX O
some XXX O
relation XXX O
to XXX O
the XXX O
mechanisms XXX O
of XXX O
epileptogenesis XXX O
in XXX O
symptomatic XXX O
epilepsies XXX O
. XXX O

Choice XXX O
of XXX O
vessel XXX O
. XXX O

Preparation XXX O
of XXX O
a XXX O
stable XXX O
phospholipid XXX O
reagent XXX O
for XXX O
coagulation XXX O
assays XXX O
. XXX O

Wave XXX O
cybernetics XXX O
: XXX O
A XXX O
simple XXX O
model XXX O
of XXX O
wave-controlled XXX O
nonlinear XXX O
and XXX O
nonlocal XXX O
cooperative XXX O
phenomena XXX O
. XXX O

The XXX O
microphthalmia-TFE XXX B-GENE
( XXX O
MiT XXX B-GENE
) XXX O
subfamily XXX O
of XXX O
basic XXX B-GENE
helix-loop-helix XXX I-GENE
leucine XXX I-GENE
zipper XXX I-GENE
( XXX I-GENE
bHLH-ZIP XXX I-GENE
) XXX I-GENE
transcription XXX I-GENE
factors XXX I-GENE
, XXX O
including XXX O
TFE3 XXX B-GENE
, XXX O
TFEB XXX B-GENE
, XXX O
TFEC XXX B-GENE
, XXX O
and XXX O
Mitf XXX B-GENE
, XXX O
has XXX O
been XXX O
implicated XXX O
in XXX O
the XXX O
regulation XXX O
of XXX O
tissue-specific XXX O
gene XXX O
expression XXX O
in XXX O
several XXX O
cell XXX O
lineages XXX O
. XXX O

Asthma XXX O
was XXX O
significantly XXX O
more XXX O
often XXX O
associated XXX O
with XXX O
ASA XXX O
group XXX O
( XXX O
91% XXX O
) XXX O
vs XXX O
46% XXX O
at XXX O
AT XXX O
and XXX O
in XXX O
only XXX O
16% XXX O
at XXX O
INTR XXX O
group XXX O
. XXX O

Moreover XXX O
, XXX O
a XXX O
severe XXX O
decrease XXX O
of XXX O
antithrombin XXX B-GENE
activity XXX O
became XXX O
evident XXX O
during XXX O
both XXX O
experiments XXX O
( XXX O
eg XXX O
, XXX O
in XXX O
experiment XXX O
2 XXX O
from XXX O
95 XXX O
. XXX O
6 XXX O
+ XXX O
/ XXX O
- XXX O
4 XXX O
. XXX O
8 XXX O
to XXX O
59 XXX O
. XXX O
2 XXX O
+ XXX O
/ XXX O
- XXX O
6 XXX O
. XXX O
6% XXX O
) XXX O
. XXX O

This XXX O
report XXX O
describes XXX O
a XXX O
patient XXX O
with XXX O
a XXX O
previous XXX O
inferior XXX O
acute XXX O
myocardial XXX O
infarction XXX O
who XXX O
developed XXX O
right XXX O
ventricular XXX O
infarction XXX O
with XXX O
significant XXX O
anterior XXX O
lead XXX O
ST XXX O
segment XXX O
elevation XXX O
( XXX O
V1-V4 XXX O
) XXX O
caused XXX O
by XXX O
the XXX O
loss XXX O
of XXX O
two XXX O
large XXX O
right XXX O
ventricular XXX O
branches XXX O
during XXX O
a XXX O
coronary XXX O
angioplasty XXX O
of XXX O
the XXX O
right XXX O
coronary XXX O
artery XXX O
. XXX O

Sprague-Dawley XXX O
newborn XXX O
rats XXX O
( XXX O
n XXX O
= XXX O
85 XXX O
) XXX O
breathed XXX O
100% XXX O
oxygen XXX O
( XXX O
O2 XXX O
) XXX O
or XXX O
room XXX O
air XXX O
( XXX O
RA XXX O
) XXX O
during XXX O
the XXX O
first XXX O
8 XXX O
days XXX O
of XXX O
life XXX O
, XXX O
and XXX O
then XXX O
RA XXX O
. XXX O

Following XXX O
20 XXX O
min XXX O
of XXX O
steady XXX O
state XXX O
anaesthesia XXX O
during XXX O
which XXX O
measurements XXX O
of XXX O
IOP XXX O
, XXX O
arterial XXX O
pressure XXX O
, XXX O
heart XXX O
rate XXX O
, XXX O
FIO2 XXX O
, XXX O
FE'CO2 XXX O
and XXX O
CVP XXX O
were XXX O
recorded XXX O
, XXX O
one XXX O
group XXX O
of XXX O
patients XXX O
received XXX O
atracurium XXX O
0 XXX O
. XXX O
45 XXX O
mg XXX O
kg-1 XXX O
and XXX O
the XXX O
other XXX O
pancuronium XXX O
0 XXX O
. XXX O
1 XXX O
mg XXX O
kg-1 XXX O
. XXX O

P XXX O
. XXX O
, XXX O
Peyron XXX O
, XXX O
J XXX O
. XXX O

Newcastle XXX B-GENE
disease XXX I-GENE
antibody XXX I-GENE
titre XXX O
is XXX O
dependent XXX O
on XXX O
serum XXX O
calcium XXX O
concentration XXX O
. XXX O

Based XXX O
on XXX O
analytic XXX O
precisions XXX O
, XXX O
a XXX O
+ XXX O
/ XXX O
- XXX O
2% XXX O
urine-plasma XXX O
difference XXX O
was XXX O
set XXX O
as XXX O
the XXX O
cut-off XXX O
value XXX O
. XXX O

A XXX O
possible XXX O
mechanism XXX O
is XXX O
that XXX O
elevated XXX O
alveolar XXX O
pressure XXX O
and XXX O
decreased XXX O
cardiac XXX O
output XXX O
eliminate XXX O
blood XXX O
flow XXX O
from XXX O
corner XXX O
vessels XXX O
in XXX O
nondependent XXX O
high XXX O
VA XXX O
/ XXX O
Q XXX O
regions XXX O
. XXX O

RESULTS XXX O
: XXX O
Soluble XXX O
CD23 XXX B-GENE
levels XXX O
were XXX O
significantly XXX O
higher XXX O
in XXX O
women XXX O
with XXX O
endometriosis XXX O
before XXX O
treatment XXX O
than XXX O
in XXX O
ten XXX O
normal XXX O
controls XXX O
. XXX O

CONCLUSIONS XXX O
: XXX O
We XXX O
obtained XXX O
normal XXX O
EPO XXX B-GENE
levels XXX O
for XXX O
mothers XXX O
and XXX O
newborns XXX O
for XXX O
our XXX O
area XXX O
, XXX O
similarly XXX O
to XXX O
the XXX O
previously XXX O
described XXX O
ones XXX O
. XXX O

Naturally XXX O
acquired XXX O
antibodies XXX O
were XXX O
demonstrated XXX O
in XXX O
some XXX O
rabbits XXX O
kept XXX O
on XXX O
commercial XXX O
farms XXX O
. XXX O

A XXX O
surgical XXX O
technique XXX O
for XXX O
correcting XXX O
this XXX O
problem XXX O
is XXX O
described XXX O
. XXX O

The XXX O
following XXX O
aspects XXX O
were XXX O
assessed XXX O
: XXX O
( XXX O
1 XXX O
) XXX O
The XXX O
effect XXX O
on XXX O
the XXX O
cardiovascular XXX O
system XXX O
in XXX O
terms XXX O
of XXX O
brachial XXX O
arterial XXX O
pressure XXX O
, XXX O
pulse XXX O
rate XXX O
, XXX O
and XXX O
oxygen XXX O
consumption XXX O
( XXX O
VO2 XXX O
) XXX O
during XXX O
exercise XXX O
in XXX O
5 XXX O
health XXX O
volunteers XXX O
; XXX O
( XXX O
2 XXX O
) XXX O
emg XXX O
activity XXX O
of XXX O
the XXX O
tibialis XXX O
anterior XXX O
and XXX O
gastrocnemius XXX O
muscles XXX O
during XXX O
exercise XXX O
in XXX O
the XXX O
same XXX O
5 XXX O
volunteers XXX O
; XXX O
and XXX O
( XXX O
3 XXX O
) XXX O
postexercise XXX O
ankle XXX O
pressure XXX O
changes XXX O
in XXX O
10 XXX O
subjects XXX O
with XXX O
angiographically XXX O
proven XXX O
occlusive XXX O
arterial XXX O
diseases XXX O
of XXX O
the XXX O
lower XXX O
extremities XXX O
. XXX O

On XXX O
the XXX O
amount XXX O
and XXX O
significance XXX O
of XXX O
the XXX O
effective XXX O
glucose XXX O
level XXX O
in XXX O
tumors XXX O
. XXX O

The XXX O
protein XXX O
encoded XXX O
by XXX O
the XXX O
fruA XXX B-GENE
transcript XXX I-GENE
is XXX O
well XXX O
conserved XXX O
with XXX O
the XXX O
D XXX B-GENE
. XXX I-GENE
melanogaster XXX I-GENE
type XXX I-GENE
A XXX I-GENE
protein XXX I-GENE
, XXX O
particularly XXX O
the XXX O
BTB XXX B-GENE
protein-protein-binding XXX I-GENE
domain XXX I-GENE
, XXX O
which XXX O
is XXX O
encoded XXX O
by XXX O
exons XXX O
I XXX O
and XXX O
II XXX O
and XXX O
is XXX O
100% XXX O
conserved XXX O
. XXX O

The XXX O
activity XXX O
of XXX O
the XXX O
minimal XXX O
promoter XXX O
was XXX O
found XXX O
to XXX O
be XXX O
controlled XXX O
by XXX O
a XXX O
combination XXX O
of XXX O
the XXX O
activities XXX O
of XXX O
the XXX O
transcription XXX O
factors XXX O
Sp1 XXX B-GENE
, XXX O
Sp3 XXX B-GENE
, XXX O
and XXX O
NF-Y XXX B-GENE
. XXX O

A XXX O
picture XXX O
is XXX O
emerging XXX O
showing XXX O
a XXX O
gradient XXX O
of XXX O
function XXX O
among XXX O
p53 XXX B-GENE
, XXX O
p73 XXX B-GENE
, XXX O
p63 XXX B-GENE
ranging XXX O
from XXX O
tumor XXX O
suppression XXX O
to XXX O
development XXX O
. XXX O

In XXX O
this XXX O
study XXX O
we XXX O
wanted XXX O
to XXX O
assess XXX O
the XXX O
DR XXX O
using XXX O
the XXX O
'combined XXX O
test' XXX O
in XXX O
an XXX O
unselected XXX O
population XXX O
of XXX O
self-referred XXX O
pregnant XXX O
women XXX O
at XXX O
a XXX O
false-positive XXX O
rate XXX O
( XXX O
FPR XXX O
) XXX O
of XXX O
about XXX O
5% XXX O
. XXX O

The XXX O
bile XXX O
acid XXX O
sequestrants XXX O
( XXX O
cholestyramine XXX O
and XXX O
colestipol XXX O
) XXX O
, XXX O
nicotinic XXX O
acid XXX O
, XXX O
fenofibrate XXX O
and XXX O
inhibitors XXX O
of XXX O
hydroxymethylglutaryl XXX B-GENE
coenzyme XXX I-GENE
A XXX I-GENE
( XXX I-GENE
HMG XXX I-GENE
CoA XXX I-GENE
) XXX I-GENE
reductase XXX I-GENE
( XXX O
e XXX O
. XXX O
g XXX O
. XXX O
lovastatin XXX O
or XXX O
simvastatin XXX O
) XXX O
are XXX O
the XXX O
most XXX O
effective XXX O
drugs XXX O
for XXX O
use XXX O
in XXX O
patients XXX O
with XXX O
primary XXX O
hypercholesterolaemia XXX O
; XXX O
these XXX O
agents XXX O
reduce XXX O
plasma XXX O
concentrations XXX O
of XXX O
total XXX O
and XXX O
LDL-cholesterol XXX O
by XXX O
15 XXX O
to XXX O
45% XXX O
. XXX O

Cloning XXX O
and XXX O
primary XXX O
structure XXX O
of XXX O
neurocan XXX O
, XXX O
a XXX O
developmentally XXX O
regulated XXX O
, XXX O
aggregating XXX O
chondroitin XXX O
sulfate XXX O
proteoglycan XXX O
of XXX O
brain XXX O
. XXX O

During XXX O
the XXX O
aftermath XXX O
of XXX O
excitation XXX O
of XXX O
the XXX O
skin XXX O
sympathetic XXX O
nerve XXX O
by XXX O
mental XXX O
arithmetics XXX O
, XXX O
3 XXX O
/ XXX O
12 XXX O
A XXX O
delta XXX O
units XXX O
were XXX O
turned XXX O
to XXX O
the XXX O
active XXX O
state XXX O
with XXX O
decreased XXX O
mechanical XXX O
threshold XXX O
. XXX O

Both XXX O
filters XXX O
equally XXX O
contributed XXX O
to XXX O
elevation XXX O
of XXX O
iliac XXX O
venous XXX O
pressure XXX O
( XXX O
median XXX O
, XXX O
9 XXX O
. XXX O
3 XXX O
and XXX O
7 XXX O
. XXX O
2 XXX O
mm XXX O
Hg XXX O
[ XXX O
n XXX O
= XXX O
9 XXX O
] XXX O
with XXX O
the XXX O
spring XXX O
filter XXX O
and XXX O
RF02 XXX O
filter XXX O
, XXX O
respectively XXX O
) XXX O
. XXX O

Phosphate XXX B-GENE
glucose XXX I-GENE
dehydrogenase XXX I-GENE
deficiency XXX O
causing XXX O
hyperbilirubinemia XXX O
in XXX O
the XXX O
newborn XXX O
. XXX O

A XXX O
total XXX O
of XXX O
1459 XXX O
men XXX O
aged XXX O
48 XXX O
to XXX O
84 XXX O
years XXX O
, XXX O
who XXX O
were XXX O
diagnosed XXX O
for XXX O
the XXX O
first XXX O
time XXX O
by XXX O
physicians XXX O
as XXX O
having XXX O
BPH XXX O
in XXX O
1994 XXX O
and XXX O
who XXX O
had XXX O
not XXX O
received XXX O
treatment XXX O
, XXX O
participated XXX O
in XXX O
the XXX O
study XXX O
. XXX O

Selective XXX O
effect XXX O
of XXX O
pulmonary XXX O
oedema XXX O
on XXX O
prostaglandin XXX O
E2 XXX O
pharmacokinetics XXX O
in XXX O
rat XXX O
lung XXX O
. XXX O

As XXX O
measured XXX O
by XXX O
the XXX O
PDQ-39 XXX O
, XXX O
STN-DBS XXX O
significantly XXX O
improves XXX O
important XXX O
aspects XXX O
of XXX O
QoL XXX O
in XXX O
patients XXX O
with XXX O
advanced XXX O
PD XXX O
. XXX O

Deletion XXX O
of XXX O
the XXX O
potential XXX O
initiator XXX O
element XXX O
does XXX O
not XXX O
affect XXX O
repression XXX O
of XXX O
the XXX O
p21 XXX B-GENE
promoter XXX I-GENE
by XXX O
c-Myc XXX B-GENE
. XXX O

Two XXX O
patients XXX O
withdrew XXX O
from XXX O
therapy XXX O
, XXX O
one XXX O
for XXX O
personal XXX O
reasons XXX O
and XXX O
one XXX O
because XXX O
a XXX O
paraspinal XXX O
mass XXX O
developed XXX O
. XXX O

CONCLUSION XXX O
: XXX O
A XXX O
valve-like XXX O
mechanism XXX O
formed XXX O
by XXX O
the XXX O
capsulorhexis XXX O
rim XXX O
partially XXX O
adhered XXX O
to XXX O
the XXX O
IOL XXX O
optic XXX O
can XXX O
occur XXX O
postoperatively XXX O
. XXX O

SUP46 XXX B-GENE
is XXX O
implicated XXX O
in XXX O
translation XXX O
fidelity XXX O
and XXX O
encodes XXX O
the XXX O
ribosomal XXX B-GENE
protein XXX I-GENE
S13 XXX I-GENE
. XXX O

The XXX O
present XXX O
study XXX O
shows XXX O
that XXX O
phosphatidylinositol XXX O
3-kinase-dependent XXX O
p38 XXX B-GENE
kinase XXX I-GENE
activation XXX O
regulates XXX O
Akt XXX B-GENE
phosphorylation XXX O
and XXX O
activity XXX O
in XXX O
human XXX O
neutrophils XXX O
. XXX O

There XXX O
were XXX O
122 XXX O
cases XXX O
of XXX O
tuberculosis XXX O
over XXX O
an XXX O
average XXX O
10 XXX O
. XXX O
3 XXX O
yr XXX O
of XXX O
follow-up XXX O
( XXX O
crude XXX O
annual XXX O
incidence XXX O
, XXX O
76 XXX O
. XXX O
2 XXX O
/ XXX O
100 XXX O
, XXX O
000 XXX O
) XXX O
. XXX O

To XXX O
lower XXX O
the XXX O
current XXX O
high XXX O
incidence XXX O
of XXX O
NANB-induced XXX O
PTH XXX O
, XXX O
in XXX O
1986 XXX O
, XXX O
the XXX O
American XXX O
Association XXX O
of XXX O
Blood XXX O
Banks XXX O
( XXX O
AABB XXX O
) XXX O
recommended XXX O
testing XXX O
for XXX O
these XXX O
PTH-associated XXX O
"surrogate" XXX O
markers XXX O
on XXX O
all XXX O
donated XXX O
units XXX O
of XXX O
blood XXX O
. XXX O

As XXX O
assessed XXX O
by XXX O
a XXX O
genetic XXX O
assay XXX O
that XXX O
measures XXX O
AAI-dependent XXX O
DNA XXX O
binding XXX O
, XXX O
TraM XXX B-GENE
inhibited XXX O
TraR XXX B-GENE
function XXX O
before XXX O
and XXX O
after XXX O
the XXX O
transcription XXX O
factor XXX O
had XXX O
bound XXX O
to XXX O
its XXX O
DNA XXX O
recognition XXX O
site XXX O
. XXX O

The XXX O
gray XXX O
matter XXX O
NAA XXX O
/ XXX O
mI XXX O
ratio XXX O
clearly XXX O
separated XXX O
the XXX O
two XXX O
groups XXX O
. XXX O

The XXX O
feed XXX O
consumed XXX O
which XXX O
was XXX O
lowered XXX O
by XXX O
25% XXX O
initially XXX O
, XXX O
did XXX O
not XXX O
alter XXX O
later XXX O
. XXX O

As XXX O
expected XXX O
, XXX O
the XXX O
insulin XXX B-GENE
effect XXX O
to XXX O
increase XXX O
ras XXX B-GENE
GTP XXX I-GENE
formation XXX O
and XXX O
MAP XXX B-GENE
kinase XXX I-GENE
activity XXX O
was XXX O
negligible XXX O
in XXX O
A XXX O
/ XXX O
K1018 XXX O
cells XXX O
but XXX O
normal XXX O
, XXX O
or XXX O
supernormal XXX O
, XXX O
in XXX O
Y XXX O
/ XXX O
F2 XXX O
cells XXX O
. XXX O

Using XXX O
a XXX O
series XXX O
of XXX O
mutant XXX O
T XXX O
antigens XXX O
expressed XXX O
by XXX O
recombinant XXX O
baculoviruses XXX O
in XXX O
Sf9 XXX O
cells XXX O
, XXX O
we XXX O
find XXX O
that XXX O
the XXX O
origin XXX O
unwinding XXX O
activities XXX O
of XXX O
both XXX O
TS677-- XXX O
> XXX O
A XXX O
and XXX O
TS677 XXX O
, XXX O
679-- XXX O
> XXX O
A XXX O
are XXX O
inhibited XXX O
by XXX O
the XXX O
T-antigen XXX B-GENE
kinase XXX I-GENE
, XXX O
as XXX O
is XXX O
wild-type XXX B-GENE
T XXX I-GENE
antigen XXX I-GENE
. XXX O

Information XXX O
on XXX O
conserved XXX O
noncoding XXX O
sequences XXX O
will XXX O
help XXX O
in XXX O
studies XXX O
on XXX O
the XXX O
regulation XXX O
of XXX O
the XXX O
pro XXX B-GENE
alpha XXX I-GENE
1 XXX I-GENE
( XXX I-GENE
II XXX I-GENE
) XXX I-GENE
collagen XXX I-GENE
gene XXX I-GENE
. XXX O

HA XXX O
resulted XXX O
in XXX O
decreased XXX O
( XXX O
p XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
Tre XXX O
( XXX O
0 XXX O
. XXX O
4 XXX O
degrees XXX O
C XXX O
) XXX O
and XXX O
HR XXX O
( XXX O
17 XXX O
b XXX O
X XXX O
min-1 XXX O
) XXX O
, XXX O
and XXX O
increased XXX O
( XXX O
p XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
Msw XXX O
( XXX O
16 XXX O
g XXX O
X XXX O
m-2 XXX O
X XXX O
h-1 XXX O
) XXX O
during XXX O
the XXX O
saline XXX O
experiments XXX O
. XXX O

Our XXX O
findings XXX O
demonstrate XXX O
a XXX O
dose-dependent XXX O
blockade XXX O
of XXX O
the XXX O
mechanical XXX O
sensitivity XXX O
caused XXX O
by XXX O
a XXX O
mild XXX O
thermal XXX O
injury XXX O
by XXX O
both XXX O
GBP XXX O
and XXX O
IBG XXX O
. XXX O

In XXX O
this XXX O
study XXX O
we XXX O
have XXX O
introduced XXX O
mutations XXX O
into XXX O
the XXX O
corresponding XXX O
elements XXX O
of XXX O
two XXX O
cox3 XXX B-GENE
promoters XXX I-GENE
and XXX O
show XXX O
that XXX O
while XXX O
the XXX O
core XXX B-GENE
element XXX I-GENE
is XXX O
essential XXX O
for XXX O
cox3 XXX B-GENE
promoter XXX I-GENE
activity XXX O
, XXX O
upstream XXX O
element XXX O
mutations XXX O
have XXX O
little XXX O
or XXX O
no XXX O
effect XXX O
. XXX O

The XXX O
method XXX O
described XXX O
may XXX O
prove XXX O
useful XXX O
in XXX O
studying XXX O
the XXX O
physiology XXX O
of XXX O
the XXX O
nasal XXX O
cycle XXX O
. XXX O

Plasma XXX B-GENE
renin XXX I-GENE
concentration XXX O
is XXX O
significantly XXX O
higher XXX O
in XXX O
the XXX O
subcapsular XXX O
venous XXX O
outflow XXX O
, XXX O
which XXX O
drains XXX O
the XXX O
superficial XXX O
cortex XXX O
, XXX O
than XXX O
in XXX O
the XXX O
deep XXX O
venous XXX O
outflow XXX O
, XXX O
which XXX O
drains XXX O
the XXX O
inner XXX O
half XXX O
of XXX O
the XXX O
cortex XXX O
and XXX O
medulla XXX O
of XXX O
the XXX O
cat XXX O
kidney XXX O
. XXX O

The XXX O
factor XXX O
designated XXX O
B XXX O
formed XXX O
a XXX O
complex XXX O
centered XXX O
on XXX O
the XXX O
sequence XXX O
TGTGGT XXX B-GENE
, XXX O
a XXX O
core XXX O
motif XXX O
recognized XXX O
by XXX O
members XXX O
of XXX O
the XXX O
AML XXX B-GENE
/ XXX I-GENE
CBFalpha XXX I-GENE
transcription XXX I-GENE
factor XXX I-GENE
family XXX I-GENE
. XXX O

A XXX O
new XXX O
vector XXX O
, XXX O
pHBK280 XXX O
, XXX O
was XXX O
designed XXX O
to XXX O
facilitate XXX O
this XXX O
analysis XXX O
. XXX O

The XXX O
DNA XXX O
binding XXX O
and XXX O
multimerization XXX O
activities XXX O
of XXX O
c-Myb XXX B-GENE
appear XXX O
to XXX O
be XXX O
unaffected XXX O
by XXX O
the XXX O
S528A XXX O
substitution XXX O
, XXX O
suggesting XXX O
that XXX O
phosphorylation XXX O
of XXX O
serine XXX O
528 XXX O
may XXX O
mediate XXX O
its XXX O
effect XXX O
on XXX O
the XXX O
transcription XXX O
transactivating XXX O
activity XXX O
of XXX O
c-Myb XXX B-GENE
by XXX O
regulating XXX O
interactions XXX O
with XXX O
other XXX O
proteins XXX O
. XXX O

RESULTS XXX O
: XXX O
Twenty-two XXX O
( XXX O
26% XXX O
) XXX O
patients XXX O
had XXX O
PHG XXX O
before XXX O
( XXX O
group XXX O
A XXX O
) XXX O
and XXX O
64 XXX O
( XXX O
74% XXX O
) XXX O
developed XXX O
PHG XXX O
after XXX O
variceal XXX O
eradication XXX O
( XXX O
group XXX O
B XXX O
) XXX O
. XXX O

PATIENTS XXX O
AND XXX O
METHODS XXX O
: XXX O
Immediately XXX O
before XXX O
radical XXX O
prostatectomy XXX O
, XXX O
bone XXX O
marrow XXX O
aspirates XXX O
from XXX O
both XXX O
sides XXX O
of XXX O
the XXX O
iliac XXX O
crest XXX O
were XXX O
taken XXX O
from XXX O
287 XXX O
patients XXX O
. XXX O

Transcription XXX O
of XXX O
these XXX O
genes XXX O
was XXX O
also XXX O
elevated XXX O
in XXX O
gut XXX O
and XXX O
lung XXX O
during XXX O
freezing XXX O
, XXX O
but XXX O
mRNA XXX O
levels XXX O
in XXX O
these XXX O
tissues XXX O
were XXX O
lower XXX O
than XXX O
in XXX O
liver XXX O
. XXX O

Findings XXX O
of XXX O
positive XXX O
potentials XXX O
showed XXX O
that XXX O
N1 XXX O
originated XXX O
in XXX O
the XXX O
area XXX O
of XXX O
ventral XXX O
gray XXX O
matter XXX O
through XXX O
the XXX O
ventro-lateral XXX O
column XXX O
and XXX O
N2 XXX O
through XXX O
the XXX O
dorsal XXX O
column XXX O
. XXX O

Chem XXX O
. XXX O
, XXX O
270 XXX O
: XXX O
7117-7124 XXX O
, XXX O
1995 XXX O
; XXX O
and XXX O
MT XXX O
Hartsough XXX O
et XXX O
al XXX O
. XXX O
, XXX O
J XXX O
. XXX O

Vector XXX O
stocks XXX O
containing XXX O
envelope XXX O
proteins XXX O
from XXX O
three XXX O
different XXX O
SIVmac XXX O
clones XXX O
, XXX O
namely XXX O
, XXX O
SIVmac239 XXX O
( XXX O
T-lymphocyte XXX O
tropic XXX O
[ XXX O
T-tropic XXX O
] XXX O
) XXX O
, XXX O
SIVmac316 XXX O
( XXX O
macrophage XXX O
tropic XXX O
[ XXX O
M-tropic XXX O
] XXX O
) XXX O
, XXX O
and XXX O
SIVmac1A11 XXX O
( XXX O
dualtropic XXX O
) XXX O
, XXX O
were XXX O
tested XXX O
. XXX O

A XXX O
twelfth XXX O
insertion XXX O
disrupts XXX O
two XXX O
genes XXX O
, XXX O
Nrk XXX B-GENE
, XXX O
a XXX O
"neurospecific" XXX B-GENE
receptor XXX I-GENE
tyrosine XXX I-GENE
kinase XXX I-GENE
, XXX O
and XXX O
Tpp XXX B-GENE
, XXX O
which XXX O
encodes XXX O
a XXX O
neuropeptidase XXX B-GENE
. XXX O

The XXX O
Southern XXX O
technique XXX O
allowed XXX O
a XXX O
further XXX O
localization XXX O
of XXX O
the XXX O
region XXX O
of XXX O
most XXX O
extensive XXX O
transcription XXX O
to XXX O
a XXX O
1 XXX B-GENE
. XXX I-GENE
8 XXX I-GENE
kb XXX I-GENE
HindIII-EcoRI XXX I-GENE
fragment XXX I-GENE
. XXX O

In XXX O
literature XXX O
, XXX O
the XXX O
HBE XXX O
has XXX O
been XXX O
displayed XXX O
by XXX O
application XXX O
of XXX O
the XXX O
averaging XXX O
method XXX O
. XXX O

One XXX O
of XXX O
its XXX O
lysine XXX O
residues XXX O
is XXX O
modified XXX O
by XXX O
spermidine XXX O
to XXX O
form XXX O
hypusine XXX O
, XXX O
a XXX O
posttranslational XXX O
modification XXX O
unique XXX O
to XXX O
eIF-5A XXX B-GENE
. XXX O

Patulin XXX O
is XXX O
extracted XXX O
from XXX O
apple XXX O
butter XXX O
samples XXX O
with XXX O
ethyl XXX O
acetate XXX O
and XXX O
the XXX O
extract XXX O
is XXX O
cleaned XXX O
up XXX O
on XXX O
a XXX O
silica XXX O
gel XXX O
column XXX O
, XXX O
using XXX O
benzene-ethyl XXX O
acetate XXX O
( XXX O
75+25 XXX O
) XXX O
as XXX O
the XXX O
eluant XXX O
. XXX O

The XXX O
lowest XXX O
culture XXX O
failure XXX O
rate XXX O
of XXX O
0 XXX O
. XXX O
2 XXX O
per XXX O
cent XXX O
was XXX O
found XXX O
after XXX O
EAF XXX O
compared XXX O
with XXX O
0 XXX O
. XXX O
9 XXX O
per XXX O
cent XXX O
among XXX O
CVS XXX O
. XXX O

Homograft XXX O
response XXX O
and XXX O
hemagglutinin XXX B-GENE
production XXX O
by XXX O
sensitized XXX O
thymectomized XXX O
irradiated XXX O
adult XXX O
mice XXX O
. XXX O

Pregnant XXX O
rats XXX O
were XXX O
exposed XXX O
to XXX O
one XXX O
of XXX O
the XXX O
following XXX O
: XXX O
( XXX O
1 XXX O
) XXX O
10% XXX O
O2 XXX O
in XXX O
N2 XXX O
or XXX O
100% XXX O
O2 XXX O
for XXX O
2 XXX O
days XXX O
beginning XXX O
at XXX O
day XXX O
7 XXX O
, XXX O
11 XXX O
, XXX O
14 XXX O
, XXX O
or XXX O
18 XXX O
of XXX O
pregnancy XXX O
; XXX O
( XXX O
2 XXX O
) XXX O
10% XXX O
O2 XXX O
in XXX O
N2 XXX O
or XXX O
100% XXX O
O2 XXX O
for XXX O
10 XXX O
h XXX O
/ XXX O
day XXX O
beginning XXX O
at XXX O
day XXX O
7 XXX O
; XXX O
or XXX O
( XXX O
3 XXX O
) XXX O
14-11% XXX O
O2 XXX O
in XXX O
N2 XXX O
continuously XXX O
beginning XXX O
at XXX O
day XXX O
14 XXX O
till XXX O
day XXX O
21 XXX O
when XXX O
they XXX O
were XXX O
sacrificed XXX O
. XXX O

Most XXX O
kinases XXX B-GENE
are XXX O
not XXX O
significantly XXX O
inhibited XXX O
by XXX O
roscovitine XXX O
. XXX O
cdc2 XXX B-GENE
/ XXX I-GENE
cyclin XXX I-GENE
B XXX I-GENE
, XXX O
cdk2 XXX B-GENE
/ XXX I-GENE
cyclin XXX I-GENE
A XXX I-GENE
, XXX O
cdk2 XXX B-GENE
/ XXX I-GENE
cyclin XXX I-GENE
E XXX I-GENE
and XXX O
cdk5 XXX B-GENE
/ XXX I-GENE
p35 XXX I-GENE
only XXX O
are XXX O
substantially XXX O
inhibited XXX O
( XXX O
IC50 XXX O
values XXX O
of XXX O
0 XXX O
. XXX O
65 XXX O
, XXX O
0 XXX O
. XXX O
7 XXX O
, XXX O
0 XXX O
. XXX O
7 XXX O
and XXX O
0 XXX O
. XXX O
2 XXX O
microM XXX O
, XXX O
respectively XXX O
) XXX O
. XXX O
cdk4 XXX B-GENE
/ XXX I-GENE
cyclin XXX I-GENE
D1 XXX I-GENE
and XXX O
cdk6 XXX B-GENE
/ XXX I-GENE
cyclin XXX I-GENE
D2 XXX I-GENE
are XXX O
very XXX O
poorly XXX O
inhibited XXX O
by XXX O
roscovitine XXX O
( XXX O
IC50 XXX O
> XXX O
100 XXX O
microM XXX O
) XXX O
. XXX O

Serum XXX O
HBV-DNA XXX O
, XXX O
viral XXX O
serology XXX O
, XXX O
and XXX O
liver XXX O
enzymes XXX O
were XXX O
measured XXX O
sequentially XXX O
; XXX O
liver XXX O
histology XXX O
was XXX O
taken XXX O
before XXX O
and XXX O
during XXX O
treatment XXX O
in XXX O
12 XXX O
patients XXX O
. XXX O

The XXX O
high XXX B-GENE
density XXX I-GENE
lipoprotein XXX I-GENE
( XXX I-GENE
HDL XXX I-GENE
) XXX I-GENE
receptor XXX I-GENE
mediates XXX O
the XXX O
uptake XXX O
of XXX O
cholesterol XXX O
and XXX O
cholesteryl XXX O
esters XXX O
, XXX O
substrates XXX O
for XXX O
steroidogenesis XXX O
, XXX O
from XXX O
an XXX O
HDL XXX O
particle XXX O
in XXX O
the XXX O
adrenal XXX O
gland XXX O
and XXX O
gonads XXX O
. XXX O

Retrograde XXX O
filling XXX O
consists XXX O
in XXX O
sealing XXX O
endodontics XXX O
system XXX O
directly XXX O
at XXX O
the XXX O
apical XXX O
zone XXX O
after XXX O
surgical XXX O
approach XXX O
. XXX O

The XXX O
hematopoietic XXX B-GENE
colony-stimulating XXX I-GENE
factors XXX I-GENE
( XXX O
CSF XXX B-GENE
) XXX O
have XXX O
been XXX O
introduced XXX O
into XXX O
clinical XXX O
practice XXX O
as XXX O
additional XXX O
supportive XXX O
measures XXX O
that XXX O
can XXX O
reduce XXX O
the XXX O
incidence XXX O
of XXX O
infectious XXX O
complications XXX O
in XXX O
patients XXX O
with XXX O
cancer XXX O
and XXX O
neutropenia XXX O
. XXX O

Furthermore XXX O
, XXX O
hormonal XXX O
regulation XXX O
of XXX O
G XXX O
( XXX O
1 XXX O
) XXX O
gene XXX O
transcription XXX O
can XXX O
occur XXX O
even XXX O
without XXX O
additional XXX O
activation XXX O
of XXX O
the XXX O
Mek-Erk1 XXX B-GENE
/ XXX I-GENE
2 XXX I-GENE
pathway XXX O
by XXX O
estrogen XXX B-GENE
receptors XXX I-GENE
. XXX O

A XXX O
critical XXX O
heart XXX O
rate XXX O
and XXX O
/ XXX O
or XXX O
appropriate XXX O
sympathetic XXX O
state XXX O
was XXX O
found XXX O
to XXX O
provoke XXX O
all XXX O
instances XXX O
of XXX O
reentrant XXX O
or XXX O
automatic XXX O
atrial XXX O
tachycardia XXX O
and XXX O
atypical XXX O
junctional XXX O
tachycardia XXX O
. XXX O

Chlorambucil XXX O
and XXX O
interferon XXX B-GENE
for XXX O
low XXX O
grade XXX O
non-Hodgkin's XXX O
lymphoma XXX O
. XXX O

The XXX O
DNA XXX O
binding XXX O
activities XXX O
of XXX O
the XXX O
three XXX O
repressor XXX O
preparations XXX O
were XXX O
studied XXX O
using XXX O
fragments XXX O
containing XXX O
CIRs XXX O
( XXX O
CIR3-CIR6 XXX O
) XXX O
from XXX O
the XXX O
essential XXX O
early XXX O
region XXX O
as XXX O
templates XXX O
for XXX O
DNase XXX B-GENE
I XXX I-GENE
footprinting XXX O
. XXX O

XII XXX O
. XXX O

This XXX O
effect XXX O
required XXX O
( XXX O
i XXX O
) XXX O
IR XXX B-GENE
activation XXX O
since XXX O
it XXX O
was XXX O
abrogated XXX O
by XXX O
IR XXX B-GENE
mutation XXX O
at XXX O
tyrosines XXX O
1162 XXX O
and XXX O
1163 XXX O
and XXX O
( XXX O
ii XXX O
) XXX O
NF-kappaB XXX B-GENE
activation XXX O
since XXX O
it XXX O
was XXX O
abolished XXX O
by XXX O
overexpression XXX O
of XXX O
dominant-negative XXX B-GENE
IkappaB-alpha XXX I-GENE
( XXX I-GENE
A32 XXX I-GENE
/ XXX I-GENE
36 XXX I-GENE
) XXX I-GENE
and XXX O
mimicked XXX O
by XXX O
overexpression XXX O
of XXX O
the XXX O
NF-kappaB XXX B-GENE
c-Rel XXX B-GENE
subunit XXX I-GENE
. XXX O

Synaptic XXX O
targeting XXX O
of XXX O
the XXX O
postsynaptic XXX B-GENE
density XXX I-GENE
protein XXX I-GENE
PSD-95 XXX I-GENE
mediated XXX O
by XXX O
a XXX O
tyrosine-based XXX O
trafficking XXX O
signal XXX O
. XXX O

Regulation XXX O
of XXX O
HIV-1 XXX O
transcription XXX O
. XXX O

We XXX O
isolated XXX O
the XXX O
human XXX B-GENE
FGF-BP XXX I-GENE
promoter XXX I-GENE
and XXX O
determined XXX O
by XXX O
deletion XXX O
analysis XXX O
that XXX O
TPA XXX B-GENE
regulatory XXX I-GENE
elements XXX I-GENE
were XXX O
all XXX O
contained XXX O
in XXX O
the XXX O
first XXX O
118 XXX O
base XXX O
pairs XXX O
upstream XXX O
of XXX O
the XXX O
transcription XXX O
start XXX O
site XXX O
. XXX O

Derivatives XXX O
of XXX O
boswellic XXX O
acids XXX O
. XXX O

Testing XXX O
was XXX O
associated XXX O
with XXX O
a XXX O
history XXX O
of XXX O
nonsexual XXX O
risk XXX O
behavior XXX O
, XXX O
increased XXX O
knowledge XXX O
of XXX O
the XXX O
hepatitis XXX O
C XXX O
virus XXX O
, XXX O
and XXX O
healthcare XXX O
provider XXX O
communication XXX O
. XXX O

Serum XXX O
prostatic XXX B-GENE
acid XXX I-GENE
phosphatase XXX I-GENE
levels XXX O
showed XXX O
a XXX O
significantly XXX O
weaker XXX O
correlation XXX O
with XXX O
cancer XXX O
volume XXX O
( XXX O
r XXX O
equals XXX O
0 XXX O
. XXX O
51 XXX O
) XXX O
and XXX O
every XXX O
other XXX O
pathological XXX O
parameter XXX O
. XXX O

With XXX O
exon XXX O
trapping XXX O
, XXX O
we XXX O
could XXX O
isolate XXX O
five XXX O
potential XXX O
exons XXX O
from XXX O
the XXX O
YAC XXX O
946E12 XXX O
that XXX O
spans XXX O
the XXX O
region XXX O
, XXX O
four XXX O
of XXX O
which XXX O
could XXX O
be XXX O
placed XXX O
in XXX O
the XXX O
contig XXX O
in XXX O
the XXX O
vicinity XXX O
of XXX O
the XXX O
breakpoints XXX O
. XXX O

No XXX O
preferential XXX O
VH XXX B-GENE
/ XXX I-GENE
VL-chains XXX I-GENE
correlated XXX O
with XXX O
any XXX O
of XXX O
the XXX O
12 XXX O
different XXX O
antigen XXX O
reactivities XXX O
, XXX O
even XXX O
for XXX O
mAbs XXX O
with XXX O
nearly XXX O
identical XXX O
cross-reactivities XXX O
. XXX O

In XXX O
Xenopus XXX O
laevis XXX O
, XXX O
the XXX O
gene XXX O
encoding XXX O
the XXX O
elongation XXX B-GENE
factor XXX I-GENE
1-alpha XXX I-GENE
variant XXX I-GENE
EF-1 XXX B-GENE
alpha XXX I-GENE
O XXX I-GENE
, XXX O
where XXX O
O XXX O
stands XXX O
for XXX O
oocyte XXX O
, XXX O
is XXX O
expressed XXX O
in XXX O
oocytes XXX O
and XXX O
early XXX O
embryos XXX O
. XXX O

Both XXX O
proteins XXX O
were XXX O
shown XXX O
to XXX O
be XXX O
constitutively XXX O
associated XXX O
with XXX O
tubulin XXX B-GENE
. XXX O

We XXX O
also XXX O
show XXX O
that XXX O
p65 XXX B-GENE
binds XXX O
to XXX O
these XXX O
targets XXX O
with XXX O
almost XXX O
equal XXX O
affinity XXX O
and XXX O
that XXX O
different XXX O
residues XXX O
have XXX O
variable XXX O
roles XXX O
in XXX O
binding XXX O
different XXX O
kappaB XXX B-GENE
targets XXX I-GENE
. XXX O

Although XXX O
the XXX O
Src XXX B-GENE
tyrosine XXX I-GENE
kinase XXX I-GENE
induces XXX O
constitutive XXX O
Stat3 XXX B-GENE
phosphorylation XXX O
on XXX O
tyrosine XXX O
, XXX O
activation XXX O
of XXX O
Stat3-mediated XXX O
gene XXX O
regulation XXX O
requires XXX O
both XXX O
tyrosine XXX O
and XXX O
serine XXX O
phosphorylation XXX O
of XXX O
Stat3 XXX B-GENE
. XXX O

IgM XXX B-GENE
and XXX O
IgG XXX B-GENE
anti XXX I-GENE
A XXX I-GENE
and XXX O
anti XXX B-GENE
B XXX I-GENE
antibody XXX I-GENE
status XXX O
of XXX O
100 XXX O
antenatal XXX O
O XXX O
group XXX O
mothers XXX O
( XXX O
who XXX O
had XXX O
non XXX O
O XXX O
group XXX O
husbands XXX O
) XXX O
were XXX O
studied XXX O
. XXX O

A XXX O
triple-mutant XXX B-GENE
TBP XXX I-GENE
( XXX O
R231E XXX O
+ XXX O
R235E XXX O
+ XXX O
R239S XXX O
) XXX O
had XXX O
greatly XXX O
reduced XXX O
activity XXX O
for XXX O
yeast XXX B-GENE
U6 XXX I-GENE
snRNA XXX I-GENE
gene XXX I-GENE
transcription XXX O
while XXX O
remaining XXX O
active XXX O
for XXX O
Pol XXX B-GENE
II XXX I-GENE
basal XXX O
transcription XXX O
. XXX O

AIDS-related XXX O
disseminated XXX O
histoplasmosis XXX O
in XXX O
San XXX O
Francisco XXX O
, XXX O
California XXX O
. XXX O

Samples XXX O
obtained XXX O
from XXX O
normal XXX O
volunteers XXX O
and XXX O
from XXX O
the XXX O
great XXX O
majority XXX O
of XXX O
the XXX O
patients XXX O
, XXX O
excluding XXX O
those XXX O
with XXX O
asthma XXX O
, XXX O
had XXX O
no XXX O
effect XXX O
on XXX O
ciliary XXX O
beating XXX O
. XXX O

Gng3lg XXX B-GENE
transcripts XXX I-GENE
are XXX O
expressed XXX O
in XXX O
a XXX O
variety XXX O
of XXX O
tissues XXX O
including XXX O
both XXX O
brain XXX O
and XXX O
testes XXX O
. XXX O

Interdigitated XXX O
residues XXX O
within XXX O
a XXX O
small XXX O
region XXX O
of XXX O
VP16 XXX B-GENE
interact XXX O
with XXX O
Oct-1 XXX B-GENE
, XXX O
HCF XXX B-GENE
, XXX O
and XXX O
DNA XXX O
. XXX O

In XXX O
an XXX O
earlier XXX O
study XXX O
( XXX O
Kimura XXX O
, XXX O
Y XXX O
. XXX O
, XXX O
Kurzydlowski XXX O
, XXX O
K XXX O
. XXX O
, XXX O
Tada XXX O
, XXX O
M XXX O
. XXX O
, XXX O
and XXX O
MacLennan XXX O
, XXX O
D XXX O
. XXX O

25-OH-D3 XXX O
did XXX O
not XXX O
adversely XXX O
affect XXX O
animal XXX O
health XXX O
at XXX O
the XXX O
proposed XXX O
use XXX O
level XXX O
of XXX O
99 XXX O
micrograms XXX O
/ XXX O
kg XXX O
feed XXX O
when XXX O
replacing XXX O
vitamin XXX O
D3 XXX O
in XXX O
turkey XXX O
rations XXX O
. XXX O

Laser XXX O
therapy XXX O
of XXX O
penile XXX O
carcinoma XXX O
. XXX O

Vocal XXX O
cord XXX O
abduction XXX O
rehabilitation XXX O
by XXX O
nervous XXX O
selective XXX O
anastomosis XXX O
. XXX O

Dissociative XXX O
anesthetics XXX O
2- XXX O
( XXX O
o-chlorophenyl XXX O
) XXX O
-2-methyl-amino XXX O
cyclohexane XXX O
HCL XXX O
( XXX O
CI-581 XXX O
) XXX O
. XXX O

If XXX O
this XXX O
is XXX O
the XXX O
case XXX O
, XXX O
identification XXX O
and XXX O
characterization XXX O
of XXX O
transcripts XXX O
from XXX O
the XXX O
Ig XXX B-GENE
loci XXX I-GENE
should XXX O
permit XXX O
a XXX O
better XXX O
understanding XXX O
of XXX O
the XXX O
gene XXX O
rearrangement XXX O
process XXX O
. XXX O

The XXX O
nucleosomal XXX O
arrays XXX O
detected XXX O
by XXX O
MPE XXX O
X XXX O
Fe XXX O
( XXX O
II XXX O
) XXX O
were XXX O
characterized XXX O
by XXX O
a XXX O
considerable XXX O
loss XXX O
of XXX O
detail XXX O
and XXX O
significantly XXX O
enhanced XXX O
accessibility XXX O
, XXX O
the XXX O
extent XXX O
of XXX O
which XXX O
probably XXX O
reflected XXX O
the XXX O
relative XXX O
transcription XXX O
rate XXX O
of XXX O
each XXX O
gene XXX O
. XXX O

Deletion XXX O
of XXX O
the XXX O
RVH XXX B-GENE
domain XXX I-GENE
resulted XXX O
in XXX O
loss XXX O
of XXX O
Ca XXX O
( XXX O
2+ XXX O
) XXX O
-dependent XXX O
activation XXX O
. XXX O

The XXX O
presence XXX O
of XXX O
the XXX O
RV XXX O
5' XXX O
( XXX O
+ XXX O
) XXX O
SL XXX O
sequence XXX O
had XXX O
the XXX O
primary XXX O
enhancing XXX O
effect XXX O
on XXX O
translation XXX O
. XXX O

Three XXX O
high XXX O
mobility XXX O
group-like XXX O
sequences XXX O
within XXX O
a XXX O
48-base XXX O
pair XXX O
enhancer XXX O
of XXX O
the XXX O
Col2a1 XXX B-GENE
gene XXX I-GENE
are XXX O
required XXX O
for XXX O
cartilage-specific XXX O
expression XXX O
in XXX O
vivo XXX O
. XXX O

The XXX O
findings XXX O
suggest XXX O
that XXX O
ERP XXX O
effects XXX O
of XXX O
distinct XXX O
memory XXX O
processes XXX O
are XXX O
differentially XXX O
influenced XXX O
by XXX O
the XXX O
encoding XXX O
instructions XXX O
. XXX O

Duch XXX O
, XXX O
and XXX O
F XXX O
. XXX O

Risk XXX O
factors XXX O
influencing XXX O
lymph XXX O
nodes XXX O
metastasis XXX O
in XXX O
lung XXX O
cancer XXX O
with XXX O
stage XXX O
I XXX O
, XXX O
II XXX O
or XXX O
IIIA XXX O
. XXX O

Our XXX O
results XXX O
establish XXX O
GKLF XXX B-GENE
as XXX O
a XXX O
sequence-specific XXX O
transcription XXX O
factor XXX O
likely XXX O
involved XXX O
in XXX O
regulation XXX O
of XXX O
expression XXX O
of XXX O
endogenous XXX O
genes XXX O
. XXX O

Sequence XXX O
comparison XXX O
and XXX O
binding XXX O
studies XXX O
of XXX O
the XXX O
18-bp XXX B-GENE
MOK2-binding XXX I-GENE
sites XXX I-GENE
present XXX O
in XXX O
intron XXX O
2 XXX O
of XXX O
human XXX O
, XXX O
bovine XXX O
, XXX O
and XXX O
mouse XXX B-GENE
IRBP XXX I-GENE
genes XXX I-GENE
show XXX O
that XXX O
the XXX O
3'-half XXX O
sequence XXX O
is XXX O
the XXX O
essential XXX O
core XXX O
element XXX O
for XXX O
MOK2 XXX B-GENE
binding XXX O
. XXX O

Carnitine XXX B-GENE
palmitoyltransferase XXX I-GENE
( XXX I-GENE
CPT XXX I-GENE
) XXX I-GENE
II XXX I-GENE
deficiency XXX O
is XXX O
the XXX O
most XXX O
common XXX O
inherited XXX O
disorder XXX O
of XXX O
lipid XXX O
metabolism XXX O
affecting XXX O
skeletal XXX O
muscle XXX O
. XXX O

The XXX O
intercistronic XXX O
gene XXX O
junctions XXX O
of XXX O
vesicular XXX O
stomatitis XXX O
virus XXX O
( XXX O
VSV XXX O
) XXX O
contain XXX O
conserved XXX O
sequence XXX O
elements XXX O
that XXX O
are XXX O
important XXX O
for XXX O
polyadenylation XXX O
and XXX O
transcription XXX O
termination XXX O
of XXX O
upstream XXX O
transcript XXX O
as XXX O
well XXX O
as XXX O
reinitiation XXX O
of XXX O
transcription XXX O
of XXX O
downstream XXX O
transcript XXX O
. XXX O

Each XXX O
trial XXX O
consisted XXX O
of XXX O
light XXX O
and XXX O
buzzer XXX O
for XXX O
five XXX O
seconds XXX O
as XXX O
conditioned XXX O
stimuli XXX O
and XXX O
electric XXX O
shock XXX O
for XXX O
five XXX O
seconds XXX O
as XXX O
an XXX O
unconditioned XXX O
stimulus XXX O
. XXX O

Conversely XXX O
, XXX O
when XXX O
VDR XXX B-GENE
is XXX O
overexpressed XXX O
, XXX O
vitamin XXX O
D3 XXX O
attenuates XXX O
9-cis XXX O
RA XXX O
induction XXX O
from XXX O
an XXX O
RXR-responsive XXX B-GENE
element XXX I-GENE
. XXX O

Rigorous XXX O
treatment XXX O
protocols XXX O
for XXX O
diet XXX O
delivery XXX O
and XXX O
EEN-related XXX O
GI XXX O
adverse XXX O
effects XXX O
were XXX O
applied XXX O
. XXX O

Furthermore XXX O
, XXX O
the XXX O
potency XXX O
of XXX O
Dacarbacine XXX O
in XXX O
the XXX O
treatment XXX O
of XXX O
carcinoid XXX O
tumors XXX O
seems XXX O
to XXX O
be XXX O
underestimated XXX O
up XXX O
to XXX O
now XXX O
. XXX O

The XXX O
induction XXX O
of XXX O
seizures XXX O
in XXX O
"Papio XXX O
papio" XXX O
following XXX O
allylglycine XXX O
alone XXX O
or XXX O
in XXX O
combination XXX O
with XXX O
intermittent XXX O
photic XXX O
stimulation XXX O
. XXX O

Thus XXX O
, XXX O
the XXX O
induction XXX O
of XXX O
E2F XXX B-GENE
binding XXX O
to XXX O
the XXX O
E2F-1 XXX B-GENE
promoter XXX I-GENE
by XXX O
the XXX O
E4-6 XXX B-GENE
/ XXX I-GENE
7 XXX I-GENE
protein XXX I-GENE
observed XXX O
in XXX O
vitro XXX O
correlates XXX O
with XXX O
transactivation XXX O
of XXX O
E2F-1 XXX B-GENE
promoter XXX I-GENE
activity XXX O
in XXX O
vivo XXX O
. XXX O

With XXX O
steady XXX O
illumination XXX O
, XXX O
outer XXX O
retinal XXX O
( XXX O
photoreceptor XXX O
) XXX O
QO2 XXX O
decreased XXX O
to XXX O
1 XXX O
. XXX O
4 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
9 XXX O
ml XXX O
O2 XXX O
/ XXX O
( XXX O
100 XXX O
g XXX O
. XXX O
min XXX O
) XXX O
, XXX O
but XXX O
inner XXX O
retinal XXX O
QO2 XXX O
remained XXX O
unchanged XXX O
at XXX O
3 XXX O
. XXX O
7 XXX O
+ XXX O
/ XXX O
- XXX O
1 XXX O
. XXX O
5 XXX O
ml XXX O
O2 XXX O
/ XXX O
( XXX O
100 XXX O
g XXX O
. XXX O
min XXX O
) XXX O
( XXX O
5 XXX O
cats XXX O
) XXX O
. XXX O

Cumulated XXX O
maximum XXX O
lod XXX O
scores XXX O
between XXX O
FRDA XXX B-GENE
and XXX O
D9S5 XXX B-GENE
and XXX O
between XXX O
FRDA XXX B-GENE
and XXX O
D9S15 XXX B-GENE
are XXX O
above XXX O
36 XXX O
and XXX O
61 XXX O
, XXX O
respectively XXX O
, XXX O
at XXX O
a XXX O
recombination XXX O
fraction XXX O
of XXX O
0 XXX O
, XXX O
indicating XXX O
that XXX O
recombination XXX O
events XXX O
needed XXX O
to XXX O
orient XXX O
the XXX O
search XXX O
of XXX O
the XXX O
gene XXX O
are XXX O
very XXX O
difficult XXX O
to XXX O
identify XXX O
and XXX O
ascertain XXX O
. XXX O

BACKGROUND XXX O
: XXX O
Fluoroquinolones XXX O
( XXX O
FQ XXX O
) XXX O
are XXX O
contraindicated XXX O
in XXX O
children XXX O
because XXX O
of XXX O
the XXX O
risk XXX O
of XXX O
cartilage XXX O
damage XXX O
. XXX O

In XXX O
infected XXX O
mammalian XXX O
cells XXX O
, XXX O
the XXX O
ARV XXX B-GENE
G XXX I-GENE
and XXX O
GNS XXX B-GENE
genes XXX I-GENE
are XXX O
transcribed XXX O
primarily XXX O
as XXX O
a XXX O
polycistronic XXX O
mRNA XXX O
which XXX O
appears XXX O
to XXX O
extend XXX O
from XXX O
the XXX O
consensus XXX O
sequence XXX O
( XXX O
AACAG XXX B-GENE
) XXX O
at XXX O
the XXX O
start XXX O
of XXX O
the XXX O
G XXX B-GENE
gene XXX I-GENE
to XXX O
the XXX O
next XXX O
recognized XXX O
polyadenylation XXX O
signal XXX O
( XXX O
CATG XXX O
[ XXX O
A XXX O
] XXX O
7 XXX O
) XXX O
located XXX O
697 XXX O
nucleotides XXX O
downstream XXX O
of XXX O
the XXX O
GNS XXX B-GENE
protein XXX I-GENE
termination XXX O
codon XXX O
. XXX O

On XXX O
the XXX O
other XXX O
hand XXX O
, XXX O
total XXX O
pinealectomy XXX O
in XXX O
these XXX O
already XXX O
sympathectomized XXX O
blinded XXX O
rabbits XXX O
always XXX O
resulted XXX O
in XXX O
a XXX O
substantial XXX O
deceleration XXX O
of XXX O
the XXX O
rhythms XXX O
( XXX O
mean XXX O
delta XXX O
tau XXX O
= XXX O
+0 XXX O
. XXX O
23 XXX O
h XXX O
) XXX O
. XXX O

NiCl XXX O
( XXX O
2 XXX O
) XXX O
-induced XXX O
MCP-1 XXX B-GENE
synthesis XXX O
required XXX O
activation XXX O
of XXX O
NF-kappaB XXX B-GENE
since XXX O
mutation XXX O
of XXX O
NF-kappaB-binding XXX B-GENE
sites XXX I-GENE
in XXX O
the XXX O
promoter XXX O
resulted XXX O
in XXX O
complete XXX O
loss XXX O
of XXX O
inducible XXX O
promoter XXX O
activity XXX O
. XXX O

A XXX O
more XXX O
complete XXX O
analysis XXX O
of XXX O
dose XXX O
response XXX O
, XXX O
time XXX O
and XXX O
mode XXX O
of XXX O
Ga XXX O
administration XXX O
( XXX O
preinjury XXX O
or XXX O
postinjury XXX O
) XXX O
, XXX O
and XXX O
availability XXX O
of XXX O
Ga XXX O
across XXX O
the XXX O
blood-brain XXX O
barrier XXX O
is XXX O
needed XXX O
to XXX O
further XXX O
evaluate XXX O
the XXX O
efficacy XXX O
of XXX O
this XXX O
compound XXX O
. XXX O

Spc42p XXX B-GENE
also XXX O
was XXX O
identified XXX O
as XXX O
a XXX O
component XXX O
of XXX O
a XXX O
cytoplasmic XXX B-GENE
SPB XXX I-GENE
subcomplex XXX I-GENE
containing XXX O
Spc94p XXX B-GENE
/ XXX I-GENE
Nud1p XXX I-GENE
, XXX O
Cnm67p XXX B-GENE
, XXX O
and XXX O
Spc42p XXX B-GENE
. XXX O

The XXX O
3-hour XXX O
test XXX O
iodine XXX O
( XXX O
I-132 XXX O
) XXX O
uptake XXX O
by XXX O
the XXX O
thyroid XXX O
in XXX O
children XXX O
with XXX O
growth XXX O
deficiency XXX O
. XXX O

However XXX O
, XXX O
such XXX O
a XXX O
mechanism XXX O
was XXX O
not XXX O
detected XXX O
in XXX O
preliminary XXX O
observations XXX O
on XXX O
M XXX O
. XXX O
synoviae XXX O
. XXX O

Ea XXX O
value XXX O
was XXX O
calculated XXX O
as XXX O
the XXX O
ratio XXX O
of XXX O
the XXX O
steady-state XXX O
end-systolic XXX O
aortic XXX O
pressure XXX O
( XXX O
ESAP XXX O
) XXX O
to XXX O
stroke XXX O
volume XXX O
( XXX O
thermodilution XXX O
) XXX O
. XXX O

The XXX O
mobility XXX O
shift XXX O
of XXX O
both XXX O
of XXX O
these XXX O
proteins XXX O
is XXX O
abolished XXX O
by XXX O
treatment XXX O
with XXX O
inhibitors XXX O
of XXX O
PKC XXX B-GENE
or XXX O
mitogen-activated XXX B-GENE
protein XXX I-GENE
kinase XXX I-GENE
/ XXX I-GENE
extracellular XXX I-GENE
signal-related XXX I-GENE
kinase XXX I-GENE
kinase XXX I-GENE
. XXX O

Amiodarone XXX O
, XXX O
seldom XXX O
used XXX O
as XXX O
first-line XXX O
treatment XXX O
, XXX O
appears XXX O
to XXX O
be XXX O
the XXX O
most XXX O
effective XXX O
drug XXX O
. XXX O

This XXX O
supports XXX O
previous XXX O
arguments XXX O
for XXX O
the XXX O
improbability XXX O
of XXX O
biological XXX O
effects XXX O
at XXX O
UHF XXX O
frequencies XXX O
unless XXX O
a XXX O
mechanism XXX O
can XXX O
be XXX O
found XXX O
for XXX O
accumulating XXX O
energy XXX O
over XXX O
time XXX O
and XXX O
space XXX O
and XXX O
focussing XXX O
it XXX O
. XXX O

These XXX O
results XXX O
indicate XXX O
that XXX O
BACM XXX O
has XXX O
antiplaque XXX O
and XXX O
stronger XXX O
antidegradation XXX O
effects XXX O
than XXX O
GLCM XXX O
. XXX O

Expression XXX O
is XXX O
exclusively XXX O
limited XXX O
to XXX O
the XXX O
CNS XXX O
at XXX O
this XXX O
and XXX O
later XXX O
stages XXX O
. XXX O

However XXX O
, XXX O
in XXX O
a XXX O
multivariate XXX O
analysis XXX O
considering XXX O
age XXX O
, XXX O
gender XXX O
, XXX O
and XXX O
a XXX O
previous XXX O
history XXX O
of XXX O
cardiovascular XXX O
diseases XXX O
, XXX O
female XXX O
gender XXX O
was XXX O
not XXX O
independently XXX O
associated XXX O
with XXX O
death XXX O
. XXX O

Antihistamines XXX O
in XXX O
asthma XXX O
. XXX O

Cloning XXX O
and XXX O
expression XXX O
of XXX O
two XXX O
genes XXX O
encoding XXX O
auxin-binding XXX B-GENE
proteins XXX I-GENE
from XXX O
tobacco XXX O
. XXX O

During XXX O
pentobarbital XXX O
anesthesia XXX O
, XXX O
the XXX O
basal XXX O
VO2 XXX O
was XXX O
5 XXX O
. XXX O
26 XXX O
ml XXX O
/ XXX O
kg XXX O
/ XXX O
min XXX O
and XXX O
was XXX O
increased XXX O
by XXX O
epinephrine XXX O
in XXX O
a XXX O
dose XXX O
dependent XXX O
manner XXX O
at XXX O
plasma XXX O
concentrations XXX O
between XXX O
3 XXX O
. XXX O
9 XXX O
ng XXX O
/ XXX O
ml XXX O
( XXX O
VO2 XXX O
= XXX O
5 XXX O
. XXX O
68 XXX O
ml XXX O
/ XXX O
kg XXX O
/ XXX O
min XXX O
) XXX O
and XXX O
36 XXX O
. XXX O
5 XXX O
ng XXX O
/ XXX O
ml XXX O
( XXX O
VO2 XXX O
= XXX O
6 XXX O
. XXX O
47 XXX O
ml XXX O
/ XXX O
kg XXX O
/ XXX O
min XXX O
) XXX O
. XXX O

Previous XXX O
studies XXX O
have XXX O
shown XXX O
[ XXX O
Hisanaga XXX O
, XXX O
S XXX O
. XXX O
, XXX O
Kusubata XXX O
, XXX O
M XXX O
. XXX O
, XXX O
Okumura XXX O
, XXX O
E XXX O
. XXX O
& XXX O
Kishimoto XXX O
, XXX O
T XXX O
. XXX O

These XXX O
findings XXX O
suggest XXX O
that XXX O
both XXX O
in XXX O
the XXX O
early XXX O
stages XXX O
( XXX O
0T XXX O
, XXX O
0N XXX O
) XXX O
and XXX O
in XXX O
more XXX O
severe XXX O
stages XXX O
of XXX O
VWF XXX O
( XXX O
stages XXX O
1-2 XXX O
) XXX O
cold XXX O
induced XXX O
hyperreactivity XXX O
in XXX O
the XXX O
digital XXX O
vessels XXX O
and XXX O
Raynaud's XXX O
syndrome XXX O
are XXX O
vascular XXX O
disorders XXX O
of XXX O
functional XXX O
origin XXX O
occurring XXX O
without XXX O
any XXX O
prethrombotic XXX O
alterations XXX O
. XXX O

Response XXX O
to XXX O
treatment XXX O
was XXX O
better XXX O
in XXX O
patients XXX O
with XXX O
less XXX O
pretreatment XXX O
( XXX O
one-two XXX O
prior XXX O
treatments XXX O
) XXX O
than XXX O
in XXX O
heavily XXX O
pretreated XXX O
ones XXX O
( XXX O
more XXX O
than XXX O
three XXX O
) XXX O
and XXX O
this XXX O
relation XXX O
was XXX O
found XXX O
to XXX O
be XXX O
statistically XXX O
significant XXX O
( XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
. XXX O

Regulation XXX O
of XXX O
yeast XXX B-GENE
LEU2 XXX I-GENE
. XXX O

Can XXX O
survival XXX O
be XXX O
prolonged XXX O
for XXX O
patients XXX O
with XXX O
hormone-resistant XXX O
prostate XXX O
cancer XXX O
? XXX O

Treatment XXX O
of XXX O
ischemic XXX O
heart XXX O
disease XXX O
in XXX O
the XXX O
elderly XXX O

Thus XXX O
, XXX O
cibenzoline XXX O
is XXX O
an XXX O
effective XXX O
antiarrhythmic XXX O
agent XXX O
with XXX O
a XXX O
favourable XXX O
pharmacokinetic XXX O
profile XXX O
that XXX O
may XXX O
be XXX O
considered XXX O
with XXX O
other XXX O
class XXX O
I XXX O
drugs XXX O
in XXX O
patients XXX O
requiring XXX O
therapy XXX O
for XXX O
high XXX O
risk XXX O
arrhythmias XXX O
. XXX O

Using XXX O
a XXX O
series XXX O
of XXX O
mutant XXX O
proteins XXX O
, XXX O
we XXX O
have XXX O
characterized XXX O
domains XXX O
responsible XXX O
for XXX O
activation XXX O
or XXX O
repression XXX O
. XXX O

Their XXX O
biosynthesis XXX O
proceeds XXX O
via XXX O
linear XXX O
precursors XXX O
that XXX O
become XXX O
branched XXX O
by XXX O
beta1 XXX B-GENE
, XXX I-GENE
6-GlcNAc XXX I-GENE
transferases XXX I-GENE
( XXX O
IGnT6 XXX O
, XXX O
GlcNAc XXX O
to XXX O
Gal XXX O
) XXX O
. XXX O

Liposomal XXX O
Amphotericin-B XXX O
failed XXX O
in XXX O
6 XXX O
/ XXX O
7 XXX O
patients XXX O
with XXX O
culture-proven XXX O
mycosis XXX O
who XXX O
died XXX O
from XXX O
infection XXX O
with XXX O
Aspergillus XXX O
( XXX O
n XXX O
= XXX O
2 XXX O
) XXX O
and XXX O
Candida XXX O
( XXX O
n XXX O
= XXX O
4 XXX O
) XXX O
, XXX O
respectively XXX O
. XXX O

In XXX O
all XXX O
instances XXX O
the XXX O
apparent XXX O
alcohol XXX O
responses XXX O
were XXX O
very XXX O
small XXX O
and XXX O
never XXX O
exceeded XXX O
a XXX O
reading XXX O
of XXX O
1 XXX O
microgram XXX O
/ XXX O
100ml XXX O
for XXX O
breath XXX O
samples XXX O
more XXX O
than XXX O
10min XXX O
post-exposure XXX O
. XXX O

Viruses XXX O
were XXX O
isolated XXX O
from XXX O
9 XXX O
lungs XXX O
: XXX O
7 XXX O
with XXX O
PI-3V XXX O
, XXX O
1 XXX O
with XXX O
NCP XXX O
BVDV XXX O
type XXX O
1 XXX O
, XXX O
and XXX O
1 XXX O
with XXX O
both XXX O
BVHV-1 XXX O
and XXX O
BVDV XXX O
. XXX O

In XXX O
consequence XXX O
, XXX O
the XXX O
gpI XXX B-GENE
derived XXX O
from XXX O
cells XXX O
infected XXX O
with XXX O
mO74 XXX O
showed XXX O
antigenic XXX O
characteristics XXX O
similar XXX O
to XXX O
those XXX O
of XXX O
gpI XXX B-GENE
from XXX O
VZV-infected XXX O
cells XXX O
as XXX O
determined XXX O
from XXX O
the XXX O
immunoprecipitation XXX O
pattern XXX O
, XXX O
although XXX O
the XXX O
molecular XXX O
weight XXX O
of XXX O
each XXX O
polypeptide XXX O
was XXX O
different XXX O
, XXX O
and XXX O
antibody XXX O
produced XXX O
in XXX O
rabbits XXX O
infected XXX O
with XXX O
recombinant XXX O
virus XXX O
had XXX O
a XXX O
high XXX O
neutralizing XXX O
activity XXX O
, XXX O
when XXX O
the XXX O
reaction XXX O
was XXX O
performed XXX O
with XXX O
complement XXX O
. XXX O

Landsberg XXX O
( XXX O
La-O XXX O
) XXX O
and XXX O
cv XXX O
. XXX O

As XXX O
an XXX O
alternative XXX O
approach XXX O
to XXX O
this XXX O
question XXX O
, XXX O
we XXX O
have XXX O
studied XXX O
the XXX O
effects XXX O
of XXX O
ectopically XXX O
expressed XXX O
SHIP XXX B-GENE
, XXX O
SHP-1 XXX B-GENE
, XXX O
or XXX O
SHP-2 XXX B-GENE
SH2-containing XXX O
decoy XXX O
proteins XXX O
on XXX O
Fc XXX B-GENE
gamma XXX I-GENE
RIIB1 XXX I-GENE
signaling XXX O
. XXX O

This XXX O
machinery XXX O
involves XXX O
a XXX O
secondary XXX O
structure XXX O
, XXX O
SECIS XXX B-GENE
element XXX I-GENE
, XXX O
in XXX O
the XXX O
selenoprotein-encoding XXX B-GENE
mRNA XXX I-GENE
, XXX O
directing XXX O
selenocysteine XXX O
insertion XXX O
at XXX O
the XXX O
position XXX O
of XXX O
an XXX O
opal XXX O
( XXX O
UGA XXX O
) XXX O
codon XXX O
, XXX O
normally XXX O
conferring XXX O
termination XXX O
of XXX O
translation XXX O
. XXX O

Infection XXX O
with XXX O
Neisseria XXX O
meningitidis XXX O
group XXX O
B XXX O
has XXX O
been XXX O
difficult XXX O
to XXX O
detect XXX O
, XXX O
partly XXX O
because XXX O
this XXX O
bacterial XXX O
group's XXX O
polysaccharide XXX O
is XXX O
a XXX O
weak XXX O
immunogen XXX O
. XXX O

The XXX O
relatively XXX O
high XXX O
level XXX O
transcription XXX O
from XXX O
this XXX O
gene XXX O
shows XXX O
that XXX O
the XXX O
polymorphic XXX O
chromosome XXX O
ends XXX O
of XXX O
P XXX O
. XXX O
falciparum XXX O
, XXX O
which XXX O
have XXX O
been XXX O
proposed XXX O
to XXX O
be XXX O
transcriptionally XXX O
silent XXX O
, XXX O
can XXX O
be XXX O
active XXX O
expression XXX O
sites XXX O
for XXX O
var XXX B-GENE
genes XXX I-GENE
. XXX O

To XXX O
identify XXX O
these XXX O
sites XXX O
, XXX O
Cdk2-phosphorylated XXX B-GENE
MARCKS XXX I-GENE
was XXX O
digested XXX O
with XXX O
lysyl XXX B-GENE
endoprotease XXX I-GENE
and XXX O
analysed XXX O
by XXX O
electrospray XXX O
MS XXX O
. XXX O

Even XXX O
if XXX O
the XXX O
electrocardiographic XXX O
signs XXX O
are XXX O
subdued XXX O
, XXX O
the XXX O
underlying XXX O
blockade XXX O
of XXX O
I XXX O
( XXX O
Kr XXX O
) XXX O
current XXX O
may XXX O
precipitate XXX O
the XXX O
occurrence XXX O
of XXX O
arrhythmia XXX O
. XXX O

To XXX O
identify XXX O
structural XXX O
features XXX O
of XXX O
residues XXX O
flanking XXX O
the XXX O
c-region XXX O
that XXX O
influence XXX O
the XXX O
fidelity XXX O
and XXX O
efficiency XXX O
of XXX O
signal XXX O
peptidase XXX B-GENE
cleavage XXX O
as XXX O
well XXX O
as XXX O
co-translational XXX O
translocation XXX O
, XXX O
we XXX O
introduced XXX O
six XXX O
amino XXX O
acid XXX O
substitutions XXX O
into XXX O
the XXX O
COOH XXX O
terminus XXX O
of XXX O
the XXX O
hydrophobic XXX O
core XXX O
and XXX O
seven XXX O
substitutions XXX O
at XXX O
the XXX O
NH2 XXX O
terminus XXX O
of XXX O
the XXX O
mature XXX O
region XXX O
( XXX O
the XXX O
+1 XXX O
position XXX O
) XXX O
of XXX O
a XXX O
model XXX O
eukaryotic XXX B-GENE
preprotein-human XXX I-GENE
pre XXX I-GENE
( XXX I-GENE
delta XXX I-GENE
pro XXX I-GENE
) XXX I-GENE
apoA-II XXX I-GENE
. XXX O

We XXX O
also XXX O
studied XXX O
a XXX O
new XXX O
parameter XXX O
: XXX O
the XXX O
angle XXX O
to XXX O
maximal XXX O
peak XXX O
torque XXX O
( XXX O
APT XXX O
) XXX O
. XXX O

Photopic XXX O
spectral XXX O
sensitivity XXX O
determined XXX O
electroretinographically XXX O
for XXX O
the XXX O
pigeon XXX O
eye XXX O
. XXX O

The XXX O
emerging XXX O
complexity XXX O
of XXX O
the XXX O
5' XXX O
regulatory XXX O
region XXX O
of XXX O
the XXX O
GH XXX B-GENE
receptor XXX I-GENE
gene XXX I-GENE
was XXX O
emphasised XXX O
by XXX O
the XXX O
observation XXX O
that XXX O
probes XXX O
derived XXX O
from XXX O
exon XXX O
1B XXX O
and XXX O
the XXX O
distal XXX O
3' XXX O
intron XXX O
boundary XXX O
do XXX O
not XXX O
hybridise XXX O
with XXX O
previously XXX O
cloned XXX O
genomic XXX O
sequences XXX O
that XXX O
span XXX O
the XXX O
liver-specific XXX B-GENE
P1 XXX I-GENE
promoter XXX I-GENE
and XXX O
exon XXX O
2 XXX O
. XXX O

The XXX O
hydrophobicity XXX O
plot XXX O
of XXX O
NHE-3 XXX B-GENE
is XXX O
very XXX O
similar XXX O
to XXX O
that XXX O
of XXX O
NHE-1 XXX B-GENE
and XXX O
NHE-2 XXX B-GENE
. XXX O

Subhuman XXX O
primates XXX O
appear XXX O
to XXX O
be XXX O
more XXX O
sensitive XXX O
to XXX O
reproductive XXX O
and XXX O
other XXX O
adverse XXX O
effects XXX O
of XXX O
PCBs XXX O
than XXX O
humans XXX O
. XXX O

CT XXX O
abnormalities XXX O
noted XXX O
in XXX O
term XXX O
babies XXX O
included XXX O
hemorrhage XXX O
( XXX O
subarachnoid XXX O
5 XXX O
. XXX O
8% XXX O
, XXX O
intracerebral XXX O
11 XXX O
. XXX O
6% XXX O
) XXX O
, XXX O
hypodensity XXX O
( XXX O
mild XXX O
23 XXX O
. XXX O
2% XXX O
, XXX O
moderate XXX O
11 XXX O
. XXX O
6% XXX O
severe XXX O
5 XXX O
. XXX O
8% XXX O
) XXX O
; XXX O
hypodensity XXX O
with XXX O
hemorrhage XXX O
5 XXX O
. XXX O
8% XXX O
and XXX O
cerebral XXX O
atrophy XXX O
5 XXX O
. XXX O
8% XXX O
. XXX O

Repeated XXX O
administration XXX O
of XXX O
GRg2 XXX O
20 XXX O
mg XXX O
/ XXX O
kg XXX O
i XXX O
. XXX O
p XXX O
. XXX O
significantly XXX O
improved XXX O
the XXX O
CYP-induced XXX O
recognitional XXX O
deficits XXX O
by XXX O
increasing XXX O
the XXX O
CYP-decreased XXX O
rate XXX O
from XXX O
55 XXX O
. XXX O
8 XXX O
+ XXX O
/ XXX O
- XXX O
9 XXX O
. XXX O
6 XXX O
to XXX O
80 XXX O
. XXX O
8 XXX O
+ XXX O
/ XXX O
- XXX O
4 XXX O
. XXX O
2 XXX O
in XXX O
d XXX O
3 XXX O
learning XXX O
acquisition XXX O
( XXX O
F XXX O
( XXX O
1 XXX O
, XXX O
14 XXX O
) XXX O
= XXX O
5 XXX O
. XXX O
6 XXX O
, XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
, XXX O
from XXX O
53 XXX O
. XXX O
4 XXX O
+ XXX O
/ XXX O
- XXX O
8 XXX O
. XXX O
4 XXX O
to XXX O
60 XXX O
. XXX O
0 XXX O
+ XXX O
/ XXX O
- XXX O
8 XXX O
. XXX O
2 XXX O
in XXX O
48 XXX O
h XXX O
memory XXX O
acquisition XXX O
( XXX O
F XXX O
( XXX O
1 XXX O
, XXX O
14 XXX O
) XXX O
= XXX O
7 XXX O
. XXX O
5 XXX O
, XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
and XXX O
from XXX O
55 XXX O
. XXX O
0 XXX O
+ XXX O
/ XXX O
- XXX O
5 XXX O
. XXX O
5 XXX O
to XXX O
88 XXX O
. XXX O
3 XXX O
+ XXX O
/ XXX O
- XXX O
2 XXX O
. XXX O
5 XXX O
in XXX O
24 XXX O
h XXX O
memory XXX O
retention XXX O
( XXX O
F XXX O
( XXX O
1 XXX O
, XXX O
12 XXX O
) XXX O
27 XXX O
. XXX O
5 XXX O
, XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
as XXX O
well XXX O
as XXX O
from XXX O
60 XXX O
. XXX O
0 XXX O
+ XXX O
/ XXX O
- XXX O
6 XXX O
. XXX O
8 XXX O
to XXX O
85 XXX O
. XXX O
6 XXX O
+ XXX O
/ XXX O
- XXX O
6 XXX O
. XXX O
9 XXX O
in XXX O
48 XXX O
h XXX O
memory XXX O
retrieval XXX O
( XXX O
F XXX O
( XXX O
1 XXX O
, XXX O
12 XXX O
) XXX O
= XXX O
5 XXX O
. XXX O
2 XXX O
, XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
, XXX O
respectively XXX O
. XXX O

Anesthesia XXX O
with XXX O
M XXX O
/ XXX O
K XXX O
was XXX O
reversed XXX O
after XXX O
41 XXX O
. XXX O
6 XXX O
min XXX O
of XXX O
immobilization XXX O
with XXX O
atipamezole XXX O
. XXX O

This XXX O
study XXX O
reports XXX O
the XXX O
effects XXX O
of XXX O
a XXX O
preparation XXX O
with XXX O
50 XXX O
micrograms XXX O
ethinyl XXX O
estradiol XXX O
and XXX O
2 XXX O
mg XXX O
cyproterone XXX O
acetate XXX O
on XXX O
gonadotropins XXX B-GENE
, XXX O
prolactin XXX B-GENE
, XXX O
testosterone XXX O
, XXX O
sex XXX B-GENE
hormone XXX I-GENE
binding XXX I-GENE
globulin XXX I-GENE
( XXX O
SHBG XXX B-GENE
) XXX O
, XXX O
androstenedione XXX O
, XXX O
and XXX O
calculated XXX O
free XXX O
testosterone XXX O
index XXX O
before XXX O
and XXX O
after XXX O
six XXX O
months XXX O
of XXX O
treatment XXX O
. XXX O

Lithium-carbonate XXX O
action XXX O
during XXX O
radiation XXX O
therapy XXX O
has XXX O
been XXX O
studied XXX O
, XXX O
valuing XXX O
the XXX O
positive XXX O
effect XXX O
on XXX O
leukopoiesis XXX O
and XXX O
the XXX O
consequent XXX O
better XXX O
clinical XXX O
conditions XXX O
of XXX O
the XXX O
patients XXX O
in XXX O
course XXX O
of XXX O
treatment XXX O
. XXX O

Yang XXX O
and XXX O
H XXX O
. XXX O

Type XXX O
I XXX O
position-vestibular-pause XXX O
( XXX O
PVP XXX O
I XXX O
) XXX O
and XXX O
vestibular-only XXX O
( XXX O
V XXX O
I XXX O
) XXX O
neurons XXX O
, XXX O
as XXX O
well XXX O
as XXX O
a XXX O
smaller XXX O
number XXX O
of XXX O
other XXX O
type XXX O
I XXX O
and XXX O
type XXX O
II XXX O
eye-plus-vestibular XXX O
neurons XXX O
were XXX O
studied XXX O
. XXX O

The XXX O
collection XXX O
of XXX O
mutants XXX O
displaying XXX O
TGN XXX O
sorting XXX O
defects XXX O
includes XXX O
members XXX O
with XXX O
mutations XXX O
in XXX O
previously XXX O
identified XXX O
vacuolar XXX B-GENE
protein XXX I-GENE
sorting XXX I-GENE
genes XXX I-GENE
( XXX O
VPS XXX B-GENE
) XXX O
, XXX O
including XXX O
the XXX O
dynamin XXX B-GENE
family XXX O
member XXX O
VPS1 XXX B-GENE
. XXX O

A XXX O
rat XXX O
cDNA XXX O
that XXX O
encodes XXX O
eIF-5 XXX B-GENE
has XXX O
been XXX O
isolated XXX O
and XXX O
expressed XXX O
in XXX O
Escherichia XXX O
coli XXX O
to XXX O
yield XXX O
a XXX O
catalytically XXX O
active XXX O
eIF-5 XXX B-GENE
protein XXX I-GENE
. XXX O

Thus XXX O
, XXX O
Hex XXX B-GENE
expression XXX O
marks XXX O
the XXX O
earliest XXX O
unequivocal XXX O
molecular XXX O
anteroposterior XXX O
asymmetry XXX O
in XXX O
the XXX O
mouse XXX O
embryo XXX O
and XXX O
indicates XXX O
that XXX O
the XXX O
anteroposterior XXX O
axis XXX O
of XXX O
the XXX O
embryo XXX O
develops XXX O
from XXX O
conversion XXX O
of XXX O
a XXX O
proximodistal XXX O
asymmetry XXX O
established XXX O
in XXX O
the XXX O
primitive XXX O
endoderm XXX O
lineage XXX O
. XXX O

The XXX O
96-bp XXX O
insert XXX O
contained XXX O
a XXX O
termination XXX O
signal XXX O
which XXX O
caused XXX O
the XXX O
premature XXX O
termination XXX O
of XXX O
the XXX O
protein XXX O
, XXX O
leading XXX O
to XXX O
the XXX O
generation XXX O
of XXX O
a XXX O
p53 XXX B-GENE
product XXX I-GENE
9 XXX O
amino XXX O
acids XXX O
shorter XXX O
than XXX O
usual XXX O
. XXX O

The XXX O
data XXX O
are XXX O
compatible XXX O
with XXX O
the XXX O
idea XXX O
that XXX O
YLL031c XXX B-GENE
transfers XXX O
the XXX O
ethanolaminephosphate XXX O
to XXX O
the XXX O
inner XXX O
alpha1-2-linked XXX O
mannose XXX O
, XXX O
i XXX O
. XXX O
e XXX O
. XXX O
the XXX O
group XXX O
that XXX O
links XXX O
the XXX O
GPI XXX O
lipid XXX O
anchor XXX O
to XXX O
proteins XXX O
, XXX O
whereas XXX O
Mcd4p XXX B-GENE
and XXX O
Gpi7p XXX B-GENE
transfer XXX O
ethanolaminephosphate XXX O
onto XXX O
the XXX O
alpha1-4- XXX O
and XXX O
alpha1-6-linked XXX O
mannoses XXX O
of XXX O
the XXX O
GPI XXX O
anchor XXX O
, XXX O
respectively XXX O
. XXX O

An XXX O
additional XXX O
9 XXX O
patients XXX O
achieved XXX O
normal XXX O
levels XXX O
with XXX O
adjunctive XXX O
drug XXX O
therapy XXX O
. XXX O

The XXX O
relative XXX O
tumor XXX O
FDG-uptake XXX O
( XXX O
Q-MRGlu XXX O
) XXX O
( XXX O
tumor XXX O
/ XXX O
contralateral XXX O
cortex XXX O
) XXX O
of XXX O
all XXX O
meningiomas XXX O
was XXX O
calculated XXX O
with XXX O
0 XXX O
. XXX O
73 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
37 XXX O
( XXX O
0 XXX O
. XXX O
24-1 XXX O
. XXX O
79 XXX O
) XXX O
. XXX O

The XXX O
minimal XXX O
region XXX O
of XXX O
overlap XXX O
of XXX O
Langer-Giedion XXX B-GENE
syndrome XXX I-GENE
deletions XXX I-GENE
, XXX O
previously XXX O
identified XXX O
by XXX O
analysis XXX O
of XXX O
15 XXX O
patients XXX O
, XXX O
was XXX O
placed XXX O
on XXX O
the XXX O
map XXX O
by XXX O
analysis XXX O
of XXX O
2 XXX O
patients XXX O
whose XXX O
deletions XXX O
define XXX O
the XXX O
endpoints XXX O
. XXX O

For XXX O
symptomatic XXX O
relief XXX O
and XXX O
inhibition XXX O
of XXX O
the XXX O
growth XXX O
of XXX O
the XXX O
metastases XXX O
interferon-a XXX B-GENE
and XXX O
somatostatin XXX B-GENE
analogues XXX O
can XXX O
be XXX O
employed XXX O
. XXX O

We XXX O
have XXX O
therefore XXX O
evaluated XXX O
the XXX O
efficacy XXX O
and XXX O
safety XXX O
of XXX O
doxazosin XXX O
, XXX O
a XXX O
new XXX O
orally XXX O
active XXX O
selective XXX O
alpha XXX B-GENE
1 XXX I-GENE
blocker XXX O
, XXX O
in XXX O
patients XXX O
with XXX O
systemic XXX O
hypertension XXX O
with XXX O
concomitant XXX O
airflow XXX O
limitation XXX O
. XXX O

A XXX O
complementary XXX O
study XXX O
, XXX O
showing XXX O
a XXX O
good XXX O
agreement XXX O
between XXX O
surface XXX O
and XXX O
oesophageal XXX O
EMGd XXX O
seems XXX O
to XXX O
confirm XXX O
that XXX O
surface XXX O
EMGd XXX O
is XXX O
a XXX O
useful XXX O
and XXX O
promising XXX O
tool XXX O
for XXX O
clinical XXX O
investigation XXX O
. XXX O

Of XXX O
419 XXX O
persons XXX O
surveyed XXX O
, XXX O
207 XXX O
( XXX O
49 XXX O
. XXX O
4% XXX O
) XXX O
were XXX O
antigen-positive XXX O
with XXX O
the XXX O
Og4C3 XXX B-GENE
assay XXX O
. XXX O

The XXX O
PEPCK XXX B-GENE
promoter XXX O
fragment XXX O
was XXX O
introduced XXX O
either XXX O
in XXX O
the XXX O
proper XXX O
orientation XXX O
for XXX O
transcription XXX O
of XXX O
the XXX O
TK XXX B-GENE
gene XXX I-GENE
or XXX O
in XXX O
the XXX O
opposite XXX O
orientation XXX O
. XXX O

Very XXX O
good XXX O
accuracy XXX O
( XXX O
r XXX O
greater XXX O
than XXX O
0 XXX O
. XXX O
9 XXX O
) XXX O
was XXX O
found XXX O
when XXX O
except XXX O
comparing XXX O
H*2 XXX O
with XXX O
the XXX O
other XXX O
machine XXX O
and XXX O
the XXX O
reference XXX O
methods XXX O
, XXX O
except XXX O
for XXX O
MCHCH XXX O
and XXX O
basophil XXX O
count XXX O
. XXX O

Primer XXX O
extension XXX O
experiments XXX O
revealed XXX O
a XXX O
strong XXX O
transcription XXX O
initiation XXX O
site XXX O
102 XXX O
bp XXX O
upstream XXX O
of XXX O
the XXX O
translational XXX O
start XXX O
site XXX O
. XXX O

Elimination XXX O
of XXX O
the XXX O
inducible XXX O
response XXX O
requires XXX O
simultaneous XXX O
mutation XXX O
of XXX O
both XXX O
sequences XXX O
, XXX O
however XXX O
, XXX O
in XXX O
the XXX O
presence XXX O
of XXX O
an XXX O
intact XXX O
EpRE XXX B-GENE
the XXX O
upstream XXX O
AP-1 XXX B-GENE
site XXX I-GENE
is XXX O
irrelevant XXX O
to XXX O
induction XXX O
. XXX O

Studies XXX O
suggest XXX O
that XXX O
the XXX O
DGOR XXX O
without XXX O
acid XXX O
reflux XXX O
may XXX O
result XXX O
in XXX O
symptoms XXX O
but XXX O
unless XXX O
acid XXX O
reflux XXX O
is XXX O
present XXX O
simultaneously XXX O
, XXX O
it XXX O
does XXX O
not XXX O
cause XXX O
oesophagitis XXX O
. XXX O

In XXX O
viral XXX O
infections XXX O
, XXX O
G-CSF XXX B-GENE
was XXX O
correlated XXX O
with XXX O
mononuclear XXX O
cells XXX O
( XXX O
rs XXX O
= XXX O
0 XXX O
. XXX O
41 XXX O
, XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
, XXX O
white XXX O
blood XXX O
cell XXX O
counts XXX O
( XXX O
rs XXX O
= XXX O
0 XXX O
. XXX O
56 XXX O
, XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
, XXX O
neutrophils XXX O
( XXX O
rs XXX O
= XXX O
0 XXX O
. XXX O
41 XXX O
, XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
and XXX O
CRP XXX B-GENE
( XXX O
rs XXX O
= XXX O
0 XXX O
. XXX O
47 XXX O
, XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
. XXX O

The XXX O
effect XXX O
of XXX O
emotional-painful XXX O
stress XXX O
( XXX O
EPS XXX O
) XXX O
on XXX O
myocardial XXX O
extensibility XXX O
and XXX O
contractility XXX O
was XXX O
studied XXX O
on XXX O
an XXX O
isolated XXX O
rat XXX O
atrium XXX O
. XXX O

We XXX O
also XXX O
recovered XXX O
mutations XXX O
in XXX O
the XXX O
60A XXX B-GENE
gene XXX I-GENE
which XXX O
encodes XXX O
another XXX O
TGF-beta-related XXX B-GENE
factor XXX I-GENE
in XXX O
Drosophila XXX O
. XXX O

Although XXX O
methods XXX O
to XXX O
align XXX O
the XXX O
control XXX O
and XXX O
activation XXX O
fMR XXX O
images XXX O
may XXX O
correct XXX O
for XXX O
some XXX O
of XXX O
this XXX O
motional XXX O
error XXX O
, XXX O
they XXX O
will XXX O
be XXX O
incomplete XXX O
in XXX O
correcting XXX O
for XXX O
those XXX O
that XXX O
depend XXX O
on XXX O
spatial XXX O
orientation XXX O
. XXX O

Factors XXX O
affecting XXX O
the XXX O
inhibition XXX O
of XXX O
phagocytosis XXX O
by XXX O
chlorpromazine XXX O
. XXX O

BACKGROUND XXX O
: XXX O
Checkpoint XXX O
pathways XXX O
prevent XXX O
cell-cycle XXX O
progression XXX O
in XXX O
the XXX O
event XXX O
of XXX O
DNA XXX O
lesions XXX O
. XXX O

There XXX O
were XXX O
18 XXX O
patients XXX O
with XXX O
Group XXX O
II XXX O
( XXX O
a XXX O
) XXX O
tumors XXX O
; XXX O
although XXX O
tumor XXX O
biopsy XXX O
was XXX O
attempted XXX O
on XXX O
eight XXX O
of XXX O
these XXX O
, XXX O
pathological XXX O
diagnosis XXX O
at XXX O
the XXX O
time XXX O
of XXX O
surgery XXX O
was XXX O
made XXX O
in XXX O
only XXX O
one XXX O
case XXX O
. XXX O

Interleukin-12 XXX B-GENE
( XXX O
IL-12 XXX B-GENE
) XXX O
is XXX O
a XXX O
cytokine XXX O
produced XXX O
by XXX O
peripheral XXX O
blood XXX O
mononuclear XXX O
cells XXX O
( XXX O
PBMC XXX O
) XXX O
that XXX O
causes XXX O
interferon-gamma XXX B-GENE
( XXX O
IFN-gamma XXX B-GENE
) XXX O
production XXX O
and XXX O
enhancement XXX O
of XXX O
cell-mediated XXX O
cytotoxicity XXX O
. XXX O

Instead XXX O
, XXX O
the XXX O
results XXX O
support XXX O
the XXX O
idea XXX O
that XXX O
Pc XXX B-GENE
group XXX I-GENE
products XXX I-GENE
provide XXX O
stable XXX O
memory XXX O
or XXX O
imprinting XXX O
of XXX O
boundaries XXX O
which XXX O
are XXX O
initially XXX O
specified XXX O
by XXX O
gap XXX O
and XXX O
pair-rule XXX O
regulators XXX O
. XXX O

Comparison XXX O
of XXX O
promoters XXX O
repressed XXX O
by XXX O
c-myc XXX B-GENE
reveals XXX O
a XXX O
weak XXX O
consensus XXX O
sequence XXX O
of XXX O
the XXX O
initiator XXX B-GENE
( XXX I-GENE
Inr XXX I-GENE
) XXX I-GENE
element XXX I-GENE
: XXX I-GENE
TCA XXX I-GENE
( XXX I-GENE
+1 XXX I-GENE
) XXX I-GENE
YYYNY XXX I-GENE
. XXX O

Ecthyma XXX O
, XXX O
a XXX O
known XXX O
disease XXX O
, XXX O
of XXX O
which XXX O
little XXX O
is XXX O
known XXX O
. XXX O

Future XXX O
analysis XXX O
of XXX O
long-term XXX O
outcome XXX O
measures XXX O
of XXX O
performance XXX O
with XXX O
the XXX O
implant XXX O
will XXX O
confirm XXX O
or XXX O
dispute XXX O
the XXX O
benefit XXX O
of XXX O
ear XXX O
selection XXX O
using XXX O
the XXX O
Prom-EABR XXX O
. XXX O

Furthermore XXX O
, XXX O
a XXX O
minor XXX O
start XXX O
site XXX O
was XXX O
localized XXX O
179 XXX O
bp XXX O
upstream XXX O
of XXX O
the XXX O
major XXX O
site XXX O
using XXX O
reverse XXX B-GENE
transcriptase-polymerase XXX I-GENE
chain XXX O
reaction XXX O
with XXX O
various XXX O
P1 XXX B-GENE
primers XXX O
( XXX O
primer XXX O
walking XXX O
) XXX O
, XXX O
primer XXX O
extension XXX O
, XXX O
and XXX O
cDNA XXX O
cloning XXX O
. XXX O

Ten XXX O
out-patients XXX O
with XXX O
pustulosis XXX O
palmaris XXX O
et XXX O
plantaris XXX O
were XXX O
examined XXX O
with XXX O
direct XXX O
immunofluorescence XXX O
( XXX O
IF XXX O
) XXX O
technique XXX O
for XXX O
deposition XXX O
of XXX O
fibrinogen XXX B-GENE
, XXX O
fibrin XXX B-GENE
or XXX O
its XXX O
degradation XXX O
products XXX O
( XXX O
FR-antigen XXX B-GENE
) XXX O
in XXX O
affected XXX O
and XXX O
unaffected XXX O
skin XXX O
, XXX O
together XXX O
with XXX O
heparin-precipitable XXX O
fraction XXX O
( XXX O
HPF XXX O
) XXX O
, XXX O
cryoglobulin XXX B-GENE
and XXX O
total XXX O
plasma XXX O
fibrinogen XXX B-GENE
in XXX O
the XXX O
blood XXX O
. XXX O

CONCLUSIONS XXX O
: XXX O
Translocation XXX O
of XXX O
bacteria XXX O
or XXX O
endotoxin XXX B-GENE
from XXX O
the XXX O
gastrointestinal XXX O
tract XXX O
into XXX O
the XXX O
bloodstream XXX O
has XXX O
been XXX O
noted XXX O
in XXX O
animal XXX O
experiments XXX O
; XXX O
however XXX O
, XXX O
translocation XXX O
was XXX O
not XXX O
detected XXX O
in XXX O
our XXX O
patients XXX O
with XXX O
hemorrhagic XXX O
shock XXX O
. XXX O

Nocodazole XXX O
arrest XXX O
of XXX O
DU249 XXX O
cells XXX O
was XXX O
exploited XXX O
for XXX O
the XXX O
detection XXX O
of XXX O
an XXX O
M-phase-activated XXX O
MBP XXX B-GENE
kinase XXX I-GENE
that XXX O
was XXX O
resolved XXX O
from XXX O
p41 XXX B-GENE
MAP XXX I-GENE
kinase XXX I-GENE
by XXX O
phenyl-Superose XXX O
chromatography XXX O
. XXX O

This XXX O
compound XXX O
is XXX O
the XXX O
main XXX O
bioactive XXX O
metabolite XXX O
of XXX O
trimebutine XXX O
II XXX O
( XXX O
Debridat XXX O
, XXX O
CAS XXX O
39133-31-8 XXX O
) XXX O
, XXX O
an XXX O
antispasmodic XXX O
widely XXX O
used XXX O
for XXX O
intestinal XXX O
diseases XXX O
since XXX O
1969 XXX O
. XXX O

There XXX O
was XXX O
a XXX O
slight XXX O
increase XXX O
in XXX O
total XXX O
transferrin XXX B-GENE
2 XXX O
hr XXX O
after XXX O
1 XXX O
tablet XXX O
and XXX O
values XXX O
remained XXX O
high XXX O
throughout XXX O
the XXX O
experiment XXX O
. XXX O

These XXX O
repressor XXX O
sites XXX O
are XXX O
pyrimidine XXX O
rich XXX O
and XXX O
bind XXX O
avidly XXX O
to XXX O
the XXX O
polypyrimidine XXX B-GENE
tract XXX I-GENE
binding XXX I-GENE
protein XXX I-GENE
( XXX O
PTB XXX B-GENE
) XXX O
in XXX O
HeLa XXX O
nuclear XXX O
extracts XXX O
as XXX O
determined XXX O
by XXX O
UV XXX O
crosslinking XXX O
/ XXX O
competition XXX O
assays XXX O
. XXX O

Rep63A XXX B-GENE
( XXX I-GENE
513 XXX I-GENE
amino XXX I-GENE
acids XXX I-GENE
[ XXX I-GENE
aa XXX I-GENE
] XXX I-GENE
) XXX I-GENE
, XXX O
encoded XXX O
by XXX O
the XXX O
largest XXX O
ORF XXX O
, XXX O
displayed XXX O
strong XXX O
similarity XXX O
( XXX O
40% XXX O
identity XXX O
) XXX O
to XXX O
the XXX O
replication XXX O
proteins XXX O
from XXX O
plasmids XXX O
pAMbeta1 XXX O
, XXX O
pIP501 XXX O
, XXX O
and XXX O
pSM19035 XXX O
, XXX O
indicating XXX O
that XXX O
the XXX O
pAW63 XXX O
replicon XXX O
belongs XXX O
to XXX O
the XXX O
pAMbeta1 XXX O
family XXX O
of XXX O
gram-positive XXX O
theta-replicating XXX O
plasmids XXX O
. XXX O

Finally XXX O
, XXX O
we XXX O
show XXX O
that XXX O
complexes XXX O
similar XXX O
to XXX O
the XXX O
C25 XXX B-GENE
, XXX O
C30 XXX B-GENE
and XXX O
C35 XXX B-GENE
complexes XXX I-GENE
are XXX O
formed XXX O
by XXX O
rat XXX O
cortex XXX O
nuclear XXX O
extracts XXX O
and XXX O
the XXX O
SAA XXX B-GENE
element XXX I-GENE
in XXX O
EMSA XXX O
experiments XXX O
, XXX O
suggesting XXX O
the XXX O
relevance XXX O
of XXX O
our XXX O
in XXX O
vitro XXX O
observations XXX O
to XXX O
the XXX O
in XXX O
vivo XXX O
functioning XXX O
of XXX O
the XXX O
rat XXX B-GENE
APP XXX I-GENE
promoter XXX I-GENE
. XXX O

The XXX O
nmr XXX B-GENE
gene XXX I-GENE
is XXX O
the XXX O
major XXX O
negative XXX O
regulatory XXX O
gene XXX O
in XXX O
the XXX O
nitrogen XXX O
control XXX O
circuit XXX O
of XXX O
Neurospora XXX O
crassa XXX O
, XXX O
which XXX O
, XXX O
together XXX O
with XXX O
positive XXX O
regulatory XXX O
genes XXX O
, XXX O
governs XXX O
the XXX O
expression XXX O
of XXX O
multiple XXX O
unlinked XXX O
structural XXX O
genes XXX O
of XXX O
the XXX O
circuit XXX O
. XXX O

At XXX O
least XXX O
one XXX O
clone XXX O
, XXX O
lambda XXX O
HHG XXX O
41 XXX O
, XXX O
contains XXX O
, XXX O
in XXX O
addition XXX O
to XXX O
the XXX O
histone XXX B-GENE
genes XXX I-GENE
, XXX O
a XXX O
region XXX O
that XXX O
hybridizes XXX O
with XXX O
a XXX O
cytoplasmic XXX O
RNA XXX O
approximately XXX O
330 XXX O
nucleotides XXX O
in XXX O
length XXX O
. XXX O

Both XXX O
the XXX O
Cmax XXX O
and XXX O
AUC XXX O
values XXX O
were XXX O
almost XXX O
doubled XXX O
with XXX O
doubling XXX O
the XXX O
dose XXX O
. XXX O

Adult XXX O
H XXX O
, XXX O
but XXX O
not XXX O
R XXX O
, XXX O
manifested XXX O
the XXX O
burrowing XXX O
preference XXX O
whenever XXX O
offered XXX O
the XXX O
opportunity XXX O
. XXX O

Thromboplastin XXX B-GENE
time XXX O
, XXX O
partial XXX O
thromboplastin XXX B-GENE
time XXX O
, XXX O
thrombin XXX B-GENE
time XXX O
, XXX O
heat-dependent XXX O
fibrin XXX B-GENE
, XXX O
clot XXX O
retraction XXX O
, XXX O
and XXX O
clotting XXX B-GENE
factors XXX I-GENE
II XXX I-GENE
, XXX I-GENE
V XXX I-GENE
, XXX I-GENE
VIII XXX I-GENE
, XXX I-GENE
IX XXX I-GENE
, XXX I-GENE
X XXX I-GENE
, XXX O
and XXX O
the XXX O
platelet XXX O
count XXX O
were XXX O
determined XXX O
. XXX O

The XXX O
elevations XXX O
achieved XXX O
by XXX O
LDEE XXX O
given XXX O
s XXX O
. XXX O
c XXX O
. XXX O
were XXX O
higher XXX O
than XXX O
those XXX O
achieved XXX O
after XXX O
i XXX O
. XXX O
p XXX O
. XXX O
administration XXX O
and XXX O
lasted XXX O
for XXX O
longer XXX O
periods XXX O
. XXX O

We XXX O
show XXX O
that XXX O
Rlm1 XXX B-GENE
and XXX O
Smp1 XXX B-GENE
have XXX O
MEF2-related XXX O
DNA-binding XXX O
specificities XXX O
: XXX O
Rlm1 XXX B-GENE
binds XXX O
with XXX O
the XXX O
same XXX O
specificity XXX O
as XXX O
MEF2 XXX B-GENE
, XXX O
CTA XXX B-GENE
( XXX I-GENE
T XXX I-GENE
/ XXX I-GENE
A XXX I-GENE
) XXX I-GENE
4TAG XXX I-GENE
, XXX O
while XXX O
SMP1 XXX B-GENE
binds XXX O
a XXX O
more XXX O
extended XXX O
consensus XXX O
sequence XXX O
, XXX O
ACTACTA XXX B-GENE
( XXX I-GENE
T XXX I-GENE
/ XXX I-GENE
A XXX I-GENE
) XXX I-GENE
4TAG XXX I-GENE
. XXX O

On XXX O
d XXX O
112 XXX O
, XXX O
progesterone XXX O
was XXX O
higher XXX O
( XXX O
P XXX O
less XXX O
than XXX O
. XXX O
05 XXX O
) XXX O
in XXX O
hysterectomized XXX O
heifers XXX O
than XXX O
in XXX O
other XXX O
treatment XXX O
groups XXX O
. XXX O

Multizone XXX O
PRK XXX O
has XXX O
been XXX O
suggested XXX O
to XXX O
increase XXX O
the XXX O
predictability XXX O
of XXX O
higher XXX O
myopic XXX O
corrections XXX O
. XXX O

A XXX O
convenient XXX O
measure XXX O
of XXX O
this XXX O
impairment XXX O
may XXX O
be XXX O
obtained XXX O
using XXX O
the XXX O
ratio XXX O
of XXX O
urine XXX O
volume XXX O
( XXX O
V XXX O
) XXX O
divided XXX O
by XXX O
lithium XXX O
clearance XXX O
( XXX O
CLi XXX O
) XXX O
. XXX O

Depleted XXX O
and XXX O
enriched XXX O
U3O8 XXX O
standard XXX O
reference XXX O
materials XXX O
were XXX O
used XXX O
to XXX O
calibrate XXX O
the XXX O
system XXX O
. XXX O

Our XXX O
study XXX O
reveals XXX O
that XXX O
the XXX O
modular XXX O
structure XXX O
of XXX O
the XXX O
FSH XXX B-GENE
receptor XXX I-GENE
gene XXX O
generates XXX O
motifs XXX O
that XXX O
allows XXX O
coupling XXX O
to XXX O
different XXX O
effectors XXX O
. XXX O

Constructs XXX O
containing XXX O
the XXX O
full-length XXX B-GENE
PfCPK XXX I-GENE
cDNA XXX I-GENE
have XXX O
been XXX O
expressed XXX O
in XXX O
Escherichia XXX O
coli XXX O
at XXX O
a XXX O
high XXX O
level XXX O
to XXX O
generate XXX O
a XXX O
60-kDa XXX O
recombinant XXX O
protein XXX O
. XXX O

The XXX O
in XXX O
vitro XXX O
relaxivity XXX O
of XXX O
the XXX O
complex XXX O
is XXX O
16 XXX O
. XXX O
24 XXX O
s XXX O
( XXX O
-1 XXX O
) XXX O
mM XXX O
( XXX O
-1 XXX O
) XXX O
. XXX O

The XXX O
possible XXX O
roles XXX O
of XXX O
HRMT1L1 XXX B-GENE
and XXX O
HRMT1L2 XXX B-GENE
in XXX O
human XXX O
disease XXX O
are XXX O
currently XXX O
unknown XXX O
. XXX O

Mutations XXX O
in XXX O
UPF1 XXX B-GENE
lead XXX O
to XXX O
the XXX O
selective XXX O
stabilization XXX O
of XXX O
mRNAs XXX O
containing XXX O
early XXX O
nonsense XXX O
mutations XXX O
without XXX O
affecting XXX O
the XXX O
decay XXX O
rates XXX O
of XXX O
most XXX O
other XXX O
mRNAs XXX O
. XXX O

Acad XXX O
. XXX O

The XXX O
median XXX O
age XXX O
was XXX O
33 XXX O
years XXX O
( XXX O
range XXX O
17-56 XXX O
years XXX O
) XXX O
. XXX O

The XXX O
roll-over XXX O
test XXX O
to XXX O
predict XXX O
toxemia XXX O
in XXX O
pregnancy XXX O
. XXX O

A XXX O
reduced XXX O
matrix XXX O
distribution XXX O
and XXX O
enhanced XXX O
cell XXX O
density XXX O
were XXX O
observed XXX O
as XXX O
the XXX O
biofilm XXX O
aged XXX O
. XXX O

The XXX O
activation XXX O
and XXX O
injury XXX O
of XXX O
endothelial XXX O
cells XXX O
induced XXX O
by XXX O
TNF XXX B-GENE
and XXX O
other XXX O
proinflammatory XXX O
cytokines XXX O
may XXX O
underlie XXX O
the XXX O
local XXX O
effects XXX O
of XXX O
these XXX O
mediators XXX O
in XXX O
vivo XXX O
. XXX O

Compensative XXX O
justice XXX O
and XXX O
moral XXX O
investment XXX O
among XXX O
Japanese XXX O
, XXX O
Chinese XXX O
, XXX O
and XXX O
Koreans XXX O
. XXX O

High-level XXX O
expression XXX O
in XXX O
Escherichia XXX O
coli XXX O
of XXX O
selenocysteine-containing XXX O
rat XXX B-GENE
thioredoxin XXX I-GENE
reductase XXX I-GENE
utilizing XXX O
gene XXX O
fusions XXX O
with XXX O
engineered XXX O
bacterial-type XXX B-GENE
SECIS XXX I-GENE
elements XXX I-GENE
and XXX O
co-expression XXX O
with XXX O
the XXX O
selA XXX B-GENE
, XXX O
selB XXX B-GENE
and XXX O
selC XXX B-GENE
genes XXX I-GENE
. XXX O

One XXX O
possible XXX O
solution XXX O
is XXX O
a XXX O
thin XXX O
radial XXX O
forearm XXX O
free XXX O
flap XXX O
. XXX O

Assuming XXX O
O2 XXX O
consumption XXX O
of XXX O
the XXX O
isolated XXX O
skin XXX O
to XXX O
be XXX O
same XXX O
as XXX O
in XXX O
situ XXX O
, XXX O
calculations XXX O
showed XXX O
that XXX O
when XXX O
water XXX O
PO2 XXX O
was XXX O
high XXX O
( XXX O
150 XXX O
mm XXX O
Hg XXX O
) XXX O
, XXX O
about XXX O
40% XXX O
of XXX O
total XXX O
cutaneous XXX O
O2 XXX O
uptake XXX O
was XXX O
consumed XXX O
by XXX O
the XXX O
skin XXX O
. XXX O

Then XXX O
, XXX O
pure XXX O
pancreatic XXX O
juice XXX O
was XXX O
infused XXX O
into XXX O
the XXX O
duodenum XXX O
. XXX O

These XXX O
clones XXX O
were XXX O
found XXX O
to XXX O
share XXX O
a XXX O
common XXX O
domain XXX O
encoded XXX O
by XXX O
p XXX O
( XXX O
CA XXX O
) XXX O
n XXX O
repeats XXX O
; XXX O
a XXX O
simple XXX O
sequence XXX O
length XXX O
polymorphism XXX O
( XXX O
SSLP XXX O
) XXX O
. XXX O

Derepression XXX O
of XXX O
gene XXX O
expression XXX O
mediated XXX O
by XXX O
the XXX O
5' XXX O
upstream XXX O
region XXX O
of XXX O
the XXX O
isocitrate XXX B-GENE
lyase XXX I-GENE
gene XXX I-GENE
of XXX I-GENE
Candida XXX I-GENE
tropicalis XXX I-GENE
is XXX O
controlled XXX O
by XXX O
two XXX O
distinct XXX O
regulatory XXX O
pathways XXX O
in XXX O
Saccharomyces XXX O
cerevisiae XXX O
. XXX O

The XXX O
other XXX O
two XXX O
clones XXX O
, XXX O
Ash-m XXX B-GENE
and XXX I-GENE
-s XXX I-GENE
, XXX O
had XXX O
nucleotide XXX O
sequences XXX O
identical XXX O
with XXX O
Ash-l XXX B-GENE
cDNA XXX O
in XXX O
the XXX O
amino-terminal XXX O
region XXX O
. XXX O

Temporal XXX O
control XXX O
of XXX O
GUS XXX B-GENE
expression XXX O
was XXX O
found XXX O
to XXX O
involve XXX O
two XXX O
negative XXX O
regulatory XXX O
sequences XXX O
, XXX O
NRS1 XXX B-GENE
( XXX I-GENE
-391 XXX I-GENE
to XXX I-GENE
-295 XXX I-GENE
) XXX I-GENE
and XXX O
NRS2 XXX B-GENE
( XXX I-GENE
-518 XXX I-GENE
to XXX I-GENE
-418 XXX I-GENE
) XXX I-GENE
, XXX O
as XXX O
well XXX O
as XXX O
the XXX O
positive XXX O
domain XXX O
UAS1 XXX B-GENE
. XXX O

In XXX O
untransformed XXX O
cells XXX O
, XXX O
three XXX O
major XXX O
proteins XXX O
coprecipitated XXX O
with XXX O
CRKL XXX B-GENE
, XXX O
identified XXX O
as XXX O
C3G XXX B-GENE
, XXX O
SOS XXX B-GENE
and XXX O
c-ABL XXX B-GENE
. XXX O

I XXX O
. XXX O

Immunohistochemical XXX O
staining XXX O
with XXX O
MIB-1 XXX B-GENE
and XXX O
p53 XXX B-GENE
antibodies XXX I-GENE
showed XXX O
low XXX O
( XXX O
< XXX O
1% XXX O
) XXX O
and XXX O
negative XXX O
reaction XXX O
. XXX O

These XXX O
results XXX O
indicate XXX O
that XXX O
both XXX O
PKC XXX B-GENE
alpha XXX I-GENE
( XXX O
calcium XXX O
dependent XXX O
) XXX O
and XXX O
PKC XXX B-GENE
delta XXX I-GENE
( XXX O
calcium XXX O
independent XXX O
) XXX O
may XXX O
mediate XXX O
the XXX O
transcription XXX O
of XXX O
TPA-inducible XXX B-GENE
genes XXX I-GENE
through XXX O
both XXX O
AP-1 XXX B-GENE
and XXX O
non-AP-1 XXX B-GENE
sequences XXX I-GENE
. XXX O

One XXX O
hundred XXX O
and XXX O
four XXX O
( XXX O
14 XXX O
per XXX O
cent XXX O
) XXX O
second XXX O
primary XXX O
tumours XXX O
were XXX O
reported XXX O
. XXX O

RegA XXX B-GENE
is XXX O
a XXX O
positive XXX O
yet XXX O
nonessential XXX O
regulator XXX O
of XXX O
tol-oprL XXX B-GENE
expression XXX O
. XXX O

The XXX O
patient XXX O
was XXX O
treated XXX O
with XXX O
benzathine XXX O
penicillin XXX O
, XXX O
2 XXX O
, XXX O
400 XXX O
, XXX O
000 XXX O
U XXX O
weekly XXX O
for XXX O
three XXX O
weeks XXX O
. XXX O

Recent XXX O
target XXX O
BP XXX O
goals XXX O
promulgated XXX O
by XXX O
the XXX O
Sixth XXX O
Report XXX O
from XXX O
the XXX O
Joint XXX O
National XXX O
Committee XXX O
( XXX O
JNC XXX O
VI XXX O
) XXX O
are XXX O
based XXX O
on XXX O
the XXX O
premise XXX O
that XXX O
the XXX O
intensity XXX O
of XXX O
treatment XXX O
directly XXX O
corresponds XXX O
to XXX O
the XXX O
magnitude XXX O
of XXX O
pretreatment XXX O
risk XXX O
. XXX O

We XXX O
have XXX O
screened XXX O
the XXX O
mouse XXX O
cDNA XXX O
library XXX O
of XXX O
an XXX O
MIN6 XXX O
cell XXX O
line XXX O
, XXX O
derived XXX O
from XXX O
pancreatic XXX O
beta XXX O
cells XXX O
, XXX O
for XXX O
its XXX O
novel XXX O
isoform XXX O
and XXX O
have XXX O
identified XXX O
a XXX O
cDNA XXX O
encoding XXX O
a XXX O
593-amino XXX O
acid XXX O
protein XXX O
having XXX O
63 XXX O
, XXX O
53 XXX O
, XXX O
and XXX O
30% XXX O
identity XXX O
with XXX O
munc-18 XXX B-GENE
/ XXX I-GENE
n-Sec1 XXX I-GENE
/ XXX I-GENE
rbSec1 XXX I-GENE
, XXX O
Caenorhabditis XXX B-GENE
elegans XXX I-GENE
unc18 XXX I-GENE
, XXX O
and XXX O
Saccharomyces XXX B-GENE
cerevisiae XXX I-GENE
Sec1p XXX I-GENE
, XXX O
respectively XXX O
. XXX O

Comparison XXX O
of XXX O
immunoassay XXX O
kits XXX O
for XXX O
detection XXX O
of XXX O
staphylococcal XXX B-GENE
enterotoxins XXX I-GENE
produced XXX O
by XXX O
Staphylococcus XXX O
aureus XXX O
. XXX O

The XXX O
C-terminal XXX O
approximately XXX O
50 XXX O
amino XXX O
acids XXX O
of XXX O
Bel-1 XXX B-GENE
are XXX O
shown XXX O
to XXX O
be XXX O
essential XXX O
for XXX O
Bel-1 XXX B-GENE
activity XXX O
but XXX O
can XXX O
be XXX O
effectively XXX O
substituted XXX O
by XXX O
the XXX O
C-terminal XXX O
activation XXX O
domain XXX O
of XXX O
VP16 XXX B-GENE
. XXX O

Our XXX O
study XXX O
also XXX O
demonstrated XXX O
significant XXX O
increases XXX O
in XXX O
the XXX O
number XXX O
of XXX O
larger XXX O
myelinated XXX O
fibers XXX O
crossing XXX O
the XXX O
repair XXX O
site XXX O
in XXX O
comparison XXX O
with XXX O
the XXX O
neonatal XXX O
and XXX O
adult XXX O
groups XXX O
( XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
04 XXX O
) XXX O
. XXX O

We XXX O
suggest XXX O
that XXX O
this XXX O
gene XXX O
cluster XXX O
codes XXX O
for XXX O
( XXX O
parts XXX O
of XXX O
) XXX O
a XXX O
multisubunit XXX B-GENE
cytochrome XXX I-GENE
c XXX I-GENE
haem XXX I-GENE
lyase XXX I-GENE
. XXX O

Hematopoietic XXX B-GENE
growth XXX I-GENE
factors XXX I-GENE
are XXX O
being XXX O
used XXX O
to XXX O
accelerate XXX O
the XXX O
recovery XXX O
of XXX O
myelopoiesis XXX O
following XXX O
high-dose XXX O
chemotherapy XXX O
in XXX O
cancer XXX O
patients XXX O
. XXX O

Man XXX O
and XXX O
insect XXX O
, XXX O
past XXX O
, XXX O
present XXX O
, XXX O
future XXX O
. XXX O

In XXX O
a XXX O
retrospective XXX O
analysis XXX O
of XXX O
data XXX O
from XXX O
35 XXX O
cases XXX O
with XXX O
malignant XXX O
lymphoma XXX O
from XXX O
a XXX O
cohort XXX O
of XXX O
2017 XXX O
HIV-infected XXX O
patients XXX O
, XXX O
the XXX O
stage XXX O
of XXX O
HIV-disease XXX O
, XXX O
the XXX O
CD4 XXX B-GENE
counts XXX O
at XXX O
the XXX O
time XXX O
of XXX O
diagnosis XXX O
, XXX O
and XXX O
the XXX O
use XXX O
of XXX O
antineoplastic XXX O
agents XXX O
or XXX O
radiotherapy XXX O
were XXX O
correlated XXX O
with XXX O
outcome XXX O
. XXX O

Further XXX O
studies XXX O
on XXX O
a XXX O
"new" XXX O
human XXX O
isoprecipitin XXX O
system XXX O
( XXX O
Australia XXX O
antigen XXX O
) XXX O
. XXX O

SvO2 XXX O
can XXX O
be XXX O
determined XXX O
in XXX O
vitro XXX O
and XXX O
in XXX O
vivo XXX O
. XXX O

A XXX O
clinical XXX O
, XXX O
serological XXX O
and XXX O
prognostic XXX O
study XXX O
. XXX O

Dermatology XXX O
is XXX O
no XXX O
exception XXX O
. XXX O

Oral XXX O
supplementation XXX O
of XXX O
L-arginine XXX O
significantly XXX O
increased XXX O
plasma XXX O
L-citrulline XXX O
, XXX O
which XXX O
indicated XXX O
enhancement XXX O
of XXX O
NO XXX O
production XXX O
. XXX O

The XXX O
relative XXX O
importance XXX O
of XXX O
these XXX O
two XXX O
mechanisms XXX O
differed XXX O
in XXX O
a XXX O
response XXX O
element-specific XXX O
manner XXX O
. XXX O

Re-evaluation XXX O
of XXX O
the XXX O
biopsy XXX O
specimen XXX O
from XXX O
the XXX O
right XXX O
hip XXX O
taken XXX O
at XXX O
the XXX O
time XXX O
of XXX O
the XXX O
initial XXX O
operation XXX O
showed XXX O
areas XXX O
of XXX O
chondrosarcoma XXX O
arising XXX O
in XXX O
the XXX O
background XXX O
of XXX O
synovial XXX O
chondromatosis XXX O
. XXX O

Invertases XXX B-GENE
are XXX O
responsible XXX O
for XXX O
the XXX O
breakdown XXX O
of XXX O
sucrose XXX O
to XXX O
fructose XXX O
and XXX O
glucose XXX O
. XXX O

Like XXX O
the XXX O
Tob XXX B-GENE
protein XXX I-GENE
, XXX O
Tob2 XXX B-GENE
inhibited XXX O
cell XXX O
cycle XXX O
progression XXX O
from XXX O
the XXX O
G0 XXX O
/ XXX O
G1 XXX O
to XXX O
S XXX O
phases XXX O
. XXX O

In XXX O
overdoses XXX O
up XXX O
to XXX O
2 XXX O
g XXX O
fluvoxamine XXX O
no XXX O
lasting XXX O
toxic XXX O
effects XXX O
were XXX O
observed XXX O
. XXX O

The XXX O
hemodynamics XXX O
of XXX O
isoproterenol-induced XXX O
cardiac XXX O
failure XXX O
in XXX O
the XXX O
rat XXX O
. XXX O

One XXX O
class XXX O
of XXX O
plasmids XXX O
contained XXX O
tRNA XXX B-GENE
( XXX I-GENE
His XXX I-GENE
) XXX I-GENE
genes XXX I-GENE
and XXX O
conferred XXX O
efficient XXX O
suppression XXX O
only XXX O
when XXX O
cells XXX O
were XXX O
starved XXX O
for XXX O
histidine XXX O
; XXX O
these XXX O
plasmids XXX O
suppressed XXX O
a XXX O
gcn2 XXX B-GENE
deletion XXX O
much XXX O
less XXX O
efficiently XXX O
than XXX O
they XXX O
suppressed XXX O
gcn2-507 XXX B-GENE
. XXX O

Like XXX O
many XXX O
eukaryotic XXX O
transcription XXX O
factors XXX O
, XXX O
these XXX O
proteins XXX O
bind XXX O
to XXX O
DNA XXX O
as XXX O
dimers XXX O
. XXX O

SSeCKS XXX B-GENE
( XXX O
pronounced XXX O
essex XXX B-GENE
) XXX O
encodes XXX O
a XXX O
major XXX O
protein XXX B-GENE
kinase XXX I-GENE
C XXX I-GENE
substrate XXX O
, XXX O
the XXX O
expression XXX O
of XXX O
which XXX O
is XXX O
down-regulated XXX O
in XXX O
src- XXX O
and XXX O
ras-transformed XXX O
rodent XXX O
fibroblasts XXX O
but XXX O
not XXX O
in XXX O
raf-transformed XXX O
rodent XXX O
fibroblasts XXX O
( XXX O
X XXX O
. XXX O

A XXX O
new XXX O
hypothesis XXX O
on XXX O
mechanisms XXX O
for XXX O
inhibiting XXX O
catalytic XXX O
subunits XXX O
by XXX O
gamma-subunits XXX O
and XXX O
activation XXX O
of XXX O
a XXX O
holoenzyme XXX O
by XXX O
transducin XXX B-GENE
. XXX O

Yeast XXX O
mutants XXX O
lacking XXX O
a XXX O
functional XXX O
NOP1 XXX B-GENE
gene XXX I-GENE
can XXX O
be XXX O
complemented XXX O
by XXX O
human XXX B-GENE
fibrillarin XXX I-GENE
but XXX O
are XXX O
temperature XXX O
sensitive XXX O
for XXX O
growth XXX O
and XXX O
impaired XXX O
in XXX O
pre-rRNA XXX O
processing XXX O
. XXX O

Specific XXX O
IgG XXX B-GENE
, XXX O
specific XXX O
IgE XXX B-GENE
and XXX O
total XXX O
IgE XXX B-GENE
immunoglobulins XXX I-GENE
against XXX O
Toxocara XXX B-GENE
canis XXX I-GENE
excretory XXX I-GENE
/ XXX I-GENE
secretory XXX I-GENE
antigens XXX I-GENE
( XXX O
TES XXX B-GENE
) XXX O
were XXX O
detected XXX O
by XXX O
using XXX O
ELISA XXX O
technique XXX O
. XXX O

2 XXX O
: XXX O
121-133 XXX O
, XXX O
1988 XXX O
) XXX O
. XXX O

We XXX O
propose XXX O
that XXX O
epigenetic XXX O
features XXX O
of XXX O
tissue-specific XXX O
control XXX O
and XXX O
of XXX O
the XXX O
control XXX O
of XXX O
allelic XXX O
expression XXX O
are XXX O
intricately XXX O
linked XXX O
. XXX O

According XXX O
to XXX O
the XXX O
results XXX O
of XXX O
assays XXX O
obtained XXX O
with XXX O
the XXX O
use XXX O
of XXX O
assay XXX O
systems XXX O
ORTHO XXX O
ELISA XXX O
and XXX O
ABBOTT XXX O
HCV XXX O
EIA XXX O
( XXX O
USA XXX O
) XXX O
, XXX O
the XXX O
detection XXX O
rate XXX O
of XXX O
anti-HCV-C100-3 XXX B-GENE
among XXX O
primary XXX O
blood XXX O
donors XXX O
in XXX O
Moscow XXX O
was XXX O
1 XXX O
. XXX O
37% XXX O
and XXX O
was XXX O
not XXX O
different XXX O
from XXX O
that XXX O
among XXX O
HBsAg XXX B-GENE
carriers XXX O
( XXX O
1 XXX O
. XXX O
8% XXX O
) XXX O
and XXX O
among XXX O
donors XXX O
with XXX O
anti-HCV-C100-3 XXX B-GENE
in XXX O
the XXX O
blood XXX O
( XXX O
1 XXX O
. XXX O
6% XXX O
) XXX O
( XXX O
p XXX O
< XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
. XXX O

Control XXX O
examination XXX O
was XXX O
performed XXX O
at XXX O
the XXX O
end XXX O
of XXX O
each XXX O
period XXX O
. XXX O

Comparison XXX O
of XXX O
data XXX O
obtained XXX O
with XXX O
the XXX O
results XXX O
of XXX O
chronic XXX O
treatment XXX O
with XXX O
the XXX O
opioid XXX O
antagonist XXX O
permits XXX O
to XXX O
conclude XXX O
that XXX O
the XXX O
chronic XXX O
blockade XXX O
increases XXX O
the XXX O
fatiguability XXX O
to XXX O
a XXX O
great XXX O
extent XXX O
than XXX O
chronic XXX O
activation XXX O
of XXX O
opioid XXX O
system XXX O
. XXX O

By XXX O
contrast XXX O
, XXX O
their XXX O
basal XXX O
adrenal XXX O
androgen XXX O
levels XXX O
were XXX O
significantly XXX O
decreased XXX O
compared XXX O
to XXX O
those XXX O
in XXX O
normal XXX O
subjects XXX O
on XXX O
both XXX O
the XXX O
day XXX O
on XXX O
and XXX O
the XXX O
day XXX O
off XXX O
prednisone XXX O
( XXX O
P XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
05 XXX O
) XXX O
. XXX O

The XXX O
aim XXX O
of XXX O
this XXX O
study XXX O
was XXX O
to XXX O
investigate XXX O
the XXX O
spontaneous XXX O
reports XXX O
of XXX O
suspected XXX O
adverse XXX O
drug XXX O
reactions XXX O
, XXX O
observed XXX O
in XXX O
elderly XXX O
patients XXX O
( XXX O
over XXX O
65 XXX O
years XXX O
of XXX O
age XXX O
) XXX O
in XXX O
Sicily XXX O
( XXX O
Italy XXX O
) XXX O
during XXX O
the XXX O
period XXX O
from XXX O
1 XXX O
January XXX O
1995 XXX O
to XXX O
31 XXX O
December XXX O
1997 XXX O
. XXX O

Second XXX O
report XXX O
of XXX O
the XXX O
Norwegian XXX O
Cancer XXX O
Society XXX O
. XXX O

These XXX O
adverse XXX O
effects XXX O
usually XXX O
abate XXX O
with XXX O
time XXX O
. XXX O

The XXX O
mean XXX O
values XXX O
of XXX O
the XXX O
concentrations XXX O
of XXX O
the XXX O
components XXX O
due XXX O
to XXX O
tobacco XXX O
smoke XXX O
are XXX O
: XXX O
CO XXX O
= XXX O
1 XXX O
. XXX O
1 XXX O
ppm XXX O
, XXX O
NO XXX O
= XXX O
32 XXX O
ppb XXX O
, XXX O
NO2 XXX O
= XXX O
24 XXX O
ppb XXX O
, XXX O
nicotine XXX O
= XXX O
0 XXX O
. XXX O
9 XXX O
micrograms XXX O
/ XXX O
m3 XXX O
, XXX O
particulate XXX O
matter XXX O
= XXX O
133 XXX O
micrograms XXX O
/ XXX O
m3 XXX O
. XXX O

Restriction XXX O
maps XXX O
of XXX O
the XXX O
cloned XXX O
plasmids XXX O
revealed XXX O
that XXX O
their XXX O
chromosomal XXX O
inserts XXX O
consisted XXX O
of XXX O
overlapping XXX O
fragments XXX O
. XXX O

Opposite XXX O
effects XXX O
of XXX O
CYP1 XXX B-GENE
are XXX O
observed XXX O
in XXX O
aerobic XXX O
, XXX O
heme-sufficient XXX O
cells XXX O
. XXX O

The XXX O
Fis XXX B-GENE
protein XXX I-GENE
regulates XXX O
site-specific XXX O
DNA XXX O
inversion XXX O
catalyzed XXX O
by XXX O
a XXX O
family XXX O
of XXX O
DNA XXX B-GENE
invertases XXX I-GENE
when XXX O
bound XXX O
to XXX O
a XXX O
cis-acting XXX O
recombinational XXX O
enhancer XXX O
. XXX O

How XXX O
plants XXX O
respond XXX O
to XXX O
attack XXX O
by XXX O
the XXX O
range XXX O
of XXX O
herbivores XXX O
and XXX O
pathogens XXX O
that XXX O
confront XXX O
them XXX O
in XXX O
the XXX O
field XXX O
is XXX O
the XXX O
subject XXX O
of XXX O
considerable XXX O
research XXX O
by XXX O
both XXX O
molecular XXX O
biologists XXX O
and XXX O
ecologists XXX O
. XXX O

Transient XXX O
transfection XXX O
analysis XXX O
with XXX O
these XXX O
mutations XXX O
revealed XXX O
that XXX O
only XXX O
a XXX O
10-bp XXX O
region XXX O
, XXX O
containing XXX O
precisely XXX O
the XXX O
Ets XXX B-GENE
and XXX O
proximal XXX O
LyF-1 XXX B-GENE
binding XXX I-GENE
sites XXX I-GENE
, XXX O
was XXX O
needed XXX O
for XXX O
D' XXX O
activity XXX O
. XXX O

DNA XXX O
hybridization XXX O
analysis XXX O
revealed XXX O
that XXX O
both XXX O
pigmented XXX O
and XXX O
nonpigmented XXX O
cells XXX O
of XXX O
Y XXX O
. XXX O
pestis XXX O
possess XXX O
a XXX O
DNA XXX O
locus XXX O
homologous XXX O
to XXX O
the XXX O
Escherichia XXX B-GENE
coli XXX I-GENE
fur XXX I-GENE
gene XXX I-GENE
. XXX O

A XXX O
large XXX O
deletion XXX O
in XXX O
the XXX O
CTD-binding XXX B-GENE
motif XXX I-GENE
blocks XXX O
down-regulation XXX O
but XXX O
does XXX O
not XXX O
affect XXX O
the XXX O
essential XXX O
function XXX O
of XXX O
Nrd1 XXX B-GENE
. XXX O

Application XXX O
of XXX O
different XXX O
criteria XXX O
of XXX O
cure XXX O
revealed XXX O
that XXX O
19 XXX O
patients XXX O
( XXX O
66% XXX O
) XXX O
had XXX O
basal XXX O
GH XXX B-GENE
levels XXX O
below XXX O
5 XXX O
ng XXX O
/ XXX O
ml XXX O
, XXX O
17 XXX O
patients XXX O
( XXX O
59% XXX O
) XXX O
had XXX O
normal XXX O
somatomedin-C XXX B-GENE
values XXX O
, XXX O
16 XXX O
patients XXX O
( XXX O
55% XXX O
) XXX O
had XXX O
complete XXX O
GH XXX B-GENE
suppression XXX O
( XXX O
less XXX O
than XXX O
1 XXX O
ng XXX O
/ XXX O
ml XXX O
) XXX O
during XXX O
OGTT XXX O
, XXX O
and XXX O
13 XXX O
patients XXX O
( XXX O
45% XXX O
) XXX O
met XXX O
the XXX O
above-mentioned XXX O
criteria XXX O
with XXX O
disappearance XXX O
of XXX O
the XXX O
paradoxical XXX O
GH XXX B-GENE
response XXX O
to XXX O
TRH XXX B-GENE
/ XXX I-GENE
GnRH XXX I-GENE
test XXX O
. XXX O

NF-kappaB XXX B-GENE
is XXX O
involved XXX O
in XXX O
the XXX O
regulation XXX O
of XXX O
CD154 XXX B-GENE
( XXX O
CD40 XXX B-GENE
ligand XXX I-GENE
) XXX O
expression XXX O
in XXX O
primary XXX O
human XXX O
T XXX O
cells XXX O
. XXX O

The XXX O
peak XXX O
velocities XXX O
of XXX O
the XXX O
atrial XXX O
systolic XXX O
waves XXX O
of XXX O
the XXX O
transmitral XXX O
and XXX O
pulmonary XXX O
venous XXX O
flow XXX O
velocities XXX O
( XXX O
A XXX O
and XXX O
PVA XXX O
, XXX O
respectively XXX O
) XXX O
and XXX O
first XXX O
systolic XXX O
wave XXX O
( XXX O
PVS1 XXX O
) XXX O
of XXX O
pulmonary XXX O
venous XXX O
flow XXX O
, XXX O
durations XXX O
of XXX O
both XXX O
atrial XXX O
systolic XXX O
waves XXX O
, XXX O
and XXX O
amplitude XXX O
of XXX O
interatrial XXX O
septal XXX O
motion XXX O
during XXX O
atrial XXX O
systole XXX O
increased XXX O
significantly XXX O
ten XXX O
days XXX O
after XXX O
cardioversion XXX O
compared XXX O
with XXX O
those XXX O
measured XXX O
within XXX O
a XXX O
day XXX O
of XXX O
cardioversion XXX O
in XXX O
all XXX O
patients XXX O
except XXX O
the XXX O
5 XXX O
patients XXX O
with XXX O
dilated XXX O
cardiomyopathy XXX O
. XXX O

Radiation-induced XXX O
changes XXX O
in XXX O
the XXX O
area XXX O
of XXX O
alveoli XXX O
and XXX O
septa XXX O
as XXX O
well XXX O
as XXX O
collagen XXX B-GENE
content XXX O
were XXX O
seen XXX O
11 XXX O
weeks XXX O
after XXX O
irradiation XXX O
. XXX O

A XXX O
favourable XXX O
response XXX O
was XXX O
achieved XXX O
with XXX O
a XXX O
combination XXX O
of XXX O
amphotericin XXX O
B XXX O
and XXX O
cotrimoxazole XXX O
. XXX O

Taken XXX O
together XXX O
, XXX O
these XXX O
results XXX O
suggest XXX O
that XXX O
the XXX O
cooperation XXX O
of XXX O
transcription XXX B-GENE
factors XXX I-GENE
NF-kappaB XXX I-GENE
and XXX O
AP-1 XXX B-GENE
is XXX O
essential XXX O
for XXX O
transactivation XXX O
of XXX O
IL-8 XXX B-GENE
gene XXX I-GENE
by XXX O
HTLV-I XXX B-GENE
Tax XXX I-GENE
. XXX O

Five XXX O
women XXX O
( XXX O
15 XXX O
. XXX O
6% XXX O
) XXX O
met XXX O
criteria XXX O
for XXX O
PMS XXX O
. XXX O

In XXX O
summary XXX O
, XXX O
DDC XXX O
express XXX O
receptors XXX O
for XXX O
a XXX O
broad XXX O
panel XXX O
of XXX O
cytokines XXX O
, XXX O
even XXX O
receptors XXX O
for XXX O
cytokines XXX O
whose XXX O
effects XXX O
on XXX O
DC XXX O
are XXX O
still XXX O
unknown XXX O
( XXX O
i XXX O
. XXX O
e XXX O
. XXX O

DNA XXX O
sequence XXX O
analysis XXX O
of XXX O
a XXX O
3213 XXX B-GENE
bp XXX I-GENE
BamHI-ClaI XXX I-GENE
fragment XXX I-GENE
revealed XXX O
that XXX O
three XXX O
open XXX O
reading XXX O
frames XXX O
( XXX O
ORFs XXX O
) XXX O
were XXX O
encoded XXX O
in XXX O
the XXX O
same XXX O
orientation XXX O
. XXX O

CONCLUSIONS XXX O
: XXX O
The XXX O
myocardial XXX O
uptake XXX O
of XXX O
99mTc XXX O
sestamibi XXX O
in XXX O
normal XXX O
subjects XXX O
and XXX O
patients XXX O
with XXX O
coronary XXX O
artery XXX O
disease XXX O
is XXX O
comparable XXX O
after XXX O
exercise XXX O
, XXX O
dipyridamole XXX O
, XXX O
and XXX O
adenosine XXX O
stress XXX O
. XXX O

The XXX O
results XXX O
suggest XXX O
that XXX O
the XXX O
organization XXX O
of XXX O
functional XXX O
units XXX O
of XXX O
the XXX O
72-bp XXX O
repeat XXX O
required XXX O
for XXX O
transcriptional XXX O
enhancement XXX O
of XXX O
the XXX O
early XXX O
promoter XXX O
is XXX O
different XXX O
from XXX O
that XXX O
required XXX O
for XXX O
late XXX O
promoter XXX O
function XXX O
. XXX O

Consistent XXX O
with XXX O
previous XXX O
reports XXX O
, XXX O
addition XXX O
of XXX O
a XXX O
myristoylation XXX O
signal XXX O
to XXX O
mSos1 XXX B-GENE
( XXX O
MyrSos1 XXX B-GENE
) XXX O
rendered XXX O
it XXX O
transforming XXX O
for XXX O
NIH XXX O
3T3 XXX O
cells XXX O
and XXX O
deletion XXX O
of XXX O
the XXX O
mSos XXX B-GENE
C XXX I-GENE
terminus XXX I-GENE
( XXX O
MyrSos1-deltaC XXX B-GENE
) XXX O
did XXX O
not XXX O
interfere XXX O
with XXX O
this XXX O
activity XXX O
. XXX O

Although XXX O
neither XXX O
constitutively XXX O
activated XXX O
MEK XXX B-GENE
( XXX O
MEK-2E XXX B-GENE
) XXX O
nor XXX O
v-Src XXX B-GENE
was XXX O
sufficient XXX O
individually XXX O
to XXX O
differentiate XXX O
the XXX O
H19-7 XXX O
cells XXX O
, XXX O
coexpression XXX O
of XXX O
constitutively XXX O
activated XXX O
MEK XXX B-GENE
and XXX O
v-Src XXX B-GENE
induced XXX O
neurite XXX O
outgrowth XXX O
. XXX O

Comparison XXX O
of XXX O
the XXX O
deduced XXX O
amino XXX B-GENE
acid XXX I-GENE
sequence XXX I-GENE
of XXX I-GENE
gamma-kafirin XXX I-GENE
with XXX O
the XXX O
published XXX O
sequences XXX B-GENE
of XXX I-GENE
gamma-prolamins XXX I-GENE
of XXX I-GENE
maize XXX I-GENE
, XXX I-GENE
and XXX I-GENE
Coix XXX I-GENE
revealed XXX O
highly XXX O
conserved XXX O
domains XXX O
. XXX O

Setting XXX O
takes XXX O
place XXX O
through XXX O
complex XXX O
formation XXX O
of XXX O
( XXX O
NH4Mg XXX O
PO4 XXX O
. XXX O
6H2O XXX O
) XXX O
n XXX O
, XXX O
excess XXX O
reactants XXX O
, XXX O
and XXX O
water XXX O
. XXX O

Airflow XXX O
through XXX O
the XXX O
dust XXX O
trap XXX O
was XXX O
controlled XXX O
with XXX O
a XXX O
vacuum XXX O
pump XXX O
. XXX O

Climatic XXX O
treatment XXX O
of XXX O
children XXX O
with XXX O
respiratory XXX O
allergy XXX O
. XXX O

Inactivity XXX O
of XXX O
the XXX O
human XXX B-GENE
cytomegalovirus XXX I-GENE
( XXX I-GENE
HCMV XXX I-GENE
) XXX I-GENE
major XXX I-GENE
immediate-early XXX I-GENE
regulatory XXX I-GENE
region XXX I-GENE
( XXX O
MIERR XXX B-GENE
) XXX O
, XXX O
which XXX O
is XXX O
composed XXX O
of XXX O
promoter XXX O
, XXX O
enhancer XXX O
, XXX O
unique XXX O
region XXX O
, XXX O
and XXX O
modulator XXX O
, XXX O
is XXX O
linked XXX O
to XXX O
lack XXX O
of XXX O
HCMV XXX O
replication XXX O
in XXX O
latently XXX O
infected XXX O
cells XXX O
and XXX O
in XXX O
other XXX O
nonpermissive XXX O
cell XXX O
types XXX O
, XXX O
including XXX O
human XXX O
embryonal XXX O
NTera2 XXX O
carcinoma XXX O
( XXX O
NT2 XXX O
) XXX O
cells XXX O
. XXX O

In XXX O
controls XXX O
, XXX O
most XXX O
of XXX O
the XXX O
output XXX O
from XXX O
the XXX O
conduit XXX O
occurred XXX O
during XXX O
type XXX O
I XXX O
activity XXX O
( XXX O
73 XXX O
+ XXX O
/ XXX O
- XXX O
14% XXX O
) XXX O
. XXX O

Thus XXX O
, XXX O
the XXX O
class XXX B-GENE
C-Vps XXX I-GENE
complex XXX I-GENE
directs XXX O
multiple XXX O
reactions XXX O
during XXX O
the XXX O
docking XXX O
and XXX O
fusion XXX O
of XXX O
vesicles XXX O
with XXX O
the XXX O
vacuole XXX O
, XXX O
each XXX O
of XXX O
which XXX O
contributes XXX O
to XXX O
the XXX O
overall XXX O
specificity XXX O
and XXX O
efficiency XXX O
of XXX O
this XXX O
transport XXX O
process XXX O
. XXX O

The XXX O
predicted XXX O
protein XXX O
products XXX O
of XXX O
ORFs XXX B-GENE
N2417 XXX I-GENE
and XXX O
N2403 XXX B-GENE
present XXX O
similarities XXX O
with XXX O
domains XXX O
from XXX O
proteins XXX O
of XXX O
other XXX O
organisms XXX O
: XXX O
the XXX O
Candida XXX O
maltosa XXX O
cycloheximide-resistance XXX B-GENE
protein XXX I-GENE
, XXX O
the XXX O
human XXX O
interleukin XXX B-GENE
enhancer-binding XXX I-GENE
factor XXX I-GENE
( XXX O
ILF-2 XXX B-GENE
) XXX O
. XXX O

Manganese XXX O
ions XXX O
were XXX O
found XXX O
to XXX O
be XXX O
essential XXX O
for XXX O
autophosphorylation XXX O
of XXX O
BGLF4 XXX B-GENE
, XXX O
and XXX O
magnesium XXX O
can XXX O
stimulate XXX O
the XXX O
activity XXX O
. XXX O

However XXX O
, XXX O
the XXX O
use XXX O
of XXX O
cyclosporin XXX O
A XXX O
is XXX O
associated XXX O
with XXX O
an XXX O
increased XXX O
prevalence XXX O
of XXX O
hypertension XXX O
in XXX O
kidney XXX O
transplant XXX O
recipients XXX O
. XXX O

The XXX O
human XXX B-GENE
MSH-2 XXX I-GENE
gene XXX I-GENE
product XXX I-GENE
is XXX O
a XXX O
member XXX O
of XXX O
a XXX O
highly XXX O
conserved XXX O
family XXX O
of XXX O
proteins XXX O
which XXX O
are XXX O
involved XXX O
in XXX O
post-replication XXX O
mismatch XXX O
repair XXX O
. XXX O
hMSH-2 XXX B-GENE
is XXX O
homologous XXX O
to XXX O
Escherichia XXX O
coli XXX O
( XXX O
E XXX O
. XXX O
coli XXX O
) XXX O
MutS XXX B-GENE
and XXX O
Sacchromyces XXX B-GENE
cerevisiae XXX I-GENE
MSH-1 XXX I-GENE
and XXX O
MSH-2 XXX B-GENE
proteins XXX I-GENE
, XXX O
which XXX O
recognise XXX O
heteroduplex XXX O
DNA XXX O
at XXX O
the XXX O
sites XXX O
of XXX O
all XXX O
single XXX O
base XXX O
mismatches XXX O
and XXX O
deletions XXX O
or XXX O
insertions XXX O
up XXX O
to XXX O
4 XXX O
base XXX O
pairs XXX O
. XXX O
hMSH-2 XXX B-GENE
is XXX O
one XXX O
of XXX O
the XXX O
hereditary XXX B-GENE
non-polyposis XXX I-GENE
colorectal XXX I-GENE
cancer XXX I-GENE
( XXX I-GENE
HNPCC XXX I-GENE
) XXX I-GENE
tumor XXX I-GENE
suppressor XXX I-GENE
genes XXX I-GENE
, XXX O
and XXX O
maps XXX O
to XXX O
human XXX O
chromosome XXX O
2p16 XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
the XXX O
-119 XXX O
to XXX O
-81 XXX O
fragment XXX O
of XXX O
the XXX O
CCK XXX B-GENE
promoter XXX I-GENE
contains XXX O
a XXX O
transcriptional XXX O
enhancer XXX O
that XXX O
potentiates XXX O
the XXX O
transcription XXX O
from XXX O
the XXX O
herpes XXX O
simplex XXX O
virus XXX O
thymidine XXX B-GENE
kinase XXX I-GENE
promoter XXX I-GENE
in XXX O
a XXX O
position- XXX O
and XXX O
orientation-independent XXX O
manner XXX O
. XXX O

This XXX O
vector XXX O
transfected XXX O
into XXX O
the XXX O
yeast XXX O
Saccharomyces XXX O
cerevisiae XXX O
directs XXX O
expression XXX O
of XXX O
a XXX O
secreted XXX O
mature XXX O
protein XXX O
at XXX O
levels XXX O
up XXX O
to XXX O
200 XXX O
mg XXX O
of XXX O
LAPP XXX O
/ XXX O
liter XXX O
of XXX O
culture XXX O
medium XXX O
. XXX O

Such XXX O
multisensory XXX O
interactions XXX O
can XXX O
be XXX O
significant XXX O
for XXX O
behavior XXX O
. XXX O

Activation XXX O
of XXX O
the XXX O
mitogen XXX B-GENE
activated XXX I-GENE
protein XXX I-GENE
( XXX I-GENE
MAP XXX I-GENE
) XXX I-GENE
kinase XXX I-GENE
is XXX O
a XXX O
primary XXX O
consequence XXX O
of XXX O
Ras XXX B-GENE
activation XXX O
and XXX O
plays XXX O
a XXX O
key XXX O
role XXX O
in XXX O
mediating XXX O
Ras XXX B-GENE
signal XXX O
transduction XXX O
. XXX O

Neither XXX O
CES1 XXX B-GENE
nor XXX O
CES4 XXX B-GENE
is XXX O
essential XXX O
for XXX O
cell XXX O
growth XXX O
, XXX O
and XXX O
a XXX O
double XXX O
deletion XXX O
mutant XXX O
is XXX O
viable XXX O
. XXX O

Alternative XXX O
splicing XXX O
of XXX O
fibroblast XXX B-GENE
growth XXX I-GENE
factor XXX I-GENE
receptor XXX I-GENE
2 XXX I-GENE
( XXX O
FGF-R2 XXX B-GENE
) XXX O
is XXX O
an XXX O
example XXX O
of XXX O
highly XXX O
regulated XXX O
alternative XXX O
splicing XXX O
in XXX O
which XXX O
exons XXX O
IIIb XXX O
and XXX O
IIIc XXX O
are XXX O
utilized XXX O
in XXX O
a XXX O
mutually XXX O
exclusive XXX O
manner XXX O
in XXX O
different XXX O
cell XXX O
types XXX O
. XXX O

This XXX O
newly XXX O
described XXX O
organism XXX O
was XXX O
difficult XXX O
to XXX O
identify XXX O
due XXX O
to XXX O
discrepancies XXX O
between XXX O
the XXX O
Vitek XXX O
and XXX O
API XXX O
20E XXX O
identification XXX O
systems XXX O
. XXX O

This XXX O
relatively XXX O
simple XXX O
and XXX O
easily XXX O
performed XXX O
technique XXX O
of XXX O
measuring XXX O
deep XXX O
muscle XXX O
temperature XXX O
appears XXX O
to XXX O
be XXX O
a XXX O
useful XXX O
adjunct XXX O
in XXX O
choosing XXX O
the XXX O
amputation XXX O
level XXX O
. XXX O

METHODS XXX O
: XXX O
Ten XXX O
influenza XXX O
A XXX O
( XXX O
H3N2 XXX O
) XXX O
viruses XXX O
isolated XXX O
during XXX O
the XXX O
outbreaks XXX O
were XXX O
examined XXX O
for XXX O
resistance XXX O
to XXX O
amantadine XXX O
and XXX O
rimantadine XXX O
by XXX O
means XXX O
of XXX O
an XXX O
enzyme XXX O
immunoassay XXX O
and XXX O
by XXX O
sequencing XXX O
of XXX O
the XXX O
viral XXX O
nucleic XXX O
acid XXX O
that XXX O
encodes XXX O
the XXX O
transmembrane XXX O
domain XXX O
of XXX O
the XXX O
M2 XXX B-GENE
protein XXX I-GENE
. XXX O

An XXX O
anatomical XXX O
and XXX O
histochemical XXX O
study XXX O
has XXX O
been XXX O
undertaken XXX O
and XXX O
as XXX O
a XXX O
result XXX O
emphasis XXX O
is XXX O
given XXX O
to XXX O
recent XXX O
hypotheses XXX O
that XXX O
suggest XXX O
there XXX O
are XXX O
similarities XXX O
with XXX O
Type XXX O
IV XXX O
glycogen XXX O
storage XXX O
disease XXX O
( XXX O
Andersen's XXX O
disease XXX O
) XXX O
which XXX O
, XXX O
although XXX O
clinically XXX O
distinct XXX O
, XXX O
has XXX O
the XXX O
same XXX O
enzyme XXX O
defect XXX O
. XXX O

Ten XXX O
volunteers XXX O
were XXX O
tested XXX O
at XXX O
18 XXX O
, XXX O
000 XXX O
ft XXX O
( XXX O
5 XXX O
, XXX O
486 XXX O
m XXX O
) XXX O
, XXX O
and XXX O
through XXX O
12 XXX O
, XXX O
000 XXX O
, XXX O
8 XXX O
, XXX O
000 XXX O
, XXX O
and XXX O
5 XXX O
, XXX O
000 XXX O
ft XXX O
( XXX O
3 XXX O
, XXX O
657 XXX O
, XXX O
2 XXX O
, XXX O
438 XXX O
, XXX O
and XXX O
1 XXX O
, XXX O
524 XXX O
m XXX O
) XXX O
with XXX O
directional XXX O
sounds XXX O
recorded XXX O
via XXX O
a XXX O
dummy XXX O
head XXX O
microphone XXX O
and XXX O
presented XXX O
binaurally XXX O
. XXX O

Because XXX O
the XXX O
high-density XXX B-GENE
lipoprotein XXX I-GENE
receptor XXX I-GENE
( XXX O
HDL-R XXX B-GENE
) XXX O
is XXX O
a XXX O
key XXX O
element XXX O
in XXX O
cholesterol XXX O
homeostasis XXX O
and XXX O
a XXX O
potential XXX O
therapeutic XXX O
target XXX O
for XXX O
hypercholesterolemic XXX O
drugs XXX O
, XXX O
an XXX O
understanding XXX O
of XXX O
HDL-R XXX B-GENE
regulation XXX O
is XXX O
essential XXX O
. XXX O

Patients XXX O
with XXX O
CF XXX O
and XXX O
meconium XXX O
ileus XXX O
presented XXX O
a XXX O
poor XXX O
nutritional XXX O
status XXX O
at XXX O
diagnosis XXX O
and XXX O
a XXX O
lower XXX O
survival XXX O
rate XXX O
compared XXX O
to XXX O
the XXX O
general XXX O
CF XXX O
population XXX O
. XXX O

A XXX O
role XXX O
for XXX O
the XXX O
small XXX B-GENE
GTPase XXX I-GENE
Rac XXX I-GENE
in XXX O
polyomavirus XXX O
middle-T XXX O
antigen-mediated XXX O
activation XXX O
of XXX O
the XXX O
serum XXX B-GENE
response XXX I-GENE
element XXX I-GENE
and XXX O
in XXX O
cell XXX O
transformation XXX O
. XXX O

Finally XXX O
, XXX O
profiling XXX O
of XXX O
a XXX O
gcn4Delta XXX B-GENE
mutant XXX I-GENE
uncovered XXX O
an XXX O
alternative XXX O
induction XXX O
pathway XXX O
operating XXX O
at XXX O
many XXX O
Gcn4p XXX B-GENE
target XXX I-GENE
genes XXX I-GENE
in XXX O
histidine-starved XXX O
cells XXX O
. XXX O

Our XXX O
results XXX O
suggest XXX O
that XXX O
the XXX O
pattern XXX O
of XXX O
blood XXX O
supply XXX O
is XXX O
relevant XXX O
to XXX O
the XXX O
structural XXX O
organisation XXX O
of XXX O
mature XXX O
lamellar XXX O
bone XXX O
around XXX O
the XXX O
implant XXX O
. XXX O

Thus XXX O
, XXX O
a XXX O
negative XXX O
test XXX O
is XXX O
compatible XXX O
with XXX O
low XXX O
disease XXX O
activity XXX O
and XXX O
/ XXX O
or XXX O
efficacy XXX O
of XXX O
calcium XXX O
antagonist XXX O
treatment XXX O
. XXX O

The XXX O
loss XXX O
of XXX O
avirulence XXX O
activity XXX O
because XXX O
of XXX O
mutations XXX O
in XXX O
the XXX O
acidic XXX O
transcriptional XXX O
activation XXX O
domain XXX O
was XXX O
restored XXX O
by XXX O
addition XXX O
of XXX O
the XXX O
activation XXX O
domain XXX O
from XXX O
the XXX O
herpes XXX B-GENE
simplex XXX I-GENE
viral XXX I-GENE
protein XXX I-GENE
VP16 XXX I-GENE
. XXX O

Nonreplicating XXX O
vaccinia XXX O
vector XXX O
efficiently XXX O
expresses XXX O
recombinant XXX O
genes XXX O
. XXX O

By XXX O
an XXX O
induced-fit XXX O
mechanism XXX O
, XXX O
contacts XXX O
with XXX O
the XXX O
anticodon XXX O
can XXX O
activate XXX O
formation XXX O
of XXX O
a XXX O
robust XXX O
transition XXX O
state XXX O
at XXX O
a XXX O
site XXX O
over XXX O
70 XXX O
A XXX O
away XXX O
. XXX O

The XXX O
effect XXX O
of XXX O
zinc XXX O
deficiency XXX O
on XXX O
trace XXX O
metals XXX O
in XXX O
the XXX O
liver XXX O
, XXX O
spleen XXX O
, XXX O
kidney XXX O
, XXX O
pancreas XXX O
and XXX O
duodenum XXX O
was XXX O
investigated XXX O
in XXX O
the XXX O
control XXX O
and XXX O
zinc-deficient XXX O
rats XXX O
at XXX O
17 XXX O
days XXX O
and XXX O
20 XXX O
days XXX O
of XXX O
pregnancy XXX O
. XXX O

Several XXX O
studies XXX O
have XXX O
characterized XXX O
the XXX O
upstream XXX O
regulatory XXX O
region XXX O
of XXX O
c-fos XXX B-GENE
, XXX O
and XXX O
identified XXX O
cis-acting XXX O
elements XXX O
termed XXX O
the XXX O
cyclic XXX B-GENE
AMP XXX I-GENE
( XXX I-GENE
cAMP XXX I-GENE
) XXX I-GENE
response XXX I-GENE
elements XXX I-GENE
( XXX O
CREs XXX B-GENE
) XXX O
that XXX O
are XXX O
critical XXX O
for XXX O
c-fos XXX B-GENE
transcription XXX O
in XXX O
response XXX O
to XXX O
a XXX O
variety XXX O
of XXX O
extracellular XXX O
stimuli XXX O
. XXX O

Using XXX O
a XXX O
high-copy XXX O
suppression XXX O
strategy XXX O
, XXX O
we XXX O
have XXX O
identified XXX O
a XXX O
yeast XXX O
gene XXX O
( XXX O
UBS1 XXX B-GENE
) XXX O
whose XXX O
elevated XXX O
expression XXX O
suppresses XXX O
the XXX O
conditional XXX O
cell XXX O
cycle XXX O
defects XXX O
associated XXX O
with XXX O
cdc34 XXX B-GENE
mutations XXX O
. XXX O

However XXX O
, XXX O
there XXX O
has XXX O
not XXX O
been XXX O
any XXX O
evidence XXX O
of XXX O
A XXX O
. XXX O
salmonicida XXX O
infections XXX O
, XXX O
specifically XXX O
furunculosis XXX O
, XXX O
associated XXX O
with XXX O
the XXX O
fish XXX O
in XXX O
this XXX O
loch XXX O
. XXX O

Dynamic XXX O
and XXX O
static XXX O
scintigrams XXX O
, XXX O
using XXX O
99mtechnetium XXX O
methylene XXX O
diphosphonate XXX O
, XXX O
were XXX O
obtained XXX O
at XXX O
zero XXX O
, XXX O
six XXX O
, XXX O
and XXX O
12 XXX O
weeks XXX O
after XXX O
fracture XXX O
. XXX O

The XXX O
persistent XXX O
fetal XXX O
dispersion XXX O
of XXX O
nodal XXX O
and XXX O
Hiss XXX O
bundle XXX O
fragments XXX O
within XXX O
the XXX O
ventricular XXX O
septum XXX O
is XXX O
proposed XXX O
as XXX O
a XXX O
possible XXX O
explanation XXX O
. XXX O

Residual XXX O
urinary XXX O
abnormalities XXX O
were XXX O
significantly XXX O
more XXX O
frequent XXX O
in XXX O
patients XXX O
with XXX O
type XXX O
III XXX O
than XXX O
type XXX O
I XXX O
MPGN XXX O
. XXX O

A XXX O
range XXX O
of XXX O
normal XXX O
ventricular XXX O
measurements XXX O
for XXX O
the XXX O
EMI XXX O
scan XXX O
is XXX O
suggested XXX O
. XXX O

Inspired XXX O
CO2 XXX O
causing XXX O
changes XXX O
from XXX O
hypo- XXX O
to XXX O
normocapnia XXX O
has XXX O
previously XXX O
been XXX O
shown XXX O
to XXX O
improve XXX O
arterial XXX O
O2 XXX O
tension XXX O
( XXX O
PaO2 XXX O
) XXX O
and XXX O
to XXX O
reduce XXX O
alveolar-arterial XXX O
O2 XXX O
difference XXX O
. XXX O

Most XXX O
likely XXX O
they XXX O
might XXX O
represent XXX O
regulatory XXX O
RNAs XXX O
or XXX O
transcribed XXX O
transposable XXX O
elements XXX O
. XXX O

A XXX O
new XXX O
UASH XXX B-GENE
consensus XXX I-GENE
sequence XXX I-GENE
derived XXX O
from XXX O
this XXX O
mutational XXX O
analysis XXX O
closely XXX O
matches XXX O
a XXX O
consensus XXX O
Abf1 XXX B-GENE
binding XXX I-GENE
site XXX I-GENE
. XXX O

A XXX O
hybridoma XXX O
clone XXX O
( XXX O
7H1 XXX O
) XXX O
resulting XXX O
from XXX O
the XXX O
fusion XXX O
between XXX O
CEMLAI XXX O
/ XXX O
NP XXX O
and XXX O
human XXX O
embryonic XXX O
fibroblasts XXX O
MRC5 XXX O
cells XXX O
produced XXX O
very XXX O
large XXX O
amounts XXX O
of XXX O
P47 XXX B-GENE
that XXX O
was XXX O
purified XXX O
using XXX O
Jacalin XXX O
lectin XXX O
( XXX O
specific XXX O
for XXX O
O-glycans XXX O
) XXX O
and XXX O
microsequenced XXX O
. XXX O

The XXX O
use XXX O
of XXX O
antibodies XXX O
to XXX O
the XXX O
polypyrimidine XXX B-GENE
tract XXX I-GENE
binding XXX I-GENE
protein XXX I-GENE
( XXX O
PTB XXX B-GENE
) XXX O
to XXX O
analyze XXX O
the XXX O
protein XXX O
components XXX O
that XXX O
assemble XXX O
on XXX O
alternatively XXX O
spliced XXX O
pre-mRNAs XXX O
that XXX O
use XXX O
distant XXX O
branch XXX O
points XXX O
. XXX O

In XXX O
control XXX O
patients XXX O
, XXX O
baseline XXX O
images XXX O
presented XXX O
Type XXX O
I XXX O
in XXX O
25 XXX O
, XXX O
Type XXX O
II XXX O
in XXX O
7 XXX O
, XXX O
and XXX O
the XXX O
Type XXX O
III XXX O
& XXX O
IV XXX O
in XXX O
0 XXX O
, XXX O
and XXX O
the XXX O
Type XXX O
after XXX O
loading XXX O
was XXX O
the XXX O
same XXX O
as XXX O
the XXX O
Type XXX O
at XXX O
baseline XXX O
. XXX O

2-AP XXX O
induced XXX O
marked XXX O
, XXX O
steady XXX O
rises XXX O
in XXX O
mRNA XXX O
accumulation XXX O
from XXX O
both XXX O
transfected XXX O
and XXX O
chromosomally XXX O
integrated XXX O
HIV-1 XXX O
constructs XXX O
but XXX O
no XXX O
increases XXX O
from XXX O
an XXX O
endogenous XXX O
gene XXX O
encoding XXX O
gamma-actin XXX B-GENE
or XXX O
glucose XXX B-GENE
6-phosphate XXX I-GENE
dehydrogenase XXX I-GENE
. XXX O

The XXX O
gene XXX O
is XXX O
essential XXX O
for XXX O
yeast XXX O
vegetative XXX O
growth XXX O
. XXX O

Group XXX O
A XXX O
( XXX O
68 XXX O
. XXX O
7+ XXX O
/ XXX O
-2 XXX O
. XXX O
7 XXX O
years XXX O
) XXX O
consisted XXX O
of XXX O
patients XXX O
with XXX O
0 XXX O
or XXX O
1 XXX O
risk XXX O
factors XXX O
; XXX O
B XXX O
( XXX O
68 XXX O
. XXX O
3+ XXX O
/ XXX O
-4 XXX O
. XXX O
2 XXX O
years XXX O
) XXX O
those XXX O
with XXX O
2 XXX O
risk XXX O
factors XXX O
; XXX O
and XXX O
C XXX O
( XXX O
69 XXX O
. XXX O
2+ XXX O
/ XXX O
-3 XXX O
. XXX O
6 XXX O
years XXX O
) XXX O
those XXX O
with XXX O
3 XXX O
or XXX O
more XXX O
risk XXX O
factors XXX O
. XXX O

50 XXX O
kDa XXX O
and XXX O
130-170 XXX O
kDa XXX O
were XXX O
detected XXX O
. XXX O

These XXX O
results XXX O
suggest XXX O
that XXX O
dietary XXX O
safflower XXX O
phospholipids XXX O
may XXX O
be XXX O
a XXX O
valuable XXX O
ingredient XXX O
to XXX O
layers XXX O
for XXX O
reducing XXX O
liver XXX O
triglycerides XXX O
and XXX O
serum XXX O
cholesterol XXX O
without XXX O
any XXX O
adverse XXX O
effects XXX O
. XXX O

Several XXX O
different XXX O
oncogenes XXX O
and XXX O
growth XXX B-GENE
factors XXX I-GENE
promote XXX O
G1 XXX O
phase XXX O
progression XXX O
. XXX O

The XXX O
opioid XXX O
antagonist XXX O
naltrexone XXX O
( XXX O
0 XXX O
. XXX O
01-1 XXX O
. XXX O
0 XXX O
mg XXX O
/ XXX O
kg XXX O
) XXX O
antagonized XXX O
the XXX O
discriminative XXX O
stimulus XXX O
effects XXX O
of XXX O
heroin XXX O
, XXX O
but XXX O
naltrexone XXX O
at XXX O
doses XXX O
up XXX O
to XXX O
10 XXX O
mg XXX O
/ XXX O
kg XXX O
had XXX O
no XXX O
effect XXX O
on XXX O
the XXX O
discriminative XXX O
stimulus XXX O
effects XXX O
of XXX O
cocaine XXX O
. XXX O

The XXX O
objective XXX O
of XXX O
our XXX O
study XXX O
was XXX O
to XXX O
evaluate XXX O
the XXX O
age XXX O
, XXX O
sex XXX O
, XXX O
clinical XXX O
conditions XXX O
, XXX O
family XXX O
history XXX O
, XXX O
site XXX O
, XXX O
catheter XXX O
association XXX O
, XXX O
means XXX O
of XXX O
radiologic XXX O
evaluation XXX O
, XXX O
development XXX O
of XXX O
pulmonary XXX O
involvement XXX O
, XXX O
prevalence XXX O
of XXX O
antithrombin XXX B-GENE
III XXX I-GENE
, XXX O
protein XXX B-GENE
C XXX I-GENE
and XXX O
protein XXX B-GENE
S XXX I-GENE
deficiencies XXX O
, XXX O
and XXX O
lupus XXX O
anticoagulants XXX O
in XXX O
children XXX O
who XXX O
suffered XXX O
a XXX O
thrombotic XXX O
event XXX O
. XXX O

Vascular XXX O
endothelial XXX O
cells XXX O
undergo XXX O
profound XXX O
changes XXX O
upon XXX O
cellular XXX O
activation XXX O
including XXX O
expression XXX O
of XXX O
a XXX O
spectrum XXX O
of XXX O
cell XXX O
activation-associated XXX O
genes XXX O
. XXX O

Cloning XXX O
, XXX O
sequencing XXX O
and XXX O
expression XXX O
of XXX O
the XXX O
3-phosphoglycerate XXX B-GENE
kinase XXX I-GENE
gene XXX I-GENE
of XXX O
Pyrococcus XXX O
woesei XXX O
in XXX O
Escherichia XXX O
coli XXX O
and XXX O
characterization XXX O
of XXX O
the XXX O
protein XXX O
. XXX O

Furthermore XXX O
, XXX O
LB1 XXX B-GENE
gene XXX I-GENE
mapped XXX O
to XXX O
chromosome XXX O
13q14 XXX O
, XXX O
a XXX O
region XXX O
that XXX O
has XXX O
been XXX O
involved XXX O
as XXX O
a XXX O
chromosomal XXX O
breakpoint XXX O
in XXX O
DLBL XXX O
. XXX O

These XXX O
results XXX O
show XXX O
that XXX O
targeting XXX O
of XXX O
Ras-GAP XXX B-GENE
could XXX O
represent XXX O
a XXX O
novel XXX O
anticancer XXX O
approach XXX O
. XXX O

The XXX O
gene XXX B-GENE
ccpA XXX I-GENE
encoding XXX O
the XXX O
catabolite XXX B-GENE
control XXX I-GENE
protein XXX I-GENE
CcpA XXX I-GENE
of XXX O
Staphylococcus XXX O
xylosus XXX O
has XXX O
been XXX O
cloned XXX O
and XXX O
characterized XXX O
. XXX O

A XXX O
total XXX O
of XXX O
194 XXX O
STSs XXX O
map XXX O
to XXX O
this XXX O
interval XXX O
of XXX O
3 XXX O
Mb XXX O
, XXX O
giving XXX O
an XXX O
average XXX O
marker XXX O
resolution XXX O
of XXX O
approximately XXX O
one XXX O
per XXX O
15 XXX O
kb XXX O
. XXX O

We XXX O
suggest XXX O
that XXX O
the XXX O
ER XXX O
lumenal XXX O
variable XXX O
domain XXX O
of XXX O
gp19K XXX B-GENE
has XXX O
a XXX O
specific XXX O
tertiary XXX O
structure XXX O
that XXX O
is XXX O
important XXX O
for XXX O
binding XXX O
to XXX O
the XXX O
polymorphic XXX O
alpha XXX O
1 XXX O
and XXX O
alpha XXX O
2 XXX O
domains XXX O
of XXX O
class XXX B-GENE
I XXX I-GENE
heavy XXX I-GENE
( XXX I-GENE
alpha XXX I-GENE
) XXX I-GENE
chains XXX I-GENE
. XXX O

The XXX O
influence XXX O
of XXX O
a XXX O
high XXX O
ionic XXX O
strength XXX O
on XXX O
the XXX O
resolution XXX O
was XXX O
clearly XXX O
shown XXX O
. XXX O

The XXX O
American XXX O
Burkitt XXX O
Lymphoma XXX O
Registry XXX O
: XXX O
a XXX O
progress XXX O
report XXX O
. XXX O

Immunoglobulin XXX B-GENE
light XXX I-GENE
chain XXX I-GENE
( XXX O
IgL XXX B-GENE
) XXX O
diversity XXX O
is XXX O
generated XXX O
in XXX O
the XXX O
chicken XXX O
by XXX O
recombination XXX O
between XXX O
the XXX O
single XXX O
functional XXX O
variable XXX B-GENE
( XXX O
VL XXX B-GENE
) XXX O
and XXX O
joining XXX B-GENE
( XXX O
JL XXX B-GENE
) XXX O
gene XXX O
segments XXX O
and XXX O
subsequent XXX O
somatic XXX O
diversification XXX O
of XXX O
the XXX O
rearranged XXX B-GENE
VL XXX I-GENE
region XXX I-GENE
. XXX O

Interactions XXX O
between XXX O
the XXX O
checkpoint XXX O
abrogator XXX O
UCN-01 XXX B-GENE
and XXX O
several XXX O
pharmacological XXX O
inhibitors XXX O
of XXX O
the XXX O
mitogen-activated XXX B-GENE
protein XXX I-GENE
kinase XXX I-GENE
( XXX I-GENE
MAPK XXX I-GENE
) XXX I-GENE
kinase XXX I-GENE
( XXX O
MEK XXX B-GENE
) XXX O
/ XXX B-GENE
MAPK XXX I-GENE
pathway XXX O
have XXX O
been XXX O
examined XXX O
in XXX O
a XXX O
variety XXX O
of XXX O
human XXX O
leukemia XXX O
cell XXX O
lines XXX O
. XXX O

Our XXX O
study XXX O
shows XXX O
that XXX O
the XXX O
area XXX O
of XXX O
Alcoy XXX O
is XXX O
a XXX O
medium XXX O
MS XXX O
risk XXX O
region XXX O
according XXX O
to XXX O
the XXX O
thesis XXX O
of XXX O
Kurzke XXX O
, XXX O
although XXX O
high XXX O
MS XXX O
areas XXX O
may XXX O
be XXX O
found XXX O
, XXX O
thus XXX O
confirming XXX O
that XXX O
MS XXX O
distribution XXX O
in XXX O
southern XXX O
Europe XXX O
is XXX O
not XXX O
uniform XXX O
. XXX O

Using XXX O
bovine XXX B-GENE
and XXX I-GENE
murine XXX I-GENE
c-myb XXX I-GENE
clones XXX O
, XXX O
no XXX O
change XXX O
in XXX O
the XXX O
rate XXX O
of XXX O
c-myb XXX B-GENE
gene XXX I-GENE
transcription XXX O
or XXX O
mRNA XXX O
stability XXX O
was XXX O
detected XXX O
during XXX O
the XXX O
cell XXX O
cycle XXX O
. XXX O

The XXX O
orbitofrontal XXX O
, XXX O
cingulate XXX O
, XXX O
and XXX O
anteromedial XXX O
part XXX O
of XXX O
the XXX O
dorsal XXX O
premotor XXX O
areas XXX O
were XXX O
preferentially XXX O
activated XXX O
by XXX O
the XXX O
self-initiated XXX O
hand XXX O
movement XXX O
task XXX O
( XXX O
SELF XXX O
) XXX O
. XXX O

An XXX O
unusual XXX O
complication XXX O
in XXX O
an XXX O
unsuitable XXX O
patient XXX O
. XXX O

C XXX B-GENE
/ XXX I-GENE
EBP XXX I-GENE
alpha XXX I-GENE
also XXX O
activates XXX O
the XXX O
promoter XXX O
of XXX O
the XXX O
rat XXX B-GENE
class-I XXX I-GENE
ADH XXX I-GENE
gene XXX I-GENE
in XXX O
a XXX O
sequence-specific XXX O
manner XXX O
[ XXX O
Potter XXX O
et XXX O
al XXX O
. XXX O
, XXX O
Arch XXX O
. XXX O

Surveillance XXX O
for XXX O
preeclampsia XXX O
was XXX O
conducted XXX O
by XXX O
personnel XXX O
unaware XXX O
of XXX O
treatment-group XXX O
assignments XXX O
, XXX O
using XXX O
standardized XXX O
measurements XXX O
of XXX O
blood XXX O
pressure XXX O
and XXX O
urinary XXX O
protein XXX O
excretion XXX O
at XXX O
uniformly XXX O
scheduled XXX O
prenatal XXX O
visits XXX O
, XXX O
protocols XXX O
for XXX O
monitoring XXX O
these XXX O
measurements XXX O
during XXX O
the XXX O
hospitalization XXX O
for XXX O
delivery XXX O
, XXX O
and XXX O
reviews XXX O
of XXX O
medical XXX O
records XXX O
of XXX O
unscheduled XXX O
outpatient XXX O
visits XXX O
and XXX O
all XXX O
hospitalizations XXX O
. XXX O

The XXX O
30-day XXX O
mortality XXX O
in XXX O
the XXX O
CPB XXX O
group XXX O
and XXX O
the XXX O
non-CPB XXX O
group XXX O
were XXX O
20% XXX O
and XXX O
4 XXX O
. XXX O
6% XXX O
, XXX O
respectively XXX O
which XXX O
was XXX O
not XXX O
statistically XXX O
significant XXX O
( XXX O
p XXX O
= XXX O
0 XXX O
. XXX O
06 XXX O
) XXX O
. XXX O

We XXX O
show XXX O
that XXX O
the XXX O
en XXX B-GENE
stripes XXX O
expand XXX O
anteriorly XXX O
in XXX O
slp XXX B-GENE
mutant XXX O
embryos XXX O
and XXX O
that XXX O
slp XXX B-GENE
activity XXX O
is XXX O
an XXX O
absolute XXX O
requirement XXX O
for XXX O
maintenance XXX O
of XXX O
wg XXX B-GENE
expression XXX O
at XXX O
the XXX O
same XXX O
time XXX O
that XXX O
wg XXX B-GENE
transcription XXX O
is XXX O
dependent XXX O
on XXX O
hh XXX B-GENE
. XXX O

Bailey XXX O
Instruments XXX O
and XXX O
Owen XXX O
Mumford XXX O
filaments XXX O
were XXX O
the XXX O
most XXX O
accurate XXX O
with XXX O
100% XXX O
buckling XXX O
within XXX O
+ XXX O
/ XXX O
-1 XXX O
. XXX O
0 XXX O
g XXX O
of XXX O
10 XXX O
g XXX O
. XXX O

In XXX O
the XXX O
budding XXX O
yeast XXX O
, XXX O
Saccharomyces XXX O
cerevisiae XXX O
, XXX O
replicators XXX O
can XXX O
function XXX O
outside XXX O
the XXX O
chromosome XXX O
as XXX O
autonomously XXX O
replicating XXX O
sequence XXX O
( XXX O
ARS XXX O
) XXX O
elements XXX O
; XXX O
however XXX O
, XXX O
within XXX O
chromosome XXX O
III XXX O
, XXX O
certain XXX O
ARSs XXX O
near XXX O
the XXX O
transcriptionally XXX O
silent XXX O
HML XXX B-GENE
locus XXX I-GENE
show XXX O
no XXX O
replication XXX O
origin XXX O
activity XXX O
. XXX O

These XXX O
cells XXX O
produce XXX O
a XXX O
low XXX O
level XXX O
of XXX O
IL-5 XXX B-GENE
when XXX O
stimulated XXX O
with XXX O
PMA XXX O
alone XXX O
; XXX O
however XXX O
, XXX O
N6 XXX O
, XXX O
O2-dibutyryl XXX O
cAMP XXX O
( XXX O
Bt2cAMP XXX O
) XXX O
, XXX O
in XXX O
combination XXX O
with XXX O
PMA XXX O
, XXX O
augmented XXX O
by XXX O
more XXX O
than XXX O
tenfold XXX O
the XXX O
IL-5 XXX B-GENE
production XXX O
at XXX O
the XXX O
mRNA XXX O
and XXX O
the XXX O
protein XXX O
levels XXX O
. XXX O

Molecular XXX O
cloning XXX O
of XXX O
the XXX O
cDNA XXX O
for XXX O
the XXX O
human XXX B-GENE
U2 XXX I-GENE
snRNA-specific XXX I-GENE
A' XXX I-GENE
protein XXX I-GENE
. XXX O

Analysis XXX O
of XXX O
the XXX O
genome XXX O
sequence XXX O
revealed XXX O
26 XXX O
, XXX O
588 XXX O
protein-encoding XXX O
transcripts XXX O
for XXX O
which XXX O
there XXX O
was XXX O
strong XXX O
corroborating XXX O
evidence XXX O
and XXX O
an XXX O
additional XXX O
approximately XXX O
12 XXX O
, XXX O
000 XXX O
computationally XXX O
derived XXX O
genes XXX O
with XXX O
mouse XXX O
matches XXX O
or XXX O
other XXX O
weak XXX O
supporting XXX O
evidence XXX O
. XXX O

Thus XXX O
, XXX O
CHOP XXX B-GENE
not XXX O
only XXX O
is XXX O
a XXX O
negative XXX O
or XXX O
a XXX O
positive XXX O
regulator XXX O
of XXX O
C XXX B-GENE
/ XXX I-GENE
EBP XXX I-GENE
target XXX O
genes XXX O
but XXX O
also XXX O
, XXX O
when XXX O
tethered XXX O
to XXX O
AP-1 XXX B-GENE
factors XXX I-GENE
, XXX O
can XXX O
activate XXX O
AP-1 XXX B-GENE
target XXX O
genes XXX O
. XXX O

The XXX O
lymph XXX O
nodes XXX O
from XXX O
two XXX O
of XXX O
the XXX O
patients XXX O
with XXX O
rheumatoid XXX O
arthritis XXX O
contained XXX O
numerous XXX O
sarcoid XXX O
like XXX O
granulomata XXX O
, XXX O
further XXX O
indicating XXX O
a XXX O
possible XXX O
association XXX O
between XXX O
sarcoidosis XXX O
and XXX O
rheumatoid XXX O
arthritis XXX O
. XXX O

Separation XXX O
of XXX O
malaria-infected XXX O
erythrocytes XXX O
from XXX O
whole XXX O
blood XXX O
: XXX O
use XXX O
of XXX O
a XXX O
selective XXX O
high-gradient XXX O
magnetic XXX O
separation XXX O
technique XXX O
. XXX O

Effects XXX O
of XXX O
prostaglandin XXX O
inhibitors XXX O
on XXX O
the XXX O
onset XXX O
of XXX O
proteinuria XXX O
and XXX O
stroke XXX O
in XXX O
stroke-prone XXX O
spontaneously XXX O
hypertensive XXX O
rats XXX O
. XXX O

Female XXX O
patients XXX O
with XXX O
breast XXX O
cancer XXX O
diagnosed XXX O
between XXX O
1982 XXX O
and XXX O
1991 XXX O
at XXX O
Roswell XXX O
Park XXX O
Cancer XXX O
Institute XXX O
( XXX O
RPCI XXX O
) XXX O
in XXX O
Buffalo XXX O
, XXX O
New XXX O
York XXX O
, XXX O
who XXX O
provided XXX O
information XXX O
on XXX O
their XXX O
cigarette XXX O
smoking XXX O
history XXX O
at XXX O
the XXX O
time XXX O
of XXX O
their XXX O
diagnosis XXX O
were XXX O
included XXX O
. XXX O

One XXX O
antibody XXX O
, XXX O
mAb1C2 XXX B-GENE
, XXX O
and XXX O
a XXX O
synthetic XXX O
peptide XXX O
comprising XXX O
its XXX O
epitope XXX O
selectively XXX O
inhibited XXX O
in XXX O
vitro XXX O
transcription XXX O
from XXX O
TATA-containing XXX O
, XXX O
but XXX O
not XXX O
from XXX O
TATA-less XXX O
promoters XXX O
, XXX O
irrespective XXX O
of XXX O
whether XXX O
they XXX O
were XXX O
transcribed XXX O
by XXX O
Pol XXX B-GENE
II XXX I-GENE
or XXX O
Pol XXX B-GENE
III XXX I-GENE
. XXX O

Supershift XXX O
EMSAs XXX O
identified XXX O
that XXX O
upstream XXX B-GENE
stimulatory XXX I-GENE
factor-1 XXX I-GENE
and XXX I-GENE
-2 XXX I-GENE
( XXX O
USF-1 XXX B-GENE
and XXX I-GENE
-2 XXX I-GENE
) XXX O
were XXX O
part XXX O
of XXX O
these XXX O
complexes XXX O
. XXX O

After XXX O
hepatitis XXX O
B XXX O
vaccine XXX O
immunization XXX O
, XXX O
serum XXX O
antibody XXX O
response XXX O
was XXX O
of XXX O
primary XXX O
type XXX O
in XXX O
33 XXX O
cases XXX O
with XXX O
anti-HBs XXX B-GENE
less XXX O
than XXX O
2 XXX O
. XXX O
1 XXX O
S XXX O
/ XXX O
N XXX O
( XXX O
S XXX O
/ XXX O
N XXX O
Ratio XXX O
Unit XXX O
) XXX O
at XXX O
T0 XXX O
, XXX O
the XXX O
anti-HBs XXX B-GENE
positive XXX O
rate XXX O
was XXX O
39 XXX O
. XXX O
4% XXX O
, XXX O
84 XXX O
. XXX O
8% XXX O
, XXX O
96 XXX O
. XXX O
7% XXX O
and XXX O
96 XXX O
. XXX O
7% XXX O
in XXX O
T1 XXX O
, XXX O
T2 XXX O
, XXX O
T0 XXX O
and XXX O
T12 XXX O
respectively XXX O
. XXX O

Abdominal XXX O
tumors XXX O
in XXX O
childhood XXX O
. XXX O

Deletion XXX O
or XXX O
inactivation XXX O
of XXX O
CRY1 XXX B-GENE
leads XXX O
to XXX O
5- XXX O
to XXX O
10-fold-increased XXX O
levels XXX O
of XXX O
CRY2 XXX B-GENE
mRNA XXX I-GENE
. XXX O

Effect XXX O
of XXX O
indomethacin XXX O
on XXX O
coronary XXX O
circulation XXX O
: XXX O
effect XXX O
on XXX O
ECG XXX O
tracing XXX O
. XXX O

Review XXX O
of XXX O
the XXX O
literature XXX O
and XXX O
report XXX O
of XXX O
a XXX O
case XXX O
of XXX O
a XXX O
dermoid XXX O
cyst XXX O
. XXX O

Treatment XXX O
with XXX O
oxyphenylbutazone XXX O
and XXX O
hydrocortisone XXX O
failed XXX O
to XXX O
inhibit XXX O
the XXX O
raised XXX O
serum XXX B-GENE
CPN XXX I-GENE
levels XXX O
. XXX O

Identification XXX O
, XXX O
purification XXX O
, XXX O
and XXX O
molecular XXX O
cloning XXX O
of XXX O
autonomously XXX B-GENE
replicating XXX I-GENE
sequence-binding XXX I-GENE
protein XXX I-GENE
1 XXX I-GENE
from XXX I-GENE
fission XXX I-GENE
yeast XXX I-GENE
Schizosaccharomyces XXX I-GENE
pombe XXX I-GENE
. XXX O

A XXX O
comparison XXX O
among XXX O
the XXX O
5' XXX O
flanking XXX O
regions XXX O
encompassing XXX O
the XXX O
presumptive XXX O
HS XXX B-GENE
promoter XXX I-GENE
of XXX O
the XXX O
soybean XXX B-GENE
HS-protein XXX I-GENE
genes XXX I-GENE
demonstrated XXX O
this XXX O
region XXX O
to XXX O
be XXX O
extremely XXX O
homologous XXX O
. XXX O

M XXX B-GENE
. XXX I-GENE
leprae XXX I-GENE
OxyR XXX I-GENE
was XXX O
overproduced XXX O
and XXX O
purified XXX O
, XXX O
and XXX O
its XXX O
binding XXX O
to XXX O
the XXX O
oxyR-ahpC XXX B-GENE
intergenic XXX I-GENE
region XXX I-GENE
of XXX I-GENE
M XXX I-GENE
. XXX I-GENE
leprae XXX I-GENE
was XXX O
demonstrated XXX O
. XXX O

Regulatory XXX O
regions XXX O
in XXX O
the XXX O
promoter XXX O
and XXX O
third XXX O
intron XXX O
of XXX O
the XXX O
growth XXX B-GENE
hormone XXX I-GENE
gene XXX I-GENE
in XXX I-GENE
rainbow XXX I-GENE
trout XXX I-GENE
, XXX O
Oncorhynchus XXX O
mykiss XXX O
walbaum XXX O
. XXX O

This XXX O
scFv XXX O
was XXX O
therefore XXX O
used XXX O
as XXX O
control XXX O
in XXX O
experiments XXX O
where XXX O
another XXX O
anti-Ras XXX B-GENE
scFv XXX I-GENE
( XXX O
Y259 XXX B-GENE
scFv XXX I-GENE
, XXX O
derived XXX O
from XXX O
the XXX O
neutralizing XXX O
anti-Ras XXX B-GENE
mAb XXX I-GENE
Y13-259 XXX I-GENE
) XXX O
blocked XXX O
the XXX O
Ras XXX B-GENE
pathway XXX I-GENE
in XXX O
vitro XXX O
and XXX O
led XXX O
to XXX O
tumor XXX O
regression XXX O
in XXX O
a XXX O
nude XXX O
mouse XXX O
model XXX O
[ XXX O
Cochet XXX O
, XXX O
O XXX O
. XXX O
, XXX O
Kenigsberg XXX O
, XXX O
M XXX O
. XXX O
, XXX O
Delumeau XXX O
, XXX O
I XXX O
. XXX O
, XXX O
Virone-Oddos XXX O
, XXX O
A XXX O
. XXX O
, XXX O
Multon XXX O
, XXX O
M XXX O
. XXX O
C XXX O
. XXX O
, XXX O
Fridman XXX O
, XXX O
W XXX O
. XXX O
H XXX O
. XXX O
, XXX O
Schweighoffer XXX O
, XXX O
F XXX O
. XXX O
, XXX O
Teillaud XXX O
, XXX O
J XXX O
. XXX O
L XXX O
. XXX O
, XXX O
Tocque XXX O
, XXX O
B XXX O
. XXX O
, XXX O
1998 XXX O
. XXX O

Proceedings XXX O
: XXX O
Barrels XXX O
and XXX O
somatotopy XXX O
in XXX O
S XXX O
I XXX O
neocortex XXX O
of XXX O
the XXX O
brush-tailed XXX O
possum XXX O
. XXX O

The XXX O
T-box XXX O
motif XXX O
is XXX O
present XXX O
in XXX O
a XXX O
family XXX O
of XXX O
genes XXX O
whose XXX O
structural XXX O
features XXX O
and XXX O
expression XXX O
patterns XXX O
support XXX O
their XXX O
involvement XXX O
in XXX O
developmental XXX O
gene XXX O
regulation XXX O
. XXX O

KAR1 XXX B-GENE
encodes XXX O
an XXX O
essential XXX O
component XXX O
of XXX O
the XXX O
yeast XXX O
spindle XXX O
pole XXX O
body XXX O
( XXX O
SPB XXX O
) XXX O
that XXX O
is XXX O
required XXX O
for XXX O
karyogamy XXX O
and XXX O
SPB XXX O
duplication XXX O
. XXX O

To XXX O
study XXX O
the XXX O
significance XXX O
of XXX O
these XXX O
domains XXX O
and XXX O
the XXX O
overall XXX O
evolutionary XXX O
conservation XXX O
of XXX O
the XXX O
gene XXX O
, XXX O
the XXX O
homolog XXX O
from XXX O
Drosophila XXX O
melanogaster XXX O
was XXX O
isolated XXX O
by XXX O
low XXX O
stringency XXX O
hybridizations XXX O
using XXX O
two XXX O
flanking XXX O
probes XXX O
of XXX O
the XXX O
human XXX B-GENE
ERCC3 XXX I-GENE
cDNA XXX I-GENE
. XXX O

SELECTION XXX O
CRITERIA XXX O
: XXX O
Randomised XXX O
controlled XXX O
trials XXX O
of XXX O
cabergoline XXX O
versus XXX O
placebo XXX O
in XXX O
patients XXX O
with XXX O
a XXX O
clinical XXX O
diagnosis XXX O
of XXX O
idiopathic XXX O
Parkinson's XXX O
disease XXX O
and XXX O
long-term XXX O
complications XXX O
of XXX O
levodopa XXX O
therapy XXX O
. XXX O

PAO XXX O
blocks XXX O
turnover XXX O
of XXX O
the XXX O
phosphoryl XXX O
group XXX O
of XXX O
pp15 XXX B-GENE
, XXX O
causing XXX O
its XXX O
accumulation XXX O
, XXX O
and XXX O
thereby XXX O
appears XXX O
to XXX O
interrupt XXX O
signal XXX O
transmission XXX O
from XXX O
the XXX O
receptor XXX O
to XXX O
the XXX O
glucose-transport XXX O
system XXX O
. XXX O

Because XXX O
L-plastin XXX B-GENE
expression XXX O
in XXX O
tissue-specifically XXX O
regulated XXX O
in XXX O
both XXX O
humans XXX O
and XXX O
rodents XXX O
, XXX O
it XXX O
is XXX O
likely XXX O
that XXX O
similar XXX O
mechanisms XXX O
regulate XXX O
L-plastin XXX B-GENE
gene XXX I-GENE
expression XXX O
in XXX O
human XXX O
and XXX O
rodent XXX O
cells XXX O
and XXX O
that XXX O
they XXX O
could XXX O
be XXX O
identified XXX O
by XXX O
comparing XXX O
the XXX O
function XXX O
and XXX O
nucleotide XXX O
sequences XXX O
of XXX O
the XXX O
human XXX O
and XXX O
murine XXX O
L-plastin XXX B-GENE
gene XXX O
promoters XXX O
. XXX O

We XXX O
studied XXX O
120 XXX O
male XXX O
and XXX O
42 XXX O
female XXX O
patients XXX O
with XXX O
early XXX O
CAD XXX O
who XXX O
were XXX O
unrelated XXX O
to XXX O
each XXX O
other XXX O
but XXX O
were XXX O
from XXX O
families XXX O
in XXX O
which XXX O
at XXX O
least XXX O
one XXX O
other XXX O
sibling XXX O
had XXX O
early XXX O
CAD XXX O
. XXX O

On XXX O
the XXX O
trail XXX O
of XXX O
Dr XXX O
. XXX O

Such XXX O
marked XXX O
differences XXX O
are XXX O
found XXX O
occasionally XXX O
in XXX O
the XXX O
literature XXX O
: XXX O
heterophile XXX O
antibodies XXX O
against XXX O
bovine XXX B-GENE
gammaglobulin XXX I-GENE
are XXX O
regarded XXX O
as XXX O
responsible XXX O
for XXX O
the XXX O
interference XXX O
in XXX O
the XXX O
Sephadex XXX O
system XXX O
of XXX O
RIST XXX O
. XXX O

Second XXX O
, XXX O
when XXX O
the XXX O
NBF1+R XXX B-GENE
protein XXX I-GENE
, XXX O
the XXX O
NBF2 XXX B-GENE
protein XXX I-GENE
, XXX O
and XXX O
a XXX O
mixture XXX O
of XXX O
the XXX O
two XXX O
proteins XXX O
were XXX O
folded XXX O
separately XXX O
and XXX O
analyzed XXX O
by XXX O
molecular XXX O
sieve XXX O
chomatography XXX O
, XXX O
the XXX O
mixture XXX O
was XXX O
found XXX O
to XXX O
elute XXX O
prior XXX O
to XXX O
either XXX O
NBF1+R XXX B-GENE
or XXX O
NBF2 XXX B-GENE
. XXX O

The XXX O
addition XXX O
of XXX O
a XXX O
Paf-containing XXX O
extract XXX O
does XXX O
not XXX O
lead XXX O
to XXX O
significant XXX O
protein XXX O
binding XXX O
to XXX O
these XXX O
two XXX O
hly XXX B-GENE
target XXX I-GENE
sequences XXX I-GENE
in XXX O
the XXX O
absence XXX O
of XXX O
PrfA XXX B-GENE
but XXX O
converts XXX O
the XXX O
complex XXX O
( XXX O
CIII XXX B-GENE
) XXX O
consisting XXX O
of XXX O
PrfA XXX B-GENE
and XXX O
the XXX O
109 XXX B-GENE
bp XXX I-GENE
hly XXX I-GENE
DNA XXX I-GENE
fragment XXX I-GENE
to XXX O
a XXX O
slower XXX O
migrating XXX O
PrfA-Paf-DNA XXX B-GENE
complex XXX I-GENE
( XXX O
CI XXX B-GENE
) XXX O
. XXX O

We XXX O
demonstrate XXX O
that XXX O
Ddc1p XXX B-GENE
interacts XXX O
physically XXX O
in XXX O
vivo XXX O
with XXX O
Mec3p XXX B-GENE
, XXX O
and XXX O
this XXX O
interaction XXX O
requires XXX O
Rad17p XXX B-GENE
. XXX O

Our XXX O
data XXX O
, XXX O
however XXX O
, XXX O
did XXX O
not XXX O
suggest XXX O
the XXX O
existence XXX O
of XXX O
a XXX O
conversion XXX O
factor XXX O
for XXX O
LDF XXX O
signal XXX O
to XXX O
absolute XXX O
flow XXX O
values XXX O
from XXX O
experiment XXX O
to XXX O
experiment XXX O
. XXX O

Children XXX O
with XXX O
defective XXX O
vision XXX O
. XXX O

Bullous XXX O
keratopathy XXX O
was XXX O
usually XXX O
aphakic XXX O
in XXX O
origin XXX O
in XXX O
1982 XXX O
, XXX O
but XXX O
after XXX O
1983 XXX O
pseudophakic XXX O
bullous XXX O
keratopathy XXX O
( XXX O
PBK XXX O
) XXX O
was XXX O
the XXX O
most XXX O
common XXX O
cause XXX O
of XXX O
bullous XXX O
keratopathy XXX O
. XXX O

Assay XXX O
of XXX O
urea XXX O
by XXX O
immobilized XXX O
urease XXX B-GENE
coupled XXX O
to XXX O
a XXX O
differential XXX O
pH-meter XXX O
. XXX O

Because XXX O
single-chamber XXX O
rate-adaptive XXX O
atrial XXX O
pacing XXX O
leaves XXX O
the XXX O
patient XXX O
exposed XXX O
to XXX O
the XXX O
risk XXX O
of XXX O
future XXX O
development XXX O
of XXX O
AV XXX O
block XXX O
and XXX O
DDD XXX O
pacing XXX O
does XXX O
not XXX O
provide XXX O
chronotropic XXX O
support XXX O
, XXX O
it XXX O
is XXX O
likely XXX O
that XXX O
the XXX O
new XXX O
rate-adaptive XXX O
dual-chamber XXX O
( XXX O
DDDR XXX O
) XXX O
devices XXX O
will XXX O
be XXX O
used XXX O
in XXX O
a XXX O
significant XXX O
number XXX O
of XXX O
these XXX O
patients XXX O
. XXX O
( XXX O
ABSTRACT XXX O
TRUNCATED XXX O
AT XXX O
250 XXX O
WORDS XXX O
) XXX O

Among XXX O
100 XXX O
cases XXX O
of XXX O
post-transfusion XXX O
hepatitis XXX O
, XXX O
10 XXX O
are XXX O
due XXX O
to XXX O
the XXX O
hepatitis XXX O
B XXX O
virus XXX O
( XXX O
despite XXX O
systematic XXX O
search XXX O
for XXX O
HBs XXX B-GENE
Ag XXX I-GENE
) XXX O
, XXX O
89 XXX O
are XXX O
due XXX O
to XXX O
one XXX O
of XXX O
the XXX O
non-A XXX O
non-B XXX O
viruses XXX O
( XXX O
not XXX O
detectable XXX O
by XXX O
specific XXX O
serological XXX O
tests XXX O
) XXX O
and XXX O
1 XXX O
to XXX O
several XXX O
viruses XXX O
, XXX O
specially XXX O
CMV XXX O
. XXX O

The XXX O
MPS1 XXX B-GENE
open XXX I-GENE
reading XXX I-GENE
frame XXX I-GENE
has XXX O
been XXX O
fused XXX O
to XXX O
those XXX O
that XXX O
encode XXX O
the XXX O
LexA XXX B-GENE
protein XXX I-GENE
or XXX O
the XXX O
GST XXX B-GENE
protein XXX I-GENE
and XXX O
both XXX O
of XXX O
these XXX O
constructs XXX O
function XXX O
in XXX O
yeast XXX O
. XXX O

Sex XXX O
of XXX O
calf XXX O
( XXX O
variate XXX O
2 XXX O
) XXX O
was XXX O
associated XXX O
most XXX O
closely XXX O
with XXX O
width XXX O
of XXX O
muzzle XXX O
and XXX O
head XXX O
. XXX O

Postglucose XXX O
serum XXX B-GENE
insulin XXX I-GENE
levels XXX O
showed XXX O
no XXX O
significant XXX O
correlations XXX O
with XXX O
systolic XXX O
or XXX O
diastolic XXX O
blood XXX O
pressure XXX O
levels XXX O
in XXX O
men XXX O
, XXX O
but XXX O
in XXX O
female XXX O
diabetic XXX O
and XXX O
non-diabetic XXX O
subjects XXX O
significant XXX O
correlations XXX O
were XXX O
found XXX O
in XXX O
particular XXX O
with XXX O
systolic XXX O
blood XXX O
pressure XXX O
level XXX O
. XXX O

Endometrial XXX O
biopsies XXX O
and XXX O
plasma XXX O
oestradiol XXX O
( XXX O
E2 XXX O
) XXX O
and XXX O
progesterone XXX O
( XXX O
P4 XXX O
) XXX O
levels XXX O
in XXX O
23 XXX O
patients XXX O
were XXX O
evaluated XXX O
during XXX O
26 XXX O
replacement XXX O
therapy XXX O
cycles XXX O
for XXX O
premature XXX O
ovarian XXX O
failure XXX O
. XXX O

We XXX O
propose XXX O
that XXX O
the XXX O
technique XXX O
of XXX O
low-frequency XXX O
kindling XXX O
is XXX O
a XXX O
useful XXX O
experimental XXX O
model XXX O
in XXX O
assessing XXX O
the XXX O
effects XXX O
of XXX O
antipsychotic XXX O
or XXX O
antiepileptic XXX O
drugs XXX O
on XXX O
the XXX O
excitability XXX O
of XXX O
the XXX O
limbic XXX O
regions XXX O
. XXX O

A XXX O
promoter XXX O
sequence XXX O
( XXX O
Goldberg-Hogness XXX O
or XXX O
TATA XXX O
box XXX O
) XXX O
is XXX O
situated XXX O
28 XXX O
base XXX O
pairs XXX O
upstream XXX O
from XXX O
the XXX O
point XXX O
of XXX O
initiation XXX O
of XXX O
transcription XXX O
which XXX O
was XXX O
found XXX O
by XXX O
S1 XXX B-GENE
nuclease XXX I-GENE
mapping XXX O
and XXX O
by XXX O
oligonucleotide-primed XXX O
reverse XXX O
transcription XXX O
of XXX O
rat XXX B-GENE
PTH XXX I-GENE
mRNA XXX I-GENE
. XXX O

RNA XXX B-GENE
polymerase XXX I-GENE
II XXX I-GENE
inhibition XXX O
increased XXX O
the XXX O
binding XXX O
of XXX O
ARE XXX O
( XXX O
AUBP XXX O
activity XXX O
) XXX O
and XXX O
poly XXX O
( XXX O
U XXX O
) XXX O
-Sepharose XXX O
by XXX O
cytoplasmic XXX B-GENE
hnRNP XXX I-GENE
A1 XXX I-GENE
, XXX O
while XXX O
nuclear XXX B-GENE
hnRNP XXX I-GENE
A1 XXX I-GENE
binding XXX O
was XXX O
unaffected XXX O
. XXX O

The XXX O
present XXX O
investigation XXX O
has XXX O
revealed XXX O
that XXX O
the XXX O
distribution XXX O
of XXX O
the XXX O
main XXX O
fatty XXX O
acids XXX O
in XXX O
Leptospira XXX O
phospholipids XXX O
is XXX O
similar XXX O
to XXX O
their XXX O
distribution XXX O
in XXX O
Leptospira XXX O
neutral XXX O
lipids XXX O
with XXX O
the XXX O
exception XXX O
of XXX O
unsaturated XXX O
fatty XXX O
acid XXX O
with XXX O
14 XXX O
carbon XXX O
atoms XXX O
, XXX O
occurring XXX O
mainly XXX O
in XXX O
phospholipids XXX O
. XXX O

The XXX O
endodontal XXX O
treatment XXX O
need XXX O
has XXX O
been XXX O
forming XXX O
a XXX O
clinical XXX O
order XXX O
of XXX O
magnitude XXX O
. XXX O

These XXX O
data XXX O
do XXX O
not XXX O
support XXX O
the XXX O
use XXX O
of XXX O
LDD XXX O
to XXX O
reduce XXX O
risk XXX O
of XXX O
progression XXX O
to XXX O
MSOF XXX O
in XXX O
sepsis XXX O
. XXX O

Partial XXX O
correction XXX O
of XXX O
anemia XXX O
with XXX O
recombinant XXX B-GENE
human XXX I-GENE
erythropoietin XXX I-GENE
likely XXX O
reduces XXX O
left XXX O
ventricular XXX O
mass XXX O
and XXX O
volume XXX O
. XXX O

The XXX O
distribution XXX O
of XXX O
body XXX O
fluids XXX O
following XXX O
hemorrhage XXX O
and XXX O
resuscitation XXX O
in XXX O
combat XXX O
casualties XXX O
. XXX O

Receptor XXX B-GENE
protein XXX I-GENE
tyrosine XXX I-GENE
phosphatases XXX I-GENE
( XXX O
RPTPs XXX B-GENE
) XXX O
comprise XXX O
a XXX O
family XXX O
of XXX O
proteins XXX O
that XXX O
feature XXX O
intracellular XXX O
phosphatase XXX B-GENE
domains XXX O
and XXX O
an XXX O
ectodomain XXX O
with XXX O
putative XXX O
ligand-binding XXX O
motifs XXX O
. XXX O

Analysis XXX O
of XXX O
the XXX O
protein XXX O
sequences XXX O
of XXX O
these XXX O
two XXX O
replicases XXX B-GENE
, XXX O
together XXX O
with XXX O
previously XXX O
characterized XXX O
H XXX O
. XXX O
pylori XXX O
plasmid XXX O
replication XXX O
proteins XXX O
, XXX O
supports XXX O
the XXX O
formation XXX O
of XXX O
a XXX O
distinct XXX O
class XXX O
of XXX O
H XXX O
. XXX O
pylori XXX O
plasmid XXX O
proteins XXX O
. XXX O

Hence XXX O
, XXX O
the XXX O
replacement XXX O
of XXX O
Phe-62 XXX O
with XXX O
Ser XXX O
specifically XXX O
affects XXX O
a XXX O
determinant XXX O
on XXX O
the XXX O
lambda XXX B-GENE
I XXX I-GENE
light XXX I-GENE
chain XXX I-GENE
that XXX O
is XXX O
necessary XXX O
for XXX O
the XXX O
intracellular XXX O
transport XXX O
of XXX O
this XXX O
molecule XXX O
. XXX O

Cerebro-oculo-facioskeletal XXX O
syndrome XXX O
( XXX O
Pena-Shokeir XXX O
syndrome XXX O
II XXX O
) XXX O
. XXX O

The XXX O
rational XXX O
for XXX O
the XXX O
prophylactic XXX O
treatment XXX O
, XXX O
the XXX O
therapy XXX O
of XXX O
the XXX O
meningopathy XXX O
and XXX O
AIL- XXX O
AIEOP XXX O
protocols XXX O
are XXX O
exposed XXX O
. XXX O

Immunolocalization XXX O
of XXX O
Sop1p XXX B-GENE
revealed XXX O
a XXX O
cytoplasmic XXX O
distribution XXX O
and XXX O
cell XXX O
fractionation XXX O
studies XXX O
showed XXX O
that XXX O
a XXX O
significant XXX O
fraction XXX O
of XXX O
Sop1p XXX B-GENE
was XXX O
recovered XXX O
in XXX O
a XXX O
sedimentable XXX O
fraction XXX O
of XXX O
the XXX O
cytosolic XXX O
material XXX O
. XXX O

These XXX O
results XXX O
indicate XXX O
that XXX O
in XXX O
addition XXX O
to XXX O
Grb2-mediated XXX O
activation XXX O
of XXX O
Ras XXX B-GENE
, XXX O
PLC-gamma1-mediated XXX O
DAG XXX O
production XXX O
is XXX O
required XXX O
for XXX O
EGF- XXX O
and XXX O
PDGF-induced XXX O
S-phase XXX O
entry XXX O
and XXX O
gene XXX O
expression XXX O
, XXX O
possibly XXX O
through XXX O
activation XXX O
of XXX O
PKC XXX B-GENE
. XXX O

For XXX O
this XXX O
, XXX O
cDNAs XXX O
containing XXX O
the XXX O
60K XXX O
, XXX O
87K XXX O
, XXX O
110K XXX O
and XXX O
170K XXX O
protein XXX O
coding XXX O
sequences XXX O
were XXX O
each XXX O
provided XXX O
with XXX O
an XXX O
ATG XXX O
start XXX O
codon XXX O
and XXX O
the XXX O
cDNA XXX O
containing XXX O
the XXX O
60K XXX O
coding XXX O
sequence XXX O
with XXX O
a XXX O
TAA XXX O
stop XXX O
codon XXX O
immediately XXX O
downstream XXX O
of XXX O
the XXX O
coding XXX O
sequence XXX O
. XXX O

As XXX O
opposed XXX O
to XXX O
in XXX O
vitro XXX O
co-precipitation XXX O
studies XXX O
, XXX O
the XXX O
yeast XXX O
two-hybrid XXX O
screen XXX O
reveals XXX O
in XXX O
vivo XXX O
protein-protein XXX O
interactions XXX O
. XXX O

Differential XXX O
signaling XXX O
and XXX O
immediate-early XXX O
gene XXX O
activation XXX O
by XXX O
four XXX O
splice XXX O
variants XXX O
of XXX O
the XXX O
human XXX B-GENE
pituitary XXX I-GENE
adenylate XXX I-GENE
cyclase-activating XXX I-GENE
polypeptide XXX I-GENE
receptor XXX I-GENE
( XXX O
hPACAP-R XXX B-GENE
) XXX O
. XXX O

Transcriptional XXX O
regulation XXX O
of XXX O
the XXX O
mouse XXX B-GENE
cytosolic XXX I-GENE
chaperonin XXX I-GENE
subunit XXX I-GENE
gene XXX I-GENE
Ccta XXX B-GENE
/ XXX I-GENE
t-complex XXX I-GENE
polypeptide XXX I-GENE
1 XXX I-GENE
by XXX O
selenocysteine XXX B-GENE
tRNA XXX I-GENE
gene XXX I-GENE
transcription XXX I-GENE
activating XXX I-GENE
factor XXX I-GENE
family XXX I-GENE
zinc XXX I-GENE
finger XXX I-GENE
proteins XXX I-GENE
. XXX O

Online XXX O
teaching XXX O
: XXX O
design XXX O
and XXX O
techniques XXX O
. XXX O

It XXX O
was XXX O
subsequently XXX O
shown XXX O
that XXX O
Tip60 XXX B-GENE
had XXX O
histone XXX B-GENE
acetyltransferase XXX I-GENE
( XXX O
HAT XXX B-GENE
) XXX O
activity XXX O
. XXX O

Electrophoretic XXX O
mobility XXX O
shift XXX O
assays XXX O
revealed XXX O
that XXX O
Sp1 XXX B-GENE
binds XXX O
to XXX O
two XXX O
different XXX O
regions XXX O
in XXX O
the XXX O
proximal XXX O
promoter XXX O
, XXX O
a XXX O
typical XXX O
Sp1 XXX B-GENE
site XXX I-GENE
located XXX O
at XXX O
( XXX O
-38 XXX O
; XXX O
-33 XXX O
) XXX O
and XXX O
a XXX O
G XXX O
/ XXX O
C-rich XXX O
region XXX O
between XXX O
( XXX O
-67 XXX O
; XXX O
-62 XXX O
) XXX O
. XXX O

The XXX O
Community XXX O
Adjustment XXX O
Scale XXX O
provided XXX O
outcome XXX O
data XXX O
related XXX O
to XXX O
the XXX O
subjects' XXX O
degree XXX O
of XXX O
productivity XXX O
, XXX O
ability XXX O
to XXX O
maintain XXX O
close XXX O
relationships XXX O
, XXX O
and XXX O
presence XXX O
/ XXX O
absence XXX O
of XXX O
symptomatology XXX O
an XXX O
average XXX O
of XXX O
32 XXX O
years XXX O
after XXX O
initial XXX O
admission XXX O
. XXX O

Volunteers XXX O
were XXX O
irradiated XXX O
on XXX O
their XXX O
backs XXX O
with XXX O
suberythemal XXX O
UV XXX O
daily XXX O
for XXX O
5 XXX O
d XXX O
after XXX O
application XXX O
of XXX O
the XXX O
sunscreens XXX O
and XXX O
their XXX O
base XXX O
lotion XXX O
to XXX O
different XXX O
sites XXX O
. XXX O

Range XXX O
, XXX O
variations XXX O
and XXX O
neoplastic XXX O
potential XXX O
. XXX O

Lipid XXX O
hydroperoxide XXX O
levels XXX O
in XXX O
plasma XXX O
and XXX O
LDL XXX B-GENE
remained XXX O
unchanged XXX O
throughout XXX O
the XXX O
study XXX O
. XXX O

Paul XXX O
Monagle XXX O
addresses XXX O
the XXX O
epidemiology XXX O
of XXX O
neonatal XXX O
thrombosis XXX O
outside XXX O
of XXX O
the XXX O
central XXX O
nervous XXX O
system XXX O
in XXX O
both XXX O
arterial XXX O
and XXX O
venous XXX O
locations XXX O
, XXX O
and XXX O
those XXX O
that XXX O
occur XXX O
in XXX O
utero XXX O
. XXX O

Patients XXX O
subsequently XXX O
returned XXX O
to XXX O
the XXX O
clinic XXX O
every XXX O
3 XXX O
days XXX O
to XXX O
have XXX O
the XXX O
wounds XXX O
checked XXX O
and XXX O
dressings XXX O
changed XXX O
. XXX O

In XXX O
an XXX O
effort XXX O
to XXX O
separate XXX O
domains XXX O
of XXX O
FadR XXX B-GENE
required XXX O
for XXX O
DNA XXX O
binding XXX O
, XXX O
dimerization XXX O
, XXX O
and XXX O
ligand XXX O
binding XXX O
, XXX O
chimeric XXX O
protein XXX O
fusions XXX O
between XXX O
the XXX O
DNA XXX O
binding XXX O
domain XXX O
of XXX O
LexA XXX B-GENE
and XXX O
different XXX O
regions XXX O
of XXX O
FadR XXX B-GENE
were XXX O
constructed XXX O
. XXX O

These XXX O
natural XXX O
antisense XXX O
S XXX B-GENE
transcripts XXX I-GENE
co-exist XXX O
with XXX O
several XXX O
less XXX O
abundant XXX O
sense XXX O
S XXX B-GENE
transcripts XXX I-GENE
. XXX O

Genoa XXX O
, XXX O
Italy XXX O
, XXX O
24-28 XXX O
August XXX O
1997 XXX O
. XXX O

Significantly XXX O
, XXX O
pPKR XXX B-GENE
is XXX O
capable XXX O
of XXX O
specifically XXX O
phosphorylating XXX O
Ser51 XXX O
in XXX O
a XXX O
synthetic XXX B-GENE
eIF-2alpha XXX I-GENE
peptide XXX I-GENE
, XXX O
a XXX O
key XXX O
characteristic XXX O
of XXX O
the XXX O
eIF-2alpha XXX B-GENE
kinase XXX I-GENE
family XXX I-GENE
. XXX O

They XXX O
have XXX O
not XXX O
been XXX O
previously XXX O
reported XXX O
as XXX O
a XXX O
reaction XXX O
to XXX O
i XXX O
. XXX O
v XXX O
. XXX O
contrast XXX O
material XXX O
. XXX O

Our XXX O
evidence XXX O
derives XXX O
from XXX O
three XXX O
principal XXX O
observations XXX O
: XXX O
1 XXX O
) XXX O
a XXX O
transfection XXX O
construct XXX O
containing XXX O
only XXX O
122 XXX O
nucleotides XXX O
( XXX O
nt XXX O
) XXX O
of XXX O
promoter XXX O
1 XXX O
and XXX O
328 XXX O
nt XXX O
of XXX O
the XXX O
5'-UTR XXX O
retained XXX O
full XXX O
PGE2-stimulated XXX O
reporter XXX O
expression XXX O
; XXX O
2 XXX O
) XXX O
maximal XXX O
PGE2-driven XXX O
reporter XXX O
expression XXX O
required XXX O
the XXX O
presence XXX O
of XXX O
nt XXX O
196 XXX O
to XXX O
328 XXX O
of XXX O
exon XXX O
1 XXX O
when XXX O
tested XXX O
within XXX O
the XXX O
context XXX O
of XXX O
IGF-I XXX B-GENE
promoter XXX I-GENE
1 XXX I-GENE
; XXX O
3 XXX O
) XXX O
cotransfection XXX O
of XXX O
IGF-I XXX B-GENE
promoter-luciferase-reporter XXX I-GENE
constructs XXX O
with XXX O
a XXX O
plasmid XXX O
encoding XXX O
the XXX O
alpha-isoform XXX O
of XXX O
the XXX O
catalytic XXX O
subunit XXX O
of XXX O
murine XXX B-GENE
cAMP-dependent XXX I-GENE
protein XXX I-GENE
kinase XXX I-GENE
( XXX O
PKA XXX B-GENE
) XXX O
produced XXX O
results XXX O
comparable XXX O
to XXX O
those XXX O
seen XXX O
with XXX O
PGE2 XXX O
treatment XXX O
, XXX O
whereas XXX O
cotransfection XXX O
with XXX O
a XXX O
plasmid XXX O
encoding XXX O
a XXX O
mutant XXX O
regulatory XXX O
subunit XXX O
of XXX O
PKA XXX B-GENE
that XXX O
cannot XXX O
bind XXX O
cAMP XXX O
blocked XXX O
PGE2-induced XXX O
reporter XXX O
expression XXX O
. XXX O

Bound-exciton XXX O
transfer XXX O
and XXX O
photoluminescence XXX O
undulation XXX O
spectra XXX O
for XXX O
acceptors XXX O
in XXX O
ZnTe XXX O
. XXX O

The XXX O
available XXX O
data XXX O
suggest XXX O
that XXX O
the XXX O
NF XXX B-GENE
kappa XXX I-GENE
B2 XXX I-GENE
nucleoprotein XXX I-GENE
complex XXX I-GENE
may XXX O
cooperate XXX O
with XXX O
DNA-bound XXX O
STAT6 XXX B-GENE
to XXX O
achieve XXX O
IL-4-dependent XXX O
activation XXX O
of XXX O
the XXX O
human XXX B-GENE
IgE XXX I-GENE
germline XXX I-GENE
gene XXX I-GENE
. XXX O

These XXX O
cells XXX O
fail XXX O
to XXX O
generate XXX O
the XXX O
signals XXX O
to XXX O
phosphorylate XXX O
CREB XXX B-GENE
and XXX O
produce XXX O
significantly XXX O
less XXX O
of XXX O
the XXX O
cytokine XXX O
Interleukin-2 XXX B-GENE
( XXX O
IL-2 XXX B-GENE
) XXX O
in XXX O
response XXX O
to XXX O
agents XXX O
that XXX O
either XXX O
increase XXX O
intracellular XXX O
Ca2+ XXX O
and XXX O
/ XXX O
or XXX O
activate XXX O
protein XXX B-GENE
kinase XXX I-GENE
C XXX I-GENE
. XXX O

Our XXX O
results XXX O
show XXX O
that XXX O
the XXX O
ORF XXX O
of XXX O
hAMPK XXX B-GENE
encodes XXX O
552 XXX O
amino XXX O
acids XXX O
( XXX O
aa XXX O
) XXX O
( XXX O
62 XXX O
. XXX O
250 XXX O
kDa XXX O
) XXX O
and XXX O
is XXX O
highly XXX O
conserved XXX O
with XXX O
rAMPK XXX B-GENE
with XXX O
identities XXX O
of XXX O
97 XXX O
. XXX O
3 XXX O
and XXX O
90% XXX O
at XXX O
the XXX O
aa XXX O
and XXX O
nt XXX O
levels XXX O
, XXX O
respectively XXX O
. XXX O

One XXX O
air XXX O
embolism XXX O
occurred XXX O
; XXX O
this XXX O
was XXX O
the XXX O
only XXX O
filter- XXX O
or XXX O
retrieval-related XXX O
complication XXX O
. XXX O

Here XXX O
, XXX O
the XXX O
cloning XXX O
and XXX O
characterization XXX O
of XXX O
S-RNase XXX B-GENE
genes XXX I-GENE
from XXX O
two XXX O
species XXX O
of XXX O
Rosaceae XXX O
, XXX O
apple XXX O
( XXX O
Malus XXX O
x XXX O
domestica XXX O
) XXX O
and XXX O
Japanese XXX O
pear XXX O
( XXX O
Pyrus XXX O
serotina XXX O
) XXX O
is XXX O
described XXX O
and XXX O
these XXX O
sequences XXX O
are XXX O
compared XXX O
with XXX O
those XXX O
of XXX O
other XXX O
T2-type XXX B-GENE
RNases XXX I-GENE
. XXX O

Angionephroscintigraphy XXX O
in XXX O
the XXX O
diagnosis XXX O
of XXX O
diseases XXX O
of XXX O
the XXX O
kidney XXX O
. XXX O

The XXX O
study XXX O
of XXX O
calcium XXX O
metabolism XXX O
in XXX O
ten XXX O
thalassaemic XXX O
children XXX O
comperatively XXX O
with XXX O
controls XXX O
after XXX O
oral XXX O
administration XXX O
of XXX O
47Ca XXX O
has XXX O
shown XXX O
diminished XXX O
intestinal XXX O
absorption XXX O
. XXX O

Supershift XXX O
assays XXX O
, XXX O
using XXX O
Jun XXX B-GENE
and XXX O
Fos XXX B-GENE
family XXX I-GENE
member-specific XXX I-GENE
antibodies XXX I-GENE
, XXX O
showed XXX O
that XXX O
protein XXX O
complexes XXX O
formed XXX O
by XXX O
AtT-20 XXX O
cell XXX O
nuclear XXX O
extracts XXX O
bound XXX O
to XXX O
the XXX O
c-jun XXX B-GENE
AP-1 XXX B-GENE
site XXX I-GENE
were XXX O
comprised XXX O
of XXX O
Jun XXX B-GENE
family XXX O
members XXX O
, XXX O
JunD XXX B-GENE
, XXX O
JunB XXX B-GENE
, XXX O
and XXX O
cJun XXX B-GENE
. XXX O

Curing XXX O
shrinkage XXX O
and XXX O
volumetric XXX O
changes XXX O
of XXX O
resin-modified XXX O
glass XXX O
ionomer XXX O
restorative XXX O
materials XXX O
. XXX O

Consistent XXX O
with XXX O
this XXX O
finding XXX O
, XXX O
wild-type XXX B-GENE
SAGA XXX I-GENE
inhibits XXX O
TBP XXX B-GENE
binding XXX O
to XXX O
the XXX O
HIS3 XXX B-GENE
promoter XXX I-GENE
in XXX O
vitro XXX O
, XXX O
while XXX O
SAGA XXX B-GENE
lacking XXX O
Spt3 XXX B-GENE
or XXX O
Spt8 XXX B-GENE
is XXX O
not XXX O
inhibitory XXX O
. XXX O

Variable XXX O
FHR XXX O
decelerations XXX O
or XXX O
bradycardias XXX O
were XXX O
encountered XXX O
on XXX O
95 XXX O
nonstress XXX O
tests XXX O
( XXX O
18 XXX O
. XXX O
8% XXX O
) XXX O
in XXX O
80 XXX O
( XXX O
33 XXX O
. XXX O
5% XXX O
) XXX O
postdate XXX O
patients XXX O
. XXX O

Twelve XXX O
patients XXX O
had XXX O
stage XXX O
IBG3 XXX O
, XXX O
14 XXX O
had XXX O
ICG1 XXX O
, XXX O
9 XXX O
had XXX O
ICG2 XXX O
, XXX O
and XXX O
3 XXX O
had XXX O
ICG3 XXX O
disease XXX O
. XXX O

Information XXX O
about XXX O
immunologic XXX O
drug XXX O
interactions XXX O
is XXX O
needed XXX O
by XXX O
pharmacists XXX O
to XXX O
make XXX O
rational XXX O
drug-use XXX O
decisions XXX O
. XXX O

The XXX O
authors XXX O
evaluated XXX O
the XXX O
potential XXX O
for XXX O
thrombotic XXX O
complications XXX O
arising XXX O
from XXX O
implantation XXX O
of XXX O
a XXX O
ventricular XXX O
assist XXX O
device XXX O
( XXX O
Sarns XXX O
/ XXX O
3M-VAD XXX O
) XXX O
in XXX O
four XXX O
calves XXX O
. XXX O

A XXX O
late XXX O
diagnosis XXX O
of XXX O
retinoblastoma XXX O
is XXX O
an XXX O
unquestionable XXX O
fact XXX O
that XXX O
allows XXX O
its XXX O
growth XXX O
and XXX O
leads XXX O
to XXX O
a XXX O
deterioration XXX O
in XXX O
the XXX O
outlook XXX O
. XXX O

Through XXX O
deletion XXX O
mutagenesis XXX O
, XXX O
we XXX O
identify XXX O
amino XXX O
acids XXX O
2003 XXX O
to XXX O
2212 XXX O
of XXX O
CBP XXX B-GENE
, XXX O
which XXX O
we XXX O
call XXX O
carboxy-terminal XXX O
region XXX O
2 XXX O
( XXX O
CR2 XXX O
) XXX O
, XXX O
as XXX O
the XXX O
minimal XXX O
region XXX O
for XXX O
Tax XXX B-GENE
interaction XXX O
. XXX O

The XXX O
galactose XXX B-GENE
transporter XXX I-GENE
shows XXX O
both XXX O
sequence XXX O
and XXX O
structural XXX O
homology XXX O
with XXX O
a XXX O
superfamily XXX O
of XXX O
sugar XXX B-GENE
transporters XXX I-GENE
which XXX O
includes XXX O
the XXX O
human XXX B-GENE
HepG2-erythrocyte XXX I-GENE
and XXX I-GENE
fetal XXX I-GENE
muscle XXX I-GENE
glucose XXX I-GENE
transporters XXX I-GENE
, XXX O
the XXX O
rat XXX B-GENE
brain XXX I-GENE
and XXX I-GENE
liver XXX I-GENE
glucose XXX I-GENE
transporters XXX I-GENE
, XXX O
the XXX O
Escherichia XXX B-GENE
coli XXX I-GENE
xylose XXX I-GENE
and XXX I-GENE
arabinose XXX I-GENE
permeases XXX I-GENE
, XXX O
and XXX O
the XXX O
S XXX B-GENE
. XXX I-GENE
cerevisiae XXX I-GENE
glucose XXX I-GENE
, XXX I-GENE
maltose XXX I-GENE
, XXX I-GENE
and XXX I-GENE
galactose XXX I-GENE
transporters XXX I-GENE
. XXX O

Our XXX O
results XXX O
demonstrate XXX O
the XXX O
importance XXX O
of XXX O
phosphate XXX O
and XXX O
calcium XXX O
in XXX O
influencing XXX O
the XXX O
secretion XXX O
of XXX O
PTH XXX B-GENE
and XXX O
CT XXX B-GENE
in XXX O
uremia XXX O
. XXX O

A XXX O
degenerate XXX O
DNA XXX O
transposon XXX O
, XXX O
Pat XXX B-GENE
, XXX O
was XXX O
identified XXX O
in XXX O
the XXX O
genomes XXX O
of XXX O
various XXX O
wild-type XXX O
strains XXX O
of XXX O
the XXX O
filamentous XXX O
fungus XXX O
Podospora XXX O
anserina XXX O
. XXX O

The XXX O
importance XXX O
of XXX O
hepatitis XXX O
C XXX O
virus XXX O
( XXX O
HCV XXX O
) XXX O
infection XXX O
as XXX O
a XXX O
cause XXX O
of XXX O
chronic XXX O
liver XXX O
disease XXX O
has XXX O
become XXX O
clear XXX O
with XXX O
the XXX O
introduction XXX O
of XXX O
serologic XXX O
detection XXX O
methods XXX O
. XXX O

XXI XXX O
. XXX O

The XXX O
gene XXX O
amplification XXX O
model XXX O
of XXX O
Coquelle XXX O
et XXX O
al XXX O
. XXX O

1111 XXX O
) XXX O
; XXX O
L XXX O
/ XXX O
H XXX O
> XXX O
0 XXX O
. XXX O
61 XXX O
( XXX O
chi XXX O
( XXX O
2 XXX O
) XXX O
= XXX O
10 XXX O
. XXX O
8 XXX O
; XXX O
P XXX O
: XXX O
< XXX O
0 XXX O
. XXX O
1111 XXX O
) XXX O
and XXX O
a XXX O
restrictive XXX O
filling XXX O
pattern XXX O
( XXX O
chi XXX O
( XXX O
2 XXX O
) XXX O
= XXX O
3 XXX O
. XXX O
6 XXX O
; XXX O
P XXX O
: XXX O
< XXX O
0 XXX O
. XXX O
09 XXX O
) XXX O
were XXX O
independent XXX O
predictors XXX O
of XXX O
events XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
we XXX O
identified XXX O
two XXX O
mutations XXX O
, XXX O
Delta XXX O
M1281 XXX O
and XXX O
IVS51+5G-- XXX O
> XXX O
A XXX O
, XXX O
in XXX O
a XXX O
German XXX O
USH1 XXX B-GENE
patient XXX O
. XXX O

We XXX O
propose XXX O
that XXX O
two XXX O
pathways XXX O
regulate XXX O
Stat5 XXX B-GENE
serine XXX O
phosphorylation XXX O
, XXX O
one XXX O
that XXX O
is XXX O
prolactin-activated XXX O
and XXX O
PD98059-resistant XXX O
and XXX O
one XXX O
that XXX O
is XXX O
constitutively XXX O
active XXX O
and XXX O
PD98059-sensitive XXX O
and XXX O
preferentially XXX O
targets XXX O
Stat5a XXX B-GENE
. XXX O

The XXX O
authors XXX O
conclude XXX O
that XXX O
nonspecificity XXX O
of XXX O
low XXX O
platelet XXX B-GENE
MAO XXX I-GENE
as XXX O
a XXX O
possible XXX O
correlate XXX O
of XXX O
bipolar XXX O
affective XXX O
disorder XXX O
, XXX O
as XXX O
well XXX O
as XXX O
schizophrenia XXX O
, XXX O
increases XXX O
the XXX O
burden XXX O
of XXX O
proof XXX O
necessary XXX O
before XXX O
findings XXX O
of XXX O
low XXX O
platelet XXX B-GENE
MAO XXX I-GENE
can XXX O
be XXX O
accepted XXX O
as XXX O
primary XXX O
. XXX O

Biol XXX O
. XXX O

The XXX O
effect XXX O
of XXX O
lithium XXX O
on XXX O
the XXX O
osmoregulation XXX O
of XXX O
arginine XXX B-GENE
vasopressin XXX I-GENE
secretion XXX O
. XXX O

Effect XXX O
of XXX O
ingestion XXX O
of XXX O
Norbiogest XXX O
during XXX O
the XXX O
quiescent XXX O
period XXX O
of XXX O
the XXX O
genital XXX O
organs XXX O
. XXX O

The XXX O
Thr161Val XXX O
mutation XXX O
causes XXX O
a XXX O
lethal XXX O
phenotype XXX O
in XXX O
the XXX O
fission XXX O
yeast XXX O
Schizosaccharomyces XXX O
pombe XXX O
, XXX O
while XXX O
replacement XXX O
of XXX O
Thr161 XXX O
with XXX O
glutamic XXX O
acid XXX O
, XXX O
potentially XXX O
mimicking XXX O
phosphorylation XXX O
, XXX O
causes XXX O
uncoordination XXX O
of XXX O
mitosis XXX O
and XXX O
multiple XXX O
cytokinesis XXX O
. XXX O

No XXX O
effect XXX O
was XXX O
found XXX O
on XXX O
grooming XXX O
behavior XXX O
. XXX O

Nitrofurazone XXX O
significantly XXX O
reduced XXX O
the XXX O
rise XXX O
in XXX O
LH XXX B-GENE
induced XXX O
by XXX O
LHRH XXX B-GENE
. XXX O

Fourth XXX O
, XXX O
sometime XXX O
between XXX O
4 XXX O
and XXX O
24 XXX O
hours XXX O
of XXX O
recovery XXX O
is XXX O
necessary XXX O
to XXX O
reverse XXX O
the XXX O
effect XXX O
of XXX O
chronic XXX O
hypoxia XXX O
on XXX O
cerebral XXX O
blood XXX O
flow XXX O
. XXX O

OBJECTIVE XXX O
: XXX O
To XXX O
perform XXX O
a XXX O
cost-effectiveness XXX O
analysis XXX O
( XXX O
CEA XXX O
) XXX O
between XXX O
a XXX O
standard XXX O
antiemetic XXX O
regimen-chlorpromazine XXX O
+ XXX O
dexamethasone XXX O
( XXX O
CPM-DEX XXX O
) XXX O
- XXX O
and XXX O
a XXX O
5-HT3 XXX B-GENE
receptor XXX I-GENE
antagonist-tropisetron XXX O
( XXX O
TROP XXX O
) XXX O
--in XXX O
the XXX O
control XXX O
of XXX O
acute XXX O
emesis XXX O
induced XXX O
by XXX O
highly XXX O
emetogenic XXX O
chemotherapy XXX O
in XXX O
children XXX O
, XXX O
considering XXX O
two XXX O
analytic XXX O
perspectives XXX O
: XXX O
hospital XXX O
and XXX O
patients XXX O
. XXX O

The XXX O
patients XXX O
were XXX O
divided XXX O
into XXX O
4 XXX O
groups XXX O
receiving XXX O
NLA XXX O
II XXX O
with XXX O
or XXX O
without XXX O
nalorphine XXX O
, XXX O
morphine XXX O
or XXX O
Micoren XXX O
. XXX O

The XXX O
promoter XXX O
segment XXX O
was XXX O
inactive XXX O
when XXX O
introduced XXX O
into XXX O
the XXX O
rat XXX O
glioma XXX O
cell XXX O
line XXX O
C6B4 XXX O
, XXX O
the XXX O
rat XXX O
submandibular XXX O
cell XXX O
line XXX O
RSMT-A5 XXX O
, XXX O
and XXX O
the XXX O
rat XXX O
pancreatic XXX O
beta XXX O
cell XXX O
line XXX O
RIN-5AH XXX O
, XXX O
all XXX O
of XXX O
which XXX O
do XXX O
not XXX O
express XXX O
the XXX O
endogenous XXX O
alpha2c-AR XXX B-GENE
gene XXX I-GENE
. XXX O

Internal XXX O
amino XXX O
acid XXX O
sequence XXX O
has XXX O
now XXX O
been XXX O
obtained XXX O
from XXX O
this XXX O
protein XXX O
which XXX O
shares XXX O
50-100% XXX O
sequence XXX O
identity XXX O
with XXX O
sequences XXX O
encoded XXX O
by XXX O
mammalian XXX B-GENE
G XXX I-GENE
alpha XXX I-GENE
11 XXX I-GENE
and XXX O
G XXX B-GENE
alpha XXX I-GENE
q XXX I-GENE
cDNAs XXX I-GENE
. XXX O

Following XXX O
treatment XXX O
, XXX O
serum XXX O
estradiol XXX O
levels XXX O
were XXX O
higher XXX O
in XXX O
groups XXX O
E XXX O
+ XXX O
T XXX O
and XXX O
E XXX O
than XXX O
in XXX O
group XXX O
C XXX O
. XXX O

These XXX O
data XXX O
suggest XXX O
that XXX O
combined XXX O
lesions XXX O
of XXX O
cholinergic XXX O
and XXX O
serotonergic XXX O
neurons XXX O
in XXX O
the XXX O
rat XXX O
brain XXX O
do XXX O
not XXX O
alter XXX O
olfactory XXX O
perception XXX O
or XXX O
olfactory XXX O
short-term XXX O
memory XXX O
. XXX O

Both XXX O
antidepressants XXX O
elevated XXX O
the XXX O
pain XXX O
threshold XXX O
acutely XXX O
, XXX O
while XXX O
pretreatment XXX O
with XXX O
pCPA XXX O
largely XXX O
blocked XXX O
the XXX O
analgesia XXX O
. XXX O

Sequence XXX O
analysis XXX O
of XXX O
cloned XXX O
PCR XXX O
products XXX O
confirmed XXX O
the XXX O
presence XXX O
of XXX O
two XXX O
different XXX O
nifV-like XXX B-GENE
DNA XXX I-GENE
fragments XXX I-GENE
, XXX O
which XXX O
were XXX O
subsequently XXX O
used XXX O
as XXX O
nifV- XXX O
and XXX O
leuA-specific XXX B-GENE
probes XXX I-GENE
, XXX O
respectively XXX O
, XXX O
to XXX O
clone XXX O
XbaI XXX B-GENE
fragments XXX I-GENE
of XXX O
2 XXX O
. XXX O
1 XXX O
kbp XXX O
( XXX O
pOST4 XXX O
) XXX O
and XXX O
2 XXX O
. XXX O
6 XXX O
kbp XXX O
( XXX O
pOST2 XXX O
) XXX O
. XXX O

The XXX O
B XXX B-GENE
cell XXX I-GENE
antigen XXX I-GENE
receptor XXX I-GENE
activates XXX O
the XXX O
Akt XXX B-GENE
( XXX O
protein XXX B-GENE
kinase XXX I-GENE
B XXX I-GENE
) XXX O
/ XXX B-GENE
glycogen XXX I-GENE
synthase XXX I-GENE
kinase-3 XXX I-GENE
signaling XXX O
pathway XXX O
via XXX O
phosphatidylinositol XXX B-GENE
3-kinase XXX I-GENE
. XXX O

A XXX O
technique XXX O
for XXX O
thermal XXX O
imaging XXX O
of XXX O
the XXX O
animal XXX O
and XXX O
human XXX O
brain XXX O
cortex XXX O
using XXX O
an XXX O
infrared XXX O
optical XXX O
system XXX O
is XXX O
described XXX O
. XXX O

Identification XXX O
and XXX O
characterization XXX O
of XXX O
IS2404 XXX B-GENE
and XXX O
IS2606 XXX B-GENE
: XXX O
two XXX O
distinct XXX O
repeated XXX O
sequences XXX O
for XXX O
detection XXX O
of XXX O
Mycobacterium XXX O
ulcerans XXX O
by XXX O
PCR XXX O
. XXX O

Cloning XXX O
of XXX O
individual XXX O
ZI XXX B-GENE
domains XXX I-GENE
upstream XXX O
of XXX O
a XXX O
minimal XXX O
promoter XXX O
demonstrated XXX O
that XXX O
the XXX O
ZIA XXX B-GENE
, XXX O
ZIC XXX B-GENE
, XXX O
and XXX O
ZID XXX B-GENE
domains XXX O
, XXX O
but XXX O
not XXX O
the XXX O
ZIB XXX B-GENE
domain XXX O
, XXX O
are XXX O
TPA XXX B-GENE
responsive XXX O
. XXX O

These XXX O
data XXX O
suggest XXX O
that XXX O
the XXX O
levels XXX O
of XXX O
oxygen XXX O
free XXX O
radicals XXX O
were XXX O
increased XXX O
in XXX O
hepatocytes XXX O
and XXX O
mitochondria XXX O
. XXX O

OBJECTIVE--To XXX O
assess XXX O
the XXX O
risk XXX O
of XXX O
hepatitis XXX O
A XXX O
in XXX O
international XXX O
travelers XXX O
and XXX O
to XXX O
recommend XXX O
preventive XXX O
measures XXX O
. XXX O

Breast XXX O
cancer XXX O
risk XXX O
assessment XXX O
: XXX O
who XXX O
holds XXX O
the XXX O
magic XXX O
crystal XXX O
ball XXX O
? XXX O

Significantly XXX O
higher XXX O
lung XXX O
function XXX O
parameters XXX O
were XXX O
obtained XXX O
in XXX O
extubated XXX O
recipients XXX O
of XXX O
LPD XXX O
preserved XXX O
grafts XXX O
2 XXX O
weeks XXX O
after XXX O
TX XXX O
. XXX O

These XXX O
mutants XXX O
all XXX O
failed XXX O
to XXX O
interact XXX O
with XXX O
the XXX O
TraR XXX B-GENE
fusion XXX I-GENE
in XXX O
the XXX O
two-hybrid XXX O
system XXX O
. XXX O

Tih1 XXX B-GENE
maps XXX O
to XXX O
distal XXX O
mouse XXX O
Chr XXX O
1 XXX O
and XXX O
human XXX O
Chr XXX O
1q31 XXX O
, XXX O
chromosomal XXX O
regions XXX O
that XXX O
have XXX O
not XXX O
shown XXX O
evidence XXX O
for XXX O
imprinting XXX O
and XXX O
, XXX O
in XXX O
contrast XXX O
to XXX O
Ipl XXX B-GENE
, XXX O
Tih1 XXX B-GENE
is XXX O
expressed XXX O
equally XXX O
from XXX O
both XXX O
parental XXX O
alleles XXX O
. XXX O

The XXX O
decrease XXX O
in XXX O
left XXX O
ventricular XXX O
( XXX O
LV XXX O
) XXX O
stroke XXX O
volume XXX O
during XXX O
positive XXX O
end-expiratory XXX O
pressure XXX O
( XXX O
PEEP XXX O
) XXX O
has XXX O
been XXX O
attributed XXX O
to XXX O
reduced XXX O
LV XXX O
filling XXX O
and XXX O
a XXX O
decreased XXX O
contractile XXX O
state XXX O
. XXX O

To XXX O
establish XXX O
a XXX O
possible XXX O
association XXX O
between XXX O
familial XXX O
dysfibrinogenemia XXX O
and XXX O
thrombophilia XXX O
, XXX O
data XXX O
on XXX O
cases XXX O
with XXX O
both XXX O
affections XXX O
were XXX O
collected XXX O
in XXX O
a XXX O
study XXX O
within XXX O
the XXX O
framework XXX O
of XXX O
the XXX O
SSC XXX O
Subcommittee XXX O
on XXX O
Fibrinogen XXX B-GENE
of XXX O
the XXX O
International XXX O
Society XXX O
on XXX O
Thrombosis XXX O
and XXX O
Haemostasis XXX O
. XXX O

Rabbit XXX B-GENE
skeletal XXX I-GENE
muscle XXX I-GENE
glycogenin XXX I-GENE
. XXX O

Furthermore XXX O
, XXX O
direct XXX O
association XXX O
with XXX O
D3 XXX O
phosphatidylinositides XXX O
seems XXX O
to XXX O
be XXX O
essential XXX O
for XXX O
activation XXX O
of XXX O
PKB XXX B-GENE
/ XXX I-GENE
Akt XXX I-GENE
. XXX O

PIP2 XXX B-GENE
, XXX O
when XXX O
incorporated XXX O
into XXX O
phosphatidylcholine XXX O
carrier XXX O
vesicles XXX O
, XXX O
binds XXX O
tightly XXX O
to XXX O
the XXX O
guanine XXX O
nucleotide-depleted XXX O
form XXX O
of XXX O
Cdc42Hs XXX B-GENE
and XXX O
weakly XXX O
to XXX O
the XXX O
GDP-bound XXX O
form XXX O
of XXX O
the XXX O
GTP-binding XXX B-GENE
protein XXX I-GENE
but XXX O
does XXX O
not XXX O
bind XXX O
to XXX O
GTP-bound XXX O
Cdc42Hs XXX B-GENE
, XXX O
similar XXX O
to XXX O
what XXX O
was XXX O
observed XXX O
for XXX O
the XXX O
Dbl XXX B-GENE
oncoprotein XXX I-GENE
. XXX O

Somatostatin-producing XXX O
endocrine XXX O
pancreatic XXX O
tumor XXX O
in XXX O
Recklinghausen's XXX O
neurofibromatosis XXX O
. XXX O

We XXX O
have XXX O
cloned XXX O
a XXX O
novel XXX O
protein XXX B-GENE
kinase XXX I-GENE
, XXX O
termed XXX O
hematopoietic XXX B-GENE
progenitor XXX I-GENE
kinase XXX I-GENE
1 XXX I-GENE
( XXX O
HPK1 XXX B-GENE
) XXX O
, XXX O
that XXX O
is XXX O
expressed XXX O
predominantly XXX O
in XXX O
hematopoietic XXX O
cells XXX O
, XXX O
including XXX O
early XXX O
progenitor XXX O
cells XXX O
. XXX O

By XXX O
progressive XXX O
5'-deletion XXX O
studies XXX O
, XXX O
we XXX O
have XXX O
identified XXX O
a XXX O
248-bp XXX O
DNA XXX O
fragment XXX O
( XXX O
-1018 XXX O
to XXX O
-771 XXX O
, XXX O
relative XXX O
to XXX O
the XXX O
translation XXX O
start XXX O
site XXX O
) XXX O
at XXX O
the XXX O
5'-flanking XXX O
region XXX O
of XXX O
the XXX O
human XXX B-GENE
GnRHR XXX I-GENE
gene XXX I-GENE
that XXX O
is XXX O
responsible XXX O
for XXX O
the XXX O
GnRHa-mediated XXX O
down-regulation XXX O
of XXX O
human XXX B-GENE
GnRHR XXX I-GENE
promoter XXX I-GENE
activity XXX O
. XXX O

Working XXX O
session XXX O
report XXX O
: XXX O
in XXX O
vivo-in XXX O
vitro XXX O
screening XXX O
. XXX O

Nearly XXX O
all XXX O
isolates XXX O
of XXX O
S XXX O
. XXX O
intermedius XXX O
and XXX O
most XXX O
isolates XXX O
of XXX O
S XXX O
. XXX O
constellatus XXX O
, XXX O
but XXX O
only XXX O
19% XXX O
of XXX O
those XXX O
of XXX O
S XXX O
. XXX O
anginosus XXX O
, XXX O
were XXX O
associated XXX O
with XXX O
abscess XXX O
. XXX O

Up XXX O
to XXX O
95% XXX O
of XXX O
the XXX O
total XXX O
UV XXX O
exposure XXX O
received XXX O
is XXX O
in XXX O
the XXX O
UV-A XXX O
waveband XXX O
( XXX O
320-400 XXX O
nm XXX O
) XXX O
. XXX O

Genetics XXX O
Institute XXX O
has XXX O
developed XXX O
and XXX O
launched XXX O
oprelvekin XXX B-GENE
( XXX O
rhIL-11 XXX B-GENE
; XXX O
Neumega XXX O
) XXX O
, XXX O
a XXX O
recombinant XXX O
form XXX O
of XXX O
human XXX B-GENE
IL-11 XXX I-GENE
. XXX O

In XXX O
order XXX O
to XXX O
provide XXX O
adequate XXX O
local XXX O
control XXX O
without XXX O
compromising XXX O
cosmetic XXX O
outcome XXX O
, XXX O
the XXX O
amount XXX O
of XXX O
breast XXX O
tissue XXX O
that XXX O
must XXX O
be XXX O
excised XXX O
in XXX O
BCT XXX O
needs XXX O
to XXX O
be XXX O
individualized XXX O
. XXX O

Fractionation XXX O
of XXX O
crude XXX O
nuclear XXX O
extracts XXX O
by XXX O
heparin-agarose XXX O
chromatography XXX O
indicates XXX O
that XXX O
PCAT-1 XXX B-GENE
is XXX O
more XXX O
prevalent XXX O
in XXX O
extracts XXX O
prepared XXX O
from XXX O
salt-stressed XXX O
leaf XXX O
tissue XXX O
. XXX O

Possibility XXX O
of XXX O
a XXX O
TSH-Screening XXX O
method XXX O
for XXX O
detection XXX O
of XXX O
hypothyroidism XXX O
in XXX O
the XXX O
newborn XXX O
. XXX O

The XXX O
effect XXX O
of XXX O
a XXX O
beta-adrenoceptor XXX B-GENE
antagonist XXX O
, XXX O
pindolol XXX O
, XXX O
on XXX O
uterine XXX O
smooth XXX O
muscle XXX O
in XXX O
term XXX O
pregnant XXX O
women XXX O
was XXX O
studied XXX O
in XXX O
vitro XXX O
and XXX O
in XXX O
vivo XXX O
( XXX O
in XXX O
hypertensive XXX O
women XXX O
) XXX O
. XXX O

The XXX O
5' XXX O
flanking XXX O
sequence XXX O
of XXX O
the XXX O
3B XXX B-GENE
gene XXX I-GENE
is XXX O
extremely XXX O
A XXX O
+ XXX O
T XXX O
rich XXX O
but XXX O
contains XXX O
five XXX O
G XXX O
/ XXX O
C XXX O
rich XXX O
stretches XXX O
, XXX O
each XXX O
approximately XXX O
7bp XXX O
long XXX O
, XXX O
which XXX O
have XXX O
strong XXX O
sequence XXX O
similarity XXX O
to XXX O
the XXX O
G XXX O
boxes XXX O
found XXX O
upstream XXX O
of XXX O
other XXX O
developmentally XXX O
regulated XXX O
Dictyostelium XXX O
genes XXX O
. XXX O

A-tracts XXX O
functioned XXX O
best XXX O
when XXX O
positioned XXX O
close XXX O
to XXX O
the XXX O
-35 XXX O
hexamer XXX O
rather XXX O
than XXX O
one XXX O
helical XXX O
turn XXX O
farther XXX O
upstream XXX O
, XXX O
similar XXX O
to XXX O
the XXX O
positioning XXX O
optimal XXX O
for XXX O
UP XXX B-GENE
element XXX I-GENE
function XXX O
. XXX O

The XXX O
total XXX O
alkaloids XXX O
contained XXX O
in XXX O
the XXX O
peel XXX O
of XXX O
Atzimba XXX O
, XXX O
Lopez XXX O
, XXX O
Marciana XXX O
, XXX O
Montsama XXX O
, XXX O
Murca XXX O
, XXX O
and XXX O
Puebla XXX O
was XXX O
lower XXX O
than XXX O
the XXX O
limits XXX O
recommended XXX O
for XXX O
food XXX O
safety XXX O
. XXX O

Scratching XXX O
during XXX O
sleep XXX O
in XXX O
children XXX O
with XXX O
atopic XXX O
dermatitis XXX O
is XXX O
associated XXX O
with XXX O
increased XXX O
VO2 XXX O
. XXX O

High XXX O
levels XXX O
of XXX O
serum XXX O
calcitonin XXX B-GENE
were XXX O
found XXX O
in XXX O
patients XXX O
with XXX O
chronic XXX O
renal XXX O
failure XXX O
. XXX O

This XXX O
enhancer XXX O
activates XXX O
both XXX O
the XXX O
K19 XXX B-GENE
and XXX O
TK XXX B-GENE
basal XXX I-GENE
promoters XXX I-GENE
in XXX O
HeLa XXX O
cells XXX O
. XXX O

The XXX O
treatment XXX O
of XXX O
hydronephrosis XXX O
in XXX O
children XXX O
. XXX O

Platelet XXX O
number XXX O
and XXX O
life XXX O
span XXX O
were XXX O
determined XXX O
in XXX O
the XXX O
last XXX O
trimester XXX O
of XXX O
pregnancy XXX O
in XXX O
22 XXX O
women XXX O
who XXX O
were XXX O
delivered XXX O
of XXX O
small-for-gestational XXX O
age XXX O
( XXX O
SGA XXX O
) XXX O
infants XXX O
and XXX O
in XXX O
21 XXX O
women XXX O
with XXX O
infants XXX O
having XXX O
normal XXX O
birth XXX O
weights XXX O
. XXX O

Significant XXX O
treatment-related XXX O
problems XXX O
appeared XXX O
during XXX O
the XXX O
second XXX O
decade XXX O
in XXX O
5 XXX O
patients XXX O
, XXX O
including XXX O
one XXX O
chest XXX O
wall XXX O
sarcoma XXX O
; XXX O
all XXX O
of XXX O
these XXX O
patients XXX O
had XXX O
received XXX O
at XXX O
least XXX O
60 XXX O
Gy XXX O
to XXX O
breast XXX O
and XXX O
regional XXX O
nodal XXX O
areas XXX O
. XXX O

In XXX O
reperfusion XXX O
B XXX O
, XXX O
only XXX O
the XXX O
diabetic XXX O
group XXX O
demonstrated XXX O
a XXX O
significant XXX O
increase XXX O
in XXX O
IL-8 XXX B-GENE
concentrations XXX O
at XXX O
1 XXX O
and XXX O
15 XXX O
min XXX O
compared XXX O
to XXX O
nondiabetics XXX O
. XXX O

Subjects XXX O
with XXX O
a XXX O
short XXX O
postexposure XXX O
time XXX O
and XXX O
a XXX O
dioxin XXX O
burden XXX O
> XXX O
0 XXX O
. XXX O
6 XXX O
pg XXX O
/ XXX O
m3 XXX O
had XXX O
a XXX O
significantly XXX O
higher XXX O
risk XXX O
of XXX O
hypoergy XXX O
than XXX O
unexposed XXX O
subjects XXX O
( XXX O
hypoergy XXX O
I XXX O
: XXX O
OR XXX O
= XXX O
9 XXX O
. XXX O
51 XXX O
, XXX O
95% XXX O
CI XXX O
= XXX O
1 XXX O
. XXX O
96-42 XXX O
. XXX O
02 XXX O
; XXX O
hypoergy XXX O
II XXX O
: XXX O
OR XXX O
= XXX O
2 XXX O
. XXX O
92 XXX O
, XXX O
95% XXX O
CI XXX O
= XXX O
1 XXX O
. XXX O
14-7 XXX O
. XXX O
5 XXX O
) XXX O
. XXX O

The XXX O
gene XXX O
( XXX O
ApxII XXX B-GENE
) XXX O
encoding XXX O
both XXX O
chloroplastic XXX B-GENE
ascorbate XXX I-GENE
peroxidase XXX I-GENE
isoenzymes XXX I-GENE
was XXX O
isolated XXX O
and XXX O
the XXX O
organization XXX O
of XXX O
the XXX O
gene XXX O
was XXX O
determined XXX O
. XXX O

The XXX O
mechanism XXX O
of XXX O
peroxisome XXX O
proliferation XXX O
is XXX O
poorly XXX O
understood XXX O
. XXX O

The XXX O
method XXX O
involved XXX O
deproteinizing XXX O
samples XXX O
with XXX O
two XXX O
volumes XXX O
of XXX O
acetonitrile XXX O
followed XXX O
by XXX O
injection XXX O
of XXX O
5 XXX O
microliters XXX O
of XXX O
deproteinized XXX O
supernatant XXX O
onto XXX O
a XXX O
C18 XXX O
reversed-phase XXX O
column XXX O
. XXX O

FOG XXX B-GENE
is XXX O
coexpressed XXX O
with XXX O
GATA-1 XXX B-GENE
during XXX O
embryonic XXX O
development XXX O
and XXX O
in XXX O
erythroid XXX O
and XXX O
megakaryocytic XXX O
cells XXX O
. XXX O

However XXX O
, XXX O
C4B XXX B-GENE
proteins XXX I-GENE
encoded XXX O
by XXX O
monomodular XXX O
short XXX O
genes XXX O
may XXX O
have XXX O
relatively XXX O
higher XXX O
concentrations XXX O
than XXX O
those XXX O
from XXX O
long XXX B-GENE
C4A XXX I-GENE
genes XXX I-GENE
. XXX O

Independent XXX O
splicing XXX O
events XXX O
involve XXX O
three XXX O
previously XXX O
described XXX O
cassette XXX O
exons XXX O
, XXX O
which XXX O
are XXX O
predicted XXX O
to XXX O
encode XXX O
most XXX O
of XXX O
the XXX O
second XXX O
transmembrane XXX O
domain XXX O
. XXX O

As XXX O
it XXX O
had XXX O
been XXX O
previously XXX O
reported XXX O
that XXX O
the XXX O
18-bp XXX O
palindrome XXX O
contains XXX O
sufficient XXX O
nucleotide XXX O
sequence XXX O
information XXX O
for XXX O
E1 XXX B-GENE
binding XXX O
, XXX O
we XXX O
speculate XXX O
that XXX O
a XXX O
minimal XXX O
E1 XXX B-GENE
recognition XXX O
motif XXX O
is XXX O
presented XXX O
in XXX O
each XXX O
half XXX O
site XXX O
. XXX O

Clinically XXX O
meaningful XXX O
decreases XXX O
due XXX O
to XXX O
alkalinization XXX O
alone XXX O
within XXX O
30 XXX O
minutes XXX O
are XXX O
unlikely XXX O
. XXX O

Using XXX O
this XXX O
method XXX O
, XXX O
we XXX O
measured XXX O
absorption XXX O
of XXX O
low XXX O
doses XXX O
of XXX O
vitamin XXX O
A XXX O
, XXX O
which XXX O
may XXX O
provide XXX O
a XXX O
more XXX O
physiological XXX O
approach XXX O
to XXX O
assessment XXX O
of XXX O
fat XXX O
malabsorption XXX O
. XXX O

To XXX O
explore XXX O
the XXX O
function XXX O
of XXX O
human XXX O
SINA-homologous XXX B-GENE
( XXX I-GENE
Siah XXX I-GENE
) XXX I-GENE
proteins XXX I-GENE
, XXX O
expression XXX O
plasmids XXX O
encoding XXX O
Siah-1A XXX B-GENE
were XXX O
transiently XXX O
transfected XXX O
into XXX O
293 XXX O
epithelial XXX O
cells XXX O
and XXX O
GM701 XXX O
fibroblast XXX O
cells XXX O
, XXX O
resulting XXX O
in XXX O
growth XXX O
arrest XXX O
without XXX O
induction XXX O
of XXX O
apoptosis XXX O
. XXX O

Airway XXX O
pressure XXX O
and XXX O
air XXX O
flow XXX O
were XXX O
measured XXX O
at XXX O
the XXX O
endotracheal XXX O
tube XXX O
in XXX O
13 XXX O
children XXX O
on XXX O
a XXX O
variety XXX O
of XXX O
ventilators XXX O
. XXX O

MAIN XXX O
OUTCOME XXX O
MEASURE XXX O
: XXX O
A XXX O
positive XXX O
test XXX O
result XXX O
for XXX O
gonococcal XXX O
or XXX O
chlamydial XXX O
infection XXX O
by XXX O
the XXX O
ligase XXX B-GENE
chain XXX O
reaction XXX O
assay XXX O
; XXX O
secondary XXX O
outcome XXX O
measure XXX O
was XXX O
a XXX O
positive XXX O
test XXX O
result XXX O
for XXX O
human XXX O
immunodeficiency XXX O
virus XXX O
( XXX O
HIV XXX O
) XXX O
. XXX O

The XXX O
GPI XXX B-GENE
anchor XXX I-GENE
moiety XXX I-GENE
is XXX O
either XXX O
absent XXX O
or XXX O
present XXX O
at XXX O
a XXX O
very XXX O
low XXX O
level XXX O
in XXX O
the XXX O
polypeptide XXX O
expressed XXX O
from XXX O
the XXX O
cDNA XXX O
that XXX O
contained XXX O
both XXX O
the XXX O
signal XXX O
peptide XXX O
and XXX O
GPI XXX B-GENE
signal XXX I-GENE
sequences XXX I-GENE
. XXX O

CDK4 XXX B-GENE
kinase XXX I-GENE
activities XXX O
were XXX O
unaffected XXX O
, XXX O
as XXX O
were XXX O
the XXX O
levels XXX O
of XXX O
the XXX O
CDK XXX B-GENE
inhibitor XXX I-GENE
p21Cip1 XXX I-GENE
present XXX O
in XXX O
cyclin XXX B-GENE
E XXX I-GENE
immunocomplexes XXX I-GENE
. XXX O

We XXX O
also XXX O
identified XXX O
an XXX O
alternative XXX O
spliced XXX O
form XXX O
of XXX O
Lyp XXX B-GENE
RNA XXX I-GENE
, XXX O
Lyp2 XXX B-GENE
. XXX O

With XXX O
regard XXX O
to XXX O
the XXX O
characteristic XXX O
expression XXX O
pattern XXX O
of XXX O
DJ XXX B-GENE
protein XXX I-GENE
and XXX O
its XXX O
conspicuous XXX O
repeat XXX O
units XXX O
possible XXX O
functional XXX O
roles XXX O
are XXX O
discussed XXX O
. XXX O

Fibrin XXX B-GENE
cloaking XXX O
along XXX O
the XXX O
catheter XXX O
was XXX O
found XXX O
in XXX O
20 XXX O
patients XXX O
studied XXX O
by XXX O
pull-out XXX O
arteriography XXX O
and XXX O
was XXX O
unassociated XXX O
with XXX O
clinical XXX O
symptoms XXX O
. XXX O

Sequence XXX O
requirements XXX O
for XXX O
premature XXX O
transcription XXX O
arrest XXX O
within XXX O
the XXX O
first XXX O
intron XXX O
of XXX O
the XXX O
mouse XXX B-GENE
c-fos XXX I-GENE
gene XXX I-GENE
. XXX O

However XXX O
, XXX O
it XXX O
remains XXX O
an XXX O
open XXX O
question XXX O
whether XXX O
vertebrate XXX B-GENE
Hox XXX I-GENE
genes XXX I-GENE
expressed XXX O
under XXX O
the XXX O
control XXX O
of XXX O
Drosophila XXX O
regulatory XXX O
sequences XXX O
can XXX O
substitute XXX O
the XXX O
function XXX O
of XXX O
Drosophila XXX B-GENE
Hox XXX I-GENE
genes XXX I-GENE
. XXX O

This XXX O
brief XXX O
hypercapnic XXX O
challenge XXX O
induced XXX O
a XXX O
rapid XXX O
increase XXX O
in XXX O
CBF XXX O
in XXX O
the XXX O
absence XXX O
of XXX O
any XXX O
change XXX O
in XXX O
MABP XXX O
. XXX O

The XXX O
sequence XXX O
was XXX O
determined XXX O
for XXX O
a XXX O
4024-base XXX O
pair XXX O
( XXX O
bp XXX O
) XXX O
segment XXX O
that XXX O
extends XXX O
from XXX O
149 XXX O
bp XXX O
5' XXX O
to XXX O
the XXX O
cap XXX O
site XXX O
of XXX O
alpha XXX B-GENE
1 XXX I-GENE
to XXX O
207 XXX O
bp XXX O
3' XXX O
to XXX O
psi XXX B-GENE
alpha XXX I-GENE
. XXX O

Collectively XXX O
, XXX O
our XXX O
findings XXX O
demonstrate XXX O
that XXX O
SF-1 XXX B-GENE
plays XXX O
a XXX O
key XXX O
role XXX O
in XXX O
controlling XXX O
the XXX O
basal XXX O
and XXX O
cAMP-stimulated XXX O
expression XXX O
of XXX O
the XXX O
StAR XXX B-GENE
gene XXX I-GENE
. XXX O

In XXX O
contrast XXX O
the XXX O
human XXX O
and XXX O
mouse XXX B-GENE
BCNT XXX I-GENE
proteins XXX I-GENE
contain XXX O
one XXX O
repeat XXX O
unit XXX O
and XXX O
lack XXX O
the XXX O
RTE-1-derived XXX O
portion XXX O
. XXX O

Competition XXX O
with XXX O
a XXX O
putative XXX O
MADS XXX B-GENE
box XXX I-GENE
consensus XXX O
binding XXX O
site XXX O
from XXX O
the XXX O
promoter XXX O
of XXX O
the XXX O
coordinately XXX O
regulated XXX O
opaque-phase-specific XXX B-GENE
gene XXX I-GENE
PEP1 XXX I-GENE
( XXX O
SAP1 XXX B-GENE
) XXX O
and XXX O
the XXX O
human XXX B-GENE
MADS XXX I-GENE
box XXX I-GENE
consensus XXX I-GENE
binding XXX I-GENE
site XXX I-GENE
for XXX O
serum XXX B-GENE
response XXX I-GENE
factor XXX I-GENE
demonstrated XXX O
that XXX O
one XXX O
of XXX O
the XXX O
three XXX O
complexes XXX O
formed XXX O
was XXX O
specific XXX O
to XXX O
the XXX O
OP4 XXX B-GENE
sequence XXX I-GENE
. XXX O

This XXX O
article XXX O
comparatively XXX O
evaluates XXX O
five XXX O
Generic XXX O
Systems XXX O
that XXX O
describe XXX O
the XXX O
basic XXX O
alternatives XXX O
to XXX O
composting XXX O
facility XXX O
design XXX O
and XXX O
control XXX O
. XXX O

ORFK10 XXX B-GENE
. XXX I-GENE
5 XXX I-GENE
encodes XXX O
a XXX O
protein XXX O
, XXX O
latency-associated XXX B-GENE
nuclear XXX I-GENE
antigen XXX I-GENE
2 XXX I-GENE
( XXX O
LANA2 XXX B-GENE
) XXX O
, XXX O
which XXX O
is XXX O
expressed XXX O
in XXX O
KSHV-infected XXX O
hematopoietic XXX O
tissues XXX O
, XXX O
including XXX O
PEL XXX O
and XXX O
CD XXX O
but XXX O
not XXX O
KS XXX O
lesions XXX O
. XXX O

In XXX O
view XXX O
of XXX O
the XXX O
presence XXX O
of XXX O
SECIS XXX B-GENE
elements XXX I-GENE
in XXX O
the XXX O
open XXX O
reading XXX O
frames XXX O
( XXX O
ORFs XXX O
) XXX O
of XXX O
bacterial XXX O
selenoproteins XXX O
, XXX O
we XXX O
examine XXX O
the XXX O
effects XXX O
in XXX O
the XXX O
type XXX B-GENE
1 XXX I-GENE
deiodinase XXX I-GENE
of XXX O
extending XXX O
the XXX O
ORF XXX O
into XXX O
the XXX O
SECIS XXX B-GENE
element XXX I-GENE
, XXX O
and XXX O
find XXX O
that XXX O
this XXX O
dramatically XXX O
inhibits XXX O
SECIS XXX B-GENE
function XXX O
. XXX O

The XXX O
dorsal XXX O
nerves XXX O
of XXX O
the XXX O
penis XXX O
were XXX O
anesthetized XXX O
bilaterally XXX O
with XXX O
lidocaine XXX O
. XXX O

Antibodies XXX O
raised XXX O
against XXX O
a XXX O
C-terminal XXX O
portion XXX O
of XXX O
Sec31A XXX B-GENE
co-precipitate XXX O
Sec13 XXX B-GENE
and XXX O
inhibit XXX O
ER-Golgi XXX O
transport XXX O
of XXX O
temperature-arrested XXX O
vesicular XXX O
stomatitis XXX B-GENE
G XXX I-GENE
protein XXX I-GENE
in XXX O
a XXX O
semi-intact XXX O
cell XXX O
assay XXX O
. XXX O

Dosimetric XXX O
estimates XXX O
for XXX O
these XXX O
organs XXX O
were XXX O
2 XXX O
. XXX O
3 XXX O
+ XXX O
/ XXX O
- XXX O
1 XXX O
. XXX O
1 XXX O
and XXX O
2 XXX O
. XXX O
3 XXX O
+ XXX O
/ XXX O
- XXX O
1 XXX O
. XXX O
4 XXX O
rad XXX O
( XXX O
. XXX O
02 XXX O
+ XXX O
/ XXX O
- XXX O
. XXX O
01 XXX O
Gy XXX O
) XXX O
, XXX O
respectively XXX O
, XXX O
with XXX O
a XXX O
whole-body XXX O
estimate XXX O
of XXX O
0 XXX O
. XXX O
28 XXX O
rad XXX O
( XXX O
. XXX O
003 XXX O
Gy XXX O
) XXX O
. XXX O

Its XXX O
early XXX O
lesions XXX O
were XXX O
characterized XXX O
by XXX O
angiomatosis XXX O
, XXX O
vasculopathy XXX O
, XXX O
and XXX O
proliferation XXX O
of XXX O
synoviocytes XXX O
and XXX O
fibroblasts XXX O
. XXX O

Ig XXX B-GENE
heavy XXX I-GENE
chain XXX I-GENE
class XXX O
switching XXX O
is XXX O
directed XXX O
by XXX O
cytokines XXX O
inducing XXX O
transcription XXX O
from XXX O
unrearranged XXX O
CH XXX B-GENE
genes XXX I-GENE
. XXX O

Conserved XXX O
and XXX O
distinct XXX O
roles XXX O
of XXX O
kreisler XXX B-GENE
in XXX O
regulation XXX O
of XXX O
the XXX O
paralogous XXX O
Hoxa3 XXX B-GENE
and XXX O
Hoxb3 XXX B-GENE
genes XXX I-GENE
. XXX O

The XXX O
Abbreviated XXX O
Injury XXX O
Scale XXX O
( XXX O
AIS XXX O
) XXX O
, XXX O
Injury XXX O
Severity XXX O
Scale XXX O
and XXX O
TRISS XXX O
methodology XXX O
comprise XXX O
a XXX O
mathematically XXX O
sound XXX O
system XXX O
for XXX O
the XXX O
analysis XXX O
of XXX O
injuries XXX O
and XXX O
injured XXX O
patients XXX O
. XXX O

The XXX O
mean XXX O
blood XXX O
flow XXX O
in XXX O
the XXX O
penile XXX O
foreskin XXX O
was XXX O
estimated XXX O
to XXX O
be XXX O
15 XXX O
ml XXX O
/ XXX O
min XXX O
/ XXX O
100 XXX O
g XXX O
and XXX O
it XXX O
increased XXX O
to XXX O
150-200% XXX O
after XXX O
the XXX O
induction XXX O
of XXX O
anesthesia XXX O
, XXX O
and XXX O
then XXX O
decreased XXX O
to XXX O
72% XXX O
at XXX O
the XXX O
tip XXX O
of XXX O
the XXX O
created XXX O
parameatal XXX O
foreskin XXX O
flap XXX O
. XXX O

A XXX O
32P-labeled XXX O
LAP XXX O
DNA-binding XXX O
and XXX O
dimerization XXX O
domain XXX O
"zipper XXX O
probe" XXX O
was XXX O
used XXX O
to XXX O
isolate XXX O
a XXX O
clone XXX O
that XXX O
encodes XXX O
a XXX O
new XXX O
C XXX B-GENE
/ XXX I-GENE
EBP-homologous XXX I-GENE
protein XXX I-GENE
: XXX O
CHOP-10 XXX B-GENE
. XXX O

Thrombocyte XXX O
function XXX O
was XXX O
impaired XXX O
in XXX O
all XXX O
patients XXX O
, XXX O
characterized XXX O
by XXX O
a XXX O
diminished XXX O
platelet XXX O
shape XXX O
change XXX O
. XXX O

The XXX O
genome XXX O
of XXX O
the XXX O
human XXX O
herpesvirus XXX O
8 XXX O
( XXX O
HHV-8 XXX O
) XXX O
contains XXX O
a XXX O
cluster XXX O
of XXX O
open XXX O
reading XXX O
frames XXX O
( XXX O
ORFs XXX O
) XXX O
encoding XXX O
proteins XXX O
with XXX O
homology XXX O
to XXX O
the XXX O
cellular XXX O
transcription XXX O
factors XXX O
of XXX O
the XXX O
interferon XXX B-GENE
regulatory XXX I-GENE
factor XXX I-GENE
( XXX O
IRF XXX B-GENE
) XXX O
family XXX O
. XXX O

The XXX O
constraints XXX O
of XXX O
primase XXX B-GENE
recognition XXX I-GENE
sequences XXX I-GENE
, XXX O
nucleotide XXX O
substrate XXX O
requirements XXX O
, XXX O
and XXX O
the XXX O
effects XXX O
of XXX O
additional XXX O
proteins XXX O
on XXX O
oligoribonucleotide XXX O
synthesis XXX O
by XXX O
the XXX O
63-kDa XXX B-GENE
gene XXX I-GENE
4 XXX I-GENE
protein XXX I-GENE
have XXX O
been XXX O
examined XXX O
using XXX O
templates XXX O
of XXX O
defined XXX O
sequence XXX O
. XXX O

Resting XXX O
VE XXX O
in XXX O
the XXX O
luteal XXX O
phase XXX O
was XXX O
7 XXX O
. XXX O
8% XXX O
greater XXX O
than XXX O
that XXX O
in XXX O
the XXX O
follicular XXX O
phase XXX O
. XXX O

However XXX O
, XXX O
its XXX O
participation XXX O
in XXX O
gagging XXX O
induced XXX O
by XXX O
oropharyngeal XXX O
irritation XXX O
is XXX O
unclear XXX O
. XXX O

Experience XXX O
with XXX O
xylene-free XXX O
sections XXX O
since XXX O
1995 XXX O
at XXX O
the XXX O
Vrinnevi XXX O
Hospital XXX O
is XXX O
favorable XXX O
. XXX O

Among XXX O
the XXX O
total XXX O
CDSs XXX O
, XXX O
8 XXX O
. XXX O
8% XXX O
match XXX O
sequences XXX O
of XXX O
proteins XXX O
found XXX O
only XXX O
in XXX O
Bacillus XXX O
subtilis XXX O
and XXX O
66 XXX O
. XXX O
7% XXX O
are XXX O
widely XXX O
conserved XXX O
in XXX O
comparison XXX O
with XXX O
the XXX O
proteins XXX O
of XXX O
various XXX O
organisms XXX O
, XXX O
including XXX O
B XXX O
. XXX O
subtilis XXX O
. XXX O

The XXX O
effects XXX O
of XXX O
these XXX O
mutations XXX O
on XXX O
protein XXX O
function XXX O
require XXX O
further XXX O
examination XXX O
. XXX O

USA XXX O
80 XXX O
, XXX O
802-806 XXX O
] XXX O
was XXX O
used XXX O
to XXX O
isolate XXX O
a XXX O
genomic XXX O
clone XXX O
lambda XXX O
PGK-1 XXX B-GENE
containing XXX O
a XXX O
portion XXX O
of XXX O
an XXX O
autosomal XXX O
locus XXX O
for XXX O
phosphoglycerate XXX B-GENE
kinase XXX I-GENE
( XXX O
PGK XXX B-GENE
) XXX O
. XXX O

Changes XXX O
in XXX O
xanthine XXX B-GENE
oxidase XXX I-GENE
activity XXX O
in XXX O
patients XXX O
with XXX O
circulatory XXX O
failure XXX O
. XXX O

Consistent XXX O
with XXX O
these XXX O
findings XXX O
, XXX O
relatively XXX O
weak XXX O
transcriptional XXX O
silencing XXX O
by XXX O
the XXX O
native XXX O
VDR XXX B-GENE
was XXX O
observed XXX O
using XXX O
the XXX O
osteopontin XXX B-GENE
VDRE XXX B-GENE
. XXX O

HER2 XXX B-GENE
overexpressing XXX O
cells XXX O
showed XXX O
a XXX O
single XXX O
prominent XXX O
DNase XXX B-GENE
I XXX I-GENE
hypersensitive XXX O
site XXX O
near XXX O
a XXX O
conserved XXX O
and XXX O
hitherto XXX O
unrecognized XXX O
ets XXX B-GENE
response XXX I-GENE
element XXX I-GENE
( XXX O
GAGGAA XXX B-GENE
) XXX O
, XXX O
located XXX O
38 XXX O
bases XXX O
down-stream XXX O
from XXX O
the XXX O
CAAT XXX O
box XXX O
and XXX O
directly XXX O
5' XXX O
of XXX O
the XXX O
TATA XXX O
box XXX O
in XXX O
the XXX O
human XXX B-GENE
HER2 XXX I-GENE
promoter XXX I-GENE
. XXX O

Most XXX O
patients XXX O
with XXX O
high XXX O
blood XXX O
pressure XXX O
( XXX O
BP XXX O
) XXX O
can XXX O
be XXX O
managed XXX O
by XXX O
using XXX O
one XXX O
of XXX O
4 XXX O
classes XXX O
of XXX O
compounds XXX O
: XXX O
a XXX O
diuretic XXX O
, XXX O
beta XXX O
blocker XXX O
, XXX O
converting XXX O
enzyme XXX O
inhibitor XXX O
or XXX O
calcium XXX O
antagonist XXX O
. XXX O

A XXX O
neonatal XXX O
alloimmune XXX O
thrombocytopenia XXX O
with XXX O
an XXX O
HPA-3a XXX O
( XXX O
Baka XXX O
) XXX O
incompatibility XXX O
was XXX O
confirmed XXX O
. XXX O

Of XXX O
the XXX O
153 XXX O
patients XXX O
studied XXX O
, XXX O
CK-MB XXX B-GENE
results XXX O
were XXX O
positive XXX O
in XXX O
91 XXX O
( XXX O
59% XXX O
) XXX O
patients XXX O
; XXX O
ECG XXX O
revealed XXX O
AMI XXX O
in XXX O
72 XXX O
( XXX O
47% XXX O
) XXX O
patients XXX O
. XXX O

Cardiovascular XXX O
risk XXX O
factors XXX O
were XXX O
measured XXX O
by XXX O
standardized XXX O
techniques XXX O
. XXX O

Such XXX O
studied XXX O
acquired XXX O
with XXX O
low XXX O
energy XXX O
or XXX O
medium XXX O
energy XXX O
collimation XXX O
and XXX O
a XXX O
window XXX O
centered XXX O
on XXX O
the XXX O
159 XXX O
keV XXX O
123I XXX O
photopeak XXX O
contain XXX O
appreciable XXX O
septal XXX O
breakthrough XXX O
signals XXX O
originating XXX O
from XXX O
Compton XXX O
scatter XXX O
of XXX O
high XXX O
energy XXX O
photons XXX O
primarily XXX O
from XXX O
124I XXX O
. XXX O

Structural XXX O
and XXX O
evolutionary XXX O
studies XXX O
on XXX O
sterol XXX B-GENE
14-demethylase XXX I-GENE
P450 XXX I-GENE
( XXX O
CYP51 XXX B-GENE
) XXX O
, XXX O
the XXX O
most XXX O
conserved XXX O
P450 XXX B-GENE
monooxygenase XXX I-GENE
: XXX O
I XXX O
. XXX O

Bites XXX O
by XXX O
two XXX O
species XXX O
of XXX O
adders XXX O
( XXX O
Vipera XXX O
aspis XXX O
and XXX O
Vipera XXX O
berus XXX O
) XXX O
can XXX O
lead XXX O
to XXX O
extensive XXX O
swelling XXX O
with XXX O
multiorgan XXX O
failure XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
the XXX O
overall XXX O
chance XXX O
that XXX O
a XXX O
patient XXX O
would XXX O
undergo XXX O
ET XXX O
was XXX O
greater XXX O
in XXX O
a XXX O
cycle XXX O
in XXX O
which XXX O
more XXX O
than XXX O
one XXX O
follicle XXX O
20 XXX O
mm XXX O
or XXX O
larger XXX O
was XXX O
developing XXX O
than XXX O
in XXX O
a XXX O
cycle XXX O
in XXX O
which XXX O
a XXX O
single XXX O
large XXX O
follicle XXX O
was XXX O
developing XXX O
. XXX O

The XXX O
87K XXX O
protein XXX O
, XXX O
together XXX O
with XXX O
proteins XXX O
of XXX O
105 XXX O
, XXX O
000 XXX O
and XXX O
75 XXX O
, XXX O
000 XXX O
daltons XXX O
, XXX O
are XXX O
translated XXX O
from XXX O
leftward XXX O
transcribed XXX O
( XXX O
1-strand XXX O
) XXX O
messenger XXX O
RNAs XXX O
that XXX O
are XXX O
complementary XXX O
to XXX O
the XXX O
viral XXX O
genome XXX O
between XXX O
positions XXX O
11 XXX O
. XXX O
2 XXX O
and XXX O
31 XXX O
. XXX O
5 XXX O
. XXX O

However XXX O
, XXX O
the XXX O
abi1-1 XXX B-GENE
gene XXX I-GENE
product XXX I-GENE
has XXX O
no XXX O
effect XXX O
on XXX O
the XXX O
ABA XXX O
suppression XXX O
of XXX O
a XXX O
GA-responsive XXX O
alpha-amylase XXX B-GENE
gene XXX I-GENE
. XXX O

The XXX O
selective XXX O
alteration XXX O
of XXX O
the XXX O
genome XXX O
using XXX O
Cre XXX B-GENE
recombinase XXX I-GENE
to XXX O
target XXX O
the XXX O
rearrangement XXX O
of XXX O
genes XXX O
flanked XXX O
by XXX O
LOX XXX B-GENE
recognition XXX I-GENE
sequences XXX I-GENE
has XXX O
required XXX O
the XXX O
use XXX O
of XXX O
two XXX O
separate XXX O
genetic XXX O
constructs XXX O
in XXX O
trans XXX O
, XXX O
one XXX O
containing XXX O
cre XXX B-GENE
and XXX O
the XXX O
other XXX O
containing XXX O
the XXX O
gene XXX O
of XXX O
interest XXX O
flanked XXX O
by XXX O
LOX XXX B-GENE
sites XXX I-GENE
. XXX O

Since XXX O
the XXX O
regulation XXX O
of XXX O
SWI4 XXX B-GENE
is XXX O
required XXX O
for XXX O
normal XXX O
cell XXX O
cycle XXX O
progression XXX O
, XXX O
we XXX O
have XXX O
characterized XXX O
cis- XXX O
and XXX O
trans-acting XXX O
regulators XXX O
of XXX O
SWI4 XXX B-GENE
transcription XXX O
. XXX O

Which XXX O
cineangiographically XXX O
assessed XXX O
anatomic XXX O
variable XXX O
correlates XXX O
best XXX O
with XXX O
functional XXX O
measurements XXX O
of XXX O
stenosis XXX O
severity XXX O
? XXX O
A XXX O
comparison XXX O
of XXX O
quantitative XXX O
analysis XXX O
of XXX O
the XXX O
coronary XXX O
cineangiogram XXX O
with XXX O
measured XXX O
coronary XXX O
flow XXX O
reserve XXX O
and XXX O
exercise XXX O
/ XXX O
redistribution XXX O
thallium-201 XXX O
scintigraphy XXX O
. XXX O

The XXX O
third XXX O
ORF XXX O
generates XXX O
a XXX O
transcript XXX O
of XXX O
1 XXX O
. XXX O
6 XXX O
kb XXX O
and XXX O
encodes XXX O
a XXX O
protein XXX O
of XXX O
382 XXX O
residues XXX O
including XXX O
a XXX O
perfect XXX O
match XXX O
to XXX O
the XXX O
consensus XXX O
sequence XXX O
of XXX O
a XXX O
C2H2 XXX B-GENE
zinc XXX I-GENE
finger XXX I-GENE
domain XXX I-GENE
; XXX O
it XXX O
shares XXX O
a XXX O
strong XXX O
homology XXX O
with XXX O
yeast XXX B-GENE
Mig1p XXX I-GENE
and XXX O
Cre-A XXX B-GENE
from XXX I-GENE
Aspergillus XXX I-GENE
, XXX I-GENE
Emericella XXX I-GENE
and XXX I-GENE
E XXX I-GENE
. XXX I-GENE
coli XXX I-GENE
. XXX O

Parasitological XXX O
and XXX O
pathological XXX O
findings XXX O
in XXX O
capuchin XXX O
monkeys XXX O
infected XXX O
with XXX O
Schistosoma XXX O
japonicum XXX O
or XXX O
Schistosoma XXX O
mansoni XXX O
. XXX O

To XXX O
test XXX O
whether XXX O
Sp1 XXX B-GENE
and XXX O
zif268 XXX B-GENE
/ XXX I-GENE
egr-1 XXX I-GENE
interact XXX O
with XXX O
this XXX O
motif XXX O
, XXX O
gel XXX O
retardation XXX O
assays XXX O
were XXX O
performed XXX O
. XXX O

The XXX O
multiple XXX O
functions XXX O
of XXX O
Pmt3p XXX B-GENE
described XXX O
here XXX O
suggest XXX O
that XXX O
several XXX O
nuclear XXX O
proteins XXX O
are XXX O
regulated XXX O
by XXX O
Pmt3p XXX B-GENE
conjugation XXX O
. XXX O

The XXX O
relationships XXX O
among XXX O
four XXX O
descriptors XXX O
of XXX O
lactate XXX O
increase XXX O
: XXX O
lactate XXX O
threshold XXX O
( XXX O
LT XXX O
) XXX O
( XXX O
the XXX O
VO2 XXX O
at XXX O
which XXX O
blood XXX O
lactate XXX O
concentration XXX O
begins XXX O
to XXX O
increase XXX O
above XXX O
the XXX O
resting XXX O
level XXX O
during XXX O
an XXX O
incremental XXX O
exercise XXX O
test XXX O
) XXX O
, XXX O
LT1 XXX O
( XXX O
the XXX O
VO2 XXX O
at XXX O
which XXX O
blood XXX O
lactate XXX O
increases XXX O
1 XXX O
mM XXX O
above XXX O
the XXX O
resting XXX O
level XXX O
) XXX O
, XXX O
LT2 XXX O
( XXX O
the XXX O
VO2 XXX O
at XXX O
which XXX O
blood XXX O
lactate XXX O
concentration XXX O
reaches XXX O
a XXX O
fixed XXX O
value XXX O
of XXX O
2 XXX O
mM XXX O
) XXX O
, XXX O
onset XXX O
of XXX O
blood XXX O
lactate XXX O
accumulation XXX O
( XXX O
OBLA XXX O
; XXX O
the XXX O
VO2 XXX O
at XXX O
which XXX O
blood XXX O
lactate XXX O
reaches XXX O
a XXX O
concentration XXX O
of XXX O
4 XXX O
mM XXX O
) XXX O
, XXX O
were XXX O
compared XXX O
with XXX O
aerobic XXX O
capacity XXX O
( XXX O
VO2max XXX O
) XXX O
and XXX O
12 XXX O
min XXX O
running XXX O
performance XXX O
in XXX O
19 XXX O
untrained XXX O
female XXX O
students XXX O
. XXX O

The XXX O
protein XXX O
encoded XXX O
is XXX O
114 XXX O
kDa XXX O
and XXX O
contains XXX O
eight XXX O
zinc XXX O
finger XXX O
motifs XXX O
, XXX O
seven XXX O
of XXX O
which XXX O
are XXX O
present XXX O
in XXX O
two XXX O
clusters XXX O
at XXX O
opposite XXX O
ends XXX O
of XXX O
the XXX O
molecule XXX O
. XXX O

INTERPRETATION XXX O
: XXX O
It XXX O
is XXX O
probable XXX O
that XXX O
the XXX O
cognitive XXX O
dissonance XXX O
created XXX O
by XXX O
more XXX O
health XXX O
information XXX O
on XXX O
smoking XXX O
after XXX O
1964 XXX O
, XXX O
i XXX O
. XXX O
e XXX O
. XXX O
the XXX O
necessary XXX O
motivation XXX O
to XXX O
quit XXX O
, XXX O
was XXX O
reduced XXX O
as XXX O
a XXX O
result XXX O
of XXX O
strategic XXX O
changes XXX O
in XXX O
the XXX O
amount XXX O
and XXX O
content XXX O
of XXX O
advertising XXX O
. XXX O

A XXX O
novel XXX O
potential XXX O
effector XXX O
of XXX O
M-Ras XXX B-GENE
and XXX O
p21 XXX B-GENE
Ras XXX I-GENE
negatively XXX O
regulates XXX O
p21 XXX B-GENE
Ras-mediated XXX O
gene XXX O
induction XXX O
and XXX O
cell XXX O
growth XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
in XXX O
vitro XXX O
mutagenesis XXX O
of XXX O
both XXX O
Engrailed XXX B-GENE
and XXX O
Pbx1 XXX B-GENE
sites XXX I-GENE
indicated XXX O
that XXX O
other XXX O
unidentified XXX O
sites XXX O
are XXX O
responsible XXX O
for XXX O
the XXX O
transcriptional XXX O
enhancement XXX O
observed XXX O
with XXX O
the XXX O
intronic XXX O
fragment XXX O
. XXX O

On XXX O
admission XXX O
to XXX O
the XXX O
ICU XXX O
, XXX O
117 XXX O
patients XXX O
( XXX O
61 XXX O
percent XXX O
) XXX O
had XXX O
hypomagnesemia XXX O
( XXX O
serum XXX O
Mg XXX O
less XXX O
than XXX O
1 XXX O
. XXX O
5 XXX O
mEq XXX O
/ XXX O
dl XXX O
) XXX O
, XXX O
66 XXX O
patients XXX O
( XXX O
34 XXX O
percent XXX O
) XXX O
had XXX O
normomagnesemia XXX O
( XXX O
1 XXX O
. XXX O
5 XXX O
to XXX O
2 XXX O
. XXX O
0 XXX O
mEq XXX O
/ XXX O
dl XXX O
) XXX O
, XXX O
and XXX O
ten XXX O
patients XXX O
( XXX O
5 XXX O
percent XXX O
) XXX O
had XXX O
hypermagnesemia XXX O
( XXX O
greater XXX O
than XXX O
2 XXX O
. XXX O
0 XXX O
mEq XXX O
/ XXX O
dl XXX O
) XXX O
. XXX O

With XXX O
aging XXX O
, XXX O
many XXX O
aspects XXX O
of XXX O
immune XXX O
function XXX O
change XXX O
. XXX O

In XXX O
the XXX O
base-case XXX O
analysis XXX O
, XXX O
total XXX O
direct XXX O
costs XXX O
per XXX O
patient XXX O
were XXX O
$728 XXX O
for XXX O
zoledronic XXX O
acid XXX O
and XXX O
$776 XXX O
for XXX O
pamidronate XXX O
. XXX O

The XXX O
splice XXX O
acceptor XXX O
site XXX O
is XXX O
ca XXX O
. XXX O

In XXX O
the XXX O
first XXX O
series XXX O
of XXX O
experiments XXX O
, XXX O
Sprague-Dawley XXX O
male XXX O
rats XXX O
were XXX O
implanted XXX O
unilaterally XXX O
with XXX O
guide XXX O
cannulas XXX O
aimed XXX O
at XXX O
the XXX O
lateral XXX O
ventricle XXX O
. XXX O

Double-blind XXX O
randomised XXX O
trial XXX O
of XXX O
intravenous XXX O
tissue-type XXX B-GENE
plasminogen XXX I-GENE
activator XXX I-GENE
versus XXX O
placebo XXX O
in XXX O
acute XXX O
myocardial XXX O
infarction XXX O
. XXX O

Up XXX O
to XXX O
now XXX O
the XXX O
number XXX O
of XXX O
patients XXX O
examined XXX O
is XXX O
about XXX O
300 XXX O
, XXX O
additionally XXX O
6 XXX O
persons XXX O
who XXX O
underwent XXX O
binephrectomy XXX O
. XXX O

An XXX O
aromatic XXX O
stacking XXX O
interaction XXX O
between XXX O
subunits XXX O
helps XXX O
mediate XXX O
DNA XXX O
sequence XXX O
specificity XXX O
: XXX O
operator XXX O
site XXX O
discrimination XXX O
by XXX O
phage XXX B-GENE
lambda XXX I-GENE
cI XXX I-GENE
repressor XXX I-GENE
. XXX O

Furthermore XXX O
, XXX O
the XXX O
identification XXX O
of XXX O
a XXX O
Dr1-like XXX B-GENE
protein XXX I-GENE
in XXX O
A XXX O
. XXX O
thaliana XXX O
strongly XXX O
argues XXX O
for XXX O
the XXX O
ubiquity XXX O
of XXX O
this XXX O
protein XXX O
among XXX O
eukaryotic XXX O
genera XXX O
and XXX O
for XXX O
a XXX O
conserved XXX O
mechanism XXX O
to XXX O
regulate XXX O
transcription XXX O
initiation XXX O
that XXX O
involves XXX O
Dr1 XXX B-GENE
. XXX O

According XXX O
to XXX O
pilot XXX O
experiments XXX O
which XXX O
considered XXX O
various XXX O
durations XXX O
of XXX O
global XXX O
no-flow XXX O
ischemia XXX O
ranging XXX O
from XXX O
10 XXX O
to XXX O
20 XXX O
minutes XXX O
, XXX O
two XXX O
durations XXX O
were XXX O
chosen XXX O
for XXX O
the XXX O
present XXX O
study XXX O
: XXX O
20 XXX O
minutes XXX O
( XXX O
group XXX O
20 XXX O
) XXX O
in XXX O
which XXX O
ventricular XXX O
fibrillation XXX O
( XXX O
VF XXX O
) XXX O
was XXX O
the XXX O
predominant XXX O
form XXX O
of XXX O
arrhythmias XXX O
, XXX O
and XXX O
18 XXX O
minutes XXX O
( XXX O
group XXX O
18 XXX O
) XXX O
in XXX O
which XXX O
the XXX O
prevalence XXX O
of XXX O
VF XXX O
was XXX O
markedly XXX O
lower XXX O
despite XXX O
the XXX O
small XXX O
difference XXX O
in XXX O
the XXX O
duration XXX O
of XXX O
ischemia XXX O
. XXX O

The XXX O
nonconsensus XXX O
TATA XXX O
box XXX O
in XXX O
promoter XXX B-GENE
B XXX I-GENE
plays XXX O
a XXX O
more XXX O
important XXX O
role XXX O
in XXX O
promoter XXX O
activity XXX O
than XXX O
the XXX O
TATA XXX O
box XXX O
in XXX O
promoter XXX B-GENE
A XXX I-GENE
. XXX O

High-resolution XXX O
computed XXX O
tomography XXX O
in XXX O
the XXX O
diagnosis XXX O
of XXX O
miliary XXX O
tuberculosis XXX O
. XXX O

State-approved XXX O
schools XXX O
of XXX O
nursing--R XXX O
. XXX O
Z XXX O
. XXX O
, XXX O
1972 XXX O
. XXX O

The XXX O
discussion XXX O
focuses XXX O
primarily XXX O
on XXX O
the XXX O
newer XXX O
drugs XXX O
like XXX O
angiotensin XXX B-GENE
converting XXX I-GENE
enzyme XXX I-GENE
inhibitors XXX O
, XXX O
alpha-adrenergic XXX B-GENE
receptor XXX I-GENE
blockers XXX O
, XXX O
and XXX O
calcium XXX O
antagonists XXX O
. XXX O

Based XXX O
on XXX O
our XXX O
observations XXX O
, XXX O
we XXX O
propose XXX O
a XXX O
model XXX O
whereby XXX O
inactive XXX O
precursor XXX O
molecules XXX O
produced XXX O
from XXX O
the XXX O
PEP4 XXX B-GENE
gene XXX I-GENE
self-activate XXX O
within XXX O
the XXX O
yeast XXX O
vacuole XXX O
and XXX O
subsequently XXX O
activate XXX O
other XXX O
vacuolar XXX O
hydrolases XXX O
. XXX O

In XXX O
this XXX O
respect XXX O
C XXX B-GENE
reactive XXX I-GENE
protein XXX I-GENE
concentrations XXX O
are XXX O
superior XXX O
to XXX O
white XXX O
cell XXX O
count XXX O
, XXX O
erythrocyte XXX O
sedimentation XXX O
rate XXX O
, XXX O
and XXX O
temperature XXX O
and XXX O
the XXX O
concentrations XXX O
of XXX O
antiproteases XXX O
. XXX O

During XXX O
both XXX O
encephalopathy XXX O
episodes XXX O
, XXX O
CSF XXX O
protein XXX O
and XXX O
immunoglobulin XXX B-GENE
G XXX I-GENE
( XXX O
IgG XXX B-GENE
) XXX O
levels XXX O
were XXX O
elevated XXX O
without XXX O
an XXX O
increased XXX O
IgG XXX B-GENE
index XXX O
or XXX O
IgG XXX B-GENE
synthesis XXX O
rate XXX O
. XXX O

Bulbar XXX O
pouches XXX O
were XXX O
perfused XXX O
with XXX O
solutions XXX O
of XXX O
0 XXX O
. XXX O
9% XXX O
Na XXX O
C1 XXX O
, XXX O
0 XXX O
. XXX O
1 XXX O
N XXX O
HC1 XXX O
, XXX O
40% XXX O
glucose XXX O
, XXX O
40% XXX O
NaC1 XXX O
, XXX O
and XXX O
40% XXX O
peptone XXX O
or XXX O
with XXX O
0 XXX O
. XXX O
1% XXX O
solutions XXX O
of XXX O
acetylcholine XXX O
chloride XXX O
. XXX O

Recurrent XXX O
G-to-A XXX O
substitution XXX O
in XXX O
a XXX O
single XXX O
codon XXX O
of XXX O
SREBP XXX B-GENE
cleavage-activating XXX I-GENE
protein XXX I-GENE
causes XXX O
sterol XXX O
resistance XXX O
in XXX O
three XXX O
mutant XXX O
Chinese XXX O
hamster XXX O
ovary XXX O
cell XXX O
lines XXX O
. XXX O

Insulin-stimulated XXX O
glucose XXX O
transport XXX O
in XXX O
adipocytes XXX O
is XXX O
mediated XXX O
by XXX O
the XXX O
insulin XXX B-GENE
receptor XXX I-GENE
. XXX O

Veterinary XXX O
certification XXX O
for XXX O
livestock XXX O
export XXX O
. XXX O

A XXX O
0 XXX O
. XXX O
5 XXX O
rating XXX O
was XXX O
intended XXX O
to XXX O
characterize XXX O
subjects XXX O
in XXX O
whom XXX O
mild XXX O
cognitive XXX O
impairment XXX O
due XXX O
to XXX O
senile XXX O
dementia XXX O
of XXX O
the XXX O
Alzheimer XXX O
type XXX O
was XXX O
suspected XXX O
but XXX O
was XXX O
insufficient XXX O
in XXX O
degree XXX O
to XXX O
warrant XXX O
a XXX O
diagnosis XXX O
of XXX O
definite XXX O
dementia XXX O
. XXX O

Selenium XXX O
( XXX O
. XXX O
1 XXX O
ppm XXX O
) XXX O
and XXX O
E XXX O
( XXX O
50 XXX O
IU XXX O
/ XXX O
kg XXX O
) XXX O
supplementation XXX O
of XXX O
the XXX O
diet XXX O
of XXX O
the XXX O
sow XXX O
increased XXX O
plasma XXX O
tocopherol XXX O
and XXX O
Se XXX O
concentrations XXX O
, XXX O
but XXX O
did XXX O
not XXX O
increase XXX O
plasma XXX B-GENE
glutathione XXX I-GENE
peroxidase XXX I-GENE
( XXX O
GSH-Px XXX B-GENE
) XXX O
activity XXX O
. XXX O

A XXX O
group XXX O
of XXX O
66 XXX O
DSM-IV XXX O
paranoid XXX O
schizophrenic XXX O
in-patients XXX O
were XXX O
assessed XXX O
three XXX O
times XXX O
using XXX O
the XXX O
SAPS XXX O
, XXX O
SANS XXX O
, XXX O
BPRS XXX O
and XXX O
PAS XXX O
. XXX O

The XXX O
interaction XXX O
of XXX O
radiation XXX O
and XXX O
hyperthermia XXX O
was XXX O
systematically XXX O
studied XXX O
in XXX O
the XXX O
Dunning XXX O
R3327G XXX O
prostatic XXX O
adenocarcinoma XXX O
, XXX O
the XXX O
preeminent XXX O
animal XXX O
model XXX O
for XXX O
human XXX O
prostatic XXX O
cancer XXX O
. XXX O

Failure XXX O
of XXX O
stapedius XXX O
reflexometry XXX O
in XXX O
the XXX O
diagnosis XXX O
of XXX O
myasthenia XXX O
gravis XXX O
. XXX O

As XXX O
an XXX O
initial XXX O
step XXX O
towards XXX O
the XXX O
characterization XXX O
of XXX O
replicative XXX O
DNA XXX B-GENE
polymerases XXX I-GENE
of XXX I-GENE
trypanosomes XXX I-GENE
, XXX O
we XXX O
have XXX O
cloned XXX O
, XXX O
sequenced XXX O
and XXX O
examined XXX O
the XXX O
expression XXX O
of XXX O
the XXX O
Trypanosoma XXX O
( XXX O
Trypanozoon XXX O
) XXX O
brucei XXX O
brucei XXX O
gene XXX O
that XXX O
encodes XXX O
the XXX O
DNA XXX B-GENE
polymerase XXX I-GENE
alpha XXX I-GENE
catalytic XXX I-GENE
core XXX I-GENE
( XXX O
pol XXX B-GENE
alpha XXX I-GENE
) XXX O
. XXX O

Encapsidation XXX O
of XXX O
poliovirus XXX O
replicons XXX O
encoding XXX O
the XXX O
complete XXX O
human XXX B-GENE
immunodeficiency XXX I-GENE
virus XXX I-GENE
type XXX I-GENE
1 XXX I-GENE
gag XXX I-GENE
gene XXX I-GENE
by XXX O
using XXX O
a XXX O
complementation XXX O
system XXX O
which XXX O
provides XXX O
the XXX O
P1 XXX B-GENE
capsid XXX I-GENE
protein XXX I-GENE
in XXX O
trans XXX O
. XXX O

The XXX O
micromethod XXX O
uses XXX O
microcuvettes XXX O
and XXX O
substitutes XXX O
ferrozine XXX O
for XXX O
the XXX O
bathophenanthroline XXX O
chromogen XXX O
of XXX O
the XXX O
ICSH XXX O
. XXX O

Beg2 XXX B-GENE
and XXX O
Beg1 XXX B-GENE
are XXX O
regulated XXX O
differently XXX O
which XXX O
may XXX O
indicate XXX O
variation XXX O
in XXX O
storage XXX O
or XXX O
utilization XXX O
properties XXX O
among XXX O
the XXX O
barley XXX B-GENE
globulins XXX I-GENE
. XXX O

An XXX O
abnormally XXX O
high XXX O
percentage XXX O
of XXX O
hypertensive XXX O
patients XXX O
( XXX O
approximately XXX O
30% XXX O
) XXX O
undergoing XXX O
cardiac XXX O
catheterization XXX O
because XXX O
of XXX O
anginal XXX O
pain XXX O
and XXX O
/ XXX O
or XXX O
exercise-induced XXX O
ST-segment XXX O
depressions XXX O
has XXX O
angiographically XXX O
normal XXX O
coronary XXX O
arteries XXX O
. XXX O

The XXX O
mature XXX O
protein XXX O
also XXX O
contains XXX O
a XXX O
cysteine-rich XXX O
, XXX O
highly XXX O
hydrophilic XXX O
region XXX O
homologous XXX O
to XXX O
the XXX O
ovomucoid XXX B-GENE
serine XXX I-GENE
protease XXX I-GENE
inhibitors XXX I-GENE
( XXX O
residues XXX O
76-132 XXX O
) XXX O
. XXX O

Severe XXX O
hemolysis XXX O
resulted XXX O
in XXX O
statistically XXX O
significant XXX O
changes XXX O
in XXX O
the XXX O
mean XXX O
values XXX O
of XXX O
the XXX O
above XXX O
analytes XXX O
in XXX O
addition XXX O
to XXX O
the XXX O
following XXX O
increases XXX O
: XXX O
alanine XXX B-GENE
aminotransferase XXX I-GENE
, XXX O
calcium XXX O
, XXX O
and XXX O
serum XXX B-GENE
globulins XXX I-GENE
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
001 XXX O
) XXX O
and XXX O
albumin XXX B-GENE
and XXX O
total XXX O
protein XXX O
( XXX O
P XXX O
< XXX O
0 XXX O
. XXX O
01 XXX O
) XXX O
. XXX O

Oncostatin XXX B-GENE
M XXX I-GENE
stimulates XXX O
c-Fos XXX B-GENE
to XXX O
bind XXX O
a XXX O
transcriptionally XXX O
responsive XXX O
AP-1 XXX B-GENE
element XXX I-GENE
within XXX O
the XXX O
tissue XXX B-GENE
inhibitor XXX I-GENE
of XXX I-GENE
metalloproteinase-1 XXX I-GENE
promoter XXX I-GENE
. XXX O

Diclofenac XXX O
sodium-chlormezanone XXX O
poisoning XXX O
. XXX O

If XXX O
you XXX O
think XXX O
education XXX O
is XXX O
expensive--try XXX O
ignorance--Bok's XXX O
Law XXX O
. XXX O

Alternatively XXX O
, XXX O
PC12-E2 XXX O
cells XXX O
were XXX O
submitted XXX O
to XXX O
treatment XXX O
with XXX O
antibodies XXX O
to XXX O
the XXX O
fibroblast XXX B-GENE
growth XXX I-GENE
factor XXX I-GENE
( XXX I-GENE
FGF XXX I-GENE
) XXX I-GENE
receptor XXX I-GENE
, XXX O
inhibitors XXX O
of XXX O
the XXX O
nonreceptor XXX B-GENE
tyrosine XXX I-GENE
kinase XXX I-GENE
p59 XXX B-GENE
( XXX I-GENE
fyn XXX I-GENE
) XXX O
, XXX O
PLC XXX B-GENE
, XXX O
PKC XXX B-GENE
and XXX O
MEK XXX B-GENE
and XXX O
an XXX O
activator XXX O
of XXX O
PKC XXX B-GENE
, XXX O
phorbol-12-myristate-13-acetate XXX O
( XXX O
PMA XXX O
) XXX O
. XXX O

However XXX O
, XXX O
experiments XXX O
with XXX O
S1 XXX B-GENE
mapping XXX O
of XXX O
in XXX O
vivo XXX O
transcripts XXX O
, XXX O
gene XXX O
disruptions XXX O
in XXX O
the XXX O
alpha XXX O
region XXX O
, XXX O
and XXX O
a XXX O
single-copy XXX O
transcriptional XXX O
fusion XXX O
vector XXX O
all XXX O
suggested XXX O
that XXX O
these XXX O
possible XXX O
promoters XXX O
were XXX O
largely XXX O
inactive XXX O
during XXX O
logarithmic XXX O
growth XXX O
, XXX O
that XXX O
the XXX O
major XXX O
promoter XXX O
for XXX O
the XXX O
alpha XXX B-GENE
operon XXX I-GENE
lay XXX O
upstream XXX O
from XXX O
the XXX O
region XXX O
cloned XXX O
, XXX O
and XXX O
that XXX O
the XXX O
genes XXX O
in XXX O
the XXX O
IF1 XXX B-GENE
to XXX O
L17 XXX B-GENE
interval XXX O
were XXX O
cotranscribed XXX O
. XXX O

A XXX O
method XXX O
for XXX O
determining XXX O
cumulative XXX O
behavioral XXX O
toxicity XXX O
after XXX O
chronic XXX O
oral XXX O
administration XXX O
of XXX O
l-alpha-acetylmethadol XXX O
to XXX O
female XXX O
rats XXX O
. XXX O

Mapping XXX O
of XXX O
intracellular XXX O
localization XXX O
domains XXX O
and XXX O
evidence XXX O
for XXX O
colocalization XXX O
interactions XXX O
between XXX O
the XXX O
IE110 XXX B-GENE
and XXX O
IE175 XXX B-GENE
nuclear XXX O
transactivator XXX O
proteins XXX O
of XXX O
herpes XXX O
simplex XXX O
virus XXX O
. XXX O

However XXX O
, XXX O
the XXX O
same XXX O
U1A XXX B-GENE
peptide XXX I-GENE
, XXX O
when XXX O
conjugated XXX O
to XXX O
BSA XXX B-GENE
, XXX O
inhibits XXX O
vertebrate XXX B-GENE
PAP XXX I-GENE
. XXX O

Lymphocyte XXX O
subpopulations XXX O
, XXX O
serum XXX B-GENE
IgE XXX I-GENE
and XXX O
total XXX O
eosinophil XXX O
counts XXX O
in XXX O
patients XXX O
with XXX O
bronchial XXX O
asthma XXX O
. XXX O

Respiratory XXX O
chain XXX O
enzyme XXX O
activity XXX O
was XXX O
normal XXX O
. XXX O

The XXX O
small XXX O
copepod XXX O
Pseudonychocamptus XXX O
proximus XXX O
progressively XXX O
replaced XXX O
the XXX O
large XXX O
Tisbe XXX O
furcata XXX O
in XXX O
sand XXX O
filters XXX O
during XXX O
the XXX O
fall XXX O
of XXX O
1995 XXX O
and XXX O
was XXX O
responsible XXX O
for XXX O
the XXX O
large XXX O
increase XXX O
in XXX O
meiofaunal XXX O
biomass XXX O
observed XXX O
after XXX O
spring XXX O
1996 XXX O
. XXX O

An XXX O
undilated XXX O
type XXX O
of XXX O
APBD XXX O
is XXX O
frequently XXX O
associated XXX O
with XXX O
AMT XXX O
and XXX O
we XXX O
believe XXX O
, XXX O
therefore XXX O
, XXX O
that XXX O
clinicians XXX O
should XXX O
be XXX O
aware XXX O
of XXX O
a XXX O
possible XXX O
coexistence XXX O
of XXX O
APBD XXX O
and XXX O
AMT XXX O
. XXX O

Cotransfection XXX O
of XXX O
the XXX O
helicase-primase XXX B-GENE
proteins XXX I-GENE
, XXX O
one XXX O
of XXX O
which XXX O
was XXX O
fused XXX O
to XXX O
a XXX O
heterologous XXX O
activation XXX O
domain XXX O
, XXX O
led XXX O
to XXX O
Zta-dependent XXX O
superactivation XXX O
of XXX O
CAT XXX B-GENE
expression XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
the XXX O
hGCSFR XXX B-GENE
gene XXX I-GENE
was XXX O
chromosomally XXX O
localized XXX O
by XXX O
Southern XXX O
blot XXX O
analysis XXX O
of XXX O
its XXX O
segregation XXX O
pattern XXX O
in XXX O
a XXX O
panel XXX O
of XXX O
rodent-human XXX O
hybrid XXX O
DNAs XXX O
using XXX O
the XXX O
radiolabeled XXX O
cDNA XXX O
probe XXX O
. XXX O

Concurrently XXX O
, XXX O
we XXX O
monitored XXX O
weather XXX O
conditions XXX O
and XXX O
used XXX O
time-activity XXX O
budget XXX O
data XXX O
of XXX O
free-living XXX O
birds XXX O
and XXX O
laboratory XXX O
data XXX O
on XXX O
resting XXX O
metabolic XXX O
rate XXX O
to XXX O
construct XXX O
time-activity XXX O
laboratory XXX O
( XXX O
TAL XXX O
) XXX O
estimates XXX O
of XXX O
daily XXX O
energy XXX O
expenditure XXX O
( XXX O
DEE XXX O
) XXX O
and XXX O
to XXX O
partition XXX O
the XXX O
verdins' XXX O
energy XXX O
budget XXX O
into XXX O
thermoregulatory XXX O
, XXX O
activity XXX O
and XXX O
basal XXX O
components XXX O
. XXX O

The XXX O
DNA XXX O
sequences XXX O
predict XXX O
proteins XXX O
for XXX O
SRP54sc XXX B-GENE
and XXX O
SRP54sp XXX B-GENE
that XXX O
are XXX O
47% XXX O
and XXX O
52% XXX O
identical XXX O
to XXX O
SRP54mam XXX B-GENE
, XXX O
respectively XXX O
. XXX O

The XXX O
proliferation XXX B-GENE
potential XXX I-GENE
protein-related XXX I-GENE
( XXX O
P2P-R XXX B-GENE
) XXX O
gene XXX O
with XXX O
domains XXX O
encoding XXX O
heterogeneous XXX O
nuclear XXX O
ribonucleoprotein XXX O
association XXX O
and XXX O
Rb1 XXX B-GENE
binding XXX O
shows XXX O
repressed XXX O
expression XXX O
during XXX O
terminal XXX O
differentiation XXX O
. XXX O

The XXX O
intracellular XXX O
basic XXX B-GENE
region XXX I-GENE
/ XXX I-GENE
helix-loop-helix XXX I-GENE
( XXX I-GENE
bHLH XXX I-GENE
) XXX I-GENE
dioxin XXX I-GENE
receptor XXX I-GENE
mediates XXX O
signal XXX O
transduction XXX O
by XXX O
dioxin XXX O
( XXX O
2 XXX O
, XXX O
3 XXX O
, XXX O
7 XXX O
, XXX O
8-tetrachlorodibenzo-p-dioxin XXX O
) XXX O
and XXX O
functions XXX O
as XXX O
a XXX O
ligand-activated XXX O
DNA XXX O
binding XXX O
protein XXX O
directly XXX O
interacting XXX O
with XXX O
target XXX O
genes XXX O
by XXX O
binding XXX O
to XXX O
dioxin XXX B-GENE
response XXX I-GENE
elements XXX I-GENE
. XXX O

We XXX O
conclude XXX O
that XXX O
solidification XXX O
could XXX O
occur XXX O
in XXX O
all XXX O
feeds XXX O
containing XXX O
casein XXX B-GENE
and XXX O
that XXX O
alternative XXX O
feeds XXX O
should XXX O
be XXX O
considered XXX O
in XXX O
patients XXX O
with XXX O
increased XXX O
gastric XXX O
acidity XXX O
. XXX O

These XXX O
results XXX O
may XXX O
suggest XXX O
involvement XXX O
of XXX O
peripheral XXX O
enkephalins XXX B-GENE
in XXX O
pain XXX O
modulation XXX O
in XXX O
patients XXX O
with XXX O
episodic XXX O
cluster XXX O
headache XXX O
. XXX O

The XXX O
stimulus XXX O
threshold XXX O
for XXX O
EER XXX O
showed XXX O
a XXX O
less XXX O
individual XXX O
variation XXX O
than XXX O
amplitude XXX O
. XXX O

Overexpression XXX O
of XXX O
mcl-1 XXX B-GENE
is XXX O
sufficient XXX O
to XXX O
protect XXX O
against XXX O
apoptosis XXX O
, XXX O
while XXX O
transfection XXX O
of XXX O
a XXX O
mcl-1 XXX B-GENE
antisense XXX O
plasmid XXX O
causes XXX O
cell XXX O
death XXX O
. XXX O

Preliminary XXX O
experiments XXX O
demonstrated XXX O
that XXX O
it XXX O
was XXX O
possible XXX O
to XXX O
produce XXX O
fasD XXX B-GENE
mutants XXX I-GENE
, XXX O
whose XXX O
products XXX O
remain XXX O
functional XXX O
for XXX O
fimbrial XXX O
export XXX O
and XXX O
assembly XXX O
. XXX O

Porcelain XXX O
to XXX O
dentin XXX B-GENE
bond XXX O
strength XXX O
with XXX O
a XXX O
dentin XXX B-GENE
adhesive XXX O
. XXX O

The XXX O
role XXX O
of XXX O
the XXX O
Vp1 XXX B-GENE
DBD XXX I-GENE
during XXX O
infection XXX O
was XXX O
investigated XXX O
by XXX O
taking XXX O
advantage XXX O
of XXX O
NLS XXX B-GENE
phenotypic XXX O
complementation XXX O
( XXX O
N XXX O
. XXX O

Recently XXX O
we XXX O
have XXX O
performed XXX O
a XXX O
detailed XXX O
analysis XXX O
of XXX O
specific XXX O
neuronal XXX O
populations XXX O
affected XXX O
by XXX O
the XXX O
mutation XXX O
which XXX O
shed XXX O
new XXX O
light XXX O
on XXX O
the XXX O
role XXX O
of XXX O
Krox-20 XXX B-GENE
in XXX O
the XXX O
segmentation XXX O
and XXX O
on XXX O
the XXX O
physiological XXX O
consequences XXX O
of XXX O
its XXX O
inactivation XXX O
. XXX O

Indeed XXX O
, XXX O
ERM XXX B-GENE
and XXX O
c-Jun XXX B-GENE
synergistically XXX O
activated XXX O
the XXX O
EBS-CRE XXX B-GENE
without XXX O
making XXX O
an XXX O
apparent XXX O
ternary XXX O
complex XXX O
. XXX O

Pentazocine XXX O
analgesia XXX O
: XXX O
is XXX O
there XXX O
a XXX O
niche XXX O
for XXX O
Talwin XXX O
Nx XXX O
? XXX O
Pentazocine XXX O
can XXX O
be XXX O
a XXX O
useful XXX O
analgesic XXX O
agent XXX O
for XXX O
the XXX O
management XXX O
of XXX O
acute XXX O
dental XXX O
pain XXX O
. XXX O

Myocardial XXX O
SPET XXX O
imaging XXX O
with XXX O
99Tcm-tetrofosmin XXX O
in XXX O
clinical XXX O
practice XXX O
: XXX O
comparison XXX O
of XXX O
a XXX O
1 XXX O
day XXX O
and XXX O
a XXX O
2 XXX O
day XXX O
imaging XXX O
protocol XXX O
. XXX O

Animals XXX O
received XXX O
a XXX O
dose XXX O
of XXX O
dexamethasone XXX O
( XXX O
10 XXX O
mg XXX O
/ XXX O
kg XXX O
i XXX O
. XXX O
p XXX O
. XXX O
) XXX O
prior XXX O
to XXX O
the XXX O
protein-free XXX O
surfactant XXX O
preparation XXX O
Exosurf XXX O
( XXX O
pure XXX O
phospholipids XXX O
containing XXX O
surfactant XXX O
, XXX O
Wellcome XXX O
GmbH XXX O
, XXX O
Burgwedel XXX O
, XXX O
Germany XXX O
) XXX O
and XXX O
a XXX O
rSP-C XXX O
based XXX O
surfactant XXX O
, XXX O
respectively XXX O
. XXX O

The XXX O
revitalization XXX O
of XXX O
surgery XXX O
for XXX O
Parkinson's XXX O
disease XXX O
( XXX O
PD XXX O
) XXX O
has XXX O
fueled XXX O
discussion XXX O
about XXX O
the XXX O
best XXX O
methodology XXX O
to XXX O
define XXX O
the XXX O
target XXX O
. XXX O

No XXX O
other XXX O
changes XXX O
in XXX O
hematopoietic XXX O
differentiation XXX O
status XXX O
were XXX O
observed XXX O
in XXX O
association XXX O
with XXX O
Id-SCL XXX B-GENE
expression XXX O
. XXX O

Thus XXX O
, XXX O
our XXX O
studies XXX O
define XXX O
Rac XXX B-GENE
/ XXX I-GENE
Cdc42 XXX I-GENE
/ XXX I-GENE
Pak XXX I-GENE
as XXX O
a XXX O
module XXX O
upstream XXX O
of XXX O
Raf-1 XXX B-GENE
during XXX O
its XXX O
activation XXX O
by XXX O
microtubule XXX O
disruption XXX O
. XXX O

RT-PCR XXX O
using XXX O
1 XXX O
. XXX O
D-specific XXX O
primers XXX O
showed XXX O
that XXX O
kidney XXX O
, XXX O
brain XXX O
and XXX O
prostate XXX O
do XXX O
not XXX O
express XXX O
1 XXX O
. XXX O
D XXX O
mRNA XXX O
even XXX O
though XXX O
kidney XXX O
and XXX O
brain XXX O
are XXX O
the XXX O
most XXX O
abundant XXX O
source XXX O
for XXX O
aFGF XXX B-GENE
protein XXX I-GENE
. XXX O

Conversely XXX O
, XXX O
activation XXX O
of XXX O
this XXX O
signaling XXX O
pathway XXX O
by XXX O
expression XXX O
of XXX O
a XXX O
constitutively XXX O
active XXX O
MKK1 XXX B-GENE
mutant XXX I-GENE
dramatically XXX O
increased XXX O
cyclin XXX B-GENE
D1 XXX I-GENE
promoter XXX O
activity XXX O
and XXX O
cyclin XXX B-GENE
D1 XXX I-GENE
protein XXX I-GENE
expression XXX O
, XXX O
in XXX O
a XXX O
growth XXX O
factor-independent XXX O
manner XXX O
. XXX O

The XXX O
product XXX O
of XXX O
the XXX O
vpr XXX B-GENE
open XXX I-GENE
reading XXX I-GENE
frame XXX I-GENE
of XXX I-GENE
human XXX I-GENE
immunodeficiency XXX I-GENE
virus XXX I-GENE
type XXX I-GENE
1 XXX I-GENE
( XXX I-GENE
HIV-1 XXX I-GENE
) XXX I-GENE
is XXX O
a XXX O
15-kDa XXX O
, XXX O
arginine-rich XXX O
protein XXX O
that XXX O
is XXX O
present XXX O
in XXX O
virions XXX O
in XXX O
molar XXX O
quantities XXX O
equivalent XXX O
to XXX O
that XXX O
of XXX O
Gag XXX B-GENE
. XXX O

Co-transfection XXX O
of XXX O
a XXX O
tat XXX B-GENE
expressing XXX O
plasmid XXX O
with XXX O
these XXX O
viruses XXX O
containing XXX O
the XXX O
tat XXX B-GENE
ORF XXX I-GENE
mutations XXX O
resulted XXX O
in XXX O
higher XXX O
levels XXX O
of XXX O
virus XXX O
production XXX O
demonstrating XXX O
that XXX O
the XXX O
effects XXX O
of XXX O
both XXX O
mutants XXX O
are XXX O
tat XXX B-GENE
specific XXX O
. XXX O

Epileptiform XXX O
activity XXX O
recorded XXX O
from XXX O
superficial XXX O
laminae XXX O
bordering XXX O
layer XXX O
4 XXX O
, XXX O
and XXX O
into XXX O
which XXX O
layer XXX O
4's XXX O
primary XXX O
projections XXX O
terminate XXX O
, XXX O
is XXX O
suppressed XXX O
preferentially XXX O
by XXX O
phenytoin XXX O
. XXX O

After XXX O
allowing XXX O
time XXX O
for XXX O
absorption XXX O
, XXX O
participants XXX O
completed XXX O
a XXX O
bridge XXX O
simulator XXX O
task XXX O
. XXX O

Static XXX O
lung XXX O
function XXX O
in XXX O
puppies XXX O
after XXX O
pneumonectomy XXX O
. XXX O

Clinical XXX O
studies XXX O
SY5555 XXX O
was XXX O
administered XXX O
to XXX O
45 XXX O
patients XXX O
with XXX O
various XXX O
infectious XXX O
diseases XXX O
( XXX O
2 XXX O
with XXX O
acute XXX O
pharyngitis XXX O
, XXX O
8 XXX O
with XXX O
acute XXX O
tonsillitis XXX O
, XXX O
4 XXX O
with XXX O
lacunar XXX O
tonsillitis XXX O
, XXX O
3 XXX O
each XXX O
with XXX O
acute XXX O
bronchitis XXX O
, XXX O
pneumonia XXX O
and XXX O
pertussis XXX O
, XXX O
7 XXX O
with XXX O
scarlet XXX O
fever XXX O
, XXX O
3 XXX O
with XXX O
impetigo XXX O
contagiosa XXX O
, XXX O
6 XXX O
with XXX O
acute XXX O
urinary XXX O
tract XXX O
infections XXX O
, XXX O
2 XXX O
with XXX O
balanoposthitis XXX O
and XXX O
1 XXX O
each XXX O
with XXX O
cervical XXX O
lymphadenitis XXX O
, XXX O
S XXX O
. XXX O
S XXX O
. XXX O
S XXX O
. XXX O
S XXX O
. XXX O
, XXX O
vulvitis XXX O
and XXX O
acute XXX O
colitis XXX O
) XXX O
at XXX O
daily XXX O
doses XXX O
between XXX O
3 XXX O
. XXX O
4-10 XXX O
mg XXX O
/ XXX O
kg XXX O
, XXX O
t XXX O
. XXX O
i XXX O
. XXX O
d XXX O
. XXX O
, XXX O
for XXX O
3-14 XXX O
days XXX O
. XXX O

This XXX O
analysis XXX O
, XXX O
together XXX O
with XXX O
a XXX O
consideration XXX O
of XXX O
the XXX O
SCBs XXX O
found XXX O
upstream XXX O
of XXX O
known XXX O
SWI4 XXX B-GENE
, XXX I-GENE
6-dependent XXX I-GENE
genes XXX I-GENE
, XXX O
leads XXX O
to XXX O
the XXX O
proposal XXX O
of XXX O
a XXX O
revised XXX O
consensus XXX O
sequence XXX O
for XXX O
this XXX O
important XXX O
regulatory XXX O
element XXX O
. XXX O

Of XXX O
the XXX O
cases XXX O
with XXX O
PLD XXX O
, XXX O
50% XXX O
had XXX O
associated XXX O
renal XXX O
cysts XXX O
and XXX O
10% XXX O
of XXX O
the XXX O
cases XXX O
with XXX O
APCD XXX O
had XXX O
associated XXX O
liver XXX O
cysts XXX O
. XXX O

It XXX O
was XXX O
postulated XXX O
that XXX O
persistent XXX O
challenge XXX O
by XXX O
M XXX O
. XXX O
leprae XXX O
or XXX O
its XXX O
antigens XXX O
to XXX O
the XXX O
IgA XXX B-GENE
immunocytes XXX O
of XXX O
the XXX O
intestinal XXX O
epithelium XXX O
might XXX O
have XXX O
induced XXX O
tolerance XXX O
leading XXX O
to XXX O
IgA XXX B-GENE
deficiency XXX O
and XXX O
subsequent XXX O
subtotal XXX O
atrophy XXX O
of XXX O
the XXX O
intestinal XXX O
villi XXX O
in XXX O
the XXX O
patients XXX O
with XXX O
lepromatous XXX O
leprosy XXX O
. XXX O

Lysozyme XXX B-GENE
activity XXX O
was XXX O
evidently XXX O
increased XXX O
as XXX O
well XXX O
in XXX O
undiluted XXX O
as XXX O
in XXX O
diluted XXX O
sera XXX O
in XXX O
all XXX O
our XXX O
tested XXX O
patients XXX O
. XXX O

Human XXX B-GENE
thymine-DNA XXX I-GENE
glycosylase XXX I-GENE
maps XXX O
at XXX O
chromosome XXX O
12q22-q24 XXX O
. XXX O
1 XXX O
: XXX O
a XXX O
region XXX O
of XXX O
high XXX O
loss XXX O
of XXX O
heterozygosity XXX O
in XXX O
gastric XXX O
cancer XXX O
. XXX O

As XXX O
well XXX O
, XXX O
IFN-gamma-induced XXX O
expression XXX O
of XXX O
IRF-1 XXX B-GENE
and XXX O
its XXX O
binding XXX O
to XXX O
the XXX O
IRF XXX B-GENE
element XXX I-GENE
is XXX O
inhibited XXX O
. XXX O

We XXX O
exploit XXX O
the XXX O
properties XXX O
of XXX O
LexA XXX B-GENE
fusion XXX I-GENE
proteins XXX I-GENE
to XXX O
study XXX O
the XXX O
dimerization XXX O
and XXX O
DNA-contacting XXX O
domains XXX O
of XXX O
cRel XXX B-GENE
. XXX O

Endocardial XXX O
fibro-elastosis XXX O
, XXX O
mitral XXX O
incompetence XXX O
, XXX O
and XXX O
coarctation XXX O
of XXX O
abdominal XXX O
aorta XXX O
. XXX O

Endothelium XXX O
of XXX O
the XXX O
central XXX O
ear XXX O
artery XXX O
of XXX O
an XXX O
anesthetized XXX O
rabbit XXX O
is XXX O
damaged XXX O
by XXX O
placing XXX O
artery XXX O
forceps XXX O
on XXX O
the XXX O
ear XXX O
directly XXX O
over XXX O
the XXX O
vessel XXX O
. XXX O

Total XXX O
cholesterol XXX O
was XXX O
measured XXX O
in XXX O
amniotic XXX O
fluids XXX O
collected XXX O
at XXX O
different XXX O
stages XXX O
of XXX O
gestation XXX O
. XXX O

These XXX O
results XXX O
demonstrate XXX O
a XXX O
specific XXX O
association XXX O
of XXX O
SIV XXX O
and XXX O
HIV-2 XXX B-GENE
nef XXX I-GENE
, XXX O
but XXX O
not XXX O
HIV-1 XXX B-GENE
nef XXX I-GENE
, XXX O
with XXX O
TCRzeta XXX B-GENE
. XXX O

This XXX O
study XXX O
was XXX O
performed XXX O
to XXX O
clarify XXX O
the XXX O
location XXX O
of XXX O
a XXX O
transesophageal XXX O
echocardiographic XXX O
( XXX O
TEE XXX O
) XXX O
transducer XXX O
when XXX O
obtaining XXX O
the XXX O
short-axis XXX O
view XXX O
of XXX O
the XXX O
left XXX O
ventricle XXX O
( XXX O
S-LV XXX O
) XXX O
. XXX O

Low XXX O
PbrO2 XXX O
readings XXX O
, XXX O
however XXX O
, XXX O
could XXX O
be XXX O
caused XXX O
by XXX O
local XXX O
microhemorrhages XXX O
, XXX O
undetectable XXX O
on XXX O
CT XXX O
or XXX O
MRI XXX O
. XXX O

One XXX O
of XXX O
the XXX O
sequelae XXX O
of XXX O
the XXX O
antiphospholipid-antibodies XXX B-GENE
is XXX O
an XXX O
impaired XXX O
uteroplacental XXX O
circulation XXX O
. XXX O

The XXX O
structure XXX O
of XXX O
the XXX O
free XXX O
SH2 XXX B-GENE
domain XXX I-GENE
has XXX O
been XXX O
compared XXX O
to XXX O
that XXX O
of XXX O
the XXX O
SH2 XXX B-GENE
complexed XXX O
with XXX O
a XXX O
doubly XXX O
phosphorylated XXX O
peptide XXX O
derived XXX O
from XXX O
polyomavirus XXX B-GENE
middle XXX I-GENE
T XXX I-GENE
antigen XXX I-GENE
( XXX O
MT XXX B-GENE
) XXX O
. XXX O

During XXX O
the XXX O
first XXX O
3 XXX O
min XXX O
of XXX O
recovery XXX O
, XXX O
plasma XXX O
potassium XXX O
fell XXX O
rapidly XXX O
in XXX O
spite XXX O
of XXX O
nearly XXX O
unchanged XXX O
blood XXX O
acidosis XXX O
and XXX O
significantly XXX O
decreasing XXX O
bicarbonate XXX O
concentration XXX O
. XXX O

All XXX O
three XXX O
genes XXX O
have XXX O
been XXX O
mapped XXX O
precisely XXX O
to XXX O
a XXX O
small XXX O
region XXX O
on XXX O
human XXX O
chromosome XXX O
16p12 XXX O
. XXX O
1-p11 XXX O
. XXX O
2 XXX O
( XXX O
homologous XXX O
to XXX O
mouse XXX O
chromosome XXX O
7 XXX O
) XXX O
, XXX O
using XXX O
somatic XXX O
cell XXX O
hybrids XXX O
and XXX O
cosmid XXX O
clones XXX O
. XXX O

The XXX O
role XXX O
of XXX O
neuroplasticity XXX O
in XXX O
the XXX O
response XXX O
to XXX O
drugs XXX O
. XXX O

Effect XXX O
of XXX O
corticosteroid-containing XXX O
antirheumatic XXX O
combination XXX O
drugs XXX O
on XXX O
endogenous XXX O
ACTH XXX B-GENE
and XXX O
cortisol XXX O
production XXX O
. XXX O

This XXX O
finding XXX O
is XXX O
the XXX O
first XXX O
example XXX O
of XXX O
utilization XXX O
of XXX O
noncomplementary XXX O
dinucleotide XXX O
primer XXX O
by XXX O
an XXX O
RNA XXX B-GENE
polymerase XXX I-GENE
. XXX O

Finally XXX O
, XXX O
the XXX O
recovery XXX O
indexes XXX O
represented XXX O
by XXX O
the XXX O
times XXX O
required XXX O
for XXX O
T1 XXX O
/ XXX O
T0 XXX O
and XXX O
T4 XXX O
/ XXX O
T1 XXX O
to XXX O
rise XXX O
from XXX O
25% XXX O
to XXX O
75% XXX O
respectively XXX O
were XXX O
studied XXX O
. XXX O

This XXX O
Tbx6-subfamily XXX B-GENE
gene XXX I-GENE
is XXX O
likely XXX O
to XXX O
participate XXX O
in XXX O
paraxial XXX O
mesoderm XXX O
formation XXX O
and XXX O
somitogenesis XXX O
in XXX O
human XXX O
embryo XXX O
. XXX O

Enantiomer XXX O
separation XXX O
of XXX O
venlafaxine XXX O
and XXX O
O-desmethylvenlafaxine XXX O
in XXX O
human XXX O
plasma XXX O
. XXX O

Acid XXX O
instilled XXX O
on XXX O
the XXX O
larynx XXX O
of XXX O
maturing XXX O
rabbits XXX O
resulted XXX O
in XXX O
significant XXX O
obstructive XXX O
, XXX O
central XXX O
, XXX O
and XXX O
mixed XXX O
apnea XXX O
. XXX O

The XXX O
calcium XXX O
ratio XXX O
( XXX O
mean XXX O
ratio XXX O
of XXX O
the XXX O
predicted XXX O
to XXX O
measured XXX O
TBCa XXX O
) XXX O
in XXX O
men XXX O
was XXX O
1 XXX O
. XXX O
000 XXX O
+ XXX O
/ XXX O
- XXX O
7 XXX O
. XXX O
8% XXX O
and XXX O
in XXX O
women XXX O
0 XXX O
. XXX O
996 XXX O
+ XXX O
/ XXX O
- XXX O
7 XXX O
. XXX O
1% XXX O
. XXX O

METHODS XXX O
: XXX O
Total XXX O
muscle XXX O
paralysis XXX O
was XXX O
induced XXX O
under XXX O
general XXX O
anesthesia XXX O
in XXX O
a XXX O
group XXX O
of XXX O
obese XXX O
persons XXX O
( XXX O
n XXX O
= XXX O
9 XXX O
; XXX O
body XXX O
mass XXX O
index XXX O
, XXX O
32 XXX O
+ XXX O
/ XXX O
- XXX O
3 XXX O
kg XXX O
[ XXX O
-2 XXX O
] XXX O
) XXX O
and XXX O
in XXX O
a XXX O
group XXX O
of XXX O
nonobese XXX O
persons XXX O
( XXX O
n XXX O
= XXX O
9 XXX O
; XXX O
body XXX O
mas XXX O
index XXX O
, XXX O
21 XXX O
+ XXX O
/ XXX O
- XXX O
2 XXX O
kg XXX O
[ XXX O
-2 XXX O
] XXX O
) XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
these XXX O
patients XXX O
show XXX O
both XXX O
quantitative XXX O
and XXX O
qualitative XXX O
differences XXX O
in XXX O
their XXX O
infectious XXX O
microbiological XXX O
spectrum XXX O
, XXX O
mainly XXX O
in XXX O
clean-contaminated XXX O
, XXX O
contaminated XXX O
and XXX O
dirty XXX O
surgical XXX O
procedures XXX O
. XXX O

Testing XXX O
gravity XXX O
to XXX O
second XXX O
post-Newtonian XXX O
order XXX O
: XXX O
A XXX O
field-theory XXX O
approach XXX O
. XXX O

Several XXX O
lines XXX O
of XXX O
evidence XXX O
presented XXX O
here XXX O
suggest XXX O
that XXX O
PKC-zeta XXX B-GENE
plays XXX O
a XXX O
role XXX O
in XXX O
alpha XXX B-GENE
2 XXX I-GENE
integrin XXX I-GENE
gene XXX I-GENE
expression XXX O
. XXX O

Comparison XXX O
with XXX O
the XXX O
bHLH XXX B-GENE
/ XXX I-GENE
PAS XXX I-GENE
family XXX I-GENE
genes XXX I-GENE
revealed XXX O
that XXX O
the XXX O
intron XXX O
/ XXX O
exon XXX O
splice XXX O
pattern XXX O
of XXX O
mBMAL1 XXX B-GENE
most XXX O
closely XXX O
matches XXX O
that XXX O
of XXX O
the XXX O
mAhr XXX B-GENE
, XXX O
which XXX O
suggests XXX O
that XXX O
BMAL1 XXX B-GENE
and XXX O
Ahr XXX B-GENE
belong XXX O
to XXX O
the XXX O
same XXX O
subclass XXX O
and XXX O
may XXX O
be XXX O
derived XXX O
from XXX O
a XXX O
common XXX O
primordial XXX O
gene XXX O
. XXX O

Each XXX O
mRNA XXX O
contained XXX O
five XXX O
or XXX O
six XXX O
internal XXX O
uridine XXX O
residues XXX O
, XXX O
which XXX O
were XXX O
transcribed XXX O
using XXX O
a XXX O
mixture XXX O
of XXX O
UTP XXX O
and XXX O
thio-UTP XXX O
. XXX O

The XXX O
total XXX O
number XXX O
of XXX O
specimens XXX O
was XXX O
131 XXX O
with XXX O
78 XXX O
nonsmokers XXX O
and XXX O
53 XXX O
smokers XXX O
. XXX O

Evidence XXX O
for XXX O
such XXX O
peak XXX O
shifts XXX O
has XXX O
been XXX O
found XXX O
in XXX O
the XXX O
responses XXX O
of XXX O
auditory XXX O
nerve XXX O
fibers XXX O
, XXX O
cochlear XXX O
microphonics XXX O
, XXX O
and XXX O
the XXX O
responses XXX O
of XXX O
outer XXX O
hair XXX O
cells XXX O
and XXX O
supporting XXX O
cells XXX O
in XXX O
the XXX O
cochlea XXX O
, XXX O
as XXX O
well XXX O
as XXX O
in XXX O
basilar XXX O
membrane XXX O
vibration XXX O
measurements XXX O
, XXX O
and XXX O
indirectly XXX O
, XXX O
in XXX O
psychophysical XXX O
data XXX O
. XXX O

The XXX O
data XXX O
normally XXX O
available XXX O
are XXX O
insufficient XXX O
and XXX O
take XXX O
no XXX O
account XXX O
of XXX O
the XXX O
direction XXX O
of XXX O
recirculation XXX O
, XXX O
which XXX O
may XXX O
be XXX O
a XXX O
determining XXX O
factor XXX O
. XXX O

Subsets XXX O
of XXX O
patients XXX O
were XXX O
performed XXX O
according XXX O
to XXX O
the XXX O
severity XXX O
of XXX O
trauma XXX O
( XXX O
ISS XXX O
< XXX O
9 XXX O
; XXX O
9-17 XXX O
; XXX O
18-31 XXX O
; XXX O
> XXX O
32 XXX O
) XXX O
, XXX O
based XXX O
on XXX O
the XXX O
different XXX O
injury XXX O
pattern XXX O
, XXX O
and XXX O
survivors XXX O
versus XXX O
nonsurvivors XXX O
as XXX O
well XXX O
. XXX O

We XXX O
present XXX O
a XXX O
case XXX O
of XXX O
carcinoma XXX O
of XXX O
the XXX O
breast XXX O
presenting XXX O
concurrently XXX O
with XXX O
SSc XXX O
that XXX O
subsequently XXX O
progressed XXX O
to XXX O
dialysis-dependent XXX O
renal XXX O
failure XXX O
in XXX O
just XXX O
1 XXX O
month XXX O
. XXX O

Accepting XXX O
arbitrarily XXX O
chosen XXX O
limits XXX O
of XXX O
maximized XXX O
errors XXX O
of XXX O
+ XXX O
/ XXX O
- XXX O
10% XXX O
, XXX O
it XXX O
could XXX O
be XXX O
shown XXX O
that XXX O
the XXX O
system XXX O
did XXX O
not XXX O
work XXX O
acceptably XXX O
when XXX O
the XXX O
mean XXX O
carbon XXX O
dioxide XXX O
concentration XXX O
was XXX O
below XXX O
1 XXX O
. XXX O
5 XXX O
vol XXX O
. XXX O
% XXX O
within XXX O
the XXX O
fresh XXX O
gas XXX O
flow XXX O
rates XXX O
( XXX O
2 XXX O
. XXX O
2--7 XXX O
. XXX O
7 XXX O
1 XXX O
min-1 XXX O
) XXX O
and XXX O
the XXX O
range XXX O
of XXX O
minute XXX O
ventilation XXX O
( XXX O
4--10 XXX O
1 XXX O
min-1 XXX O
) XXX O
employed XXX O
. XXX O

Overall XXX O
agreement XXX O
between XXX O
rest XXX O
/ XXX O
postnitroglycerin XXX O
technetium-99m XXX O
tetrofosmin XXX O
SPET XXX O
studies XXX O
and XXX O
rest XXX O
/ XXX O
redistribution XXX O
or XXX O
rest XXX O
/ XXX O
reinjection XXX O
thallium-201 XXX O
SPET XXX O
studies XXX O
, XXX O
regarding XXX O
the XXX O
presence XXX O
of XXX O
myocardial XXX O
viability XXX O
, XXX O
was XXX O
87% XXX O
and XXX O
90% XXX O
, XXX O
respectively XXX O
. XXX O

Southern XXX O
blot XXX O
analysis XXX O
using XXX O
probes XXX O
from XXX O
the XXX O
3' XXX O
portions XXX O
of XXX O
the XXX O
genomic XXX O
and XXX O
B XXX B-GENE
. XXX I-GENE
napus XXX I-GENE
MA XXX I-GENE
and XXX O
MB XXX B-GENE
cDNA XXX I-GENE
clones XXX O
showed XXX O
that XXX O
MA XXX B-GENE
type XXX I-GENE
myrosinases XXX B-GENE
are XXX O
encoded XXX O
by XXX O
approximately XXX O
4 XXX O
genes XXX O
, XXX O
while XXX O
MB XXX B-GENE
type XXX I-GENE
myrosinases XXX B-GENE
are XXX O
encoded XXX O
by XXX O
more XXX O
than XXX O
10 XXX O
genes XXX O
in XXX O
B XXX O
. XXX O
napus XXX O
. XXX O

The XXX O
loss XXX O
of XXX O
SKO1 XXX B-GENE
completely XXX O
restored XXX O
ENA1 XXX B-GENE
expression XXX O
in XXX O
a XXX O
hog1 XXX B-GENE
mutant XXX I-GENE
and XXX O
partially XXX O
suppressed XXX O
the XXX O
osmotic XXX O
stress XXX O
sensitivity XXX O
, XXX O
qualifying XXX O
Sko1p XXX B-GENE
as XXX O
a XXX O
downstream XXX O
effector XXX O
of XXX O
the XXX O
HOG XXX O
pathway XXX O
. XXX O

Congruent XXX O
with XXX O
empirical XXX O
predictions XXX O
, XXX O
the XXX O
most XXX O
homesick XXX O
children XXX O
perceived XXX O
low XXX O
control XXX O
over XXX O
homesickness XXX O
and XXX O
separation XXX O
, XXX O
and XXX O
coped XXX O
by XXX O
relinquishing XXX O
control XXX O
. XXX O

Downregulation XXX O
of XXX O
FUS XXX B-GENE
expression XXX O
in XXX O
BCR XXX O
/ XXX O
ABL-expressing XXX O
32Dcl3 XXX O
cells XXX O
was XXX O
associated XXX O
with XXX O
suppression XXX O
of XXX O
growth XXX O
factor-independent XXX O
colony XXX O
formation XXX O
, XXX O
restoration XXX O
of XXX O
G-CSF-induced XXX O
granulocytic XXX O
differentiation XXX O
and XXX O
reduced XXX O
tumorigenic XXX O
potential XXX O
in XXX O
vivo XXX O
. XXX O

Differential XXX O
expression XXX O
was XXX O
confirmed XXX O
by XXX O
Northern XXX O
blot XXX O
analysis XXX O
employing XXX O
multiple XXX O
normal XXX O
and XXX O
tumor XXX O
cell XXX O
lines XXX O
. XXX O

To XXX O
examine XXX O
the XXX O
biochemical XXX O
basis XXX O
of XXX O
the XXX O
end XXX O
joining XXX O
, XXX O
nuclear XXX O
extracts XXX O
were XXX O
prepared XXX O
from XXX O
a XXX O
wide XXX O
variety XXX O
of XXX O
mammalian XXX O
cell XXX O
lines XXX O
and XXX O
tested XXX O
for XXX O
their XXX O
ability XXX O
to XXX O
join XXX O
test XXX O
plasmid XXX O
substrates XXX O
. XXX O

Deletion XXX O
of XXX O
the XXX O
apeA XXX B-GENE
gene XXX I-GENE
, XXX O
either XXX O
with XXX O
or XXX O
without XXX O
deletion XXX O
of XXX O
other XXX O
proteinases XXX B-GENE
( XXX O
protease XXX B-GENE
IV XXX I-GENE
and XXX O
aminopeptidase XXX B-GENE
N XXX I-GENE
) XXX O
, XXX O
did XXX O
not XXX O
have XXX O
any XXX O
effect XXX O
on XXX O
cell XXX O
growth XXX O
in XXX O
the XXX O
various XXX O
media XXX O
tested XXX O
. XXX O

Genomic XXX O
DNA XXX O
sequencing XXX O
in XXX O
the XXX O
vicinity XXX O
of XXX O
methylmalonyl-CoA XXX B-GENE
mutase XXX I-GENE
gene XXX I-GENE
( XXX O
mutAB XXX B-GENE
) XXX O
from XXX O
a XXX O
rifamycin XXX O
SV-producing XXX O
Amycolatopsis XXX O
mediterranei XXX O
U32 XXX O
allowed XXX O
us XXX O
to XXX O
clone XXX O
, XXX O
sequence XXX O
, XXX O
and XXX O
identify XXX O
a XXX O
gene XXX O
encoding XXX O
a XXX O
novel XXX O
serine XXX B-GENE
/ XXX I-GENE
threonine XXX I-GENE
protein XXX I-GENE
kinase XXX I-GENE
( XXX O
amk XXX B-GENE
) XXX O
. XXX O

The XXX O
genes XXX O
at XXX O
each XXX O
locus XXX O
are XXX O
divergently XXX O
transcribed XXX O
and XXX O
the XXX O
coding XXX O
sequences XXX O
are XXX O
separated XXX O
by XXX O
646 XXX O
base-pairs XXX O
at XXX O
one XXX O
locus XXX O
and XXX O
676 XXX O
base-pairs XXX O
at XXX O
the XXX O
other XXX O
. XXX O

Surprisingly XXX O
, XXX O
the XXX O
full-deletion XXX O
mutant XXX O
showed XXX O
a XXX O
strong XXX O
block XXX O
in XXX O
virus XXX O
release XXX O
, XXX O
suggesting XXX O
that XXX O
NC XXX B-GENE
is XXX O
involved XXX O
in XXX O
virus XXX O
assembly XXX O
. XXX O

It XXX O
has XXX O
come XXX O
out XXX O
that XXX O
CAEC XXX O
is XXX O
between XXX O
CC XXX O
and XXX O
CIEC XXX O
and XXX O
that XXX O
attacks XXX O
of XXX O
biliary XXX O
fever XXX O
and XXX O
high XXX O
levels XXX O
of XXX O
alkaline XXX B-GENE
phosphatase XXX I-GENE
and XXX O
transaminases XXX B-GENE
in XXX O
the XXX O
serum XXX O
are XXX O
the XXX O
helpful XXX O
findings XXX O
for XXX O
preoperative XXX O
diagnosis XXX O
. XXX O

CONCLUSION XXX O
: XXX O
Our XXX O
results XXX O
suggest XXX O
that XXX O
AIF XXX O
peak XXX O
saturation XXX O
leads XXX O
to XXX O
a XXX O
significant XXX O
systematic XXX O
error XXX O
in XXX O
the XXX O
determination XXX O
of XXX O
CBV XXX O
and XXX O
CBF XXX O
values XXX O
and XXX O
has XXX O
necessarily XXX O
to XXX O
be XXX O
taken XXX O
into XXX O
account XXX O
for XXX O
dynamic XXX O
contrast-enhanced XXX O
MR XXX O
perfusion XXX O
studies XXX O
. XXX O

The XXX O
Mig1 XXX B-GENE
repressor XXX I-GENE
is XXX O
a XXX O
zinc XXX B-GENE
finger XXX I-GENE
protein XXX I-GENE
that XXX O
mediates XXX O
glucose XXX O
repression XXX O
in XXX O
yeast XXX O
. XXX O

Combined XXX O
immunochemotherapy XXX O
with XXX O
cyclophosphamide XXX O
plus XXX O
BCG XXX O
gave XXX O
a XXX O
better XXX O
enhancement XXX O
of XXX O
the XXX O
antitumor XXX O
effect XXX O
of XXX O
the XXX O
cytostatic XXX O
than XXX O
that XXX O
of XXX O
the XXX O
combination XXX O
of XXX O
methotrexate XXX O
plus XXX O
BCG XXX O
and XXX O
cyclophosphamide XXX O
plus XXX O
levamisole XXX O
. XXX O

In XXX O
addition XXX O
, XXX O
SLK XXX B-GENE
displays XXX O
high XXX O
homology XXX O
to XXX O
microtubule XXX B-GENE
and XXX I-GENE
nuclear XXX I-GENE
associated XXX I-GENE
protein XXX I-GENE
( XXX O
M-NAP XXX B-GENE
) XXX O
and XXX O
AT1-46 XXX B-GENE
, XXX O
both XXX O
of XXX O
unknown XXX O
function XXX O
. XXX O

In XXX O
the XXX O
DNA XXX O
recognition XXX O
helix XXX O
of XXX O
finger XXX O
II XXX O
, XXX O
the XXX O
conserved XXX O
Arg XXX O
at XXX O
position XXX O
62 XXX O
( XXX O
N-terminal XXX O
side XXX O
of XXX O
the XXX O
first XXX O
zinc-coordinating XXX O
histidine XXX O
) XXX O
was XXX O
changed XXX O
to XXX O
a XXX O
Leu XXX O
or XXX O
Gln XXX O
. XXX O

Plants XXX O
transformed XXX O
with XXX O
the XXX O
35S-1-sst XXX B-GENE
construct XXX I-GENE
accumulated XXX O
the XXX O
oligofructans XXX O
1-kestose XXX O
( XXX O
GF2 XXX O
) XXX O
, XXX O
1 XXX O
, XXX O
1-nystose XXX O
( XXX O
GF3 XXX O
) XXX O
and XXX O
1 XXX O
, XXX O
1 XXX O
, XXX O
1-fructosylnystose XXX O
( XXX O
GF4 XXX O
) XXX O
. XXX O

The XXX O
IL-8 XXX B-GENE
receptor XXX I-GENE
is XXX O
a XXX O
seven-transmembrane XXX O
spanning XXX O
receptor XXX O
coupled XXX O
to XXX O
specific XXX O
heterotrimeric XXX B-GENE
G XXX I-GENE
proteins XXX I-GENE
including XXX O
Gi XXX B-GENE
and XXX O
G16 XXX B-GENE
. XXX O

The XXX O
gene XXX O
contains XXX O
six XXX O
exons XXX O
separated XXX O
by XXX O
1 XXX O
. XXX O
1-5 XXX O
. XXX O
8 XXX O
kb XXX O
introns XXX O
and XXX O
has XXX O
been XXX O
localized XXX O
to XXX O
the XXX O
murine XXX O
chromosome XXX O
2 XXX O
by XXX O
linkage XXX O
analysis XXX O
. XXX O

RNA XXX O
blot XXX O
hybridizations XXX O
identified XXX O
an XXX O
1 XXX O
. XXX O
8-kb XXX O
mRNA XXX O
common XXX O
to XXX O
cytochrome XXX B-GENE
b6 XXX I-GENE
and XXX O
subunit XXX B-GENE
IV XXX I-GENE
, XXX O
and XXX O
an XXX O
intensely XXX O
hybridizing XXX O
0 XXX O
. XXX O
8-kb XXX O
mRNA XXX O
specific XXX O
to XXX O
the XXX O
subunit XXX B-GENE
IV XXX I-GENE
gene XXX O
probe XXX O
. XXX O

To XXX O
address XXX O
the XXX O
biological XXX O
effect XXX O
of XXX O
specific XXX O
isoform XXX O
expression XXX O
, XXX O
NIH3T3 XXX O
cells XXX O
were XXX O
transfected XXX O
with XXX O
a XXX O
eukaryotic XXX O
expression XXX O
vector XXX O
containing XXX O
cDNA XXX O
for XXX O
FGF8a XXX B-GENE
, XXX O
FGF8b XXX B-GENE
, XXX O
or XXX O
FGF8e XXX B-GENE
. XXX O

A XXX O
hospital-based XXX O
study XXX O
of XXX O
the XXX O
relationship XXX O
between XXX O
retained XXX O
placenta XXX O
and XXX O
mastitis XXX O
in XXX O
dairy XXX O
cows XXX O
. XXX O

Mutational XXX O
analysis XXX O
of XXX O
essential XXX O
IncP XXX B-GENE
alpha XXX I-GENE
plasmid XXX I-GENE
transfer XXX I-GENE
genes XXX I-GENE
traF XXX I-GENE
and XXX O
traG XXX B-GENE
and XXX O
involvement XXX O
of XXX O
traF XXX B-GENE
in XXX O
phage XXX O
sensitivity XXX O
. XXX O

Substitution XXX O
of XXX O
either XXX O
Val33 XXX O
( XXX O
by XXX O
Gly XXX O
) XXX O
or XXX O
Gly28 XXX O
( XXX O
by XXX O
Ser XXX O
) XXX O
, XXX O
two XXX O
of XXX O
the XXX O
most XXX O
conserved XXX O
residues XXX O
in XXX O
all XXX O
protein XXX B-GENE
kinases XXX I-GENE
, XXX O
resulted XXX O
in XXX O
enzyme XXX O
with XXX O
marginally XXX O
detectable XXX O
activity XXX O
. XXX O

Sites XXX O
1 XXX O
and XXX O
4 XXX O
in XXX O
lumican XXX B-GENE
and XXX O
keratocan XXX B-GENE
are XXX O
in XXX O
a XXX O
homologous XXX O
location XXX O
. XXX O

Genomic XXX O
organization XXX O
of XXX O
the XXX O
human XXX B-GENE
beta-catenin XXX I-GENE
gene XXX I-GENE
( XXX O
CTNNB1 XXX B-GENE
) XXX O
. XXX O

We XXX O
examined XXX O
the XXX O
binding XXX O
of XXX O
purified XXX O
T3 XXX B-GENE
receptor XXX I-GENE
alpha XXX I-GENE
( XXX O
T3R XXX B-GENE
alpha XXX I-GENE
) XXX O
, XXX O
overexpressed XXX O
in XXX O
Escherichia XXX O
coli XXX O
, XXX O
to XXX O
wild-type XXX O
and XXX O
up XXX O
and XXX O
down XXX O
mutations XXX O
of XXX O
the XXX O
rGH XXX B-GENE
T3RE XXX B-GENE
to XXX O
evaluate XXX O
whether XXX O
transcriptional XXX O
potency XXX O
correlates XXX O
with XXX O
changes XXX O
in XXX O
T3R XXX B-GENE
binding XXX O
. XXX O

Analysis XXX O
of XXX O
the XXX O
mouse XXX B-GENE
STAP XXX I-GENE
gene XXX I-GENE
isolated XXX O
from XXX O
the XXX O
genomic XXX O
library XXX O
revealed XXX O
that XXX O
the XXX O
STAP XXX B-GENE
gene XXX I-GENE
spans XXX O
a XXX O
region XXX O
of XXX O
over XXX O
11 XXX O
kb XXX O
and XXX O
comprises XXX O
eight XXX O
exons XXX O
. XXX O

Glomerular XXX O
hemodynamics XXX O
during XXX O
abortion XXX O
induced XXX O
by XXX O
RU XXX O
486 XXX O
and XXX O
sepsis XXX O
in XXX O
rats XXX O
. XXX O

Southern XXX O
blot XXX O
analyses XXX O
demonstrated XXX O
a XXX O
low XXX O
, XXX O
if XXX O
not XXX O
single XXX O
, XXX O
copy XXX O
number XXX O
for XXX O
this XXX O
gene XXX O
and XXX O
conservation XXX O
of XXX O
this XXX O
domain XXX O
in XXX O
other XXX O
vertebrates XXX O
. XXX O

Handling XXX O
on XXX O
PND XXX O
9 XXX O
did XXX O
not XXX O
result XXX O
in XXX O
elevated XXX O
CORT XXX O
levels XXX O
in XXX O
any XXX O
of XXX O
the XXX O
groups XXX O
. XXX O

We XXX O
describe XXX O
a XXX O
novel XXX O
method XXX O
using XXX O
Saccharomyces XXX O
cerevisiae XXX O
for XXX O
detecting XXX O
protein-truncating XXX O
mutations XXX O
in XXX O
any XXX O
gene XXX O
of XXX O
interest XXX O
. XXX O

Familial XXX O
glutathione XXX B-GENE
reductase XXX I-GENE
deficiency XXX O
and XXX O
disorder XXX O
of XXX O
glutathione XXX O
synthesis XXX O
in XXX O
the XXX O
erythrocyte XXX O
. XXX O

Stable XXX O
expression XXX O
of XXX O
truncated XXX B-GENE
inositol XXX I-GENE
1 XXX I-GENE
, XXX I-GENE
4 XXX I-GENE
, XXX I-GENE
5-trisphosphate XXX I-GENE
receptor XXX I-GENE
subunits XXX I-GENE
in XXX O
3T3 XXX O
fibroblasts XXX O
. XXX O

Naval XXX O
personnel XXX O
who XXX O
exceed XXX O
standards XXX O
for XXX O
%BF XXX O
can XXX O
be XXX O
separated XXX O
from XXX O
active XXX O
duty XXX O
. XXX O

Transcription XXX O
of XXX O
the XXX O
six XXX O
EBNA XXX B-GENE
genes XXX I-GENE
, XXX O
which XXX O
are XXX O
expressed XXX O
in XXX O
EBV-immortalized XXX O
primary XXX O
B XXX O
cells XXX O
, XXX O
arises XXX O
from XXX O
one XXX O
of XXX O
two XXX O
promoters XXX O
, XXX O
Cp XXX B-GENE
and XXX O
Wp XXX B-GENE
, XXX O
located XXX O
near XXX O
the XXX O
left XXX O
end XXX O
of XXX O
the XXX O
viral XXX O
genome XXX O
. XXX O

Moreover XXX O
, XXX O
the XXX O
Rho XXX B-GENE
family XXX I-GENE
protein XXX I-GENE
Cdc42 XXX B-GENE
, XXX O
a XXX O
conserved XXX O
morphogenetic XXX B-GENE
G XXX I-GENE
protein XXX I-GENE
, XXX O
is XXX O
also XXX O
a XXX O
potent XXX O
regulator XXX O
of XXX O
filamentous XXX O
growth XXX O
and XXX O
FG XXX B-GENE
( XXX I-GENE
TyA XXX I-GENE
) XXX I-GENE
: XXX O
: XXX O
lacZ XXX B-GENE
expression XXX O
in XXX O
S XXX O
. XXX O
cerevisiae XXX O
. XXX O

BACKGROUND XXX O
: XXX O
Gamma XXX O
knife XXX O
radiosurgery XXX O
( XXX O
GKR XXX O
) XXX O
is XXX O
a XXX O
safe XXX O
and XXX O
effective XXX O
alternative XXX O
to XXX O
surgery XXX O
for XXX O
intracranial XXX O
lesions XXX O
. XXX O

Furthermore XXX O
, XXX O
the XXX O
3'-untranslated XXX O
regions XXX O
of XXX O
pmGT10 XXX B-GENE
display XXX O
a XXX O
marked XXX O
degree XXX O
of XXX O
homology XXX O
to XXX O
the XXX O
3' XXX O
region XXX O
of XXX O
the XXX O
rat XXX B-GENE
Yb1 XXX I-GENE
gene XXX I-GENE
, XXX O
while XXX O
this XXX O
region XXX O
of XXX O
pmGT2 XXX B-GENE
displays XXX O
marked XXX O
homology XXX O
to XXX O
the XXX O
corresponding XXX O
region XXX O
of XXX O
the XXX O
rat XXX B-GENE
Yb2 XXX I-GENE
gene XXX I-GENE
. XXX O

Based XXX O
on XXX O
AUC XXX O
infinity XXX O
analyses XXX O
, XXX O
the XXX O
pharmacokinetics XXX O
of XXX O
buflomedil XXX O
were XXX O
found XXX O
to XXX O
be XXX O
linear XXX O
within XXX O
the XXX O
dose XXX O
ranges XXX O
studied XXX O
( XXX O
50 XXX O
to XXX O
200 XXX O
mg XXX O
for XXX O
i XXX O
. XXX O
v XXX O
. XXX O
injection XXX O
and XXX O
150 XXX O
to XXX O
450 XXX O
mg XXX O
for XXX O
oral XXX O
administration XXX O
) XXX O
. XXX O

Translational XXX O
fusions XXX O
of XXX O
the XXX O
aroF XXX B-GENE
regulatory XXX I-GENE
regions XXX I-GENE
to XXX O
lacZ XXX B-GENE
were XXX O
constructed XXX O
and XXX O
then XXX O
introduced XXX O
in XXX O
single XXX O
copy XXX O
into XXX O
the XXX O
E XXX O
. XXX O
coli XXX O
chromosome XXX O
. XXX O
beta-Galactosidase XXX B-GENE
assays XXX O
for XXX O
tyrR-mediated XXX O
regulation XXX O
of XXX O
aroF-lacZ XXX B-GENE
expression XXX O
revealed XXX O
that XXX O
the XXX O
E XXX B-GENE
. XXX I-GENE
coli XXX I-GENE
TyrR XXX I-GENE
repressor XXX I-GENE
apparently XXX O
recognizes XXX O
the XXX O
operators XXX O
of XXX O
both XXX O
organisms XXX O
with XXX O
about XXX O
equal XXX O
efficiency XXX O
. XXX O

Enzyme XXX O
histochemical XXX O
findings XXX O
in XXX O
the XXX O
ultimobranchial XXX O
body XXX O
of XXX O
the XXX O
horse XXX O
. XXX O

The XXX O
integration XXX O
at XXX O
the XXX O
VIP XXX B-GENE
CyRE XXX B-GENE
of XXX O
the XXX O
Jak-Stat XXX B-GENE
and XXX O
AP-1 XXX B-GENE
signaling XXX I-GENE
pathways XXX I-GENE
with XXX O
other XXX O
pre-existing XXX O
proteins XXX O
provides XXX O
a XXX O
cellular XXX O
mechanism XXX O
for XXX O
cell- XXX O
and XXX O
cytokine-specific XXX O
signaling XXX O
. XXX O

ORF1 XXX O
( XXX O
1029 XXX O
bp XXX O
; XXX O
EMBL XXX O
databank XXX O
, XXX O
Accession XXX O
No XXX O
. XXX O

Members XXX O
of XXX O
the XXX O
MAPK XXX B-GENE
family XXX I-GENE
include XXX O
the XXX O
extracellular XXX B-GENE
response XXX I-GENE
kinases XXX I-GENE
( XXX O
ERKs XXX B-GENE
or XXX O
p42 XXX B-GENE
/ XXX I-GENE
44 XXX I-GENE
( XXX I-GENE
MAPK XXX I-GENE
) XXX I-GENE
) XXX O
, XXX O
the XXX O
c-Jun XXX B-GENE
amino-terminal XXX I-GENE
kinases XXX I-GENE
( XXX O
JNKs XXX B-GENE
) XXX O
, XXX O
and XXX O
the XXX O
p38 XXX B-GENE
/ XXX I-GENE
Hog XXX I-GENE
1 XXX I-GENE
protein XXX I-GENE
kinases XXX I-GENE
. XXX O

Technique XXX O
for XXX O
obtaining XXX O
refined XXX O
ceramics XXX O
with XXX O
dense XXX O
mass XXX O
. XXX O

Employing XXX O
fluorescence XXX O
spectroscopy XXX O
and XXX O
circular XXX O
dichroism XXX O
, XXX O
we XXX O
showed XXX O
that XXX O
the XXX O
binding XXX O
of XXX O
Ca2+ XXX O
to XXX O
ALG-2 XXX B-GENE
induced XXX O
significant XXX O
conformational XXX O
changes XXX O
in XXX O
both XXX O
the XXX O
N-terminal XXX O
and XXX O
C-terminal XXX O
domains XXX O
of XXX O
the XXX O
protein XXX O
. XXX O

We XXX O
report XXX O
the XXX O
isolation XXX O
of XXX O
human XXX O
cDNAs XXX O
homologous XXX O
to XXX O
the XXX O
Drosophila XXX B-GENE
dishevelled XXX I-GENE
( XXX O
dsh XXX B-GENE
) XXX O
segment-polarity XXX O
gene XXX O
. XXX O

Closeup XXX O
: XXX O
a XXX O
resource XXX O
for XXX O
nurses XXX O
who XXX O
smoke XXX O
. XXX O

No XXX O
ISREs XXX B-GENE
could XXX O
be XXX O
identified XXX O
in XXX O
the XXX O
mouse XXX O
promoter XXX O
. XXX O

The XXX O
hydrophobicity XXX O
profile XXX O
of XXX O
the XXX O
methyltransferase XXX B-GENE
reveals XXX O
the XXX O
presence XXX O
of XXX O
at XXX O
least XXX O
five XXX O
potential XXX O
transmembrane XXX O
domains XXX O
. XXX O

We XXX O
describe XXX O
a XXX O
novel XXX O
cytoplasmic XXX B-GENE
tyrosine XXX I-GENE
kinase XXX I-GENE
, XXX O
termed XXX O
BPK XXX B-GENE
( XXX O
B XXX B-GENE
cell XXX I-GENE
progenitor XXX I-GENE
kinase XXX I-GENE
) XXX O
, XXX O
which XXX O
is XXX O
expressed XXX O
in XXX O
all XXX O
stages XXX O
of XXX O
the XXX O
B XXX O
lineage XXX O
and XXX O
in XXX O
myeloid XXX O
cells XXX O
. XXX O

The XXX O
data XXX O
support XXX O
the XXX O
notion XXX O
that XXX O
suppression XXX O
of XXX O
images XXX O
during XXX O
binocular XXX O
rivalry XXX O
is XXX O
independent XXX O
in XXX O
both XXX O
eyes XXX O
. XXX O

RESULTS XXX O
: XXX O
Prevalence XXX O
of XXX O
obesity XXX O
( XXX O
BMI XXX O
SDS XXX O
> XXX O
2 XXX O
. XXX O
0 XXX O
) XXX O
was XXX O
< XXX O
2% XXX O
at XXX O
diagnosis XXX O
, XXX O
but XXX O
increased XXX O
to XXX O
16% XXX O
at XXX O
3y XXX O
. XXX O

The XXX O
purpose XXX O
of XXX O
this XXX O
investigation XXX O
was XXX O
to XXX O
describe XXX O
a XXX O
new XXX O
formulation XXX O
of XXX O
silver XXX O
sulfadiazine XXX O
in XXX O
a XXX O
water XXX O
soluble XXX O
gel XXX O
, XXX O
poloxamer XXX O
188 XXX O
. XXX O

These XXX O
mutations XXX O
create XXX O
stop XXX O
codons XXX O
in XXX O
exon XXX O
7 XXX O
and XXX O
8 XXX O
, XXX O
respectively XXX O
, XXX O
and XXX O
probably XXX O
result XXX O
in XXX O
truncated XXX O
proteins XXX O
lacking XXX O
HLH-Zip XXX B-GENE
or XXX O
Zip XXX B-GENE
structure XXX O
. XXX O

Glycogen XXX B-GENE
utilization XXX O
was XXX O
increased XXX O
, XXX O
but XXX O
tissue XXX O
levels XXX O
of XXX O
creatine XXX O
phosphate XXX O
, XXX O
ATP XXX O
, XXX O
and XXX O
lactate XXX O
were XXX O
similar XXX O
to XXX O
those XXX O
in XXX O
hearts XXX O
receiving XXX O
normal XXX O
flow XXX O
. XXX O

Two XXX O
sterol XXX B-GENE
regulatory XXX I-GENE
element-like XXX I-GENE
sequences XXX I-GENE
mediate XXX O
up-regulation XXX O
of XXX O
caveolin XXX B-GENE
gene XXX I-GENE
transcription XXX O
in XXX O
response XXX O
to XXX O
low XXX B-GENE
density XXX I-GENE
lipoprotein XXX I-GENE
free XXX O
cholesterol XXX O
. XXX O

2 XXX O
were XXX O
nonviable XXX O
, XXX O
and XXX O
the XXX O
mutant XXX B-GENE
Vp1s XXX I-GENE
unexpectedly XXX O
failed XXX O
to XXX O
localize XXX O
to XXX O
the XXX O
nucleus XXX O
though XXX O
Vp2 XXX B-GENE
and XXX O
Vp3 XXX B-GENE
did XXX O
, XXX O
suggesting XXX O
that XXX O
the XXX O
mutated XXX B-GENE
NLS1 XXX I-GENE
acted XXX O
as XXX O
a XXX O
dominant XXX O
signal XXX O
for XXX O
the XXX O
cytoplasmic XXX O
localization XXX O
of XXX O
Vp1 XXX B-GENE
. XXX O

Underestimations XXX O
by XXX O
as XXX O
much XXX O
as XXX O
35% XXX O
may XXX O
occur XXX O
due XXX O
to XXX O
the XXX O
problems XXX O
in XXX O
the XXX O
existing XXX O
methodologies XXX O
. XXX O

This XXX O
laser XXX O
provided XXX O
sufficient XXX O
power XXX O
in XXX O
an XXX O
amniotic XXX O
fluid XXX O
medium XXX O
to XXX O
occlude XXX O
placental XXX O
vessels XXX O
as XXX O
large XXX O
as XXX O
7 XXX O
mm XXX O
in XXX O
diameter XXX O
within XXX O
6 XXX O
seconds XXX O
at XXX O
a XXX O
power XXX O
density XXX O
of XXX O
2000 XXX O
W XXX O
/ XXX O
cm2 XXX O
. XXX O

The XXX O
HMG XXX B-GENE
domain XXX I-GENE
of XXX O
both XXX O
HMG20 XXX B-GENE
proteins XXX I-GENE
is XXX O
most XXX O
similar XXX O
to XXX O
that XXX O
of XXX O
yeast XXX B-GENE
NHP6A XXX I-GENE
( XXX O
38% XXX O
to XXX O
42% XXX O
) XXX O
. XXX O

We XXX O
have XXX O
found XXX O
that XXX O
mcs4- XXX B-GENE
cells XXX O
are XXX O
defective XXX O
at XXX O
activation XXX O
of XXX O
Spc1 XXX B-GENE
in XXX O
response XXX O
to XXX O
various XXX O
forms XXX O
of XXX O
stress XXX O
. XXX O

Cloning XXX O
of XXX O
a XXX O
human XXX O
cDNA XXX O
encoding XXX O
a XXX O
CDC2-related XXX B-GENE
kinase XXX I-GENE
by XXX O
complementation XXX O
of XXX O
a XXX O
budding XXX B-GENE
yeast XXX I-GENE
cdc28 XXX I-GENE
mutation XXX O
. XXX O

A XXX O
7-day XXX O
treatment XXX O
of XXX O
amphotericin XXX O
B XXX O
( XXX O
5 XXX O
mg XXX O
/ XXX O
kg XXX O
/ XXX O
day XXX O
i XXX O
. XXX O
p XXX O
. XXX O
) XXX O
significantly XXX O
reduced XXX O
the XXX O
glomerular XXX O
filtration XXX O
rate XXX O
( XXX O
GFR XXX O
) XXX O
measured XXX O
as XXX O
inuline XXX O
clearance XXX O
and XXX O
creatinine XXX O
clearance XXX O
( XXX O
0 XXX O
. XXX O
74 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
29 XXX O
and XXX O
0 XXX O
. XXX O
16 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
04 XXX O
ml XXX O
/ XXX O
min XXX O
, XXX O
respectively XXX O
) XXX O
in XXX O
comparison XXX O
to XXX O
vehicle-treated XXX O
rats XXX O
( XXX O
2 XXX O
. XXX O
04 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
23 XXX O
and XXX O
1 XXX O
. XXX O
29 XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
19 XXX O
ml XXX O
/ XXX O
min XXX O
, XXX O
respectively XXX O
) XXX O
. XXX O

The XXX O
mutant XXX O
receptors XXX O
, XXX O
as XXX O
well XXX O
as XXX O
sBMPR-IA XXX B-GENE
, XXX O
were XXX O
expressed XXX O
as XXX O
fusion XXX O
proteins XXX O
with XXX O
thioredoxin XXX B-GENE
in XXX O
Escherichia XXX O
coli XXX O
, XXX O
and XXX O
purified XXX O
using XXX O
reverse XXX O
phase XXX O
high XXX O
performance XXX O
liquid XXX O
chromatography XXX O
( XXX O
RP-HPLC XXX O
) XXX O
after XXX O
digestion XXX O
with XXX O
enterokinase XXX B-GENE
. XXX O

Effect XXX O
of XXX O
phenformin XXX O
on XXX O
gluconeogenesis XXX O
in XXX O
perfused XXX O
rat XXX O
liver XXX O
. XXX O

The XXX O
Ig-related XXX O
, XXX O
typical XXX O
metazoan XXX O
, XXX O
module XXX O
is XXX O
classified XXX O
to XXX O
the XXX O
disulphide XXX O
lacking XXX O
Ig XXX B-GENE
members XXX I-GENE
and XXX O
represents XXX O
the XXX O
phylogenetic XXX O
earliest XXX O
member XXX O
of XXX O
this XXX O
group XXX O
. XXX O

Comparison XXX O
of XXX O
the XXX O
sequences XXX O
of XXX O
the XXX O
xFxFG XXX B-GENE
repeat XXX I-GENE
regions XXX I-GENE
of XXX O
p62 XXX B-GENE
and XXX O
Nsplp XXX B-GENE
indicated XXX O
that XXX O
NTF2 XXX B-GENE
was XXX O
probably XXX O
interacting XXX O
with XXX O
the XXX O
phenylalanine-containing XXX O
core XXX O
of XXX O
these XXX O
repeats XXX O
and XXX O
not XXX O
the XXX O
intervening XXX O
hydrophilic XXX O
linkers XXX O
. XXX O

These XXX O
fusion XXX O
proteins XXX O
also XXX O
allowed XXX O
the XXX O
localization XXX O
of XXX O
the XXX O
transcriptional XXX O
activation XXX O
and XXX O
DNA XXX O
binding XXX O
domains XXX O
of XXX O
the XXX O
ToxR XXX B-GENE
protein XXX I-GENE
to XXX O
its XXX O
cytoplasmically XXX O
located XXX O
N-terminal XXX O
portion XXX O
. XXX O

Site-directed XXX O
mutagenesis XXX O
of XXX O
residues XXX O
in XXX O
this XXX O
domain XXX O
( XXX O
R82A XXX O
, XXX O
K85A XXX O
, XXX O
K88A XXX O
, XXX O
and XXX O
V89A XXX O
) XXX O
resulted XXX O
in XXX O
proteins XXX O
which XXX O
failed XXX O
to XXX O
transactivate XXX O
from XXX O
the XXX O
HTLV-1 XXX B-GENE
LTR XXX I-GENE
in XXX O
vivo XXX O
. XXX O

Fibromuscular XXX O
intimal XXX O
thickening XXX O
was XXX O
seen XXX O
in XXX O
the XXX O
ascending XXX O
and XXX O
thoracic XXX O
aorta XXX O
of XXX O
the XXX O
swine XXX O
fed XXX O
62 XXX O
, XXX O
500 XXX O
IU XXX O
of XXX O
vitamin XXX O
D3 XXX O
/ XXX O
kg XXX O
of XXX O
diet XXX O
for XXX O
three XXX O
months XXX O
duration XXX O
; XXX O
and XXX O
after XXX O
3 XXX O
months XXX O
of XXX O
vitamin XXX O
D3 XXX O
withdrawal XXX O
, XXX O
atherosclerotic XXX O
lesions XXX O
were XXX O
found XXX O
. XXX O

Naltrexone XXX O
hydrochloride XXX O
is XXX O
a XXX O
synthetic XXX O
opioid XXX O
receptor XXX O
antagonist XXX O
recently XXX O
used XXX O
in XXX O
efforts XXX O
to XXX O
provide XXX O
rapid XXX O
opioid XXX O
detoxification XXX O
. XXX O

The XXX O
survival XXX O
in XXX O
the XXX O
case XXX O
of XXX O
these XXX O
patients XXX O
was XXX O
studied XXX O
five XXX O
years XXX O
later XXX O
. XXX O

Receptors XXX O
for XXX O
interleukin XXX B-GENE
( XXX I-GENE
IL XXX I-GENE
) XXX I-GENE
-10 XXX I-GENE
and XXX O
IL-6-type XXX B-GENE
cytokines XXX I-GENE
use XXX O
similar XXX O
signaling XXX O
mechanisms XXX O
for XXX O
inducing XXX O
transcription XXX O
through XXX O
IL-6 XXX B-GENE
response XXX I-GENE
elements XXX I-GENE
. XXX O

This XXX O
new XXX O
knowledge XXX O
has XXX O
contributed XXX O
to XXX O
the XXX O
development XXX O
of XXX O
a XXX O
successful XXX O
immunoprophylactic XXX O
strategy XXX O
for XXX O
eliminating XXX O
Hib XXX O
disease XXX O
. XXX O

Self XXX O
or XXX O
foreign XXX O
cellular XXX O
proteins XXX O
provide XXX O
peptides XXX O
for XXX O
presentation XXX O
by XXX O
major XXX B-GENE
histocompatibility XXX I-GENE
complex XXX I-GENE
( XXX I-GENE
MHC XXX I-GENE
) XXX I-GENE
class XXX I-GENE
I XXX I-GENE
molecules XXX I-GENE
on XXX O
the XXX O
surface XXX O
of XXX O
antigen XXX O
presenting XXX O
cells XXX O
( XXX O
APC XXX O
) XXX O
. XXX O

The XXX O
yeast XXX O
retrotransposon XXX B-GENE
Ty5 XXX I-GENE
preferentially XXX O
integrates XXX O
into XXX O
regions XXX O
of XXX O
silent XXX O
chromatin XXX O
. XXX O

Finding XXX O
of XXX O
Rhodnius XXX O
prolixus XXX O
Stal XXX O
, XXX O
1859 XXX O
, XXX O
in XXX O
babassu XXX O
palm XXX O
trees XXX O
. XXX O

In XXX O
the XXX O
first XXX O
, XXX O
homologous XXX O
sequences XXX O
were XXX O
deleted XXX O
from XXX O
a XXX O
mouse XXX O
enhancer XXX O
, XXX O
resulting XXX O
in XXX O
a XXX O
tissue-specific XXX O
loss XXX O
of XXX O
activity XXX O
when XXX O
assayed XXX O
in XXX O
transgenic XXX O
mice XXX O
. XXX O

Parasitological XXX O
post-mortem XXX O
examination XXX O
of XXX O
all XXX O
seropositive XXX O
animals XXX O
showed XXX O
five XXX O
and XXX O
seven XXX O
false-positive XXX O
animals XXX O
when XXX O
E XXX B-GENE
/ XXX I-GENE
S XXX I-GENE
and XXX I-GENE
CWE XXX I-GENE
antigens XXX I-GENE
were XXX O
used XXX O
, XXX O
respectively XXX O
. XXX O

Diagnostic XXX O
value XXX O
of XXX O
cerebrospinal XXX B-GENE
fluid XXX I-GENE
immunoglobulin XXX I-GENE
G XXX I-GENE
( XXX O
IgG XXX B-GENE
) XXX O
in XXX O
pediatric XXX O
neurological XXX O
diseases XXX O
. XXX O

Children's XXX O
temperament XXX O
and XXX O
maternal XXX O
socialization XXX O
at XXX O
Time XXX O
1 XXX O
( XXX O
n XXX O
= XXX O
103 XXX O
, XXX O
aged XXX O
2-3 XXX O
years XXX O
) XXX O
were XXX O
considered XXX O
predictors XXX O
of XXX O
future XXX O
conscience XXX O
, XXX O
assessed XXX O
using XXX O
new XXX O
observational XXX O
and XXX O
narrative XXX O
measures XXX O
. XXX O

The XXX O
assay XXX O
herein XXX O
described XXX O
allows XXX O
the XXX O
comparison XXX O
of XXX O
relative XXX O
FGFR XXX B-GENE
expression XXX O
levels XXX O
, XXX O
both XXX O
within XXX O
a XXX O
single XXX O
RNA XXX O
pool XXX O
and XXX O
among XXX O
multiple XXX O
RNA XXX O
pool XXX O
samples XXX O
. XXX O

The XXX O
%SVend XXX O
of XXX O
HCM-I XXX O
was XXX O
significantly XXX O
lower XXX O
than XXX O
the XXX O
respective XXX O
values XXX O
of XXX O
the XXX O
HCM-II XXX O
and XXX O
Control XXX O
groups XXX O
. XXX O

All XXX O
patients XXX O
then XXX O
received XXX O
suxamethonium XXX O
1 XXX O
. XXX O
5 XXX O
mg XXX O
kg-1 XXX O
i XXX O
. XXX O
v XXX O
. XXX O

Serological XXX O
studies XXX O
at XXX O
the XXX O
early XXX O
relapse XXX O
stage XXX O
of XXX O
this XXX O
disease XXX O
showed XXX O
increased XXX O
serum XXX B-GENE
ANA XXX I-GENE
, XXX O
IgA XXX B-GENE
and XXX O
IgM XXX B-GENE
level XXX O
with XXX O
normal XXX O
IgG XXX B-GENE
and XXX O
decrease XXX O
of XXX O
C3 XXX O
and XXX O
C4 XXX O
. XXX O

Magnetic XXX O
resonance XXX O
spectroscopy XXX O
( XXX O
MRS XXX O
) XXX O
and XXX O
imaging XXX O
( XXX O
MRI XXX O
) XXX O
are XXX O
now XXX O
well XXX O
established XXX O
techniques XXX O
for XXX O
the XXX O
study XXX O
of XXX O
cellular XXX O
metabolism XXX O
and XXX O
gross XXX O
structure XXX O
of XXX O
muscle XXX O
. XXX O

The XXX O
peroxisome XXX B-GENE
proliferator-activated XXX I-GENE
receptors XXX I-GENE
( XXX O
PPARs XXX B-GENE
) XXX O
are XXX O
members XXX O
of XXX O
the XXX O
nuclear XXX B-GENE
hormone XXX I-GENE
receptor XXX I-GENE
superfamily XXX I-GENE
. XXX O

The XXX O
unexpected XXX O
presence XXX O
of XXX O
the XXX O
tRNA XXX B-GENE
( XXX I-GENE
trp XXX I-GENE
) XXX I-GENE
( XXX I-GENE
CCA XXX I-GENE
) XXX I-GENE
-gene XXX I-GENE
transcript XXX I-GENE
in XXX I-GENE
mitochondria XXX I-GENE
is XXX O
also XXX O
reported XXX O
. XXX O

Cyclin XXX B-GENE
A XXX I-GENE
expression XXX O
is XXX O
repressed XXX O
in XXX O
quiescent XXX O
cells XXX O
by XXX O
E2F XXX B-GENE
acting XXX O
in XXX O
conjunction XXX O
with XXX O
its XXX O
pocket XXX O
protein XXX O
partners XXX O
Rb XXX B-GENE
, XXX O
p107 XXX B-GENE
, XXX O
and XXX O
p130 XXX B-GENE
; XXX O
however XXX O
, XXX O
v-Jun XXX B-GENE
overrides XXX O
this XXX O
control XXX O
, XXX O
causing XXX O
phosphorylated XXX O
Rb XXX B-GENE
and XXX O
proliferation-specific XXX O
E2F-p107 XXX B-GENE
complexes XXX I-GENE
to XXX O
persist XXX O
after XXX O
mitogen XXX O
withdrawal XXX O
. XXX O

Thus XXX O
the XXX O
present XXX O
data XXX O
also XXX O
suggest XXX O
that XXX O
BP XXX O
and XXX O
HR XXX O
measurements XXX O
are XXX O
influenced XXX O
not XXX O
only XXX O
by XXX O
state-dependent XXX O
factors XXX O
but XXX O
also XXX O
by XXX O
at XXX O
least XXX O
three XXX O
different XXX O
factors XXX O
that XXX O
are XXX O
each XXX O
independent XXX O
of XXX O
the XXX O
state XXX O
: XXX O
one XXX O
leads XXX O
to XXX O
BP XXX O
and XXX O
HR XXX O
values XXX O
that XXX O
are XXX O
influenced XXX O
by XXX O
the XXX O
cycle XXX O
the XXX O
animal XXX O
is XXX O
in XXX O
and XXX O
the XXX O
other XXX O
two XXX O
influence XXX O
, XXX O
respectively XXX O
, XXX O
the XXX O
ranking XXX O
of XXX O
the XXX O
individual's XXX O
BP XXX O
and XXX O
HR XXX O
levels XXX O
within XXX O
the XXX O
population XXX O
. XXX O

The XXX O
present XXX O
findings XXX O
revealed XXX O
that XXX O
the XXX O
rib-2 XXX B-GENE
protein XXX I-GENE
was XXX O
a XXX O
unique XXX O
alpha1 XXX B-GENE
, XXX I-GENE
4-N-acetylglucosaminyltransferase XXX I-GENE
involved XXX O
in XXX O
the XXX O
biosynthetic XXX O
initiation XXX O
and XXX O
elongation XXX O
of XXX O
heparan XXX O
sulfate XXX O
. XXX O

The XXX O
ipiO XXX B-GENE
genes XXX I-GENE
code XXX O
for XXX O
two XXX O
almost XXX O
identical XXX O
152-aa XXX O
proteins XXX O
which XXX O
do XXX O
not XXX O
have XXX O
any XXX O
homology XXX O
with XXX O
sequences XXX O
present XXX O
in XXX O
data XXX O
libraries XXX O
. XXX O

RESULTS XXX O
: XXX O
The XXX O
analyzed XXX O
fragment XXX O
has XXX O
significant XXX O
activity XXX O
in XXX O
EpCAM XXX B-GENE
positive XXX O
cells XXX O
, XXX O
and XXX O
it XXX O
is XXX O
regulated XXX O
negatively XXX O
by XXX O
tumor XXX B-GENE
necrosis XXX I-GENE
factor XXX I-GENE
alpha XXX I-GENE
( XXX O
TNFalpha XXX B-GENE
) XXX O
. XXX O

Because XXX O
PET XXX O
is XXX O
also XXX O
useful XXX O
for XXX O
the XXX O
pretreatment XXX O
and XXX O
follow-up XXX O
evaluation XXX O
, XXX O
the XXX O
use XXX O
of XXX O
stereotactic XXX O
PET XXX O
in XXX O
these XXX O
patients XXX O
can XXX O
enable XXX O
an XXX O
accurate XXX O
comparison XXX O
of XXX O
PET-based XXX O
metabolic XXX O
data XXX O
with XXX O
MR-based XXX O
anatomical XXX O
data XXX O
. XXX O

To XXX O
do XXX O
this XXX O
, XXX O
segments XXX O
of XXX O
DNA XXX O
from XXX O
the XXX O
5' XXX O
flank XXX O
of XXX O
the XXX O
initiation XXX O
sites XXX O
for XXX O
germline XXX O
epsilon XXX B-GENE
RNA XXX I-GENE
were XXX O
ligated XXX O
to XXX O
a XXX O
luciferase XXX B-GENE
reporter XXX I-GENE
gene XXX I-GENE
and XXX O
transfected XXX O
into XXX O
two XXX O
mouse XXX O
B XXX O
cell XXX O
lines XXX O
, XXX O
one XXX O
of XXX O
which XXX O
can XXX O
be XXX O
induced XXX O
to XXX O
switch XXX O
to XXX O
IgE XXX B-GENE
. XXX O

In XXX O
eight XXX O
groups XXX O
of XXX O
subjects XXX O
operating XXX O
various XXX O
hand-held XXX O
vibrating XXX O
tools XXX O
and XXX O
aged XXX O
from XXX O
30 XXX O
to XXX O
59 XXX O
years XXX O
, XXX O
the XXX O
prevalence XXX O
rates XXX O
of XXX O
vibration-induced XXX O
white XXX O
finger XXX O
( XXX O
VWF XXX O
) XXX O
and XXX O
numbness XXX O
, XXX O
pain XXX O
, XXX O
or XXX O
stiffness XXX O
in XXX O
the XXX O
upper XXX O
and XXX O
lower XXX O
extremities XXX O
were XXX O
investigated XXX O
. XXX O

Among XXX O
non-cirrhotics XXX O
, XXX O
lack XXX O
of XXX O
portal XXX O
vein XXX O
visualisation XXX O
had XXX O
a XXX O
90% XXX O
sensitivity XXX O
, XXX O
88% XXX O
specificity XXX O
, XXX O
94% XXX O
negative XXX O
predictive XXX O
value XXX O
, XXX O
and XXX O
83% XXX O
positive XXX O
predictive XXX O
value XXX O
in XXX O
the XXX O
diagnosis XXX O
of XXX O
pre-sinusoidal XXX O
portal XXX O
hypertension XXX O
. XXX O

The XXX O
activation XXX O
of XXX O
the XXX O
HIV XXX O
promoter XXX O
required XXX O
the XXX O
nuclear XXX O
localization XXX O
of XXX O
c-Abl XXX B-GENE
and XXX O
could XXX O
be XXX O
correlated XXX O
with XXX O
increased XXX O
tyrosine XXX O
phosphorylation XXX O
of XXX O
RNA XXX B-GENE
polymerase XXX I-GENE
II XXX I-GENE
. XXX O

The XXX O
SEB1 XXX B-GENE
homologue XXX O
thus XXX O
isolated XXX O
, XXX O
SEB2 XXX B-GENE
, XXX O
encodes XXX O
a XXX O
protein XXX O
53% XXX O
identical XXX O
to XXX O
Seb1p XXX B-GENE
. XXX O

CONCLUSIONS XXX O
: XXX O
Fission XXX B-GENE
yeast XXX I-GENE
SCF XXX I-GENE
is XXX O
composed XXX O
of XXX O
Pop1 XXX B-GENE
and XXX O
Pop2 XXX B-GENE
, XXX O
two XXX O
structurally XXX O
related XXX O
but XXX O
functionally XXX O
independent XXX O
F-box XXX B-GENE
/ XXX I-GENE
WD-repeat XXX I-GENE
proteins XXX I-GENE
. XXX O

Carbohydrates XXX O
and XXX O
glycoconjugates XXX O
biophysical XXX O
methods XXX O
. XXX O

Molecular XXX O
cloning XXX O
and XXX O
characterisation XXX O
of XXX O
the XXX O
two XXX O
homologous XXX O
genes XXX O
coding XXX O
for XXX O
nitrate XXX B-GENE
reductase XXX I-GENE
in XXX I-GENE
tobacco XXX I-GENE
. XXX O

IL-2 XXX B-GENE
is XXX O
accepted XXX O
as XXX O
a XXX O
standard XXX O
treatment XXX O
used XXX O
alone XXX O
, XXX O
or XXX O
in XXX O
combination XXX O
with XXX O
chemotherapy XXX O
or XXX O
biotherapy XXX O
in XXX O
the XXX O
management XXX O
of XXX O
metastatic XXX O
melanoma XXX O
and XXX O
metastatic XXX O
renal XXX O
cell XXX O
carcinoma XXX O
. XXX O

Cloning XXX O
and XXX O
sequencing XXX O
of XXX O
the XXX O
upstream XXX O
region XXX O
of XXX O
pepX XXX B-GENE
revealed XXX O
the XXX O
presence XXX O
of XXX O
two XXX O
ORFs XXX O
of XXX O
360 XXX O
and XXX O
1 XXX O
, XXX O
338 XXX O
bp XXX O
that XXX O
were XXX O
shown XXX O
to XXX O
be XXX O
able XXX O
to XXX O
encode XXX O
proteins XXX O
with XXX O
high XXX O
homology XXX O
to XXX O
GlnR XXX B-GENE
and XXX O
GlnA XXX B-GENE
proteins XXX I-GENE
, XXX O
respectively XXX O
. XXX O

The XXX O
transcript XXX O
was XXX O
initially XXX O
identified XXX O
as XXX O
a XXX O
partial XXX O
cDNA XXX O
sequence XXX O
in XXX O
the XXX O
course XXX O
of XXX O
constructing XXX O
a XXX O
transcript XXX O
map XXX O
of XXX O
the XXX O
region XXX O
between XXX O
markers XXX O
D11S1765 XXX B-GENE
and XXX O
uteroglobin XXX B-GENE
known XXX O
to XXX O
encompass XXX O
the XXX O
gene XXX O
causing XXX O
Best XXX O
disease XXX O
. XXX O

DESIGN XXX O
: XXX O
Serum XXX O
aldosterone XXX O
and XXX O
plasma XXX B-GENE
renin XXX I-GENE
activity XXX O
were XXX O
measured XXX O
supine XXX O
prior XXX O
to XXX O
and XXX O
60 XXX O
, XXX O
90 XXX O
, XXX O
120 XXX O
minutes XXX O
after XXX O
oral XXX O
captopril XXX O
, XXX O
25 XXX O
mg XXX O
. XXX O

At XXX O
43% XXX O
blood XXX O
pressure XXX O
reduction XXX O
, XXX O
PCO2 XXX O
fell XXX O
by XXX O
0 XXX O
. XXX O
53 XXX O
kPa XXX O
, XXX O
a XXX O
decrease XXX O
which XXX O
could XXX O
not XXX O
explain XXX O
the XXX O
observed XXX O
CBF XXX O
fall XXX O
of XXX O
27% XXX O
. XXX O

Chronic XXX O
hepatitis XXX O
B XXX O
in XXX O
adopted XXX O
Romanian XXX O
children XXX O
. XXX O

This XXX O
coat XXX B-GENE
protein XXX I-GENE
consists XXX O
of XXX O
Sar1p XXX B-GENE
, XXX O
the XXX O
Sec23p XXX B-GENE
protein XXX I-GENE
complex XXX I-GENE
containing XXX O
Sec23p XXX B-GENE
and XXX O
Sec24p XXX B-GENE
, XXX O
and XXX O
the XXX O
Sec13p XXX B-GENE
protein XXX I-GENE
complex XXX I-GENE
containing XXX O
Sec13p XXX B-GENE
and XXX O
a XXX O
novel XXX O
150-kDa XXX B-GENE
protein XXX I-GENE
, XXX I-GENE
p150 XXX I-GENE
. XXX O

Felodipine XXX O
did XXX O
not XXX O
alter XXX O
the XXX O
baseline XXX O
FEV1 XXX O
, XXX O
but XXX O
showed XXX O
a XXX O
small XXX O
significant XXX O
inhibitory XXX O
effect XXX O
upon XXX O
histamine XXX O
and XXX O
AMP XXX O
induced XXX O
bronchoconstriction XXX O
. XXX O

Thus XXX O
, XXX O
Esigma54 XXX B-GENE
promoters XXX I-GENE
are XXX O
responsive XXX O
to XXX O
CRP XXX B-GENE
, XXX O
a XXX O
protein XXX O
unrelated XXX O
to XXX O
sigma54 XXX B-GENE
activators XXX I-GENE
, XXX O
and XXX O
the XXX O
repression XXX O
exerted XXX O
is XXX O
the XXX O
direct XXX O
result XXX O
of XXX O
an XXX O
interaction XXX O
between XXX O
Esigma54 XXX B-GENE
and XXX O
the XXX O
CRP-cAMP XXX B-GENE
complex XXX I-GENE
. XXX O

Three XXX O
different XXX O
techniques XXX O
of XXX O
EA XXX O
analysis XXX O
were XXX O
used XXX O
in XXX O
the XXX O
study XXX O
: XXX O
1 XXX O
) XXX O
fast XXX O
Fourier XXX O
transformation XXX O
( XXX O
FFT XXX O
) XXX O
of XXX O
EA XXX O
in XXX O
a XXX O
broad XXX O
band XXX O
, XXX O
2 XXX O
) XXX O
developed XXX O
by XXX O
us XXX O
alternative XXX O
method XXX O
of XXX O
non-harmonic XXX O
expansion XXX O
of XXX O
the XXX O
EEG XXX O
curves XXX O
taking XXX O
into XXX O
account XXX O
their XXX O
shape XXX O
, XXX O
3 XXX O
) XXX O
factor XXX O
analysis XXX O
of XXX O
the XXX O
EA XXX O
spectral XXX O
densities XXX O
. XXX O

We XXX O
show XXX O
that XXX O
these XXX O
three XXX O
gain-of-function XXX O
mutants XXX O
differ XXX O
considerably XXX O
in XXX O
their XXX O
ability XXX O
to XXX O
bypass XXX O
the XXX O
sex XXX O
determination XXX O
signal XXX O
, XXX O
with XXX O
SxlM4 XXX B-GENE
being XXX O
the XXX O
strongest XXX O
and XXX O
SxlM1 XXX B-GENE
the XXX O
weakest XXX O
. XXX O

These XXX O
studies XXX O
identify XXX O
several XXX O
of XXX O
the XXX O
signal-transduction XXX O
events XXX O
involved XXX O
in XXX O
the XXX O
apoptosis XXX O
of XXX O
malignant XXX O
B XXX O
cells XXX O
that XXX O
transpire XXX O
following XXX O
ligation XXX O
of XXX O
CD20 XXX B-GENE
by XXX O
anti-CD20 XXX B-GENE
antibodies XXX I-GENE
in XXX O
the XXX O
presence XXX O
of XXX O
Fc-receptor-expressing XXX O
cells XXX O
or XXX O
secondary XXX O
goat XXX O
anti- XXX B-GENE
( XXX I-GENE
mouse XXX I-GENE
Ig XXX I-GENE
) XXX I-GENE
antibodies XXX I-GENE
and XXX O
which XXX O
may XXX O
contribute XXX O
to XXX O
the XXX O
tumor XXX O
regressions XXX O
observed XXX O
in XXX O
mouse XXX O
models XXX O
and XXX O
clinical XXX O
trials XXX O
. XXX O

Orientation XXX O
of XXX O
the XXX O
nuclear XXX O
spin XXX O
system XXX O
by XXX O
optical XXX O
pumping XXX O
causes XXX O
an XXX O
Overhauser XXX O
shift XXX O
of XXX O
the XXX O
excitonic XXX O
energy XXX O
levels XXX O
proportional XXX O
to XXX O
the XXX O
degree XXX O
of XXX O
nuclear XXX O
orientation XXX O
. XXX O

The XXX O
findings XXX O
demonstrate XXX O
that XXX O
AMPH XXX O
administration XXX O
induces XXX O
a XXX O
significant XXX O
increase XXX O
in XXX O
the XXX O
height XXX O
of XXX O
a XXX O
major XXX O
electroactive XXX O
peak XXX O
in XXX O
the XXX O
caudate XXX O
nucleus XXX O
of XXX O
pigtail XXX O
monkeys XXX O
, XXX O
and XXX O
further XXX O
that XXX O
such XXX O
amphetamine-induced XXX O
increases XXX O
can XXX O
be XXX O
manipulated XXX O
by XXX O
altering XXX O
the XXX O
affective XXX O
and XXX O
/ XXX O
or XXX O
emotional XXX O
state XXX O
of XXX O
the XXX O
animal XXX O
. XXX O

Cloning XXX O
and XXX O
sequencing XXX O
of XXX O
the XXX O
corresponding XXX O
cDNAs XXX O
indicates XXX O
that XXX O
, XXX O
via XXX O
alternative XXX O
splicing XXX O
, XXX O
the XXX O
rearranged XXX O
gene XXX O
codes XXX O
for XXX O
two XXX O
proteins XXX O
of XXX O
84 XXX O
and XXX O
85 XXX O
kD XXX O
( XXX O
p84 XXX B-GENE
/ XXX I-GENE
85 XXX I-GENE
) XXX O
which XXX O
retain XXX O
the XXX O
DNA-binding XXX O
rel XXX B-GENE
domain XXX I-GENE
and XXX O
the XXX O
first XXX O
five XXX O
ankyrin XXX B-GENE
repeats XXX O
, XXX O
but XXX O
have XXX O
lost XXX O
their XXX O
carboxy-terminus XXX O
including XXX O
the XXX O
seventh XXX O
ankyrin XXX B-GENE
repeat XXX O
. XXX O

Light XXX B-GENE
regulatory XXX I-GENE
unit XXX I-GENE
1 XXX I-GENE
( XXX O
LRU1 XXX B-GENE
) XXX O
is XXX O
necessary XXX O
for XXX O
and XXX O
sufficient XXX O
to XXX O
mediate XXX O
light-dependent XXX O
activation XXX O
of XXX O
the XXX O
chalcone XXX B-GENE
synthase XXX I-GENE
( XXX I-GENE
CHS XXX I-GENE
) XXX I-GENE
minimal XXX I-GENE
promoter XXX I-GENE
in XXX O
Petroselinum XXX O
crispum XXX O
. XXX O

One XXX O
patient XXX O
only XXX O
had XXX O
any XXX O
test XXX O
abnormalities XXX O
. XXX O

Isolation XXX O
of XXX O
cDNAs XXX B-GENE
encoding XXX I-GENE
gibbon XXX I-GENE
and XXX I-GENE
monkey XXX I-GENE
platelet XXX I-GENE
and XXX I-GENE
T XXX I-GENE
cell XXX I-GENE
activation XXX I-GENE
antigen XXX I-GENE
1 XXX I-GENE
( XXX O
PTA1 XXX B-GENE
) XXX O
. XXX O

JNK XXX B-GENE
is XXX O
additionally XXX O
regulated XXX O
by XXX O
the XXX O
Ras-related XXX O
G XXX B-GENE
proteins XXX I-GENE
Rac XXX B-GENE
and XXX O
Cdc42 XXX B-GENE
. XXX O

Expression XXX O
of XXX O
the XXX O
second XXX O
gene XXX O
( XXX O
XT3 XXX B-GENE
) XXX O
was XXX O
found XXX O
to XXX O
be XXX O
conserved XXX O
in XXX O
human XXX O
kidney XXX O
, XXX O
and XXX O
partial XXX O
sequence XXX O
was XXX O
obtained XXX O
from XXX O
a XXX O
human XXX O
cDNA XXX O
library XXX O
. XXX O

Genetic XXX O
experiments XXX O
using XXX O
mutants XXX O
defective XXX O
in XXX O
apontic XXX B-GENE
and XXX O
bruno XXX B-GENE
reveal XXX O
a XXX O
functional XXX O
interaction XXX O
between XXX O
these XXX O
genes XXX O
. XXX O

Deletion XXX O
of XXX O
the XXX O
POR2 XXX B-GENE
gene XXX I-GENE
alone XXX O
had XXX O
no XXX O
detectable XXX O
phenotype XXX O
, XXX O
while XXX O
yeasts XXX O
with XXX O
deletions XXX O
of XXX O
both XXX O
the XXX O
POR1 XXX B-GENE
and XXX O
POR2 XXX B-GENE
genes XXX I-GENE
were XXX O
viable XXX O
and XXX O
able XXX O
to XXX O
grow XXX O
on XXX O
glycerol XXX O
at XXX O
30 XXX O
degrees XXX O
C XXX O
, XXX O
albeit XXX O
more XXX O
slowly XXX O
than XXX O
delta XXX B-GENE
por1 XXX I-GENE
single XXX I-GENE
mutants XXX I-GENE
. XXX O

The XXX O
history XXX O
of XXX O
exposure XXX O
and XXX O
carboxyhemoglobin XXX B-GENE
levels XXX O
should XXX O
alert XXX O
the XXX O
physician XXX O
to XXX O
this XXX O
diagnosis XXX O
. XXX O

The XXX O
salient XXX O
clinical XXX O
features XXX O
, XXX O
the XXX O
problems XXX O
of XXX O
management XXX O
and XXX O
the XXX O
modern XXX O
approaches XXX O
to XXX O
the XXX O
reconstruction XXX O
of XXX O
facial XXX O
deformities XXX O
seen XXX O
in XXX O
this XXX O
disease XXX O
are XXX O
described XXX O
. XXX O

CsA XXX O
alone XXX O
resulted XXX O
in XXX O
elevated XXX O
bone XXX O
turnover XXX O
. XXX O

Mutational XXX O
analysis XXX O
of XXX O
potential XXX O
activating XXX O
phosphorylation XXX O
sites XXX O
found XXX O
in XXX O
NIMA XXX B-GENE
, XXX O
NIM-1 XXX B-GENE
, XXX O
and XXX O
related XXX O
protein XXX B-GENE
kinases XXX I-GENE
was XXX O
performed XXX O
on XXX O
NIMA XXX B-GENE
. XXX O

In XXX O
the XXX O
8 XXX O
patients XXX O
the XXX O
difference XXX O
betweent XXX O
he XXX O
mean XXX O
diastolic XXX O
values XXX O
of XXX O
delta XXX O
PU XXX O
and XXX O
delta XXX O
PM XXX O
was XXX O
- XXX O
0 XXX O
. XXX O
54 XXX O
+ XXX O
/ XXX O
- XXX O
1 XXX O
. XXX O
0 XXX O
( XXX O
SD XXX O
) XXX O
mmHg XXX O
. XXX O

As XXX O
expected XXX O
for XXX O
a XXX O
positive XXX O
SpHE XXX B-GENE
transcriptional XXX I-GENE
regulator XXX I-GENE
, XXX O
the XXX O
timing XXX O
of XXX O
SpEts4 XXX B-GENE
gene XXX I-GENE
expression XXX O
precedes XXX O
the XXX O
transient XXX O
expression XXX O
of XXX O
SpHE XXX B-GENE
in XXX O
the XXX O
very XXX O
early XXX O
sea XXX O
urchin XXX O
blastula XXX O
. XXX O

The XXX O
structure XXX O
has XXX O
been XXX O
established XXX O
by XXX O
a XXX O
study XXX O
of XXX O
its XXX O
mono- XXX O
and XXX O
bidimensional XXX O
NMR XXX O
spectra XXX O
and XXX O
mass XXX O
spectrometry XXX O
. XXX O

Interaction XXX O
of XXX O
Ets-1 XXX B-GENE
and XXX O
the XXX O
POU-homeodomain XXX B-GENE
protein XXX I-GENE
GHF-1 XXX B-GENE
/ XXX I-GENE
Pit-1 XXX I-GENE
reconstitutes XXX O
pituitary-specific XXX O
gene XXX O
expression XXX O
. XXX O

These XXX O
bacteria XXX O
produce XXX O
and XXX O
export XXX O
proteins XXX O
capable XXX O
of XXX O
specific XXX O
interactions XXX O
with XXX O
key XXX O
mammalian XXX O
cell XXX O
regulatory XXX O
molecules XXX O
in XXX O
order XXX O
to XXX O
derail XXX O
the XXX O
normal XXX O
functions XXX O
of XXX O
the XXX O
cells XXX O
. XXX O

Seventeen XXX O
of XXX O
the XXX O
35 XXX O
patients XXX O
were XXX O
randomly XXX O
chosen XXX O
to XXX O
receive XXX O
a XXX O
training XXX O
program XXX O
( XXX O
lasting XXX O
approximately XXX O
1 XXX O
month XXX O
) XXX O
designed XXX O
to XXX O
establish XXX O
a XXX O
systematic XXX O
strategy XXX O
of XXX O
organizing XXX O
complex XXX O
visual XXX O
material XXX O
. XXX O

Hair XXX O
and XXX O
blood XXX O
samples XXX O
were XXX O
taken XXX O
before XXX O
vitamin XXX O
C XXX O
or XXX O
placebo XXX O
supplementation XXX O
was XXX O
started XXX O
and XXX O
at XXX O
monthly XXX O
intervals XXX O
thereafter XXX O
for XXX O
three XXX O
months XXX O
. XXX O

A XXX O
one-way XXX O
analysis XXX O
of XXX O
variance XXX O
, XXX O
performed XXX O
separately XXX O
for XXX O
men XXX O
and XXX O
women XXX O
for XXX O
differences XXX O
among XXX O
the XXX O
three XXX O
phobic XXX O
groups XXX O
on XXX O
field XXX O
dependence XXX O
, XXX O
showed XXX O
significance XXX O
( XXX O
rho XXX O
less XXX O
than XXX O
. XXX O
05 XXX O
) XXX O
for XXX O
the XXX O
females XXX O
, XXX O
with XXX O
the XXX O
famale XXX O
agoraphobic XXX O
being XXX O
more XXX O
field XXX O
dependent XXX O
than XXX O
the XXX O
female XXX O
simple XXX O
phobic XXX O
groups XXX O
, XXX O
but XXX O
not XXX O
for XXX O
the XXX O
males XXX O
. XXX O

Inactivation XXX O
of XXX O
the XXX O
Neurospora XXX B-GENE
crassa XXX I-GENE
mitochondrial XXX I-GENE
outer XXX I-GENE
membrane XXX I-GENE
protein XXX I-GENE
TOM70 XXX I-GENE
by XXX O
repeat-induced XXX O
point XXX O
mutation XXX O
( XXX O
RIP XXX O
) XXX O
causes XXX O
defects XXX O
in XXX O
mitochondrial XXX O
protein XXX O
import XXX O
and XXX O
morphology XXX O
. XXX O

A XXX O
minimal XXX O
ER3 XXX B-GENE
sequence XXX I-GENE
of XXX O
DNA XXX O
was XXX O
further XXX O
demonstrated XXX O
to XXX O
function XXX O
as XXX O
a XXX O
FXR XXX B-GENE
HRE XXX I-GENE
and XXX O
was XXX O
bound XXX O
in XXX O
vitro XXX O
by XXX O
FXR-expressing XXX O
yeast XXX O
extracts XXX O
. XXX O

Radiosensitive XXX O
nature XXX O
of XXX O
paravascular XXX O
infiltrate-producing XXX O
potential XXX O
of XXX O
parental XXX O
spleen XXX O
cells XXX O
. XXX O

205 XXX O
, XXX O
285-290 XXX O
] XXX O
and XXX O
was XXX O
subsequently XXX O
cloned XXX O
and XXX O
sequenced XXX O
[ XXX O
J XXX O
. XXX O

Thus XXX O
, XXX O
Pet111p XXX B-GENE
could XXX O
play XXX O
dual XXX O
roles XXX O
in XXX O
both XXX O
membrane XXX O
localization XXX O
and XXX O
regulation XXX O
of XXX O
Cox2p XXX B-GENE
synthesis XXX O
within XXX O
mitochondria XXX O
. XXX O

Small XXX O
Maf XXX B-GENE
proteins XXX I-GENE
interact XXX O
with XXX O
the XXX O
human XXX O
transcription XXX O
factor XXX O
TCF11 XXX B-GENE
/ XXX I-GENE
Nrf1 XXX I-GENE
/ XXX I-GENE
LCR-F1 XXX I-GENE
. XXX O

A XXX O
study XXX O
of XXX O
chromosomes XXX O
of XXX O
lymphocytes XXX O
from XXX O
patients XXX O
treated XXX O
with XXX O
hycanthone XXX O
. XXX O

These XXX O
results XXX O
suggest XXX O
that XXX O
HAPE-S-S XXX O
are XXX O
prone XXX O
to XXX O
irregular XXX O
nocturnal XXX O
breathing XXX O
patterns XXX O
at XXX O
high XXX O
altitude XXX O
, XXX O
which XXX O
is XXX O
associated XXX O
with XXX O
the XXX O
development XXX O
of XXX O
AMS XXX O
, XXX O
but XXX O
it XXX O
was XXX O
not XXX O
possible XXX O
to XXX O
determine XXX O
whether XXX O
these XXX O
abnormal XXX O
breathing XXX O
patterns XXX O
are XXX O
a XXX O
cause XXX O
or XXX O
an XXX O
effect XXX O
of XXX O
AMS XXX O
. XXX O

Reproducing XXX O
populations XXX O
of XXX O
this XXX O
aphid XXX O
were XXX O
first XXX O
detected XXX O
in XXX O
Puerto XXX O
Rico XXX O
in XXX O
April XXX O
1992 XXX O
. XXX O

The XXX O
deduced XXX O
amino XXX O
acid XXX O
sequence XXX O
exhibited XXX O
98% XXX O
identity XXX O
to XXX O
the XXX O
human XXX O
cellular XXX O
transglutaminase XXX B-GENE
sequence XXX O
. XXX O

However XXX O
, XXX O
the XXX O
inability XXX O
to XXX O
export XXX O
RNA XXX O
from XXX O
the XXX O
nucleus XXX O
to XXX O
the XXX O
cytoplasm XXX O
was XXX O
not XXX O
limited XXX O
to XXX O
a XXX O
particular XXX O
phase XXX O
of XXX O
the XXX O
cell XXX O
division XXX O
cycle XXX O
. XXX O

Alanine XXX B-GENE
aminotransferase XXX I-GENE
( XXX O
ALT XXX B-GENE
) XXX O
levels XXX O
had XXX O
been XXX O
elevated XXX O
for XXX O
six XXX O
months XXX O
in XXX O
all XXX O
patients XXX O
and XXX O
hepatitis XXX O
B XXX O
viral XXX O
infection XXX O
was XXX O
replicative XXX O
. XXX O

Marked XXX O
elevation XXX O
of XXX O
creatine XXX B-GENE
kinase XXX I-GENE
was XXX O
observed XXX O
while XXX O
serum XXX O
albumin XXX B-GENE
, XXX O
immunoglobulin XXX B-GENE
, XXX O
and XXX O
complement XXX O
were XXX O
decreased XXX O
. XXX O

Gastrin XXX B-GENE
secretion XXX O
during XXX O
food XXX O
stimulation XXX O
in XXX O
digestive XXX O
system XXX O
diseases XXX O
. XXX O

Endothelial XXX O
cells XXX O
stored XXX O
with XXX O
University XXX O
of XXX O
Wisconsin XXX O
solution XXX O
excluded XXX O
trypan XXX O
blue XXX O
better XXX O
( XXX O
1 XXX O
. XXX O
0% XXX O
+ XXX O
/ XXX O
- XXX O
0 XXX O
. XXX O
5% XXX O
cells XXX O
stained XXX O
, XXX O
p XXX O
less XXX O
than XXX O
0 XXX O
. XXX O
001 XXX O
. XXX O

A XXX O
comparison XXX O
of XXX O
the XXX O
predicted XXX O
amino XXX O
acid XXX O
sequences XXX O
of XXX O
the XXX O
two XXX O
human XXX B-GENE
PKC-delta XXX I-GENE
clones XXX O
with XXX O
the XXX O
rat XXX O
and XXX O
mouse XXX O
homologues XXX O
indicated XXX O
a XXX O
greater XXX O
degree XXX O
of XXX O
sequence XXX O
divergence XXX O
( XXX O
89-90% XXX O
homology XXX O
) XXX O
compared XXX O
to XXX O
the XXX O
high XXX O
degree XXX O
of XXX O
sequence XXX O
conservation XXX O
observed XXX O
with XXX O
other XXX O
human XXX B-GENE
PKC XXX I-GENE
family XXX I-GENE
members XXX I-GENE
and XXX O
their XXX O
mammalian XXX O
counterparts XXX O
. XXX O

Students XXX O
, XXX O
parents XXX O
, XXX O
teachers XXX O
and XXX O
hearing XXX O
disorders XXX O
. XXX O

Therefore XXX O
, XXX O
Mxi1 XXX B-GENE
and XXX O
Mad XXX B-GENE
might XXX O
antagonize XXX O
Myc XXX B-GENE
function XXX O
and XXX O
are XXX O
candidate XXX O
tumor XXX O
suppressor XXX O
genes XXX O
. XXX O

Analysis XXX O
of XXX O
a XXX O
set XXX O
of XXX O
deletion XXX O
constructs XXX O
in XXX O
transient XXX O
transfection XXX O
assays XXX O
measuring XXX O
heterologous XXX O
reporter XXX O
gene XXX O
( XXX O
luciferase XXX B-GENE
) XXX O
activity XXX O
demonstrated XXX O
that XXX O
the XXX O
182-bp XXX O
5'-flanking XXX O
region XXX O
provides XXX O
full XXX O
promoter XXX O
activity XXX O
in XXX O
IL-2-stimulated XXX O
L2 XXX O
cells XXX O
. XXX O

When XXX O
excluding XXX O
children XXX O
with XXX O
ocular XXX O
and XXX O
cerebral XXX O
pathology XXX O
, XXX O
32 XXX O
matched XXX O
pairs XXX O
of XXX O
premature XXX O
and XXX O
control XXX O
children XXX O
remained XXX O
. XXX O

Optically XXX O
detected XXX O
librons XXX O
and XXX O
phonons XXX O
in XXX O
crystalline XXX O
C60 XXX O
. XXX O

The XXX O
effects XXX O
of XXX O
loading XXX O
the XXX O
respiratory XXX O
pumps XXX O
on XXX O
the XXX O
oxygen XXX O
consumption XXX O
of XXX O
Callionymus XXX O
lyra XXX O
. XXX O

Expression XXX O
of XXX O
the XXX O
phenylalanine XXX B-GENE
hydroxylase XXX I-GENE
gene XXX I-GENE
in XXX O
livers XXX O
and XXX O
kidneys XXX O
of XXX O
rodents XXX O
is XXX O
activated XXX O
at XXX O
birth XXX O
and XXX O
is XXX O
induced XXX O
by XXX O
glucocorticoids XXX O
and XXX O
cyclic XXX O
AMP XXX O
in XXX O
the XXX O
liver XXX O
. XXX O

From XXX O
transient XXX O
expression XXX O
studies XXX O
, XXX O
we XXX O
could XXX O
demonstrate XXX O
that XXX O
the XXX O
SH3 XXX B-GENE
domain XXX I-GENE
of XXX O
PLC-gamma1 XXX B-GENE
is XXX O
necessary XXX O
for XXX O
the XXX O
association XXX O
with XXX O
SOS1 XXX B-GENE
in XXX O
vivo XXX O
. XXX O

EB-1 XXX B-GENE
, XXX O
a XXX O
tyrosine XXX B-GENE
kinase XXX I-GENE
signal XXX I-GENE
transduction XXX I-GENE
gene XXX I-GENE
, XXX O
is XXX O
transcriptionally XXX O
activated XXX O
in XXX O
the XXX O
t XXX O
( XXX O
1 XXX O
; XXX O
19 XXX O
) XXX O
subset XXX O
of XXX O
pre-B XXX O
ALL XXX O
, XXX O
which XXX O
express XXX O
oncoprotein XXX B-GENE
E2a-Pbx1 XXX I-GENE
. XXX O

C3 XXX B-GENE
toxin XXX I-GENE
completely XXX O
inhibited XXX O
RhoA XXX B-GENE
function XXX O
, XXX O
partially XXX O
inhibited XXX O
SRE XXX B-GENE
: XXX O
Luc XXX B-GENE
activity XXX O
, XXX O
but XXX O
had XXX O
no XXX O
effect XXX O
on XXX O
LPA-stimulated XXX O
c-Fos XXX B-GENE
expression XXX O
. XXX O

It XXX O
is XXX O
impossible XXX O
to XXX O
define XXX O
only XXX O
one XXX O
clinical XXX O
outline XXX O
because XXX O
both XXX O
symptomatic XXX O
and XXX O
asymptomatic XXX O
infected XXX O
NB XXX O
may XXX O
be XXX O
found XXX O
with XXX O
gestational XXX O
age XXX O
at XXX O
term XXX O
and XXX O
pre-term XXX O
and XXX O
when XXX O
born XXX O
with XXX O
a XXX O
weight XXX O
above XXX O
or XXX O
below XXX O
2000 XXX O
g XXX O
. XXX O

Mutation XXX O
of XXX O
either XXX O
the XXX O
AP-1 XXX B-GENE
or XXX O
the XXX O
ets XXX B-GENE
component XXX O
of XXX O
this XXX O
site XXX O
also XXX O
prevented XXX O
promoter XXX O
activity XXX O
in XXX O
SMCs XXX O
. XXX O

Binding XXX O
of XXX O
SSP XXX B-GENE
to XXX O
the XXX O
stage XXX B-GENE
selector XXX I-GENE
element XXX I-GENE
( XXX O
SSE XXX B-GENE
) XXX O
in XXX O
the XXX O
proximal XXX O
gamma-globin XXX B-GENE
promoter XXX I-GENE
is XXX O
integral XXX O
to XXX O
the XXX O
competitive XXX O
silencing XXX O
of XXX O
a XXX O
linked XXX O
beta-promoter XXX B-GENE
in XXX O
embryonic XXX O
/ XXX O
fetal XXX O
stage XXX O
erythroleukemia XXX O
( XXX O
K562 XXX O
) XXX O
cells XXX O
. XXX O

Novel XXX O
8-base XXX O
pair XXX O
sequence XXX O
( XXX O
Drosophila XXX B-GENE
DNA XXX I-GENE
replication-related XXX I-GENE
element XXX I-GENE
) XXX O
and XXX O
specific XXX O
binding XXX O
factor XXX O
involved XXX O
in XXX O
the XXX O
expression XXX O
of XXX O
Drosophila XXX O
genes XXX O
for XXX O
DNA XXX B-GENE
polymerase XXX I-GENE
alpha XXX I-GENE
and XXX O
proliferating XXX B-GENE
cell XXX I-GENE
nuclear XXX I-GENE
antigen XXX I-GENE
. XXX O

Mutational XXX O
analysis XXX O
supports XXX O
a XXX O
role XXX O
for XXX O
multiple XXX O
structural XXX O
features XXX O
in XXX O
the XXX O
C-terminal XXX O
secretion XXX O
signal XXX O
of XXX O
Escherichia XXX B-GENE
coli XXX I-GENE
haemolysin XXX I-GENE
. XXX O

Five XXX O
out XXX O
of XXX O
eight XXX O
consecutive XXX O
cases XXX O
with XXX O
initial XXX O
symptoms XXX O
of XXX O
a XXX O
'midline XXX O
granuloma' XXX O
were XXX O
identified XXX O
as XXX O
malignant XXX O
histiocytosis XXX O
( XXX O
histiocytic XXX O
sarcoma XXX O
) XXX O
which XXX O
within XXX O
5 XXX O
months XXX O
to XXX O
4 XXX O
years XXX O
led XXX O
to XXX O
generalization XXX O
and XXX O
death XXX O
. XXX O

Thus XXX O
, XXX O
these XXX O
studies XXX O
indicate XXX O
that XXX O
the XXX O
104-kDa XXX O
isoform XXX O
is XXX O
required XXX O
for XXX O
normal XXX O
proliferation XXX O
of XXX O
female XXX O
germline XXX O
cells XXX O
and XXX O
perhaps XXX O
for XXX O
oocyte XXX O
differentiation XXX O
. XXX O

Twenty XXX O
food XXX O
products XXX O
were XXX O
contaminated XXX O
with XXX O
V XXX O
. XXX O
cholerae XXX O
O1 XXX O
, XXX O
Ogawa XXX O
, XXX O
toxigenic XXX O
and XXX O
not XXX O
toxigenic XXX O
strains XXX O
: XXX O
yoghurt XXX O
, XXX O
cream XXX O
cheese XXX O
, XXX O
apricot XXX O
marmelade XXX O
, XXX O
hip XXX O
rose XXX O
marmelade XXX O
, XXX O
mayonnaise XXX O
, XXX O
italian XXX O
pasta XXX O
for XXX O
"empanadas" XXX O
, XXX O
"dulce XXX O
de XXX O
leche" XXX O
, XXX O
meat XXX O
sausage XXX O
, XXX O
meat XXX O
and XXX O
spinach XXX O
ravioli XXX O
, XXX O
margarine XXX O
, XXX O
milk XXX O
dessert XXX O
( XXX O
made XXX O
with XXX O
cocoa XXX O
, XXX O
milk XXX O
confiture XXX O
, XXX O
starch XXX O
and XXX O
additives XXX O
) XXX O
, XXX O
lettuce XXX O
, XXX O
tuna XXX O
fish XXX O
, XXX O
ricotta XXX O
and XXX O
sterilized XXX O
milk XXX O
. XXX O

A XXX O
region XXX O
of XXX O
the XXX O
deduced XXX O
protein XXX O
shares XXX O
extensive XXX O
homology XXX O
with XXX O
a XXX O
catalytic XXX O
region XXX O
of XXX O
Raf XXX B-GENE
kinases XXX I-GENE
, XXX O
a XXX O
feature XXX O
shared XXX O
only XXX O
with XXX O
TFIIE XXX B-GENE
among XXX O
transcription XXX O
factors XXX O
. XXX O

Conjugated XXX O
and XXX O
unconjugated XXX O
phenylacetic XXX O
acid XXX O
and XXX O
m- XXX O
and XXX O
p-hydroxyphenylacetic XXX O
acid XXX O
have XXX O
been XXX O
determined XXX O
in XXX O
the XXX O
plasma XXX O
of XXX O
normal XXX O
, XXX O
healthy XXX O
subjects XXX O
after XXX O
fasting XXX O
, XXX O
consumption XXX O
of XXX O
a XXX O
meal XXX O
and XXX O
ingestion XXX O
of XXX O
deuterium XXX O
labelled XXX O
amine XXX O
precursors XXX O
, XXX O
by XXX O
high-resolution XXX O
gas XXX O
chromatography--high XXX O
resolution XXX O
mass XXX O
spectrometry XXX O
with XXX O
selected XXX O
ion XXX O
monitoring XXX O
of XXX O
their XXX O
trifluoroethyl-pentafluoropropionyl XXX O
derivatives XXX O
. XXX O

We XXX O
calculated XXX O
differences XXX O
in XXX O
late XXX O
occlusion XXX O
rates XXX O
by XXX O
the XXX O
chi2 XXX O
( XXX O
chi-square XXX O
) XXX O
test XXX O
, XXX O
and XXX O
found XXX O
these XXX O
differences XXX O
were XXX O
significant XXX O
( XXX O
P XXX O
= XXX O
. XXX O
04 XXX O
) XXX O
. XXX O

Plasma XXX B-GENE
renin XXX I-GENE
activity XXX O
does XXX O
not XXX O
predict XXX O
the XXX O
antihypertensive XXX O
efficacy XXX O
of XXX O
chlorthalidone XXX O
. XXX O

CONCLUSION XXX O
: XXX O
The XXX O
authors XXX O
emphasize XXX O
that XXX O
the XXX O
initial XXX O
management XXX O
of XXX O
primary XXX O
STS XXX O
should XXX O
be XXX O
adequate XXX O
and XXX O
suggest XXX O
that XXX O
safty XXX O
margin XXX O
of XXX O
> XXX O
or XXX O
= XXX O
2 XXX O
cm XXX O
should XXX O
be XXX O
adhered XXX O
to XXX O
. XXX O

Nitric XXX O
oxide XXX O
inhalation XXX O
selectively XXX O
reduces XXX O
pulmonary XXX O
hypertension XXX O
in XXX O
porcine XXX O
endotoxin XXX B-GENE
shock XXX O
and XXX O
improves XXX O
arterial XXX O
oxygenation XXX O
and XXX O
pH XXX O
with XXX O
a XXX O
marked XXX O
attenuation XXX O
of XXX O
sympathetic XXX O
activation XXX O
. XXX O

SNAC XXX O
or XXX O
PBS XXX O
was XXX O
infused XXX O
for XXX O
6 XXX O
. XXX O
5 XXX O
h XXX O
, XXX O
beginning XXX O
30 XXX O
min XXX O
before XXX O
ischemia XXX O
and XXX O
continuing XXX O
throughout XXX O
the XXX O
duration XXX O
of XXX O
reperfusion XXX O
. XXX O

Wild-type XXX O
and XXX O
mutant XXX O
MyoD XXX B-GENE
were XXX O
introduced XXX O
into XXX O
cells XXX O
using XXX O
an XXX O
E1 XXX B-GENE
, XXX O
E3-deleted XXX O
adenoviral XXX O
vector XXX O
. XXX O

Results XXX O
of XXX O
the XXX O
recognition XXX O
task XXX O
revealed XXX O
significant XXX O
effects XXX O
of XXX O
consonant XXX O
voicing XXX O
, XXX O
position XXX O
and XXX O
vowel XXX O
context XXX O
on XXX O
syllable XXX O
recognition XXX O
. XXX O

Thus XXX O
, XXX O
the XXX O
pol XXX B-GENE
alpha-primase XXX I-GENE
complex XXX I-GENE
appears XXX O
to XXX O
act XXX O
processively XXX O
for XXX O
only XXX O
a XXX O
short XXX O
distance XXX O
. XXX O

Pharmacokinetic XXX O
profile XXX O
of XXX O
clonazepam XXX O
in XXX O
rhesus XXX O
monkeys XXX O
. XXX O

NH2-terminal XXX O
trimming XXX O
of XXX O
Xenopus XXX O
and XXX O
mammalian XXX B-GENE
FGF3s XXX I-GENE
may XXX O
therefore XXX O
be XXX O
a XXX O
prerequisite XXX O
of XXX O
optimal XXX O
biological XXX O
activity XXX O
. XXX O

In XXX O
vitro XXX O
precipitation XXX O
with XXX O
a XXX O
glutathione-S-transferase-fusion XXX B-GENE
protein XXX I-GENE
containing XXX O
the XXX O
C-terminal XXX O
transactivation XXX O
domain XXX O
of XXX O
STAT5a XXX B-GENE
showed XXX O
GH-regulated XXX O
association XXX O
of XXX O
ERK1 XXX B-GENE
/ XXX I-GENE
2 XXX I-GENE
with XXX O
the XXX O
fusion XXX O
protein XXX O
, XXX O
while XXX O
this XXX O
was XXX O
not XXX O
seen XXX O
when XXX O
serine XXX O
780 XXX O
in XXX O
STAT5a XXX B-GENE
was XXX O
changed XXX O
to XXX O
alanine XXX O
. XXX O

The XXX O
biochemical XXX O
and XXX O
molecular XXX O
spectrum XXX O
of XXX O
ornithine XXX B-GENE
transcarbamylase XXX I-GENE
deficiency XXX O
. XXX O

IL-1beta XXX B-GENE
( XXX O
10 XXX O
ng XXX O
/ XXX O
ml XXX O
) XXX O
drastically XXX O
increased XXX O
both XXX O
PDGFalphaR XXX B-GENE
and XXX O
CCAAT XXX B-GENE
/ XXX I-GENE
enhancer-binding XXX I-GENE
protein XXX I-GENE
delta XXX I-GENE
( XXX O
C XXX B-GENE
/ XXX I-GENE
EBPdelta XXX I-GENE
) XXX O
mRNA XXX O
levels XXX O
in XXX O
a XXX O
time XXX O
dependent XXX O
manner XXX O
. XXX O

Temperature XXX O
measurement XXX O
in XXX O
microfluidic XXX O
systems XXX O
using XXX O
a XXX O
temperature-dependent XXX O
fluorescent XXX O
dye XXX O
. XXX O

Holliday XXX B-GENE
junction XXX I-GENE
resolvase XXX I-GENE
in XXX O
Schizosaccharomyces XXX O
pombe XXX O
has XXX O
identical XXX O
endonuclease XXX B-GENE
activity XXX O
to XXX O
the XXX O
CCE1 XXX B-GENE
homologue XXX O
YDC2 XXX B-GENE
. XXX O

The XXX O
negative XXX O
regulatory XXX O
activity XXX O
of XXX O
the XXX O
N-terminal XXX O
domain XXX O
was XXX O
antagonized XXX O
by XXX O
a XXX O
C-terminal XXX O
segment XXX O
of XXX O
Pho81p XXX B-GENE
supplied XXX O
in XXX O
trans XXX O
. XXX O

IE2-IE2 XXX B-GENE
interactions XXX O
were XXX O
mapped XXX O
to XXX O
a XXX O
domain XXX O
containing XXX O
a XXX O
putative XXX O
helix-turn-helix XXX B-GENE
motif XXX I-GENE
located XXX O
near XXX O
the XXX O
C XXX O
terminus XXX O
of XXX O
IE2 XXX B-GENE
, XXX O
between XXX O
amino XXX O
acids XXX O
456 XXX O
and XXX O
539 XXX O
. XXX O

Previously XXX O
, XXX O
we XXX O
characterized XXX O
a XXX O
DNA-binding XXX O
protein XXX O
, XXX O
HS2NF5 XXX B-GENE
, XXX O
that XXX O
bound XXX O
tightly XXX O
to XXX O
a XXX O
conserved XXX O
region XXX O
within XXX O
hypersensitive XXX B-GENE
site XXX I-GENE
2 XXX I-GENE
( XXX O
HS2 XXX B-GENE
) XXX O
of XXX O
the XXX O
human XXX B-GENE
beta-globin XXX I-GENE
locus XXX I-GENE
control XXX I-GENE
region XXX I-GENE
( XXX O
LCR XXX B-GENE
) XXX O
( XXX O
Lam XXX O
, XXX O
L XXX O
. XXX O

Middle-latency XXX O
auditory XXX O
evoked XXX O
potentials XXX O
( XXX O
MAEPs XXX O
) XXX O
were XXX O
recorded XXX O
in XXX O
controls XXX O
and XXX O
patients XXX O
with XXX O
focal XXX O
lesions XXX O
in XXX O
dorsolateral XXX O
prefrontal XXX O
cortex XXX O
. XXX O

From XXX O
the XXX O
15-kb XXX O
clone XXX O
a XXX O
4-kb XXX B-GENE
EcoRI XXX I-GENE
fragment XXX I-GENE
containing XXX O
the XXX O
first XXX O
two XXX O
exons XXX O
and XXX O
2 XXX O
. XXX O
6 XXX O
kb XXX O
of XXX O
the XXX O
5' XXX O
flanking XXX O
region XXX O
of XXX O
the XXX O
opn XXX B-GENE
gene XXX I-GENE
was XXX O
sequenced XXX O
, XXX O
and XXX O
the XXX O
transcriptional XXX O
start XXX O
site XXX O
determined XXX O
by XXX O
primer XXX O
extension XXX O
analysis XXX O
and XXX O
S1 XXX B-GENE
nuclease XXX I-GENE
mapping XXX O
. XXX O

With XXX O
a XXX O
BMI XXX O
cutoff XXX O
of XXX O
27 XXX O
, XXX O
mean XXX O
cardiac XXX O
NE XXX O
spillover XXX O
was XXX O
46% XXX O
lower XXX O
in XXX O
the XXX O
obese XXX O
subjects XXX O
when XXX O
compared XXX O
with XXX O
the XXX O
lean XXX O
subjects XXX O
( XXX O
P XXX O
= XXX O
. XXX O
017 XXX O
) XXX O
. XXX O

However XXX O
, XXX O
the XXX O
favored XXX O
, XXX O
parallel XXX O
beta XXX O
helix XXX O
model XXX O
is XXX O
a XXX O
compact XXX O
coil XXX O
of XXX O
ten XXX O
helically XXX O
arranged XXX O
beta XXX O
strands XXX O
forming XXX O
two XXX O
parallel XXX O
beta XXX O
sheet XXX O
faces XXX O
. XXX O

C-SP XXX O
duration XXX O
was XXX O
significantly XXX O
reduced XXX O
in XXX O
ALS XXX O
patients XXX O
compared XXX O
to XXX O
controls XXX O
at XXX O
low XXX O
stimulation XXX O
intensity XXX O
corresponding XXX O
to XXX O
an XXX O
MEP XXX O
threshold XXX O
increased XXX O
by XXX O
15% XXX O
. XXX O

Small-molecule XXX O
control XXX O
of XXX O
insulin XXX B-GENE
and XXX O
PDGF XXX B-GENE
receptor XXX I-GENE
signaling XXX O
and XXX O
the XXX O
role XXX O
of XXX O
membrane XXX O
attachment XXX O
. XXX O

The XXX O
Trk XXX B-GENE
/ XXX I-GENE
Nerve XXX I-GENE
Growth XXX I-GENE
Factor XXX I-GENE
receptor XXX I-GENE
mediates XXX O
the XXX O
rapid XXX O
activation XXX O
of XXX O
a XXX O
number XXX O
of XXX O
intracellular XXX O
signaling XXX O
proteins XXX O
, XXX O
including XXX O
phosphatidylinositol XXX B-GENE
3-kinase XXX I-GENE
( XXX O
PI XXX B-GENE
3-kinase XXX I-GENE
) XXX O
. XXX O

Roux-en-Y XXX O
gastroenterostomy XXX O
severely XXX O
disturbs XXX O
emptying XXX O
of XXX O
the XXX O
gallbladder XXX O
. XXX O

Levels XXX O
of XXX O
both XXX O
PGF XXX O
and XXX O
PGFM XXX O
were XXX O
significantly XXX O
higher XXX O
during XXX O
early XXX O
spontaneous XXX O
labour XXX O
, XXX O
at XXX O
a XXX O
cervical XXX O
dilatation XXX O
of XXX O
less XXX O
than XXX O
4 XXX O
cm XXX O
, XXX O
than XXX O
before XXX O
the XXX O
onset XXX O
of XXX O
labour XXX O
. XXX O

These XXX O
included XXX O
HNF-3 XXX B-GENE
beta XXX I-GENE
, XXX O
HFH-1 XXX B-GENE
, XXX O
HFH-2 XXX B-GENE
, XXX O
HFH-3 XXX B-GENE
, XXX O
C XXX B-GENE
/ XXX I-GENE
EBP XXX I-GENE
, XXX O
and XXX O
C XXX B-GENE
/ XXX I-GENE
EBP XXX I-GENE
beta XXX I-GENE
, XXX O
all XXX O
of XXX O
which XXX O
are XXX O
consistent XXX O
with XXX O
the XXX O
tissue-specific XXX O
expression XXX O
profiles XXX O
of XXX O
the XXX O
gene XXX O
. XXX O

After XXX O
nadolol XXX O
, XXX O
heart XXX O
rate XXX O
decreased XXX O
( XXX O
-22 XXX O
+ XXX O
/ XXX O
- XXX O
8% XXX O
) XXX O
, XXX O
and XXX O
so XXX O
did XXX O
PBV XXX O
and XXX O
PBF XXX O
( XXX O
8 XXX O
. XXX O
8 XXX O
+ XXX O
/ XXX O
- XXX O
3 XXX O
. XXX O
4 XXX O
vs XXX O
. XXX O

The XXX O
mRNAs XXX O
of XXX O
the XXX O
GRF XXX B-GENE
genes XXX I-GENE
are XXX O
encoded XXX O
by XXX O
six XXX O
exons XXX O
interrupted XXX O
by XXX O
five XXX O
introns XXX O
. XXX O

Changes XXX O
in XXX O
muscarinic XXX B-GENE
acetylcholine XXX I-GENE
receptors XXX I-GENE
in XXX O
guinea-pig XXX O
lung XXX O
: XXX O
effects XXX O
of XXX O
aging XXX O
, XXX O
inhalation XXX O
of XXX O
an XXX O
allergen XXX O
, XXX O
administration XXX O
of XXX O
drugs XXX O
, XXX O
and XXX O
vagotomy XXX O
. XXX O

No XXX O
reflow XXX O
occurred XXX O
in XXX O
approximately XXX O
30 XXX O
percent XXX O
of XXX O
the XXX O
muscle XXX O
microvasculature XXX O
upon XXX O
reperfusion XXX O
. XXX O

All XXX O
were XXX O
tested XXX O
for XXX O
serum XXX O
ferritin XXX B-GENE
( XXX O
SF XXX O
) XXX O
, XXX O
hemoglobin XXX B-GENE
( XXX O
Hb XXX B-GENE
) XXX O
level XXX O
and XXX O
asked XXX O
for XXX O
detailed XXX O
histories XXX O
of XXX O
donations XXX O
and XXX O
iron XXX O
supplementation XXX O
. XXX O

Type XXX O
II XXX O
could XXX O
be XXX O
divided XXX O
further XXX O
into XXX O
two XXX O
forms XXX O
( XXX O
IIA XXX O
and XXX O
IIB XXX O
) XXX O
that XXX O
may XXX O
represent XXX O
two XXX O
underscribed XXX O
species XXX O
or XXX O
developmental XXX O
stages XXX O
of XXX O
the XXX O
same XXX O
species XXX O
. XXX O

Net XXX O
lift XXX O
and XXX O
combined XXX O
drag XXX O
from XXX O
all XXX O
8 XXX O
bearings XXX O
of XXX O
the XXX O
4-bladed XXX O
impeller XXX O
are XXX O
compared XXX O
with XXX O
predictions XXX O
based XXX O
on XXX O
2-D XXX O
theory XXX O
. XXX O

Transvenous XXX O
serial XXX O
xeroradiography XXX O
. XXX O

Of XXX O
the XXX O
single-stranded XXX O
DNA XXX O
transformants XXX O
, XXX O
65% XXX O
resulted XXX O
from XXX O
replacement XXX O
of XXX O
the XXX O
resident XXX O
met2 XXX B-GENE
mutation XXX I-GENE
by XXX O
the XXX O
exogenous XXX O
wild-type XXX O
allele XXX O
. XXX O

The XXX O
effect XXX O
of XXX O
MIB XXX O
on XXX O
the XXX O
dose-response XXX O
curve XXX O
of XXX O
externally XXX O
applied XXX O
noradrenaline XXX O
was XXX O
also XXX O
studied XXX O
. XXX O

Laboratory XXX O
evaluation XXX O
was XXX O
normal XXX O
, XXX O
and XXX O
neuroimaging XXX O
failed XXX O
to XXX O
confirm XXX O
obstruction XXX O
of XXX O
venous XXX O
or XXX O
lymphatic XXX O
drainage XXX O
. XXX O

The XXX O
Fyn XXX B-GENE
NH2 XXX I-GENE
terminus XXX I-GENE
was XXX O
necessary XXX O
but XXX O
not XXX O
sufficient XXX O
for XXX O
interaction XXX O
with XXX O
zeta XXX B-GENE
and XXX O
both XXX O
Fyn XXX B-GENE
kinase XXX I-GENE
and XXX O
SH2 XXX B-GENE
domains XXX I-GENE
were XXX O
required XXX O
, XXX O
directing XXX O
phosphorylation XXX O
of XXX O
zeta XXX B-GENE
ITAM XXX I-GENE
tyrosines XXX O
and XXX O
binding XXX O
to XXX O
zeta XXX B-GENE
ITAM XXX I-GENE
phosphotyrosines XXX O
. XXX O

These XXX O
offspring XXX O
of XXX O
the XXX O
alpha-MSH XXX B-GENE
treated XXX O
mothers XXX O
were XXX O
less XXX O
sensitive XXX O
to XXX O
pain XXX O
and XXX O
as XXX O
adults XXX O
showed XXX O
a XXX O
reduced XXX O
analgesic XXX O
response XXX O
to XXX O
morphine XXX O
. XXX O

Although XXX O
eight XXX O
contiguous XXX O
genes XXX O
necessary XXX O
for XXX O
urease XXX B-GENE
activity XXX O
have XXX O
been XXX O
cloned XXX O
and XXX O
sequenced XXX O
, XXX O
the XXX O
transcriptional XXX O
organization XXX O
and XXX O
regulation XXX O
of XXX O
specific XXX O
genes XXX O
within XXX O
the XXX O
Proteus XXX B-GENE
gene XXX I-GENE
cluster XXX I-GENE
has XXX O
not XXX O
been XXX O
investigated XXX O
in XXX O
detail XXX O
. XXX O

The XXX O
small XXX B-GENE
monomeric XXX I-GENE
GTP-binding XXX I-GENE
proteins XXX I-GENE
of XXX O
the XXX O
RAB XXX B-GENE
subfamily XXX I-GENE
are XXX O
key XXX O
regulatory XXX O
elements XXX O
of XXX O
the XXX O
machinery XXX O
that XXX O
controls XXX O
membrane XXX O
traffic XXX O
in XXX O
eukaryotic XXX O
cells XXX O
. XXX O

The XXX O
cases XXX O
included XXX O
35 XXX O
de XXX O
novo XXX O
diffuse XXX O
aggressive XXX O
lymphomas XXX O
( XXX O
DAL XXX O
; XXX O
19 XXX O
large-cell XXX O
, XXX O
4 XXX O
mixed-cell XXX O
, XXX O
and XXX O
12 XXX O
large-cell XXX O
immunoblastic XXX O
) XXX O
, XXX O
52 XXX O
transformed XXX O
aggressive XXX O
lymphomas XXX O
derived XXX O
from XXX O
follicular XXX O
lymphomas XXX O
( XXX O
TFL XXX O
) XXX O
, XXX O
42 XXX O
indolent XXX O
follicular XXX O
lymphomas XXX O
( XXX O
FL XXX O
) XXX O
, XXX O
14 XXX O
mantle XXX O
cell XXX O
lymphomas XXX O
( XXX O
MCL XXX O
) XXX O
, XXX O
and XXX O
27 XXX O
small XXX O
noncleaved XXX O
cell XXX O
lymphomas XXX O
( XXX O
SNCL XXX O
) XXX O
. XXX O

Furthermore XXX O
, XXX O
this XXX O
study XXX O
demonstrates XXX O
that XXX O
reduced XXX O
inotropy XXX O
with XXX O
timolol XXX O
helped XXX O
uniform XXX O
local XXX O
contraction XXX O
as XXX O
estimated XXX O
by XXX O
the XXX O
increased XXX O
LONG XXX O
/ XXX O
CIRC XXX O
ratio XXX O
, XXX O
a XXX O
transition XXX O
that XXX O
could XXX O
improve XXX O
contraction XXX O
efficacy XXX O
. XXX O

Splenectomized XXX O
patients XXX O
are XXX O
predisposed XXX O
toward XXX O
developing XXX O
overwhelming XXX O
bacterial XXX O
infections XXX O
. XXX O

In XXX O
humans XXX O
, XXX O
three XXX O
tissue-specific XXX B-GENE
plastin XXX I-GENE
isoforms XXX I-GENE
have XXX O
been XXX O
identified XXX O
. XXX O

Static XXX O
magnetic XXX O
fields XXX O
affect XXX O
the XXX O
diffusion XXX O
of XXX O
biological XXX O
particles XXX O
in XXX O
solutions XXX O
through XXX O
the XXX O
Lorentz XXX O
force XXX O
and XXX O
Maxwell XXX O
stress XXX O
. XXX O

In XXX O
the XXX O
mouse XXX O
, XXX O
both XXX O
genes XXX O
reside XXX O
in XXX O
the XXX O
syntenic XXX B-GENE
region XXX I-GENE
8E1 XXX I-GENE
on XXX O
chromosome XXX O
8 XXX O
. XXX O

Although XXX O
upstream XXX O
regulators XXX O
of XXX O
Tec XXX B-GENE
family XXX I-GENE
kinases XXX I-GENE
are XXX O
relatively XXX O
well XXX O
characterized XXX O
, XXX O
little XXX O
is XXX O
known XXX O
of XXX O
the XXX O
downstream XXX O
effectors XXX O
of XXX O
these XXX O
enzymes XXX O
. XXX O

The XXX O
drug XXX O
packets XXX O
contained XXX O
acetyl XXX O
aspirin XXX O
, XXX O
acetaminophen XXX O
and XXX O
chloramphenicol XXX O
. XXX O

Anterior XXX O
body XXX O
pattern XXX O
in XXX O
Drosophila XXX O
is XXX O
specified XXX O
by XXX O
the XXX O
graded XXX O
distribution XXX O
of XXX O
the XXX O
bicoid XXX B-GENE
protein XXX I-GENE
( XXX O
bcd XXX B-GENE
) XXX O
, XXX O
which XXX O
activates XXX O
subordinate XXX O
genes XXX O
in XXX O
distinct XXX O
anterior XXX O
domains XXX O
. XXX O

Sample XXX O
treatment XXX O
was XXX O
optimized XXX O
in XXX O
order XXX O
to XXX O
achieve XXX O
a XXX O
complete XXX O
extraction XXX O
of XXX O
labetalol XXX O
diastereoisomers XXX O
and XXX O
to XXX O
avoid XXX O
racemization XXX O
during XXX O
extraction XXX O
. XXX O

Serotonin XXX O
concentration XXX O
in XXX O
the XXX O
blood XXX O
of XXX O
patients XXX O
with XXX O
hemorrhagic XXX O
fever XXX O
with XXX O
renal XXX O
syndrome XXX O
. XXX O

Primer XXX O
extension XXX O
experiments XXX O
indicated XXX O
that XXX O
the XXX O
transcription XXX O
initiation XXX O
site XXX O
mapped XXX O
to XXX O
a XXX O
position XXX O
on XXX O
gene XXX B-GENE
IV XXX I-GENE
that XXX O
was XXX O
analogous XXX O
to XXX O
that XXX O
reported XXX O
for XXX O
the XXX O
structurally XXX O
similar XXX O
P-450e XXX B-GENE
gene XXX I-GENE
. XXX O

Actuarial XXX O
freedom XXX O
from XXX O
ventricular XXX O
arrhythmias XXX O
at XXX O
4-year XXX O
follow-up XXX O
was XXX O
74 XXX O
. XXX O
1 XXX O
+ XXX O
/ XXX O
- XXX O
6 XXX O
. XXX O
0% XXX O
in XXX O
group XXX O
A XXX O
vs XXX O
. XXX O

Similarly XXX O
, XXX O
maternal XXX B-GENE
serum XXX I-GENE
somatomedin XXX I-GENE
A XXX I-GENE
was XXX O
significantly XXX O
reduced XXX O
in XXX O
rats XXX O
nursing XXX O
large XXX O
litters XXX O
. XXX O

Recently XXX O
, XXX O
roles XXX O
also XXX O
have XXX O
been XXX O
suggested XXX O
for XXX O
the XXX O
nuclear XXX O
trans-factor XXX O
GATA-1 XXX B-GENE
in XXX O
regulating XXX O
progenitor XXX O
cell XXX O
proliferation XXX O
. XXX O

They XXX O
self-completed XXX O
the XXX O
SF-36 XXX O
questionnaire XXX O
and XXX O
their XXX O
QoL XXX O
was XXX O
described XXX O
and XXX O
retrospectively XXX O
compared XXX O
to XXX O
that XXX O
of XXX O
historical XXX O
controls XXX O
. XXX O

Ligand XXX O
binding XXX O
to XXX O
the XXX O
receptor XXX O
complex XXX O
leads XXX O
to XXX O
tyrosine XXX O
phosphorylation XXX O
and XXX O
activation XXX O
of XXX O
Janus XXX B-GENE
kinases XXX I-GENE
( XXX O
Jak XXX B-GENE
) XXX O
, XXX O
phosphorylation XXX O
of XXX O
the XXX O
signal XXX B-GENE
transducing XXX I-GENE
subunit XXX I-GENE
gp130 XXX I-GENE
, XXX O
followed XXX O
by XXX O
recruitment XXX O
and XXX O
phosphorylation XXX O
of XXX O
the XXX O
signal XXX B-GENE
transducer XXX I-GENE
and XXX I-GENE
activator XXX I-GENE
of XXX I-GENE
transcription XXX I-GENE
factors XXX I-GENE
STAT3 XXX B-GENE
and XXX O
STAT1 XXX B-GENE
and XXX O
the XXX O
src XXX B-GENE
homology XXX I-GENE
domain XXX I-GENE
( XXX O
SH2 XXX B-GENE
) XXX O
-containing XXX O
protein XXX B-GENE
tyrosine XXX I-GENE
phosphatase XXX I-GENE
( XXX O
SHP2 XXX B-GENE
) XXX O
. XXX O

Alanine XXX B-GENE
aminotransferase XXX I-GENE
in XXX O
clinical XXX O
practice XXX O
. XXX O

An XXX O
open XXX O
reading XXX O
frame XXX O
of XXX O
2862 XXX O
bp XXX O
encoding XXX O
a XXX O
954 XXX O
amino XXX O
acid XXX O
protein XXX O
was XXX O
identified XXX O
. XXX O

In XXX O
this XXX O
regard XXX O
, XXX O
it XXX O
differs XXX O
from XXX O
a XXX O
recently XXX O
reported XXX O
BFA-sensitive XXX O
ARF-GEP XXX B-GENE
that XXX O
contains XXX O
a XXX O
Sec7 XXX B-GENE
domain XXX I-GENE
. XXX O

The XXX O
Sp1 XXX B-GENE
region XXX I-GENE
, XXX O
however XXX O
, XXX O
is XXX O
converted XXX O
to XXX O
a XXX O
functionally XXX O
strong XXX O
TRE XXX O
by XXX O
the XXX O
viral XXX B-GENE
tat XXX I-GENE
factor XXX I-GENE
. XXX O

Disruption XXX O
of XXX O
the XXX O
chromosomal XXX B-GENE
AAR1 XXX I-GENE
gene XXX I-GENE
in XXX O
alpha XXX O
and XXX O
a XXX O
/ XXX O
alpha XXX O
cells XXX O
conferred XXX O
the XXX O
nonmating XXX O
phenotype XXX O
, XXX O
and XXX O
the XXX O
a XXX O
/ XXX O
alpha XXX O
diploids XXX O
could XXX O
not XXX O
sporulate XXX O
. XXX O

All XXX O
clinical XXX O
isolates XXX O
were XXX O
concomitantly XXX O
tested XXX O
by XXX O
disk XXX O
diffusion XXX O
and XXX O
agar XXX O
dilution XXX O
procedures XXX O
as XXX O
outlined XXX O
by XXX O
the XXX O
National XXX O
Committee XXX O
for XXX O
Clinical XXX O
Laboratory XXX O
Standards XXX O
. XXX O

Movement XXX O
time XXX O
and XXX O
kinematic XXX O
characteristics XXX O
were XXX O
analyzed XXX O
together XXX O
with XXX O
the XXX O
magnitude XXX O
of XXX O
cerebral XXX O
blood XXX O
flow XXX O
to XXX O
identify XXX O
areas XXX O
of XXX O
brain XXX O
activity XXX O
proportionate XXX O
to XXX O
task XXX O
and XXX O
movement XXX O
variables XXX O
. XXX O

Using XXX O
a XXX O
degenerate XXX O
oligodeoxyribonucleotide XXX O
( XXX O
oligo XXX O
) XXX O
based XXX O
on XXX O
the XXX O
N-terminal XXX O
aa XXX O
sequence XXX O
, XXX O
plus XXX O
an XXX O
internal XXX O
oligo XXX O
homologous XXX O
to XXX O
a XXX O
conserved XXX O
region XXX O
within XXX O
the XXX O
portion XXX O
of XXX O
CYP1 XXX B-GENE
and XXX O
CYP2 XXX B-GENE
that XXX O
had XXX O
been XXX O
deleted XXX O
in XXX O
the XXX O
genome XXX O
, XXX O
a XXX O
CYP3-specific XXX B-GENE
DNA XXX I-GENE
fragment XXX I-GENE
was XXX O
generated XXX O
by XXX O
the XXX O
polymerase XXX B-GENE
chain XXX O
reaction XXX O
( XXX O
PCR XXX O
) XXX O
using XXX O
GL81 XXX O
genomic XXX O
DNA XXX O
as XXX O
a XXX O
substrate XXX O
. XXX O

We XXX O
have XXX O
determined XXX O
the XXX O
nucleotide XXX O
( XXX O
nt XXX O
) XXX O
sequence XXX O
of XXX O
the XXX O
7 XXX B-GENE
. XXX I-GENE
5-kb XXX I-GENE
COR XXX I-GENE
segment XXX I-GENE
that XXX O
encompasses XXX O
a XXX O
cluster XXX O
of XXX O
six XXX O
genes XXX O
( XXX O
CYC1 XXX B-GENE
, XXX O
UTR1 XXX B-GENE
, XXX O
UTR3 XXX B-GENE
, XXX O
OSM1 XXX B-GENE
, XXX O
tRNA XXX B-GENE
( XXX I-GENE
Gly XXX I-GENE
) XXX I-GENE
and XXX O
RAD7 XXX B-GENE
) XXX O
located XXX O
on XXX O
chromosome XXX O
X XXX O
of XXX O
the XXX O
yeast XXX O
Saccharomyces XXX O
cerevisiae XXX O
. XXX O

The XXX O
effect XXX O
of XXX O
sodium XXX O
18 XXX O
beta-glycyrrhetate XXX O
( XXX O
SGA XXX O
) XXX O
on XXX O
experimental XXX O
arrhythmia XXX O
was XXX O
investigated XXX O
. XXX O

Extraction XXX O
procedure XXX O
for XXX O
the XXX O
measurement XXX O
of XXX O
butyltin XXX O
compounds XXX O
in XXX O
biological XXX O
tissues XXX O
using XXX O
toluene XXX O
, XXX O
HBr XXX O
, XXX O
and XXX O
tropolone XXX O
. XXX O

In XXX O
untreated XXX O
mice XXX O
, XXX O
bactericidal XXX O
activity XXX O
of XXX O
peritoneal XXX O
macrophages XXX O
decreased XXX O
from XXX O
one XXX O
day XXX O
to XXX O
3 XXX O
days XXX O
after XXX O
ip XXX O
injection XXX O
of XXX O
killed XXX O
L XXX O
. XXX O
monocytogenes XXX O
. XXX O

In XXX O
conclusion XXX O
, XXX O
obesity XXX O
, XXX O
alcohol XXX O
intake XXX O
, XXX O
and XXX O
multimetabolic XXX O
disorders XXX O
were XXX O
determined XXX O
to XXX O
be XXX O
independent XXX O
predictors XXX O
for XXX O
the XXX O
development XXX O
of XXX O
hyperuricemia XXX O
. XXX O

The XXX O
structural XXX O
gene XXX O
for XXX O
copper- XXX B-GENE
and XXX I-GENE
topa XXX I-GENE
quinone-containing XXX I-GENE
monoamine XXX I-GENE
oxidase XXX I-GENE
( XXX O
maoA XXX B-GENE
) XXX O
and XXX O
an XXX O
unknown XXX O
amine XXX B-GENE
oxidase XXX I-GENE
gene XXX I-GENE
have XXX O
been XXX O
located XXX O
at XXX O
30 XXX O
. XXX O
9 XXX O
min XXX O
on XXX O
the XXX O
Escherichia XXX O
coli XXX O
chromosome XXX O
. XXX O

METHODS XXX O
: XXX O
Humphrey XXX O
Field XXX O
Analyzer XXX O
model XXX O
630 XXX O
( XXX O
HFA XXX O
I XXX O
, XXX O
program XXX O
30-2 XXX O
with XXX O
a XXX O
rectangular XXX O
6 XXX O
degrees XXX O
x XXX O
6 XXX O
degrees XXX O
grid XXX O
) XXX O
was XXX O
used XXX O
as XXX O
the XXX O
conventional XXX O
perimetric XXX O
method XXX O
. XXX O

Methyl XXX O
mercury XXX O
intoxication XXX O
in XXX O
rat XXX O
kidneys XXX O
. XXX O

Cyclic XXX O
loading XXX O
of XXX O
bone XXX O
during XXX O
normal XXX O
daily XXX O
activity XXX O
leads XXX O
to XXX O
the XXX O
formation XXX O
of XXX O
microcracks XXX O
within XXX O
the XXX O
tissue XXX O
matrix XXX O
of XXX O
compact XXX O
bone XXX O
. XXX O

Because XXX O
the XXX O
human XXX B-GENE
Antp XXX I-GENE
TATAA XXX B-GENE
binding XXX I-GENE
protein XXX I-GENE
is XXX O
expressed XXX O
in XXX O
both XXX O
lymphoid XXX O
and XXX O
non-lymphoid XXX O
cells XXX O
, XXX O
we XXX O
suggest XXX O
that XXX O
this XXX O
homeobox XXX B-GENE
gene XXX I-GENE
has XXX O
evolved XXX O
a XXX O
more XXX O
general XXX O
transcriptional XXX O
regulatory XXX O
function XXX O
in XXX O
higher XXX O
eukaryotic XXX O
cells XXX O
. XXX O

The XXX O
clinical XXX O
application XXX O
of XXX O
the XXX O
antibody-targeted XXX O
Phthalocyanine XXX O
was XXX O
performed XXX O
in XXX O
3 XXX O
patients XXX O
suffering XXX O
from XXX O
an XXX O
advanced XXX O
ovarian XXX O
carcinoma XXX O
( XXX O
FIGO XXX O
III XXX O
) XXX O
. XXX O

The XXX O
DNA XXX O
sequence XXX O
immediately XXX O
upstream XXX O
from XXX O
the XXX O
- XXX O
10 XXX O
hexamer XXX O
contained XXX O
the XXX O
TGn XXX B-GENE
motif XXX I-GENE
described XXX O
as XXX O
an XXX O
extended XXX O
-10 XXX O
region XXX O
in XXX O
prokaryotic XXX O
promoters XXX O
. XXX O

Because XXX O
of XXX O
the XXX O
small XXX O
number XXX O
of XXX O
visceral XXX O
angiography XXX O
procedures XXX O
performed XXX O
( XXX O
38 XXX O
) XXX O
, XXX O
no XXX O
definitive XXX O
conclusions XXX O
could XXX O
be XXX O
drawn XXX O
as XXX O
to XXX O
the XXX O
differences XXX O
between XXX O
ionic XXX O
and XXX O
nonionic XXX O
agents XXX O
regarding XXX O
grade-2 XXX O
and XXX O
grade-3 XXX O
adverse XXX O
events XXX O
. XXX O

Growth XXX O
curves XXX O
indicated XXX O
that XXX O
proliferation XXX O
of XXX O
clone XXX O
CA9 XXX O
in XXX O
the XXX O
presence XXX O
of XXX O
10% XXX O
serum XXX O
was XXX O
reduced XXX O
by XXX O
60% XXX O
compared XXX O
with XXX O
clone XXX O
ME10 XXX O
. XXX O

Takayasu's XXX O
disease XXX O
: XXX O
association XXX O
with XXX O
HLA-B5 XXX B-GENE
. XXX O

These XXX O
data XXX O
suggest XXX O
that XXX O
spontaneous XXX O
recovery XXX O
of XXX O
central XXX O
respiratory XXX O
function XXX O
after XXX O
intoxication XXX O
with XXX O
Soman XXX O
or XXX O
Sarin XXX O
may XXX O
not XXX O
be XXX O
related XXX O
to XXX O
the XXX O
return XXX O
of XXX O
AChE XXX B-GENE
activity XXX O
. XXX O

Additionally XXX O
, XXX O
although XXX O
c-fos XXX B-GENE
and XXX O
egr-1 XXX B-GENE
mRNAs XXX I-GENE
are XXX O
expressed XXX O
at XXX O
elevated XXX O
levels XXX O
in XXX O
stimulated XXX O
liver XXX O
cells XXX O
, XXX O
fos-B XXX B-GENE
, XXX O
fra-1 XXX B-GENE
, XXX O
and XXX O
egr-2 XXX B-GENE
are XXX O
not XXX O
, XXX O
which XXX O
suggests XXX O
that XXX O
factors XXX O
in XXX O
addition XXX O
to XXX O
the XXX O
serum XXX B-GENE
response XXX I-GENE
factor XXX I-GENE
participate XXX O
in XXX O
the XXX O
regulation XXX O
of XXX O
immediate-early XXX B-GENE
gene XXX I-GENE
induction XXX O
. XXX O

We XXX O
describe XXX O
here XXX O
17 XXX O
dominant XXX B-GENE
GCN2 XXX I-GENE
mutations XXX I-GENE
that XXX O
lead XXX O
to XXX O
derepression XXX O
of XXX O
GCN4 XXX B-GENE
expression XXX O
in XXX O
the XXX O
absence XXX O
of XXX O
amino XXX O
acid XXX O
starvation XXX O
. XXX O

Baseline XXX O
variables XXX O
associated XXX O
with XXX O
CD XXX O
included XXX O
a XXX O
less XXX O
frequent XXX O
use XXX O
of XXX O
prestroke XXX O
aspirin XXX O
and XXX O
a XXX O
higher XXX O
incidence XXX O
of XXX O
early XXX O
CT XXX O
changes XXX O
of XXX O
edema XXX O
or XXX O
mass XXX O
effect XXX O
or XXX O
dense XXX O
middle XXX O
cerebral XXX O
artery XXX O
sign XXX O
. XXX O

The XXX O
effects XXX O
of XXX O
intracisternal XXX O
injection XXX O
( XXX O
i XXX O
. XXX O
c XXX O
. XXX O
i XXX O
. XXX O
) XXX O
of XXX O
clonidine XXX O
( XXX O
1 XXX O
microgram XXX O
kg-1 XXX O
) XXX O
on XXX O
blood XXX O
pressure XXX O
and XXX O
heart XXX O
rate XXX O
were XXX O
studied XXX O
in XXX O
conscious XXX O
rabbits XXX O
with XXX O
an XXX O
implanted XXX O
catheter XXX O
in XXX O
the XXX O
cisterna XXX O
magna XXX O
. XXX O

These XXX O
findings XXX O
indicate XXX O
that XXX O
autophosphorylation XXX O
of XXX O
Thr286 XXX O
( XXX O
alpha XXX O
subunit XXX O
) XXX O
and XXX O
Thr287 XXX O
( XXX O
beta XXX O
subunit XXX O
) XXX O
is XXX O
responsible XXX O
for XXX O
transition XXX O
of XXX O
CaM-kinase XXX B-GENE
II XXX I-GENE
to XXX O
the XXX O
Ca2+-independent XXX O
form XXX O
. XXX O

For XXX O
replication XXX O
reporter XXX O
constructs XXX O
where XXX O
E1 XXX B-GENE
and XXX O
E2 XXX B-GENE
are XXX O
supplied XXX O
in XXX O
trans XXX O
by XXX O
the XXX O
respective XXX O
expression XXX O
vectors XXX O
, XXX O
distance XXX O
between XXX O
the XXX O
half XXX O
sites XXX O
seems XXX O
to XXX O
play XXX O
a XXX O
major XXX O
role XXX O
, XXX O
yet XXX O
the XXX O
phasing XXX O
relationships XXX O
are XXX O
measurable XXX O
. XXX O

Transcripts XXX O
of XXX O
the XXX O
immunoglobulin XXX B-GENE
C XXX I-GENE
mu XXX I-GENE
gene XXX I-GENE
vary XXX O
in XXX O
structure XXX O
and XXX O
splicing XXX O
during XXX O
lymphoid XXX O
development XXX O
. XXX O

Within XXX O
the XXX O
span XXX O
of XXX O
attenuator XXX O
region XXX O
encoding XXX O
the XXX O
three XXX O
stem-loop XXX O
structures XXX O
of XXX O
mRNA XXX O
secondary XXX O
configuration XXX O
, XXX O
hot XXX O
spots XXX O
of XXX O
base-residue XXX O
divergence XXX O
were XXX O
localized XXX O
to XXX O
looped-out XXX O
regions XXX O
. XXX O

Repair XXX O
of XXX O
a XXX O
cosmetic XXX O
defect XXX O
of XXX O
the XXX O
lower XXX O
leg XXX O
with XXX O
a XXX O
myocutaneous XXX O
free XXX O
flap XXX O
. XXX O

In XXX O
a XXX O
112-d XXX O
feedlot XXX O
trial XXX O
, XXX O
105 XXX O
heifers XXX O
were XXX O
assigned XXX O
to XXX O
light XXX O
, XXX O
medium XXX O
and XXX O
heavy XXX O
weight XXX O
blocks XXX O
on XXX O
five XXX O
treatments XXX O
: XXX O
dietary XXX O
MGA XXX O
( XXX O
. XXX O
5 XXX O
mg XXX O
. XXX O
hd-1 XXX O
. XXX O
d-1 XXX O
) XXX O
, XXX O
control XXX O
( XXX O
no XXX O
MGA XXX O
) XXX O
or XXX O
DEPO-MGA XXX O
on XXX O
d XXX O
1 XXX O
at XXX O
. XXX O
5 XXX O
, XXX O
1 XXX O
. XXX O
0 XXX O
or XXX O
1 XXX O
. XXX O
5 XXX O
ml XXX O
/ XXX O
hd XXX O
( XXX O
30 XXX O
, XXX O
60 XXX O
or XXX O
90 XXX O
mg XXX O
MGA XXX O
/ XXX O
hd XXX O
, XXX O
respectively XXX O
) XXX O
. XXX O

Escherichia XXX O
of XXX O
a XXX O
single XXX O
sero-anzymatic XXX O
type XXX O
( XXX O
06a6b XXX O
: XXX O
K13 XXX O
: XXX O
H1 XXX O
) XXX O
were XXX O
isolated XXX O
in XXX O
a XXX O
group XXX O
affection XXX O
. XXX O

Lung XXX O
function XXX O
tests XXX O
( XXX O
EFR XXX O
) XXX O
were XXX O
performed XXX O
on XXX O
these XXX O
patients XXX O
for XXX O
a XXX O
period XXX O
of XXX O
19 XXX O
. XXX O
2 XXX O
+ XXX O
/ XXX O
- XXX O
3 XXX O
. XXX O
4 XXX O
months XXX O
. XXX O

Respiratory XXX O
parameters XXX O
suggested XXX O
that XXX O
M6G XXX O
produced XXX O
less XXX O
respiratory XXX O
depression XXX O
than XXX O
morphine XXX O
. XXX O

Copyright XXX O
2000 XXX O
Academic XXX O
Press XXX O
. XXX O

Eight XXX O
patients XXX O
received XXX O
1 XXX O
. XXX O
5 XXX O
mg XXX O
of XXX O
adefovir XXX O
dipivoxil XXX O
per XXX O
kg XXX O
of XXX O
body XXX O
weight XXX O
, XXX O
and XXX O
six XXX O
patients XXX O
received XXX O
3 XXX O
. XXX O
0 XXX O
mg XXX O
of XXX O
adefovir XXX O
dipivoxil XXX O
per XXX O
kg XXX O
. XXX O

A XXX O
fine-structure XXX O
deletion XXX O
map XXX O
of XXX O
human XXX O
chromosome XXX O
11p XXX O
: XXX O
analysis XXX O
of XXX O
J1 XXX O
series XXX O
hybrids XXX O
. XXX O

Rifabutin XXX O
has XXX O
substantial XXX O
efficacy XXX O
when XXX O
combined XXX O
with XXX O
other XXX O
agents XXX O
. XXX O

However XXX O
, XXX O
only XXX O
complete XXX B-GENE
DnaJ XXX I-GENE
can XXX O
cooperate XXX O
with XXX O
DnaK XXX B-GENE
and XXX O
a XXX O
third XXX O
protein XXX O
, XXX O
GrpE XXX B-GENE
, XXX O
in XXX O
refolding XXX O
denatured XXX B-GENE
firefly XXX I-GENE
luciferase XXX I-GENE
. XXX O

Expression XXX O
, XXX O
cellular XXX O
localization XXX O
and XXX O
in XXX O
vitro XXX O
transcription XXX O
studies XXX O
establish XXX O
that XXX O
cloned XXX B-GENE
hUBF XXX I-GENE
encodes XXX O
a XXX O
nucleolar XXX O
factor XXX O
that XXX O
binds XXX O
specifically XXX O
to XXX O
the XXX O
upstream XXX O
control XXX O
element XXX O
and XXX O
core XXX O
of XXX O
the XXX O
rRNA XXX B-GENE
gene XXX I-GENE
promoter XXX I-GENE
to XXX O
activate XXX O
transcription XXX O
in XXX O
a XXX O
binding XXX O
site-dependent XXX O
manner XXX O
. XXX O

We XXX O
have XXX O
recently XXX O
discovered XXX O
that XXX O
CCAAAT XXX B-GENE
/ XXX I-GENE
Enhancer XXX I-GENE
binding XXX I-GENE
protein-beta XXX I-GENE
( XXX O
C XXX B-GENE
/ XXX I-GENE
EBP-b XXX I-GENE
) XXX O
induces XXX O
gene XXX O
transcription XXX O
through XXX O
a XXX O
novel XXX O
IFN-response XXX B-GENE
element XXX I-GENE
called XXX O
, XXX O
gamma-IFN XXX B-GENE
activated XXX I-GENE
transcriptional XXX I-GENE
element XXX I-GENE
( XXX O
GATE XXX B-GENE
) XXX O
. XXX O

Spore XXX O
inocula XXX O
( XXX O
approximately XXX O
10 XXX O
( XXX O
6 XXX O
) XXX O
/ XXX O
coupon XXX O
) XXX O
were XXX O
dried XXX O
onto XXX O
0 XXX O
. XXX O
5-in XXX O
. XXX O

Basal XXX O
components XXX O
of XXX O
the XXX O
transcription XXX O
apparatus XXX O
( XXX O
RNA XXX B-GENE
polymerase XXX I-GENE
II XXX I-GENE
, XXX O
TATA-binding XXX B-GENE
protein XXX I-GENE
) XXX O
contain XXX O
activation XXX O
domains XXX O
: XXX O
is XXX O
the XXX O
repetitive XXX O
C-terminal XXX O
domain XXX O
( XXX O
CTD XXX O
) XXX O
of XXX O
RNA XXX B-GENE
polymerase XXX I-GENE
II XXX I-GENE
a XXX O
"portable XXX O
enhancer XXX O
domain" XXX O
? XXX O
Regions XXX O
rich XXX O
in XXX O
serine XXX O
, XXX O
threonine XXX O
, XXX O
and XXX O
proline XXX O
residues XXX O
can XXX O
be XXX O
found XXX O
in XXX O
transcriptional XXX O
activation XXX O
domains XXX O
, XXX O
as XXX O
well XXX O
as XXX O
in XXX O
the XXX O
N-terminal XXX O
parts XXX O
of XXX O
mammalian XXX B-GENE
TATA-binding XXX I-GENE
proteins XXX I-GENE
, XXX O
where XXX O
they XXX O
are XXX O
interrupted XXX O
by XXX O
polyglutamine XXX O
stretches XXX O
. XXX O

The XXX O
pretransplant XXX O
regimen XXX O
consisted XXX O
of XXX O
cyclophosphamide XXX O
( XXX O
120 XXX O
mg XXX O
/ XXX O
kg XXX O
) XXX O
and XXX O
total XXX O
body XXX O
irradiation XXX O
. XXX O

